PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Bao, M; Booth, JL; Elmendorf, BJ; Canfield, WM				Bao, M; Booth, JL; Elmendorf, BJ; Canfield, WM			Bovine UDP-N-acetylglucosamine:lysosomal-enzyme N-acetylglucosamine-1-phosphotransferase .1. Purification and subunit structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-CELL DISEASE; GLYCOPROTEIN N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE; RAT-LIVER; CDNA CLONING; PROTEINS; ACETYLGLUCOSAMINYLPHOSPHOTRANSFERASE; PHOSPHODIESTERASE; PHOSPHORYLATION; EXPRESSION; IDENTIFICATION	UDP-N-acetylglucosamine:lysosomal-enzyme N-acetylglucosamine-1-phosphotransferase (GlcNAc-phosphotransferase) catalyzes the initial step in the synthesis of the mannose 6-phosphate determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome, The enzyme was partially purified similar to 30,000-fold by chromatography of solubilized membrane proteins from lactating bovine mammary glands on DEAE-Sepharose, reactive green 19-agarose, and Superose 6, The partially purified enzyme was used to generate a panel of murine monoclonal antibodies, The anti-GlcNAc-phosphotransferase monoclonal antibody PT18 was coupled to a solid support and used to immunopurify the enzyme similar to 480,000-fold to apparent homogeneity with an overall yield of 29%, The purified enzyme has a specific activity of 10-12 mu mol of GlcNAc phosphate transferred per h/mg using 100 mM alpha-methylmannoside as acceptor. The subunit structure of the enzyme was determined using a combination of analytical gel filtration chromatography, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and amino-terminal sequencing. The data indicate that bovine GlcNAc-phosphotransferase is a 540,000-Da complex composed of disulfide-linked homodimers of 166,000- and 51,000-Da subunits and two identical, noncovalently associated 56,000-Da subunits.	UNIV OKLAHOMA,HLTH SCI CTR,WK WARREN MED RES INST,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT MED,OKLAHOMA CITY,OK 73104	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center								BARPELED M, 1991, J BIOL CHEM, V266, P20953; BENDIAK B, 1987, J BIOL CHEM, V262, P5775; BENYOSEPH Y, 1986, BIOCHEM J, V235, P883, DOI 10.1042/bj2350883; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BROWN EG, 1982, ANAL BIOCHEM, V123, P378, DOI 10.1016/0003-2697(82)90461-4; DAGOSTARO GAF, 1995, J BIOL CHEM, V270, P15211, DOI 10.1074/jbc.270.25.15211; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; Harlow E., 1988, ANTIBODIES LAB MANUA; HONEY NK, 1982, P NATL ACAD SCI-BIOL, V79, P7420, DOI 10.1073/pnas.79.23.7420; IHARA Y, 1993, J BIOCHEM-TOKYO, V113, P692, DOI 10.1093/oxfordjournals.jbchem.a124105; KETCHAM CM, 1992, J BIOL CHEM, V267, P11645; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG L, 1986, J BIOL CHEM, V261, P6320; LANG L, 1984, J BIOL CHEM, V259, P4663; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; REITMAN ML, 1981, J CLIN INVEST, V67, P1574, DOI 10.1172/JCI110189; REITMAN ML, 1981, J BIOL CHEM, V256, P4275; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; REITMAN ML, 1984, METHOD ENZYMOL, V107, P163; ROPP PA, 1990, ANAL BIOCHEM, V187, P104, DOI 10.1016/0003-2697(90)90424-8; SAITO H, 1994, BIOCHEM BIOPH RES CO, V198, P318, DOI 10.1006/bbrc.1994.1045; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHAILUBHAI K, 1988, J BIOL CHEM, V263, P15964; SHOWS TB, 1982, AM J MED GENET, V12, P343, DOI 10.1002/ajmg.1320120312; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITHIES O, 1971, BIOCHEMISTRY-US, V10, P4912, DOI 10.1021/bi00802a013; VARKI A, 1981, J BIOL CHEM, V256, P9937; VIJAY IK, 1977, J SUPRAMOL STR CELL, V7, P251, DOI 10.1002/jss.400070209; WAHEED A, 1982, J BIOL CHEM, V257, P2322; WAHEED A, 1981, J BIOL CHEM, V256, P5717; ZHAO KW, 1992, GLYCOBIOLOGY, V2, P119, DOI 10.1093/glycob/2.2.119	35	101	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31437	31445		10.1074/jbc.271.49.31437	http://dx.doi.org/10.1074/jbc.271.49.31437			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940155	hybrid			2022-12-27	WOS:A1996VW68600066
J	Jacobsen, L; Madsen, P; Moestrup, SK; Lund, AH; Tommerup, N; Nykjaer, A; SottrupJensen, L; Gliemann, J; Petersen, CM				Jacobsen, L; Madsen, P; Moestrup, SK; Lund, AH; Tommerup, N; Nykjaer, A; SottrupJensen, L; Gliemann, J; Petersen, CM			Molecular characterization of a novel human hybrid-type receptor that binds the alpha(2)-macroglobulin receptor-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; ALPHA-2-MACROGLOBULIN RECEPTOR; PLASMINOGEN-ACTIVATOR; CYTOPLASMIC DOMAIN; LIGAND-BINDING; CELL-ADHESION; GENE; INTERNALIZATION; SEQUENCE; MEGALIN	The 39-40-kDa receptor-associated protein (RAP) binds to the members of the low density lipoprotein receptor gene family and functions as a specialized endoplasmic reticulum/Golgi chaperone, Using RAP affinity chromatography, we have purified a novel similar to 250-kDa brain protein and isolated the corresponding cDNA. The gene, designated SORL1, maps to chromosome 11q 23/24 and encodes a 2214-residue type 1 receptor containing a furin cleavage site immediately preceding the N terminus determined in the purified protein. The receptor, designated sorLA-1, has a short cytoplasmic tail containing a tyrosine-based internalization signal and a large external part containing (from the N-terminal): 1) a segment homologous to domains in the yeast vacuolar protein sorting 10 protein, Vps10p, that binds carboxypeptidase Y, 2) five tandemly arranged YWTD repeats and a cluster of 11 class A repeats characteristic of the low density lipoprotein receptor gene family receptors, and 3) six tandemly arranged fibronectin type III repeats also found in certain neural adhesion proteins. sorLA-1 may therefore be classified as a hybrid receptor, Northern blotting revealed specific mRNA transcripts in brain, spinal cord, and testis but not in several major organs, Both RAP and an antibody against a synthetic peptide derived from a sequence determined in the mature protein detected sorLA-1 in crude human brain extracts. The domain structure suggests that sorLA-1 is an endocytic receptor possibly implicated in the uptake of lipoproteins and of proteases.	AARHUS UNIV,DEPT BIOL MOL & STRUCT,DK-8000 AARHUS C,DENMARK; UNIV COPENHAGEN,PANUM INST,DEPT MED GENET,DK-2200 COPENHAGEN N,DENMARK	Aarhus University; University of Copenhagen	Jacobsen, L (corresponding author), AARHUS UNIV,DEPT BIOCHEM MED,OLE WORMS ALLE,BLDG 170,DK-8000 AARHUS C,DENMARK.		Moestrup, Søren Kragh/A-1403-2014; Moestrup, Søren Kragh/AAD-1735-2019; Lund, Anders H./F-4786-2014; Tommerup, Niels/T-8776-2017	Moestrup, Søren Kragh/0000-0003-3862-2107; Lund, Anders H./0000-0002-7407-3398; Tommerup, Niels/0000-0003-2304-0112; Madsen, Peder Sondergaard/0000-0002-8845-4802; Nykjaer, Anders/0000-0001-6422-6736				ATHERTON D, 1993, ANAL BIOCHEM, V212, P98, DOI 10.1006/abio.1993.1297; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; BURGOON MP, 1995, J CELL BIOL, V130, P733, DOI 10.1083/jcb.130.3.733; DALY NL, 1995, P NATL ACAD SCI USA, V92, P6334, DOI 10.1073/pnas.92.14.6334; FARQUHAR MG, 1995, J AM SOC NEPHROL, V6, P35; FERNANDEZ J, 1992, ANAL BIOCHEM, V210, P265; HONORE B, 1993, J BIOCHEM BIOPH METH, V27, P39, DOI 10.1016/0165-022X(93)90066-W; Jingami Hisato, 1995, Current Opinion in Lipidology, V6, P104, DOI 10.1097/00041433-199504000-00008; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; NIELSEN MS, 1995, J BIOL CHEM, V270, P23713, DOI 10.1074/jbc.270.40.23713; Novak S, 1996, J BIOL CHEM, V271, P11732, DOI 10.1074/jbc.271.20.11732; Petersen CM, 1996, EMBO J, V15, P4165, DOI 10.1002/j.1460-2075.1996.tb00791.x; PRINCE JT, 1991, J NEUROSCI RES, V30, P567, DOI 10.1002/jnr.490300315; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; Schneider Wolfgang J., 1993, Current Opinion in Lipidology, V4, P205, DOI 10.1097/00041433-199306000-00005; SOTTRUPJENSEN L, 1995, ANAL BIOCHEM, V225, P187, DOI 10.1006/abio.1995.1137; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; TENSEN CP, 1994, P NATL ACAD SCI USA, V91, P4816, DOI 10.1073/pnas.91.11.4816; TOMMERUP N, 1995, GENOMICS, V27, P259, DOI 10.1006/geno.1995.1040; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827	31	201	210	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31379	31383		10.1074/jbc.271.49.31379	http://dx.doi.org/10.1074/jbc.271.49.31379			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940146	hybrid			2022-12-27	WOS:A1996VW68600057
J	Nielsen, AL; Norby, PL; Pedersen, FS; Jorgensen, P				Nielsen, AL; Norby, PL; Pedersen, FS; Jorgensen, P			E-box sequence and context-dependent TAL1/SCL modulation of basic helix-loop-helix protein-mediated transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL LEUKEMIA; DNA-BINDING MOTIF; SCL GENE-PRODUCT; ERYTHROID-DIFFERENTIATION; MYELOID DIFFERENTIATION; ENHANCER-BINDING; E2A PROTEINS; ID PROTEINS; IN-VIVO; EXPRESSION	TAL1/SCL is a basic helix-loop-helix (bHLH) oncoprotein that is expressed in several cell lines including many hematolymphoid cells, but not in T- and B-lineage cells. The TALI gene was originally discovered as being transcriptionally activated by chromosomal rearrangements in T-cell acute lymphoblastic leukemia (T-ALL). Here we have shown that TAL1 and the ubiquitously expressed murine bHLH transcription factor ALF1 formed heterodimers that, compared with ALF1 homodimers, had a more restricted E-box specificity and bound preferentially to the glucocorticoid-responsive E-box (E(gre)) motif (AACGATGGT). Overexpression of the dominant inhibitory HLH protein Id1 in NIH3T3 cells reduced the transcriptional activity mediated by ALF1 homodimers, whereas the transcriptional activity mediated by TAL1/ALF1 heterodimers was resistant to Id overexpression. Our results show that ALF1 may serve as a dimerization partner for the bHLH oncoprotein TAL1 and form a complex with a distinctive DNA binding property. These findings support the hypothesis that the leukemic characteristics of the TAL1 oncoprotein could be mediated by activation of a set of target genes as heterodimeric complexes with ubiquitously expressed bHLH transcription factors such as ALF1 and that a principal role of TAL1 might be to neutralize an Id-mediated inactivation.	AARHUS UNIV,DEPT MOL BIOL,DK-8000 AARHUS C,DENMARK; AARHUS UNIV,DEPT MED MICROBIOL & IMMUNOL,DK-8000 AARHUS C,DENMARK	Aarhus University; Aarhus University			Nielsen, Anders Lade L/Q-9604-2016	Nielsen, Anders Lade L/0000-0003-4372-9961				APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CORNELIUSSEN B, 1991, J VIROL, V65, P6084, DOI 10.1128/JVI.65.11.6084-6093.1991; DOYLE K, 1994, J BIOL CHEM, V269, P12099; FINKEL T, 1993, J BIOL CHEM, V268, P5; GOLDFARB AN, 1995, BLOOD, V85, P465; GOLEMIS EA, 1990, J VIROL, V64, P534, DOI 10.1128/JVI.64.2.534-542.1990; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; Hoang T, 1996, BLOOD, V87, P102; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; HWANG LY, 1993, ONCOGENE, V8, P3043; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Nielsen AL, 1996, J VIROL, V70, P5893, DOI 10.1128/JVI.70.9.5893-5901.1996; NIELSEN AL, 1992, MOL CELL BIOL, V12, P3449, DOI 10.1128/MCB.12.8.3449; NIELSEN AL, 1994, J VIROL, V68, P5638, DOI 10.1128/JVI.68.9.5638-5647.1994; PALLISGAARD N, 1994, GENE, V138, P115, DOI 10.1016/0378-1119(94)90791-9; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; SAWADA S, 1993, MOL CELL BIOL, V13, P5620, DOI 10.1128/MCB.13.9.5620; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SHOJI W, 1994, J BIOL CHEM, V269, P5078; SPECK NA, 1990, J VIROL, V64, P543, DOI 10.1128/JVI.64.2.543-550.1990; SPIRO C, 1988, VIROLOGY, V164, P350, DOI 10.1016/0042-6822(88)90548-X; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TANIGAWA T, 1993, P NATL ACAD SCI USA, V90, P7864, DOI 10.1073/pnas.90.16.7864; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VISVADER J, 1991, TRENDS BIOCHEM SCI, V16, P330, DOI 10.1016/0968-0004(91)90137-K; VORONOVA AF, 1994, P NATL ACAD SCI USA, V91, P5952, DOI 10.1073/pnas.91.13.5952; WADMAN IA, 1994, ONCOGENE, V9, P3713; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416; ZHANG Y, 1991, NUCLEIC ACIDS RES, V19, P4555, DOI 10.1093/nar/19.16.4555; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	47	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31463	31469		10.1074/jbc.271.49.31463	http://dx.doi.org/10.1074/jbc.271.49.31463			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940159	hybrid			2022-12-27	WOS:A1996VW68600070
J	OkudaAshitaka, E; Sakamoto, K; Ezashi, T; Miwa, K; Ito, S; Hayaishi, O				OkudaAshitaka, E; Sakamoto, K; Ezashi, T; Miwa, K; Ito, S; Hayaishi, O			Suppression of prostaglandin E receptor signaling by the variant form of EP(1) subtype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL TAIL; EXPRESSION CLONING; EP(3) RECEPTOR; MESSENGER-RNA; CDNA; PROTEIN; ISOFORMS; SEQUENCE; CELLS; INHIBITION	A cDNA clone of prostaglandin (PG) E receptor EP(1) subtype (rEP(1)) was isolated from a rat uterus cDNA library, It encodes 405 amino acid residues with seven transmembrane spanning domains and couples to Ca2+ mobilization, In addition, three cDNA clones encoding a variant form of rEP(1) were isolated, The open reading frame can code a 366-amino acid protein carrying a specific change of 49 amino acids from the middle of transmembrane segment VI to COOK terminus; it possesses a transmembrane segment VII-like structure lacking an intracellular COOK-terminal tail, Southern blot analysis of rat genomic DNA and genomic polymerase chain reaction demonstrated that these cDNAs were derived from a single copy gene, Northern blot analysis and ribonuclease protection assay revealed that both rEP(1) and rEP(1)-variant receptor mRNAs were highly expressed in the kidney, Immunoblot with an antibody directed toward the specific region of rEP(1)-variant receptor showed that rEP(1)-variant receptor protein was expressed in the membrane of the kidney and Chinese hamster ovary (CHO) cells transfected with rEP(1)-variant cDNA, Thus, the rEP(1)-variant receptor is translated from mRNA which is not spliced at nucleotide position 952 in the segment VI transmembrane region, rEP(1)-variant receptor retained the ligand binding activity with affinity and specificity similar to rEP(1) receptor, but lost the coupling of signal transduction systems by itself, However, when rEP(1)-variant receptor was stably co-expressed with rEP(1) receptor in CHO cells, the Ca2+ mobilization mediated by EP(1) receptor was significantly suppressed, Furthermore, when rEP(1)-variant receptor was expressed in CHO cells, cAMP formation by activation of endogenous EP(4) receptor was strongly blocked, These results suggest that the rEP(1)-variant receptor may affect the efficiency of signal coupling of PGE receptors and attenuate the action of PGE(2) on tissues.	OSAKA BIOSCI INST,DEPT CELL BIOL,SUITA,OSAKA 565,JAPAN; KANSAI MED UNIV,DEPT MED CHEM,MORIGUCHI,OSAKA 570,JAPAN	Kansai Medical University				ito, Seiji/0000-0002-0942-1624				ADAM M, 1994, FEBS LETT, V338, P170, DOI 10.1016/0014-5793(94)80358-7; BOIE Y, 1994, J BIOL CHEM, V269, P12173; BREYER RM, 1994, J BIOL CHEM, V269, P6163; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; COLEMAN RA, 1990, COMPREHENSIVE MED CH, V3, P643; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; FUNK CD, 1993, J BIOL CHEM, V268, P26767; FUNK CD, 1993, MOL PHARMACOL, V44, P934; HONDA A, 1993, J BIOL CHEM, V268, P7759; IRIE A, 1993, EUR J BIOCHEM, V217, P313, DOI 10.1111/j.1432-1033.1993.tb18248.x; KATOH H, 1995, BBA-GEN SUBJECTS, V1244, P41, DOI 10.1016/0304-4165(94)00182-W; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MARUYAMA K, 1994, 9 INT C PROST REL CO; MINAMI T, 1995, BRIT J PHARMACOL, V115, P73, DOI 10.1111/j.1476-5381.1995.tb16321.x; MIWA N, 1988, J NEUROCHEM, V50, P1418, DOI 10.1111/j.1471-4159.1988.tb03025.x; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAMBA T, 1994, J BIOL CHEM, V269, P9986; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NEGISHI M, 1987, J BIOL CHEM, V262, P12077; NUSING RM, 1993, J BIOL CHEM, V268, P25253; OKUDAASHITAKA E, 1990, EICOSANOIDS, V3, P213; REGAN JW, 1994, MOL PHARMACOL, V46, P213; SAKAI H, 1995, J BIOL CHEM, V270, P18781, DOI 10.1074/jbc.270.32.18781; SAKAMOTO K, 1994, J BIOL CHEM, V269, P3881; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMID A, 1995, EUR J BIOCHEM, V228, P23, DOI 10.1111/j.1432-1033.1995.tb20223.x; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SOMPAYRAC LM, 1981, P NATL ACAD SCI-BIOL, V78, P7575, DOI 10.1073/pnas.78.12.7575; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; TYKOCINSKI ML, 1988, P NATL ACAD SCI USA, V85, P3555, DOI 10.1073/pnas.85.10.3555; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; WATABE A, 1993, J BIOL CHEM, V268, P20175; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YAMASHITA M, 1991, P NATL ACAD SCI USA, V88, P11515, DOI 10.1073/pnas.88.24.11515	39	79	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31255	31261		10.1074/jbc.271.49.31255	http://dx.doi.org/10.1074/jbc.271.49.31255			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940129	hybrid			2022-12-27	WOS:A1996VW68600040
J	Shi, WX; Chammas, R; Varki, A				Shi, WX; Chammas, R; Varki, A			Regulation of sialic acid 9-O-acetylation during the growth and differentiation of murine erythroleukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-C-VIRUS; HUMAN-MELANOMA CELLS; HEPARAN-SULFATE PROTEOGLYCANS; O-ACETYL GROUPS; MONOCLONAL-ANTIBODY; 9-O-ACETYL-N-ACETYLNEURAMINIC ACID; LINKED OLIGOSACCHARIDES; HUMAN-LEUKOCYTES; SURFACE; GANGLIOSIDES	Sialic acids are typically found at the terminal position on vertebrate oligosaccharides. They are sometimes modified by an O-acetyl ester at the 9-position, potentially altering recognition of sialic acid by antibodies, lectins, and viruses, 9-O-Acetylation is known to be selectively expressed on gangliosides in melanoma cells and on N-linked chains in hepatocytes, Using a recently developed probe, we show here that in murine erythroleukemia cells, this modification is selectively expressed on another class of oligosaccharides, O-linked chains carried on cell surface sialomucins, These cells also express 9-O-acetylation on the ganglioside G(Da), but this modification appears to be undetectable on the cell surface, Increasing cell density in culture is associated with a decrease in cell surface 9-O-acetylation of sialomucins. This change correlates with the spontaneous differentiation toward a mature erythroid phenotype, This down-regulation upon differentiation and entry into the G(0)/G(1) stage of the cell cycle is confirmed by differentiation-inducing agents, In contrast, cells arrested in G(2)/M by the microtubule depolymerizing agent nocodazole show increased expression of cell surface 9-O-acetylated sialomucins (but not the 9-O-acetylated ganglioside), However, the microtubule stabilizer taxol does not induce this increase, showing that the nocodazole effect is independent of cell cycle stage, Indeed, direct analysis showed no correlation of 9-O-acetylation with cell cycle stage in rapidly growing cells, and shorter treatments with nocodazole also increased expression, Western blots of cell extracts confirmed that changes caused by differentiation and nocodazole are not due to redistribution of molecules from the cell surface, Indeed, follow ing selective removal of 9-O-acetyl groups from the cell surface by a specific esterase, the recovery of expression is mediated by new synthesis rather than by redistribution from an internal pool, Thus, 9-O-acetylation on these sialomucins appears to be primarily regulated by the rate of synthesis, and the increase with nocodazole treatment is likely due to the inhibition of turnover of cell surface molecules, These data show that 9-O-acetylation of sialic acids in murine erythroleukemia cells is a highly regulated modification, being selectively expressed in a cell type-specific manner on certain classes of oligosaccharides and differentially regulated with regard to subcellular localization and to the state of cellular differentiation.	UNIV CALIF SAN DIEGO,CTR CANC,GLYCOBIOL PROGRAM,DIV CELLULAR & MOL MED,LA JOLLA,CA 92093	University of California System; University of California San Diego			Chammas, Roger/A-8004-2011	Chammas, Roger/0000-0003-0342-8726	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA5869] Funding Source: Medline; NIGMS NIH HHS [R01-GM32373] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUM AS, 1987, P NATL ACAD SCI USA, V84, P8716, DOI 10.1073/pnas.84.23.8716; BUTOR C, 1993, J BIOL CHEM, V268, P10197; CHERESH DA, 1984, SCIENCE, V225, P844, DOI 10.1126/science.6206564; CHERESH DA, 1984, J BIOL CHEM, V259, P7453; CONSTANTINEPATON M, 1986, NATURE, V324, P459, DOI 10.1038/324459a0; CORFIELD AP, 1986, BIOL CHEM H-S, V367, P433, DOI 10.1515/bchm3.1986.367.1.433; DIAZ S, 1985, ANAL BIOCHEM, V150, P32, DOI 10.1016/0003-2697(85)90438-5; DOLCI ED, 1989, J CELL SCI, V93, P191; DRAZBA J, 1991, DEV BIOL, V145, P154, DOI 10.1016/0012-1606(91)90221-N; ELKJAER ML, 1995, EUR J CELL BIOL, V67, P57; FRASER IP, 1994, EUR J CELL BIOL, V64, P217; GOLTZ JS, 1992, P NATL ACAD SCI USA, V89, P7026, DOI 10.1073/pnas.89.15.7026; Guimaraes MJ, 1996, J BIOL CHEM, V271, P13697, DOI 10.1074/jbc.271.23.13697; JIN M, 1983, J BIOL CHEM, V268, P18390; KAMERLING JP, 1982, BIOCHIM BIOPHYS ACTA, V714, P351, DOI 10.1016/0304-4165(82)90344-0; KAMERLING JP, 1987, EUR J BIOCHEM, V162, P601, DOI 10.1111/j.1432-1033.1987.tb10681.x; KELM S, 1994, GLYCOCONJUGATE J, V11, P576, DOI 10.1007/BF00731309; KLEIN A, 1994, P NATL ACAD SCI USA, V91, P7782, DOI 10.1073/pnas.91.16.7782; KNIEP B, 1992, BIOCHEM BIOPH RES CO, V187, P1343, DOI 10.1016/0006-291X(92)90450-Y; KNIEP B, 1993, BLOOD, V82, P1776; KNIEP B, 1995, J BIOL CHEM, V270, P30173; KREIS TE, 1990, CELL MOTIL CYTOSKEL, V15, P67, DOI 10.1002/cm.970150202; LEVINE JM, 1984, J NEUROSCI, V4, P820; LLOYD KO, 1992, CANCER RES, V52, P4948; MANZI AE, 1990, J BIOL CHEM, V265, P13091; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MELLORS A, 1995, METHOD ENZYMOL, V248, P728; MISAWA Y, 1992, ONCOGENE, V7, P919; Morrison SJ, 1995, ANNU REV CELL DEV BI, V11, P35, DOI 10.1146/annurev.cb.11.110195.000343; MUCHMORE EA, 1987, SCIENCE, V236, P1293, DOI 10.1126/science.3589663; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; OKAYAMA M, 1991, J BIOL CHEM, V266, P3808; REUTER G, 1980, BIOCHEM BIOPH RES CO, V94, P567, DOI 10.1016/0006-291X(80)91269-3; ROGERS GN, 1986, J BIOL CHEM, V261, P5947; SARRIS AH, 1979, J BIOL CHEM, V254, P6724; SCHAUER R, 1991, Glycobiology, V1, P449, DOI 10.1093/glycob/1.5.449; Schauer R., 1982, CELL BIOL MONOGRAPHS, V10; SEN G, 1994, MOL CELL BIOCHEM, V136, P65, DOI 10.1007/BF00931606; Shi WX, 1996, J BIOL CHEM, V271, P31526, DOI 10.1074/jbc.271.49.31526; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; SJOBERG ER, 1995, J BIOL CHEM, V270, P2921, DOI 10.1074/jbc.270.7.2921; TAKEUCHI Y, 1992, J BIOL CHEM, V267, P14685; THURIN J, 1985, J BIOL CHEM, V260, P4556; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; VARKI A, 1980, J EXP MED, V152, P532, DOI 10.1084/jem.152.3.532; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; VLASAK R, 1987, VIROLOGY, V160, P419, DOI 10.1016/0042-6822(87)90013-4; WALLICK SC, 1988, J EXP MED, V168, P1099, DOI 10.1084/jem.168.3.1099; ZIMMER G, 1992, EUR J BIOCHEM, V204, P209, DOI 10.1111/j.1432-1033.1992.tb16626.x; ZIMMER G, 1994, GLYCOBIOLOGY, V4, P343, DOI 10.1093/glycob/4.3.343	52	32	32	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31517	31525		10.1074/jbc.271.49.31517	http://dx.doi.org/10.1074/jbc.271.49.31517			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940167	hybrid			2022-12-27	WOS:A1996VW68600078
J	Wright, DA; Futcher, B; Ghosh, P; Geha, RS				Wright, DA; Futcher, B; Ghosh, P; Geha, RS			Association of human Fas (CD95) with a ubiquitin-conjugating enzyme (UBC-FAP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CELL-DEATH; LYMPHOPROLIFERATIVE SYNDROME; S-PHASE; APOPTOSIS; PROTEIN; ANTIGEN; GENE; ACTIVATION; RECEPTOR	A novel human ubiquitin conjugating enzyme (UBC) was found to associate with Fas (CD95). The mRNA for this UBC Fas-associated protein (FAP) was widely expressed in human tissues, and the protein was identified in several mammalian cell lines, UBC-FAP shows strong homology to two recently identified UBCs, Hus5 and Ubc9, which control yeast cell cycle progression, UBC-FAP, but not an active site mutant, complemented ubc9-1(ts) mutants, This suggests that UBC-FAP is a human homologue of Ubc9, possesses ubiquitin conjugating activity, and may play an important role in mammalian cell cycle regulation, A single amino acid substitution in the death domain of Fas that abolishes Fas-mediated apoptosis also abolished Fas association with UBC-FAP, suggesting that UBC-FAP may play a role in Fas signal transduction, The sequence of UBC-FAP is identical to that of HsUbc9, a UBC recently shown to interact with Rad51.	CHILDRENS HOSP,DIV IMMUNOL,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Cold Spring Harbor Laboratory					NIAMS NIH HHS [AR-43985] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043985] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALKHODAIRY F, 1995, J CELL SCI, V108, P475; BISSONNETTE RP, 1994, J EXP MED, V180, P2413, DOI 10.1084/jem.180.6.2413; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cenciarelli C, 1996, J BIOL CHEM, V271, P8709, DOI 10.1074/jbc.271.15.8709; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CHU KT, 1995, P NATL ACAD SCI USA, V92, P11894, DOI 10.1073/pnas.92.25.11894; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; HANDLEYGEARHART PM, 1994, J BIOL CHEM, V269, P33171; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; PLON SE, 1993, P NATL ACAD SCI USA, V90, P10484, DOI 10.1073/pnas.90.22.10484; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; VACCA A, 1992, J EXP MED, V175, P637, DOI 10.1084/jem.175.3.637; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	38	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31037	31043		10.1074/jbc.271.49.31037	http://dx.doi.org/10.1074/jbc.271.49.31037			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940097	hybrid			2022-12-27	WOS:A1996VW68600008
J	Pollenz, RS; Sullivan, HR; Holmes, J; Necela, B; Peterson, RE				Pollenz, RS; Sullivan, HR; Holmes, J; Necela, B; Peterson, RE			Isolation and expression of cDNAs from rainbow trout (Oncorhynchus mykiss) that encode two novel basic helix-loop-helix/PER-ARNT-SIM (bHLH/PAS) proteins with distinct functions in the presence of the aryl hydrocarbon receptor - Evidence for alternative mRNA splicing and dominant negative activity in the bhlh/pas family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; MOUSE HEPATOMA-CELLS; AH-RECEPTOR; NUCLEAR TRANSLOCATOR; DIOXIN RECEPTOR; DNA RECOGNITION; MESSENGER-RNAS; TRANSCRIPTION FACTOR; TERMINAL DOMAINS; BINDING-SITE	cDNAs encoding two distinct basic helix-loop-helix/ PER-ARNT-SIM (bHLH/PAS) proteins with similarity to the mammalian aryl hydrocarbon nuclear translocator (ARNT) protein were isolated from RTG-2 rainbow trout gonad cells, The deduced proteins, termed rtARNT(a) and rtARNT(b), are identical over the first 533 amino acids and contain a basic helix-loop-helix domain that is 100% identical to human ARNT. rtARNT(a) and rtARNT(b) differ in their COOH terminal domains due to the presence of an additional 373 base pairs of sequence that have the characteristics of an alternatively spliced exon, The presence of the 373-base pair region causes a shift in the reading frame, rtARNT(b) lacks the sequence and has a COOH-terminal domain of 104 residues rich in proline, serine, and threonine. rtARNT, contains the sequence and has a COOH-terminal domain of 190 residues rich in glutamine and asparagine. mRNAs for both rtARNT splice variants were detected in RTG-2 gonad cells, trout liver, and gonad tissue, rtARNT(a) and rtARN(b), protein were identified in cell lysates from RTG-2 cells, Transfection of rtARNT expression vectors into murine Hepa-1 cells that are defective in ARNT function (type II) result in rtARNT protein expression localized to the nucleus. Treatment of these cells with 2,3,7,8-tetrachlo rodibenzo-p-dioxin results in a 20-fold greater induction of endogenous P4501A1 protein in cells expressing rtARNT(a) when compared with rtARNT(b), even though both proteins effectively dimerize with the aryl hydrocarbon receptor, The decreased function of rtARNT(a), appears to be due to inefficient binding of rtARNT(a) AHR complexes to DNA, In addition, the presence of rtARNT(a) can reduce the aryl hydrocarbon receptor-dependent function of rtARNT(b) in vivo and in vitro.	UNIV WISCONSIN, CTR ENVIRONM TOXICOL, MADISON, WI 53706 USA; UNIV WISCONSIN, SCH PHARM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Pollenz, RS (corresponding author), MED UNIV S CAROLINA, DEPT BIOCHEM & MOL BIOL, 171 ASHLEY AVE, CHARLESTON, SC 29425 USA.							ABBOTT BD, 1994, TOXICOL APPL PHARM, V126, P16, DOI 10.1006/taap.1994.1085; ANTONSSON C, 1995, J BIOL CHEM, V270, P13968, DOI 10.1074/jbc.270.23.13968; Bacsi SG, 1996, J BIOL CHEM, V271, P8843, DOI 10.1074/jbc.271.15.8843; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CARVER LA, 1994, NUCLEIC ACIDS RES, V22, P3038, DOI 10.1093/nar/22.15.3038; CHEVAILLIER P, 1993, INT J BIOCHEM, V25, P479, DOI 10.1016/0020-711X(93)90653-V; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; DOLWICK KM, 1993, MOL PHARMACOL, V44, P911; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GIANNONE JV, 1995, CAN J PHYSIOL PHARM, V73, P7, DOI 10.1139/y95-002; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HEIN J, 1990, METHOD ENZYMOL, V183, P626; Hirose K, 1996, MOL CELL BIOL, V16, P1706; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HORD NG, 1994, MOL PHARMACOL, V46, P618; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; JAIN S, 1994, J BIOL CHEM, V269, P31518; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEGRAVEREND C, 1982, J BIOL CHEM, V257, P6402; LEWIN B, 1994, RNA CATALYST, P941; LI H, 1994, J BIOL CHEM, V269, P28098; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; Ma Q, 1996, MOL CELL BIOL, V16, P2144; MILLER AG, 1983, J BIOL CHEM, V258, P3523; NAGATA Y, 1995, BIOCHEM BIOPH RES CO, V207, P916, DOI 10.1006/bbrc.1995.1273; NEGISHI M, 1993, J BIOL CHEM, V268, P9517; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PESCE S, 1993, MOL CELL BIOL, V13, P7874, DOI 10.1128/MCB.13.12.7874; PETERSON RE, 1993, CRIT REV TOXICOL, V23, P283, DOI 10.3109/10408449309105013; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1990, MOL PHARMACOL, V38, P306; POLAND A, 1994, MOL PHARMACOL, V46, P915; POLAND A, 1986, J BIOL CHEM, V261, P6352; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; Pollenz RS, 1996, MOL PHARMACOL, V49, P391; POLLENZ RS, 1996, ECL HIGHLIGHTS, V9, P2; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SHEN ES, 1992, J BIOL CHEM, V267, P6815; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; SWANSON HI, 1991, TOXICOL LETT, V58, P85, DOI 10.1016/0378-4274(91)90194-B; WALKER MK, 1991, AQUAT TOXICOL, V21, P219, DOI 10.1016/0166-445X(91)90074-J; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WATSON AJ, 1992, MOL CELL BIOL, V12, P2115, DOI 10.1128/MCB.12.5.2115; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8843; WHITLOCK JP, 1984, J BIOL CHEM, V259, P980; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003; ZABEL E, 1996, IN PRESS ENV TOXICOL, V125; ZACHARIAS DA, 1994, BIOTECHNIQUES, V17, P652	64	73	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30886	30896		10.1074/jbc.271.48.30886	http://dx.doi.org/10.1074/jbc.271.48.30886			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940073	hybrid			2022-12-27	WOS:A1996VV15800090
J	Qian, SW; Burmester, JK; Tsang, MLS; Weatherbee, JA; Hinck, AP; Ohlsen, DJ; Sporn, MB; Roberts, AB				Qian, SW; Burmester, JK; Tsang, MLS; Weatherbee, JA; Hinck, AP; Ohlsen, DJ; Sporn, MB; Roberts, AB			Binding affinity of transforming growth factor-beta for its type II receptor is determined by the C-terminal region of the molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC PROGENITOR CELLS; HUMAN ENDOTHELIAL-CELLS; EXPRESSION CLONING; CRYSTAL-STRUCTURE; 2 FORMS; ENDOGLIN; PROTEIN; SYSTEM; COMPLEX; LINES	Transforming growth factor-beta (TGF-beta) isoforms have differential binding affinities for the TGF-beta type II receptor (T beta RII). In most cells, TGF-beta 1 and TGF-beta 3 bind to T beta RII with much higher affinity than TGF-beta 2. Here, we report an analysis of the effect of TGF-beta structure on its binding to T beta RII by using TGF-beta mutants with domain deletions, amino acid replacements, and isoform chimeras, Examination of the binding of TGF-beta mutants to the recombinant extracellular domain of T beta RII by a solid-phase TGF-beta/T beta RII assay demonstrated that only those TGF-beta mutants containing the C terminus of TGF-beta 1 (TGF-beta 1-(Delta 69-73), TGF-beta 1-(Trp(71)), and TGF-beta 2/beta 1-(83-112)) bind with high affinity to T beta RII, similar to native TGF-beta 1. Moreover, replacement of only 6 amino acids in the C terminus of TGF-beta 1 with the corresponding sequence of TGF-beta 2 (TGF-beta 1/beta 2-(91-96)) completely eliminated the high affinity binding of TGF-beta 1. Proliferation of fetal bovine heart endothelial (FBHE) cells was inhibited to a similar degree by all of the TGF-beta mutants. However, recombinant soluble T beta RII blocked the inhibition of FBHE cell proliferation induced by TGF-beta mutants retaining the C terminus of TGF-beta 1, consistent with the high binding affinity between these TGF-beta molecules and T beta RII, It was further confirmed that the TGF-beta 2 mutant with its C terminus replaced by that of TGF-beta 1 (TGF-beta 2/beta 1-(83-112)) competed as effectively as TGF-beta 1 with I-125-TGF-beta 1 for binding to membrane T beta RI and T beta RII on FBHE cells. These observations clearly indicate that the domain in TGF-beta 1 responsible for its high affinity binding to T beta RII, both the soluble and membrane-bound forms, is located at C terminus of the molecule.	NCI,NIH,CHEMOPREVENT LAB,BETHESDA,MD 20892; MARSHFIELD MED RES FDN,MARSHFIELD,WI 54449; R&D SYST,MINNEAPOLIS,MN 55413; NIDR,NIH,STRUCT MOL BIOL UNIT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)				Hinck, Andrew/0000-0003-3320-8054				AMATAYAKULCHANTLER S, 1994, J BIOL CHEM, V269, P27687; ARCHER SJ, 1993, BIOCHEMISTRY-US, V32, P1164, DOI 10.1021/bi00055a022; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; BURMESTER JK, 1993, P NATL ACAD SCI USA, V90, P8628, DOI 10.1073/pnas.90.18.8628; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; DANIELPOUR D, 1989, J CELL PHYSIOL, V138, P79, DOI 10.1002/jcp.1041380112; Danielpour D, 1989, GROWTH FACTORS, V2, P61, DOI 10.3109/08977198909069082; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; FLANDERS KC, 1991, DEVELOPMENT, V113, P183; FLANDERS KC, 1988, BIOCHEMISTRY-US, V27, P739, DOI 10.1021/bi00402a037; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Griffith DL, 1996, P NATL ACAD SCI USA, V93, P878, DOI 10.1073/pnas.93.2.878; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; JENNINGS JC, 1988, J CELL PHYSIOL, V137, P167, DOI 10.1002/jcp.1041370120; KENNEY WC, 1994, J BIOL CHEM, V269, P12351; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIN HY, 1995, J BIOL CHEM, V270, P2747, DOI 10.1074/jbc.270.6.2747; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MASSAGUE J, 1992, MOL REPROD DEV, V32, P99, DOI 10.1002/mrd.1080320204; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; MERWIN JR, 1991, AM J PATHOL, V138, P37; MOREN A, 1992, BIOCHEM BIOPH RES CO, V189, P356, DOI 10.1016/0006-291X(92)91566-9; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; OGAWA Y, 1992, J BIOL CHEM, V267, P2325; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; OTTMANN OG, 1988, J IMMUNOL, V140, P2661; POSTLETHWAITE AE, 1995, J CELL PHYSIOL, V164, P587, DOI 10.1002/jcp.1041640317; QIAN SW, 1992, P NATL ACAD SCI USA, V89, P6290, DOI 10.1073/pnas.89.14.6290; QIAN SW, 1994, BIOCHEMISTRY-US, V33, P12298, DOI 10.1021/bi00206a037; ROBERTS AB, 1992, GROWTH FACTORS, V8, P1; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; RODRIGUEZ C, 1995, J BIOL CHEM, V270, P15919, DOI 10.1074/jbc.270.27.15919; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; STJACQUES S, 1994, BIOL REPROD, V51, P405, DOI 10.1095/biolreprod51.3.405; SUARDET L, 1992, CANCER RES, V52, P3705; SUN LZ, 1994, J BIOL CHEM, V269, P26449; TSANG MLS, 1995, CYTOKINE, V7, P389, DOI 10.1006/cyto.1995.0054; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WEBB DJ, 1994, J BIOL CHEM, V269, P30402; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	54	55	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30656	30662		10.1074/jbc.271.48.30656	http://dx.doi.org/10.1074/jbc.271.48.30656			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940041	hybrid			2022-12-27	WOS:A1996VV15800058
J	Yokote, K; Margolis, B; Heldin, CH; ClaessonWelsh, L				Yokote, K; Margolis, B; Heldin, CH; ClaessonWelsh, L			Grb7 is a downstream signaling component of platelet-derived growth factor alpha- and beta-receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2 DOMAIN PROTEINS; PHOSPHOLIPASE C-GAMMA-1; KINASE-ACTIVITY; PDGF RECEPTOR; BINDING; TRANSDUCTION; CLONING; FAMILY; IDENTIFICATION; ESTABLISHES	Ligand stimulation of the platelet-derived growth factor (PDGF) alpha- or beta-receptors leads to activation of their intrinsic tyrosine kinases and autophosphorylation of tyrosine residues. Grb7 is an SH2 and PH domain-con taining molecule that is known to be overexpressed in some breast cancer tissues and cell lines. Here we show that the SH2 domain of Grb7 can directly bind to the autophosphorylated PDGF beta-receptor in vitro, Grb7 association to the PDGF beta-receptor was dramatically reduced by replacement of tyrosine residues 716 or 775 with phenylalanine residues. Synthetic phosphorylated peptides containing Tyr-716 or Tyr 775 inhibited binding of the Grb7 SH2 domain to the autophosphorylated PDGF beta receptor in a manner similar to but distinct from the binding of the Grb2 SH2 domain. Grb7 associated with activated PDGF beta-receptors in vivo, and the association was dramatically reduced by substitution of Tyr-716 or Tyr-775 with a phenylalanine residue, Furthermore, complex formation between She and Grb7 was observed after ligand stimulation of PDGF alpha- or beta-receptors in cells transfected with Grb7 cDNA or in the breast cancer cell line BT-474. Thus, Grb7 is implicated in PDGF signaling pathways in certain cell types by binding to the receptor directly or indirectly via She.	LUDWIG INST CANC RES, CTR BIOMED, S-75124 UPPSALA, SWEDEN; UNIV MICHIGAN, SCH MED, DEPT INTERNAL MED & BIOCHEM, ANN ARBOR, MI 48109 USA	Ludwig Institute for Cancer Research; University of Michigan System; University of Michigan								ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; ERIKSSON A, 1995, J BIOL CHEM, V270, P7773, DOI 10.1074/jbc.270.13.7773; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; KARLSSON T, 1995, ONCOGENE, V10, P1475; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LAROSE L, 1993, ONCOGENE, V8, P2493; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MARGOLIS B, 1994, PROG BIOPHYS MOL BIO, V62, P223, DOI 10.1016/0079-6107(94)90013-2; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MORI S, 1994, J BIOL CHEM, V269, P4917; OOI J, 1995, ONCOGENE, V10, P1621; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; RUPP E, 1994, EUR J BIOCHEM, V225, P29, DOI 10.1111/j.1432-1033.1994.00029.x; SALCINI AE, 1994, ONCOGENE, V9, P2827; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; STEIN J, 1991, ONCOGENE, V6, P601; TAVERNA D, 1991, CELL GROWTH DIFFER, V2, P145; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1995, MOL CELL BIOL, V15, P3058; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; Yokote K, 1996, J BIOL CHEM, V271, P5101; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	33	64	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30942	30949		10.1074/jbc.271.48.30942	http://dx.doi.org/10.1074/jbc.271.48.30942			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940081	hybrid			2022-12-27	WOS:A1996VV15800098
J	Alam, KY; Frostholm, A; Hackshaw, KV; Evans, JE; Rotter, A; Chiu, IM				Alam, KY; Frostholm, A; Hackshaw, KV; Evans, JE; Rotter, A; Chiu, IM			Characterization of the 1B promoter of fibroblast growth factor 1 and its expression in the adult and developing mouse brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; FACTOR MESSENGER-RNA; FACTOR FAMILY; RAT-BRAIN; BACTERIOPHAGE-P1 SYSTEM; NUCLEOTIDE-SEQUENCE; FGF-RECEPTOR; ACIDIC FGF; FACTOR-I; CLONING	The present study elucidates the molecular structure of a murine fibroblast growth factor 1 (FGF-1) promoter and describes its distribution in the adult and developing mouse brain, A cDNA clone coding for FGF-1 was isolated from a mouse brain cDNA library. Nucleotide sequence analysis revealed that the clone contained, in addition to the protein coding region, an untranslated exon (FGF-1B) 34 base pairs upstream of the translation start codon ATG. The mouse cDNA clone corresponded to the sole FGF-1 transcript in the brain. An RNase protection assay was used to map the transcription start site of the 1B promoter. The sequences upstream from the major transcription initiation site lacked consensus TATA or CAAT boxes, In situ hybridization with cRNA probes specific for the 1B transcript showed the message to be restricted largely to sensory and motor nuclei in the brainstem, and to the ventral spinal cord and cerebellum, Although occasional brainstem nuclei were labeled at low levels by embryonic day 18, the majority of nuclei became detectable autoradiographically during postnatal weeks 1 and 2, and adult levels of grain density were reached during the 3rd and 4th postnatal weeks. FGF-1B mRNA was expressed in phylogenetically older brain regions, which are involved primarily in processing information from exteroceptive sensory mechanoreceptors and in motor control. The relatively late developmental expression suggests a role for FGF-1 in neuronal maturation, rather than in neurogenesis.	OHIO STATE UNIV, DEPT INTERNAL MED, COLL MED, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DEPT PHARMACOL, COLL MED, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University			Chiu, Ing-Ming/B-1534-2008		NIAID NIH HHS [K11 AI01048] Funding Source: Medline; NINDS NIH HHS [R01 NS18089, R01 NS32276] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K11AI001048] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018089, R01NS032276] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTERIO J, 1988, FEBS LETT, V242, P41, DOI 10.1016/0014-5793(88)80981-5; Ausubel FM, 1988, MOL REPROD DEV; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BESNARD F, 1989, INT J DEV NEUROSCI, V7, P401, DOI 10.1016/0736-5748(89)90061-0; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CADAY CG, 1990, DEV BRAIN RES, V52, P241, DOI 10.1016/0165-3806(90)90240-Y; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU IM, 1990, ONCOGENE, V5, P755; CHOTANI MA, 1995, NUCLEIC ACIDS RES, V23, P434, DOI 10.1093/nar/23.3.434; CORDEIRO PG, 1989, PLAST RECONSTR SURG, V83, P1013, DOI 10.1097/00006534-198906000-00014; DAVIS JB, 1990, J CELL BIOL, V110, P1353, DOI 10.1083/jcb.110.4.1353; ELDE R, 1991, NEURON, V7, P349, DOI 10.1016/0896-6273(91)90288-B; Fallon JH, 1992, GROWTH FACTORS, V6, P139; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; GOODRICH SP, 1989, NUCLEIC ACIDS RES, V17, P2867, DOI 10.1093/nar/17.7.2867; GOSPODAROWICZ D, 1987, METHOD ENZYMOL, V147, P106; HALLEY C, 1988, NUCLEIC ACIDS RES, V16, P10913, DOI 10.1093/nar/16.22.10913; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; HEUER JG, 1990, NEURON, V5, P283, DOI 10.1016/0896-6273(90)90165-C; KUZIS K, 1995, J COMP NEUROL, V358, P142, DOI 10.1002/cne.903580109; LIPTON SA, 1988, P NATL ACAD SCI USA, V85, P2388, DOI 10.1073/pnas.85.7.2388; LORET C, 1989, J BIOL CHEM, V264, P8319; LUNTZLEYBMAN V, 1993, MOL BRAIN RES, V19, P9, DOI 10.1016/0169-328X(93)90143-D; MATTSON MP, 1989, J NEUROSCI, V9, P3728; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MYERS RL, 1995, ONCOGENE, V11, P785; MYERS RL, 1995, J BIOL CHEM, V270, P8257, DOI 10.1074/jbc.270.14.8257; MYERS RL, 1993, ONCOGENE, V8, P341; NIETOSAMPEDRO M, 1988, NEUROSCI LETT, V86, P361, DOI 10.1016/0304-3940(88)90511-3; OELLIG C, 1995, EUR J NEUROSCI, V7, P863, DOI 10.1111/j.1460-9568.1995.tb01073.x; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PAYSON RA, 1993, NUCLEIC ACIDS RES, V21, P489, DOI 10.1093/nar/21.3.489; PIERCE JC, 1992, METHOD ENZYMOL, V216, P549; PIERCE JC, 1992, MAMM GENOME, V3, P550, DOI 10.1007/BF00350620; PIERCE JC, 1992, P NATL ACAD SCI USA, V89, P2056, DOI 10.1073/pnas.89.6.2056; POULIN ML, 1995, DEV DYNAM, V202, P378, DOI 10.1002/aja.1002020407; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; RYDEL RE, 1987, J NEUROSCI, V7, P3639; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STOCK A, 1992, J NEUROSCI, V12, P4688; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; UNSICKER K, 1987, P NATL ACAD SCI USA, V84, P5459, DOI 10.1073/pnas.84.15.5459; WALICKE PA, 1988, DEV BRAIN RES, V40, P71, DOI 10.1016/0165-3806(88)90009-0; WANAKA A, 1990, NEURON, V5, P267, DOI 10.1016/0896-6273(90)90164-B; WANG WP, 1989, MOL CELL BIOL, V9, P2387, DOI 10.1128/MCB.9.6.2387; WILCOX BJ, 1991, NEURON, V6, P397, DOI 10.1016/0896-6273(91)90248-X; WU DK, 1988, J CELL PHYSIOL, V136, P367, DOI 10.1002/jcp.1041360222	49	38	43	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30263	30271		10.1074/jbc.271.47.30263	http://dx.doi.org/10.1074/jbc.271.47.30263			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939980	hybrid			2022-12-27	WOS:A1996VU52500108
J	Jin, MJ; Saucan, L; Farquhar, MG; Palade, GE				Jin, MJ; Saucan, L; Farquhar, MG; Palade, GE			Rab1a and multiple other Rab proteins are associated transcytotic pathway in rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEINS; POLYMERIC IGA RECEPTOR; TRANS-GOLGI NETWORK; ZYMOGEN GRANULE MEMBRANES; ENDOPLASMIC-RETICULUM; EPITHELIAL-CELLS; PLASMA-MEMBRANE; MEDIATED ENDOCYTOSIS; VESICULAR TRANSPORT; IMMUNOELECTRON MICROSCOPY	To better understand the function of Rab1a, we have immunoisolated Rab1a-associated transport vesicles from rat liver using affinity-purified anti-Rab1a-coated magnetic beads. A fraction enriched in endoplasmic reticulum (ER) to Golgi transport vesicles (CV2, rho = 1.158) was subjected to immunoisolation, and proteins of the bound and non-bound subfractions were analyzed by Western blotting. To our surprise, we found that immunoisolated vesicles contained not only ER markers (105-kDa form of the polymeric IgA receptor (pIgAR)) but also transcytotic markers (dIgA and the 120-kDa form of pIgAR), suggesting that Rab1a is associated with transcytotic vesicles in rat liver. To investigate this possibility, we used an antibody to the cytoplasmic domain of pIgAR to immunoisolate transcytotic vesicles from a fraction (CV1, rho = 1.146) known to be enriched in these vesicles, Rab1a was detected in the immunoadsorbed subfractions. The composition of the vesicles immunoisolated from the CV1 fraction on anti-Rab1a was similar to that of transcytotic vesicles immunoisolated from the same fraction on pIgAR. Both were enriched in transcytotic markers and depleted in ER and Golgi markers. The main difference between the two was that those isolated on anti-Rab1a appeared to be enriched in post-endosomal transcytotic vesicles, whereas those isolated on pIgAR contained both pre- and postendosomal elements. Analysis of anti-Rab1a isolated vesicles using [alpha-P-32]GTP overlay demonstrated the presence of multiple GTP-binding proteins. Some of these were identified by immunoblotting as epithelia-specific Rab17 and ubiquitous Rabs1b, -2, and -6. Taken together, these results indicate that: 1) Rab1a is associated with both ER to Golgi and postendosomal transcytotic vesicles, and 2) multiple GTP-binding proteins are associated with each class of isolated vesicle.	UNIV CALIF SAN DIEGO, DIV CELL & MOL MED, SAN DIEGO, CA 92103 USA; UNIV CALIF SAN DIEGO, DEPT PATHOL, SAN DIEGO, CA 92103 USA; UNIV CALIF SAN DIEGO, DEPT MED, SAN DIEGO, CA 92103 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NCI NIH HHS [CA58689] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BARR VA, 1993, GASTROENTEROLOGY, V105, P554, DOI 10.1016/0016-5085(93)90734-T; BARR VA, 1995, J BIOL CHEM, V270, P27834, DOI 10.1074/jbc.270.46.27834; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BARTLES JR, 1988, TRENDS BIOCHEM SCI, V13, P181, DOI 10.1016/0968-0004(88)90147-8; Bollag D. M., 1991, PROTEIN METHODS, P161; BOMSEL M, 1989, J CELL BIOL, V109, P3243, DOI 10.1083/jcb.109.6.3243; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BUCCI C, 1988, NUCLEIC ACIDS RES, V16, P9979, DOI 10.1093/nar/16.21.9979; BUCCI C, 1994, P NATL ACAD SCI USA, V91, P5061, DOI 10.1073/pnas.91.11.5061; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1992, GENE, V112, P261, DOI 10.1016/0378-1119(92)90387-5; CORMONT M, 1993, J BIOL CHEM, V268, P19491; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; FARNSWORTH CC, 1994, P NATL ACAD SCI USA, V91, P11963, DOI 10.1073/pnas.91.25.11963; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; GEUZE HJ, 1984, CELL, V37, P195, DOI 10.1016/0092-8674(84)90315-5; GEUZE HJ, 1983, EUR J CELL BIOL, V32, P38; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; HOPPE CA, 1985, J CELL BIOL, V101, P2113, DOI 10.1083/jcb.101.6.2113; HOWELL KE, 1988, CELL FREE ANAL MEMBR, P77; HUBER LA, 1993, J CELL BIOL, V123, P47, DOI 10.1083/jcb.123.1.47; HUBER LA, 1994, P NATL ACAD SCI USA, V91, P7874, DOI 10.1073/pnas.91.17.7874; JENA BP, 1994, J CELL BIOL, V124, P43, DOI 10.1083/jcb.124.1.43; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; LAMBERT M, 1990, FEBS LETT, V271, P19, DOI 10.1016/0014-5793(90)80362-M; LARKIN JM, 1986, P NATL ACAD SCI USA, V83, P4759, DOI 10.1073/pnas.83.13.4759; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; LUTCKE A, 1993, J CELL BIOL, V121, P553, DOI 10.1083/jcb.121.3.553; LUTCKE A, 1994, J CELL SCI, V107, P3437; MCCAFFERY JM, 1995, METHOD ENZYMOL, V257, P259; MUELLER SC, 1986, J CELL BIOL, V102, P932, DOI 10.1083/jcb.102.3.932; NICKEL W, 1994, J CELL BIOL, V125, P721, DOI 10.1083/jcb.125.4.721; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; OLKKONEN VM, 1993, J CELL SCI, V106, P1249; PADFIELD PJ, 1991, BIOCHEM BIOPH RES CO, V174, P600, DOI 10.1016/0006-291X(91)91459-P; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; PETER F, 1994, J CELL BIOL, V126, P1393, DOI 10.1083/jcb.126.6.1393; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; SARASTE J, 1995, J CELL SCI, V108, P1541; SAUCAN L, 1994, J CELL BIOL, V125, P733, DOI 10.1083/jcb.125.4.733; SCHNEFEL S, 1992, Cellular Physiology and Biochemistry, V2, P77, DOI 10.1159/000154628; SMELAND TE, 1994, P NATL ACAD SCI USA, V91, P10712, DOI 10.1073/pnas.91.22.10712; SZTUL E, 1991, CELL, V64, P81, DOI 10.1016/0092-8674(91)90210-P; SZTUL ES, 1985, J CELL BIOL, V100, P1248, DOI 10.1083/jcb.100.4.1248; SZTUL ES, 1985, J CELL BIOL, V100, P1255, DOI 10.1083/jcb.100.4.1255; SZTUL ES, 1983, J CELL BIOL, V97, P1582, DOI 10.1083/jcb.97.5.1582; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; TOUCHOT N, 1989, FEBS LETT, V256, P79, DOI 10.1016/0014-5793(89)81722-3; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WALL DA, 1985, J CELL BIOL, V101, P2104, DOI 10.1083/jcb.101.6.2104; WEBER E, 1994, J CELL BIOL, V125, P583, DOI 10.1083/jcb.125.3.583; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P1294; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	68	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30105	30113		10.1074/jbc.271.47.30105	http://dx.doi.org/10.1074/jbc.271.47.30105			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939959	hybrid			2022-12-27	WOS:A1996VU52500087
J	Kang, C; Kim, S; Fromm, HJ				Kang, C; Kim, S; Fromm, HJ			Subunit complementation of Escherichia coli adenylosuccinate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ACTIVE-SITE; CHEMICAL MODIFICATION; THYMIDYLATE SYNTHASE; CONSENSUS SEQUENCE; BINDING-SITE; PROTEINS; IDENTIFICATION; SPECIFICITY; MUTANTS	Data are presented, based upon subunit complementation experiments, that suggest that Escherichia coli adenylosuccinate synthetase contains two shared active sites between its dimeric interface, This conclusion was alluded to by use of mutant forms of adenylosuccinate synthetase previously prepared by site-directed mutagenesis, The experiments indicate that, although the R143L and D13A mutants have low or no activity independently, when they are mixed, a significant amount of activity was obtained, These results indicate that the subunits exchange with each other to form heterodimers with a single viable wild-type active site, The k(cat) value for the active hybrid active site in the R143L-D13A heterodimer is virtually identical to that observed with the wild-type enzyme, and the other kinetic parameters are very similar to those found for the wild-type enzyme, An analysis of the restoration of the activity in the presence of substrates suggests that GTP and IMP stabilize the dimeric structure of the protein, A comparison of the restoration of the activity using different combinations of mutants provides evidence indicating that some of the GTP binding elements, including the P-loop, in the protein are important for subunit integrity, Also, for the first time, a comprehensive analysis of subunit complementation is performed for the two inactive mutants (R143L and D13A) where the dissociation constants for the R143L-D13A heterodimer and the D13A homodimer were determined to be 21 and 2.9 mu M, respectively, A concentration dependence of the specific activity of the wild-type protein in this study shows that the K-d for dimer dissociation is approximately 1 mu M.	IOWA STATE UNIV,DEPT BIOCHEM & BIOPHYS,AMES,IA 50011	Iowa State University					NINDS NIH HHS [NS 10546] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARNARA AS, 1974, EUR J BIOCHEM, V41, P421; BASS MB, 1987, ARCH BIOCHEM BIOPHYS, V256, P335, DOI 10.1016/0003-9861(87)90454-1; CASHEL M, 1975, ANNU REV MICROBIOL, V29, P301, DOI 10.1146/annurev.mi.29.100175.001505; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DISTEFANO MD, 1990, BIOCHEMISTRY-US, V29, P2703, DOI 10.1021/bi00463a013; DONG Q, 1991, J BIOL CHEM, V266, P12228; DONG Q, 1990, J BIOL CHEM, V265, P6235; HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389; KANG C, 1994, J BIOL CHEM, V269, P24046; KANG CH, 1994, ARCH BIOCHEM BIOPHYS, V310, P475, DOI 10.1006/abbi.1994.1195; KANG CH, 1995, J BIOL CHEM, V270, P15539, DOI 10.1074/jbc.270.26.15539; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARIMER FW, 1987, J BIOL CHEM, V262, P15327; LIU F, 1992, J BIOL CHEM, V267, P2388; MANFREDI JP, 1989, AM J PHYSIOL, V257, pC29, DOI 10.1152/ajpcell.1989.257.1.C29; MATSUDA Y, 1982, CANCER RES, V42, P112; Moe OA, 1996, BIOCHEMISTRY-US, V35, P9024, DOI 10.1021/bi960426j; MONACO HL, 1978, P NATL ACAD SCI USA, V75, P5276, DOI 10.1073/pnas.75.11.5276; POLAND BW, 1993, J BIOL CHEM, V268, P25334; POOKANJANATAVIP M, 1992, BIOCHEMISTRY-US, V31, P10303, DOI 10.1021/bi00157a018; RUDOLPH FB, 1971, THESIS IOWA STATE U; SCHULZ GE, 1978, NATURE, V273, P120, DOI 10.1038/273120a0; SILVA MM, 1995, J MOL BIOL, V254, P431, DOI 10.1006/jmbi.1995.0629; SPECTOR T, 1979, J BIOL CHEM, V254, P8422; STAYTON MM, 1983, CURR TOP CELL REGUL, V22, P103; WENTE SR, 1987, P NATL ACAD SCI USA, V84, P31, DOI 10.1073/pnas.84.1.31; WOLFE SA, 1988, J BIOL CHEM, V263, P19147; ZEIDLER R, 1993, J BIOL CHEM, V268, P20191	29	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29722	29728		10.1074/jbc.271.47.29722	http://dx.doi.org/10.1074/jbc.271.47.29722			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939906	hybrid			2022-12-27	WOS:A1996VU52500034
J	Kokame, K; Kato, H; Miyata, T				Kokame, K; Kato, H; Miyata, T			Homocysteine-respondent genes in vascular endothelial cells identified by differential display analysis - GRP78/BiP and novel genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC MESSENGER-RNA; PROTEIN-C ACTIVATION; RISK FACTOR; ATHEROGENIC STIMULUS; TRANSCRIPTION FACTOR; NUCLEOTIDE-SEQUENCE; THROMBOGENIC AGENT; NORMAL FIBROBLASTS; DISEASE; EXPRESSION	An elevated blood level of homocysteine is associated with arteriosclerosis and thrombosis. The mechanisms by which homocysteine may promote vascular diseases have not been elucidated yet, In the present study, we have applied a modified nonradioactive differential display analysis to evaluate changes in gene expression induced by homocysteine treatment of cultured human umbilical vein endothelial cells (HUVEC). We identified six up-regulated and one down-regulated genes. One up-regulated gene was GRP78/BiP, a stress protein, suggesting that misfolded proteins would accumulate in the endoplasmic reticulum because of redox potential changes caused by homocysteine. Another up-regulated gene encoded a bifunctional enzyme with activities of methylenetetrahydrofolate dehydrogenase and methenyltetrahydrofolate cyclohydrolase, which is involved in a homocysteine metabolism, A third up-regulated gene encoded activating transcription factor 4, and a fourth was a gene whose function is not identified yet. The remaining three were novel genes, We isolated a full-length cDNA of one of the up-regulated genes from a HUVEC library, It encoded a novel protein with 394 amino acids, which was termed reducing agents and tunicamycin-responsive protein (RTP). Northern blot analysis revealed that RTP gene expression was induced in HUVEC after 4 h incubation with homocysteine. RTP mRNA was also observed in unstimulated cells and induced by not only homocysteine but also S-mercaptoethanol and tunicamycin. The mRNA was ubiquitously expressed in human tissues, These observations indicate that homocysteine can alter the expressivity of multiple genes, including a stress protein and several novel genes. These responses may contribute to atherogenesis.			Kokame, K (corresponding author), NATL CARDIOVASC CTR,RES INST,FUJISHIRODAI 5-7-1,SUITA,OSAKA 565,JAPAN.			Kokame, Koichi/0000-0002-9654-6299				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; DEGROOT PG, 1983, EUR J CLIN INVEST, V13, P405, DOI 10.1111/j.1365-2362.1983.tb00121.x; ESTES SD, 1995, EXP CELL RES, V220, P47, DOI 10.1006/excr.1995.1290; EWADH MJA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P263, DOI 10.1016/0167-4889(90)90097-W; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; FRYER RH, 1993, ARTERIOSCLER THROMB, V13, P1327, DOI 10.1161/01.ATV.13.9.1327; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HAJJAR KA, 1993, J CLIN INVEST, V91, P2873, DOI 10.1172/JCI116532; HARPEL PC, 1992, P NATL ACAD SCI USA, V89, P10193, DOI 10.1073/pnas.89.21.10193; HAYASHI T, 1992, BLOOD, V79, P2930; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LENTZ SR, 1993, BLOOD, V81, P683; LENTZ SR, 1991, J CLIN INVEST, V88, P1906, DOI 10.1172/JCI115514; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; McCully KS, 1996, NAT MED, V2, P386, DOI 10.1038/nm0496-386; Mudd Sh, 1989, METABOLIC BASIS INHE, V1, P693; NISHINAGA M, 1993, J CLIN INVEST, V92, P1381, DOI 10.1172/JCI116712; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; OLDEN K, 1979, P NATL ACAD SCI USA, V76, P791, DOI 10.1073/pnas.76.2.791; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERI KG, 1989, NUCLEIC ACIDS RES, V17, P8853, DOI 10.1093/nar/17.21.8853; POUYSSEGUR J, 1977, CELL, V11, P941, DOI 10.1016/0092-8674(77)90305-1; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; REES MM, 1993, THROMB RES, V71, P337, DOI 10.1016/0049-3848(93)90160-P; RESENDEZ E, 1985, MOL CELL BIOL, V5, P1212, DOI 10.1128/MCB.5.6.1212; RODGERS GM, 1986, J CLIN INVEST, V77, P1909, DOI 10.1172/JCI112519; RODGERS GM, 1990, BLOOD, V75, P895; ROLL DE, 1991, MOL CELL BIOCHEM, V103, P141; TING J, 1988, DNA-J MOLEC CELL BIO, V7, P275, DOI 10.1089/dna.1988.7.275; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; TSUJIMOTO A, 1991, J VIROL, V65, P1420, DOI 10.1128/JVI.65.3.1420-1426.1991; UELAND PM, 1989, J LAB CLIN MED, V114, P473; WANG J, 1992, ATHEROSCLEROSIS, V97, P97, DOI 10.1016/0021-9150(92)90055-L; WHELAN SA, 1985, J CELL PHYSIOL, V125, P251, DOI 10.1002/jcp.1041250212; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YANG XM, 1993, BIOCHEMISTRY-US, V32, P1118, DOI 10.1021/bi00092a022	39	289	315	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29659	29665		10.1074/jbc.271.47.29659	http://dx.doi.org/10.1074/jbc.271.47.29659			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939898	hybrid			2022-12-27	WOS:A1996VU52500026
J	Lenka, N; Basu, A; Mullick, J; Avadhani, NG				Lenka, N; Basu, A; Mullick, J; Avadhani, NG			The role of an E box binding basic helix loop helix protein in the cardiac muscle-specific expression of the rat cytochrome oxidase subunit VIII gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ACTIN PROMOTER; C-OXIDASE; DNA-BINDING; IV GENE; STRUCTURAL ORGANIZATION; TRANSCRIPTION FACTORS; NUCLEOTIDE-SEQUENCE; BOVINE GENE; ACTIVATION; ELEMENTS	We have characterized the rat gene for muscle-specific cytochrome oxidase VIII (COX VIII(H)) and mapped the distal promoter region responsible for transcription activation in C2C12 skeletal myocytes and H9C2 cardiomyocytes. In both cell types, the promoter elements responding to the induced differentiation of myocytes map to two E boxes, designated as El and E2 boxes with a core sequence of CAGCTG. Gel mobility shift analysis showed that both El and E2 box motifs form complexes with nuclear extracts from H9C2 cardiomyocytes that were supershifted with monoclonal antibody to E2A but not with antibody to myo-D. Extracts from induced and uninduced H9C2 cardiomyocytes yielded different gel mobility patterns and also different E2A antibody supershifts suggesting a difference in the DNA-bound protein complexes cross-reacting with the E2A antibody. Transcriptional activity of the promoter construct containing intact E boxes was inhibited by coexpression with Id in differentiated H9C2 cardiomyocytes. Our results show the involvement of an E box binding basic helix loop helix protein in the cardiac muscle-specific regulation of the COX VIII(H) promoter.	UNIV PENN,SCH VET MED,DEPT ANIM BIOL,BIOCHEM LAB,PHILADELPHIA,PA 19104	University of Pennsylvania					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049683] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-49683] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMACHER SL, 1993, MOL CELL BIOL, V13, P2757; BASU A, 1993, J BIOL CHEM, V268, P4188; BASU A, 1991, J BIOL CHEM, V266, P15450; Basu A., UNPUB; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CARTER RS, 1992, J BIOL CHEM, V267, P23418; CARTER RS, 1991, ARCH BIOCHEM BIOPHYS, V288, P97, DOI 10.1016/0003-9861(91)90169-J; CARTER RS, 1994, J BIOL CHEM, V269, P4381; CATALA F, 1995, MOL CELL BIOL, V15, P4585; CHAU CMA, 1992, J BIOL CHEM, V267, P6999; CROSS JC, 1995, DEVELOPMENT, V121, P2513; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; Emerson CP, 1990, CURR OPIN CELL BIOL, V2, P1065, DOI 10.1016/0955-0674(90)90157-A; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FORSBURG SL, 1989, ANNU REV CELL BIOL, V5, P153, DOI 10.1146/annurev.cb.05.110189.001101; Genuario R. Robert, 1993, Gene Expression, V3, P279; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARAGUCHI Y, 1994, J BIOL CHEM, V269, P9330; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; IANNELLO RC, 1991, J BIOL CHEM, V266, P3309; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LITVIN J, 1993, DEV BIOL, V156, P409, DOI 10.1006/dbio.1993.1088; LOMAX MI, 1995, MAMM GENOME, V6, P118, DOI 10.1007/BF00303255; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MOSS JB, 1994, J BIOL CHEM, V269, P12731; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; NAGLEY P, 1991, TRENDS GENET, V7, P1, DOI 10.1016/0168-9525(91)90002-8; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; OLSON EN, 1990, GENE DEV, V4, P2104; PFEIFER K, 1987, CELL, V49, P9, DOI 10.1016/0092-8674(87)90750-1; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; SADASIVAN E, 1994, J BIOL CHEM, V269, P4725; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SAWADA J, 1994, EMBO J, V13, P1396, DOI 10.1002/j.1460-2075.1994.tb06393.x; SCHEJA K, 1992, BIOCHIM BIOPHYS ACTA, V1132, P91, DOI 10.1016/0167-4781(92)90059-9; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEELAN RS, 1992, BIOCHEMISTRY-US, V31, P4696, DOI 10.1021/bi00134a024; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SMITH EO, 1993, BIOCHIM BIOPHYS ACTA, V1174, P63, DOI 10.1016/0167-4781(93)90092-R; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; Sucharov C, 1995, GENE EXPRESSION, V5, P93; SUSKE G, 1988, DNA-J MOLEC CELL BIO, V7, P163, DOI 10.1089/dna.1988.7.163; SUZUKI H, 1991, J BIOL CHEM, V266, P2333; TAANMAN JW, 1991, BIOCHIM BIOPHYS ACTA, V1089, P283, DOI 10.1016/0167-4781(91)90027-J; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; VINCENT CK, 1993, MOL CELL BIOL, V13, P1264, DOI 10.1128/MCB.13.2.1264; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1994, GENE DEV, V8, P2203, DOI 10.1101/gad.8.18.2203; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; YAMADA M, 1990, J BIOL CHEM, V265, P7687	67	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30281	30289		10.1074/jbc.271.47.30281	http://dx.doi.org/10.1074/jbc.271.47.30281			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939982	hybrid			2022-12-27	WOS:A1996VU52500110
J	Melcher, ML; Thorner, J				Melcher, ML; Thorner, J			Identification and characterization of the CLK1 gene product, a novel CaM kinase-like protein kinase from the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-EFFICIENCY TRANSFORMATION; ELONGATION FACTOR-II; SPINDLE POLE BODY; CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; CONSERVED FEATURES; SHUTTLE VECTORS; CALMODULIN; SEQUENCE; DNA	The CLK1 gene of Saccharomyces cerevisiae encodes a 610-residue protein kinase that resembles known type II Ca2+/calmodulin-dependent protein kinases (CaM kinases), including the CMK1 and CMK2 gene products from the same yeast, The Clk1 kinase domain is preceded by a 162-residue N-terminal extension, followed by a 132-residue C-terminal extension (which contains a basic segment resembling known calmodulin-binding sites) and is as similar to mammalian CaM kinase (38% identity to rat CaM kinase cu) as it is to yeast CaM kinase (37% identity to Cmk2). However, Clk1 shares 52% identity with Rck1, another putative protein kinase encoded in the S. cerevisiae genome, Clk1 tagged with a c-myc epitope (expressed in yeast) and a GST-Clk1 fusion (expressed in bacteria) underwent autophosphorylation and phosphorylated an exogenous substrate (yeast protein synthesis elongation factor 2), primarily on Ser. Neither Clk1 activity was stimulated by purified yeast calmodulin (CMD1 gene product), with or without Ca2+; no association of Clk1 with Cmd1 was detectable by other methods, C-terminally truncated Clk1(Delta 487-610) was growth-inhibitory when overexpressed, whereas catalytically inactive Clk1(K201R Delta 487-610) was not, suggesting that the C terminus is a negative regulatory domain. Using immunofluorescence, Clk1 was localized to the cytosol and excluded from the nucleus, A clk1 Delta. mutant, a clk1 Delta rck1 Delta double mutant, a clk1 Delta cmk1 Delta cmk2 Delta triple mutant, and a clk1 Delta rck1 Delta cmk1 Delta cmk2 Delta quadruple mutant were all viable and manifested no other overt growth phenotype.	UNIV CALIF BERKELEY, DEPT CELL & MOL BIOL, DIV BIOCHEM & MOL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley			THORNER, Jeremy/O-6132-2019; Melcher, Marc L./AAC-6130-2020	THORNER, Jeremy/0000-0002-2583-500X; Melcher, Marc L./0000-0002-7185-4383	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007232, R37GM021841, R01GM021841] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21841, GM07232] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANRAKU Y, 1991, BIOCHIM BIOPHYS ACTA, V1093, P169, DOI 10.1016/0167-4889(91)90119-I; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BENTON BM, 1994, J CELL BIOL, V127, P623, DOI 10.1083/jcb.127.3.623; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BROCKERHOFF SE, 1994, J CELL BIOL, V124, P315, DOI 10.1083/jcb.124.3.315; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; DAHLKVIST A, 1994, GENE, V139, P27, DOI 10.1016/0378-1119(94)90519-3; DAHLKVIST A, 1995, MOL GEN GENET, V246, P316, DOI 10.1007/BF00288604; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; DAVIS TN, 1986, YEAST CELL BIOL, V33, P477; DONOVAN MG, 1991, FEBS LETT, V291, P303, DOI 10.1016/0014-5793(91)81307-T; DUMONTMISCOPEIN A, 1994, FEBS LETT, V356, P283, DOI 10.1016/0014-5793(94)01272-5; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GEISER JR, 1993, MOL CELL BIOL, V13, P7913, DOI 10.1128/MCB.13.12.7913; GERRING SL, 1991, METHOD ENZYMOL, V194, P57; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HARRIS E, 1994, J CELL SCI, V107, P3235; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOLMBERG L, 1994, BIOCHEMISTRY-US, V33, P15159, DOI 10.1021/bi00254a027; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IIDA H, 1995, CURR GENET, V27, P190, DOI 10.1007/BF00313434; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; JONES EW, 1991, METHOD ENZYMOL, V194, P428; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KUCHLER K, 1993, J CELL BIOL, V120, P1203, DOI 10.1083/jcb.120.5.1203; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINK AJ, 1991, GENETICS, V127, P681; MEANS AR, 1994, FEBS LETT, V347, P1, DOI 10.1016/0014-5793(94)00492-7; MELCHER ML, 1995, THESIS U CALIFORNIA; MITSUI K, 1993, J BIOL CHEM, V268, P13422; NAIRN AC, 1985, P NATL ACAD SCI USA, V82, P7939, DOI 10.1073/pnas.82.23.7939; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; NEMETH EF, 1990, CELL CALCIUM, V11, P319, DOI 10.1016/0143-4160(90)90032-P; OHYA Y, 1991, J BIOL CHEM, V266, P12784; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PAUSCH MH, 1991, EMBO J, V10, P1511, DOI 10.1002/j.1460-2075.1991.tb07671.x; PERENTESIS JP, 1992, J BIOL CHEM, V267, P1190; PLANASSILVA MD, 1992, EMBO J, V11, P507, DOI 10.1002/j.1460-2075.1992.tb05081.x; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; QIN SL, 1987, J BIOL CHEM, V262, P7802; QIN SL, 1990, J BIOL CHEM, V265, P1903; RASMUSSEN C, 1994, MOL BIOL CELL, V5, P785, DOI 10.1091/mbc.5.7.785; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHULMAN H, 1989, TRENDS BIOCHEM SCI, V14, P62, DOI 10.1016/0968-0004(89)90045-5; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; Sherman F, 1986, LAB COURSE MANUAL ME; SIKORSKI RS, 1989, GENETICS, V122, P19; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STIRLING DA, 1994, EMBO J, V13, P4329, DOI 10.1002/j.1460-2075.1994.tb06753.x; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEINSTEIN H, 1994, ANNU REV PHYSIOL, V56, P213, DOI 10.1146/annurev.ph.56.030194.001241; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895	68	34	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29958	29968		10.1074/jbc.271.47.29958	http://dx.doi.org/10.1074/jbc.271.47.29958			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939941	hybrid			2022-12-27	WOS:A1996VU52500069
J	Ruan, HJ; Shantz, LM; Pegg, AE; Morris, DR				Ruan, HJ; Shantz, LM; Pegg, AE; Morris, DR			The upstream open reading frame of the mRNA encoding S-adenosylmethionine decarboxylase is a polyamine-responsive translational control element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE DECARBOXYLASE; MESSENGER-RNA; PROTEIN-SYNTHESIS; MAMMALIAN-CELLS; LEADER PEPTIDE; EXPRESSION; GROWTH; TRANSFORMATION; REPRESSION; METABOLISM	S-Adenosylmethionine decarboxylase (AdoMetDC) is a key enzyme in the pathway of polyamine biosynthesis. The cellular levels of the polyamines specifically regulate AdoMetDC translation through the 5'-leader of the mRNA, which contains a small upstream open reading frame (uORF) 14 nucleotides from the cap. Mutating the initiation codon of the uORF, which encodes a peptide product with the sequence MAGDIS, abolished regula tion, In addition, the uORF is sufficient, by itself, to provide polyamine regulation when inserted into the 5'-leader of the human growth hormone mRNA. Changing the amino acid sequence at the carboxyl terminus of the peptide product of the uORF abolished polyamine regulation. In contrast, altering the nucleotide sequence of the uORF at degenerate positions, without changing the amino acid sequence of the peptide, did not affect regulation. Extending the distance between cap and uORF, thereby changing the rate of initiation at the initiator AUG of the uORF, did not alter polyamine regulation. When the uORF was extended so as to overlap, out of frame, the downstream major cistron, polyamine regulation was abolished, We propose that polyamines do not modulate the rate of recognition of the uORF but rather regulate interaction of the peptide product of the uORF with its target.	UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT CELLULAR & MOL PHYSIOL,HERSHEY,PA 17033; PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT PHARMACOL,HERSHEY,PA 17033	University of Washington; University of Washington Seattle; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health			Morris, David/G-4503-2011	Shantz, Lisa/0000-0001-8814-4022	NATIONAL CANCER INSTITUTE [R01CA018138, R01CA039053, R37CA018138] Funding Source: NIH RePORTER; NCI NIH HHS [CA39053, CA18138] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BITONTI AJ, 1988, BIOCHEM J, V250, P295, DOI 10.1042/bj2500295; Cao JH, 1996, MOL CELL BIOL, V16, P603; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELBECQ P, 1994, MOL CELL BIOL, V14, P2378, DOI 10.1128/MCB.14.4.2378; FAJUNEN A, 1988, J BIOL CHEM, V263, P17040; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; GRILLO MA, 1994, BIOCHEM SOC T, V22, P894, DOI 10.1042/bst0220894; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; HILL JR, 1993, J BIOL CHEM, V268, P726; HILL JR, 1992, J BIOL CHEM, V267, P21886; JANNE J, 1991, ANN MED, V23, P241, DOI 10.3109/07853899109148056; KAMEJI T, 1987, J BIOL CHEM, V262, P2427; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LARGE PJ, 1992, FEMS MICROBIOL REV, V8, P249; LOWKVIST B, 1987, CELL TISSUE RES, V249, P151, DOI 10.1007/BF00215429; MACH M, 1986, J BIOL CHEM, V261, P1697; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; Marton LJ, 1987, INHIB POLYAM METABOL, P79; MEGOSH L, 1995, CANCER RES, V55, P4205; MIHM S, 1989, EXP CELL RES, V180, P383, DOI 10.1016/0014-4827(89)90065-7; MORRIS DR, 1991, J CELL BIOCHEM, V46, P102, DOI 10.1002/jcb.240460203; MOSHIER JA, 1993, CANCER RES, V53, P2618; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1989, BIOCHEMISTRY-US, V28, P8446, DOI 10.1021/bi00447a026; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; PERSSON L, 1989, BIOCHEM BIOPH RES CO, V160, P1196, DOI 10.1016/S0006-291X(89)80130-5; Poulin R, 1995, BIOCHEM J, V312, P749, DOI 10.1042/bj3120749; PULKKA A, 1993, GENOMICS, V16, P342, DOI 10.1006/geno.1993.1195; RUAN HJ, 1994, J BIOL CHEM, V269, P17905; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHANTZ LM, 1994, CANCER RES, V54, P2313; SHANTZ LM, 1994, BIOCHEM J, V302, P765, DOI 10.1042/bj3020765; SHIRAHATA A, 1985, J BIOL CHEM, V260, P9583; SHIRAHATA A, 1986, J BIOL CHEM, V261, P3833; STJERNBORG L, 1993, EUR J BIOCHEM, V214, P671, DOI 10.1111/j.1432-1033.1993.tb17967.x; WARIS T, 1993, BIOCHEM BIOPH RES CO, V189, P424; WERNER M, 1987, CELL, V49, P805, DOI 10.1016/0092-8674(87)90618-0; WHITE MW, 1990, BIOCHEM J, V268, P657, DOI 10.1042/bj2680657; [No title captured]	44	86	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29576	29582		10.1074/jbc.271.47.29576	http://dx.doi.org/10.1074/jbc.271.47.29576			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939886	hybrid			2022-12-27	WOS:A1996VU52500014
J	Scherman, MS; KalbeBournonville, L; Bush, D; Deng, LY; McNeil, M				Scherman, MS; KalbeBournonville, L; Bush, D; Deng, LY; McNeil, M			Polyprenylphosphate-pentoses in mycobacteria are synthesized from 5-phosphoribose pyrophosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALLS; ARABINOGALACTAN; SMEGMATIS; BIOSYNTHESIS; ETHAMBUTOL; TUBERCULOSIS; DONOR	Polyprenylphosphate-arabinose (in which the polyprenyl unit is found both as decaprenyl and octahydroheptaprenyl) is a donor of mycobacterial cell wall arabinosyl residues. Because of this important role, its biosynthetic pathway, and that of the related lipid, polyprenylphosphate-D-ribose, was investigated. Surprisingly, phosphoribose pyrophosphate was shown to be a key intermediate on the pathway to both polyprenylphosphate-D-pentoses. Thus, incubation of 5-phospho-D-[C-14]ribose pyrophosphate with membranes prepared from Mycobacterium smegmatis resulted in the presence of organic-soluble radioactivity that was shown to be, in part, polyprenylphosphate-[C-14]arabinose and polyprenylphosphate-[C-14]ribose. Two additional intermediates, polyprenylphosphate-5-phospho[C-14]ribose and polyprenylphosphate-5-phospho[C-14]arabinose, were identified, Further experiments showed that the mature polyprenylphosphate-ribose is formed from phosphoribose pyrophosphate via a two-step pathway involving a transferase to form polyprenylphosphate-5-phosphoribose and then a phosphatase to form the final polyprenylphosphate-ribose. Polyprenylphosphate-arabinose is formed by a similar pathway with an additional step being the epimerization of the ribosyl residue, This epimerization at either the level of phosphoribose pyrophosphate or at the level of polyprenylphosphate-5-phosphoribose.	COLORADO STATE UNIV, DEPT MICROBIOL, FT COLLINS, CO 80523 USA	Colorado State University			McNeil, Michael/G-3325-2019	Deng, Lingyi Lynn/0000-0002-1906-8457	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033706] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-33706] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DAFFE M, 1990, J BIOL CHEM, V265, P6734; KALBEBOURNONVIL.L, 1994, THESIS U CATHOLIQUE, P49; LEE RE, 1995, J AM CHEM SOC, V117, P11829, DOI 10.1021/ja00153a002; MCNEIL M, 1990, J BIOL CHEM, V265, P18200; MCNEIL M, 1991, J BIOL CHEM, V266, P13217; MORISAKI N, 1995, J ANTIBIOT, V48, P1299, DOI 10.7164/antibiotics.48.1299; SCHERMAN M, 1995, J BACTERIOL, V177, P7125, DOI 10.1128/jb.177.24.7125-7130.1995; SCHULTZ J, 1974, ARCH BIOCHEM BIOPHYS, V160, P311, DOI 10.1016/S0003-9861(74)80039-1; SHIBAEV VN, 1986, ADV CARBOHYD CHEM BI, V44, P277; SINGH S, 1994, MICROBIOS, V77, P217; TAKAYAMA K, 1970, J BIOL CHEM, V245, P6251; TAKAYAMA K, 1989, ANTIMICROB AGENTS CH, V33, P1493, DOI 10.1128/AAC.33.9.1493; WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328; WOLUCKA BA, 1995, J BIOL CHEM, V270, P20151, DOI 10.1074/jbc.270.34.20151; WOLUCKA BA, 1995, J CELL BIOCHEM, V19, P71; YOKOYAMA K, 1989, J BIOL CHEM, V264, P21621	16	93	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29652	29658		10.1074/jbc.271.47.29652	http://dx.doi.org/10.1074/jbc.271.47.29652			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939897	hybrid			2022-12-27	WOS:A1996VU52500025
J	Vallejo, AN; Pease, LR				Vallejo, AN; Pease, LR			The locus-specific enhancer activity of the class I major histocompatibility complex interferon-responsive element is associated with a gamma-interferon (IFN)-inducible factor distinct from STAT1 alpha, p48, and IFN regulatory factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HLA CLASS-I; TRANSCRIPTION FACTOR ISGF3; MHC ANTIGEN EXPRESSION; TUMOR-NECROSIS-FACTOR; GENE-EXPRESSION; BETA-2-MICROGLOBULIN-DEFICIENT MICE; PROMOTER ELEMENTS; STIMULATED GENES; SYNTHETASE GENE; DOWN-REGULATION	Recent analyses of the upstream regulatory regions of the class I major histocompatibility complex genes in higher primates provided a generalized structural basis for the differential expression of A- and B-locus gene products in response to specific physiological stimulus, Among the regulatory sequences that differ between the loci is the interferon-responsive element (IRE), While the B-IRE is conserved, the A-IREs have species-specific sequence variation, We previously demonstrated that the B-IRE was an interferon (IFN)-inducible enhancer, whereas none of the A-IREs were functional, In the present study, we examined the biochemical basis for the enhancer activity of the conserved B-IRE and found that this may be attributed to a novel gamma-IFN-inducible factor, This factor accumulated in nuclei of cells within minutes of exposure to gamma-IFN. Its appearance was independent of de novo protein synthesis, However, it was not detected in nuclei of cells treated with herbimycin A, suggesting that its appearance depends on a protein kinase activation pathway, Supershift assays indicated that it was distinct from STAT1 alpha, IFN regulatory factor-1, and p48, transcription factors known to bind IRE-like sequences found in regulatory regions of many nonmajor histocompatibility complex gamma-IFN-responsive genes, Competition assays show that this novel factor bound B-IRE with relatively high affinity, about 100-fold more than that for the A-IRE sequence, This factor was also present in STAT1 alpha and p48 somatic mutants that also exhibited B-IRE enhancer activity in reporter gene bioassays in a manner similar to those seen with wild type cells, These observations indicate the existence of a novel gamma-IFN-dependent transcriptional activation pathway that correlates with the differential enhancer activity of the HLA-B IRE.	MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55905	Mayo Clinic					NIAID NIH HHS [AI-22420] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022420] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTINTAS A, 1993, J IMMUNOL, V151, P2803; BENDER BS, 1992, J EXP MED, V175, P1143, DOI 10.1084/jem.175.4.1143; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; BRIKEN V, 1995, MOL CELL BIOL, V15, P975; BRUNN GJ, 1995, J BIOL CHEM, V270, P11628, DOI 10.1074/jbc.270.19.11628; CHANG CH, 1992, IMMUNOGENETICS, V35, P378; COCCIA EM, 1995, VIROLOGY, V211, P113, DOI 10.1006/viro.1995.1384; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID-WATINE B, 1990, IMMUNOL TODAY, V11, P286, DOI 10.1016/0167-5699(90)90114-O; EILERS A, 1994, MOL CELL BIOL, V14, P1364, DOI 10.1128/MCB.14.2.1364; FIETTE L, 1993, J VIROL, V67, P589, DOI 10.1128/JVI.67.1.589-592.1993; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; GAMBON F, 1988, EUR J IMMUNOL, V18, P153, DOI 10.1002/eji.1830180123; GARRIDO F, 1993, IMMUNOL TODAY, V14, P491, DOI 10.1016/0167-5699(93)90264-L; GE RW, 1994, VIROLOGY, V203, P389, DOI 10.1006/viro.1994.1499; GILMORE W, 1994, J EXP MED, V180, P1013, DOI 10.1084/jem.180.3.1013; GIRDLESTONE J, 1988, EUR J IMMUNOL, V18, P139, DOI 10.1002/eji.1830180121; GIRDLESTONE J, 1993, P NATL ACAD SCI USA, V90, P11568, DOI 10.1073/pnas.90.24.11568; HAKEM R, 1991, J IMMUNOL, V147, P2384; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HOWCROFT TK, 1993, EMBO J, V12, P3163, DOI 10.1002/j.1460-2075.1993.tb05985.x; IMREH MP, 1995, INT J CANCER, V62, P90, DOI 10.1002/ijc.2910620117; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JOHNSON DR, 1994, MOL CELL BIOL, V14, P1322, DOI 10.1128/MCB.14.2.1322; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6886; KRALLI A, 1992, J VIROL, V66, P6979, DOI 10.1128/JVI.66.12.6979-6988.1992; LAPIERRE LA, 1988, J EXP MED, V167, P794, DOI 10.1084/jem.167.3.794; LAWLOR DA, 1990, ANNU REV IMMUNOL, V8, P23, DOI 10.1146/annurev.iy.08.040190.000323; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; MANSKY P, 1994, J IMMUNOL, V153, P5082; MARCHE PN, 1985, IMMUNOGENETICS, V21, P71, DOI 10.1007/BF00372243; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MAUDSLEY DJ, 1991, IMMUNOL TODAY, V12, P429, DOI 10.1016/0167-5699(91)90013-J; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MOLLER P, 1992, CANCER SURV, V13, P101; NIELSCH U, 1991, EMBO J, V10, P4169, DOI 10.1002/j.1460-2075.1991.tb04995.x; OPELZ G, 1987, TRANSPLANT P, V19, P641; PARRINGTON J, 1993, EUR J BIOCHEM, V214, P617, DOI 10.1111/j.1432-1033.1993.tb17961.x; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PEASE LR, 1991, CRIT REV IMMUNOL, V11, P1; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; POGULIS RJ, 1993, J BIOL CHEM, V268, P2493; PROFFITT JL, 1994, NUCLEIC ACIDS RES, V22, P4779, DOI 10.1093/nar/22.22.4779; RAULET DH, 1994, ADV IMMUNOL, V55, P381; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; REIN T, 1994, NUCLEIC ACIDS RES, V22, P3033, DOI 10.1093/nar/22.15.3033; ROTH C, 1994, ADV IMMUNOL, V57, P281, DOI 10.1016/S0065-2776(08)60675-6; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; SHARROW SO, 1994, J IMMUNOL, V153, P110; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; SINGER DS, 1990, CRIT REV IMMUNOL, V10, P235; SOONG TW, 1992, J IMMUNOL, V149, P2008; STREHLOW I, 1993, J BIOL CHEM, V268, P16590; TARLETON RL, 1992, NATURE, V356, P338, DOI 10.1038/356338a0; THOROGOOD J, 1990, TRANSPLANTATION, V50, P146, DOI 10.1097/00007890-199007000-00027; VALLEJO AN, 1995, J IMMUNOL, V154, P3912; VALLEJO AN, 1995, IMMUNOL REV, V143, P249, DOI 10.1111/j.1600-065X.1995.tb00678.x; VALLEJO AN, 1995, INT IMMUNOL, V7, P853, DOI 10.1093/intimm/7.5.853; VALLEJO AN, 1994, PCR METH APPL, V4, pS123; van Meerwijk J P, 1994, Semin Immunol, V6, P231, DOI 10.1006/smim.1994.1030; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VERSTEEG R, 1990, MOL CELL BIOL, V10, P5416, DOI 10.1128/MCB.10.10.5416; VERSTEEG R, 1989, J EXP MED, V170, P612; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WARING JF, 1995, J BIOL CHEM, V270, P12276, DOI 10.1074/jbc.270.20.12276; YAMITHEZI A, 1994, ONCOGENE, V9, P1065; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	74	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29813	29821		10.1074/jbc.271.47.29813	http://dx.doi.org/10.1074/jbc.271.47.29813			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939920	hybrid			2022-12-27	WOS:A1996VU52500048
J	Waxman, DJ; Zhao, SP; Choi, HK				Waxman, DJ; Zhao, SP; Choi, HK			Interaction of a novel sex-dependent, growth hormone-regulated liver nuclear factor with CYP2C12 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATIC CYTOCHROME-P-450; GENE-EXPRESSION; STEROID 16-ALPHA-HYDROXYLASE; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; DIFFERENTIAL REGULATION; INVITRO TRANSCRIPTION; PITUITARY REGULATION; BINDING PROTEIN; MESSENGER-RNAS	CYP2C12 is a steroid hydroxylase cytochrome P450 whose female specific expression in adult rat liver is transcriptionally activated by the continuous plasma growth hormone (GH) profile characteristic of adult fe male rats, DNase I footprinting and gel mobility shift analysis of the 5'-flank of the CYP2C12 gene were carried out to identify cis-acting elements and trans-acting factors that may contribute to the GH-regulated, sex-dependent transcription of this P450 gene, DNase I footprinting analysis revealed sex- and GH-regulated DNase I hypersensitivity sites at the boundaries of several protein binding sites detected along a 1560-nucleotide upstream segment of CYP2C12, Five distinct sites bound a novel continuous GH-regulated nuclear factor, GHNF, which is enriched in adult female and continuous GH-treated male liver nuclear extracts compared to untreated male liver nuclear extracts, Two other foot-printed sites correspond to binding sites for the liver transcription factors C/EBP and albumin D element-binding protein and a third to an HNF1 binding site. A specific binding site for GHNF was also found in the 5'-proximal promoter of CYP2C11, an adult male-specific liver P450 gene, suggesting that GHNF may contribute to the doum-regulation of that gene by continuous GH, GHNF was distinguished from the nuclear factors that bind to a GH response element upstream of the rat Spi 2.1 gene and is also distinct from the GH-activatable latent cytoplasmic transcription factors STAT 1, STAT 3, and STAT 5. These findings support the hypothesis that continuous GH-activated transcription of CYP2C12 in adult female rat liver (a) involves the activation of a novel GH-regulated nuclear factor which binds to multiple sites along the 5'-flank of this cytochrome P450 gene, and (b) proceeds via a signaling pathway distinct from the GH pulse-activated STAT5 pathway proposed to induce CYP2C11 and other male-expressed liver genes.			Waxman, DJ (corresponding author), BOSTON UNIV, DEPT BIOL, DIV CELL & MOL BIOL, 5 CUMMINGTON ST, BOSTON, MA 02215 USA.			Waxman, David/0000-0001-7982-9206				BERGAD PL, 1995, J BIOL CHEM, V270, P24903, DOI 10.1074/jbc.270.42.24903; BILLESTRUP N, 1995, P NATL ACAD SCI USA, V92, P2725, DOI 10.1073/pnas.92.7.2725; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; CLARKSON RWE, 1995, MOL ENDOCRINOL, V9, P108, DOI 10.1210/me.9.1.108; GONZALEZ FJ, 1986, MOL CELL BIOL, V6, P2969, DOI 10.1128/MCB.6.8.2969; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRONOWSKI AM, 1995, MOL ENDOCRINOL, V9, P171, DOI 10.1210/me.9.2.171; GUZELIAN PS, 1988, P NATL ACAD SCI USA, V85, P9783, DOI 10.1073/pnas.85.24.9783; JANSSON JO, 1985, ENDOCR REV, V6, P128, DOI 10.1210/edrv-6-2-128; JEFFERY S, 1990, BIOCHEM J, V266, P69, DOI 10.1042/bj2660069; LECAM A, 1987, EMBO J, V6, P1225, DOI 10.1002/j.1460-2075.1987.tb02358.x; LEE YH, 1994, J BIOL CHEM, V269, P14681; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; LEGRAVEREND C, 1992, MOL ENDOCRINOL, V6, P259, DOI 10.1210/me.6.2.259; LIU SY, 1995, DNA CELL BIOL, V14, P285, DOI 10.1089/dna.1995.14.285; MACGEOCH C, 1985, ENDOCRINOLOGY, V117, P2085, DOI 10.1210/endo-117-5-2085; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MORGAN ET, 1985, J BIOL CHEM, V260, P1895; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; NOSHIRO M, 1986, J BIOL CHEM, V261, P5923; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; SHAYIQ RM, 1992, J BIOL CHEM, V267, P2421; SILVA CM, 1994, J BIOL CHEM, V269, P27532; SONDERFAN AJ, 1987, ARCH BIOCHEM BIOPHYS, V255, P27, DOI 10.1016/0003-9861(87)90291-8; SQUIRES EJ, 1988, J BIOL CHEM, V263, P4166; SRIVASTAVA PK, 1993, BIOCHEM J, V294, P159, DOI 10.1042/bj2940159; STROM A, 1995, J BIOL CHEM, V270, P11276, DOI 10.1074/jbc.270.19.11276; STROM A, 1994, DNA CELL BIOL, V13, P805, DOI 10.1089/dna.1994.13.805; SUBRAMANIAN A, 1995, MOL CELL BIOL, V15, P4672; SUNDSETH SS, 1992, J BIOL CHEM, V267, P3915; SUNDSETH SS, 1992, J BIOL CHEM, V267, P3907; TOLLET P, 1995, MOL ENDOCRINOL, V9, P1771, DOI 10.1210/me.9.12.1771; TOLLET P, 1990, MOL ENDOCRINOL, V4, P1934, DOI 10.1210/mend-4-12-1934; TOLLET P, 1995, J BIOL CHEM, V270, P12569, DOI 10.1074/jbc.270.21.12569; VENEPALLY P, 1992, J BIOL CHEM, V267, P17333; Waxman David J., 1995, P391; WAXMAN DJ, 1991, METHOD ENZYMOL, V206, P249; WAXMAN DJ, 1988, BIOCHEM PHARMACOL, V37, P71, DOI 10.1016/0006-2952(88)90756-3; WAXMAN DJ, 1985, BIOCHEMISTRY-US, V24, P4409, DOI 10.1021/bi00337a023; WAXMAN DJ, 1984, J BIOL CHEM, V259, P5481; WAXMAN DJ, 1990, MOL ENDOCRINOL, V4, P447, DOI 10.1210/mend-4-3-447; WAXMAN DJ, 1988, J BIOL CHEM, V263, P11396; WAXMAN DJ, 1992, J STEROID BIOCHEM, V43, P1055, DOI 10.1016/0960-0760(92)90333-E; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; WAXMAN DJ, 1991, P NATL ACAD SCI USA, V88, P6868, DOI 10.1073/pnas.88.15.6868; WESTIN S, 1990, MOL PHARMACOL, V38, P192; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; YAMAZOE Y, 1988, J BIOCHEM-TOKYO, V104, P785, DOI 10.1093/oxfordjournals.jbchem.a122550; YANO M, 1992, MOL CELL BIOL, V12, P2847, DOI 10.1128/MCB.12.6.2847; YOON JB, 1990, J BIOL CHEM, V265, P19947; YOSHIOKA H, 1990, J BIOL CHEM, V265, P14612; ZHAO SP, 1994, FASEB J, V8, pA1250	54	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29978	29987		10.1074/jbc.271.47.29978	http://dx.doi.org/10.1074/jbc.271.47.29978			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939943	hybrid			2022-12-27	WOS:A1996VU52500071
J	Huston, E; Pooley, L; Julien, P; Scotland, G; McPhee, I; Sullivan, M; Bolger, G; Houslay, MD				Huston, E; Pooley, L; Julien, P; Scotland, G; McPhee, I; Sullivan, M; Bolger, G; Houslay, MD			The human cyclic AMP-specific phosphodiesterase PDE-46 (HSPDE4A4B) expressed in transfected COS7 cells occurs as both particulate and cytosolic species that exhibit distinct kinetics of inhibition by the antidepressant rolipram	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-SPECIFIC PHOSPHODIESTERASE; LIVER PLASMA-MEMBRANES; N-TERMINAL DOMAIN; MOLECULAR-CLONING; NUCLEOTIDE PHOSPHODIESTERASES; SPLICE VARIANT; MONOPHOSPHATE PHOSPHODIESTERASE; DROSOPHILA-MELANOGASTER; IV INHIBITORS; BINDING-SITE	Transfection of COS7 cells with a plasmid encoding the human cyclic A-specific PDE4A phosphodiesterase PDE-46 (HSPDE4A4B) led to the expression of a rolipram-inhibited PDE4 activity, which contributed similar to-96% of the total COS cell PDE activity, A fusion protein was generated which encompassed residues (788-886) at the extreme C terminus of PDE-46 and was used to generate an antiserum that detected PDE-46 in transfected COS7 cells, Immunoblotting studies identified PDE-46 as a similar to 125-kDa species that was associated with both the soluble and particulate fractions. The relative V-max of particulate PDE-46 was similar to 56% that of cytosolic PDE-46. Particulate PDE-46 was not solubilized using Triton X-100 or high NaCl concentrations, Immunofluorescence analysis by laser scanning confocal micros copy showed that PDE-46 was located at discrete margins of the cen, indicative of association with membrane cortical regions. The human PDE4A species, h6.1 (HSPDE4A4C), which lacks the N-terminal extension of PDE-46, was found as an entirely soluble species when expressed in COS7 cells, h6.1 was shown to have an similar to 11-fold higher V-max relative to that of PDE-46. In dose-response studies rolipram inhibited particulate PDE-46 at much lower concentrations (IC50 = 0.195 mu M) than those needed to inhibit the cytosolic enzyme (IC50 = 1.6 mu M). The basis of this difference lag in the fact that rolipram served as a simple competitive inhibitor of the cytosol enzyme (K-i = 1.6 mu M) but as a partial competitive inhibitor of the particulate enzyme (K-i = 0.037 mu M; K-i' = 2.3 mu M) Particulate PDE-46 thus showed a similar to 60-fold higher affinity for rolipram than cytosolic PDE-46.	UNIV GLASGOW, DIV BIOCHEM & MOL BIOL, MOL PHARMACOL GRP, IBLS, GLASGOW G12 8QQ, LANARK, SCOTLAND; UNIV UTAH, VET ADM MED CTR, HUNTSMAN CTR INST, DEPT MED, SALT LAKE CITY, UT 84148 USA; UNIV UTAH, VET ADM MED CTR, HUNTSMAN CTR INST, DEPT ONCOL SCI, SALT LAKE CITY, UT 84148 USA	University of Glasgow; US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah			Houslay, Miles D/A-6825-2011; Houslay, Miles/AAM-5281-2020	Houslay, Miles/0000-0002-3826-8091	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALVAREZ R, 1995, MOL PHARMACOL, V48, P616; AMEGADZIE BY, 1995, CELL BIOL INT, V19, P477, DOI 10.1006/cbir.1995.1091; BAECKER PA, 1994, GENE, V138, P253, DOI 10.1016/0378-1119(94)90818-4; BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BOLGER G, 1993, MOL CELL BIOL, V13, P6558, DOI 10.1128/MCB.13.10.6558; BOLGER GB, 1994, CELL SIGNAL, V6, P851, DOI 10.1016/0898-6568(94)90018-3; Bolger GB, 1996, J BIOL CHEM, V271, P1065, DOI 10.1074/jbc.271.2.1065; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG JB, 1995, BIOORG MED CHEM LETT, V5, P1969, DOI 10.1016/0960-894X(95)00334-P; CHERRY JA, 1995, J NEUROBIOL, V28, P102, DOI 10.1002/neu.480280109; CONTI M, 1995, BIOCHEMISTRY-US, V34, P7979, DOI 10.1021/bi00025a003; CONTI M, 1995, ENDOCR REV, V16, P370, DOI 10.1210/er.16.3.370; CONTI M, 1992, ADV SEC MESS PHOSPH, V25, P87; DAVIS RL, 1988, METHOD ENZYMOL, V159, P786; DAVIS RL, 1989, P NATL ACAD SCI USA, V86, P3604, DOI 10.1073/pnas.86.10.3604; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; Dixon M., 1979, ENZYMES, Vthird; ENGELS P, 1995, FEBS LETT, V358, P305, DOI 10.1016/0014-5793(94)01460-I; HORTON YM, 1995, BIOCHEM J, V308, P683, DOI 10.1042/bj3080683; HOUSLAY MD, 1995, BIOCHEM SOC T, V23, P393, DOI 10.1042/bst0230393; HOUSLAY MD, 1974, BIOCHEM J, V139, P645, DOI 10.1042/bj1390645; HOUSLAY MD, 1992, BIOCHEM SOC T, V20, P140, DOI 10.1042/bst0200140; HOUSLAY MD, 1990, MOL PHARM CELL REGUL, V2, P185; JIN SLC, 1992, J BIOL CHEM, V267, P18929; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIVI GP, 1990, MOL CELL BIOL, V10, P2678, DOI 10.1128/MCB.10.6.2678; LOBBAN M, 1994, BIOCHEM J, V304, P399, DOI 10.1042/bj3040399; MANGANIELLO VC, 1995, ARCH BIOCHEM BIOPHYS, V322, P1, DOI 10.1006/abbi.1995.1429; MARCHMONT RJ, 1980, BIOCHEM J, V187, P381, DOI 10.1042/bj1870381; MARCHMONT RJ, 1981, BIOCHEM J, V195, P645, DOI 10.1042/bj1950645; MASAMUNE H, 1995, BIOORG MED CHEM LETT, V5, P1965, DOI 10.1016/0960-894X(95)00333-O; MCLAUGHLIN MM, 1993, J BIOL CHEM, V268, P6470; MCPHEE I, 1995, BIOCHEM J, V310, P965, DOI 10.1042/bj3100965; MERILAINEN J, 1993, J CELL SCI, V105, P647; MICHAELI T, 1993, J BIOL CHEM, V268, P12925; MILATOVICH A, 1994, SOMAT CELL MOLEC GEN, V20, P75, DOI 10.1007/BF02290677; PILLAI R, 1994, J BIOL CHEM, V269, P30676; REEVES ML, 1987, BIOCHEM J, V241, P535, DOI 10.1042/bj2410535; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; RUTTEN WJ, 1973, BIOCHIM BIOPHYS ACTA, V315, P378, DOI 10.1016/0005-2744(73)90267-2; SCHNEIDER HH, 1986, EUR J PHARMACOL, V127, P105, DOI 10.1016/0014-2999(86)90210-4; SCOTLAND G, 1995, BIOCHEM J, V308, P673, DOI 10.1042/bj3080673; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SHAKUR Y, 1993, BIOCHEM J, V292, P677, DOI 10.1042/bj2920677; SHAKUR Y, 1995, BIOCHEM J, V306, P801, DOI 10.1042/bj3060801; SULLIVAN M, 1994, CELL SIGNAL, V6, P793, DOI 10.1016/0898-6568(94)00039-5; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P5325, DOI 10.1073/pnas.86.14.5325; SZPIRER C, 1995, CYTOGENET CELL GENET, V69, P11, DOI 10.1159/000133927; THOMPSON WJ, 1991, PHARMACOL THERAPEUT, V51, P13, DOI 10.1016/0163-7258(91)90039-O; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; THOMPSON WJ, 1979, BIOCHEMISTRY-US, V18, P5228, DOI 10.1021/bi00590a030; TOHDA M, 1994, NEUROSCI LETT, V175, P89, DOI 10.1016/0304-3940(94)91085-5; TORPHY TJ, 1992, J BIOL CHEM, V267, P1798; VERGHESE MW, 1995, MOL PHARMACOL, V47, P1164; WILSON M, 1994, BIOCHEM J, V304, P407, DOI 10.1042/bj3040407; WOODS A, 1989, J CELL SCI, V93, P491; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417	59	93	94	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31334	31344		10.1074/jbc.271.49.31334	http://dx.doi.org/10.1074/jbc.271.49.31334			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940140	hybrid			2022-12-27	WOS:A1996VW68600051
J	Kohn, AD; Summers, SA; Birnbaum, MJ; Roth, RA				Kohn, AD; Summers, SA; Birnbaum, MJ; Roth, RA			Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; GLUT4 TRANSLOCATION; S6 KINASE; PLASMA-MEMBRANE; INSULIN; ACTIVATION; CELLS; PHOSPHORYLATION; INHIBITION	Akt is a serine/threonine kinase that requires a functional phosphatidylinositol 3-kinase to be stimulated by insulin and other growth factors. When directed to membranes by the addition of a are myristoylation sequence, Akt becomes constitutively active. In the present studies, the constitutively active Akt and a nonmyristoylated control mutant were expressed in 3T3-L1 cells that can be induced to differentiate into adipocytes. The constitutively active Akt induced glucose uptake into adipocytes in the absence of insulin by stimulating translocation of the insulin-responsive glucose transporter 4 to the plasma membrane. The constitutively active Akt also increased the synthesis of the ubiquitously expressed glucose transporter 1. The increased glucose influx in the 3T3-L1 adipocytes directed Lipid but not glycogen synthesis. These results indicate that Akt can regulate glucose uptake and metabolism.	STANFORD UNIV,MED CTR,DEPT MOL PHARMACOL,STANFORD,CA 94305; UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104	Stanford University; Howard Hughes Medical Institute; University of Pennsylvania			/AAE-5384-2020	Birnbaum, Morris/0000-0001-9972-8680	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034926, R01DK034926, R01DK039615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 34926, DK39615] Funding Source: Medline; NIGMS NIH HHS [5T32 GM07365] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; HARUTA T, 1995, J BIOL CHEM, V270, P27991; HASPEL HC, 1985, J BIOL CHEM, V260, P7219; HAUSDORFF SF, 1994, J BIOL CHEM, V269, P21391; KANAI F, 1993, J BIOL CHEM, V268, P14523; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; Katagiri H, 1996, J BIOL CHEM, V271, P16987, DOI 10.1074/jbc.271.29.16987; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; KOZKA IJ, 1991, J BIOL CHEM, V266, P11726; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; OKADA T, 1994, J BIOL CHEM, V269, P3568; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RAMIREZZACARIAS JL, 1992, HISTOCHEMISTRY, V97, P493, DOI 10.1007/BF00316069; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TORDJMAN KM, 1990, BIOCHEM J, V271, P201, DOI 10.1042/bj2710201; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WHITE MF, 1994, J BIOL CHEM, V269, P1; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; WINZ R, 1994, J BIOL CHEM, V269, P14438; YEH WC, 1995, P NATL ACAD SCI USA, V92, P11086, DOI 10.1073/pnas.92.24.11086; YEH WC, 1995, CURR OPIN CELL BIOL, V7, P885, DOI 10.1016/0955-0674(95)80074-3	36	1054	1080	0	55	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31372	31378		10.1074/jbc.271.49.31372	http://dx.doi.org/10.1074/jbc.271.49.31372			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940145	hybrid			2022-12-27	WOS:A1996VW68600056
J	Sekimoto, T; Nakajima, K; Tachibana, T; Hirano, T; Yoneda, Y				Sekimoto, T; Nakajima, K; Tachibana, T; Hirano, T; Yoneda, Y			Interferon-gamma-dependent nuclear import of Stat1 is mediated by the GTPase activity of Ran/TC4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE-TARGETING COMPLEX; WHEAT-GERM AGGLUTININ; PROTEIN IMPORT; BINDING PROTEIN; LIVING CELLS; IDENTIFICATION; ACTIVATION; INHIBITION; TRANSPORT; RCC1	In response to interferon-gamma (IFN-gamma), Stat1 enters the nucleus, where it activates transcription. In order to better understand the mechanism of the extracellular signal-induced protein import into the nucleus, we have established an in vivo assay system that uses recombinant Stat1 protein as a model transport substrate. Using this system, we found that Stat1 is actively transported through the nuclear pores in an IFN-gamma dependent manner and tyrosine (Tyr(701)) phosphorylation of Stat1 is actually required for its nuclear import. When the antibody against Ran, which was identified as an essential factor for active nuclear protein transport, was injected, the IFN-gamma-dependent nuclear transport of Stat1 was completely inhibited, Furthermore, nuclear import of Stat1 was suppressed by microinjection of two mutant Ran proteins, one defective in GTP hydrolysis (G19V) and the other with little or no binding to GTP (T24N), both of which are known to act as dominant negative inhibitors of nuclear import. These results indicate that the conditional nuclear import of Stat1 requires GTP hydrolysis by Ran.	OSAKA UNIV, SCH MED, DEPT ANAT & CELL BIOL, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DIV MOL ONCOL, BIOMED RES CTR, SUITA, OSAKA 565, JAPAN	Osaka University; Osaka University			Hirano, Toshio/C-8194-2009					BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; Carey KL, 1996, J CELL BIOL, V133, P985, DOI 10.1083/jcb.133.5.985; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; CORDES V, 1991, EUR J CELL BIOL, V55, P31; DABAUVALLE MC, 1988, EXP CELL RES, V174, P291, DOI 10.1016/0014-4827(88)90163-2; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dickmanns A, 1996, J CELL SCI, V109, P1449; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Higuchi R., 1989, PCR TECHNOLOGY, P61; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; IMAMOTO N, 1995, FEBS LETT, V368, P415; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; LOEB JDJ, 1995, P NATL ACAD SCI USA, V92, P7647, DOI 10.1073/pnas.92.17.7647; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MELCHIOR F, 1995, METHOD ENZYMOL, V257, P279; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Nakajima K, 1995, ANN NY ACAD SCI, V762, P55; Palacios I, 1996, J CELL BIOL, V133, P485, DOI 10.1083/jcb.133.3.485; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; STARR CM, 1990, J CELL BIOL, V110, P1861, DOI 10.1083/jcb.110.6.1861; TACHIBANA T, 1994, J BIOL CHEM, V269, P24542; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; YONEDA Y, 1987, EXP CELL RES, V170, P439, DOI 10.1016/0014-4827(87)90319-3; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7	35	99	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31017	31020		10.1074/jbc.271.49.31017	http://dx.doi.org/10.1074/jbc.271.49.31017			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940092	hybrid			2022-12-27	WOS:A1996VW68600003
J	Singh, S; Darnay, BG; Aggarwal, BB				Singh, S; Darnay, BG; Aggarwal, BB			Site-specific tyrosine phosphorylation of I kappa B alpha negatively regulates its inducible phosphorylation and degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SIGNAL-INDUCED PHOSPHORYLATION; UBIQUITIN-PROTEASOME PATHWAY; ACTIVATION; DISSOCIATION; PROTEOLYSIS; SUFFICIENT; INHIBITOR; STIMULATION; PHOSPHATASE	The transcription factor NF-kappa B is retained in the cytoplasm by its interaction with the inhibitory subunit known as I kappa B, Signal-induced serine phosphorylation and subsequent ubiquitination of I kappa B alpha target it for degradation by the 26 S proteasome, Recently, pervanadate, a protein-tyrosine phosphatase inhibitor, was shown to block the degradation of I kappa B alpha, thus inhibiting NF-kappa B activation, We investigated the mechanism by which pervanadate inhibits the degradation of I kappa B alpha, Western blot analysis of I kappa B alpha from tumor necrosis factor-treated cells revealed a slower migrating I kappa B alpha species that was subsequently degraded, However, pervanadate-treated cells also revealed a slower migrating species of I kappa B alpha that appeared in a time- and dose dependent manner and was not degraded by tumor necrosis factor, The slower migrating species of I kappa B alpha from pervanadate-treated cells was tyrosine-phosphorylated as revealed by cross-reactivity with anti-phosphotyrosine antibodies, by the ability of the specific tyrosine phosphatase PTP1B to dephosphorylate it, and by phosphoamino acid analysis of I kappa B alpha immunoprecipitated from P-32-labeled cells. By site-specific mutagenesis and deletion analysis, we identified Tyr-42 on I kappa B alpha as the phosphoacceptor site, Furthermore, in an in vitro reconstitution system, tyrosine-phosphorylated I kappa B alpha was protected from degradation, Our results demonstrate that inducible phosphorylation and degradation of I kappa B alpha are negatively regulated by phosphorylation at Tyr-42, thus preventing NF-kappa B activation.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT MOL ONCOL, CYTOKINE RES LAB, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center			Aggarwal, Bharat B/G-3388-2013					ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; Lin RT, 1996, MOL CELL BIOL, V16, P1401; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; MENON SD, 1995, J BIOL CHEM, V270, P18881; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339	36	111	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31049	31054		10.1074/jbc.271.49.31049	http://dx.doi.org/10.1074/jbc.271.49.31049			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940099	hybrid			2022-12-27	WOS:A1996VW68600010
J	Giasson, BI; Mushynski, WE				Giasson, BI; Mushynski, WE			Aberrant stress-induced phosphorylation of perikaryal neurofilaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; NERVE GROWTH-FACTOR; MONOCLONAL-ANTIBODIES DISTINGUISH; ACTIVATED PROTEIN-KINASES; MOTOR-NEURON DISEASE; NF-H; AXONAL-TRANSPORT; C-JUN; MAMMALIAN NEUROFILAMENTS; INTERMEDIATE FILAMENTS	The aberrant phosphorylation of the neurofilament high molecular weight subunit (NFH) in the neuronal perikaryon is a common feature of several neurological diseases. We demonstrated a strong correlation between hyperphosphorylation of the NFH carboxyl-terminal domain and activation of stress-activated protein kinase (SAPK)-gamma in PC12 cells. Agents that activated SAPK gamma in PC12 cells also caused the hyperphosphorylation of perikaryal NFH in cultured dorsal root ganglion neurons. The NFH carboxyl-terminal domain was phosphorylated by SAPK gamma in vitro, and the use of peptide substrates indicated that this event occurred preferentially at KSPXE motifs. We propose that SAPK gamma, perhaps in concert with other SAPKs, is involved in the abnormal phosphorylation of perikaryal NFH. This finding could lead to new insights into the etiology of several neurological diseases.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA	McGill University								BERGERON C, 1995, J NEUROL SCI, V129, P81, DOI 10.1016/0022-510X(95)00071-9; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CARLETTI R, 1995, NEUROSCIENCE, V69, P1103, DOI 10.1016/0306-4522(95)00284-P; CHIN SSM, 1990, J NEUROSCI, V10, P3714; CHING GY, 1993, J CELL BIOL, V122, P1323, DOI 10.1083/jcb.122.6.1323; COLLARD JF, 1995, NATURE, V375, P61, DOI 10.1038/375061a0; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; DELISLE MB, 1984, J NEUROL SCI, V63, P241, DOI 10.1016/0022-510X(84)90199-0; EISEN A, 1995, MUSCLE NERVE, V18, P741, DOI 10.1002/mus.880180711; ELHANANY E, 1994, J NEUROCHEM, V63, P2324; FIGLEWICZ DA, 1994, HUM MOL GENET, V3, P1757, DOI 10.1093/hmg/3.10.1757; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GEISLER N, 1983, EMBO J, V2, P1295, DOI 10.1002/j.1460-2075.1983.tb01584.x; GLICKSMAN MA, 1987, J NEUROBIOL, V18, P167, DOI 10.1002/neu.480180205; GOLDSTEIN ME, 1987, J NEUROSCI, V7, P1586; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Griffin JW, 1988, INTRINSIC DETERMINAN, P403; GUAN RJ, 1991, J BIOL CHEM, V266, P8262; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HARRIS J, 1991, J NEUROSCI RES, V30, P47, DOI 10.1002/jnr.490300107; Heasley LE, 1996, MOL CELL BIOL, V16, P648; HIROKAWA N, 1984, J CELL BIOL, V98, P1523, DOI 10.1083/jcb.98.4.1523; HISANAGA S, 1988, J MOL BIOL, V202, P297, DOI 10.1016/0022-2836(88)90459-7; HISANAGA S, 1990, J BIOL CHEM, V265, P21852; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; Jayaraman D, 1995, INT J DEV NEUROSCI, V13, P753, DOI 10.1016/0736-5748(95)00060-7; Julien JP, 1995, BIOCHEM CELL BIOL, V73, P593, DOI 10.1139/o95-064; JULIEN JP, 1982, J BIOL CHEM, V257, P467; JULIEN JP, 1983, J BIOL CHEM, V258, P4019; JULIEN JP, 1988, GENE, V68, P307, DOI 10.1016/0378-1119(88)90033-9; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; LEE MK, 1994, NEURON, V13, P975, DOI 10.1016/0896-6273(94)90263-1; LEE VMY, 1987, J NEUROSCI, V7, P3474; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; LEES JF, 1988, EMBO J, V7, P1947, DOI 10.1002/j.1460-2075.1988.tb03032.x; LEW J, 1992, J BIOL CHEM, V267, P25922; LEWIS SE, 1988, J CELL BIOL, V107, P2689, DOI 10.1083/jcb.107.6.2689; LINDENBAUM MH, 1988, J BIOL CHEM, V263, P5662; MACKLIS JD, 1985, IN VITRO CELL DEV B, V21, P189; MANETTO V, 1988, J NEUROPATH EXP NEUR, V47, P642, DOI 10.1097/00005072-198811000-00007; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NIXON RA, 1989, MOL BRAIN RES, V5, P93, DOI 10.1016/0169-328X(89)90001-6; NIXON RA, 1993, BRAIN PATHOL, V3, P29, DOI 10.1111/j.1750-3639.1993.tb00723.x; OBLINGER MM, 1987, J NEUROSCI, V7, P453; OHARA O, 1993, J CELL BIOL, V121, P387, DOI 10.1083/jcb.121.2.387; POLLANEN MS, 1994, ACTA NEUROPATHOL, V88, P1, DOI 10.1007/BF00294352; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RODER HM, 1991, J NEUROSCI, V11, P3325; RODER HM, 1945, J NEUROCHEM, V64, P2203; ROOTS BI, 1983, SCIENCE, V221, P971, DOI 10.1126/science.6192501; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SAITO KI, 1993, NEUROCHEM RES, V18, P231, DOI 10.1007/BF01474689; SAITO Y, 1989, J BIOCHEM, V106, P1035, DOI 10.1093/oxfordjournals.jbchem.a122960; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLAEPFER WW, 1987, J NEUROPATH EXP NEUR, V46, P117, DOI 10.1097/00005072-198703000-00001; SHAW G, 1986, EUR J CELL BIOL, V42, P1; SHEA TB, 1993, J NEUROIMMUNOL, V44, P117, DOI 10.1016/0165-5728(93)90274-3; SHETTY KT, 1993, P NATL ACAD SCI USA, V90, P6844, DOI 10.1073/pnas.90.14.6844; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SOBUE G, 1990, ACTA NEUROPATHOL, V79, P402, DOI 10.1007/BF00308716; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; STERNBERGER NH, 1985, P NATL ACAD SCI USA, V82, P4274, DOI 10.1073/pnas.82.12.4274; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TSUBUKI S, 1993, BIOCHEM BIOPH RES CO, V196, P1195, DOI 10.1006/bbrc.1993.2378; VICKERS JC, 1994, J NEUROSCI, V14, P5603; WATSON DF, 1991, BRAIN RES, V539, P103, DOI 10.1016/0006-8993(91)90691-N; WUERKER RB, 1972, INT REV CYTOL, V33, P45, DOI 10.1016/S0074-7696(08)61448-5; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; YAN MH, 1994, NATURE, V372, P798	77	117	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30404	30409		10.1074/jbc.271.48.30404	http://dx.doi.org/10.1074/jbc.271.48.30404			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940004	hybrid			2022-12-27	WOS:A1996VV15800021
J	Hoober, KL; Joneja, B; White, HB; Thorpe, C				Hoober, KL; Joneja, B; White, HB; Thorpe, C			A sulfhydryl oxidase from chicken egg white	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOFLAVIN-BINDING PROTEIN; TRIMETHYLAMINE DEHYDROGENASE; DIFFERENTIAL REACTIVITY; LIPOAMIDE DEHYDROGENASE; GLUTATHIONE-REDUCTASE; ASPERGILLUS-NIGER; GLUCOSE-OXIDASE; PIG-KIDNEY; FLAVOPROTEIN; ENZYME	A dimeric glycoprotein containing one FAD per similar to 80,000 M(r) subunit has been isolated from chicken egg white and found to have sulfhydryl oxidase activity with a range of small molecular weight thiols, Dithiothreitol was the best substrate of those tested, with a turnover number of 1030/min, a K-m, of 150 mu M, and a pH optimum of about 7.5, Oxidation of thiol substrates generates hydrogen peroxide in aerobic solution, Anaerobically, the ferricenium ion is a facile alternative electron acceptor, Reduction of the oxidase with dithionite or dithiothreitol under anaerobic conditions yields a two electron intermediate (EH(2)) showing a charge transfer band (lambda(max) 560 nm; epsilon(obs) 2.5 mM(-1) cm(-1)). Complete bleaching of the flavin and discharge of the charge transfer complex require a total of four electrons, Borohydride and catalytic photoreduction give the same spectral changes, EH(2), but not the oxidized enzyme, is inactivated by iodoacetamide with alkylation of 2.7 cysteine residues/subunit. These data indicate that the oxidase contains a redox-active disulfide bridge generating a thiolate to oxidized flavin charge transfer complex at the EH(2) level, Sulfite treatment does not form the expected flavin adduct with the native enzyme but cleaves the active site disulfide, yielding an air-stable EH(2)-like species. The close functional resemblance of the oxidase to the pyridine nucleotide-dependent disulfide oxidoreductase family is discussed.	UNIV DELAWARE,DEPT CHEM & BIOCHEM,NEWARK,DE 19716	University of Delaware			White, Harold B/B-8024-2008		NIGMS NIH HHS [GM26643] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026643] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARSCOTT LD, 1981, BIOCHEMISTRY-US, V20, P1513, DOI 10.1021/bi00509a016; BANCROFT JD, 1990, THEORY PRACTICE HIST, V3, P187; CLARE DA, 1988, ARCH BIOCHEM BIOPHYS, V265, P351, DOI 10.1016/0003-9861(88)90138-5; DELAMOTTE RS, 1987, BIOCHEMISTRY-US, V26, P7363, DOI 10.1021/bi00397a025; DELAMOTTE RS, 1987, FED PROC, V46, P3529; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; FOX BS, 1983, BIOCHEMISTRY-US, V22, P4082, DOI 10.1021/bi00286a014; FREDERICK KR, 1990, J BIOL CHEM, V265, P3793; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; GOLDSMITH LA, 1987, METHOD ENZYMOL, V143, P510; GORELICK RJ, 1985, BIOCHEMISTRY-US, V24, P6830, DOI 10.1021/bi00345a015; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JANOLINO VG, 1987, ARCH BIOCHEM BIOPHYS, V258, P265, DOI 10.1016/0003-9861(87)90344-4; JANOLINO VG, 1975, J BIOL CHEM, V250, P2532; JIANG ZY, 1983, BIOCHEMISTRY-US, V22, P3752, DOI 10.1021/bi00285a006; JOCELYN PC, 1972, BIOCH SH GROUP; KIERMEIER F., 1967, Zeitschrift fur Lebensmittel-Untersuchung und -Forschung, V132, P342, DOI 10.1007/BF01045314; KUSAKABE H, 1982, AGR BIOL CHEM TOKYO, V46, P2057, DOI 10.1080/00021369.1982.10865382; LASH LH, 1994, BIOCHIM BIOPHYS ACTA, V779, P191; LEHMAN TC, 1990, ANAL BIOCHEM, V186, P280, DOI 10.1016/0003-2697(90)90080-S; MACLACHLAN I, 1993, J BIOL CHEM, V268, P23222; MASSEY V, 1963, BIOCHEM Z, V338, P474; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MASSEY V, 1974, ANN NY ACAD SCI, V227, P446, DOI 10.1111/j.1749-6632.1974.tb14407.x; MASSEY V, 1969, J BIOL CHEM, V244, P3999; MASSEY V, 1966, BIOCHEMISTRY-US, V5, P3181, DOI 10.1021/bi00874a016; Massey V, 1980, BIOCHEM SOC T, V8, P246, DOI 10.1042/bst0080246; ODONNELL ME, 1985, BIOCHEMISTRY-US, V24, P7617, DOI 10.1021/bi00347a018; OSTROWSKI MC, 1980, BIOCHEMISTRY-US, V19, P2639, DOI 10.1021/bi00553a016; RHODES MB, 1959, J BIOL CHEM, V234, P2054; ROHLFS RJ, 1994, J BIOL CHEM, V269, P30869; ROHRER JS, 1993, ANAL BIOCHEM, V212, P7, DOI 10.1006/abio.1993.1283; ROHRER JS, 1995, TECHNIQUES PROTEIN C, V4, P65; SCHMELZER CH, 1982, BIOCHEM BIOPH RES CO, V107, P196, DOI 10.1016/0006-291X(82)91688-6; SLIWKOWSKI MX, 1984, BIOCHEM J, V220, P551; TEGOULIA V, 1993, BIOCHEM MOL BIOL INT, V31, P769; THORPE C, 1976, J BIOL CHEM, V251, P3553; THORPE C, 1979, BIOCHEMISTRY-US, V18, P331, DOI 10.1021/bi00569a016; TORCHINSKY YM, 1981, SULFUR PROTEINS, P75; WAITE JH, 1995, METHOD ENZYMOL, V258, P1; WHITE HB, 1988, ANNU REV NUTR, V8, P279, DOI 10.1146/annurev.nu.08.070188.001431; WHITE HB, 1992, ARCH BIOCHEM BIOPHYS, V295, P29, DOI 10.1016/0003-9861(92)90483-D; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; WILSON EK, 1995, BIOCHEMISTRY-US, V34, P2584, DOI 10.1021/bi00008a024; WINTER WP, 1967, COMP BIOCHEM PHYSIOL, V22, P897, DOI 10.1016/0010-406X(67)90780-3; YAMADA H, 1989, J JPN DERMATOL SOC, V99, P861; ZIEGLER DM, 1977, TRENDS BIOCHEM SCI, V2, P79, DOI 10.1016/0968-0004(77)90042-1	48	88	94	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30510	30516		10.1074/jbc.271.48.30510	http://dx.doi.org/10.1074/jbc.271.48.30510			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940019	hybrid			2022-12-27	WOS:A1996VV15800036
J	Puddicombe, SM; Wood, L; Chamberlin, SG; Davies, DE				Puddicombe, SM; Wood, L; Chamberlin, SG; Davies, DE			The interaction of an epidermal growth factor transforming growth factor alpha tail chimera with the human epidermal growth factor receptor reveals unexpected complexities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR EGF RECEPTOR; TGF-ALPHA; SIDE-CHAIN; BINDING; CELLS; YEAST; SITE	It has been assumed that substitution of homologous regions of transforming growth factor alpha (TGF-alpha) into epidermal growth factor (EGF) can be used to probe ligand-receptor recognition without detrimental effects on ligand characteristics for the human EGF receptor (EGFR), We show that a chimera of murine (m) EGF in which the carboxyl-terminal tail is substituted for that of TGF-alpha (mEGF/TGF-alpha(44-50)) results in complex features that belie this initial simplistic assumption, Comparison of EGF and mEGF/TGF-alpha(44-50) in equilibrium binding assays showed that although the relative binding affinity of the chimera was reduced 80-200-fold, it was more potent than EGF in mitogenesis assays using NR6/HER cells, This superagonist activity could not be attributed to differences in ligand processing or to binding to other members of the c-erbB family. It appeared to be due, in part, to choice of an EGFR overexpressing target cell where high receptor number compensated for the low affinity of the ligand; it also appeared to be related to the ability of the chimera to activate the EGFR tyrosine kinase, Thus, when EGFR autophosphorylation was measured, mEGF/TGF-alpha(44-50) was more potent than EGF, despite its low affinity, When tested using chicken embryo fibroblasts, substitution of the TGF-alpha carboxyl-terminal tail into mEGF failed to enhance its binding affinity for chicken EGFRs; however, the chimera was intermediate in potency between TGF-alpha and mEGF in mitogenesis assays, Our results suggest a contextual requirement for EGFR recognition which is ligand-specific, Further, the unpredictable responses to chimeric ligands underline the complex nature of the processes of ligand recognition, receptor activation, and the ensuing cellular response.	SOUTHAMPTON GEN HOSP, CANC RES CAMPAIGN MED ONCOL UNIT, SOUTHAMPTON SO16 6YD, HANTS, ENGLAND	University of Southampton			Davies, Donna E/H-2993-2012	Davies, Donna/0000-0002-5117-2991	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; CARPENTER G, 1976, J CELL PHYSIOL, V88, P227, DOI 10.1002/jcp.1040880212; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; CLARE JJ, 1991, GENE, V105, P205, DOI 10.1016/0378-1119(91)90152-2; COWLEY GP, 1986, BRIT J CANCER, V53, P223, DOI 10.1038/bjc.1986.39; DAVIES DE, 1996, FASEB J, V10, P1376; ENGLER DA, 1992, J BIOL CHEM, V267, P2274; ENGLER DA, 1991, MOL CELL BIOL, V11, P2425, DOI 10.1128/MCB.11.5.2425; GEORGENASCIMENTO C, 1988, BIOCHEMISTRY-US, V27, P797, DOI 10.1021/bi00402a046; GREGORY H, 1988, REGUL PEPTIDES, V22, P217, DOI 10.1016/0167-0115(88)90034-1; GRONEN LC, 1994, GROWTH FACTORS, V11, P235; HARTE MT, 1995, ARCH BIOCHEM BIOPHYS, V322, P378, DOI 10.1006/abbi.1995.1478; HOYT DW, 1994, BIOCHEMISTRY-US, V33, P15283, DOI 10.1021/bi00255a009; KLINE TP, 1990, BIOCHEMISTRY-US, V29, P7805, DOI 10.1021/bi00486a005; KOHDA D, 1992, BIOCHEMISTRY-US, V31, P11928, DOI 10.1021/bi00162a036; KRAMER RH, 1994, J BIOL CHEM, V269, P8708; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LAZAR E, 1989, MOL CELL BIOL, V9, P860, DOI 10.1128/MCB.9.2.860; MATSUNAMI RK, 1991, J CELL BIOCHEM, V46, P242, DOI 10.1002/jcb.240460307; PUDDICOMBE S, 1996, FASEB J, V10, P1376; Puddicombe SM, 1996, J BIOL CHEM, V271, P15367, DOI 10.1074/jbc.271.26.15367; Reddy CC, 1996, J CELL PHYSIOL, V166, P512, DOI 10.1002/(SICI)1097-4652(199603)166:3<512::AID-JCP6>3.0.CO;2-S; RICHTER A, 1995, J BIOL CHEM, V270, P1612, DOI 10.1074/jbc.270.4.1612; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; TADAKI DK, 1993, J BIOL CHEM, V268, P10114; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; WALKER F, 1990, BIOCHEMISTRY-US, V29, P10635, DOI 10.1021/bi00499a009; WINKLER ME, 1989, BIOCHEMISTRY-US, V28, P6373, DOI 10.1021/bi00441a033	29	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30392	30397		10.1074/jbc.271.48.30392	http://dx.doi.org/10.1074/jbc.271.48.30392			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940002	hybrid			2022-12-27	WOS:A1996VV15800019
J	Loh, E; Qi, WW; Vilaire, G; Bennett, JS				Loh, E; Qi, WW; Vilaire, G; Bennett, JS			Effect of cytoplasmic domain mutations on the agonist-stimulated ligand binding activity of the platelet integrin alpha IIb beta 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; FUNCTION-ASSOCIATED ANTIGEN-1; PHORBOL ESTER; GLANZMANN THROMBASTHENIA; ENDOPLASMIC-RETICULUM; FIBRINOGEN BINDING; FLOW-CYTOMETRY; CELL-ADHESION; BETA-SUBUNIT; MEMBRANE	Function of the platelet integrin alpha IIb beta 3 is regulated by agonist-generated signals interacting with its cytoplasmic tails, When alpha IIb beta 3 is expressed in Epstein-Barr virus-transformed B lymphocytes, stimulation of the cells with phorbol 12-myristate 13-acetate results in alpha IIb beta 3-mediated lymphocyte adherence to immobilized fibrinogen, as well as soluble fibrinogen binding to alpha IIb beta 3, indicating that agonists increase the affinity of alpha IIb beta 3 for fibrinogen in these cells, To address the contribution of the alpha IIb and beta 3 cytoplasmic tails to this process, we mutated each tail and expressed the mutants in B lymphocytes. Truncation of the alpha IIb tail did not impair unstimulated or stimulated lymphocyte adherence to fibrinogen, regardless whether the truncation was proximal or distal to the conserved GFFKR sequence. However, deleting GFFKR or replacing it with alanines markedly reduced alpha IIb beta 3 expression due to impaired intracellular assembly of alpha IIb beta 3 heterodimers, probably due to a mutation-induced change in the conformation of alpha IIb. Introducing beta 3 mutations known to impair alpha IIb beta 3 function in platelets into the cytoplasmic tail of beta 3 in lymphocytes also impaired alpha IIb beta 3 function in these cells, These studies demonstrate that the cytoplasmic tail of alpha IIb is not required for alpha IIb beta 3 function in lymphocytes, although the presence of GFFKR in the alpha IIb, tail is required for alpha IIb to interact with beta 3. Additionally, they indicate that signals interacting with the beta 3 cytoplasmic tail are responsible for the ability of agonists to stimulate alpha IIb beta 3 function.	UNIV PENN,SCH MED,DIV HEMATOL ONCOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania					NHLBI NIH HHS [HL51258, HL40387] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, R01HL051258] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUER JS, 1993, J CELL BIOL, V122, P209, DOI 10.1083/jcb.122.1.209; BENNETT JS, 1993, J BIOL CHEM, V268, P3580; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BENNETT JS, 1996, TRENDS CARDIOVAS MED, V16, P31; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BRAY PF, 1986, P NATL ACAD SCI USA, V83, P1480, DOI 10.1073/pnas.83.5.1480; CHEN YP, 1994, BLOOD, V84, P1857; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DU XP, 1993, J BIOL CHEM, V268, P23087; FARADAY N, 1994, J LAB CLIN MED, V123, P728; FILARDO EJ, 1994, J BIOL CHEM, V269, P4641; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GROGER RK, 1989, GENE, V81, P285, DOI 10.1016/0378-1119(89)90189-3; HAVERSTICK DM, 1992, AM J PHYSIOL, V262, pC916, DOI 10.1152/ajpcell.1992.262.4.C916; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; JOHNSTON GI, 1987, BLOOD, V69, P1401; KASSNER PD, 1993, J EXP MED, V178, P649, DOI 10.1084/jem.178.2.649; KASSNER PD, 1994, J BIOL CHEM, V269, P19859; KAWAGUCHI S, 1993, J BIOL CHEM, V268, P16279; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; KUROIWA T, 1991, J BIOL CHEM, V266, P9251; LAM SCT, 1992, J BIOL CHEM, V267, P5649; LOH E, 1995, J BIOL CHEM, V270, P18631, DOI 10.1074/jbc.270.31.18631; LOLLO BA, 1993, J BIOL CHEM, V268, P21693; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PALMER EL, 1993, J CELL BIOL, V123, P1289, DOI 10.1083/jcb.123.5.1289; PONCZ M, 1994, J CLIN INVEST, V93, P172, DOI 10.1172/JCI116942; RABB H, 1993, J IMMUNOL, V151, P990; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHAW LM, 1993, J CELL BIOL, V123, P1017, DOI 10.1083/jcb.123.4.1017; SILVER SM, 1987, BLOOD, V69, P1031; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; WANG RG, 1994, BLOOD, V84, pA244; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; Xia Z, 1996, BRIT J HAEMATOL, V93, P204, DOI 10.1046/j.1365-2141.1996.445980.x	45	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30233	30241		10.1074/jbc.271.47.30233	http://dx.doi.org/10.1074/jbc.271.47.30233			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939976	hybrid			2022-12-27	WOS:A1996VU52500104
J	Sato, M; Ribas, C; Hildebrandt, JD; Lanier, SM				Sato, M; Ribas, C; Hildebrandt, JD; Lanier, SM			Characterization of a G-protein activator in the neuroblastoma-glioma cell hybrid NG108-15	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; GUANINE-NUCLEOTIDE-BINDING; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; BETA-GAMMA; ADENYLYL-CYCLASE; ALPHA-SUBUNITS; BRAIN; SPECIFICITY; PRECURSOR	Purified bovine brain G-protein was used in a solution phase assay to identify membrane-associated proteins that influenced the activation of heterotrimeric G-proteins, Detergent-solubilized membrane extracts from the neuroblastoma-glioma cell hybrid NG108-15, but not the parent C6B4 glioma cell line, increased [S-35]GTP gamma S binding to purified G-protein by similar to 460%. The G-protein activator was heat sensitive, and the magnitude of its action was related to the amount of extract protein. The biophysical and biochemical properties of the G-protein activator were determined using DEAE ion exchange chromatography, gel filtration, and a lectin affinity ma trix. In the presence of added GDP (1 mu M), the enriched G-protein activator increased the initial rate of [S-35]GTP gamma S binding to brain G-protein by up to 4-fold. In the absence of added GDP, the G-protein activator elicited an initial burst in [S-35]GTP gamma S binding to brain G-protein within the first 30 s, after which the rate of nucleotide binding to G-protein was similar in the absence or presence of the G-protein activator, The stimulation of nucleotide binding to brain G-protein by the activator was also observed after resolution of G alpha from G beta gamma. The G-protein activator was distinct from other proteins (neuromodulin, tubulin, and p-amyloid precursor protein) that influence nucleotide binding to G-protein, indicating the existence of a novel signal accelerator.	MED UNIV S CAROLINA,DEPT CELL & MOL PHARMACOL & EXPT THERAPEUT,CHARLESTON,SC 29425; MED UNIV S CAROLINA,DEPT PHARMACOL,CHARLESTON,SC 29425	Medical University of South Carolina; Medical University of South Carolina				Lanier, Stephen/0000-0002-2740-7607	NIDDK NIH HHS [DK37219] Funding Source: Medline; NINDS NIH HHS [R01-NS821] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037219] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; COUPRY I, 1992, J BIOL CHEM, V267, P9852; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DINGUS J, 1994, METHOD ENZYMOL, V237, P457; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; DUZIC E, 1992, J BIOL CHEM, V267, P24045; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; HANLEY MR, 1993, NATURE, V362, P14, DOI 10.1038/362014a0; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HILDEBRANDT JD, 1990, J BIOL CHEM, V265, P9825; HUFF RM, 1985, J BIOL CHEM, V260, P864; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; MASURE HR, 1986, BIOCHEMISTRY-US, V25, P7553, DOI 10.1021/bi00371a044; MOUSLI M, 1990, FEBS LETT, V259, P260, DOI 10.1016/0014-5793(90)80023-C; NAOFF C, 1995, MOL PHARMACOL, V48, P806; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; POPOVA JS, 1994, J BIOL CHEM, V269, P21748; ROYCHOWDHURY S, 1993, BIOCHEMISTRY-US, V32, P4955, DOI 10.1021/bi00069a034; SATO M, 1995, J BIOL CHEM, V270, P15269, DOI 10.1074/jbc.270.25.15269; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SIM LJ, 1995, P NATL ACAD SCI USA, V92, P7242, DOI 10.1073/pnas.92.16.7242; STRITTMATTER SM, 1991, J BIOL CHEM, V266, P22465; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; STRITTMATTER SM, 1993, P NATL ACAD SCI USA, V90, P5327, DOI 10.1073/pnas.90.11.5327; WANG N, 1990, J BIOL CHEM, V265, P1239; WESSLINGRESNICK M, 1987, BIOCHEMISTRY-US, V26, P4316, DOI 10.1021/bi00388a020; WILCOX MD, 1995, J BIOL CHEM, V270, P4189, DOI 10.1074/jbc.270.9.4189	34	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30052	30060		10.1074/jbc.271.47.30052	http://dx.doi.org/10.1074/jbc.271.47.30052			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939952	hybrid			2022-12-27	WOS:A1996VU52500080
J	Michalak, M; Burns, K; Andrin, C; Mesaeli, N; Jass, GH; Busaan, JL; Opas, M				Michalak, M; Burns, K; Andrin, C; Mesaeli, N; Jass, GH; Busaan, JL; Opas, M			Endoplasmic reticulum form of calreticulin modulates glucocorticoid-sensitive gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; MUSCLE SARCOPLASMIC-RETICULUM; CELL-SURFACE CALRETICULIN; AMINO-ACID-SEQUENCE; NF-KAPPA-B; TRANSCRIPTIONAL ACTIVATION; TRANSMEMBRANE PROTEIN; SIGNAL-TRANSDUCTION; ESCHERICHIA-COLI; CA2+ BINDING	Calreticulin is a ubiquitously expressed Ca2+-binding protein of the endoplasmic reticulum (ER), which inhibits DNA binding in vitro and transcriptional activation in vivo by steroid hormone receptors. Transient transfection assays were carried out to investigate the effects of different intracellular targeting of calreticulin on transactivation mediated by glucocorticoid receptor. BSC40 cells were transfected with either calreticulin expression vector (ER form of calreticulin) or calreticulin expression vector encoding calreticulin minus leader peptide, resulting in cytoplasmic localization of the recombinant protein. Transfection of BSC40 cells with calreticulin expression vector encoding the ER form of the protein led to 40-50% inhibition of the dexamethasone-sensitive stimulation of luciferase expression. However, in a similar experiment, but using the calreticulin expression vector encoding cytoplasmic calreticulin, dexamethasone-stimulated activation of the luciferase reporter gene was inhibited by only 10%. We conclude that the ER, but not cytosolic, form of calreticulin is responsible for inhibition of glucocorticoid receptor-mediated gene expression. These effects are specific to calreticulin, since overexpression of the ER lumenal proteins (BiP, ERp72, or calsequestrin) has no effect on glucocorticoid-sensitive gene expression. The N domain of calreticulin binds to the DNA binding domain of the glucocorticoid receptor in vitro; however, we show that the N+P domain of calreticulin, when synthesized without the ER signal sequence, does not inhibit glucocorticoid receptor function in vivo. Furthermore, expression of the N domain of calreticulin and the DNA binding domain of glucocorticoid receptor as fusion proteins with GAL4 in the yeast two-hybrid system revealed that calreticulin does not interact with glucocorticoid receptor under these conditions. We conclude that calreticulin and glucocorticoid receptor may not interact in vivo and that the calreticulin-dependent modulation of the glucocorticoid receptor function may therefore be due to a calreticulin-dependent signaling from the ER.	UNIV TORONTO,DEPT ANAT & CELL BIOL,TORONTO,ON M5S 1A8,CANADA	University of Toronto	Michalak, M (corresponding author), UNIV ALBERTA,DEPT BIOCHEM,MED RES COUNCIL GRP MOL BIOL MEMBRANES,EDMONTON,AB T6G 2S2,CANADA.			Mesaeli, Nasrin/0000-0003-1456-4643				Ausubel FM, 1988, MOL REPROD DEV; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAKSH S, 1991, J BIOL CHEM, V266, P21458; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BENNETT DL, 1995, CURR BIOL, V5, P1225, DOI 10.1016/S0960-9822(95)00243-0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; Burns Kimberly, 1994, Trends in Cell Biology, V4, P152, DOI 10.1016/0962-8924(94)90190-2; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; CAO XJ, 1995, J BIOL CHEM, V270, P494, DOI 10.1074/jbc.270.1.494; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COPPOLINO M, 1995, J BIOL CHEM, V270, P23132, DOI 10.1074/jbc.270.39.23132; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; DEDHAR S, 1994, TRENDS BIOCHEM SCI, V19, P269, DOI 10.1016/0968-0004(94)90001-9; Desai D, 1996, J BIOL CHEM, V271, P15153, DOI 10.1074/jbc.271.25.15153; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; GRAY AJ, 1995, J BIOL CHEM, V270, P26602, DOI 10.1074/jbc.270.44.26602; GREBER UF, 1995, J CELL BIOL, V128, P5, DOI 10.1083/jcb.128.1.5; HARLOW E, 1988, ANTIBODIES; HOPPS HE, 1963, J IMMUNOL, V91, P416; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; JOHNSON E, 1992, J BIOL CHEM, V267, P14412; KENNEDY TE, 1992, NEURON, V9, P1013, DOI 10.1016/0896-6273(92)90062-I; KUWABARA K, 1995, J BIOL CHEM, V270, P8179, DOI 10.1074/jbc.270.14.8179; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; Lin F, 1996, HEPATOLOGY, V23, P57, DOI 10.1002/hep.510230109; LIU NG, 1994, J BIOL CHEM, V269, P28635; Macaulay C, 1996, J CELL BIOL, V132, P5, DOI 10.1083/jcb.132.1.5; MCMILLAN A, 1994, CURR OPIN BIOTECH, V6, P540; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; MICHALAK M, 1996, CALRETICULIN; MILNER RE, 1992, BIOCHEM J, V288, P1037, DOI 10.1042/bj2881037; MILNER RE, 1991, J BIOL CHEM, V266, P7155; MORI K, 1993, CELL, V74, P743; NAKAMURA M, 1993, EXP CELL RES, V205, P101, DOI 10.1006/excr.1993.1063; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; OPAS M, 1991, J CELL PHYSIOL, V149, P160, DOI 10.1002/jcp.1041490120; Otteken A, 1996, J BIOL CHEM, V271, P97, DOI 10.1074/jbc.271.1.97; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; Pahl HL, 1996, J CELL BIOL, V132, P511, DOI 10.1083/jcb.132.4.511; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; SATO R, 1994, J BIOL CHEM, V269, P17267; SCOTT BT, 1988, J BIOL CHEM, V263, P8958; SINGH NK, 1994, P NATL ACAD SCI USA, V91, P12770, DOI 10.1073/pnas.91.26.12770; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; Sontheimer RD, 1993, IMMUNOLOGIST, V1, P155; STARNAUD R, 1995, J CELL BIOL, V131, P1351, DOI 10.1083/jcb.131.5.1351; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; STENDAHL O, 1994, SCIENCE, V265, P1439, DOI 10.1126/science.8073285; TARTAKOFF AM, 1983, J CELL BIOL, V97, P1243, DOI 10.1083/jcb.97.4.1243; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIRTANEN I, 1980, J CELL BIOL, V85, P429, DOI 10.1083/jcb.85.2.429; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WHEELER DG, 1995, NUCLEIC ACIDS RES, V23, P3268, DOI 10.1093/nar/23.16.3268; WHITE TK, 1995, J BIOL CHEM, V270, P15926, DOI 10.1074/jbc.270.27.15926; WINROW CJ, 1995, MOL CELL ENDOCRINOL, V111, P175, DOI 10.1016/0303-7207(95)03563-M; YE Q, 1994, J BIOL CHEM, V269, P11306	64	80	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29436	29445		10.1074/jbc.271.46.29436	http://dx.doi.org/10.1074/jbc.271.46.29436			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910610	hybrid			2022-12-27	WOS:A1996VT05200102
J	Furukawa, Y; Iwase, S; Terui, Y; Kikuchi, J; Sakai, T; Nakamura, M; Kitagawa, S; Kitagawa, M				Furukawa, Y; Iwase, S; Terui, Y; Kikuchi, J; Sakai, T; Nakamura, M; Kitagawa, S; Kitagawa, M			Transcriptional activation of the cdc2 gene is associated with Fas-induced apoptosis of human hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; INHIBITS PHOSPHORYLATION; PROTEIN-KINASES; BUTYROLACTONE-I; LEUKEMIC-CELLS; CYCLE ARREST; ANTI-FAS; C-MYC; EXPRESSION; DEATH	Apoptosis has recently been hypothesized to be the result of aberrant cell cycle control. In this study, we have investigated the role of cell cycle regulatory elements in Fas-induced apoptosis of hematopoietic cells. When HL-60 cells were treated with anti-Fas antibody, rapid activation of growth-associated histone H1 kinase was observed without any change in cell cycle distribution, This was accompanied by the increase in cdc2 mRNA expression and Cdc2 kinase activity. Up-regulation of cdcs mRNA was similarly induced in BCL-2-over-expressing HL-60 subline by anti-Fas treatment independently of the appearance of apoptotic phenotypes. Fas-induced apoptosis was completely inhibited by butyrolactone I, a specific inhibitor of Cdc2 kinase. Moreover, the same phenomenon was observed during Fas-induced but not spontaneous apoptosis of postmitotic granulocytes. Finally, we have found that ''Fas-responsive element'' was located between nucleotides -730 and -552 of the cdc2 promoter and was responsive for transcriptional activation of the cdc2 gene during Fas-induced apoptosis. These results indicate that aberrant activation of Cdc2 is associated with Fas-induced apoptosis of hematopoietic cells, and that the mechanism of cdc2 transcription during Fas-induced apoptosis is different from that in normal cell cycle control.	JICHI MED SCH,DEPT HEMATOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; HITACHI KOKI CO LTD,KATSUTA RES LAB,KATSUTA,IBARAKI 312,JAPAN; BANYU PHARMACEUT CO LTD,TSUKUBA RES INST,TSUKUBA,IBARAKI 30033,JAPAN	Jichi Medical University; Hitachi Limited; Merck & Company; Novartis	Furukawa, Y (corresponding author), JICHI MED SCH,INST HEMATOL,DIV HEMOPOIESIS,MINAMI KAWACHI,TOCHIGI 32904,JAPAN.		Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418				ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BELIZARIO JE, 1991, CANCER RES, V51, P2379; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BRADBURY EM, 1974, NATURE, V247, P257, DOI 10.1038/247257a0; COLOMBEL M, 1992, CANCER RES, V52, P4313; COX G, 1995, J IMMUNOL, V154, P4719; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; FURUKAWA Y, 1992, J BIOL CHEM, V267, P17121; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; FURUKAWA Y, 1995, BRIT J HAEMATOL, V90, P94, DOI 10.1111/j.1365-2141.1995.tb03385.x; FURUKAWA Y, 1995, JPN J CANCER RES, V86, P208, DOI 10.1111/j.1349-7006.1995.tb03041.x; FURUKAWA Y, 1994, J BIOL CHEM, V269, P26249; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; ISHIDA Y, 1992, J CELL PHYSIOL, V150, P484, DOI 10.1002/jcp.1041500308; IWAI K, 1994, BLOOD, V84, P1201; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KITAGAWA M, 1994, ONCOGENE, V9, P2549; KITAGAWA M, 1993, ONCOGENE, V8, P2425; KORSMEYER SJ, 1992, BLOOD, V80, P879; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; LANG RA, 1987, CELL, V51, P675, DOI 10.1016/0092-8674(87)90136-X; LEITHAUSER F, 1993, LAB INVEST, V69, P415; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; MCGOWAN CH, 1990, MOL CELL BIOL, V10, P3847, DOI 10.1128/MCB.10.7.3847; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RAZA A, 1995, BLOOD, V86, P268, DOI 10.1182/blood.V86.1.268.bloodjournal861268; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHIMIZU M, 1995, MOL CELL BIOL, V15, P2882; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TERUI Y, 1995, J BIOCHEM-TOKYO, V117, P77, DOI 10.1093/oxfordjournals.jbchem.a124725; TERUI Y, 1995, J CELL PHYSIOL, V164, P74, DOI 10.1002/jcp.1041640110; Terui Y, 1996, J IMMUNOL, V156, P1981; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186; YAMADA H, 1991, BLOOD, V78, P1988; YAMAMOTO M, 1994, EXP CELL RES, V210, P94, DOI 10.1006/excr.1994.1014; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	59	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28469	28477		10.1074/jbc.271.45.28469	http://dx.doi.org/10.1074/jbc.271.45.28469			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910474	hybrid			2022-12-27	WOS:A1996VU03300074
J	Funderburgh, JL; Funderburgh, ML; Mann, MM; Prakash, S; Conrad, GW				Funderburgh, JL; Funderburgh, ML; Mann, MM; Prakash, S; Conrad, GW			Synthesis of corneal keratan sulfate proteoglycans by bovine keratocytes in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE PROTEIN; LINKAGE-REGION; ORGAN-CULTURE; GLYCOSAMINOGLYCANS; BIOSYNTHESIS; FIBROBLASTS; LUMICAN; STROMA; GALACTOSIDASE; KERATOCONUS	Keratan sulfate proteoglycans (KSPGs) are the major proteoglycans of the cornea and are secreted by keratocytes in the corneal stroma. Previous studies have been able to show only transient secretion of KSPG in cell culture, In this study, cultures of bovine keratocytes were found to secrete the three previously characterized KSPG proteins into culture medium, Reactivity with monoclonal antibody 122 demonstrated substitution of these proteins with keratan sulfate chains. KSPG constituted 15% of the proteoglycan metabolically labeled with [S-35]sulfate in keratocyte culture medium. This labeled KSPG contained keratan sulfate chains of 4700 Da compared to 21,000 Da for bovine corneal keratan sulfate. Labeled keratan sulfate from cultures contained nonsulfated, monosulfated, and disulfated disaccharides that were released by digestion with endo-beta-galactosidase or keratanase II, Nonsulfated disaccharides were relatively more abundant in keratan sulfate from culture than in corneal keratan sulfate, These results show that cultured bovine keratocytes maintain the ability to express all three of the known KSPG proteins, modified with keratan sulfate chains and sulfated on both N-acetylglucosamine and galactose moieties. KSPG made in vitro differs from that found in vivo in the length and sulfation of its keratan sulfate chains, The availability of cell cultures secreting corneal keratan sulfate proteoglycans provides an opportunity to examine biosynthesis and control of this important class of molecules.			Funderburgh, JL (corresponding author), KANSAS STATE UNIV,DIV BIOL,ACKERT HALL,MANHATTAN,KS 66506, USA.				NATIONAL EYE INSTITUTE [R01EY000952, R01EY009368] Funding Source: NIH RePORTER; NEI NIH HHS [EY00952, EY09368] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AXELSSON I, 1975, BIOCHEM J, V145, P491, DOI 10.1042/bj1450491; BLECKMANN H, 1980, EXP EYE RES, V30, P469, DOI 10.1016/0014-4835(80)90031-7; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; CINTRON C, 1977, DEV BIOL, V61, P346, DOI 10.1016/0012-1606(77)90304-9; CONRAD GW, 1982, J BIOL CHEM, V257, P464; CONRAD GW, 1974, EXP EYE RES, V18, P421, DOI 10.1016/0014-4835(74)90079-7; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; COSTER L, 1983, EXP EYE RES, V36, P517, DOI 10.1016/0014-4835(83)90045-3; DAHL IMS, 1978, EXP EYE RES, V27, P175, DOI 10.1016/0014-4835(78)90087-8; DAHL IMS, 1982, EXP EYE RES, V34, P83, DOI 10.1016/0014-4835(82)90011-2; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; FUKUDA MN, 1981, J BIOL CHEM, V256, P3900; FUNDERBURGH JL, 1989, INVEST OPHTH VIS SCI, V30, P2278; FUNDERBURGH JL, 1988, INVEST OPHTH VIS SCI, V29, P1116; FUNDERBURGH JL, 1989, INVEST OPHTH VIS SCI, V30, P435; FUNDERBURGH JL, 1983, CURR EYE RES, V2, P769; FUNDERBURGH JL, 1991, BIOCHEM SOC T, V19, P871, DOI 10.1042/bst0190871; FUNDERBURGH JL, 1983, INVEST OPHTH VIS SCI, V24, P208; FUNDERBURGH JL, 1990, INVEST OPHTH VIS SCI, V31, P419; FUNDERBURGH JL, 1986, DEV BIOL, V116, P267, DOI 10.1016/0012-1606(86)90130-2; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P24773; FUNDERBURGH JL, 1987, J BIOL CHEM, V262, P11634; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P14226; FUNDERBURGH JL, 1993, J BIOL CHEM, V268, P11874; FUNDERBURGH JL, 1990, J BIOL CHEM, V265, P8297; FUNDERBURGH JL, 1989, KERATAN SULPHATE CHE, P39; HART GW, 1976, J BIOL CHEM, V251, P6513; HART GW, 1978, DEV BIOL, V62, P78, DOI 10.1016/0012-1606(78)90094-5; HASCALL VC, 1991, LIMB DEV REGENERAT B, P3; HASSELL JR, 1992, INVEST OPHTH VIS SCI, V33, P547; HASSELL JR, 1983, ARCH BIOCHEM BIOPHYS, V222, P362, DOI 10.1016/0003-9861(83)90532-5; HOPWOOD JJ, 1973, BIOCHEM J, V135, P631, DOI 10.1042/bj1350631; KELLER R, 1983, H-S Z PHYSIOL CHEM, V364, P253; KELLER R, 1981, H-S Z PHYSIOL CHEM, V362, P327, DOI 10.1515/bchm2.1981.362.1.327; MELROSE J, 1988, ANAL BIOCHEM, V170, P293, DOI 10.1016/0003-2697(88)90634-3; Nakazawa K., 1989, KERATAN SULPHATE CHE, P99; NILSSON B, 1983, J BIOL CHEM, V258, P6056; OBEN M, 1987, BIOCHEM J, V248, P85; SAWAGUCHI S, 1991, INVEST OPHTH VIS SCI, V32, P1846; SCHRECENGOST PK, 1992, ARCH BIOCHEM BIOPHYS, V292, P54, DOI 10.1016/0003-9861(92)90050-7; YUE BYJ, 1976, J BIOCH, V158, P567	41	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31431	31436		10.1074/jbc.271.49.31431	http://dx.doi.org/10.1074/jbc.271.49.31431			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940154	hybrid			2022-12-27	WOS:A1996VW68600065
J	Maggio, R; Barbier, P; Fornai, F; Corsini, GU				Maggio, R; Barbier, P; Fornai, F; Corsini, GU			Functional role of the third cytoplasmic loop in muscarinic receptor dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; ADRENERGIC-RECEPTORS; CHOLINERGIC RECEPTOR; SUBTYPES; CELLS; INTERNALIZATION; GENES; COEXPRESSION; DELINEATION; EXPRESSION	By means of the expression of two chimeric receptors, alpha(2)/m3 and m3/alpha(2), in which the carboxyl-terminal receptor portions, containing transmembrane (TM) domains VI and VII, were exchanged between the alpha(2C) adrenergic and the m3 muscarinic receptor, Maggio ct al, (Maggio, R., Vogel, Z., and Wess, J. (1993) Proc, Natl. Acad. Sci. U.S.A, 90, 3103-31073) demonstrated that G protein-linked receptors are able to interact functionally with each other at the molecular level to form (hetero)dimers. In the present study we tested the hypothesis that interaction between receptors might depend on the presence of a long third intracellular (i3) loop and that shortening this loop could impair the capability of receptors to form dimers, To address this question, we initially created short chimeric alpha(2) adrenergic/m3 muscarinic receptors in which 196 amino acids were deleted from the i3 loop (alpha(2)/m3-short and m3/alpha(2)-short). Although co-transfection of alpha(2)/m3 and m3/alpha(2) resulted in the appearance of specific binding, the co-expression of the two short constructs (alpha(2)/m3-short and m3/alpha(2)-short), either together or in combination, respectively, with m8/alpha(2) and alpha(2)/m3 did not result in any detectable binding activity, In another set of experiments, a mutant m3 receptor, m3/m2(16aa), containing 16 amino acids of the m2 receptor sequence at the amino terminus of the third cytoplasmic loop, which was capable of binding muscarinic ligands but was virtually unable to stimulate phosphatidylinositol hydrolysis, was also mutated in the i3 loop, resulting in the m3/m2(16aa)-short receptor, Although co-transfection of m3/m2(16aa) with a truncated form of the m3 receptor (m8-trunc, containing an in frame stop codon after amino acid codon 272 of the rat m3 sequence) resulted in a considerable carbachol-stimulated phosphatidylinositol breakdown, the co-transfection of m3/m2(16aa) short with the truncated form of the m3 receptor did not result in any recovery of the functional activity, Thus, these data suggest that intermolecular interaction between muscarinic receptors, involving the exchange of amino-terminal (containing TM domains I-V) and carboxyl-terminal (containing TRI domains VI and MI) receptor fragments depends on the presence of a long ia loop, One may speculate that when alternative forms of receptors with a different length of the i3 loop exist, they could have a different propensity to dimerize.	ASSOC ANNI VERDI,I-00152 ROME,ITALY		Maggio, R (corresponding author), UNIV PISA,SCH MED,INST PHARMACOL,VIA ROMA 55,I-56100 PISA,ITALY.		maggio, Roberto/Q-2032-2015; FORNAI, FRANCESCO/AAA-5312-2019	FORNAI, FRANCESCO/0000-0002-3883-5084; Maggio, Roberto/0000-0003-4436-2356				BARBIER P, 1995, EUR J PHARM-MOLEC PH, V290, P125, DOI 10.1016/0922-4106(95)90024-1; BERNHEIM L, 1992, P NATL ACAD SCI USA, V89, P9544, DOI 10.1073/pnas.89.20.9544; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CONKLIN BR, 1988, P NATL ACAD SCI USA, V85, P8698, DOI 10.1073/pnas.85.22.8698; GIROS B, 1989, NATURE, V342, P923, DOI 10.1038/342923a0; HU JG, 1993, J NEUROCHEM, V61, P578; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LAMEH J, 1992, J BIOL CHEM, V267, P13406; MAEDA S, 1990, FEBS LETT, V269, P386, DOI 10.1016/0014-5793(90)81199-X; MAGGIO R, 1995, J NEUROCHEM, V65, P943; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MAGGIO R, 1993, FEBS LETT, V319, P195, DOI 10.1016/0014-5793(93)80066-4; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249; SCHONEBERG T, 1995, J BIOL CHEM, V270, P18000; SHAPIRO RA, 1989, BIOCHEMISTRY-US, V28, P8946, DOI 10.1021/bi00448a039; VOIGT MM, 1991, FEBS LETT, V278, P45, DOI 10.1016/0014-5793(91)80080-M; WESS J, 1990, MOL PHARMACOL, V38, P517; WREGGETT KA, 1995, J BIOL CHEM, V270, P22488, DOI 10.1074/jbc.270.38.22488	23	91	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31055	31060		10.1074/jbc.271.49.31055	http://dx.doi.org/10.1074/jbc.271.49.31055			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940100	hybrid			2022-12-27	WOS:A1996VW68600011
J	Ullsperger, C; Cozzarelli, NR				Ullsperger, C; Cozzarelli, NR			Contrasting enzymatic activities of topoisomerase IV and DNA gyrase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERTWINED CATENATED DIMERS; NICKING-CLOSING ENZYME; REPLICATION IN-VITRO; CHROMOSOME SEGREGATION; RECOMBINATION SITE; TN3 RESOLVASE; PURIFICATION; MECHANISM; PROTEIN; DECATENATION	DNA gyrase and topoisomerase IV (Topo IV) have distinct roles as unlinking enzymes during DNA replication despite 40% sequence identity between them, DNA gyrase unlinks replicating DNA by introducing negative supercoils while Topo IV decatenates the two daughter molecules, For this study, we measured the rates of unlinking of various topoisomers of DNA by DNA gyrase and Topo TV, Each enzyme has marked preferences for certain strand-passage reactions. DNA gyrase is a relatively poor decatenase, catalyzing strand-passage events that result in supercoiling at rates several orders of magnitude faster than those causing decatenation, Topo IV, in contrast, decatenates linked circles 10-40 times more quickly than it removes the intramolecular crossings from supercoiled DNA. Supercoiled catenanes are unlinked at an even more increased rate by Topo IV. Thus, the supercoils augment decatenation rather than compete with catenane crossings for their removal. Knot crossings and the crossings of multiply interlinked catenanes are also preferentially removed by Topo TV, This ability of Topo IV to selectively unlink catenated molecules mirrors its key role in decatenation of replicating chromosomes in vivo.	UNIV CALIF BERKELEY,DEPT CELLULAR & MOL BIOL,DIV BIOCHEM & MOL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley								Bates AD, 1996, BIOCHEMISTRY-US, V35, P1408, DOI 10.1021/bi952433y; BENJAMIN HW, 1990, J BIOL CHEM, V265, P6441; BENJAMIN HW, 1985, CELL, V40, P147, DOI 10.1016/0092-8674(85)90318-6; BENJAMIN HW, 1986, P RA WELCH F C CHEM, V29, P107; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BIRD RE, 1970, J MOL BIOL, V49, P343, DOI 10.1016/0022-2836(70)90249-4; BLISKA JB, 1988, THESIS U CALIFORNIA; BROWN PO, 1979, SCIENCE, V206, P1081, DOI 10.1126/science.227059; Champoux J J, 1994, Adv Pharmacol, V29A, P71; CHAMPOUX JJ, 1980, MECH STUDIES DNA REP, V19, P809; COZZARELLI NR, 1992, P S APPL MATH, V45, P1; CRISONA NJ, 1994, J MOL BIOL, V243, P437, DOI 10.1006/jmbi.1994.1671; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DYNAN WS, 1981, J BIOL CHEM, V256, P5860; Eckstein F., 1995, NUCLEIC ACIDS MOL BI, P115; HIASA H, 1994, J BIOL CHEM, V269, P2093; Hiasa H, 1996, J BIOL CHEM, V271, P21529, DOI 10.1074/jbc.271.35.21529; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KATO J, 1992, J BIOL CHEM, V267, P25676; KIRKEGAARD K, 1981, CELL, V23, P721, DOI 10.1016/0092-8674(81)90435-9; KREUZER KN, 1980, CELL, V20, P245, DOI 10.1016/0092-8674(80)90252-4; KREUZER KN, 1979, J BACTERIOL, V140, P425; LEVENE SD, 1995, BIOPHYS J, V69, P1036, DOI 10.1016/S0006-3495(95)79978-7; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU LF, 1978, CELL, V15, P979, DOI 10.1016/0092-8674(78)90281-7; MARIANS KJ, 1987, J BIOL CHEM, V262, P10362; MORRISON A, 1980, J BIOL CHEM, V255, P2211; MORRISON A, 1981, P NATL ACAD SCI-BIOL, V78, P1416, DOI 10.1073/pnas.78.3.1416; NASH HA, 1983, METHOD ENZYMOL, V100, P210; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; PEEBLES CL, 1979, COLD SPRING HARB SYM, V43, P41, DOI 10.1101/SQB.1979.043.01.008; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; PENG H, 1995, J BIOL CHEM, V270, P25286, DOI 10.1074/jbc.270.42.25286; PENG H, 1993, J BIOL CHEM, V268, P24481; PETTIJOHN DE, 1982, CELL, V30, P667, DOI 10.1016/0092-8674(82)90269-0; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; REED RR, 1981, CELL, V25, P721, DOI 10.1016/0092-8674(81)90179-3; ROCA J, 1993, J BIOL CHEM, V268, P14250; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROCA J, 1995, TRENDS BIOCHEM SCI, V20, P156, DOI 10.1016/S0968-0004(00)88993-8; Roca J, 1996, GENES CELLS, V1, P17, DOI 10.1046/j.1365-2443.1996.01001.x; Sambrook J., 2002, MOL CLONING LAB MANU; STECK TR, 1984, CELL, V36, P1081, DOI 10.1016/0092-8674(84)90058-8; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; SUNDIN O, 1980, CELL, V21, P103, DOI 10.1016/0092-8674(80)90118-X; SUNDIN O, 1981, CELL, V25, P659, DOI 10.1016/0092-8674(81)90173-2; TSE YC, 1980, J BIOL CHEM, V255, P5560; Tse-Dinh Y C, 1994, Adv Pharmacol, V29A, P21; VARSHAVSKY A, 1983, MECHANISMS DNA REPLI, P463; Vologodskii A, 1996, BIOPHYS J, V70, P2548, DOI 10.1016/S0006-3495(96)79826-0; VOLOGODSKII AV, 1994, ANNU REV BIOPH BIOM, V23, P609, DOI 10.1146/annurev.bb.23.060194.003141; VOLOGODSKII AV, 1993, J MOL BIOL, V232, P1130, DOI 10.1006/jmbi.1993.1465; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WANG JC, 1981, MECHANISTIC STUDIES, P769; WASSERMAN SA, 1988, NATURE, V334, P448, DOI 10.1038/334448a0; WATSON JD, 1953, NATURE, V171, P123; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WEAVER DT, 1985, CELL, V41, P565, DOI 10.1016/S0092-8674(85)80029-5; ZECHIEDRICH EL, 1995, GENE DEV, V9, P2859, DOI 10.1101/gad.9.22.2859	64	105	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31549	31555		10.1074/jbc.271.49.31549	http://dx.doi.org/10.1074/jbc.271.49.31549			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940171	hybrid			2022-12-27	WOS:A1996VW68600082
J	Decroly, E; Wouters, S; DiBello, C; Lazure, C; Ruysschaert, JM; Seidah, NG				Decroly, E; Wouters, S; DiBello, C; Lazure, C; Ruysschaert, JM; Seidah, NG			Identification of the paired basic convertases implicated in HIV gp160 processing based on in vitro assays and expression in CD4(+) cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEIN; PROPROTEIN CONVERTASE; PROTEOLYTIC CLEAVAGE; PRO-PROTEIN; PROHORMONE CONVERTASES; MUTATIONAL ANALYSIS; HTLV-III/LAV; VIRAL FUSION; HUMAN FURIN	The human immunodeficiency virus HIV envelope glycoprotein gp160 is synthesized as an inactive precursor, which is processed into its fusiogenic form gp120/gp41 by host cell proteinases during its intracellular trafficking. Hexin/subtilisin-related endoproteases have been proposed to be enzyme candidates for this maturation process. In the present study, 1) we examined the ability of partially purified precursor convertases and their isoforms to cleave gp160 in vitro. The data demonstrate that all the convertases tested specifically cleave the HIV envelope glycoprotein into gp120 and gp41. 2) We demonstrated that a 19-amino acid model peptide spanning the gp120/gp41 junction is cleaved by all convertases at the same gp160 site as that recognized in HIV-infected cells. 3) In an effort to evaluate specific convertase inhibitors, we showed that the alpha(1)-antitrypsin variant, alpha(1)-PDX, inhibits equally well the ability of the tested convertases to cleave gp160 in vitro. 4) Three lymphocyte cell lines were screened by reverse transcription polymerase chain reaction in an effort to identify which are the convertases expressed in the most common HIV target, the CD4(+) lymphocytes. The data demonstrate that furin, PC5/6, and the newly cloned PC7 are the main transcribed convertases, suggesting that these proteinases are the major gp160-converting enzymes in T4 lymphocytes.	CLIN RES INST MONTREAL,BIOCHEM NEUROENDOCRINOL LAB,MONTREAL,PQ H2W 1R7,CANADA; CLIN RES INST MONTREAL,PEPTIDE METAB & STRUCT LAB,MONTREAL,PQ H2W 1R7,CANADA; FREE UNIV BRUSSELS,CHIM PHYS MACROMOL INTERFACES LAB,B-1050 BRUSSELS,BELGIUM; UNIV PADUA,INST IND CHEM,I-35131 PADUA,ITALY	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Padua			Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342; DECROLY, Etienne/0000-0002-6046-024X				ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Basak A, 1995, J Pept Sci, V1, P385, DOI 10.1002/psc.310010606; BENJANNET S, 1995, J NEUROCHEM, V64, P2303; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BOSCH V, 1990, J VIROL, V64, P2337, DOI 10.1128/JVI.64.5.2337-2344.1990; BRAKCH N, 1995, BIOCHEM BIOPH RES CO, V213, P356, DOI 10.1006/bbrc.1995.2137; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1029, P267, DOI 10.1016/0005-2736(90)90163-I; Bruzzaniti A, 1996, BIOCHEM J, V314, P727, DOI 10.1042/bj3140727; CLEMENTS GJ, 1991, AIDS RES HUM RETROV, V7, P3, DOI 10.1089/aid.1991.7.3; DEBIE I, 1996, IN PRESS J CELL BIOL; DECROLY E, 1994, J BIOL CHEM, V269, P12240; DEWAR RL, 1989, J VIROL, V63, P2452, DOI 10.1128/JVI.63.6.2452-2456.1989; FENOUILLET E, 1992, VIROLOGY, V187, P825, DOI 10.1016/0042-6822(92)90487-A; FRANZUSOFF A, 1995, J BIOL CHEM, V270, P3154, DOI 10.1074/jbc.270.7.3154; FREED EO, 1989, J VIROL, V63, P4670, DOI 10.1128/JVI.63.11.4670-4675.1989; FTOUHI N, 1994, DNA CELL BIOL, V13, P395, DOI 10.1089/dna.1994.13.395; GU ML, 1995, FEBS LETT, V365, P95, DOI 10.1016/0014-5793(95)00447-H; GUO HG, 1990, VIROLOGY, V174, P217, DOI 10.1016/0042-6822(90)90070-8; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HATSUZAWA K, 1992, J BIOCHEM-TOKYO, V111, P296, DOI 10.1093/oxfordjournals.jbchem.a123753; Hruby D E, 1986, Methods Enzymol, V124, P295; IVANOFF LA, 1992, VIROLOGY, V187, P423, DOI 10.1016/0042-6822(92)90444-T; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; KAMOSHITA K, 1995, J BIOCHEM, V117, P1244, DOI 10.1093/oxfordjournals.jbchem.a124851; KIDO H, 1993, J BIOL CHEM, V268, P13406; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; LEBEAU MC, 1991, NUCLEIC ACIDS RES, V19, P1337, DOI 10.1093/nar/19.6.1337; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; MALIDE D, 1995, J HISTOCHEM CYTOCHEM, V43, P11, DOI 10.1177/43.1.7822759; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; Meerabux J, 1996, CANCER RES, V56, P448; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Moore J P, 1991, AIDS, V5 Suppl 2, pS21, DOI 10.1097/00002030-199101001-00004; MORIKAWA Y, 1993, J VIROL, V67, P3601, DOI 10.1128/JVI.67.6.3601-3604.1993; MOULARD M, 1994, FEBS LETT, V338, P281, DOI 10.1016/0014-5793(94)80284-X; NAKAGAWA T, 1993, FEBS LETT, V327, P165, DOI 10.1016/0014-5793(93)80163-O; OHNISHI Y, 1994, J VIROL, V68, P4075, DOI 10.1128/JVI.68.6.4075-4079.1994; PAQUET L, 1994, J BIOL CHEM, V269, P19279; REHEMTULLA A, 1993, BIOCHEMISTRY-US, V32, P11586, DOI 10.1021/bi00094a015; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; Seidah NG, 1996, BIOCHEM J, V314, P951, DOI 10.1042/bj3140951; Seidah NG, 1996, FEBS LETT, V379, P247, DOI 10.1016/0014-5793(95)01520-5; SEIDAH NG, 1994, METHOD ENZYMOL, V244, P175; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; SHENNAN KIJ, 1991, FEBS LETT, V284, P277, DOI 10.1016/0014-5793(91)80703-6; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; VERONESE FD, 1985, SCIENCE, V229, P1402, DOI 10.1126/science.2994223; VEY M, 1992, VIROLOGY, V188, P408, DOI 10.1016/0042-6822(92)90775-K; VIDRICAIRE G, 1993, BIOCHEM BIOPH RES CO, V195, P1011, DOI 10.1006/bbrc.1993.2145; Vollenweider F, 1996, BIOCHEM J, V314, P521, DOI 10.1042/bj3140521; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580	61	100	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30442	30450		10.1074/jbc.271.48.30442	http://dx.doi.org/10.1074/jbc.271.48.30442			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940009	hybrid			2022-12-27	WOS:A1996VV15800026
J	Faure, E; Gouedard, L; Imbeaud, S; Cate, R; Picard, JY; Josso, N; diClemente, N				Faure, E; Gouedard, L; Imbeaud, S; Cate, R; Picard, JY; Josso, N; diClemente, N			Mutant isoforms of the anti-Mullerian hormone type II receptor are not expressed at the cell membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA RECEPTOR; TRANSFORMING GROWTH-FACTOR-BETA-2; ENDOPLASMIC-RETICULUM; ACTIVIN RECEPTORS; CRYSTAL-STRUCTURE; KINASE; MUTATION; FAMILY; ACTIVATION; TRANSPORT	Anti-Mullerian hormone, a member of the transforming growth factor beta superfamily, produces early regression of Mullerian ducts in the male fetus through binding to a serine/threonine kinase receptor, homologous to type II receptors of the transforming growth factor beta (TGF-beta) family. A splice mutation of this receptor, described in a patient with abnormal retention of Mullerian derivatives, generates two mutant isoforms, one lacking the second exon and the other bearing an insertion of 12 bases between exons 2 and 3. Using hemagglutinin-tagged recombinant receptors, we have visualized wild type and mutant receptors in COS cells by Western blotting and immunoprecipitation. The 82-kDa, endoglycosidase H-insensitive, mature form of the wild type receptor is reduced to 68 kDa by N-glycosidase F treatment. Mutant receptor isoforms, 73 and 63 kDa for the long and short form, respectively, are sensitive to endoglycosidase H, suggesting that they are retained in the endoplasmic reticulum. Indeed, only the wild type receptor was expressed on the cell surface and bound iodinated anti-Mullerian hormone. These results provide a biological explanation for the failure of the mutant receptor to induce Mullerian regression.	ECOLE NORMALE SUPER,UNITE RECH ENDOCRINOL DEV,INSERM,F-92120 MONTROUGE,FRANCE; BIOGEN INC,CAMBRIDGE,MA 02142	Institut National de la Sante et de la Recherche Medicale (Inserm); Biogen			Imbeaud, Sandrine/P-8780-2017	Imbeaud, Sandrine/0000-0001-8439-6732; di Clemente, Nathalie/0000-0001-9087-3486				ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BAARENDS WM, 1994, DEVELOPMENT, V120, P189; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CREIGHTON T, 1995, PHILOS T ROY SOC B, V348, P5, DOI 10.1098/rstb.1995.0039; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; DICLEMENTE N, 1994, MOL ENDOCRINOL, V8, P1006, DOI 10.1210/me.8.8.1006; Griffith DL, 1996, P NATL ACAD SCI USA, V93, P878, DOI 10.1073/pnas.93.2.878; Hirai R, 1996, EXP CELL RES, V223, P135, DOI 10.1006/excr.1996.0066; IMBEAUD S, 1994, HUM MOL GENET, V3, P125, DOI 10.1093/hmg/3.1.125; IMBEAUD S, 1995, NAT GENET, V11, P382, DOI 10.1038/ng1295-382; JOST A, 1953, RECENT PROG HORM RES, V8, P379; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Kosugi S, 1996, BIOCHEM BIOPH RES CO, V221, P636, DOI 10.1006/bbrc.1996.0648; LAU MMH, 1989, J BIOL CHEM, V264, P21376; LEHRMAN MA, 1987, J BIOL CHEM, V262, P401; LINGAPPA VR, 1989, J CLIN INVEST, V83, P739, DOI 10.1172/JCI113952; LODISH HF, 1988, J BIOL CHEM, V263, P2107; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MISRAHI M, 1994, EUR J BIOCHEM, V222, P711, DOI 10.1111/j.1432-1033.1994.tb18916.x; OKADOME T, 1994, J BIOL CHEM, V269, P30753; ROZELL TG, 1995, MOL ENDOCRINOL, V9, P1727; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SUZUKI A, 1994, FEBS LETT, V355, P19, DOI 10.1016/0014-5793(94)01156-7; Taubes G, 1996, SCIENCE, V271, P1493, DOI 10.1126/science.271.5255.1493; THOMAS PJ, 1992, FEBS LETT, V312, P7, DOI 10.1016/0014-5793(92)81399-7; VISSER JA, 1995, BIOCHEM BIOPH RES CO, V215, P1029, DOI 10.1006/bbrc.1995.2567; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zhang R, 1996, J BIOL CHEM, V271, P5755, DOI 10.1074/jbc.271.10.5755	31	47	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30571	30575		10.1074/jbc.271.48.30571	http://dx.doi.org/10.1074/jbc.271.48.30571			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940028	hybrid			2022-12-27	WOS:A1996VV15800045
J	Guo, DP; Liu, J; Motlagh, A; Jewell, J; Miller, KW				Guo, DP; Liu, J; Motlagh, A; Jewell, J; Miller, KW			Efficient insertion of odd-numbered transmembrane segments of the tetracycline resistance protein requires even-numbered segments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER MEMBRANE-PROTEINS; ESCHERICHIA-COLI; MALTOSE-BINDING; TOPOLOGY; DOMAIN; CARBOXYPEPTIDASE; MECHANISM; SEQUENCES; FRAGMENTS; PEPTIDES	Functional membrane insertion elements in the pBR322 tetracycline resistance protein were identified by comparing the ability of odd-numbered transmembrane segments and their attached periplasmic loops to insert into the membrane individually or when combined with the next even-numbered segment in the tetracycline resistance protein sequence, The efficiency with which individual odd-numbered segments and periplasmic loops inserted was probed by treating proteins truncated at the distal ends of periplasmic loops P2-P6 with carboxypeptidases and endoproteases in inside-out membrane vesicles, Insertion of odd-numbered segments and attached loops is inefficient when they occupy a C-terminal position in the protein, The C-terminal odd-numbered segment and loop sequences of 34-54% of the molecules of periplasmic loop truncation mutants could be removed by carboxypeptidase Y, In contrast, odd-numbered segments and loops insert efficiently if the next even-numbered segment in the sequence is present, In such cytoplasmic loop truncation mutants, only the cytoplasmic tail sequences of the proteins could be removed by carboxypeptidases. Remarkably, insertion of individual odd-numbered segments and loops is inefficient even though free energies for insertion of these sequences are highly favorable. The results indicate that pairs of adjacent segments, possibly ''helical hairpins,'' are necessary for efficient membrane insertion of the tetracycline resistance protein.	UNIV WYOMING,DEPT MOL BIOL,LARAMIE,WY 82071	University of Wyoming					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047269, R01GM047269] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47269] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLARD JD, 1992, J BIOL CHEM, V267, P17809; ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; CAO GQ, 1994, J BIOL CHEM, V269, P26898; CURIALE MS, 1984, J BACTERIOL, V157, P211, DOI 10.1128/JB.157.1.211-217.1984; ECKERT B, 1989, J BIOL CHEM, V264, P11663; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P3211; FUTAI M, 1974, J MEMBRANE BIOL, V15, P15, DOI 10.1007/BF01870079; HAYASHI R, 1973, J BIOL CHEM, V248, P2296; HENGGE R, 1985, J BACTERIOL, V162, P972, DOI 10.1128/JB.162.3.972-978.1985; KUHN A, 1988, EUR J BIOCHEM, V177, P267, DOI 10.1111/j.1432-1033.1988.tb14372.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY SB, 1984, ANTIMICROBIAL DRUG R, P191; LEWIS WS, 1991, J BIOL CHEM, V266, P20818; LIAO MJ, 1984, J BIOL CHEM, V259, P4194; MILLER KW, 1993, ANAL BIOCHEM, V215, P118, DOI 10.1006/abio.1993.1563; MILLER KW, 1995, ARCH BIOCHEM BIOPHYS, V322, P445, DOI 10.1006/abbi.1995.1487; NGUYEN TT, 1983, GENE, V25, P83, DOI 10.1016/0378-1119(83)90170-1; NIKAIDO H, 1992, SCIENCE, V258, P936, DOI 10.1126/science.1279804; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHOLTZ JM, 1992, ANNU REV BIOPH BIOM, V21, P95, DOI 10.1146/annurev.bb.21.060192.000523; SHAINSKAYA A, 1994, J BIOL CHEM, V269, P10780; Soekarjo M, 1996, BIOCHEMISTRY-US, V35, P1232, DOI 10.1021/bi951087h; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WEISS JB, 1990, J BACTERIOL, V172, P3023, DOI 10.1128/jb.172.6.3023-3029.1990; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZEN KH, 1994, BIOCHEMISTRY-US, V33, P8198, DOI 10.1021/bi00193a005	31	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30829	30834		10.1074/jbc.271.48.30829	http://dx.doi.org/10.1074/jbc.271.48.30829			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940065	hybrid			2022-12-27	WOS:A1996VV15800082
J	Hansen, S; Midgley, CA; Lane, DP; Freeman, BC; Morimoto, RI; Hupp, TR				Hansen, S; Midgley, CA; Lane, DP; Freeman, BC; Morimoto, RI; Hupp, TR			Modification of two distinct COOH-terminal domains is required for murine p53 activation by bacterial Hsp70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING FUNCTION; HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONE BIP; ESCHERICHIA-COLI DNAK; PEPTIDE-BINDING; PHOSPHORYLATION SITE; COATED VESICLES; ATPASE ACTIVITY; GENE-PRODUCT; MUTANT P53	Activation of the latent DNA binding function of human p53 protein by the bacterial Hsp70, DnaK, represents a unique reaction in which a heat shock protein can interact with a native protein to affect its function, We have localized a likely DnaK interaction site on native human p53 tetramers to a motif flanking the COOH-terminal casein kinase II and protein kinase C phosphorylation sites, Murine p53 is less efficiently activated by DnaK, which has permitted a search for factors that might cooperate in p53 activation by DnaK. We show that optimal activation by DnaK may be dependent upon the phosphorylation state of murine p53, in particular, modification of p53 at the cdc2 phosphorylation site by point mutation decreases the extent of activation by DnaK. Additionally, the monoclonal antibody PAb241, binding in the vicinity of the cdc2 phosphorylation site, is able to activate the specific DNA binding function of p53. This has led us to propose a second regulatory motif flanking the tetramerization domain of p53 that cooperates with factors binding at the negative regulatory domain in the extreme COOH terminus.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT MOL & CELLULAR PATHOL, DUNDEE DD1 9SY, SCOTLAND; UNIV DUNDEE, CANC RES CAMPAIGN LABS, DEPT BIOCHEM, DUNDEE DD1 4HN, SCOTLAND; NORTHWESTERN UNIV, DEPT BIOCHEM MOL & CELL BIOL, EVANSTON, IL 60208 USA	University of Dundee; University of Dundee; Northwestern University			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				ABARZUA P, 1995, CANCER RES, V55, P3490; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; DELPHIN C, 1994, J BIOL CHEM, V269, P29579; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FISCELLA M, 1994, ONCOGENE, V9, P3249; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; FUCHS B, 1995, EUR J BIOCHEM, V228, P625, DOI 10.1111/j.1432-1033.1995.0625m.x; FUCHS B, 1995, ONCOGENE, V10, P789; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GRAGEROV A, 1994, J MOL BIOL, V241, P133, DOI 10.1006/jmbi.1994.1482; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HALL AR, 1995, ONCOGENE, V10, P561; Hansen S, 1996, J BIOL CHEM, V271, P3917; Harlow E., 1988, ANTIBODIES LAB MANUA, V2nd, P479; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1993, J BIOL CHEM, V268, P13137; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Kernohan NM, 1996, J BIOL CHEM, V271, P4954; Lane DP, 1996, ONCOGENE, V12, P2461; LIBEREK K, 1988, P NATL ACAD SCI USA, V85, P6632, DOI 10.1073/pnas.85.18.6632; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NIHEI T, 1993, CANCER RES, V53, P1702; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; RASSOW J, 1995, TRENDS CELL BIOL, V5, P207, DOI 10.1016/S0962-8924(00)89001-7; ROTHMAN JE, 1986, CELL, V46, P5, DOI 10.1016/0092-8674(86)90852-4; SAKAKIBARA Y, 1988, J BACTERIOL, V170, P972, DOI 10.1128/jb.170.2.972-979.1988; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; STURZBECHER HW, 1987, ONCOGENE, V1, P201; SUGITO K, 1995, FEBS LETT, V358, P161, DOI 10.1016/0014-5793(94)01417-Y; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19307, DOI 10.1074/jbc.270.33.19307; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19300, DOI 10.1074/jbc.270.33.19300; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; YEHIELY F, 1992, CELL GROWTH DIFFER, V3, P803	60	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30922	30928		10.1074/jbc.271.48.30922	http://dx.doi.org/10.1074/jbc.271.48.30922			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940078	hybrid			2022-12-27	WOS:A1996VV15800095
J	Haslam, SM; Coles, GC; Munn, EA; Smith, TS; Smith, HF; Morris, HR; Dell, A				Haslam, SM; Coles, GC; Munn, EA; Smith, TS; Smith, HF; Morris, HR; Dell, A			Haemonchus contortus glycoproteins contain N-linked oligosaccharides with novel highly fucosylated core structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VENOM PHOSPHOLIPASE-A2; PROTECTIVE ANTIGEN; MASS-SPECTROMETRY; SURFACE; VACCINATION; PROTEINS; GLYCANS; LAMBS; ACETYLGLUCOSAMINE; PURIFICATION	Structural studies on the N-linked oligosaccharides of Haemonchus contortus, an economically important nematode that parasitizes domestic ruminants, have revealed core fucosylation of a type not previously observed in any eukaryotic glycoprotein. Mass spectrometric analyses were performed on detergent extracts of homogenized adult H. contortus and on purified H11, a glycoprotein isolated from intestinal brush borders which has been previously shown to be an effective vaccine antigen. The major N-linked glycans identified in the present study have up to three fucose residues attached to their chitobiose cores. The fucoses are found at the 3- and/or 6-positions of the proximal GlcNAc and at the 3-position of the distal GlcNAc. The latter substitution is unique in N-glycans. Most anti-H11 monoclonal antibodies are known to recognize carbohydrate epitopes, and it is possible that the newly discovered multifucosylated core structures are highly immunogenic in this glycoprotein.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOCHEM,LONDON SW7 2AY,ENGLAND; UNIV BRISTOL,DEPT VET CLIN SCI,BRISTOL BS18 7DU,AVON,ENGLAND; BABRAHAM INST,DEPT IMMUNOL,CAMBRIDGE CB2 4AT,ENGLAND	Imperial College London; University of Bristol; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASHMAN K, 1995, MOL BIOCHEM PARASIT, V70, P175, DOI 10.1016/0166-6851(94)00210-E; COX GN, 1989, MOL BIOCHEM PARASIT, V36, P233, DOI 10.1016/0166-6851(89)90171-0; DELL A, 1994, METHOD ENZYMOL, V230, P108; DOUBET S, 1992, GLYCOBIOLOGY, V2, P505, DOI 10.1093/glycob/2.6.505; HANDMAN E, 1987, IMMUNOL TODAY, V8, P181, DOI 10.1016/0167-5699(87)90036-3; HIRAISHI K, 1993, GLYCOBIOLOGY, V3, P381, DOI 10.1093/glycob/3.4.381; JASMER DP, 1993, J IMMUNOL, V151, P5450; KHOO KH, 1995, J BIOL CHEM, V270, P17114, DOI 10.1074/jbc.270.29.17114; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUBELKA V, 1993, EUR J BIOCHEM, V213, P1193, DOI 10.1111/j.1432-1033.1993.tb17870.x; LEMOINE J, 1991, CARBOHYD RES, V221, P209, DOI 10.1016/0008-6215(91)80057-T; MAIZELS RM, 1987, J IMMUNOL, V139, P207; MUNN EA, 1993, INT J PARASITOL, V23, P261, DOI 10.1016/0020-7519(93)90149-S; MUNN EA, 1987, PARASITOLOGY, V94, P385, DOI 10.1017/S0031182000054032; NEWTON SE, 1995, INT J PARASITOL, V25, P511, DOI 10.1016/0020-7519(94)00143-C; PRENNER C, 1992, BIOCHEM J, V284, P377, DOI 10.1042/bj2840377; Raju TS, 1996, J BIOL CHEM, V271, P7484, DOI 10.1074/jbc.271.13.7484; Raju TS, 1995, J BIOL CHEM, V270, P30294, DOI 10.1074/jbc.270.51.30294; RAMIREZSOTO D, 1991, CARBOHYD RES, V213, P27, DOI 10.1016/S0008-6215(00)90595-0; RHOADS ML, 1990, MOL BIOCHEM PARASIT, V42, P155, DOI 10.1016/0166-6851(90)90158-I; RHOADS ML, 1994, J PARASITOL, V80, P756, DOI 10.2307/3283254; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; SCHACHTER H, 1995, N COMP BIOC A, V29, P153; SMITH TS, 1993, INT J PARASITOL, V23, P271, DOI 10.1016/0020-7519(93)90150-W; SMITH WD, 1994, PARASITE IMMUNOL, V16, P231, DOI 10.1111/j.1365-3024.1994.tb00345.x; Sturm A., 1995, N COMP BIOC A, V29, P521; TAKAHASHI N, 1978, J BIOCHEM-TOKYO, V84, P1467, DOI 10.1093/oxfordjournals.jbchem.a132270; TAVERNOR AS, 1992, PARASITE IMMUNOL, V14, P645, DOI 10.1111/j.1365-3024.1992.tb00036.x; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; VELUPILLAI P, 1994, P NATL ACAD SCI USA, V91, P18, DOI 10.1073/pnas.91.1.18; WEBER A, 1987, ALLERGY, V42, P464, DOI 10.1111/j.1398-9995.1987.tb00364.x	32	130	133	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30561	30570		10.1074/jbc.271.48.30561	http://dx.doi.org/10.1074/jbc.271.48.30561			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940027	hybrid			2022-12-27	WOS:A1996VV15800044
J	Hwang, HY; Gilberts, T; Jardim, A; Shih, S; Ullman, B				Hwang, HY; Gilberts, T; Jardim, A; Shih, S; Ullman, B			Creation of homozygous mutants of Leishmania donovani with single targeting constructs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE; HOMOLOGOUS RECOMBINATION; MITOTIC RECOMBINATION; TRYPANOSOMA-BRUCEI; GENE REPLACEMENT; ADENINE PHOSPHORIBOSYLTRANSFERASE; STABLE TRANSFECTION; PARASITIC PROTOZOA; MOLECULAR-CLONING; TUBULIN GENE	Homozygous null mutants of the hypoxanthine-guanine phosphoribosyltransferase (hgprt) and adenine phosphoribosyltransferase (aprt) loci were created in Leishmania donovani in which both alleles were elimi nated using only a single targeting construct, Functional heterozygotes mere first generated by homologous recombination after transfection with vectors containing 5'- and 3'-flanking regions of either the hgprt or the aprt gene circumscribing drug resistance markers. Homozygous null mutants were then isolated from the heterozygotes by negative selection in media containing subversive substrates of the encoded proteins, i.e. allopurinol for HGPRT and 4-aminopyrazolopyrimidine for APRT, The novel alleles created by homologous recombination were verified by Southern blotting, and the effects of gene replacement upon gene expression in intact parasites were evaluated by direct enzymatic assay and by immunoblotting, All mutant strains were viable under the selection conditions and exhibited appropriate drug resistance phenotypes. The ability to generate homozygous knockouts with single targeting constructs greatly facilitates the genetic dissection and subsequent biochemical investigations of the purine pathway in Leishmania and has important general implications for the genetic manipulation and analysis of the leishmanial genome.	OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOL BIOL,PORTLAND,OR 97201	Oregon Health & Science University				Hwang, Ho-Yon/0000-0003-0204-8932	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI023682, R01AI023682] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-23682] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allen T, 1995, MOL BIOCHEM PARASIT, V74, P99, DOI 10.1016/0166-6851(95)02475-1; ALLEN T, 1989, MOL BIOCHEM PARASIT, V33, P273, DOI 10.1016/0166-6851(89)90089-3; ALLEN TE, 1995, MOL BIOCHEM PARASIT, V73, P133, DOI 10.1016/0166-6851(94)00105-V; BERENS RL, 1995, BIOCH PARASITIC ORGA, pCH16; BEVERLEY SM, 1991, ANNU REV MICROBIOL, V45, P417, DOI 10.1146/annurev.mi.45.100191.002221; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL CE, 1981, MOL CELL BIOL, V1, P336, DOI 10.1128/MCB.1.4.336; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0; DELAFAILLE MAC, 1992, J BIOL CHEM, V267, P23839; EID J, 1991, P NATL ACAD SCI USA, V88, P2118, DOI 10.1073/pnas.88.6.2118; FREEDMAN DJ, 1993, MOL BIOCHEM PARASIT, V62, P37, DOI 10.1016/0166-6851(93)90175-W; GueirosFilho FJ, 1996, MOL CELL BIOL, V16, P5655; HANSON S, 1992, J BIOL CHEM, V267, P2350; HASSAN HF, 1985, COMP BIOCHEM PHYS B, V81, P1037, DOI 10.1016/0305-0491(85)90110-5; IOVANNISCI DM, 1989, MOL BIOCHEM PARASIT, V34, P177, DOI 10.1016/0166-6851(89)90009-1; IOVANNISCI DM, 1984, J BIOL CHEM, V259, P4617; IOVANNISCI DM, 1984, MOL BIOCHEM PARASIT, V12, P139, DOI 10.1016/0166-6851(84)90131-2; IOVANNISCI DM, 1983, J PARASITOL, V69, P633, DOI 10.2307/3281131; JOSHI PB, 1995, GENE, V156, P145, DOI 10.1016/0378-1119(95)00042-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MGS, 1990, SCIENCE, V250, P1583, DOI 10.1126/science.2177225; LEON W, 1978, NUCLEIC ACIDS RES, V5, P491, DOI 10.1093/nar/5.2.491; MARR JJ, 1983, MOL BIOCHEM PARASIT, V7, P339, DOI 10.1016/0166-6851(83)90016-6; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; NELSON FK, 1989, MOL CELL BIOL, V9, P1284, DOI 10.1128/MCB.9.3.1284; NOZAKI T, 1994, MOL BIOCHEM PARASIT, V67, P91, DOI 10.1016/0166-6851(94)90099-X; PANTON LJ, 1991, J PROTOZOOL, V38, P224, DOI 10.1111/j.1550-7408.1991.tb04433.x; ROVAI L, 1992, MOL BIOCHEM PARASIT, V50, P115, DOI 10.1016/0166-6851(92)90249-J; Sambrook J., 2002, MOL CLONING LAB MANU; Sommer JM, 1996, MOL BIOCHEM PARASIT, V76, P83, DOI 10.1016/0166-6851(95)02543-X; SOUZA AE, 1994, MOL BIOCHEM PARASIT, V63, P213, DOI 10.1016/0166-6851(94)90057-4; TAIT A, 1983, PARASITOLOGY, V86, P29, DOI 10.1017/S0031182000050836; TENASBROEK ALMA, 1990, NATURE, V348, P174, DOI 10.1038/348174a0; TIBAYRENC M, 1990, P NATL ACAD SCI USA, V87, P2414, DOI 10.1073/pnas.87.7.2414; TOBIN JF, 1991, P NATL ACAD SCI USA, V88, P864, DOI 10.1073/pnas.88.3.864; TUTTLE JV, 1980, J BIOL CHEM, V255, P909; WASMUTH JJ, 1984, CELL, V36, P697, DOI 10.1016/0092-8674(84)90350-7; WEBB JR, 1994, MOL BIOCHEM PARASIT, V63, P231, DOI 10.1016/0166-6851(94)90059-0; WILSON K, 1991, J BIOL CHEM, V266, P1665; WILSON K, 1992, MOL BIOCHEM PARASIT, V55, P197, DOI 10.1016/0166-6851(92)90140-F	41	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30840	30846		10.1074/jbc.271.48.30840	http://dx.doi.org/10.1074/jbc.271.48.30840			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940067	hybrid			2022-12-27	WOS:A1996VV15800084
J	Kumar, S; Orsini, MJ; Lee, JC; McDonnell, PC; Debouck, C; Young, PR				Kumar, S; Orsini, MJ; Lee, JC; McDonnell, PC; Debouck, C; Young, PR			Activation of the HIV-1 long terminal repeat by cytokines and environmental stress requires an active CSBP/p38 MAP kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; HEAT-SHOCK PROTEIN; SIGNAL-TRANSDUCTION PATHWAYS; TRANSFECTED HUMAN-CELLS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; MAMMALIAN-CELLS; ULTRAVIOLET-LIGHT	The human immunodeficiency virus, type 1 (HIV-1) promoter is known to be activated by proinflammatory cytokines and UV light, These stimuli also activate various members of the mitogen-activated protein kinase family, including JNK/SAPK and CSBP/p38. In HeLa cells containing an integrated HIV-1 long terminal repeat (LTR)-driven reporter, we now show that the specific p38 inhibitor, SB203580, inhibits activation of the HIV-1 LTR by interleukin-1, tumor necrosis factor, UV light, and osmotic stress, Inhibition was 70-90% in all but the case of tumor necrosis factor stimulation, where inhibition was 50%. Each of these stimuli activated p38, which was inhibited by SB203580 in vitro and in vivo with an IC50 (between 0.1 and 1 mu M) similar to that required to inhibit transcription. In contrast, SB203580 had no effect on JNK, which was also activated by these stimuli, The NF kappa B sites in the HIV-1 LTR were required for a response to cytokines but not to UV, and SB203580 remained capable of inhibiting UV activation in the absence of the NF kappa B sites, Studies in which SB203580 was added at different times relative to UV stimulation suggested that the critical p38-mediated phosphorylation event occurred between 2 and 4 h after UV treatment. These data indicate that p38 is required for HIV-1 LTR activation but that the action of p38 is delayed, presumably due to substrate unavailability or inaccessibility.	SMITHKLINE BEECHAM PHARMACEUT,DEPT MOL IMMUNOL,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT MOL GENET,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT CELLULAR BIOCHEM,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline								Adamczewski JP, 1996, EMBO J, V15, P1877, DOI 10.1002/j.1460-2075.1996.tb00538.x; AHLERS A, 1994, MOL PHARMACOL, V46, P1077; BARILLARI G, 1992, J IMMUNOL, V149, P3727; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BIRD TA, 1994, FEBS LETT, V338, P31, DOI 10.1016/0014-5793(94)80111-8; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHESEBRO B, 1991, J INFECT DIS, V163, P64, DOI 10.1093/infdis/163.1.64; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; ElKharroubi A, 1996, MOL CELL BIOL, V16, P2958; FRESHNEY NW, 1994, CELL, V78, P10399; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUESDON F, 1993, J BIOL CHEM, V268, P4236; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HUUOT J, 1995, EUR J BIOCHEM, V227, P416; JEANG KT, 1993, J BIOL CHEM, V268, P24940; KRAMER M, 1993, J BIOL CHEM, V268, P6734; KRETZREMY C, 1994, FEBS LETT, V351, P191, DOI 10.1016/S0014-5793(94)80103-7; LEE JC, 1993, ANN NY ACAD SCI, V696, P149; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEGRANDPOELS S, 1990, AIDS RES HUM RETROV, V6, P1389, DOI 10.1089/aid.1990.6.1389; LEGRANDPOELS S, 1995, J BIOL CHEM, V270, P6925, DOI 10.1074/jbc.270.12.6925; LEGRANDPOELS S, 1993, J PHOTOCH PHOTOBIO B, V17, P229, DOI 10.1016/1011-1344(93)80020-A; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PIRET B, 1995, EUR J BIOCHEM, V228, P447, DOI 10.1111/j.1432-1033.1995.tb20283.x; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SACHSENMAIER C, 1994, BIOCHEM PHARMACOL, V47, P129, DOI 10.1016/0006-2952(94)90446-4; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SADAIE M R, 1990, New Biologist, V2, P479; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SMITH ML, 1995, ONCOGENE, V10, P1053; STEIN B, 1989, J VIROL, V63, P4540, DOI 10.1128/JVI.63.11.4540-4544.1989; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; VALERIE K, 1990, New Biologist, V2, P712; VALERIE K, 1995, BIOCHEMISTRY-US, V34, P15768, DOI 10.1021/bi00048a022; VALERIE K, 1995, BIOCHEMISTRY-US, V34, P15760, DOI 10.1021/bi00048a021; VALERIE K, 1988, NATURE, V333, P78, DOI 10.1038/333078a0; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WOLOSCHAK GE, 1995, CANCER RES, V55, P1696; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798	58	94	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30864	30869		10.1074/jbc.271.48.30864	http://dx.doi.org/10.1074/jbc.271.48.30864			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940070	hybrid			2022-12-27	WOS:A1996VV15800087
J	Loris, R; Maes, D; Poortmans, F; Wyns, L; Bouckaert, J				Loris, R; Maes, D; Poortmans, F; Wyns, L; Bouckaert, J			A structure of the complex between concanavalin A and methyl-3,6-di-O-(alpha-D-mannopyranosyl)-alpha-D-mannopyranoside reveals two binding modes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED GLYCOPEPTIDES; HYBRID-TYPE GLYCOPEPTIDES; AMINO-ACID SEQUENCE; 3-DIMENSIONAL STRUCTURE; CARBOHYDRATE-BINDING; LEGUME LECTIN; HIGH MANNOSE; RESOLUTION; COVALENT; FRAGMENT	The structure of concanavalin A in complex with the trimannoside methyl-3,6-di-O-(alpha-D-mannopyranosyl)-alpha-D-mannopyranoside has been determined in a novel space group, In three of the four subunits of the concanavalin A tetramer, the interactions between the protein and the bound saccharide are essentially identical to those reported previously by other authors (Naismith, J, H., and Field, R, A. (1996) J, Biol, Chem, 271, 972-976), In the fourth subunit, however, the alpha 1-->3 linkage has a different conformation, resulting in a different part of the alpha 1-->3-linked mannose interacting with essentially the same surface of the protein, Furthermore, significant differences are observed in the quaternary associations of the subunits compared with the saccharide-free structures and other carbohydrate complexes, suggesting that the concanavalin A tetramer is a rather flexible entity.	FREE UNIV BRUSSELS VIB, LAB ULTRASTRUKTUUR, B-1640 RHODE ST GENESE, BELGIUM; VLAAMSE INSTELLING TECHNOL ONDERZOEK, B-2400 MOL, BELGIUM	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; VITO			Loris, Remy/GPG-0894-2022	Bouckaert, Julie/0000-0001-8112-1442; Loris, Remy/0000-0002-8862-3338				BECKER JW, 1975, J BIOL CHEM, V250, P1513; BHATTACHARYYA L, 1989, EUR J BIOCHEM, V178, P721, DOI 10.1111/j.1432-1033.1989.tb14503.x; BHATTACHARYYA L, 1987, J BIOL CHEM, V262, P1288; Bouckaert J, 1996, J BIOL CHEM, V271, P16144, DOI 10.1074/jbc.271.27.16144; Bouckaert J, 1996, ACTA CRYSTALLOGR D, V52, P879, DOI 10.1107/S0907444996001953; BOURNE Y, 1994, NAT STRUCT BIOL, V1, P863, DOI 10.1038/nsb1294-863; BOURNE Y, 1994, STRUCTURE, V2, P209, DOI 10.1016/S0969-2126(00)00022-8; BREWER F, 1985, BIOCHEM BIOPH RES CO, V127, P1066, DOI 10.1016/S0006-291X(85)80053-X; BRISSON JR, 1983, BIOCHEMISTRY-US, V22, P1362, DOI 10.1021/bi00275a007; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BUNGER AT, 1992, XPLOR SYSTEM XRAY CR; CASSET F, 1995, J BIOL CHEM, V270, P25619, DOI 10.1074/jbc.270.43.25619; CHERVENAK MC, 1995, BIOCHEMISTRY-US, V34, P5685, DOI 10.1021/bi00016a045; CUNNINGHAM BA, 1975, J BIOL CHEM, V250, P1503; DEBRAY H, 1981, EUR J BIOCHEM, V117, P41; DELBAERE LTJ, 1993, J MOL BIOL, V230, P950, DOI 10.1006/jmbi.1993.1212; DEREWENDA Z, 1989, EMBO J, V8, P2189, DOI 10.1002/j.1460-2075.1989.tb08341.x; GOLDSTEIN IJ, 1965, BIOCHEMISTRY-US, V4, P876, DOI 10.1021/bi00881a013; HARDMAN KD, 1972, BIOCHEMISTRY-US, V11, P4910, DOI 10.1021/bi00776a006; Harrop SJ, 1996, ACTA CRYSTALLOGR D, V52, P143, DOI 10.1107/S0907444995008742; IMBERTY A, 1990, GLYCOCONJUGATE J, V7, P27, DOI 10.1007/BF01050401; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KALB AJ, 1995, ACTA CRYSTALLOGR D, V51, P1077, DOI 10.1107/S0907444995002769; KIM MJ, 1992, BIOCHEM J, V287, P797, DOI 10.1042/bj2870797; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; KLEYWEGT GJ, 1996, IN PRESS METHODS ENZ; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MANDAL DK, 1992, BIOCHEMISTRY-US, V31, P12602, DOI 10.1021/bi00165a009; MANDAL DK, 1994, BIOCHEMISTRY-US, V33, P1157, DOI 10.1021/bi00171a015; MANDAL DK, 1994, BIOCHEMISTRY-US, V33, P1149, DOI 10.1021/bi00171a014; McDonald I, 1993, HBPLUS COMPUTER PROG; MIN W, 1992, EMBO J, V11, P1303, DOI 10.1002/j.1460-2075.1992.tb05174.x; NAISMITH JH, 1994, ACTA CRYSTALLOGR D, V50, P847, DOI 10.1107/S0907444994005287; Naismith JH, 1996, J BIOL CHEM, V271, P972, DOI 10.1074/jbc.271.2.972; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; QUIOCHO FA, 1989, NATURE, V340, P404, DOI 10.1038/340404a0; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; SUMNER JB, 1936, J BIOL CHEM, V115, P583; VYAS NK, 1991, J BIOL CHEM, V266, P5226; WANG JL, 1975, J BIOL CHEM, V250, P1490; WILLIAMS BA, 1992, J BIOL CHEM, V267, P22907	41	64	65	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30614	30618		10.1074/jbc.271.48.30614	http://dx.doi.org/10.1074/jbc.271.48.30614			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940035	hybrid			2022-12-27	WOS:A1996VV15800052
J	Oh, YM; Nagalla, SR; Yamanaka, Y; Kim, HS; Wilson, E; Rosenfeld, RG				Oh, YM; Nagalla, SR; Yamanaka, Y; Kim, HS; Wilson, E; Rosenfeld, RG			Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7 - Recombinant human mac25 protein specifically binds IGF-I and II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; EPITHELIAL-CELLS; IDENTIFICATION; INHIBITION; RECEPTORS	The mac25 cDNA was originally cloned from leptomeningial cells and subsequently reisolated through differential display as a sequence preferentially expressed in senescent human mammary epithelial cells. The deduced amino acid sequence of the human mac25 propeptide shares a 20-25% identity to human insulin-like growth factor-binding proteins (IGFBPs), suggesting that mac25 could be another member of the IGFBP family. In the present study, we have generated recombinant human mac25 (rh-mac25) in a baculovirus expression system and assessed its affinity for IGFs and have evaluated the pattern of expression of the mac25 gene in human tissues. Binding of I-125-IGF-I and I-125-IGF-II to rh-mac25 was demonstrated by Western ligand blotting after nondenaturing polyacrylamide gel electrophoresis and by affinity cross-linking with as little as 2 nM rh-mac25. Specificity of rh-mac25 binding to I-125-IGFs was demonstrated by competition for rh-mac25 binding with unlabeled IGFs, but not with [QAYLL]IGF-II analog, which has 100-fold less affinity for IGFBPs. In comparison with IGFBP-3, rh-mac25 has at least a 5-6-fold lower affinity for IGF-I and 20-25-fold lower affinity for IGF-II. mac25 mRNA was detectable in a wide range of normal human tissues, with decreased expression in breast, prostate, colon, and lung cancer cell lines, In conclusion, mac25 specifically binds IGFs and constitutes a new member of the IGFBP family, IGFBP-7. Its wider distribution in normal tissue and lower expression in several cancer cells indicate that IGFBP-7 may function as a growth-suppressing factor, as well as an IGF-binding protein.			Oh, YM (corresponding author), OREGON HLTH SCI UNIV,SCH MED NRC5,DEPT PEDIAT,PORTLAND,OR 97201, USA.				NATIONAL CANCER INSTITUTE [R01CA058110] Funding Source: NIH RePORTER; NCI NIH HHS [CA58110] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAXTER RC, 1989, P NATL ACAD SCI USA, V86, P6869; COHEN P, 1991, J CLIN ENDOCR METAB, V73, P401, DOI 10.1210/jcem-73-2-401; Conover CA, 1996, ENDOCRINOLOGY, V137, P2286, DOI 10.1210/en.137.6.2286; GARGOSKY SE, 1992, ENDOCRINOLOGY, V131, P3051, DOI 10.1210/en.131.6.3051; GIUDICE LC, 1990, J CLIN ENDOCR METAB, V71, P806, DOI 10.1210/jcem-71-4-806; Gucev ZS, 1996, CANCER RES, V56, P1545; GULER HP, 1989, ACTA ENDOCRINOL-COP, V121, P753, DOI 10.1530/acta.0.1210753; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; MCCUSKER RH, 1991, ENDOCRINOLOGY, V129, P939, DOI 10.1210/endo-129-2-939; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; NAGALLA SR, 1995, P NATL ACAD SCI USA, V92, P6205, DOI 10.1073/pnas.92.13.6205; OH Y, 1993, J BIOL CHEM, V268, P26045; OH Y, 1995, J BIOL CHEM, V270, P13589, DOI 10.1074/jbc.270.23.13589; OH Y, 1994, ADV EXP MED BIOL, V343, P41; OH YM, 1993, J BIOL CHEM, V268, P14964; ROSENFELD RG, 1994, ACTA PAEDIAT S, V339, P154; Shi Q., 1990, GEL ELECTROPHORESIS; SHIMASAKI S, 1991, Progress in Growth Factor Research, V3, P243, DOI 10.1016/0955-2235(91)90003-M; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472	19	314	345	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30322	30325		10.1074/jbc.271.48.30322	http://dx.doi.org/10.1074/jbc.271.48.30322			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939990	hybrid			2022-12-27	WOS:A1996VV15800007
J	Harada, S; Smith, RM; Smith, JA; White, MF; Jarett, L				Harada, S; Smith, RM; Smith, JA; White, MF; Jarett, L			Insulin-induced egr-1 and c-fos expression in 32D cells requires insulin receptor, Shc, and mitogen-activated protein kinase, but not insulin receptor substrate-1 and phosphatidylinositol 3-kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; GENE-EXPRESSION; DNA-SYNTHESIS; MAP KINASE; S6 KINASE; STIMULATION; TRANSLOCATION; PATHWAY; IDENTIFICATION; ADIPOCYTES	Many studies suggest that insulin utilizes multiple signal transduction pathways. Insulin's effects are initiated by insulin binding to the insulin receptor, resulting in tyrosine phosphorylation of insulin receptor and in tracellular substrates, such as insulin receptor substrate-1 (IRS-1), IRS-2, or She. We recently demonstrated that immediate-early gene egr-1 transcription was fully induced without phosphorylation of IRS-1 in Chinese hamster ovary cells (Harada, S., Smith, R. M., Smith, J. A., Shah, N., Hu, D.-Q. & Jarett, L. (1995) J. Biol. Chem. 270, 26632-26638). In the present study, we examined the effects of insulin on immediate-early gene egr-1 and c-fos expression in 32D cells overexpressing the insulin receptor (32D/IR), IRS-1 (32D/IRS), or both (32D/IR+IRS) and compared these effects with insulin induced tyrosine phosphorylation. Insulin (17 nM) increased egr-1 and c-fos expression in 32D-IR and 32D/IR+IRS cells, but not in parental cells or 32D/IRS cells, as determined by Northern blot analysis. Insulin treatment (5 min at 37 degrees C) markedly increased tyrosine phosphorylation of several proteins, including the insulin receptor, IRS-1, and She, in 32D/IR+IRS cells as determined by immunoprecipitation and Western blot analysis with anti-phosphotyrosine antibody. In contrast, only two tyrosine-phosphorylated proteins, i.e. insulin receptor and She, were detected in 32D/IR cells. These data suggest that insulin receptor and She phosphorylation is necessary for insulin-induced egr-1 and c-fos expression, but IRS-I phosphorylation is not necessary or sufficient for the expression of these genes. Furthermore, the effect of specific inhibitors on insulin-induced egr-1 expression was examined. Wortmannin (25 nM), a phosphatidylinositol 3-kinase inhibitor, had no effect on insulin-induced egr-1 expression. In contrast, PD 98059 (30 mu M), a mitogen-activated protein kinase kinase inhibitor, totally blocked egr-1 expression induced by insulin. These data indicate that mitogen-activated protein kinase activation, but not phosphatidylinositol 3-kinase activation, is involved in insulin-induced egr-1 expression. Taken together, insulin receptor tyrosine phosphorylation, She tyrosine phosphorylation, and mitogen-activated protein kinase activation appear to be the signal transduction pathway responsible for insulin induced egr-1 expression in 32D cells. These data demonstrate that insulin has multiple signal transduction pathways that vary from cell to cell.	UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; JOSLIN DIABET CTR,BOSTON,MA 02215	University of Pennsylvania; Harvard University; Joslin Diabetes Center, Inc.					NIDDK NIH HHS [DK 43808, DK28143, DK28144] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028144, R01DK028143, R01DK043808] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Azpiazu I, 1996, J BIOL CHEM, V271, P5033; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; ELDREDGE ER, 1994, MOL CELL BIOL, V14, P7527, DOI 10.1128/MCB.14.11.7527; GOULD GW, 1994, CELL SIGNAL, V6, P313, DOI 10.1016/0898-6568(94)90036-1; HARADA S, 1995, J BIOL CHEM, V270, P26632, DOI 10.1074/jbc.270.44.26632; HARUTA T, 1995, J BIOL CHEM, V270, P27991; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; HUANG RP, 1994, J CELL BIOCHEM, V56, P469, DOI 10.1002/jcb.240560407; JHUN BH, 1994, J BIOL CHEM, V269, P5699; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MENDES P, 1996, MOL CELL BIOL, V16, P2857; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MUNDSCHAU LJ, 1994, J BIOL CHEM, V269, P16137; MYERS MG, 1994, J BIOL CHEM, V269, P28783; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; TAUB R, 1987, J BIOL CHEM, V262, P10893; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; Yenush L, 1996, MOL CELL BIOL, V16, P2509	24	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30222	30226		10.1074/jbc.271.47.30222	http://dx.doi.org/10.1074/jbc.271.47.30222			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939974	hybrid			2022-12-27	WOS:A1996VU52500102
J	Conn, KJ; Rich, CB; Jensen, DE; Fontanilla, MR; Bashir, MM; Rosenbloom, J; Foster, JA				Conn, KJ; Rich, CB; Jensen, DE; Fontanilla, MR; Bashir, MM; Rosenbloom, J; Foster, JA			Insulin-like growth factor-I regulates transcription of the elastin gene through a putative retinoblastoma control element - A role for Sp3 acting as a repressor of elastin gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC PROMOTER; RB PROTEIN; BINDING; CELLS; EXPRESSION; FAMILY; DNA; TROPOELASTIN; DISRUPTION; ACTIVATION	Previous studies have demonstrated that insulin-like growth factor-I (IGF-I) increases elastin gene transcription in aortic smooth muscle cells and that this up-regulation is accompanied by a loss of protein binding to the proximal promoter. Sp1 has been identified as one of the factors whose binding is lost, and in the present study we show that Sp3 binding is also abrogated by IGF-I, but in a selected manner. In functional analyses using Drosophila SL-2 cells, Sp1 expression can drive transcription from the elastin proximal promoter, while co expression of Sp3 results in a repression of Sp1 activity. Footprint and gel shift analyses position the IGF-I responsive sequences to a putative retinoblastoma control element (RCE). Mutation of the putative RCE sequence as assessed by transient transfection of smooth muscle cells results in an increase in reporter activity equal in magnitude to that conferred by IGF-I on the wild type promoter. Together these results support the hypothesis that IGF-I-mediated increase in elastin transcription occurs via a mechanism of derepression involving the abrogation of a repressor that appears to be Sp3 binding to the RCE.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; UNIV PENN,SCH DENT MED,DEPT ANAT & HISTOL,PHILADELPHIA,PA 19104	Boston University; University of Pennsylvania					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL13262] Funding Source: Medline; NIA NIH HHS [AG00115] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BASHIR MM, 1989, J BIOL CHEM, V264, P8887; BIRNBAUM MJ, 1995, BIOCHEMISTRY-US, V34, P7648, DOI 10.1021/bi00023a011; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BURNETT W, 1980, BIOCHEMISTRY-US, V19, P1106, DOI 10.1021/bi00547a010; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; FOSTER J, 1987, COLLAGEN REL RES, V7, P161; FOSTER JA, 1989, MATRIX, V9, P328, DOI 10.1016/S0934-8832(89)80009-5; FOSTER JA, 1990, J GERONTOL, V13, P113; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; JENSEN DE, 1995, J BIOL CHEM, V270, P6555, DOI 10.1074/jbc.270.12.6555; JENSEN DE, 1996, THESIS BOSTON U; KINGSLEY C, 1990, MOL CELL BIOL, V13, P2776; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFEVRE M, 1983, BIOCHIM BIOPHYS ACTA, V743, P338, DOI 10.1016/0167-4838(83)90391-6; MAJELLO B, 1995, ONCOGENE, V10, P1841; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; MAYFIELD C, 1994, J BIOL CHEM, V269, P18232; MICHELOTTI EF, 1995, J BIOL CHEM, V270, P9494, DOI 10.1074/jbc.270.16.9494; RICH CB, 1993, BIOCHEM BIOPH RES CO, V196, P1316, DOI 10.1006/bbrc.1993.2396; RITZENTHALER JD, 1991, BIOCHEM J, V280, P157, DOI 10.1042/bj2800157; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SHIBAHARA S, 1981, BIOCHEMISTRY-US, V20, P6577, DOI 10.1021/bi00526a009; SWEE MH, 1995, J BIOL CHEM, V270, P1489; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TERPSTRA AJ, 1994, THESIS BOSTON U; TOWBIN H, 1982, J BIOL CHEM, V257, P2709; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOLFE BL, 1993, J BIOL CHEM, V268, P12418; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4	44	73	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28853	28860		10.1074/jbc.271.46.28853	http://dx.doi.org/10.1074/jbc.271.46.28853			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910531	hybrid			2022-12-27	WOS:A1996VT05200023
J	Kincaid, JR; Zheng, YH; AlMustafa, J; Czarnecki, K				Kincaid, JR; Zheng, YH; AlMustafa, J; Czarnecki, K			Resonance Raman spectra of native and mesoheme-reconstituted horseradish peroxidase and their catalytic intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; PI-CATION RADICALS; HEME-LINKED IONIZATION; PORPHYRIN FORCE-FIELD; COMPOUND-I; ENZYMIC CATALYSIS; ISOTOPE SHIFTS; SPECTROSCOPY; CATALASE; METALLOPORPHYRINS	Resonance Raman studies of native and mesohemere-constituted horseradish peroxidase and their catalytic intermediates, known as Compounds I and II, have been conducted using both near UV (similar to 350 nm) and visible (406.7 nm) excitation. Careful power studies indicate that the authentic Compound I spectra are obtainable using near UV excitation, but that use of visible excitation results in contamination of the Compound I spectrum with the spectrum of a Compound II-like photoproduct. Using (H2O2)-O-18, the nu(Fe=O) stretching modes for both systems are unambiguously identified, for the first time, at similar to 790 cm(-1). The authentic Compound I spectra are indicative of an (2)A(1u)-like ground state for both the native and the mesoheme-reconstituted proteins. Finally, the possible biological implications of such information are briefly discussed.			Kincaid, JR (corresponding author), MARQUETTE UNIV,DEPT CHEM,MILWAUKEE,WI 53201, USA.				NIDDK NIH HHS [DK35153] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035153] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASADA K, 1984, PLANT CELL PHYSIOL, V25, P1169; BROWETT WR, 1988, J AM CHEM SOC, V110, P3633, DOI 10.1021/ja00219a044; CHUANG WJ, 1992, J BIOL CHEM, V267, P13293; CZARNECKI K, 1995, THESIS MARQUETTE U; CZERNUSZEWICZ RS, 1989, J AM CHEM SOC, V111, P3860, DOI 10.1021/ja00193a017; DOLPHIN D, 1974, ACCOUNTS CHEM RES, V7, P26, DOI 10.1021/ar50073a005; DU P, 1995, BIOPHYS J, V68, P69, DOI 10.1016/S0006-3495(95)80160-8; DUNFORD HB, 1982, ADV INORG BIOCHEM, V4, P41; Frew J. E., 1984, ADV INORG BIOINORG M, V3, P175; FUJITA I, 1983, J AM CHEM SOC, V105, P3296, DOI 10.1021/ja00348a056; GODZIELA GM, 1986, J AM CHEM SOC, V108, P2237, DOI 10.1021/ja00269a019; GODZIELA GM, 1986, INORG CHEM, V25, P4286, DOI 10.1021/ic00243a044; HANSON LK, 1981, J AM CHEM SOC, V103, P663, DOI 10.1021/ja00393a028; HASHIMOTO S, 1986, P NATL ACAD SCI USA, V83, P2417, DOI 10.1073/pnas.83.8.2417; HU SH, 1991, J AM CHEM SOC, V113, P7189, DOI 10.1021/ja00019a015; KITAGAWA T, 1994, COORDIN CHEM REV, V135, P685, DOI 10.1016/0010-8545(94)80081-2; LAMAR GN, 1981, J BIOL CHEM, V256, P237; LAMAR GN, 1989, J BIOL CHEM, V264, P5428; LI XY, 1990, J PHYS CHEM-US, V94, P47, DOI 10.1021/j100364a008; LI XY, 1990, J PHYS CHEM-US, V94, P31, DOI 10.1021/j100364a007; MACOR KA, 1990, INORG CHEM, V29, P1996, DOI 10.1021/ic00335a044; MORISHIMA I, 1986, BIOCHEMISTRY-US, V25, P3576, DOI 10.1021/bi00360a016; MORISHIMA I, 1984, J AM CHEM SOC, V106, P7666, DOI 10.1021/ja00337a002; OERTLING WA, 1985, J AM CHEM SOC, V107, P6406, DOI 10.1021/ja00308a050; OERTLING WA, 1988, BIOCHEMISTRY-US, V27, P3331, DOI 10.1021/bi00409a032; OERTLING WA, 1989, J PHYS CHEM-US, V93, P1311, DOI 10.1021/j100341a028; OGURA T, 1987, J AM CHEM SOC, V109, P2177, DOI 10.1021/ja00241a044; PAENG KJ, 1988, J AM CHEM SOC, V110, P7913, DOI 10.1021/ja00231a073; PALANIAPPAN V, 1989, J BIOL CHEM, V264, P16046; ROBERTS JE, 1981, J BIOL CHEM, V256, P2118; RUTTER R, 1983, BIOCHEMISTRY-US, V22, P4769, DOI 10.1021/bi00289a024; SANDUSKY PO, 1989, J AM CHEM SOC, V111, P6437, DOI 10.1021/ja00198a074; SHANNON LM, 1966, J BIOL CHEM, V241, P2166; SIMPSON SF, 1986, ANAL CHEM, V58, P3163, DOI 10.1021/ac00127a054; SIMPSON SF, 1983, ANAL CHEM, V55, P1420, DOI 10.1021/ac00259a054; SITTER AJ, 1985, J BIOL CHEM, V260, P7515; Spiro T.G., 1988, BIOL APPL RAMAN SPEC; STILLMAN JS, 1975, BIOCHEMISTRY-US, V14, P3183, DOI 10.1021/bi00685a023; STILLMAN JS, 1975, BIOCHEM BIOPH RES CO, V63, P32, DOI 10.1016/S0006-291X(75)80006-4; TEALE FWJ, 1959, BIOCHIM BIOPHYS ACTA, V35, P543, DOI 10.1016/0006-3002(59)90407-X; TERAOKA J, 1982, J AM CHEM SOC, V104, P7354, DOI 10.1021/ja00389a094; VANWART HE, 1985, J AM CHEM SOC, V107, P3379, DOI 10.1021/ja00297a072; YONETANI T, 1968, J BIOL CHEM, V243, P4715	43	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28805	28811		10.1074/jbc.271.46.28805	http://dx.doi.org/10.1074/jbc.271.46.28805			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910524	hybrid			2022-12-27	WOS:A1996VT05200016
J	Rooney, E; Meldolesi, J				Rooney, E; Meldolesi, J			The endoplasmic reticulum in PC12 cells - Evidence for a mosaic of domains differently specialized in Ca2+ handling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; INTRACELLULAR CALCIUM STORES; YEAST SECRETORY PATHWAY; TRANS-GOLGI NETWORK; SUBCELLULAR-DISTRIBUTION; SARCOPLASMIC-RETICULUM; TISSUE DISTRIBUTION; CA-2+ TRANSPORT; RAT-LIVER; PUMP	Velocity and isopycnic gradient centrifugation were employed to fractionate post-nuclear supernatants rapidly prepared from PC12 cells in order to characterize areas of the endoplasmic reticulum involved in various aspects of intracellular Ca2+ homeostasis. The endoplasmic reticulum Ca2+ pumping activity, defined by three properties studied in parallel in the isolated fractions; thapsigargin-sensitive uptake of Ca-45(2+), Ca2+-dependent, thapsigargin-sensitive protein phosphorylation and Western blotting of sarcoplasmic reticulum calcium ATPase (SERCA) 2b and putative SERCA3 ATPases, was concentrated primarily in a few fractions located at the top and toward the bottom of velocity and isopycnic gradients, respectively. The endoplasmic reticulum Ca2+ release channel, the inositol 1,4,5-trisphosphate receptor, was concentrated in the same fractions as the Ca2+ pumps, and additionally in a few fractions distinctly poor in SERCAs. In contrast, two lumenal markers (protein disulfide isomerase and calreticulin, the major Ca2+ storage protein of non-muscle endoplasmic reticulum) were enriched in the middle fractions of the velocity gradients while calnexin, a Ca2+-binding membrane protein, was more widely distributed throughout the gradients. These results document a considerable degree of functional and compositional heterogeneity in the endoplasmic reticulum of neurosecretory PC12 cells. Even in the limited areas that appear specialized for rapid Ca2+ uptake and release the ratio between pumps and channels varies considerably Within the rest of the system, insulated hom short-term fluctuations of Ca2+ concentration, Ca2+-binding proteins appear to be extensively distributed, in agreement with the idea that the Ca2+ content of the endoplasmic reticulum serves multiple functions.	UNIV MILAN,DEPT PHARMACOL,MILAN,ITALY; UNIV MILAN,B CECCARELLI CTR,MILAN,ITALY; SAN RAFFAELE SCI INST,CNR,CTR MOL & CELLULAR PHARMACOL,I-20132 MILAN,ITALY; SAN RAFFAELE SCI INST,DIBIT,I-20132 MILAN,ITALY	University of Milan; University of Milan; Consiglio Nazionale delle Ricerche (CNR); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele								BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BOBE R, 1994, J BIOL CHEM, V269, P1417; BOSSHART H, 1992, EUR J BIOCHEM, V208, P341, DOI 10.1111/j.1432-1033.1992.tb17192.x; BURK SE, 1989, J BIOL CHEM, V264, P18561; Caspersen C, 1995, FEBS LETT, V377, P31, DOI 10.1016/0014-5793(95)01304-0; COLYER J, 1989, BIOCHEM J, V262, P439, DOI 10.1042/bj2620439; ENGELENDER S, 1995, J BIOL CHEM, V270, P21050, DOI 10.1074/jbc.270.36.21050; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; FISCHER GA, 1994, J BIOL CHEM, V269, P19216; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUNTESKIHAMBLIN AM, 1992, BIOCHEMISTRY-US, V31, P7600, DOI 10.1021/bi00148a023; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; KASAI H, 1995, CIBA F SYMP, V188, P104; KOVACS T, 1994, J BIOL CHEM, V269, P6177; LIEVREMONT JP, 1994, BIOCHEM J, V300, P419, DOI 10.1042/bj3000419; Lievremont JP, 1996, BIOCHEM J, V314, P189, DOI 10.1042/bj3140189; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; LYTTON J, 1992, J BIOL CHEM, V267, P14483; NIGAM SK, 1990, J CELL BIOL, V111, P197, DOI 10.1083/jcb.111.1.197; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; OU WJ, 1995, J BIOL CHEM, V270, P18051, DOI 10.1074/jbc.270.30.18051; PENG YW, 1991, NEURON, V6, P525, DOI 10.1016/0896-6273(91)90055-5; PERRIN D, 1991, FEBS LETT, V294, P47, DOI 10.1016/0014-5793(91)81340-E; POULSEN JCJ, 1995, BIOCHEM J, V307, P749, DOI 10.1042/bj3070749; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; RABOUILLE C, 1995, J CELL SCI, V108, P1617; ROONEY EK, 1994, CELL CALCIUM, V16, P509, DOI 10.1016/0143-4160(94)90081-7; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SHARP AH, 1992, J BIOL CHEM, V267, P7444; SITIA R, 1992, MOL BIOL CELL, V3, P1067, DOI 10.1091/mbc.3.10.1067; TOOZE SA, 1992, METHOD ENZYMOL, V219, P81; TUNWELL REA, 1991, BIOCHEM J, V279, P203, DOI 10.1042/bj2790203; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; VILLA A, 1992, NEUROSCIENCE, V49, P467, DOI 10.1016/0306-4522(92)90111-E; VILLA A, 1993, J CELL BIOL, V121, P1041, DOI 10.1083/jcb.121.5.1041; VIRK SS, 1985, BIOCHEM J, V226, P741, DOI 10.1042/bj2260741; VOLPE P, 1992, P NATL ACAD SCI USA, V89, P6142, DOI 10.1073/pnas.89.13.6142; WICTOME M, 1995, BIOCHEM J, V310, P859, DOI 10.1042/bj3100859; WU KD, 1995, AM J PHYSIOL-CELL PH, V269, pC775, DOI 10.1152/ajpcell.1995.269.3.C775; WUYTACK F, 1989, BIOCHEM J, V264, P765, DOI 10.1042/bj2640765; WUYTACK F, 1994, J BIOL CHEM, V269, P1410; ZACHETTI D, 1991, J BIOL CHEM, V266, P20152	46	42	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29304	29311		10.1074/jbc.271.46.29304	http://dx.doi.org/10.1074/jbc.271.46.29304			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910591				2022-12-27	WOS:A1996VT05200083
J	Sun, YH; Gailani, D				Sun, YH; Gailani, D			Identification of a factor IX binding site on the third apple domain of activated factor XI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION FACTOR; FUNCTIONAL-CHARACTERIZATION; PLASMA; PURIFICATION; DEFICIENCY; MECHANISM; CHAIN	Activated factor XI (factor XIa) participates in blood coagulation by activating factor IX. Previous work has demonstrated that a binding site for factor IX is present on the noncatalytic heavy chain of factor XIa (Sinha, D., Seaman, F. S., and Walsh, P. N. (1987) Biochemistry 26, 3768-3775). Recombinant factor XI proteins were expressed in which each of the four apple domains of the heavy chain (designated A1 through A4) were individually replaced with the corresponding domain from the homologous but functionally distinct protease prekallikrein (PK). To identify the site of factor IX binding, the chimeric proteins were activated with factor Wa and tested for their capacity to activate factor IX in plasma coagulation and purified protein assays. The chimera with the substitution in the third apple domain (factor XI/PKA3) had <1% of the coagulant activity of wild type factor XIa in a plasma coagulation assay, whereas the chimeras with substitutions in A1, A2, and A4 demonstrated significant activity (68-140% of wild type activity). The K-m for activation of factor IX by factor XIa/PKA3 (12.7 mu M) is more than 30-fold higher than the K-m for activation by wild type factor XIa or the other factor XI/PK chimeras (0.11-0.37 mu M) Two monoclonal antibodies (2A12 and 11AE) that recognize epitopes on the factor XI A3 domain were potent inhibitors of factor IX activation by factor XIa, whereas antibodies against the A2 (1A6) and A4 (3G4) domains were poor inhibitors. The data indicate that a binding site for factor IX is present on the third apple domain of factor XIa.	VANDERBILT UNIV,SCH MED,DEPT PATHOL,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DIV HEMATOL,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University								BAGLIA FA, 1991, J BIOL CHEM, V266, P24190; BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734; BAGLIA FA, 1992, J BIOL CHEM, V267, P4247; Baglia FA, 1996, J BIOL CHEM, V271, P3652; BAGLIA FA, 1993, J BIOL CHEM, V268, P3838; BAJAJ SP, 1982, J BIOL CHEM, V257, P4127; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GAILANI D, 1993, BLOOD, V82, P813; Herwald H, 1996, J BIOL CHEM, V271, P13061, DOI 10.1074/jbc.271.22.13061; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P376; KURACHI K, 1977, BIOCHEMISTRY-US, V16, P5831, DOI 10.1021/bi00645a030; MCCONNELL DJ, 1970, BRIT J PHARMACOL, V38, P490, DOI 10.1111/j.1476-5381.1970.tb10591.x; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008; MEIJERS JCM, 1992, BLOOD, V79, P1435; MEIJERS JCM, 1992, BIOCHEMISTRY-US, V31, P4680, DOI 10.1021/bi00134a021; NAITO K, 1991, J BIOL CHEM, V266, P2667; OSTERUD B, 1978, J BIOL CHEM, V253, P5946; PUGH RE, 1995, BLOOD, V85, P1509, DOI 10.1182/blood.V85.6.1509.bloodjournal8561509; SINHA D, 1985, J BIOL CHEM, V260, P714; SINHA D, 1987, BIOCHEMISTRY-US, V26, P3768, DOI 10.1021/bi00387a005; VANDERGRAAF F, 1983, J BIOL CHEM, V258, P9669; WAGENVOORD R, 1990, HAEMOSTASIS, V20, P276; WALSH PN, 1984, J CLIN INVEST, V73, P1392, DOI 10.1172/JCI111343	27	92	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29023	29028		10.1074/jbc.271.46.29023	http://dx.doi.org/10.1074/jbc.271.46.29023			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910554	hybrid			2022-12-27	WOS:A1996VT05200046
J	Tsiotra, PC; Theodorakis, K; Papamatheakis, J; Karagogeos, D				Tsiotra, PC; Theodorakis, K; Papamatheakis, J; Karagogeos, D			The fibronectin domains of the neural adhesion molecule TAX-1 are necessary and sufficient for homophilic binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AXONAL GLYCOPROTEIN TAG-1; CELL-ADHESION; NEURITE OUTGROWTH; IMMUNOGLOBULIN SUPERFAMILY; EXTRACELLULAR DOMAINS; NERVOUS-SYSTEM; NG-CAM; SIGNAL-TRANSDUCTION; L1-LIKE MOLECULE; FASCICLIN-III	Cell adhesion molecules belonging to thcomb come immunoglobulin superfamily promote cell aggregation and neurite outgrowth. These proteins are multidomain molecules comprising a number of distinct modules, notably Ig domains of the C2 class and fibronectin type III repeats. A subgroup of these neural adhesion molecules are linked to the membrane with a glycosylphosphatidylinositol anchor and show a more restricted pattern of expression in the embryo. Among them, the human homologue of the transient axonal glycoprotein, named TAX-1, shares a great degree of similarity at the protein level with rodent TAG-1. In the present study we set out to determine which domains of TAX-1 are involved in promoting the hemophilic, adhesive properties of the molecule. We established stable Schneider-2 cell lines expressing the intact molecule, the fibronectin, or the immunoglobulin domains. The fibronectin domains were necessary and sufficient to mediate homophilic binding and induce cell aggregation, a response also observed with cells expressing the intact TAX-1 molecule. Aggregation was inhibited by the secreted form of the TAG-1 protein. On the other hand, the immunoglobulin domains by themselves mere not able to induce cell aggregation. In addition, TAX-1 was localized in areas of cell contact among aggregating cells, justifying its role as an adhesion molecule.	UNIV CRETE, FDN RES & TECHNOL, INST MOL BIOL & BIOTECHNOL, IRAKLION 71110, CRETE, GREECE; UNIV CRETE, DEPT BIOL, IRAKLION 71110, CRETE, GREECE; UNIV CRETE, SCH MED, DEPT BASIC SCI, IRAKLION 71110, CRETE, GREECE	University of Crete; University of Crete; University of Crete			Tsiotra, Panayoula C./AAE-6086-2019	Tsiotra, Panayoula C./0000-0002-1702-5840; THEODORAKIS, KOSTAS/0000-0002-3933-795X; Karagogeos, Domna/0000-0002-8129-9731				APPEL F, 1993, J NEUROSCI, V13, P4764; ATTASHI JR, 1992, NEURON, V8, P831; Bailly Y, 1996, J COMP NEUROL, V369, P150; BEGGS HE, 1994, J CELL BIOL, V127, P825, DOI 10.1083/jcb.127.3.825; BELOSTA P, 1995, MOL CELL BIOL, V15, P614; BOCIAN M, 1987, AM J MED GENET, V26, P437, DOI 10.1002/ajmg.1320260223; BRONNERFRASER M, 1992, DEV BIOL, V153, P291, DOI 10.1016/0012-1606(92)90114-V; BRUMMENDORF T, 1993, J NEUROCHEM, V61, P1207, DOI 10.1111/j.1471-4159.1993.tb13611.x; BRUMMENDORF T, 1993, NEURON, V10, P711; BURGOON MP, 1995, J CELL BIOL, V130, P733, DOI 10.1083/jcb.130.3.733; COLE GJ, 1989, NEURON, V2, P1157, DOI 10.1016/0896-6273(89)90182-7; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; DOHERTY P, 1989, J CELL BIOL, V109, P789, DOI 10.1083/jcb.109.2.789; Doherty Patrick, 1994, Current Opinion in Neurobiology, V4, P49, DOI 10.1016/0959-4388(94)90031-0; DURBEC P, 1993, EUR J NEUROSCI, V6, P461; ELKINS T, 1990, J CELL BIOL, V110, P1825, DOI 10.1083/jcb.110.5.1825; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FELSENFELD DP, 1994, NEURON, V12, P675, DOI 10.1016/0896-6273(94)90222-4; FREI T, 1992, J CELL BIOL, V118, P177, DOI 10.1083/jcb.118.1.177; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; HOLM J, 1995, J NEUROSCI RES, V42, P9, DOI 10.1002/jnr.490420103; HORSTKORTE R, 1993, J CELL BIOL, V121, P1409, DOI 10.1083/jcb.121.6.1409; HORTSCH M, 1995, J BIOL CHEM, V270, P18809, DOI 10.1074/jbc.270.32.18809; HORTSCH M, 1991, TRENDS BIOCHEM SCI, V16, P283, DOI 10.1016/0968-0004(91)90116-D; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; KARAGOGEOS D, 1991, DEVELOPMENT, V112, P51; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; KUHN TB, 1991, J CELL BIOL, V115, P1113, DOI 10.1083/jcb.115.4.1113; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; LANDMESSER L, 1988, DEV BIOL, V130, P645, DOI 10.1016/0012-1606(88)90358-2; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; MAURO VP, 1992, J CELL BIOL, V119, P191, DOI 10.1083/jcb.119.1.191; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; PEREZCASTILLO A, 1984, HUM GENET, V67, P230, DOI 10.1007/BF00273009; PESHEVA P, 1993, NEURON, V10, P69, DOI 10.1016/0896-6273(93)90243-K; RADER C, 1993, EUR J BIOCHEM, V215, P133, DOI 10.1111/j.1432-1033.1993.tb18015.x; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; RATHJEN FG, 1991, NEUROSCIENCES, V3, P297; SARDA P, 1992, CLIN GENET, V41, P25; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; SONDEREGGER P, 1992, J CELL BIOL, V119, P1387, DOI 10.1083/jcb.119.6.1387; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STOECKLI ET, 1995, NEURON, V14, P1165, DOI 10.1016/0896-6273(95)90264-3; TSIOTRA PC, 1993, GENOMICS, V18, P562, DOI 10.1016/S0888-7543(05)80357-X; WALSH FS, 1991, CELL BIOL INT REP, V15, P1151, DOI 10.1016/0309-1651(91)90061-M; YAMAMOTO M, 1990, J NEUROCYTOL, V19, P619, DOI 10.1007/BF01188031; ZICH AH, 1995, MOL CELL NEUROSCI, V6, P263; ZISCH AH, 1992, J CELL BIOL, V119, P203, DOI 10.1083/jcb.119.1.203	52	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29216	29222		10.1074/jbc.271.46.29216	http://dx.doi.org/10.1074/jbc.271.46.29216			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910580	hybrid			2022-12-27	WOS:A1996VT05200072
J	Alam, MR; Caldwell, BD; Johnson, RC; Darlington, DN; Mains, RE; Eipper, BA				Alam, MR; Caldwell, BD; Johnson, RC; Darlington, DN; Mains, RE; Eipper, BA			Novel proteins that interact with the COOH-terminal cytosolic routing determinants of an integral membrane peptide-processing enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; ALPHA-AMIDATING MONOOXYGENASE; CYTOPLASMIC DOMAIN; CELL-SURFACE; LOCALIZATION; SPECTRIN; TGN38; FURIN; ORGANIZATION; TRAFFICKING	The steady state distribution of membrane forms of peptidylglycine alpha-amidating monooxygenase (PAM) in the secretory pathway of neurons and endocrine cells depends on signals in its cytosolic COOH-terminal domain (CD). Mutagenesis studies yielded catalytically active PAM proteins that are not properly localized or internalized. Employing the yeast two-hybrid system, we isolated two distinct cDNAs whose protein products showed a strong interaction with the CD of PAM. The interaction of these novel PAM COOH-terminal interactor proteins (P-CIPs) did not occur with a misrouted CD mutant as bait in the yeast system. Both proteins, P-CIP2 and P-CIP10, were expressed as fusion proteins that interacted in vitro with solubilized integral membrane PAM. P-CIP2 was homologous to several serine/threonine and dual specificity protein kinases, while P-CIP10 contained spectrin-like repeats. Endogenous P-CIP2 was localized to the Golgi region of AtT-20 corticotrope tumor cells, and expression of integral membrane PAM disrupted the distribution of endogenous P-CIP2. Both P-CIP2 and P-CIP10 mRNAs were found to be expressed in rat brain neurons also expressing PAM proteins. P-CIP2 and P-CIP10 may be members of a family of cytosolic proteins involved in the routing of membrane proteins that function in the regulated secretory pathway.	JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205; UNIV MARYLAND,SCH MED,DEPT SURG,BALTIMORE,MD 21201	Johns Hopkins University; University System of Maryland; University of Maryland Baltimore	Alam, MR (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205, USA.		Darlington, Daniel/CAG-1917-2022		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032948, R37DK032949, R56DK032948, R01DK032948, R01DK032949, R56DK032949] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-32949, DK-32948] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECK KA, 1996, AM J PHYSIOL, V39, pC1263; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; Calakos N, 1996, PHYSIOL REV, V76, P1; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CLERMONT Y, 1995, ANAT REC, V242, P289, DOI 10.1002/ar.1092420302; DARLINGTON DN, 1996, J NEUROSCI, V71, P477; DECAMILLI P, 1995, CURR OPIN NEUROBIOL, V5, P559, DOI 10.1016/0959-4388(95)80059-X; DHERMY D, 1991, BIOL CELL, V71, P249; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; EIPPER BA, 1993, PROTEIN SCI, V2, P489; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; JAHN R, 1993, J NEUROCHEM, V61, P12, DOI 10.1111/j.1471-4159.1993.tb03533.x; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; Milgram SL, 1996, J BIOL CHEM, V271, P17526, DOI 10.1074/jbc.271.29.17526; MILGRAM SL, 1994, J CELL BIOL, V124, P33, DOI 10.1083/jcb.124.1.33; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; OUAFIK L, 1992, MOL ENDOCRINOL, V6, P1571, DOI 10.1210/me.6.10.1571; OYARCE AM, 1993, J NEUROCHEM, V60, P1105, DOI 10.1111/j.1471-4159.1993.tb03261.x; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; TAUSK FA, 1992, MOL ENDOCRINOL, V6, P2185, DOI 10.1210/me.6.12.2185; TAYLOR SS, 1994, PROTEIN KINASES, P1; Viel A, 1996, CURR OPIN CELL BIOL, V8, P49, DOI 10.1016/S0955-0674(96)80048-2; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; WINOGRAD E, 1991, P NATL ACAD SCI USA, V88, P10788, DOI 10.1073/pnas.88.23.10788; YUN HY, 1995, J BIOL CHEM, V270, P30075; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0	36	72	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28636	28640		10.1074/jbc.271.45.28636	http://dx.doi.org/10.1074/jbc.271.45.28636			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910496	hybrid			2022-12-27	WOS:A1996VU03300096
J	Kolaczkowski, M; vanderRest, M; CybularzKolaczkowska, A; Soumillion, JP; Konings, WN; Goffeau, A				Kolaczkowski, M; vanderRest, M; CybularzKolaczkowska, A; Soumillion, JP; Konings, WN; Goffeau, A			Drugs, ionophoric peptides, and steroids as substrates of the yeast multidrug transporter Pdr5p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-CASSETTE TRANSPORTER; ATP-DEPENDENT TRANSPORT; P-GLYCOPROTEIN; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; GENE-PRODUCT; FUNCTIONAL CONSEQUENCES; RESISTANT CELLS; VESICLES; TRIPHOSPHATASE	Pdr5p is the yeast Saccharomyces cerevisiae ATP-binding cassette transporter conferring resistance to several unrelated drugs. Its high overproduction in Pdr1p transcription factor mutants allows us to study the molecular mechanism of multidrug transport and substrate specificity. We have developed new in vivo and in vitro assays of Pdr5p-mediated drug transport. We show that in spite of little sequence homology, and inverted topology in respect to that of mammalian P-glycoproteins, Pdr5p shares with them common substrate. Pdr5p extrudes rhodamines 6G and 123, from intact yeast cells in an energy dependent manner. Plasma membrane preparations from a Pdr5p-overproducing strain exhibit ATP hydrolysis-dependent, osmotically sensitive rhodamine 6G fluorescence quenching. The quenching is competitively inhibited by micromolar concentrations of many anticancer drugs, such as vinblastine, vincristine, taxol, and verapamil, and of ionophoric peptides as well as steroids. In contrast, other anticancer drugs, like colchicine and some multidrug resistance modifiers, such as quinidine, exert noncompetitive inhibition. Our experimental system opens new possibilities for the analysis of structure-function relationship of multidrug transporter substrates and inhibitors.	UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, B-1348 LOUVAIN, BELGIUM; UNIV GRONINGEN, DEPT MICROBIOL, NL-9751 NN HAREN, NETHERLANDS; UNIV CATHOLIQUE LOUVAIN, DEPT CHIM, LAB CHIM ORGAN PHYS & PHOTOCHIM, B-1348 LOUVAIN, BELGIUM	Universite Catholique Louvain; University of Groningen; Universite Catholique Louvain			Konings, Wilhelmus N./C-7063-2013					ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; ARBELOA FL, 1988, J CHEM SOC FARAD T 2, V84, P1903, DOI 10.1039/f29888401903; BALZI E, 1987, J BIOL CHEM, V262, P16871; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; BALZI E, 1994, J BIOL CHEM, V269, P3206; BEAUDET L, 1995, J BIOL CHEM, V270, P17159, DOI 10.1074/jbc.270.29.17159; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Bolhuis H, 1996, EMBO J, V15, P4239, DOI 10.1002/j.1460-2075.1996.tb00798.x; DECOTTIGNIES A, 1995, J BIOL CHEM, V270, P18150, DOI 10.1074/jbc.270.30.18150; DECOTTIGNIES A, 1994, J BIOL CHEM, V269, P12797; DELAHODDE A, 1995, MOL CELL BIOL, V15, P4043; DEMAIS L, 1991, J BIOL CHEM, V266, P5736; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; DUFOUR JP, 1988, METHOD ENZYMOL, V157, P513; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; EIDELMAN O, 1989, BIOCHIM BIOPHYS ACTA, V988, P319, DOI 10.1016/0304-4157(89)90008-7; FERRY DR, 1992, BIOCHEM BIOPH RES CO, V188, P440, DOI 10.1016/0006-291X(92)92404-L; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GOTTESMAN MM, 1994, CURR TOP MEMBR, V41, P3, DOI 10.1016/S0070-2161(08)60451-7; GUIRAL M, 1994, FEBS LETT, V346, P141, DOI 10.1016/0014-5793(94)00447-1; HIGGINS CF, 1994, CELL, V79, P393, DOI 10.1016/0092-8674(94)90248-8; HIRATA D, 1994, CURR GENET, V26, P285, DOI 10.1007/BF00310491; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; Katzmann DJ, 1996, J BIOL CHEM, V271, P23049, DOI 10.1074/jbc.271.38.23049; KESSEL D, 1991, CANCER RES, V51, P4665; KRALLI A, 1995, P NATL ACAD SCI USA, V92, P4701, DOI 10.1073/pnas.92.10.4701; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; LEE JS, 1994, MOL PHARMACOL, V46, P627; LEONARD PJ, 1994, ANTIMICROB AGENTS CH, V38, P2492, DOI 10.1128/AAC.38.10.2492; LEPPERT G, 1990, GENETICS, V125, P13; LOO TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1994, J BIOL CHEM, V269, P7243; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALKHANDI J, 1994, EUR J PHARM-MOLEC PH, V288, P105, DOI 10.1016/0922-4106(94)90015-9; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; Michaelis S, 1995, COLD SPRING HARB SYM, V60, P291, DOI 10.1101/SQB.1995.060.01.034; MICHELSON S, 1992, B MATH BIOL, V54, P1023; Pierce J. S., 1970, Journal of the Institute of Brewing, V76, P442; REUTZ S, 1994, CELL, V77, P1071; REUTZ S, 1994, J BIOL CHEM, V269, P12277; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; SHAPIRO AB, 1995, J BIOL CHEM, V270, P16167, DOI 10.1074/jbc.270.27.16167; SIKORSKI RS, 1989, GENETICS, V122, P19; TAMAI I, 1991, J BIOL CHEM, V266, P16796; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107	50	262	273	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31543	31548		10.1074/jbc.271.49.31543	http://dx.doi.org/10.1074/jbc.271.49.31543			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940170	hybrid			2022-12-27	WOS:A1996VW68600081
J	Larose, M; CassardDoulcier, AM; Fleury, C; Serra, F; Champigny, O; Bouillaud, F; Ricquier, D				Larose, M; CassardDoulcier, AM; Fleury, C; Serra, F; Champigny, O; Bouillaud, F; Ricquier, D			Essential cis-acting elements in rat uncoupling protein gene are in an enhancer containing a complex retinoic acid response domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; BETA-ADRENERGIC AGONIST; AP1 BINDING-SITE; MESSENGER-RNA; TRANSGENIC MICE; CELL-CULTURE; X-RECEPTOR; EXPRESSION; THERMOGENESIS; ADIPOCYTES	Transgenic mice were generated with a transgene containing the 211-base pair (bp) enhancer and 0.4 kilobase pairs of 5'-flanking DNA of the uncoupling protein (ucp) gene. Expression of this transgene was restricted to brown adipose tissue and was inducible by cold exposure or treatment of transgenic mice by norepinephrine, retinoic acid (RA), or CL-316,243 beta 3-adrenoreceptor agonist. A search for retinoic acid response elements in the ucp gene enhancer was undertaken using mutagenesis and transfection of cultured cells with chloramphenicol acetyltransferase constructs. Deletion or mutations of several putative retinoic acid response elements were ineffective. Mutations of a TGAATCA region dramatically decreased the transcriptional activity in the presence of RA, In vitro this region was able to bind a complex containing proteins recognized by antibodies against Jun or Fos. Mutations of an adjacent region related to an inverted repeat of type 2 also markedly decreased RA effect. This region was able to bind in vitro retinoid X receptor alpha and retinoic acid receptor beta. The two regions form an activating region between bp -2421 and -2402 (referred to as the ucp gene-activating region), which has an enhancer activity but cannot confer RA response to a promoter, This response was obtained with a larger DNA fragment (bp -2489 to -2398) constituting a complex RA response domain.	CNRS, CEREMOD, F-92190 MEUDON, FRANCE	Centre National de la Recherche Scientifique (CNRS)			Serra, Francisca/B-8641-2008; Bouillaud, Frédéric R/L-3238-2017; CASSARD, Anne-Marie/B-6095-2019	Serra, Francisca/0000-0002-8307-9732; Bouillaud, Frédéric R/0000-0002-7518-9237; CASSARD, Anne-Marie/0000-0002-1813-5128				ALVAREZ R, 1995, J BIOL CHEM, V270, P5666, DOI 10.1074/jbc.270.10.5666; ANTRASFERRY J, 1994, BIOCHEM J, V302, P943, DOI 10.1042/bj3020943; BIANCO AC, 1988, J BIOL CHEM, V263, P18168; BLOOM JD, 1992, J MED CHEM, V35, P3081, DOI 10.1021/jm00094a025; BOUILLAUD F, 1988, BIOCHEM BIOPH RES CO, V157, P783, DOI 10.1016/S0006-291X(88)80318-8; BOUILLAUD F, 1985, P NATL ACAD SCI USA, V82, P445, DOI 10.1073/pnas.82.2.445; BOUILLAUD F, 1984, J BIOL CHEM, V259, P1583; BOYER BB, 1991, MOL CELL BIOL, V11, P4147, DOI 10.1128/MCB.11.8.4147; CANNON B, 1985, ESSAYS BIOCHEM, V20, P110; CASSARDDOULCIER AM, 1993, MOL ENDOCRINOL, V7, P497, DOI 10.1210/me.7.4.497; CASSARDDOULCIER AM, 1994, J BIOL CHEM, V269, P24335; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHAMPIGNY O, 1992, MOL CELL ENDOCRINOL, V86, P73, DOI 10.1016/0303-7207(92)90177-8; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; COUSIN B, 1992, J CELL SCI, V103, P931; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; HIMMESHAGEN J, 1996, IN PRESS HDB OBESITY; HIMMSHAGEN J, 1994, AM J PHYSIOL, V266, pR1371, DOI 10.1152/ajpregu.1994.266.4.R1371; HOGAN B, 1986, MANIPULATING MOUSE E; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; KATO S, 1995, MOL CELL BIOL, V15, P5858; KLAUS S, 1994, J CELL SCI, V107, P313; KLAUS S, 1991, INT J BIOCHEM, V23, P791, DOI 10.1016/0020-711X(91)90062-R; KLAUS S, 1991, J CELL BIOL, V115, P1783, DOI 10.1083/jcb.115.6.1783; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KOPECKY J, 1990, J BIOL CHEM, V265, P22204; KOZAK UC, 1994, MOL CELL BIOL, V14, P59, DOI 10.1128/MCB.14.1.59; KOZAK UC, 1992, MOL ENDOCRINOL, V6, P763, DOI 10.1210/me.6.5.763; LEPAR GJ, 1992, MOL CELL ENDOCRINOL, V84, P65, DOI 10.1016/0303-7207(92)90072-E; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MEANS AL, 1995, ANNU REV BIOCHEM, V64, P201, DOI 10.1146/annurev.bi.64.070195.001221; MUKAI K, 1995, MOL CELL BIOL, V15, P6003; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; RABELO R, 1995, ENDOCRINOLOGY, V136, P1003, DOI 10.1210/en.136.3.1003; REHNMARK S, 1990, J BIOL CHEM, V265, P16464; RICQUIER D, 1986, J BIOL CHEM, V261, P13905; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; ROSS SR, 1992, P NATL ACAD SCI USA, V89, P7561, DOI 10.1073/pnas.89.16.7561; ROY DY, 1995, MOL CELL BIOL, V15, P6481; SAFONOVA I, 1994, BIOCHEM BIOPH RES CO, V204, P498, DOI 10.1006/bbrc.1994.2487; SAFONOVA I, 1994, MOL CELL ENDOCRINOL, V104, P201, DOI 10.1016/0303-7207(94)90123-6; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; Scott DK, 1996, J BIOL CHEM, V271, P6260, DOI 10.1074/jbc.271.11.6260; Sears IB, 1996, MOL CELL BIOL, V16, P3410; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SILVA JE, 1993, TRENDS ENDOCRIN MET, V4, P25, DOI 10.1016/1043-2760(93)90060-R; SISTA ND, 1995, NUCLEIC ACIDS RES, V23, P1729; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THONBERG H, 1994, J BIOL CHEM, V269, P33179; WU FK, 1988, EMBO J, V7, P2117, DOI 10.1002/j.1460-2075.1988.tb03051.x; Xia CL, 1996, BIOCHEM J, V313, P155, DOI 10.1042/bj3130155; YANGYEN HF, 1991, NEW BIOL, V3, P1206	54	67	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31533	31542		10.1074/jbc.271.49.31533	http://dx.doi.org/10.1074/jbc.271.49.31533			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940169	hybrid			2022-12-27	WOS:A1996VW68600080
J	Nantel, A; Quatrano, RS				Nantel, A; Quatrano, RS			Characterization of three rice basic/leucine zipper factors, including two inhibitors of EmBP-1 DNA binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTIONAL ACTIVATOR; ABSCISIC-ACID; BZIP PROTEINS; MOLECULAR CHARACTERIZATION; NEGATIVE REGULATOR; SEED DEVELOPMENT; HISTONE GENES; BASIC REGION; EXPRESSION	The promoter of the wheat Em gene contains elements with a CACGTG core sequence (G-boxes), which are recognized by EmBP-1, a wheat basic/leucine zipper (bZIP) protein, G-boxes are required for Em expression in response to the phytohormone abscisic acid and for transactivation by the Viviparous-1 protein (VP1) using transient expression systems, In order to identify other factors that are part of the transcriptional complex that associates with Gr-boxes, we have screened a rice (Oryza sativa) cDNA library with biotinylated EmBP-1. We have isolated osZIP-1a, a homolog of EmBP-1 and other plant G-box-binding factors. me show that EmBP-1 and osZIP-1a will preferentially heterodimerize in vitro, Over-expression of osZIP-1a in rice protoplasts can enhance expression from the Em promoter only in the presence of abscisic acid. Two Other clones have been identified by screening with EmBP-1: osZIP-2a and osZIP-2b. These osZIP-2 factors represent a novel class of bZIP proteins with an unusual DNA-binding domain that does not recognize G-boxes, The osZIP-2 factors can heterodimerize with EmBP-1 and prevent it from binding to the Em promoter. Interestingly, osZIP-1a does not heterodimerize with the osZIP-2 factors and its DNA binding activity is unaffected by their presence. Thus, osZIP-2 factors may be involved in sequestering a particular group of G-box binding factors into inactive heterodimers.	UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					NIGMS NIH HHS [GM44288] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AESCHBACHER RA, 1991, PLANT J, V1, P303, DOI 10.1046/j.1365-313X.1991.t01-1-00999.x; AGUAN K, 1993, MOL GEN GENET, V240, P1, DOI 10.1007/BF00276876; ARMSTRONG GA, 1992, PLANT CELL, V4, P525, DOI 10.1105/tpc.4.5.525; AUKERMAN MJ, 1991, GENE DEV, V5, P310, DOI 10.1101/gad.5.2.310; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONAWAY RC, 1994, TRANSCRIPTION MECH R; DELISLE AJ, 1990, PLANT CELL, V2, P547, DOI 10.1105/tpc.2.6.547; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVETTEN NC, 1994, INT J BIOCHEM, V26, P1055, DOI 10.1016/0020-711X(94)90128-7; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FELDBRUGGE M, 1994, PLANT CELL, V6, P1607, DOI 10.1105/tpc.6.11.1607; FOLEY RC, 1993, PLANT J, V3, P669, DOI 10.1111/j.1365-313X.1993.00669.x; FOSTER R, 1994, FASEB J, V8, P192, DOI 10.1096/fasebj.8.2.8119490; GIULIANO G, 1988, P NATL ACAD SCI USA, V85, P7089, DOI 10.1073/pnas.85.19.7089; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GUILTINAN MJ, 1994, PLANT MOL BIOL, V26, P1041, DOI 10.1007/BF00040687; GUILTINAN MJ, 1990, SCIENCE, V250, P267, DOI 10.1126/science.2145628; GYURIS J, 1993, CELL, V74, P205; HARTER K, 1994, PLANT CELL, V6, P545, DOI 10.1105/tpc.6.4.545; HURST HC, 1994, PROTEIN PROFILE, V1, P123; IZAWA T, 1993, J MOL BIOL, V230, P1131, DOI 10.1006/jmbi.1993.1230; IZAWA T, 1994, PLANT CELL, V6, P1277, DOI 10.1105/tpc.6.9.1277; KATAGIRI F, 1989, NATURE, V340, P727, DOI 10.1038/340727a0; Litts J C, 1991, DNA Seq, V1, P263, DOI 10.3109/10425179109020781; LOHMER S, 1993, PLANT CELL, V5, P65, DOI 10.1105/tpc.5.1.65; LU GH, 1992, P NATL ACAD SCI USA, V89, P11490, DOI 10.1073/pnas.89.23.11490; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MARCOTTE WR, 1988, NATURE, V335, P454, DOI 10.1038/335454a0; MARCOTTE WR, 1989, PLANT CELL, V1, P969, DOI 10.2307/3868997; MCCARTY DR, 1991, CELL, V66, P895, DOI 10.1016/0092-8674(91)90436-3; MCELROY D, 1990, PLANT CELL, V2, P163, DOI 10.1105/tpc.2.2.163; MEIER I, 1994, NUCLEIC ACIDS RES, V22, P470, DOI 10.1093/nar/22.3.470; MENKENS AE, 1994, P NATL ACAD SCI USA, V91, P2522, DOI 10.1073/pnas.91.7.2522; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MIKAMI K, 1994, J BIOL CHEM, V269, P9974; MONTECLARO FS, 1993, P NATL ACAD SCI USA, V90, P6726, DOI 10.1073/pnas.90.14.6726; NANTEL A, 1995, PLANT MOL BIOL REP, V13, P164, DOI 10.1007/BF02668788; NEUHAUS G, 1994, PLANT CELL, V6, P827, DOI 10.1105/tpc.6.6.827; OEDA K, 1991, EMBO J, V10, P1793, DOI 10.1002/j.1460-2075.1991.tb07704.x; PARCY F, 1994, PLANT CELL, V6, P1567, DOI 10.1105/tpc.6.11.1567; PIETRZAK M, 1986, NUCLEIC ACIDS RES, V14, P5857, DOI 10.1093/nar/14.14.5857; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PYSH LD, 1993, PLANT CELL, V5, P227, DOI 10.1105/tpc.5.2.227; Rogers S.O., 1988, PLANT MOL BIOL MANUA, pA6/1; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUTH J, 1994, PLANT MOL BIOL, V25, P323, DOI 10.1007/BF00023248; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHINDLER U, 1992, EMBO J, V11, P1275, DOI 10.1002/j.1460-2075.1992.tb05171.x; SCHINDLER U, 1992, PLANT CELL, V4, P1309, DOI 10.1105/tpc.4.10.1309; SCHINDLER U, 1992, EMBO J, V11, P1261, DOI 10.1002/j.1460-2075.1992.tb05170.x; SCHMIDT RJ, 1990, P NATL ACAD SCI USA, V87, P46, DOI 10.1073/pnas.87.1.46; SINGH K, 1990, PLANT CELL, V2, P891, DOI 10.1105/tpc.2.9.891; SUCKOW M, 1994, NUCLEIC ACIDS RES, V22, P4395, DOI 10.1093/nar/22.21.4395; TABATA T, 1989, SCIENCE, V245, P965, DOI 10.1126/science.2772648; TABATA T, 1991, EMBO J, V10, P1459, DOI 10.1002/j.1460-2075.1991.tb07666.x; THOMAS D, 1992, MOL CELL BIOL, V12, P1719, DOI 10.1128/MCB.12.4.1719; TORRES JT, 1993, PLANT J, V4, P587, DOI 10.1046/j.1365-313X.1993.04030587.x; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; UNGER E, 1993, PLANT CELL, V5, P831, DOI 10.1105/tpc.5.8.831; VASIL V, 1995, PLANT CELL, V7, P1511, DOI 10.1105/tpc.7.9.1511; WILLIAMSON JD, 1988, PLANT PHYSIOL, V86, P208, DOI 10.1104/pp.86.1.208; YAMAZAKI K, 1990, P NATL ACAD SCI USA, V87, P7035, DOI 10.1073/pnas.87.18.7035	70	63	67	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31296	31305		10.1074/jbc.271.49.31296	http://dx.doi.org/10.1074/jbc.271.49.31296			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940135	Green Published, hybrid			2022-12-27	WOS:A1996VW68600046
J	Wang, XP; Sheikh, S; Saigal, D; Robinson, L; Weiner, H				Wang, XP; Sheikh, S; Saigal, D; Robinson, L; Weiner, H			Heterotetramers of human liver mitochondrial (class 2) aldehyde dehydrogenase expressed in Escherichia coli - A model to study the heterotetramers expected to be found in oriental people	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETALDEHYDE METABOLISM; ALCOHOL SENSITIVITY; ALDH2 LOCUS; GENOTYPES; DEFICIENCY; ALLELE; POPULATION; ISOZYMES; JAPANESE; VARIANT	About 50% of the Oriental population have less liver mitochondrial aldehyde dehydrogenase (ALDH2) activity than do other people. It was found that they possessed an enzyme with a lysine at position 487 (E487K) instead of glutamate (GlU(487)). We previously found that the K-m, for NAD of recombinant human and rat E487K enzymes increased more than 150-fold (Farres, J., Wang X., Takahashi, IC, Cunningham, S. J., Wang, T.T., and Weiner, H (1994) J, Biol. Chem 269, 13854-13860). Many aldehyde dehydrogenase-deficient people were found to be heterozygous when genotyped for ALDH2, In this study liver tissue from heterozygous people was analyzed and found to possess mRNAs for both the glutamate and the lysine subunits, Western blot analysis showed that the glutamate subunit was present, The cDNAs for Glu(487) and E487K were coexpressed on one plasmid in Escherichia coli, and the enzyme forms were separated from each other by isoelectric focusing to show that heterotetramers were formed. Only one LC, value for NAD could be measured with the purified heterotetrameric enzyme that possessed just 16-18% activity of the glutamate homotetrameric enzyme, The E487K homotetramers had 8% specific activity of the GlU(487) enzyme, There was no pre-steady state burst of NADH formation with the heterotetramer, a property found with the glutamate enzyme, Similar results were found for the coexpressed rat liver enzyme, except that a higher specific activity, 48%, was obtained, Thus, we conclude that presence of the lysine subunit altered the activity of the glutamate subunit in the heterotetramer to make it function more like an E487K enzyme.	PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NIAAA NIH HHS [AA05812] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA005812, R01AA005812] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AINSLIE GR, 1982, ARCH BIOCHEM BIOPHYS, V216, P101, DOI 10.1016/0003-9861(82)90193-X; Chao You-Chen, 1993, Proceedings of the National Science Council Republic of China Part B Life Sciences, V17, P98; CRABB DW, 1989, J CLIN INVEST, V83, P314, DOI 10.1172/JCI113875; EISENSTEIN E, 1992, J BIOL CHEM, V267, P22148; ENOMOTO N, 1991, ALCOHOL CLIN EXP RES, V15, P141, DOI 10.1111/j.1530-0277.1991.tb00532.x; FARRES J, 1994, J BIOL CHEM, V269, P13854; FERENCZBIRO K, 1984, BIOCHEM BIOPH RES CO, V118, P97, DOI 10.1016/0006-291X(84)91072-6; GHENBOT G, 1992, PROTEIN EXPRES PURIF, V3, P470, DOI 10.1016/1046-5928(92)90064-4; GOEDDE HW, 1985, ALCOHOL, V2, P383, DOI 10.1016/0741-8329(85)90099-0; GOEDDE HW, 1989, HUM GENET, V81, P305, DOI 10.1007/BF00283679; GREENFIELD NJ, 1977, BIOCHIM BIOPHYS ACTA, V483, P35, DOI 10.1016/0005-2744(77)90005-5; HARADA S, 1981, LANCET, V2, P982; HEMPEL J, 1984, FEBS LETT, V173, P367, DOI 10.1016/0014-5793(84)80807-8; HEMPEL J, 1993, PROTEIN SCI, V2, P1890, DOI 10.1002/pro.5560021111; HSU LC, 1987, AM J HUM GENET, V41, P996; IKAWA M, 1983, J BIOL CHEM, V258, P6282; IMPRAIM C, 1982, AM J HUM GENET, V34, P837; MIZOI Y, 1979, PHARMACOL BIOCHEM BE, V10, P303, DOI 10.1016/0091-3057(79)90105-9; QING NC, 1988, ALCOHOL CLIN EXP RES, V12, P720, DOI 10.1111/j.1530-0277.1988.tb00271.x; SVANAS GW, 1985, ARCH BIOCHEM BIOPHYS, V236, P36, DOI 10.1016/0003-9861(85)90603-4; TAKAHASHI K, 1980, ARCH BIOCHEM BIOPHYS, V205, P571, DOI 10.1016/0003-9861(80)90140-X; TAKESHITA T, 1994, HUM GENET, V94, P217; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TENG YS, 1981, BIOCHEM GENET, V19, P107, DOI 10.1007/BF00486141; TU GC, 1993, EUR J CLIN CHEM CLIN, V31, P591; WANG XP, 1995, BIOCHEMISTRY-US, V34, P237, DOI 10.1021/bi00001a028; WEINER H, 1976, J BIOL CHEM, V251, P3853; XIAO Q, 1995, J CLIN INVEST, V96, P2180, DOI 10.1172/JCI118272; Yamamoto Kenji, 1993, Japanese Journal of Alcohol Studies and Drug Dependence, V28, P13; YOSHIDA A, 1984, P NATL ACAD SCI-BIOL, V81, P258, DOI 10.1073/pnas.81.1.258; ZHENG CF, 1993, ALCOHOL CLIN EXP RES, V17, P828, DOI 10.1111/j.1530-0277.1993.tb00849.x	32	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31172	31178		10.1074/jbc.271.49.31172	http://dx.doi.org/10.1074/jbc.271.49.31172			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940116	hybrid			2022-12-27	WOS:A1996VW68600027
J	Weisel, JW; Nagaswami, C; Young, TA; Light, DR				Weisel, JW; Nagaswami, C; Young, TA; Light, DR			The shape of thrombomodulin and interactions with thrombin as determined by electron microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN THROMBOMODULIN; HUMAN SOLUBLE THROMBOMODULIN; PROTEIN-C ACTIVATION; COFACTOR ACTIVITY; RABBIT THROMBOMODULIN; ANTICOAGULANT ACTIVITIES; FUNCTIONAL DOMAINS; SHUNT THROMBOSIS; MOLECULAR-WEIGHT; HOMOLOGY DOMAIN	Studies have been carried out to investigate aspects of the structure of thrombomodulin, an endothelial cell glycoprotein that binds thrombin and accelerates both the thrombin-dependent activation of protein C and the inhibition of antithrombin III. We have determined the shape of Solulin(TM), a soluble recombinant form of human thrombomodulin missing the transmembrane and cytoplasmic domains, by electron microscopy of preparations rotary-shadowed with tungsten. Solulin appears to be an elongated molecule about 20 nm long that has a large nodule at one end and a smaller nodule near the other end from which extends a thin strand. About half of the molecules form bipolar dimers apparently via interactions between these thin strands, Electron microscopy of complexes formed between Solulin and human alpha-thrombin revealed that a single thrombin molecule appears to bind to the smaller nodule of Solulin, suggesting that this region contains the epidermal growth factor-like domains 5 and 6. Epidermal growth factor-like domains 1-4 comprise the connector between the small and large nodule, which is the lectin-like domain; the thin strand at the other end of the molecule is the carbohydrate rich region. With chondroitin sulfate-containing soluble thrombomodulin produced from either human melanoma cells Bowes or Chinese hamster ovary cells, a higher percentage of molecules bound thrombin and, in some cases, two thrombin molecules were attached to one soluble thrombomodulin in approximately the same region, These structural studies provide insight into the structure of thrombomodulin and its interactions with thrombin as well as aspects of the mechanisms of its actions.	BERLEX BIOSCI, DEPT PROT CHEM, RICHMOND, CA 94804 USA		Weisel, JW (corresponding author), UNIV PENN, SCH MED, DEPT CELL & DEV BIOL, PHILADELPHIA, PA 19104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030954] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30954] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AOKI Y, 1994, AM J HEMATOL, V47, P162, DOI 10.1002/ajh.2830470303; BODE W, 1993, SEMIN THROMB HEMOST, V19, P321, DOI 10.1055/s-2007-993283; BOURIN MC, 1988, J BIOL CHEM, V263, P8044; CLARKE JH, 1993, J BIOL CHEM, V268, P6309; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; DEBAULT LE, 1986, LAB INVEST, V54, P179; DITTMAN WA, 1990, BLOOD, V75, P329; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P29; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; ESMON NL, 1989, PROG HEMOST THROMB, V9, P29; FENTON JW, 1991, BLOOD COAGUL FIBRIN, V2, P69, DOI 10.1097/00001721-199102000-00011; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; FOWLER WE, 1983, J ULTRA MOL STRUCT R, V83, P319, DOI 10.1016/S0022-5320(83)90139-9; GAN ZR, 1993, ARCH BIOCHEM BIOPHYS, V301, P228, DOI 10.1006/abbi.1993.1138; GLASER CB, 1992, J CLIN INVEST, V90, P2565, DOI 10.1172/JCI116151; HEALY AM, 1995, P NATL ACAD SCI USA, V92, P850, DOI 10.1073/pnas.92.3.850; HORVAT R, 1993, EUR J CELL BIOL, V61, P299; JACKMAN RW, 1986, P NATL ACAD SCI USA, V83, P8834, DOI 10.1073/pnas.83.23.8834; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; KUROSAWA S, 1987, J BIOL CHEM, V262, P2206; LENTZ SR, 1993, J BIOL CHEM, V268, P15312; LIGHT DR, 1993, Patent No. 9315755; LIN JH, 1994, J BIOL CHEM, V269, P25021; LU RL, 1989, J BIOL CHEM, V264, P12956; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P13547, DOI 10.1021/bi00250a006; MCLEAN K, 1992, ZIMM C PROGR VASC BI; MEDVED LV, 1995, J BIOL CHEM, V270, P13652, DOI 10.1074/jbc.270.23.13652; MEININGER DP, 1995, PROTEIN SCI, V4, P1683, DOI 10.1002/pro.5560040904; MORGELIN M, 1992, J BIOL CHEM, V267, P14275; NAGASHIMA M, 1993, J BIOL CHEM, V268, P2888; NAWA K, 1990, BIOCHEM BIOPH RES CO, V171, P729, DOI 10.1016/0006-291X(90)91207-9; OHLIN AK, 1995, BLOOD, V85, P330; ONO M, 1994, THROMB HAEMOSTASIS, V72, P421; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; PARKINSON JF, 1992, ADV EXP MED BIOL, V313, P177; SADLER JE, 1993, HAEMOSTASIS, V23, P183; SASAKI T, 1995, J MOL BIOL, V245, P241, DOI 10.1006/jmbi.1994.0020; SOLIS MM, 1994, THROMB RES, V73, P385, DOI 10.1016/0049-3848(94)90040-X; SRINIVASAN J, 1994, BIOCHEMISTRY-US, V33, P13553, DOI 10.1021/bi00250a007; STEARNS DJ, 1989, J BIOL CHEM, V264, P3352; STENFLO J, 1991, BLOOD, V78, P1637; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; STUBBS MT, 1995, TRENDS BIOCHEM SCI, V20, P23, DOI 10.1016/S0968-0004(00)88945-8; SUZUKI K, 1989, J BIOL CHEM, V264, P4872; TIMPL R, 1993, EXPERIENTIA, V49, P417, DOI 10.1007/BF01923586; TSIANG M, 1992, J BIOL CHEM, V267, P6164; TULINSKY A, 1993, BLOOD COAGUL FIBRIN, V4, P305, DOI 10.1097/00001721-199304000-00012; VEKLICH YI, 1993, J BIOL CHEM, V268, P13577; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; WEISEL JW, 1994, J BIOL CHEM, V269, P10100; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058; WINNARD PT, 1989, ARCH BIOCHEM BIOPHYS, V269, P339, DOI 10.1016/0003-9861(89)90115-X; YE J, 1993, J BIOL CHEM, V268, P2373	54	41	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31485	31490		10.1074/jbc.271.49.31485	http://dx.doi.org/10.1074/jbc.271.49.31485			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940162	hybrid			2022-12-27	WOS:A1996VW68600073
J	Ho, LB; Fukuchi, K; Younkin, SG				Ho, LB; Fukuchi, K; Younkin, SG			The alternatively spliced Kunitz protease inhibitor domain alters amyloid beta protein precursor processing and amyloid beta protein production in cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE-LIKE HISTOPATHOLOGY; EARLY ALZHEIMERS-DISEASE; MESSENGER-RNA; TRANSGENIC MICE; NEXIN-II; PEPTIDE; BRAIN; EXPRESSION; GENE; AGE	The insoluble amyloid deposited extracellularly in the brains of patients with Alzheimer's disease (AD) is composed of amyloid beta protein, a similar to 4-kDa secreted protein that is derived from a set of large proteins collectively referred to as the amyloid beta protein precursor (beta APP). During normal processing the beta APP is cleaved by beta secretase, producing a large NH2-terminal secreted derivative (sAPP beta) and a COOH-terminal fragment beginning at A beta 1, which is subsequently cleaved by gamma secretase releasing secreted A beta. Most secreted A beta is A beta 1-40, but similar to 10% of secreted A beta is A beta 1-42. Alternative beta APP cleavage by alpha secretase produces a slightly longer NH2-terminal secreted derivative (sAPP alpha) and a COOH-terminal fragment beginning at A beta 17, which is subsequently cleaved by gamma secretase releasing a similar to 3-kDa secreted form of A beta (P3), Several of the beta APP isoforms that are produced by alternative splicing contain a 56-amino acid Kunitz protease inhibitor (KPI) domain known to inhibit proteases such as trypsin and chymotrypsin, To determine whether the KPI domain influences the proteolytic cleavages that generate A beta, we compared A beta production in transfected cells expressing human KPI-containing beta APP751 or KPI-free beta APP695. We focused on A beta s ending at A beta 42 because these forms appear to be most relevant to AD. Using specific sandwich enzyme-linked immunosorbent assays, we analysed full-length A beta 1-42 and total A beta ending at A beta 42 (A beta 1-42 + P3(42)). In addition, we analysed the large secreted derivatives produced by alpha secretase (sAPP alpha) and beta secretase (sAPP beta). In mouse teratocarcinoma (P19) cells expressing beta APP695 or beta APP751, expression of the KPI-containing beta APP751 resulted in the secretion of a lower percentage of P3(42) and sAPP alpha and a correspondingly higher percentage of A beta 1-42 and sAPP beta. Similar results were obtained in human embryonic kidney (293) cells. These results indicate that expression of the KPI domain reduces alpha secretase cleavage so that less P3 and relatively more full-length A beta are produced. Thus, in human brain and in animal models of AD, the amount of KPI-containing beta APP produced may be an important factor influencing A beta deposition.	MAYO CLIN JACKSONVILLE,JACKSONVILLE,FL 32224; CASE WESTERN RESERVE UNIV,DEPT NEUROSCI,CLEVELAND,OH 44106; UNIV ALABAMA,DEPT COMPARAT MED,BIRMINGHAM,AL 35294	Mayo Clinic; Case Western Reserve University; University of Alabama System; University of Alabama Birmingham								BHASIN R, 1991, P NATL ACAD SCI USA, V88, P10307, DOI 10.1073/pnas.88.22.10307; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHEUNG TT, 1994, AMYLOID, V1, P30, DOI 10.3109/13506129409148622; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1994, J BIOL CHEM, V269, P17741; HIGGINS LS, 1993, ANN NY ACAD SCI, V695, P224, DOI 10.1111/j.1749-6632.1993.tb23056.x; HIGGINS LS, 1994, ANN NEUROL, V35, P598, DOI 10.1002/ana.410350514; HIGGINS LS, 1995, P NATL ACAD SCI USA, V92, P4402, DOI 10.1073/pnas.92.10.4402; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KONIG G, 1992, J BIOL CHEM, V267, P10804; KOO EH, 1994, J BIOL CHEM, V269, P17386; LEMAIRE HG, 1989, NUCLEIC ACIDS RES, V17, P517, DOI 10.1093/nar/17.2.517; MORGAN PM, 1995, P NATL ACAD SCI USA, V92, P5341; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; QUON D, 1991, NATURE, V352, P239, DOI 10.1038/352239a0; ROBAKIS NK, 1987, LANCET, V1, P384; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHIMOKAWA M, 1993, BIOCHIMIE, V75, P911, DOI 10.1016/0300-9084(93)90048-W; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TANAKA S, 1992, MOL BRAIN RES, V15, P303, DOI 10.1016/0169-328X(92)90122-R; TANAKA S, 1993, NEUROSCI LETT, V163, P19, DOI 10.1016/0304-3940(93)90219-B; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; VANNOSTRAND WE, 1989, NATURE, V341, P546; WERTKIN AM, 1993, P NATL ACAD SCI USA, V90, P9513, DOI 10.1073/pnas.90.20.9513; YAMAGUCHI F, 1991, NEUROREPORT, V2, P781, DOI 10.1097/00001756-199112000-00013; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N	42	56	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30929	30934		10.1074/jbc.271.48.30929	http://dx.doi.org/10.1074/jbc.271.48.30929			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940079	hybrid			2022-12-27	WOS:A1996VV15800096
J	Jubete, Y; Maurizi, MR; Gottesman, S				Jubete, Y; Maurizi, MR; Gottesman, S			Role of the heat shock protein DnaJ in the Lon-dependent degradation of naturally unstable proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; FUSION PROTEIN; ION GENE; LAMBDA-N; PROTEOLYSIS; CHAPERONE; MUTANTS; GRPE; SULA; PURIFICATION	We have investigated the role of DnaJ in protein degradation by examining the degradation of intrinsically unstable proteins by Lon protease in vivo. In Escherichia coli, Lon protease is responsible for the rate-limiting step in degradation of highly unstable proteins such as SulA, RcsA, and lambda N protein, as well as for about 50% of the rapid degradation of abnormal proteins such as canavanine-containing proteins. We found that Lon-dependent degradation of both SulA and AN protein was unaffected in cells lacking functional DnaJ, whereas Lon-dependent turnover of canavanine containing proteins was slower in dnaJ mutant cells. DnaJ also affected the slow SulA degradation seen in the absence of Lon. The rate of degradation of RcsA was reduced in dnaJ mutants, but both Lon-dependent and Lon-independent degradation was affected; abnormal, canavanine-containing proteins were similarly affected. Both the RcsA that accumulated in dnaJ mutant cells and the SulA that accumulated in ion dnaJ mutant cells was aggregated. The abnormal proteins that partitioned to the insoluble pellet became solubilized over time in dnaJ(+) cells but not in dnaJ(-) cells. Therefore, the co-chaperone DnaJ is not essential for Lon-dependent degradation and may act in protein turnover only as an accessory factor helping to maintain substrates in a soluble form. Such an accessory factor is apparently necessary for abnormal proteins and for RcsA. The relative rates of degradation and aggregation of specific protein targets may determine the importance of the chaperone systems in turnover of a given protein.	NCI, MOL BIOL LAB, BETHESDA, MD 20892 USA; NCI, CELL BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BARTON GJ, 1990, J MOL BIOL, V212, P389, DOI 10.1016/0022-2836(90)90133-7; BRILL JA, 1988, J BACTERIOL, V170, P2599, DOI 10.1128/jb.170.6.2599-2611.1988; CANCEILL D, 1990, J BACTERIOL, V172, P7297, DOI 10.1128/jb.172.12.7297-7300.1990; GOFF SA, 1984, P NATL ACAD SCI-BIOL, V81, P6647, DOI 10.1073/pnas.81.21.6647; GOLDBERG AL, 1972, P NATL ACAD SCI USA, V69, P422, DOI 10.1073/pnas.69.2.422; GOTTESMAN S, 1989, ANNU REV GENET, V23, P163, DOI 10.1146/annurev.ge.23.120189.001115; GOTTESMAN S, 1981, CELL, V24, P225, DOI 10.1016/0092-8674(81)90518-3; Gottesman S, 1995, COLD SPRING HARB SYM, V60, P533, DOI 10.1101/SQB.1995.060.01.057; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10341, DOI 10.1073/pnas.89.21.10341; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; HUISMAN O, 1984, P NATL ACAD SCI-BIOL, V81, P4490, DOI 10.1073/pnas.81.14.4490; KELLER JA, 1988, MOL MICROBIOL, V2, P31, DOI 10.1111/j.1365-2958.1988.tb00004.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LAROSSA RA, 1991, MOL MICROBIOL, V5, P529, DOI 10.1111/j.1365-2958.1991.tb00724.x; MAGUIN E, 1986, J BACTERIOL, V166, P733, DOI 10.1128/jb.166.3.733-738.1986; MAURIZI MR, 1987, J BIOL CHEM, V262, P2696; MAURIZI MR, 1985, J BACTERIOL, V164, P1124, DOI 10.1128/JB.164.3.1124-1135.1985; MAURIZI MR, 1988, UBIQUITIN SYSTEM CUR, P147; MILLER JH, 1992, SHORT COURSE BACTERI, P287; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; MIZUSAWA S, 1983, P NATL ACAD SCI-BIOL, V80, P358, DOI 10.1073/pnas.80.2.358; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; RICHARME G, 1993, J BIOL CHEM, V268, P24074; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SHERMAN MY, 1991, J BACTERIOL, V173, P7249, DOI 10.1128/jb.173.22.7249-7256.1991; SHERMAN MY, 1992, EMBO J, V11, P71; Silhavy T. J., 1984, EXPT GENE FUSIONS, P107; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SONEZAKI S, 1995, APPL MICROBIOL BIOT, V43, P304; STOUT V, 1991, J BACTERIOL, V173, P1738, DOI 10.1128/jb.173.5.1738-1747.1991; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; TILLY K, 1990, New Biologist, V2, P812; TORRESCABASSA AS, 1987, J BACTERIOL, V169, P981, DOI 10.1128/jb.169.3.981-989.1987; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREMPY JE, 1989, J BACTERIOL, V171, P3348, DOI 10.1128/jb.171.6.3348-3353.1989; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VANMELDEREN L, 1996, IN PRESS J BIOL CHEM, V271; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; [No title captured]	45	66	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30798	30803		10.1074/jbc.271.48.30798	http://dx.doi.org/10.1074/jbc.271.48.30798			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940060	hybrid			2022-12-27	WOS:A1996VV15800077
J	Kato, Y; Komatsu, S				Kato, Y; Komatsu, S			ASABF, a novel cysteine-rich antibacterial peptide isolated from the nematode Ascaris suum - Purification, primary structure, and molecular cloning of cDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSECT IMMUNITY; ANTIMICROBIAL PEPTIDES; CAENORHABDITIS-ELEGANS; PARASITIC NEMATODE; SEQUENCE HOMOLOGY; INNATE IMMUNITY; DROSOPHILA; PROTEINS; DEFENSINS	Previously, we reported antibacterial activity in the body fluid of the nematode Ascaris suum (Kato, Y. (1995) Zool. Sci. 12, 225-230). The antibacterial activity is due to a heat-stable and trypsin-sensitive molecule that was designated as ASABF (A. suum antibacterial factor). In the present study, the purification, determination of primary structure, and cDNA cloning of ASABF were carried out. The mature peptide of ASABF is a basic peptide consisting of 71 residues and containing four intramolecular disulfide bridges. The amino acid sequence of a precursor for ASABF, deduced from a cDNA clone, indicates that Banking peptides both at the N terminus and at the C terminus are eliminated by processing. ASABF exhibits potent antibacterial activity particularly against Gram-positive bacteria. ASABF has several features that resemble those of insect/arthropod defensins, whereas the statistical significance of the similarity is not observed on comparison of amino acid sequences. A search of data bases revealed ASABF homologues in Caenorhabditis elegans.	NATL INST AGROBIOL RESOURCES, DEPT MOL BIOL, TSUKUBA, IBARAKI 305, JAPAN	National Institute of Agrobiological Sciences - Japan	Kato, Y (corresponding author), NATL INST SERICULTURAL & ENTOMOL SCI, DEPT INSECT PHYSIOL & BEHAV, METAB LAB, OOWASHI 1-2, TSUKUBA, IBARAKI 305, JAPAN.			Kato, Yusuke/0000-0003-2424-4571				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ALVAREZBRAVO J, 1994, BIOCHEM J, V302, P535, DOI 10.1042/bj3020535; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BROEKAERT WF, 1995, PLANT PHYSIOL, V108, P1353, DOI 10.1016/j.chiabu.2021.105188; BULET P, 1993, J BIOL CHEM, V268, P14893; Chernysh S, 1996, J INSECT PHYSIOL, V42, P81, DOI 10.1016/0022-1910(95)00085-2; COCIANCICH S, 1993, BIOCHEM BIOPH RES CO, V194, P17, DOI 10.1006/bbrc.1993.1778; DOOLITTLE RF, 1990, METHOD ENZYMOL, V183, P99; FEHLBAUM P, 1994, J BIOL CHEM, V269, P33159; HULTMARK D, 1993, TRENDS GENET, V9, P178, DOI 10.1016/0168-9525(93)90165-E; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; KATO Y, 1995, ZOOL SCI, V12, P225, DOI 10.2108/zsj.12.225; KAZUHARA T, 1990, J BIOCHEM-TOKYO, V107, P514; KENNEDY MW, 1995, BIOCHEMISTRY-US, V34, P6700, DOI 10.1021/bi00020a015; KURAMOCHI T, 1994, MOL BIOCHEM PARASIT, V68, P177, DOI 10.1016/0166-6851(94)90163-5; LAMBERT J, 1989, P NATL ACAD SCI USA, V86, P262, DOI 10.1073/pnas.86.1.262; LEE JY, 1989, P NATL ACAD SCI USA, V86, P9159, DOI 10.1073/pnas.86.23.9159; MARONEY PA, 1995, RNA, V1, P714; MOON HJ, 1994, J BIOCHEM-TOKYO, V116, P53, DOI 10.1093/oxfordjournals.jbchem.a124502; NAGATA A, 1991, P NATL ACAD SCI USA, V88, P4020, DOI 10.1073/pnas.88.9.4020; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schwartz RM, 1978, ATLAS PROTEIN SEQ S3, P353; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; VANFLETEREN JR, 1990, BIOCHEM J, V271, P613, DOI 10.1042/bj2710613; YAMADA K, 1993, BIOCHEM J, V291, P275, DOI 10.1042/bj2910275; ZEYA HI, 1963, SCIENCE, V142, P1085, DOI 10.1126/science.142.3595.1085	28	68	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30493	30498		10.1074/jbc.271.48.30493	http://dx.doi.org/10.1074/jbc.271.48.30493			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940016	hybrid			2022-12-27	WOS:A1996VV15800033
J	Silverman, SK; Lester, HA; Dougherty, DA				Silverman, SK; Lester, HA; Dougherty, DA			Subunit stoichiometry of a heteromultimeric G protein-coupled inward-rectifier K+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT POTASSIUM CHANNEL; COOPERATIVE INTERACTIONS; BINDING-SITE; SHAKER; TETRAETHYLAMMONIUM; EXPRESSION; CLONING; DROSOPHILA; CDNAS	We investigated the stoichiometry of the heteromultimeric G protein-coupled inward-recitfier K+ channel (GIRK) formed from GIRK1 and GIRK4 subunits. Multimeric GIRK constructs with several concatenated channel subunits were expressed in Xenopus oocytes. Coexpression of various trimeric constructs with different monomers clearly showed that the functional chan nel has stoichiometry (GIRK1)(2)(GIRK4)(2). Efforts to establish a preferred arrangement of subunits around the channel pore suggest that more than one arrangement may be viable.	CALTECH,DIV BIOL 15629,PASADENA,CA 91125; CALTECH,DIV CHEM,PASADENA,CA 91125; CALTECH,DIV CHEM ENGN,PASADENA,CA 91125	California Institute of Technology; California Institute of Technology; California Institute of Technology				Silverman, Scott/0000-0001-8166-3460	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH049176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011756] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29836] Funding Source: Medline; NIMH NIH HHS [MH49176] Funding Source: Medline; NINDS NIH HHS [NS11756] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; GLOWATZKI E, 1995, P ROY SOC B-BIOL SCI, V261, P251, DOI 10.1098/rspb.1995.0145; GORDON SE, 1995, P NATL ACAD SCI USA, V92, P10222, DOI 10.1073/pnas.92.22.10222; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HURST RS, 1992, J BIOL CHEM, V267, P23742; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; IVERSON LE, 1988, P NATL ACAD SCI USA, V85, P5723, DOI 10.1073/pnas.85.15.5723; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MACKINNON R, 1993, SCIENCE, V262, P757, DOI 10.1126/science.7694359; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PASCUAL JM, 1995, BIOPHYS J, V69, P428, DOI 10.1016/S0006-3495(95)79915-5; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; QUICK MW, 1994, ION CHANNELS EXCITAB, P261; SLESINGER PA, 1995, NEURON, V15, P1145, DOI 10.1016/0896-6273(95)90102-7; TYTGAT J, 1992, NATURE, V359, P420, DOI 10.1038/359420a0; WEI A, 1994, NEURON, V13, P671, DOI 10.1016/0896-6273(94)90034-5; Yang J, 1995, NEURON, V15, P1441, DOI 10.1016/0896-6273(95)90021-7	24	71	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30524	30528		10.1074/jbc.271.48.30524	http://dx.doi.org/10.1074/jbc.271.48.30524			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940021	Green Accepted, hybrid			2022-12-27	WOS:A1996VV15800038
J	Uchiyama, A; Aoyama, T; Kamijo, K; Uchida, Y; Kondo, N; Orii, T; Hashimoto, T				Uchiyama, A; Aoyama, T; Kamijo, K; Uchida, Y; Kondo, N; Orii, T; Hashimoto, T			Molecular cloning of cDNA encoding rat very long-chain acyl-CoA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED ADRENOLEUKODYSTROPHY; ACID BETA-OXIDATION; ALD GENE; CHILDHOOD ADRENOLEUKODYSTROPHY; FRAMESHIFT MUTATION; MISSENSE MUTATION; PROTEIN; IDENTIFICATION; LIVER; PEROXISOMES	The cDNA encoding rat very long-chain acyl-CoA synthetase (VLACS) was cloned, using degenerative primers synthesized according to the partial amino acid sequences of the peptide fragments of the purified rat liver enzyme. The longest cDNA insert was 2972 base pairs with a 1860-base pair open reading frame encoding 620 amino acids. The calculated molecular mass of 70,692 daltons was consistent with size of the purified enzyme. In Northern blot analysis, a single band was detected at the position of about 3 kilobases, corresponding to the size of the cloned cDNA. cDNA-directed expression in Escherichia coli resulted in accumulation of expressed protein, as an inclusion body. An antibody was raised using this expressed protein to characterize the cDNA and the enzyme. The subcellular localization of VLACS in peroxisomes and microsomes was demonstrated in Western blot analysis. The specific activity and the substrate specificity of the cDNA expressed enzyme in COS-1 cells were consistent with those of the purified rat enzyme. The predicted amino acid sequence of VLACS had a high sequence similarity to fatty acid transport protein (Schaffer, J. E., and Lodish, H. F. (1994) Cell 79, 427-436), and was considered to have domains for adenylation and thioester formation. The entire structure of VLACS was dissimilar to that of long-chain acyl-CoA synthetase (Suzuki, H., Kawarabayashi, Y., Kondo, Y., Abe, T., Nishikawa, K., Kimura, S., Hashimoto, T., and Yamamoto, T. (1990) J. Biol. Chen. 265, 8681-8685), except for the domains.	SHINSHU UNIV, SCH MED, DEPT BIOCHEM, MATSUMOTO, NAGANO 390, JAPAN	Shinshu University	Uchiyama, A (corresponding author), GIFU UNIV, SCH MED, DEPT PEDIAT, GIFU 500, JAPAN.							Aebi H., 1974, METHODS ENZYMATIC AN, Vsecond, P673, DOI [DOI 10.1016/B978-0-12-091302-2.50032-3, 10.1016/B978-0-12-091302-2.50032-3]; AOYAMA T, 1989, J BIOL CHEM, V264, P10388; BARCELO A, 1995, HUM GENET, V95, P235; BARCELO A, 1994, HUM MOL GENET, V3, P1889, DOI 10.1093/hmg/3.10.1889; BERGER J, 1994, BIOCHEM BIOPH RES CO, V205, P1638, DOI 10.1006/bbrc.1994.2855; BRAUN A, 1995, AM J HUM GENET, V56, P854; CARTIER N, 1995, P NATL ACAD SCI USA, V92, P1674, DOI 10.1073/pnas.92.5.1674; CARTIER N, 1993, HUM MOL GENET, V2, P1949, DOI 10.1093/hmg/2.11.1949; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FANEN P, 1994, J CLIN INVEST, V94, P516, DOI 10.1172/JCI117363; FUCHS S, 1994, HUM MOL GENET, V3, P1903, DOI 10.1093/hmg/3.10.1903; FUJINO T, 1992, J BIOCHEM-TOKYO, V111, P197, DOI 10.1093/oxfordjournals.jbchem.a123737; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HASHMI M, 1986, FEBS LETT, V196, P247, DOI 10.1016/0014-5793(86)80256-3; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JOHNSON DR, 1994, J BIOL CHEM, V269, P18037; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KEMP S, 1994, BIOCHEM BIOPH RES CO, V202, P647, DOI 10.1006/bbrc.1994.1979; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZO O, 1988, P NATL ACAD SCI USA, V85, P7647, DOI 10.1073/pnas.85.20.7647; LIGTENBERG MJL, 1995, AM J HUM GENET, V56, P44; MACCABE AP, 1991, J BIOL CHEM, V266, P12646; Masters B, 1967, METHOD ENZYMOL, V10, P565; MIURA S, 1992, J BIOL CHEM, V267, P14405; MIYAZAWA S, 1985, J BIOCHEM, V98, P723, DOI 10.1093/oxfordjournals.jbchem.a135330; MOSER HW, 1992, J INHERIT METAB DIS, V15, P645, DOI 10.1007/BF01799621; MOSER HW, 1989, METABOLIC BASIS INHE, P1511; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SCHMIDT E, 1974, METHOD ENZYMAT AN, V2, P650; SINGH H, 1988, ARCH BIOCHEM BIOPHYS, V266, P486, DOI 10.1016/0003-9861(88)90281-0; SINGH H, 1987, ARCH BIOCHEM BIOPHYS, V259, P382, DOI 10.1016/0003-9861(87)90504-2; SINGH I, 1984, P NATL ACAD SCI-BIOL, V81, P4203, DOI 10.1073/pnas.81.13.4203; SONG XQ, 1995, HUM MOL GENET, V4, P1093, DOI 10.1093/hmg/4.6.1093; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; TANIGUCHI S, 1991, NUCLEIC ACIDS RES, V19, P6949, DOI 10.1093/nar/19.24.6949; TOH H, 1991, Protein Sequences and Data Analysis, V4, P111; Uchida Y, 1996, J BIOCHEM, V119, P565; UCHIYAMA A, 1994, BIOCHEM BIOPH RES CO, V198, P632, DOI 10.1006/bbrc.1994.1092; WANDERS RJA, 1988, J INHERIT METAB DIS, V11, P173, DOI 10.1007/BF01804228; WILCKE M, 1995, J BIOL CHEM, V270, P6949, DOI 10.1074/jbc.270.12.6949	46	118	125	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30360	30365		10.1074/jbc.271.48.30360	http://dx.doi.org/10.1074/jbc.271.48.30360			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939997	hybrid			2022-12-27	WOS:A1996VV15800014
J	Kerry, DM; Dwivedi, PP; Hahn, CN; Morris, HA; Omdahl, JL; May, BK				Kerry, DM; Dwivedi, PP; Hahn, CN; Morris, HA; Omdahl, JL; May, BK			Transcriptional synergism between vitamin D-responsive elements in the rat 25-hydroxyvitamin D-3 24-hydroxylase (CYP24) promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X RECEPTORS; CELL-LINE HL-60; THYROID-HORMONE; GENE-EXPRESSION; CALCITROIC ACID; IN-VIVO; IDENTIFICATION; 1,25-DIHYDROXYVITAMIN-D3; KIDNEY; METABOLISM	Transcription of the CYP24 gene is induced by 1,25-(OH)(2)D-3 through a vitamin D receptor-dependent process. The functional activities of three possible vitamin D response elements (VDREs), located on the antisense strand of the rat CYP24 promoter, were investigated by transient expression of native and mutant promoter constructs in COS-1, JTC-12, and ROS 17/2.8 cells. A putative VDRE with a half-site spacing of 6 base pairs at -249/-232 (VDRE-3) did not contribute to 1,25-(OH)(2)D-3 induced expression in the native promoter, although activity has been reported when the element was fused to the heterologous thymidine kinase promoter, Two VDREs with half-site spacings of 3 base pairs at -150/-136 and -258/-244 (VDRE-1 and VDRE-2, respectively), showed transcriptional synergism in COS-1 cells when treated with 1,25-(OH)(2)D-3 (10(-7) to 10(-11) M). The contribution of both VDREs was hormone-concentration dependent from 10(-10) to 10(-12) M, with VDRE-1 demonstrating greatest sensitivity to 1,25-(OH)(2)D-3. Transactivation by VDRE-1 was always greater than VDRE-2, but the converse was observed for the binding of vitamin D receptor-retinoid X receptor complex by each VDRE in gel mobility shift assays, The synergy observed between VDRE-1 and VDRE-2 may have important implications in cellular responses to different circulating levels of 1,25-(OH)(2)D-3.	UNIV NEW MEXICO, DEPT BIOCHEM, ALBUQUERQUE, NM 87131 USA; UNIV ADELAIDE, DEPT BIOCHEM, ADELAIDE, SA 5005, AUSTRALIA	University of New Mexico; University of Adelaide			Morris, Howard A/G-4564-2010; Morris, Howard/L-6272-2019; Hahn, Christopher/C-1369-2009	Hahn, Christopher/0000-0001-5105-2554				ARMBRECHT HJ, 1991, FEBS LETT, V292, P17, DOI 10.1016/0014-5793(91)80823-L; BULUWELA L, 1989, NUCLEIC ACIDS RES, V17, P452, DOI 10.1093/nar/17.1.452; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CARLBERG C, 1995, EUR J BIOCHEM, V231, P517, DOI 10.1111/j.1432-1033.1995.0517d.x; CHEN KS, 1995, BBA-GENE STRUCT EXPR, V1263, P1, DOI 10.1016/0167-4781(95)00060-T; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; Darwish Hisham, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P89; DELUCA HF, 1983, ANNU REV BIOCHEM, V52, P411, DOI 10.1146/annurev.bi.52.070183.002211; EIL C, 1996, ADV EXP MED BIOL, V196, P407; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAHN CN, 1994, NUCLEIC ACIDS RES, V22, P2410, DOI 10.1093/nar/22.12.2410; HANNAH SS, 1994, NUTR REV, V52, P376, DOI 10.1111/j.1753-4887.1994.tb01368.x; KAHLEN JP, 1994, BIOCHEM BIOPH RES CO, V202, P1366, DOI 10.1006/bbrc.1994.2081; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; KURIBAYASHI T, 1983, ENDOCRINOLOGY, V113, P1992, DOI 10.1210/endo-113-6-1992; LEMAY J, 1995, J BONE MINER RES, V10, P1148; LIU M, 1994, MOL ENDOCRINOL, V8, P1593, DOI 10.1210/me.8.12.1593; MACDONALD PN, 1995, J BIOL CHEM, V270, P4748, DOI 10.1074/jbc.270.9.4748; MAKIN G, 1989, BIOCHEM J, V262, P173, DOI 10.1042/bj2620173; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANOLAGAS SC, 1990, KIDNEY INT, V38, pS9; MATKOVITS T, 1995, ENDOCRINOLOGY, V136, P3971, DOI 10.1210/en.136.9.3971; MATSUMOTO T, 1985, BIOCHIM BIOPHYS ACTA, V845, P358, DOI 10.1016/0167-4889(85)90199-5; MORGAN JW, 1994, J BIOL CHEM, V269, P13437; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; NISHIMURA A, 1994, ENDOCRINOLOGY, V134, P1794, DOI 10.1210/en.134.4.1794; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; OHYAMA Y, 1994, J BIOL CHEM, V269, P10545; OMDAHL JL, 1978, J BIOL CHEM, V253, P8474; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; REDDY GS, 1989, BIOCHEMISTRY-US, V28, P1763, DOI 10.1021/bi00430a051; REICHEL H, 1986, ARCH BIOCHEM BIOPHYS, V251, P222, DOI 10.1016/0003-9861(86)90069-X; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; RUBIN LP, 1993, PEDIATR RES, V34, P98, DOI 10.1203/00006450-199307000-00023; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHRADER M, 1994, NATURE, V370, P382, DOI 10.1038/370382a0; SCHRADER M, 1994, J BIOL CHEM, V269, P5501; SCHRADER M, 1994, J MOL ENDOCRINOL, V12, P327, DOI 10.1677/jme.0.0120327; SHINKI T, 1992, J BIOL CHEM, V267, P13757; SMITH R, 1993, METABOLIC BONE STONE, P213; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; ZIEROLD C, 1994, P NATL ACAD SCI USA, V91, P900, DOI 10.1073/pnas.91.3.900; ZIEROLD C, 1995, J BIOL CHEM, V270, P1675, DOI 10.1074/jbc.270.4.1675	45	101	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29715	29721		10.1074/jbc.271.47.29715	http://dx.doi.org/10.1074/jbc.271.47.29715			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939905	hybrid			2022-12-27	WOS:A1996VU52500033
J	Sakamoto, K; Miyoshi, H; Takegami, K; Mogi, T; Anraku, Y; Iwamura, H				Sakamoto, K; Miyoshi, H; Takegami, K; Mogi, T; Anraku, Y; Iwamura, H			Probing substrate binding site of the Escherichia coli quinol oxidases using synthetic ubiquinol analogues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-D COMPLEX; TERMINAL OXIDASE; BO COMPLEX; PARACOCCUS-DENITRIFICANS; MONOCLONAL-ANTIBODIES; BIOLOGICAL PROPERTIES; C-OXIDASE; DERIVATIVES; PROTEIN; BD	Substrate binding sites of the Escherichia cell bo- and bd-type quinol oxidases were probed with systematically synthesized ubiquinol analogues, The apparent K-m values of ubiquinol-2 derivatives to the be-type enzyme were much lower than that of the corresponding 6-n-decyl derivatives, The isoprenoid structure is less hydrophobic than the saturated n-alkyl group with the same carbon number; therefore, the native isoprenoid side chain appears to play a specific role in quinol binding besides simply increasing hydrophobicity of the molecule, The V-max values of 2-methoxy-3-ethoxy analogues were greater than that of 2-ethoxy-3-methoxy analogues irrespective of the side chain structure, This result indicates not only that a methoxy group in the 2-position is recognized more strictly than the S-position by the binding site but also that the side chain structure does not affect binding of the quinol ring moiety, Systematic analysis of the electron-donating activities of the analogues with different substituents in the 5-position revealed that the B-methyl group is important for the activity, In the parallel studies with the bd-type enzyme, we obtained similar observations except that almost all quinol analogues, but not ubiquinol-1, elicited a remarkable substrate inhibition at higher concentrations, These results indicate that the two structurally unrelated terminal oxidases share common structural properties for the quinol-oxidation site.	KYOTO UNIV,DEPT AGR CHEM,SAKYO KU,KYOTO 606,JAPAN; UNIV TOKYO,GRAD SCH SCI,DEPT BIOL SCI,BUNKYO KU,TOKYO 113,JAPAN	Kyoto University; University of Tokyo			Sakamoto, Kimitoshi/G-4539-2014					ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P5730, DOI 10.1073/pnas.84.16.5730; ANRAKU Y, 1987, TRENDS BIOCHEM SCI, V12, P262, DOI 10.1016/0968-0004(87)90131-9; CHEPURI V, 1990, J BIOL CHEM, V265, P11185; DASSA J, 1991, MOL GEN GENET, V229, P341, DOI 10.1007/BF00267454; DUEWEKE TJ, 1990, J BIOL CHEM, V265, P4273; DUEWEKE TJ, 1991, BIOCHEMISTRY-US, V30, P3401, DOI 10.1021/bi00228a007; ESTORNELL E, 1993, FEBS LETT, V332, P127, DOI 10.1016/0014-5793(93)80498-J; Fato R, 1996, BIOCHEMISTRY-US, V35, P2705, DOI 10.1021/bi9516034; GARCIAHORSMAN JA, 1994, J BACTERIOL, V176, P5587, DOI 10.1128/JB.176.18.5587-5600.1994; GREEN GN, 1988, J BIOL CHEM, V263, P13138; GREEN GN, 1984, GENE, V32, P99, DOI 10.1016/0378-1119(84)90037-4; HASTINGS SF, 1995, BIOCHEM SOC T, V24, P131; HE DY, 1994, J BIOL CHEM, V269, P27885; HE DY, 1994, BIOCHEMISTRY-US, V33, P880, DOI 10.1021/bi00170a005; INGLEDEW WJ, 1995, EUR J BIOCHEM, V227, P903, DOI 10.1111/j.1432-1033.1995.tb20217.x; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; JUNEMANN S, 1995, BIOCHEMISTRY-US, V34, P14861; KITA K, 1982, J BIOL CHEM, V257, P7933; KRANZ RG, 1984, J BIOL CHEM, V259, P7998; LORENCE RM, 1988, J BIOL CHEM, V263, P5271; MERZ A, 1993, SYNTHESIS-STUTTGART, P797; MEUNIER B, 1995, BIOCHEMISTRY-US, V34, P1076, DOI 10.1021/bi00003a044; MOGI T, 1994, J BIOCHEM-TOKYO, V116, P741; PUUSTINEN A, 1989, FEBS LETT, V249, P163, DOI 10.1016/0014-5793(89)80616-7; Rieske J. S., 1967, METHOD ENZYMOL, V10, P239; ROBINSON HH, 1990, J AM CHEM SOC, V112, P4728, DOI 10.1021/ja00168a017; SAITOH I, 1992, EUR J BIOCHEM, V209, P73, DOI 10.1111/j.1432-1033.1992.tb17262.x; Sakamoto K, 1996, EUR J BIOCHEM, V237, P128, DOI 10.1111/j.1432-1033.1996.0128n.x; SARASTE M, 1991, BIOCHEM SOC T, V19, P608, DOI 10.1042/bst0190608; SATOWATANABE M, 1995, FEBS LETT, V374, P265, DOI 10.1016/0014-5793(95)01125-X; SATOWATANABE M, 1994, J BIOL CHEM, V269, P28908; SATOWATANABE M, 1994, J BIOL CHEM, V269, P28899; SATOWATANABE M, 1995, BIOPHYS J, V68, P319; TSUBAKI M, 1995, J BIOL CHEM, V270, P28565, DOI 10.1074/jbc.270.48.28565; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P6065, DOI 10.1021/bi00074a018; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; WARNCKE K, 1994, BIOCHEMISTRY-US, V33, P7830, DOI 10.1021/bi00191a010; WELTER R, 1994, J BIOL CHEM, V269, P28834; XIA D, 1996, BIOPHYS J, V70, P253; YANG FD, 1986, J BIOL CHEM, V261, P4987; YU CA, 1985, BIOCHEMISTRY-US, V24, P3897, DOI 10.1021/bi00336a013	41	47	49	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29897	29902		10.1074/jbc.271.47.29897	http://dx.doi.org/10.1074/jbc.271.47.29897			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939932	hybrid			2022-12-27	WOS:A1996VU52500060
J	Deng, L; Shuman, S				Deng, L; Shuman, S			An ATPase component of the transcription elongation complex is required for factor-dependent transcription termination by vaccinia RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS EARLY TRANSCRIPTION; CAPPING ENZYME; MESSENGER-RNA; TERNARY COMPLEXES; NASCENT RNA; EARLY GENES; PROMOTER; PURIFICATION; VIRIONS; TRIPHOSPHATE	Vaccinia virus RNA polymerase terminates transcription in response to a specific signal UUUUUNU in the nascent transcript. Transduction of this signal to the elongating polymerase requires a virus-encoded termination factor, VTF. The existence of a second termination factor was suggested by the finding that transient exposure of purified elongation complexes to heparin rendered them refractory to VTF-induced termination. Loss of termination competence correlated with the removal of several polypeptide components of the elongation complex. We present the identification of factor X, an activity that restored VTF responsiveness to heparin-stripped ternary complexes. We propose that factor X, which has an associated DNA-dependent ATPase activity, mediates the requirement for ATP hydrolysis during transcription termination.	SLOAN KETTERING INST,PROGRAM MOL BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NIGMS NIH HHS [GM42498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN BY, 1994, J BIOL CHEM, V269, P7552; BALDICK CJ, 1994, J VIROL, V68, P6052, DOI 10.1128/JVI.68.9.6052-6056.1994; BROYLES SS, 1988, J BIOL CHEM, V263, P10754; BROYLES SS, 1987, MOL CELL BIOL, V7, P7, DOI 10.1128/MCB.7.1.7; BROYLES SS, 1988, J BIOL CHEM, V263, P10761; Condit RC, 1996, VIROLOGY, V218, P169, DOI 10.1006/viro.1996.0177; DENG L, 1994, J BIOL CHEM, V269, P14323; Deng L, 1996, J BIOL CHEM, V271, P19556, DOI 10.1074/jbc.271.32.19556; GERSHOWITZ A, 1978, J VIROL, V27, P399, DOI 10.1128/JVI.27.2.399-408.1978; GOLINI F, 1985, J VIROL, V53, P205, DOI 10.1128/JVI.53.1.205-213.1985; Gross CH, 1996, J VIROL, V70, P2615, DOI 10.1128/JVI.70.4.2615-2619.1996; HAGLER J, 1992, P NATL ACAD SCI USA, V89, P10099, DOI 10.1073/pnas.89.21.10099; HAGLER J, 1994, J BIOL CHEM, V269, P10050; HAGLER J, 1993, J BIOL CHEM, V268, P2166; HAGLER J, 1992, J VIROL, V66, P2982, DOI 10.1128/JVI.66.5.2982-2989.1992; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; KATES J, 1970, J MOL BIOL, V50, P1, DOI 10.1016/0022-2836(70)90100-2; LI J, 1993, J BIOL CHEM, V268, P20016; LI J, 1993, J BIOL CHEM, V268, P2773; LUO Y, 1991, J BIOL CHEM, V266, P13303; LUO Y, 1995, J VIROL, V69, P3852, DOI 10.1128/JVI.69.6.3852-3856.1995; PAOLETTI E, 1974, J BIOL CHEM, V249, P3281; RICHARDSON JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P127, DOI 10.1016/0167-4781(90)90048-7; SHUMAN S, 1992, P NATL ACAD SCI USA, V89, P10935, DOI 10.1073/pnas.89.22.10935; SHUMAN S, 1980, J BIOL CHEM, V255, P5396; SHUMAN S, 1990, J BIOL CHEM, V265, P11960; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1980, J BIOL CHEM, V255, P1588; SHUMAN S, 1988, J BIOL CHEM, V263, P6220; VOS JC, 1991, EMBO J, V10, P2553, DOI 10.1002/j.1460-2075.1991.tb07795.x; Yu L, 1996, J VIROL, V70, P6162, DOI 10.1128/JVI.70.9.6162-6168.1996; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6417, DOI 10.1073/pnas.84.18.6417	32	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29386	29392		10.1074/jbc.271.46.29386	http://dx.doi.org/10.1074/jbc.271.46.29386			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910603	hybrid			2022-12-27	WOS:A1996VT05200095
J	Holloway, DE; Chen, HP; Marsh, ENG				Holloway, DE; Chen, HP; Marsh, ENG			Carboxymethylation of MutS-cysteine-15 specifically inactivates adenosylcobalamin-dependent glutamate mutase - Examination of the role of this residue in coenzyme-binding and catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOND-DISSOCIATION ENERGY; ESCHERICHIA-COLI; CLOSTRIDIUM-TETANOMORPHUM; METHIONINE SYNTHASE; COMPONENT-S; REDUCTION; ENZYMES; CLONING; B-12	The sensitivity of adenosylcobalamin (AdoCbl)-dependent glutamate mutase toward thiol-directed reagents has been investigated. Iodoacetate specifically alkylates one cysteine residue, Cys-15, in MutS with concomitant irreversible loss of enzyme activity. Cys-15 lies between the conserved residues Asp-14 and His-16, that are believed to coordinate cobalt to form a Co-His-Asp hydrogen-bonded ''triad'' when AdoCbl is bound by the enzyme. Although inactive, carboxymethylated MutS still bound AdoCbl with only a 5-fold increase in apparent K-d. To determine whether Cys-15 plays an essential role in catalysis, it was mutated to serine and to alanine. These mutants were active, but both exhibited decreased V-max and increased apparent K-m and K-d for AdoCbl. To mimic the effect of carboxymethylation, Cys15 was mutated to aspartate and, as an isosteric control, to asparagine, Neither of these mutants was active: MutS-C15N bound AdoCbl approximately 10-fold weaker than wild type, whereas MutS-C15N bound AdoCbl over 100 times less strongly than wild type. The results demonstrate both coenzyme-binding and catalysis to be very sensitive to mutations at position 15 that could potentially perturb the Co-His-Asp hydrogen-bonding network.	UNIV MICHIGAN,DEPT CHEM,ANN ARBOR,MI 48109; UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND; UNIV CAMBRIDGE,CAMBRIDGE CTR MOL RECOGNIT,CAMBRIDGE CB2 1QW,ENGLAND	University of Michigan System; University of Michigan; University of Cambridge; University of Cambridge			Marsh, Neil/G-7553-2016; Holloway, Daniel E/S-4944-2016; Chen, Hao-Ping/Q-3283-2019	Marsh, Neil/0000-0003-1713-1683; Holloway, Daniel E/0000-0003-0155-6978; Chen, Hao-Ping/0000-0002-6491-2178				BABIOR BM, 1979, CRC CR REV BIOCH MOL, V6, P35, DOI 10.3109/10409237909105424; BARKER HA, 1964, J BIOL CHEM, V239, P3260; BEATRIX B, 1994, EUR J BIOCHEM, V221, P101, DOI 10.1111/j.1432-1033.1994.tb18718.x; BOOKER S, 1994, BIOCHEMISTRY-US, V33, P12676, DOI 10.1021/bi00208a019; DRENNAN CL, 1994, CURR OPIN STRUC BIOL, V4, P919, DOI 10.1016/0959-440X(94)90275-5; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; FINKE RG, 1990, MOLECULAR MECHANISMS IN BIOORGANIC PROCESSES, P244; GEO MK, 1987, J AM CHEM SOC, V107, P1238; GOLDING BT, 1986, ENZYME MECHANISMS, P404; GOODIN DB, 1993, BIOCHEMISTRY-US, V32, P3313, DOI 10.1021/bi00064a014; HALPERN J, 1984, J AM CHEM SOC, V106, P8317, DOI 10.1021/ja00338a065; HALPERN J, 1985, SCIENCE, V227, P869, DOI 10.1126/science.2857503; HAY BP, 1986, J AM CHEM SOC, V108, P4820, DOI 10.1021/ja00276a020; HOLLOWAY DE, 1994, J BIOL CHEM, V269, P20425; HOLLOWAY DE, 1993, FEBS LETT, V317, P44, DOI 10.1016/0014-5793(93)81488-L; HSIANG MW, 1967, J BIOL CHEM, V242, P3079; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; Jarrett JT, 1996, BIOCHEMISTRY-US, V35, P2464, DOI 10.1021/bi952389m; KIM SH, 1988, J AM CHEM SOC, V110, P1320; KRATKY C, 1995, J AM CHEM SOC, V117, P4654, DOI 10.1021/ja00121a022; Mancia F, 1996, STRUCTURE, V4, P339, DOI 10.1016/S0969-2126(96)00037-8; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9752, DOI 10.1021/bi00155a031; MARSH ENG, 1992, FEBS LETT, V310, P167, DOI 10.1016/0014-5793(92)81321-C; MARSH ENG, 1995, BIOCHEMISTRY-US, V34, P7542, DOI 10.1021/bi00022a030; MARSH ENG, 1995, BIOESSAYS, V17, P431, DOI 10.1002/bies.950170511; NG FTT, 1982, J AM CHEM SOC, V104, P621, DOI 10.1021/ja00366a045; OCHIAI EI, 1994, MET IONS BIOL SYST, V30, P255; Sambrook J., 2002, MOL CLONING LAB MANU; STUBBE JA, 1989, ANNU REV BIOCHEM, V58, P257; SWITZER RL, 1967, J BIOL CHEM, V242, P2658; SWITZER RL, 1969, J BIOL CHEM, V244, P5263; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; ZELDER O, 1995, FEBS LETT, V369, P252, DOI 10.1016/0014-5793(95)00762-X	33	3	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29121	29125		10.1074/jbc.271.46.29121	http://dx.doi.org/10.1074/jbc.271.46.29121			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910568	hybrid			2022-12-27	WOS:A1996VT05200060
J	Kim, KK; Daud, AI; Wong, SC; Pajak, L; Tsai, SC; Wang, H; Henzel, WJ; Field, LJ				Kim, KK; Daud, AI; Wong, SC; Pajak, L; Tsai, SC; Wang, H; Henzel, WJ; Field, LJ			Mouse RAD50 has limited epitopic homology to p53 and is expressed in the adult myocardium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-ANTIGEN TRANSGENES; STRAND BREAK REPAIR; DNA-BINDING DOMAIN; WILD-TYPE P53; SACCHAROMYCES-CEREVISIAE; INSITU HYBRIDIZATION; GENE AMPLIFICATION; TERMINAL DOMAIN; NUCLEIC-ACIDS; HEPTAD-REPEAT	Previous studies have identified a 18O-kDa mouse cardiomyocyte phosphoprotein with limited epitopic homology to p53. In this study, the protein was purified and partially sequenced. Oligonucleotide probes based on the available amino acid sequence data were used to isolate cDNA clones. Sequence analyses revealed that the clones encoded a protein with regional homology to the yeast RAD50 gene product. Expression of the mouse cDNA rescued the methyl methanesulfonate-sensitive phenotype in rad50 mutant yeast, indicating that the cardiomyocyte phosphoprotein is the mammalian homologue of the yeast RAD5O gene product. Fluorescence in situ hybridization analyses localized the mouse RAD50 gene to the A5-B1 region of chromosome 11. Northern blot analyses demonstrated a complex pattern of RAD5O expression during mouse development which was further complicated by the presence of several alternatively spliced transcripts. High levels of RAD5O expression was evident in the adult myocardium, a somewhat surprising observation given the absence of DNA synthesis in adult cardiomyocytes.	INDIANA UNIV,SCH MED,KRANNERT INST CARDIOL,INDIANAPOLIS,IN 46202; GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080	Indiana University System; Indiana University-Purdue University Indianapolis; Roche Holding; Genentech			Daud, Adil/T-3079-2019	Daud, Adil/0000-0002-6617-8421; Henzel, William/0000-0003-2940-3797	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045453] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45453, HL06308] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALANI E, 1989, GENETICS, V122, P47; ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DAUD AI, 1993, AM J PHYSIOL, V264, pH1693, DOI 10.1152/ajpheart.1993.264.5.H1693; FENG GS, 1994, ONCOGENE, V9, P1545; FIELD LJ, 1988, SCIENCE, V239, P1029, DOI 10.1126/science.2964082; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GAME JC, 1974, MUTAT RES, V24, P281, DOI 10.1016/0027-5107(74)90176-6; Guthrie C, 1991, GUIDE YEAST GENETICS; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HENZEL WJ, 1987, J CHROMATOGR, V404, P41, DOI 10.1016/S0021-9673(01)86835-7; HENZEL WJ, 1990, ANAL BIOCHEM, V187, P228, DOI 10.1016/0003-2697(90)90448-I; HEUDE M, 1988, MUTAT RES, V194, P151, DOI 10.1016/0167-8817(88)90017-X; IVANOV EL, 1994, MOL CELL BIOL, V14, P3414, DOI 10.1128/MCB.14.5.3414; JOHZUKA K, 1995, GENETICS, V139, P1521; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATZ EB, 1992, AM J PHYSIOL, V262, pH1867, DOI 10.1152/ajpheart.1992.262.6.H1867; KIM KK, 1994, J BIOL CHEM, V269, P22607; KIM KK, 1995, GENOMICS, V28, P520, DOI 10.1006/geno.1995.1184; KOZAK M, 1994, BIOCHIMIE, V76, P815, DOI 10.1016/0300-9084(94)90182-1; KRUTZSCH HC, 1993, ANAL BIOCHEM, V209, P109, DOI 10.1006/abio.1993.1089; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANE DP, 1980, NATURE, V288, P167, DOI 10.1038/288167a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOEB LA, 1991, CANCER RES, V51, P3075; LUDLOW JW, 1995, VIRUS RES, V35, P113, DOI 10.1016/0168-1702(94)00094-S; MALONE RE, 1990, CURR GENET, V18, P111, DOI 10.1007/BF00312598; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; PARRY DAD, 1982, BIOSCIENCE REP, V2, P1017, DOI 10.1007/BF01122170; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; RAYMOND WE, 1993, NUCLEIC ACIDS RES, V21, P3851, DOI 10.1093/nar/21.16.3851; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Sambrook J., 1989, MOL CLONING; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHIESTL RH, 1994, MOL CELL BIOL, V14, P4493, DOI 10.1128/MCB.14.7.4493; SHEN ZY, 1995, GENOMICS, V25, P199, DOI 10.1016/0888-7543(95)80126-7; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SOONPAA MH, 1994, AM J PHYSIOL, V266, pH1439, DOI 10.1152/ajpheart.1994.266.4.H1439; STEINHELPER ME, 1990, AM J PHYSIOL, V259, pH1826, DOI 10.1152/ajpheart.1990.259.6.H1826; STEINHELPER ME, 1990, TOXICOL PATHOL, V18, P464, DOI 10.1177/0192623390004Part_104; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	57	18	21	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29255	29264		10.1074/jbc.271.46.29255	http://dx.doi.org/10.1074/jbc.271.46.29255			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910585	hybrid			2022-12-27	WOS:A1996VT05200077
J	Lindahl, M; Tabak, S; Cseke, L; Pichersky, E; Andersson, B; Adam, Z				Lindahl, M; Tabak, S; Cseke, L; Pichersky, E; Andersson, B; Adam, Z			Identification, characterization, and molecular cloning of a homologue of the bacterial FtsH protease in chloroplasts of higher plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; ATP-DEPENDENT PROTEASE; ESCHERICHIA-COLI FTSH; PHOTOSYSTEM-II; CHLAMYDOMONAS-REINHARDTII; SPINACH-CHLOROPLASTS; THYLAKOID MEMBRANES; DEGRADATION; CHLOROPHYLL; GENES	In an attempt to identify and characterize chloroplast proteases, we performed an immunological analysis of chloroplasts using an antibody against Escherichia coli FtsH protease, which is an ATP-dependent metalloprotease bound to the cytoplasmic membrane. A cross-reacting protein of 78 kDa was found in the thylakoid membrane of spinach, but not in the soluble stromal fraction. Alkali and high salt washes, as well as trypsin treatment of thylakoid membranes, suggest that the chloroplastic FtsH protein is integral to the membrane, with its hydrophilic portion exposed to the stroma. The protein is not bound to any photosynthetic complex and is exclusively located in the stromally exposed regions of the thylakoid membrane. Its expression is dependent on light, as it is present in green pea seedlings, but absent from etiolated ones. An Arabidopsis cDNA was isolated, and the deduced amino acid sequence demonstrated high similarity to the E. coli FtsH protein, especially in the central region of the protein, containing the ATP- and zinc-binding sites. The product of this clone was capable of import into isolated pea chloroplasts, where it was processed to its mature form and targeted to the thylakoid membrane. The trans-bilayer orientation and lateral location of the FtsH protein in the thylakoid membrane suggest its involvement in the degradation of both soluble stromal proteins and newly inserted or turning-over thylakoid proteins.	HEBREW UNIV JERUSALEM,FAC AGR,DEPT AGR BOT,IL-76100 REHOVOT,ISRAEL; UNIV STOCKHOLM,ARRHENIUS LABS NAT SCI,DEPT BIOCHEM,S-10691 STOCKHOLM,SWEDEN; UNIV MICHIGAN,DEPT BIOL,ANN ARBOR,MI 48109	Hebrew University of Jerusalem; Stockholm University; University of Michigan System; University of Michigan			Lindahl, Marika/H-2259-2017; Andersson, Bertil/C-9328-2009	Lindahl, Marika/0000-0003-1627-0809				ADAM Z, 1993, PLANT PHYSIOL, V102, P35, DOI 10.1104/pp.102.1.35; Adamska I, 1996, EUR J BIOCHEM, V236, P591, DOI 10.1111/j.1432-1033.1996.00591.x; ANDERSON JM, 1982, TRENDS BIOCHEM SCI, V7, P288, DOI 10.1016/0968-0004(82)90014-7; ANDERSSON B, 1980, BIOCHIM BIOPHYS ACTA, V593, P427, DOI 10.1016/0005-2728(80)90078-X; ANDERSSON B, 1976, BIOCHIM BIOPHYS ACTA, V423, P122, DOI 10.1016/0005-2728(76)90106-7; APEL K, 1980, PLANTA, V150, P426, DOI 10.1007/BF00390180; ARELLANO JB, 1994, PHYSIOL PLANTARUM, V91, P369, DOI 10.1111/j.1399-3054.1994.tb02962.x; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; BARBER J, 1994, NATURE, V370, P31, DOI 10.1038/370031a0; BURKE JJ, 1978, ARCH BIOCHEM BIOPHYS, V187, P252, DOI 10.1016/0003-9861(78)90031-0; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; Halperin T, 1996, PLANT MOL BIOL, V30, P925, DOI 10.1007/BF00020804; HERMAN C, 1995, P NATL ACAD SCI USA, V92, P3516, DOI 10.1073/pnas.92.8.3516; HOOBER JK, 1992, PLANT PHYSIOL, V99, P932, DOI 10.1104/pp.99.3.932; HUANG LQ, 1992, PLANT PHYSIOL, V99, P247, DOI 10.1104/pp.99.1.247; HUGUENEY P, 1995, P NATL ACAD SCI USA, V92, P5630, DOI 10.1073/pnas.92.12.5630; HURT E, 1981, EUR J BIOCHEM, V117, P591; KIHARA A, 1995, P NATL ACAD SCI USA, V92, P4532, DOI 10.1073/pnas.92.10.4532; Kowallik KV, 1995, PLANT MOL BIOL REP, V13, P336, DOI 10.1007/BF02669188; KYLE DJ, 1984, BIOCHIM BIOPHYS ACTA, V765, P89, DOI 10.1016/0005-2728(84)90001-X; LEVY M, 1995, PLANT MOL BIOL, V29, P53, DOI 10.1007/BF00019118; LINDAHL M, 1995, EUR J BIOCHEM, V231, P503, DOI 10.1111/j.1432-1033.1995.tb20725.x; MATTOO AK, 1989, CELL, V56, P241, DOI 10.1016/0092-8674(89)90897-0; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MERCHANT S, 1986, J BIOL CHEM, V261, P5850; MULLET JE, 1980, PLANT PHYSIOL, V65, P814, DOI 10.1104/pp.65.5.814; NAKAI T, 1995, MOL CELL BIOL, V15, P4441; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; Ostersetzer O, 1996, PLANT MOL BIOL, V31, P673, DOI 10.1007/BF00042238; Ostersetzer O, 1996, EUR J BIOCHEM, V236, P932, DOI 10.1111/j.1432-1033.1996.00932.x; PAJIC A, 1994, FEBS LETT, V353, P201, DOI 10.1016/0014-5793(94)01046-3; Reith M, 1995, PLANT MOL BIOL REP, V13, P333, DOI 10.1007/BF02669187; SCHMIDT GW, 1983, P NATL ACAD SCI USA, V80, P2623; SHANKLIN J, 1995, PLANT CELL, V7, P1713, DOI 10.1105/tpc.7.10.1713; THOMAS BR, 1993, GENETICS, V135, P895; TOMOYASU T, 1993, J BACTERIOL, V175, P1352, DOI 10.1128/JB.175.5.1352-1357.1993; TOMOYASU T, 1995, EMBO J, V14, P2551, DOI 10.1002/j.1460-2075.1995.tb07253.x; TOMOYASU T, 1993, J BACTERIOL, V175, P1344, DOI 10.1128/JB.175.5.1344-1351.1993; vanWijk KJ, 1996, J BIOL CHEM, V271, P9627, DOI 10.1074/jbc.271.16.9627; YALOVSKY S, 1990, PLANT MOL BIOL, V14, P753, DOI 10.1007/BF00016508; YANG DH, 1995, PHOTOSYNTHESIS LIGHT, V4, P453; [No title captured]	42	159	171	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29329	29334		10.1074/jbc.271.46.29329	http://dx.doi.org/10.1074/jbc.271.46.29329			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910594	hybrid			2022-12-27	WOS:A1996VT05200086
J	Rova, EM; McEwen, B; Fredriksson, PO; Styring, S				Rova, EM; McEwen, B; Fredriksson, PO; Styring, S			Photoactivation and photoinhibition are competing in a mutant of Chlamydomonas reinhardtii lacking the 23-kDa extrinsic subunit of photosystem II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC OXYGEN-EVOLUTION; TYROSINE Y-Z; ELECTRON-TRANSFER; MANGANESE CATALYST; EVOLVING COMPLEX; WATER OXIDATION; CHLORIDE-IONS; O2 EVOLUTION; PROTEIN; MEMBRANES	The process of photoactivation has been studied in dark grown cells of Chlamydomonas reinhardtii. A mutant, FUD 39, lacking the Cl--concentrating 23-kDa psbP protein of photosystem II was found to have a decreased capability to perform photoactivation. The yield of the process never reached wild type level, and contrary to the wild type, it was highly dependent on the intensity of the activating Light, with a very narrow optimum around 1 mu E m(-2) s(-1). The different behavior in the mutant can be explained by a requirement for a longer dark period, between the two photoacts, during the photoactivation. This is proposed to reflect the decreased Cl--affinity in the mutant. Photoactivation in the mutant was also found to be very sensitive to competing photoinhibitory processes. The inhibition was located to the donor side of photosystem II and affected the photoactivation capability before electron transfer from Tyr(z) was inhibited. We propose an extended model for photoactivation in which an intermediate that is sensitive to photoinhibition is formed if Cl- is not functionally bound to the manganese cluster.	LUND UNIV,CTR CHEM,DEPT BIOCHEM,S-22100 LUND,SWEDEN; UNIV KARLSTAD,DEPT CHEM,S-65188 KARLSTAD,SWEDEN	Lund University; Karlstad University			Styring, Stenbjörn/L-8414-2016	Styring, Stenbjörn/0000-0002-2803-9244				ANDERSSON B, 1984, FEBS LETT, V168, P113, DOI 10.1016/0014-5793(84)80217-3; ANDERSSON B, 1992, NEW COMPREHENSIVE BI, V23, P121; ANDERSSON B, 1987, TOPICS PHOTOSYNTHESI, V8, P379; ANDREASSON LE, 1995, BBA-BIOENERGETICS, V1230, P155, DOI 10.1016/0005-2728(95)00047-M; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; BLUBAUGH DJ, 1990, BIOCHEMISTRY-US, V29, P5109, DOI 10.1021/bi00473a016; CHENIAE GM, 1971, BIOCHIM BIOPHYS ACTA, V253, P167, DOI 10.1016/0005-2728(71)90242-8; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DEVITRY C, 1989, J CELL BIOL, V109, P991, DOI 10.1083/jcb.109.3.991; GHANOTAKIS DF, 1990, ANNU REV PLANT PHYS, V41, P255, DOI 10.1146/annurev.pp.41.060190.001351; GHANOTAKIS DF, 1984, FEBS LETT, V167, P127, DOI 10.1016/0014-5793(84)80846-7; GILCHRIST ML, 1995, P NATL ACAD SCI USA, V92, P9545, DOI 10.1073/pnas.92.21.9545; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; Hoganson CW, 1995, PHOTOSYNTH RES, V46, P177, DOI 10.1007/BF00020428; HOMANN PH, 1987, J BIOENERG BIOMEMBR, V19, P105, DOI 10.1007/BF00762720; JEGERSCHOLD C, 1991, FEBS LETT, V280, P87, DOI 10.1016/0014-5793(91)80210-T; JEGERSCHOLD C, 1990, BIOCHEMISTRY-US, V29, P6179, DOI 10.1021/bi00478a010; JEGERSCHOLD C, 1996, IN PRESS BIOCHEMISTR; JOHNSON GN, 1995, BBA-BIOENERGETICS, V1229, P202, DOI 10.1016/0005-2728(95)00003-2; KLIMOV VV, 1990, PHOTOSYNTH RES, V23, P59, DOI 10.1007/BF00030063; KRIEGER A, 1995, BBA-BIOENERGETICS, V1229, P193, DOI 10.1016/0005-2728(95)00002-Z; KUWABARA T, 1985, BIOCHIM BIOPHYS ACTA, V806, P283, DOI 10.1016/0005-2728(85)90107-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAYFIELD SP, 1987, EMBO J, V6, P313, DOI 10.1002/j.1460-2075.1987.tb04756.x; MAYFIELD SP, 1987, P NATL ACAD SCI USA, V84, P749, DOI 10.1073/pnas.84.3.749; MILLER AF, 1991, BIOCHIM BIOPHYS ACTA, V1056, P1, DOI 10.1016/S0005-2728(05)80067-2; MILLER AF, 1990, BIOCHEMISTRY-US, V29, P1385, DOI 10.1021/bi00458a007; MILLER AF, 1989, BIOCHEMISTRY-US, V28, P8181, DOI 10.1021/bi00446a033; MIYAO M, 1985, FEBS LETT, V180, P303, DOI 10.1016/0014-5793(85)81091-7; MIYAO M, 1984, FEBS LETT, V170, P350, DOI 10.1016/0014-5793(84)81342-3; MIYAO M, 1991, BIOCHEMISTRY-US, V30, P5379, DOI 10.1021/bi00236a008; MIYAO M, 1989, BIOCHIM BIOPHYS ACTA, V977, P315, DOI 10.1016/S0005-2728(89)80086-6; MURATA N, 1985, TRENDS BIOCHEM SCI, V10, P122, DOI 10.1016/0968-0004(85)90272-5; RADMER R, 1971, BIOCHIM BIOPHYS ACTA, V253, P182, DOI 10.1016/0005-2728(71)90243-X; Radmer R., 1977, PRIMARY PROCESSES PH, P303; ROVA M, 1994, PHOTOSYNTH RES, V39, P75, DOI 10.1007/BF00027145; RUTHERFORD AW, 1992, TOPICS PHOTOSYNTHESI, V11, P179; Styring Stenbjorn, 1994, P51; TAMURA N, 1987, BIOCHIM BIOPHYS ACTA, V890, P179, DOI 10.1016/0005-2728(87)90019-3; THOMPSON LK, 1989, BIOCHEMISTRY-US, V28, P6686, DOI 10.1021/bi00442a023; TOMMOS C, 1995, J AM CHEM SOC, V117, P10325, DOI 10.1021/ja00146a017; VASS I, 1991, BIOCHEMISTRY-US, V30, P830, DOI 10.1021/bi00217a037; VERMAAS WFJ, 1993, PHOTOSYNTH RES, V38, P249, DOI 10.1007/BF00046750	43	38	38	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28918	28924		10.1074/jbc.271.46.28918	http://dx.doi.org/10.1074/jbc.271.46.28918			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910540	hybrid			2022-12-27	WOS:A1996VT05200032
J	Chen, CD; Kemper, B				Chen, CD; Kemper, B			Different structural requirements at specific proline residue positions in the conserved proline-rich region of cytochrome P450 2C2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDENTIFICATION; SIGNAL; MEMBRANE; PROTEINS; SEQUENCE; DOMAIN; SUFFICIENT; INSERTION; PEPTIDES; MODEL	Cytochrome P450 is anchored to the endoplasmic reticulum membrane by an N-terminal transmembrane sequence with the catalytic domain facing the cytoplasmic side. Within the peptide sequence linking these two domains is a highly conserved proline-rich region. In cytochrome P450 2C2, this region has the sequence (30)PPG-PTFP37. To examine the structural requirements at these proline residues, each proline was replaced with alanine, glycine, valine, or an acidic amino acid, and the activities of the mutated proteins were determined in transfected COS-1 cells. Lauric acid 1 omega-hydroxylase activities of Pro(30) and Pro(33) mutants were less than 10% of wild type for each substitution except for alanine, which was 25-30%. In striking contrast, substitutions at Pro(31) including an acidic residue, did not substantially alter activity. At positions 35 and 37, acidic amino acid substitutions reduced activity to less than 10% of wild type while substitution of the other three amino acids had little effect. The tolerance of substitutions of charged residues at Pro(31) suggests that the side chain at this position is exposed to a polar environment; conversely, the reduced activity with charged substitutions, but not with uncharged substitutions at positions 35 and 37, suggests that these residues are exposed to a hydrophobic environment, presumably within the folded protein. The loss of activity with substitutions at Pro(30) and Pro(33) implies that the motif PXXP is important for the formation of a functional cytochrome P450 and that this sequence might have a helical structure with a repeat of three, as in the left handed poly-L-proline II helix. Insertion of alanine between positions 29 and 30 did not substantially affect activity, but insertions between either 33 and 34 or 37 and 38 resulted in activity less than 25% of wild type. These data indicate that the position of PXXP, relative to the sequence flanking it on the C-terminal side, may be important for its function.	UNIV ILLINOIS, COLL MED URBANA CHAMPAIGN, DEPT MOL & INTEGRAT PHYSIOL, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035897] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35897] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CORNILLE F, 1995, J BIOL CHEM, V270, P16826, DOI 10.1074/jbc.270.28.16826; DONOHUE J, 1953, P NATL ACAD SCI USA, V39, P470, DOI 10.1073/pnas.39.6.470; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; GrahamLorence S, 1996, FASEB J, V10, P206, DOI 10.1096/fasebj.10.2.8641554; GRAHAMLORENCE S, 1995, PROTEIN SCI, V4, P1065, DOI 10.1002/pro.5560040605; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; ISHIHARA N, 1995, J BIOCHEM-TOKYO, V118, P397, DOI 10.1093/oxfordjournals.jbchem.a124920; KAGIMOTO M, 1990, J BIOL CHEM, V265, P17209; Kouro T, 1996, INT IMMUNOL, V8, P237, DOI 10.1093/intimm/8.2.237; LAETHEM RM, 1992, MOL PHARMACOL, V42, P958; LEBRUN JJ, 1995, J BIOL CHEM, V270, P10664, DOI 10.1074/jbc.270.18.10664; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; NARHI LO, 1987, J BIOL CHEM, V262, P6683; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NELSON DR, 1987, MOL BIOL EVOL, V4, P572; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SAKAGUCHI M, 1984, P NATL ACAD SCI-BIOL, V81, P3361, DOI 10.1073/pnas.81.11.3361; SAKAGUCHI M, 1987, EMBO J, V6, P2425, DOI 10.1002/j.1460-2075.1987.tb02521.x; STRAUB P, 1993, J BIOL CHEM, V268, P21997; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; SZCZESNASKORUPA E, 1993, ARCH BIOCHEM BIOPHYS, V304, P170, DOI 10.1006/abbi.1993.1335; SZCZESNASKORUPA E, 1988, P NATL ACAD SCI USA, V85, P738, DOI 10.1073/pnas.85.3.738; SZCZESNASKORUPA E, 1989, J CELL BIOL, V108, P1237, DOI 10.1083/jcb.108.4.1237; TSUJITA M, 1993, BIOCHIM BIOPHYS ACTA, V1161, P124, DOI 10.1016/0167-4838(93)90205-6; TUSIELUNA MT, 1991, MOL ENDOCRINOL, V5, P685, DOI 10.1210/mend-5-5-685; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; YAMAZAKI S, 1993, J BIOCHEM-TOKYO, V114, P652, DOI 10.1093/oxfordjournals.jbchem.a124232	31	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28607	28611		10.1074/jbc.271.45.28607	http://dx.doi.org/10.1074/jbc.271.45.28607			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910491	hybrid			2022-12-27	WOS:A1996VU03300091
J	Macalma, T; Otte, J; Hensler, ME; Bockholt, SM; Louis, HA; KalffSuske, M; Grzeschik, KH; vonderAhe, D; Beckerle, MC				Macalma, T; Otte, J; Hensler, ME; Bockholt, SM; Louis, HA; KalffSuske, M; Grzeschik, KH; vonderAhe, D; Beckerle, MC			Molecular characterization of human zyxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROFILAMENT PROTEIN VASP; GLYCOPROTEIN-IIB-IIIA; ACTIN-BASED MOTILITY; RICH FOCAL ADHESION; TYROSINE PHOSPHORYLATION; LISTERIA-MONOCYTOGENES; REGIONAL LOCALIZATION; SIGNAL-TRANSDUCTION; LIM DOMAIN; SEQUENCE	Zyxin is a component of adhesion plaques that has been suggested to perform regulatory functions at these specialized regions of the plasma membrane, Here we describe the isolation and characterization of cDNAs encoding human and mouse zyxin. Both the human and mouse zyxin proteins display a collection of proline-rich sequences as well as three copies of the LIM domain, a zinc finger domain found in many signaling molecules. The human zyxin protein is closely related in sequence to proteins implicated in benign tumorigenesis and steroid receptor binding. Antibodies raised against human zyxin recognize an 84-kDa protein by Western immunoblot analysis. The protein is localized at focal contacts in adherent erythroleukemia cells. By Northern analysis, we show that zyxin is widely expressed in human tissues. The zyxin gene maps to human chromosome 7q32-q36.	UNIV UTAH, DEPT BIOL, SALT LAKE CITY, UT 84112 USA; MAX PLANCK INST, KERCKHOFF KLIN, HEMOSTASIS RES UNIT, D-61231 BAD NAUHEIM, GERMANY; UNIV MARBURG, MED CTR HUMAN GENET, D-35037 MARBURG, GERMANY	Utah System of Higher Education; University of Utah; Kerckhoff Clinic; Max Planck Society; Philipps University Marburg					NCI NIH HHS [CA42014] Funding Source: Medline; NHLBI NIH HHS [HL41553] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041553] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; ASHAR HR, 1995, CELL, V82, P57; BECKERLE MC, 1986, J CELL BIOL, V103, P1679, DOI 10.1083/jcb.103.5.1679; BECKERLE MC, 1984, J CELL BIOL, V98, P2126, DOI 10.1083/jcb.98.6.2126; BOYLE JM, 1992, GENOMICS, V12, P693, DOI 10.1016/0888-7543(92)90296-5; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; CROCE CM, 1974, J EXP MED, V140, P1221, DOI 10.1084/jem.140.5.1221; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOMANN E, 1992, EMBO J, V11, P1981, DOI 10.1002/j.1460-2075.1992.tb05252.x; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; *GEN COMP GROUP, 1994, PROGR MAN GCG SEQ AN; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HAFFNER C, 1995, EMBO J, V14, P19, DOI 10.1002/j.1460-2075.1995.tb06971.x; HALBRUGGE M, 1989, EUR J BIOCHEM, V185, P41, DOI 10.1111/j.1432-1033.1989.tb15079.x; Hobert O, 1996, ONCOGENE, V12, P1577; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASA I, 1995, MOL MICROBIOL, V18, P425, DOI 10.1111/j.1365-2958.1995.mmi_18030425.x; Lasa I, 1996, TRENDS CELL BIOL, V6, P109, DOI 10.1016/0962-8924(96)81001-4; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LUERSSEN H, 1990, GENOMICS, V8, P324, DOI 10.1016/0888-7543(90)90289-7; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; PETIT MMR, 1996, IN PRESS GENOMICS; PISTOR S, 1994, EMBO J, V13, P758, DOI 10.1002/j.1460-2075.1994.tb06318.x; PISTOR S, 1995, CURR BIOL, V5, P517, DOI 10.1016/S0960-9822(95)00104-7; REINHARD M, 1995, P NATL ACAD SCI USA, V92, P7956, DOI 10.1073/pnas.92.17.7956; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROMMENS JM, 1988, AM J HUM GENET, V43, P645; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; SCHUURMAN R, 1991, BIOTECHNIQUES, V10, P185; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SOUTHWICK FS, 1994, P NATL ACAD SCI USA, V91, P5168, DOI 10.1073/pnas.91.11.5168; SPANAKIS E, 1993, NUCLEIC ACIDS RES, V21, P3809, DOI 10.1093/nar/21.16.3809; STRYER L, 1967, P NATL ACAD SCI USA, V58, P719, DOI 10.1073/pnas.58.2.719; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Tilney Lewis G., 1993, Trends in Microbiology, V1, P25, DOI 10.1016/0966-842X(93)90021-I; VORTKAMP A, 1991, GENOMICS, V11, P737, DOI 10.1016/0888-7543(91)90082-P; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; WU RY, 1994, J BIOL CHEM, V269, P25085; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	58	97	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31470	31478		10.1074/jbc.271.49.31470	http://dx.doi.org/10.1074/jbc.271.49.31470			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940160	hybrid			2022-12-27	WOS:A1996VW68600071
J	Cohen, BD; Kiener, PA; Green, JM; Foy, L; Fell, HP; Zhang, K				Cohen, BD; Kiener, PA; Green, JM; Foy, L; Fell, HP; Zhang, K			The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; TYROSINE KINASE-ACTIVITY; EGF RECEPTOR; PROTO-ONCOGENE; INTERMOLECULAR ASSOCIATION; SIGNAL TRANSDUCTION; POINT MUTATION; TUMOR-CELLS; HEREGULIN; FAMILY	A collection of cell lines expressing each human epidermal growth factor receptor (HER) family member alone or in all pairwise combinations in a clone of NIH3T3 cells (3T3-7d) devoid of detectable epidermal growth factor receptor family members has been generated. Transformation, as measured by growth in soft agar, occurred only in the presence of appropriate ligand and only in cells expressing two different HER family members, Transfection of oncogenic neu (Tneu), conferred ligand-independent transformation only in cells which co-expressed HER1, HER3, or HER4, but not when expressed alone or with HERS, Cell lines were also tested for their ability to form tumors in animals, None of the cell lines expressing single HER family members was able to form tumors in animals with the exception of HER1, which was weakly tumorigenic. Although unable to form tumors when expressed alone, HERS was tumorigenic when expressed with HER1 or HER3, but not HER4. Of all complexes analyzed, cells expressing HER1 + HERS were the most aggressive, The relationship between HER1 activation, intracellular calcium fluxes, and phospholipase C gamma 1 activation is web established, We found that activation of HER1 was required for the induction of a calcium flux and the phosphorylation of phospholipase C gamma 1. These activities were independent of, and unaffected by, the co-expression of any other family member. Further, heregulin stimulation of all cell lines including those containing HER1 did not demonstrate any effect on intracellular calcium levels or phospholipase C gamma 1 phosphorylation, This demonstrates that heregulin induced cellular transformation by activating HER3- and HER4-containing complexes does not require the activation of either phospholipase C gamma 1 or the mobilization of intracellular calcium.	AMGEN INC, THOUSAND OAKS, CA 91320 USA	Amgen	Cohen, BD (corresponding author), BRISTOL MYERS SQUIBB CO, PHARMACEUT RES INST, DEPT MOL IMMUNOL, SEATTLE, WA 98121 USA.							BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BASELGA J, 1994, PHARMACOL THERAPEUT, V64, P127, DOI 10.1016/0163-7258(94)90036-1; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1993, ADV SEC MESS PHOSPH, V28, P179; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Cohen BM, 1996, J BIOL CHEM, V271, P4813; CULOUSCOU JM, 1995, J BIOL CHEM, V270, P12857, DOI 10.1074/jbc.270.21.12857; Decker SJ, 1995, J BIOL CHEM, V270, P30841, DOI 10.1074/jbc.270.52.30841; DIEGEL ML, 1994, J BIOL CHEM, V269, P11409; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; GULLICK WJ, 1990, INT J CANCER, P55; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; JALLAL B, 1992, J BIOL CHEM, V267, P4357; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; QIAN XL, 1995, ONCOGENE, V10, P211; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SASADA R, 1993, BIOCHEM BIOPH RES CO, V190, P1173, DOI 10.1006/bbrc.1993.1173; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SIEGALL CB, 1995, J BIOL CHEM, V270, P7625, DOI 10.1074/jbc.270.13.7625; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEIGL ML, 1983, BIOCHIM BIOPHYS ACTA, V738, P21, DOI 10.1016/0304-419X(84)90018-0; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; Zhang K, 1996, J BIOL CHEM, V271, P3884	56	100	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30897	30903		10.1074/jbc.271.48.30897	http://dx.doi.org/10.1074/jbc.271.48.30897			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940074	hybrid			2022-12-27	WOS:A1996VV15800091
J	Kume, T; Watanabe, T; Sanokawo, R; Chida, D; Nakamura, T; Oishi, M				Kume, T; Watanabe, T; Sanokawo, R; Chida, D; Nakamura, T; Oishi, M			Expression of the protein tyrosine phosphatase beta 2 gene in mouse erythroleukemia cells induces terminal erythroid differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVITRO DIFFERENTIATION; MOLECULAR-CLONING; MEL CELLS; INDUCTION; TRANSCRIPTION; KINASES; INHIBITORS; COMMITMENT; GENISTEIN	We have cloned cDNA for protein tyrosine phosphatase beta 2, which had been implicated in erythroid differentiation of mouse erythroleukemia cells. Expression of cDNA constructs, in which beta 2 cDNA is placed under the control of mouse metallothionein-I promoter, by ZnCl2, converted a significant portion (20 to 38%) of the cells to erythroid-like cells, which is 25-50% of the erythroid differentiation efficiency observed by conventional erythroid-inducing agents, Furthermore, introduction and expression of altered protein tyrosine phosphatase beta 2 cDNA constructs designed to produce the enzyme lacking the phosphatase activity inhibited erythroid differentiation by 100-20%, depending upon the concentration of erythroid-inducing agents employed. These results strongly suggest that protein tyrosine phosphatase beta 2 is involved in triggering erythroid differentiation in mouse erythroleukemia cells.	UNIV TOKYO,INST MOL & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN; TOHOKU UNIV,INST DEV AGING & CANC,SENDAI,MIYAGI 980,JAPAN; SUMITOMO ELECT IND LTD,BIOMED RES & DEV DEPT,SAKAE KU,YOKOHAMA,KANAGAWA 244,JAPAN; NATL INST BIOSCI & HUMAN TECHNOL,TSUKUBA,IBARAKI 305,JAPAN	University of Tokyo; Tohoku University; Sumitomo Electric Industries; National Institute of Advanced Industrial Science & Technology (AIST)								APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BOER PH, 1990, BIOCHEM GENET, V28, P299, DOI 10.1007/BF02401419; CHIDA D, 1995, FEBS LETT, V358, P233, DOI 10.1016/0014-5793(94)01432-Z; FIBACH E, 1977, CANCER RES, V37, P440; GUSELLA J, 1976, CELL, V9, P221, DOI 10.1016/0092-8674(76)90113-6; HONDA H, 1994, BLOOD, V84, P4186, DOI 10.1182/blood.V84.12.4186.bloodjournal84124186; IGARASHI K, 1995, P NATL ACAD SCI USA, V92, P7445, DOI 10.1073/pnas.92.16.7445; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KONDO K, 1989, J CELL BIOL, V109, P285, DOI 10.1083/jcb.109.1.285; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUME T, 1994, J BIOL CHEM, V269, P4709; Kuramochi S, 1996, FEBS LETT, V378, P7, DOI 10.1016/0014-5793(95)01415-2; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MUNAKATA H, 1993, J BIOCHEM, V114, P103, DOI 10.1093/oxfordjournals.jbchem.a124123; OISHI M, 1990, MECHANISM DIFFERENTI, V2, P129; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; THOMAS ML, 1993, PROG IMMUNOL, V8, P213; THOMAS PE, 1994, J BIOL CHEM, V269, P19953; WATANABE T, 1991, CANCER RES, V51, P764; WATANABE T, 1992, EXP CELL RES, V199, P269, DOI 10.1016/0014-4827(92)90434-A; WATANABE T, 1995, GENOMICS, V29, P793, DOI 10.1006/geno.1995.9932; WATANABE T, 1989, EXP CELL RES, V183, P335, DOI 10.1016/0014-4827(89)90394-7; WATANABE T, 1992, CELL GROWTH DIFFER, V3, P865; WATANABE T, 1992, J BIOL CHEM, V67, P17116; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4	29	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30916	30921		10.1074/jbc.271.48.30916	http://dx.doi.org/10.1074/jbc.271.48.30916			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940077	hybrid			2022-12-27	WOS:A1996VV15800094
J	Nakagawa, T; Higashiyama, S; Mitamura, T; Mekada, E; Taniguchi, N				Nakagawa, T; Higashiyama, S; Mitamura, T; Mekada, E; Taniguchi, N			Amino-terminal processing of cell surface heparin-binding epidermal growth factor-like growth factor up-regulates its juxtacrine but not its paracrine growth factor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN RECEPTOR; SMOOTH-MUSCLE CELLS; EGF-RECEPTOR; KIT-LIGAND; SIGNAL TRANSDUCTION; MITOGENIC ACTIVITY; PHORBOL ESTER; EXPRESSION; PROTEIN; TRANSMEMBRANE	Human heparin-binding epidermal growth factor (EGF)-like growth factor (HB-EGF) expressed on Chinese hamster ovary (CHO) cells is synthesized as a 19-kDa major, and 22- and 27-kDa minor, membrane-anchored precursors (proHB-EGF). In contrast, the 27-kDa species is major and the 19- and 22-kDa ones are minor in mouse proHB-EGF. The juxtacrine growth factor activities of human and mouse proHB-EGFs on CHO cells toward EP170.7 cells in co-culture are significantly different. To investigate the relationship between the juxtacrine growth factor activities and the molecular species, we prepared human-mouse chimeras. Chimeras that have the human amino-terminal sequence with a mouse EGF-like domain showed approximately 8 fold up-regulation of the juxtacrine growth factor activity and the predominance of a 19-22-kDa major species. In contrast, chimeras that have the mouse amino-terminal sequence with a human EGF-like domain showed approximately B-fold down-regulation of the juxtacrine activity and the predominance of the 27-kDa major species. A Gly(32)HB-EGF (117-amino acid form), which is amino-terminally extended, induced the same mitogenic activity as that of Arg(73)-HB-EGF (75-amino acid form), which is amino-terminally truncated. These results strongly suggested that amino-terminal processing of human proHB-EGF would be required for up-regulation of its juxtacrine growth factor activity, but not for its paracrine activity.	OSAKA UNIV,SCH MED,DEPT BIOCHEM,SUITA,OSAKA 565,JAPAN; KURUME UNIV,INST LIFE SCI,DIV CELL BIOL,KURUME,FUKUOKA 830,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,DEPT MOL PROTOZOOL,SUITA,OSAKA 565,JAPAN	Osaka University; Kurume University; Osaka University			Taniguchi, Naoyuki/I-4182-2014; Taniguchi, Naoyuki/A-7086-2016	Taniguchi, Naoyuki/0000-0001-5889-5968; Mekada, Eisuke/0000-0001-8858-4781				ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BESNER G, 1990, CELL REGUL, V1, P811, DOI 10.1091/mbc.1.11.811; BLASBAND AJ, 1990, ONCOGENE, V5, P1213; BLOTNICK S, 1994, P NATL ACAD SCI USA, V91, P2890, DOI 10.1073/pnas.91.8.2890; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAS SK, 1994, DEVELOPMENT, V120, P1071; DLUZ SM, 1993, J BIOL CHEM, V268, P18330; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; HASHIMOTO K, 1994, J BIOL CHEM, V269, P20060; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; ITO N, 1994, BIOCHEM BIOPH RES CO, V198, P25, DOI 10.1006/bbrc.1994.1004; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; MITAMURA T, 1992, J CELL BIOL, V118, P1389, DOI 10.1083/jcb.118.6.1389; MIYAGAWA J, 1995, J CLIN INVEST, V95, P404, DOI 10.1172/JCI117669; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; ONO M, 1994, J BIOL CHEM, V269, P31315; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; RAAB G, 1994, BIOCHEM BIOPH RES CO, V204, P592, DOI 10.1006/bbrc.1994.2500; Raab G, 1996, DEVELOPMENT, V122, P637; Sambrook J., 2002, MOL CLONING LAB MANU; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHISHIDO Y, 1995, J BIOL CHEM, V270, P29578, DOI 10.1074/jbc.270.49.29578; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; STROOBANT P, 1985, CELL, V42, P383, DOI 10.1016/S0092-8674(85)80133-1; THOMPSON SA, 1994, J BIOL CHEM, V269, P2541; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	42	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30858	30863		10.1074/jbc.271.48.30858	http://dx.doi.org/10.1074/jbc.271.48.30858			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940069	hybrid			2022-12-27	WOS:A1996VV15800086
J	Ohyama, Y; Ozono, K; Uchida, M; Yoshimura, M; Shinki, T; Suda, T; Yamamoto, O				Ohyama, Y; Ozono, K; Uchida, M; Yoshimura, M; Shinki, T; Suda, T; Yamamoto, O			Functional assessment of two vitamin D-responsive elements in the rat 25-hydroxyvitamin D-3 24-hydroxylase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-RECEPTOR; OSTEOCALCIN GENE; 1,25-DIHYDROXYVITAMIN-D3 RECEPTOR; IDENTIFICATION; EXPRESSION; PROMOTER; DNA; HORMONE; BINDING; KIDNEY	Two vitamin D-responsive elements (VDRE-1 and VDRE-2) were recently identified in the 5'-upstream region of the rat 25-hydroxyvitamin D-3 24-hydroxylase gene at -151/-137 and -259/-245, respectively. We studied the transcriptional regulation of this gene by vitamin D by means of mutational analysis. Introducing mutations into VDRE-1 and VDRE-2 in the native promoter -291/+9 reduced vitamin D-dependent chloramphenicol acetyltransferase activity by 86 and 41%, respectively. Mutation of the direct repeat -169/-155 located at 3 base pairs upstream of VDRE-1 also caused 50% decrease of chloramphenicol acetyltransferase activity. Connection of the element -169/-155 to VDRE-1 enhanced the vitamin D responsiveness of VDRE-1 5-fold through the heterologous beta-globin promoter. The fragment -291/-102 containing the two VDREs showed two shifted bands in the presence of the vitamin D receptor and retinoid X receptor in gel retardation analysis, and the appearance of the slower migrating band indicates that two sets of receptor complexes bind to this fragment simultaneously. These results demonstrate that VDRE-1 is a stronger mediator of vitamin D function than VDRE-2 due to the presence of the accessory element -169/-155 located adjacent to VDRE-1, although VDRE-2 exhibits a smaller dissociation constant for the vitamin D receptor-retinoid X receptor complex than VDRE-1.	OSAKA MED CTR MATERNAL & CHILD HLTH, IZUMI, OSAKA 59002, JAPAN; KUREHA CHEM IND CO LTD, BIOMED RES LABS, SHINJYUKU KU, TOKYO 169, JAPAN; SHOWA UNIV, SCH DENT, DEPT BIOCHEM, SHINAGAWA KU, TOKYO 142, JAPAN	Showa University	Ohyama, Y (corresponding author), HIROSHIMA UNIV, FAC SCI, GRAD DEPT GENE SCI, 1-3-1 KAGAMIYAMA, HIGASHIHIROSHIMA 739, JAPAN.							BROMMAGE R, 1985, ENDOCR REV, V6, P491, DOI 10.1210/edrv-6-4-491; CHEN KS, 1995, BBA-GENE STRUCT EXPR, V1263, P1, DOI 10.1016/0167-4781(95)00060-T; DELUCA HF, 1988, FASEB J, V2, P224, DOI 10.1096/fasebj.2.3.3280376; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GILL RK, 1993, P NATL ACAD SCI USA, V90, P2984, DOI 10.1073/pnas.90.7.2984; HAHN CN, 1994, NUCLEIC ACIDS RES, V22, P2410, DOI 10.1093/nar/22.12.2410; HAUSSLER MR, 1988, RECENT PROG HORM RES, V44, P263; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; IIDA K, 1995, P NATL ACAD SCI USA, V92, P6112, DOI 10.1073/pnas.92.13.6112; KAHLEN JP, 1994, BIOCHEM BIOPH RES CO, V202, P1366, DOI 10.1006/bbrc.1994.2081; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LIU M, 1994, MOL ENDOCRINOL, V8, P1593, DOI 10.1210/me.8.12.1593; MACDONALD PN, 1995, J BIOL CHEM, V270, P4748, DOI 10.1074/jbc.270.9.4748; MACDONALD PN, 1991, J BIOL CHEM, V266, P18808; MARKOSE ER, 1990, P NATL ACAD SCI USA, V87, P1701, DOI 10.1073/pnas.87.5.1701; MINGHETTI PP, 1988, FASEB J, V2, P3043, DOI 10.1096/fasebj.2.15.2847948; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NISHIMURA A, 1994, ENDOCRINOLOGY, V134, P1794, DOI 10.1210/en.134.4.1794; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; OHYAMA Y, 1993, BIOCHEMISTRY-US, V32, P76, DOI 10.1021/bi00052a011; OHYAMA Y, 1994, J BIOL CHEM, V269, P10545; OHYAMA Y, 1991, FEBS LETT, V278, P195, DOI 10.1016/0014-5793(91)80115-J; OHYAMA Y, 1991, J BIOL CHEM, V266, P8690; OZONO K, 1990, J BIOL CHEM, V265, P21881; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; REINHARDT TA, 1989, J BIOL CHEM, V264, P15917; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCARLETT CO, 1995, MOL ENDOCRINOL, V9, P413, DOI 10.1210/me.9.4.413; SHINKI T, 1992, J BIOL CHEM, V267, P13757; SONE T, 1991, J BIOL CHEM, V266, P23296; SUDA T, 1990, ANNU REV NUTR, V10, P195, DOI 10.1146/annurev.nu.10.070190.001211; TANAKA Y, 1974, SCIENCE, V183, P1198, DOI 10.1126/science.183.4130.1198; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZIEROLD C, 1994, P NATL ACAD SCI USA, V91, P900, DOI 10.1073/pnas.91.3.900; ZIEROLD C, 1995, J BIOL CHEM, V270, P1675, DOI 10.1074/jbc.270.4.1675	39	78	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30381	30385		10.1074/jbc.271.48.30381	http://dx.doi.org/10.1074/jbc.271.48.30381			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940000	hybrid			2022-12-27	WOS:A1996VV15800017
J	Gleizes, PE; Beavis, RC; Mazzieri, R; Shen, B; Rifkin, DB				Gleizes, PE; Beavis, RC; Mazzieri, R; Shen, B; Rifkin, DB			Identification and characterization of an eight-cysteine repeat of the latent transforming growth factor-beta binding protein-1 that mediates bonding to the latent transforming growth factor-beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; EXTRACELLULAR-MATRIX; MARFAN-SYNDROME; EXPRESSION; CELLS; TGF-BETA-1; ACTIVATION; COMPONENT	Most cultured cell types secrete small latent transforming growth factor-beta (TGF-beta) as a disulfide-bonded complex with a member of the latent TGF-beta binding protein (LTBP) family. Using the baculovirus expression system, we have mapped the domain of LTBP-1 mediating covalent association with small latent TGF-beta 1. Coexpression in Sf9 cells of small latent TGF-beta 1 with deletion mutants of LTBP-1 showed that the third eight-cysteine repeat of LTBP-1 is necessary and sufficient for covalent interaction with small latent TGF-beta 1. Analysis by mass spectrometry of this eight-cysteine repeat, produced as a recombinant peptide in Sf9 cells, confirmed that it was N-glycosylated, as expected from the primary sequence, No other post-translational modifications of this domain were detected. Alkylation of the recombinant peptide with vinyl pyridine failed to reveal any free cysteines, indicating that, in the absence of small latent TGF-beta, the eight cysteines of this domain are engaged in intramolecular bonds. These data demonstrate that the third LTBP-1 eight-cysteine repeat recognizes and associates covalently with small latent TGF-beta 1 through a mechanism that does not require any specific post-translational modification of this domain. They also suggest that this domain adopts different conformations depending on whether it is free or bound to small latent TGF-beta.	NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016; NYU,MED CTR,RAYMOND & BEVERLY SACKLER FDN LAB,NEW YORK,NY 10016; NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; NYU,MED CTR,SKIRBALL INST BIOMED RES,NEW YORK,NY 10016; NYU,DEPT CHEM,NEW YORK,NY 10003	New York University; New York University; New York University; New York University; New York University	Gleizes, PE (corresponding author), NYU,MED CTR,DEPT CELL BIOL,550 1ST AVE,NEW YORK,NY 10016, USA.		Gleizes, Pierre-Emmanuel/H-3821-2014; Gleizes, Pierre-Emmanuel/ABB-9653-2021; Mazzieri, Roberta/C-9773-2015	Gleizes, Pierre-Emmanuel/0000-0003-0830-7341; Gleizes, Pierre-Emmanuel/0000-0003-0830-7341; Mazzieri, Roberta/0000-0002-5172-0927	NATIONAL CANCER INSTITUTE [T32CA009161] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA 09161, CA 23753] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; BRUNNER AM, 1989, J BIOL CHEM, V264, P13660; DALLAS SL, 1995, J CELL BIOL, V131, P539, DOI 10.1083/jcb.131.2.539; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P5584, DOI 10.1021/bi00475a024; DAVIDSON DJ, 1991, BIOCHEMISTRY-US, V30, P6689, DOI 10.1021/bi00241a008; FLAUMENHAFT R, 1993, J CELL BIOL, V120, P995, DOI 10.1083/jcb.120.4.995; GENTRY LE, 1988, MOL CELL BIOL, V8, P4162, DOI 10.1128/MCB.8.10.4162; GIBSON MA, 1995, MOL CELL BIOL, V15, P6932; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; MOREN A, 1994, J BIOL CHEM, V269, P32469; NUNES I, 1995, J IMMUNOL, V155, P1450; Olofsson A, 1995, J BIOL CHEM, V270, P31294, DOI 10.1074/jbc.270.52.31294; Saharinen J, 1996, EMBO J, V15, P245, DOI 10.1002/j.1460-2075.1996.tb00355.x; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; STAUDACHER E, 1992, EUR J BIOCHEM, V207, P987, DOI 10.1111/j.1432-1033.1992.tb17134.x; TAIPALE J, 1995, J BIOL CHEM, V270, P4689, DOI 10.1074/jbc.270.9.4689; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; TSUJI T, 1990, P NATL ACAD SCI USA, V87, P8835, DOI 10.1073/pnas.87.22.8835; WAHL SM, 1992, J CLIN IMMUNOL, V12, P1; YIN WS, 1995, J BIOL CHEM, V270, P10147, DOI 10.1074/jbc.270.17.10147; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	27	109	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29891	29896		10.1074/jbc.271.47.29891	http://dx.doi.org/10.1074/jbc.271.47.29891			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939931	hybrid			2022-12-27	WOS:A1996VU52500059
J	Lang, IM; Chuang, TL; Barbas, CF; Schleef, RR				Lang, IM; Chuang, TL; Barbas, CF; Schleef, RR			Purification of storage granule protein-23 - A novel protein identified by phage display technology and interaction with type 1 plasminogen activator inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED SECRETORY PATHWAY; ENDOTHELIAL-CELLS; GROWTH-FACTOR; EPITOPE LIBRARIES; HUMAN-PLATELETS; MESSENGER-RNA; ATT-20 CELLS; CDNA CLONING; P-SELECTIN; SIS GENE	Type 1 plasminogen activator inhibitor (PAI-1) is a key regulator of the fibrinolytic cascade that is stored in a rapidly releasable form within platelet alpha-granules. To identify proteins that may participate in the targeting or storage of this potent inhibitor, this report investigates the applicability of utilizing filamentous bacteriophages to display proteins expressed by cells containing a regulated secretory pathway and their enrichment based upon an interaction with PAI-1, For this purpose, RNA was extracted from AtT-20 cells (i.e. a classical model cell system for intracellular protein sorting), reverse transcribed, amplified using polymerase chain reaction primers containing internal restriction sites, and cloned into the phagemid pCOMB3H for expression as fusion constructs with the bacteriophage gene III protein, Escherichia coli was transformed with the phagemids and infected with VCSM13 helper phage, and the resulting AtT-20 cDNA-bacteriophage library was enriched by panning against solid- and solution-phase PAI-1, The enriched cDNA library was subcloned into a prokaryotic expression vector system that replaces the gene III protein with a decapeptide tag for immunologic quantitation, One novel cDNA clone (i.e. A-61), which preferentially recognized solution-phase PAI-1 and reacted positively with antibodies derived from a rabbit immunized with alpha-granules, was subcloned into the prokaryotic expression vector pTrcHis to create a construct containing an N-terminal six-histidine purification tag, This construct was expressed in E. coli, purified by nickel-chelate chromatography followed by preparative SDS-polyacrylamide gel electrophoresis, and utilized for the generation of polyclonal antibodies, Immunoblotting analysis employing antibodies against the purified A-61 construct revealed a 23-kDa protein present in the regulated secretory pathway of AtT-20 cells, The 23-kDa molecule was purified from media conditioned by AtT-20 cells by ion exchange chromatography on DEAE-Sephacel, molecular sieve chromatography on Sephacryl S-100, chromatofocusing on Polybuffer exchanger 94, and affinity chromatography on PAI-1-Sepharose, N-terminal amino acid sequencing of a 16-kDa Lys-C proteolytic fragment of the 23-kDa storage granule protein was employed to confirm its identity with the cDNA sequence of clone A-61, These data indicate that phage display of cDNA libraries fused to the C-terminal region of the gene III protein and their enrichment via an interaction with a target molecule can be utilized to define other proteins present within a particular cellular pathway.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT MOL BIOL & CHEM, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute				Lang, Irene/0000-0003-0485-2692	NHLBI NIH HHS [HL45954, HL49563] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045954, R01HL049563] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSI MC, 1994, THROMB HAEMOSTASIS, V72, P931; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BARRETT TB, 1984, P NATL ACAD SCI-BIOL, V81, P6772, DOI 10.1073/pnas.81.21.6772; BITHELL TC, 1993, WINTROBES CLIN HEMAT, P511; BOOTH NA, 1985, J CLIN PATHOL, V38, P825, DOI 10.1136/jcp.38.7.825; BOOTH NA, 1988, BRIT J HAEMATOL, V70, P327, DOI 10.1111/j.1365-2141.1988.tb02490.x; BOOTH NA, 1990, FIBRINOLYSIS, V4, P138, DOI 10.1016/0268-9499(90)90391-V; BURGESS TL, 1985, J CELL BIOL, V101, P639, DOI 10.1083/jcb.101.2.639; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; BURGESS TL, 1987, J CELL BIOL, V105, P659, DOI 10.1083/jcb.105.2.659; BURTON DR, 1994, ADV IMMUNOL, V57, P191, DOI 10.1016/S0065-2776(08)60674-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS T, 1985, NATURE, V316, P748, DOI 10.1038/316748a0; CRAMERI R, 1994, EUR J BIOCHEM, V226, P53, DOI 10.1111/j.1432-1033.1994.tb20025.x; CRAMERI R, 1993, GENE, V137, P69, DOI 10.1016/0378-1119(93)90253-Y; DECLERCK PJ, 1988, BLOOD, V71, P220; DIEVAL J, 1991, BLOOD, V77, P528; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; ERICKSON LA, 1984, J CLIN INVEST, V74, P1465, DOI 10.1172/JCI111559; FAY WP, 1992, NEW ENGL J MED, V327, P1729, DOI 10.1056/NEJM199212103272406; FINK LM, 1994, VIRCHOWS ARCH, V424, P1; GOMBAU L, 1994, J BIOL CHEM, V269, P3875; GRAMATIKOFF K, 1994, NUCLEIC ACIDS RES, V22, P5761, DOI 10.1093/nar/22.25.5761; GREENBERG SM, 1988, BLOOD, V72, P1968; GUMBINER B, 1982, CELL, V28, P51, DOI 10.1016/0092-8674(82)90374-9; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HOESS RH, 1994, J IMMUNOL, V153, P724; HOTTIGER M, 1995, NUCLEIC ACIDS RES, V23, P736; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; JOHNSSON A, 1984, EMBO J, V3, P921, DOI 10.1002/j.1460-2075.1984.tb01908.x; KELLY R B, 1991, Current Opinion in Cell Biology, V3, P654, DOI 10.1016/0955-0674(91)90037-Y; KOEDAM JA, 1992, J CELL BIOL, V116, P617, DOI 10.1083/jcb.116.3.617; KONKLE BA, 1993, ARTERIOSCLER THROMB, V13, P669, DOI 10.1161/01.ATV.13.5.669; KRUITHOF EKO, 1987, BLOOD, V70, P1645; KRUITHOF EKO, 1986, THROMB HAEMOSTASIS, V55, P201; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1993, CURR OPIN IMMUNOL, V5, P268, DOI 10.1016/0952-7915(93)90016-L; Lang IM, 1996, GENE, V172, P295, DOI 10.1016/0378-1119(96)00021-2; LANG IM, 1992, BLOOD, V80, P2269; Lang IM, 1996, J BIOL CHEM, V271, P2754, DOI 10.1074/jbc.271.5.2754; LEE MH, 1993, BLOOD, V81, P2357; LERNER RA, 1992, SCIENCE, V258, P1313, DOI 10.1126/science.1455226; MANIATIS T, 1992, MOL CLONING; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; MIMURO J, 1987, BLOOD, V70, P721; MOORE HPH, 1986, NATURE, V321, P443, DOI 10.1038/321443a0; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; PANNEKOEK H, 1993, GENE, V128, P135, DOI 10.1016/0378-1119(93)90164-X; PAULSSON Y, 1987, NATURE, V328, P715, DOI 10.1038/328715a0; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P123; REILLY TM, 1994, BLOOD COAGUL FIBRIN, V5, P73, DOI 10.1097/00001721-199402000-00011; RINDLER M J, 1992, Current Opinion in Cell Biology, V4, P616, DOI 10.1016/0955-0674(92)90080-V; ROBBINS KC, 1983, NATURE, V305, P605, DOI 10.1038/305605a0; RUSSELL R, 1986, CELL, V46, P155; Salonen EM, 1996, FEBS LETT, V393, P216, DOI 10.1016/0014-5793(96)00865-4; SCHLEEF RR, 1991, J CELL BIOL, V113, P1413, DOI 10.1083/jcb.113.6.1413; SCHLEEF RR, 1988, J BIOL CHEM, V263, P5797; SCHLEEF RR, 1989, J CLIN INVEST, V83, P1747, DOI 10.1172/JCI114076; SCOTT JK, 1992, TRENDS BIOCHEM SCI, V17, P241, DOI 10.1016/0968-0004(92)90401-T; SIMPSON AJ, 1991, J CLIN PATHOL, V44, P139, DOI 10.1136/jcp.44.2.139; SIMPSON AJ, 1990, BRIT J HAEMATOL, V75, P543, DOI 10.1111/j.1365-2141.1990.tb07796.x; SPRENGERS ED, 1986, THROMB HAEMOSTASIS, V55, P325; VANMEIJER M, 1995, FIBRINOLYSIS, V9, P263, DOI 10.1016/S0268-9499(95)80015-8; WAGNER DD, 1991, CELL, V64, P403, DOI 10.1016/0092-8674(91)90648-I; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245	65	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30126	30135		10.1074/jbc.271.47.30126	http://dx.doi.org/10.1074/jbc.271.47.30126			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939962	hybrid, Green Submitted			2022-12-27	WOS:A1996VU52500090
J	Mazzoni, MR; Hamm, HE				Mazzoni, MR; Hamm, HE			Interaction of transducin with light-activated rhodopsin protects it from proteolytic digestion by trypsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; BOVINE PHOTORECEPTOR-MEMBRANES; GTP-BINDING PROTEIN; ALPHA-SUBUNIT; MONOCLONAL-ANTIBODY; AMINO TERMINUS; BETA-GAMMA; LIPID MODIFICATIONS; CRYSTAL-STRUCTURE; GDP	The tryptic cleavage pattern of transducin (G(t)) in solution was compared with that in the presence of phospholipid vesicles, rod outer segment (ROS) membranes kept in the dark, or ROS membranes containing light-activated rhodopsin, metarhodopsin II (Rh*). When G(t) was in the high affinity complex with Rh*, the alpha(t) subunit was almost completely protected from proteolysis. The protection of at at Arg(310) was complete, while Arg(204) was substantially protected. The cleavage of alpha(t) at Lys's was protected in the presence of phospholipid vesicles, ROS membranes kept in the dark, or ROS membranes containing Rh*. The cleavage of beta(t) was slower in the presence of ROS membranes or phospholipid vesicles. When the Rh*. G(t) complex was incubated with guanyl-5'-yl thiophosphate, a guanine nucleotide analog known to release the high affinity interaction between G(t) and Rh*, the protection at Arg(310) and Arg(304) was diminished. From our results, we propose that Rh* either physically blocks access of trypsin to Arg(204) and Arg(310) or maintains the heterotrimer in such a conformation that these cleavage sites are not available. Since Arg(204) is involved in the switch interface with beta gamma(t) (Lambright, D. G., Sondek, J., Bohm, A., Skiba, N. P., Hamm, H. E., and Sigler, P. B. (1996) Nature 379, 311-319), it may be that beta gamma(t) is implicated in protecting this cleavage site in the receptor-bound, stabilized heterotrimer. Arg(310) is not near the beta gamma(t) subunit, thus we believe that the high affinity binding of G(t) to Rh* physically or sterically blocks access of trypsin to this site. Thus, Arg(310), only a few angstroms away from the carboxyl terminus of a,, which is known to directly bind to Rh*, is likely to also be a part of the Rh* binding site. This is in agreement with other studies and has implications for the mechanism by which receptors catalyze GDP release from G proteins. The protection of Lys(18) in the presence of phospholipid vesicles suggests that the amino-terminal region is in contact with the membrane, consistent with the crystal structure of the heterotrimer (Lambright, D. G., Sondek, J., Bohm, A., Skiba, N. P., Hamm, H. E., and Sigler, P. B.(1996) Nature 379, 311-319).	UNIV ILLINOIS, DEPT PHYSIOL & BIOPHYS, CHICAGO, IL 60612 USA; UNIV PISA, IST POLICATTEDRA DISCIPLINE BIOL, I-56126 PISA, ITALY	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Pisa			Hamm, Heidi E/G-2374-2014; Mazzoni, Maria Rosa/AAA-2366-2022	Mazzoni, Maria Rosa/0000-0003-2612-432X	NATIONAL EYE INSTITUTE [R01EY006062] Funding Source: NIH RePORTER; NEI NIH HHS [EY 06062] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BIGAY J, 1994, BIOCHEMISTRY-US, V33, P14081, DOI 10.1021/bi00251a017; BOURNAUCIN F, 1989, EUR J BIOCHEM, V184, P687; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; COLEMAN DE, 1994, J MOL BIOL, V238, P630, DOI 10.1006/jmbi.1994.1320; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; DENKER BM, 1992, J BIOL CHEM, V267, P9998; DENKER BM, 1992, J BIOL CHEM, V267, P6272; EMEIS D, 1982, FEBS LETT, V143, P29, DOI 10.1016/0014-5793(82)80266-4; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; GRAF R, 1992, J BIOL CHEM, V267, P24307; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HAMM HE, 1990, ADV SEC MESS PHOSPH, V24, P76; HAMM HE, 1984, J GEN PHYSIOL, V84, P265, DOI 10.1085/jgp.84.2.265; HARGRAVE PA, 1993, BIOESSAYS, V15, P43, DOI 10.1002/bies.950150107; HEIN L, 1995, NEUROPHARMACOLOGY, V34, P357, DOI 10.1016/0028-3908(95)00018-2; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; IYENGAR R, 1980, J BIOL CHEM, V255, P312; KAHLERT M, 1990, J BIOL CHEM, V265, P18928; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE CH, 1995, MOL PHARMACOL, V47, P218; MALINSKI JA, 1992, BIOCHEMISTRY-US, V31, P9502, DOI 10.1021/bi00154a024; MAZZONI MR, 1993, J PROTEIN CHEM, V12, P215, DOI 10.1007/BF01026043; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MAZZONI MR, 1989, BIOCHEMISTRY-US, V28, P9873, DOI 10.1021/bi00451a047; NAVON SE, 1987, J BIOL CHEM, V262, P15746; NEER EJ, 1988, J BIOL CHEM, V263, P8996; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PANICO J, 1990, J BIOL CHEM, V265, P18922; PFISTER C, 1983, EUR J BIOCHEM, V136, P489, DOI 10.1111/j.1432-1033.1983.tb07767.x; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; ROJAS FJ, 1985, J BIOL CHEM, V260, P7829; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STRYER L, 1983, METHOD ENZYMOL, V96, P617; THOMAS TC, 1993, P NATL ACAD SCI USA, V90, P10295, DOI 10.1073/pnas.90.21.10295; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WITT PL, 1984, J GEN PHYSIOL, V84, P251, DOI 10.1085/jgp.84.2.251; YAMANAKA G, 1985, BIOCHEMISTRY-US, V24, P8094, DOI 10.1021/bi00348a039; YAMANE HK, 1993, ANN REV PHARM TOXICO, V32, P201	51	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30034	30040		10.1074/jbc.271.47.30034	http://dx.doi.org/10.1074/jbc.271.47.30034			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939950	hybrid			2022-12-27	WOS:A1996VU52500078
J	Perregaux, DG; Laliberte, RE; Gabel, CA				Perregaux, DG; Laliberte, RE; Gabel, CA			Human monocyte interleukin-1 beta posttranslational processing - Evidence of a volume-regulated response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DEATH GENE CED-3; K-CL COTRANSPORT; EXTRACELLULAR ATP; IL-1-BETA PRODUCTION; MOUSE MACROPHAGES; MESSENGER-RNA; IL-1-BETA-CONVERTING ENZYME; MONONUCLEAR PHAGOCYTES; BUMETANIDE BINDING	Interleukin (IL)-1 beta produced by monocytes and macrophages is not released via the normal secretory apparatus, and prior to its release, this cytokine must be proteolytically processed to generate a mature biologically active species, Biochemical mechanisms that regulate these posttranslational steps are not well understood, Lipopolysaccharide (LPS) is a poor activator of IL-1 posttranslational processing despite serving as a potent inducer of IL-1 synthesis, For example, freshly isolated human monocytes treated with LPS released <30% of their newly synthesized IL-1 beta as the mature 17-kDa cytokine species, and monocytes that were aged overnight in culture prior to LPS treatment released no 17-kDa cytokine. In contrast, addition of extracellular ATP promoted IL-1 beta posttranslational processing from both monocyte populations, Previous studies indicated that ATP, acting via surface P-2Z-type receptors, promoted major intracellular ionic changes, To explore whether these ionic changes were required for cytokine posttranslational processing, LPS-stimulated human monocytes were maintained in ionically altered media, Hypotonic conditions promoted an efficient and selective release of mature 17-kDa IL-1 beta from LPS-activated monocytes in the absence of ATP, In contrast, hypertonic conditions blocked the ATP-induced posttranslational processing reactions, Both hypotonic stress- and ATP-induced processing were blocked when NaI was substituted for NaCl within the medium; substitution with NaSCN or NaNO3 also blocked the ATP response, but these salts were less inhibitory against the hypotonic stimulus, Sodium glucuronate substitution did not inhibit cytokine processing induced by either stimulus, Removal of divalent cations from the medium did not affect the ATP response, but pretreatment of monocytes with the phosphatase inhibitor okadaic acid dose-dependently suppressed ATP-induced IL-1 beta posttranslational processing. A volume-induced change to the intracellular ionic environment, therefore, may represent a key element of the mechanism by which IL-1 beta posttranslational processing is initiated, The strong dependence of this cytokine release mechanism on chloride anions suggests that selective anion transporters function as important components of this response.	PFIZER INC,CENT RES,DEPT CANC IMMUNOL & INFECT DIS,GROTON,CT 06340	Pfizer								ALONSOTORRE SR, 1993, J BIOL CHEM, V268, P18640; AREND WP, 1989, J IMMUNOL, V143, P118; AYALA JM, 1994, J IMMUNOL, V153, P2592; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BLANCHARD DK, 1991, J LEUKOCYTE BIOL, V50, P28, DOI 10.1002/jlb.50.1.28; BLANCHARD DK, 1991, J IMMUNOL, V147, P2579; BURCHETT SK, 1988, J IMMUNOL, V140, P3473; CABANTCHIK ZI, 1992, AM J PHYSIOL, V262, pC803, DOI 10.1152/ajpcell.1992.262.4.C803; CHIN J, 1993, J IMMUNOL, V151, P5574; DAYER JM, 1986, J CLIN INVEST, V77, P645, DOI 10.1172/JCI112350; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1986, J EXP MED, V163, P1433, DOI 10.1084/jem.163.6.1433; DODGE GR, 1989, J CLIN INVEST, V83, P647, DOI 10.1172/JCI113929; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; ELMOATASSIM C, 1992, BIOCHIM BIOPHYS ACTA, V1134, P31, DOI 10.1016/0167-4889(92)90025-7; FALZONI S, 1995, J CLIN INVEST, V95, P1207, DOI 10.1172/JCI117770; Ferrari D, 1996, J IMMUNOL, V156, P1531; FONG P, 1995, J MEMBRANE BIOL, V144, P189; GALLIN EK, 1994, J CELL PHYSIOL, V159, P573, DOI 10.1002/jcp.1041590321; GAMBA G, 1994, J BIOL CHEM, V269, P17713; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; GRINSTEIN S, 1984, AM J PHYSIOL, V246, pC204, DOI 10.1152/ajpcell.1984.246.3.C204; HARA N, 1990, FEBS LETT, V267, P281, DOI 10.1016/0014-5793(90)80945-F; HASS M, 1994, AM J PHYSIOL, V267, pC869; HEGDE RS, 1992, J MEMBRANE BIOL, V126, P27; HERZYK DJ, 1992, J IMMUNOL, V149, P3052; HICKMAN SE, 1994, BLOOD, V84, P2452; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; HOGQUIST KA, 1991, J IMMUNOL, V147, P2181; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; JENNINGS ML, 1991, J GEN PHYSIOL, V97, P799, DOI 10.1085/jgp.97.4.799; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALIBERTE R, 1994, J IMMUNOL, V153, P2168; LANDIS RC, 1991, J IMMUNOL, V146, P128; LAUF PK, 1988, AM J PHYSIOL, V255, pC331, DOI 10.1152/ajpcell.1988.255.3.C331; LAUF PK, 1992, AM J PHYSIOL, V263, pC917, DOI 10.1152/ajpcell.1992.263.5.C917; LEWIS CE, 1990, IMMUNOLOGY, V69, P402; LI M, 1990, AM J PHYSIOL, V259, pC295, DOI 10.1152/ajpcell.1990.259.2.C295; MATSUURA H, 1992, CIRC RES, V70, P851, DOI 10.1161/01.RES.70.4.851; MCKINNEY LC, 1990, J MEMBRANE BIOL, V116, P47, DOI 10.1007/BF01871671; MILLER BE, 1995, J IMMUNOL, V154, P1331; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NELSON DJ, 1992, J MEMBRANE BIOL, V125, P207; NELSON DJ, 1990, J MEMBRANE BIOL, V117, P29, DOI 10.1007/BF01871563; OGRADY SM, 1987, AM J PHYSIOL, V253, pC177, DOI 10.1152/ajpcell.1987.253.2.C177; ONEILL WC, 1987, AM J PHYSIOL, V253, pC883, DOI 10.1152/ajpcell.1987.253.6.C883; PALFREY HC, 1993, AM J PHYSIOL, V264, pC1270, DOI 10.1152/ajpcell.1993.264.5.C1270; PERREGAUX D, 1992, J IMMUNOL, V149, P1294; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; SARKADI B, 1991, BIOCHIM BIOPHYS ACTA, V1071, P407, DOI 10.1016/0304-4157(91)90005-H; SCHINDLER R, 1990, BLOOD, V76, P1631; SIDERS WM, 1993, J BIOL CHEM, V268, P22170; SOLER A, 1993, J PHYSIOL-LONDON, V465, P387, DOI 10.1113/jphysiol.1993.sp019682; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; STEPHENSON ML, 1987, BIOCHEM BIOPH RES CO, V144, P583, DOI 10.1016/S0006-291X(87)80006-2; STUTTS MJ, 1992, P NATL ACAD SCI USA, V89, P1621, DOI 10.1073/pnas.89.5.1621; SUNG SSJ, 1985, J BIOL CHEM, V260, P3442; TSAI V, 1992, CELL IMMUNOL, V144, P203, DOI 10.1016/0008-8749(92)90237-J; WALEV I, 1995, EMBO J, V14, P1607, DOI 10.1002/j.1460-2075.1995.tb07149.x; WANG SY, 1992, IMMUNOLOGY, V77, P298; WEWERS MD, 1989, J IMMUNOL, V143, P1635; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	65	87	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29830	29838		10.1074/jbc.271.47.29830	http://dx.doi.org/10.1074/jbc.271.47.29830			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939922	hybrid			2022-12-27	WOS:A1996VU52500050
J	Rehberg, EF; SamsonBouma, ME; Kienzle, B; Blinderman, L; Jamil, H; Wetterau, JR; Aggerbeck, LP; Gordon, DA				Rehberg, EF; SamsonBouma, ME; Kienzle, B; Blinderman, L; Jamil, H; Wetterau, JR; Aggerbeck, LP; Gordon, DA			A novel abetalipoproteinemia genotype - Identification of a missense mutation in the 97-kDa subunit of the microsomal triglyceride transfer protein that prevents complex formation with protein disulfide isomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CONTAINING LIPOPROTEINS; GENE; CELLS; EXPRESSION; SECRETION; DEFECTS; CLONING	The microsomal triglyceride transfer protein (MTP) is a heterodimer composed of the ubiquitous multifunctional protein, protein disulfide isomerase, and a unique 97-kDa subunit, Mutations that lead to the absence of a functional 97-kDa subunit cause abetalipoproteinemia, an autosomal recessive disease characterized by a defect in the assembly and secretion of apolipoprotein B (apoB) containing lipoproteins, Previous studies of abetalipoproteinemic patient, C.L., showed that the 97-kDa subunit was undetectable, In this report, [S-35]methionine labeling showed that this tissue was capable of synthesizing the 97-kDa MTP subunit, Electrophoretic analysis showed two bands, one with a molecular mass of the wild type 97-kDa subunit and the other with a slightly lower molecular weight, Sequence analysis of cDNAs from additional intestinal biopsies showed this patient to be a compound heterozygote. One allele contained a perfect in-frame deletion of exon 10, explaining the lower molecular weight band, cDNAs of the second allele were found to contain 3 missense mutations: His(297) --> Gln, Asp(384) --> Ala, and Arg(540) --> His. Transient expression of each mutant showed that only the Arg(540) His mutant was non-functional based upon its inability to reconstitute apoB secretion in a cell culture system, The other amino acid changes are silent polymorphisms, High level coexpression in a baculovirus system of the wild type 97-kDa subunit or the Arg(540) --> His mutant along with human protein disulfide isomerase showed that the wild type was capable of forming an active MTP complex while the mutant was not, Biochemical analysis of lysates from these cells showed that the Arg to His conversion interrupted the interaction between the 97-kDa subunit and protein disulfide isomerase, Replacement of Arg(540) With a lysine residue maintained the ability of the 97-kDa subunit to complex with protein disulfide isomerase and form the active MTP holoprotein, These results indicate that a positively charged amino acid at position 540 in the 97-kDa subunit is critical for the productive association with protein disulfide isomerase, Of the 13 mutant MTP 97-kDa subunit alleles described to date, this is the first encoding a missense mutation.	BRISTOL MYERS SQUIBB,DEPT METAB DIS,PRINCETON,NJ 08543; UNIV PARIS 07,U327 INSERM,F-75870 PARIS 18,FRANCE; CNRS,CTR GENET MOL,F-91198 GIF SUR YVETTE,FRANCE	Bristol-Myers Squibb; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay								BOUMA ME, 1990, J LIPID RES, V31, P1; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Kawasaki ES, 1990, PCR PROTOCOLS GUIDE; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; LIN MCM, 1994, J BIOL CHEM, V269, P29138; LIN MCM, 1995, J LIPID RES, V36, P1073; MAROTTI KR, 1989, GENE ANAL TECH, V6, P67, DOI 10.1016/0735-0651(89)90017-4; NAIM HY, 1988, J BIOL CHEM, V263, P19709; NARCISI TME, 1995, AM J HUM GENET, V57, P1298; RICCI B, 1995, J BIOL CHEM, V270, P14281, DOI 10.1074/jbc.270.24.14281; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHARP D, 1994, BIOCHEMISTRY-US, V33, P9057, DOI 10.1021/bi00197a005; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; SHOULDERS CC, 1994, NAT STRUCT BIOL, V1, P285, DOI 10.1038/nsb0594-285; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; WETTERAU JR, 1986, BIOCHIM BIOPHYS ACTA, V875, P610, DOI 10.1016/0005-2760(86)90084-6	21	68	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29945	29952		10.1074/jbc.271.47.29945	http://dx.doi.org/10.1074/jbc.271.47.29945			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939939	hybrid			2022-12-27	WOS:A1996VU52500067
J	Robinson, MJ; Cheng, M; Khokhlatchev, A; Ebert, D; Ahn, N; Guan, KL; Stein, B; Goldsmith, E; Cobb, MH				Robinson, MJ; Cheng, M; Khokhlatchev, A; Ebert, D; Ahn, N; Guan, KL; Stein, B; Goldsmith, E; Cobb, MH			Contributions of the mitogen-activated protein (MAP) kinase backbone and phosphorylation loop to MEK specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; GROWTH-FACTOR; MAMMALIAN-CELLS; PURIFICATION; CASCADE; COMPONENTS; INVITRO; STRESS	To examine the specificity of MEKs for MAP kinase family members, we determined the abilities of several MEK isoforms to phosphorylate mutants of the MAP kinase ERK2 and the related kinase ERK3 which are modified in the phosphorylation loop, The ERK2 mutants included mutations of the two phosphorylation sites, mutations of the acidic residue between these two sites, and mutations that shorten the length of this loop. All mutants were tested for phosphorylation by six mammalian MEKs and compared with several wild type MAP kinases. MEK1 and MEK2 phosphorylate a major ity of the ERK2 mutants. MEK2 but not MEK1 will phosphorylate ERK3. Alteration of the residue between the two phosphorylation sites neither dramatically affected the activity of MEK1 and MEK2 toward ERK2 nor conferred recognition by other MEKs. Likewise, reduction of the length of the phosphorylation loop only partially reduces recognition by MEK1 and MEK2 but does not promote recognition by other MEKs. Thus other yet to be identified factors must contribute to the specificity of MEK recognition of MAP kinases.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV COLORADO,HOWARD HUGHES MED INST,BOULDER,CO 80309; UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; SIGNAL PHARMACEUT INC,SAN DIEGO,CA 92121	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Michigan System; University of Michigan				Cobb, Melanie/0000-0003-0833-5473	NIDDK NIH HHS [DK34128] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034128, R01DK034128] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1991, J BIOL CHEM, V266, P4220; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; Butch ER, 1996, J BIOL CHEM, V271, P4230; Cheng M, 1996, J BIOL CHEM, V271, P8951, DOI 10.1074/jbc.271.15.8951; Cheng M, 1996, J BIOL CHEM, V271, P12057, DOI 10.1074/jbc.271.20.12057; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Mansour SJ, 1996, CELL GROWTH DIFFER, V7, P243; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1996, BIOCHEMISTRY-US, V35, P5641, DOI 10.1021/bi952723e; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCOTT A, 1995, J BIOL CHEM, V270, P24540, DOI 10.1074/jbc.270.41.24540; SEGER R, 1992, J BIOL CHEM, V267, P14373; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; Wu XY, 1996, J BIOL CHEM, V271, P3265, DOI 10.1074/jbc.271.6.3265; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	35	65	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29734	29739		10.1074/jbc.271.47.29734	http://dx.doi.org/10.1074/jbc.271.47.29734			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939908	hybrid			2022-12-27	WOS:A1996VU52500036
J	Argetsinger, LS; Norstedt, G; Billestrup, N; White, MF; CarterSu, C				Argetsinger, LS; Norstedt, G; Billestrup, N; White, MF; CarterSu, C			Growth hormone, interferon-gamma, and leukemia inhibitory factor utilize insulin receptor substrate-2 in intracellular signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; MEMBRANE-PROXIMAL REGION; C-FOS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOTYROSINE PHOSPHATASE; 3T3-F442A PREADIPOCYTES; CYTOPLASMIC REGIONS; HEMATOPOIETIC-CELLS; 2-HYBRID SYSTEM; SYP PHOSPHATASE	In this report, we demonstrate that insulin receptor substrate-2 (IRS-2) is tyrosyl-phosphorylated following stimulation of 3T3-F442A fibroblasts with growth hormone (GH), leukemia inhibitory factor and interferon-gamma. In response to GH and leukemia inhibitory factor, IRS-2 is immediately phosphorylated, with maximal phosphorylation detected at 15 min; the signal is substantially diminished by 60 min. In response to interferon-gamma, tyrosine phosphorylation of IRS-S was prolonged, with substantial signal still detected at 60 min. Characterization of the mechanism of signaling utilized by GH indicated that tyrosine residues in GH receptor are not necessary for tyrosyl phosphorylation of IRS-2; however, the regions of GH receptor necessary for IRS-2 tyrosyl phosphorylation are the same as those required for JAK2 association and tyrosyl phosphorylation. The role of IRS-2 as a signaling molecule for GH is further demonstrated by the finding that GH stimulates association of IRS-2 with the 85-kDa regulatory subunit of phosphatidylinositol 3'-kinase and with the protein-tyrosine phosphatase SHP2. These results are consistent with the possibility that IRS-2 is a downstream signaling partner of multiple members of the cytokine family of receptors that activate JAK kinases.	UNIV MICHIGAN, SCH MED, DEPT PHYSIOL, ANN ARBOR, MI 48109 USA; JOSLIN DIABET CTR, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02215 USA; KAROLINSKA INST, CTR BIOTECHNOL, S-14157 STOCKHOLM, SWEDEN; HAGEDORN RES LAB, DK-2820 GENTOFTE, DENMARK	University of Michigan System; University of Michigan; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Karolinska Institutet; Novo Nordisk; Hagedorn Research Institute				Billestrup, Nils/0000-0002-4968-8067	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034171, R01DK043808] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK36836, R01 DK034171, R01 DK043808, R01-DK34171, R01-DK 43808] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; ANDERSON NG, 1992, BIOCHEM J, V284, P649, DOI 10.1042/bj2840649; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; DASILVA L, 1994, J BIOL CHEM, V269, P18267; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P2228, DOI 10.1210/en.135.5.2228; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GURLAND G, 1990, ENDOCRINOLOGY, V127, P3187, DOI 10.1210/endo-127-6-3187; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; KAMEGAI J, 1994, ENDOCRINOLOGY, V135, P2765, DOI 10.1210/en.135.6.2765; Kaplan DH, 1996, J BIOL CHEM, V271, P9, DOI 10.1074/jbc.271.1.9; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KHARITONENKOV A, 1995, J BIOL CHEM, V270, P29189, DOI 10.1074/jbc.270.49.29189; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MALABARBA MG, 1995, J BIOL CHEM, V270, P9630, DOI 10.1074/jbc.270.16.9630; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; MEYER DJ, 1993, P NATL ACAD SCI USA, V90, P6721, DOI 10.1073/pnas.90.14.6721; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MOLDRUP A, 1991, J BIOL CHEM, V266, P17441; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OKADA S, 1995, 77 ANN M END SOC JUN, P80; ONEAL KD, 1993, LYMPHOKINE CYTOK RES, V12, P309; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; RIDDERSTRALE M, 1994, BIOCHEM BIOPH RES CO, V203, P306, DOI 10.1006/bbrc.1994.2182; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROUPAS P, 1995, 77 ANN M END SOC BET, P346; SILVA CM, 1994, J BIOL CHEM, V269, P27532; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TANNER JW, 1992, BIOCHEM J, V282, P99, DOI 10.1042/bj2820099; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; TOKER A, 1994, J BIOL CHEM, V269, P32358; URICH M, 1995, J BIOL CHEM, V270, P29286, DOI 10.1074/jbc.270.49.29286; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; VANDERKUUR JA, 1995, J BIOL CHEM, V270, P21738, DOI 10.1074/jbc.270.37.21738; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WANG YD, 1995, MOL ENDOCRINOL, V9, P303, DOI 10.1210/me.9.3.303; WHITE MF, 1994, J BIOL CHEM, V269, P1; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; XIAO S, 1994, J BIOL CHEM, V269, P21244; XU B, 1995, J BIOL CHEM, V270, P29825; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YIN TG, 1994, J BIOL CHEM, V269, P26614; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	63	105	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29415	29421		10.1074/jbc.271.46.29415	http://dx.doi.org/10.1074/jbc.271.46.29415			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910607				2022-12-27	WOS:A1996VT05200099
J	Marino, MW; Dunbar, JD; Wu, LW; Ngaiza, JR; Han, HM; Guo, DQ; Matsushita, M; Nairn, AC; Zhang, YH; Kolesnick, R; Jaffe, EA; Donner, DB				Marino, MW; Dunbar, JD; Wu, LW; Ngaiza, JR; Han, HM; Guo, DQ; Matsushita, M; Nairn, AC; Zhang, YH; Kolesnick, R; Jaffe, EA; Donner, DB			Inhibition of tumor necrosis factor signal transduction in endothelial cells by dimethylaminopurine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CERVICAL-CARCINOMA CELLS; PROTEIN-KINASE ACTIVITY; ELONGATION FACTOR-II; FACTOR RECEPTOR; PROSTACYCLIN SYNTHESIS; CYTOPLASMIC DOMAIN; TNF RECEPTOR; OOCYTE MATURATION; HUMAN FIBROBLASTS; MAMMALIAN-CELLS	Tumor necrosis factor (TNF) promotes diverse responses in endothelial cells that are important to the host response to infections and malignancies; however, less is known of the postreceptor events important to TNF action in endothelial cells than in many other cell types. Since phosphorylation cascades are implicated in cytokine signaling, the effects of the protein kinase inhibitor dimethylaminopurine (DMAP) on TNF action in bovine aortic endothelial cells (BAEC) were investigated. In BAEC, TNF promotes phosphorylation of eukaryotic initiation factor 4E (eIF-4E), c-Jun N-terminal kinase (JNK) and ceramide-activated protein kinase activities, Jun-b expression, prostacyclin production, and, when protein synthesis is inhibited, cytotoxicity. DMAP abrogated or significantly attenuated each of these responses to TNF, without affecting the specific binding of TNF to its receptors. Histamine, another agent active in the endothelium, promotes phosphorylation of elongation factor-2 (EF-2) and prostacyclin production, but not phosphorylation of eIF-4E in BAEC. Histamine-stimulated EF-2 phosphorylation was not inhibited and prostacyclin production was unaffected by DMAP. These observations demonstrate that a distinct signal transduction cascade, which can be selectively inhibited by DMAP, promotes the response of BAEC to TNF. Thus, we have identified a reagent, DMAP, that may be useful for characterizing the TNF signal transduction pathway.	INDIANA UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, INDIANAPOLIS, IN 46202 USA; ROCKEFELLER UNIV, MEM SLOAN KETTERING CANC CTR, NEW YORK, NY 10021 USA; ROCKEFELLER UNIV, LUDWIG INST CANC RES, NEW YORK, NY 10021 USA; ROCKEFELLER UNIV, MOL & CELLULAR NEUROSCI LAB, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, DEPT MED, DIV HEMATOL ONCOL, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, SPECIALIZED CTR RES THROMBOSIS, NEW YORK, NY 10021 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Memorial Sloan Kettering Cancer Center; Rockefeller University; Ludwig Institute for Cancer Research; Rockefeller University; Rockefeller University; Cornell University; Cornell University			Wu, Li-Wha/AAH-7768-2021	Wu, Li-Wha/0000-0001-7010-6220; Nairn, Angus/0000-0002-7075-0195	NATIONAL CANCER INSTITUTE [R01CA067891, R55CA067891] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL018828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050402] Funding Source: NIH RePORTER; NCI NIH HHS [CA-67891] Funding Source: Medline; NHLBI NIH HHS [SCOR HL18828] Funding Source: Medline; NIGMS NIH HHS [GM-50402] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAENZIGER NL, 1980, BIOCHEM BIOPH RES CO, V92, P1435, DOI 10.1016/0006-291X(80)90447-7; BEYAERT R, 1993, CANCER RES, V53, P2623; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DARNAY BG, 1994, J BIOL CHEM, V269, P20299; DARNAY BG, 1994, J BIOL CHEM, V269, P19687; DUSTING GJ, 1977, PROSTAGLANDINS, V13, P3, DOI 10.1016/0090-6980(77)90037-5; ENDO H, 1988, BIOCHEM BIOPH RES CO, V156, P1007, DOI 10.1016/S0006-291X(88)80944-6; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; GRAU GE, 1993, RES IMMUNOL, V144, P355, DOI 10.1016/S0923-2494(93)80080-I; GUY GR, 1991, J BIOL CHEM, V266, P14343; GUY GR, 1992, J BIOL CHEM, V267, P1846; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HELLER RA, 1992, CELL, V70, P47; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jaffe EA, 1984, BIOL ENDOTHELIAL CEL, P1; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KAWAKAMI M, 1986, BIOCHEM BIOPH RES CO, V141, P482, DOI 10.1016/S0006-291X(86)80198-X; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LANGELER EG, 1991, ARTERIOSCLER THROMB, V11, P872, DOI 10.1161/01.ATV.11.4.872; LESSLAUER W, 1992, IMMUNOL RES, V11, P81; LIU J, 1994, J BIOL CHEM, V269, P3047; MACKIE KP, 1989, J BIOL CHEM, V264, P1748; MANCHESTER KM, 1993, BIOCHEM J, V290, P185, DOI 10.1042/bj2900185; MARINO MW, 1989, P NATL ACAD SCI USA, V86, P8417, DOI 10.1073/pnas.86.21.8417; MARINO MW, 1991, J BIOL CHEM, V266, P2685; MONCADA S, 1977, LANCET, V1, P18; NAIRN AC, 1987, J BIOL CHEM, V262, P17299; NEANT I, 1988, EXP CELL RES, V176, P68, DOI 10.1016/0014-4827(88)90121-8; NGAIZA JR, 1992, J CELL PHYSIOL, V151, P190, DOI 10.1002/jcp.1041510124; NOLOP KB, 1990, AM J PHYSIOL, V259, pL123, DOI 10.1152/ajplung.1990.259.2.L123; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; POHLMAN TH, 1989, CELL IMMUNOL, V119, P41, DOI 10.1016/0008-8749(89)90222-0; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; RIME H, 1989, DEV BIOL, V133, P169, DOI 10.1016/0012-1606(89)90308-4; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SATO N, 1986, JNCI-J NATL CANCER I, V76, P1113; SCHLEGEL R, 1990, CELL GROWTH DIFFER, V1, P171; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; SCHUTZE S, 1992, SEMIN ONCOL, V19, P16; SHIMADA Y, 1990, J CELL PHYSIOL, V142, P31, DOI 10.1002/jcp.1041420105; SIDHU RS, 1993, PHARMACOL THERAPEUT, V57, P79, DOI 10.1016/0163-7258(93)90037-E; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; SONG HY, 1995, BIOCHEM J, V309, P825, DOI 10.1042/bj3090825; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; SUN XJ, 1992, J BIOL CHEM, V267, P22662; SZOLLOSI MS, 1991, CHROMOSOMA, V100, P339, DOI 10.1007/BF00360533; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TOTPAL K, 1992, CANCER RES, V52, P2557; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043; VIETOR I, 1993, J BIOL CHEM, V268, P18994; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WONG GHW, 1992, J IMMUNOL, V149, P3350; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	65	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28624	28629		10.1074/jbc.271.45.28624	http://dx.doi.org/10.1074/jbc.271.45.28624			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910494	hybrid			2022-12-27	WOS:A1996VU03300094
J	Blystone, SD; Lindberg, FP; Williams, MP; McHugh, KP; Brown, EJ				Blystone, SD; Lindberg, FP; Williams, MP; McHugh, KP; Brown, EJ			Inducible tyrosine phosphorylation of the beta(3) integrin requires the alpha(v) integrin cytoplasmic tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NPXY MOTIF; ENDOTHELIAL-CELLS; RESPIRATORY BURST; PROTEIN CD47; IN-VIVO; DOMAIN; VITRONECTIN; ALPHA-V-BETA-3; FIBRONECTIN; ADHESION	We have found that the integrin pa chain can be phosphorylated on tyrosine residues in K562 cells transfected with alpha(v) beta(3). Tyrosine phosphorylation of the beta(3) cytoplasmic tail is induced by adhesion to alpha(v) beta(3)-specific ligand or antibody or by incubation in manganese-containing buffer, Under the same conditions, beta(5) does not become tyrosine-phosphorylated in K562 transfected with alpha(v) beta(5). Phosphorylation of the beta(3) subunit requires the simultaneous presence of the alpha(v) subunit cytoplasmic tail, because neither the alpha(IIb) subunit nor a truncated alpha(v) subunit is sufficient to permit phosphorylation of beta(3), when coexpressed as a heterodimer with beta(3). Finally, tyrosine phosphorylation of the beta(3) cytoplasmic tail occurs on both human and murine beta(3) and is inducible in the ovarian carcinoma OV10 as well, independent of expression of integrin-associated protein (CD47), Tyrosine phosphorylation of the beta(3) integrin subunit facilitates association of Grb-2, an adaptor protein leading to activation of the Ras signaling pathway, and may contribute to the unique functional and signaling capabilities of alpha(v) beta(3).	WASHINGTON UNIV,SCH MED,DEPT MED,DIV INFECT DIS,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NIAID NIH HHS [AI24674, AI08990-02] Funding Source: Medline; NIAMS NIH HHS [F32 AR008335] Funding Source: Medline; NIGMS NIH HHS [GM38330] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024674, R37AI024674] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR008335] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038330] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANESKIEVICH BJ, 1991, ONCOGENE, V6, P1381; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BLYSTONE SD, 1995, J CELL BIOL, V130, P745, DOI 10.1083/jcb.130.3.745; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; BROWN EJ, 1991, RECEPTORS EXTRACELLU, P39; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHEN YP, 1995, BLOOD, V86, P2606, DOI 10.1182/blood.V86.7.2606.bloodjournal8672606; COOPER D, 1995, P NATL ACAD SCI USA, V92, P3978, DOI 10.1073/pnas.92.9.3978; DELANNET M, 1994, DEVELOPMENT, V120, P2687; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; JOHANSSON MW, 1994, J CELL BIOL, V126, P1299, DOI 10.1083/jcb.126.5.1299; LAFRENIE RM, 1992, CANCER RES, V52, P2202; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; NIP J, 1992, J CLIN INVEST, V90, P1406, DOI 10.1172/JCI116007; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; PIALI L, 1995, J CELL BIOL, V130, P451, DOI 10.1083/jcb.130.2.451; PRIGENT SA, 1995, J BIOL CHEM, V270, P22097, DOI 10.1074/jbc.270.38.22097; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; REINHOLD MI, 1995, J CELL SCI, V108, P3419; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; SCHWARTZ MA, 1993, J BIOL CHEM, V268, P19931; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; WHITE MF, 1994, J BIOL CHEM, V269, P1; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; YLANNE J, 1995, J BIOL CHEM, V270, P9550; ZHOU MJ, 1995, J BIOL CHEM, V270, P13553, DOI 10.1074/jbc.270.22.13553; ZHOU MJ, 1993, J EXP MED, V178, P1165, DOI 10.1084/jem.178.4.1165	37	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31458	31462		10.1074/jbc.271.49.31458	http://dx.doi.org/10.1074/jbc.271.49.31458			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940158				2022-12-27	WOS:A1996VW68600069
J	Li, HH; Quinn, J; Culler, D; GirardBascou, J; Merchant, S				Li, HH; Quinn, J; Culler, D; GirardBascou, J; Merchant, S			Molecular genetic analysis of plastocyanin biosynthesis in Chlamydomonas reinhardtii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC TOBACCO PLANTS; MESSENGER-RNA STABILITY; PROTEIN-TRANSPORT; TRANSCRIPTIONAL REGULATION; THYLAKOID MEMBRANE; NONSENSE MUTATIONS; PEA PLASTOCYANIN; OXYGEN EVOLUTION; EXPRESSION; COPPER	Five plastocyanin-deficient mutants were identified from a population of W-mutagenized Chlamydomonas reinhardtii cells, Genetic complementation experiments indicated that four mutants represented alleles at the PCY1 locus (pcy1-2, pcy1-3, pcy1-4, and pcy1-5), Sequence analysis confirmed that two strains, pcy1-2 and pcy1-3, carry a frameshift (-1) and a nonsense mutation, respectively, while strains pcy1-4 and pcy1-5 synthesize an extended protein as a result of read-through mutations at the stop codon, The C-terminal extension does not affect synthesis or processing of the pre-proteins, but the polypeptides are rapidly degraded after the second (lumenal) processing event, The frameshift mutation in pcy1-2 results in loss of Pcy1 mRNA, as noted previously for strain ac208 (pcy1-1), but the abundance of Pcy1 mRNA in strain pcy1-3, which carries a nonsense mutation at codon 26, is unaffected relative to wild-type cells, The decreased abundance of frameshifted Pcy1 mRNA is attributed to increased degradation rather than decreased synthesis, since the mRNAs can be stabilized by treatment of cells with cycloheximide or anisomycin, The fifth strain has a wild-type plastocyanin-encoding gene, but the strain accumulates apoplastocyanin at the expense of holoplastocyanin. We suggest that the mutation identifies a new locus (PCY2) whose function is required for normal holoplastocyanin accumulation, Like ac208 (pcy1-1), several of the new mutants were suppressed spontaneously owing to accumulation of cytochrome c(6) (a functional substitute for plastocyanin), The suppressor mutation(s) displayed Mendelian inheritance and segregated independently from the PCY1 locus, which confirms that regulation of Cyc6 expression is not tightly linked to plastocyanin function.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90095; INST BIOL PHYSICOCHIM,SERV PHOTOSYNTH,F-75005 PARIS,FRANCE	University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K04GM000594] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 00594] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER EJ, 1993, NUCLEIC ACIDS RES, V21, P2237, DOI 10.1093/nar/21.9.2237; BARKAN A, 1995, PHYSIOL PLANTARUM, V93, P163, DOI 10.1034/j.1399-3054.1995.930123.x; BARKAN A, 1993, PLANT CELL, V5, P389, DOI 10.1105/tpc.5.4.389; BARTSEVICH VV, 1995, EMBO J, V14, P1845, DOI 10.1002/j.1460-2075.1995.tb07176.x; BEELMAN CA, 1994, J BIOL CHEM, V269, P9687; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; Bennoun P, 1982, METHODS CHLOROPLAST, P25; BOVY A, 1992, MOL MICROBIOL, V6, P1507, DOI 10.1111/j.1365-2958.1992.tb00871.x; CHEN LY, 1992, J BIOL CHEM, V267, P20100; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; Cline K, 1996, ANNU REV CELL DEV BI, V12, P1, DOI 10.1146/annurev.cellbio.12.1.1; ERICKSON JM, 1996, OXYGENIC PHOTOSYNTHE, P589; FISSCHER U, 1994, PLANT MOL BIOL, V26, P873, DOI 10.1007/BF00028855; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; GOLDSCHMIDTCLERMONT M, 1986, J MOL BIOL, V191, P421, DOI 10.1016/0022-2836(86)90137-3; GOLDSCHMIDTCLERMONT M, 1990, MOL GEN GENET, V223, P417, DOI 10.1007/BF00264448; GORMAN DS, 1965, P NATL ACAD SCI USA, V54, P1665, DOI 10.1073/pnas.54.6.1665; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HILL KL, 1991, J BIOL CHEM, V266, P15060; HOWE G, 1995, MOL GEN GENET, V246, P156, DOI 10.1007/BF00294678; HOWE G, 1993, P NATL ACAD SCI USA, V90, P1862, DOI 10.1073/pnas.90.5.1862; HOWE G, 1992, EMBO J, V11, P2789, DOI 10.1002/j.1460-2075.1992.tb05346.x; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KINDLE KL, 1989, J CELL BIOL, V109, P2589, DOI 10.1083/jcb.109.6.2589; KIRWIN PM, 1988, J BIOL CHEM, V263, P18128; KOIDE S, 1993, BIOCHEMISTRY-US, V32, P12299, DOI 10.1021/bi00097a005; LAST DI, 1990, PLANT MOL BIOL, V14, P229, DOI 10.1007/BF00018563; LEE MH, 1992, J BACTERIOL, V174, P4324, DOI 10.1128/JB.174.13.4324-4330.1992; LI HH, 1995, J BIOL CHEM, V270, P23504, DOI 10.1074/jbc.270.40.23504; LI HH, 1992, J BIOL CHEM, V267, P9368; LI HM, 1990, P NATL ACAD SCI USA, V87, P6748, DOI 10.1073/pnas.87.17.6748; Li JM, 1996, PLANT MOL BIOL, V30, P15, DOI 10.1007/BF00017800; LOSSON R, 1979, P NATL ACAD SCI USA, V76, P5134, DOI 10.1073/pnas.76.10.5134; MAQUAT LE, 1981, CELL, V27, P543, DOI 10.1016/0092-8674(81)90396-2; MAYFIELD SP, 1987, EMBO J, V6, P313, DOI 10.1002/j.1460-2075.1987.tb04756.x; MERCHANT S, 1987, EMBO J, V6, P2531, DOI 10.1002/j.1460-2075.1987.tb02540.x; MERCHANT S, 1986, MOL CELL BIOL, V6, P462, DOI 10.1128/MCB.6.2.462; MERCHANT S, 1991, EMBO J, V10, P1383, DOI 10.1002/j.1460-2075.1991.tb07658.x; MERCHANT S, 1990, J BIOL CHEM, V265, P12372; MERCHANT S, 1986, J BIOL CHEM, V261, P5850; MERCHANT S, 1997, IN PRESS METAL IONS; NIELSEN PS, 1993, EUR J BIOCHEM, V217, P97, DOI 10.1111/j.1432-1033.1993.tb18223.x; NILSSON G, 1987, P NATL ACAD SCI USA, V84, P4890, DOI 10.1073/pnas.84.14.4890; PWEE KH, 1993, PLANT J, V3, P437, DOI 10.1046/j.1365-313X.1993.t01-22-00999.x; QUINN J, 1993, J BIOL CHEM, V268, P7832; REDINBO MR, 1994, J BIOENERG BIOMEMBR, V26, P49, DOI 10.1007/BF00763219; ROBINSON C, 1994, PLANT MOL BIOL, V26, P15, DOI 10.1007/BF00039516; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHMIDT GW, 1977, P NATL ACAD SCI USA, V74, P610, DOI 10.1073/pnas.74.2.610; SIMPSON SB, 1994, MOL CELL BIOL, V14, P1835, DOI 10.1128/MCB.14.3.1835; SMEEKENS S, 1990, TRENDS BIOCHEM SCI, V15, P73, DOI 10.1016/0968-0004(90)90180-J; TAUTZ D, 1983, ANAL BIOCHEM, V132, P14, DOI 10.1016/0003-2697(83)90419-0; THOMPSON WF, 1991, ANNU REV PLANT PHYS, V42, P423, DOI 10.1146/annurev.pp.42.060191.002231; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; VOELKER R, 1995, EMBO J, V14, P3905, DOI 10.1002/j.1460-2075.1995.tb00062.x; VORST O, 1993, PLANT J, V4, P933, DOI 10.1046/j.1365-313X.1993.04060933.x; WYNN RM, 1988, BIOCHEMISTRY-US, V27, P5863, DOI 10.1021/bi00416a007; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633	60	27	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31283	31289		10.1074/jbc.271.49.31283	http://dx.doi.org/10.1074/jbc.271.49.31283			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940133	hybrid			2022-12-27	WOS:A1996VW68600044
J	Chin, D; Means, AR				Chin, D; Means, AR			Methionine to glutamine substitutions in the C-terminal domain of calmodulin impair the activation of three protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; SEQUENCE-INDEPENDENT RECOGNITION; TARGET ENZYMES; CENTRAL HELIX; ALPHA-HELICES; CALCIUM; BINDING; FRAGMENTS; PEPTIDE; PARAMETERS	The 9 methionine residues of vertebrate calmodulin (CaM) were individually changed to glutamine residues in order to investigate their roles in enzyme binding and activation. The mutant proteins showed three classes of effect on the activation of smooth muscle myosin light chain kinase, CaM-dependent protein kinase II alpha, and CaM-dependent protein kinase IV. First, some mutations had no appreciable effect on the ability of CaM to activate the three protein kinases. Included in this category were glutamine substitutions at residues 36 and 51 in the N-terminal domain, at residue 76 in the domain linker sequence, and at residues 144 and 145 in the C-terminal domain. Second, glutamine substitutions in the N-terminal domain of CaM, particularly those at positions 71 and 72, lowered the maximal activity of smooth muscle myosin light chain kinase while having no effect on the other two enzymes. Finally the affinity of CaM for all three enzymes was lowered by glutamine mutations at the neighboring methionines 109 and 124, located on a solvent-accessible surface of the C-terminal domain of Ca2+/CaM. This last result provides the first demonstration of the involvement of the same hydrophobic groups in the high affinity binding of CaM to three different enzymes.	DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710	Duke University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033976] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33976] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BLUMENTHAL DK, 1982, BIOCHEMISTRY-US, V21, P2386, DOI 10.1021/bi00539a017; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAKRABARTTY A, 1995, ADV PROTEIN CHEM, V46, P141, DOI 10.1016/S0065-3233(08)60334-4; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; COX JA, 1988, BIOCHEM J, V249, P621, DOI 10.1042/bj2490621; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; GELLMAN SH, 1991, BIOCHEMISTRY-US, V30, P6633, DOI 10.1021/bi00241a001; GEORGE SE, 1990, J BIOL CHEM, V265, P9228; GEORGE SE, 1993, J BIOL CHEM, V268, P25213; GEORGE SE, 1996, BIOCHEMISTRY-US, V35, P3807; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; GUERINI D, 1987, EUR J BIOCHEM, V170, P35, DOI 10.1111/j.1432-1033.1987.tb13664.x; GUERINI D, 1984, J BIOL CHEM, V259, P5172; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Johnson JD, 1996, J BIOL CHEM, V271, P761, DOI 10.1074/jbc.271.2.761; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KINCAID RL, 1986, P NATL ACAD SCI USA, V83, P1193, DOI 10.1073/pnas.83.5.1193; KLEVIT RE, 1983, METHOD ENZYMOL, V102, P82; LAPORTE DC, 1980, BIOCHEMISTRY-US, V19, P3814, DOI 10.1021/bi00557a025; MAMARBACHI A, 1987, CELL CALCIUM, V8, P473, DOI 10.1016/0143-4160(87)90030-3; MATSUSHIMA S, 1994, BIOCHEM BIOPH RES CO, V202, P1329, DOI 10.1006/bbrc.1994.2076; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1995, NAT STRUCT BIOL, V2, P943, DOI 10.1038/nsb1195-943; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MILOS M, 1987, J BIOL CHEM, V262, P2746; MINOWA O, 1988, J BIOCHEM-TOKYO, V103, P531, DOI 10.1093/oxfordjournals.jbchem.a122303; Nakashima K, 1996, BIOCHEMISTRY-US, V35, P5602, DOI 10.1021/bi952586l; NEWTON DL, 1987, METHOD ENZYMOL, V139, P405; NEWTON DL, 1984, J BIOL CHEM, V259, P4419; OHYA Y, 1994, GENETICS, V138, P1041; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; TANAKA M, 1995, EMBO J, V14, P2839, DOI 10.1002/j.1460-2075.1995.tb07283.x; URBAUER JL, 1995, BIOCHEMISTRY-US, V34, P8099, DOI 10.1021/bi00025a016; VANBERKUM MFA, 1990, J BIOL CHEM, V265, P3750; VANBERKUM MFA, 1991, J BIOL CHEM, V266, P21488; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; WALSH M, 1978, BIOCHEMISTRY-US, V17, P3924, DOI 10.1021/bi00612a006; WEBER PC, 1989, PROTEINS, V6, P70, DOI 10.1002/prot.340060107; WOJCIK J, 1990, BIOPOLYMERS, V30, P121, DOI 10.1002/bip.360300113; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758; ZHANG MJ, 1994, J BIOL CHEM, V269, P15546	49	66	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30465	30471		10.1074/jbc.271.48.30465	http://dx.doi.org/10.1074/jbc.271.48.30465			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940012	hybrid			2022-12-27	WOS:A1996VV15800029
J	Koshkin, V; Lotan, O; Pick, E				Koshkin, V; Lotan, O; Pick, E			The cytosolic component p47(phox) is not a sine qua non participant in the activation of NADPH oxidase but is required for optimal superoxide production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; RESPIRATORY BURST OXIDASE; ADENINE-DINUCLEOTIDE PHOSPHATE; CHRONIC GRANULOMATOUS-DISEASE; SODIUM DODECYL-SULFATE; SRC HOMOLOGY-3 DOMAINS; HUMAN-NEUTROPHILS; PLASMA-MEMBRANE; FLAVOCYTOCHROME B(558); ELECTRON FLOW	The superoxide (O-2(radical anion))-generating NADPH oxidase of phagocytes is a multicomponent complex consisting of a membrane-associated flavocytochrome (cytochrome b(559)), bearing the NADPH binding site and two redox centers (FAD and heme) and three cytosolic activating components: p47(phox), p67(phox), and the small GTPase Rac (1 or 2). The canonical view is that the induction of OX generation involves the stimulus-dependent assembly of all three cytosolic components with cytochrome b(559), a process mimicked in vitro by a cell-free system activated by anionic amphiphiles. We studied the requirement for individual cytosolic components in the activation of NADPH oxidase in a cell-free system consisting of purified and relipidated cytochrome b(559), recombinant p47(phox), p67(phox), and Rac1, and the amphiphile, lithium dodecyl sulfate. We found that pronounced activation of NADPH oxidase can be achieved by exposing cytochrome b(559) to p67(phox) and Rac1, in the total absence of p47(phox) (turnover = 60 mol O-2((radical anion))/mol cytochrome b(559)). However, maximal activation (turnover = 153 mol O-2((radical anion))/s/mol cytochrome b(559)) could only be obtained in the presence of p47(phox). O-2((radical anion)) production, in the absence of p47(phox), was dependent on: high molar ratios of p67(phox) and Rac1 to cytochrome b(559), Rac1 being in the GTP-bound form, cytochrome b(559) being saturated with FAD, and an optimal concentration of amphiphile. Single cytosolic components or combinations of two cytosolic components, other than p67(phox) and Rac1, were incapable of activation. We conclude that p67(phox) and Rac1 are the only cytosolic components directly involved in the induction of electron transport in cytochrome b(559). p47(phox) appears to facilitate or stabilize the interaction of p67(phox) and, possibly, Rac1 with cytochrome b(559), and is required for optimal generation of O-2((radical anion)) under physiological conditions.			Koshkin, V (corresponding author), TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN MICROBIOL,IL-69978 TEL AVIV,ISRAEL.		Pick, Edgar/B-1795-2008	Pick, Edgar/0000-0003-4625-3233				ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BELLAVITE P, 1988, J BIOL CHEM, V263, P8210; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CROSS AR, 1995, J BIOL CHEM, V270, P6543, DOI 10.1074/jbc.270.12.6543; CROSS AR, 1994, J BIOL CHEM, V269, P21448; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DELEO FR, 1995, J BIOL CHEM, V270, P26246, DOI 10.1074/jbc.270.44.26246; DeLeo FR, 1996, J BIOL CHEM, V271, P17013, DOI 10.1074/jbc.271.29.17013; DELEO FR, 1995, P NATL ACAD SCI USA, V92, P7110, DOI 10.1073/pnas.92.15.7110; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; deMendez I, 1996, EMBO J, V15, P1211, DOI 10.1002/j.1460-2075.1996.tb00462.x; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DUSI S, 1995, BIOCHEM J, V308, P991, DOI 10.1042/bj3080991; FINAN P, 1994, J BIOL CHEM, V269, P13752; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; IYER SS, 1994, J BIOL CHEM, V269, P22405; JOUAN A, 1993, ANAL BIOCHEM, V214, P252, DOI 10.1006/abio.1993.1485; KNOLLER S, 1991, J BIOL CHEM, V266, P2795; KOSHKIN V, 1993, FEBS LETT, V327, P57, DOI 10.1016/0014-5793(93)81039-3; KOSHKIN V, 1994, FEBS LETT, V338, P285, DOI 10.1016/0014-5793(94)80285-8; KOSHKIN V, 1995, BBA-BIOENERGETICS, V1229, P329, DOI 10.1016/0005-2728(95)00009-8; KWONG CH, 1993, BIOCHEMISTRY-US, V32, P5711, DOI 10.1021/bi00072a029; LECABEC V, 1994, BIOCHEM BIOPH RES CO, V198, P1216, DOI 10.1006/bbrc.1994.1172; LETO TL, 1991, J BIOL CHEM, V266, P19812; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1995, J BIOL CHEM, V270, P11216, DOI 10.1074/jbc.270.19.11216; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; MCPHAIL LC, 1994, J EXP MED, V180, P2011, DOI 10.1084/jem.180.6.2011; NAUSEEF WM, 1993, J BIOL CHEM, V268, P23646; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; OKAMURA N, 1988, J BIOL CHEM, V263, P6777; PARK JW, 1992, J BIOL CHEM, V267, P17327; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; QUINN MT, 1993, J BIOL CHEM, V268, P20983; ROBINSON JM, 1995, HISTOCHEM CELL BIOL, V103, P163, DOI 10.1007/BF01454021; ROTROSEN D, 1993, J BIOL CHEM, V268, P14256; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROTROSEN D, 1990, J BIOL CHEM, V265, P8745; ROTROSEN D, 1992, INFLAMMATION BASIC P, P589; SHPUNGIN S, 1989, J BIOL CHEM, V264, P9195; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7; UHLINGER DJ, 1994, J BIOL CHEM, V269, P22095; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138	51	133	134	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30326	30329		10.1074/jbc.271.48.30326	http://dx.doi.org/10.1074/jbc.271.48.30326			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939991	hybrid			2022-12-27	WOS:A1996VV15800008
J	Mellet, P; Michels, B; Bieth, JG				Mellet, P; Michels, B; Bieth, JG			Heat-induced conversion of ovalbumin into a proteinase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1-PROTEINASE INHIBITOR; MOLECULAR CHARACTERIZATION; CRYSTAL-STRUCTURE; ANTITHROMBIN-III; S-OVALBUMIN; SERPINS; ELASTASE; KINETICS; MODEL; ALPHA-1-ANTICHYMOTRYPSIN	Ovalbumin is a member of the serine proteinase inhibitor (serpin) family but is unable to inhibit proteinases. Here we show that heating transforms it into inhibitory ovalbumin (I-ovalbumin), a potent reversible competitive inhibitor of human neutrophil elastase (K-i = 5 nM) and cathepsin G (K-i = 60 nM) and bovine chymotrypsin (K-i = 30 nM). I-ovalbumin also inhibits bovine trypsin, porcine elastase and alpha-lytic proteinase with K-i values in the micromolar range, Thus, I-ovalbumin differs from active serpins by its inability to form irreversible complexes with proteinases. I-ovalbumin is unusually thermostable: it does not undergo any structural transition between 45 degrees C and 120 degrees C as tested by differential scanning calorimetry, and it retains full inhibitory capacity after heating at 120 degrees C. It has 8% less alpha-helices and 9% more beta-sheet structures than native ovalbumin, as shown by circular dichroism, Our results show that the primary sequence of ovalbumin contains the information required for enabling the first step of the serpin-proteinase interaction to occur, i.e. the formation of the Michaelis-like reversible complex, but does not contain the information needed for stabilizing this initial complex.	UNIV STRASBOURG 1,ENZYMOL LAB,INSERM U392,F-67400 ILLKIRCH GRAFFENS,FRANCE; UNIV STRASBOURG 1,LAB ULTRASONS & DYNAM FLUIDES COMPLEXES,CNRS URA 851,F-67070 STRASBOURG,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg				Mellet, Philippe/0000-0001-5499-9735				BEATTY K, 1980, J BIOL CHEM, V255, P3931; BELITZ HD, 1987, FOOD CHEM, P403; BIETH JG, 1995, METHOD ENZYMOL, V248, P59; BRUCH M, 1989, BIOCHEM J, V259, P929, DOI 10.1042/bj2590929; COUGHLIN P, 1993, P NATL ACAD SCI USA, V90, P9417, DOI 10.1073/pnas.90.20.9417; DONOVAN JW, 1976, J SCI FOOD AGR, V27, P197, DOI 10.1002/jsfa.2740270220; GOUX WJ, 1986, BIOCHEMISTRY-US, V25, P84, DOI 10.1021/bi00349a013; HUNKAPILLER MW, 1973, BIOCHEMISTRY-US, V12, P4733; HUNT LT, 1980, BIOCHEM BIOPH RES CO, V95, P864, DOI 10.1016/0006-291X(80)90867-0; HUNTINGTON JA, 1995, PROTEIN SCI, V4, P613; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KINT S, 1979, BIOPOLYMERS, V18, P1073, DOI 10.1002/bip.1979.360180505; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; MARTODAM RR, 1979, PREP BIOCHEM, V9, P15, DOI 10.1080/00327487908061669; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; NAKAMURA R, 1981, AGR BIOL CHEM TOKYO, V45, P1653, DOI 10.1080/00021369.1981.10864762; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; PRIVALOV PL, 1980, PURE APPL CHEM, V52, P479, DOI 10.1351/pac198052020479; Rasmussen SK, 1996, PLANT MOL BIOL, V30, P673, DOI 10.1007/BF00049343; REMOLDODONNELL E, 1992, P NATL ACAD SCI USA, V89, P5635, DOI 10.1073/pnas.89.12.5635; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SHIEH BH, 1989, J BIOL CHEM, V264, P13420; Shotton D. M., 1970, METHOD ENZYMOL, V19, P113, DOI 10.1016/0076-6879(70)19009-4; SMITH MB, 1965, AUST J BIOL SCI, V18, P365, DOI 10.1071/BI9650365; Song HK, 1995, FEBS LETT, V377, P150; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303; WRIGHT HT, 1990, J MOL BIOL, V213, P513; WRIGHT HT, 1984, J BIOL CHEM, V259, P4335	31	20	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30311	30314		10.1074/jbc.271.48.30311	http://dx.doi.org/10.1074/jbc.271.48.30311			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939987	hybrid			2022-12-27	WOS:A1996VV15800004
J	Neddermann, P; Graziani, R; Ciliberto, G; Paonessa, G				Neddermann, P; Graziani, R; Ciliberto, G; Paonessa, G			Functional expression of soluble human interleukin-11 (IL-11) receptor alpha and stoichiometry of in vitro IL-11 receptor complexes with gp130	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CILIARY NEUROTROPHIC FACTOR; SIGNAL TRANSDUCER GP130; PHASE RESPONSE FACTOR; MOLECULAR-CLONING; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC CYTOKINE; HEXAMERIC COMPLEX; FACTOR-BINDING; GROWTH-FACTORS; CNTF RECEPTOR	The interleukin-6 (IL-6) family of cytokines activates signaling through the formation of either gp130 homodimers, as for IL-6, or gp130-leukemia inhibitory factor receptor (LLFR) heterodimers as for ciliary neurotrophic factor (CNTF), leukemia inhibitory factor, oncostatin(M), and cardiotrophin-1. Recent in vitro studies with IL-6 and CNTF have demonstrated that higher order hexameric receptor complexes are assembled in which signaling chain dimerization is accompanied by the dimerization of both the cytokine molecule and its specific receptor alpha subunits (IL-6R alpha or CNTFR alpha, respectively), IL-11 is a member of the IL-6 family and known to require gp130 but not LIFR for signaling, In this study we investigate the functional and biochemical composition of the IL-11 receptor complex. The human IL-11 receptor alpha-chain was cloned from a human bone marrow cDNA library. IL-11R alpha was shown to confer IL-11 responsiveness to human hepatoma cells either by cDNA transfection or by adding a soluble form of the receptor (sHL11R alpha) expressed in the baculovirus system to the culture medium. Iii vitro immunoprecipitation experiments showed that sIL11R alpha specifically binds IL-11 and that binding is enhanced by gp130, Similarly to IL-6 and CNTF, gp130 is able to induce dimerization of the IL-11 . IL-11R alpha subcomplex, the result of which is the formation of a pentameric receptor complex, However, in contrast to the other two cytokines, IL-ll was unable to induce either gp130 homodimerization or gp130/LIFR heterodimerization. These results strongly suggest that an as yet unidentified receptor beta-chain is involved in IL-11 signaling.			Neddermann, P (corresponding author), IST RIC BIOL MOL P ANGELETTI,DEPT GENET,VIA PONTINA KM 30600,I-00040 POMEZIA,ROMA,ITALY.		Ciliberto, Gennaro/J-4131-2017	Ciliberto, Gennaro/0000-0003-2851-8605				AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; CHEREL M, 1995, BLOOD, V86, P2534; CZUPRYN MJ, 1995, J BIOL CHEM, V270, P978, DOI 10.1074/jbc.270.2.978; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DESERIO A, 1995, J MOL BIOL, V254, P795, DOI 10.1006/jmbi.1995.0655; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; Heaney ML, 1996, BLOOD, V87, P847, DOI 10.1182/blood.V87.3.847.bloodjournal873847; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; LIU JW, 1992, J BIOL CHEM, V267, P16763; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MULLER G, 1988, EMBO J, V7, P2723, DOI 10.1002/j.1460-2075.1988.tb03126.x; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Nandurkar HH, 1996, ONCOGENE, V12, P585; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NEUHAUS H, 1994, DEV BIOL, V166, P531, DOI 10.1006/dbio.1994.1335; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WARD LD, 1994, J BIOL CHEM, V269, P23286; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YANG YC, 1993, STEM CELLS, V11, P474, DOI 10.1002/stem.5530110617; YIN TG, 1993, J IMMUNOL, V151, P2555; YIN TG, 1993, CELL GROWTH DIFFER, V4, P603; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	48	41	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30986	30991		10.1074/jbc.271.48.30986	http://dx.doi.org/10.1074/jbc.271.48.30986			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940087	hybrid			2022-12-27	WOS:A1996VV15800104
J	Pathan, NI; Ashendel, CL; Geahlen, RL; Harrison, ML				Pathan, NI; Ashendel, CL; Geahlen, RL; Harrison, ML			Activation of T cell Raf-1 at mitosis requires the protein-tyrosine kinase Lck	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-DEPENDENT PATHWAY; ANTIGEN RECEPTOR; SIGNAL TRANSDUCTION; PHOSPHORYLATION; ASSOCIATION; STIMULATION; COMPLEX; LSTRA	The serine/threonine protein kinase Raf-1 is activated in response to a variety of growth factors in fibroblasts and hematopoietic cells. In T cells, Raf-1 is activated in response to stimulation through the T cell antigen receptor, the interleukin-2 receptor, and by stimulation of protein kinase C. We demonstrate here that in T cells, Raf-1 is also activated during mitosis. The mitotic activation of Raf-1 was not observed in the Lck-deficient cell line, J.CaM.1. During mitosis, Raf-1 was found to interact selectively with a mitotic form of Lck that migrated with a reduced electrophoretic mobility on SDS-polyacrylamide gels. We conclude that Raf-1 is activated during mitosis in T cells and that this mitotic activation of Raf-1 is dependent on the presence of Lck.	PURDUE UNIV,DEPT MED CHEM & MOL PHARMACOL,W LAFAYETTE,IN 47907; PURDUE UNIV,DEPT BIOL,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus				Geahlen, Robert/0000-0001-8400-2924	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048099] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48099] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAN AC, 1995, CURR OPIN IMMUNOL, V8, P394; GUPTA S, 1994, J BIOL CHEM, V269, P17349; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; IZQUIERDO M, 1994, J EXP MED, V180, P401, DOI 10.1084/jem.180.1.401; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; LAIRD AD, 1995, J BIOL CHEM, V270, P26742, DOI 10.1074/jbc.270.45.26742; LOH C, 1994, J BIOL CHEM, V269, P8817; Lovric J, 1996, ONCOGENE, V12, P1109; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; OWAKI H, 1993, EMBO J, V12, P4367, DOI 10.1002/j.1460-2075.1993.tb06121.x; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; PASTOR MI, 1995, CANCER SURV, V22, P75; Pathan NI, 1996, J BIOL CHEM, V271, P27517, DOI 10.1074/jbc.271.44.27517; RAPP UR, 1991, ONCOGENE, V6, P495; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SIEGEL JN, 1993, J IMMUNOL, V151, P4116; SOZERI O, 1992, ONCOGENE, V7, P2259; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; THOMPSON PA, 1991, CELL GROWTH DIFFER, V2, P609; TURNER BC, 1993, P NATL ACAD SCI USA, V90, P5544, DOI 10.1073/pnas.90.12.5544; VORONOVA AF, 1984, MOL CELL BIOL, V4, P2705, DOI 10.1128/MCB.4.12.2705; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Whitehurst CE, 1996, J IMMUNOL, V156, P1020; WLODZIMIERZ M, 1992, J BIOL CHEM, V267, P15281; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	27	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30315	30317		10.1074/jbc.271.48.30315	http://dx.doi.org/10.1074/jbc.271.48.30315			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939988	hybrid			2022-12-27	WOS:A1996VV15800005
J	Roberson, ED; Sweatt, JD				Roberson, ED; Sweatt, JD			Transient activation of cyclic AMP-dependent protein kinase during hippocampal long-term potentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; PYRAMIDAL CELLS; CA1 REGION; AREA CA1; CAMP; INHIBITOR; NEURONS; APLYSIA; LTP; PHOSPHORYLATION	Long-term potentiation (LTP) in the hippocampus is a possible mechanism for mammalian learning and memory in which protein kinases play critical roles. We have investigated the involvement of cyclic AMP dependent protein kinase (PKA) in LTP by directly studying its activation. We developed an in vitro assay which is useful for selective and accurate measurement of stimulus-induced changes in PKA activity in hippocampal slices. PKA was transiently activated 2 and 10 min after delivery of LTP-inducing stimuli in area CA1 of the hip pocampus. This activation did not persist during early or late phases of LTP, suggesting that the role of PKA is in the induction of LTP, not in its expression. LTP was not associated with any change in the total activity of PKA, consistent with activation by cyclic AMP, as opposed to an increase in the amount or efficacy of the enzyme. The LTP-associated activation of PKA required stimulation of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor, and bath application of NMDA was sufficient to activate PKA. Together, these results indicate that at the initiation of LTP, NMDA receptor stimulation leads to transient activation of PKA, and support a role for PKA in the induction of LTP.	BAYLOR COLL MED,DIV NEUROSCI,HOUSTON,TX 77030	Baylor College of Medicine			Roberson, Erik/A-5718-2009	Roberson, Erik/0000-0002-1810-9763; Sweatt, J. David/0000-0003-3567-485X	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH048186] Funding Source: NIH RePORTER; NIMH NIH HHS [MH48186] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABRAMS TW, 1991, J NEUROSCI, V11, P2655; BEAVO JA, 1974, P NATL ACAD SCI USA, V71, P3580, DOI 10.1073/pnas.71.9.3580; BERGOLD PJ, 1990, P NATL ACAD SCI USA, V87, P3788, DOI 10.1073/pnas.87.10.3788; Blitzer RD, 1995, NEURON, V15, P1403, DOI 10.1016/0896-6273(95)90018-7; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; CHETKOVICH DM, 1993, J NEUROCHEM, V61, P1933, DOI 10.1111/j.1471-4159.1993.tb09836.x; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; CORBIN JD, 1975, J BIOL CHEM, V250, P218; CORBIN JD, 1973, J BIOL CHEM, V248, P1813; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GLASS DB, 1986, J BIOL CHEM, V261, P2166; GREENBERG SM, 1987, NATURE, V329, P62, DOI 10.1038/329062a0; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; HELL JW, 1995, EMBO J, V14, P3036, DOI 10.1002/j.1460-2075.1995.tb07306.x; Huang Y Y, 1994, Learn Mem, V1, P74; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; KEMP BE, 1977, J BIOL CHEM, V252, P4888; Klann E., 1995, Society for Neuroscience Abstracts, V21, P1809; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MATTHIES H, 1993, NEUROREPORT, V4, P712, DOI 10.1097/00001756-199306000-00028; MIYAKAWA H, 1992, NEURON, V9, P1163, DOI 10.1016/0896-6273(92)90074-N; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; Osten P, 1996, J NEUROSCI, V16, P2444; PALMER WK, 1980, J BIOL CHEM, V255, P2663; REGEHR WG, 1992, J NEUROSCI, V12, P4202; Roberson ED, 1996, LEARN MEMORY, V3, P1, DOI 10.1101/lm.3.1.1; Sah P, 1996, J NEUROSCI, V16, P4537; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SMITH MK, 1990, J BIOL CHEM, V265, P1837; SWEATT JD, 1989, NATURE, V339, P51, DOI 10.1038/339051a0; WALSH DA, 1971, J BIOL CHEM, V246, P1977; WANG LY, 1993, SCIENCE, V259, P1173, DOI 10.1126/science.8382377; WISE BC, 1982, J BIOL CHEM, V257, P8499; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T	38	130	133	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30436	30441		10.1074/jbc.271.48.30436	http://dx.doi.org/10.1074/jbc.271.48.30436			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940008	hybrid			2022-12-27	WOS:A1996VV15800025
J	Tinhofer, I; Maly, K; Dietl, P; Hochholdinger, F; Mayr, S; Obermeier, A; Grunicke, HH				Tinhofer, I; Maly, K; Dietl, P; Hochholdinger, F; Mayr, S; Obermeier, A; Grunicke, HH			Differential Ca2+ signaling induced by activation of the epidermal growth factor and nerve growth factor receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE C-GAMMA-1; CELL-PROLIFERATION; RAS ONCOGENE; BINDING-SITE; EGF-RECEPTOR; HA-RAS; PROTEIN; SPECIFICITY; INHIBITION	Stimulation by epidermal growth factor (EGF) of NIH3T3 cells overexpressing the EGF receptor (EGFR) results in a release of Ca2+ from internal stores, Ca2+ release is followed by an influx of extracellular calcium which can be recorded by the influx of the calcium surrogate Mn2+, Both Ca2+ release and Mn2+/Ca2+ influx are inhibited by expression of the dominant negative Asn(17)-Ras mutant and abrogated by microinjected neutralizing anti-aas antibody Y13-259, whereas microinjection of the anti-Ras antibody Y13-238 which does not interact with the effector binding domain of pas is without any effect on the EGF-induced Ca2+ transient, Neither Asn(17)-Ha-Ras nor the Y13-259 antibody interferes with the thapsigargin-induced Mn2+/Ca2+ influx. The nerve growth factor receptor (Trk)-mediated Ca2+ transient was found to be unaffected by the dominant negative Ras mutant or microinjected neutralizing anti-Ras antibodies, Substitution of the phospholipase C gamma 1 (PLC gamma 1) binding site of the EGFR by the PLC gamma binding domain of Trk renders the EGFR-induced Ca2+ influx insensitive to the expression of Asn(17)-Ha-Ras, whereas the Ca2+ signal induced by Trk carrying the PLC binding site of EGFR is Ras-dependent and abrogated by the dominant negative Ras mutant. It is concluded that the Ca2+ transient induced by the activated EGFR, not, however, the Ca2+ transient elicited by the activated NGFR/Trk, is a Ras-mediated phenomenon and that the role of Ras in regulating EGFR-induced Ca2+ influx depends on the structure of the PLC gamma binding domain.	UNIV INNSBRUCK, DEPT MED CHEM & BIOCHEM, A-6020 INNSBRUCK, AUSTRIA; MAX PLANCK INST BIOCHEM, DEPT BIOL MOL, D-82152 MARTINSRIED, GERMANY; UNIV INNSBRUCK, DEPT PHYSIOL, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck; Max Planck Society; University of Innsbruck				Mayr, Stefan/0000-0002-3319-4396; Tinhofer, Ingeborg/0000-0002-0512-549X				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CARDO CC, 1991, CELL, V66, P173; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHEN CF, 1988, SCIENCE, V239, P1024, DOI 10.1126/science.2449730; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COLLIN C, 1990, SCIENCE, V250, P1743, DOI 10.1126/science.2176747; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GRUNICKE HH, 1993, CRIT REV ONCOGENESIS, V4, P389; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HUANG Y, 1993, J PHYSIOL-LONDON, V461, P601, DOI 10.1113/jphysiol.1993.sp019531; KASS GEN, 1990, J BIOL CHEM, V265, P17486; LANG F, 1991, J BIOL CHEM, V266, P4938; LANG F, 1992, PFLUG ARCH EUR J PHY, V421, P416, DOI 10.1007/BF00370251; MALY K, 1995, CELL CALCIUM, V18, P120, DOI 10.1016/0143-4160(95)90003-9; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MILARSKI KL, 1993, J BIOL CHEM, V268, P23634; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; Obermeier A, 1996, EMBO J, V15, P73, DOI 10.1002/j.1460-2075.1996.tb00335.x; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; PANDIELLA A, 1988, BIOCHEM J, V254, P223, DOI 10.1042/bj2540223; Peppelenbosch MP, 1996, J BIOL CHEM, V271, P7883, DOI 10.1074/jbc.271.14.7883; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SERTH J, 1992, BIOCHEMISTRY-US, V31, P6361, DOI 10.1021/bi00143a001; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; SOLER C, 1994, J BIOL CHEM, V269, P12320; VALIUS M, 1995, MOL CELL BIOL, V15, P3058; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251	43	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30505	30509		10.1074/jbc.271.48.30505	http://dx.doi.org/10.1074/jbc.271.48.30505			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940018	hybrid			2022-12-27	WOS:A1996VV15800035
J	Klein, M; Weissenbock, G; Dufaud, A; Gaillard, C; Kreuz, K; Martinoia, E				Klein, M; Weissenbock, G; Dufaud, A; Gaillard, C; Kreuz, K; Martinoia, E			Different energization mechanisms drive the vacuolar uptake of a flavonoid glucoside and a herbicide glucoside	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONJUGATE EXPORT PUMP; BILE-ACID TRANSPORT; MEMBRANE-VESICLES; PLANT VACUOLES; ACCUMULATION; PROTOPLASTS; ATPASES; SYSTEM	Glycosylation of endogenous secondary plant products and abiotic substances such as herbicides increases their water solubility and enables vacuolar deposition of these potentially toxic substances. We characterized and compared the transport mechanisms of two glucosides, isovitexin, a native barley flavonoid C-glucoside and hydroxyprimisulfuron-glucoside, a herbicide glucoside, into barley vacuoles, Uptake of isovitexin is saturable (K-m=82 mu M) and stimulated by MgATP 1.3-1.5-fold. ATP-dependent uptake was inhibited by bafilomycin Al, a specific inhibitor of vacuolar H+-ATPase, but not by vanadate, Transport of isovitexin is strongly inhibited after dissipation of the Delta pH or the Delta psi across the vacuolar membrane. Uptake experiments with the heterologue flavonoid orientin and competition experiments with other phenolic compounds suggest that transport of flavonoid glucosides into barley vacuoles is specific for apigenin derivatives. In contrast, transport of hydroxyprimisulfuron-glucoside is strongly stimulated by MgATP (2.5-3 fold), not sensitive toward bafilomycin, and much less sensitive to dissipation of the Delta pH, but strongly inhibited by vanadate, Uptake of hydroxyprimisulfuron-glucoside is also stimulated by MgGTP or MgUTP by about 2-fold. Transport of both substrates is not stimulated by ATP or Mg2+ alone, ADP, or the nonhydrolyzable ATP analogue 5'-adenylyl-beta,gamma-imido-diphosphate. Our results suggest that different uptake mechanisms exist in the vacuolar membrane, a Delta pH-dependent uptake mechanism for specific endogenous flavonoid-glucosides, and a directly energized mechanism for abiotic glucosides, which appears to be the main transport system for these substrates. The herbicide glucoside may therefore be transported by an additional member of the ABC transporters.	UNIV POITIERS,FAC SCI,PHYSIOL & BIOCHIM VEGETALES LAB,F-86022 POITIERS,FRANCE; UNIV COLOGNE,INST BOT,D-50931 COLOGNE,GERMANY; CIBA GEIGY AG,CROP PROTECT WEED CONTROL PLANT BIOCHEM,CH-4002 BASEL,SWITZERLAND	Universite de Poitiers; University of Cologne; Novartis								[Anonymous], 1990, FLAVONOID METABOLISM; BALZI E, 1994, BBA-BIOENERGETICS, V1187, P152, DOI 10.1016/0005-2728(94)90102-3; BLUME DE, 1979, PLANTA, V146, P199, DOI 10.1007/BF00388232; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; DEUSNEUMANN B, 1986, PLANTA, V167, P44, DOI 10.1007/BF00446367; DEUSNEUMANN B, 1984, PLANTA, V162, P250, DOI 10.1007/BF00397447; GAILLARD C, 1994, FEBS LETT, V352, P219, DOI 10.1016/0014-5793(94)00961-9; GETZ HP, 1995, PLANT PHYSIOL, V107, P459, DOI 10.1104/pp.107.2.459; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HOPP W, 1987, PLANTA, V170, P74, DOI 10.1007/BF00392383; HORTENSTEINER S, 1993, J BIOL CHEM, V268, P18446; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; Kreuz K, 1996, PLANT PHYSIOL, V111, P349, DOI 10.1104/pp.111.2.349; LI ZS, 1995, PLANT PHYSIOL, V107, P1257, DOI 10.1104/pp.107.4.1257; MARGNA U, 1978, BIOCHEM PHYSIOL PFL, V173, P2; MARRS KA, 1995, NATURE, V375, P397, DOI 10.1038/375397a0; MARTINOIA E, 1993, NATURE, V364, P247, DOI 10.1038/364247a0; MARTINOIA E, 1992, BOT ACTA, V105, P232, DOI 10.1111/j.1438-8677.1992.tb00293.x; MATERN U, 1986, PLANTA, V167, P183, DOI 10.1007/BF00391413; NISHIDA T, 1991, P NATL ACAD SCI USA, V88, P6590, DOI 10.1073/pnas.88.15.6590; RATABOUL P, 1985, BIOCHIM BIOPHYS ACTA, V816, P25, DOI 10.1016/0005-2736(85)90389-X; RENTSCH D, 1991, PLANTA, V184, P532, DOI 10.1007/BF00197903; REUBER S, 1993, Z NATURFORSCH C, V48, P749; Reuber S, 1996, PLANT CELL ENVIRON, V19, P593, DOI 10.1111/j.1365-3040.1996.tb00393.x; SANDERMANN H, 1992, TRENDS BIOCHEM SCI, V17, P82, DOI 10.1016/0968-0004(92)90507-6; SEIKEL MK, 1957, ARCH BIOCHEM BIOPHYS, V71, P17, DOI 10.1016/0003-9861(57)90004-8; SZE H, 1992, J BIOENERG BIOMEMBR, V24, P371, DOI 10.1007/BF00762530; WERNER C, 1985, J PLANT PHYSIOL, V118, P237, DOI 10.1016/S0176-1617(85)80225-X	28	100	117	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29666	29671		10.1074/jbc.271.47.29666	http://dx.doi.org/10.1074/jbc.271.47.29666			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939899	hybrid			2022-12-27	WOS:A1996VU52500027
J	Bottger, G; Nagelkerken, B; vanderSluijs, P				Bottger, G; Nagelkerken, B; vanderSluijs, P			Rab4 and Rab7 define distinct nonoverlapping endosomal compartments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN RAB4; TRANS-GOLGI NETWORK; ENDOCYTIC PATHWAY; FUSION INVITRO; MDCK CELLS; RECEPTOR; BIOGENESIS; ANTIBODIES; LYSOSOMES; HEMAGGLUTININ	Several Rab GTPases have been localized to distinct compartments of the endocytic pathway. Rab4 is associated with early endosomes and recycling vesicles and regulates membrane recycling from early endosomes. Rab7 is localized to late endosomes and is involved in the regulation of membrane transport between late endosomes and lysosomes. Although Rab4 and Rab7 appear to regulate distinct transport events in endocytosis, it is not clear whether they perform their activities in related or entirely distinct intracellular compartments. To address this question, we generated stable cell lines expressing Rab4 tagged with a novel X31 influenza hemagglutinin (NH) epitope tag. These antibodies are characterized in this paper and were used to immunoisolate endocytic vesicles with cytoplasmically exposed NHRab4. Immunoisolated membranes contain internalized I-I25-transferrin, but are devoid of Rab7. Confocal immunofluorescence microscopy showed that the early endosomal GTPases Rab4 and Rab5 both do not codistribute with Rab7 within the same cell. These observations suggest that each of the three Rab GTPases operationally defines a distinct station of the endocytic pathway.	UNIV UTRECHT,SCH MED,DEPT CELL BIOL,NL-3584 CX UTRECHT,NETHERLANDS	Utrecht University								APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; DUNN KW, 1992, J CELL BIOL, V117, P301, DOI 10.1083/jcb.117.2.301; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GETHING MJ, 1980, NATURE, V287, P301, DOI 10.1038/287301a0; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P45; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; MERESSE S, 1995, J CELL SCI, V108, P3349; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOLARI R, 1985, J BIOL CHEM, V260, P1141; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; STOORVOGEL W, 1991, CELL, V65, P417, DOI 10.1016/0092-8674(91)90459-C; VANDERSLUIJS P, 1990, J CELL SCI, V95, P545; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VANDERSLUIJS P, 1992, EMBO J, V11, P4379, DOI 10.1002/j.1460-2075.1992.tb05538.x; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; WILSON IA, 1981, NATURE, V289, P367; ZERIAL M, 1995, SMALL GTPASES, P295	35	72	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29191	29197		10.1074/jbc.271.46.29191	http://dx.doi.org/10.1074/jbc.271.46.29191			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910576	hybrid			2022-12-27	WOS:A1996VT05200068
J	Cianflone, K; Zhang, ZJ; Vu, H; KohenAvramoglu, R; Kalant, D; Sniderman, AD				Cianflone, K; Zhang, ZJ; Vu, H; KohenAvramoglu, R; Kalant, D; Sniderman, AD			The effect of individual amino acids on ApoB100 and Lp(a) secretion by HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-B GENE; DENSITY LIPOPROTEIN SECRETION; CULTURED RAT HEPATOCYTES; SOYBEAN PROTEIN-DIET; SOY PROTEIN; RECEPTOR ACTIVITY; MESSENGER-RNA; APO-B; HYPERCHOLESTEROLEMIC PATIENTS; HEPATOMA-CELLS	The rate at which HepG2 cells secrete apoB100 lipoproteins is inversely related to the concentration of amino acids in the medium (Zhang, Z., Sniderman, A. D., Kalant, D., Vu, H., Monge, J. C., Tao, Y., and Cianflone, g. (1993) J. Biol. Chem. 268, 26920-26926). The purpose of the present study was to determine the effect of individual amino acids on apoB100 and lipoprotein secretion. Asparagine was associated with modestly increased secretion. The branched chain amino acids (leucine, isoleucine, and valine) and lysine had minor inhibitory effects. The other amino acids, by contrast, decreased apoB secretion, although the magnitude of the effect varied considerably, the most potent being tyrosine, cysteine, phenylalanine, tryptophan, methionine, and glutamine. Although the effect on Lp(a) generally paralleled that on apoB100, it was usually much less pronounced. No amino acid caused a marked decrease in albumin, apoAI, or total protein secreted from the HepG2 cells. The amino acid effect on apoB was paralleled by similar decreases in secreted cholesterol ester (CE) primarily in the low density lipoprotein density range (d < 1.006-1.063 g/ml), although there was no significant change in intracellular CE. Neither intracellular nor secreted triglycerides (TG) or free cholesterol changed, resulting in a slightly larger TG-enriched particle being secreted The effect was confirmed in cultured primary hamster hepatocytes, where a mixture of amino acids also caused a decrease in apoB secretion (up to 40%). ApoAI appeared to increase as with the HepG2 cells. Secreted CE paralleled apoB. There was no change in intracellular or secreted TG or free cholesterol, resulting in a substantially larger TG-rich particle being secreted. mRNA for apoB100 increased with asparagine, decreased moderately with branched chain amino acids, and decreased further with glutamine, as shown by dot blot and Northern blotting. Pulse chase studies indicated that there was no change in apoB secretion efficiency under any condition. These results extend our previous observations by demonstrating specificity of the amino acid effect on apoB100 secretion. Although an effect on transcription is the likely mechanism, the exact basis for this remains to be determined.	MCGILL UNIV, MCGILL UNIT PREVENT CARDIOVASC DIS, MONTREAL, PQ H3A 1A1, CANADA	McGill University								Avramoglu RK, 1995, J LIPID RES, V36, P2513; BOSELLO O, 1988, ANN NUTR METAB, V32, P206, DOI 10.1159/000177443; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS AR, 1992, MOL CELL BIOL, V12, P1134, DOI 10.1128/MCB.12.3.1134; CARLSSON P, 1990, GENE, V94, P295, DOI 10.1016/0378-1119(90)90401-C; CARROLL KK, 1991, J AM DIET ASSOC, V91, P820; CARROLL KK, 1981, J AM OIL CHEM SOC, V58, P416, DOI 10.1007/BF02582391; CIANFLONE K, 1994, ATHEROSCLEROSIS, V107, P125, DOI 10.1016/0021-9150(94)90014-0; COHN JS, 1985, ATHEROSCLEROSIS, V56, P247, DOI 10.1016/0021-9150(85)90024-3; DASHTI N, 1992, J BIOL CHEM, V267, P7160; DAVIS RA, 1980, J BIOL CHEM, V255, P2039; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; EAGLE H, 1959, SCIENCE, V130, P432, DOI 10.1126/science.130.3373.432; EVERSON WV, 1989, AM J PHYSIOL, V256, pC18, DOI 10.1152/ajpcell.1989.256.1.C18; FILLIOS LC, 1954, METABOLISM, V3, P16; FLAIM KE, 1982, J BIOL CHEM, V257, P2939; FLESS GM, 1989, J LIPID RES, V30, P651; FUMAGALLI R, 1982, ATHEROSCLEROSIS, V43, P341, DOI 10.1016/0021-9150(82)90034-X; GARLICH JD, 1970, AM J CLIN NUTR, V23, P1626; GERBER DA, 1971, AM J CLIN NUTR, V24, P1382; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HEVIA P, 1980, J NUTR, V110, P1231, DOI 10.1093/jn/110.6.1231; HILL EG, 1966, J NUTR, V89, P143, DOI 10.1093/jn/89.2.143; HOPGOOD MF, 1977, BIOCHEM J, V164, P399, DOI 10.1042/bj1640399; HUFF MW, 1984, AM J CLIN NUTR, V39, P888, DOI 10.1093/ajcn/39.6.888; KALOPISSIS AD, 1995, METABOLISM, V44, P19, DOI 10.1016/0026-0495(95)90284-8; KARDASSIS D, 1992, J BIOL CHEM, V267, P2622; KATAN MB, 1982, ATHEROSCLEROSIS, V43, P381, DOI 10.1016/0021-9150(82)90037-5; KHOSLA P, 1989, BIOCHIM BIOPHYS ACTA, V1002, P157, DOI 10.1016/0005-2760(89)90282-8; KRITCHEVSKY D, 1987, J AM OIL CHEM SOC, V64, P1167, DOI 10.1007/BF02612995; KUROWSKA EM, 1992, BIOCHIM BIOPHYS ACTA, V1126, P185, DOI 10.1016/0005-2760(92)90289-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAINE RO, 1991, J BIOL CHEM, V266, P16969; LEVEILLE GA, 1962, J NUTR, V76, P321, DOI 10.1093/jn/76.4.321; LINCOLN AJ, 1994, GENE DEV, V8, P1131, DOI 10.1101/gad.8.9.1131; LOVATI MR, 1987, J CLIN INVEST, V80, P1498, DOI 10.1172/JCI113232; LOVATI MR, 1992, J NUTR, V122, P1971, DOI 10.1093/jn/122.10.1971; LOVATI MR, 1985, ATHEROSCLEROSIS, V56, P243, DOI 10.1016/0021-9150(85)90023-1; MANN GV, 1960, AM J CLIN NUTR, V8, P491, DOI 10.1093/ajcn/8.4.491; MANN GV, 1953, J EXP MED, V98, P195, DOI 10.1084/jem.98.3.195; MARTEN NW, 1994, FASEB J, V8, P538, DOI 10.1096/fasebj.8.8.8181673; METZGER S, 1990, J BIOL CHEM, V265, P9978; METZGER S, 1993, J BIOL CHEM, V268, P16831; MONTOYA A, 1989, IN VITRO CELL DEV B, V25, P358; MURTHY S, 1992, ARTERIOSCLER THROMB, V12, P691, DOI 10.1161/01.ATV.12.6.691; NOSEDA G, 1980, DRUGS AFFECTING LIPI, P355; Olson R E, 1970, Trans Assoc Am Physicians, V83, P196; OLSON RE, 1970, AM J CLIN NUTR, V23, P1614; PENTTILA IM, 1987, CLIN CHIM ACTA, V170, P143, DOI 10.1016/0009-8981(87)90122-7; PERET J, 1994, METAZBOLISM, V33, P200; PFEUFFER M, 1986, ANN NUTR METAB, V30, P281, DOI 10.1159/000177205; PHILLIPS LS, 1991, DIABETES, V40, P1525, DOI 10.2337/diabetes.40.11.1525; PHILLIPS ML, 1993, BIOCHEMISTRY-US, V32, P3722, DOI 10.1021/bi00065a026; POHJANPELTO P, 1990, MOL CELL BIOL, V10, P5814, DOI 10.1128/MCB.10.11.5814; RAJA PK, 1975, J PHARM SCI, V64, P691, DOI 10.1002/jps.2600640427; ROCHA DM, 1972, J CLIN INVEST, V51, P2346, DOI 10.1172/JCI107046; RODA E, 1983, NEW TRENDS PATHOPHYS, P309; ROTHSCHILD MA, 1969, J NUTR, V98, P395, DOI 10.1093/jn/98.4.395; SAMMAN S, 1989, LIPIDS, V24, P169, DOI 10.1007/BF02535230; SANCHEZ A, 1991, MED HYPOTHESES, V36, P27, DOI 10.1016/0306-9877(91)90160-Z; SCANU AM, 1988, SEMIN THROMB HEMOST, V14, P266, DOI 10.1055/s-2007-1002788; SEIDEL J. C, 1960, JOUR LIPID RES, V1, P474; SIDRANSKY H, 1990, ANN NY ACAD SCI, V598, P464, DOI 10.1111/j.1749-6632.1990.tb42317.x; SIDRANSKY H, 1989, EXP MOL PATHOL, V51, P68, DOI 10.1016/0014-4800(89)90008-7; SIRTORI CR, 1993, ANN NY ACAD SCI, V676, P188, DOI 10.1111/j.1749-6632.1993.tb38734.x; SIRTORI CR, 1984, J NUTR, V114, P1493, DOI 10.1093/jn/114.8.1493; SNIDERMAN AD, 1993, ARTERIOSCLER THROMB, V13, P629, DOI 10.1161/01.ATV.13.5.629; SNIDERMAN AD, 1993, CIRCULATION, V88, P176; SOMMERCORN JM, 1981, J BIOL CHEM, V256, P4816; Sparks Janet D., 1993, Current Opinion in Lipidology, V4, P177, DOI 10.1097/00041433-199306000-00002; STRAUS DS, 1993, ENDOCRINOLOGY, V132, P1090, DOI 10.1210/en.132.3.1090; SUGANO M, 1982, J NUTR, V112, P855, DOI 10.1093/jn/112.5.855; TRUSWELL AS, 1964, P NUTR SOC, V23, pR46; Wade David P., 1993, Current Opinion in Lipidology, V4, P244, DOI 10.1097/00041433-199306000-00011; WHITE AL, 1994, J BIOL CHEM, V269, P28716; WILKINSON J, 1994, J LIPID RES, V35, P1896; WOLFE BM, 1991, METABOLISM, V40, P338, DOI 10.1016/0026-0495(91)90142-J; WOODSIDE KH, 1972, J BIOL CHEM, V247, P6474; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6; YOUNG SG, 1986, CLIN CHEM, V32, P1484; ZHANG XZ, 1993, BRIT J NUTR, V69, P767, DOI 10.1079/BJN19930077; ZHANG ZJ, 1993, J BIOL CHEM, V268, P26920	83	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29136	29145		10.1074/jbc.271.46.29136	http://dx.doi.org/10.1074/jbc.271.46.29136			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910570	hybrid			2022-12-27	WOS:A1996VT05200062
J	Coe, IR; Yao, LN; Diamond, I; Gordon, AS				Coe, IR; Yao, LN; Diamond, I; Gordon, AS			The role of protein kinase C in cellular tolerance to ethanol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; ANCHORING PROTEINS; ADENOSINE UPTAKE; XENOPUS-OOCYTES; RECEPTORS; CELLS; INCREASES; PHOSPHORYLATION; LOCALIZATION; ACTIVATION	We have shown that ethanol inhibits uptake of adenosine by a specific nucleoside transporter in NG108-15 neuroblastoma x glioma cells and that cAMP-dependent protein kinase (PKA) activity is required for this inhibition. After chronic exposure to ethanol, adenosine uptake is no longer inhibited on rechallenge with ethanol, i.e. transport has become tolerant to ethanol. Here we show that protein kinase C (PKC) contributes to ethanol-induced tolerance of adenosine transport. Activation of PKC by phorbol esters in control cells results in an ethanol-tolerant phenotype, similar to that produced by chronic ethanol exposure. In addition, chronic exposure to ethanol increases the amounts of alpha, delta, and epsilon PKC. However, reducing PKC activity by inhibition with chelerythrine during chronic exposure to ethanol or down-regulation by phorbol esters prevents the development of ethanol-induced tolerance of adenosine transport. By contrast, the inhibition of PKA activity produces tolerance to ethanol inhibition of adenosine uptake. When protein phosphatase inhibitors are present, inhibiting PKA activity has no effect on ethanol sensitivity of adenosine uptake, suggesting a role for protein phosphatases in the regulation of ethanol sensitivity of uptake. Taken together, our results suggest that PKA and PKC have opposing effects on the ethanol sensitivity of adenosine transport; PKA activity is required for ethanol sensitivity, and PKC activation produces tolerance. Based on these data, we propose that chronic ethanol exposure increases PKC activity, leading to the activation of a protein phosphatase (1 or 2A). This phosphatase then dephosphorylates a PKA-phosphorylated site, which is required for ethanol to inhibit adenosine uptake. Therefore, the sensitivity of adenosine transport to ethanol appears to be maintained by a balance of PKA and protein phosphatase activities, and PKC may regulate phosphatase activity.	UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,ERNEST GALLO CLIN & RES CTR,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DEPT NEUROL,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DEPT MOL & CELLULAR PHARMACOL,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,PROGRAM NEUROSCI,SAN FRANCISCO,CA 94110	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco								BECKMANN R, 1994, EUR J BIOCHEM, V222, P335, DOI 10.1111/j.1432-1033.1994.tb18872.x; BLACKSHEAR PJ, 1988, AM J MED SCI, V296, P231, DOI 10.1016/S0002-9629(15)40866-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN Y, 1994, J BIOL CHEM, V269, P7839; Coe IR, 1996, J PHARMACOL EXP THER, V276, P365; DEPETRILLO PB, 1993, ALCOHOL CLIN EXP RES, V17, P351, DOI 10.1111/j.1530-0277.1993.tb00774.x; DILDYMAYFIELD JE, 1995, J NEUROSCI, V15, P3162; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; GERWINS P, 1995, N-S ARCH PHARMACOL, V351, P186; GORDON AS, 1986, P NATL ACAD SCI USA, V83, P2105, DOI 10.1073/pnas.83.7.2105; HARRIS RA, 1995, P NATL ACAD SCI USA, V92, P3658, DOI 10.1073/pnas.92.9.3658; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HOEK JB, 1993, ALCOHOL, CELL MEMBRANES, AND SIGNAL TRANSDUCTION IN BRAIN, P219; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; INAGAKI N, 1994, TRENDS BIOCHEM SCI, V19, P448, DOI 10.1016/0968-0004(94)90128-7; KHARBANDA S, 1993, BIOCHEM PHARMACOL, V45, P675, DOI 10.1016/0006-2952(93)90142-J; KRAUSS SW, 1993, MOL PHARMACOL, V44, P1021; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MESSING RO, 1991, J BIOL CHEM, V266, P23428; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NAGY LE, 1991, MOL PHARMACOL, V40, P812; NAGY LE, 1990, J BIOL CHEM, V265, P1946; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; SANNA E, 1994, MOL PHARMACOL, V45, P1004; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SKWISH S, 1990, LIFE SCI, V47, P1037, DOI 10.1016/0024-3205(90)90476-8; SNELL LD, 1994, J NEUROCHEM, V62, P1783; SRINIVASAN M, 1994, J BIOL CHEM, V269, P16662; TIPPMER S, 1994, EUR J BIOCHEM, V225, P297, DOI 10.1111/j.1432-1033.1994.00297.x; TRACYS, 1995, J BIOL CHEM, V270, P10587; VAELLO ML, 1994, J BIOL CHEM, V269, P2002; WAFFORD KA, 1992, FEBS LETT, V313, P113, DOI 10.1016/0014-5793(92)81424-K; WEINER JL, 1994, J PHARMACOL EXP THER, V268, P1388; WOLSING DH, 1991, J PHARMACOL EXP THER, V257, P621	34	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29468	29472		10.1074/jbc.271.46.29468	http://dx.doi.org/10.1074/jbc.271.46.29468			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910614	hybrid			2022-12-27	WOS:A1996VT05200106
J	DAndrea, L; Lytle, C; Matthews, JB; Hofman, P; Forbush, B; Madara, JL				DAndrea, L; Lytle, C; Matthews, JB; Hofman, P; Forbush, B; Madara, JL			Na:K:2Cl cotransporter (NKCC) of intestinal epithelial cells - Surface expression in response to cAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-CL COTRANSPORTER; FUNCTIONAL EXPRESSION; F-ACTIN; PROTEINS; CLONING	During intestinal chloride secretion, epithelial uptake of salts is accomplished largely by a bumetanide-sensitive Na:K:2Cl cotransporter designated here as NKCC, Using monoclonal antibodies directed against NKCC from the human crypt epithelial cell line, T84, we define its surface localization as a function of cotransporter activation, Immunoelectron microscopy, confocal localization, and selective surface biotinylation studies revealed that the 195-kDa NKCC protein is polarized to the basolateral domain. Following immunoprecipitation, several polypeptides coprecipitated with the 195-kDa cotransporter including two prominent proteins of molecular mass 160 and 130 kDa, Immunoblotting with three distinct anti NKCC monoclonal antibodies in conjunction with deglycosylation experiments suggested that the 160- and 130-kDa bands represented novel proteins unrelated to the cotransporter. Stimulation of T84 monolayers with cAMP agonists, a condition which elicits chloride secretion and leads to microfilament-dependent NKCC activation, did not significantly increase the number of bumetanide-binding sites and only marginally increased surface expression of the 195-kDa cotransporter available for surface biotinylation, In contrast, cAMP agonist stimulation increased the surface expression of the coprecipitating 160- and 130-kDa proteins similar to 6-fold, The increase in surface 160- and 130-kDa proteins was attenuated by phalloidin preloading the cells, a condition which also prevents activation of NKCC without influencing the activity of other membrane transporters participating in chloride secretion, These studies define the polarized distribution of the NKCC protein on intestinal epithelia, indicate that NKCC may be associated with two other previously unidentified membrane proteins and such association is influenced by the F-actin cytoskeleton.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; UNIV CALIF RIVERSIDE, DIV BIOMED SCI, RIVERSIDE, CA 92521 USA; BETH ISRAEL HOSP, DEPT SURG, BOSTON, MA 02115 USA; YALE UNIV, DEPT CELLULAR & MOL PHYSIOL, NEW HAVEN, CT 06510 USA	Harvard University; Harvard Medical School; University of California System; University of California Riverside; Harvard University; Beth Israel Deaconess Medical Center; Yale University	DAndrea, L (corresponding author), BRIGHAM & WOMENS HOSP, DEPT PATHOL, DIV GASTROINTESTINAL PATHOL, 75 FRANCIS ST, THORN 1423, BOSTON, MA 02115 USA.		Hofman, Paul/P-7654-2018; Lytle, Christian/X-2836-2019	Hofman, Paul/0000-0003-0431-9353; Lytle, Christian/0000-0001-5442-1546	NIDDK NIH HHS [DK47662, DK35932, DK48010] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047662, R37DK035932, R29DK048010, R01DK035932, R01DK048010] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DAWSON DC, 1991, ANNU REV PHYSIOL, V53, P321; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, pG204, DOI 10.1152/ajpgi.1984.246.2.G204; DIAMOND JM, 1982, NATURE, V300, P683, DOI 10.1038/300683a0; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; HAAS M, 1994, AM J PHYSIOL-CELL PH, V267, pC869, DOI 10.1152/ajpcell.1994.267.4.C869; HAAS M, 1989, ANNU REV PHYSIOL, V51, P443, DOI 10.1146/annurev.physiol.51.1.443; KAOUTZANI P, 1993, AM J PHYSIOL, V264, pC1327, DOI 10.1152/ajpcell.1993.264.5.C1327; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYTLE C, 1992, J BIOL CHEM, V267, P25438; Lytle C, 1995, AM J PHYSIOL-CELL PH, V269, pC1496, DOI 10.1152/ajpcell.1995.269.6.C1496; MADARA JL, 1993, AM J PHYSIOL, V264, pC1096, DOI 10.1152/ajpcell.1993.264.5.C1096; MADARA JL, 1985, J CELL BIOL, V101, P2124, DOI 10.1083/jcb.101.6.2124; MATSUDAIRA PT, 1978, ANAL BIOCHEM, V87, P386, DOI 10.1016/0003-2697(78)90688-7; MATTHEWS JB, 1994, J BIOL CHEM, V269, P15703; MATTHEWS JB, 1992, J CLIN INVEST, V90, P1608, DOI 10.1172/JCI116030; OGRADY SM, 1987, AM J PHYSIOL, V253, pC177, DOI 10.1152/ajpcell.1987.253.2.C177; PAYNE JA, 1995, CURR OPIN CELL BIOL, V7, P493, DOI 10.1016/0955-0674(95)80005-0; ROTH J, 1982, TECHNIQUES IMMUNOCYT, V1, P107; SHAPIRO M, 1991, J CLIN INVEST, V87, P1903, DOI 10.1172/JCI115215; SUN A, 1991, J MEMBRANE BIOL, V120, P83, DOI 10.1007/BF01868594; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VEYHL M, 1993, J BIOL CHEM, V268, P25041; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201	23	84	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28969	28976		10.1074/jbc.271.46.28969	http://dx.doi.org/10.1074/jbc.271.46.28969			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910547				2022-12-27	WOS:A1996VT05200039
J	Hausken, ZE; DellAcqua, ML; Coghlan, VM; Scott, JD				Hausken, ZE; DellAcqua, ML; Coghlan, VM; Scott, JD			Mutational analysis of the A-kinase anchoring protein (AKAP)-binding site on RII - Classification of side chain determinants for anchoring and isoform selective association with AKAPs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT RII; II-BETA; BINDING PROTEINS; BOVINE BRAIN; CLONING; DOMAIN; CELLS; IDENTIFICATION; LOCALIZATION; CYTOSKELETON	Compartmentalization of the type II cAMP-dependent protein kinase is conferred by interaction of the regulatory subunit (RII) with (A) under bar-(K) under bar inase (A) under bar nchoring (P) under bar roteins (AKAPs). The AKAP-binding site involves amino-terminal residues on each RII protomer and is formed through dimerization. A site-directed mutagenesis strategy was utilized to assess the contribution of individual residues in either RII isoform, RII alpha or RII beta, for interaction with various anchoring proteins. Substitution of long-chain or bulky hydrophobic groups (leucines or phenylalanines) for isoleucines at positions 3 and 5 in RII alpha decreased AKAP-binding up to 24 +/- 3 (n = 8)-fold, whereas introduction of valines had minimal effects. Replacement with hydrophilic residues (serine or asparigine) at both positions abolished AKAP binding. Mutation of proline 6 in RII alpha reduced binding for four AKAPs (Ht31, MAP2, AKAP79, and AKAP95) from 2.3 to 20-fold (n = 4) whereas introduction of an additional proline at position 6 in RII beta increased or conferred binding toward these anchoring proteins. Therefore, we conclude thats-branched side chains at positions 3 and 5 are favored determinants for AKAP-binding and pro lines at positions 6 and 7 increase or stabilize RII alpha interaction with selected anchoring proteins.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Oregon Health & Science University				Dell'Acqua, Mark/0000-0003-3798-3461	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044239] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 44239] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRANDON EP, 1995, RECENT PROG HORM RES, V50, P403; BRANDON EP, 1995, P NATL ACAD SCI USA, V92, P8851, DOI 10.1073/pnas.92.19.8851; BROSTROM CO, 1971, P NATL ACAD SCI USA, V68, P2444, DOI 10.1073/pnas.68.10.2444; CARR DW, 1992, TRENDS BIOCHEM SCI, V17, P246, DOI 10.1016/0968-0004(92)90402-U; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; CARR DW, 1993, J BIOL CHEM, V268, P20729; COGHLAN VM, 1994, J BIOL CHEM, V269, P7658; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; CORBIN JD, 1977, J BIOL CHEM, V252, P910; FLETCHER WH, 1986, J BIOL CHEM, V261, P5504; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; GOODMAN RH, 1990, ANNU REV NEUROSCI, V13, P111, DOI 10.1146/annurev.neuro.13.1.111; HARPER JF, 1985, VITAM HORM, V42, P197; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; HAUSKEN ZE, 1996, OVERLAY LIGAND BLOTT; Huang YY, 1995, CELL, V83, P1211, DOI 10.1016/0092-8674(95)90146-9; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; KERYER G, 1993, P NATL ACAD SCI USA, V90, P5418, DOI 10.1073/pnas.90.12.5418; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEISER M, 1986, J BIOL CHEM, V261, P1904; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; LUO ZJ, 1990, J BIOL CHEM, V265, P21804; RANNELS SR, 1985, J BIOL CHEM, V260, P3423; REIMANN EM, 1986, BIOCHEMISTRY-US, V25, P119, DOI 10.1021/bi00349a018; RINGHEIM GE, 1990, J BIOL CHEM, V265, P4800; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; STOFKOHAHN RE, 1992, FEBS LETT, V302, P274, DOI 10.1016/0014-5793(92)80458-S; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALSH DA, 1968, J BIOL CHEM, V243, P3763; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503	40	66	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29016	29022		10.1074/jbc.271.46.29016	http://dx.doi.org/10.1074/jbc.271.46.29016			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910553	hybrid			2022-12-27	WOS:A1996VT05200045
J	Tebar, F; Sorkina, T; Sorkin, A; Ericsson, M; Kirchhausen, T				Tebar, F; Sorkina, T; Sorkin, A; Ericsson, M; Kirchhausen, T			Eps15 is a component of clathrin-coated pits and vesicles and is located at the rim of coated pits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE SUBSTRATE; GROWTH-FACTOR RECEPTOR; PROTEIN; DYNAMIN; DOMAIN; AP-2; ENDOCYTOSIS	Eps15, a phosphorylation substrate of the epidermal growth factor (EGF) receptor kinase, has been shown to bind to the alpha-subunit of the clathrin-associated protein complex AP-2. Here we report that in cells, virtually all Eps15 interacts with the cytosol and membrane-bound forms of AP-2. This association is not affected by the treatment of cells with EGF. Immunofluorescence microscopy reveals nearly absolute co-localization of Eps15 with AP-2 and clathrin, and analysis by immunoelectron microscopy shows that the localization of membrane-associated Eps15 is restricted to the profiles corresponding to endocytic coated pits and vesicles. Unexpectedly, Eps15 was found at the edge of forming coated pits and at the rim of budding coated vesicles. This asymmetric distribution is in sharp contrast to the localization of AP-2 that shows an even distribution along the same types of clathrin-coated structures. These findings suggest several possible regulatory roles of Eps15 during the formation of coated pits.	UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02215; CTR BLOOD RES,BOSTON,MA 02115	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM)			Tebar, Francesc/H-1498-2015	Tebar, Francesc/0000-0002-9522-9726; Sorkin, Alexander/0000-0002-4446-1920	NIDDK NIH HHS [DK46817] Funding Source: Medline; NIGMS NIH HHS [GM36548] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046817] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036548] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECK KA, 1991, J BIOL CHEM, V266, P4442; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; BOLL W, 1996, IN PRESS EMBO J; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; GOODMAN OB, 1995, J BIOL CHEM, V270, P23768, DOI 10.1074/jbc.270.40.23768; GRIFFITHS G, 1993, FINE STRUCTURE IMMUN; HARRISON SC, 1983, CELL, V33, P650, DOI 10.1016/0092-8674(83)90007-7; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; KIRCHHAUSEN T, 1993, CURR OPIN STRUC BIOL, V3, P182, DOI 10.1016/S0959-440X(05)80150-2; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; SCHMID SL, 1995, FASEB J, V9, P1445, DOI 10.1096/fasebj.9.14.7589986; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; Seaman MNJ, 1996, CURR OPIN CELL BIOL, V8, P549, DOI 10.1016/S0955-0674(96)80034-2; Shih W, 1995, J BIOL CHEM, V270, P31083, DOI 10.1074/jbc.270.52.31083; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; VELU TJ, 1989, MOL CELL BIOL, V9, P1772, DOI 10.1128/MCB.9.4.1772; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	26	211	214	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28727	28730		10.1074/jbc.271.46.28727	http://dx.doi.org/10.1074/jbc.271.46.28727			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910509	hybrid			2022-12-27	WOS:A1996VT05200001
J	Krane, SM; Byrne, MH; Lemaitre, V; Henriet, P; Jeffrey, JJ; Witter, JP; Liu, X; Wu, H; Jaenisch, R; Eeckhout, Y				Krane, SM; Byrne, MH; Lemaitre, V; Henriet, P; Jeffrey, JJ; Witter, JP; Liu, X; Wu, H; Jaenisch, R; Eeckhout, Y			Different collagenase gene products have different roles in degradation of type I collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASES; INTERSTITIAL COLLAGENASE; FIBROBLAST COLLAGENASE; SEQUENCE-ANALYSIS; HUMAN STROMELYSIN; CLEAVAGE SITE; MESSENGER-RNA; CELLS; PURIFICATION; CLONING	Vertebrate collagenases, matrix metalloproteinases (MMPs), cleave type I collagen at a single helical locus. We show here that rodent interstitial collagenases (MMP-13), but not human fibroblast collagenase (MMP-1), cleave type I collagen at an additional aminoitelopeptide locus. Collagenase cDNAs and chimeric constructs in pET-3d, juxtaposing MMP-13 sequences amino-terminal to the active site in the catalytic domain and MMP-1 sequences carboxyl-terminal and vice versa, were expressed in Escherichia coli. Assays utilized collagen from wild type (+/+) mice or mice that carry a targeted mutation (r/r) that encodes substitutions in alpha 1(I) chains that prevent collagenase cleavage at the helical locus, MMP-13 and chimeric molecules that contained the MMP-13 sequences amino-terminal to the active site cleaved (+/+) collagen at the helical locus and cleaved cross-linked (r/r) collagen in the aminotelopeptide (beta components converted to ct chains), Human MMP-1 and chimeric MMP-1/MMP-13 with MMP-1 sequences aminoterminal to the active site cleaved collagen at the helical locus but not in the aminotelopeptide. All activities were inhibited by TIMP-1, 1,10-phenanthroline, and EDTA. Sequences in the distal two-thirds of the catalytic domain determine the aminotelopeptide-degrading capacity of MMP-13.	MASSACHUSETTS GEN HOSP, ARTHRIT UNIT, BOSTON, MA 02114 USA; UNIV LOUVAIN, CONNECT TISSUE GRP, B-1200 BRUSSELS, BELGIUM; INT INST CELLULAR & MOL PATHOL, B-1200 BRUSSELS, BELGIUM; ALBANY MED COLL, DEPT MED, DIV HEMATOL, ALBANY, NY 12208 USA; WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Harvard University; Massachusetts General Hospital; Universite Catholique Louvain; Albany Medical College; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Krane, SM (corresponding author), HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02114 USA.			Henriet, Patrick/0000-0003-4602-8888	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD005291, R01HD005291] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR003564, T32AR007258] Funding Source: NIH RePORTER; NIAMS NIH HHS [TR-AR-07258, AR-03564] Funding Source: Medline; NICHD NIH HHS [HD-05291] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alexander CM, 1989, CURR OPIN CELL BIOL, V1, P974, DOI 10.1016/0955-0674(89)90068-9; BAILEY AJ, 1995, BIOCHEM J, V305, P385, DOI 10.1042/bj3050385; BERGMAN I, 1963, ANAL CHEM, V35, P1961, DOI 10.1021/ac60205a053; BIRKEDALHANSEN H, 1987, METHOD ENZYMOL, V144, P140; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; Burleigh M. C., 1977, PROTEINASES MAMMALIA, P285; DAYER JM, 1981, FEBS LETT, V124, P253, DOI 10.1016/0014-5793(81)80149-4; DELAISSE JM, 1993, J CELL SCI, V106, P1071; EECKHOUT Y, 1977, BIOCHEM J, V166, P21, DOI 10.1042/bj1660021; FIELDS GB, 1987, J BIOL CHEM, V262, P6221; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GACK S, 1995, CELL GROWTH DIFFER, V6, P759; GOLDRING MB, 1987, J BIOL CHEM, V262, P16724; GROSS J, 1981, CELL BIOL EXTRACELLU, P217; HENRIET P, 1992, FEBS LETT, V310, P175, DOI 10.1016/0014-5793(92)81323-E; HIROSE T, 1993, P NATL ACAD SCI USA, V90, P2569, DOI 10.1073/pnas.90.7.2569; KRANE SM, 1993, ARTHRITIS ALLIED CON, P763; LIGHT ND, 1980, BIOCHEM J, V189, P111, DOI 10.1042/bj1890111; LIU X, 1995, J CELL BIOL, V130, P227, DOI 10.1083/jcb.130.1.227; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MATTOT V, 1995, J CELL SCI, V108, P529; Moore DD, 1995, GLOB MOB SURV; MURPHY G, 1992, J BIOL CHEM, V267, P9612; MURPHY G, 1992, AM J RESP CELL MOL, V7, P120, DOI 10.1165/ajrcmb/7.2.120; NAGASE H, 1981, J BIOL CHEM, V256, P1951; QUINN CO, 1990, J BIOL CHEM, V265, P22342; ROSWIT WT, 1983, ARCH BIOCHEM BIOPHYS, V225, P285, DOI 10.1016/0003-9861(83)90032-2; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P393; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WU H, 1994, P NATL ACAD SCI USA, V91, P2819, DOI 10.1073/pnas.91.7.2819; WU H, 1990, P NATL ACAD SCI USA, V87, P5888, DOI 10.1073/pnas.87.15.5888; YE QZ, 1992, BIOCHEMISTRY-US, V31, P11231, DOI 10.1021/bi00160a038	36	98	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28509	28515		10.1074/jbc.271.45.28509	http://dx.doi.org/10.1074/jbc.271.45.28509			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910479	hybrid			2022-12-27	WOS:A1996VU03300079
J	Zhang, WY; Gaynor, PM; Kruth, HS				Zhang, WY; Gaynor, PM; Kruth, HS			Apolipoprotein E produced by human monocyte-derived macrophages mediates cholesterol efflux that occurs in the absence of added cholesterol acceptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEINS; MOUSE MACROPHAGES; APOPROTEIN-E; DIFFERENT MECHANISMS; CA++ ANTAGONISTS; E GENE; A-I; EXPRESSION; SECRETION; PROTEIN	Human monocyte-derived macrophages can efflux accumulated cholesterol without exogenously added cholesterol accepters (Kruth, H. S., Skarlatos, S. I., Gaynor, P. M., and Gamble, W. (1994) J. Biol. Chem. 269, 24511-24518). Most of the effluxed cholesterol accumulates in the medium as apolipoprotein E-discoidal lipid particles. In the current study, we determined whether and to what degree cholesterol efflux from human monocyte-macrophages depended on apolipoprotein E secretion. Unexpectedly, 2-week-old differentiated monocyte-macrophages secreted similar amounts of apolipoprotein E without or with cholesterol enrichment. Apolipoprotein E mRNA levels in these macrophages were not increased by cholesterol enrichment and were comparable with levels in HepG2 cells. Without cholesterol enrichment, monocyte-macrophages secreted lipid-poor apolipoprotein E with a density > 1.21 g/ml. By contrast, cholesterol enrichment of monocyte macrophages induced the association of apoE with phospholipid and cholesterol to form discoidal particles that floated at densities of 1.08-1.10 g/ml. An anti-apolipoprotein E monoclonal antibody added to the culture medium significantly inhibited cholesterol and phospholipid efflux from the monocyte-macrophages. This showed that apolipoprotein E was required for most of the cholesterol efflux, and that apolipoprotein E did not leave macrophages with lipid but rather associated with lipid after it was secreted. Thus, 1) apolipoprotein E was constitutively secreted by differentiated human monocyte-macrophages, 2) apolipoprotein E only formed discoidal particles following macrophage cholesterol enrichment, 3) apolipoprotein E was necessary for cholesterol efflux to occur in the absence of added cholesterol accepters and, in addition 4) the level of macrophage unesterified cholesterol was not rate-limiting for this cholesterol efflux, and 5) net phospholipid synthesis occurred in macrophages secondary to apoE-mediated loss of macrophage phospholipid. In conclusion, apolipoprotein E functions in an autocrine pathway that mediates cholesterol efflux from human monocyte-derived macrophages.	NIH,NHLBI,SECT EXPT ATHEROSCLEROSIS,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								BASU SK, 1981, P NATL ACAD SCI-BIOL, V78, P7545, DOI 10.1073/pnas.78.12.7545; BASU SK, 1983, SCIENCE, V219, P871, DOI 10.1126/science.6823554; BASU SK, 1982, J BIOL CHEM, V257, P9788; BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; BIELICKI JK, 1992, J LIPID RES, V33, P1699; BROWN MS, 1980, J BIOL CHEM, V255, P9344; DORY L, 1989, J LIPID RES, V30, P809; FORTE TM, 1993, J LIPID RES, V34, P317; GORDON V, 1983, J BIOL CHEM, V258, P6202; HARA H, 1991, J BIOL CHEM, V266, P3080; HERSCOVITZ H, 1992, J LIPID RES, V33, P971; KOO C, 1985, J BIOL CHEM, V260, P1934; KRUTH HS, 1995, J CELL BIOL, V129, P133, DOI 10.1083/jcb.129.1.133; KRUTH HS, 1994, J BIOL CHEM, V269, P24511; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAHLEY RW, 1989, J CLIN INVEST, V83, P2125, DOI 10.1172/JCI114126; MAZZONE T, 1987, J BIOL CHEM, V262, P11657; MAZZONE T, 1989, J LIPID RES, V30, P1055; MAZZONE T, 1994, J LIPID RES, V35, P1345; REARDON CA, 1986, J BIOL CHEM, V261, P9858; ROBENEK H, 1988, ARTERIOSCLEROSIS, V8, P57, DOI 10.1161/01.ATV.8.1.57; SCHMITZ G, 1985, EMBO J, V4, P2773, DOI 10.1002/j.1460-2075.1985.tb04003.x; SCHMITZ G, 1988, ARTERIOSCLEROSIS, V8, P46, DOI 10.1161/01.ATV.8.1.46; SCHMITZ G, 1990, J LIPID RES, V31, P1741; SHIMANO H, 1991, BIOCHIM BIOPHYS ACTA, V1086, P245, DOI 10.1016/0005-2760(91)90166-F; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; SHIRATORI Y, 1994, J BIOL CHEM, V269, P11337; VOGEL T, 1985, P NATL ACAD SCI USA, V82, P8696, DOI 10.1073/pnas.82.24.8696; WERB Z, 1983, J BIOL CHEM, V258, P642; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; YAMADA N, 1989, P NATL ACAD SCI USA, V86, P665, DOI 10.1073/pnas.86.2.665; ZANNIS VI, 1984, J BIOL CHEM, V259, P5495; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028	33	133	133	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28641	28646		10.1074/jbc.271.45.28641	http://dx.doi.org/10.1074/jbc.271.45.28641			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910497	hybrid			2022-12-27	WOS:A1996VU03300097
J	Kuroda, S; Tokunaga, C; Kiyohara, Y; Higuchi, O; Konishi, H; Mizuno, K; Gill, GN; Kikkawa, U				Kuroda, S; Tokunaga, C; Kiyohara, Y; Higuchi, O; Konishi, H; Mizuno, K; Gill, GN; Kikkawa, U			Protein-protein interaction of zinc finger LIM domains with protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTIF; HETEROGENEITY; PURIFICATION; SPECIFICITY; EXPRESSION; INHIBITOR	The LIM domain comprising two zinc-finger motifs is found in a variety of proteins and has been proposed to direct protein-protein interactions. During the identification of protein kinase C (PKC)-interacting proteins by a yeast two-hybrid assay, a novel protein containing three LIM domains, designated ENH, was shown to associate with PKC in an isoform-specific manner. Deletion analysis demonstrated that any single LIM domain of ENH associates with the NH2-terminal region of PKC, ENH associated with PKC in COS-7 cells and was phosphorylated by PKC in vitro. Upon treatment of the cells with phorbol ester, ENH in the membrane fraction was translocated to the cytosol fraction in vivo. Other LIM domain-containing proteins, such as Enigma and LIM-kinase 1, also interacted with PKC through their LIM domains. These results suggest that the LIM domain is one of the targets of PHC and that the LIM-PKC interaction may shed light on undefined roles of LIM domain-containing proteins.	KYUSHU UNIV,FAC MED,DEPT BIOL,FUKUOKA 81281,JAPAN; RES DEV CORP JAPAN,PRESTO,INHERITANCE & VARIAT GRP,KYOTO 61902,JAPAN; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	Kyushu University; Japan Science & Technology Agency (JST); University of California System; University of California San Diego	Kuroda, S (corresponding author), KOBE UNIV,BIOL RES CTR,NADA KU,1-1 ROKKODAI CHO,KOBE 657,JAPAN.		Mizuno, Kensaku/G-8631-2015					CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; IWASA Y, 1980, BIOCHEM BIOPH RES CO, V96, P180, DOI 10.1016/0006-291X(80)91198-5; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KIKKAWA U, 1986, BIOCHEM BIOPH RES CO, V135, P636, DOI 10.1016/0006-291X(86)90040-9; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KOBAYASHI E, 1989, J ANTIBIOT, V42, P153, DOI 10.7164/antibiotics.42.153; KOSA JL, 1994, BIOCHEMISTRY-US, V33, P468, DOI 10.1021/bi00168a011; MICHELSEN JW, 1994, J BIOL CHEM, V269, P11108; MIZUNO K, 1994, ONCOGENE, V9, P1605; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1988, NUCLEIC ACIDS RES, V16, P5199, DOI 10.1093/nar/16.11.5199; ONO Y, 1986, FEBS LETT, V206, P347, DOI 10.1016/0014-5793(86)81010-9; ONO Y, 1988, J BIOL CHEM, V263, P6927; PEREZALVARADO GC, 1994, STRUCT BIOL, V1, P388; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WU RY, 1994, J BIOL CHEM, V269, P25085	32	210	221	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31029	31032		10.1074/jbc.271.49.31029	http://dx.doi.org/10.1074/jbc.271.49.31029			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940095	hybrid			2022-12-27	WOS:A1996VW68600006
J	Condon, TP; Bennett, CF				Condon, TP; Bennett, CF			Altered mRNA splicing and inhibition of human E-selectin expression by an antisense oligonucleotide in human umbilical vein endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE EXPRESSION; MESSENGER-RNA; GENE-EXPRESSION; RIBONUCLEASE; RECOGNITION	We have characterized the mechanism of action of an antisense oligodeoxynucleotide (ASO) targeting human endothelial leukocyte adhesion molecule, E-selectin. LSIS 4730, a 20-base ASO designed to be complementary to a region in the 3'-untranslated region (3'-UTR) of human E-selectin, is a potent and specific inhibitor of both mRNA and protein expression in human umbilical vein endothelial cells, Following treatment with ISIS 4730, a lower molecular weight mRNA (3300 bases) species was detected by Northern blot analysis with a corresponding decrease in the mature E-selectin transcript (3875 bases). The ASO-induced low molecular weight mRNA is stable and remains in the nucleus. We demonstrate that ISIS 4730 targets E-selectin pre-mRNA in the nucleus and promotes cleavage of the pre-mRNA at the hybridization site, resulting in prevention of splicing of the last intron, The change in molecular weight of the E-selectin transcript is the result of loss of the 3'-UTR due to ASO-mediated RNA cleavage and retention of the last intron, Cleavage of the E-selectin pre-mRNA appears to be due to endogenous RNase H or a related enzyme activity.			Condon, TP (corresponding author), ISIS PHARMACEUT,DEPT MOL PHARMACOL,2292 FARADAY AVE,CARLSBAD,CA 92008, USA.							ALTAVILLA D, 1994, EUR J PHARM-ENVIRON, V270, P45, DOI 10.1016/0926-6917(94)90079-5; BEDNARCZUK TA, 1991, BIOTECHNIQUES, V10, P478; Bennett C F, 1994, Adv Pharmacol, V28, P1, DOI 10.1016/S1054-3589(08)60492-5; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BENNETT CF, 1994, J IMMUNOL, V152, P3530; BERGAN R, 1993, NUCLEIC ACIDS RES, V21, P3567, DOI 10.1093/nar/21.15.3567; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CAMPBELL JM, 1990, J BIOCHEM BIOPH METH, V20, P259, DOI 10.1016/0165-022X(90)90084-P; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU W, 1994, J IMMUNOL, V153, P4179; COLLINS T, 1991, J BIOL CHEM, V266, P2466; COWSERT LM, 1993, ANTIMICROB AGENTS CH, V37, P171, DOI 10.1128/AAC.37.2.171; Crooke ST., 1995, THERAPEUTIC APPL OLI; DAHLE CE, 1993, BIOTECHNIQUES, V15, P1; DOMINSKI Z, 1993, P NATL ACAD SCI USA, V90, P8673, DOI 10.1073/pnas.90.18.8673; FISHER TL, 1993, NUCLEIC ACIDS RES, V21, P3857, DOI 10.1093/nar/21.16.3857; GILES RV, 1992, ANTI-CANCER DRUG DES, V7, P37; GILES RV, 1995, ANTISENSE RES DEV, V5, P23, DOI 10.1089/ard.1995.5.23; GREENBERG ME, 1994, CURRENT PROTOCOLS MO; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HODGE D, 1995, MOL PHARMACOL, V48, P905; HOGREFE HH, 1990, J BIOL CHEM, V265, P5561; Lebleu B., 1993, ANTISENSE RES APPL; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; MIRABELLI CK, 1991, ANTI-CANCER DRUG DES, V6, P647; MONIA BP, 1993, J BIOL CHEM, V268, P14514; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515	33	52	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30398	30403		10.1074/jbc.271.48.30398	http://dx.doi.org/10.1074/jbc.271.48.30398			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940003	hybrid			2022-12-27	WOS:A1996VV15800020
J	Karecla, PI; Green, SJ; Bowden, SJ; Coadwell, J; Kilshaw, PJ				Karecla, PI; Green, SJ; Bowden, SJ; Coadwell, J; Kilshaw, PJ			Identification of a binding site for integrin alpha E beta(7) in the N-terminal domain of E-cadherin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; INTRAEPITHELIAL LYMPHOCYTES; INTESTINAL LYMPHOCYTES; CYTOPLASMIC DOMAIN; SURFACE-ANTIGEN; BINDING; UVOMORULIN; VCAM-1; ALPHA-4-BETA-1; SUPERFAMILY	The integrin alpha E beta 7, which is predominantly expressed on mucosal T lymphocytes, has recently been shown to recognize the cell adhesion molecule, E-cadherin, on epithelial cells. We have carried out mutations on E-cadherin, involving domain deletions as web as substitutions of specific amino acids, in order to identify the sites recognized by the integrin. Binding of alpha E beta 7 required the presence of the first two N-terminal domains of E-cadherin, Deletion of extracellular domains 3 and 4 or truncation of the cytoplasmic domain of E-cadherin had no consequence on integrin binding, Substitution of a glutamic acid in the BC loop of the Ig structure of the fist, N-terminal, domain of E-cadherin abrogated binding of alpha E beta 7. This mutation did not appear to affect the conformation of the domain nor the pattern of expression of E-cadherin on the cell surface, Synthetic peptides encompassing the first domain of E-cadherin had very little inhibitory effect on the interaction with alpha E beta 7. Our results highlight structural dissimilarities between recognition of E-cadherin by alpha E beta 7 and recognition of other members of the IgSF by integrins and show that the heterophilic (integrin binding) and homophilic sites in the N-terminal domain of E-cadherin are distinct.	BABRAHAM INST, DEPT IMMUNOL, CAMBRIDGE CB2 4AT, ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute				Bowden, Simon/0000-0003-4609-8114				AUSTRUP F, 1995, EUR J IMMUNOL, V25, P1487, DOI 10.1002/eji.1830250602; BOLLER K, 1985, J CELL BIOL, V100, P3327; Briskin MJ, 1996, J IMMUNOL, V156, P719; CEPEK KL, 1994, NATURE, V372, P1190; CERFBENSUSSAN N, 1987, EUR J IMMUNOL, V17, P1279, DOI 10.1002/eji.1830170910; CERFBENSUSSAN N, 1992, EUR J IMMUNOL, V22, P273, DOI 10.1002/eji.1830220140; CLEMENTS JM, 1994, J CELL SCI, V107, P2127; COWIN P, 1994, P NATL ACAD SCI USA, V91, P10759, DOI 10.1073/pnas.91.23.10759; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; Grunwald GB, 1993, CURR OPIN CELL BIOL, V5, P797, DOI 10.1016/0955-0674(93)90028-O; HAMANN A, 1994, J IMMUNOL, V152, P3282; HAURY M, 1993, EUR J IMMUNOL, V23, P313, DOI 10.1002/eji.1830230202; HINCK L, 1994, TRENDS BIOCHEM SCI, V19, P538, DOI 10.1016/0968-0004(94)90057-4; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLNESS CL, 1995, J BIOL CHEM, V270, P877, DOI 10.1074/jbc.270.2.877; HOLNESS CL, 1994, J CELL SCI, V107, P2065; KARECLA PI, 1995, EUR J IMMUNOL, V25, P852, DOI 10.1002/eji.1830250333; KILSHAW PJ, 1990, EUR J IMMUNOL, V20, P2201, DOI 10.1002/eji.1830201008; KILSHAW PJ, 1988, IMMUNOL LETT, V18, P149, DOI 10.1016/0165-2478(88)90056-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LI R, 1993, J BIOL CHEM, V268, P17513; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; NOSE A, 1987, EMBO J, V6, P3655, DOI 10.1002/j.1460-2075.1987.tb02698.x; OSBORN L, 1994, J CELL BIOL, V124, P601, DOI 10.1083/jcb.124.4.601; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; OZAWA M, 1991, MECH DEVELOP, V33, P49; POKUTTA S, 1994, EUR J BIOCHEM, V223, P1019, DOI 10.1111/j.1432-1033.1994.tb19080.x; RENZ ME, 1994, J CELL BIOL, V125, P1395, DOI 10.1083/jcb.125.6.1395; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; ROBERTS K, 1993, EUR J IMMUNOL, V23, P1630, DOI 10.1002/eji.1830230735; SARNACKI S, 1991, IMMUNOL RES, V10, P302, DOI 10.1007/BF02919711; SHAPIROO L, 1994, NATURE, V374, P327; SHIRAYOSHI Y, 1986, CELL STRUCT FUNCT, V11, P245, DOI 10.1247/csf.11.245; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Viney JL, 1996, J IMMUNOL, V157, P2488; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; VONDERHEIDE RH, 1994, J CELL BIOL, V125, P215, DOI 10.1083/jcb.125.1.215; WANG JH, 1995, P NATL ACAD SCI USA, V92, P5714, DOI 10.1073/pnas.92.12.5714	48	75	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30909	30915		10.1074/jbc.271.48.30909	http://dx.doi.org/10.1074/jbc.271.48.30909			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940076	hybrid			2022-12-27	WOS:A1996VV15800093
J	Niimura, Y; Massey, V				Niimura, Y; Massey, V			Reaction mechanism of Amphibacillus xylanus NADH oxidase alkyl hydroperoxide reductase flavoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA GLUTATHIONE-PEROXIDASE; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; THIOREDOXIN REDUCTASE; LACKING CYTOCHROME; PURIFICATION; CATALASE; QUINONE; DISTINCT; ENZYME	NADH oxidase from Amphibacillus xylanus is a potent alkyl hydroperoxide reductase in the presence of the small disulfide-containing protein (AhpC) of Salmonella typhimurium, In the presence of saturating AhpC, k(cat) values for reduction of hydroperoxides are approximately 180 s(-1), and the double mutant flavoprotein enzyme C337S/C340S cannot support hydroperoxide reduction (Niimura, Y., Poole, L. B., and Massey, V. (1995) J. Biol. Chem. 270, 25645-25650). Kinetics of reduction of wild-type and mutant enzymes are reported here with wild-type enzyme; reduction by NADH was triphasic, with consumption of 2.6 equivalents of NADH, consistent with the known composition of one FAD and two disulfides per subunit, Rate constants for the first two phases (each approximately 200 s(-1)) where FAD and one disulfide are reduced are slightly greater than k(cat) values for AhpC-linked hydroperoxide reduction, The rate constant for the third phase (reduction to the 6-electron level) is too small for catalysis, Only the first phase of the wild-type enzyme occurs with the mutant enzyme. These results and the stoichiometry of NADH consumption indicate Cys(337) and Cys(340) as the active site disulfide of the flavoprotein and that electrons from FADH(2) must pass through this disulfide to reduce the disulfide of AhpC.	TOKYO UNIV AGR, DEPT FOOD SCI & TECHNOL, ABASHIRI, HOKKAIDO 09924, JAPAN	Tokyo University of Agriculture	Niimura, Y (corresponding author), UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, 1301 CATHERINE RD, ANN ARBOR, MI 48109 USA.				NIGMS NIH HHS [GM-11106] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011106, R37GM011106] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEATY NB, 1981, J BIOL CHEM, V256, P4611; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; BRISSETTE P, 1989, ANAL BIOCHEM, V181, P234, DOI 10.1016/0003-2697(89)90235-2; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAUDIERE J, 1983, ARCH BIOCHEM BIOPHYS, V226, P448, DOI 10.1016/0003-9861(83)90314-4; COCCO D, 1988, EUR J BIOCHEM, V174, P267, DOI 10.1111/j.1432-1033.1988.tb14093.x; FLOHE L, 1972, H-S Z PHYSIOL CHEM, V353, P987, DOI 10.1515/bchm2.1972.353.1.987; HIGUCHI M, 1993, J GEN MICROBIOL, V139, P2343, DOI 10.1099/00221287-139-10-2343; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; KOIKE K, 1985, J BIOCHEM, V97, P1279, DOI 10.1093/oxfordjournals.jbchem.a135179; KOYAMA N, 1988, FEMS MICROBIOL LETT, V49, P128; LITTLE C, 1972, BIOCHIM BIOPHYS ACTA, V284, P375, DOI 10.1016/0005-2744(72)90133-7; NIIMURA Y, 1993, J BACTERIOL, V175, P7945, DOI 10.1128/JB.175.24.7945-7950.1993; NIIMURA Y, 1995, J BIOL CHEM, V270, P25645, DOI 10.1074/jbc.270.43.25645; NIIMURA Y, 1987, AGR BIOL CHEM TOKYO, V51, P2271; NIIMURA Y, 1990, INT J SYST BACTERIOL, V40, P297, DOI 10.1099/00207713-40-3-297; NIIMURA Y, 1989, FEMS MICROBIOL LETT, V61, P79, DOI 10.1016/S0378-1097(98)00072-X; OGURA Y, 1955, ARCH BIOCHEM BIOPHYS, V57, P288, DOI 10.1016/0003-9861(55)90291-5; OHNISHI K, 1995, J BIOL CHEM, V270, P5812, DOI 10.1074/jbc.270.11.5812; OHNISHI K, 1994, J BIOL CHEM, V269, P31418; PARK HJ, 1992, EUR J BIOCHEM, V205, P881, DOI 10.1111/j.1432-1033.1992.tb16853.x; PARSONAGE D, 1993, J BIOL CHEM, V268, P3161; PRONGAY AJ, 1989, J BIOL CHEM, V264, P2656; REINARDS R, 1981, EUR J BIOCHEM, V120, P329, DOI 10.1111/j.1432-1033.1981.tb05708.x; SAEKI Y, 1985, J BIOCHEM-TOKYO, V98, P1433, DOI 10.1093/oxfordjournals.jbchem.a135411; SCHMIDT HL, 1986, EUR J BIOCHEM, V156, P149, DOI 10.1111/j.1432-1033.1986.tb09560.x; TAKAHASHI K, 1987, ARCH BIOCHEM BIOPHYS, V256, P677, DOI 10.1016/0003-9861(87)90624-2; TARTAGLIA LA, 1990, J BIOL CHEM, V265, P10535; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121	31	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30459	30464		10.1074/jbc.271.48.30459	http://dx.doi.org/10.1074/jbc.271.48.30459			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940011	hybrid			2022-12-27	WOS:A1996VV15800028
J	Wakiya, K; Begue, A; Stehelin, D; Shibuya, M				Wakiya, K; Begue, A; Stehelin, D; Shibuya, M			A cAMP response element and an Ets motif are involved in the transcriptional regulation of flt-1 tyrosine kinase (vascular endothelial growth factor receptor 1) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; PERMEABILITY FACTOR; TUMOR ANGIOGENESIS; BINDING PROTEINS; CELLS SECRETE; C-FOS; EXPRESSION; FAMILY; PROMOTER; IDENTIFICATION	The fit-1 gene encodes a transmembrane tyrosine kinase, Fit-1, a receptor for vascular endothelial growth factor. The expression of fit-1 gene is restricted to endothelial cells in vivo, To understand the molecular mechanism underlying endothelial-specific expression of this gene, we studied the functional significance of transcriptional motifs in the 200-base pair region of the human fit-1 gene promoter, which has been identified to confer cell type specificity. By point mutation analysis using chloramphenicol acetyltransferase plasmids in 293E1 cells, which express significant levels of fit-1 mRNA, me found that an Ets motif, E4, at -54 to -51 and a cAMP response element (GRE) at -83 to -76 are involved in the transcriptional regulation of this gene, Disruption of either this GRE or E4 within the promoter sequence of 90 base pairs resulted in a decrease in chloramphenicol acetyltransferase activity of 90%, indicating that co-existence of both of CRE and Ets motif E4 is necessary for transcription of the fit-1 gene. Go-transfection of an expression vector containing c-ets-l, c-ets-2, or c-erg cDNA with this 90-base pair sequence yielded a 5-8-fold elevation of chloramphenicol acetyltransferase activity, further supporting the idea that Ets family protein(s) participates in the regulation of the fit-1 gene. Gel shift assays using nuclear extracts of 293E1 and endothelial cells demonstrated the existence of protein factor(s) that specifically binds to CRE and Ets motif E4, respectively. Taken together, our results strongly suggest cooperation of a GRE and an Ets motif for the function of the fit-1 gene promoter.	UNIV TOKYO,INST MED SCI,DEPT GENET,MINATO KU,TOKYO 108,JAPAN; INST PASTEUR,CNRS URA 1160,UNITE ONCOL MOL,F-59019 LILLE,FRANCE	University of Tokyo; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille								AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BREIER G, 1992, DEVELOPMENT, V114, P521; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRISCUOLO GR, 1993, YALE J BIOL MED, V66, P277; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUTERQUECOQUILLAUD M, 1993, ONCOGENE, V8, P1865; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GALLAND F, 1993, ONCOGENE, V8, P1233; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IKEDA T, 1996, IN PRESS GROWTH FACT; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MCCLURE N, 1994, LANCET, V344, P235, DOI 10.1016/S0140-6736(94)93001-5; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MORISHITA K, 1995, J BIOL CHEM, V270, P27948, DOI 10.1074/jbc.270.46.27948; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLATE KH, 1993, CANCER RES, V53, P5822; Sambrook J., 2002, MOL CLONING LAB MANU; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; Shibuya M, 1995, ADV CANCER RES, V67, P281, DOI 10.1016/S0065-230X(08)60716-2; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; VANDENBUNDER B, 1989, DEVELOPMENT, V106, P265; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WERNERT N, 1994, CANCER RES, V54, P5683; WERNERT N, 1992, AM J PATHOL, V140, P119; YAMANE A, 1994, ONCOGENE, V9, P2683	50	128	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30823	30828		10.1074/jbc.271.48.30823	http://dx.doi.org/10.1074/jbc.271.48.30823			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940064	hybrid			2022-12-27	WOS:A1996VV15800081
J	Yanagi, S; Sugawara, H; Kurosaki, M; Sabe, H; Yamamura, H; Kurosaki, T				Yanagi, S; Sugawara, H; Kurosaki, M; Sabe, H; Yamamura, H; Kurosaki, T			CD45 modulates phosphorylation of both autophosphorylation and negative regulatory tyrosines of Lyn in B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR COMPLEX; NATURAL-KILLER CELLS; FC-GAMMA-RECEPTOR; SIGNAL-TRANSDUCTION; AUTOIMMUNE-DISEASE; DEFICIENT MICE; PROTEIN-KINASE; PHOSPHATASE; ACTIVATION; SRC	CD45 is a tyrosine phosphatase that is required for normal B cell receptor (BCR)-mediated signaling. It has been shown that Src-family tyrosine kinases such as Lyn could be a potential substrate for CD45. In vitro studies indicate that activities of Src family tyrosine kinases are regulated by tyrosine phosphorylation; C-terminal phosphorylation is inhibitory, and autophosphorylation is stimulatory. We report here that both autophosphorylation and C-terminal negative regulatory tyrosines of Lyn were hyperphosphorylated in CD45-deficient DT40 B cells, In this mutant cell, BCR-induced protein-tyrosine phosphorylation and calcium mobilization were severely compromised, as seen in Lyn-deficient cells. Consistent with this observation, Lyn activation upon receptor ligation was profoundly decreased in CD45-deficient cells. Taken together, our results suggest that dephosphorylation of tyrosine residues at both autophosphorylation and negative regulatory sites is mediated by CD45 in vivo, and that dephosphorylation of C-terminal tyrosine is a prerequisite for participation of Lyn in BCR signaling.	KANSAI MED UNIV, INST HEPAT RES, DEPT MOL GENET, MORIGUCHI, OSAKA 570, JAPAN; YALE UNIV, SCH MED, IMMUNOBIOL SECT, NEW HAVEN, CT 06510 USA; KOBE UNIV, SCH MED, DEPT BIOCHEM, KOBE 650, JAPAN; JAPAN SCI & TECHNOL CORP, PRECURSOR RES & EMBRYON SCI & TECHNOL, KYOTO 606, JAPAN; KYOTO UNIV, INST VIRUS RES, SAKYO KU, KYOTO 606, JAPAN	Kansai Medical University; Yale University; Kobe University; Japan Science & Technology Agency (JST); Kyoto University			Sugawara, Hitoshi/Y-5081-2019; Sabe, Hisataka/A-4066-2012; Sabe, Hisataka/GPF-4385-2022; Kurosaki, Tomohiro/D-1306-2009	Sugawara, Hitoshi/0000-0002-5060-9020; Kurosaki, Tomohiro/0000-0002-6352-304X				BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROWN VK, 1994, J BIOL CHEM, V269, P17238; BURNS CM, 1994, J BIOL CHEM, V269, P13594; CLARK MR, 1994, EMBO J, V13, P1911, DOI 10.1002/j.1460-2075.1994.tb06460.x; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; FANG KS, 1994, J BIOL CHEM, V269, P14056; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HATA A, 1994, MOL CELL BIOL, V14, P7306, DOI 10.1128/MCB.14.11.7306; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; JUSTEMENT LB, 1994, IMMUNOL TODAY, V15, P399, DOI 10.1016/0167-5699(94)90268-2; KATAGIRI T, 1995, J BIOL CHEM, V270, P27987; KAWAUCHI K, 1994, J IMMUNOL, V152, P3306; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; OGIMOTO M, 1995, EUR J IMMUNOL, V25, P2265, DOI 10.1002/eji.1830250823; OGIMOTO M, 1994, INT IMMUNOL, V6, P647, DOI 10.1093/intimm/6.4.647; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PELTZ GA, 1989, P NATL ACAD SCI USA, V86, P1013, DOI 10.1073/pnas.86.3.1013; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SAGA Y, 1986, P NATL ACAD SCI USA, V83, P6940, DOI 10.1073/pnas.83.18.6940; SCALLON BJ, 1989, P NATL ACAD SCI USA, V86, P5079, DOI 10.1073/pnas.86.13.5079; SIMMONS D, 1988, NATURE, V333, P568, DOI 10.1038/333568a0; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; VOLAREVIC S, 1993, SCIENCE, V260, P541, DOI 10.1126/science.8475386	39	94	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30487	30492		10.1074/jbc.271.48.30487	http://dx.doi.org/10.1074/jbc.271.48.30487			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940015	hybrid			2022-12-27	WOS:A1996VV15800032
J	Zhang, JZ; Redman, C				Zhang, JZ; Redman, C			Fibrinogen assembly and secretion - Role of intrachain disulfide loops	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CHAIN; ELECTRON-MICROSCOPY; ALPHA-CHAINS; SEQUENCES; BONDS; CELLS; IDENTIFICATION; MOLECULES; HOMOLOGY; DOMAINS	Human fibrinogen is a homodimer composed of three different (A alpha, B beta, gamma) polypeptide chains, The chains are linked by 29 inter- and intrachain disulfide bonds. Each half-molecule has 6 intrachain disulfide bonds, which form loops in the carboxyl-terminal region of each of the chains, A alpha chain has one disufide loop (Cys(442)-Cys(472)), B beta has three (Cys(201)-Cys(286), Cys(211)-Cys(240), and Cys(394)-Cys(407)), and gamma has two loops (Cys(153)-Cys(182) and Cys(826)-Cys(339)). The intrachain loops are conserved in fibrinogens of different species, We changed, by site-directed mutagenesis, the cysteines, which form the intrachain loops, to serine or alanine, Fibrinogen chain assembly and secretion was determined in transiently transfected COS cells expressing two normal and a mutant fibrinogen chain. In the B beta and gamma chains, disruption of the disulfide loops closest to the ''coiled-coil'' region (Cys(B beta 211)-Cys(240), Cys(B beta 201)-Cys(286), and Cys(gamma 153)-Cys(182)) abolished chain assembly and secretion, indicating that the disulfide loops closest to the coiled-coil region are essential for chain assembly, By contrast, preventing formation of the disulfide loops, which are toward the carboxyl termini of each of the chains, had different effects, Disruption of the single A alpha disulfide loop had no effect, as did disruption of B beta Cys(394)-Cys(407). However, disruption of Cys(gamma 326)-Cys(339), which is similar in size and location to Cys(B beta 394)-Cys(407), allowed chain assembly to occur, but the assembled chains were not secreted.	NEW YORK BLOOD CTR, LINDSLEY F KIMBALL RES INST, NEW YORK, NY 10021 USA	New York Blood Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037457] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37457] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKER NE, 1990, SCIENCE, V250, P1370, DOI 10.1126/science.2175046; BLOMBACK B, 1968, NATURE, V218, P130, DOI 10.1038/218130a0; Blomback B, 1996, THROMB RES, V83, P1, DOI 10.1016/0049-3848(96)00111-9; BLOMBACK B, 1976, THROMB RES, V8, P639, DOI 10.1016/0049-3848(76)90245-0; BOUMA H, 1978, THROMB RES, V13, P557, DOI 10.1016/0049-3848(78)90142-1; DANISHEFSKY K, 1990, BIOCHIM BIOPHYS ACTA, V1048, P202, DOI 10.1016/0167-4781(90)90057-9; DOOLITTLE RF, 1978, J MOL BIOL, V120, P311, DOI 10.1016/0022-2836(78)90070-0; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; DOOLITTLE RF, 1981, SCI AM, V245, P126, DOI 10.1038/scientificamerican1281-126; FU YP, 1992, BIOCHEMISTRY-US, V31, P11968, DOI 10.1021/bi00163a002; FU YP, 1994, P NATL ACAD SCI USA, V91, P2625, DOI 10.1073/pnas.91.7.2625; HALL CE, 1959, J BIOPHYS BIOCHEM CY, V5, P11, DOI 10.1083/jcb.5.1.11; HENSCHEN A, 1983, ANN NY ACAD SCI, V408, P28, DOI 10.1111/j.1749-6632.1983.tb23232.x; HOEPRICH PD, 1983, BIOCHEMISTRY-US, V22, P2049, DOI 10.1021/bi00278a003; HUANG SM, 1993, J BIOL CHEM, V268, P8919; HUANG SM, 1993, BIOCHEM BIOPH RES CO, V190, P488, DOI 10.1006/bbrc.1993.1074; IWANAGA S, 1967, BIOCHIM BIOPHYS ACTA, V147, P606, DOI 10.1016/0005-2795(67)90025-6; JONES FS, 1988, P NATL ACAD SCI USA, V85, P2186, DOI 10.1073/pnas.85.7.2186; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KOYAMA T, 1987, P NATL ACAD SCI USA, V84, P1609, DOI 10.1073/pnas.84.6.1609; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MOSESSON MW, 1981, J MOL BIOL, V153, P695, DOI 10.1016/0022-2836(81)90414-9; MURAKAWA M, 1993, THROMB HAEMOSTASIS, V69, P351; PAN Y, 1992, P NATL ACAD SCI USA, V89, P2066, DOI 10.1073/pnas.89.6.2066; RAO SPS, 1991, J MOL BIOL, V222, P89, DOI 10.1016/0022-2836(91)90739-S; ROY SN, 1991, J BIOL CHEM, V266, P4758; ROY SN, 1990, J BIOL CHEM, V265, P6389; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WEISEL JW, 1981, NATURE, V289, P263, DOI 10.1038/289263a0; YU S, 1984, J BIOL CHEM, V259, P574; YU S, 1983, J BIOL CHEM, V258, P3407; ZHANG JZ, 1992, J BIOL CHEM, V267, P21727; ZHANG JZ, 1994, J BIOL CHEM, V269, P652; ZHANG JZ, 1993, J BIOL CHEM, V268, P11278; Zhang JZ, 1996, J BIOL CHEM, V271, P12674, DOI 10.1074/jbc.271.21.12674	35	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30083	30088		10.1074/jbc.271.47.30083	http://dx.doi.org/10.1074/jbc.271.47.30083			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939956	hybrid			2022-12-27	WOS:A1996VU52500084
J	Zhao, Y; Bjorbaek, C; Moller, DE				Zhao, Y; Bjorbaek, C; Moller, DE			Regulation and interaction of pp90(rsk) isoforms with mitogen-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL S6 KINASE; NERVE GROWTH-FACTOR; NIH 3T3 CELLS; MAP KINASE; SIGNAL-TRANSDUCTION; NUCLEAR TRANSLOCATION; XENOPUS OOCYTES; SKELETAL-MUSCLE; PHORBOL ESTER; PC12 CELLS	Each of the three known mammalian 90-kDa S6 kinase (pp90(rsk)) isoforms (RSK1, RSK2, and RSK3) was expressed in transfected cells and further characterized, The kinase activity (immunocomplex toward S6 peptide) of each isoform was activated by in vivo growth factor (epidermal growth factor (EGF)) stimulation; RSK1 was more responsive (10-15-fold) versus RSK2 and RSK3 (2-4-fold). Pretreatment with PD98059 (MEK1 inhibitor) partially (80%) blocked EGF-mediated ERK1 activation and had similar effects on EGF stimulation of each ribosomal S6 kinase (RSK). Cotransfection with dominant-negative MEK1 inhibited activation of each RSK; furthermore, the kinase activity of RSK1, RSK2, and RSK3 was markedly increased by cotransfection with constitutively active MEK1. A specific association between mitogen-activated protein kinases (MAPKs) (ERK1 and ERK2) and RSK isoforms was tested by MAPK immunoblotting after immunoprecipitation of RSKs. ERK1 and ERK2 were present in RSK3 (and to a lesser extent, RSK2) immunoprecipitates, but were absent in RSK1 immunoprecipitates. Both dephosphorylated (from quiescent cells) and phosphorylated (from stimulated cells) MAPKs were associated with RSK2 and RSK3. Deletion mutants of RSK3 were characterized: the C terminus (33 residues) was shown to be required for association with MAPKs. The kinase activity of RSK1 or RSK2 was enhanced by in vitro incubation with ERK1. In contrast, RSK3 activity was not affected by exposure to ERK1. Furthermore, MAPKs in RSK3 immunoprecipitates were phosphorylated by purified MEK1; however, RSK3 kinase activity was unaffected. We conclude that 1) the MEK1-MAPK signaling pathway is both necessary and sufficient for in vivo growth factor-mediated activation of all three RSK isoforms; 2) RSK isoforms differ with respect to growth factor responsiveness and their physical association with MAPK; and 3) formation of the MAPK RSK complex is mediated by the RSK C terminus.	MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT MOL ENDOCRINOL,RAHWAY,NJ 07065; BETH ISRAEL HOSP,DEPT MED,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215	Merck & Company; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School			Bjorbaek, Christian/S-4727-2019		PHS HHS [R01 45874-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AHN NG, 1991, J BIOL CHEM, V266, P4220; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ANDERSON NG, 1993, BIOCHEM BIOPH RES CO, V193, P284, DOI 10.1006/bbrc.1993.1621; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; BJORBAEK C, 1995, DIABETES, V44, P90, DOI 10.2337/diabetes.44.1.90; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P336; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1993, BIOCHEM SOC T, V21, P895, DOI 10.1042/bst0210895; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ERIKSON E, 1987, MOL CELL BIOL, V7, P3147, DOI 10.1128/MCB.7.9.3147; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; GROVE JR, 1993, BIOCHEMISTRY-US, V32, P7727, DOI 10.1021/bi00081a018; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; JURIVICH DA, 1991, J CELL PHYSIOL, V148, P252, DOI 10.1002/jcp.1041480210; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KHARBANDA S, 1994, P NATL ACAD SCI USA, V91, P5416, DOI 10.1073/pnas.91.12.5416; KYRIAKIS JM, 1993, PROTEIN KINASES FRON; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MOLLER DE, 1994, AM J PHYSIOL, V266, pC351, DOI 10.1152/ajpcell.1994.266.2.C351; MOLLER DE, 1990, J BIOL CHEM, V265, P14979; MYERS MP, 1994, MOL CELL BIOL, V14, P6954, DOI 10.1128/MCB.14.10.6954; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCIMECA JC, 1992, J BIOL CHEM, V267, P17369; SEGER R, 1994, J BIOL CHEM, V269, P25699; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; THOMAS G, 1993, BIOCHEM SOC T, V21, P901, DOI 10.1042/bst0210901; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	51	141	149	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29773	29779		10.1074/jbc.271.47.29773	http://dx.doi.org/10.1074/jbc.271.47.29773			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939914	hybrid			2022-12-27	WOS:A1996VU52500042
J	Ahmed, MM; Venkatasubbarao, K; Fruitwala, SM; Muthukkumar, S; Wood, DP; Sells, SF; Mohiuddin, M; Rangnekar, VM				Ahmed, MM; Venkatasubbarao, K; Fruitwala, SM; Muthukkumar, S; Wood, DP; Sells, SF; Mohiuddin, M; Rangnekar, VM			EGR-1 induction is required for maximal radiosensitivity in A375-C6 melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR EGR-1; TUMOR-GROWTH ARREST; WILD-TYPE P53; PROTEIN; APOPTOSIS; DIFFERENTIATION; IRRADIATION; EXPRESSION; RADIATION	Exposure to ionizing radiation leads to induction of the immediate-early gene, early growth response-1 (Egr-1). Previous studies have suggested distinct cell type- and inducer-specific roles for EGR-1 protein in cellular growth inhibition. The present study was undertaken to determine the functional role of EGR-1 in growth inhibition caused by exposure of tumor cells to ionizing radiation. Exposure to ionizing radiation caused induction of EGR-1 protein in human melanoma cells A375-C6. Inhibition of either the function of EGR-1 protein by stable transfection with a dominant-negative mutant or the expression of EGR-1 by transient transfection with an antisense oligomer resulted in a diminished growth-inhibitory response to ionizing radiation. Because previous studies have suggested that mutations in the tumor-suppressor gene p53 confer radio-resistance, we examined the p53 status of A375-C6 cells. Interestingly, both the parental and the transfected A375-C6 cells showed trisomy for wild-type p53 alleles. Exposure to ionizing radiation resulted in induction of p53 protein that localized to the nucleus in A375-C6 cells. These data suggest that inhibition of EGR-1 function confers radio resistance despite the induction of wild-type nuclear p53. Thus, EGR-1 is required for the growth-inhibitory response to ionizing radiation in A375-C6 cells.	UNIV KENTUCKY,DEPT SURG,DIV UROL,LEXINGTON,KY 40536; UNIV KENTUCKY,DEPT RADIAT MED,LEXINGTON,KY 40536; UNIV KENTUCKY,DEPT MICROBIOL & IMMUNOL,LEXINGTON,KY 40536; UNIV KENTUCKY,LUCILLE P MARKEY CANC CTR,LEXINGTON,KY 40536	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky			Ahmed, Mansoor/AAK-5988-2020		NATIONAL CANCER INSTITUTE [R29CA052837, R01CA060872] Funding Source: NIH RePORTER; NCI NIH HHS [CA52837, CA60872] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HOPMAN AHN, 1988, HISTOCHEMISTRY, V89, P307, DOI 10.1007/BF00500631; HUANG RP, 1995, ONCOGENE, V10, P467; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MUTHUKKUMAR S, 1995, MOL CELL BIOL, V15, P6262; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; RANGNEKAR VV, 1992, J BIOL CHEM, V267, P6240; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; SELLS SF, 1995, MOL CELL BIOL, V15, P682; SUGGS SV, 1990, NUCLEIC ACIDS RES, V18, P4283, DOI 10.1093/nar/18.14.4283; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Svaren J, 1996, MOL CELL BIOL, V16, P3545; URMANSKY SR, 1991, APOPTOSIS MOL BASIS, P193	23	68	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29231	29237		10.1074/jbc.271.46.29231	http://dx.doi.org/10.1074/jbc.271.46.29231			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910582	hybrid			2022-12-27	WOS:A1996VT05200074
J	Ariazi, EA; Gould, MN				Ariazi, EA; Gould, MN			Identifying differential gene expression in monoterpene-treated mammary carcinomas using subtractive display	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; FACTOR-II RECEPTOR; PROTEIN MESSENGER-RNA; FACTOR-BETA RECEPTORS; D-LIMONENE; PERILLYL ALCOHOL; INDUCED REGRESSION; AMYLOID PROTEIN; PCR PRODUCTS; INHIBITION	Monoterpene-induced/repressed genes were identified in regressing rat mammary carcinomas treated with dietary limonene using a newly developed method termed subtractive display. The subtractive display screen identified 42 monoterpene-induced genes comprising 9 known genes and 33 unidentified genes, as well as 58 monoterpene-repressed genes comprising I known gene and 57 unidentified genes. Several of the identified differentially expressed genes are involved in the mitoinhibitory transforming growth factor beta signal tranduction pathway, as demonstrated by isolation of the mannose 6-phosphate/insulin-like growth factor II receptor and the transforming growth factor beta type II receptor. The monoterpene-induced/repressed genes indicate that apoptosis and differentiation act in concert to effect-carcinoma regression. Apoptosis is suggested by the cloning of a marker of programmed cell death, lipocortin 1. Consistent with a differentiation/remodeling process occurring during tumor regression, subtractive display identified YWK-II and neuroligin 1. Thus far, of the cDNAs putatively identified as differentially expressed in this complex in situ carcinoma model, 5 were tested, and each one has been confirmed to be differentially expressed. Additionally, many of the identified known genes are expressed as rare transcripts and exhibit small but significant changes in abundance. Together, these points demonstrate the unique utility of this new gene expression screen to identify altered gene expression in a complex in vivo environment.	UNIV WISCONSIN,DEPT HUMAN ONCOL,MADISON,WI 53792	University of Wisconsin System; University of Wisconsin Madison			Gould, Michael N/C-7414-2014		NATIONAL CANCER INSTITUTE [R37CA038128] Funding Source: NIH RePORTER; NCI NIH HHS [R37-CA38128] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschul SF, 1990, J MOL BIOL, V215, P403; ARAKI N, 1993, J BONE MINER RES, V8, P313; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; CALLARD D, 1994, BIOTECHNIQUES, V16, P1096; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; CHEN RH, 1995, J BIOL CHEM, V270, P12235, DOI 10.1074/jbc.270.20.12235; CROWELL PL, 1992, CARCINOGENESIS, V13, P1261, DOI 10.1093/carcin/13.7.1261; CROWELL PL, 1994, CRIT REV ONCOGENESIS, V5, P1; CROWELL PL, 1991, J BIOL CHEM, V266, P17679; CROWELL PL, 1994, BIOCHEM PHARMACOL, V47, P1405, DOI 10.1016/0006-2952(94)90341-7; DEBUIRE B, 1995, CLIN CHEM, V41, P819; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; DESOUZA AT, 1995, ONCOGENE, V10, P1725; ELEGBEDE JA, 1984, CARCINOGENESIS, V5, P661, DOI 10.1093/carcin/5.5.661; ELSON CE, 1988, CARCINOGENESIS, V9, P331, DOI 10.1093/carcin/9.2.331; Filmus Jorge, 1993, Current Opinion in Oncology, V5, P123; FUKUCHI K, 1992, J NEUROCHEM, V58, P1863, DOI 10.1111/j.1471-4159.1992.tb10063.x; GEBHARDT A, 1994, J LIPID RES, V35, P976; GELB MH, 1995, CANCER LETT, V91, P169, DOI 10.1016/0304-3835(95)03747-K; GOULD MN, 1994, CANCER RES, V54, P3540; GOULD MN, 1995, J CELL BIOCHEM, P139; HAAG JD, 1994, CANCER CHEMOTH PHARM, V34, P477, DOI 10.1007/BF00685658; HAAG JD, 1992, CANCER RES, V52, P4021; HADMAN M, 1995, ANAL BIOCHEM, V266, P383; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; JIRTLE RL, 1993, CANCER RES, V53, P3849; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KAWAGUCHI H, 1994, ENDOCR RES, V20, P219, DOI 10.1080/07435809409035860; KONIG G, 1990, FEBS LETT, V269, P305, DOI 10.1016/0014-5793(90)81181-M; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KOVACINA KS, 1989, BIOCHEM BIOPH RES CO, V160, P393, DOI 10.1016/0006-291X(89)91669-0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1995, METHOD ENZYMOL, V254, P304; LIANG P, 1995, CURR OPIN IMMUNOL, V7, P274, DOI 10.1016/0952-7915(95)80015-8; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; MALTZMAN TH, 1989, CARCINOGENESIS, V10, P781, DOI 10.1093/carcin/10.4.781; MCKANNA JA, 1995, ANAT REC, V242, P1, DOI 10.1002/ar.1092420102; MCNAMEE D, 1993, LANCET, V342, P801, DOI 10.1016/0140-6736(93)91561-Y; MOU LJ, 1994, BIOCHEM BIOPH RES CO, V199, P564, DOI 10.1006/bbrc.1994.1265; Mularoni A, 1995, BIOCHEM BIOPH RES CO, V217, P1105, DOI 10.1006/bbrc.1995.2883; REN ZB, 1994, CANCER LETT, V76, P185, DOI 10.1016/0304-3835(94)90396-4; RUSSIN WA, 1989, CARCINOGENESIS, V10, P2161, DOI 10.1093/carcin/10.11.2161; SANGUINETTI CJ, 1994, BIOTECHNIQUES, V17, P914; SHI WG, 1995, CANCER LETT, V95, P1, DOI 10.1016/0304-3835(95)03859-U; SUE SR, 1995, ANN SURG, V222, P171, DOI 10.1097/00000658-199508000-00009; VANAGE G, 1992, BIOCHEM BIOPH RES CO, V183, P538, DOI 10.1016/0006-291X(92)90515-M; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAN YC, 1990, P NATL ACAD SCI USA, V87, P2405, DOI 10.1073/pnas.87.7.2405; YAN YC, 1992, ARCH ANDROLOGY, V28, P1; ZHAO JS, 1995, GENE, V155, P159, DOI 10.1016/0378-1119(94)00895-Y; ZHAO S, 1995, BIOTECHNIQUES, V18, P842	54	31	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29286	29294		10.1074/jbc.271.46.29286	http://dx.doi.org/10.1074/jbc.271.46.29286			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910589	hybrid			2022-12-27	WOS:A1996VT05200081
J	Diamond, SE; GutierrezHartmann, A				Diamond, SE; GutierrezHartmann, A			A 26-amino acid insertion domain defines a functional transcription switch motif in Pit-1 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; GROWTH-HORMONE; POU-DOMAIN; PITUITARY; PROMOTER; PROTEIN; RAS; PIT-1/GHF-1; ACTIVATION; SEQUENCE	Pit-1, a pituitary-specific POU homeodomain transcription factor, specifies three anterior pituitary lineages; governs growth hormone, prolactin, and thyrotropin gene expression; and mediates basal and Ras-stimulated prolactin promoter activity in GH(4) pituitary cells. Alternate splicing of the Pit-1 message produces the Pit-1 beta isoform, which contains a 26 amino acid insertion, the beta-domain, within the amino-terminal transactivation domain. The beta-domain functions as a molecular switch, such that Pit-1 beta blocks both basal and Ras-stimulated prolactin promoter activity in GH(4) pituitary cells yet preferentially enhances protein kinase A-stimulated prolactin promoter activity in a HeLa reconstitution system. To determine whether the amino acid sequence of the beta-domain dictates function, we replaced it with five different 26-amino acid sequences. These mutants fail to block basal or Ras stimulated rat prolactin promoter activity and fail to optimally enhance the protein kinase A response of prolactin promoter. These data demonstrate that the amino acid sequence of the beta-domain specifies its role as a molecular switch. Additionally, the presence of both Pit-1 and Pit-1 beta in pituitary cells allows diverse incoming signals to utilize structurally different forms of the same gene product, which can interact with distinct co-factors, integrating multiple signaling pathways at the level of the nucleus.	UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,PROGRAM MOL BIOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,COLORADO CANC CTR,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Gutierrez-Hartmann, Arthur/F-1295-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009160] Funding Source: NIH RePORTER; NIDDK NIH HHS [F32 DK09160, DK37644] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; CONRAD KE, 1992, ONCOGENE, V7, P1279; DELHASE M, 1995, GENE, V155, P273, DOI 10.1016/0378-1119(94)00757-J; DEMINIE CA, 1993, J VIROL, V67, P6499, DOI 10.1128/JVI.67.11.6499-6506.1993; DIAMOND SE, 1994, J VIROL, V68, P863, DOI 10.1128/JVI.68.2.863-876.1994; DOLLE P, 1990, CELL, V60, P809, DOI 10.1016/0092-8674(90)90095-V; HAUGEN BR, 1994, MOL ENDOCRINOL, V8, P1574, DOI 10.1210/me.8.11.1574; HAUGEN BR, 1993, J BIOL CHEM, V268, P20818; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JARVIS TC, 1992, EMBO J, V11, P3135, DOI 10.1002/j.1460-2075.1992.tb05386.x; KEECH CA, 1989, MOL ENDOCRINOL, V3, P832, DOI 10.1210/mend-3-5-832; KONZAK KE, 1992, MOL ENDOCRINOL, V6, P241, DOI 10.1210/me.6.2.241; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MORRIS AE, 1992, NUCLEIC ACIDS RES, V20, P1355, DOI 10.1093/nar/20.6.1355; ONO M, 1992, GENE, V116, P275, DOI 10.1016/0378-1119(92)90525-T; OTTAVIANO Y, 1985, J BIOL CHEM, V260, P624; PICKETT CA, 1996, PITUITARY DIS DIAGNO; RAJNARAYAN S, 1995, MOL ENDOCRINOL, V9, P502, DOI 10.1210/me.9.4.502; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; TASHJIAN AH, 1968, ENDOCRINOLOGY, V82, P342, DOI 10.1210/endo-82-2-342; THEILL LE, 1992, EMBO J, V11, P2261, DOI 10.1002/j.1460-2075.1992.tb05285.x; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WONG EA, 1992, DNA CELL BIOL, V11, P651, DOI 10.1089/dna.1992.11.651; YEN PM, 1994, MOL ENDOCRINOL, V8, P1450, DOI 10.1210/me.8.11.1450	35	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28925	28932		10.1074/jbc.271.46.28925	http://dx.doi.org/10.1074/jbc.271.46.28925			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910541	hybrid			2022-12-27	WOS:A1996VT05200033
J	Dong, MQ; Penin, F; Baggetto, LG				Dong, MQ; Penin, F; Baggetto, LG			Efficient purification and reconstitution of P-glycoprotein for functional and structural studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE VESICLES; PERFORMANCE LIQUID-CHROMATOGRAPHY; HAMSTER OVARY CELLS; MULTIDRUG-RESISTANT CELLS; NUCLEOTIDE-BINDING DOMAIN; SODIUM DODECYL-SULFATE; ATPASE ACTIVITY; ESCHERICHIA-COLI; DRUG TRANSPORT; PROTEINS	Plasma membrane P-glycoprotein is known as an ATP-dependent drug efflux pump that confers multidrug resistance to tumor cells. None of the reported purification procedures worked properly for our P-glycoprotein overproducing cell lines, i.e. murine lymphoid leukemia P388/ADR25, rat hepatoma AS30-D/COL10 and human lymphoblastic leukemia CEM/VLB5 cells. We have thus developed a general procedure for efficient purification of P-glycoprotein by combining solubilization with sodium dodecyl sulfate and chromatography on ceramic hydroxyapatite. This procedure was successful for the three cell lines and yielded 70% of the P-glycoprotein present in the starting plasma membranes with more than 99% purity. After exchanging sodium dodecyl sulfate into dodecyl maltoside and reconstitution into liposomes, purified P-glycoprotein exhibited a specific ATPase activity of about 200 nmol/min/mg, which was very similar to that obtained for P-glycoprotein solubilized and purified with 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonic acid. This ATPase activity was sensitive to orthovanadate inhibition and stimulated by verapamil and other drugs. More importantly, drug transport properties of the reconstituted P-glycoprotein were comparable with those of P-glycoprotein embedded in plasma membranes. Since it is virtually devoid of lipids, this preparation is suitable for both functional and structural investigations.	INST BIOL & CHIM PROT, CNRS, UPR 412, F-69367 LYON 07, FRANCE	Centre National de la Recherche Scientifique (CNRS)			PENIN, Francois/A-7315-2008	, Loris G/0000-0002-2412-8661				AMBUDKAR SV, 1995, J BIOENERG BIOMEMBR, V27, P23, DOI 10.1007/BF02110327; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AULAND ME, 1994, P NATL ACAD SCI USA, V91, P10938, DOI 10.1073/pnas.91.23.10938; BAGGETTO LG, 1987, J BIOL CHEM, V262, P9535; BAUBICHONCORTAY H, 1994, J BIOL CHEM, V269, P22983; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BLOOM H, 1987, ELECTROPHORESIS, V8, P93; BOSCOBOINIK D, 1990, BIOCHIM BIOPHYS ACTA, V1027, P225, DOI 10.1016/0005-2736(90)90311-B; BRAIMAN MS, 1987, J BIOL CHEM, V262, P9271; DOIGE CA, 1993, BIOCHIM BIOPHYS ACTA, V1146, P65, DOI 10.1016/0005-2736(93)90339-2; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P161, DOI 10.1016/0005-2736(92)90079-2; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; Eytan GD, 1996, J BIOL CHEM, V271, P3172, DOI 10.1074/jbc.271.6.3172; FOX JL, 1978, ANAL BIOCHEM, V87, P253, DOI 10.1016/0003-2697(78)90591-2; GARRIGOS M, 1993, BIOCHEM BIOPH RES CO, V196, P1034, DOI 10.1006/bbrc.1993.2355; GONZALO P, 1995, ANAL BIOCHEM, V225, P178, DOI 10.1006/abio.1995.1133; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAGIWARA M, 1991, CANCER LETT, V60, P103, DOI 10.1016/0304-3835(91)90215-4; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1995, J BIOENERG BIOMEMBR, V27, P63, DOI 10.1007/BF02110332; HJERTEN S, 1988, BIOCHIM BIOPHYS ACTA, V939, P476, DOI 10.1016/0005-2736(88)90094-6; HORIGOME T, 1989, EUR J BIOCHEM, V186, P63, DOI 10.1111/j.1432-1033.1989.tb15178.x; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; ICHIMURA T, 1995, ANAL BIOCHEM, V224, P250, DOI 10.1006/abio.1995.1037; KADOYA T, 1988, J LIQ CHROMATOGR, V11, P2951, DOI 10.1080/01483918808076771; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LELONG IH, 1992, FEBS LETT, V304, P256, DOI 10.1016/0014-5793(92)80632-Q; LONDON E, 1982, BIOTECHNIQUES, V6, P47; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; MOLLER JV, 1988, METHOD ENZYMOL, V157, P261; NAITO M, 1995, J CANCER RES CLIN, V121, P582, DOI 10.1007/BF01197774; OBLAS B, 1983, ANAL BIOCHEM, V130, P1, DOI 10.1016/0003-2697(83)90641-3; PENIN F, 1984, BIOCHIM BIOPHYS ACTA, V775, P239, DOI 10.1016/0005-2736(84)90175-5; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PORUCHYNSKY MS, 1994, BIOCHEMISTRY-US, V33, P4163, DOI 10.1021/bi00180a009; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; RIORDAN JR, 1979, J BIOL CHEM, V254, P2701; RIVAS E, 1982, ANAL BIOCHEM, V123, P194, DOI 10.1016/0003-2697(82)90643-1; SCHLEMMER SR, 1994, J BIOL CHEM, V269, P31059; SHAPIRO AB, 1995, J BIOL CHEM, V270, P16167, DOI 10.1074/jbc.270.27.16167; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHARMA S, 1995, J BIOL CHEM, V270, P14085, DOI 10.1074/jbc.270.23.14085; SHAROM FJ, 1995, BIOCHEM J, V308, P381, DOI 10.1042/bj3080381; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; SHAROM FJ, 1995, J BIOENERG BIOMEMBR, V27, P15, DOI 10.1007/BF02110326; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; WATTS CKW, 1986, BIOCHEM J, V236, P903, DOI 10.1042/bj2360903	50	58	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28875	28883		10.1074/jbc.271.46.28875	http://dx.doi.org/10.1074/jbc.271.46.28875			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910534				2022-12-27	WOS:A1996VT05200026
J	Sanderson, RJ; Mosbaugh, DW				Sanderson, RJ; Mosbaugh, DW			Identification of specific carboxyl groups on uracil-DNA glycosylase inhibitor protein that are required for activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; POLYMERASE-BETA; RAT-LIVER; COMPLEX; BACTERIOPHAGE-PBS2; PROCESSIVITY; CARBODIIMIDE; GLYCOSIDASE	The bacteriophage PBS2 uracil-DNA glycosylase inhibitor (Ugi) protein inactivates uracil-DNA glycosylase (Ung) by forming an exceptionally stable protein-protein complex in which Ugi mimics electronegative and structural features of duplex DNA (Beger, R. D., Balasubramanian, S., Bennett, S. E., Mosbaugh, D. W., and Bolton, P. H. (1995) J. Biol. Chem. 270, 16840-16847; Mol, C. D., Arvai, A. S., Sanderson, a J., Slupphaug, G., Kavli, B., Krokan, H. E., Mosbaugh, D. W., and Tainer, J. A. (1995) Cell 82, 701-708). The role of specific carboxylic amino acid residues in forming the Ung-Ugi complex was investigated using selective chemical modification techniques. Ugi treated with carbodiimide and glycine ethyl ester produced five discrete protein species (forms I-V) that were purified and characterized. Analysis by mass spectrometry revealed that Ugi form I escaped protein modification, and forms II-V showed increasing incremental amounts of acyl-glycine ethyl ester adduction. Ugi forms II-V retained their ability to form a Ung Ugi complex but exhibited a reduced ability to inactivate Escherichia coli Ung, directly reaecting the extent of modification. Competition experiments using modified forms II-V with unmodified Ugi as a competitor protein revealed that unmodified Ugi preferentially formed complex. Furthermore, unmodified Ugi and poly(U) were capable of displacing forms II-V from a preformed Ung Ugi complex but were unable to displace Ugi form I. The primary sites of acyl-glycine ethyl ester adduction were located in the alpha 2-helix of Ugi at Glu-28 and Glu-31. We infer that these two negatively charged amino acids play an important role in mediating a conformational change in Ugi that precipitates the essentially irreversible Ung/Ugi interaction.	OREGON STATE UNIV,DEPT AGR CHEM,CORVALLIS,OR 97331; OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331; OREGON STATE UNIV,CTR ENVIRONM HLTH SCI,CORVALLIS,OR 97331	Oregon State University; Oregon State University; Oregon State University					NIEHS NIH HHS [ES00210] Funding Source: Medline; NIGMS NIH HHS [GM32823] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032823] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALASUBRAMANIAN S, 1995, J BIOL CHEM, V270, P296, DOI 10.1074/jbc.270.1.296; BEGER RD, 1995, J BIOL CHEM, V270, P16840, DOI 10.1074/jbc.270.28.16840; BENNETT SE, 1993, J BIOL CHEM, V268, P26879; BENNETT SE, 1992, J BIOL CHEM, V267, P22512; BENNETT SE, 1995, BIOCHEMISTRY-US, V34, P6109, DOI 10.1021/bi00018a014; BUECHLER JA, 1990, BIOCHEMISTRY-US, V29, P1937, DOI 10.1021/bi00459a039; CARADONNA S, 1996, EXP CELL RES, V222, P245; Carraway K L, 1972, Methods Enzymol, V25, P616, DOI 10.1016/S0076-6879(72)25060-1; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DOMENA JD, 1985, BIOCHEMISTRY-US, V24, P7320, DOI 10.1021/bi00346a045; FRIEDBERG EC, 1975, J VIROL, V16, P315, DOI 10.1128/JVI.16.2.315-321.1975; GEREN LM, 1984, J BIOL CHEM, V259, P2155; HAUGLAND RP, 1992, HDB FLUORESCENT PROB, P22; HIGLEY M, 1993, MUTAT RES, V294, P109, DOI 10.1016/0921-8777(93)90019-D; JENSEN ON, 1993, RAPID COMMUN MASS SP, V7, P496, DOI 10.1002/rcm.1290070619; KARRAN P, 1981, BIOCHEMISTRY-US, V20, P6092, DOI 10.1021/bi00524a027; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE TD, 1989, P 37 AM SOC MASS SPE; LINDAHL T, 1977, J BIOL CHEM, V252, P3286; MEDINA M, 1992, EUR J BIOCHEM, V203, P373, DOI 10.1111/j.1432-1033.1992.tb16560.x; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; MOSBAUGH DW, 1994, PROG NUCLEIC ACID RE, V48, P315, DOI 10.1016/S0079-6603(08)60859-4; MOSBAUGH DW, 1983, J BIOL CHEM, V258, P108; OLSEN LC, 1989, EMBO J, V8, P3121, DOI 10.1002/j.1460-2075.1989.tb08464.x; REISNER AH, 1984, METHOD ENZYMOL, V104, P439; ROBERTS RJ, 1995, CELL, V82, P9, DOI 10.1016/0092-8674(95)90046-2; SAVVA R, 1995, NAT STRUCT BIOL, V2, P752, DOI 10.1038/nsb0995-752; SAVVA R, 1995, PROTEINS, V22, P287, DOI 10.1002/prot.340220310; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; TAKAHASHI I, 1963, NATURE, V197, P194; TIMKOVICH R, 1977, ANAL BIOCHEM, V79, P135, DOI 10.1016/0003-2697(77)90387-6; VARSHNEY U, 1988, J BIOL CHEM, V263, P7776; WANG Z, 1989, J BIOL CHEM, V264, P1163; WANG ZG, 1991, GENE, V99, P31	38	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29170	29181		10.1074/jbc.271.46.29170	http://dx.doi.org/10.1074/jbc.271.46.29170			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910574	hybrid			2022-12-27	WOS:A1996VT05200066
J	Warren, RS; Yuan, H; Matli, MR; Ferrara, N; Donner, DB				Warren, RS; Yuan, H; Matli, MR; Ferrara, N; Donner, DB			Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; MESSENGER-RNA EXPRESSION; PERMEABILITY FACTOR; RAT GLIOBLASTOMA; TUMOR-GROWTH; DEVELOPMENTAL EXPRESSION; FACTOR FAMILY; FACTOR VEGF; ANGIOGENESIS; CELLS	Vascular endothelial growth factor (VEGF) is an angiogenic hormone that is produced by and supports the growth of many types of malignancies. The present study shows that insulin-like growth factor 1 (IGF-I), a mitogen that promotes the propagation of cancers through autocrine and paracrine mechanisms, in creases the expression of mRNA for VEGF and production of VEGF protein by COLO 205 colon carcinoma cells. IGF-I also induces expression of VEGF mRNA in SW620, LSLiM6, and HCT15 colon carcinoma cells showing that this is a common response to IGF-I. Whereas IGF-I induced VEGF mRNA in each cell line examined (2.3-12-fold), it induced proliferation only in COLO 205 and LSLiM6 cells. Thus, the proliferative response induced by IGF-I and its ability to induce VEGF occur through distinguishable mechanisms. IGF-I increases the cellular content of VEGF mRNA by increasing the rate of transcription (5-fold after 4 h) and also by increasing the half-life of VEGF mRNA (0.6 +/- 0.07 h in control cells to 2.0 +/- 0.37 h in IGF-I-treated cells). Monoclonal antibody (alpha IR3) directed against the type 1 IGF receptor significantly attenuated the ability of IGF-I to promote expression of VEGF mRNA. interestingly, by itself alpha IR3 acted as a weak agonist and induced a modest increase in the cellular content of VEGF mRNA. alpha IR3 also promoted tyrosine phosphorylation of the beta subunit of the IGF-I receptor, and the magnitude of this response was comparable with that induced by IGF-I. These observations point to a nonlinear relationship between activation of the IGF-I receptor and induction of VEGF mRNA. Thus, in addition to its direct, growth stimulatory effect on transformed cells, IGF-I induces the expression of VEGF which can promote the progression of cancer by regulating the development of new blood vessels.	GENENTECH INC, DEPT CARDIOVASC RES, San Francisco, CA 94080 USA; INDIANA UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, INDIANAPOLIS, IN 46202 USA	Roche Holding; Genentech; Indiana University System; Indiana University-Purdue University Indianapolis	Warren, RS (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT SURG, SCH MED, 533 PARNASSUS AVE, ROOM U-372, SAN FRANCISCO, CA 94143 USA.				NCI NIH HHS [CA52863, CA67891] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA067891, R29CA052863, R01CA067891] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010; ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; BASERGA R, 1995, CANCER RES, V55, P249; BERGMANN U, 1995, CANCER RES, V55, P2007; BREIER G, 1992, DEVELOPMENT, V114, P521; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; BROWN LF, 1993, CANCER RES, V53, P4727; COHICK WS, 1993, ANNU REV PHYSIOL, V55, P131, DOI 10.1146/annurev.ph.55.030193.001023; COLVILLENASH PR, 1992, ANN RHEUM DIS, V51, P919, DOI 10.1136/ard.51.7.919; CULLEN KJ, 1991, CANCER RES, V51, P4978; DAUGHADAY WH, 1990, ENDOCRINOLOGY, V127, P1; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; DILLS DG, 1991, DIABETES, V40, P1725, DOI 10.2337/diabetes.40.12.1725; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; GARTNER MH, 1992, J SURG RES, V52, P389, DOI 10.1016/0022-4804(92)90121-F; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOWARD LA, 1989, BIOTECHNIQUES, V7, P940; JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KOHN EC, 1990, INT J CANCER, V46, P287, DOI 10.1002/ijc.2910460225; KONDO S, 1994, BBA-MOL CELL RES, V1221, P211, DOI 10.1016/0167-4889(94)90016-7; KONDO S, 1993, BIOCHEM BIOPH RES CO, V194, P1234, DOI 10.1006/bbrc.1993.1955; LONG L, 1994, CANCER RES, V54, P3732; LONG L, 1995, CANCER RES, V55, P1006; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; MEYERSCHWICKERATH R, 1993, J CLIN INVEST, V92, P2620, DOI 10.1172/JCI116877; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MIURA M, 1995, J BIOL CHEM, V270, P22639, DOI 10.1074/jbc.270.38.22639; OLSON TA, 1994, CANCER RES, V54, P276; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; RESNICOFF M, 1994, CANCER RES, V54, P2218; ROWEIN P, 1986, P NATL ACAD SCI USA, V83, P77; SATO K, 1995, J CLIN INVEST, V96, P1295, DOI 10.1172/JCI118164; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SENGER DR, 1990, CANCER RES, V50, P1774; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; SLADOWSKI D, 1993, J IMMUNOL METHODS, V157, P203, DOI 10.1016/0022-1759(93)90088-O; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; TROJAN J, 1992, P NATL ACAD SCI USA, V89, P4874, DOI 10.1073/pnas.89.11.4874; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857	57	211	225	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29483	29488		10.1074/jbc.271.46.29483	http://dx.doi.org/10.1074/jbc.271.46.29483			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910616	hybrid			2022-12-27	WOS:A1996VT05200108
J	Keenleyside, WJ; Whitfield, C				Keenleyside, WJ; Whitfield, C			A novel pathway for O-polysaccharide biosynthesis in Salmonella enterica serovar Borreze	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; RFB GENE-CLUSTER; ENTEROBACTERIAL COMMON ANTIGEN; NEISSERIA-GONORRHOEAE LIPOOLIGOSACCHARIDE; KLEBSIELLA-PNEUMONIAE SEROTYPE-O1; CASSETTE TRANSPORT-SYSTEM; GRAM-NEGATIVE BACTERIA; D-GALACTAN-I; RHIZOBIUM-MELILOTI; NUCLEOTIDE-SEQUENCE	The plasmid-encoded gene cluster for O:54 O-polysaccharide synthesis in Salmonella enterica serovar Borreze (rfb(O:54)) contains three genes that direct synthesis of a ManNAc homopolymer with alternating beta 1,3 and beta 1,4 linkages. In Escherichia coli K-12, RfbA(O:54) adds the first ManNAc residue to the Rfe (UDP-GlcpNac::undecaprenylphosphate GlcpNAc-1-phosphate transferase)modified lipopolysaccharide core. Hydrophobic cluster analysis of RfbA(O:54) indicates this protein belongs to the ExoU family of nonprocessive beta-glycosyltransferases. Two putative catalytic residues and a potential substrate-binding motif were identified in RfbA(O:54). Topological analysis of RfbB(O:54) predicts four transmembrane domains and a large central cytoplasmic domain. The latter shares homology with a similar domain in the processive beta-glycosyltransferases Cps3S of Streptococcus pneumoniae and HasA of Streptococcus pyogenes. Hydrophobic cluster analysis of RfbB(O:54) and Cps3S indicates both possess the structural features characteristic of the HasA family of processive beta-glycosyltransferases. Four potential catalytic residues and a putative substrate-binding motif were identified in RfbB(O:54). In Delta rfb E. coli K-12, RfbA(O:54) and RfbB(O:54) direct synthesis of smooth O:54 lipopolysaccharide, indicating that this O-polysaccharide involves a novel pathway for O-antigen transport. Based on sequence and structural conservation, 15 new ExoU-related and 17 new HasA-related transferases were identified.	UNIV GUELPH, DEPT MICROBIOL, GUELPH, ON N1G 2W1, CANADA	University of Guelph								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Arrecubieta C, 1995, GENE, V167, P1, DOI 10.1016/0378-1119(95)00657-5; BECKER A, 1993, MOL GEN GENET, V241, P367, DOI 10.1007/BF00284690; BRONNER D, 1994, MOL MICROBIOL, V14, P505, DOI 10.1111/j.1365-2958.1994.tb02185.x; BUGERT P, 1995, MOL MICROBIOL, V15, P917, DOI 10.1111/j.1365-2958.1995.tb02361.x; BULAWA CE, 1986, CELL, V46, P213, DOI 10.1016/0092-8674(86)90738-5; BULAWA CE, 1992, MOL CELL BIOL, V12, P1764, DOI 10.1128/MCB.12.4.1764; CABIB E, 1983, P NATL ACAD SCI-BIOL, V80, P3318, DOI 10.1073/pnas.80.11.3318; CHENWU JL, 1992, MOL MICROBIOL, V6, P497, DOI 10.1111/j.1365-2958.1992.tb01494.x; CLARKE AJ, 1991, ANAL BIOCHEM, V199, P68, DOI 10.1016/0003-2697(91)90270-4; CLARKE AJ, 1996, BIODEGRADATION CELLU, P113; CLARKE BR, 1995, J BACTERIOL, V177, P5411, DOI 10.1128/jb.177.19.5411-5418.1995; CLARKE BR, 1992, J BACTERIOL, V174, P4614, DOI 10.1128/JB.174.14.4614-4621.1992; COLLINSEMERSON JM, 1990, NUCLEIC ACIDS RES, V18, P6690, DOI 10.1093/nar/18.22.6690; DANAHER RJ, 1995, J BACTERIOL, V177, P7275, DOI 10.1128/jb.177.24.7275-7279.1995; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; DENARIE J, 1993, CELL, V74, P951, DOI 10.1016/0092-8674(93)90717-5; DILLARD JP, 1995, J EXP MED, V181, P973, DOI 10.1084/jem.181.3.973; DOUGHERTY BA, 1994, J BIOL CHEM, V269, P169; EGELHOFF TT, 1985, DNA-J MOLEC CELL BIO, V4, P241, DOI 10.1089/dna.1985.4.241; EWING WH, 1984, METHOD MICROBIOL, V14, P113, DOI 10.1016/S0580-9517(08)70448-3; FALT IC, 1993, EUR J BIOCHEM, V213, P573, DOI 10.1111/j.1432-1033.1993.tb17796.x; FernandezLopez M, 1996, MOL MICROBIOL, V20, P993, DOI 10.1111/j.1365-2958.1996.tb02540.x; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; GEREMIA RA, 1994, P NATL ACAD SCI USA, V91, P2669, DOI 10.1073/pnas.91.7.2669; GLUCKSMANN MA, 1993, J BACTERIOL, V175, P7033, DOI 10.1128/jb.175.21.7033-7044.1993; GOETHALS K, 1989, MOL GEN GENET, V219, P289, DOI 10.1007/BF00261190; GOHMANN S, 1994, MICROB PATHOGENESIS, V16, P53, DOI 10.1006/mpat.1994.1005; GOTSCHLICH EC, 1994, J EXP MED, V180, P2181, DOI 10.1084/jem.180.6.2181; Heilmann C, 1996, MOL MICROBIOL, V20, P1083, DOI 10.1111/j.1365-2958.1996.tb02548.x; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; HOLLAND D, 1990, J BACTERIOL, V172, P3131, DOI 10.1128/jb.172.6.3131-3137.1990; HOLST O, 1991, CARBOHYD RES, V215, P323, DOI 10.1016/0008-6215(91)84031-9; JANN K, 1982, EUR J BIOCHEM, V127, P157, DOI 10.1111/j.1432-1033.1982.tb06850.x; JANSSON PE, 1981, EUR J BIOCHEM, V115, P571; KEENLEYSIDE WJ, 1994, MOL MICROBIOL, V11, P437, DOI 10.1111/j.1365-2958.1994.tb00325.x; KEENLEYSIDE WJ, 1995, J BACTERIOL, V177, P5247, DOI 10.1128/jb.177.18.5247-5253.1995; KENT JL, 1968, BIOCHEMISTRY-US, V7, P4396, DOI 10.1021/bi00852a036; KIDO N, 1995, J BACTERIOL, V177, P2178, DOI 10.1128/jb.177.8.2178-2187.1995; KLENA JD, 1992, J BACTERIOL, V174, P7297, DOI 10.1128/jb.174.22.7297-7307.1992; KLENA JD, 1993, MOL MICROBIOL, V9, P393, DOI 10.1111/j.1365-2958.1993.tb01700.x; KNIREL YA, 1994, BIOCHEMISTRY-MOSCOW+, V59, P1325; KUHN HM, 1988, FEMS MICROBIOL LETT, V54, P195, DOI 10.1111/j.1574-6968.1988.tb02743.x; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; LIDHOLT K, 1994, CARBOHYD RES, V255, P87, DOI 10.1016/S0008-6215(00)90972-8; Liu D, 1996, J BACTERIOL, V178, P2102, DOI 10.1128/jb.178.7.2102-2107.1996; MAHARAJ R, 1993, GENE, V136, P267, DOI 10.1016/0378-1119(93)90477-K; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MAROLDA CL, 1993, J BACTERIOL, V175, P148, DOI 10.1128/JB.175.1.148-158.1993; MATTHYSSE AG, 1995, J BACTERIOL, V177, P1069, DOI 10.1128/jb.177.4.1069-1075.1995; MEIERDIETER U, 1990, J BIOL CHEM, V265, P13490; MEIERDIETER U, 1992, J BIOL CHEM, V267, P746; NAGAHASHI S, 1995, J BIOL CHEM, V270, P13961, DOI 10.1074/jbc.270.23.13961; NEUHARD J, 1976, J BACTERIOL, V126, P999, DOI 10.1128/JB.126.2.999-1001.1976; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; REEVES PR, 1992, FEMS MICROBIOL LETT, V100, P509, DOI 10.1016/0378-1097(92)90254-L; REEVES PR, 1994, BACTERIAL CELL WALL, V27, P281; REIZER J, 1992, PROTEIN SCI, V1, P1326, DOI 10.1002/pro.5560011012; REUBER TL, 1993, CELL, V74, P269, DOI 10.1016/0092-8674(93)90418-P; RICK PD, 1994, J BACTERIOL, V176, P2877, DOI 10.1128/JB.176.10.2877-2884.1994; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; ROSSEN L, 1984, NUCLEIC ACIDS RES, V12, P9497, DOI 10.1093/nar/12.24.9497; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAXENA IM, 1990, PLANT MOL BIOL, V15, P673, DOI 10.1007/BF00016118; SAXENA IM, 1994, J BACTERIOL, V176, P5735, DOI 10.1128/JB.176.18.5735-5752.1994; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; SHUTTLEWORTH H, 1986, NUCLEIC ACIDS RES, V14, P8689, DOI 10.1093/nar/14.21.8689; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SKURNIK M, 1995, MOL MICROBIOL, V17, P575, DOI 10.1111/j.1365-2958.1995.mmi_17030575.x; SMITS PHM, 1994, YEAST, V10, pS75, DOI 10.1002/yea.320100010; Stingele F, 1996, J BACTERIOL, V178, P1680, DOI 10.1128/jb.178.6.1680-1690.1996; SUDOH M, 1993, MOL GEN GENET, V241, P351, DOI 10.1007/BF00284688; SZABO M, 1995, J BACTERIOL, V177, P1544, DOI 10.1128/jb.177.6.1544-1553.1995; TOROK I, 1984, NUCLEIC ACIDS RES, V12, P9509, DOI 10.1093/nar/12.24.9509; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; VALDIVIESO MH, 1991, J CELL BIOL, V114, P101, DOI 10.1083/jcb.114.1.101; VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x; VAZQUEZ M, 1991, J BACTERIOL, V173, P1250, DOI 10.1128/jb.173.3.1250-1258.1991; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WEISGERBER C, 1982, EUR J BIOCHEM, V127, P165, DOI 10.1111/j.1432-1033.1982.tb06851.x; WHITFIELD C, 1993, ADV MICROB PHYSIOL, V35, P135, DOI 10.1016/S0065-2911(08)60099-5; WHITFIELD C, 1995, TRENDS MICROBIOL, V3, P178, DOI 10.1016/S0966-842X(00)88917-9	87	109	118	5	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28581	28592		10.1074/jbc.271.45.28581	http://dx.doi.org/10.1074/jbc.271.45.28581			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910488	hybrid			2022-12-27	WOS:A1996VU03300088
J	Klafki, HW; Abramowski, D; Swoboda, R; Paganetti, PA; Staufenbiel, M				Klafki, HW; Abramowski, D; Swoboda, R; Paganetti, PA; Staufenbiel, M			The carboxyl termini of beta-amyloid peptides 1-40 and 1-42 are generated by distinct gamma-secretase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; MAMMALIAN-CELLS; MUTATION; PATHWAY; RELEASE; APP	We have studied the effects of peptide aldehyde protease inhibitors on the secretion of beta-amyloid peptide 1-40 (A beta(1-40)) and A beta(1-42) by HEK 293 and COS-1 cells expressing beta-amyloid precursor protein with the Swedish double mutation. A multiphasic SDS-polyacrylamide gel electrophoresis system was used for the discrimination of A beta(1-40) and A beta(1-42). Calpain inhibitor I, carbobenzoxyl-Leu-Leu-leucinal, and calpeptin were found to reduce the amount of A beta(1-40) released into the medium in a dose-dependent manner. The reduction of A beta(1-40) after treatment with 50 mu M calpain inhibitor I or 5 mu M carbobenzoxyl-Leu-Leu-leucinal was accompanied by a slight increase of A beta(1-42) released into the medium. These observations suggest that the cleavages at residues 40 and 42 are accomplished by different enzyme activities.	SANDOZ PHARMA LTD,DEPT PRECLIN RES,CH-4002 BASEL,SWITZERLAND; SANDOZ RES INST BERN LTD,CH-3001 BERN,SWITZERLAND	Novartis; Sandoz; Novartis; Sandoz			Paganetti, Paolo/AAF-8039-2020	Paganetti, Paolo/0000-0003-1896-6324				Andra K, 1996, NEUROBIOL AGING, V17, P183, DOI 10.1016/0197-4580(95)02066-7; ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DOVEY HF, 1993, NEUROREPORT, V4, P1039, DOI 10.1097/00001756-199308000-00011; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; EVIN G, 1994, AMYLOID, V1, P263, DOI 10.3109/13506129409146118; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JOHNSTON JA, 1994, FEBS LETT, V354, P274, DOI 10.1016/0014-5793(94)01137-0; Klafki HW, 1996, ANAL BIOCHEM, V237, P24, DOI 10.1006/abio.1996.0195; Klafki HW, 1995, NEUROSCI LETT, V201, P29, DOI 10.1016/0304-3940(95)12122-K; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SchraderFischer G, 1996, BRAIN RES, V716, P91, DOI 10.1016/0006-8993(96)00002-9; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TAMAOKA A, 1994, J BIOL CHEM, V269, P32721; TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X; VIGOPELFREY C, 1993, J NEUROCHEM, V61, P1965, DOI 10.1111/j.1471-4159.1993.tb09841.x; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	32	155	162	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28655	28659		10.1074/jbc.271.45.28655	http://dx.doi.org/10.1074/jbc.271.45.28655			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910499	hybrid			2022-12-27	WOS:A1996VU03300099
J	Plater, ML; Goode, D; Crabbe, MJC				Plater, ML; Goode, D; Crabbe, MJC			Effects of site-directed mutations on the chaperone-like activity of alpha B-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; HETEROLOGOUS EXPRESSION; MOLECULAR CHAPERONE; ESCHERICHIA-COLI; GAMMA; EVOLUTION; STABILITY; GENE; DNA	Recombinant alpha B-crystallin has been shown to exhibit chaperone-like activity, suppressing the thermal aggregation of gamma-crystallin and aggregation of the reduced insulin B chain conferring thermotolerance to Escherichia coli BL21(DE3) cells. Mutations were made in three specific areas of the alpha B-crystallin, the N terminus D2G, the conserved phenylalanine-rich region, F24R, F27R, F27A, and the two C-terminal lysines K174L/K175L, K174G/K175G. Biophysical characterization of the mutant alpha B-crystallins using far-UV CD revealed no change in secondary structural elements. Tryptophan fluorescence demonstrated global structural changes. Heat stability of the mutant alpha B-crystallins was not significantly affected as indicated by tryptophan fluorescence of heat-treated proteins. Mutations within the phenylalanine-rich region abolish the chaperone-like activity as measured by bath in vivo and in vitro assays. Proteins with mutations at the C terminus demonstrated no significant chaperone-like activity, failing to confer thermotolerance on E. coli and demonstrating no significant inhibition of protein aggregation in either gamma-crystallin or reduced insulin B chain assays. The N-terminal mutation D2G demonstrated a significant reduction in efficiency of the chaperone-like activity although some thermotolerance was conferred in the E. coli assay. In vitro assays showed that complete inhibition of aggregation was only achieved at 10-fold higher concentrations of D2G than that required by the native alpha B-crystallin. Consistent changes in the chaperone-like activity of the site-directed mutants were demonstrated by the three assays. The results suggested that both charge-charge and hydrophobic interactions are important in protein binding by alpha B-crystallin and that the conserved RLFDQFF region is vital for chaperone-like activity.	UNIV READING, SCH ANIM & MICROBIAL SCI, WOLFSON LAB, READING RG6 6AJ, BERKS, ENGLAND	University of Reading					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARBOSA P, 1991, J BIOL CHEM, V266, P5286; BETTELHEIM FA, 1992, BIOCHEM BIOPH RES CO, V187, P39, DOI 10.1016/S0006-291X(05)81455-X; BOYLE D, 1994, EXP EYE RES, V58, P9, DOI 10.1006/exer.1994.1190; CARVER JA, 1995, BBA-PROTEIN STRUCT M, V1252, P251, DOI 10.1016/0167-4838(95)00146-L; CHITPINITYOL S, 1996, PERSPECTIVES PROTEIN, P29; CRABBE MJC, 1994, BIOCHEM J, V297, P653, DOI 10.1042/bj2970653; CRABBE MJC, 1994, DESKTOP MOL MODELLER; CRABBE MJC, 1995, PP INT FOR ADV TECHN, P28; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; DILSIZ N, 1994, ANAL BIOCHEM, V222, P510, DOI 10.1006/abio.1994.1527; DILSIZ N, 1995, BIOCHEM J, V305, P753, DOI 10.1042/bj3050753; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GOODE D, 1995, COMPUT CHEM, V19, P65, DOI 10.1016/0097-8485(95)00027-P; GOODE D, 1994, ARCH BIOCHEM BIOPHYS, V315, P104, DOI 10.1006/abbi.1994.1477; Harding J., 1991, CATARACT BIOCH EPIDE; Harding JJ, 1991, POST TRANSLATIONAL M; Harding JJ, 1984, EYE B, V1b, P207; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; IWAKI T, 1994, J CELL BIOL, V125, P1385, DOI 10.1083/jcb.125.6.1385; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; KLEMENZ R, 1991, MOL CELL BIOL, V11, P803, DOI 10.1128/MCB.11.2.803; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LUBSEN NH, 1988, PROG BIOPHYS MOL BIO, V51, P47, DOI 10.1016/0079-6107(88)90010-7; PALMISANO DV, 1995, BBA-PROTEIN STRUCT M, V1246, P91, DOI 10.1016/0167-4838(94)00176-H; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; Rao PV, 1995, BBA-GEN SUBJECTS, V1245, P439, DOI 10.1016/0304-4165(95)00125-5; RENKAWEK K, 1992, ACTA NEUROPATHOL, V83, P323; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Smith JB, 1996, EXP EYE RES, V63, P125, DOI 10.1006/exer.1996.0100; SMULDERS RHPH, 1995, EUR J BIOCHEM, V232, P834, DOI 10.1111/j.1432-1033.1995.834zz.x; TAKEMOTO L, 1993, BIOCHEM J, V294, P435, DOI 10.1042/bj2940435; VANNOORT JM, 1995, NATURE, V375, P798, DOI 10.1038/375798a0; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; WOLFF SP, 1985, BIOCHEM J, V226, P625, DOI 10.1042/bj2260625; Zahn R, 1996, SCIENCE, V271, P642, DOI 10.1126/science.271.5249.642	42	127	131	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28558	28566		10.1074/jbc.271.45.28558	http://dx.doi.org/10.1074/jbc.271.45.28558			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910485	hybrid			2022-12-27	WOS:A1996VU03300085
J	Rudolph, AE; Mullane, MP; PorcheSorbet, R; Tsuda, S; Miletich, JP				Rudolph, AE; Mullane, MP; PorcheSorbet, R; Tsuda, S; Miletich, JP			Factor X(St Louis II) - Identification of a glycine substitution at residue 7 and characterization of the recombinant protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RUSSELLS VIPER VENOM; HUMAN FACTOR-X; COAGULATION FACTOR; BLOOD-COAGULATION; ACTIVATING ENZYME; FACTOR-IX; DEFICIENCY	A molecular defect in factor X (fX) results from a point mutation that causes glycine substitution for gamma-carboxylated glutamic acid at position 7. The variant (fX(St. Louis II)) and wild type (fX(WT)) proteins were produced in a mammalian expression system and characterized. fX(St. Louis II) has <1% and similar to 3% of normal clotting activity in modified prothrombin time and partial thromboplastin time assays, respectively. The rate of activation of fX(St. Louis II) by factor VIIa and tissue factor is undetectable under conditions that result in complete activation of fX(WT); activation by factors VIIIa and IXa is similar to 30% of normal activation. The X-activating protein from Russell's viper venom activates fX(St. Louis II) completely but at a reduced rate. Thrombin generation on phoshopolipid vesicles or activated platelets is similar to 30% or similar to 5%, respectively. Membrane-dependent autolysis is markedly reduced for fX(St. Louis II). In reactions that are not surface-dependent, fX(St. Louis II) is nearly identical to that of fX(WT). The rate of inhibition by antithrombin is indistiguishable, as is the rate of thrombin formation in the absence of phospholipid, with or without factor Va.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,DIV LAB MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,DIV LAB MED,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NHLBI NIH HHS [HL14147] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BROZE GJ, 1984, J CLIN INVEST, V73, P933, DOI 10.1172/JCI111317; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P5253, DOI 10.1021/bi00643a015; FASS DN, 1982, BLOOD, V59, P594; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JESTY J, 1975, J BIOL CHEM, V250, P4497; JESTY J, 1974, J BIOL CHEM, V249, P5614; KIM DJ, 1995, HUM GENET, V95, P212; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P5098, DOI 10.1021/bi00366a018; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MILETICH JP, 1980, ANAL BIOCHEM, V105, P304, DOI 10.1016/0003-2697(80)90462-5; NEMERSON Y, 1982, PROG HEMOST THROMB, V6, P237; NEMERSON Y, 1986, BLOOD, V71, P1; PFEIFFER RA, 1982, HUM GENET, V62, P358, DOI 10.1007/BF00304557; REDDY SV, 1989, BLOOD, V74, P1486; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; TAKEYA H, 1992, J BIOL CHEM, V267, P14109; TENG CM, 1981, THROMB RES, V22, P213, DOI 10.1016/0049-3848(81)90323-6; WATZKE HH, 1990, J BIOL CHEM, V265, P11982	23	29	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28601	28606		10.1074/jbc.271.45.28601	http://dx.doi.org/10.1074/jbc.271.45.28601			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910490	hybrid			2022-12-27	WOS:A1996VU03300090
J	Thomas, JE; Smith, M; Rubinfeld, B; Gutowski, M; Beckmann, RP; Polakis, P				Thomas, JE; Smith, M; Rubinfeld, B; Gutowski, M; Beckmann, RP; Polakis, P			Subcellular localization and analysis of apparent 180-kDa and 220-kDa proteins of the breast cancer susceptibility gene, BRCA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARIAN-CANCER; FAMILIAL BREAST; TYROSINE KINASE; EXPRESSION; DIFFERENTIATION; TISSUES; REGION; CELLS	The breast cancer susceptibility gene BRCA1 encodes an 1863-amino acid protein that acts as a tumor suppressor. The biochemical function of BRCA1 is unknown, and there are conflicting results describing its subcellular location. We have identified a 220-kDa protein, which is reactive with three antibodies raised against the amino- and carboxy-terminal regions of BRCA1. Immunoflourescence staining with an antibody to the carboxyl terminus of BRCA1 localized the protein to the nucleus of breast, ovarian, and cervical carcinoma-derived cell lines. A similar result was observed by biochemical subcellular fractionation that indicated that the 220-kDa protein was localized primarily to the nucleus of cell lines established from breast carcinomas. In addition to the 220-kDa protein, one antibody, C-20, also recognized a 180-kDa protein in MDA-MB-468 total cell lysates that was not detected by the other two antibodies. Several observations suggest the 180-kDa protein is the epidermal growth factor (EGF) receptor: (i) C-20 reacted avidly with a 180-kDa protein immunoprecipitated by an antibody to the EGF receptor; (ii) an EGF receptor antibody detected a 180-kDa protein immunoprecipitated by C-20; (iii) the affinity purified EGF receptor was both immunoprecipitated and detected on immunoblots by the C-20 antibody but not another BRCA1 antibody; (iv) similar phosphopeptide maps were generated from the EGF receptor and the 180-kDa protein immunoprecipitated by C-20, and this peptide map was distinct from the 220-kDa phosphoprotein; and (v) the C-20 immunizing peptide bears sequence identity to the EGF receptor. These results indicate that BRCA1 is a 220-kDa nuclear protein and that the 180-kDa protein reported previously may be unrelated to BRCA1.	ONYX PHARMACEUT INC,RICHMOND,CA 94806		Thomas, JE (corresponding author), ELI LILLY & CO,LILLY CORP CTR,CANC RES,LILLY RES LABS,DC0434,INDIANAPOLIS,IN 46285, USA.			Rubinfeld, Bonnee/0000-0001-9861-6775				BATES RC, 1994, J CELL BIOL, V125, P403, DOI 10.1083/jcb.125.2.403; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; EASTON DF, 1993, AM J HUM GENET, V52, P678; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Genetic Computer Group, 1994, PROGR MAN WISC PACK; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; GUDAS JM, 1995, CANCER RES, V55, P4561; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; Jensen RA, 1996, NAT GENET, V13, P269, DOI 10.1038/ng0796-269; KELSELL DP, 1993, HUM MOL GENET, V2, P1823; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; Merajver SD, 1995, CLIN CANCER RES, V1, P539; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Wilson CA, 1996, NAT GENET, V13, P264, DOI 10.1038/ng0796-264	26	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28630	28635		10.1074/jbc.271.45.28630	http://dx.doi.org/10.1074/jbc.271.45.28630			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910495	hybrid			2022-12-27	WOS:A1996VU03300095
J	Nissim, I; Yudkoff, M; Brosnan, JT				Nissim, I; Yudkoff, M; Brosnan, JT			Regulation of [N-15]urea synthesis from [5-N-15]glutamine - Role of pH, hormones, and pyruvate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMOYL-PHOSPHATE SYNTHETASE; N-ACETYLGLUTAMATE CONTENT; RAT-LIVER GLUTAMINASE; UREA SYNTHESIS; GLUTAMATE-DEHYDROGENASE; NITROGEN-METABOLISM; GLUCAGON ACTIONS; TERM REGULATION; UREAGENESIS; HEPATOCYTES	We have utilized both [5-N-15]glutamine and [3-C-13] pyruvate as metabolic tracers in order to: (i) examine the effect of pH, glucagon (GLU), or insulin on the precursor-product relationship between (NH3)-N-15, [N-15]citrulline, and, thereby, [N-15]urea synthesis and (ii) elucidate the mechanism(s) by which pyruvate stimulates [N-15] urea synthesis. Hepatocytes isolated from rat were incubated at pH 6.8, 7.4, or 7.6 with 1 mM [5-N-15]glutamine and 0.1 mM (NH4Cl)-N-14 in the presence or the absence of [3-C-13] pyruvate (2 mM). A separate series of experiments was performed at pH 7.4 in the presence of insulin or GLU. (NH3)-N-15 enrichment exceeded or was equal to that of [N-15]citrulline under all conditions except for pH 7.6, when the N-15 enrichment in citrulline exceeded that in ammonia. The formation of [N-15]citrulline (atom % excess) was increased with higher pH. Flux through phosphate-dependent glutaminase (PDG) and [N-15]urea synthesis were stimulated (p < 0.05) at pH 7.6 or with GLU and decreased (p < 0.05) at pH 6.8. Insulin had no significant effect on flux through PDG or on [N-15]urea synthesis, Decreased [N-15]urea production at pH 6.8 was associated with depleted aspartate and glutamate levels, Pyruvate attenuated this decrease in the aspartate and glutamate pools and stimulated [N-15]urea synthesis. Production of Asp from pyruvate was increased with increasing medium pH. Approximately 80% of Asp was derived from [3-C-13]pyruvate regardless of incubation pH or addition of hormone. Furthermore, approxiately 20, 40, and 50% of the mitochondrial N-acetylglutamate (NAG) pool was derived from [3-C-13]pyruvate at pH 6.8, 7.4, and 7.6, respectively. Both the concentration and formation of [C-13]NAG from [3-C-13]pyruvate were increased (p < 0.05) with glucagon and decreased (p < 0.05) with insulin or at pH 6.8. The data suggest a correlation between changes in [N-15]urea synthesis and alterations in the level and synthesis of [C-13]NAG from pyruvate, The current observations suggest that the stimulation of [N-15]urea synthesis in acute alkalosis is mediated via increased flux through PDG and subsequent increased utilization of [5-N-15] Of glutamine for [N-15]citrulline synthesis and/or increased synthesis of NAG from glutamate and pyruvate. The opposite may have occurred in acute acidosis. Glucagon, but not insulin, stimulated [N-15]urea synthesis via increased flux through PDG and synthesis of NAG. Pyruvate stimulated urea synthesis via increased availability of aspartate and/or increased synthesis of NAG, The formation of NAG and aspartate from pyruvate are both pH-sensitive processes.	UNIV PENN, SCH MED,CHILDRENS HOSP PHILADELPHIA,DEPT PEDIAT, DIV BIOCHEM DEV & MOL DIS, PHILADELPHIA, PA USA; UNIV PENN, SCH MED,CHILDRENS HOSP PHILADELPHIA,DEPT PEDIAT, DIV CHILD DEV, PHILADELPHIA, PA USA; MEM UNIV NEWFOUNDLAND, DEPT BIOCHEM, St John, NF A1B 3X9, CANADA	University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania; Childrens Hospital of Philadelphia; Memorial University Newfoundland					NIDDK NIH HHS [DK-39348] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039348] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMDAL TP, 1994, METABOLISM, V43, P328, DOI 10.1016/0026-0495(94)90101-5; BEAN ES, 1984, J BIOL CHEM, V259, P1552; BLACKMORE PF, 1979, J BIOL CHEM, V254, P2828; BOON L, 1994, AM J PHYSIOL-RENAL, V267, pF1015, DOI 10.1152/ajprenal.1994.267.6.F1015; BROSNAN JT, 1974, BIOCHEM J, V138, P453, DOI 10.1042/bj1380453; Brosnan JT, 1996, J BIOL CHEM, V271, P16199, DOI 10.1074/jbc.271.27.16199; BROSNAN JT, 1982, FED PROC, V41, P91; BROSNAN JT, 1995, ADV ENZYME REGUL, V35, P131, DOI 10.1016/0065-2571(94)00003-L; COHEN NS, 1985, BIOCHEM J, V229, P205, DOI 10.1042/bj2290205; COHEN NS, 1984, ARCH BIOCHEM BIOPHYS, V234, P31, DOI 10.1016/0003-9861(84)90321-7; COHEN NS, 1980, J BIOL CHEM, V255, P248; COOPER AJL, 1990, ANN NY ACAD SCI, V585, P118, DOI 10.1111/j.1749-6632.1990.tb28048.x; COOPER AJL, 1988, J BIOL CHEM, V263, P12268; CORVERA S, 1983, BIOCHEM J, V210, P957, DOI 10.1042/bj2100957; CYR DM, 1991, BIOCHEM PHARMACOL, V42, P645, DOI 10.1016/0006-2952(91)90328-3; DODGSON SJ, 1987, AM J PHYSIOL, V63, pF2134; EXTON JH, 1980, AM J PHYSIOL, V238, pE3, DOI 10.1152/ajpendo.1980.238.1.E3; FAHIEN LA, 1964, J BIOL CHEM, V239, P1935; GARCIASAINZ JA, 1989, BIOCHEM INT, V18, P243; HALL LM, 1958, J BIOL CHEM, V230, P1013; HALPERIN ML, 1986, AM J PHYSIOL, V250, pF605, DOI 10.1152/ajprenal.1986.250.4.F605; HAMBERG O, 1994, J HEPATOL, V21, P381, DOI 10.1016/S0168-8278(05)80317-4; HAUSSINGER D, 1990, BIOCHEM J, V267, P281; HENSGENS HESJ, 1980, EUR J BIOCHEM, V107, P197, DOI 10.1111/j.1432-1033.1980.tb04640.x; KAMEMOTO ES, 1985, ARCH BIOCHEM BIOPHYS, V243, P100, DOI 10.1016/0003-9861(85)90777-5; KASHIWAGURA T, 1985, J BIOL CHEM, V260, P407; KUN E, 1974, METHOD ENZYMAT AN, V4, P1704; LUND P, 1984, BIOCHEM J, V218, P991, DOI 10.1042/bj2180991; LUND P, 1986, BIOCHEM J, V239, P773, DOI 10.1042/bj2390773; MARIUSZ K, 1994, AM J PHYSIOL, V267, pG754; MARTINREQUERO A, 1992, AM J PHYSIOL, V263, pE493, DOI 10.1152/ajpendo.1992.263.3.E493; MCGIVAN JD, 1983, BIOCHIM BIOPHYS ACTA, V759, P296, DOI 10.1016/0304-4165(83)90327-6; MCGIVAN JD, 1975, FEBS LETT, V52, P1, DOI 10.1016/0014-5793(75)80624-7; MCGIVAN JD, 1991, BIOCHEM J, V274, P103, DOI 10.1042/bj2740103; MEIJER AJ, 1978, J BIOL CHEM, V253, P2308; MEIJER AJ, 1990, PHYSIOL REV, V70, P701, DOI 10.1152/physrev.1990.70.3.701; MEIJER AJ, 1985, FEBS LETT, V191, P249, DOI 10.1016/0014-5793(85)80018-1; NISSIM I, 1991, BIOCHEM J, V277, P33, DOI 10.1042/bj2770033; NISSIM I, 1995, KIDNEY INT, V47, P96, DOI 10.1038/ki.1995.11; NISSIM I, 1993, J AM SOC NEPHROL, V3, P1416; NISSIM I, 1985, J BIOL CHEM, V260, P3955; NISSIM I, 1992, ARCH BIOCHEM BIOPHYS, V292, P393, DOI 10.1016/0003-9861(92)90008-K; STEWART PM, 1980, J BIOL CHEM, V255, P5270; SZWEDA LI, 1989, J BIOL CHEM, V264, P15357; TUCHMAN M, 1990, PEDIATR RES, V27, P408, DOI 10.1203/00006450-199004000-00020; TUCHMAN M, 1990, BIOCHEM J, V271, P325, DOI 10.1042/bj2710325; VERHOEVEN AJ, 1983, EUR J BIOCHEM, V133, P241, DOI 10.1111/j.1432-1033.1983.tb07454.x; VINAY P, 1980, KIDNEY INT, V17, P312, DOI 10.1038/ki.1980.37; WILLIAMSON JR, 1980, FEBS LETT, V117, pK73, DOI 10.1016/0014-5793(80)80572-2; WOLFE RR, 1992, RADIOACTIVE STABLE I, P49	50	41	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31234	31242		10.1074/jbc.271.49.31234	http://dx.doi.org/10.1074/jbc.271.49.31234			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940126	hybrid			2022-12-27	WOS:A1996VW68600037
J	Freire, R; Serrano, M; Salas, M; Hermoso, JM				Freire, R; Serrano, M; Salas, M; Hermoso, JM			Activation of replication origins in phi 29-related phages requires the recognition of initiation proteins to specific nucleoprotein complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHI-29 DNA-REPLICATION; TERMINAL PROTEIN; BACTERIOPHAGE PHI-29; INVITRO; TRANSCRIPTION; SIGNALS; BINDING; GENES; P6; M2	Protein p6 of Bacillus subtilis phage phi 29 activates the initiation of viral DNA replication by forming a multimeric nucleoprotein complex at the origins of replication, located at both ends of the linear genome, This activation requires a precise positioning of the protein p6 array with respect to the initiation site, To investigate this activation mechanism, we have purified the phi 29 protein p6 counterparts from the related phages Nf and GA-1 and analyzed the formation of complexes with DNA. In the homologous protein p6-DNA complexes the phi 29 and Nf protein arrays showed an identical positioning, different than that of the GA-1 protein array, In contrast, in the heterologous complexes the protein showed a different arrangement except in the case of the Nf protein-phi 29 DNA complex. We have also purified the proteins involved in the initiation of replication (terminal protein and DNA polymerase) from phages Nf and GA-1 and measured the ability of the different p6 proteins to activate homologous and heterologous replication origins. The results obtained indicate that the activation requires not only the formation of a specific nucleoprotein complex but also its specific recognition by the proteins involved in the initiation of DNA and the initiation sites, in which the protein p6 moiety was replication.	UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOL,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)			Salas, Margarita/J-9873-2014; Freire, Raimundo/Q-7660-2019; Serrano, Manuel/H-2634-2015	Salas, Margarita/0000-0001-5939-3441; Freire, Raimundo/0000-0003-4473-8894; Serrano, Manuel/0000-0001-7177-9312	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER; NIGMS NIH HHS [5R01 GM27242-16] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARWERT F, 1974, J VIROL, V13, P584, DOI 10.1128/JVI.13.3.584-589.1974; BLANCO L, 1986, NUCLEIC ACIDS RES, V14, P4923, DOI 10.1093/nar/14.12.4923; BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BRAMHILL D, 1988, CELL, V52, P747; BRAVO A, 1994, GENE, V148, P107, DOI 10.1016/0378-1119(94)90242-9; CARRASCOSA JL, 1976, EUR J BIOCHEM, V66, P229, DOI 10.1111/j.1432-1033.1976.tb10512.x; CHEN M, 1990, J BIOL CHEM, V265, P18634; DIXON WJ, 1991, METHOD ENZYMOL, V208, P380; DODSON M, 1986, P NATL ACAD SCI USA, V83, P7638, DOI 10.1073/pnas.83.20.7638; DURKHOFF AM, 1987, CELL, V48, P935; FREIRE R, 1994, EMBO J, V13, P4353, DOI 10.1002/j.1460-2075.1994.tb06755.x; GALAS D, 1978, NUCLEIC ACIDS RES, V9, P3157; GUTIERREZ C, 1994, EMBO J, V13, P269, DOI 10.1002/j.1460-2075.1994.tb06257.x; GUTIERREZ J, 1986, VIROLOGY, V155, P474, DOI 10.1016/0042-6822(86)90209-6; HIROKAWA H, 1972, P NATL ACAD SCI USA, V69, P1555, DOI 10.1073/pnas.69.6.1555; HIROKAWA H, 1977, MODERN TRENDS BACTER, P3; INIS MA, 1988, P NATL ACAD SCI USA, V85, P9436; KISHI T, 1993, JPN J GENET, V68, P243, DOI 10.1266/jjg.68.243; MATSUMOTO K, 1983, MOL GEN GENET, V191, P26, DOI 10.1007/BF00330885; MELLADO RP, 1980, VIROLOGY, V104, P84, DOI 10.1016/0042-6822(80)90367-0; MUL YM, 1990, J VIROL, V64, P5510, DOI 10.1128/JVI.64.11.5510-5518.1990; MURRAY CL, 1982, J BIOL CHEM, V257, P1053; PASTRANA R, 1985, NUCLEIC ACIDS RES, V85, P314; PENALVA MA, 1982, P NATL ACAD SCI-BIOL, V79, P5522, DOI 10.1073/pnas.79.18.5522; PRIETO I, 1988, P NATL ACAD SCI USA, V85, P314, DOI 10.1073/pnas.85.2.314; ROJO F, 1990, J MOL BIOL, V211, P713, DOI 10.1016/0022-2836(90)90072-T; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; Salas Margarita, 1993, P843; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERRANO M, 1993, J MOL BIOL, V230, P248, DOI 10.1006/jmbi.1993.1140; SERRANO M, 1990, SCIENCE, V248, P1012, DOI 10.1126/science.2111580; SERRANO M, 1989, EMBO J, V8, P1879, DOI 10.1002/j.1460-2075.1989.tb03584.x; SERRANO M, 1991, THESIS U AUTONOMA MA; YOSHIKAWA H, 1986, J GEN APPL MICROBIOL, V33, P39	34	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					31000	31007		10.1074/jbc.271.48.31000	http://dx.doi.org/10.1074/jbc.271.48.31000			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940089	hybrid			2022-12-27	WOS:A1996VV15800106
J	Gramatikova, SI; Christen, P				Gramatikova, SI; Christen, P			Pyridoxal 5'-phosphate-dependent catalytic antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Cofactors might efficiently extend the catalytic potential of antibodies. Monoclonal antibodies against N-alpha-phosphopyridoxyl-L-lysine were screened for: 1) binding of 5'-phosphopyridoxyl amino acids, 2) binding of Schiff base of pyridoxal 5'-phosphate (PLP) and amino acids, the first intermediate of all PLP-dependent reactions, and 3) catalysis of PLP-dependent alpha,beta-elimination with beta-chloro-D/L-alanine. All three criteria were met by antibody 15A9. Further analysis for PLP-dependent reactions showed that this antibody catalyzes the cofactor-dependent transamination of hydrophobic D-amino acids and oxo acids (k(cat) = 0.42 min(-1) with D-alanine). No other reactions with either D- or L-amino acids were taking place. PLP markedly contributes to catalytic efficacy, being a 10(4) times more efficient acceptor of the amino group than pyruvate. The antibody further accelerates the reaction (k'(cat(antibody))/k'(cat(PLP)) = 5 x 10(3) with D-alanine as substrate) and ensures reaction specificity, stereospecificity, as well as limited substrate specificity.	UNIV ZURICH,INST BIOCHEM,CH-8057 ZURICH,SWITZERLAND	University of Zurich								Christen P, 1985, TRANSAMINASES; COCHRAN AG, 1991, J AM CHEM SOC, V113, P6670, DOI 10.1021/ja00017a046; Coligan JKA, 1991, CURRENT PROTOCOLS IM; FREEDMAN MH, 1968, BIOCHEMISTRY-US, V7, P1941, DOI 10.1021/bi00845a044; Harlow E, 1988, ANTIBODIES LAB MANUA, P211; HELLER JS, 1975, BIOCHIM BIOPHYS ACTA, V403, P197, DOI 10.1016/0005-2744(75)90022-4; JENCKS WP, 1969, CATALYSIS CHEM ENZYM, P133; KHOMUTOV RM, 1971, BIOCHEM J, V124, P99, DOI 10.1042/bj1240099; KIRSCH JF, 1984, J MOL BIOL, V174, P497, DOI 10.1016/0022-2836(84)90333-4; KOCHHAR S, 1989, ANAL BIOCHEM, V178, P17, DOI 10.1016/0003-2697(89)90348-5; MORINO Y, 1974, J BIOL CHEM, V249, P6684; RASO V, 1975, BIOCHEMISTRY-US, V14, P591, DOI 10.1021/bi00674a020	12	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30583	30586		10.1074/jbc.271.48.30583	http://dx.doi.org/10.1074/jbc.271.48.30583			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940030	hybrid			2022-12-27	WOS:A1996VV15800047
J	Gresham, HD; Graham, IL; Griffin, GL; Hsieh, JC; Dong, LJ; Chung, AE; Senior, RM				Gresham, HD; Graham, IL; Griffin, GL; Hsieh, JC; Dong, LJ; Chung, AE; Senior, RM			Domain-specific interactions between entactin and neutrophil integrins - G2 domain ligation of integrin alpha(3)beta(1) and E domain ligation of the leukocyte response integrin signal for different responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE GLYCOPROTEIN ENTACTIN; MATRIX METALLOPROTEINASES; TYROSINE PHOSPHORYLATION; PHAGOCYTIC FUNCTION; RESPIRATORY BURST; RGD SEQUENCE; RECEPTOR; LAMININ; BINDING; FIBRONECTIN	Extracellular matrix proteins activate neutrophils to up-regulate many physiologic functions that are necessary at sites of tissue injury. To elucidate the ligand-receptor interactions that mediate these functions, we examined neutrophil activation by the basement membrane protein, entactin. Entactin is structurally and functionally organized into distinct domains; therefore, we utilized glutathione S-transferase -fusion proteins encompassing its four major domains, G1, G2, E, and G3, to assess interactions between entactin and neutrophil integrin receptors. We show that the E domain, which contains the single RGD sequence of entactin, is sufficient for ligation of the beta(3)-like integrin, leukocyte response integrin, and signaling for chemotaxis. Moreover, the G2 domain signals for stimulation of Fc receptor-mediated phagocytosis via ligation of alpha(3) beta(1). This receptor-ligand interaction was revealed only after stimulation of neutrophil by immune complexes or phorbol esters. Interestingly, the E domain does not enhance phagocytosis, and the G2 domain is not chemotactic. Furthermore, cleavage of entactin with the matrix metalloproteinase, matrilysin, liberates peptides that retain E domain-mediated chemotaxis and G2 domain-mediated enhancement of phagocytosis. These studies indicate that multiple domains of entactin have the ability to ligate individual integrins expressed by neutrophils and to activate distinct functions.	UNIV MISSOURI,RES SERV,TRAUMA VET ADM MED CTR,COLUMBIA,MO 65201; UNIV MISSOURI,DEPT PHARMACOL,COLUMBIA,MO 65201; UNIV MISSOURI,DEPT MOL MICROBIOL & IMMUNOL,COLUMBIA,MO 65201; WASHINGTON UNIV,SCH MED,BARNES JEWISH HOSP,DEPT MED,RESP & CRIT CARE DIV,ST LOUIS,MO 63110; UNIV PITTSBURGH,DEPT BIOL SCI,PITTSBURGH,PA 15260	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; Barnes-Jewish Hospital; Washington University (WUSTL); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NCI NIH HHS [CA-21246] Funding Source: Medline; NHLBI NIH HHS [HL-29594] Funding Source: Medline; NIAID NIH HHS [AI-36309] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA021246] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F30AI136309, R29AI036309] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; BATTAGLIA C, 1992, EUR J BIOCHEM, V208, P359, DOI 10.1111/j.1432-1033.1992.tb17195.x; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BOHNSACK JF, 1990, J EXP MED, V171, P1221, DOI 10.1084/jem.171.4.1221; BOHNSACK JF, 1992, J IMMUNOL, V149, P1340; BOHNSACK JF, 1992, BLOOD, V79, P1545; CARRENO MP, 1993, CLIN IMMUNOL IMMUNOP, V69, P43, DOI 10.1006/clin.1993.1148; CHUNG AE, 1990, AM J RESP CELL MOL, V3, P275, DOI 10.1165/ajrcmb/3.4.275; COLOGNATOPYKE H, 1995, J BIOL CHEM, V270, P9398, DOI 10.1074/jbc.270.16.9398; DEDHAR S, 1992, J BIOL CHEM, V267, P18908; DELWEL GO, 1994, MOL BIOL CELL, V5, P203, DOI 10.1091/mbc.5.2.203; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DONG LJ, 1995, J BIOL CHEM, V270, P15838, DOI 10.1074/jbc.270.26.15838; DURKIN ME, 1988, J CELL BIOL, V107, P2749, DOI 10.1083/jcb.107.6.2749; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; FUORTES M, 1994, J CELL BIOL, V127, P1477, DOI 10.1083/jcb.127.5.1477; GRAHAM IL, 1994, J CELL BIOL, V127, P1139, DOI 10.1083/jcb.127.4.1139; GRESHAM HD, 1987, J IMMUNOL, V139, P4159; GRESHAM HD, 1992, J BIOL CHEM, V267, P13895; GRESHAM HD, 1991, J CLIN INVEST, V88, P588, DOI 10.1172/JCI115343; GRESHAM HD, 1989, J CELL BIOL, V108, P1935, DOI 10.1083/jcb.108.5.1935; HENDEY B, 1992, SCIENCE, V258, P296, DOI 10.1126/science.1384129; HSIEH JC, 1994, BIOCHEM BIOPH RES CO, V199, P1509, DOI 10.1006/bbrc.1994.1402; ISHIBASHI Y, 1994, J EXP MED, V180, P1225, DOI 10.1084/jem.180.4.1225; MURPHY G, 1992, AM J RESP CELL MOL, V7, P120, DOI 10.1165/ajrcmb/7.2.120; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; SENIOR RM, 1989, AM J RESP CELL MOL, V1, P479, DOI 10.1165/ajrcmb/1.6.479; SENIOR RM, 1992, J CLIN INVEST, V90, P2251, DOI 10.1172/JCI116111; SHARMA CP, 1995, J IMMUNOL, V154, P3461; SIRES UI, 1993, J BIOL CHEM, V268, P2069; SUCHARD SJ, 1991, J IMMUNOL, V147, P651; TSAO T, 1990, J BIOL CHEM, V265, P5188; VANSTRIJP JAG, 1993, J IMMUNOL, V151, P3324; VUORI K, 1993, J BIOL CHEM, V268, P21459; WAYNER EA, 1993, J CELL BIOL, V121, P1141, DOI 10.1083/jcb.121.5.1141; WU CY, 1995, J CELL SCI, V108, P2511; ZHOU MJ, 1993, J EXP MED, V178, P1165, DOI 10.1084/jem.178.4.1165	41	34	34	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30587	30594		10.1074/jbc.271.48.30587	http://dx.doi.org/10.1074/jbc.271.48.30587			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940031	hybrid			2022-12-27	WOS:A1996VV15800048
J	Tikhonenko, AT; Black, DJ; Linial, ML				Tikhonenko, AT; Black, DJ; Linial, ML			Viral Myc oncoproteins in infected fibroblasts down-modulate thrombospondin-1, a possible tumor suppressor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTHYMOSIN-ALPHA GENE; 3' UNTRANSLATED REGION; C-MYC; ENDOTHELIAL-CELLS; GROWTH-FACTOR; V-MYC; TRANSCRIPTIONAL REGULATION; NUCLEOTIDE-SEQUENCE; CYCLIN D1; EXPRESSION	We are interested in identifying the transcriptional targets of the Myc oncoproteins, To this end, we have fused Myc of the MC29 retrovirus with the rat glucocorticoid receptor, This chimeric protein requires dexamethasone to undergo nuclear translocation and achieve an active conformation, We employed a differential hybridization approach to identify mRNAs that are induced or repressed in infected avian fibroblasts in response to dexamethasone. This screen yielded one mRNA underrepresented in the dexamethasone-treated cells. In Myc-transformed cell clones, its level decreases B-fold as early as 4 h and more than 30-fold after 32 h of exposure to the hormone, This mRNA was also downregulated by recombinant Myc retroviruses in rodent fibroblasts, including those refractory to transformation, Sequence analysis revealed that it is homologous to the 3' untranslated regions of the mammalian thrombospondin-l genes, Using an anti-thrombospondin antibody, we confirmed that rodent cells overexpressing Myc produce very small amounts of this protein. Also, they do not support efficient expression of a reporter gene driven by the thrombospondin-l promoter. Thus, thrombospondin-l is a bona fide target of Myc. Moreover, its silencing might pertain to the transforming activity of Myc, since in several systems thrombospondin-l exhibits tumor suppressor properties, presumably due to its negative effect on neovascularization.			Tikhonenko, AT (corresponding author), FRED HUTCHINSON CANC RES CTR, DIV BASIC SCI, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.		Thomas-Tikhonenko, Andrei/E-5329-2011	Thomas-Tikhonenko, Andrei/0000-0002-2739-2206	NATIONAL CANCER INSTITUTE [R01CA058809, P30CA015704] Funding Source: NIH RePORTER; NCI NIH HHS [CA58809, P30 CA15704] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P100, DOI 10.1073/pnas.80.1.100; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Baulieu EE., 1991, ANN NY ACAD SCI, V626, P545, DOI 10.1111/j.1749-6632.1991.tb37946.x; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERNARDS R, 1995, CURR BIOL, V5, P859, DOI 10.1016/S0960-9822(95)00173-4; BLACKWOOD EM, 1994, MOL BIOL CELL, V5, P597, DOI 10.1091/mbc.5.5.597; BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; CASTLE VP, 1993, J BIOL CHEM, V268, P2899; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; DONOVIEL DB, 1988, J BIOL CHEM, V263, P18590; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; ENRIETTO PJ, 1987, CANCER SURV, V6, P85; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HENNESSY SW, 1989, J CELL BIOL, V108, P729, DOI 10.1083/jcb.108.2.729; HUANG LQ, 1995, BLOOD COAGUL FIBRIN, V6, P438, DOI 10.1097/00001721-199507000-00011; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JOHNSTON JM, 1992, LEUKEMIA LYMPHOMA, V8, P431, DOI 10.3109/10428199209051025; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LABELL TL, 1993, GENOMICS, V17, P225, DOI 10.1006/geno.1993.1308; LAHAV J, 1993, BIOCHIM BIOPHYS ACTA, V1182, P1, DOI 10.1016/0925-4439(93)90146-R; LAHERTY CD, 1989, J BIOL CHEM, V264, P11222; LAWLER J, 1991, J BIOL CHEM, V266, P8039; LAWLER J, 1991, GENOMICS, V11, P587, DOI 10.1016/0888-7543(91)90066-N; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LOVEC H, 1994, ONCOGENE, V9, P323; MAJACK RA, 1987, J BIOL CHEM, V262, P8821; MATTIONI T, 1994, METHOD CELL BIOL, V43, P335; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; MOL PC, 1995, MOL CELL BIOL, V15, P6999; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; SALNIKOW K, 1994, MOL CELL BIOL, V14, P851, DOI 10.1128/MCB.14.1.851; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; SHEIBANI N, 1995, P NATL ACAD SCI USA, V92, P6788, DOI 10.1073/pnas.92.15.6788; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; Shrivastava A, 1995, Curr Top Microbiol Immunol, V194, P273; SLACK JL, 1994, CELL GROWTH DIFFER, V5, P1373; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; SMITH JB, 1995, J BIOL CHEM, V270, P16756, DOI 10.1074/jbc.270.28.16756; SPAETE RR, 1985, J VIROL, V56, P135, DOI 10.1128/JVI.56.1.135-143.1985; TIKHONENKO AT, 1992, J VIROL, V66, P946, DOI 10.1128/JVI.66.2.946-955.1992; TIKHONENKO AT, 1995, ONCOGENE, V11, P1499; TIKHONENKO AT, 1993, MOL CELL BIOL, V13, P3623, DOI 10.1128/MCB.13.6.3623; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; TUCKER RP, 1995, DEV DYNAM, V203, P477, DOI 10.1002/aja.1002030410; Tuszynski GP, 1996, BIOESSAYS, V18, P71, DOI 10.1002/bies.950180113; VANDEVIJVER MJ, 1993, ADV CANCER RES, V61, P25; VOLPERT OV, 1995, BIOCHEM BIOPH RES CO, V217, P326, DOI 10.1006/bbrc.1995.2780; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P2146, DOI 10.1073/pnas.80.8.2146; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209	70	81	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30741	30747		10.1074/jbc.271.48.30741	http://dx.doi.org/10.1074/jbc.271.48.30741			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940053	hybrid			2022-12-27	WOS:A1996VV15800070
J	Vance, BA; Zacharchuk, CM; Segal, DM				Vance, BA; Zacharchuk, CM; Segal, DM			Recombinant mouse Bcl-2((1-203)) - Two domains connected by a long protease-sensitive linker	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; BCL-2 GENE; CONSERVED DOMAINS; INDUCED APOPTOSIS; BAX; HETERODIMERIZATION; BCL-2-ALPHA; PROTEINS; FAMILY; BH1	Bcl-2 is a cytoplasmic integral membrane protein with potent anti-apoptotic activity but whose mechanism of action is poorly understood. The purpose of this paper was to obtain large amounts of soluble Bcl-2 protein for structural and functional studies. Mouse Bcl-2((1-203)) (missing the COOH-terminal hydrophobic tail) was produced in bacterial inclusion bodies, solubilized in guanidine, and refolded by dialysis. The resulting protein was monomeric in nondenaturing solution and was active in protecting mouse T hybridoma cells from glucocorticoid-induced apoptosis. Refolded Bcl-2((1-203)) showed no tendency to homodimerize by gel filtration or analytical ultracentrifugation. Limited proteolysis experiments identified a region between the BH3 and BH4 homology domains of Bcl-2((1-203)) which was extremely susceptible to digestion by several common proteases, but not by a cell extract known to contain CPP-32-like (interleukin-1 beta-converting enzyme family) protease activity. The protease-sensitive sites were located within a 50-residue stretch that contained most of the nonconserved and proline residues of Bcl-2((1-203)). Trypsin-cleaved Bcl-2((1-203)) eluted in the same position as the undigested protein on gel filtration in nondenaturing solution, indicating that the two portions of the molecule connected by the protease-sensitive region associate stably and noncovalently. The solution properties of Bcl-2((1-203)) suggest that it consists of two noncovalently associated domains connected by a long protease-sensitive linker and that its structure is similar to that of Bcl-x(L), which has been determined by x-ray and NMR analysis.	NCI,NIH,EXPT IMMUNOL BRANCH,BETHESDA,MD 20892; NCI,NIH,LAB IMMUNE CELL BIOL,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Vance, Barbara/GYA-0940-2022					Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; BORNER C, 1994, BIOCHEM CELL BIOL, V72, P463, DOI 10.1139/o94-062; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HOCKENBERY DM, 1995, BIOESSAYS, V17, P631, DOI 10.1002/bies.950170709; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; KURUCZ I, 1993, P NATL ACAD SCI USA, V90, P3830, DOI 10.1073/pnas.90.9.3830; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MEMON SA, 1995, J IMMUNOL, V155, P4644; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SCHLEGEL J, 1995, FEBS LETT, V364, P139, DOI 10.1016/0014-5793(95)00374-I; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; YIN XM, 1994, COLD SPRING HARB SYM, V59, P387, DOI 10.1101/SQB.1994.059.01.043; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	25	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30811	30815		10.1074/jbc.271.48.30811	http://dx.doi.org/10.1074/jbc.271.48.30811			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940062	hybrid			2022-12-27	WOS:A1996VV15800079
J	Murguia, JR; Belles, JM; Serrano, R				Murguia, JR; Belles, JM; Serrano, R			The yeast HAL2 nucleotidase is an in vivo target of salt toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SULFATE ACTIVATION; PAPS-REDUCTASE; TOLERANCE; GENE; PLANTS; ENZYME; 3'(2')-PHOSPHOHYDROLASE; EXPRESSION	The yeast halotolerance gene HAL2 encodes a nucleotidase that dephosphorylates 3'-phosphoadenosine 5'-phosphate (PAP) and 3'-phosphoadenosine 5'-phosphosulfate (PAPS), intermediates of the sulfate assimilation pathway. This nucleotidase is inhibited by Na+ and Li+ but not by K+. Incubation of wild-type yeast cells with NaCl and LiCl, but not with KCl, increased intracellular PAP to millimolar concentrations. No depletion of the pool of adenine nucleotides (AMP, ADP, ATP) was observed. Other stresses such as heat shock or oxidative stress did not result in PAP accumulation. PAPS concentrations also increased during salt stress but remained lower than 0.5 mu M. S-Adenosylmethionine concentrations decreased by 50%, reflecting inhibition of sulfate assimilation during salt stress. Salt-induced PAP accumulation was attenuated in a yeast strain overexpressing HAL2. This strain grew better than the wild type under salt stress. These results suggest that the cation sensitivity of the HAL2 nucleotidase is an important determinant of the inhibition of yeast growth by sodium and lithium salts. In addition to blocking sulfate assimilation by product inhibition of PAPS reductase, PAP accumulation may have other unidentified toxic effects.	UNIV POLITECN VALENCIA, CSIC, INST BIOL MOL & CELULAR PLANTAS, VALENCIA 46022, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); Universitat Politecnica de Valencia; CSIC-UPV - Instituto de Biologia Molecular y Celular de Plantas (IBMCP)			Murguia, Jose R./H-4419-2015; Bellés, José María/H-4734-2015	Murguia, Jose R./0000-0001-9364-4603; Bellés, José María/0000-0003-0362-9616				ASHRAF M, 1994, CRIT REV PLANT SCI, V13, P17, DOI 10.1080/713608051; BRUNNGRABER EG, 1958, J BIOL CHEM, V233, P472; FERRANDO A, 1995, MOL CELL BIOL, V15, P5470; GAXIOLA R, 1992, EMBO J, V11, P3157, DOI 10.1002/j.1460-2075.1992.tb05392.x; GIMMLER H, 1984, Z PFLANZENPHYSIOL, V114, P131, DOI 10.1016/S0044-328X(84)80026-4; GLASER HU, 1993, EMBO J, V12, P3105, DOI 10.1002/j.1460-2075.1993.tb05979.x; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; International Union of Biochemistry and Molecular Biology, 1992, ENZ NOM; JAKUBOWSKI H, 1993, J BACTERIOL, V175, P5469, DOI 10.1128/JB.175.17.5469-5476.1993; JAKUBOWSKI H, 1991, EMBO J, V10, P593, DOI 10.1002/j.1460-2075.1991.tb07986.x; JAKUBOWSKI H, 1986, P NATL ACAD SCI USA, V83, P2378, DOI 10.1073/pnas.83.8.2378; Wyn Jones R. G., 1983, Inorganic plant nutrition, P528; KEATING DH, 1995, J BIOL CHEM, V270, P22229, DOI 10.1074/jbc.270.38.22229; LEYH TS, 1993, CRIT REV BIOCHEM MOL, V28, P515, DOI 10.3109/10409239309085137; LI F, 1989, J CHROMATOGR, V461, P353, DOI 10.1016/S0021-9673(00)94302-4; METZLER DE, 1977, BIOCHEMISTRY-US, P686; MOUNTAIN HA, 1991, YEAST, V7, P781, DOI 10.1002/yea.320070804; MURGUIA JR, 1995, SCIENCE, V267, P232; MURGUIA JR, UNPUB; NAHORSKI SR, 1991, TRENDS PHARMACOL SCI, V12, P297, DOI 10.1016/0165-6147(91)90581-C; NEUWALD AF, 1992, J BACTERIOL, V174, P415, DOI 10.1128/jb.174.2.415-425.1992; PENG ZH, 1995, J BIOL CHEM, V270, P29105, DOI 10.1074/jbc.270.49.29105; Quintero FJ, 1996, PLANT CELL, V8, P529, DOI 10.1105/tpc.8.3.529; RAMASWAMY SG, 1987, J BIOL CHEM, V262, P10044; SCHMIDT A, 1992, ANNU REV PLANT PHYS, V43, P325, DOI 10.1146/annurev.pp.43.060192.001545; SCHWENN JD, 1988, ARCH MICROBIOL, V150, P313, DOI 10.1007/BF00408300; SCHWENN JD, 1987, Z NATURFORSCH C, V42, P93; SERRANO R, 1994, CRIT REV PLANT SCI, V13, P121, DOI 10.1080/713608057; Serrano R, 1995, METHOD CELL BIOL, V50, P481, DOI 10.1016/S0091-679X(08)61052-3; THOMAS D, 1992, J GEN MICROBIOL, V138, P2021, DOI 10.1099/00221287-138-10-2021; TSANG MLS, 1976, EUR J BIOCHEM, V65, P113; VALLEJO CG, 1989, YEAST, V5, P307, DOI 10.1002/yea.320050411; WATSON TG, 1970, J GEN MICROBIOL, V64, P91, DOI 10.1099/00221287-64-1-91; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; YANG LM, 1994, EUR J BIOCHEM, V224, P743, DOI 10.1111/j.1432-1033.1994.00743.x; YORK JD, 1990, P NATL ACAD SCI USA, V87, P9548, DOI 10.1073/pnas.87.24.9548; [No title captured]	37	105	112	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29029	29033		10.1074/jbc.271.46.29029	http://dx.doi.org/10.1074/jbc.271.46.29029			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910555				2022-12-27	WOS:A1996VT05200047
J	OGrady, SM; Elmquist, E; Filtz, TM; Nicholas, RA; Harden, TK				OGrady, SM; Elmquist, E; Filtz, TM; Nicholas, RA; Harden, TK			A guanine nucleotide-independent inwardly rectifying cation permeability is associated with P2Y(1) receptor expression in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TURKEY ERYTHROCYTE-MEMBRANES; GATED ION CHANNELS; PHOSPHOLIPASE-C; ATP RECEPTOR; FUNCTIONAL EXPRESSION; PURINERGIC RECEPTOR; CLONING; PURINOCEPTORS; KINETICS; CELLS	The functional properties of the G protein-coupled P2Y(1) receptor were investigated in Xenopus oocytes. Incubation of oocytes expressing either the human or turkey P2Y(1) receptor with adenine nucleotide agonists resulted in an increase in Cl- current and activation of a novel cation current with an inwardly rectifying current-voltage relationship. Activation of either the human P2Y(2) (P-2U-purinergic) or M1 muscarinic receptor expressed in oocytes resulted in an increase in Cl- current similar to that observed in P2Y(1) receptor-expressing oocytes but had no effect on cation current. P2 receptor agonists stimulated both the cation current and Cl- current in P2Y(1) receptor expressing oocytes with EC(50) values and an order of potency (2-methylthioadenosine diphosphate > 2-methylthioadenosine triphosphate (2MeSATP) > ATP > UTP) that were similar to those previously observed for activation of phospholipase C in 1321N1 human astrocytoma cells stably expressing the human or turkey P2Y(1) receptor. The P2Y receptor antagonists suramin and pyridoxal phosphate 6-azophenyl-2'-4'-disulfonic acid both shifted to the right the concentration-response relationship for 2MeSATP for stimulation of oocyte currents. Although injection of oocytes with either GDP beta S (granuyl-5'-yl thiophosphate) or GTP gamma S (guanosine 5'3-O-(thio)triphosphate) resulted in loss of adenine nucleotide-promoted Cl- channel activation, neither guanine nucleotide altered the 2MeSATP-stimulated cation current. These data are consistent with the view that activation of the novel cation current by the P2Y(1) receptor does not involve a G protein. Tail current analysis of the novel P2Y(1) receptor-associated cation conductance revealed that the open channel current-voltage relationship was outwardly rectifying with a reversal potential of -38 mV for the turkey P2Y(1) receptor and -36 mV for the human P2Y(1) receptor. Replacement of Na+ with K+ ions in the bathing solution produced a shift in reversal potential to near zero mV, but significant outward rectification remained. The cation current was not permeable to either Ca2+ or Ba2+ and exhibited steady-state inactivation at holding potentials below -60 mV. These results indicate that the P2Y(1) receptor exhibits both metabotropic properties and a novel G protein-independent ionotropic response when expressed in Xenopus oocytes.	UNIV N CAROLINA,SCH MED,DEPT PHARMACOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	OGrady, SM (corresponding author), UNIV MINNESOTA,DEPT PHYSIOL & ANIM SCI,495 ANIM SCI VET MED BLDG,ST PAUL,MN 55108, USA.			Filtz, Theresa/0000-0002-5348-1114	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038213] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32322] Funding Source: Medline; NIGMS NIH HHS [GM38213] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; BOARDER MR, 1995, TRENDS PHARMACOL SCI, V16, P133, DOI 10.1016/S0165-6147(00)89001-X; BOYER JL, 1989, J BIOL CHEM, V264, P884; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1; CHANG KG, 1995, J BIOL CHEM, V270, P26152, DOI 10.1074/jbc.270.44.26152; Communi D, 1995, J BIOL CHEM, V270, P30849, DOI 10.1074/jbc.270.52.30849; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; FILTZ TM, 1994, MOL PHARMACOL, V46, P8; FILTZ TM, 1996, IN PRESS PURINERGIC; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; FURUKAWA K, 1994, J NEUROPHYSIOL, V71, P868, DOI 10.1152/jn.1994.71.3.868; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; HARDEN TK, 1987, J BIOL CHEM, V262, P9057; HARDEN TK, 1988, BIOCHEM J, V252, P583, DOI 10.1042/bj2520583; HENDERSON DJ, 1995, BIOCHEM BIOPH RES CO, V212, P648, DOI 10.1006/bbrc.1995.2018; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; Nguyen T, 1995, J BIOL CHEM, V270, P30845, DOI 10.1074/jbc.270.52.30845; Nicholas RA, 1996, MOL PHARMACOL, V50, P224; PARKER KE, 1995, AM J PHYSIOL-HEART C, V269, pH789, DOI 10.1152/ajpheart.1995.269.3.H789; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; Schachter JB, 1996, BRIT J PHARMACOL, V118, P167, DOI 10.1111/j.1476-5381.1996.tb15381.x; SHAPIRO RA, 1988, J BIOL CHEM, V263, P18397; SHIBASAKI T, 1987, J PHYSIOL-LONDON, V387, P227, DOI 10.1113/jphysiol.1987.sp016571; SURPRENANT A, 1995, TRENDS NEUROSCI, V18, P224, DOI 10.1016/0166-2236(95)93907-F; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; Zuhlke R.D., 1995, METHODS NEUROSCI, V25, P67	29	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29080	29087		10.1074/jbc.271.46.29080	http://dx.doi.org/10.1074/jbc.271.46.29080			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910562	Green Published, hybrid			2022-12-27	WOS:A1996VT05200054
J	Osborne, MA; Zenner, G; Lubinus, M; Zhang, XL; Songyang, Z; Cantley, LC; Majerus, P; Burn, P; Kochan, JP				Osborne, MA; Zenner, G; Lubinus, M; Zhang, XL; Songyang, Z; Cantley, LC; Majerus, P; Burn, P; Kochan, JP			The inositol 5'-phosphatase SHIP binds to immunoreceptor signaling motifs and responds to high affinity IgE receptor aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHORYLATED PROTEINS; T-CELL ACTIVATION; FC-EPSILON-RI; SH2 DOMAINS; POLYPHOSPHATE 5-PHOSPHATASE; CROSS-LINKING; PHOSPHOTYROSINE; GRB2; MEMBRANE; YEAST	Immunoreceptors such as the high affinity IgE receptor, Fc epsilon RI, and T-cell receptor associated proteins share a common motif, the immunoreceptor tyrosine-based activation motif (ITAM). We used the yeast tribrid system to identify downstream effecters of the phosphorylated Fc epsilon RI ITAM-containing subunits beta and gamma. One novel cDNA was isolated that encodes a protein that is phosphorylated on tyrosine, contains a Src-homology 2 (SH2) domain, inositolpolyphosphate 5-phosphatase activity, three NXXY motifs, several proline-rich regions, and is called SHIP. Mutation of the conserved tyrosine or leucine residues within the Fc epsilon RI beta or ITAMs eliminates SHIP binding and indicates that the SHIP-ITAM interaction is specific. SHIP also binds to ITAMs from the CD3 complex and T cell receptor zeta chain in vitro. SHIP protein possesses both phosphatidylinositol-3,4,5-trisphosphate 5'-phosphatase and inositol-1,3,4,5-tetrakisphosphate 5'-phosphatase activity. Phosphorylation of SHIP by a protein-tyrosine kinase, Lck, results in a reduction in enzyme activity. Fc epsilon RI activation induces the association of several tyrosine phosphoproteins with SHIP. SHIP is constitutively tyrosine-phosphorylated and associated with She and Grb2. These data suggest that SHIP may serve as a multifunctional linker protein in receptor activation.	HOFFMANN LA ROCHE INC, DEPT METAB DIS, NUTLEY, NJ 07110 USA; WASHINGTON UNIV, SCH MED, DIV HEMATOL, ST LOUIS, MO 63110 USA; BETH ISRAEL HOSP, DEPT MED, DIV SIGNAL TRANSDUCT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Roche Holding; Washington University (WUSTL); Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School			Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147, R01HL016634, R37HL016634, T32HL007088] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16634, HL14147, HL07088] Funding Source: Medline; NIGMS NIH HHS [R01 GM041890] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTREE O, 1992, NATURE, V358, P239; BARKER SA, 1995, MOL BIOL CELL, V6, P1145, DOI 10.1091/mbc.6.9.1145; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BUDAY L, 1994, J BIOL CHEM, V269, P9019; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; CASTELLANOS RMP, 1985, J BIOL CHEM, V260, P8240; Crowley MT, 1996, J BIOL CHEM, V271, P1145, DOI 10.1074/jbc.271.2.1145; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; deKoning JP, 1996, BLOOD, V87, P132; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Galandrini R, 1996, J EXP MED, V183, P179, DOI 10.1084/jem.183.1.179; HOWE LR, 1995, TRENDS BIOCHEM SCI, V20, P59, DOI 10.1016/S0968-0004(00)88958-6; JEFFERSON AB, 1995, J BIOL CHEM, V270, P9370, DOI 10.1074/jbc.270.16.9370; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; KIHARA H, 1994, J BIOL CHEM, V269, P22427; Kimura T, 1996, MOL CELL BIOL, V16, P1471; KORNBLUTH S, 1987, P NATL ACAD SCI USA, V84, P4455, DOI 10.1073/pnas.84.13.4455; KOYASU S, 1994, P NATL ACAD SCI USA, V91, P6693, DOI 10.1073/pnas.91.14.6693; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; LAXMINARAYAN KM, 1994, J BIOL CHEM, V269, P17305; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; OSBORNE MA, 1997, YEAST 2 HYBRID SYSTE; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROSS TS, 1991, J BIOL CHEM, V266, P20283; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SAXTON TM, 1994, J IMMUNOL, V153, P623; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TOKER A, 1994, J BIOL CHEM, V269, P32358; TURNER H, 1995, J BIOL CHEM, V270, P9500, DOI 10.1074/jbc.270.16.9500; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; Wolfe PC, 1996, J BIOL CHEM, V271, P6658, DOI 10.1074/jbc.271.12.6658; ZENNER G, 1996, IN PRESS J CELL BIOC; ZHANG XL, 1995, P NATL ACAD SCI USA, V92, P4853, DOI 10.1073/pnas.92.11.4853; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	47	161	165	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29271	29278		10.1074/jbc.271.46.29271	http://dx.doi.org/10.1074/jbc.271.46.29271			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910587	hybrid			2022-12-27	WOS:A1996VT05200079
J	Pillot, T; Goethals, M; Vanloo, B; Talussot, C; Brasseur, R; Vandekerckhove, J; Rosseneu, M; Lins, L				Pillot, T; Goethals, M; Vanloo, B; Talussot, C; Brasseur, R; Vandekerckhove, J; Rosseneu, M; Lins, L			Fusogenic properties of the C-terminal domain of the Alzheimer beta-amyloid peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; MEMBRANE-FUSION ACTIVITY; PHOSPHOLIPID-VESICLES; STRUCTURAL REQUIREMENTS; BILAYER-MEMBRANES; LIPID BILAYER; PROTEIN; DISEASE; MODEL; AGGREGATION	A series of natural peptides and mutants, derived from the Alzheimer beta-amyloid peptide, was synthesized, and the potential of these peptides to induce fusion of unilamellar lipid vesicles was investigated. These peptide domains were identified by computer modeling and correspond to respectively the C-terminal (e.g. residues 29-40 and 29-42) and a central domain (13-28) of the beta-amyloid peptide. The C-terminal peptides are predicted to insert in an oblique way into a lipid membrane through their N-terminal end, while the mutants are either parallel or perpendicular to the lipid bilayer. Peptide induced vesicle fusion was demonstrated by several techniques, including lipid-mixing and core-mixing assays using pyrene-labeled vesicles. The effect of peptide elongation toward the N-terminal end of the entire beta-amyloid peptide was also investigated. Peptides corresponding to residues 22-42 and 12-42 were tested using the same techniques. Both the 29-40 and 29-42 beta-amyloid peptides were able to induce fusion of unilamellar lipid vesicles and calcein leakage, and the amyloid 29-42 peptide was the most potent fusogenic peptide. Neither the two mutants or the 13-28 beta-amyloid peptide had any fusogenic activity. Circular dichroism measurements showed an increase of the alpha-helical content of the two C-terminal peptides at increasing concentrations of trifluoroethanol, which was accompanied by an increase of the fusogenic potential of the peptides. Our data suggest that the alpha-helical content and the angle of insertion of the peptide into a lipid bilayer are critical for the fusogenic activity of the C-terminal domain of the amyloid peptide. The differences observed between the fusogenic capacity of the amyloid 29-40 and 29-42 peptides might result from differences in the degree of penetration of the peptides into the membrane and the resulting membrane destabilization. The longer peptides, residues 22-42 and 12-42, had decreased, but significant, fusogenic properties associated with perturbation of the membrane permeability. These data suggest that the fusogenic properties of the C-terminal domain of the beta-amyloid peptide might contribute to the cytotoxicity of the peptide by destabilizing the cell membrane.	STATE UNIV GHENT, LAB LIPOPROT CHEM, FAC MED, B-9000 GHENT, BELGIUM; STATE UNIV GHENT VIB, FAC MED, DEPT BIOCHEM, B-9000 GHENT, BELGIUM; FAC SCI AGRON ETAT GEMBLOUX, CTR BIOPHYS MOL NUMER, GEMBLOUX, BELGIUM	Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University; University of Liege			LINS, LAURENCE/Y-1661-2019; lins, laurence/E-3953-2012	LINS, LAURENCE/0000-0001-7772-6748; 				ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P567, DOI 10.1073/pnas.90.2.567; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BLUMENTHAL R, 1983, J BIOL CHEM, V258, P3409; BRASSEUR R, 1986, BIOCHEM J, V238, P1; BRASSEUR R, 1993, BIOCHIM BIOPHYS ACTA, V1170, P1, DOI 10.1016/0005-2760(93)90168-9; BRASSEUR R, 1991, J BIOL CHEM, V266, P16120; BURDICK D, 1992, J BIOL CHEM, V267, P546; DEFRISEQUERTAIN F, 1989, BIOCHEMISTRY-US, V28, P3406, DOI 10.1021/bi00434a040; DOMS RW, 1985, J BIOL CHEM, V260, P2973; GASSET M, 1990, BIOCHEM J, V265, P815, DOI 10.1042/bj2650815; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; HORTH M, 1991, EMBO J, V10, P2747, DOI 10.1002/j.1460-2075.1991.tb07823.x; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KENDALL DA, 1982, J BIOL CHEM, V257, P3892; LANSBURY PT, 1995, NAT STRUCT BIOL, V2, P990, DOI 10.1038/nsb1195-990; MARTIN I, 1994, J VIROL, V68, P1139, DOI 10.1128/JVI.68.2.1139-1148.1994; MATTSON MP, 1995, NAT STRUCT BIOL, V2, P926, DOI 10.1038/nsb1195-926; MATTSON MP, 1992, J NEUROSCI, V12, P379; MOE GR, 1985, BIOCHEMISTRY-US, V24, P1971, DOI 10.1021/bi00329a026; MORRIS SJ, 1988, SPECTROSCOPIC MEMBRA, V1, P161; MOUSLI M, 1990, TRENDS PHARMACOL SCI, V11, P358, DOI 10.1016/0165-6147(90)90179-C; MUGA A, 1994, BIOCHEMISTRY-US, V33, P4444, DOI 10.1021/bi00181a002; NIEVA JL, 1994, BIOCHEMISTRY-US, V33, P3201, DOI 10.1021/bi00177a009; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Poduslo S E, 1975, Methods Enzymol, V35, P561, DOI 10.1016/0076-6879(75)35185-9; RAFALSKI M, 1991, BIOCHEMISTRY-US, V30, P10211, DOI 10.1021/bi00106a020; RAPAPORT D, 1994, J BIOL CHEM, V269, P15124; SCHUBERT D, 1995, P NATL ACAD SCI USA, V92, P1989, DOI 10.1073/pnas.92.6.1989; Selkoe Dennis J., 1994, Current Opinion in Neurobiology, V4, P708, DOI 10.1016/0959-4388(94)90014-0; SIMMONS LK, 1993, MOL PHARMACOL, V15, P373; SONG DL, 1993, EUR J PHARM-MOLEC PH, V247, P283; UEDA K, 1994, BRAIN RES, V639, P240, DOI 10.1016/0006-8993(94)91736-1; VANCOMPERNOLLE K, 1992, EMBO J, V11, P4739, DOI 10.1002/j.1460-2075.1992.tb05579.x; VANLOO B, 1991, J LIPID RES, V32, P1253; VONECHE V, 1992, P NATL ACAD SCI USA, V89, P3810, DOI 10.1073/pnas.89.9.3810; WEISS JH, 1994, J NEUROCHEM, V62, P372; ZIMMERBERG J, 1993, ANNU REV BIOPH BIOM, V22, P433, DOI 10.1146/annurev.bb.22.060193.002245	40	142	148	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28757	28765		10.1074/jbc.271.46.28757	http://dx.doi.org/10.1074/jbc.271.46.28757			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910517	hybrid			2022-12-27	WOS:A1996VT05200009
J	Zhang, B; Peng, ZY				Zhang, B; Peng, ZY			Defective folding of mutant p16(INK4) proteins encoded by tumor-derived alleles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; FAMILIAL MELANOMA; BETA-LACTAMASE; MUTATIONS; BINDING; P16; INHIBITION; STATE; GENE	p16(INK4) is a specific cyclin D-dependent kinase inhibitor and a multiple tumor suppressor. Inactivation of p16 is frequent in both primary tumors and tumor-derived cell lines. We describe here the conformational properties and oligomerization state of seven mutant p16 proteins; all of them are deficient in function. Four of the seven proteins show significantly disrupted secondary structure and backbone folding. The other three adopt partially folded, molten globule-like conformations. These proteins have near-native levels of secondary structure, but lack the ability to undergo a cooperative thermal transition and are substantially less resistant to proteolysis than is wild type p16. At low concentrations, two of the seven proteins are monomers, three exhibit an apparent molecular weight between the value of a monomer and a dimer, and the other two aggregate significantly. Our results strongly suggest that defective protein folding and/or aggregation is a common mechanism for inactivation of p16.	UNIV CONNECTICUT,CTR HLTH,DEPT BIOCHEM,FARMINGTON,CT 06032	University of Connecticut			Zhang, Bin/AAJ-1481-2020					Blacklow SC, 1996, NAT STRUCT BIOL, V3, P758, DOI 10.1038/nsb0996-758; Boice JA, 1996, PROTEIN SCI, V5, P1776, DOI 10.1002/pro.5560050903; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; BYCHKOVA VE, 1995, FEBS LETT, V359, P6, DOI 10.1016/0014-5793(95)00004-S; CORDONCARDO C, 1995, AM J PATHOL, V147, P545; CRAIG S, 1985, J MOL BIOL, V185, P681, DOI 10.1016/0022-2836(85)90053-1; DOERING D, 1992, THESIS MIT; DOLGIKH DA, 1984, FEBS LETT, V165, P88, DOI 10.1016/0014-5793(84)80020-4; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; GOTO Y, 1989, BIOCHEMISTRY-US, V28, P945, DOI 10.1021/bi00429a004; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HEROLD M, 1990, BIOCHEMISTRY-US, V29, P1907, DOI 10.1021/bi00459a035; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KO YH, 1993, J BIOL CHEM, V268, P24330; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUWAJIMA K, 1989, J MOL BIOL, V206, P547, DOI 10.1016/0022-2836(89)90500-7; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LIM WA, 1992, BIOCHEMISTRY-US, V31, P4324, DOI 10.1021/bi00132a025; Liu X, 1996, P NATL ACAD SCI USA, V93, P4554, DOI 10.1073/pnas.93.10.4554; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; PARRY D, 1996, MOL CELL BIOL, V7, P3844; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Taubes G, 1996, SCIENCE, V271, P1493, DOI 10.1126/science.271.5255.1493; Tevelev A, 1996, BIOCHEMISTRY-US, V35, P9475, DOI 10.1021/bi960211+; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; WICK ST, 1995, ONCOGENE, V11, P2013; WU YS, 1995, CHEM BIOL, V2, P91, DOI 10.1016/1074-5521(95)90281-3; YANG R, 1995, CANCER RES, V55, P2503; YU MH, 1995, NAT STRUCT BIOL, V2, P363, DOI 10.1038/nsb0595-363	37	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28734	28737		10.1074/jbc.271.46.28734	http://dx.doi.org/10.1074/jbc.271.46.28734			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910511	hybrid			2022-12-27	WOS:A1996VT05200003
J	Fang, YF; Fliss, AE; Robins, DM; Caplan, AJ				Fang, YF; Fliss, AE; Robins, DM; Caplan, AJ			Hsp90 regulates androgen receptor hormone binding affinity in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; GLUCOCORTICOID RECEPTOR; STEROID-RECEPTOR; LIGAND-BINDING; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; EXPRESSION SYSTEM; DUAL ROLES; COMPLEXES; DNA	The regulation of human androgen receptor (AR) by the molecular chaperone Hsp90 was investigated using the yeast Saccharomyces cerevisiae as a model system. These studies were performed in strains expressing a conditional temperature-sensitive mutant allele of the hsp82 gene, which encodes Hsp90 protein. At the restrictive temperature in the mutant, there is a decrease in hormone-dependent transactivation by the AR, although steady state levels of AR protein are unchanged. Quantitative hormone binding studies at the permissive temperature revealed the presence of both high affinity and low affinity hormone binding states. At the restrictive temperature in the hsp82 mutant, the high affinity state was abolished, and only the low affinity state was observed. The change in hormone binding affinity was further investigated by a competition assay with the anti-androgen hydroxyflutamide. Under permissive conditions, hydroxyflutamide competes poorly for the synthetic androgen R1881, but under restrictive conditions in the hsp82 mutant strain, hydroxyflutamide was shown to be a potent competitive inhibitor. Our findings indicate that Hsp90 participates in the activation process by maintaining apoAR in a high affinity ligand binding conformation which is important for efficient response to hormone.	CUNY, MT SINAI MED CTR, DEPT CELL BIOL & ANAT, NEW YORK, NY 10029 USA; UNIV MICHIGAN, SCH MED, DEPT HUMAN GENET, ANN ARBOR, MI 48109 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Michigan System; University of Michigan			Caplan, Avrom/GPT-0824-2022	Robins, Diane M./0000-0001-6727-6309	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049065] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-49065] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; BOHEN SP, 1995, J BIOL CHEM, V270, P29433, DOI 10.1074/jbc.270.49.29433; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; Bohen SP., 1994, BIOL HEAT SHOCK PROT, V26, P313; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CAPLAN AJ, 1995, J BIOL CHEM, V270, P5251, DOI 10.1074/jbc.270.10.5251; CHANG CS, 1992, P NATL ACAD SCI USA, V89, P5946, DOI 10.1073/pnas.89.13.5946; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; Dey B, 1996, MOL BIOL CELL, V7, P91, DOI 10.1091/mbc.7.1.91; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOHFELD J, 1995, CELL, V83, P589; HOLLEY SJ, 1995, MOL BIOL CELL, V6, P1833, DOI 10.1091/mbc.6.12.1833; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; MAK P, 1994, RECENT PROG HORM RES, V49, P347; MARIVOET S, 1992, MOL CELL ENDOCRINOL, V88, P165, DOI 10.1016/0303-7207(92)90021-W; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; NEMOTO T, 1990, BIOCHEMISTRY-US, V29, P1880, DOI 10.1021/bi00459a031; NEMOTO T, 1992, J STEROID BIOCHEM, V42, P803, DOI 10.1016/0960-0760(92)90088-Z; NEMOTO T, 1993, J BIOCHEM-TOKYO, V113, P769; OHARANEMOTO Y, 1991, J BIOCHEM, V109, P113, DOI 10.1093/oxfordjournals.jbchem.a123330; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; PRATT WB, 1993, J BIOL CHEM, V268, P21455; PURVIS IJ, 1991, GENE, V106, P35, DOI 10.1016/0378-1119(91)90563-Q; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SCHMID FX, 1993, ANNU REV BIOPH BIOM, V22, P123, DOI 10.1146/annurev.bb.22.060193.001011; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; VELDSCHOLTE J, 1992, BIOCHEMISTRY-US, V31, P742, DOI 10.1021/bi00147a029; WAKELING AE, 1981, J STEROID BIOCHEM, V15, P355, DOI 10.1016/0022-4731(81)90297-1; WONG CI, 1995, J BIOL CHEM, V270, P19998, DOI 10.1074/jbc.270.34.19998; XIE YB, 1992, J BIOL CHEM, V267, P4939	37	170	176	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28697	28702		10.1074/jbc.271.45.28697	http://dx.doi.org/10.1074/jbc.271.45.28697			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910505	hybrid			2022-12-27	WOS:A1996VU03300105
J	OgierDenis, E; Houri, JJ; Bauvy, C; Codogno, P				OgierDenis, E; Houri, JJ; Bauvy, C; Codogno, P			Guanine nucleotide exchange on heterotrimeric G(i3) protein controls autophagic sequestration in HT-29 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; GTP-BINDING PROTEINS; N-LINKED GLYCOPROTEINS; ENTEROCYTIC DIFFERENTIATION; ADENYLATE-CYCLASE; ADP-RIBOSYLATION; ALPHA-SUBUNIT; REGULATORY COMPONENT; EPITHELIAL-CELLS; GOLGI MEMBRANES	Recent results have shown that autophagic sequestration in the human colon cancer cell line HT-29 is controlled by the pertussis toxin-sensitive heterotrimeric G(i3) protein. Here we show that transfection of an antisense oligodeoxynucleotide to the alpha(i3)-subunit markedly inhibits autophagic sequestration, whereas transfection of an antisense oligodeoxynucleotide to the alpha(i2)-subunit does not change the rate of autophagy in HT-29 cells. Autophagic sequestration was arrested in cells transfected with a mutant of the alpha(i3)-subunit (Q204L) that is restricted to the GTP-bound form. In Q204L expressing cells, 3-methyladenine-sensitive degradation of long lived [C-14]valine-labeled proteins was severely impaired and could not be stimulated by nutrient deprivation. Autophagy was also reduced when dissociation of the beta gamma dimer from the GTP-bound alpha(i3)-subunit was impaired in cells transfected with the G203A mutant. In contrast, a high rate of pertussis toxin-sensitive autophagy was observed in cells transfected with an alpha(i3)-subunit mutant (S47N) which has an increased guanine nucleotide exchange rate and increased preference for GDP over GTP. Cells that express pertussis toxin-insensitive mutants of either wild-type alpha(i3)-subunit (C351S) or S47N alpha(i3)-subunit (S47N/C351S) exhibit a high rate of autophagy.	UNIV PARIS 07,INSERM,U410,F-75018 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Ogier-Denis, Eric/E-5030-2016; Codogno, Patrice/G-1384-2013	Codogno, Patrice/0000-0002-5492-3180; Ogier-Denis, Eric/0000-0002-0057-7593				ARIDOR M, 1993, SCIENCE, V262, P1569, DOI 10.1126/science.7504324; BARR FA, 1991, FEBS FED EUR BIOCH S, V293, P1; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; BOMSEL M, 1993, J BIOL CHEM, V268, P25824; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COLEMAN DE, 1994, J MOL BIOL, V238, P630, DOI 10.1006/jmbi.1994.1320; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; FENGSRUD M, 1995, EXP CELL RES, V221, P504, DOI 10.1006/excr.1995.1402; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; HERMOUET S, 1992, FEBS LETT, V312, P223, DOI 10.1016/0014-5793(92)80940-I; HILDEBRANDT JD, 1991, MOL CELL BIOL, V11, P4830, DOI 10.1128/MCB.11.10.4830; HOLEN I, 1995, J BIOL CHEM, V270, P12823, DOI 10.1074/jbc.270.21.12823; HOURI JJ, 1995, BIOCHEM J, V309, P521, DOI 10.1042/bj3090521; HOURI JJ, 1992, EUR J BIOCHEM, V205, P1169, DOI 10.1111/j.1432-1033.1992.tb16887.x; HUNT TW, 1994, J BIOL CHEM, V269, P29565; ITOH H, 1988, J BIOL CHEM, V263, P6656; JOURNOT L, 1991, J BIOL CHEM, V266, P9009; KADOWAKI M, 1994, J BIOL CHEM, V269, P3703; KOPITZ J, 1990, J CELL BIOL, V111, P941, DOI 10.1083/jcb.111.3.941; KOVACS AL, 1985, EXP CELL RES, V157, P83, DOI 10.1016/0014-4827(85)90154-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE BP, 1992, J CELL SCI, V102, P515; LEE E, 1992, J BIOL CHEM, V267, P1212; MAIER O, 1995, BIOCHEM BIOPH RES CO, V208, P135, DOI 10.1006/bbrc.1995.1315; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MIOTTO G, 1994, J BIOL CHEM, V269, P25348; Mortimore G. E., 1994, CELLULAR PROTEOLYTIC, P65; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; MURAYAMA T, 1983, J BIOL CHEM, V258, P3319; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; OGIERDENIS E, 1988, J BIOL CHEM, V263, P6031; OGIERDENIS E, 1995, J BIOL CHEM, V270, P13, DOI 10.1074/jbc.270.1.13; OHASHI M, 1994, J BIOL CHEM, V269, P24897; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; PUNNONEN EL, 1993, EUR J CELL BIOL, V61, P54; RABOUILLE C, 1993, J CELL BIOL, V120, P897, DOI 10.1083/jcb.120.4.897; RIBEIRONETO FAP, 1989, P NATL ACAD SCI USA, V86, P2577, DOI 10.1073/pnas.86.8.2577; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SCHWORER CM, 1981, J BIOL CHEM, V256, P7652; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; SEGLEN PO, 1986, EXP CELL RES, V162, P273, DOI 10.1016/0014-4827(86)90446-5; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Seglen PO, 1987, LYSOSOMES THEIR ROLE, P369; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; TRUGNAN G, 1991, J BIOL CHEM, V266, P20849; VANDENBERGHE N, 1991, BIOCHEM J, V278, P565, DOI 10.1042/bj2780565; VITALE N, 1993, J BIOL CHEM, V268, P14715; Voisin T, 1996, J BIOL CHEM, V271, P574, DOI 10.1074/jbc.271.1.574; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; WILSON BS, 1993, P NATL ACAD SCI USA, V90, P1681, DOI 10.1073/pnas.90.5.1681; ZWEIBAUM A, 1985, J CELL PHYSIOL, V122, P21, DOI 10.1002/jcp.1041220105	62	94	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28593	28600		10.1074/jbc.271.45.28593	http://dx.doi.org/10.1074/jbc.271.45.28593			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910489	hybrid			2022-12-27	WOS:A1996VU03300089
J	Smith, LL; Cheung, HK; Ling, LE; Chen, J; Sheppard, D; Pytela, R; Giachelli, CM				Smith, LL; Cheung, HK; Ling, LE; Chen, J; Sheppard, D; Pytela, R; Giachelli, CM			Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha(9)beta(1) integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR CELL-ADHESION; SMOOTH-MUSCLE CELLS; EXTRACELLULAR-MATRIX; IN-VITRO; FUNCTIONAL REGULATION; FIBRONECTIN RECEPTOR; TISSUE DISTRIBUTION; CYTOPLASMIC DOMAIN; THROMBIN-CLEAVAGE; BETA(3) INTEGRIN	Osteopontin is an adhesive glycoprotein implicated in numerous diseases associated with inflammation and remodeling. There are several structural domains in osteopontin that are of particular interest. The RGD motif is a cell attachment sequence shown to be critical for cell adhesion through alpha(v)-containing integrins. In close proximity to the RGD domain is the thrombin cleavage site. Previous observations suggest that thrombin cleavage of osteopontin occurs in vivo and may be physiologically important. To study the functional significance of osteopontin cleavage by thrombin, we made glutathione S-transferase-osteopontin fusion proteins. These proteins contain either the N- or C-terminal domains expected to be formed following thrombin cleavage at the Arg(169)Ser(170) peptide bond, We compared these osteopontin fragments with native osteopontin in their ability to support adhesion of several different cell lines and identified the receptors mediating these interactions. Our data show that the N-terminal osteopontin fragment, which contains the RGD domain, supports adhesion of a melanoma cell line that is unable to bind native osteopontin. This suggests that osteopontin adhesive interactions may be regulated by thrombin cleavage. We also demonstrate that osteopontin contains a cryptic binding activity, which can be recognized by a novel osteopontin receptor. This receptor has been identified as the alpha(9) beta(1) integrin.	UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195; BIOGEN INC,DEPT BIOL RES,CAMBRIDGE,MA 02142; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; SAN FRANCISCO GEN HOSP,LUNG BIOL CTR,SAN FRANCISCO,CA 94110	University of Washington; University of Washington Seattle; Biogen; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-18645] Funding Source: Medline; NIGMS NIH HHS [5T32 GM07270-20] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLYSTONE SD, 1995, J CELL BIOL, V130, P745, DOI 10.1083/jcb.130.3.745; BROWN LF, 1992, MOL BIOL CELL, V3, P1169, DOI 10.1091/mbc.3.10.1169; BUSCH G, 1989, EUR J CELL BIOL, V50, P257; BUSK M, 1992, J BIOL CHEM, V267, P5790; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CHEN YP, 1994, BLOOD, V84, P1857; CHEN YP, 1995, BLOOD, V86, P2606, DOI 10.1182/blood.V86.7.2606.bloodjournal8672606; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; DAMSKY CH, 1992, J CLIN INVEST, V89, P210, DOI 10.1172/JCI115565; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DERRICO JA, 1995, J PERIODONTAL RES, V30, P34, DOI 10.1111/j.1600-0765.1995.tb01250.x; DEVRIES JE, 1986, INT J CANCER, V38, P465, DOI 10.1002/ijc.2910380403; GAILIT J, 1988, J BIOL CHEM, V263, P12927; Gajdusek C. M., 1983, IN VITRO, V19, P394; GIACHELLI CM, 1995, TRENDS CARDIOVAS MED, V5, P88, DOI 10.1016/1050-1738(95)00005-T; GIACHELLI CM, 1993, J CLIN INVEST, V92, P1686, DOI 10.1172/JCI116755; GIACHELLI CM, 1995, ANN NY ACAD SCI, V760, P109, DOI 10.1111/j.1749-6632.1995.tb44624.x; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; HELFRICH MH, 1992, J BONE MINER RES, V7, P335; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HORTON MA, 1994, BONE, V15, P639, DOI 10.1016/8756-3282(94)90312-3; HU DD, 1995, J BIOL CHEM, V270, P26232, DOI 10.1074/jbc.270.44.26232; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KIEFER MC, 1989, NUCLEIC ACIDS RES, V17, P3306, DOI 10.1093/nar/17.8.3306; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; LIAW L, 1995, CIRC RES, V77, P665, DOI 10.1161/01.RES.77.4.665; LIAW L, 1994, CIRC RES, V74, P214, DOI 10.1161/01.RES.74.2.214; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; LUQUE A, 1994, FEBS LETT, V346, P278, DOI 10.1016/0014-5793(94)00490-0; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; MURRY CE, 1994, AM J PATHOL, V145, P1450; NASU K, 1995, BIOCHEM J, V307, P257, DOI 10.1042/bj3070257; OBRIEN KD, 1995, CIRCULATION, V92, P2163, DOI 10.1161/01.CIR.92.8.2163; PACIFICI R, 1994, J IMMUNOL, V153, P2222; PALMER EL, 1993, J CELL BIOL, V123, P1289, DOI 10.1083/jcb.123.5.1289; SCHNAPP LM, 1995, J CELL SCI, V108, P537; SENGER DR, 1989, BIOCHIM BIOPHYS ACTA, V996, P43, DOI 10.1016/0167-4838(89)90092-7; SENGER DR, 1995, ANN NY ACAD SCI, V760, P83, DOI 10.1111/j.1749-6632.1995.tb44622.x; SENGER DR, 1994, MOL BIOL CELL, V5, P565, DOI 10.1091/mbc.5.5.565; SENGER DR, 1989, ANTICANCER RES, V9, P1291; STEPP MA, 1995, J HISTOCHEM CYTOCHEM, V43, P353, DOI 10.1177/43.4.7534781; VANDIJK S, 1993, J BONE MINER RES, V8, P1499; VANSTRIJP JAG, 1993, J IMMUNOL, V151, P3324; WANG A, 1996, IN PRESS AM J RESP C; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WEINACKER A, 1995, AM J RESP CELL MOL, V12, P547, DOI 10.1165/ajrcmb.12.5.7537970; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; XUAN JW, 1995, J CELL BIOCHEM, V57, P680, DOI 10.1002/jcb.240570413; XUAN JW, 1994, J CELL BIOCHEM, V54, P247, DOI 10.1002/jcb.240540213; YOKOSAKI Y, 1994, J BIOL CHEM, V269, P26691; YOUNG MF, 1990, GENOMICS, V7, P491, DOI 10.1016/0888-7543(90)90191-V	55	220	225	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28485	28491		10.1074/jbc.271.45.28485	http://dx.doi.org/10.1074/jbc.271.45.28485			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910476	hybrid			2022-12-27	WOS:A1996VU03300076
J	Christoffels, VM; vandenHoff, MJB; Lamers, MC; vanRoon, MA; deBoer, PAJ; Moorman, AFM; Lamers, WH				Christoffels, VM; vandenHoff, MJB; Lamers, MC; vanRoon, MA; deBoer, PAJ; Moorman, AFM; Lamers, WH			The upstream regulatory region of the carbamoyl-phosphate synthetase I gene controls its tissue-specific, developmental, and hormonal regulation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOENOLPYRUVATE CARBOXYKINASE; TYROSINE AMINOTRANSFERASE GENE; LIVER-SPECIFIC GENES; RAT-LIVER; MESSENGER-RNA; TRANSCRIPTION FACTORS; GLUTAMINE-SYNTHETASE; TRANSGENIC MICE; ORNITHINE AMINOTRANSFERASE; HEPATOCYTE HETEROGENEITY	The carbamoyl-phosphate synthetase I gene is expressed in the periportal region of the liver, where it is activated by glucocorticosteroids and glucagon (via cyclic AMP), and in the crypts of the intestinal mucosa. The enhancer of the gene is located 6.3 kilobase pairs upstream of the transcription start site and has been shown to direct the hormone-dependent hepatocyte-specific expression in vitro, To analyze the function of the upstream region in vivo, three groups of transgenic mice were generated, In the first group the promoter drives expression of the reporter gene, whereas the prometer and upstream region including the far upstream enhancer drive expression of the reporter gene in the second group. In the third group the far upstream enhancer was directly coupled to a minimized promoter fragment. Reporter-gene expression was virtually undetectable in the first group. In the second group spatial, temporal, and hormonal regulation of expression of the reporter gene and the endogenous carbamoyl-phosphate synthetase gene were identical, The third group showed liver-specific periportal reporter gene expres sion, but failed to activate expression in the intestine. These results show that the upstream region of the carbamoyl phosphate synthetase gene controls four characteristics of its expression: tissue specificity, spatial pattern of expression within the liver and intestine, hormone sensitivity, and developmental regulation, Within the upstream region, the far upstream enhancer at -6.3 kilobase pairs is the determinant of the characteristic hepatocyte-specific periportal expression pattern of carbamoyl-phosphate synthetase.	UNIV AMSTERDAM, DEPT ANAT & EMBRYOL, NL-1105 AZ AMSTERDAM, NETHERLANDS; MAX PLANCK INST IMMUNBIOL, D-79108 FREIBURG, GERMANY; ACAD MED CTR, GENETICALLY MODIFIED MICE FACIL, NL-1105 AZ AMSTERDAM, NETHERLANDS	University of Amsterdam; Max Planck Society; University of Amsterdam; Academic Medical Center Amsterdam			Lamers, Wouter H./D-2965-2012					ADCOCK MW, 1984, J BIOL CHEM, V259, P3471; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BEALE EG, 1992, FASEB J, V6, P3330, DOI 10.1096/fasebj.6.15.1281456; BERTHOUD VM, 1992, AM J PHYSIOL, V263, pG650, DOI 10.1152/ajpgi.1992.263.5.G650; CHRISTOFFELS VM, 1995, J BIOL CHEM, V270, P24932, DOI 10.1074/jbc.270.42.24932; DEGROOT CJ, 1986, BIOCHIM BIOPHYS ACTA, V866, P61, DOI 10.1016/0167-4781(86)90101-6; DESIMONE V, 1992, BIOCHIM BIOPHYS ACTA, V1132, P119, DOI 10.1016/0167-4781(92)90001-G; Dingemanse MA, 1996, HEPATOLOGY, V24, P407; DINGEMANSE MA, 1994, DIFFERENTIATION, V56, P153, DOI 10.1046/j.1432-0436.1994.5630153.x; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GEBHARDT R, 1992, PHARMACOL THERAPEUT, V53, P275, DOI 10.1016/0163-7258(92)90055-5; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOPING IS, 1994, J BIOL CHEM, V269, P3891; GOPING IS, 1995, NUCLEIC ACIDS RES, V23, P1717, DOI 10.1093/nar/23.10.1717; GOPING IS, 1992, GENE, V118, P283, DOI 10.1016/0378-1119(92)90201-Y; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; HAUSSINGER D, 1992, ENZYME, V46, P72; HOGAN B, 1986, MANIPULATING MOUSE E; JANZEN JWG, 1988, J HISTOCHEM CYTOCHEM, V36, P1223, DOI 10.1177/36.10.2458406; JANZEN JWG, 1985, J HISTOCHEM CYTOCHEM, V339, P1205; JOHNSON PF, 1990, CELL GROWTH DIFFER, V1, P47; JUNGERMANN K, 1995, HISTOCHEM CELL BIOL, V103, P81, DOI 10.1007/BF01454004; KUO CF, 1988, MOL CELL BIOL, V8, P4966, DOI 10.1128/MCB.8.11.4966; KUO CF, 1989, J MOL BIOL, V208, P45, DOI 10.1016/0022-2836(89)90086-7; KUO FC, 1991, P NATL ACAD SCI USA, V88, P9468, DOI 10.1073/pnas.88.21.9468; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAGACE M, 1987, J BIOL CHEM, V262, P10415; LAGACE M, 1992, GENE, V118, P231, DOI 10.1016/0378-1119(92)90193-S; LAI E, 1991, TRENDS BIOCHEM SCI, V16, P427, DOI 10.1016/0968-0004(91)90169-V; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAMERS WH, 1981, MECH AGEING DEV, V15, P93, DOI 10.1016/0047-6374(81)90010-5; LAMERS WH, 1987, DIFFERENTIATION, V35, P228, DOI 10.1111/j.1432-0436.1987.tb00173.x; LAMERS WH, 1984, DEV BIOL, V105, P500, DOI 10.1016/0012-1606(84)90307-5; LAMERS WH, 1990, ANAT REC, V228, P297, DOI 10.1002/ar.1092280309; LIEVENEMA H, 1995, J BIOL CHEM, V270, P28251; MEEHAN R, 1992, J CELL SCI, P9; MEIJER AJ, 1990, PHYSIOL REV, V70, P701, DOI 10.1152/physrev.1990.70.3.701; MIZUTANI A, 1968, J HISTOCHEM CYTOCHEM, V16, P172, DOI 10.1177/16.3.172; MOORMAN AFM, 1990, HISTOCHEM J, V22, P457, DOI 10.1007/BF01007229; MOORMAN AFM, 1993, HISTOCHEM J, V25, P251, DOI 10.1007/BF00159117; MOORMAN AFM, 1991, FEBS LETT, V288, P133, DOI 10.1016/0014-5793(91)81019-5; MOORMAN AFM, 1990, FEBS LETT, V276, P9, DOI 10.1016/0014-5793(90)80494-4; MOORMAN AFM, 1994, FEBS LETT, V356, P76, DOI 10.1016/0014-5793(94)01230-X; MORRIS SM, 1992, ANNU REV NUTR, V12, P81, DOI 10.1146/annurev.nu.12.070192.000501; MORRIS SM, 1987, ARCH BIOCHEM BIOPHYS, V256, P343, DOI 10.1016/0003-9861(87)90455-3; MUECKLER MM, 1983, J BIOL CHEM, V258, P6109; NAGY P, 1994, J CELL BIOL, V126, P223, DOI 10.1083/jcb.126.1.223; NISHIYORI A, 1994, J BIOL CHEM, V269, P1323; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; NOTENBOOM RGE, 1996, IN PRESS MICROSC RES; NYUNOYA H, 1985, J BIOL CHEM, V260, P9346; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; PATEL YM, 1994, J BIOL CHEM, V269, P5619; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; ROUX J, 1995, DNA CELL BIOL, V14, P385, DOI 10.1089/dna.1995.14.385; RYALL JC, 1986, EUR J BIOCHEM, V156, P453, DOI 10.1111/j.1432-1033.1986.tb09603.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; Takiguchi M, 1995, BIOCHEM J, V312, P649, DOI 10.1042/bj3120649; THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378-1119(91)90270-L; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; VANDENHOFF MJB, 1993, NUCLEIC ACIDS RES, V21, P4987, DOI 10.1093/nar/21.21.4987; VANDENHOFF MJB, 1995, EUR J BIOCHEM, V228, P351; VANROON MA, 1989, DIFFERENTIATION, V41, P139, DOI 10.1111/j.1432-0436.1989.tb00741.x; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656	68	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31243	31250		10.1074/jbc.271.49.31243	http://dx.doi.org/10.1074/jbc.271.49.31243			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940127	hybrid			2022-12-27	WOS:A1996VW68600038
J	Jung, YS; Vassiliev, IR; Qiao, FY; Yang, F; Bryant, DA; Golbeck, JH				Jung, YS; Vassiliev, IR; Qiao, FY; Yang, F; Bryant, DA; Golbeck, JH			Modified ligands to F-A and F-B in Photosystem I - Proposed chemical rescue of a [4Fe-4S] cluster with an external thiolate in alanine, glycine, and serine mutants of PsaC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; IRON-SULFUR CLUSTERS; COLI FUMARATE REDUCTASE; ESCHERICHIA-COLI; ELECTRON-TRANSFER; PROTEIN; CONVERSION; CYSTEINE; COMPLEX; BINDING	The F-B and F-A electron accepters in Photosystem I (PS I) are [4Fe-4S] clusters ligated by cysteines provided by PsaC. In a previous study (Mehari, T., Qiao, F., Scott, M. P., Nellis, D., Zhao, J., Bryant, D., and Golbeck, J. H. (1995) J. Biol. Chem. 270, 28108-28117), we showed that when cysteines 14 and 51 were replaced with serine or alanine, the free proteins contained a S = 1/2, [4Fe-4S] cluster at the unmodified site and a mixed population of S = 1/2, [3Fe-4S] and S = 3/2, [4Fe-4S] clusters at the modified site. We show here that these mutant PsaC proteins can be rebound to P700-F-X cores, resulting in fully functional PS I complexes. The low temperature EPR spectra of the C14X(PsaC). PS I complexes (where X = S, A, or G) show the photoreduction of a wild-type F-A cluster and a modified F-B cluster, the latter with g values of 2.115, 1.899, and 1.852 and linewidths of 110, 70, and 85 MHz. Since neither alanine nor glycine contains a suitable side group, an external thiolate provided by beta-mercaptoethanol has likely been recruited to supply the requisite ligand to the [4Fe-4S] cluster. The EPR spectrum of the C51S(PsaC). PS I complex differs from that of the C51A(PsaC). PS I or C51G(PSaC). PS I complexes by the presence of an additional set of resonances, which may be derived from the serine oxygen-ligated cluster. In all other mutant PS I complexes, a wild-type spin-coupled interaction spectrum appears when FA and F, are simultaneously reduced. Single turnover flash studies indicate similar to 50% efficient electron transfer to F-A/F-B in the C14SP(Sac). PS I, C51S(PsaC). PS I, C14G(PSaC). PS I, and CB14S(PsaC). PS I mutants and less than 40% in the C14A(PsaC). PS I and C51A(PsaC). PS I mutants, compared with similar to 76% in the PS I core reconstructed with wild-type PsaC. These data are consistent with the measurements of the rates of cytochrome c(6)-NADP(+) reductase activity, indicating lower rates in the alanine mutants. It is proposed that the chemical rescue of a [4Fe-4S] cluster with a recruited external thiolate at the modified site allows the mutant PsaC proteins to rebind to PS I and to function in forward electron transfer.	PENN STATE UNIV,DEPT BIOCHEM & MOL BIOL,UNIVERSITY PK,PA 16802; PENN STATE UNIV,CTR BIOMOL STRUCT & FUNCT,UNIVERSITY PK,PA 16802; UNIV NEBRASKA,DEPT BIOCHEM,GEORGE W BEADLE CTR,LINCOLN,NE 68588; UNIV NEBRASKA,CTR BIOL CHEM,GEORGE W BEADLE CTR,LINCOLN,NE 68588	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln								ALTMAN TE, 1981, THESIS U ILLINOIS UR; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BASSILIEV I, 1996, IN PRESS BIOPHYS J; BEINERT H, 1989, EUR J BIOCHEM, V186, P5, DOI 10.1111/j.1432-1033.1989.tb15170.x; BEINERT H, 1983, ARCH BIOCHEM BIOPHYS, V222, P333, DOI 10.1016/0003-9861(83)90531-3; Belford R L., 1979, EPR S 21 ROCK MOUNT; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brettel K, 1995, PHOTOSYNTH RES, V45, P183, DOI 10.1007/BF00015559; BRITT RD, 1991, BIOCHEMISTRY-US, V30, P1892, DOI 10.1021/bi00221a023; CONOVER RC, 1990, J BIOL CHEM, V265, P8533; DAVIDSON E, 1992, BIOCHEMISTRY-US, V31, P3342, DOI 10.1021/bi00128a006; DUNN PPJ, 1988, FEBS LETT, V228, P157, DOI 10.1016/0014-5793(88)80607-0; Golbeck J. H., 1995, CRC HDB ORGANIC PHOT, P1407; GOLBECK JH, 1993, CURR OPIN STRUC BIOL, V3, P508, DOI 10.1016/0959-440X(93)90076-W; Jung YS, 1995, PHOTOSYNTH RES, V46, P249, DOI 10.1007/BF00020437; JUNG YS, 1995, PHOTOSYNTHESIS LIGHT, V2, P127; KOJIMA Y, 1987, PROGR PHOTOSYNTHESIS, V2, P57; KOWAL AT, 1995, BIOCHEMISTRY-US, V34, P12284, DOI 10.1021/bi00038a024; KRAUSS N, 1993, NATURE, V361, P326, DOI 10.1038/361326a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; Mannan RM, 1996, EMBO J, V15, P1826, DOI 10.1002/j.1460-2075.1996.tb00532.x; MANODORI A, 1992, BIOCHEMISTRY-US, V31, P2703, DOI 10.1021/bi00125a010; MATHIS P, 1988, PHOTOSYNTH RES, V16, P203, DOI 10.1007/BF00028839; MEHARI T, 1995, J BIOL CHEM, V270, P28108; MEYER TE, 1994, METHOD ENZYMOL, V243, P435; MOUESCA JM, 1994, INORG CHEM, V33, P4819, DOI 10.1021/ic00100a004; MOURA JJG, 1994, METHOD ENZYMOL, V243, P165; Muhlenhoff U, 1996, EUR J BIOCHEM, V235, P324, DOI 10.1111/j.1432-1033.1996.00324.x; Nilges M. J., 1979, THESIS U ILLINOIS UR; OHOKA H, 1989, PLANT CELL PHYSIOL, V30, P869, DOI 10.1093/oxfordjournals.pcp.a077818; ROTHERY RA, 1991, BIOCHEMISTRY-US, V30, P8296, DOI 10.1021/bi00098a003; SAKURAI H, 1991, PHOTOSYNTH RES, V27, P65, DOI 10.1007/BF00029977; SHERGILL JK, 1994, BBA-BIOENERGETICS, V1185, P35, DOI 10.1016/0005-2728(94)90190-2; THOMSON AJ, 1992, J INORG BIOCHEM, V47, P197, DOI 10.1016/0162-0134(92)84065-U; THOMSON AJ, 1991, BIOCHEM SOC T, V19, P594, DOI 10.1042/bst0190594; VASSILIEV IR, 1995, BIOPHYS J, V69, P1544, DOI 10.1016/S0006-3495(95)80026-3; WARREN PV, 1993, BIOCHEMISTRY-US, V32, P4411, DOI 10.1021/bi00067a034; WERTH MT, 1990, P NATL ACAD SCI USA, V87, P8965, DOI 10.1073/pnas.87.22.8965; YU J, 1995, PLANT MOL BIOL, V29, P311; YU L, 1995, BIOCHEMISTRY-US, V34, P7861, DOI 10.1021/bi00024a010; YU LA, 1995, J BIOL CHEM, V270, P28118; ZHAO JD, 1992, BIOCHEMISTRY-US, V31, P5093, DOI 10.1021/bi00137a001; ZHAO JD, 1990, FEBS LETT, V276, P175, DOI 10.1016/0014-5793(90)80536-R	44	27	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31135	31144		10.1074/jbc.271.49.31135	http://dx.doi.org/10.1074/jbc.271.49.31135			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940111	hybrid			2022-12-27	WOS:A1996VW68600022
J	Chu, BY; Soncin, F; Price, BD; Stevenson, MA; Calderwood, SK				Chu, BY; Soncin, F; Price, BD; Stevenson, MA; Calderwood, SK			Sequential phosphorylation by mitogen-activated protein kinase and glycogen synthase kinase 3 represses transcriptional activation by heat shock factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; MAP KINASE; CELLS; STRESS; EXPRESSION; YEAST; GENE; MECHANISMS; TRANSITION; PATHWAYS	Mammalian heat shock genes are regulated at the transcriptional level by heat shock factor-1 (HSF-1), a sequence-specific transcription factor. We have examined the role of serine phosphorylation of HSF-1 in the regulation of heat shock gene transcription, Our experiments show that mitogen-activated protein kinases (MAPKs) of the ERK-1 family phosphorylate HSF-1 on serine residues and repress the transcriptional activation of the heat shock protein 70B (HSP70B) promoter by HSP-1 in vivo, These effects of MAPK are transmitted through a specific serine residue (Ser-303) located in a proline-rich sequence within the transcriptional regulatory domain of human HSF-1, However, despite the importance of Ser-303 in transmitting the signal from the MAPK cascade to HSP70 transcription, there was no evidence that Ser-303 could be phosphorylated by MAPK in vitro, although an adjacent residue (Ser-307) was avidly phosphorylated by MAPK. Further studies revealed that Ser-303 is phosphorylated by glycogen synthase kinase 3 (GSK3) through a mechanism dependent on primary phosphorylation of Ser-307 by MAPK, Secondary phosphorylation of Ser-303 by GSK3 may thus repress the activity of HSF-1, and its requirement for priming by MAPK phosphorylation of Ser-307 provides a potential link between the MAPK cascade and HSF-1, Our experiments thus indicate that MAPK is a potent inhibitor of HSF-1 function and may be involved in repressing the heat shock response during normal growth and development and deactivating the heat shock response during recovery from stress.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, JOINT CTR RADIAT THERAPY, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			SONCIN, Fabrice/A-1475-2009	SONCIN, Fabrice/0000-0001-6312-0673	NCI NIH HHS [CA50642, CA31303, CA47407] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050642, R01CA047407, P01CA031303] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRUCE JL, 1993, CANCER RES, V53, P12; Cahill CM, 1996, J BIOL CHEM, V271, P24874; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; ENGELBERG D, 1994, MOL CELL BIOL, V14, P4929, DOI 10.1128/MCB.14.7.4929; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GREEN M, 1995, MOL CELL BIOL, V15, P3354; HENSOLD JO, 1990, MOL CELL BIOL, V10, P1600, DOI 10.1128/MCB.10.4.1600; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOJ A, 1994, EMBO J, V13, P2617; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; KEMP BE, 1991, METHOD ENZYMOL, V200, P121; LANDRY J, 1992, J BIOL CHEM, V267, P794; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MIVECHI NF, 1995, CANCER RES, V55, P5512; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; Newton EM, 1996, MOL CELL BIOL, V16, P839; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SCHILLER P, 1988, J MOL BIOL, V203, P97, DOI 10.1016/0022-2836(88)90094-0; SHI YH, 1995, MOL CELL BIOL, V15, P4309; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; STEVENSON MA, 1994, CANCER RES, V54, P12; STEVENSON MA, 1996, IN PRESS BIOCH BIOPH; VENETIANER A, 1995, EUR J BIOCHEM, V233, P83, DOI 10.1111/j.1432-1033.1995.083_1.x; Voellmy Richard, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P357; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; Woodgett JR, 1991, METHOD ENZYMOL, V200, P564; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	40	310	330	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30847	30857		10.1074/jbc.271.48.30847	http://dx.doi.org/10.1074/jbc.271.48.30847			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940068	hybrid			2022-12-27	WOS:A1996VV15800085
J	Kamalati, T; Jolin, HE; Mitchell, PJ; Barker, KT; Jackson, LE; Dean, CJ; Page, MJ; Gusterson, BA; Crompton, MR				Kamalati, T; Jolin, HE; Mitchell, PJ; Barker, KT; Jackson, LE; Dean, CJ; Page, MJ; Gusterson, BA; Crompton, MR			Brk, a breast tumor-derived non-receptor protein-tyrosine kinase, sensitizes mammary epithelial cells to epidermal growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC-FAMILY KINASES; C-SRC; SIGNAL-TRANSDUCTION; FACTOR-ALPHA; MITOGENIC RESPONSIVENESS; NEU PROTOONCOGENE; PDGF RECEPTOR; SH2 DOMAIN; HUMAN-MILK; CANCER	brk (breast tumor kinase) shows homology to the src family of non-receptor protein-tyrosine kinases and is expressed in breast carcinomas. in order to investigate the role of brk in breast tumor development, we have examined the growth and transformation properties of human mammary epithelial cells engineered to overexpress Brk, interestingly, like c-Src, overexpression of Brk leads to sensitization to EGF, and also results in a partially transformed phenotype. Further investigation of the latter activity was attempted by mutational analysis, targeting key residues known to affect tyrosine kinase activity in Src-like kinases. Mutation of amino acid residue Lys-219 to Met, by analogy to Src, abolished both kinase activity and transformation capacity. Mutation of amino acid residue Tyr-447 to Phe, however, resulted in a decrease in transforming potential without affecting kinase activity, These results suggest that while Src and Brk share some functional properties, they act differently during transformation. These differences are discussed in the context of the mechanisms underlying breast cancer development.	INST CANC RES,IMMUNOL SECT,SUTTON SM2 5NG,SURREY,ENGLAND; GLAXO WELLCOME RES & DEV LTD,RES LABS,STEVENAGE SG1 2NY,HERTS,ENGLAND	University of London; Institute of Cancer Research - UK; GlaxoSmithKline	Kamalati, T (corresponding author), INST CANC RES,SECT CELL BIOL & EXPT PATHOL,15 COTSWOLD RD,SUTTON SM2 5NG,SURREY,ENGLAND.		Mitchell, Philip J/F-6393-2013; gusterson, barry a/D-3752-2009		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BERNS EMJJ, 1992, CANCER RES, V52, P1107; BOLEN JB, 1993, ONCOGENE, V8, P2025; BOLLA M, 1993, BREAST CANCER RES TR, V26, P283, DOI 10.1007/BF00665806; BORG A, 1991, BRIT J CANCER, V63, P136, DOI 10.1038/bjc.1991.28; BORG A, 1992, CANCER RES, V52, P2991; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; COLEMAN S, 1988, DEV BIOL, V127, P304, DOI 10.1016/0012-1606(88)90317-X; COLLINS MKL, 1983, J BIOL CHEM, V258, P1689; CONNOLLY JM, 1988, LIFE SCI, V42, P1751, DOI 10.1016/0024-3205(88)90041-0; COUGHLIN SR, 1989, SCIENCE, V243, P1191; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COURTNEIDGE SA, 1993, DEVELOPMENT, P57; DANIEL CW, 1990, REGULATORY MECH BREA, P79; DAVIDSON D, 1994, J BIOL CHEM, V269, P10956; DEAN CJ, 1986, METHOD ENZYMOL, V121, P52; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; EELES RA, 1993, CANCER SURV, V18, P57; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GREEN MR, 1983, DEV BIOL, V100, P506, DOI 10.1016/0012-1606(83)90243-9; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GUSTERSON BA, 1982, CANCER RES, V42, P4763; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAYMAN MJ, 1991, CANCER CELL-MON REV, V3, P302; HENNIPMAN A, 1989, CANCER RES, V49, P516; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HU WL, 1992, MOL CELL BIOL, V12, P5824; JACOBS C, 1983, CANCER RES, V43, P1696; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JOHNSON GD, 1982, J IMMUNOL METHODS, V55, P231, DOI 10.1016/0022-1759(82)90035-7; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KAMALATI T, 1996, MAMMARY TUMOUR CELL, P227; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; KELSEY JL, 1988, CANCER RES, V48, P5615; KLIJN JGM, 1994, BREAST CANCER RES TR, V29, P73, DOI 10.1007/BF00666183; KLIJN JGM, 1995, DRUG HORMONAL RESIST, P134; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; LIN PH, 1995, ONCOGENE, V10, P401; LISCIA DS, 1990, DEV BIOL, V140, P123, DOI 10.1016/0012-1606(90)90059-R; Liu QY, 1996, CANCER RES, V56, P1155; LIU XQ, 1994, RECENT PROG HORM RES, V49, P149; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LOWER EE, 1993, BREAST CANCER RES TR, V26, P217, DOI 10.1007/BF00665799; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; NIRANJAN B, 1995, DEVELOPMENT, V121, P2897; NORMANNO N, 1994, BREAST CANCER RES TR, V29, P11, DOI 10.1007/BF00666178; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; OUDE WPA, 1994, FEBS LETT, V352, P296; OUDE WPA, 1995, J BIOL CHEM, V270, P2264; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RAJKUMAR T, 1994, BREAST CANCER RES TR, V29, P3, DOI 10.1007/BF00666177; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROSEN N, 1986, J BIOL CHEM, V261, P3754; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SALOMON DS, 1990, REGULATORY MECH BREA, P107; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SIERKE SL, 1993, BIOCHEM BIOPH RES CO, V191, P45, DOI 10.1006/bbrc.1993.1182; SOULE HD, 1990, CANCER RES, V50, P6075; STAMPS AC, 1994, INT J CANCER, V57, P865, DOI 10.1002/ijc.2910570616; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIPATHY D, 1995, DRUG HORMONAL RESIST, P3; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; VANDERHAAR BK, 1987, J CELL PHYSL, V132, P581; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; YEE D, 1990, REGULATORY MECH BREA, P79; ZIEGLER SF, 1989, MOL CELL BIOL, V9, P2724, DOI 10.1128/MCB.9.6.2724; ZWIEBEL JA, 1986, CANCER RES, V46, P933	89	105	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30956	30963		10.1074/jbc.271.48.30956	http://dx.doi.org/10.1074/jbc.271.48.30956			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940083	hybrid			2022-12-27	WOS:A1996VV15800100
J	Mandal, M; Maggirwar, SB; Sharma, N; Kaufmann, SH; Sun, SC; Kumar, R				Mandal, M; Maggirwar, SB; Sharma, N; Kaufmann, SH; Sun, SC; Kumar, R			Bcl-2 prevents CD95 (Fas/APO-1)-induced degradation of lamin B and poly(ADP-ribose) polymerase and restores the NF-kappa B signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS-MEDIATED APOPTOSIS; PROGRAMMED CELL-DEATH; TNF RECEPTOR; ACTIVATION; GENE; ALPHA; EXPRESSION; INDUCTION; PHOSPHORYLATION; REQUIREMENT	In the study presented here, we investigated the possible interactions between CD95 (Fas/APO-1) and Bcl-2 by studying the effects of Bcl-2 on the modulation of cellular pathways activated by CD95 using HeLa cells as a model system, We report that stable expression of Bcl-2 in HeLa cells is associated with multiple phenotypic changes. Treatment of HeLa cells with anti-CD95 monoclonal antibody (mAb) resulted in preferential degradation of lamin B compared with lamins A and C. Significant lamin B degradation was detected as early as 1 h after anti-CD95 mAb treatment. In contrast, lamins A and C as well as actin remained unchanged until 4 h after treatment with anti-CD95 mAb, a time point that correlated with the period of DNA fragmentation, These results indicate that selective degradation of lamin B is an early cellular event in response to activation of the CD95 pathway and that it precedes DNA fragmentation, Overexpression of Bcl-2 resulted in prevention of lamin B degradation and DNA fragmentation into oligonucleosome fragments in response to the apoptotic signal by anti-CD95 mAb. In addition, in Bcl-2-overexpressing cells that were protected against apoptosis, anti-CD95 mAb-induced cleavage of poly(ADP-ribose) polymerase was completely blocked. Overexpression of Bcl-2 also resulted in restoration of the CD95-mediated signaling pathway involving activation of the transcription factor NF-kappa B (p50/RelA). These findings suggest that Bcl-2 prevents apoptosis in part by preventing the degradation of major nuclear polypeptides such as lamin B and poly(ADP-ribose) polymerase, In addition, our results demonstrate that CD95-mediated signaling involves activation of NF-kappa B (p50/RelA).	PENN STATE UNIV,COLL MED,DEPT MED,HERSHEY,PA 17033; PENN STATE UNIV,COLL MED,DEPT CELLULAR & MOL PHYSIOL,HERSHEY,PA 17033; PENN STATE UNIV,COLL MED,DEPT MICROBIOL & IMMUNOL,HERSHEY,PA 17033; MAYO CLIN & MAYO GRAD SCH MED,DIV ONCOL RES,ROCHESTER,MN 55905	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Mayo Clinic			Mandal, Mahitosh/GMW-6195-2022	Mandal, Mahitosh/0000-0003-3861-3323; Kaufmann, Scott/0000-0002-4900-7145	NCI NIH HHS [CA 56564, R01 CA069008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069008, R01CA056564] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRECHT H, 1994, FEBS LETT, V351, P45, DOI 10.1016/0014-5793(94)00817-5; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Boulakia CA, 1996, ONCOGENE, V12, P529; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; HUG H, 1994, FEBS LETT, V351, P311, DOI 10.1016/0014-5793(94)00852-3; ITOH N, 1993, J BIOL CHEM, V268, P10932; JAATTELA M, 1995, ONCOGENE, V10, P2297; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1989, J BIOL CHEM, V264, P13946; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KUMAR R, 1995, EXP CELL RES, V216, P143, DOI 10.1006/excr.1995.1018; KUMAR R, 1992, P NATL ACAD SCI USA, V89, P6599, DOI 10.1073/pnas.89.14.6599; Kumar R, 1996, CLIN CANCER RES, V2, P1215; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Mandal M, 1996, CELL GROWTH DIFFER, V7, P311; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NEAMATI N, 1995, J IMMUNOL, V154, P3788; NICOLSON DW, 1995, NATURE, V376, P37; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TIWARI M, 1995, CELL, V81, P801; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	41	106	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30354	30359		10.1074/jbc.271.48.30354	http://dx.doi.org/10.1074/jbc.271.48.30354			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939996	hybrid			2022-12-27	WOS:A1996VV15800013
J	Deryckere, F; Burgert, HG				Deryckere, F; Burgert, HG			Tumor necrosis factor alpha induces the adenovirus early 3 promoter by activation of NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; CLASS-I ANTIGENS; NUCLEOTIDE-SEQUENCE; ENDOPLASMIC-RETICULUM; STIMULATES EXPRESSION; INFECTED-CELLS; E3/19K PROTEIN; EIII PROMOTER; DNA-SEQUENCE; BINDING	The early transcription unit 3 (E3) of human adenoviruses encodes proteins which appear to subvert host defense mechanisms. For example, the E3/19K protein inhibits the transport of major histocompatibility complex (MHC) class I molecules to the cell surface and thereby prevents cell lysis by cytotoxic T cells. Tumor necrosis factor alpha (TNF) stimulates expression of MHC molecules on the cell surface of normal cells but not of E3(+) cells, rather, a further reduction of MHC expression is evident. This was attributed to the increased expression of E3/19K upon TNF treatment, an effect also observed for other E3 proteins. We investigated the mechanism of the TNF-mediated up-regulation of E3 products. We show that TNF stimulates expression of a luciferase reporter gene driven by the E3 promoter. Mutation of individual transcription factor binding sites within the E3 promoter reveals the importance of the NF-kappa B binding site kappa 2 for TNF inducibility. Electrophoretic mobility shift assays using antibodies directed against various members of the NF-kappa B family demonstrate that stimulation by TNF is mediated by the p50-p65 NF-kappa B complex. TNF inducibility does not depend on coexpression of E1A and can be observed during infection. Interestingly, the E3 promoter seems to be the only early promoter responsive to TNF and the only adenovirus promoter containing an NF-kappa B site. The implications of this regulatory mechanism for the adenovirus life cycle and its pathogenesis are discussed.	MAX PLANCK INST IMMUNBIOL, HANS SPEMANN LAB, D-79108 FREIBURG, GERMANY	Max Planck Society			Burgert, Hans-Gerhard/AAE-6668-2020	Burgert, Hans-Gerhard/0000-0002-1650-9878				Akusjarvi G, 1993, Trends Microbiol, V1, P163, DOI 10.1016/0966-842X(93)90085-6; ANDERSSON M, 1987, J IMMUNOL, V138, P3960; ANDERSSON M, 1985, CELL, V43, P215, DOI 10.1016/0092-8674(85)90026-1; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; Basler CF, 1996, GENE, V170, P249, DOI 10.1016/0378-1119(95)00898-5; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BEUTLER BE, 1992, TUMOR NECROSIS FACTO; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BUCKBINDER L, 1989, EMBO J, V8, P4239, DOI 10.1002/j.1460-2075.1989.tb08609.x; BURGERT HG, 1985, CELL, V41, P987, DOI 10.1016/S0092-8674(85)80079-9; Burgert HG, 1996, TRENDS MICROBIOL, V4, P107, DOI 10.1016/0966-842X(96)81527-7; BURGERT HG, 1987, P NATL ACAD SCI USA, V84, P1356, DOI 10.1073/pnas.84.5.1356; CLADARAS C, 1985, VIROLOGY, V140, P28, DOI 10.1016/0042-6822(85)90443-X; COX JH, 1990, SCIENCE, V247, P715, DOI 10.1126/science.2137259; COX JH, 1991, J EXP MED, V174, P1629, DOI 10.1084/jem.174.6.1629; DAVISON AJ, 1993, J MOL BIOL, V234, P1308, DOI 10.1006/jmbi.1993.1687; DERY CV, 1987, ONCOGENE, V2, P15; DERYCKERE F, 1995, IMMUNOBIOLOGY, V193, P186, DOI 10.1016/S0171-2985(11)80542-5; Deryckere F, 1996, J VIROL, V70, P2832, DOI 10.1128/JVI.70.5.2832-2841.1996; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EFRAT S, 1995, P NATL ACAD SCI USA, V92, P6947, DOI 10.1073/pnas.92.15.6947; FEJER G, 1994, J VIROL, V68, P5871, DOI 10.1128/JVI.68.9.5871-5881.1994; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; FOX JP, 1977, AM J EPIDEMIOL, V105, P362, DOI 10.1093/oxfordjournals.aje.a112394; GARCIA J, 1987, NUCLEIC ACIDS RES, V15, P8367, DOI 10.1093/nar/15.20.8367; GINSBERG HS, 1989, P NATL ACAD SCI USA, V86, P3823, DOI 10.1073/pnas.86.10.3823; GINSBERG HS, 1991, P NATL ACAD SCI USA, V88, P1651, DOI 10.1073/pnas.88.5.1651; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HAGMEYER BM, 1995, BIOESSAYS, V17, P621, DOI 10.1002/bies.950170708; HERISSE J, 1980, NUCLEIC ACIDS RES, V8, P2173, DOI 10.1093/nar/8.10.2173; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Horwitz M.S., 1996, VIROLOGY, P2149; HURST HC, 1987, GENE DEV, V1, P1132, DOI 10.1101/gad.1.10.1132; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; KORNER H, 1992, P NATL ACAD SCI USA, V89, P11857, DOI 10.1073/pnas.89.24.11857; KORNUC M, 1990, J VIROL, V64, P2004, DOI 10.1128/JVI.64.5.2004-2013.1990; LEFF T, 1985, NUCLEIC ACIDS RES, V13, P1209, DOI 10.1093/nar/13.4.1209; LEFF T, 1984, P NATL ACAD SCI-BIOL, V81, P4381, DOI 10.1073/pnas.81.14.4381; MESTAN J, 1986, NATURE, V323, P816, DOI 10.1038/323816a0; MISTCHENKO AS, 1994, J PEDIATR-US, V124, P714, DOI 10.1016/S0022-3476(05)81360-5; Pahl HL, 1996, J CELL BIOL, V132, P511, DOI 10.1083/jcb.132.4.511; PIENIAZEK N, 1989, NUCLEIC ACIDS RES, V17, P5398, DOI 10.1093/nar/17.13.5398; RAWLE FC, 1991, J IMMUNOL, V146, P3977; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SESTER M, 1994, J VIROL, V68, P5423, DOI 10.1128/JVI.68.9.5423-5432.1994; SHENK T, 1984, CURR TOP MICROBIOL, V111, P1; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SPRENGEL J, 1994, J VIROL, V68, P379, DOI 10.1128/JVI.68.1.379-389.1994; Strauss SE, 1984, ADENOVIRUSES, P451; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WEEKS DL, 1985, NUCLEIC ACIDS RES, V13, P5389, DOI 10.1093/nar/13.14.5389; WILLIAMS JL, 1990, EMBO J, V9, P4435, DOI 10.1002/j.1460-2075.1990.tb07894.x; WOLD WSM, 1993, J CELL BIOCHEM, V53, P329, DOI 10.1002/jcb.240530410; WOLD WSM, 1991, VIROLOGY, V184, P1, DOI 10.1016/0042-6822(91)90815-S; WONG GHW, 1986, NATURE, V323, P819, DOI 10.1038/323819a0	58	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30249	30255		10.1074/jbc.271.47.30249	http://dx.doi.org/10.1074/jbc.271.47.30249			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939978	hybrid			2022-12-27	WOS:A1996VU52500106
J	DiazGuerra, MJM; Velasco, M; MartinSanz, P; Bosca, L				DiazGuerra, MJM; Velasco, M; MartinSanz, P; Bosca, L			Evidence for common mechanisms in the transcriptional control of type II nitric oxide synthase in isolated hepatocytes - Requirement of NF-kappa B activation after stimulation with bacterial cell wall products and phorbol esters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MURINE PERITONEAL-MACROPHAGES; NECROSIS-FACTOR-ALPHA; INTERFERON-GAMMA; MAMMALIAN-CELLS; AP-1 ACTIVITY; INDUCTION; LIPOPOLYSACCHARIDE; GENE; EXPRESSION	Incubation of primary cultures of rat hepatocytes with lipopolysaccharide (LPS), S-[2,3-bis(palmitoyloxy)(2-R,S)-propyl] -N-palmitoyl-(R)-Cys-Ser-Lys(4) (TPP), a synthetic lipopeptide present in bacterial cell wall lipoproteins, or with phorbol 12,13-dibutyrate (PDBu) induced an increase in nitric oxide synthesis through the expression of type II nitric oxide synthase (iNOS), Transfection of hepatocytes with a HindII fragment corresponding to the promoter region of the murine iNOS gene (from nucleotide -1588 to +165) resulted in the expression of the reporter gene when cells were stimulated with these factors, The transcription factors activated by these stimuli involved an increase in the nuclear content of proteins that bind to kappa B, AP-1, GAS, and SIE sequences, Inhibition of NF-kappa B activation with pyrrolidine dithiocarbamate eliminated the expression of iNOS in hepatocytes stimulated with LPS, TPP, or PDBu. In addition to this, transfection of hepatocytes with promoter mutants in which a sequential 2-base pair change within the kappa B sites was introduced (position -971 to -961 and -85 to -75, respectively), resulted in approximately 17 and 35%, respectively, of the activity of the naive promoter, Simultaneous mutation of both kappa B sites abolished the promoter activity. Analysis of the proteins involved in kappa B binding showed the presence of p50/p65 dimers in the nuclei of activated cells at the time that an important decrease of I kappa B-alpha was observed soon after cell stimulation with LPS, TPP, or PDBu. However, only LPS was able to decrease the amount of I kappa B-beta. These results suggest that LPS, TPP, and PDBu, although activating different signal transduction pathways, use a common mechanism mediating iNOS expression in cultured hepatocytes.	UNIV COMPLUTENSE,FAC FARM,INST BIOQUIM,CSIC,UCM,E-28040 MADRID,SPAIN	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Bosca, Lisardo/A-2059-2008; Díaz-Guerra, María José M/M-2855-2014; Martín-Sanz, Paloma/K-1303-2014	Bosca, Lisardo/0000-0002-0253-5469; Díaz-Guerra, María José M/0000-0003-3843-3912; 				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BESSLER WG, 1992, RES IMMUNOL, V143, P548, DOI 10.1016/0923-2494(92)80067-U; BOMZON A, 1994, HEPATOLOGY, V20, P1343, DOI 10.1002/hep.1840200535; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU SC, 1995, J BIOL CHEM, V270, P10625, DOI 10.1074/jbc.270.18.10625; DELUDE RL, 1994, J BIOL CHEM, V269, P22253; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; FAUSTO N, 1990, HEPATOLOGY TXB LIVER, P49; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; HABRECHT BG, 1994, AM J PHYSIOL, V266, pG1004; HORTELANO S, 1993, FEBS LETT, V320, P135, DOI 10.1016/0014-5793(93)80078-9; HORTELANO S, 1992, J BIOL CHEM, V267, P24937; HORTELANO S, 1995, HEPATOLOGY, V21, P776; JUN CD, 1995, J IMMUNOL, V154, P6541; JUN CD, 1994, J IMMUNOL, V153, P3684; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NUSSLER AK, 1995, HEPATOLOGY, V21, P1552, DOI 10.1016/0270-9139(95)90459-X; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; PIMENTELMUINOS FX, 1994, J BIOL CHEM, V269, P24424; PIMENTELMUINOS FX, 1994, J IMMUNOL, V152, P5714; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SIMMONS ML, 1994, GLIA, V11, P227, DOI 10.1002/glia.440110303; SPINK J, 1995, J BIOL CHEM, V270, P29541, DOI 10.1074/jbc.270.49.29541; TERENZI F, 1995, J BIOL CHEM, V270, P6017, DOI 10.1074/jbc.270.11.6017; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; WEISZ A, 1994, J BIOL CHEM, V269, P8324; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	51	92	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30114	30120		10.1074/jbc.271.47.30114	http://dx.doi.org/10.1074/jbc.271.47.30114			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939960	hybrid			2022-12-27	WOS:A1996VU52500088
J	EhretSabatier, L; Loew, D; Goyffon, M; Fehlbaum, P; Hoffmann, JA; vanDorsselaer, A; Bulet, P				EhretSabatier, L; Loew, D; Goyffon, M; Fehlbaum, P; Hoffmann, JA; vanDorsselaer, A; Bulet, P			Characterization of novel cysteine-rich antimicrobial peptides from scorpion blood	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROCTONUS-MAURETANICUS-MAURETANICUS; INDUCIBLE ANTIBACTERIAL PEPTIDE; CRAB TACHYPLEUS-TRIDENTATUS; K+ CHANNELS; INSECT DEFENSINS; ALPHA-CONOTOXIN; HEBRAEUS VENOM; PURIFICATION; CHARYBDOTOXIN; INHIBITOR	We have isolated, from the hemolymph of unchallenged scorpions of the species Androctonus australis, three distinct antimicrobial peptides, which we have fully characterized by Edman degradation, electrospray ionization mass spectrometry, and matrix-assisted laser desorption/ionization mass spectrometry. Two are novel molecules: (i) androctonin, a 25-residue peptide with two disulfide bridges, active against both bacteria (Gram-positive and Gram-negative) and fungi and showing marked sequence homology to tachyplesins and polyphemusins from horseshoe crabs; and (ii) buthinin, a 34-residue antibacterial (Gram-positive and Gram-negative) peptide with three disulfide bridges. The third peptide contains 37 residues and three disulfide bridges and clearly belongs to the family of anti-Gram-positive insect defensins, We have synthesized androctonin and explored its activity spectrum and mode of action.	INST BIOL MOL & CELLULAIRE,UPR 9022 CNRS,F-67084 STRASBOURG,FRANCE; UNIV STRASBOURG 1,FAC CHIM,LAB SPECTROMETRIE MASSE BIOORGAN,URA 31 CNRS,F-67008 STRASBOURG,FRANCE; MUSEUM NATL HIST NAT,F-75005 PARIS,FRANCE; DIV BIOL GEN & ECOL,LAB ETUD & RECH ARTHROPODES IRRADIES,F-75005 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Museum National d'Histoire Naturelle (MNHN)			BULET, Philippe/C-8557-2014	BULET, Philippe/0000-0001-9016-265X; Damarys, Loew/0000-0002-9111-8842				AUGUSTE P, 1990, J BIOL CHEM, V265, P4753; BONTEMS F, 1991, SCIENCE, V254, P1521, DOI 10.1126/science.1720574; BULET P, 1991, J BIOL CHEM, V266, P24520; BULET P, 1992, EUR J BIOCHEM, V209, P977, DOI 10.1111/j.1432-1033.1992.tb17371.x; BULET P, 1993, J BIOL CHEM, V268, P14893; CHICCHI GG, 1988, J BIOL CHEM, V263, P10192; COCIANCICH S, 1993, BIOCHEM BIOPH RES CO, V194, P17, DOI 10.1006/bbrc.1993.1778; CORNET B, 1995, STRUCTURE, V3, P435, DOI 10.1016/S0969-2126(01)00177-0; COURAUD F, 1982, TOXICON, V20, P9, DOI 10.1016/0041-0101(82)90138-6; CREST M, 1992, J BIOL CHEM, V267, P1640; Fehlbaum P, 1996, P NATL ACAD SCI USA, V93, P1221, DOI 10.1073/pnas.93.3.1221; FEHLBAUM P, 1994, J BIOL CHEM, V269, P33159; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; GARCIA ML, 1994, BIOCHEMISTRY-US, V33, P6834, DOI 10.1021/bi00188a012; GIMENEZGALLEGO G, 1988, P NATL ACAD SCI USA, V85, P3329, DOI 10.1073/pnas.85.10.3329; HOFFMANN JA, 1992, IMMUNOL TODAY, V13, P411, DOI 10.1016/0167-5699(92)90092-L; HOFFMANN JA, 1995, CURR OPIN IMMUNOL, V7, P4, DOI 10.1016/0952-7915(95)80022-0; IWANAGA S, 1994, ANTIMICROBIAL PEPTID, P160; KATSU T, 1993, BIOL PHARM BULL, V16, P178; KAWANO K, 1990, J BIOL CHEM, V265, P15365; KING DS, 1990, INT J PEPT PROT RES, V36, P255; LARABADJEBARI F, 1994, J BIOL CHEM, V269, P32835; MCINTOSH JM, 1994, J BIOL CHEM, V269, P16733; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; MIYATA T, 1989, J BIOCHEM, V106, P663, DOI 10.1093/oxfordjournals.jbchem.a122913; NAKAMURA T, 1988, J BIOL CHEM, V263, P16709; NEIMARK J, 1993, PEPTIDE RES, V6, P219; PARK CS, 1992, NEURON, V9, P307, DOI 10.1016/0896-6273(92)90169-E; RAMILO CA, 1992, BIOCHEMISTRY-US, V31, P9919, DOI 10.1021/bi00156a009; ZERROUK H, 1993, FEBS LETT, V320, P189, DOI 10.1016/0014-5793(93)80583-G	31	167	181	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29537	29544		10.1074/jbc.271.47.29537	http://dx.doi.org/10.1074/jbc.271.47.29537			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939880	hybrid			2022-12-27	WOS:A1996VU52500008
J	Herzig, MCS; Nash, NR; Connolly, M; Kyle, DJ; LeebLundberg, LMF				Herzig, MCS; Nash, NR; Connolly, M; Kyle, DJ; LeebLundberg, LMF			The N terminus of bradykinin when bound to the human bradykinin B2 receptor is adjacent to extracellular Cys(20) and Cys(277) in the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; LIGAND-BINDING; PHARMACOLOGICAL CHARACTERIZATION; FUNCTIONAL EXPRESSION; ENDOTHELIN RECEPTOR; AGONIST BINDING; CLONING; PROTEIN; RESIDUES; BACTERIORHODOPSIN	Chemical cross-linking combined with site-directed mutagenesis was used to evaluate the role of extracellular cysteines and their positions relative to the binding site for the agonist bradykinin (BK) in the human BK B2 receptor. All extracellular cysteines, Cys(20), Cys(103) Cys(184), and Cys(277), in the receptor were mutated to serines, and single and double mutants were transfected into COS-7 cells. The Ser(20) and Ser(277) single mutants and the Ser(20)/Ser(277) double mutant bound [H-3]BK and the antagonist [H-3]NPC17731 with pharmacological profiles identical to the wild-type B2 receptor, in contrast, the Ser(103) and Ser(184) single mutants were unable to bind either of the two radioligands. However, these mutants were still expressed as determined by immunoblotting with anti-B2 receptor antibodies. Previous studies on the bovine B2 receptor showed that bifunctional reagents, which are reactive to amines at one end and to free sulfhydryls in the opposite end, cross-link the N terminus of receptor-bound BK to a sulfhydryl in the receptor (Herzig, M. C. S., and Leeb-Lundberg, L. M. F. (1995) J. Biol, Chem. 270, 20591-20598), Here, we show that m-maleimidobenzoyl-N-hydroxysuccinimide ester and 1,5-difluoro-2,4-dinitrobenzene cross-linked BK to the wild-type human B2 receptor and the Ser(20) and Ser(277) Single mutant receptors, whereas these reagents were unable to cross-link BK to the Ser(20)/Ser(277) double mutant, These results show that Cys(103) and Cys(184) are both required for expression of high affinity agonist and antagonist binding sites in the human B2 receptor, while Cys(20) and Cys(277) are not required. Furthermore, the results provide direct biochemical evidence that the N terminus of BK, when bound to the B2 receptor, is adjacent to Cys(277) in extracellular domain 4 and Cys(20) in extracellular domain 1 of the receptor.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284; EMORY UNIV,DEPT NEUROL,ATLANTA,GA 30322; GUILFORD PHARMACEUT,BALTIMORE,MD 21224; SCIOS INC,DEPT STRUCT BIOL & MED CHEM,SUNNYVALE,CA 94086	University of Texas System; University of Texas Health San Antonio; Emory University; Scios					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041659, R01GM041659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abd Alla S., 1996, J BIOL CHEM, V271, P1748; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; Bachvarov DR, 1995, J PHARMACOL EXP THER, V275, P1623; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; COUGHLIN SR, 1994, CURR OPIN CELL BIOL, V6, P191, DOI 10.1016/0955-0674(94)90135-X; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DOHLMAN HG, 1990, BIOCHEMISTRY-US, V29, P2335, DOI 10.1021/bi00461a018; EGGERICKX D, 1992, BIOCHEM BIOPH RES CO, V187, P1306, DOI 10.1016/0006-291X(92)90445-Q; ENGELMAN DM, 1980, P NATL ACAD SCI-BIOL, V77, P2023, DOI 10.1073/pnas.77.4.2023; FRASER CM, 1989, J BIOL CHEM, V264, P9266; FREDRICK MJ, 1984, BIOCHEM PHARMACOL, V33, P2887, DOI 10.1016/0006-2952(84)90212-0; FREEDMAN R, 1992, RECENT PROGR KININS, P487; HERZIG MCS, 1995, J BIOL CHEM, V270, P20591, DOI 10.1074/jbc.270.35.20591; HESS JF, 1994, MOL PHARMACOL, V45, P1; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KHORANA HG, 1988, J BIOL CHEM, V263, P7439; Kyle D. J., 1995, CURR PHARM DESIGN, V1, P233; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P25970; LEEBLUNDBERG LMF, 1990, J BIOL CHEM, V265, P9621; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACNEIL T, 1995, BBA-GENE STRUCT EXPR, V1264, P223, DOI 10.1016/0167-4781(95)00152-7; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MENKE JG, 1994, J BIOL CHEM, V269, P21583; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NARDONE J, 1994, P NATL ACAD SCI USA, V91, P4417, DOI 10.1073/pnas.91.10.4417; NOVOTNY EA, 1994, BIOCHEM BIOPH RES CO, V201, P523, DOI 10.1006/bbrc.1994.1733; REGOLI D, 1980, PHARMACOL REV, V32, P1; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SANDBERG K, 1994, TRENDS ENDOCRIN MET, V5, P28, DOI 10.1016/1043-2760(94)90118-X; SCHERTLER GF, 1993, NATURE, V362, P7700; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; YAMANO Y, 1992, BIOCHEM BIOPH RES CO, V187, P1426, DOI 10.1016/0006-291X(92)90461-S	37	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29746	29751		10.1074/jbc.271.47.29746	http://dx.doi.org/10.1074/jbc.271.47.29746			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939910	hybrid			2022-12-27	WOS:A1996VU52500038
J	Peterson, SN; Trabalzini, L; Brtva, TR; Fischer, T; Altschuler, DL; Martelli, P; Lapetina, EG; Der, CJ; White, GC				Peterson, SN; Trabalzini, L; Brtva, TR; Fischer, T; Altschuler, DL; Martelli, P; Lapetina, EG; Der, CJ; White, GC			Identification of a novel RalGDS-related protein as a candidate effector for Ras and Rap1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPPRESSOR ACTIVITY; POINT MUTATIONS; RAS-P21 GTPASE; R-RAS; TRANSFORMATION; ACTIVATION; GENE; BINDING; DOMAIN; INHIBITION	Although Ras and Rap1 share interaction with common candidate effector proteins, Rap1 lacks the transforming activity exhibited by Ras proteins, It has been speculated that Rap antagonizes Ras transformation through the formation of nonproductive complexes with critical Ras effector targets. To understand further the distinct biological functions of these two closely related proteins, we searched for Rap1b-binding proteins by yeast two-hybrid screening, We identified multiple clones that encode the COOH-terminal sequences of a protein that shares sequence identity with Ra1GDS and RGL, which we have designated RGL2. A 158-amino acid COOH-terminal fragment of RGL2 (RGL2 C-158) bound to Ras superfamily proteins which shared identical effector domain sequences with Rap1 (Ha-Ras, R-Ras, and TC21), RGL2 C-158 binding was impaired by effector domain mutations in Rap1b and Ha-Ras. Furthermore, RGL2 C-158 bound exclusively to the GTP-, but not the GDP-bound form of Ha-Ras. Finally, coexpression of RGL2 C-158 impaired oncogenic Ras activation of transcription from a Ras-responsive promoter element and focus-forming activity in NIH 3T3 cells, We conclude that RGL2 may be an effector for Ras and/or Rap proteins.	GLAXO WELLCOME INC,DIV CELL BIOL,RES TRIANGLE PK,NC 27709; UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CURRICULUM GEN & MOL BIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV SIENA,DEPT MOL BIOL,I-53100 SIENA,ITALY	GlaxoSmithKline; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Siena				Der, Channing/0000-0002-7751-2747; Trabalzini, Lorenza/0000-0002-0850-7186	NATIONAL CANCER INSTITUTE [R01CA042978, R01CA055008] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL026309] Funding Source: NIH RePORTER; NCI NIH HHS [CA42978, CA55008] Funding Source: Medline; NHLBI NIH HHS [HL26309] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOTWELL D, 1992, P NATL ACAD SCI USA, V89, P6511; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CAMPA MJ, 1991, BIOCHEM BIOPH RES CO, V174, P1, DOI 10.1016/0006-291X(91)90475-M; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COX AD, 1994, METHOD ENZYMOL, V238, P277; COX AD, 1994, ONCOGENE, V9, P3281; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GALANG CK, 1994, ONCOGENE, V9, P2913; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; HATA Y, 1990, J BIOL CHEM, V265, P7104; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JELINEK MA, 1992, ONCOGENE, V7, P1687; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KHOSRAVIFAR R, 1996, IN PRESS MOL CELL BI; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LopezBarahona M, 1996, ONCOGENE, V12, P463; MCCABE PC, 1992, MOL CELL BIOL, V12, P4084, DOI 10.1128/MCB.12.9.4084; PIZON V, 1988, ONCOGENE, V3, P201; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P1719; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SAEZ R, 1994, ONCOGENE, V9, P2977; SAKODA T, 1992, ONCOGENE, V7, P1705; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; YATANI A, 1991, J BIOL CHEM, V266, P22222; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	50	56	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29903	29908		10.1074/jbc.271.47.29903	http://dx.doi.org/10.1074/jbc.271.47.29903			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939933	Green Published, hybrid			2022-12-27	WOS:A1996VU52500061
J	Arnold, CS; Johnson, GVW; Cole, RN; Dong, DLY; Lee, M; Hart, GW				Arnold, CS; Johnson, GVW; Cole, RN; Dong, DLY; Lee, M; Hart, GW			The microtubule-associated protein tau is extensively modified with O-linked N-acetylglucosamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; CYTOPLASMIC PROTEINS; ALZHEIMERS-DISEASE; 67-KDA POLYPEPTIDE; PHOSPHORYLATION; GLYCOSYLATION; NUCLEAR; GLCNAC; PEPTIDE; KINASE	Tau is a family of phosphoproteins that are important in modulating microtubule stability in neurons. In Alzheimer's disease tau is abnormally hyperphosphorylated, no longer binds microtubules, and self-assembles to form paired helical filaments that likely contribute to neuron death. Here we demonstrate that normal bovine tau is multiply modified by Ser(Thr)-O-linked N-acetylglucosamine, a dynamic and abundant post-translational modification that is often reciprocal to Ser(Thr)phosphorylation. O-GlcNAcylation of tau was demonstrated by blotting with succinylated wheat germ agglutinin and by probing with bovine milk beta(1,4)galactosyltransferase. Structural analyses confirm the linkage and the saccharide structure. Tau splicing variants are multiply O-GlcNAcylated at similar sites, with an average stoichiometry of greater than 4 mol of O-linked N-acetylglucosamine/mol of tau. However, the number of sites occupied appears to be greater than 12, suggesting substoichiometric occupancy at any given site. A similar relationship between average stoichiometry and site-occupancy has also been described for the phosphorylation of tau. Site-specific or stoichiometric changes in O-GlcNAcylation may not only modulate tau function but may also play a role in the formation of paired helical filaments.	UNIV ALABAMA, SCH MED, DEPT BIOCHEM & MOL GENET, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH MED, DEPT PSYCHIAT & BEHAV NEUROBIOL, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH DENT, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham			Lee, Michael K/D-9491-2013; Johnson, Gail V.W./K-4723-2012	Lee, Michael K/0000-0001-5865-9682; Johnson, Gail V.W./0000-0003-3464-0404; Hart, Gerald/0000-0001-7812-4351	NATIONAL CANCER INSTITUTE [R01CA042486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008111] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027538] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 42486] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM08111-10] Funding Source: Medline; NINDS NIH HHS [R01 NS 27538] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANCHER C, 1991, BRAIN RES, V539, P11, DOI 10.1016/0006-8993(91)90681-K; BRANDT R, 1995, J CELL BIOL, V131, P1327, DOI 10.1083/jcb.131.5.1327; CHOU CF, 1992, J BIOL CHEM, V267, P3901; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; DATTA B, 1989, J BIOL CHEM, V264, P20620; DATTA B, 1988, P NATL ACAD SCI USA, V85, P3324, DOI 10.1073/pnas.85.10.3324; Ding M, 1996, J BIOL CHEM, V271, P12555, DOI 10.1074/jbc.271.21.12555; DONG DLY, 1993, J BIOL CHEM, V268, P16679; DONG DLY, 1994, J BIOL CHEM, V269, P19321; DRESCHEL DN, 1992, MOL BIOL CELL, V3, P1141; DREWES G, 1995, J BIOL CHEM, V270, P7679, DOI 10.1074/jbc.270.13.7679; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; Fleming LM, 1996, EXP NEUROL, V138, P252, DOI 10.1006/exnr.1996.0064; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; Greis KD, 1996, ANAL BIOCHEM, V234, P38, DOI 10.1006/abio.1996.0047; GRIFFITH LS, 1995, J NEUROSCI RES, V41, P270, DOI 10.1002/jnr.490410214; GRIFFITH LS, 1995, BIOCHEM BIOPH RES CO, V213, P424, DOI 10.1006/bbrc.1995.2149; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HART GW, 1995, PURE APPL CHEM, V67, P1637, DOI 10.1351/pac199567101637; HART GW, 1994, ALFRED BENZON SYMP S, V36, P280; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HART GW, 1993, DNA REPLICATION CELL, P91; HART GW, 1987, IN PRESS ANN REV BIO, V66; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; HAYES BK, 1995, ANAL BIOCHEM, V228, P115, DOI 10.1006/abio.1995.1322; HAYES BK, 1993, J BIOL CHEM, V268, P16170; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; HIMMLER A, 1989, MOL CELL BIOL, V9, P1381, DOI 10.1128/MCB.9.4.1381; HOLT GE, 1997, J CELL BIOL, V104, P1157; HUANG CC, 1970, CARBOHYD RES, V13, P127, DOI 10.1016/S0008-6215(00)84902-2; IHARA Y, 1986, J BIOCH, V99, P1087; JOHNSON GVW, 1989, BIOCHEM BIOPH RES CO, V163, P1505, DOI 10.1016/0006-291X(89)91150-9; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KELLY WG, 1993, J BIOL CHEM, V268, P10416; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDESMA MD, 1994, J BIOL CHEM, V269, P26164; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LITERSKY JM, 1992, J BIOL CHEM, V267, P1563; LOOMIS PA, 1990, P NATL ACAD SCI USA, V87, P8422, DOI 10.1073/pnas.87.21.8422; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTHI T, 1991, J NEUROCHEM, V56, P1493; MEEK JL, 1980, P NATL ACAD SCI-BIOL, V77, P1632, DOI 10.1073/pnas.77.3.1632; MONSIGNY M, 1980, EUR J BIOCHEM, V104, P147, DOI 10.1111/j.1432-1033.1980.tb04410.x; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; MORISHIMAKAWASHIMA M, 1993, NEURON, V10, P1151, DOI 10.1016/0896-6273(93)90063-W; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; ROQUEMORE EP, 1992, J BIOL CHEM, V267, P555; Roquemore EP, 1996, BIOCHEMISTRY-US, V35, P3578, DOI 10.1021/bi951918j; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SCHAFFNER W, 1973, ANAL BIOCHEM, V197, P65; Shaw P, 1996, ONCOGENE, V12, P921; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TORRES CR, 1984, J BIOL CHEM, V259, P3308; Wang JZ, 1996, NAT MED, V2, P871, DOI 10.1038/nm0896-871; Wang XH, 1996, BIOCHEM BIOPH RES CO, V219, P591, DOI 10.1006/bbrc.1996.0278; WATANABE N, 1992, J NEUROCHEM, V58, P960, DOI 10.1111/j.1471-4159.1992.tb09349.x	61	276	295	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28741	28744		10.1074/jbc.271.46.28741	http://dx.doi.org/10.1074/jbc.271.46.28741			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910513	hybrid			2022-12-27	WOS:A1996VT05200005
J	Biscardi, JS; Denhez, F; Buehler, GF; Chesnutt, DA; Baragona, SC; OBryan, JP; Der, CJ; Fiordalisi, JJ; Fults, DW; Maness, PF				Biscardi, JS; Denhez, F; Buehler, GF; Chesnutt, DA; Baragona, SC; OBryan, JP; Der, CJ; Fiordalisi, JJ; Fults, DW; Maness, PF			rek, A gene expressed in retina and brain, encodes a receptor tyrosine kinase of the Axl/Tyro3 family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK NEURAL RETINA; GROWTH-FACTOR; NERVOUS-SYSTEM; PROTEIN-S; CHROMOSOMAL LOCALIZATION; MOLECULAR-CLONING; CELL TYPE; PROTOONCOGENE; ONCOGENE; LIGANDS	Rek (retina-expressed kinase) has been identified as a putative novel receptor-type tyrosine kinase of the Axl/Tyro3 family with a potential role in neural cell development, rek clones were isolated from a chick embryonic brain cDNA library with a DNA probe obtained by reverse transcriptase-polymerase chain reaction of mRNA from Muller glia-like cells cultured from chick embryonic retina. Sequence analysis indicated that Rek is a protein of 873 amino acids with an extracellular region composed of two immunoglobulin-like domains followed by two fibronectin type III domains with eight predicted N-glycosylation sites. Two consensus src homology 2 domain binding sites are present in the cytoplasmic domain, suggesting that Rek activates several signal transduction pathways. Northern analysis of rek mRNA revealed a 5.5-kilobase transcript in chick brain, retina, and kidney and in primary cultures of retinal Muller glia-like cells. Rek protein was identified by immunoprecipitation and immunoblotting as a 140-kDa protein expressed in the chick retina at embryonic days 6-13, which corresponded to the major period of neuronal and glial differentiation. Transfection of rek cDNA into COS cells resulted in transient expression of a putative precursor of 106 kDa that autophosphorylated in immune complex protein kinase assays. Overexpression of rek cDNA in mouse NIH3T3 fibroblasts resulted in activation of the 140-kDa rek kinase and induction of morphologically transformed foci. These properties indicated that Rek has oncogenic potential when overexpressed, but its normal function is likely to be related to cell-cell recognition events governing the differentiation or proliferation of neural cells.	UNIV N CAROLINA, SCH MED, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA; UNIV UTAH, SCH MED, DEPT NEUROL SURG, SALT LAKE CITY, UT 84132 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Utah System of Higher Education; University of Utah				O'Bryan, John/0000-0001-5386-1080; Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA042978] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY008975] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026620] Funding Source: NIH RePORTER; NCI NIH HHS [CA42978] Funding Source: Medline; NEI NIH HHS [EY08975] Funding Source: Medline; NINDS NIH HHS [NS26620] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADLER R, 1989, SCIENCE, V243, P391, DOI 10.1126/science.2911751; ADLER R, 1990, METHODS NEUROSCIENCE, V2, P134; ANCHAN RM, 1991, NEURON, V6, P923, DOI 10.1016/0896-6273(91)90233-P; APPEL F, 1993, J NEUROSCI, V13, P4764; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; BISCARDI JS, 1993, EXP EYE RES, V56, P281, DOI 10.1006/exer.1993.1037; BISCARDI JS, 1991, CURR EYE RES, V10, P1121, DOI 10.3109/02713689109024129; BORK P, 1992, P NATL ACAD SCI USA, V89, P8990, DOI 10.1073/pnas.89.19.8990; BRUMMENDORF T, 1993, NEURON, V10, P711; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; DAI W, 1994, ONCOGENE, V9, P975; DEPOMERAI DI, 1982, EXP EYE RES, V34, P553; DEPOMERAI DL, 1982, DEV BRAIN RES, V2, P303; DERYNCK R, 1980, NATURE, V287, P193, DOI 10.1038/287193a0; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOUPE AJ, 1985, J NEUROSCI, V5, P2119; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; FAUST M, 1992, ONCOGENE, V7, P1287; Fridell YWC, 1996, MOL CELL BIOL, V16, P135; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUJIMOTO J, 1994, ONCOGENE, V9, P693; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; GODOWSKI PJ, 1995, CELL, V82, P355, DOI 10.1016/0092-8674(95)90424-7; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; INGRAHAM CA, 1992, ONCOGENE, V7, P95; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JIA R, 1994, J BIOL CHEM, V269, P1839; KAHN AJ, 1974, DEV BIOL, V38, P30, DOI 10.1016/0012-1606(74)90256-5; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LAI C, 1994, ONCOGENE, V9, P2567; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEMMON V, 1986, J NEUROSCI, V6, P43; Lemmon V, 1983, Brain Res, V313, P191; LEWIS GP, 1992, J NEUROSCI, V12, P3968; LI HP, 1984, TISSUE CELL, V16, P843, DOI 10.1016/0040-8166(84)90066-1; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LINSER P, 1983, DEV BIOL, V96, P529, DOI 10.1016/0012-1606(83)90190-2; Maness P.F., 1992, Seminars in Cell Biology, V3, P117; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARK MR, 1994, J BIOL CHEM, V269, P10720; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARU Y, 1990, ONCOGENE, V5, P445; NEWMAN EA, 1986, ASTROCYTES DEV MORPH, V1, P149; OBRYAN JP, 1995, J BIOL CHEM, V270, P551, DOI 10.1074/jbc.270.2.551; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1994, ONCOGENE, V9, P699; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; RESCIGNO J, 1991, ONCOGENE, V6, P1909; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAP J, 1994, MOL CELL BIOL, V14, P1; SCHWECHHEIMER K, 1994, HUM PATHOL, V25, P772, DOI 10.1016/0046-8177(94)90246-1; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHORES CG, 1989, J NEUROSCI RES, V24, P59, DOI 10.1002/jnr.490240109; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; STEMPLE DL, 1988, NEURON, V1, P517, DOI 10.1016/0896-6273(88)90182-1; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; SWOFFORD DL, 1993, J GEN PHYSIOL, V102, pA9; Taylor ICA, 1995, ONCOGENE, V11, P2619; TAYLOR ICA, 1995, J BIOL CHEM, V270, P6872, DOI 10.1074/jbc.270.12.6872; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732; WIEDEMANN P, 1992, SURV OPHTHALMOL, V36, P373, DOI 10.1016/0039-6257(92)90115-A; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	85	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29049	29059		10.1074/jbc.271.46.29049	http://dx.doi.org/10.1074/jbc.271.46.29049			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910558	hybrid			2022-12-27	WOS:A1996VT05200050
J	Quilliam, LA; Lambert, QT; MickelsonYoung, LA; Westwick, JK; Sparks, AB; Kay, BK; Jenkins, NA; Gilbert, DJ; Copeland, NG; Der, CJ				Quilliam, LA; Lambert, QT; MickelsonYoung, LA; Westwick, JK; Sparks, AB; Kay, BK; Jenkins, NA; Gilbert, DJ; Copeland, NG; Der, CJ			Isolation of a NCK-associated kinase, PRK2, an SH3-binding protein and potential effector of Rho protein signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH SYNDROME; EPIDERMAL GROWTH-FACTOR; C-CBL PROTOONCOGENE; TRANSCRIPTIONAL ACTIVATION; SH3 DOMAINS; MOUSE; GENE; PHOSPHORYLATION; RECEPTORS; CELLS	The NCK adapter protein is comprised of three consecutive Src homology 3 (SH3) protein-protein interaction domains and a C-terminal SH2 domain. Although the association of NCK with activated receptor protein-tyrosine kinases, via its SH2 domain, implicates NCK as a mediator of growth factor-induced signal transduction, little is known about the pathway(s) downstream of NCK. recruitment. To identify potential downstream effecters of NCR we screened a bacterial expression library to isolate proteins that bind its SH3 domains. Two molecules were isolated, the Wiskott-Aldrich syndrome protein (WASP, a putative CDC42 effector) and a serine/threonine protein kinase (PRK2, closely related to the putative Rho effector PKN). Using interspecific backcross analysis the Prk2 gene was mapped to mouse chromosome 3. Unlike WASP, which bound the SH3 domains of several signaling proteins, PRK2 specifically bound to the middle SH3 domain of NCK and (weakly) that of phospholipase C gamma. PRK2 also specifically bound to Rho in a GTP-dependent manner and cooperated with Rho family proteins to induce transcriptional activation via the serum response factor. These data suggest that PRK2 may coordinately mediate signal transduction from activated receptor protein-tyrosine kinases and Rho and that NCK may function as an adapter to connect receptor-mediated events to Rho protein signaling.	INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,INDIANAPOLIS,IN 46202; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599; NCI,MAMMALIAN GENET LAB,ABL,BASIC RES PROGRAM,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Quilliam, LA (corresponding author), INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,635 BARNHILL DR,MS 410,INDIANAPOLIS,IN 46202, USA.		Quilliam, Lawrence/B-6447-2015; Quilliam, Lawrence/Q-4987-2019	Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA042978, R01CA052072, R29CA063139] Funding Source: NIH RePORTER; NCI NIH HHS [CA52072, CA63139, CA42978] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; GALANG CK, 1994, ONCOGENE, V9, P2913; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Green EL, 1981, GENETICS PROBABILITY, P77; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HAMEL CP, 1994, GENOMICS, V20, P509, DOI 10.1006/geno.1994.1212; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HU QJ, 1995, MOL CELL BIOL, V15, P1169; HUFF SY, 1997, IN PRESS ONCOGENE; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; LANE PW, 1992, J HERED, V83, P315, DOI 10.1093/oxfordjournals.jhered.a111221; LANE PW, 1972, J HERED, V63, P135, DOI 10.1093/oxfordjournals.jhered.a108252; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P8978; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RemoldODonnell E, 1996, BLOOD, V87, P2621, DOI 10.1182/blood.V87.7.2621.bloodjournal8772621; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WESTWICK JK, 1995, METHOD ENZYMOL, V255, P342; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	43	136	141	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28772	28776		10.1074/jbc.271.46.28772	http://dx.doi.org/10.1074/jbc.271.46.28772			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910519	hybrid, Green Published			2022-12-27	WOS:A1996VT05200011
J	Campos, M; Fadden, P; Alms, G; Qian, ZD; Haystead, TAJ				Campos, M; Fadden, P; Alms, G; Qian, ZD; Haystead, TAJ			Identification of protein phosphatase-1-binding proteins by microcystin-biotin affinity chromatography	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; LIGHT-CHAIN PHOSPHATASE; KINASE-II-BETA; SMOOTH-MUSCLE; REGULATORY SUBUNIT; CELLULAR-REGULATION; MOLECULAR-CLONING; CATALYTIC SUBUNIT; BINDING SUBUNIT; GLYCOGEN	Biotinylated microcystin was used to affinity purify over avidin-Sepharose the entire cellular content of active forms of protein phosphatase (PP) 1 and 2A holoenzymes present in three subcellular fractions of skeletal muscle. Biotinylated microcystin displayed IC,, values in the nM range against PP-1C (1.58 +/- 0.61 nM S.E., n = 3), PP-2AC (0.63 +/- 0.2 nM S.E., n = 3) and SMPP-1M (5.9 +/- 1.3 S.E., n = 3). Subsequent anion-exchange chromatography and SDS-polyacrylamide gel electrophoresis of the microcystin-biotin eluates of the three fractions revealed a complex pattern of proteins associated with PP-1C and PP-2AC, Far Western analysis and the rebinding interaction with recombinant PP-1C distinguished proteins in the eluates that bound PP-1C from those that bound PP-2AC. In Far Western analysis, 29 distinct proteins were identified to bind PP-1C, Significantly, these same proteins, plus seven others, were also recovered fi om the isothiocyanate eluates from microcystin-Sepharose by a rebinding interaction with PP-1C-microcystin-biotin. The number of proteins and range of novel molecular masses (18-125 kDa) identified to interact with PP-1C by these two techniques cannot be accounted for by the previously characterized subunits of PP-1. Our findings further support the concept that PP-1C is regulated in vivo by multiple and distinct substrate-targeting subunits.	UNIV VIRGINIA, HLTH SCI CTR, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, MARKEY CTR CELL SIGNALING, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia					NHLBI NIH HHS [P01 HL19242-20] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019242] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AITKEN A, 1982, EUR J BIOCHEM, V126, P235, DOI 10.1111/j.1432-1033.1982.tb06771.x; ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; CHEN YH, 1994, FEBS LETT, V356, P51, DOI 10.1016/0014-5793(94)01231-8; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; DOONAN JH, 1989, CELL, V57, P987, DOI 10.1016/0092-8674(89)90337-1; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; Haystead CMM, 1995, FEBS LETT, V377, P123, DOI 10.1016/0014-5793(95)01318-0; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; Helps NR, 1995, FEBS LETT, V377, P295, DOI 10.1016/0014-5793(95)01347-4; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; HIRAGA A, 1986, EUR J BIOCHEM, V161, P763, DOI 10.1111/j.1432-1033.1986.tb10505.x; HIRANO K, 1995, J BIOL CHEM, V270, P19786, DOI 10.1074/jbc.270.34.19786; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HUBBARD MJ, 1990, EUR J BIOCHEM, V189, P243, DOI 10.1111/j.1432-1033.1990.tb15483.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P701, DOI 10.1111/j.1432-1033.1989.tb15263.x; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Ichikawa K, 1996, J BIOL CHEM, V271, P4733; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MACKINTOSH RW, 1995, FEBS LETT, V371, P236, DOI 10.1016/0014-5793(95)00888-G; MOORHEAD G, 1994, FEBS LETT, V356, P46, DOI 10.1016/0014-5793(94)01232-6; MOORHEAD G, 1995, FEBS LETT, V362, P101, DOI 10.1016/0014-5793(95)00197-H; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; RUNNEGAR M, 1995, BIOCHEM BIOPH RES CO, V216, P162, DOI 10.1006/bbrc.1995.2605; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P3; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; SHIRAZI A, 1994, J BIOL CHEM, V269, P31598; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; STEWART AA, 1981, EUR J BIOCHEM, V115, P197; STRSLFORS P, 1985, EUR J BIOCH A, V149, P295; TANG PM, 1991, J BIOL CHEM, V266, P15782; TRINKLEMULCAHY L, 1995, J BIOL CHEM, V270, P18191, DOI 10.1074/jbc.270.31.18191; WU J, 1992, BIOCHEM J, V285, P701, DOI 10.1042/bj2850701	46	68	73	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28478	28484		10.1074/jbc.271.45.28478	http://dx.doi.org/10.1074/jbc.271.45.28478			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910475	hybrid			2022-12-27	WOS:A1996VU03300075
J	Ducancel, F; Merienne, K; FromenRomano, C; Tremeau, O; Pillet, L; Drevet, P; ZinnJustin, S; Boulain, JC; Menez, A				Ducancel, F; Merienne, K; FromenRomano, C; Tremeau, O; Pillet, L; Drevet, P; ZinnJustin, S; Boulain, JC; Menez, A			Mimicry between receptors and antibodies - Identification of snake toxin determinants recognized by the acetylcholine receptor and an acetylcholine receptor-mimicking monoclonal antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; GATED ION CHANNELS; STAPHYLOCOCCAL PROTEIN-A; BINDING-SITE; CURAREMIMETIC TOXINS; ALPHA-BUNGAROTOXIN; CRYSTAL-STRUCTURE; ANTIGEN INTERACTIONS; CATALYTIC ANTIBODY; FUNCTIONAL EPITOPE	In several instances, a monoclonal antibody raised against a receptor ligand has been claimed to mimic the ligand receptor, Thus, a specific monoclonal antibody (M alpha 2-3) raised against a short chain toxin from snake was proposed to mimic the nicotinic acetylcholine receptor (AChR) (1), Further confirming this mimicry, we show that (i) like AChR, M alpha 2-3 elicits anti-AChR antibodies, which in turn elicit anti-toxin antibodies; and (ii) the region 106-122 of the alpha-chain of AChR shares 66% primary structure identity with complementarity-determining regions of M alpha 2-3. Also, a mutational analysis of erabutoxin a reveals that the epitope recognized by M alpha 2-3 consists of 10 residues, distributed within the three toxin loops, Eight of these residues also belong to the 10-residue epitope recognized by AChR, a result that offers an explanation as to the functional similarities between the receptor and the antibody, Strikingly, however, most of the residues common to the two epitopes contribute differentially to the energetic formation of the antibody-toxin and the receptor-toxin complexes, Together, the data suggest that the mimicry between AChR and M alpha 2-3 is partial only.	CEA SACLAY, DSV, DEPT INGN & ETUD PROT, F-91191 GIF SUR YVETTE, FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay				Merienne, Karine/0000-0003-2549-2315				AMATI V, 1995, PROTEIN ENG, V8, P403, DOI 10.1093/protein/8.4.403; ARNOUX B, 1994, FEBS LETT, V342, P12, DOI 10.1016/0014-5793(94)80574-1; BASUS VJ, 1993, BIOCHEMISTRY-US, V32, P12290, DOI 10.1021/bi00097a004; Benkovic SJ., 1990, CHEMTRACTS ORG CHEM, V3, P1; BOULAIN JC, 1982, SCIENCE, V217, P732, DOI 10.1126/science.7100919; BOULAIN JC, 1982, BIOCHEMISTRY-US, V21, P2910, DOI 10.1021/bi00541a016; BOULTER J, 1985, J NEUROSCI, V5, P2545; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BOYOT P, 1990, FEBS LETT, V266, P87, DOI 10.1016/0014-5793(90)81513-N; BRADEN BC, 1995, FASEB J, V9, P9, DOI 10.1096/fasebj.9.1.7821765; BRUCK C, 1986, P NATL ACAD SCI USA, V83, P6578, DOI 10.1073/pnas.83.17.6578; Chang C.C., 1979, SNAKE VENOMS, P309; CHANGEUX JP, 1990, TRENDS PHARMACOL SCI, V11, P485, DOI 10.1016/0165-6147(90)90049-E; Charpentier I, 1990, J Mol Recognit, V3, P74, DOI 10.1002/jmr.300030204; CHINCHETRU MA, 1989, BIOCHEMISTRY-US, V28, P4222, DOI 10.1021/bi00436a015; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DAVIS SJ, 1992, NATURE, V358, P76, DOI 10.1038/358076a0; DEVILLERSTHIERY A, 1993, J MEMBRANE BIOL, V136, P97, DOI 10.1007/BF02505755; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DORING E, 1994, MOL IMMUNOL, V31, P1059, DOI 10.1016/0161-5890(94)90101-5; DUCANCEL F, 1989, PROTEIN ENG, V3, P139, DOI 10.1093/protein/3.2.139; Endo T., 1991, P165; FAMBROUGH DM, 1973, SCIENCE, V182, P293, DOI 10.1126/science.182.4109.293; FAURE G, 1983, BIOCHEMISTRY-US, V22, P2068, DOI 10.1021/bi00278a006; FIELDS BA, 1995, NATURE, V374, P739, DOI 10.1038/374739a0; FULACHIER MH, 1994, FEBS LETT, V338, P331, DOI 10.1016/0014-5793(94)80294-7; GALZI JL, 1994, CURR OPIN STRUC BIOL, V4, P554, DOI 10.1016/S0959-440X(94)90218-6; GAUCHER JF, 1996, THESIS U PARIS 11 PA; GIBBS RA, 1991, P NATL ACAD SCI USA, V88, P4001, DOI 10.1073/pnas.88.9.4001; HERVE M, 1992, EUR J BIOCHEM, V208, P125, DOI 10.1111/j.1432-1033.1992.tb17165.x; HILL BL, 1988, ENDOCRINOLOGY, V122, P2840, DOI 10.1210/endo-122-6-2840; ISHIKAWA Y, 1977, TOXICON, V15, P477, DOI 10.1016/0041-0101(77)90098-8; JANIN J, 1990, J BIOL CHEM, V265, P16027; JARRIN A, 1994, FEBS LETT, V354, P169, DOI 10.1016/0014-5793(94)01113-3; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; Kabat EA, 1991, SEQUENCES PROTEINS I; KAMMORGAN LNW, 1993, P NATL ACAD SCI USA, V90, P3958, DOI 10.1073/pnas.90.9.3958; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; LENTZ TL, 1995, BIOCHEMISTRY-US, V34, P1316, DOI 10.1021/bi00004a026; LEU JG, 1994, P NATL ACAD SCI USA, V91, P10690, DOI 10.1073/pnas.91.22.10690; LINDSTROM J, 1988, ADV IMMUNOL, V42, P233, DOI 10.1016/S0065-2776(08)60847-0; LOW BW, 1976, P NATL ACAD SCI USA, V73, P2991, DOI 10.1073/pnas.73.9.2991; LOWENADLER B, 1987, GENE, V58, P87, DOI 10.1016/0378-1119(87)90032-1; MENEZ A, 1971, FEBS LETT, V17, P333, DOI 10.1016/0014-5793(71)80180-1; MENEZ A, 1984, J PHYSIOLOGY PARIS, V79, P196; NILSSON B, 1985, EMBO J, V4, P1075, DOI 10.1002/j.1460-2075.1985.tb03741.x; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; NOVOTNY J, 1989, BIOCHEMISTRY-US, V28, P4735, DOI 10.1021/bi00437a034; NOVOTNY J, 1991, MOL IMMUNOL, V28, P201, DOI 10.1016/0161-5890(91)90062-O; PATRICK J, 1973, SCIENCE, V180, P871, DOI 10.1126/science.180.4088.871; PEARCE SF, 1990, BIOCHEMISTRY-US, V29, P10649, DOI 10.1021/bi00499a011; PILLET L, 1993, J BIOL CHEM, V268, P909; PILLET L, 1992, BIOCHIM BIOPHYS ACTA, V1138, P282, DOI 10.1016/0925-4439(92)90005-8; POLJAK RJ, 1994, P NATL ACAD SCI USA, V91, P1599, DOI 10.1073/pnas.91.5.1599; PRASAD L, 1993, J BIOL CHEM, V268, P10705; PRIDE MW, 1992, P NATL ACAD SCI USA, V89, P11900, DOI 10.1073/pnas.89.24.11900; RUAN KH, 1991, BIOCHEM J, V274, P849, DOI 10.1042/bj2740849; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARAGOVI HU, 1991, SCIENCE, V253, P792, DOI 10.1126/science.1876837; SATO S, 1971, BIOCHEM J, V122, P453, DOI 10.1042/bj1220453; SMITH AM, 1991, J IMMUNOL, V146, P1259; SMITHGILL SJ, 1984, J IMMUNOL, V133, P384; SUGIYAMA H, 1973, FEBS LETT, V35, P124, DOI 10.1016/0014-5793(73)80592-7; TAMIYA T, 1985, BIOCHIMIE, V67, P185, DOI 10.1016/S0300-9084(85)80046-8; TAUB R, 1989, J BIOL CHEM, V264, P259; Tenette C, 1996, PROTEINS, V26, P9, DOI 10.1002/(SICI)1097-0134(199609)26:1<9::AID-PROT2>3.0.CO;2-E; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TREMEAU O, 1986, FEBS LETT, V208, P236, DOI 10.1016/0014-5793(86)81024-9; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362; VINCENT A, 1983, TRENDS NEUROCHEM SCI, P249; WANG MW, 1989, P NATL ACAD SCI USA, V86, P7098, DOI 10.1073/pnas.86.18.7098; WEBSTER DM, 1994, CURR OPIN STRUC BIOL, V4, P123, DOI 10.1016/S0959-440X(94)90070-1; WILLIAMS WV, 1991, J BIOL CHEM, V266, P5182; WILLIAMS WV, 1989, P NATL ACAD SCI USA, V86, P5537, DOI 10.1073/pnas.86.14.5537; WILLIAMS WV, 1989, VIROL IMMUNOL, V22, P321; WILSON IA, 1993, CURR OPIN STRUC BIOL, V3, P113, DOI 10.1016/0959-440X(93)90210-C; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444; [No title captured]	82	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31345	31353		10.1074/jbc.271.49.31345	http://dx.doi.org/10.1074/jbc.271.49.31345			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940141	hybrid			2022-12-27	WOS:A1996VW68600052
J	Groblewski, GE; Wishart, MJ; Yoshida, M; Williams, JA				Groblewski, GE; Wishart, MJ; Yoshida, M; Williams, JA			Purification and identification of a 28-kDa calcium-regulated heat-stable protein - A novel secretagogue-regulated phosphoprotein in exocrine pancreas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE ACTIVITY; ACINAR-CELLS; PHOSPHORYLATION; CARBACHOL; SEQUENCE	This study reports the purification and identification of a novel 28 kDa phosphoprotein from rat pancreatic acini, previously described as being highly regulated by calcium mobilizing secretagogues, which we have designated calcium-regulated heat-stable protein 28 (CRHSP-28). Internal amino acid sequences of purified CRHSP-28 were obtained following trypsin digestion and found to match with >95% identity the predicted amino acid sequence of a novel cDNA recently identified as being highly expressed in human breast carcinomas, Verification that this cDNA codes for human CRHSP-28 was demonstrated by the ability of antiserum raised against purified rat CRHSP-28 to recognize the recombinant human protein when expressed in bacteria. Furthermore, this antibody was found to specifically react with CRHSP-28 in rat acini following one- and tno dimensional electrophoresis and underwent a marked acidic shift in mobility after cholecystokinin stimulation, a phenomenon indicative of an increase in its phosphorylation. CRHSP-28 is predicted to be extremely hydrophilic, is phosphorylated entirely on serine residues, and bears little homology to any known proteins, Finally, the distribution of the CRHSP-28 protein in various rat tissues revealed that although it was present at low levels in almost all tissues, it was most highly expressed in pancreas, followed by the gastric, intestinal, and colonic mucosa. In view of its relative abundance throughout the digestive system and its apparent regulation by calcium-mobilizing agents, this protein may provide valuable insight into the mechanism(s) of calcium signaling in these tissues.	UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	Groblewski, GE (corresponding author), UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,7737 MED SCI I,ANN ARBOR,MI 48109, USA.			Williams, John/0000-0002-6063-7615	NIDDK NIH HHS [DK-08819, DK-41122] Funding Source: Medline; PHS HHS [P30 KD34922] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK041122, R01DK041122, F32DK008819] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BROWN MR, 1989, AM J PHYSIOL, V257, pG99, DOI 10.1152/ajpgi.1989.257.1.G99; BURNHAM DB, 1984, AM J PHYSIOL, V246, pG500, DOI 10.1152/ajpgi.1984.246.5.G500; BURNHAM DB, 1988, AM J PHYSIOL, V254, pG130, DOI 10.1152/ajpgi.1988.254.1.G130; BURNHAM DB, 1982, J BIOL CHEM, V257, P523; BURNHAM DB, 1986, BIOCHEM J, V235, P125, DOI 10.1042/bj2350125; BYRNE JA, 1995, CANCER RES, V55, P2896; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHN JA, 1989, BIOCHEM BIOPH RES CO, V165, P819; DUAN RD, 1994, BIOCHEM BIOPH RES CO, V199, P368, DOI 10.1006/bbrc.1994.1238; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; GORELICK FS, 1983, J CELL BIOL, V97, P1294, DOI 10.1083/jcb.97.4.1294; GROBLEWSKI GE, 1994, J BIOL CHEM, V269, P15111; GROBLEWSKI GE, IN PRESS 2 MESSENGER; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; JELINEK T, 1993, BIOTECHNIQUES, V15, P628; MATOZAKI T, 1991, AM J PHYSIOL, V260, pG858, DOI 10.1152/ajpgi.1991.260.6.G858; NAIRN AC, 1985, P NATL ACAD SCI USA, V82, P7939, DOI 10.1073/pnas.82.23.7939; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; Parente JA, 1996, J BIOL CHEM, V271, P20096, DOI 10.1074/jbc.271.33.20096; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; Williams John A., 1993, P167; WISHART MJ, 1994, AM J PHYSIOL-GASTR L, V267, pG676, DOI 10.1152/ajpgi.1994.267.4.G676	24	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31502	31507		10.1074/jbc.271.49.31502	http://dx.doi.org/10.1074/jbc.271.49.31502			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940165	hybrid			2022-12-27	WOS:A1996VW68600076
J	Zhang, X; Bennett, V				Zhang, X; Bennett, V			Identification of O-linked N-acetylglucosamine modification of ankyrin(G) isoforms targeted to nodes of Ranvier	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROCYTE ANKYRIN; AXONAL-TRANSPORT; SCHWANN-CELLS; GENE FAMILY; C-MYC; GLYCOSYLATION; NUCLEAR; DOMAIN; PHOSPHORYLATION; GLCNAC	Ankyrin(G)s of 270 and 480 kDa are localized at nodes of Ranvier and are candidates to couple the voltage-dependent sodium channel and neurofascin to the spectrin/actin network. This study presents evidence that these ankyrins contain O-linked GlcNAc residues and identifies as the site of glycosylation a serine-rich domain that distinguishes them from other ankyrin isoforms. The 480-kDa ankyrin(G), extracted from brain membranes associated with wheat germ agglutinin-affinity columns, was [H-3]galactose-labeled with UDP-[H-3] galactose and galactosyltransferase, and cross-reacted with an antibody against O-GlcNAc monosaccharides. Ankyrin(G)-associated sugars are O-linked monosaccharides based on resistance to peptide-N-glycosidase F and analysis of saccharides released by beta-elimination. The serine-rich domain is the site of glycosylation based on wheat germ agglutinin binding activity of polypeptides produced by in vitro translation in reticulocyte lysates. Immunofluorescence revealed co-localization of ankyrin, and O-GlcNAc immunoreactivity at nodes of Ranvier. These observations suggest that ankyrin at the node of Ranvier is O-GlcNAc glycosylated and are the first demonstration of a post translational modification that is concentrated at the node of Ranvier and not in adjacent areas of myelinated axons.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710	Duke University; Duke University; Howard Hughes Medical Institute	Zhang, X (corresponding author), DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710, USA.							BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Brady Scott T., 1993, P7; CHAN W, 1993, J CELL BIOL, V123, P1463, DOI 10.1083/jcb.123.6.1463; CHOU CF, 1992, J BIOL CHEM, V267, P3901; CHOU TY, 1995, P NATL ACAD SCI USA, V92, P4417, DOI 10.1073/pnas.92.10.4417; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; Davis J., 1995, Molecular Biology of the Cell, V6, p177A; DAVIS J, 1983, J BIOL CHEM, V258, P7757; DAVIS JQ, 1984, J BIOL CHEM, V259, P3550; DAVIS LI, 1987, P NATL ACAD SCI USA, V84, P7552, DOI 10.1073/pnas.84.21.7552; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; DEWAEGH SM, 1991, J NEUROSCI RES, V30, P201, DOI 10.1002/jnr.490300121; DONG DLY, 1993, J BIOL CHEM, V268, P16679; ELLIOT SP, 1993, J NEUROSCI, V13, P2424, DOI 10.1523/JNEUROSCI.13-06-02424.1993; GRIFFITH LS, 1995, J NEUROSCI RES, V41, P270, DOI 10.1002/jnr.490410214; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; HART GW, 1995, ADV EXP MED BIOL, V376, P115; HOLT GD, 1987, J BIOL CHEM, V262, P14847; HSIEH ST, 1994, J NEUROSCI, V14, P6392; KELLY WG, 1993, J BIOL CHEM, V268, P10416; KORDELI E, 1990, J CELL BIOL, V110, P1341, DOI 10.1083/jcb.110.4.1341; KORDELI E, 1991, J CELL BIOL, V114, P1243, DOI 10.1083/jcb.114.6.1243; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; Kunimoto M, 1995, J CELL BIOL, V131, P1821, DOI 10.1083/jcb.131.6.1821; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LAMBERT S, 1993, EUR J BIOCHEM, V211, P1, DOI 10.1111/j.1432-1033.1993.tb19863.x; Lambert S., 1995, Molecular Biology of the Cell, V6, p98A; LUTHI T, 1991, J NEUROCHEM, V56, P1493; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MATA M, 1992, J NEUROCYTOL, V21, P199, DOI 10.1007/BF01194978; MURPHY JE, 1995, J BIOL CHEM, V269, P21346; OTTO E, 1991, J CELL BIOL, V114, P241, DOI 10.1083/jcb.114.2.241; PETERS LL, 1995, J CELL BIOL, V130, P313, DOI 10.1083/jcb.130.2.313; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; Sambrook J., 2002, MOL CLONING LAB MANU; SRINIVASAN Y, 1992, J BIOL CHEM, V267, P7483; STARR CM, 1990, J BIOL CHEM, V265, P6868; TRAVELYAN WE, 1950, NATURE, V166, P444; TURNER JR, 1990, P NATL ACAD SCI USA, V87, P5608, DOI 10.1073/pnas.87.15.5608	40	56	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31391	31398		10.1074/jbc.271.49.31391	http://dx.doi.org/10.1074/jbc.271.49.31391			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940148	hybrid			2022-12-27	WOS:A1996VW68600059
J	Bloom, LB; Turner, J; Kelman, Z; Beechem, JM; ODonnell, M; Goodman, MF				Bloom, LB; Turner, J; Kelman, Z; Beechem, JM; ODonnell, M; Goodman, MF			Dynamics of loading the beta sliding clamp of DNA polymerase III onto DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL REPLICATION MACHINE; ONE HOLOENZYME PARTICLE; ESCHERICHIA-COLI; ACCESSORY PROTEINS; SUBUNIT; LOADER; COMPLEX; PURIFICATION; EXONUCLEASE; MECHANISM	A ''minimal'' DNA primer-template system, consisting of an 80-mer template and 30-mer primer, supports processive DNA synthesis by DNA polymerase III core in the presence of the beta sliding clamp, gamma complex clamp loader, and single-stranded binding protein from Escherichia coli, This primer-template system was used to measure the loading of the beta sliding clamp by the gamma complex in an ATP-dependent reaction, Bound protein-DNA complexes were detected by monitoring fluorescence depolarization of DNA. Steady state and time-resolved anisotropies were measured, and stopped-flow pre-steady state fluorescence measurements allowed visualization of the loading reactions in real time. The rate of loading beta onto DNA was 12 s(-1), demonstrating that clamp assembly is rapid on the time scale required for lagging strand Okazaki fragment synthesis. The association rate appears to be limited by an intramolecular step occurring prior to the clamp-loading reaction, possibly the opening of the toroidal beta dimer.	UNIV SO CALIF,HEDCO MOL BIOL LABS,DEPT BIOL SCI,LOS ANGELES,CA 90089; HEARST RES FDN,DEPT MICROBIOL,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,HOWARD HUGHES MED INST,NEW YORK,NY 10021; VANDERBILT UNIV,DEPT MOL PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	University of Southern California; Cornell University; Howard Hughes Medical Institute; Vanderbilt University			Bloom, Linda B/F-3684-2014		NIGMS NIH HHS [GM21422, GM38839, GM42554] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R01GM042554, R37GM038839, R01GM021422, R37GM021422] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONNER CA, 1992, J BIOL CHEM, V267, P11431; DIFRANCESCO R, 1984, J BIOL CHEM, V259, P5567; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FAY PJ, 1981, J BIOL CHEM, V256, P976; GUPTA A, 1982, J BIOL CHEM, V257, P7689; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KELMAN Z, 1994, CURR OPIN GENET DEV, V4, P185, DOI 10.1016/S0959-437X(05)80044-9; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KORNBERG A, 1992, DNA REPLICATION, P169; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P145; LETILLY V, 1993, BIOCHEMISTRY-US, V32, P7753, DOI 10.1021/bi00081a021; MAKI H, 1985, J BIOL CHEM, V260, P2987; MAKI S, 1988, J BIOL CHEM, V263, P6555; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; ONRUST R, 1991, J BIOL CHEM, V266, P21681; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; OTTO MR, 1994, BIOPHYS J, V67, P2511, DOI 10.1016/S0006-3495(94)80741-6; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SINHA NK, 1980, J BIOL CHEM, V263, P6561; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; STUKENBERG PT, 1995, J BIOL CHEM, V270, P13384, DOI 10.1074/jbc.270.22.13384; XIAO H, 1993, J BIOL CHEM, V268, P11773	30	55	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30699	30708		10.1074/jbc.271.48.30699	http://dx.doi.org/10.1074/jbc.271.48.30699			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940047	hybrid			2022-12-27	WOS:A1996VV15800064
J	Dan, N; Middleton, RB; Lehrman, MA				Dan, N; Middleton, RB; Lehrman, MA			Hamster UDP-N-acetylglucosamine:dolichol-P N-acetylglucosamine-1-P transferase has multiple transmembrane spans and a critical cytosolic loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-D-GLUCOSAMINE; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; LINKED OLIGOSACCHARIDES; MICROSOMAL VESICLES; MOLECULAR-CLONING; MEMBRANE TOPOLOGY; OVARY CELLS; PHOSPHATE; GLCNAC	UDP-GlcNAc:dolichol-P GlcNAc-1-P transferase (GPT) is an endoplasmic reticulum (ER) enzyme responsible for synthesis of GlcNAc-P-P-dolichol, the committed step of dolichol-P-P-oligosaccharide synthesis. The sequence of hamster GPT predicted multiple transmembrane segments (Zhu, X, and Lehrman, M. A. (1990) J. Biol. Chem. 265, 14250-14255). GPT has also been predicted to act on the cytosolic face of the ER membrane, based on topological studies of its substrates and products. In this report we test these predictions by: (i) immunofluorescence microscopy with antibodies specific for native GPT sequences or epitope tags inserted into GPT, after selective permeabilization of the plasma membrane with digitonin; (ii) insertion of Factor Xa cleavage sites; (iii) in vitro translation of GPT; and (iv) site-directed mutagenesis, The loops between the Ist and 2nd and between the 9th and 10th predicted transmembrane spans of GPT were found to be cytosolic. In contrast, the loop between the 6th and 7th transmembrane spans, as well as the carboxyl terminus, were lumenal. Thus, hamster GPT must cross the ER membrane at least three times, consistent with previous computer-assisted predictions. There was no apparent N-glycosylation or signal sequence cleavage detected by in vitro translation. The cytosolic loop between the 9th and 10th transmembrane spans is the largest hydrophilic segment in GPT and, as judged by site-directed mutagenesis, has a number of conserved residues essential for activity. Hence, these results directly support the hypothesis that dolichol-PP-oligosaccharide assembly is initiated in the cytosol and that a downstream intermediate must translocate to the lumenal face of the ER membrane.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIGMS NIH HHS [GM38545] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038545, R56GM038545] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1990, J BIOL CHEM, V265, P14691; BORJIGIN J, 1994, J BIOL CHEM, V269, P14715; DATTA AK, 1993, J BIOL CHEM, V268, P12663; HANOVER JA, 1979, J BIOL CHEM, V254, P9237; HARTOG KO, 1987, NUCLEIC ACIDS RES, V15, P3627, DOI 10.1093/nar/15.8.3627; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; JACKSON BJ, 1989, ARCH BIOCHEM BIOPHYS, V272, P203, DOI 10.1016/0003-9861(89)90211-7; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; KAST C, 1995, BIOCHEMISTRY-US, V34, P4402, DOI 10.1021/bi00013a032; KEAN EL, 1991, J BIOL CHEM, V266, P942; KEAN EL, 1994, BIOCHEMISTRY-US, V33, P10508, DOI 10.1021/bi00200a036; KEAN EL, 1993, BIOCHIM BIOPHYS ACTA, V1168, P321, DOI 10.1016/0005-2760(93)90189-G; LEHRMAN M A, 1991, Glycobiology, V1, P553, DOI 10.1093/glycob/1.6.553; LEHRMAN MA, 1994, GLYCOBIOLOGY, V4, P768, DOI 10.1093/glycob/4.6.768; LEHRMAN MA, 1988, J BIOL CHEM, V263, P19796; LENNARZ WJ, 1987, BIOCHEMISTRY-US, V26, P7205, DOI 10.1021/bi00397a001; LIU X, 1992, MOL CELL BIOL, V12, P4112, DOI 10.1128/MCB.12.9.4112; MIDDLETON RB, 1993, BIOCHEM J, V296, P511, DOI 10.1042/bj2960511; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; PATTERSON SI, 1994, J CELL BIOL, V124, P521, DOI 10.1083/jcb.124.4.521; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; RAJPUT B, 1992, BIOCHEM J, V285, P985, DOI 10.1042/bj2850985; RINE J, 1983, P NATL ACAD SCI-BIOL, V80, P6750, DOI 10.1073/pnas.80.22.6750; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; SCOCCA JR, 1990, J BIOL CHEM, V265, P20621; SHAILUBHAI K, 1988, J BIOL CHEM, V263, P15964; SINGH P, 1993, MOL CELL BIOL, V13, P6435, DOI 10.1128/MCB.13.10.6435; SLONINA AE, 1993, J BIOL CHEM, V268, P6729; SNIDER MD, 1980, CELL, V21, P385, DOI 10.1016/0092-8674(80)90475-4; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; TAKEDA J, 1995, TRENDS BIOCHEM SCI, V20, P367, DOI 10.1016/S0968-0004(00)89078-7; TEHEESEN S, 1994, EUR J BIOCHEM, V224, P71, DOI 10.1111/j.1432-1033.1994.tb19996.x; THIGPEN AE, 1993, J BIOL CHEM, V268, P17404; VALTERSSON C, 1985, J BIOL CHEM, V260, P2742; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; YOON KL, 1994, J BIOL CHEM, V269, P28249; ZARA J, 1994, J BIOL CHEM, V269, P19108; ZHU XY, 1990, J BIOL CHEM, V265, P14250; ZHU XY, 1992, J BIOL CHEM, V267, P8895; ZOU J, 1995, ARCH BIOCHEM BIOPHYS, V317, P487, DOI 10.1006/abbi.1995.1192	42	32	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30717	30724		10.1074/jbc.271.48.30717	http://dx.doi.org/10.1074/jbc.271.48.30717			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940049	hybrid			2022-12-27	WOS:A1996VV15800066
J	Greene, J; Wang, MS; Liu, YLE; Raymond, LA; Rosen, C; Shi, YNE				Greene, J; Wang, MS; Liu, YLE; Raymond, LA; Rosen, C; Shi, YNE			Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-SITU HYBRIDIZATION; C-TERMINAL DOMAIN; TIMP GENE FAMILY; GELATINASE-A; MATRIX METALLOPROTEINASES; MESSENGER-RNAS; CELL-LINES; HORMONAL-REGULATION; BREAST CARCINOMAS; IV COLLAGENASE	The tissue inhibitors of metalloproteinases (TIMPs) constitute a family of proteins, of which three members have so far been described. Using the expressed sequence tag sequencing approach, we have identified a novel TIMP-related cDNA fragment and subsequently cloned a fourth human TIMP (TIMP-4) from a human heart cDNA library. The open reading frame encodes a 224-amino acid precursor including a 29-residue secretion signal. The predicted structure of the new protein shares 37% sequence identity with TIMP-1 and 51% identity with TIMP-2 and -3. The protein has a predicted isoelectric point of 7.34. The open reading frame-directed expression of TIMP-4 protein in MDA-MB-435 human breast cancer cells showed metalloproteinase inhibitory activity on reverse zymography. By Northern analysis, only the adult heart showed abundant TIMP-4 transcripts with a 1.4-kilobase predominant transcript band; very low levels of the transcripts were detected in the kidney, placenta, colon, and testes, and no transcripts were detected in the liver, brain, lung, thymus, and spleen. This unique expression pattern suggests that TIMP-4 may function in a tissue-specific fashion in extracellular matrix homeostasis.	HUMAN GENOME SCI INC,ROCKVILLE,MD 20850; ALBERT EINSTEIN COLL MED,LONG ISL JEWISH MED CTR,DEPT PEDIAT,NEW HYDE PK,NY 11042	GlaxoSmithKline; Human Genome Sciences Inc; Northwell Health; Yeshiva University					NATIONAL CANCER INSTITUTE [R29CA068064] Funding Source: NIH RePORTER; NCI NIH HHS [CA68064-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ALVAREZ OA, 1990, J NATL CANCER I, V82, P589, DOI 10.1093/jnci/82.7.589; APODACA G, 1990, CANCER RES, V50, P2322; APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BASSET P, 1994, CANCER-AM CANCER SOC, V74, P1045, DOI 10.1002/1097-0142(19940801)74:3+<1045::AID-CNCR2820741511>3.0.CO;2-7; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; CARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407, DOI 10.1073/pnas.83.8.2407; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECLERCK YA, 1993, BIOCHEM J, V289, P65, DOI 10.1042/bj2890065; DECLERCK YA, 1992, CANCER RES, V52, P701; Denhardt D T, 1992, Matrix Suppl, V1, P281; DENHARDT DT, 1993, PHARMACOL THERAPEUT, V59, P329, DOI 10.1016/0163-7258(93)90074-N; DOCHERTY AJP, 1992, TRENDS BIOTECHNOL, V10, P200, DOI 10.1016/0167-7799(92)90214-G; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; HOYHTYA M, 1994, INT J CANCER, V56, P500, DOI 10.1002/ijc.2910560408; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KHOKHA R, 1994, J NATL CANCER I, V86, P299, DOI 10.1093/jnci/86.4.299; KLEINER DE, 1992, BIOCHEMISTRY-US, V31, P1665, DOI 10.1021/bi00121a013; KOSSAKOWSKA AE, 1991, BLOOD, V77, P2475; LECO KJ, 1994, J BIOL CHEM, V269, P9352; LENNARZ WJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P149, DOI 10.1016/0304-4157(91)90022-O; Liotta L A, 1990, Semin Cancer Biol, V1, P99; LOTZ M, 1991, J BIOL CHEM, V266, P2017; MANN JS, 1991, ENDOCRINOLOGY, V128, P1825, DOI 10.1210/endo-128-4-1825; MCLESKEY SW, 1993, CANCER RES, V53, P2168; MIYAZAKI K, 1993, J BIOL CHEM, V268, P14387; MOHANAM S, 1995, CLIN EXP METASTAS, V13, P57, DOI 10.1007/BF00144019; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; NAYLOR MS, 1994, INT J CANCER, V58, P50, DOI 10.1002/ijc.2910580110; POLETTE M, 1993, INVAS METAST, V13, P31; POLETTE M, 1994, VIRCHOWS ARCH, V424, P641, DOI 10.1007/BF01069745; POLETTE M, 1993, PATHOL RES PRACT, V189, P1052; POULSOM R, 1993, J CLIN PATHOL, V46, P429, DOI 10.1136/jcp.46.5.429; PYKE C, 1993, AM J PATHOL, V142, P359; SATO T, 1991, BIOCHEM J, V275, P645, DOI 10.1042/bj2750645; STASKUS PW, 1991, J BIOL CHEM, V266, P449; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; TESTA JE, 1992, CANCER RES, V52, P5597; TSUCHIYA Y, 1993, CANCER RES, V53, P1397; URIA JA, 1994, CANCER RES, V54, P2091; VISSCHER DW, 1994, INT J CANCER, V59, P339, DOI 10.1002/ijc.2910590308; WICK M, 1994, J BIOL CHEM, V269, P18953; WILDE CG, 1994, DNA CELL BIOL, V13, P711, DOI 10.1089/dna.1994.13.711; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; WILLIAMSON RA, 1990, BIOCHEM J, V268, P267, DOI 10.1042/bj2680267; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOLF C, 1993, P NATL ACAD SCI USA, V90, P1843, DOI 10.1073/pnas.90.5.1843	52	363	396	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30375	30380		10.1074/jbc.271.48.30375	http://dx.doi.org/10.1074/jbc.271.48.30375			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939999	hybrid			2022-12-27	WOS:A1996VV15800016
J	Igarashi, T; Kono, Y; Tanaka, K				Igarashi, T; Kono, Y; Tanaka, K			Molecular cloning of manganese catalase from Lactobacillus plantarum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; THERMUS-THERMOPHILUS; BEEF-LIVER; T-CATALASE; PROTEINS; RESOLUTION; PSEUDOCATALASE; STATE	A genomic clone encoding manganese-containing catalase has been isolated from lactic acid bacterium Lactobacillus plantarum, sequenced, and expressed in Escherichia coli cells with an inducible expression system. The primary structure of the enzyme deduced from the nucleotide sequence, that comprises 266 amino acid residues, showed no significant homology with that of any other proteins registered on the available data bases. No peptide motifs conserved among active sites of proteins including manganese-containing enzymes were found. The E. coli cells carrying an expression construct, in which the 5'-noncoding region of the manganese catalase gene was replaced with the lac promoter, highly induced a protein reacting with the antiserum to manganese catalase. The prediction of secondary structure from the deduced primary structure suggested that the L. plantarum manganese catalase, that is classified as a novel protein on the basis of its primary structure, has a main structural motif formed by four near parallel helices between which is the catalytic site manganese.	SHIMANE UNIV, FAC LIFE & ENVIRONM SCI, DEPT LIFE SCI & BIOTECHNOL, MATSUE, SHIMANE 690, JAPAN; TOTTORI UNIV, FAC AGR, DEPT BIOCHEM & BIOTECHNOL, LAB PLANT BIOTECHNOL, TOTTORI 680, JAPAN	Shimane University; Tottori University	Igarashi, T (corresponding author), NATL INST ENVIRONM STUDIES, DIV ENVIRONM BIOL, TSUKUBA, IBARAKI 305, JAPAN.							ALLGOOD GS, 1986, J BACTERIOL, V168, P563, DOI 10.1128/jb.168.2.563-567.1986; BALDWIN ET, 1990, THESIS U N CAROLINA; BARYNIN VV, 1986, DOKL AKAD NAUK SSSR+, V288, P877; BARYNIN VV, 1986, DOKL AKAD NAUK SSSR+, V286, P461; BERNS KI, 1965, J MOL BIOL, V11, P476, DOI 10.1016/S0022-2836(65)80004-3; BEYER WF, 1985, BIOCHEMISTRY-US, V24, P6460, DOI 10.1021/bi00344a023; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; FRONKO RM, 1988, J AM CHEM SOC, V110, P7554, DOI 10.1021/ja00230a055; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GREGORY EM, 1974, ANAL BIOCHEM, V58, P57, DOI 10.1016/0003-2697(74)90440-0; IVANCICH A, 1995, BIOCHEMISTRY-US, V34, P6628, DOI 10.1021/bi00020a008; KHANGULOV SV, 1990, BIOCHIM BIOPHYS ACTA, V1020, P25, DOI 10.1016/0005-2728(90)90089-M; KONO Y, 1983, J BIOL CHEM, V258, P6015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T, 1989, MOL CLONING; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MELIKADAMYAN WR, 1986, J MOL BIOL, V188, P63, DOI 10.1016/0022-2836(86)90480-8; MURSHUDOV GN, 1992, FEBS LETT, V312, P127, DOI 10.1016/0014-5793(92)80919-8; MURTHY MRN, 1981, J MOL BIOL, V152, P465, DOI 10.1016/0022-2836(81)90254-0; Penner-Hahn J.E., 1992, MANGANESE REDOX ENZY, P29; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SHANK M, 1994, BIOCHEMISTRY-US, V33, P15433, DOI 10.1021/bi00255a025; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; TAKEDA Y, 1986, NUCLEIC ACIDS RES, V14, P4577, DOI 10.1093/nar/14.11.4577; VAINSHTEIN BK, 1985, J BIOSCIENCE, V8, P471, DOI 10.1007/BF02703998; VILLAFRANCA JJ, 1974, J BIOL CHEM, V249, P3532; WALDO GS, 1995, BIOCHEMISTRY-US, V34, P1507, DOI 10.1021/bi00005a006; WALDO GS, 1991, BIOCHEMISTRY-US, V30, P10486, DOI 10.1021/bi00107a017; WEBER PC, 1980, NATURE, V287, P82, DOI 10.1038/287082a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	30	58	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29521	29524		10.1074/jbc.271.47.29521	http://dx.doi.org/10.1074/jbc.271.47.29521			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939876	hybrid			2022-12-27	WOS:A1996VU52500004
J	Panda, D; Jordan, MA; Chu, KC; Wilson, L				Panda, D; Jordan, MA; Chu, KC; Wilson, L			Differential effects of vinblastine on polymerization and dynamics at opposite microtubule ends	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDIVIDUAL MICROTUBULES; MITOTIC SPINDLE; GTP HYDROLYSIS; ANTIMICROTUBULE AGENTS; TRANSITION FREQUENCIES; KINETIC STABILIZATION; CELL-PROLIFERATION; INTERPHASE CELLS; VINCA ALKALOIDS; PLUS-END	We have characterized the effects of vinblastine on the growing and shortening dynamics at opposite ends of individual bovine brain microtubules at steady state in vitro by video microscopy. Vinblastine exerted strikingly different effects on the dynamics and polymer mass at the plus and minus ends of microtubules. At concentrations between 0.1 and 0.4 mu M, the drug strongly depolymerized microtubules at minus ends, whereas it did not significantly depolymerize microtubules at plus ends, Vinblastine stabilized plus ends by suppressing the rate and extent of growth and shortening, decreasing the catastrophe frequency, and increasing the rescue frequency, In contrast, vinblastine destabilized minus ends by increasing the catastrophe frequency and decreasing the rescue frequency, whereas it had no effect on the rate or extent of growth or shortening, Thus, vinblastine moderately increased the overall dynamicity at minus ends while strongly suppressing dynamicity at plus ends. Both the kinetic destabilization of microtubules at minus ends and the stabilization at plus ends may contribute to the altered function of mitotic spindle Microtubules of cells blocked in mitosis by low concentrations of vinblastine.			Panda, D (corresponding author), UNIV CALIF SANTA BARBARA, DEPT MOL CELLULAR & DEV BIOL, SANTA BARBARA, CA 93106 USA.							BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burns Roy G., 1994, V13, P3; CARLIER MF, 1989, INT REV CYTOL, V115, P139; CASSIMERIS L, 1988, CELL MOTIL CYTOSKEL, V10, P185, DOI 10.1002/cm.970100123; CUTTS JH, 1960, CANCER RES, V20, P1023; DAVIDPFEUTY T, 1979, J BIOL CHEM, V254, P1696; DHAMODHARAN R, 1995, MOL BIOL CELL, V6, P1215, DOI 10.1091/mbc.6.9.1215; GLIKSMAN NR, 1993, MOL BIOL CELL, V4, P1035, DOI 10.1091/mbc.4.10.1035; HAYDEN JH, 1990, J CELL BIOL, V111, P1039, DOI 10.1083/jcb.111.3.1039; HIMES RH, 1976, CANCER RES, V36, P3798; HORIO T, 1986, NATURE, V321, P605, DOI 10.1038/321605a0; HYMAN AA, 1995, J CELL BIOL, V128, P117, DOI 10.1083/jcb.128.1.117; JORDAN MA, 1990, BIOCHEMISTRY-US, V29, P2730, DOI 10.1021/bi00463a016; JORDAN MA, 1991, CANCER RES, V51, P2212; JORDAN MA, 1992, J CELL SCI, V102, P401; JORDAN MA, 1986, J MOL BIOL, V187, P61, DOI 10.1016/0022-2836(86)90406-7; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; KOWALSKI RJ, 1993, CELL MOTIL CYTOSKEL, V26, P282, DOI 10.1002/cm.970260403; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; LUDUENA RF, 1991, PHARMACOL THERAPEUT, V49, P133, DOI 10.1016/0163-7258(91)90027-J; MARGOLIS RL, 1981, NATURE, V293, P705, DOI 10.1038/293705a0; MICKEY B, 1995, J CELL BIOL, V130, P909, DOI 10.1083/jcb.130.4.909; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MITCHISON TJ, 1993, SCIENCE, V261, P1044, DOI 10.1126/science.8102497; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; NA GC, 1980, BIOCHEMISTRY-US, V19, P1347, DOI 10.1021/bi00548a013; NA GC, 1982, J MOL BIOL, V160, P499; OBRIEN ET, 1987, BIOCHEMISTRY-US, V26, P4148, DOI 10.1021/bi00387a061; PANDA D, 1995, BIOCHEMISTRY-US, V34, P9921, DOI 10.1021/bi00031a014; PIERSON GB, 1978, J CELL BIOL, V76, P223, DOI 10.1083/jcb.76.1.223; RIEDER CL, 1990, ELECTRON MICROSC REV, V3, P269, DOI 10.1016/0892-0354(90)90005-D; ROWINSKY EK, 1991, PHARMACOL THERAPEUT, V52, P35, DOI 10.1016/0163-7258(91)90086-2; SAXTON WM, 1984, J CELL BIOL, V99, P2175, DOI 10.1083/jcb.99.6.2175; SCHULZE E, 1986, J CELL BIOL, V102, P1020, DOI 10.1083/jcb.102.3.1020; SINGER WD, 1989, MOL PHARMACOL, V36, P366; SONG YH, 1995, J CELL BIOL, V128, P81, DOI 10.1083/jcb.128.1.81; Spittle CS, 1996, CELL MOTIL CYTOSKEL, V34, P324; STEWART RJ, 1990, BIOCHEMISTRY-US, V29, P6489, DOI 10.1021/bi00479a022; TOSO RJ, 1993, BIOCHEMISTRY-US, V32, P1285, DOI 10.1021/bi00056a013; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WENDELL KL, 1993, J CELL SCI, V104, P261; WILSON L, 1982, J MOL BIOL, V159, P125, DOI 10.1016/0022-2836(82)90035-3; Wilson Leslie, 1994, V13, P59	44	93	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29807	29812		10.1074/jbc.271.47.29807	http://dx.doi.org/10.1074/jbc.271.47.29807			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939919	hybrid			2022-12-27	WOS:A1996VU52500047
J	Sakakibara, H; Shimizu, H; Hase, T; Yamazaki, Y; Takao, T; Shimonishi, Y; Sugiyama, T				Sakakibara, H; Shimizu, H; Hase, T; Yamazaki, Y; Takao, T; Shimonishi, Y; Sugiyama, T			Molecular identification and characterization of cytosolic isoforms of glutamine synthetase in maize roots	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASEOLUS-VULGARIS L; AMINO-ACID SEQUENCE; DIFFERENTIAL EXPRESSION; ESCHERICHIA-COLI; GENE FAMILY; LEAVES; SYNTHASE; PROTEINS; NODULES; CLONING	In maize, a small multigene family encodes the cytosolic isoforms of glutamine synthetase (GS), and five cDNAs, designated pGS1a, pGS1b, pGS1c, pGS1d, and pGS1e, have been cloned (Sakakibara, H., Kawabata, S., Takahashi, H., Hase, T., and Sugiyama, T. (1992) Plant Cell Physiol. 33, 49-58; Li, M., Villemur, R., Hussey, P. J., Silflow, C. D., Gantt, J. S., and Snustad, D. P. (1993) Plant Mel. Biol. 23, 401-407). This report describes the identification and enzymatic characterization of the cytosolic isoforms of GS in maize roots, namely GS1 and GSr. The purified isoforms, as well as recombinant enzymes that had been overexpressed in Escherichia coli, were analyzed by capillary liquid chromatography/electrospray ionization-mass spectrometry, and GSI and GSr were identified as the products of the GS1a/GS1b and GS1c/GS1d genes, respectively. Upon the addition of ammonia to the culture medium, significant amounts of GSr accumulated and a preferential increase in GS synthetase activity, as compared to G:S transferase activity, was found in the root extract. Assays with the purified recombinant enzymes confirmed that the specific biosynthetic and synthetase activities of GSr were 1.6-fold higher than those of GS1. Marked differences in stability were also found between the two isoforms: GSr was more sensitive to heat than GS1 and octameric aggregates of the subunits of GSr were easily dissociated to monomers than those of GS1 at low concentrations of Mn2+ and Mg2+ ions. These characteristics of the ammonia-induced isoform of GS seem to be physiologically important for the primary assimilation of external ammonia by roots.	OSAKA UNIV, INST PROT RES, SUITA, OSAKA 565, JAPAN	Osaka University	Sakakibara, H (corresponding author), NAGOYA UNIV, SCH AGR SCI, DEPT APPL BIOL SCI, NAGOYA, AICHI 46401, JAPAN.		Sakakibara, Hitoshi/A-6040-2010; Hase, Toshiharu/H-9271-2013	Sakakibara, Hitoshi/0000-0001-5449-6492; 				Arnon DI, 1940, SOIL SCI, V50, P463; BENNETT MJ, 1989, PLANTA, V179, P433, DOI 10.1007/BF00397582; BENNETT MJ, 1989, PLANT MOL BIOL, V12, P553, DOI 10.1007/BF00036969; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COCK JM, 1990, PLANT MOL BIOL, V14, P549, DOI 10.1007/BF00027500; COLOMBO G, 1986, J BIOL CHEM, V261, P587; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; CULLIMORE JV, 1980, PLANTA, V150, P392, DOI 10.1007/BF00390175; CULLIMORE JV, 1992, SOC EXP BIOL SEMIN S, V49, P79, DOI 10.1017/CBO9780511600395.005; DELAMARTER JF, 1985, EMBO J, V4, P2575, DOI 10.1002/j.1460-2075.1985.tb03973.x; GEBHARDT C, 1986, EMBO J, V5, P1429, DOI 10.1002/j.1460-2075.1986.tb04379.x; HASE T, 1991, PLANT PHYSIOL, V97, P1395, DOI 10.1104/pp.97.4.1395; HEINRIKSON RL, 1971, J BIOL CHEM, V246, P1099; HIREL B, 1987, EMBO J, V6, P1167, DOI 10.1002/j.1460-2075.1987.tb02350.x; HIREL B, 1980, PLANT PHYSIOL, V66, P619, DOI 10.1104/pp.66.4.619; KNIGHT TJ, 1988, J BIOL CHEM, V263, P11084; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lea P.J., 1990, METHODS PLANT BIOCH, V3, P257, DOI [10.1016/B978-0-12-461013-2.50022-8, DOI 10.1016/B978-0-12-461013-2.50022-8]; Lea PJ, 1990, INTERMEDIARY NITROGE, V16, P121, DOI [10.1016/B978-0-08-092616-2.50010-3, DOI 10.1016/B978-0-08-092616-2.50010-3]; LI MG, 1993, PLANT MOL BIOL, V23, P401, DOI 10.1007/BF00029015; MANCO G, 1992, J GEN MICROBIOL, V138, P1453, DOI 10.1099/00221287-138-7-1453; MANN AF, 1979, BIOCHEM BIOPH RES CO, V88, P515, DOI 10.1016/0006-291X(79)92078-3; Miflin B. J., 1980, The biochemistry of plants. A comprehensive treatise. Volume 5. Amino acids and derivatives., P169; MITCHELL AP, 1984, J BIOL CHEM, V259, P2054; MURATA H, 1994, RAPID COMMUN MASS SP, V8, P205, DOI 10.1002/rcm.1290080216; MURATA H, 1993, ANAL BIOCHEM, V210, P206, DOI 10.1006/abio.1993.1174; PALACIOS R, 1976, J BIOL CHEM, V251, P4787; PETERMAN TK, 1991, MOL GEN GENET, V230, P145, DOI 10.1007/BF00290662; RHEE SG, 1989, ADV ENZYMOL RAMB, V62, P37; SAKAKIBARA H, 1992, PLANT CELL PHYSIOL, V33, P1193; SAKAKIBARA H, 1991, J BIOL CHEM, V266, P2028; SAKAKIBARA H, 1992, PLANT CELL PHYSIOL, V33, P49; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHAPIRO BM, 1967, J BIOL CHEM, V242, P5069; SHAPIRO BM, 1968, BIOCHEMISTRY-US, V7, P2153, DOI 10.1021/bi00846a018; STANFORD AC, 1993, PLANT PHYSIOL, V103, P73, DOI 10.1104/pp.103.1.73; TINGEY SV, 1987, EMBO J, V6, P1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VEZINA LP, 1989, PLANT PHYSIOL, V90, P1129, DOI 10.1104/pp.90.3.1129; WADSWORTH GJ, 1988, ANAL BIOCHEM, V172, P279, DOI 10.1016/0003-2697(88)90443-5; WOOLFOLK CA, 1967, ARCH BIOCHEM BIOPHYS, V122, P174, DOI 10.1016/0003-9861(67)90137-3	41	64	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29561	29568		10.1074/jbc.271.47.29561	http://dx.doi.org/10.1074/jbc.271.47.29561			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939884	hybrid			2022-12-27	WOS:A1996VU52500012
J	Swarts, HGP; Klaassen, CHW; deBoer, M; Fransen, JAM; DePont, JJHHM				Swarts, HGP; Klaassen, CHW; deBoer, M; Fransen, JAM; DePont, JJHHM			Role of negatively charged residues in the fifth and sixth transmembrane domains of the catalytic subunit of gastric H+,K+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; RAT-KIDNEY NA+,K+-ATPASE; INHIBITORY MONOCLONAL-ANTIBODY; IN-VITRO TRANSLATION; SARCOPLASMIC-RETICULUM; ALPHA-SUBUNIT; CATION-BINDING; H+/K+-ATPASE; FUNCTIONAL CONSEQUENCES; MEMBRANE TOPOLOGY	The role of six negatively charged residues located in or around the fifth and sixth transmembrane domain of the catalytic subunit of gastric H+,K+-ATPase, which are conserved in P-type ATPases, was investigated by site-directed mutagenesis of each of these residues. The acid residues were converted into their corresponding acid amides, Sf9 cells were used as the expression system using a baculovirus with coding sequences for the alpha- and beta-subunits of H+,K+-ATPase behind two different promoters, Both subunits of all mutants were expressed like the wild type enzyme in intracellular membranes of Sf9 cells as indicated by Western blotting experiments, an enzyme-linked immunosorbent assay, and confocal laser scan microscopy studies, The mutants D824N, E834Q, E837Q, and D839N showed no 3-(cyanomethyl)-2-methyl-8(phenylmethoxy)-imidazo[1,2a]pyridine (SCH 28080)-sensitive ATP dependent phosphorylation capacity, Mutants E795Q and E820Q formed a phosphorylated intermediate, which, like the wild type enzyme, was hydroxylamine-sensitive, indicating that an acylphosphate was formed, Formation of the phosphorylated intermediate from the E795Q mutant was similarly inhibited by K+ (I-50 = 0.4 mM) and SCH 28080 (I-50 = 10 nM) as the wild type enzyme, when the membranes were preincubated with these ligands before phosphorylation, The dephosphorylation reaction was K+-sensitive, whereas ADP had hardly any effect, Formation of the phosphorylated intermediate of mutant E820Q was much less sensitive toward K+ (I-50 = 4.5 mM) and SCH 28080 (I-50 = 1.7 mu M) than the wild type enzyme, The dephosphorylation reaction of this intermediate was not stimulated by either K+ or ADP, In contrast to the wild type enzyme and mutant E795Q, mutant E820Q did not show any K+-stimulated ATPase activity, These findings indicate that residue Glu(820) might be involved in K+ binding and transition to the E(2) form of gastric H+,K+-ATPase.	UNIV NIJMEGEN,DEPT BIOCHEM,NL-6500 HB NIJMEGEN,NETHERLANDS; UNIV NIJMEGEN,INST CELLULAR SIGNALLING,DEPT CELL BIOL & HISTOL,NL-6500 HB NIJMEGEN,NETHERLANDS	Radboud University Nijmegen; Radboud University Nijmegen			Fransen, Jack/E-8924-2010	Fransen, Jack/0000-0002-0571-7639				ADEBAYO AO, 1995, J BIOL CHEM, V270, P27812, DOI 10.1074/jbc.270.46.27812; ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; ANDERSEN JP, 1994, FEBS LETT, V354, P93, DOI 10.1016/0014-5793(94)01100-1; ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; ARGUELLO JM, 1991, J BIOL CHEM, V266, P14627; ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; Asano S, 1996, J BIOL CHEM, V271, P2740, DOI 10.1074/jbc.271.5.2740; BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BAYLE D, 1995, J BIOL CHEM, V270, P25678, DOI 10.1074/jbc.270.43.25678; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; BLANCO G, 1994, J BIOL CHEM, V269, P23420; BLOSTEIN R, 1993, J BIOL CHEM, V268, P10654; BRENNA E, 1994, GUT, V35, P1547, DOI 10.1136/gut.35.11.1547; CHOW DC, 1993, AM J PHYSIOL, V265, pC1562, DOI 10.1152/ajpcell.1993.265.6.C1562; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DETOMASO AW, 1993, J BIOL CHEM, V268, P1470; FENG JN, 1995, CELL MOL BIOL RES, V41, P29; GOLDSHLEGER R, 1995, BIOCHEMISTRY-US, V34, P8668, DOI 10.1021/bi00027a016; GOLDSHLEGER R, 1992, P NATL ACAD SCI USA, V89, P6911, DOI 10.1073/pnas.89.15.6911; HELMICHDEJONG ML, 1985, BIOCHIM BIOPHYS ACTA, V821, P377, DOI 10.1016/0005-2736(85)90041-0; HERSEY SJ, 1995, PHYSIOL REV, V75, P155, DOI 10.1152/physrev.1995.75.1.155; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; KEELING DJ, 1989, J BIOL CHEM, V264, P5545; KLAASSEN CHW, 1994, CELL PHYSIOL BIOCHEM, V4, P115, DOI 10.1159/000154716; KLAASSEN CHW, 1995, BIOCHEM BIOPH RES CO, V210, P907, DOI 10.1006/bbrc.1995.1743; KLAASSEN CHW, 1993, FEBS LETT, V329, P277, DOI 10.1016/0014-5793(93)80237-O; Koster JC, 1996, J BIOL CHEM, V271, P2413, DOI 10.1074/jbc.271.5.2413; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MATTHEWS PM, 1995, AM J PHYSIOL, V37, pC1207; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; RAY TK, 1976, BIOCHIM BIOPHYS ACTA, V443, P451, DOI 10.1016/0005-2736(76)90465-X; Sambrook J., 2002, MOL CLONING LAB MANU; SHIN JM, 1993, BIOCHIM BIOPHYS ACTA, V1148, P223, DOI 10.1016/0005-2736(93)90133-K; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P391; SKERJANC IS, 1993, J BIOL CHEM, V268, P15944; SMOLKA A, 1991, BIOCHEM BIOPH RES CO, V180, P1356, DOI 10.1016/S0006-291X(05)81345-2; SWARTS HGP, 1995, J BIOL CHEM, V270, P7890, DOI 10.1074/jbc.270.14.7890; SWARTS HGP, 1991, BIOCHIM BIOPHYS ACTA, V1070, P283, DOI 10.1016/0005-2736(91)90068-J; SWEADNER KJ, 1992, ANN NY ACAD SCI, V671, P217, DOI 10.1111/j.1749-6632.1992.tb43798.x; VANDERHIJDEN HTWM, 1991, BIOCHIM BIOPHYS ACTA, V1061, P141, DOI 10.1016/0005-2736(91)90278-G; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; VANHUYSSE JW, 1993, BIOCHEMISTRY-US, V32, P819, DOI 10.1021/bi00054a012; VANHUYSSE JW, 1993, CELL MOL BIOL RES, V39, P497; VANUEM TJF, 1991, BIOCHEM J, V280, P243, DOI 10.1042/bj2800243; VANUEM TJF, 1990, BIOCHIM BIOPHYS ACTA, V1023, P56, DOI 10.1016/0005-2736(90)90009-D; VANUEM TJF, 1992, MOL ASPECTS TRANSPOR, P27; VERMA AK, 1988, J BIOL CHEM, V263, P14152; VILSEN B, 1992, J BIOL CHEM, V267, P25739; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; VILSEN B, 1993, FEBS LETT, V333, P44, DOI 10.1016/0014-5793(93)80372-2; VLAK JM, 1990, VIROLOGY, V179, P312, DOI 10.1016/0042-6822(90)90299-7	60	74	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29764	29772		10.1074/jbc.271.47.29764	http://dx.doi.org/10.1074/jbc.271.47.29764			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939913	Green Published, hybrid			2022-12-27	WOS:A1996VU52500041
J	Zanke, BW; Rubie, EA; Winnett, E; Chan, J; Randall, S; Parsons, M; Boudreau, K; McInnis, M; Yan, MH; Templeton, DJ; Woodgett, JR				Zanke, BW; Rubie, EA; Winnett, E; Chan, J; Randall, S; Parsons, M; Boudreau, K; McInnis, M; Yan, MH; Templeton, DJ; Woodgett, JR			Mammalian mitogen-activated protein kinase pathways are regulated through formation of specific kinase-activator complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; HEAT-SHOCK PROTEINS; C-JUN; MAPKAP KINASE-2; PHOSPHORYLATION; STRESS; CASCADE; YEAST; CELLS; DOMAIN	Mammalian cells contain at least three signaling systems which are structurally related to the mitogen-activated protein kinase (MAPK) pathway, Growth factors acting through Ras primarily stimulate the Raf/MEK/MAPK cascade of protein kinases, In contrast, many stress-related signals such as heat shock, inflammatory cytokines, and hyperosmolarity induce the MEKK/SEK(MKK4)/SAPK(JNK) and/or the MKK3 or MKK6/p38(hog) pathways. Physiological agonists of these pathway types are either qualitatively or quantitatively distinct, suggesting few common proximal signaling elements, although past studies performed in vitro, or in cells using transient over-expression, reveal interaction between the components of all three pathways, These studies suggest a high degree of cross-talk apparently not seen in vivo. We have examined the possible molecular basis of the differing agonist profiles of these three MAPK pathways, We report preferential association between MAP kinases and their activators in eukaryotic cells. Furthermore, using the yeast 8-hybrid system, we show that association between these components can occur independent of additional eukaryotic proteins, We show that SAPK(JNK) or p38(hog) activation is specifically impaired by co-expression of cognate dominant negative MAP kinase kinase mutants, demonstrating functional specificity at this level. Further divergence and insulation of the stress pathways occurs proximal to the MAPK kinases since activation of the MAPK kinase kinase MEKK results in SAPK(JNK) activation but does not cause p38(hog) phosphorylation, Therefore, in intact cells, the three MAPK pathways may be independently regulated and their components show specificity in their interaction with cognate cascade members, The degree of intermolecular specificity suggests that mammalian MAPK signaling pathways may remain distinct without the need for specific scaffolding proteins to sequester components of individual pathways.	PRINCESS MARGARET HOSP,ONTARIO CANC INST,TORONTO,ON M5G 2M9,CANADA; CASE WESTERN RESERVE UNIV,INST PATHOL,CLEVELAND,OH 44106	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Case Western Reserve University	Zanke, BW (corresponding author), PRINCESS MARGARET HOSP,DEPT MED,610 UNIV AVE,TORONTO,ON M5G 2M9,CANADA.		McInnes, Matthew/D-4532-2013; Templeton, Dennis J/F-7695-2011; Woodgett, Jim/F-1087-2010	McInnes, Matthew/0000-0001-8404-4075; Woodgett, Jim/0000-0003-3731-5797				BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CHOI KY, 1994, CELL, V78, P499; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HAHN GM, 1988, CANCER RES, V48, P1803; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LASZLO A, 1993, INT J RADIAT BIOL, V63, P569, DOI 10.1080/09553009314450751; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LIN A, 1993, ADV SEC MESS PHOSPH, V28, P255; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; POMBO CM, 1994, J BIOL CHEM, V269, P26546; PRINTEN JA, 1994, GENETICS, V138, P609; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; XIA A, 1996, SCIENCE, V270, P1326; YAN MH, 1994, NATURE, V372, P798; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	36	102	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29876	29881		10.1074/jbc.271.47.29876	http://dx.doi.org/10.1074/jbc.271.47.29876			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939929	hybrid			2022-12-27	WOS:A1996VU52500057
J	Agou, F; Waller, JP; Mirande, M				Agou, F; Waller, JP; Mirande, M			Expression of rat aspartyl-tRNA synthetase in Saccharomyces cerevisiae - Role of the NH2-terminal polypeptide extension on enzyme activity and stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; AMINOACYL-TRANSFER-RNA; ASPARAGINYL-TRANSFER RNA; ARGINYL-TRANSFER RNA; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; THERMUS-THERMOPHILUS; SHEEP LIVER; AMPHIPHILIC HELIX; DELETION ANALYSIS	Cytoplasmic aspartyl-tRNA synthetase from mammals is one of the components of a multienzyme complex comprising nine synthetase activities. The presence of an amino-terminal extension composed of about 40 residues is a characteristic of the eukaryotic enzyme. We report here the expression in the yeast Saccharomyces cerevisiae of a native form of rat aspartyl-tRNA synthetase and of two truncated derivatives lacking 20 or 36 amino acid residues from their amino-terminal polypeptide extension. The three recombinant enzyme species were purified to homogeneity. They behave as alpha(2) dimers and display catalytic parameters in the tRNA aminoacylation reaction identical to those determined for the native, complex-associated form of aspartyl-tRNA synthetase isolated from rat liver. Because the dimer dissociation constant of rat AspRS is much higher than that of its bacterial and yeast counterparts, we could establish a direct correlation between dissociation of the dimer and inactivation of the enzyme. Our results clearly show that the monomer is devoid of amino acid activation and tRNA aminoacylation activities, indicating that dimerization is essential to confer an active conformation on the catalytic site. The two NH2-terminal truncated derivatives were fully active, but proved to be more unstable than the recombinant native enzyme, suggesting that the polypeptide extension fulfills structural rather than catalytic requirements.	CNRS, ENZYMOL & BIOCHIM STRUCT LAB, GIF SUR YVETTE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			, AGOU/GXA-2760-2022					ARNEZ JG, 1995, EMBO J, V14, P4143, DOI 10.1002/j.1460-2075.1995.tb00088.x; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BEC G, 1994, J BIOL CHEM, V269, P2086; BELRHALI H, 1994, SCIENCE, V263, P1432, DOI 10.1126/science.8128224; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; CAVARELLI J, 1993, FASEB J, V7, P79, DOI 10.1096/fasebj.7.1.8422978; CAVARELLI J, 1994, EMBO J, V13, P327, DOI 10.1002/j.1460-2075.1994.tb06265.x; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; CIRAKOGLU B, 1985, BIOCHIM BIOPHYS ACTA, V829, P173, DOI 10.1016/0167-4838(85)90186-4; CIRAKOGLU B, 1985, EUR J BIOCHEM, V151, P101, DOI 10.1111/j.1432-1033.1985.tb09074.x; COMMANS S, 1995, BIOCHEMISTRY-US, V34, P8180, DOI 10.1021/bi00025a025; DAVIS MW, 1994, BIOCHEMISTRY-US, V33, P9904, DOI 10.1021/bi00199a012; DELARUE M, 1994, EMBO J, V13, P3219, DOI 10.1002/j.1460-2075.1994.tb06623.x; ERIANI G, 1990, NUCLEIC ACIDS RES, V18, P7109, DOI 10.1093/nar/18.23.7109; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; ERIANI G, 1991, EUR J BIOCHEM, V200, P337, DOI 10.1111/j.1432-1033.1991.tb16190.x; ERIANI G, 1993, P NATL ACAD SCI USA, V90, P10816, DOI 10.1073/pnas.90.22.10816; ESCALANTE C, 1993, J BIOL CHEM, V268, P6014; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACOBOMOLINA A, 1989, J BIOL CHEM, V264, P16608; KELLERMANN O, 1979, EUR J BIOCHEM, V99, P541, DOI 10.1111/j.1432-1033.1979.tb13286.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LAZARD M, 1985, BIOCHEMISTRY-US, V24, P5099, DOI 10.1021/bi00340a021; LEE ML, 1969, J BIOL CHEM, V244, P223; LOGAN DT, 1995, EMBO J, V14, P4156, DOI 10.1002/j.1460-2075.1995.tb00089.x; LU Y, 1994, J BIOL CHEM, V269, P12137; LUDMERER SW, 1993, J BIOL CHEM, V268, P5519; MADERN D, 1992, FEBS LETT, V299, P85, DOI 10.1016/0014-5793(92)80106-Q; MARTINEZ R, 1992, EUR J BIOCHEM, V207, P1, DOI 10.1111/j.1432-1033.1992.tb17012.x; MIRANDE M, 1992, EUR J BIOCHEM, V203, P459, DOI 10.1111/j.1432-1033.1992.tb16570.x; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; MIRANDE M, 1989, J BIOL CHEM, V264, P842; MOSYAK L, 1995, NAT STRUCT BIOL, V2, P537, DOI 10.1038/nsb0795-537; ONESTI S, 1995, STRUCTURE, V3, P163, DOI 10.1016/S0969-2126(01)00147-2; REED VS, 1994, J BIOL CHEM, V269, P32937; RIPMASTER TL, 1995, P NATL ACAD SCI USA, V92, P4932, DOI 10.1073/pnas.92.11.4932; ROMANOS MA, 1992, YEAST, V8, P423, DOI 10.1002/yea.320080602; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANNI A, 1991, P NATL ACAD SCI USA, V88, P8387, DOI 10.1073/pnas.88.19.8387; SCHIMMEL PR, 1979, ANNU REV BIOCHEM, V48, P601, DOI 10.1146/annurev.bi.48.070179.003125; URBAN P, 1990, BIOCHIMIE, V72, P463, DOI 10.1016/0300-9084(90)90070-W; VELLEKAMP G, 1985, J BIOL CHEM, V260, P9843; WALTER P, 1989, J BIOL CHEM, V264, P17126	47	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29295	29303		10.1074/jbc.271.46.29295	http://dx.doi.org/10.1074/jbc.271.46.29295			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910590	Green Published, hybrid			2022-12-27	WOS:A1996VT05200082
J	Rizzo, C; Califano, D; ColucciDAmato, GL; DeVita, G; DAlessio, A; Dathan, NA; Fusco, A; Monaco, C; Santelli, G; Vecchio, G; Santoro, M; deFranciscis, V				Rizzo, C; Califano, D; ColucciDAmato, GL; DeVita, G; DAlessio, A; Dathan, NA; Fusco, A; Monaco, C; Santelli, G; Vecchio, G; Santoro, M; deFranciscis, V			Ligand stimulation of a Ret chimeric receptor carrying the activating mutation responsible for the multiple endocrine neoplasia type 2B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; TYROSINE KINASE; PC12 CELLS; PROTOONCOGENE; GENE; SPECIFICITY; SEQUENCE; CLONING; LINE; 2A	Inherited activating mutations of Ret, a receptor tyrosine kinase, predispose to multiple endocrine neoplasia (MEN) types 2A and 2B and familial medullary thyroid carcinoma. To investigate the effects induced by acute stimulation of Ret, we transfected both PC12 and NIH 3T3 cells with a molecular construct in which the ligand-binding domain of the epidermal growth factor receptor was fused to the catalytic domain of Ret. Acute stimulation of the chimeric receptor induced PC12 cells to express a neuronal-like phenotype. Moreover, we introduced the dominant mutation, responsible for the multiple endocrine neoplasia type 2B, in the catalytic domain of the Ret chimera. Expression of the mutant chimera, in the absence of ligand stimulation, induces the PC12 cells to acquire a flat morphology with short neuritic processes and transforms the NIH 3T3 cells. Stimulation of the mutant chimera with epidermal growth factor causes a drastic overgrowth of long neuritic processes, with the induction of the suc1-associated protein tyrosine phosphorylation in PC12 cells and higher transforming efficiency in NIH 3T3 cells. These data indicate that the gain-of-function MEN2B mutation does not abrogate ligand responsiveness of Ret and suggest that the presence of Ret ligand could play a role in the pathogenesis of the MEN2B syndrome.	UNIV NAPLES FEDERICO II,CNR,CTR ENDOCRINOL & ONCOL SPERIMENTALE,FAC MED & CHIRURG,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY; FDN G PASCALE,IST NAZL TUMORI,I-80131 NAPLES,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Universita Mediterranea di Reggio Calabria; IRCCS Fondazione Pascale			Califano, Daniela/Y-6313-2018; De Vita, Gabriella/H-4422-2011	Califano, Daniela/0000-0001-6945-3209; De Vita, Gabriella/0000-0002-7302-1174; Fusco, Alfredo/0000-0003-3332-5197				ASAI N, 1995, MOL CELL BIOL, V15, P1613; Borrello MG, 1995, ONCOGENE, V11, P2419; CALIFANO D, 1995, ONCOGENE, V11, P107; Califano D, 1996, P NATL ACAD SCI USA, V93, P7933, DOI 10.1073/pnas.93.15.7933; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; GOODFELLOW PJ, 1994, CURR OPIN GENET DEV, V4, P446, DOI 10.1016/0959-437X(94)90034-5; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; LEVI A, 1991, ANNU REV PHARMACOL, V31, P205; LEVI A, 1985, SCIENCE, V229, P393, DOI 10.1126/science.3839317; Mak YF, 1996, CURR OPIN GENET DEV, V6, P82, DOI 10.1016/S0959-437X(96)90015-5; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; POSSENTI R, 1992, P NATL ACAD SCI USA, V89, P3815, DOI 10.1073/pnas.89.9.3815; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; vanWeering DHJ, 1995, ONCOGENE, V11, P2207	29	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29497	29501		10.1074/jbc.271.46.29497	http://dx.doi.org/10.1074/jbc.271.46.29497			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910618	hybrid			2022-12-27	WOS:A1996VT05200110
J	Dillon, DA; Wu, WI; Riedel, B; Wissing, JB; Dowhan, W; Carman, GM				Dillon, DA; Wu, WI; Riedel, B; Wissing, JB; Dowhan, W; Carman, GM			The Escherichia coli pgpB gene encodes for a diacylglycerol pyrophosphate phosphatase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-MIXED MICELLES; MEMBRANE-BOUND PHOSPHATASES; RAT-LIVER; PHOSPHATIDYLINOSITOL SYNTHASE; SUBCELLULAR-LOCALIZATION; SACCHAROMYCES-CEREVISIAE; ACID; PURIFICATION; YEAST; PHOSPHOHYDROLASE	We provided genetic and biochemical evidence that supported the conclusion that the product of pgpB gene of Escherichia coli exhibited diacylglycerol pyrophosphate (DGPP) phosphatase activity. DGPP phosphatase activity was absent in pgpB mutant cells and was expressed at high levels in cells carrying the wild-type pgpB gene on a runaway replication plasmid. The pgpB mutant has been primarily characterized by a defect in phosphatidate (PA) phosphatase activity and also exhibits defects in lyse-PA phosphatase and phosphatidylglycerophosphate phosphatase activities. The defective PA phosphatase in the pgpB mutant was shown to be a Mg2+-independent PA phosphatase activity of the DGPP phosphatase enzyme. We characterized DG:PP phosphatase activity in membranes from cells overproducing the pgpB gene product. DGPP phosphatase catalyzed the dephosphorylation of the beta phosphate of DGPP to form PA followed by the dephosphorylation of PA to form diacylglycerol. The specificity constant (V-max/K-m) for DG:PP was 9.3-fold greater than that for PA. The pH optimum for the DGPP phosphatase reaction was 6.5. Activity was independent of a divalent cation requirement, was potently inhibited by Mn2+ ions, and was insensitive to inhibition by N-ethylmaleimide. Pure DGPP phosphatase from Saccharomyces cerevisiae was shown to be similar to the E. coli DGPP phosphatase in its ability to utilize lyso-PA and phosphatidylglycerophosphate as substrates in vitro.	RUTGERS STATE UNIV, COOK COLL, NEW JERSEY AGR EXPT STN, DEPT FOOD SCI, NEW BRUNSWICK, NJ 08903 USA; GESELL BIOTECHNOL FORSCH MBH, ENZYMOL, D-38124 BRAUNSCHWEIG, GERMANY; UNIV TEXAS, SCH MED, DEPT BIOCHEM & MOL BIOL, HOUSTON, TX 77225 USA	Rutgers State University New Brunswick; Gesellschaft fur Biotechnologische Forschung mbH; University of Texas System					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028140, R37GM028140] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-20487, GM-28140] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAELEE M, 1990, J BIOL CHEM, V265, P7221; BHAT BG, 1994, J BIOL CHEM, V269, P13172; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARMAN GM, 1991, METHOD ENZYMOL, V197, P548; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; CARMAN GM, 1992, METHOD ENZYMOL, V209, P305; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; EXTON JH, 1990, J BIOL CHEM, V265, P1; FLEMING IN, 1995, BIOCHEM J, V308, P983, DOI 10.1042/bj3080983; FUNK CR, 1992, J BACTERIOL, V174, P205, DOI 10.1128/jb.174.1.205-213.1992; GARMAN GM, 1995, J BIOL CHEM, V270, P18711; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; ICHO T, 1983, J BACTERIOL, V153, P722, DOI 10.1128/JB.153.2.722-730.1983; ICHO T, 1988, J BACTERIOL, V170, P5117, DOI 10.1128/jb.170.11.5117-5124.1988; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; JONES GA, 1993, J BIOL CHEM, V268, P20845; KANOH H, 1992, J BIOL CHEM, V267, P25309; Kennedy E. P., 1986, LIPIDS MEMBRANES PRE, P171; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LIN YP, 1989, J BIOL CHEM, V264, P8641; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MORITZ A, 1992, J BIOL CHEM, V267, P7207; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; Munnik T, 1995, PLANT CELL, V7, P2197, DOI 10.1105/tpc.7.12.2197; Munnik T, 1996, J BIOL CHEM, V271, P15708, DOI 10.1074/jbc.271.26.15708; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; QUARMBY LM, 1992, J CELL BIOL, V116, P737, DOI 10.1083/jcb.116.3.737; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; VANDENBOSCH H, 1970, BIOCHIM BIOPHYS ACTA, V218, P233, DOI 10.1016/0005-2760(70)90142-6; Waggoner DW, 1996, J BIOL CHEM, V271, P16506, DOI 10.1074/jbc.271.28.16506; WAGGONER DW, 1995, J BIOL CHEM, V270, P19422, DOI 10.1074/jbc.270.33.19422; WALSH JP, 1986, J BIOL CHEM, V261, P6239; WISSING JB, 1993, PLANT PHYSIOL, V102, P1243, DOI 10.1104/pp.102.4.1243; WISSING JB, 1993, FEBS LETT, V315, P95, DOI 10.1016/0014-5793(93)81141-L; Wu WI, 1996, J BIOL CHEM, V271, P1868, DOI 10.1074/jbc.271.4.1868; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	39	81	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30548	30553		10.1074/jbc.271.48.30548	http://dx.doi.org/10.1074/jbc.271.48.30548			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940025	hybrid			2022-12-27	WOS:A1996VV15800042
J	Goetz, J; Chatton, B; Mattei, MG; Kedinger, C				Goetz, J; Chatton, B; Mattei, MG; Kedinger, C			Structure and expression of the ATFa gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GENE; AMP RESPONSE ELEMENT; NUCLEAR TARGETING SEQUENCE; HUMAN ESTROGEN-RECEPTOR; IN-SITU HYBRIDIZATION; BINDING PROTEIN; LEUCINE ZIPPER; SIGNAL-TRANSDUCTION; MYXOID LIPOSARCOMA; REGULATOR BINDING	The human ATFa proteins belong to the ATF/CREB family of transcription factors, We have previously shown that they mediate the transcriptional activation by the largest Ela protein and can heterodimerize with members of the Jun/Fos family, ATFa proteins have also been found tightly associated with JNK2, a stress-activated kinase. We now report on the structure of the ATFa gene, which mapped to chromosome 12 (band 12q13). Sequence analysis revealed that ATFa isoforms are generated by alternative splice donor site usage, A minimal promoter region of similar to 200 base pairs was identified that retained nearly full transcriptional activity, Binding sites for potential transcription factors were delineated within a GC-rich segment by DNase I foot printing. Expression studies revealed that ATFa accumulates in the nuclei of transfected cells, and the nuclear localization signal was defined next to the leucine zipper domain. As revealed by hybridization with mouse ATFa sequences, low levels of ATFa mRNAs were ubiquitously distributed in fetal or adult mice, with enhanced expression in particular tissues, like squamous epithelia and specific brain cell layers. The possible significance of coexpression of ATFa, ATF-2, and Jun at similar sites in the brain is discussed.	UNIV STRASBOURG 1,IGBMC,CNRS,INSERM,F-67404 ILLKIRCH GRAFFENS,FRANCE; FAC MED MARSEILLE,INSERM U406,F-13385 MARSEILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite			CHATTON, Bruno/R-3813-2019	CHATTON, Bruno/0000-0003-4515-7119				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; AUSUBUEL FM, 1987, CURRENT PROTOCOLS MO; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BENBROOK DM, 1990, ONCOGENE, V5, P295; Bocco JL, 1996, ONCOGENE, V12, P1971; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; BUREAU JF, 1995, GENOMICS, V28, P109, DOI 10.1006/geno.1995.1114; CANNIZZARO LA, 1987, AM J HUM GENET, V41, P1; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHATTON B, 1994, ONCOGENE, V9, P375; CHATTON B, 1995, BIOTECHNIQUES, V18, P142; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DAI TN, 1995, ONCOGENE, V10, P849; DECIMO D, 1995, GENE PROBES PRACTICA, V2, P183; DEMETRICK DJ, 1994, CYTOGENET CELL GENET, V66, P72, DOI 10.1159/000133669; DESMAZE C, 1994, HUM GENET, V93, P207; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HABER N, 1994, HUM GENET, V94, P69, DOI 10.1007/BF02272844; HAGMEYER BM, 1995, BIOESSAYS, V17, P621, DOI 10.1002/bies.950170708; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KAZMIERCZAK B, 1995, CANCER RES, V55, P2497; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MAEKAWA T, 1991, ONCOGENE, V6, P627; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; MATERA AG, 1993, GENOMICS, V17, P793, DOI 10.1006/geno.1993.1413; MATTEI MG, 1985, HUM GENET, V69, P327, DOI 10.1007/BF00291650; MATTEI MG, 1991, GENOMICS, V10, P1061, DOI 10.1016/0888-7543(91)90199-O; MELLSTROM B, 1991, ONCOGENE, V6, P1959; MENDELSOHN C, 1994, DEV BIOL, V166, P246, DOI 10.1006/dbio.1994.1311; MIKAELIAN I, 1993, J VIROL, V67, P734; NAGASE T, 1990, J BIOL CHEM, V265, P17300; PANAGOPOULOS I, 1995, ONCOGENE, V11, P1133; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; PESCINI R, 1994, J BIOL CHEM, V269, P1159; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; ROUSSEAUMERCK MF, 1990, CYTOGENET CELL GENET, V53, P2, DOI 10.1159/000132883; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SZPIRER J, 1991, GENOMICS, V11, P168, DOI 10.1016/0888-7543(91)90114-T; TAKEDA J, 1991, ONCOGENE, V6, P1009; TRATNER I, 1991, ONCOGENE, V6, P2049; VANDAM H, 1995, EMBO J, V14, P1785; WEBSTER NJG, 1989, EMBO J, V8, P1441, DOI 10.1002/j.1460-2075.1989.tb03526.x; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x; ZU YL, 1991, J BIOL CHEM, V266, P24134; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	68	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29589	29598		10.1074/jbc.271.47.29589	http://dx.doi.org/10.1074/jbc.271.47.29589			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939888	hybrid			2022-12-27	WOS:A1996VU52500016
J	Katoh, H; Negishi, M; Ichikawa, A				Katoh, H; Negishi, M; Ichikawa, A			Prostaglandin E receptor EP3 subtype induces neurite retraction via small GTPase Rho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-RHO; EP(3) SUBTYPE; ADP-RIBOSYLTRANSFERASE; NORADRENALINE RELEASE; PROSTANOID RECEPTORS; NERVOUS-SYSTEM; MESSENGER-RNA; RAT-BRAIN; EXPRESSION; CLONING	Prostaglandin E receptor EP3 subtype is widely distributed in the nervous system and is specifically localized to neurons, suggesting that the EP3 receptor plays important roles in the nervous system. We established a PC12 cell line that stably expresses the EP3B receptor isoform isolated from bovine adrenal chromaffin cells and examined the effect of agonist stimulation on the neuronal morphology of the PC12 cells, In the differentiated cells, M&B28767, an EP3 agonist, caused neurite retraction in a pertussis toxin-insensitive manner, 12-O-Tetradecanoylphorbol-13-acetate (TPA) also induced neurite retraction. However, when protein kinase C was down-regulated by long term exposure to TPA, TPA failed to induce neurite retraction, while the EP3B receptor-mediated retraction occurred normally, Clostridium botulinum C3 exoenzyme completely inhibited both EP3 agonist- and TPA-induced neurite retraction when microinjected into the cells, indicating that the morphological effect of the EP3B receptor is dependent on Rho activity, Thus, the activation of the EP3B receptor induced neurite retraction through a protein kinase C-independent Rho-activation pathway.	KYOTO UNIV, FAC PHARMACEUT SCI, DEPT PHYSIOL CHEM, SAKYO KU, KYOTO 606, JAPAN	Kyoto University								AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; COLEMAN RA, 1994, PROSTAGLANDINS, V47, P151, DOI 10.1016/0090-6980(94)90084-1; Coleman RA, 1990, COMPREHENSIVE MED CH, P643; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; DYER D, 1992, MOL BRAIN RES, V14, P293, DOI 10.1016/0169-328X(92)90096-T; ELLIS E F, 1989, Journal of Neurotrauma, V6, P31, DOI 10.1089/neu.1989.6.31; EXNER HJ, 1995, N-S ARCH PHARMACOL, V351, P46; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FERREIRA SH, 1972, NATURE-NEW BIOL, V240, P200, DOI 10.1038/newbio240200a0; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HERTTING G, 1989, ANN NY ACAD SCI, V559, P84; Holscher C, 1995, EUR J PHARMACOL, V294, P253, DOI 10.1016/0014-2999(95)00541-2; HONDA A, 1993, J BIOL CHEM, V268, P7759; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; KATSUYAMA M, 1995, FEBS LETT, V372, P151, DOI 10.1016/0014-5793(95)00966-D; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; KUMAZAWA T, 1993, BRAIN RES, V632, P321, DOI 10.1016/0006-8993(93)91169-S; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; MATTHIES HJG, 1987, J NEUROSCI, V7, P1198; MENT LR, 1987, J NEUROSURG, V67, P278, DOI 10.3171/jns.1987.67.2.0278; MILTON AS, 1970, J PHYSIOL-LONDON, V207, pP76; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NEGISHI M, 1995, BBA-LIPID LIPID MET, V1259, P109, DOI 10.1016/0005-2760(95)00146-4; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; OIDA H, 1995, BRIT J PHARMACOL, V116, P2828, DOI 10.1111/j.1476-5381.1995.tb15933.x; OJEDA SR, 1982, ENDOCRINOLOGY, V111, P1031, DOI 10.1210/endo-111-4-1031; REIMANN W, 1981, EUR J PHARMACOL, V69, P421, DOI 10.1016/0014-2999(81)90445-3; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBERTS PJ, 1976, BRAIN RES, V112, P425, DOI 10.1016/0006-8993(76)90299-7; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; STITT JT, 1986, YALE J BIOL MED, V59, P137; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; SUGIMOTO Y, 1994, NEUROSCIENCE, V62, P919, DOI 10.1016/0306-4522(94)90483-9; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1995, ONCOGENE, V11, P39; Tigyi G, 1996, J NEUROCHEM, V66, P549; Tigyi G, 1996, J NEUROCHEM, V66, P537; WATABE A, 1993, J BIOL CHEM, V268, P20175; WOLFE LS, 1982, J NEUROCHEM, V38, P1, DOI 10.1111/j.1471-4159.1982.tb10847.x; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T	43	63	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29780	29784		10.1074/jbc.271.47.29780	http://dx.doi.org/10.1074/jbc.271.47.29780			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939915	hybrid			2022-12-27	WOS:A1996VU52500043
J	Lustigman, S; McKerrow, JH; Shah, K; Lui, J; Huima, T; Hough, M; Brotman, B				Lustigman, S; McKerrow, JH; Shah, K; Lui, J; Huima, T; Hough, M; Brotman, B			Cloning of a cysteine protease required for the molting of Onchocerca volvulus third stage larvae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4TH-STAGE LARVAE; CATHEPSIN-B; CAENORHABDITIS-ELEGANS; DIROFILARIA-IMMITIS; PROTOZOAN PARASITES; SPLICED LEADER; SEQUENCE; 3RD-STAGE; ECDYSIS; IDENTIFICATION	We have investigated the involvement of a cysteine protease in the development of Onchocerca volvulus fourth stage larvae (L4) by testing the effect of cysteine protease inhibitors on the survival of third stage larvae (L3), and the molting of L3 to L4 in vitro. When larvae were cultured in the presence of specific inhibitors, the peptidyl monofluoromethylketones, viability of either L3 or L4 was not affected, However, the inhibitors reduced the number of L3 that molted to L4 in vitro in a time- and dose-dependent manner, Molting was completely inhibited in the presence of 50-250 mu M inhibitor, Ultrastructural examination of L3 that did not molt in the presence of inhibitors indicated that new L4 cuticle was synthesized, but there was no separation between the L3 and the L4 cuticles, The endogenous cysteine protease was detected in molting larvae after binding to labeled inhibitors, and by antibodies directed against a recombinant O. volvulus L3 cysteine protease that was cloned and expressed. The enzyme was detected in cuticle regions where the separation between the cuticles occurs in molting larvae, These studies suggest that molting and successful development of L4 depends on the expression and release of a cysteine protease.	UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94121 USA; DEPT VET AFFAIRS MED CTR, SAN FRANCISCO, CA 94121 USA; LIBERIAN INST BIOMED RES, VILAB 2, ROBERTSFIELD, LIBERIA	University of California System; University of California San Francisco	Lustigman, S (corresponding author), NEW YORK BLOOD CTR, LINDSLEY F KIMBALL RES INST, LAB VIROL & PARASITOL, 310 E 67TH ST, NEW YORK, NY 10021 USA.							BARKER GC, 1990, PARASITOL TODAY, V6, P384, DOI 10.1016/0169-4758(90)90147-V; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; BEKTESH SL, 1988, NUCLEIC ACIDS RES, V16, P5692, DOI 10.1093/nar/16.12.5692; BIRD AL, 1991, STRUCTURE NEMATODES, P81; CHUNG YB, 1995, J PARASITOL, V81, P137, DOI 10.2307/3283911; COMLEY JCW, 1989, TROP MED PARASITOL, V40, P311; COX GN, 1981, DEV BIOL, V86, P456, DOI 10.1016/0012-1606(81)90204-9; CULLEN BM, 1992, BIOCHEM J, V283, P461, DOI 10.1042/bj2830461; DAVEY KG, 1968, CAN J ZOOLOG, V46, P893, DOI 10.1139/z68-125; DUFOUR E, 1988, BIOCHIMIE, V70, P1335, DOI 10.1016/0300-9084(88)90004-1; EAKIN AE, 1990, MOL BIOCHEM PARASIT, V39, P1, DOI 10.1016/0166-6851(90)90002-4; EAKIN AE, 1992, J BIOL CHEM, V267, P7411; FRANK GR, 1991, J PARASITOL, V77, P950, DOI 10.2307/3282748; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAMBLE HR, 1989, J PARASITOL, V75, P303, DOI 10.2307/3282779; GAMBLE HR, 1989, MOL BIOCHEM PARASIT, V33, P49, DOI 10.1016/0166-6851(89)90041-8; HONG XQ, 1993, EXP PARASITOL, V76, P127, DOI 10.1006/expr.1993.1015; HOTEZ P, 1990, INFECT IMMUN, V58, P3883, DOI 10.1128/IAI.58.12.3883-3892.1990; IRVINE M, 1994, MOL BIOCHEM PARASIT, V65, P35; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAPAGE G., 1935, Parasitology, V27, P186, DOI 10.1017/S0031182000015079; LUSTIGMAN S, 1990, EXP PARASITOL, V71, P489, DOI 10.1016/0014-4894(90)90075-N; LUSTIGMAN S, 1995, ANTIMICROB AGENTS CH, V39, P1913, DOI 10.1128/AAC.39.9.1913; LUSTIGMAN S, 1993, PARASITOL TODAY, V9, P294, DOI 10.1016/0169-4758(93)90128-3; LUSTIGMAN S, 1992, J BIOL CHEM, V267, P17339; MASON RW, 1989, BIOCHEM J, V257, P125, DOI 10.1042/bj2570125; McKerrow J. H., 1994, PERSPECT DRUG DISCOV, V2, P437; MILLER KM, 1990, TROP MED PARASITOL, V41, P221; RASNICK D, 1985, ANAL BIOCHEM, V149, P461, DOI 10.1016/0003-2697(85)90598-6; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P461; RICHER JK, 1992, EXP PARASITOL, V75, P213, DOI 10.1016/0014-4894(92)90181-9; SAKANARI JA, 1989, P NATL ACAD SCI USA, V86, P4863, DOI 10.1073/pnas.86.13.4863; Sambrook J., 2002, MOL CLONING LAB MANU; SAMUALS RI, 1995, COMP BIOCH PHYSL B, V110, P66661; SMITH SM, 1989, J BIOL CHEM, V264, P20487; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WHO Expert Committee on Onchocerciasis, 1987, WHO TECH REP SER, V752, P1; ZENG WL, 1990, MOL CELL BIOL, V10, P2765, DOI 10.1128/MCB.10.6.2765	38	92	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30181	30189		10.1074/jbc.271.47.30181	http://dx.doi.org/10.1074/jbc.271.47.30181			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939969	hybrid			2022-12-27	WOS:A1996VU52500097
J	Ahmed, SA; McPhie, P; Miles, EW				Ahmed, SA; McPhie, P; Miles, EW			Mechanism of activation of the tryptophan synthase alpha(2)beta(2) complex - Solvent effects of the co-substrate beta-mercaptoethanol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ULTRAVIOLET VISIBLE SPECTROSCOPY; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; BIENZYME COMPLEX; L-SERINE; ASPARTATE-AMINOTRANSFERASE; 3-DIMENSIONAL STRUCTURE; ALLOSTERIC INTERACTIONS; 10-18-PPM RANGE; H-1 RESONANCES	To characterize the conformational transitions that lead to activation of catalysis by the tryptophan synthase alpha(2) beta(2), complex, we have determined the solvent effects of a co-substrate, beta-mercaptoethanol, and of a model nonsubstrate, ethanol, on the catalytic and spectroscopic properties of the enzyme. Our results show that ethanol and beta-mercaptoethanol both alter the equilibrium distribution of pyridoxal 5'-phosphate intermediates formed in the reactions of L-serine at the beta site in the alpha(2) beta(2) complex. Addition of increasing concentrations of ethanol increases the proportion of the external aldimine of L-serine and decreases the proportion of the external aldimine of aminoacrylate. Low concentrations of the co-substrate beta-mercaptoethanol (K-d = similar to 13 mM) decrease the proportion of the external aldimine of aminoacrylate and induce formation of the quinonoid of S-hydroxyethyl-L-cysteine. Higher concentrations of beta-mercaptoethanol decrease the concentration of the quinonoid intermediate and increase the proportion of the external aldimine of L-serine. Data analysis shows that beta-mercaptoethanol and ethanol both interact or bind preferentially with the conformer of the enzyme that predominates when the aldimine of L-serine is formed and shift the equilibrium in favor of this conformer. We propose that a nonpolar region of the beta subunit, possibly the hydrophobic indole tunnel, becomes less exposed to solvent in the conformational transition that activates the alpha(2) beta(2) complex.	NIDDK, BIOCHEM PHARMACOL LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								AHMED SA, 1991, J BIOL CHEM, V266, P21548; AHMED SA, 1994, J BIOL CHEM, V269, P16486; ANDERSON KS, 1995, J BIOL CHEM, V270, P29936; ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; ARAKAWA T, 1990, CRYOBIOLOGY, V27, P401, DOI 10.1016/0011-2240(90)90017-X; AVDULOV NA, 1996, BICOHEMISTRY, V35, P840; BANIK U, 1995, BIOCHEMISTRY-US, V34, P12704, DOI 10.1021/bi00039a029; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P3831, DOI 10.1021/bi00130a014; Butler JAV, 1933, J CHEM SOC, P674, DOI 10.1039/jr9330000674; COOK PF, 1976, J BIOL CHEM, V251, P2023; DREWE WF, 1986, BIOCHEMISTRY-US, V25, P2494, DOI 10.1021/bi00357a032; DREWE WF, 1985, BIOCHEMISTRY-US, V24, P3977, DOI 10.1021/bi00336a027; DUNN MF, 1987, INDIAN J BIOCHEM BIO, V24, P44; DUNN MF, 1994, ADV LIF SCI-SERIES, P119; EINHOFF W, 1987, BIOL CHEM H-S, V368, P405, DOI 10.1515/bchm3.1987.368.1.405; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; GOLDBERG ME, 1968, BIOCHEMISTRY-US, V7, P3662, DOI 10.1021/bi00850a045; HOUBEN KF, 1990, BIOCHEMISTRY-US, V29, P2421, DOI 10.1021/bi00461a028; Hur O, 1996, BIOCHEMISTRY-US, V35, P7378, DOI 10.1021/bi960240k; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JACOBSON RH, 1992, PROTEIN SCI, V1, P46; KALLEN RG, 1985, TRANSAMINASES, P37; KAWASAKI H, 1987, J BIOL CHEM, V262, P10678; KIRLEY TL, 1990, J BIOL CHEM, V265, P4227; LANE AN, 1981, EUR J BIOCHEM, V120, P379, DOI 10.1111/j.1432-1033.1981.tb05715.x; LANE AN, 1983, EUR J BIOCHEM, V129, P561; LANE AN, 1983, EUR J BIOCHEM, V129, P571; LEJA CA, 1995, BIOCHEMISTRY-US, V34, P6552, DOI 10.1021/bi00019a037; METZLER CM, 1980, J AM CHEM SOC, V102, P6075, DOI 10.1021/ja00539a017; METZLER DE, 1994, J BIOL CHEM, V269, P28027; METZLER DE, 1994, J BIOL CHEM, V269, P28017; Miles E W, 1995, Subcell Biochem, V24, P207; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; Miles E.W., 1986, PYRIDOXAL PHOSPHAT B, V1, P253; Miles Edith Wilson, 1994, P127, DOI 10.1002/9783527615971.ch7; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1989, J BIOL CHEM, V264, P6280; MILES EW, 1968, BIOCHEMISTRY-US, V7, P2742, DOI 10.1021/bi00848a008; MILES EW, 1980, BIOCH MED ASPECTS TR, P137; MOZZARELLI A, 1989, J BIOL CHEM, V264, P15774; MOZZARELLI A, 1991, INT UNION B, V199, P273; Pan P, 1996, BIOCHEMISTRY-US, V35, P5002, DOI 10.1021/bi960033k; Peracchi A, 1996, BIOCHEMISTRY-US, V35, P1872, DOI 10.1021/bi951889c; PERRY LJ, 1984, SCIENCE, V226, P555, DOI 10.1126/science.6387910; REKKER RF, 1979, EUR J MED CHEM, V14, P479; RUVINOV SB, 1995, J BIOL CHEM, V270, P17333, DOI 10.1074/jbc.270.29.17333; RUVINOV SB, 1995, J BIOL CHEM, V270, P6357, DOI 10.1074/jbc.270.11.6357; SCHNACKERZ KD, 1979, BIOCHEMISTRY-US, V18, P3557, DOI 10.1021/bi00583a019; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; Swift S, 1991, Biotechnol Genet Eng Rev, V9, P229; Timasheff S N, 1995, Methods Mol Biol, V40, P253; TIMASHEFF SN, 1993, ANNU REV BIOPH BIOM, V22, P67, DOI 10.1146/annurev.bb.22.060193.000435; TONG HX, 1995, BIOCHEMISTRY-US, V34, P3362, DOI 10.1021/bi00010a027; WOEHL EU, 1995, BIOCHEMISTRY-US, V34, P9466, DOI 10.1021/bi00029a023; Wyman J, 1968, Q Rev Biophys, V1, P35; YANG XJ, 1992, PROTEIN EXPRES PURIF, V3, P347, DOI 10.1016/1046-5928(92)90011-K; YANOFSKY C, 1972, ENZYMES, V7, P1	58	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29100	29106		10.1074/jbc.271.46.29100	http://dx.doi.org/10.1074/jbc.271.46.29100			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910565	hybrid			2022-12-27	WOS:A1996VT05200057
J	Nakshatri, H; BhatNakshatri, P; Currie, RA				Nakshatri, H; BhatNakshatri, P; Currie, RA			Subunit association and DNA binding activity of the heterotrimeric transcription factor NF-Y is regulated by cellular redox	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT-BINDING; CLASS-II; HETEROLOGOUS SUBUNITS; GENE-TRANSCRIPTION; ACTIVITY INVITRO; REPAIR ENZYME; KAPPA-B; PROTEIN; ACTIVATION; COMPLEX	NF-Y is a heterotrimeric transcription factor that specifically recognizes a CCAAT box motif found in a variety of eukaryotic promoter and enhancer elements. The subunit association and DNA binding properties of the NF-Y complex were examined as a function of redox state using recombinant NP-YA, NF-YB, and NF-YC subunits. Reduction of NF-YB by dithiothreitol (DTT) was essential for reconstitution of specific NF-Y CCAAT box DNA binding activity in vitro. Approximately 30% of the Escherichia coli-derived NF-YB subunit existed as intermolecular disulfide-linked dimers. NF-YB mutants in which the highly conserved cysteine residues at positions 85 and 89 had been converted to serines existed only as monomers and did not require DTT for functional NF-Y DNA binding activity. DTT was required, however, for the functional association of NF-YC with wild-type NF-YB but not with the NF-YB cysteine mutants. The cellular redox factors Ref-1 and adult T-cell leukemia-derived factor stimulated the DNA binding activity of recombinant NF-Y in the absence of DTT. Cells treated with 1-chloro-2,4-dinitrobenzene, an irreversible inhibitor of thioredoxin reductase, exhibited reduced endogenous NF-Y DNA binding activity. Together these results suggest that the cellular redox environment of mammalian cells is an important posttranscriptional regulator of NF-Y subunit association and DNA binding activities.	PICOWER INST MED RES,LAB GENE REGULAT,MANHASSET,NY 11030	Northwell Health			; Currie, Richard/N-6074-2017	Nakshatri, Harikrishna/0000-0001-8876-0052; Currie, Richard/0000-0002-6528-3326	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047272, R29DK047272] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 47272] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ARNER ESJ, 1995, J BIOL CHEM, V270, P3479, DOI 10.1074/jbc.270.8.3479; ARNONE MI, 1995, J BIOL CHEM, V270, P12048, DOI 10.1074/jbc.270.20.12048; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; BENEZRA R, 1994, CELL, V79, P1057, DOI 10.1016/0092-8674(94)90036-1; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BOUCHER PD, 1995, MOL CELL BIOL, V15, P5144; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLELAND JL, 1992, BIO-TECHNOL, V10, P1013, DOI 10.1038/nbt0992-1013; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; Duh JL, 1995, J BIOL CHEM, V270, P30499, DOI 10.1074/jbc.270.51.30499; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; Harlow E., 1988, ANTIBODIES LAB MANUA; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; INOSTROZA JA, 1992, CELL, V70, P477; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; KWON JB, 1993, GENE, V132, P227, DOI 10.1016/0378-1119(93)90200-M; LARSSON LG, 1993, LEUKEMIA, V7, P226; LI XY, 1992, NUCLEIC ACIDS RES, V20, P1087, DOI 10.1093/nar/20.5.1087; LI XY, 1992, J BIOL CHEM, V267, P8984; LLOBERAS J, 1995, MOL CELL BIOL, V15, P5092; MAITY SN, 1992, J BIOL CHEM, V267, P8286; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; MATHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821; MCBRIDE AA, 1992, P NATL ACAD SCI USA, V89, P7531, DOI 10.1073/pnas.89.16.7531; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; NAKSHATRI H, 1995, J BIOL CHEM, V270, P19613, DOI 10.1074/jbc.270.33.19613; OLESEN JT, 1990, GENE DEV, V4, P1714, DOI 10.1101/gad.4.10.1714; PELEG S, 1989, BIOCHEMISTRY-US, V28, P7373, DOI 10.1021/bi00444a034; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; Sambrook J., 2002, MOL CLONING LAB MANU; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SILVA CM, 1989, J BIOL CHEM, V264, P6638; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SINHA S, 1996, MOL CELL BIOL, V16, P31; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; TING JPY, 1994, J EXP MED, V179, P1605, DOI 10.1084/jem.179.5.1605; VANHUIJSDUIJNEN RAMH, 1987, NUCLEIC ACIDS RES, V15, P7265, DOI 10.1093/nar/15.18.7265; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; WALKER LJ, 1993, MOL CELL BIOL, V13, P5370, DOI 10.1128/MCB.13.9.5370; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XING YY, 1993, EMBO J, V12, P4647, DOI 10.1002/j.1460-2075.1993.tb06153.x; XING YY, 1994, P NATL ACAD SCI USA, V91, P3009, DOI 10.1073/pnas.91.8.3009; YAO Y, 1995, ENVIRON HEALTH PERSP, V103, P366, DOI 10.2307/3432290; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	57	82	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28784	28791		10.1074/jbc.271.46.28784	http://dx.doi.org/10.1074/jbc.271.46.28784			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910521	hybrid, Green Published			2022-12-27	WOS:A1996VT05200013
J	Tachias, K; Madison, EL				Tachias, K; Madison, EL			Converting tissue-type plasminogen activator into a zymogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; SITE-DIRECTED MUTAGENESIS; REFINED CRYSTAL-STRUCTURE; STRONG LIGAND-BINDING; BOVINE TRYPSINOGEN; CRYSTALLOGRAPHIC REFINEMENT; PROTEOLYTIC-ENZYMES; ONE-CHAIN; STREPTOKINASE; RESOLUTION	In striking contrast to most other members of the chymotrypsin family of serine proteases, tissue-type plasminogen activator (t-PA) is not synthesized and secreted as a true zymogen. The zymogenicity, or ratio of the catalytic efficiencies of the mature, two-chain enzyme and the single-chain precursor, is only 5-10 for t-PA. This exceptional property of t-PA, however, is not shared by urokinase (u-PA), a plasminogen activator that is very closely related to t-PA. The molecular basis of this important functional distinction between these two intimately related serine proteases has not been previously investigated. Based on observation of the recently described structures of the protease domains of two-chain t-PA and u-PA, and molecular modeling of the corresponding single-chain enzymes, we propose that the presence or absence of an acidic residue at position 144 (chymotrypsin numbering system) is the primary determinant of the distinct zymogenicities of the two enzymes. Consistent with this hypothesis, mutation of histidine 144 of t-PA to an acidic residue, as in u-PA, selectively suppressed the activity of single-chain t-PA and thereby significantly enhanced the enzyme's zymogenicity. A variant of t-PA containing an aspartate residue at position 144, for example, exhibited a zymogenicity of 150, compared to a value of 9 for wild type t-PA and 250 for u-PA.	Scripps Res Inst, RES INST, DEPT VASC BIOL VB1, LA JOLLA, CA 92037 USA	Scripps Research Institute					NHLBI NIH HHS [P01 HL31950, R01 HL52475] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052475, P01HL031950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEATTY K, 1980, J BIOL CHEM, V255, P3931; BLOW DM, 1969, NATURE, V221, P337, DOI 10.1038/221337a0; BODE W, 1976, FEBS LETT, V68, P231, DOI 10.1016/0014-5793(76)80443-7; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BODE W, 1979, J MOL BIOL, V127, P357, DOI 10.1016/0022-2836(79)90227-4; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; BOOSE JA, 1989, BIOCHEMISTRY-US, V28, P635, DOI 10.1021/bi00428a033; COLLEN D, 1991, BLOOD, V78, P3114; COLLEN D, 1995, THROMB HAEMOSTASIS, V74, P167; COLLEN D, 1992, HEART CARDIOVASCULAR, P275; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P3585, DOI 10.1021/bi00466a023; FEHLHAMMER H, 1977, J MOL BIOL, V111, P415, DOI 10.1016/S0022-2836(77)80062-4; FREER ST, 1970, BIOCHEMISTRY-US, V9, P1997, DOI 10.1021/bi00811a022; GERTLER A, 1974, BIOCHEMISTRY-US, V13, P1302, DOI 10.1021/bi00703a038; HEMKER HC, 1975, BIOCHIM BIOPHYS ACTA, V379, P180, DOI 10.1016/0005-2795(75)90020-3; HENDRIX H, 1983, J BIOL CHEM, V258, P3637; HIGH K, 1995, MOL BASIS THROMBOSIS; HOLMES WE, 1987, BIOCHEMISTRY-US, V26, P5133, DOI 10.1021/bi00390a036; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; HUBER R, 1983, BIOPOLYMERS, V22, P261, DOI 10.1002/bip.360220136; KERR MA, 1976, BIOCHEMISTRY-US, V15, P5566, DOI 10.1021/bi00670a022; KOSSIAKOFF AA, 1977, BIOCHEMISTRY-US, V16, P654, DOI 10.1021/bi00623a016; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMBA B, 1996, J MOL BIOL, V258, P117; LIJNEN HR, 1992, FIBRINOLYSIS, V6, P33, DOI 10.1016/0268-9499(92)90045-J; LIJNEN HR, 1990, J BIOL CHEM, V265, P5232; LIJNEN HR, 1991, THROMB HAEMOSTASIS, V66, P88; LIJNEN HR, 1988, ENZYME, V40, P90, DOI 10.1159/000469150; LIJNEN HR, 1990, THROMB RES S10, V57, P45; MADISON EL, 1990, J BIOL CHEM, V265, P21423; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MADISON EL, 1993, SCIENCE, V262, P419, DOI 10.1126/science.8211162; MADISON EL, 1994, FIBRINOLYSIS, V8, P221, DOI 10.1016/0268-9499(94)90720-X; MANN K, 1993, METHOD ENZYMOL, V223, P145; MATTHEWS BW, 1967, NATURE, V214, P652, DOI 10.1038/214652a0; MILES LA, 1985, J BIOL CHEM, V260, P4303; NEINABER VL, 1992, BIOCHEMISTRY-US, V31, P3852; NEURATH H, 1989, TRENDS BIOCHEM SCI, V14, P268, DOI 10.1016/0968-0004(89)90061-3; NEURATH H, 1986, J CELL BIOCHEM, V32, P35, DOI 10.1002/jcb.240320105; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; PETERSEN LC, 1988, BIOCHIM BIOPHYS ACTA, V952, P245, DOI 10.1016/0167-4838(88)90123-9; RANBY M, 1982, THROMB RES, V27, P175, DOI 10.1016/0049-3848(82)90197-9; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; REDDY KNN, 1988, ENZYME, V40, P79, DOI 10.1159/000469149; ROBINSON NC, 1973, BIOCHEMISTRY-US, V12, P420, DOI 10.1021/bi00727a010; SCHICK LA, 1973, BIOCHEMISTRY-US, V12, P4315, DOI 10.1021/bi00746a003; SIGLER PB, 1968, J MOL BIOL, V35, P143, DOI 10.1016/S0022-2836(68)80043-9; SILVERBERG M, 1982, BLOOD, V60, P64; Smith JW, 1995, J BIOL CHEM, V270, P30486, DOI 10.1074/jbc.270.51.30486; SPRAGGON G, 1995, STRUCTURE, V3, P681, DOI 10.1016/S0969-2126(01)00203-9; STEITZ TA, 1969, J MOL BIOL, V46, P337, DOI 10.1016/0022-2836(69)90426-4; STRANDBERG L, 1995, J BIOL CHEM, V270, P23444, DOI 10.1074/jbc.270.40.23444; STROUD RM, 1974, J MOL BIOL, V83, P185, DOI 10.1016/0022-2836(74)90387-8; SUMMARIA L, 1974, J BIOL CHEM, V249, P4760; TACHIAS K, 1995, J BIOL CHEM, V270, P18319, DOI 10.1074/jbc.270.31.18319; TATE KM, 1987, BIOCHEMISTRY-US, V26, P338, DOI 10.1021/bi00376a002; WANG DC, 1985, J MOL BIOL, V185, P595, DOI 10.1016/0022-2836(85)90074-9; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	59	31	44	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28749	28752		10.1074/jbc.271.46.28749	http://dx.doi.org/10.1074/jbc.271.46.28749			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910515	hybrid			2022-12-27	WOS:A1996VT05200007
J	Dang, Q; Taylor, J				Dang, Q; Taylor, J			In vivo footprinting analysis of the hepatic control region of the human apolipoprotein E/C-I/C-IV/C-II gene locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; LIGATION-MEDIATED PCR; DOMINANT CONTROL REGION; MOUSE ALBUMIN PROMOTER; TRANSGENIC MICE; GLOBIN GENE; C-I; NUCLEAR PROTEINS; ALZHEIMERS-DISEASE; REGULATORY ELEMENT	Expression of both the apolipoprotein (apo)E and apoC-I genes in the liver is specified by a 319-nucleotide hepatic control region (HCR-1) that is located 15 kilobase pairs downstream of the apoE gene and 5 kilobase pairs downstream of the apoC-I gene. In vivo footprint analysis of HCR-1 in intact nuclei revealed several liver-specific protein-binding sites that were not detectable by in vitro methods. In addition to three previously identified in vitro footprints, four in vivo footprints were identified in a region of HCR-1 that is required for directing gene expression to hepatocytes. Prominent liver-specific DNase I-hypersensitive sites were associated with these footprints. Liver-specific nuclear protein binding to these sites was confirmed by oligonucleotide gel-retention assays. The in vivo analysis also identified a cluster of nuclear protein-binding sites in the Alu family repeat segment adjacent to the domain required for liver expression. Micrococcal nuclease digestion indicated the presence of a nucleosome in the central domain of HCR-1 in liver chromatin that was in phase with the nucleosome location in tissues that did not express the transgene. These results suggest that HCR-1 functions in a highly structured chromatin environment requiring a complex interaction of liver enriched transcription factors.	UNIV CALIF SAN FRANCISCO, GLADSTONE INST CARDIOVASC DIS, CARDIOVASC RES INST, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco					NHLBI NIH HHS [HL07731, HL37063] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037063] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAN CM, 1995, J BIOL CHEM, V270, P26278, DOI 10.1074/jbc.270.44.26278; ALLAN CM, 1995, GENOMICS, V28, P291, DOI 10.1006/geno.1995.1144; ARCINAS M, 1994, J BIOL CHEM, V269, P21919; BRECKENRIDGE WC, 1978, NEW ENGL J MED, V298, P1265, DOI 10.1056/NEJM197806082982301; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHANG DJ, 1990, J BIOL CHEM, V265, P9496; CHURCHILL MEA, 1995, EMBO J, V14, P1264, DOI 10.1002/j.1460-2075.1995.tb07110.x; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; COWIE A, 1988, MOL CELL BIOL, V8, P3122, DOI 10.1128/MCB.8.8.3122; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DANG Q, 1995, J BIOL CHEM, V270, P22577, DOI 10.1074/jbc.270.38.22577; DAS HK, 1985, J BIOL CHEM, V260, P6240; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; ENGLANDER EW, 1995, J BIOL CHEM, V270, P10091, DOI 10.1074/jbc.270.17.10091; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FENG WC, 1994, J BIOL CHEM, V269, P1493; FRAMPTON J, 1990, MOL CELL BIOL, V10, P3838, DOI 10.1128/MCB.10.7.3838; GANTER B, 1993, J MOL BIOL, V234, P975, DOI 10.1006/jmbi.1993.1652; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GONG QH, 1991, MOL CELL BIOL, V11, P2558, DOI 10.1128/MCB.11.5.2558; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GUMUCIO DL, 1992, MOL CELL BIOL, V12, P4919, DOI 10.1128/MCB.12.11.4919; HAMBOR JE, 1993, MOL CELL BIOL, V13, P7056, DOI 10.1128/MCB.13.11.7056; JACKSON JR, 1993, NUCLEIC ACIDS RES, V21, P957, DOI 10.1093/nar/21.4.957; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; LAUER SJ, 1988, J BIOL CHEM, V263, P7277; LI Q, 1995, MOL CELL BIOL, V15, P4375; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; LIU JK, 1988, GENE DEV, V2, P528, DOI 10.1101/gad.2.5.528; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1984, J LIPID RES, V25, P1277; Maxam A M, 1980, Methods Enzymol, V65, P499; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; METZGER S, 1990, J BIOL CHEM, V265, P9978; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; OCHOA A, 1989, NUCLEIC ACIDS RES, V17, P119, DOI 10.1093/nar/17.1.119; OLAISEN B, 1982, HUM GENET, V62, P233, DOI 10.1007/BF00333526; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PAIK YK, 1985, P NATL ACAD SCI USA, V82, P3445, DOI 10.1073/pnas.82.10.3445; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PHILIPSEN S, 1993, EMBO J, V12, P1077, DOI 10.1002/j.1460-2075.1993.tb05749.x; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; REARDON CA, 1986, J BIOL CHEM, V261, P9858; SAFFER JD, 1989, MOL CELL BIOL, V9, P355, DOI 10.1128/MCB.9.2.355; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAUNDERS AM, 1993, LANCET, V342, P710, DOI 10.1016/0140-6736(93)91709-U; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SEHAYEK E, 1991, J BIOL CHEM, V266, P18259; SHACHTER NS, 1993, J LIPID RES, V34, P1699; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; SIMONET WS, 1991, J BIOL CHEM, V266, P8651; SIMONET WS, 1990, J BIOL CHEM, V265, P10809; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; SUN JM, 1992, NUCLEIC ACIDS RES, V20, P6385, DOI 10.1093/nar/20.23.6385; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; WATT P, 1990, NUCLEIC ACIDS RES, V18, P1339, DOI 10.1093/nar/18.6.1339; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; WHITELAW E, 1990, MOL CELL BIOL, V10, P6596, DOI 10.1128/MCB.10.12.6596; Wolffe AP, 1996, TRENDS GENET, V12, P58, DOI 10.1016/0168-9525(96)81401-6; ZHANG QY, 1993, MOL CELL BIOL, V13, P2298, DOI 10.1128/MCB.13.4.2298	71	18	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28667	28676		10.1074/jbc.271.45.28667	http://dx.doi.org/10.1074/jbc.271.45.28667			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910501	hybrid			2022-12-27	WOS:A1996VU03300101
J	Ershov, AV; Lukiw, WJ; Bazan, NG				Ershov, AV; Lukiw, WJ; Bazan, NG			Selective transcription factor induction in retinal pigment epithelial cells during photoreceptor phagocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTORS ENCODES; ROD OUTER SEGMENTS; BINDING PROTEIN; PHYSIOLOGICAL-ROLE; GENE-EXPRESSION; DNA-BINDING; RAT; RECEPTOR; CULTURE; SPECIFICITY	Expression of early response genes during rod outer segment phagocytosis by normal Long Evans and Royal College of Surgeons-rdy(+)p(+) rats and by dystrophic Royal College of Surgeons-p(+) rat retinal pigment epithelial cells was studied in primary cell culture. Northern analysis revealed that the abundance of zif-268 (egr-1), c-fos, and tis-1 (NGF1-B) mRNA was rapidly and transiently increased in normal retinal pigment epithelial cells during rod outer segment phagocytosis but not during phagocytosis of latex particles. No increase in gene expression was found in Royal College of Surgeons-p(+) dystrophic retinal pigment epithelial cells challenged with rod outer segments. As shown by electrophoretic mobility shift assay, a prominent short term increase in the intensity of the gel-shifted band was detected using nuclear protein extracts derived from rod outer segment-challenged, control retinal pigment epithelial cells and zif-268, AP-1, AP-2, or tis-1 consensus oligonucleotides. No such increase was detected when using nuclear factor KB consensus oligonucleotide or when the early response gene prostaglandin H synthase-2 mRNA was measured over the time course studied. The results suggest that in retinal pigment epithelial cells, rad outer segment-specific phagocytosis is accompanied by the selective expression of early response genes coding for transcription factors. The specific pattern of the induction of these transcription factors is predicted to modulate the expression of gene cascades.	LOUISIANA STATE UNIV,MED CTR,CTR NEUROSCI,NEW ORLEANS,LA 70112; LOUISIANA STATE UNIV,MED CTR,DEPT OPHTHALMOL,NEW ORLEANS,LA 70112	Louisiana State University System; Louisiana State University System			Bazan, Nicolas/AAN-4121-2020	Bazan, Nicolas/0000-0002-9243-5444	NEI NIH HHS [EY05121] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY005121] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adunyah SE, 1996, BIOCHEM BIOPH RES CO, V221, P213, DOI 10.1006/bbrc.1996.0576; ARENANDER AT, 1989, J NEUROSCI RES, V23, P257, DOI 10.1002/jnr.490230303; BAUER R, 1994, NUCLEIC ACIDS RES, V22, P1413, DOI 10.1093/nar/22.8.1413; BAZAN NG, 1992, ADV EXP MED BIOL, V318, P295; BAZAN NG, 1985, J BIOL CHEM, V260, P3677; BOK D, 1971, J CELL BIOL, V49, P664, DOI 10.1083/jcb.49.3.664; BOYLE D, 1991, INVEST OPHTH VIS SCI, V32, P1464; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CEGLAREK JA, 1989, ELECTROPHORESIS, V10, P360, DOI 10.1002/elps.1150100514; CHAITIN MH, 1983, INVEST OPHTH VIS SCI, V24, P812; CHEN HM, 1993, EXP EYE RES, V57, P369, DOI 10.1006/exer.1993.1136; CHEN Y, 1994, BIOCHEMISTRY-US, V33, P10658, DOI 10.1021/bi00201a013; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COLLART MA, 1989, ONCOGENE, V4, P237; DOUCET JP, 1990, MOL NEUROBIOL, V4, P27, DOI 10.1007/BF02935584; EDWARDS RB, 1977, SCIENCE, V197, P1001, DOI 10.1126/science.560718; ERSHOV AV, 1995, INVEST OPHTH VIS SCI, V36, pS815; HALL MO, 1987, EXP EYE RES, V45, P907, DOI 10.1016/S0014-4835(87)80105-7; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; LAVAIL MM, 1981, INVEST OPHTH VIS SCI, V20, P671; LIM RW, 1987, ONCOGENE, V1, P263; LUKIW WJ, 1994, MOL BRAIN RES, V22, P121, DOI 10.1016/0169-328X(94)90039-6; MAASS A, 1994, BIOCHEM BIOPH RES CO, V202, P1337, DOI 10.1006/bbrc.1994.2077; MAYERSON PL, 1986, J CELL BIOL, V103, P299, DOI 10.1083/jcb.103.1.299; MAYERSON PL, 1985, INVEST OPHTH VIS SCI, V26, P1599; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MOSER M, 1993, NUCLEIC ACIDS RES, V21, P4844, DOI 10.1093/nar/21.20.4844; OBANION MK, 1991, J BIOL CHEM, V266, P23261; OKAJIMA TIL, 1990, P NATL ACAD SCI USA, V87, P6907, DOI 10.1073/pnas.87.17.6907; OKAJIMA TIL, 1994, J BIOL CHEM, V269, P21983; ONG DE, 1994, BIOCHEMISTRY-US, V33, P1835, DOI 10.1021/bi00173a029; PEPPERBERG DR, 1993, MOL NEUROBIOL, V7, P61, DOI 10.1007/BF02780609; PHILP NJ, 1981, EXP EYE RES, V33, P47, DOI 10.1016/S0014-4835(81)80080-2; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; RYSECK RP, 1992, CELL GROWTH DIFFER, V3, P443; SEYFRIEDWILLIAMS R, 1984, EXP CELL RES, V154, P500, DOI 10.1016/0014-4827(84)90174-5; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; ZHANG DE, 1990, J BIOL CHEM, V265, P3382	46	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28458	28462		10.1074/jbc.271.45.28458	http://dx.doi.org/10.1074/jbc.271.45.28458			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910472	hybrid			2022-12-27	WOS:A1996VU03300072
J	Strub, JM; Goumon, Y; Lugardon, K; Capon, C; Lopez, M; Moniatte, M; VanDorsselaer, A; Aunis, D; MetzBoutigue, MH				Strub, JM; Goumon, Y; Lugardon, K; Capon, C; Lopez, M; Moniatte, M; VanDorsselaer, A; Aunis, D; MetzBoutigue, MH			Antibacterial activity of glycosylated and phosphorylated chromogranin A-derived peptide 173-194 from bovine adrenal medullary chromaffin granules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ANTIMICROBIAL PEPTIDES; MAGNETIC-RESONANCE; MASS-SPECTROMETRY; TERMINAL DOMAIN; SECRETOGRANIN-I; CDNA SEQUENCE; AMINO-ACIDS; PANCREASTATIN; SECRETION	Recently, we have isolated from bovine chromaffin granules and identified two natural peptides possessing antibacterial activity: secretolytin (chromogranin B 614-626) and enkelytin (proenkephalin-A 209-237). Here, we characterize a large natural fragment, corresponding to chromogranin A 79-431, that inhibits growth of both Gram-positive and Gram-negative bacteria. The aim of the present work was to determine the shortest active peptide located in the 79-431 chromogranin A region. Three peptides, which shared the same 173-194 chromogranin A sequence (YPGPQAKEDSEGPSQGPASREK) but differed in post-translational modifications, including O-glycosylation and tyrosine phosphorylation, were isolated. A detailed study using microsequencing and mass spectrometry allowed us to correlate their antibacterial activity with these posttranslational modifications. The chromogranin A precursor fragment (79-431) and the active glycosylated and phosphorylated peptides were, respectively, named prochromacin and chromacin (P, G, and PG for phosphorylated, glycosylated, and phosphorylated-glycosylated form).	INSERM,U338,UNITE BIOL COMMUN CELLULAIRE,F-67084 STRASBOURG,FRANCE; CNRS,CHIM BIOL LAB,UMR 111,F-59655 VILLENEUVE DASCQ,FRANCE; CNRS,LAB SPECTROMETRIE MASSE BIOORGAN,URA 31,F-67084 STRASBOURG,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)			Dominique, Aunis/W-1419-2019	Strub, Jean-Marc/0000-0001-6224-3428; Moniatte, Marc/0000-0003-2235-4523				AARDAL S, 1993, J NEUROENDOCRINOL, V5, P405, DOI 10.1111/j.1365-2826.1993.tb00501.x; AARDAL S, 1992, REGUL PEPTIDES, V41, P9, DOI 10.1016/0167-0115(92)90509-S; AUNIS D, 1977, J NEUROCHEM, V29, P439, DOI 10.1111/j.1471-4159.1977.tb10692.x; BAUER JW, 1991, BIOCHIM BIOPHYS ACTA, V1089, P124, DOI 10.1016/0167-4781(91)90094-3; BENEDUM UM, 1987, EMBO J, V6, P1203, DOI 10.1002/j.1460-2075.1987.tb02355.x; BERGEY EJ, 1986, BIOCHEM J, V234, P43, DOI 10.1042/bj2340043; BULET P, 1995, BIOCHEMISTRY-US, V34, P7394, DOI 10.1021/bi00022a012; BULET P, 1993, J BIOL CHEM, V268, P14893; BURTON PM, 1987, INT J IMMUNOPHARMACO, V9, P297, DOI 10.1016/0192-0561(87)90054-3; CASTEELS P, 1989, EMBO J, V8, P2387, DOI 10.1002/j.1460-2075.1989.tb08368.x; CASTEELS P, 1990, EUR J BIOCHEM, V187, P381, DOI 10.1111/j.1432-1033.1990.tb15315.x; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COCIANCICH S, 1994, BIOCHEM J, V300, P567, DOI 10.1042/bj3000567; DILLEN L, 1993, NEUROCHEM INT, V22, P315, DOI 10.1016/0197-0186(93)90016-X; DREE BM, 1994, ENDOCRINOLOGY, V129, P3381; EFENDIC S, 1987, P NATL ACAD SCI USA, V84, P7257, DOI 10.1073/pnas.84.20.7257; FASCIOTTO BH, 1993, ENDOCRINOLOGY, V133, P461, DOI 10.1210/en.133.2.461; FRANK RW, 1990, J BIOL CHEM, V265, P18871; Goumon Y, 1996, EUR J BIOCHEM, V235, P516, DOI 10.1111/j.1432-1033.1996.t01-1-00516.x; HARA S, 1995, BIOCHEM J, V310, P651, DOI 10.1042/bj3100651; HELLE KB, 1993, J NEUROENDOCRINOL, V5, P413, DOI 10.1111/j.1365-2826.1993.tb00502.x; HELLE KB, 1990, NEUROCHEM INT, V17, P165, DOI 10.1016/0197-0186(90)90139-K; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HOBBS MV, 1987, J IMMUNOL, V138, P2581; HOLAK TA, 1988, BIOCHEMISTRY-US, V27, P7620, DOI 10.1021/bi00420a008; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; HUTTON JC, 1988, ENDOCRINOLOGY, V122, P1014, DOI 10.1210/endo-122-3-1014; IACANGELO A, 1988, FEBS LETT, V227, P115, DOI 10.1016/0014-5793(88)80880-9; IACANGELO A, 1986, NATURE, V323, P82, DOI 10.1038/323082a0; IACANGELO AL, 1988, ENDOCRINOLOGY, V122, P2339, DOI 10.1210/endo-122-5-2339; ISHIZUKA J, 1989, PANCREAS, V4, P277, DOI 10.1097/00006676-198906000-00001; JANUSZ M, 1987, MOL IMMUNOL, V24, P1029, DOI 10.1016/0161-5890(87)90069-1; KAMERLING JP, 1975, BIOCHEM J, V151, P491, DOI 10.1042/bj1510491; KAWASAKI K, 1992, CHEM PHARM BULL, V40, P3253, DOI 10.1248/cpb.40.3253; KIANG WL, 1982, J BIOL CHEM, V257, P1651; KONECKI DS, 1987, J BIOL CHEM, V262, P17026; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS JJ, 1989, BIOCHEM BIOPH RES CO, V163, P667, DOI 10.1016/0006-291X(89)92275-4; LINARD CG, 1990, NUCLEIC ACIDS RES, V18, P1298, DOI 10.1093/nar/18.5.1298; LOTAN R, 1975, J BIOL CHEM, V250, P8518; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; METZBOUTIGUE MH, 1984, EUR J BIOCHEM, V145, P659, DOI 10.1111/j.1432-1033.1984.tb08607.x; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; Montreuil J, 1986, CARBOHYDRATE ANAL PR, P143; RINDERLE SJ, 1989, J BIOL CHEM, V264, P16123; ROSA P, 1985, J CELL BIOL, V101, P1999, DOI 10.1083/jcb.101.5.1999; SCHLUESENER HJ, 1993, J NEUROIMMUNOL, V47, P199, DOI 10.1016/0165-5728(93)90030-3; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; SETTLEMAN J, 1985, J BIOL CHEM, V260, P1645; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; SIMON JP, 1988, P NATL ACAD SCI USA, V85, P1712, DOI 10.1073/pnas.85.5.1712; SIMON JP, 1989, BIOCHEM J, V262, P1; SMITH AD, 1967, BIOCHEM J, V103, P483, DOI 10.1042/bj1030483; Strub JM, 1996, FEBS LETT, V379, P273, DOI 10.1016/0014-5793(95)01529-9; STRUB JM, 1995, EUR J BIOCHEM, V229, P356, DOI 10.1111/j.1432-1033.1995.0356k.x; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; VAESSEN RTMJ, 1981, FEBS LETT, V124, P193, DOI 10.1016/0014-5793(81)80134-2; VANHOOF G, 1995, FASEB J, V9, P736, DOI 10.1096/fasebj.9.9.7601338; VORM O, 1994, ANAL CHEM, V66, P3281, DOI 10.1021/ac00091a044; VORM O, 1994, J AM SOC MASS SPECTR, V5, P955, DOI 10.1016/1044-0305(94)80013-8; WANG WC, 1988, J BIOL CHEM, V263, P4576; WILLIAMS KA, 1991, BIOCHEMISTRY-US, V30, P8919, DOI 10.1021/bi00101a001; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WU HJ, 1991, J BIOL CHEM, V266, P13130	66	108	114	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28533	28540		10.1074/jbc.271.45.28533	http://dx.doi.org/10.1074/jbc.271.45.28533			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910482	hybrid			2022-12-27	WOS:A1996VU03300082
J	Badminton, MN; Campbell, AK; Rembold, CM				Badminton, MN; Campbell, AK; Rembold, CM			Differential regulation of nuclear and cytosolic Ca2+ in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; TARGETED RECOMBINANT AEQUORIN; RAT-LIVER NUCLEI; INOSITOL TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; ION CHANNELS; INTACT-CELLS; CALCIUM; ENVELOPE; BINDING	The results reported in this study address the controversial issue that nuclear free Ca2+ ([Ca2+](n)) may be regulated independently of cytosolic free Ca2+ ([Ca2+](c)), We have measured [Ca2+](n) and [Ca2+](c) with recombinant aequorin targeted to the nucleus and cytosol in HeLa cells. We found that histamine, ATP, and ionomycin increased [Ca2+](c) quantitatively more than [Ca2+](n), although the time course of these changes was similar. The difference between [Ca2+](c) and [Ca2+](n) depended on the stimulus, and the relative difference between [Ca2+](n) and [Ca2+]c was less with ionomycin than with histamine or ATP. After depletion of the internal Ca2+ store, restoration of extracellular Ca2+ resulted in only increased [Ca2+](c) without a significant increase in [Ca2+](n). Treatment with cyclopiazonic acid resulted in a delayed increases in [Ca2+](n) compared to [Ca2+](c). These differences in both timing and magnitude of nuclear Ca2+ signals confirm that the cell can Limit or delay increases in nuclear free Ca2+. Taken with the fact that an inositol phosphate signaling system resides in the nucleus and its envelope, our data support the hypothesis that [Ca2+](n) may be independently regulated.	UNIV VIRGINIA,HLTH SCI CTR,DIV CARDIOVASC,CHARLOTTESVILLE,VA 22908	University of Virginia	Badminton, MN (corresponding author), UNIV WALES COLL MED,DEPT MED BIOCHEM,HEATH PK,CARDIFF CF4 4XN,S GLAM,WALES.		Campbell, Anthony K/N-5855-2014; Rembold, Christopher/K-8359-2013	Campbell, Anthony K/0000-0002-2506-5500; Rembold, Christopher/0000-0003-0819-7488	NHLBI NIH HHS [HL38918] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL038918, R01HL038918] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRITTON NL, 1994, P NATL ACAD SCI USA, V91, P12458; ALMOHANNA FA, 1994, NATURE, V367, P745, DOI 10.1038/367745a0; BACHS O, 1992, BIOCHIM BIOPHYS ACTA, V1113, P259, DOI 10.1016/0304-4157(92)90041-8; BADMINTON MN, 1995, EXP CELL RES, V216, P236, DOI 10.1006/excr.1995.1030; BADMINTON MN, 1996, BIOCHEM BIOPH RES CO, V217, P950; BELLOMO G, 1992, CANCER RES, V52, P1342; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; BRINI M, 1993, EMBO J, V12, P4813, DOI 10.1002/j.1460-2075.1993.tb06170.x; BRINI M, 1994, CELL CALCIUM, V16, P259, DOI 10.1016/0143-4160(94)90089-2; BUSTAMANTE JO, 1994, MOL MEMBR BIOL, V11, P141, DOI 10.3109/09687689409162232; Campbell A. K., 1988, CHEMILUMINESCENCE PR, P374; Campbell AK, 1996, CELL CALCIUM, V19, P211, DOI 10.1016/S0143-4160(96)90022-6; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COBBOLD PH, 1992, CELLULAR CALCIUM PRA, P55; CONNOR JA, 1993, CELL CALCIUM, V14, P185, DOI 10.1016/0143-4160(93)90066-F; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; GILCHRIST JSC, 1994, MOL CELL BIOCHEM, V135, P79, DOI 10.1007/BF00925963; GREBER UF, 1995, J CELL BIOL, V128, P4; HENNAGER DJ, 1995, J BIOL CHEM, V270, P4959, DOI 10.1074/jbc.270.10.4959; HERNANDEZCRUZ A, 1990, SCIENCE, V247, P858, DOI 10.1126/science.2154851; HIMPENS B, 1992, AM J PHYSIOL, V263, pC978, DOI 10.1152/ajpcell.1992.263.5.C978; HIMPENS B, 1992, AM J PHYSIOL, V263, pC95, DOI 10.1152/ajpcell.1992.263.1.C95; Humbert JP, 1996, J BIOL CHEM, V271, P478, DOI 10.1074/jbc.271.1.478; Kendall JM, 1996, CELL CALCIUM, V19, P133, DOI 10.1016/S0143-4160(96)90082-2; KENDALL JM, 1994, ANAL BIOCHEM, V221, P173, DOI 10.1006/abio.1994.1394; Kong SK, 1996, BIOCHEM BIOPH RES CO, V218, P595, DOI 10.1006/bbrc.1996.0105; KOPPLER P, 1993, J BIOL CHEM, V268, P26248; MALVIYA AN, 1990, P NATL ACAD SCI USA, V87, P9270, DOI 10.1073/pnas.87.23.9270; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MAZZANTI M, 1990, NATURE, V343, P764, DOI 10.1038/343764a0; MAZZANTI M, 1994, FASEB J, V8, P231, DOI 10.1096/fasebj.8.2.7509760; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; OMALLEY DM, 1994, J NEUROSCI, V14, P5741; PETERS R, 1986, BIOCHIM BIOPHYS ACTA, V864, P305, DOI 10.1016/0304-4157(86)90003-1; REMBOLD CM, 1995, J PHYSIOL-LONDON, V488, P549, DOI 10.1113/jphysiol.1995.sp020989; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; SANTELLA L, 1994, BIOCHEM BIOPH RES CO, V203, P950; SHANKAR G, 1993, J CELL SCI, V105, P61; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; WILLIAMS DA, 1985, NATURE, V318, P558, DOI 10.1038/318558a0	41	87	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31210	31214		10.1074/jbc.271.49.31210	http://dx.doi.org/10.1074/jbc.271.49.31210			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940122	hybrid			2022-12-27	WOS:A1996VW68600033
J	Bhardwaj, D; Iino, M; Kontoyianni, M; Smith, KJ; Foster, DC; Kisiel, W				Bhardwaj, D; Iino, M; Kontoyianni, M; Smith, KJ; Foster, DC; Kisiel, W			Factor VII central - A novel mutation in the catalytic domain that reduces tissue factor binding, impairs activation by factor XA and abolishes amidolytic and coagulant activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRINSIC PATHWAY INHIBITOR; GAMMA-CARBOXYGLUTAMIC ACID; CLOTTING FACTOR-VII; BLOOD-COAGULATION; DEFICIENCY; SITE; AUTOACTIVATION; INITIATION; CLEAVAGE; PROTEINS	Factor VII is a vitamin K-dependent zymogen of a serine protease that participates in the initial phase of blood coagulation. A factor VII molecular variant (factor VII Central) was identified in a 24-year-old male with severe factor VII deficiency and whose plasma factor VII antigen was 38% of normal, but expressed <1% factor VII procoagulant activity. DNA sequence analysis of the patients factor VII gene revealed a thymidine to cytidine transition at nucleotide 10907 in exon VIII that results in a novel amino acid substitution of phe(328) to Ser. The patient was homozygous for this mutation, whereas each parent of the patient was heterozygous for this mutation. To investigate the molecular properties of this variant, a recombinant F328S factor VII mutant was prepared and analyzed in relation to wild-type factor VII. F328S factor VII exhibited < 1% factor VII procoagulant activity and a 2-fold decreased affinity for tissue factor and failed to activate factor X or IX in the presence of tissue factor following activation by factor Xa. In addition, F328S factor VIIa exhibited no detectable amidolytic activity in the presence of tissue factor. The rate of F328S factor VII activation by factor Xa was markedly decreased relative to the rate of wild-type factor VII activation as revealed by densitometry scanning of SDS gels. Temporal analysis, of this reaction by SDS-polyacrylamide gel electrophoresis also revealed the formation of two novel F328S factor VII degradation products (40 and 9 kDa) resulting from factor Xa proteolysis of the Arg(315)-Lys(316) peptide bond in intact F3285 factor VII. Computer modeling and molecular dynamics simulations of the serine protease domain of factor VIIa suggested that the inability of F3285 factor VIIa to cleave substrates may result hom the apparent formation of a hydrogen bond between Tyr(377) and Asp(338), a residue at the bottom of the substrate-binding pocket important for the interaction of substrate arginine side chains with the enzyme. These findings suggest that Phe(328), which is conserved in prothrombin, factor IX, factor X, factor VII, and trypsin, is important for factor VIIa catalysis.	UNIV NEW MEXICO,SCH MED,DEPT PATHOL,ALBUQUERQUE,NM 87131; ZYMOGENET INC,SEATTLE,WA 98102	University of New Mexico; Zymogenet Inc.				Bharadwaj, Dwaipayan/0000-0001-5268-8482	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035246] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35246] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BELL WN, 1954, NATURE, V174, P880, DOI 10.1038/174880a0; CHAING S, 1994, BLOOD, V83, P3524; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DEGROUCHY J, 1984, HUM GENET, V66, P230, DOI 10.1007/BF00286607; Engvall E, 1980, Methods Enzymol, V70, P419; HAGEN FS, 1986, P NATL ACAD SCI USA, V83, P2412, DOI 10.1073/pnas.83.8.2412; KAZAMA Y, 1993, J BIOL CHEM, V268, P16231; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KONDO S, 1987, BLOOD, V70, P1947; Kontoyianni Maria, 1993, Perspectives in Drug Discovery and Design, V1, P291, DOI 10.1007/BF02174530; KUWADA M, 1981, ANAL BIOCHEM, V117, P259, DOI 10.1016/0003-2697(81)90720-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALONEYHUSS K, 1992, J MOL BIOL, V225, P859, DOI 10.1016/0022-2836(92)90406-A; MARIANI G, 1981, BRIT J HAEMATOL, V48, P7; MATSUSHITA T, 1994, J BIOL CHEM, V269, P7355; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; NAKAGAKI T, 1992, THROMB RES, V65, P105, DOI 10.1016/0049-3848(92)90230-8; NAWROTH PP, 1986, THROMB RES, V44, P625, DOI 10.1016/0049-3848(86)90164-7; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; OHARA PJ, 1987, P NATL ACAD SCI USA, V84, P5158, DOI 10.1073/pnas.84.15.5158; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PEDERSEN AH, 1990, J BIOL CHEM, V265, P16786; PEDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P9331, DOI 10.1021/bi00450a013; Petersen LC, 1996, BIOCHEMISTRY-US, V35, P266, DOI 10.1021/bi951501d; RAGNI MV, 1981, AM J HEMATOL, V10, P79, DOI 10.1002/ajh.2830100112; SCHULLEK JR, 1994, J BIOL CHEM, V269, P19399; SHAPIRO R, 1989, BIOCHEMISTRY-US, V28, P7401, DOI 10.1021/bi00444a038; STONE MJ, 1995, BIOCHEM J, V310, P605, DOI 10.1042/bj3100605; TRIPLETT DA, 1985, BLOOD, V66, P1284; TUDDENHAM EGD, 1995, THROMB HAEMOSTASIS, V74, P313; WILDGOOSE P, 1990, BIOCHEMISTRY-US, V29, P3413, DOI 10.1021/bi00465a039; WILDGOOSE P, 1989, BLOOD, V73, P1888; Wu, 1996, Mol Diagn, V1, P89, DOI 10.1016/S1084-8592(96)70024-3	34	28	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30685	30691		10.1074/jbc.271.48.30685	http://dx.doi.org/10.1074/jbc.271.48.30685			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940045	hybrid			2022-12-27	WOS:A1996VV15800062
J	Sung, YJ; Hwang, MCC; Hwang, YW				Sung, YJ; Hwang, MCC; Hwang, YW			The dominant negative effects of H-Ras harboring a Gly to Ala mutation at position 60	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; XENOPUS-LAEVIS OOCYTES; NUCLEOTIDE DISSOCIATION STIMULATOR; SIGNAL-REGULATED KINASE; BINDING DOMAIN; PLASMA-MEMBRANE; MEK ACTIVATION; MAP KINASE; IN-VITRO; RAF-1	v-H-Ras harboring the Gly-60 to Ala mutation (G60A) lacks the ability to induce germinal vesicle breakdown in Xenopus oocytes. Moreover, this mutant is capable of inhibiting the activity of v-H-Ras to induce oocyte germinal vesicle breakdown when co-injected. The duration and the extent of inhibition depends on the molar ratio of v-H-Ras(G60A) to v-H-Ras. The inhibition is not due to a general toxicity of v-H-Ras(G60A) to oocytes because oocytes injected with v-H-Ras(G60A) can be readily induced to mature by other mitogenic agents, such as insulin, insulin-like growth factor 1, insulin-like growth factor 2, and phosphatidylcholine-specific phospholipase C. The dominant negative effect of v-H-Ras(G60A) requires proper membrane attachment of v-H-Ras(G60A). By using a competition assay, it was concluded that the dominant negative phenotype of v-H-Ras(G60A) resulted from sequestering H-Ras downstream effector(s). Raf-1 was identified as one of the sequestered targets.	NEW YORK STATE INST BASIC RES DEV DISABIL, DEPT BIOL MOL, STATEN ISL, NY 10314 USA; CUNY COLL STATEN ISL, INST BASIC RES, CTR DEV NEUROSCI, NEW YORK, NY 10036 USA; CUNY COLL STATEN ISL, GRAD PROGRAM BIOL, NEW YORK, NY 10036 USA	Institute for Basic Research in Developmental Disabilities; City University of New York (CUNY) System; College of Staten Island (CUNY); City University of New York (CUNY) System; College of Staten Island (CUNY)					NATIONAL CANCER INSTITUTE [R29CA053782] Funding Source: NIH RePORTER; NCI NIH HHS [CA53782] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DEHERREROS AG, 1991, J BIOL CHEM, V266, P6825; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; ELETR M, 1979, SCIENCE, V205, P1397, DOI 10.1126/science.472755; EPPIG JJ, 1976, IN VITRO CELL DEV B, V12, P418; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Hwang MCC, 1996, J BIOL CHEM, V271, P8196, DOI 10.1074/jbc.271.14.8196; HWANG YW, 1989, NATO ADV SCI I A-LIF, V165, P77; HWANG YW, 1993, J BIOL CHEM, V268, P24692; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KJAERSGARD IVH, 1995, EUR J BIOCHEM, V228, P184; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KURODA S, 1995, J BIOL CHEM, V270, P2460, DOI 10.1074/jbc.270.6.2460; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE E, 1992, J BIOL CHEM, V267, P1212; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASUDA T, 1995, J BIOL CHEM, V270, P1979, DOI 10.1074/jbc.270.5.1979; MICHAELI T, 1989, EMBO J, V8, P3039, DOI 10.1002/j.1460-2075.1989.tb08454.x; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MOODIE SA, 1993, SCIENCE, V260, P1588; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; OGISO Y, 1990, CELL GROWTH DIFFER, V1, P217; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SADLER SE, 1987, J BIOL CHEM, V262, P10644; SCHEFFLER JE, 1994, J BIOL CHEM, V269, P22340; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SHIROUZU M, 1994, ONCOGENE, V9, P2153; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STOUTEN PFW, 1993, FEBS LETT, V320, P1, DOI 10.1016/0014-5793(93)81644-F; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUNG YJ, 1995, BIOCHEMISTRY-US, V34, P3470, DOI 10.1021/bi00010a040; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1994, BIOCHEMISTRY-US, V33, P5595, DOI 10.1021/bi00184a031	67	16	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30537	30543		10.1074/jbc.271.48.30537	http://dx.doi.org/10.1074/jbc.271.48.30537			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940023	hybrid			2022-12-27	WOS:A1996VV15800040
J	Dong, G; Schulick, AH; DeYoung, MB; Dichek, DA				Dong, G; Schulick, AH; DeYoung, MB; Dichek, DA			Identification of a cis-acting sequence in the human plasminogen activator inhibitor type-1 gene that mediates transforming growth factor-beta 1 responsiveness in endothelium in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; NECROSIS-FACTOR-ALPHA; MESSENGER-RNA LEVELS; HEP G2 CELLS; FACTOR-BETA; EXPRESSION; TISSUE; INDUCTION; PAI-1; LIPOPOLYSACCHARIDE	The mechanism of regulation of the plasminogen activator inhibitor type-1 (PAI-1) gene by transforming growth factor-beta 1 (TGF-beta 1) was studied in vitro and in vivo in endothelial cells. We constructed adenovirus vectors containing PAI-1 5'-flanking sequences driving expression of a beta p-galactosidase (beta-gal) reporter gene, Cultured bovine endothelial cells were transduced with the vectors and treated with TGF-beta 1. beta-Gal expression was up-regulated 10-20-fold by TGF-beta 1 when vectors contained 799-base pair (bp) of 5'-flanking sequence, but only minimally (2-3 fold) from a vector containing only 82-bp of 5' PAI-1 flanking sequence. TGF-beta 1 up-regulated p-gal expression at the mRNA level, congruently with TGF-beta P1 up-regulation of expression of the endogenous PAI-1 gene. The constructs were transduced into intact rat carotid endothelium, and TGF-P1 was injected systemically. In vivo, TGF-beta 1 up-regulated endothelium-specific expression of beta-gal 3-fold (p < 0.03) from a vector containing the 799-bp sequence, but did not alter expression from a vector containing the 82-bp sequence. The sequence between -799 and -82 mediates up-regulation of reporter gene expression by TGF-beta 1 in endothelial cells in vitro and in vivo. This general method permits the elucidation of mechanisms of gene regulation by physiologic stimuli delivered to the endothelium of intact animals.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141; NHLBI,MOL HEMATOL BRANCH,NIH,BETHESDA,MD 20892	University of California System; University of California San Francisco; The J David Gladstone Institutes; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)				Dichek, David/0000-0002-5224-2736				AIRD WC, 1995, P NATL ACAD SCI USA, V92, P4567, DOI 10.1073/pnas.92.10.4567; ALESSI MC, 1995, FIBRINOLYSIS, V9, P237, DOI 10.1016/S0268-9499(08)80065-3; ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; BRAND T, 1993, J BIOL CHEM, V268, P11500; CHANG E, 1995, J BIOL CHEM, V270, P4473, DOI 10.1074/jbc.270.9.4473; COLUCCI M, 1985, J CLIN INVEST, V75, P818, DOI 10.1172/JCI111777; DAVIDSON BL, 1994, EXP NEUROL, V125, P258, DOI 10.1006/exnr.1994.1028; DESCHEEMAEKER KA, 1992, J BIOL CHEM, V267, P15086; DEWEY CF, 1979, DYNAMICS ARTERIAL FL, P55; DICHEK D, 1989, BLOOD, V74, P222; DICHEK D, 1989, IN VITRO CELL DEV B, V25, P289; EMEIS JJ, 1986, J EXP MED, V163, P1260, DOI 10.1084/jem.163.5.1260; FUJII S, 1992, CIRCULATION, V86, P2000, DOI 10.1161/01.CIR.86.6.2000; GALILEO DS, 1990, P NATL ACAD SCI USA, V87, P458, DOI 10.1073/pnas.87.1.458; GINSBERG HS, 1989, P NATL ACAD SCI USA, V86, P3823, DOI 10.1073/pnas.86.10.3823; Ginsberg HS, 1984, ADENOVIRUSES; HASENSTAB D, 1994, FASEB J, V8, pA319; IADEMARCO MF, 1993, P NATL ACAD SCI USA, V90, P3943, DOI 10.1073/pnas.90.9.3943; JUHANVAGUE I, 1993, THROMB HAEMOSTASIS, V70, P138; KEETON M, 1993, AM J PATHOL, V142, P59; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13695; LEE SW, 1993, CIRC RES, V73, P797, DOI 10.1161/01.RES.73.5.797; MIMURO J, 1987, THROMB HAEMOSTASIS, V58, P447; Newman KD, 1995, J CLIN INVEST, V96, P2955, DOI 10.1172/JCI118367; PRALONG G, 1989, THROMB HAEMOSTASIS, V61, P459; RADE JJ, 1993, CIRCULATION, V88, P1; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; RICCIO A, 1992, MOL CELL BIOL, V12, P1846, DOI 10.1128/MCB.12.4.1846; SAKSELA O, 1987, J CELL BIOL, V105, P957, DOI 10.1083/jcb.105.2.957; SAMUEL SK, 1992, EMBO J, V11, P1599, DOI 10.1002/j.1460-2075.1992.tb05205.x; SANDLER MA, 1994, J BIOL CHEM, V269, P21500; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; SAWDEY MS, 1991, J CLIN INVEST, V88, P1346, DOI 10.1172/JCI115440; SCHLEEF RR, 1988, J BIOL CHEM, V263, P5797; SCHNEIDERMAN J, 1992, P NATL ACAD SCI USA, V89, P6998, DOI 10.1073/pnas.89.15.6998; SCHULICK AH, 1995, CIRC RES, V77, P475, DOI 10.1161/01.RES.77.3.475; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; SIMPSON AJ, 1991, J CLIN PATHOL, V44, P139, DOI 10.1136/jcp.44.2.139; SLIVKA SR, 1991, BLOOD, V77, P1013; SPRENGERS ED, 1987, BLOOD, V69, P381; VANLEEUWEN RTJ, 1994, CIRCULATION, V90, P362, DOI 10.1161/01.CIR.90.1.362; VANMEIJER M, 1995, FIBRINOLYSIS, V9, P263, DOI 10.1016/S0268-9499(95)80015-8; VANMOURIK JA, 1984, J BIOL CHEM, V259, P14914; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WATSON CA, 1995, SCIENCE, V268, P447, DOI 10.1126/science.7716553; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; ZEHEB R, 1988, GENE, V73, P459, DOI 10.1016/0378-1119(88)90510-0	50	40	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29969	29977		10.1074/jbc.271.47.29969	http://dx.doi.org/10.1074/jbc.271.47.29969			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939942	hybrid			2022-12-27	WOS:A1996VU52500070
J	Jiang, YW; Lu, ZM; Zang, Q; Foster, DA				Jiang, YW; Lu, ZM; Zang, Q; Foster, DA			Regulation of phosphatidic acid phosphohydrolase by epidermal growth factor - Reduced association with the EGF receptor followed by increased association with protein kinase C epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; PHOSPHOLIPASE-D ACTIVITY; ADP-RIBOSYLATION FACTOR; SIGNAL-TRANSDUCTION; SERUM STIMULATION; V-SRC; RAS; CELLS; PHOSPHORYLATION; MECHANISM	An important component of receptor-mediated intracellular signal transduction is the generation of lipid second messengers. Lipid second messenger production is a complex process involving a variety of regulatory enzymes that control the intracellular response to the extracellular signal. Phosphatidic acid (PA) is generated in response to phospholipase D and can be con verted to other lipid second messengers including diacylglycerol (DG) and lysophosphatidic acid. PA is converted to DG by PA phosphohydrolase (PAP). We report here that PAP activity can be detected in epidermal growth factor (EGF) receptor immunoprecipitates. Following treatment with EGF, there is a substantial reduction in the PAP activity that co-precipitates with the EGF receptor, The loss of EGF receptor-associated PAP activity occurs with a concomitant increase in PAP activity associated with the epsilon isoform of protein kinase C (PKC). The PAP activity associated with PKC epsilon was dependent upon the PKC co-factors phosphatidylserine and DG but was independent of the kinase activity of PKC epsilon. These data suggest a novel signaling mechanism for the regulation of lipid second messenger production and implicate PAP as an important regulatory component for lipid second messenger production in receptor-mediated intracellular signaling.	CUNY HUNTER COLL,DEPT BIOL SCI,NEW YORK,NY 10021	City University of New York (CUNY) System; Hunter College (CUNY)				Zang, Qun (Sophia)/0000-0002-6397-8896	NATIONAL CANCER INSTITUTE [R01CA046677, R29CA046677] Funding Source: NIH RePORTER; NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RR-03037] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARNERO A, 1994, ONCOGENE, V9, P1387; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FOSTER DA, 1993, CELL SIGNAL, V5, P389, DOI 10.1016/0898-6568(93)90078-Z; JADMAR SC, 1994, BIOCHEM J, V301, P793; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JIANG H, 1995, J BIOL CHEM, V270, P6006, DOI 10.1074/jbc.270.11.6006; JIANG YW, 1994, BIOCHEM BIOPH RES CO, V203, P1195, DOI 10.1006/bbrc.1994.2309; JONES GA, 1993, J BIOL CHEM, V268, P20845; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARTIN A, 1993, J BIOL CHEM, V268, P23924; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; MORITZ A, 1992, J BIOL CHEM, V267, P7207; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; Singer WD, 1996, J BIOL CHEM, V271, P4504; SONG JG, 1994, CELL GROWTH DIFFER, V5, P79; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vance DE., 1985, BIOCH LIPIDS MEMBRAN; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; YU CL, 1990, MOL CELL BIOL, V10, P6683, DOI 10.1128/MCB.10.12.6683	29	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29529	29532		10.1074/jbc.271.47.29529	http://dx.doi.org/10.1074/jbc.271.47.29529			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939878	hybrid			2022-12-27	WOS:A1996VU52500006
J	Rosenfeld, SS; Correia, JJ; Xing, J; Rener, B; Cheung, HC				Rosenfeld, SS; Correia, JJ; Xing, J; Rener, B; Cheung, HC			Structural studies of kinesin-nucleotide intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; MYOSIN SUBFRAGMENT-1; BOUNDARY ANALYSIS; SEDIMENTATION; ATPASE; DOMAIN; MOTOR; MICROTUBULES; COMPLEXES; KINETICS	We have investigated the structural changes that occur in the molecular motor kinesin during its ATPase cycle, utilizing two bacterially expressed constructs, The structure of both constructs has been examined as a function of the nature of the nucleotide intermediate occupying the active site by means of sedimentation velocity, sedimentation equilibrium, fluorescence solute quenching, fluorescence anisotropy decay, and limited proteolysis, While the molecular weight of monomeric and dimeric human kinesin constructs, as measured by sedimentation velocity and sedimentation equilibrium, and the tryptic cleavage pattern are unaffected by the nucleotide intermediate occupying the active site, significant changes in the rotational correlation time of fluorescently labeled kinesin-nucleotide intermediates can be detected, These results suggest that kinesin contains an internal ''hinge'' whose flexibility varies through the course of the ATPase cycle, In prehydrolytic, ''strong'' binding states, this hinge is relatively rigid, while in posthydrolytic, ''weak'' binding states, it is more flexible. Our results, in conjunction with anisotropy decay studies of myosin, suggest that these two molecular motors may share a common structural feature; viz. weak binding states are characterized by segmental flexibility, which is lost upon assumption of a strong binding conformation.	UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT BIOCHEM & MOL GENET,BIRMINGHAM,AL 35294; UNIV MISSISSIPPI,MED CTR,DEPT BIOCHEM,JACKSON,MS 39216	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Mississippi; University of Mississippi Medical Center	Rosenfeld, SS (corresponding author), UNIV ALABAMA,DEPT NEUROL,UAB STN,BIRMINGHAM,AL 35294, USA.				NINDS NIH HHS [NS 01500, NS 31096] Funding Source: Medline; PHS HHS [BIR-9216150] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P20NS031096] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CORREIA JJ, 1995, BIOCHEMISTRY-US, V34, P4898, DOI 10.1021/bi00014a047; CREMO CR, 1990, BIOCHEMISTRY-US, V29, P3309, DOI 10.1021/bi00465a023; ENDOW SA, 1992, ANNU REV CELL BIOL, V8, P29; GILBERT GA, 1959, PROC R SOC LON SER-A, V250, P377, DOI 10.1098/rspa.1959.0070; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GILBERT SP, 1994, BIOCHEMISTRY-US, V33, P1951, DOI 10.1021/bi00173a044; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HACKNEY DD, 1994, P NATL ACAD SCI USA, V76, P2620; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Kashina AS, 1996, NATURE, V379, P270, DOI 10.1038/379270a0; KOENIG SH, 1975, BIOPOLYMERS, V14, P2421, DOI 10.1002/bip.1975.360141115; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; Lansing WD, 1935, J AM CHEM SOC, V57, P1369, DOI 10.1021/ja01310a058; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LEHRER SS, 1978, METHOD ENZYMOL, V49, P220; Ma Y. Z., 1995, Biophysical Journal, V68, pA28; NA GC, 1985, METHOD ENZYMOL, V117, P459; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; Phan BC, 1996, BIOPHYS CHEM, V59, P341, DOI 10.1016/0301-4622(95)00127-1; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; Rosenfeld SS, 1996, J BIOL CHEM, V271, P9473, DOI 10.1074/jbc.271.16.9473; ROSENFELD SS, 1994, J BIOL CHEM, V269, P30187; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SADHU A, 1992, J BIOL CHEM, V267, P11352; SHRIVER JW, 1981, BIOCHEMISTRY-US, V20, P2004, DOI 10.1021/bi00510a041; SHRIVER JW, 1981, BIOCHEMISTRY-US, V20, P6357, DOI 10.1021/bi00525a011; Stafford Walter F., 1996, Biophysical Journal, V70, pA231; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; STAFFORD WF, 1994, METHOD ENZYMOL, V240, P478; STAFFORD WF, 1992, ANAL ULTRACENTRIFUGA, P353; Stern O, 1919, PHYS Z, V20, P183; WALKER RA, 1993, ANNU REV BIOCHEM, V62, P429; WANG CK, 1992, BIOCHIM BIOPHYS ACTA, V1121, P16, DOI 10.1016/0167-4838(92)90331-7; Waxman E, 1994, MODERN ANAL ULTRACEN, P189; YPHANTIS DA, 1956, J PHYS CHEM-US, V60, P623; [No title captured]	40	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30212	30221		10.1074/jbc.271.47.30212	http://dx.doi.org/10.1074/jbc.271.47.30212			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939973	hybrid			2022-12-27	WOS:A1996VU52500101
J	Hodgins, R; Gwozd, C; Arnason, T; Cummings, M; Ellison, MJ				Hodgins, R; Gwozd, C; Arnason, T; Cummings, M; Ellison, MJ			The tail of a ubiquitin-conjugating enzyme redirects multi-ubiquitin chain synthesis from the lysine 48-linked configuration to a novel nonlysine-linked form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; MULTIUBIQUITIN CHAIN; DNA-REPAIR; CARRIER PROTEIN; RNA-POLYMERASE; CDC34 UBC3; DEGRADATION; GENE; EXPRESSION; RAD6	The UBC1 ubiquitin-conjugating enzyme from Saccharomyces cerevisiae has an overlapping function with the UBC4 and UBC5 enzymes in the yeast stress response and an important role in the G(0) to G(1) transition that accompanies spore germination (Seufert, W., McGrath, J. P., and Jentsch, S. (1990) EMBO J. 9, 4573-4541). In the present work we report that the UBC1 enzyme assembles onto itself a multi-ubiquitin chain in vitro whose linkage configuration is dependent on the unconserved carboxyl-terminal extension or tail that is appended to its catalytic domain. Using chemical cleavage and site-specific mutagenesis, we have mapped the location of the chain to lysine 93 which lies near the active site within the catalytic domain The ubiquitin molecule that anchors the chain is transferred to this lysine from the active site of the same UBC1 molecule. When the tail of UBC1 is deleted, the catalytic-domain synthesizes a chain that consists of ubiquitin molecules uniformly linked to one another via lysine 48. In the presence of the tail, however, a chain is assembled that is composed of linkages that are stable to alkali but which do not utilize lysines. Furthermore, when the amino terminus of ubiquitin is blocked by an appended peptide tag, chain assembly reverts from this alternative configuration to the canonical lysine 48 variety. Taken together, these results suggest that the alternative chain is composed of linkages in which one ubiquitin molecule forms a peptide bond with the alpha-amino terminus of another, thereby supporting the emerging view that Ub can be attached to itself or other proteins in a variety of ways.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA	University of Alberta								ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; BANERJEE A, 1993, J BIOL CHEM, V268, P5668; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; COOK WJ, 1992, J BIOL CHEM, V267, P15116; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; GONDA DK, 1989, J BIOL CHEM, V264, P16700; GREGORI L, 1990, J BIOL CHEM, V265, P8354; HAAS AL, 1991, J BIOL CHEM, V266, P5104; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HODGINS RRW, 1992, J BIOL CHEM, V267, P8807; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; PTAK C, 1994, J BIOL CHEM, V269, P26539; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SILVER ET, 1992, EMBO J, V11, P3091, DOI 10.1002/j.1460-2075.1992.tb05381.x; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VANNOCKER S, 1991, P NATL ACAD SCI USA, V88, P10297, DOI 10.1073/pnas.88.22.10297; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	31	53	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28766	28771		10.1074/jbc.271.46.28766	http://dx.doi.org/10.1074/jbc.271.46.28766			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910518	hybrid			2022-12-27	WOS:A1996VT05200010
J	Mahoney, CW; Pak, JH; Huang, KP				Mahoney, CW; Pak, JH; Huang, KP			Nitric oxide modification of rat brain neurogranin - Identification of the cysteine residues involved in intramolecular disulfide bridge formation using site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; KINASE-C SUBSTRATE; CALMODULIN-BINDING-PROTEIN; AMINO-ACID-SEQUENCE; RC3 NEUROGRANIN; PHOSPHORYLATION; LOCALIZATION; GLUTAREDOXIN; PEROXYNITRITE; NITROSYLATION	Neurogranin (Ng) is a neuron-specific protein kinase C-selective substrate, which binds calmodulin (CaM) in the dephosphorylated form at low levels of Ca2+. This protein contains redox active Cys residues that are readily oxidized by several nitric oxide (NO) donors and other oxidants to form intramolecular disulfide. Identification of the Cys residues of rat brain Ng, Cys(3), Cys(4), Cys(9), and Cys(51), involved in NO-mediated intramolecular disulfide bridge formation was examined by site-directed mutagenesis. Mutation of all four Cys residues or single mutation of Cys(51) blocked the oxidant-mediated intramolecular disulfide formation as monitored by the downward mobility shift under nonreducing SDS-polyacrylamide gel electrophoresis. Single mutation of Cys(3), Cys(4), or Cys(9) or double mutation of any pair of these three Cys residues did not block such intramolecular disulfide formation, although the rates of oxidation of these mutant proteins were different. Thus, Cys(51) is an essential pairing partner in NO-mediated intramolecular disulfide formation in Ng. Cys(3), Cys(4), and Cys(9) individually could pair with Cys(51), and the order of reactivity was Cys(9) > Cys(4) > Cys(3), suggesting that Cys(9) and Cys(51) form the preferential disulfide bridge. In all cases tested, the intramolecularly disulfide bridged Ng proteins displayed dramatically attenuated CaM-binding affinity and similar to 2-3-fold weaker protein kinase C substrate phosphorylation activity. The data indicate that the N-terminal Cys(3), Cys(4), and Cys(9) are in close proximity to the C-terminal Cys(51) in solution. The disulfide bridge between the N- and C-terminal domains of Ng renders the central CaM-binding and phosphorylation site domain in a fixed conformation unfavorable for binding to CaM and as a substrate of protein kinase C.	NICHHD, METAB REGULAT SECT, ENDOCRINOL & REPROD RES BRANCH, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; COGGINS PJ, 1991, NEUROSCI RES COMMUN, V8, P49; COHEN RW, 1993, BRAIN RES, V627, P147, DOI 10.1016/0006-8993(93)90758-F; COLLEY PA, 1993, BRAIN RES REV, V18, P115, DOI 10.1016/0165-0173(93)90009-O; DEKKER LV, 1989, NATURE, V342, P74, DOI 10.1038/342074a0; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; GERENDASY DD, 1995, J BIOL CHEM, V270, P6741, DOI 10.1074/jbc.270.12.6741; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; HESS DT, 1993, NATURE, V366, P562, DOI 10.1038/366562a0; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOLMGREN A, 1986, THIOREDOXIN GLUTARED, P1; HUANG KP, 1993, ARCH BIOCHEM BIOPHYS, V305, P570, DOI 10.1006/abbi.1993.1463; HUANG KP, 1991, METHOD ENZYMOL, V200, P241; KLANN E, 1993, P NATL ACAD SCI USA, V90, P8337, DOI 10.1073/pnas.90.18.8337; KLANN E, 1992, J NEUROCHEM, V58, P1576, DOI 10.1111/j.1471-4159.1992.tb11382.x; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; MARTZEN MR, 1995, J NEUROCHEM, V64, P92; ODONNELL ME, 1983, J BIOL CHEM, V258, P3795; RADI R, 1991, J BIOL CHEM, V266, P4244; RAMAKERS GMJ, 1995, J BIOL CHEM, V270, P13892, DOI 10.1074/jbc.270.23.13892; REPRESA A, 1990, J NEUROSCI, V10, P3782, DOI 10.1523/JNEUROSCI.10-12-03782.1990; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sheu FS, 1996, J BIOL CHEM, V271, P22407, DOI 10.1074/jbc.271.37.22407; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; WAKIM BT, 1987, BIOCHEMISTRY-US, V26, P7466, DOI 10.1021/bi00397a040; WATSON JB, 1992, P NATL ACAD SCI USA, V89, P8581, DOI 10.1073/pnas.89.18.8581; WATSON JB, 1994, MOL BRAIN RES, V27, P323, DOI 10.1016/0169-328X(94)90017-5; WATSON JB, 1990, J NEUROSCI RES, V26, P397, DOI 10.1002/jnr.490260402; ZHANG J, 1995, ANNU REV PHARMACOL, V35, P213	39	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28798	28804		10.1074/jbc.271.46.28798	http://dx.doi.org/10.1074/jbc.271.46.28798			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910523				2022-12-27	WOS:A1996VT05200015
J	Seckl, MJ; Higgins, T; Rozengurt, E				Seckl, MJ; Higgins, T; Rozengurt, E			[D-Arg(1),D-Trp(5,7,9),Leu(11)]substance P coordinately and reversibly inhibits bombesin- and vasopressin-induced signal transduction pathways in Swiss 3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE HYDROLYSIS; STIMULATE TYROSINE PHOSPHORYLATION; PASTEURELLA-MULTOCIDA TOXIN; PEPTIDE ANTAGONIST RC-3095; LUNG-CANCER CELLS; PHOSPHOLIPASE-C; RAPIDLY STIMULATE; ALPHA-SUBUNITS; PHORBOL ESTERS	The novel substance P (SP) analogue, [D-Arg(1),D-Trp(5,7,9),Leu(11)]SP like [D-Arg(1),D-Phe(5),D-Trp(7,9),Leu(11)]SP inhibited DNA synthesis induced by bombesin, vasopressin, and bradykinin, but did not interfere with the mitogenic response induced by other growth factors or pharmacological agents in Swiss 3T3 cells. [D-Arg(1),D-Trp(5,7,9),Leu(11)]SP reversibly inhibited bombesin-induced DNA synthesis, causing a 6-fold greater rightward shift in the bombesin dose response than [D-Arg(1),D-Phe(5),D-Trp(7,9),Leu(11)]SP at identical concentrations (10 mu M). We found that the new, more potent, SP analogue coordinately and reversibly inhibited bombesin-induced Ca2+ mobilization and protein kinase C (PKC) and mitogen-activated protein (MAP) kinase activation. The dose-response curves for bombesin-induced Ca2+ mobilization and MAP kinase activation were similarly displaced (51- and 40-fold, respectively) by [D-Arg(1),D-Trp(5,7,9),Leu(11)]SP. In addition, [D-Arg(1),D-Trp(5,7,9),Leu(11)]SP reversibly inhibited bombesin-induced tyrosine phosphorylation of M(r) 110,000-130,000 and 70,000-80,000 bands as well. as p125 focal adhesion kinase. [D-Arg(1),D-Trp(5,7,9),Leu(11)]SP also reversibly and coordinately inhibited vasopressin-induced Ca2+ mobilization, PKC stimulation, MAP kinase activation, tyrosine phosphorylation, and DNA synthesis in Swiss 3T3 cells. Surprisingly, deletion of the terminal Leu of [D-Arg(1),D-Phe(5),D-Trp(7,9),Leu(11)]SP to yield [D-Arg(1),D-Phe(5),D-Trp(7,9)]SP1-10 resulted in a selective loss of inhibitory activity of this analogue against bombesin but not vasopressin-stimulated DNA synthesis, Ca2+ mobilization, and MAP kinase activation. Collectively, these results suggest that SP analogues act at the receptor level to coordinately and reversibly antagonize bombesin- or vasopressin-induced signal transduction in Swiss 3T3 cells.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK								BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BROOKS SF, 1991, EMBO J, V10, P2497, DOI 10.1002/j.1460-2075.1991.tb07789.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Charlesworth A, 1996, ONCOGENE, V12, P1337; COFFER A, 1990, FEBS LETT, V263, P80, DOI 10.1016/0014-5793(90)80710-Z; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; ERUSALIMSKY JD, 1989, J CELL PHYSIOL, V141, P253, DOI 10.1002/jcp.1041410204; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HESLOP JP, 1986, CELL, V47, P703, DOI 10.1016/0092-8674(86)90513-1; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; JONES DA, 1995, PEPTIDES, V16, P777, DOI 10.1016/0196-9781(95)00048-O; KIEHNE K, 1994, J CELL PHYSIOL, V160, P502, DOI 10.1002/jcp.1041600313; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGDON S, 1992, CANCER RES, V52, P4554; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; MURPHY AC, 1992, J BIOL CHEM, V267, P25296; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; OFFERMANNS S, 1994, FEBS LETT, V349, P201, DOI 10.1016/0014-5793(94)00667-9; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; PINSKI J, 1994, CANCER RES, V54, P169; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RODRIGUEZPENA A, 1986, EMBO J, V5, P77, DOI 10.1002/j.1460-2075.1986.tb04180.x; ROZENGURT E, 1988, PROG NUCLEIC ACID RE, V35, P261, DOI 10.1016/S0079-6603(08)60616-9; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; ROZENGURT E, 1995, OXFORD TXB ONCOLOGY, P12; ROZENGURT E, 1993, TRENDS EXP CLIN MED, V3, P145; SECKL M, 1993, J BIOL CHEM, V268, P9548; SECKL MJ, 1995, J CELL PHYSIOL, V163, P87, DOI 10.1002/jcp.1041630110; SECKL MJ, 1995, J BIOL CHEM, V270, P6984, DOI 10.1074/jbc.270.12.6984; SETHI T, 1992, CANCER RES, V52, pS2737; Seufferlein T, 1996, J BIOL CHEM, V271, P21471, DOI 10.1074/jbc.271.35.21471; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SINNETTSMITH J, 1990, BIOCHEM J, V265, P485, DOI 10.1042/bj2650485; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STADDON JM, 1991, J BIOL CHEM, V266, P4840; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WITHERS DJ, 1995, J BIOL CHEM, V270, P21411, DOI 10.1074/jbc.270.36.21411; WOLL PJ, 1990, CANCER RES, V50, P3968; WOLL PJ, 1988, P NATL ACAD SCI USA, V85, P1859, DOI 10.1073/pnas.85.6.1859; WOLL PJ, 1993, CANC CHEMOTHER, P128; YANO T, 1992, CANCER RES, V52, P4545; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211; ZACHARY I, 1985, P NATL ACAD SCI USA, V82, P7616, DOI 10.1073/pnas.82.22.7616; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1987, BIOCHEM BIOPH RES CO, V146, P456, DOI 10.1016/0006-291X(87)90551-1; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	61	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29453	29460		10.1074/jbc.271.46.29453	http://dx.doi.org/10.1074/jbc.271.46.29453			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910612	hybrid			2022-12-27	WOS:A1996VT05200104
J	Yang, WL; Carman, GM				Yang, WL; Carman, GM			Phosphorylation and regulation of CTP synthetase from Saccharomyces cerevisiae by protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTIDINE 5'-TRIPHOSPHATE SYNTHETASE; HAMSTER OVARY CELLS; SUBSTRATE-SPECIFICITY; MUTATOR GENE; URA7 GENE; MUTANTS; PHOSPHATASES; TUMORS; YEAST	The phosphorylation and regulation of the URA7-encoded CTP synthetase (EC 6.3.4.2, UTP:ammonia ligase (ADP-forming)) from Saccharomyces cerevisiae by cAMP-dependent protein kinase (protein kinase A) were examined. Protein kinase A is the principal mediator of signals transmitted through the RAS/cAMP pathway in S. cerevisiae. The results of labeling experiments indicated that the phosphorylation of CTP synthetase was mediated by the RAS/cAMP pathway in vivo. In vitro, protein kinase A phosphorylated CTP synthetase at a serine residue with a stoichiometry consistent with one phosphorylation site per CTP synthetase subunit. Protein kinase A activity was dose- and time-dependent using CTP synthetase as a substrate. The dependence of protein kinase A activity on CTP synthetase was cooperative (n = 1.8) and the K-m value for CTP synthetase was 73 nM. Phosphorylation of CTP synthetase with protein kinase A resulted in the stimulation (190%) of activity. The mechanism of this stimulation included an increase in the V-max of the reaction with respect to UTP and ATP, a decrease in the K-m for ATP, and a decrease in the cooperative kinetic behavior of the enzyme. Phosphorylated CTP synthetase was less sensitive to product inhibition by CTP, Protein kinase C also phosphorylates and activates CTP synthetase. Phosphorylation of CTP synthetase with protein kinases A and C together resulted in an increase in CTP synthetase activity that was slightly greater than that obtained when the enzyme was phosphorylated with either protein kinase alone.	RUTGERS STATE UNIV, COOK COLL, NEW JERSEY AGR EXPT STN, DEPT FOOD SCI, NEW BRUNSWICK, NJ 08903 USA	Rutgers State University New Brunswick					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-50679] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONOW B, 1984, J BIOL CHEM, V259, P9035; BEULLENS M, 1993, J BIOL CHEM, V268, P13172; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; CHU EHY, 1984, BIOCHEM GENET, V22, P701, DOI 10.1007/BF00485854; CULBERTSON MR, 1975, GENETICS, V80, P23; HAID A, 1983, METHOD ENZYMOL, V96, P192; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KAUFMAN ER, 1986, MUTAT RES, V161, P19, DOI 10.1016/0027-5107(86)90096-5; KAWAMOTO S, 1987, J BIOL CHEM, V262, P7282; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIZAKI H, 1980, CANCER RES, V40, P3921; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P241, DOI 10.1021/bi00752a015; LIEBERMAN I, 1956, J BIOL CHEM, V222, P765; LONG CW, 1967, J BIOL CHEM, V242, P4715; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; MEUTH M, 1979, P NATL ACAD SCI USA, V76, P6505, DOI 10.1073/pnas.76.12.6505; MEUTH M, 1982, SOMAT CELL GENET, V8, P423, DOI 10.1007/BF01538705; NADKARNI AK, 1995, J BIOL CHEM, V270, P24982, DOI 10.1074/jbc.270.42.24982; OZIERKALOGEROPOULOS O, 1991, MOL GEN GENET, V231, P7, DOI 10.1007/BF00293815; OZIERKALOGEROPOULOS O, 1994, MOL GEN GENET, V242, P431, DOI 10.1007/BF00281793; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; THEVELEIN JM, 1994, YEAST, V10, P1753, DOI 10.1002/yea.320101308; THEVELEIN JM, 1985, J GEN MICROBIOL, V131, P3199; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; TRUDEL M, 1984, J BIOL CHEM, V259, P2355; VANDENBERG AA, 1993, EUR J BIOCHEM, V216, P161; VINCENT BRD, 1980, BIOCHIM BIOPHYS ACTA, V610, P352; WARNER JR, 1991, METHOD ENZYMOL, V194, P423; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WEBER G, 1980, LIFE SCI, V27, P793, DOI 10.1016/0024-3205(80)90333-1; Weber G, 1978, Adv Enzyme Regul, V17, P1; Yang WL, 1996, J BIOL CHEM, V271, P11113, DOI 10.1074/jbc.271.19.11113; YANG WL, 1994, BIOCHEMISTRY-US, V33, P10785, DOI 10.1021/bi00201a028; YANG WL, 1995, J BIOL CHEM, V270, P14983, DOI 10.1074/jbc.270.25.14983	43	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28777	28783		10.1074/jbc.271.46.28777	http://dx.doi.org/10.1074/jbc.271.46.28777			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910520	hybrid			2022-12-27	WOS:A1996VT05200012
J	Fu, HW; Moomaw, JF; Moomaw, CR; Casey, PJ				Fu, HW; Moomaw, JF; Moomaw, CR; Casey, PJ			Identification of a cysteine residue essential for activity of protein farnesyltransferase - Cys(299) is exposed only upon removal of zinc from the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERANYLGERANYLTRANSFERASE TYPE-I; ALPHA-SUBUNIT; METAL REQUIREMENTS; KINETIC MECHANISM; PEPTIDE-BINDING; CDNA CLONING; EXPRESSION; RAT; TRANSFERASE; SYSTEM	Protein farnesyltransferase (FTase) is a zinc metalloenzyme that performs a post-translational modification on many proteins that is critical for their function. The importance of cysteine residues in FTase activity was investigated using cysteine-specific reagents. Zinc-depleted FTase (apo-FTase), but not the holoenzyme, was completely inactivated by treatment with N-ethylmaleimide (NEM). Similar effects were detected after treatment of the enzyme with iodoacetamide. The addition of zinc to apo-FTase protects it from inactivation by NEM, These findings indicated the presence of specific cysteine residue(s), potentially located at the zinc binding site, that are required for FTase activity. We performed a selective labeling strategy whereby the cysteine residues exposed upon removal of zinc from the enzyme were modified with [H-3]NEM. The enzyme so modified was digested with trypsin, and four labeled peptides were identified and sequenced, one peptide being the major site of labeling and the remaining three labeled to lesser extents. The major labeled peptide contained a radiolabeled cysteine residue, Cys(299), that is in the beta subunit of FTase and is conserved in all known protein prenyltransferases. This cysteine residue was changed to both alanine and serine by site-directed mutagenesis, and the mutant proteins were produced in Escherichia coli and purified, While both mutant proteins retained the ability to bind farnesyl diphosphate, they were found to have lost essentially all catalytic activity and ability to bind zinc. These results indicate that the Cys(299) in the beta subunit of FTase plays a critical role in catalysis by the enzyme and is likely to be one of the residues that directly coordinate the zinc atom in this enzyme.	DUKE UNIV,MED CTR,DEPT MOL CANC BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	Duke University; Duke University; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Fu, Hua-Wen/0000-0002-6346-2785; Casey, Patrick/0000-0002-7366-9309	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046372] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46372] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRES DA, 1993, J BIOL CHEM, V268, P1383; BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; BUKHTIYAROV YE, 1995, J BIOL CHEM, V270, P19035, DOI 10.1074/jbc.270.32.19035; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHEN WJ, 1993, J BIOL CHEM, V268, P9675; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CHEN WJ, 1991, P NATL ACAD SCI USA, V88, P11368, DOI 10.1073/pnas.88.24.11368; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; FURFINE ES, 1995, BIOCHEMISTRY-US, V34, P6857, DOI 10.1021/bi00020a032; LIU TY, 1977, PROTEINS, V3, P239; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P610; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MOOMAW JF, 1995, METHOD ENZYMOL, V250, P12; OMER CA, 1993, BIOCHEMISTRY-US, V32, P5167, DOI 10.1021/bi00070a028; RAY K, 1995, J BIOL CHEM, V270, P21765, DOI 10.1074/jbc.270.37.21765; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, J BIOL CHEM, V266, P10672; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAFER WR, 1992, ANNU REV GENET, V30, P209; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; STONE KL, 1993, PRACTICAL GUIDE PROT, P55; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; YING WL, 1994, J BIOL CHEM, V269, P470; YOKOYAMA K, 1995, BIOCHEMISTRY-US, V34, P1344, DOI 10.1021/bi00004a029; ZHANG FL, 1994, J BIOL CHEM, V269, P3175; Zhang FL, 1996, BIOCHEMISTRY-US, V35, P8166, DOI 10.1021/bi960574+; ZHANG FL, 1994, J BIOL CHEM, V269, P23465; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; ZHANG FL, 1996, IN PRESS BIOCH J	31	45	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28541	28548		10.1074/jbc.271.45.28541	http://dx.doi.org/10.1074/jbc.271.45.28541			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910483	hybrid			2022-12-27	WOS:A1996VU03300083
J	Grigoryev, S; Stewart, AE; Kwon, YT; Arfin, SM; Bradshaw, RA; Jenkins, NA; Copeland, NG; Varshavsky, A				Grigoryev, S; Stewart, AE; Kwon, YT; Arfin, SM; Bradshaw, RA; Jenkins, NA; Copeland, NG; Varshavsky, A			A mouse amidase specific for N-terminal asparagine - The gene, the enzyme, and their function in the N-end rule pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-DEPENDENT PROTEOLYSIS; SHORT-LIVED PROTEIN; SACCHAROMYCES-CEREVISIAE; DEGRADATION SIGNAL; RECOGNITION COMPONENT; TRANSCRIPTION FACTORS; MULTIUBIQUITIN CHAIN; ESCHERICHIA-COLI; BINDING-PROTEINS; MESSENGER-RNA	The N-end rule relates the in vivo half-life of a protein to the identity of its N-terminal residue. In both fungi and mammals, the tertiary destabilizing N-terminal residues asparagine and glutamine function through their conversion, by enzymatic deamidation, into the secondary destabilizing residues aspartate and glutamate, whose destabilizing activity requires their enzymatic conjugation to arginine, one of the primary destabilizing residues. We report the isolation and analysis of a mouse cDNA and the corresponding gene (termed Ntan1) that encode a 310-residue amidohydrolase (termed Nt(N)-amidase) specific for N-terminal asparagine, The similar to 17-kilobase pair Ntan1 gene is located in the proximal region of mouse chromosome 16 and contains 10 exons ranging from 54 to 177 base pairs in length. The similar to 1.4 kilobase pair Ntan1 mRNA is expressed in all of the tested mouse tissues and cell lines and is down-regulated upon the conversion of myoblasts into myotubes. The Ntan1 promoter is located similar to 500 base pairs upstream of the Ntan1 start codon. The deduced amino acid sequence of mouse Nt(N)-amidase is 88% identical to the sequence of its porcine counterpart, but bears no significant similarity to the sequence of the NTA1-encoded N-terminal amidohydrolase of the yeast Saccharomyces cerevisiae, which can deamidate either N-terminal asparagine or glutamine. The expression of mouse Nt(N)-amidase in S. cerevisiae nta1 Delta was used to verify that Nt(N)-amidase retains its asparagine selectivity in. vivo and can implement the asparagine-specific subset of the N-end rule. Further dissection of mouse Ntan1, including its null phenotype analysis, should illuminate the functions of the N-end rule, most of which are still unknown.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA; UNIV CALIF IRVINE, COLL MED, DEPT BIOL CHEM, IRVINE, CA 92717 USA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA	California Institute of Technology; University of California System; University of California Irvine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Bradshaw, Ralph A/K-1515-2013		NIDDK NIH HHS [DK32461, DK39520] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039520, R37DK039520, R56DK039520] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAGRAMAM K, 1995, MOL MICROBIOL, V15, P225, DOI 10.1111/j.1365-2958.1995.tb02237.x; ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P7979, DOI 10.1021/bi00421a001; ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; AUGEREAU P, 1986, EMBO J, V5, P1791, DOI 10.1002/j.1460-2075.1986.tb04428.x; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER RT, 1995, J BIOL CHEM, V270, P12065, DOI 10.1074/jbc.270.20.12065; BAKER RT, 1991, P NATL ACAD SCI USA, V88, P1090, DOI 10.1073/pnas.88.4.1090; BALZI E, 1990, J BIOL CHEM, V265, P7464; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; BURATOWSKI S, 1992, TRANSCRIPTIONAL REGU, P227; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; DEGROOT RJ, 1991, P NATL ACAD SCI USA, V88, P8967, DOI 10.1073/pnas.88.20.8967; DESHAIES RJ, 1995, TRENDS CELL BIOL, V5, P428, DOI 10.1016/S0962-8924(00)89102-3; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; DOHMEN RJ, 1991, YEAST, V7, P691, DOI 10.1002/yea.320070704; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GHISLAIN M, 1996, IN PRESS EMBO J; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GONDA DK, 1989, J BIOL CHEM, V264, P16700; Green EL, 1981, GENETICS PROBABILITY, P77; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HILL CP, 1993, P NATL ACAD SCI USA, V90, P4136, DOI 10.1073/pnas.90.9.4136; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HONDERMARCK H, 1992, BIOCHEM BIOPH RES CO, V189, P280, DOI 10.1016/0006-291X(92)91555-5; JAKOBY WB, 1988, METHOD ENZYMOL, V58; JENKINS NA, 1995, GENOMICS, V28, P333, DOI 10.1006/geno.1995.1150; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; Levy F, 1996, P NATL ACAD SCI USA, V93, P4907, DOI 10.1073/pnas.93.10.4907; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; MADURA K, 1993, J BIOL CHEM, V268, P12046; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Mount SM, 1996, SCIENCE, V271, P1690, DOI 10.1126/science.271.5256.1690; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; PIERCE JC, 1992, MAMM GENOME, V3, P550, DOI 10.1007/BF00350620; PUHLER G, 1994, SYST APPL MICROBIOL, V16, P734; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RITHETTI PG, 1990, GEL ELECTROPHORESIS, P149; ROMANOSPICA V, 1995, J IMMUNOL, V154, P2724; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHWARZENBACH H, 1995, J BIOL CHEM, V270, P898, DOI 10.1074/jbc.270.2.898; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Sherman F., 1986, METHODS YEAST GENETI; SHRADER TE, 1993, J BACTERIOL, V175, P4364, DOI 10.1128/JB.175.14.4364-4374.1993; SIKORSKI RS, 1989, GENETICS, V122, P19; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; STEWART A, 1995, TRENDS GENETICS GENE; STEWART AE, 1994, J BIOL CHEM, V269, P23509; STEWART AE, 1995, J BIOL CHEM, V270, P25, DOI 10.1074/jbc.270.1.25; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; TRONCHE F, 1992, BIOESSAYS, V14, P579, DOI 10.1002/bies.950140902; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VARSHAVSKY A, 1991, CELL, V64, P13, DOI 10.1016/0092-8674(91)90202-A; Varshavsky A, 1995, COLD SPRING HARB SYM, V60, P461, DOI 10.1101/SQB.1995.060.01.051; VIERSTRA RD, 1993, ANNU REV PLANT PHYS, V44, P385, DOI 10.1146/annurev.pp.44.060193.002125; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WING SS, 1992, J BIOL CHEM, V267, P6495; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; [No title captured]	86	71	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28521	28532		10.1074/jbc.271.45.28521	http://dx.doi.org/10.1074/jbc.271.45.28521			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910481	Green Accepted, hybrid			2022-12-27	WOS:A1996VU03300081
J	Laakkonen, P; Ahola, T; Kaariainen, L				Laakkonen, P; Ahola, T; Kaariainen, L			The effects of palmitoylation on membrane association of Semliki Forest virus RNA capping enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS PROTEINS; FATTY ACYLATION; PLASMA-MEMBRANE; ATTACHMENT; EXPRESSION; PALMITATE; METHYLTRANSFERASE; IDENTIFICATION; STIMULATION; REPLICASE	The nonstructural protein Nsp1 of Semliki Forest virus has guanine-7-methyltransferase and guanylyltransferase-like activities, required in the capping of viral mRNAs. It is palmitoylated and tightly associated with the cytoplasmic surface of the plasma membrane, endosomes, and lysosomes, To localize the acylation site(s) and the putative membrane-targeting domain, a number of deletions were made in the nsp1 gene. Most deletions resulted in the expression of nonpalmitoylated, enzymatically inactive, cytoplasmic protein. Palmitate could be released from Nsp1 with neutral hydroxylamine, indicating a thioester linkage to a cysteine residue, Therefore we mutated the conserved cysteine residues of Nsp1 to alanine. Triple mutation of Cys(418), Cys(419), and Cys(420) resulted in nonpalmitoylated Nsp1, which was enzymatically active and still associated with membranes. However, it could be released from the membranes with 1 M NaCl, whereas 50 mm sodium carbonate (pH 12) was required to release wild type Nsp1, suggesting a conversion from an integral to a peripheral membrane protein, Indirect confocal immunofluorescence microscopy showed that the nonpalmitoylated Nsp1 colocalized with the plasma membrane marker, concanavalin A. However, it was not detected in filopodia, which were heavily stained in cells expressing wild type Nsp1. These results indicate that the acylation of Nsp1 was not needed for its targeting to the plasma membrane, but it was necessary for the migration to the filopodial extensions of the plasma membrane.			Laakkonen, P (corresponding author), UNIV HELSINKI,INST BIOTECHNOL,POB 56,VIIKINKAARI 9,FIN-00014 HELSINKI,FINLAND.			Laakkonen, Pirjo/0000-0002-9620-095X				AHOLA T, 1995, P NATL ACAD SCI USA, V92, P507, DOI 10.1073/pnas.92.2.507; BIZZOZERO OA, 1994, NEUROCHEM RES, V19, P923, DOI 10.1007/BF00968702; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; COUVE A, 1995, P NATL ACAD SCI USA, V92, P5987, DOI 10.1073/pnas.92.13.5987; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; FROSHAUER S, 1988, J CELL BIOL, V107, P2075, DOI 10.1083/jcb.107.6.2075; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GRIMLEY PM, 1968, J VIROL, V2, P1326, DOI 10.1128/JVI.2.11.1326-1338.1968; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; JAMES G, 1989, J BIOL CHEM, V264, P20998; JING S, 1987, EMBO J, V6, P327, DOI 10.1002/j.1460-2075.1987.tb04758.x; JUNG V, 1995, MOL CELL BIOL, V15, P1333; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LAAKKONEN P, 1994, J VIROL, V68, P7418, DOI 10.1128/JVI.68.11.7418-7425.1994; MCILHINNEY RAJ, 1990, TRENDS BIOCHEM SCI, V15, P387; MCILHINNEY RAJ, 1985, EMBO J, V4, P1145, DOI 10.1002/j.1460-2075.1985.tb03752.x; MI S, 1989, VIROLOGY, V170, P385, DOI 10.1016/0042-6822(89)90429-7; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OLSON EN, 1986, J BIOL CHEM, V261, P2458; OLSON EN, 1988, PROG LIPID RES, V27, P177, DOI 10.1016/0163-7827(88)90012-4; PEPPERBERG DR, 1995, METHOD ENZYMOL, V250, P348; PERANEN J, 1995, VIROLOGY, V208, P610, DOI 10.1006/viro.1995.1192; PERANEN J, 1991, J VIROL, V65, P1623; PERANEN J, 1988, J GEN VIROL, V69, P2165, DOI 10.1099/0022-1317-69-9-2165; PERANEN J, 1990, THESIS YLIOPISTOPAIN; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; ROSE JK, 1984, P NATL ACAD SCI-BIOL, V81, P2050, DOI 10.1073/pnas.81.7.2050; Sambrook J., 2002, MOL CLONING LAB MANU; SHI YG, 1994, J CELL BIOL, V124, P927, DOI 10.1083/jcb.124.6.927; SKENE JHP, 1989, J CELL BIOL, V108, P613, DOI 10.1083/jcb.108.2.613; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; Wang HL, 1996, VIROLOGY, V217, P527, DOI 10.1006/viro.1996.0147; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001	37	88	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28567	28571		10.1074/jbc.271.45.28567	http://dx.doi.org/10.1074/jbc.271.45.28567			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910486	hybrid			2022-12-27	WOS:A1996VU03300086
J	Mitsuhashi, S; Miyachi, S				Mitsuhashi, S; Miyachi, S			Amino acid sequence homology between N- and C-terminal halves of a carbonic anhydrase in Porphyridium purpureum, as deduced from the clotted cDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CHLAMYDOMONAS-REINHARDTII; ESCHERICHIA-COLI; PHOTOSYNTHESIS; PURIFICATION; EXPRESSION; IDENTIFICATION; FIXATION; BINDING; ENZYME	Carbonic anhydrase (CA) from Porphyridium purpureum, a unicellular red alga, was purified >209-fold to a specific activity of 1,147 units/mg protein, cDNA clones for this CA were isolated. The longest clone, comprising 1,960 base pairs, contained an open reading frame which encoded a 571-amino acid polypeptide with a calculated molecular mass of 62,094 Da. The N- and C-terminal halves of the putative mature Porphyridium CA have amino acid sequence homology to each other (>70%) and to other prokaryotic-type CAs. Both regions contain, at equivalent positions, one set of three possible zinc-liganding amino acid residues conserved among prokaryotic-type CAs. CA purified from Porphyridium contained two atoms of zinc per molecule. We propose that the Porphyridium CA has evolved by duplication of an ancestral CA gene followed by the fusion of the duplicated CA gene. The CA truncated into the putative mature form was overexpressed in Escherichia coli, and the expressed protein was active. Clones expressing separately the N- and C-terminal halves of the CA were constructed. CA activity was present in extracts of E. coli cells expressing the N-terminal half, while no detectable activity was found in cells expressing the C-terminal half.	MARINE BIOTECHNOL INST,HEAD OFF,BUNKYO KU,TOKYO 113,JAPAN; MARINE BIOTECHNOL INST,KAMAISHI LABS,KAMAISHI,IWATE 026,JAPAN									AIZAWA K, 1986, FEMS MICROBIOL LETT, V39, P215, DOI 10.1016/0378-1097(86)90447-7; AIZAWA K, 1984, FEBS LETT, V173, P41, DOI 10.1016/0014-5793(84)81013-3; ALBER BE, 1994, P NATL ACAD SCI USA, V91, P6909, DOI 10.1073/pnas.91.15.6909; BAIJAL M, 1992, ARCH BIOCHEM BIOPHYS, V298, P271, DOI 10.1016/0003-9861(92)90123-E; BRACEY MH, 1994, BIOCHEMISTRY-US, V33, P13126, DOI 10.1021/bi00248a023; BRACEY MH, 1995, PLANT PHYSIOL, V108, P433, DOI 10.1104/pp.108.1.433; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; FAWCETT TW, 1990, J BIOL CHEM, V265, P5414; FUJIWARA S, 1990, P NATL ACAD SCI USA, V87, P9779, DOI 10.1073/pnas.87.24.9779; FUKUZAWA H, 1992, P NATL ACAD SCI USA, V89, P4437, DOI 10.1073/pnas.89.10.4437; FUKUZAWA H, 1990, P NATL ACAD SCI USA, V87, P4348; GRAHAM D, 1984, ANN NY ACAD SCI, V429, P222, DOI 10.1111/j.1749-6632.1984.tb12340.x; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUILLOTON MB, 1992, J BIOL CHEM, V267, P3731; HILTONEN T, 1995, PLANTA, V195, P345; HUSIC HD, 1994, PLANT PHYSIOL, V105, P133, DOI 10.1104/pp.105.1.133; HUSIC HD, 1989, PLANT PHYSIOL, V89, P904, DOI 10.1104/pp.89.3.904; KAMO T, 1990, EUR J BIOCHEM, V192, P557, DOI 10.1111/j.1432-1033.1990.tb19261.x; KANNAN KK, 1984, ANN NY ACAD SCI, V429, P49, DOI 10.1111/j.1749-6632.1984.tb12314.x; KARLSSON J, 1995, PLANT PHYSIOL, V109, P533, DOI 10.1104/pp.109.2.533; KIM HJ, 1994, PLANT PHYSIOL, V105, P449, DOI 10.1104/pp.105.1.449; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAJEAU N, 1991, PLANT PHYSIOL, V95, P264, DOI 10.1104/pp.95.1.264; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; PROVART NJ, 1993, PLANT MOL BIOL, V22, P937, DOI 10.1007/BF00028967; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWAB DA, 1989, P NATL ACAD SCI USA, V86, P2563, DOI 10.1073/pnas.86.8.2563; SU X, 1988, ANAL BIOCHEM, V174, P650, DOI 10.1016/0003-2697(88)90068-1; SUNG YC, 1988, J BIOL CHEM, V263, P14769; TASHIAN RE, 1989, BIOESSAYS, V10, P186, DOI 10.1002/bies.950100603; Tsai HJ, 1996, ARCH BIOCHEM BIOPHYS, V329, P17, DOI 10.1006/abbi.1996.0186; TSUZUKI M, 1980, PLANT CELL PHYSIOL, V21, P677, DOI 10.1093/oxfordjournals.pcp.a076042; TSUZUKI M, 1989, AQUAT BOT, V34, P85, DOI 10.1016/0304-3770(89)90051-X; YAGAWA Y, 1987, PLANT CELL PHYSIOL, V28, P1253; YAGAWA Y, 1987, PLANT CELL PHYSL, V28, P1502; YANG SY, 1985, PLANT CELL PHYSIOL, V26, P25	37	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28703	28709		10.1074/jbc.271.45.28703	http://dx.doi.org/10.1074/jbc.271.45.28703			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910506	hybrid			2022-12-27	WOS:A1996VU03300106
J	Bao, M; Elmendorf, BJ; Booth, JL; Drake, RR; Canfield, WM				Bao, M; Elmendorf, BJ; Booth, JL; Drake, RR; Canfield, WM			Bovine UDP-N-acetylglucosamine:lysosomal-enzyme N-acetylglucosamine-1-phosphotransferase .2. Enzymatic characterization and identification of the catalytic subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN RECOGNITION DETERMINANTS; GLYCOPROTEIN N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE; ACANTHAMOEBA-CASTELLANII; CARBOHYDRATE STRUCTURE; PROCATHEPSIN-D; CATHEPSIN-D; PHOSPHORYLATION; UTEROFERRIN; OLIGOSACCHARIDES; PURIFICATION	The kinetic properties of UDP-N-acetylglucosamine: lysosomal-enzyme N-acetylglucosamine-1-phosphotransferase (GlcNAc-phosphotransferase) purified to homogeneity from lactating bovine mammary gland have been investigated. GlcNAc-phosphotransferase transferred GlcNAc 1-phosphate from UDP-GlcNAc to the synthetic acceptor alpha-methylmannoside, generating GlcNAc-1-phospho-6-mannose alpha-methyl, the structure of which was confirmed by mass spectroscopy, GlcNAc-phosphotransferase was active between pH 5.7 and 9.3, with optimal activity between pH 6.6 and 7.5, Activity was strictly dependent on Mg2+ or Mn2+. The K-m for Mn2+ was 185 mu M. The K-m for UDP-GlcNAc was 30 mu M, and that for alpha-methylmannoside was 63 mM. The enzyme was competitively inhibited by UDP-Glc, with a K-i of 733 mu M. The 166-kDa subunit was identified as the catalytic subunit by photoaffinity labeling with azido-[beta-P-32]UDP-Glc. Purified GlcNAc-phosphotransferase utilizes the lysosomal enzyme uteroferrin similar to 163-fold more effectively than the non-lysosomal glycoprotein ribonuclease B. Antibodies to GlcNAc-phosphotransferase blocked the transfer to cathepsin D, but not to alpha-methylmannoside, suggesting that protein-protein interactions are required for the efficient utilization of glycoprotein accepters, These results indicate that the purified bovine GlcNAc-phosphotransferase retains the specificity for lysosomal enzymes as accepters previously observed with crude preparations.	UNIV OKLAHOMA,HLTH SCI CTR,WK WARREN MED RES INST,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT MED,OKLAHOMA CITY,OK 73104; UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOL BIOL,LITTLE ROCK,AR 72205	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Arkansas System; University of Arkansas Medical Sciences								Bao M, 1996, J BIOL CHEM, V271, P31437, DOI 10.1074/jbc.271.49.31437; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BUHI WC, 1982, BIOCHIM BIOPHYS ACTA, V701, P32, DOI 10.1016/0167-4838(82)90308-9; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; COUSO R, 1986, J BIOL CHEM, V261, P6326; DRAKE RR, 1989, J BIOL CHEM, V264, P11928; HUANG JS, 1979, J BIOL CHEM, V254, P1405; KETCHAM CM, 1992, J BIOL CHEM, V267, P11645; KETCHAM CM, 1992, J BIOL CHEM, V267, P11654; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG L, 1986, J BIOL CHEM, V261, P6320; LANG L, 1984, J BIOL CHEM, V259, P4663; MULLIS KG, 1992, ANAL BIOCHEM, V205, P200, DOI 10.1016/0003-2697(92)90424-6; RADOMINSKA A, 1994, METHOD ENZYMOL, V230, P330; REITMAN ML, 1984, METHOD ENZYMOL, V107, P163; SAUNDERS PTK, 1985, J BIOL CHEM, V260, P3658; SHERWOOD LM, 1965, J BIOL CHEM, V240, P3799; TAKAHASHI T, 1983, J BIOL CHEM, V258, P2819	19	51	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31446	31451		10.1074/jbc.271.49.31446	http://dx.doi.org/10.1074/jbc.271.49.31446			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940156	hybrid			2022-12-27	WOS:A1996VW68600067
J	Lai, TS; Slaughter, TF; Koropchak, CM; Haroon, ZA; Greenberg, CS				Lai, TS; Slaughter, TF; Koropchak, CM; Haroon, ZA; Greenberg, CS			C-terminal deletion of human tissue transglutaminase enhances magnesium-dependent GTP/ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG LIVER TRANSGLUTAMINASE; GTP-BINDING PROTEIN; CROSS-LINKING ENZYMES; PROGRAMMED CELL-DEATH; FACTOR-XIII; SITE; IDENTIFICATION; HYDROLYSIS; G(H)	Tissue transglutaminase (tTG) exhibits a magnesium-dependent GTP/ATPase activity that is involved in the regulation of the cell cycle and cell receptor signaling, The portion of the molecule involved in GTP/ATP hydrolysis is unknown, We expressed and purified a series of C-terminal truncation mutants of human tTG as glutathione S-transferase fusion proteins (Delta S538, Delta E447, Delta P345, Delta C290, Delta V228, and Delta F185) to determine the effect on GTP/ATPase activity, The truncation of the C terminus did not change significantly the apparent k(m) value for either GTP or ATP, In contrast, the K-cat value for GTP was increased by 4.6- and S-fold for the Delta 5538 and Delta E447 mutants, respectively, The Delta P845 mutant had the highest hydrolysis activity with a 34-fold increase, The hydrolysis activity then declined to 8.1, 8.7-, and 1.9-fold for the Delta C240, Delta V228, and Delta F185 mutants, respectively, The K-cat for ATP changed in parallel with the GTPase results, Thin layer chromatography analysis of the hydrolysis reaction products revealed that ATP was rapidly converted to ADP followed by a much slower conversion of ADP to AMP when incubated with wild type tTG or the Delta P345 mutant, There was a substantial decrease in the calcium-dependent TGase activity when the last 149 amino acid residues were deleted from the C terminus, Less than 5% of the TGase activity was detected for the Delta S538 and Delta E447 mutants, In conclusion, we have located the ATP and GTP hydrolytic domain to amino acid residues 1-185, The C terminus functions to inhibit the expression of endogenous GTP/ATPase activity of tTG, and the potential role of the C terminus in modulating this activity is discussed.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT ANESTHESIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710	Duke University; Duke University; Duke University				, Thung-Shen/0000-0002-8791-9698	NHLBI NIH HHS [HL28391, HL 38245] Funding Source: Medline; NIAMS NIH HHS [AR 39162] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038245, P60HL028391] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039162] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; Azim AC, 1996, BIOCHEMISTRY-US, V35, P3001, DOI 10.1021/bi951745y; BERGAMINI CM, 1988, FEBS LETT, V239, P255, DOI 10.1016/0014-5793(88)80928-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN ZP, 1995, J NEUROENDOCRINOL, V7, P83, DOI 10.1111/j.1365-2826.1995.tb00671.x; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FRAIJ BM, 1992, J BIOL CHEM, V267, P22616; Fraij BM, 1996, BIOCHEM BIOPH RES CO, V218, P45, DOI 10.1006/bbrc.1996.0009; Fraij BM, 1996, BBA-GENE STRUCT EXPR, V1306, P63, DOI 10.1016/0167-4781(95)00219-7; GENTILE V, 1991, J BIOL CHEM, V266, P478; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HWANG KC, 1995, J BIOL CHEM, V270, P27058, DOI 10.1074/jbc.270.45.27058; IKURA K, 1995, ARCH BIOCHEM BIOPHYS, V318, P307, DOI 10.1006/abbi.1995.1234; JEONG JM, 1995, J BIOL CHEM, V270, P5654, DOI 10.1074/jbc.270.10.5654; JOHNSON TS, 1994, ONCOGENE, V9, P2935; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KORNER G, 1989, BIOCHEM J, V262, P633, DOI 10.1042/bj2620633; LAI TS, 1994, J BIOL CHEM, V269, P24596; LEE KN, 1993, BIOCHIM BIOPHYS ACTA, V1202, P1, DOI 10.1016/0167-4838(93)90055-V; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; MIAN S, 1995, FEBS LETT, V370, P27, DOI 10.1016/0014-5793(95)00782-5; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; RINAS U, 1990, BIOL CHEM H-S, V371, P49, DOI 10.1515/bchm3.1990.371.1.49; SINGH US, 1995, BIOCHEMISTRY-US, V34, P15863, DOI 10.1021/bi00048a032; SLAUGHTER TF, 1992, ANAL BIOCHEM, V205, P166, DOI 10.1016/0003-2697(92)90594-W; TAKEUCHI Y, 1992, FEBS LETT, V307, P177, DOI 10.1016/0014-5793(92)80762-6; TAKEUCHI Y, 1994, Z NATURFORSCH C, V49, P453; UPCHURCH HF, 1991, J CELL PHYSIOL, V149, P375, DOI 10.1002/jcp.1041490304; YEE VC, 1994, P NATL ACAD SCI USA, V91, P7296, DOI 10.1073/pnas.91.15.7296	32	72	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31191	31195		10.1074/jbc.271.49.31191	http://dx.doi.org/10.1074/jbc.271.49.31191			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940119	hybrid			2022-12-27	WOS:A1996VW68600030
J	Metz, AM; Browning, KS				Metz, AM; Browning, KS			Mutational analysis of the functional domains of the large subunit of the isozyme form of wheat initiation factor eIF4F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS INITIATION; MESSENGER-RNA; TRANSLATION INITIATION; ELONGATION-FACTORS; GERM; PHOSPHORYLATION; BINDING; COMPLEX; INSULIN; SEQUENCE	The isozyme form of plant eukaryotic initiation factor 4F (eIF(iso)4F) contains two subunits: p28, a cap-binding protein, and p86. To identify the functional domains of p86, truncations of the p86 cDNA were made, and the protein was expressed in Escherichia coli and purified, The deletion mutants were tested for the ability to bind the p28 subunit by two methods, In addition, these deletion mutants were evaluated in vitro by the ability to catalyze eIF4A and RNA-dependent ATP hydrolysis and to support polypeptide synthesis. The loss of the ability to bind p28 occurs within the first 90 amino acids of the N terminus and abrogates the ability of pad to participate in translation initiation and bind to eIF4A, but does not affect ATP hydrolysis, Up to 299 amino acid residues from the C terminus of p86 must be deleted before an effect is observed on the ATP hydrolysis activity. Thus, the p28 binding and ATP hydrolysis activities appear to lie on two separate domains and are functionally uncoupled. In addition, at least a portion of the eIF4A binding domain appears to be in close proximity to the p28 binding domain and is also uncoupled from the ATP hydrolysis activity.	UNIV TEXAS, DEPT CHEM & BIOCHEM, AUSTIN, TX 78712 USA	University of Texas System; University of Texas Austin								ABRAMSON RD, 1988, J BIOL CHEM, V263, P5462; ALLEN ML, 1992, J BIOL CHEM, V267, P23232; BOKROS CL, 1995, P NATL ACAD SCI USA, V92, P7120, DOI 10.1073/pnas.92.15.7120; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; BROWNING KS, 1992, J BIOL CHEM, V267, P10096; BROWNING KS, 1990, J BIOL CHEM, V265, P17967; BROWNING KS, 1996, IN PRESS PLANT MOL B; BU X, 1993, J BIOL CHEM, V268, P4975; ETCHISON D, 1987, MOL CELL BIOCHEM, V76, P15; GOYER C, 1993, MOL CELL BIOL, V13, P4860, DOI 10.1128/MCB.13.8.4860; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LAX S, 1985, P NATL ACAD SCI USA, V82, P330, DOI 10.1073/pnas.82.2.330; LAX SR, 1986, METHOD ENZYMOL, V118, P109; LAX SR, 1986, J BIOL CHEM, V261, P5632; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MADER S, 1995, MOL CELL BIOL, V15, P4990; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MERRICK WC, 1994, BIOCHIMIE, V76, P822, DOI 10.1016/0300-9084(94)90183-X; MORLEY SJ, 1995, J CELL SCI, V108, P1751; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; Ohlmann T, 1996, EMBO J, V15, P1371, DOI 10.1002/j.1460-2075.1996.tb00479.x; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; RHOADS RE, 1994, BIOCHIMIE, V76, P831, DOI 10.1016/0300-9084(94)90184-8; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SHA M, 1995, J BIOL CHEM, V270, P29904; SONENBERG N, 1994, BIOCHIMIE, V76, P839, DOI 10.1016/0300-9084(94)90185-6; SONENBERG N, 1990, New Biologist, V2, P402; TIMMER RT, 1993, J BIOL CHEM, V268, P9504; TIMMER RT, 1993, J BIOL CHEM, V268, P24863; VANHEERDEN A, 1994, J BIOL CHEM, V269, P17454; WEBSTER C, 1991, J BIOL CHEM, V266, P23341; YAN RQ, 1992, J BIOL CHEM, V267, P23226	36	27	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31033	31036		10.1074/jbc.271.49.31033	http://dx.doi.org/10.1074/jbc.271.49.31033			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940096	hybrid			2022-12-27	WOS:A1996VW68600007
J	Sah, VP; Hoshijima, M; Chien, KR; Brown, JH				Sah, VP; Hoshijima, M; Chien, KR; Brown, JH			Rho is required for G alpha(q) and alpha(1)-adrenergic receptor signaling in cardiomyocytes - Dissociation of Ras and Rho pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; MYOSIN LIGHT CHAIN-2; ATRIAL-NATRIURETIC-FACTOR; MUSCLE CELL HYPERTROPHY; ACTIN STRESS FIBERS; SWISS 3T3 CELLS; GENE-EXPRESSION; TYROSINE PHOSPHORYLATION; VENTRICULAR MYOCYTES; MYOCARDIAL-CELLS	G protein coupled receptor agonists initiate a cascade of signaling events in neonatal rat ventricular myocytes that culminates in changes in gene expression and cell growth characteristic of hypertrophy, These responses have been previously shown to be dependent on G(q) and Ras, Rho, a member of the Ras superfamily of GTPases, regulates cytoskeletal rearrangement and transcrip tional activation of the c-fos serum response element, Immunofluorescence staining of cardiomyocytes shows that Rho is present and predominantly cytosolic, We used two inhibitors of Rho function, dominant negative N19RhoA and Clostridium botulinum C3 transferase, to examine the possible requirement for Rho in alpha(1)-adrenergic receptor mediated hypertrophy, Both inhibitors markedly attenuated atrial natriuretic factor (ANF) reporter gene expression induced by alpha(1)-adrenergic receptor stimulation with phenylephrine, and virtually abolished the increase in ANF reporter gene expression induced by GTPase-deficient G alpha(q). These effects were reproduced with the myosin light chain-g reporter gene, Notably, N19RhoA did not block the ability of activated Ras to induce ANF and myosin light chain-a reporter gene expression, Furthermore, activation of the extracellular signal-regulated kinase by phenylephrine was not blocked by N19RhoA, nor was it stimulated by an activated mutant of RhoA, Since activated RhoA and Ras produce a large synergistic effect on ANF-luciferase gene expression, we conclude that Rho functions in a pathway separate from but complementary to Ras, Our results provide direct evidence that Rho is an effector of G alpha(q) signaling and suggest for the first time that a low molecular weight GTPase other than Ras is involved in regulating myocardial cell growth and gene expression in response to heterotrimeric G protein-linked receptor activation.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, SAN DIEGO, CA 92093 USA; UNIV CALIF SAN DIEGO, GRAD PROGRAM BIOMED SCI, SAN DIEGO, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, CTR MOL GENET, SAN DIEGO, CA 92093 USA; UNIV CALIF SAN DIEGO, AMER HEART ASSOC, BUGHER FDN CTR MOL BIOL, SAN DIEGO, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028143, R37HL028143, P01HL046345] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28143, HL46345] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; BISHOPRIC NH, 1987, J CLIN INVEST, V80, P1194, DOI 10.1172/JCI113179; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P26303, DOI 10.1074/jbc.270.44.26303; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BRYANT SS, 1995, J BIOL CHEM, V270, P17947, DOI 10.1074/jbc.270.30.17947; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; FRITZ G, 1994, BBA-MOL CELL RES, V1222, P331, DOI 10.1016/0167-4889(94)90038-8; GILLESPIEBROWN J, 1995, J BIOL CHEM, V270, P28092; Glennon PE, 1996, CIRC RES, V78, P954, DOI 10.1161/01.RES.78.6.954; HENDERSON SA, 1989, J BIOL CHEM, V264, P18142; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; IWAKI K, 1990, J BIOL CHEM, V265, P13809; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; JUST I, 1992, J BIOL CHEM, V267, P10274; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KNOWLTON KU, 1993, J BIOL CHEM, V268, P15374; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LEE HR, 1988, J BIOL CHEM, V263, P7352; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOHR C, 1992, FEBS LETT, V297, P95, DOI 10.1016/0014-5793(92)80335-E; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; Post GR, 1996, MOL BIOL CELL, V7, P1679, DOI 10.1091/mbc.7.11.1679; RAMIREZ MT, 1995, J BIOL CHEM, V270, P8446, DOI 10.1074/jbc.270.15.8446; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SCHLAEPFER DD, 1994, NATURE, V372, P786; SECKL MJ, 1995, J BIOL CHEM, V270, P6984, DOI 10.1074/jbc.270.12.6984; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; THORBURN A, 1994, BIOCHEM BIOPH RES CO, V205, P1417, DOI 10.1006/bbrc.1994.2823; THORBURN A, 1993, J BIOL CHEM, V268, P2244; THORBURN J, 1994, J BIOL CHEM, V269, P30580; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; Tigyi G, 1996, J NEUROCHEM, V66, P537; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WASPE LE, 1990, J CLIN INVEST, V85, P1206, DOI 10.1172/JCI114554; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	62	193	204	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31185	31190		10.1074/jbc.271.49.31185	http://dx.doi.org/10.1074/jbc.271.49.31185			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940118	hybrid			2022-12-27	WOS:A1996VW68600029
J	Tabuchi, A; Oh, E; Taoka, A; Sakurai, H; Tsuchiya, T; Tsuda, M				Tabuchi, A; Oh, E; Taoka, A; Sakurai, H; Tsuchiya, T; Tsuda, M			Rapid attenuation of AP-1 transcriptional factors associated with nitric oxide (NO)-mediated neuronal cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; CEREBELLAR GRANULE CELLS; METHYL-D-ASPARTATE; C-FOS; MESSENGER-RNA; ACTIVATION; PROTEIN; JUN; APOPTOSIS; CULTURES	Stimulation of glutamate receptors causes several intracellular reactions including activation of activator protein-1 (AP-1) production and nitric oxide (NO) generation, Exposing mouse cerebellar granule cells to N-methyl-D-aspartate or kainate (KA) in culture induced an increase of AP 1 DNA binding activity that was blocked by further addition of sodium nitroprusside (SNP), a typical NO donor. Immunoblotting using antic-Fos antiserum revealed the specific attenuation of AP-1, although total protein synthesis was not affected, Since the level of c-fos mRNA expression stimulated by KA remained constant even after exposure to SNP, the AP-1 attenuation can be post-transcriptionally induced. SNP did not affect the Ca2+ influx into the cells stimulated by KA. The involvement of NO in the AP-1 attenuation was supported by the fact that potassium ferrocyanide (K4Fe(CN)(6)), an analogue of SNP but devoid of NO, failed to inhibit the AP-1 DNA binding activity stimulated by Kk SNP alone induced neuronal cell death, which was blocked by the simultaneous addition of antioxidants, superoxide dismutase and catalase, and an NO scavenger, suggesting a direct role of peroxynitrite in the cell death. In good agreement with Obese effects, the AP-I attenuation by SNP was also blocked by anti oxidants. These results indicated that post-transcriptional attenuation of AP-1 is involved in the early processes of NO-mediated neuronal cell death.	OKAYAMA UNIV,FAC PHARMACEUT SCI,DEPT MICROBIOL,OKAYAMA 700,JAPAN	Okayama University			Sakurai, Hiroaki/AAE-4294-2019	Sakurai, Hiroaki/0000-0003-0657-9570				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AKAIKE T, 1993, BIOCHEMISTRY-US, V32, P827, DOI 10.1021/bi00054a013; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; BATES JN, 1991, BIOCHEM PHARMACOL, V42, pS157, DOI 10.1016/0006-2952(91)90406-U; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUISSON A, 1993, J NEUROCHEM, V61, P690; CURRAN RD, 1991, FASEB J, V5, P2085, DOI 10.1096/fasebj.5.7.1707021; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DRAGUNOW M, 1995, BRAIN RES REV, V21, P1, DOI 10.1016/0165-0173(95)00003-L; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; HEALES SJR, 1994, BRAIN RES, V668, P243, DOI 10.1016/0006-8993(94)90530-4; KIEDROWSKI L, 1992, MOL PHARMACOL, V41, P779; KIESSLING M, 1993, J CEREBR BLOOD F MET, V13, P914, DOI 10.1038/jcbfm.1993.114; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MAKI A, 1992, FASEB J, V6, P919, DOI 10.1096/fasebj.6.3.1740241; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MURPHY TH, 1988, BRAIN RES, V460, P155, DOI 10.1016/0006-8993(88)91216-4; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OHTANI K, 1995, J NEUROCHEM, V65, P605; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; SAKURAI H, 1992, J NEUROCHEM, V59, P2067; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; SZEKELY AM, 1989, MOL PHARMACOL, V35, P401; SZEKELY AM, 1990, MOL PHARMACOL, V38, P624; TABUCHI A, 1994, FEBS LETT, V351, P123, DOI 10.1016/0014-5793(94)00839-6; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; WANG XD, 1995, J BIOL CHEM, V270, P18044, DOI 10.1074/jbc.270.30.18044; WILKINSON M, 1988, NUCLEIC ACIDS RES, V16, P10933, DOI 10.1093/nar/16.22.10933; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	42	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31061	31067		10.1074/jbc.271.49.31061	http://dx.doi.org/10.1074/jbc.271.49.31061			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940101	hybrid			2022-12-27	WOS:A1996VW68600012
J	Zhang, JM; Carrell, CJ; Huang, DR; Sled, V; Ohnishi, T; Smith, JL; Cramer, WA				Zhang, JM; Carrell, CJ; Huang, DR; Sled, V; Ohnishi, T; Smith, JL; Cramer, WA			Characterization and crystallization of the lumen side domain of the chloroplast Rieske iron-sulfur protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME B(6)F COMPLEX; 2FE-2S CLUSTER; RHODOBACTER-SPHAEROIDES; SPINACH-CHLOROPLASTS; CHLAMYDOMONAS-REINHARDTII; RESONANCE SPECTROSCOPY; MEMBRANE ASSOCIATION; MUTATIONAL ANALYSIS; 2 HISTIDINES; BC1 COMPLEX	A soluble, 139-residue COOH-terminal polypeptide fragment of the Rieske iron-sulfur protein of the cytochrome b(6)f complex from spinach chloroplasts was obtained by Limited proteolysis of the complex and a two-step chromatography purification protocol, The purified Rieske iron-sulfur protein fragment was characterized by: (i) a single NH2-terminal sequence, NH2-Phe-Val-Pro-Pro-Gly-Gly, starting with residue 41 of the intact Rieske protein; (ii) a single molecular weight species determined by mass spectrometry with a molecular weight of 14,620 +/- 2 without the [2Fe-2S] cluster; (iii) an optical absorbance spectrum with redox- and pH-dependent maxima and minima; and (iv) a reduced-oxidized optical difference spectrum characterized by Delta epsilon(mM) = 3.8 mM(-1) cm(-1) for Delta A at 394 versus 409 nm, which was used to determine the midpoint oxidation-reduction potential, which is +359 +/- 7 mV at 25 degrees C from pH 5.5-6.5, and +319 +/- 2 mV at pH 7, with an apparent pK(ox) = 6.5 +/- 0.2 for the oxidized protein The EPR spectrum measured at 17 K was characterized by the g values, g(z) = 2.03 and g(y) = 1.90, and a broad band centered at g(x) approximate to 1.74, very similar or identical to those of the Rieske cluster in the b(6)f complex, implying that the environment of the [2Fe-2S] cluster is similar to that in the complex, Midpoint potential determination by low temperature EPR yielded a redox midpoint potential (E(m)) of +365-375 mV of the soluble Rieske fragment at pH 6 and 7 and an E(m) of +295-300 mV of the Rieske cluster in the cytochrome b(6)f complex at pH 6 and 7, The E(m) difference implies that the environment of the cluster in the soluble Rieske fragment is slightly more polar than that of the cluster in the intact complex, Single crystals of the Rieske poly-peptide were obtained that are capable of x-ray diffraction to atomic resolution (<2.5 Angstrom), contain one molecule per assymetric unit, a solvent content of approximately 30%, and belong to the triclinic space group P1 with cell dimensions, a = 29.1 Angstrom b = 31.9 Angstrom, c = 35.8 Angstrom, alpha = 95.6 degrees, beta = 107.1 degrees, gamma = 117.3 degrees.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907; UNIV PENN,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Pennsylvania					NIGMS NIH HHS [GM-18457] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018457] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARR R, 1967, PLANT PHYSIOL, V42, P1246, DOI 10.1104/pp.42.9.1246; BATES R, 1968, HDB BIOCH, P7; BLACK MT, 1987, ARCH BIOCHEM BIOPHYS, V252, P655, DOI 10.1016/0003-9861(87)90071-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREYTON C, 1994, J BIOL CHEM, V269, P7597; BRITT RD, 1991, BIOCHEMISTRY-US, V30, P1892, DOI 10.1021/bi00221a023; Brumby P.E., 1967, METHOD ENZYMOL, V10, P463, DOI DOI 10.1016/0076-6879(67)10078-5; CRAMER WA, 1994, CURR OPIN STRUC BIOL, V4, P536, DOI 10.1016/S0959-440X(94)90216-X; DAVIDSON E, 1992, BIOCHEMISTRY-US, V31, P3342, DOI 10.1021/bi00128a006; DING HG, 1992, BIOCHEMISTRY-US, V31, P3144, DOI 10.1021/bi00127a015; Dutton P L, 1978, Methods Enzymol, V54, P411; FEE JA, 1984, J BIOL CHEM, V259, P124; Furbacher P. N., 1996, P221; GATTI DL, 1989, J MOL BIOL, V205, P421, DOI 10.1016/0022-2836(89)90352-5; GENNIS RB, 1993, J BIOENERG BIOMEMBR, V25, P195, DOI 10.1007/BF00762582; GRAHAM LA, 1993, J BIOENERG BIOMEMBR, V25, P245, DOI 10.1007/BF00762586; Gurbiel RJ, 1996, BIOCHEMISTRY-US, V35, P7834, DOI 10.1021/bi960380u; GURBIEL RJ, 1989, BIOCHEMISTRY-US, V28, P4861, DOI 10.1021/bi00437a051; GURBIEL RJ, 1991, BIOCHEMISTRY-US, V30, P11579, DOI 10.1021/bi00113a013; HAUSKA G, 1986, METHOD ENZYMOL, V126, P271; HAUSKA G, 1983, BIOCHIM BIOPHYS ACTA, V726, P97, DOI 10.1016/0304-4173(83)90002-2; HUANG D, 1994, BIOCHEMISTRY-US, V33, P4401, DOI 10.1021/bi00180a038; HURT E, 1981, EUR J BIOCHEM, V117, P591; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; JAENICKE L, 1974, ANAL BIOCHEM, V61, P623, DOI 10.1016/0003-2697(74)90429-1; KUILA D, 1986, J BIOL CHEM, V261, P2768; Link TA, 1996, EUR J BIOCHEM, V237, P71, DOI 10.1111/j.1432-1033.1996.0071n.x; LINK TA, 1992, EUR J BIOCHEM, V208, P685, DOI 10.1111/j.1432-1033.1992.tb17235.x; MALKIN R, 1982, BIOCHEMISTRY-US, V21, P2945, DOI 10.1021/bi00541a022; Martinez SE, 1996, PROTEIN SCI, V5, P1081; MARTINEZ SE, 1994, STRUCTURE, V2, P95, DOI 10.1016/S0969-2126(00)00012-5; NITSCHKE W, 1992, BIOCHIM BIOPHYS ACTA, V1102, P266, DOI 10.1016/0167-4838(92)90519-J; PIERRE Y, 1995, J BIOL CHEM, V270, P29342, DOI 10.1074/jbc.270.49.29342; POWERS L, 1989, BIOCHIM BIOPHYS ACTA, V975, P293, DOI 10.1016/S0005-2728(89)80261-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHERGILL JK, 1994, BBA-BIOENERGETICS, V1185, P35, DOI 10.1016/0005-2728(94)90190-2; STEPPUHN J, 1987, MOL GEN GENET, V210, P171, DOI 10.1007/BF00337775; SZCZEPANIAK A, 1995, Z NATURFORSCH C, V50, P535; TELSER J, 1987, FEBS LETT, V214, P117, DOI 10.1016/0014-5793(87)80024-8; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANDOREN SR, 1993, BIOCHEMISTRY-US, V32, P8083, DOI 10.1021/bi00083a005; VANDOREN SR, 1993, BIOCHEMISTRY-US, V32, P628, DOI 10.1021/bi00053a031; WHITMARSH J, 1979, P NATL ACAD SCI USA, V76, P4417, DOI 10.1073/pnas.76.9.4417; WILLIAMSSMITH DL, 1977, BIOCHEM J, V167, P593, DOI 10.1042/bj1670593	44	66	67	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31360	31366		10.1074/jbc.271.49.31360	http://dx.doi.org/10.1074/jbc.271.49.31360			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940143				2022-12-27	WOS:A1996VW68600054
J	Barth, A; vonGermar, F; Kreutz, W; Mantele, W				Barth, A; vonGermar, F; Kreutz, W; Mantele, W			Time-resolved infrared spectroscopy of the Ca2+-ATPase - The enzyme at work	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; QUANTITATIVE IR SPECTROPHOTOMETRY; CALCIUM ADENOSINE-TRIPHOSPHATASE; CA2+-DEPENDENT ATP HYDROLYSIS; PROTEIN SECONDARY STRUCTURE; WATER H2O SOLUTIONS; ALKALI-METAL SALTS; REACTION-MECHANISM; SKELETAL-MUSCLE; PEPTIDE COMPOUNDS	Changes in the vibrational spectrum of the sarcoplasmic reticulum Ca2+-ATPase in the course of its catalytic cycle were followed in real time using rapid scan Fourier transform infrared spectroscopy, In the presence of Ca2+, the cycle was induced by the photochemical release of ATP from a biologically inactive precursor (caged ATP, P-3-1-(2-nitro)phenylethyladenosine 5'-triphosphate), Absorbance changes arising from ATP binding to the ATPase were observed within the first 65 ms after initiation of ATP release, After ATP binding, up to two subsequent partial reactions of the ATPase reaction cycle were observed depending on the buffer composition (10 nM CaCl2 + 330 mM KCl or 1 mM CaCl2 + 20% Me(2)SO): (i) formation of the ADP-sensitive phosphoenzyme (k(app) = 0.79 s(-1) +/- 15% at 1 degrees C, pH 7.0, 10 mM CaCl2, 330 mM KCl) and (ii) phosphoenzyme conversion to the ADP-insensitive phosphoenzyme concomitant with Ca2+ release (k(app) = 0.092 s(-1) +/- 7% at 1 degrees C, pH 7.0, 1 mM CaCl2, 20% Me(2)SO). Each reaction step could well be described by a single time constant for all associated changes in the vibrational spectrum, and no intermediates other than those mentioned above were found. In particular, there is no evidence for a delay between the transition from ADP-sensitive to ADP-insensitive phosphoenzyme and Ca2+ release, In (H2O)-H-2 a kinetic isotope effect was observed: both the phosphorylation reaction and phosphoenzyme conversion were slowed down by factors of 1.5 and 3.0, respectively, The small amplitudes of the observed changes in the infrared spectrum indicate that the net change of secondary structure is very small and of the same order of magnitude for ATP binding, phosphorylation, and phosphoenzyme conversion, Therefore, our results do not support a distinction between minor and major secondary structure changes in the catalytic cycle of the ATPase, which might be expected according to the classical E(1)-E(2) model.	UNIV FREIBURG, INST BIOPHYS & STRAHLENBIOL, D-79104 FREIBURG, GERMANY	University of Freiburg			Barth, Andreas/N-8872-2013	Barth, Andreas/0000-0001-5784-7673				ANDERSEN JP, 1989, BIOCHIM BIOPHYS ACTA, V988, P47, DOI 10.1016/0304-4157(89)90003-8; ANDERSEN JP, 1985, J BIOL CHEM, V260, P371; ARRONDO JLR, 1993, PROG BIOPHYS MOL BIO, V59, P23, DOI 10.1016/0079-6107(93)90006-6; BAKER KJ, 1994, BBA-BIOMEMBRANES, V1192, P53, DOI 10.1016/0005-2736(94)90142-2; BARTH A, 1994, BBA-BIOMEMBRANES, V1194, P75, DOI 10.1016/0005-2736(94)90205-4; BARTH A, 1991, BIOCHIM BIOPHYS ACTA, V1057, P115, DOI 10.1016/S0005-2728(05)80091-X; BARTH A, 1995, J AM CHEM SOC, V117, P10311, DOI 10.1021/ja00146a015; BIGELOW DJ, 1992, BIOCHIM BIOPHYS ACTA, V1113, P323, DOI 10.1016/0304-4157(92)90005-U; BLASIE JK, 1985, BIOPHYS J, V48, P9, DOI 10.1016/S0006-3495(85)83756-5; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BUCHET R, 1991, BIOCHIM BIOPHYS ACTA, V1069, P209, DOI 10.1016/0005-2736(91)90126-S; CHAMPEIL P, 1986, BIOCHEMISTRY-US, V25, P7623, DOI 10.1021/bi00371a053; CHAMPEIL P, 1988, J BIOL CHEM, V263, P12288; CHIRGADZE YN, 1973, BIOPOLYMERS, V12, P1337, DOI 10.1002/bip.1973.360120610; CHIRGADZE YN, 1975, BIOPOLYMERS, V14, P679, DOI 10.1002/bip.1975.360140402; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DORGAN LJ, 1981, J BIOL CHEM, V256, P3910; FERNANDEZBELDA F, 1984, J BIOL CHEM, V259, P9687; Ferreira ST, 1996, BIOSCIENCE REP, V16, P87, DOI 10.1007/BF01206199; GEORG H, 1994, BBA-BIOENERGETICS, V1188, P139, DOI 10.1016/0005-2728(94)90032-9; GIRARDET JL, 1992, FEBS LETT, V296, P103, DOI 10.1016/0014-5793(92)80413-B; Haris P I, 1994, Methods Mol Biol, V22, P183; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1984, TOPICS MOL STRUCTURA, V4, P355; INESI G, 1985, ENZYMES BIOL MEMBR, V3, P157; ISAACS NS, 1987, PHYSICAL ORGANIC CHE, P255; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; JAWORSKY M, 1986, SPECTROCHIM ACTA A, V42, P191, DOI 10.1016/0584-8539(86)80179-9; JENCKS WP, 1993, BIOCHEMISTRY-US, V32, P7030, DOI 10.1021/bi00078a031; KALNIN NN, 1990, BIOPOLYMERS, V30, P1273, DOI 10.1002/bip.360301311; Kanazawa T, 1995, BIOSCIENCE REP, V15, P317, DOI 10.1007/BF01788364; KHANANSHVILI D, 1988, BIOCHEMISTRY-US, V27, P2943, DOI 10.1021/bi00408a041; LACAPERE JJ, 1990, J BIOL CHEM, V265, P8583; Lin SH, 1996, BIOCHEMISTRY-US, V35, P8419, DOI 10.1021/bi960407+; LINSE S, 1995, P NATL ACAD SCI USA, V92, P4748, DOI 10.1073/pnas.92.11.4748; MAHANEY JE, 1995, BIOCHEMISTRY-US, V34, P4864, DOI 10.1021/bi00014a044; MAKINOSE M, 1969, EUR J BIOCHEM, V10, P74; MARTINEZ G, 1995, J STRUCT BIOL, V114, P23, DOI 10.1006/jsbi.1995.1002; MEIS LD, 1971, J BIOL CHEM, V246, P4759; MYUNG J, 1995, BIOCHEMISTRY-US, V34, P3077, DOI 10.1021/bi00009a039; NAKAMURA Y, 1982, J BIOCHEM-TOKYO, V91, P449, DOI 10.1093/oxfordjournals.jbchem.a133717; PETITHORY JR, 1986, BIOCHEMISTRY-US, V25, P4493, DOI 10.1021/bi00364a006; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; PICKART CM, 1984, J BIOL CHEM, V259, P1629; PRIBIC R, 1993, ANAL BIOCHEM, V214, P366, DOI 10.1006/abio.1993.1511; SARVER RW, 1991, ANAL BIOCHEM, V194, P89, DOI 10.1016/0003-2697(91)90155-M; SCHOWEN KB, 1982, METHOD ENZYMOL, V87, P551; SHIGEKAWA M, 1983, J BIOL CHEM, V258, P8698; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1458; SHIGEKAWA M, 1983, J BIOL CHEM, V258, P4157; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1442; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1451; STAHL N, 1987, BIOCHEMISTRY-US, V26, P7654, DOI 10.1021/bi00398a019; STEFANOVA HI, 1993, BIOCHEMISTRY-US, V32, P356, DOI 10.1021/bi00052a044; STEFANOVA HI, 1993, BIOCHEMISTRY-US, V32, P6095, DOI 10.1021/bi00074a022; SUZUKI H, 1994, BIOCHEMISTRY-US, V33, P8240, DOI 10.1021/bi00193a010; URBAUER JL, 1984, ARCH BIOCHEM BIOPHYS, V231, P498, DOI 10.1016/0003-9861(84)90413-2; VENYAMINOV SY, 1990, BIOPOLYMERS, V30, P1259, DOI 10.1002/bip.360301310; VENYAMINOV SY, 1990, BIOPOLYMERS, V30, P1243, DOI 10.1002/bip.360301309; VONGERMAR F, 1994, INVESTIGATION NUCL B; WAKABAYASHI S, 1986, J BIOL CHEM, V261, P9762; WALKER JW, 1988, J AM CHEM SOC, V110, P7170, DOI 10.1021/ja00229a036; YAMADA S, 1980, J BIOL CHEM, V255, P3108	63	73	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30637	30646		10.1074/jbc.271.48.30637	http://dx.doi.org/10.1074/jbc.271.48.30637			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940039	hybrid			2022-12-27	WOS:A1996VV15800056
J	Moxham, CM; Tabrizchi, A; Davis, RJ; Malbon, CC				Moxham, CM; Tabrizchi, A; Davis, RJ; Malbon, CC			jun N-terminal kinase mediates activation of skeletal muscle glycogen synthase by insulin in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED PROTEIN-KINASE; P70 S6 KINASE; C-JUN; IN-VIVO; SIGNAL-TRANSDUCTION; MAMMALIAN-TISSUES; AP-1 ACTIVITY; HA-RAS; PHOSPHORYLATION; JNK	Mitogen-activated protein kinases (MAPKs) represent a conserved family of Ser/Thr protein kinases with central roles in intracellular signaling. Activation of three prominent members of the MAPK family, i.e. extracellular response kinases (ERR), jun N-terminal kinase (JNK), and p38, was defined in vivo in order to establish their role, if any, in the cardinal response of skeletal muscle to insulin, the activation of glycogen synthesis. Insulin was found to activate ERK, JNK, and p38 in skeletal muscle. The time courses for activation of the three MAPKs by insulin, however, are distinctly different. Activation of JNK occurs most rapidly, within seconds. Activation of p38 by insulin follows that of JNK, within minutes. Activation of ERK occurs last, 4 min after administration of insulin. The temporal relationship between the activation of ERR, JNK, p38 and the downstream elements p90(rsk) and PP-1 in vivo suggest that JNK, but neither ERR nor p38 MAPKs, mediates insulin activation of glycogen synthase in vivo. Activation of JNK by anisomycin in vivo mimics activation of glycogen synthase by insulin. Challenge by anisomycin and insulin, in combination, are not additive, suggesting a common mode of glycogen synthase activation. The p90(rsk) isoform rapidly activated by insulin is identified as RSK3. In addition, RSK3 can be activated by JNK in vitro. Based upon these data a signal linkage map for activation of glycogen synthase in vivo in skeletal muscle can be constructed in which JNK mediates activation of glycogen synthase via RSK3.	SUNY STONY BROOK,HLTH SCI CTR,DEPT MOL PHARMACOL,DMDRP,MED CTR,STONY BROOK,NY 11794; UNIV MASSACHUSETTS,MED CTR,PROGRAM MOL MED,WORCESTER,MA 01605; UNIV MASSACHUSETTS,MED CTR,HOWARD HUGHES MED INST,WORCESTER,MA 01605	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester			malbon, craig/ABF-3604-2020		NIDDK NIH HHS [T32 DK07521] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007521] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; BARON AD, 1988, AM J PHYSIOL, V255, pE769, DOI 10.1152/ajpendo.1988.255.6.E769; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; BJORBAEK C, 1995, DIABETES, V44, P90, DOI 10.2337/diabetes.44.1.90; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CHANG PY, 1995, J BIOL CHEM, V270, P29928; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COHEN P, 1993, BIOCHEM SOC T, V21, P555, DOI 10.1042/bst0210555; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CZECH MP, 1988, J BIOL CHEM, V263, P11017; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENTON RM, 1995, EUR J BIOCHEM, V227, P597, DOI 10.1111/j.1432-1033.1995.tb20179.x; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; ERIKSON E, 1987, MOL CELL BIOL, V7, P3147, DOI 10.1128/MCB.7.9.3147; GALCHEVAGARGOVN.Z, 1994, SCIENCE, V265, P308; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; GROVE JR, 1993, BIOCHEMISTRY-US, V32, P7727, DOI 10.1021/bi00081a018; GUINOVART JJ, 1979, FEBS LETT, V106, P284, DOI 10.1016/0014-5793(79)80515-3; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAYES N, 1993, BIOCHEM BIOPH RES CO, V190, P881, DOI 10.1006/bbrc.1993.1131; HEI YJ, 1993, J BIOL CHEM, V268, P13203; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P711, DOI 10.1111/j.1432-1033.1989.tb15264.x; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P297, DOI 10.1111/j.1432-1033.1983.tb07362.x; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KIM SJ, 1994, J BIOL CHEM, V269, P11887; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MOLLER DE, 1994, AM J PHYSIOL, V266, pC351, DOI 10.1152/ajpcell.1994.266.2.C351; Moxham CM, 1996, NATURE, V379, P840, DOI 10.1038/379840a0; MOXHAM CM, 1993, DEV GENET, V14, P266, DOI 10.1002/dvg.1020140404; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; PARKER PJ, 1983, EUR J BIOCHEM, V130, P227; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCIMECA JC, 1992, J BIOL CHEM, V267, P17369; SHULMAN RG, 1995, P NATL ACAD SCI USA, V92, P8535, DOI 10.1073/pnas.92.19.8535; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITMARSH AJ, 1996, IN PRESS J MOL MED; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353	67	92	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30765	30773		10.1074/jbc.271.48.30765	http://dx.doi.org/10.1074/jbc.271.48.30765			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940056	hybrid			2022-12-27	WOS:A1996VV15800073
J	Olashaw, NE				Olashaw, NE			Inducible activation of RelB in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR; GROWTH-FACTOR; CYCLIC-AMP; SIGNAL-TRANSDUCTION; MOUSE FIBROBLASTS; BALB/C-3T3 CELLS; GENE-EXPRESSION; B/REL FAMILY; INDUCTION	RelB, a member of NF-kappa B/Rel family of transcriptional regulators, is an immediate-early gene product that mediates constitutive lymphoid-specific kappa B-directed gene expression. Data presented here show that RelB also functions as a mitogen-inducible DNA binding activity in fibroblasts. Activation of RelB was observed in three mouse fibroblast lines, and agents activating RelB in quiescent and cycling cells included platelet-derived growth factor, phorbol ester, and serum. Additional data implicate cyclic AMP in the regulation of RelB activity. These findings suggest that RelB may play different roles in different cell types.	UNIV S FLORIDA,DEPT ANAT,TAMPA,FL 33612; UNIV S FLORIDA,H LEE MOFFITT CANC CTR,TAMPA,FL 33612	State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida					NIGMS NIH HHS [GM8476-04] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BERTRAND F, 1995, J BIOL CHEM, V270, P24435, DOI 10.1074/jbc.270.41.24435; BOMSZTYK K, 1990, J BIOL CHEM, V265, P9413; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; DUCKETT CS, 1995, J BIOL CHEM, V270, P18836, DOI 10.1074/jbc.270.32.18836; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FRANTZ CN, 1979, J CELL PHYSIOL, V100, P413, DOI 10.1002/jcp.1041000305; GRILLI M, 1993, INT REV CYTOL, V143, P1; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LEOF EB, 1982, J CELL BIOCHEM, V19, P93, DOI 10.1002/jcb.240190108; LERNBECHER T, 1994, EMBO J, V13, P4060, DOI 10.1002/j.1460-2075.1994.tb06723.x; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; OLASHAW NE, 1988, J BIOL CHEM, V263, P1111; OLASHAW NE, 1992, MOL BIOL CELL, V3, P1131, DOI 10.1091/mbc.3.10.1131; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHER CD, 1979, NATURE, V281, P390, DOI 10.1038/281390a0; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; WEIH F, 1994, ONCOGENE, V9, P3289; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; WHARTON W, 1982, J CELL PHYSIOL, V111, P201, DOI 10.1002/jcp.1041110212; WU J, 1993, SCIENCE, V262, P1965; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	40	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30307	30310						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939986				2022-12-27	WOS:A1996VV15800003
J	Patel, N; Herrman, JM; Timans, JC; Kastelein, RA				Patel, N; Herrman, JM; Timans, JC; Kastelein, RA			Functional replacement of cytokine receptor extracellular domains by leucine zippers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; INTERFERON-GAMMA RECEPTOR; HIGH-AFFINITY RECEPTOR; HUMAN GROWTH-HORMONE; GM-CSF RECEPTOR; BETA-SUBUNIT; NEU ONCOGENE; TRANSMEMBRANE DOMAIN; SIGNAL-TRANSDUCTION; EXPRESSION CLONING	Granulocyte-macrophage colony-stimulating factor receptor signals by a complex which includes the ligand and two different receptor subunits: a low affinity alpha receptor binding chain (granulocyte-macrophage colony-stimulating factor receptor or subunit (GM-R alpha)) and a signal-transducing beta chain (GM-R beta). To investigate two unresolved issues in the initiation of signaling, the role of receptor extracellular domains and receptor stoichiometry, we replaced the mouse GM-R alpha and GM-R beta extracellular domains with the leucine zipper domain of either the Fos or Jun molecule. We co transfected combinations of chimeric receptors into Ba/F3 cells and found that both simple heterodimers of the GM-R alpha and GM-R beta intracellular domains and homodimers of the GM-R beta intracellular domain signaled for proliferation. Surprisingly, homodimers of the GM-R alpha intracellular domain also signaled for prevention of apoptosis in transfected cells. We similarly engineered dimers of the intracellular domain of the human interferon gamma receptor beta subunit and found that homodimers of the intracellular lar domain signaled for proliferation. When Fos peptide was added to Ba/F3 cells expressing the human interferon gamma receptor beta subunit construct, thereby preventing homodimer formation, the cells no longer proliferated in the absence of mouse interleukin 3.	DNAX RES INST MOL & CELLULAR BIOL INC,DEPT MOL BIOL,PALO ALTO,CA 94304	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.								AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRANDTRAUF PW, 1989, J PROTEIN CHEM, V8, P749, DOI 10.1007/BF01024899; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EDER M, 1994, J BIOL CHEM, V269, P30173; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOODALL GJ, 1993, GROWTH FACTORS, V8, P87, DOI 10.3109/08977199309046929; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; HANNEMANN J, 1995, MOL CELL BIOL, V15, P2402; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; JENKINS BJ, 1995, EMBO J, V14, P4276, DOI 10.1002/j.1460-2075.1995.tb00102.x; KASTELEIN RA, 1993, ONCOGENE, V8, P231; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KOSTELNY SA, 1992, J IMMUNOL, V148, P1547; KOTENKO SV, 1995, J BIOL CHEM, V270, P20915, DOI 10.1074/jbc.270.36.20915; LIU Y, 1994, J IMMUNOL, V152, P1821; MARSTERS SA, 1995, P NATL ACAD SCI USA, V92, P5401, DOI 10.1073/pnas.92.12.5401; MUTO A, 1995, BIOCHEM BIOPH RES CO, V208, P368, DOI 10.1006/bbrc.1995.1347; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PARK LS, 1992, P NATL ACAD SCI USA, V89, P4295, DOI 10.1073/pnas.89.10.4295; POLOTSKAYA A, 1994, J BIOL CHEM, V269, P14607; ROZWARSKI DA, 1994, STRUCTURE, V2, P159, DOI 10.1016/S0969-2126(00)00018-6; SAKATSUME M, 1995, J BIOL CHEM, V270, P17528, DOI 10.1074/jbc.270.29.17528; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WEISS M, 1993, BLOOD, V82, P3298; WELLS JA, 1993, ANNU REV BIOPH BIOM, V22, P329, DOI 10.1146/annurev.bb.22.060193.001553	37	20	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30386	30391		10.1074/jbc.271.48.30386	http://dx.doi.org/10.1074/jbc.271.48.30386			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940001	hybrid			2022-12-27	WOS:A1996VV15800018
J	Tarcsa, E; Marekov, LN; Mei, G; Melino, G; Lee, SC; Steinert, PM				Tarcsa, E; Marekov, LN; Mei, G; Melino, G; Lee, SC; Steinert, PM			Protein unfolding by peptidylarginine deiminase - Substrate specificity and structural relationships of the natural substrates trichohyalin and filaggrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; CORNIFIED CELL-ENVELOPE; INTERMEDIATE FILAMENTS; GEL-ELECTROPHORESIS; HAIR FOLLICLE; MOLECULAR-CLONING; ARGININE RESIDUE; SKELETAL-MUSCLE; MOUSE; PURIFICATION	Peptidylarginine deiminases, which are commonly found in mammalian cells, catalyze the deimination of protein-bound arginine residues to citrullines. However, very little is known about their substrate requirements and the significance or consequences of this postsynthetic modification. We have explored this reaction in vitro with two known substrates filaggrin and trichohyalin. First, the degree and rate of modification of arginines to citrullines directly correlates with the structural order of the substrate. In filaggrin, which has little structural order, the reaction proceeded rapidly to >95% completion. However, in the highly a-helical protein trichohyalin, the reaction proceeded slowly to about 25% and could be forced to a maximum of about 65%. Second, the rate and degree of modification depends on the sequence location of the target arginines. Third, we show by gel electrophoresis, circular dichroism, and fluorescence spectroscopy that the reaction interferes with organized protein structure: the net formation of greater than or equal to 10% citrulline results in protein denaturation. Cyanate modification of the lysines in model alpha-helix-rich proteins to homocitrullines also results in loss of organized structure. These data suggest that the ureido group on the citrulline formed by the peptidylarginine deiminase enzyme modification functions to unfold proteins due to decrease in net charge, loss of potential ionic bonds, and interference with H bonds.	NIAMSD, SKIN BIOL LAB, NIH, BETHESDA, MD 20892 USA; UNIV ROMA TOR VERGATA, IST DERMOPAT IMMACOLATA, BIOCHEM LABS, DEPT EXPT MED & BIOCHEM SCI, I-00133 ROME, ITALY; UNIV AQUILA, DEPT BIOL, I-67100 LAQUILA, ITALY	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; University of L'Aquila								AUBER L., 1952, TRANS ROY SOC EDINBURGH, V62, P191; BIRBECK MSC, 1957, J BIOPHYS BIOCHEM CY, V3, P223, DOI 10.1083/jcb.3.2.223; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRESLOW E, 1965, J BIOL CHEM, V240, P304; CANDI E, 1995, J BIOL CHEM, V270, P26382, DOI 10.1074/jbc.270.44.26382; COHEN LH, 1971, J BIOL CHEM, V246, P1841; FARNSWORTH V, 1993, ANAL BIOCHEM, V215, P190, DOI 10.1006/abio.1993.1575; FIETZ MJ, 1993, J CELL BIOL, V121, P855, DOI 10.1083/jcb.121.4.855; FUJISAKI M, 1981, J BIOCHEM, V89, P257, DOI 10.1093/oxfordjournals.jbchem.a133189; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; HAMILTON EH, 1992, J INVEST DERMATOL, V98, P881, DOI 10.1111/1523-1747.ep12459412; HARDING CR, 1983, J MOL BIOL, V170, P651, DOI 10.1016/S0022-2836(83)80126-0; HARDING HWJ, 1976, BIOCHIM BIOPHYS ACTA, V427, P315, DOI 10.1016/0005-2795(76)90307-X; HARDING HWJ, 1971, BIOCHEMISTRY-US, V10, P624, DOI 10.1021/bi00780a013; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; INAGAKI M, 1989, J BIOL CHEM, V264, P18119; KIM SY, 1994, J BIOL CHEM, V269, P27979; KUBILUS J, 1983, BIOCHIM BIOPHYS ACTA, V745, P285, DOI 10.1016/0167-4838(83)90060-2; KUBILUS J, 1980, BIOCHIM BIOPHYS ACTA, V615, P246, DOI 10.1016/0005-2744(80)90027-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SC, 1993, J BIOL CHEM, V268, P12164; MACK JW, 1993, J MOL BIOL, V232, P50, DOI 10.1006/jmbi.1993.1369; MANABE M, 1994, DIFFERENTIATION, V58, P65, DOI 10.1046/j.1432-0436.1994.5810065.x; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; MEI G, 1992, BIOCHEMISTRY-US, V31, P7224, DOI 10.1021/bi00147a003; NISHIIYO T, 1995, J INVEST DERMATOL, V104, P577; NOEL D, 1979, BIOCHEMISTRY-US, V18, P4159, DOI 10.1021/bi00586a017; NOMURA K, 1992, ARCH BIOCHEM BIOPHYS, V293, P362, DOI 10.1016/0003-9861(92)90407-N; OGUIN WM, 1992, J INVEST DERMATOL, V98, P24, DOI 10.1111/1523-1747.ep12494172; OKEEFE EJ, 1993, J INVEST DERMATOL, V101, pS65, DOI 10.1111/1523-1747.ep12362866; PANYIM S, 1971, J BIOL CHEM, V246, P7557; REYNOLDS JA, 1970, J BIOL CHEM, V245, P5161; RICKWOOD D, 1981, GEL ELECT PROTEINS P; Rogers G E, 1977, Adv Exp Med Biol, V86A, P283; ROGERS GE, 1977, BIOCHIM BIOPHYS ACTA, V495, P159, DOI 10.1016/0005-2795(77)90250-1; ROGERS GE, 1963, J HISTOCHEM CYTOCHEM, V11, P700, DOI 10.1177/11.6.700; ROGERS GE, 1964, EPIDERMIS, V179; ROTHNAGEL JA, 1990, J BIOL CHEM, V265, P1862; ROTHNAGEL JA, 1986, J CELL BIOL, V102, P1419, DOI 10.1083/jcb.102.4.1419; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANTUCCI R, 1987, BIOCHIM BIOPHYS ACTA, V914, P185, DOI 10.1016/0167-4838(87)90062-8; SENSHU T, 1995, J INVEST DERMATOL, V105, P163, DOI 10.1111/1523-1747.ep12317070; Stark GR., 1967, METHOD ENZYMOL, V25, P590; STEINERT PM, 1981, P NATL ACAD SCI-BIOL, V78, P4097, DOI 10.1073/pnas.78.7.4097; STEINERT PM, 1978, BIOCHEMISTRY-US, V17, P5045, DOI 10.1021/bi00616a029; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; STEINERT PM, 1979, BIOCHEMISTRY-US, V18, P5664, DOI 10.1021/bi00592a022; STEINERT PM, 1969, BIOCHIM BIOPHYS ACTA, V175, P1, DOI 10.1016/0005-2795(69)90138-X; TAKAGI T, 1975, J BIOCHEM, V77, P939, DOI 10.1093/oxfordjournals.jbchem.a130818; TAKAHARA H, 1983, J BIOCHEM, V94, P1945, DOI 10.1093/oxfordjournals.jbchem.a134548; TAKAHARA H, 1989, J BIOL CHEM, V264, P13361; TAKAHARA H, 1987, AGR BIOL CHEM TOKYO, V51, P1657, DOI 10.1080/00021369.1987.10868246; TAKAHARA H, 1985, J BIOL CHEM, V260, P8378; TERAKAWA H, 1991, J BIOCHEM, V110, P661, DOI 10.1093/oxfordjournals.jbchem.a123636; TSUCHIDA M, 1991, AGR BIOL CHEM TOKYO, V55, P295, DOI 10.1080/00021369.1991.10870549; TSUCHIDA M, 1993, EUR J BIOCHEM, V215, P677, DOI 10.1111/j.1432-1033.1993.tb18079.x; TUNG JS, 1971, BIOCHEM BIOPH RES CO, V42, P1117, DOI 10.1016/0006-291X(71)90020-9; WATANABE K, 1988, BIOCHIM BIOPHYS ACTA, V966, P375, DOI 10.1016/0304-4165(88)90088-8; WATANABE K, 1989, J BIOL CHEM, V264, P15255	59	274	288	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30709	30716		10.1074/jbc.271.48.30709	http://dx.doi.org/10.1074/jbc.271.48.30709			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940048	hybrid			2022-12-27	WOS:A1996VV15800065
J	Wolf, MJ; Gross, RW				Wolf, MJ; Gross, RW			Expression, purification, and kinetic characterization of a recombinant 80-kDa intracellular calcium-independent phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE-A2; INHIBITION; MECHANISM; CELLS; ATP; TRANSLOCATION	A CHO cell-derived 80-kDa recombinant polypeptide (GenBank number I15470) putatively encoding a calcium-independent phospholipase A, was expressed in S. frugiperda cells resulting in over a 15-fold increase in a calcium-independent phospholipase A(1)/A(2) activity which was entirely inhibitable by (E)-6-(bromomethylene)-3-(1-naphthalenyl)-2H-tetrahydropyran-2-one. The recombinant polypeptide was purified from cytosol by sequential tandem affinity chromatographies employing ATP-agarose and calmodulin-Sepharose stationary phases. This strategy resulted in the rapid purification (36 h) of recombinant phospholipase A, activity in 56% overall yield to a single intense 80-kDa protein band on SDS-polyacrylamide gel electrophoresis after silver staining. The purified protein possessed phospholipase A,, phospholipase A,, and lysophospholipase activities, Microbore anion exchange chromatography demonstrated that the 80-kDa protein band was comprised of multiple distinct isoforms including an anionic isoform which possessed over a B-fold higher specific activity (5 mu mo/mg . min) than earlier eluting isoforms. Collectively, these results unambiguously demonstrate that: 1) the 80-kDa polypeptide catalyzes phospholipase A(1)/A(2) and lysophospholipase activities with distinct kinetic parameters; 2) calmodulin and ATP both interact with the catalytic polypeptide independent of regulatory proteins; and 3) distinct isoforms of this polypeptide exist which possess markedly different specific activities.	WASHINGTON UNIV,SCH MED,DIV BIOORGAN CHEM & MOL PHARMACOL,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV BIOORGAN CHEM & MOL PHARMACOL,DEPT CHEM,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV BIOORGAN CHEM & MOL PHARMACOL,DEPT PHARMACOL & MOL BIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			WOLF, MATTHEW/AHC-5201-2022; wolf, matthew/C-2315-2008	Wolf, Matthew/0000-0001-8004-4852	NHLBI NIH HHS [1 PO1 HL57278-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057278] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GONES SS, 1996, FASEB J, V10, pL15; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HAZEN SL, 1991, J BIOL CHEM, V266, P14526; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HAZEN SL, 1991, BIOCHEM J, V280, P581, DOI 10.1042/bj2800581; JAKOBY WB, 1979, METHOD ENZYMOL, V58, P132; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; RAMANADHAM S, 1994, BIOCHEMISTRY-US, V33, P7442, DOI 10.1021/bi00189a052; Sambrook J., 2002, MOL CLONING LAB MANU; SHARP JD, 1991, J BIOL CHEM, V266, P14850; STAFFORD RE, 1989, BIOCHEMISTRY-US, V28, P5113, DOI 10.1021/bi00438a031; STURDIER FW, 1991, J MOL BIOL, V2119, P37; STURDIER FW, 1986, J MOL BIOL, V189, P113; Wolf MJ, 1996, J BIOL CHEM, V271, P20989, DOI 10.1074/jbc.271.35.20989; ZUPAN LA, 1991, J MED CHEM, V336, P95	25	81	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30879	30885		10.1074/jbc.271.48.30879	http://dx.doi.org/10.1074/jbc.271.48.30879			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940072	hybrid			2022-12-27	WOS:A1996VV15800089
J	Ernst, M; Oates, A; Dunn, AR				Ernst, M; Oates, A; Dunn, AR			gp130-mediated signal transduction in embryonic stem cells involves activation of Jak and Ras/mitogen-activated protein kinase pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; PHEOCHROMOCYTOMA PC12 CELLS; TYROSINE KINASE; FACTOR-RECEPTOR; HEMATOPOIETIN RECEPTORS; INTERLEUKIN-6 FAMILY; CYTOPLASMIC DOMAIN; MOUSE EMBRYOS; GROWTH-FACTOR; MAP KINASE	The leukemia inhibitory factor/interleukin 6 (LIF/IL6) family of cytokines promotes cell type-specific pleiotropic effects by engaging multimeric receptor complexes that share the common affinity converter/signal transducing subunit gp130, While the maintenance of embryonic stem (ES) cell self-renewal is an activity unique to this family of cytokines, the intracellular signaling events mediated by gp130 remain largely unknown, Here we show a rapid and transient increase in the specific activity of the Src-related kinase Hck as well as of the Janus kinases Jak1, Jak2, and Tyk2 following treatment of ES cells with LIF or a combination of IL6 plus a soluble form of the IL6 receptor, Within 2 min of stimulation, we also observed increased tyrosine phosphorylation of SHC, activation of the guanidine nucleotide exchange activity on p21(ras), and an electrophoretic mobility shift of MBP kinase. Functional involvement of Hck and p21(ras) activation in gp130-mediated signaling is supported by the finding that the introduction of constitutively activated Hck or v-Ha-ras partially alleviates the requirement of ES cells for LIF to remain undifferentiated. In contrast, suppression of Jak1 in ES cells by antisense technology increased the amount of LIF required to retain their pluripotentiality. These results are consistent with the notion that gp130-mediated suppression of ES cell differentiation depends on signaling through at least two cascades, namely a p21(ras)-dependent pathway that possibly involves Hck, as well as a Jak kinase-dependent pathway.	ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,MELBOURNE TUMOUR BIOL BRANCH,PARKVILLE,VIC 3050,AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital			Ernst, Matthias/D-5111-2012	Ernst, Matthias/0000-0002-6399-1177				BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMANN H, 1994, J BIOL CHEM, V269, P16297; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CONOVER JC, 1993, DEVELOPMENT, V119, P559; CONQUET F, 1990, MOL CELL BIOL, V10, P3801, DOI 10.1128/MCB.10.7.3801; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DURDEN DL, 1995, J IMMUNOL, V154, P4039; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GEARING DP, 1993, CURR OPIN HEMATOL, V3, P138; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HASHIMOTO Y, 1994, ONCOGENE, V9, P869; HE TC, 1995, J BIOL CHEM, V270, P11055, DOI 10.1074/jbc.270.19.11055; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JOHN J, 1988, J BIOL CHEM, V263, P11792; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KUMAR G, 1994, J IMMUNOL, V153, P4436; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; Li BQ, 1996, P NATL ACAD SCI USA, V93, P1001, DOI 10.1073/pnas.93.3.1001; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MATSUI Y, 1991, NATURE, V353, P750, DOI 10.1038/353750a0; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MURRAY R, 1990, MOL CELL BIOL, V10, P4953, DOI 10.1128/MCB.10.9.4953; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NICHOLS J, 1994, EXP CELL RES, V215, P237, DOI 10.1006/excr.1994.1338; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; ROSE TM, 1994, CYTOKINE, V6, P48, DOI 10.1016/1043-4666(94)90007-8; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WANG YP, 1995, BLOOD, V86, P1671, DOI 10.1182/blood.V86.5.1671.bloodjournal8651671; WARE CB, 1995, DEVELOPMENT, V121, P1283; WHYATT LM, 1993, MOL CELL BIOL, V13, P7971, DOI 10.1128/MCB.13.12.7971; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; YASUKAWA K, 1990, J BIOCHEM-TOKYO, V108, P673, DOI 10.1093/oxfordjournals.jbchem.a123261; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHANG JG, 1992, EUR J BIOCHEM, V207, P903, DOI 10.1111/j.1432-1033.1992.tb17123.x	56	112	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30136	30143		10.1074/jbc.271.47.30136	http://dx.doi.org/10.1074/jbc.271.47.30136			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939963	hybrid			2022-12-27	WOS:A1996VU52500091
J	Jez, JM; Schlegel, BP; Penning, TM				Jez, JM; Schlegel, BP; Penning, TM			Characterization of the substrate binding site in rat liver 3 alpha-hydroxysteroid dihydrodiol dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDOSE REDUCTASE INHIBITORS; MOLECULAR-CLONING; TRIOSEPHOSPHATE ISOMERASE; CONFORMATIONAL CHANGE; KINETIC MECHANISM; CDNA; SUPERFAMILY; MUTAGENESIS; ZOPOLRESTAT; CYSTEINES	Rat liver 3 alpha-hydroxysteroid dehydrogenase (3 alpha-HSD), a member of the aldoketoreductase superfamily, inactivates circulating steroid hormones using NAD(P)H as cofactor, Despite determination of the 3 alpha-HSD . NADP(+) binary complex structure, the functional elements that dictate the binding of steroids remain unclear (Bennett, M.J., Schlegel, B.P., Jez, J.M., Penning, T.M., and Lewis, M. (1996) Biochemistry 35, 10702-10711), Two tryptophans (Trp(86) and Trp(227)) near the active site may have roles in substrate binding, and their fluorescence may be quenched upon binding of NADPH, Trp(86) is located within an apolar cleft, while Trp(227) is found on an opposing loop near the active site, A third tryptophan, Trp(148), is on the periphery of the structure, To investigate the roles of these tryptophans in protein fluorescence and ligand binding, we generated three mutant enzymes (W86Y, W148Y, and W227Y) by site-directed mutagenesis, Spectroscopic measurements on these proteins showed that Trp(148) contributed the most to the enzyme fluorescence spectra, with Trp(227) adding the least, Trp(86) was identified as the tryptophan quenched by bound NADPH through an energy transfer mechanism, The W86Y mutant altered binding of cofactor (a 3-fold increase in K-d for NADPH) and steroid (a 7-fold increase in K-d for testosterone). This mutation also dramatically decreased the catalytic efficiency observed with one-, two-, and three-ring substrates and decreased the binding affinity for nonsteroidal anti-inflammatory drugs but had little effect on the binding of aldose reductase inhibitors, Interestingly, mutation of Trp(227) significantly impaired steroid binding (a 22-fold increase in k(d) for testosterone), but did not alter binding of cofactor, smaller substrates, or inhibitors, Kinetically, the W148Y mutant was similar to wild-type enzyme, Our results demonstrate that Trp(86) and the apolar cleft is part of the substrate binding pocket, In addition, we propose a role for Trp(227) and its associated loop in binding steroids, but not small substrates or inhibitors, most likely through interaction with the C- and D-rings of the steroid. This work provides the first evidence that tryptophans on opposite sides of the apolar cleft are part of the steroid binding pocket and suggests how the enzymemay discriminate between nonsteroidal anti-inflammatory drugs and aldose reductase Inhibitors like zopolrestat, A model of how androstanedione binds in the apolar cleft is developed, These data provide further evidence that loop structures in members of the aldoketoreductase superfamily are critical determinants of ligand binding.	UNIV PENN, SCH MED, DEPT PHARMACOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT BIOCHEM & BIOPHYS, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania				Penning, Trevor/0000-0002-3937-1066	NIDDK NIH HHS [DK47015] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047015] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASKONAS LJ, 1991, BIOCHEM J, V278, P835, DOI 10.1042/bj2780835; Bennett MJ, 1996, BIOCHEMISTRY-US, V35, P10702, DOI 10.1021/bi9604688; BOHREN KM, 1989, J BIOL CHEM, V264, P9547; BORHANI DW, 1992, J BIOL CHEM, V267, P24841; BRUCE NC, 1994, BIOCHEM J, V299, P805, DOI 10.1042/bj2990805; CHOU TC, 1981, EUR J BIOCHEM, V115, P207, DOI 10.1111/j.1432-1033.1981.tb06218.x; COIRO VM, 1973, ACTA CRYSTALLOGR B, VB 29, P1404, DOI 10.1107/S0567740873004644; DEYASHIKI Y, 1995, J BIOL CHEM, V270, P10461, DOI 10.1074/jbc.270.18.10461; DEYASHIKI Y, 1994, BIOCHEM J, V299, P545, DOI 10.1042/bj2990545; EHRIG T, 1994, BIOCHEMISTRY-US, V33, P7157, DOI 10.1021/bi00189a019; EVANS SY, 1990, J MOL GRAPHICS, V12, P134; FORSTER T, 1948, ANN PHYS-LEIPZIG, V2, P3110; HOFF HG, 1973, H-S Z PHYSIOL CHEM, V354, P507, DOI 10.1515/bchm2.1973.354.1.507; HOOG SS, 1994, P NATL ACAD SCI USA, V91, P2517, DOI 10.1073/pnas.91.7.2517; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; KADOR PF, 1983, MOL PHARMACOL, V24, P521; KHANNA M, 1995, J BIOL CHEM, V270, P20162, DOI 10.1074/jbc.270.34.20162; KUBISESKI TJ, 1992, J BIOL CHEM, V267, P6510; LACY WR, 1993, MOL ENDOCRINOL, V7, P58, DOI 10.1210/me.7.1.58; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIURA R, 1994, BIOCHEM J, V299, P561, DOI 10.1042/bj2990561; MYLARI BL, 1991, J MED CHEM, V34, P108, DOI 10.1021/jm00105a018; PAWLOWSKI JE, 1994, J BIOL CHEM, V269, P13502; PAWLOWSKI JE, 1991, J BIOL CHEM, V266, P8820; Penning TM, 1996, CHEM RES TOXICOL, V9, P84, DOI 10.1021/tx950055s; PENNING TM, 1993, CHEM-BIOL INTERACT, V89, P1, DOI 10.1016/0009-2797(93)03203-7; PENNING TM, 1983, P NATL ACAD SCI-BIOL, V80, P4504, DOI 10.1073/pnas.80.14.4504; PENNING TM, 1991, J BIOL CHEM, V266, P8826; Permyakov E. A., 1993, LUMINESCENT SPECTROS, P57; PETRASH JM, 1994, DIABETES, V43, P955, DOI 10.2337/diabetes.43.8.955; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; RICIGLIANO JW, 1990, BIOCHEM J, V269, P749, DOI 10.1042/bj2690749; SCHLEGEL BP, 1994, BIOCHEMISTRY-US, V33, P10367, DOI 10.1021/bi00200a017; SHEN TY, 1965, NONSTEROIDAL ANTIINF, P13; SMITHGALL TE, 1988, BIOCHEM J, V254, P715, DOI 10.1042/bj2540715; SMITHGALL TE, 1986, J BIOL CHEM, V261, P6184; TETEFAVIER F, 1995, EUR J MED CHEM, V30, pS589; TOMLINSON DR, 1994, TRENDS PHARMACOL SCI, V15, P293, DOI 10.1016/0165-6147(94)90010-8; WERMUTH B, 1983, EUR J BIOCHEM, V131, P423, DOI 10.1111/j.1432-1033.1983.tb07280.x; WIERENGA RK, 1992, J MOL BIOL, V224, P1115, DOI 10.1016/0022-2836(92)90473-W; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; WILSON DK, 1993, P NATL ACAD SCI USA, V90, P9847, DOI 10.1073/pnas.90.21.9847	44	62	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30190	30198		10.1074/jbc.271.47.30190	http://dx.doi.org/10.1074/jbc.271.47.30190			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939970	hybrid			2022-12-27	WOS:A1996VU52500098
J	Kent, C				Kent, C			Protein translocation minireview series	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Editorial Material											Kent, C (corresponding author), UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109, USA.								0	0	0	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29513	29513		10.1074/jbc.271.47.29513	http://dx.doi.org/10.1074/jbc.271.47.29513			1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939873	hybrid			2022-12-27	WOS:A1996VU52500001
J	Liu, QL; Levy, EJ; Chirico, WJ				Liu, QL; Levy, EJ; Chirico, WJ			N-ethylmaleimide inactivates a nucleotide-free Hsp70 molecular chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAJ; HEAT-SHOCK PROTEINS; ATPASE ACTIVITY; BINDING-SPECIFICITY; MITOCHONDRIAL HSP70; IMPORT COMPETENCE; SUBSTRATE-BINDING; CYTOSOLIC FACTORS; POTASSIUM AFFECTS; STRESS PROTEINS	Hsp70 molecular chaperones are ATPases that bind to hydrophobic regions of proteins and guide their folding, assembly, and translocation across membranes. The ability of purified Hsp70s to uncoat clathrin-coated vesicles or to stimulate the post-translational translocation of precursor proteins into the endoplasmic reticulum, mitochondria, and the nucleus was previously shown not to be sensitive to the sulfhydryl-modifying reagent N-ethylmaleimide (NEM). During purification of factors required for protein folding in the cytosol, we found that the ATP-agarose binding activity of the yeast Hsp70 Ssa1p in postribosomal supernatants was inhibited by NEM. We also found that completely removing nucleo tides from purified Ssa1p rendered its ATP-agarose binding activity, ATPase activity, and post-translational translocation-stimulating activity sensitive to NEM, We modified nucleotide-free Ssa1p with [C-14]NEM and then digested it with proteases. Purification and sequencing of the radiolabeled proteolytic fragments revealed that each of Ssa1p's three cysteine residues (Cys-15, Cys-264, and Cys-303) was modified with [C-14]NEM. ADP protected each of the cysteine residues from modification and protected Ssa1p from inactivation. The cysteine residues are the reactive centers of three NEM-reactive sites (NRS1-3). A comparison of Ssa1p's NRSs to sequences of other Hsp70s and actin revealed that Cys-15 of NRS1 is highly conserved and that sensitivity to NEM may be a property of many Hsp70s. Based on the three-dimensional structure of Hsc70, the predicted locations of Ssa1p's cysteine residues suggest that NEM may disrupt the conformation of Ssa1p or interfere with its ability to bind nucleotides, Together the results demonstrate that Ssa1p is an NEM-sensitive factor in cytosolic extracts from yeast that stimulates post-translational translocation of proteins into organelles.	SUNY HLTH SCI CTR,DEPT ANAT & CELL BIOL,BROOKLYN,NY 11203	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center								BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODSKY JL, 1996, TRENDS BIOCHEM SCI, V21, P51; BROT N, 1994, P NATL ACAD SCI USA, V91, P12120, DOI 10.1073/pnas.91.25.12120; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DUPONT D, 1988, USER B APPL BIOSYSTE, V2; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; FRESE R, 1972, EXPERIENTIA, V28, P1013, DOI 10.1007/BF01918643; Fung KL, 1996, J BIOL CHEM, V271, P21559, DOI 10.1074/jbc.271.35.21559; GAO BC, 1994, BIOCHEMISTRY-US, V33, P2048, DOI 10.1021/bi00174a010; HACHIYA N, 1993, EMBO J, V12, P1579, DOI 10.1002/j.1460-2075.1993.tb05802.x; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; LAIN B, 1994, J BIOL CHEM, V269, P15588; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; LAMBETH DO, 1993, ANAL BIOCHEM, V209, P192, DOI 10.1006/abio.1993.1102; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEVY EJ, 1995, FEBS LETT, V368, P435, DOI 10.1016/0014-5793(95)00704-D; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; NAKAI M, 1994, BIOCHEM BIOPH RES CO, V200, P435, DOI 10.1006/bbrc.1994.1468; NICOLET CM, 1991, YEAST, V726, P699; OBRIEN MC, 1995, J BIOL CHEM, V270, P2247, DOI 10.1074/jbc.270.5.2247; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Penefsky H S, 1979, Methods Enzymol, V56, P527; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SHEFFIELD WP, 1990, J BIOL CHEM, V265, P11069; SHETERLINE P, 1994, PROTEIN PROFILE, V1, P1; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; WATERS MG, 1986, J CELL BIOL, V103, P2629, DOI 10.1083/jcb.103.6.2629; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677; WERNERWASHBURNE M, 1987, MOL CELL BIOL, V7, P2568, DOI 10.1128/MCB.7.7.2568; WILBANKS SM, 1995, J BIOL CHEM, V270, P2251, DOI 10.1074/jbc.270.5.2251; [No title captured]	49	28	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29937	29944		10.1074/jbc.271.47.29937	http://dx.doi.org/10.1074/jbc.271.47.29937			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939938	hybrid			2022-12-27	WOS:A1996VU52500066
J	Passafaro, M; Rosa, P; Sala, C; Clementi, F; Sher, E				Passafaro, M; Rosa, P; Sala, C; Clementi, F; Sher, E			N-type Ca2+ channels are present in secretory granules and are transiently translocated to the plasma membrane during regulated exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHEOCHROMOCYTOMA CELL-LINES; OPERATED CALCIUM CHANNELS; NEUROBLASTOMA IMR32 CELLS; GLUCOSE-TRANSPORTER GLUT4; SENSITIVE CA-2+ CHANNELS; HUMAN NEURO-BLASTOMA; NERVE GROWTH-FACTOR; OMEGA-CONOTOXIN; RAT PHEOCHROMOCYTOMA	An intracellular pool of N-type voltage-operated calcium channels has recently been described in different neuronal cell lines, We have now further characterized the intracellular pool of N-type calcium channels in both IMR32 human neuroblastoma and PC12 rat pheochromocytoma cells, Intracellular N-type calcium channels were found to be accumulated in subcellular fractions where the chromogranin B-containing secretory granules were also enriched, I-125-omega-Conotoxin GVIA binding assays on fixed and permeabilized cells revealed that intracellular N-type calcium channels translocate to the plasma membrane in cells exposed to secretagogues (KCl, ionomycin, and phorbol esters). The kinetics, Ca2+ and protein kinase C dependence, and brefeldin A insensitivity of N-type calcium channels translocation were similar to the regulated release of chromogranin B, while no correlation was found with the constitutive secretion of a heparan sulfate proteoglycan. A PC12 subclone deficient in the regulated but not in the constitutive pathway of secretion had a small intracellular pool of N-type calcium channels, and no secretagogue-induced translocation occurred in these cells, Calcium channel translocation was accompanied by a stronger response of Fura-2-loaded cells to depolarizing stimuli, suggesting that the newly inserted channels are functional.	UNIV MILAN,CNR,CELLULAR & MOL PHARMACOL CTR,DEPT MED PHARMACOL,I-20129 MILAN,ITALY; CNR,INST BIOTECHNOL APPL PHARMACOL,I-88021 ROCCELLETTA BORGI,CZ,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Milan; Consiglio Nazionale delle Ricerche (CNR)			Sala, Carlo/A-2493-2009	Sala, Carlo/0000-0003-0662-9523; Rosa, Patrizia/0000-0002-2590-6955	Multiple Sclerosis Society [858] Funding Source: Medline; Fondazione Telethon Funding Source: Custom	Multiple Sclerosis Society(National Multiple Sclerosis Society); Fondazione Telethon(Fondazione Telethon)		AHLIJANIAN MK, 1991, J BIOL CHEM, V266, P20192; BASSETTI M, 1995, ENDOCRINOLOGY, V136, P1168, DOI 10.1210/en.136.3.1168; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CARBONE E, 1990, PFLUG ARCH EUR J PHY, V416, P170, DOI 10.1007/BF00370239; CARBONE E, 1989, PROG BIOPHYS MOL BIO, V54, P31, DOI 10.1016/0079-6107(89)90008-4; CAVALIE A, 1994, J PHYSIOL-LONDON, V479, P11, DOI 10.1113/jphysiol.1994.sp020274; CLEMENTI E, 1992, EUR J NEUROSCI, V4, P944, DOI 10.1111/j.1460-9568.1992.tb00121.x; DOHERTY P, 1993, J CELL BIOL, V122, P181, DOI 10.1083/jcb.122.1.181; FRANKLIN JL, 1992, J NEUROSCI, V12, P1726; GARCIA DE, 1994, J NEUROSCI, V14, P545; HAYDON PG, 1994, NEURON, V13, P1275, DOI 10.1016/0896-6273(94)90414-6; HERMAN GA, 1994, P NATL ACAD SCI USA, V91, P12750, DOI 10.1073/pnas.91.26.12750; HUDSON AW, 1993, J CELL BIOL, V122, P579, DOI 10.1083/jcb.122.3.579; JONES OT, 1989, SCIENCE, V244, P1189, DOI 10.1126/science.2543080; KNOX RJ, 1992, NEURON, V8, P883, DOI 10.1016/0896-6273(92)90202-O; KOIKE T, 1987, J NEUROCHEM, V49, P1784, DOI 10.1111/j.1471-4159.1987.tb02436.x; KOMURO H, 1992, SCIENCE, V257, P806, DOI 10.1126/science.1323145; KUO CC, 1993, NATURE, V365, P258, DOI 10.1038/365258a0; LUEBKE JI, 1994, PFLUG ARCH EUR J PHY, V428, P499, DOI 10.1007/BF00374571; MILLER RJ, 1992, J BIOL CHEM, V267, P1403; MILLER SG, 1992, J CELL BIOL, V118, P267, DOI 10.1083/jcb.118.2.267; OCONNOR VM, 1993, FEBS LETT, V326, P255, DOI 10.1016/0014-5793(93)81802-7; OLIVERA BM, 1994, ANNU REV BIOCHEM, V63, P823, DOI 10.1146/annurev.bi.63.070194.004135; PASSAFARO M, 1994, NEURON, V12, P317, DOI 10.1016/0896-6273(94)90274-7; PASSAFARO M, 1992, J NEUROSCI, V12, P3372; PASSAFARO M, 1993, CLIN CHEM ENZYME COM, V6, P15; PIETRINI G, 1992, P NATL ACAD SCI USA, V89, P8414, DOI 10.1073/pnas.89.18.8414; POLLO A, 1992, PFLUG ARCH EUR J PHY, V422, P75; PUGH PC, 1994, J NEUROSCI, V14, P889; REEVE HL, 1995, PFLUG ARCH EUR J PHY, V429, P729, DOI 10.1007/BF00373996; REGNIERVIGOUROUX A, 1991, EMBO J, V10, P3589, DOI 10.1002/j.1460-2075.1991.tb04925.x; ROSA P, 1989, J CELL BIOL, V109, P17, DOI 10.1083/jcb.109.1.17; ROSA P, 1985, J CELL BIOL, V101, P1999, DOI 10.1083/jcb.101.5.1999; ROSA P, 1992, EUR J CELL BIOL, V59, P265; SCHULTZ G, 1990, ANNU REV PHYSIOL, V52, P275, DOI 10.1146/annurev.ph.52.030190.001423; SCHWEITZER ES, 1993, J CELL SCI, V106, P731; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; SHER E, 1989, LANCET, V2, P640; SHER E, 1989, J CELL BIOL, V108, P2291, DOI 10.1083/jcb.108.6.2291; SHER E, 1988, FEBS LETT, V235, P178, DOI 10.1016/0014-5793(88)81258-4; SHER E, 1991, NEUROSCIENCE, V42, P301, DOI 10.1016/0306-4522(91)90376-Y; STINCHCOMBE JC, 1994, CELL BIOL LAB HDB, P557; STRONG JA, 1987, NATURE, V325, P714, DOI 10.1038/325714a0; TAGAYA M, 1995, J BIOL CHEM, V270, P15930, DOI 10.1074/jbc.270.27.15930; TARELLI FT, 1991, BRAIN RES, V547, P331, DOI 10.1016/0006-8993(91)90981-Z; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; USOWICZ MM, 1990, J PHYSIOL-LONDON, V426, P95, DOI 10.1113/jphysiol.1990.sp018128; WOLLHEIM CB, 1988, EMBO J, V7, P2443, DOI 10.1002/j.1460-2075.1988.tb03090.x; WOOD MR, 1992, J NEUROSCI, V12, P2948, DOI 10.1523/JNEUROSCI.12-08-02948.1992	53	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30096	30104		10.1074/jbc.271.47.30096	http://dx.doi.org/10.1074/jbc.271.47.30096			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939958	hybrid			2022-12-27	WOS:A1996VU52500086
J	Wen, PH; Blumenthal, KM				Wen, PH; Blumenthal, KM			Role of electrostatic interactions in defining the potency of neurotoxin B-IV from Cerebratulus lacteus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETERONEMERTINE POLYPEPTIDE TOXINS; HYDROPHOBIC PROTEIN CRAMBIN; SENSITIVE SODIUM-CHANNELS; AXON MEMBRANE-VESICLES; CIRCULAR-DICHROISM; SECONDARY STRUCTURE; SCORPION; SITE; BINDING; VENOM	Chemical modification implicates arginine residues of the Cerebratulus lacteus neurotoxin B-IV in biological activity, In the present study, we used site-directed mutagenesis to assess the functional contributions of each of these residues.]Panels of mutants at each site have been constructed by polymerase chain reaction and recombinant proteins expressed and purified to homogeneity using an Escherichia coli expression system developed in this laboratory, All substitutions for Arg-17 (Gin, Ala, or Lys) yield proteins having undetectable levels of activity, while charge neutralizing replacement of Arg-25 (R25Q) causes a 400-fold reduction in specific toxicity, However, the R25K mutein is almost as active as natural toxin. Circular dichroism spectroscopy indicates that there are no major conformational changes in any of these muteins. These results therefore demonstrate the requirement for a guanidinium group at position 17, and a positive charge at position 25. NMR analyses (Hansen, P. E., Mem, W. R., Bieber, A. L., and Norton, R. S. (1992) fur. J. Biochem. 210, 231-240) reveal neurotoxin B-TV to contain two antiparallel alpha-helices, which together include 57% of the sequence. Both Arg-17 and Arg-25 lie on the same face of the N-terminal helix (residues 13-26), as do the carboxyl groups of Glu-13 and Asp-al, However, charge neutralizing mutations of the latter two sites have no effects on biological activity, Arg-34, situated near the N terminus of helix 2 (residues 33-49) is also important for activity, as its replacement by Gin or Ala diminishes activity by 20- and 80-fold, respectively, However, unlike Arg-17 and Arg-25, thermal denaturation experiments suggest that R34Q may be structurally destabilized relative to wild-type B-TV.	UNIV CINCINNATI,COLL MED,DEPT MOL GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	University of Cincinnati					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048676] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48676] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUMENTHAL KM, 1980, ARCH BIOCHEM BIOPHYS, V203, P822, DOI 10.1016/0003-9861(80)90244-1; BLUMENTHAL KM, 1980, ARCH BIOCHEM BIOPHYS, V203, P816, DOI 10.1016/0003-9861(80)90243-X; BLUMENTHAL KM, 1986, TOXICON, V24, P63, DOI 10.1016/0041-0101(86)90166-2; CATTERALL WA, 1980, ANNU REV PHARMACOL, V20, P15, DOI 10.1146/annurev.pa.20.040180.000311; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CATTERALL WA, 1978, J BIOL CHEM, V253, P7393; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COURAUD F, 1978, BIOCHEM BIOPH RES CO, V83, P1525, DOI 10.1016/0006-291X(78)91394-3; FAINZILBER M, 1992, TOXICON, V30, P465, DOI 10.1016/0041-0101(92)90543-E; FAINZILBER M, 1991, EUR J BIOCHEM, V202, P589, DOI 10.1111/j.1432-1033.1991.tb16412.x; GALLAGHER MJ, 1994, J BIOL CHEM, V269, P254; Gordon D, 1996, J BIOL CHEM, V271, P8034, DOI 10.1074/jbc.271.14.8034; HANSEN PE, 1992, EUR J BIOCHEM, V210, P231, DOI 10.1111/j.1432-1033.1992.tb17413.x; HENDRICKSON WA, 1981, NATURE, V290, P107, DOI 10.1038/290107a0; HILLE B, 1975, BIOPHYS J, V15, P615, DOI 10.1016/S0006-3495(75)85842-5; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOWELL ML, 1991, J BIOL CHEM, V266, P12884; HOWELL ML, 1989, J BIOL CHEM, V264, P15268; KEM WR, 1990, J PROTEIN CHEM, V9, P433, DOI 10.1007/BF01024619; KEM WR, 1976, J BIOL CHEM, V251, P4184; KEM WR, 1978, FED PROC, V37, P559; KHARRAT R, 1989, EUR J BIOCHEM, V181, P381, DOI 10.1111/j.1432-1033.1989.tb14735.x; LEBRETON F, 1994, BIOCHEMISTRY-US, V33, P11135, DOI 10.1021/bi00203a010; LIEBERMAN DL, 1986, BIOCHIM BIOPHYS ACTA, V855, P41, DOI 10.1016/0005-2736(86)90186-0; LORET EP, 1990, BIOCHEMISTRY-US, V29, P1492, DOI 10.1021/bi00458a021; NORTON RS, 1991, TOXICON, V29, P1051, DOI 10.1016/0041-0101(91)90205-6; PERCZEL A, 1991, PROTEIN ENG, V4, P669, DOI 10.1093/protein/4.6.669; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUKUMAR M, 1995, PROTEIN SCI, V4, P1718, DOI 10.1002/pro.5560040907; TEETER MM, 1993, J MOL BIOL, V230, P292, DOI 10.1006/jmbi.1993.1143; TEETER MM, 1981, BIOCHEMISTRY-US, V20, P5437, DOI 10.1021/bi00522a013; TOTH GP, 1983, BIOCHIM BIOPHYS ACTA, V732, P160, DOI 10.1016/0005-2736(83)90199-2; ZLOTKIN E, 1985, ARCH BIOCHEM BIOPHYS, V240, P877, DOI 10.1016/0003-9861(85)90098-0; ZLOTKIN E, 1991, BIOCHEMISTRY-US, V30, P4814, DOI 10.1021/bi00233a025; ZLOTKIN E, 1972, TOXICON, V10, P207, DOI 10.1016/0041-0101(72)90004-9	36	6	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29752	29758		10.1074/jbc.271.47.29752	http://dx.doi.org/10.1074/jbc.271.47.29752			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939911	hybrid			2022-12-27	WOS:A1996VU52500039
J	Bouvier, F; dHarlingue, A; Hugueney, P; Marin, E; MarionPoll, A; Camara, B				Bouvier, F; dHarlingue, A; Hugueney, P; Marin, E; MarionPoll, A; Camara, B			Xanthophyll biosynthesis - Cloning, expression, functional reconstitution, and regulation of beta-cyclohexenyl carotenoid epoxidase from pepper (Capsicum annuum)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCES; SQUALENE EPOXIDASE; MOLECULAR-CLONING; CHROMOPLAST MEMBRANES; ESCHERICHIA-COLI; LYCOPENE CYCLIZATION; HIGHER-PLANTS; FATTY-ACIDS; PROTEIN; INHIBITION	Pepper (Capsicum annuum) beta-cyclohexenyl xanthophyll epoxidase cDNA was cloned and the corresponding enzyme overexpressed and purified from Escherichia coli, for investigation of its catalytic activity. The recombinant protein did not directly accept NADPH for epoxidation of cyclohexenyl carotenoids, nor did it operate according to a peroxygenase-based mechanism. Instead, the reducing power of NADPH was transferred to the epoxidase via reduced ferredoxin as shown by reconstitution of epoxidase activity in the presence of NADPH, ferredoxin oxidoreductase, and ferredoxin. Bacterial rubredoxin could be substituted for ferredoxin. The pepper epoxidase acted specifically on the beta-ring of xanthophylls such as beta-cryptoxanthin, zeaxan thin, and antheraxanthin. The proposed reaction mechanism for epoxidation involves the formation of a transient carbocation. This characteristic allows selective inhibition of the epoxidase activity by different nucleophilic diethylamine derivatives, p-dimethylaminobenzenediazonium fluoroborate and N,N-dimethyl-2-phenylaziridinium. It was also shown that the epoxidase gene was up-regulated during oxidative stress and when chloroplasts undergo differentiation into chromoplasts in pepper fruit.	UNIV STRASBOURG 1,CNRS,INST BIOL MOL PLANTES,F-67084 STRASBOURG,FRANCE; UNIV PARIS 06,LAB PATHOL & BIOCHIM VEGETALES,F-75250 PARIS,FRANCE; INST BIOL ZELLBIOL 2,D-79104 FREIBURG,GERMANY; INRA,BIOL CELLULAIRE LAB,F-78026 VERSAILLES,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Sorbonne Universite; INRAE; UDICE-French Research Universities; Universite Paris Saclay			Hugueney, Philippe/AAU-5903-2020	Hugueney, Philippe/0000-0002-1641-9274				Alonso JM, 1995, PLANT MOL BIOL, V29, P1211, DOI 10.1007/BF00020463; ATTAASAFOADJEI E, 1993, J BIOL CHEM, V268, P9681; BLEE E, 1990, J BIOL CHEM, V265, P12887; BODEA C, 1969, Pure and Applied Chemistry, V20, P517, DOI 10.1351/pac196920040517; BOTTING CH, 1995, BIOTECHNIQUES, V19, P362; BOUVIER F, 1994, PLANT J, V6, P45, DOI 10.1046/j.1365-313X.1994.6010045.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMARA B, 1985, PHYTOCHEMISTRY, V24, P2751, DOI 10.1016/S0031-9422(00)80718-9; CAMARA B, 1993, METHOD ENZYMOL, V214, P352; CAMARA B, 1985, METHOD ENZYMOL, V110, P244; CAMARA B, 1985, BIOCHIM BIOPHYS ACTA, V836, P262, DOI 10.1016/0005-2760(85)90074-8; Camara B, 1995, INT REV CYTOL, V163, P175, DOI 10.1016/S0074-7696(08)62211-1; CAMARA B, 1986, PLANT PHYSIOL, V80, P172, DOI 10.1104/pp.80.1.172; CAMARA B, 1985, METHOD ENZYMOL, V110, P274; CHANGEUX JP, 1967, P NATL ACAD SCI USA, V58, P2063, DOI 10.1073/pnas.58.5.2063; COGDELL RJ, 1987, BIOCHIM BIOPHYS ACTA, V895, P63, DOI 10.1016/S0304-4173(87)80008-3; COSTES C, 1979, FEBS LETT, V103, P17, DOI 10.1016/0014-5793(79)81241-7; Davies B., 1976, CAROTENOIDS CHEM BIO, P38, DOI [DOI 10.1590/S0101-20612001000200017, 10.1007/978-3-642-66632-2_11, DOI 10.1007/978-3-642-66632-2_11]; DEMMIGADAMS B, 1992, ANNU REV PLANT PHYS, V43, P599, DOI 10.1146/annurev.pp.43.060192.003123; ENTSCH B, 1995, FASEB J, V9, P476, DOI 10.1096/fasebj.9.7.7737455; GALLIARD T, 1977, PHYTOCHEMISTRY, V16, P339, DOI 10.1016/0031-9422(77)80060-5; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; GOELDNER MP, 1980, P NATL ACAD SCI-BIOL, V77, P6439, DOI 10.1073/pnas.77.11.6439; GREEN BR, 1991, TRENDS BIOCHEM SCI, V16, P181, DOI 10.1016/0968-0004(91)90072-4; GREEN LS, 1991, PLANT PHYSIOL, V96, P1207, DOI 10.1104/pp.96.4.1207; GRUSZECKI WI, 1993, BIOCHIM BIOPHYS ACTA, V1144, P97, DOI 10.1016/0005-2728(93)90036-F; HAGER A, 1994, PLANTA, V192, P581, DOI 10.1007/BF00203597; HAMBERG M, 1990, ARCH BIOCH BIOPHYS, V283; HENGEN PN, 1995, TRENDS BIOCHEM SCI, V20, P285, DOI 10.1016/S0968-0004(00)89045-3; HIRASAWA M, 1990, ARCH BIOCHEM BIOPHYS, V276, P251, DOI 10.1016/0003-9861(90)90035-W; HUGUENEY P, 1992, EUR J BIOCHEM, V209, P399, DOI 10.1111/j.1432-1033.1992.tb17302.x; HUNDLE BS, 1993, FEBS LETT, V315, P329, DOI 10.1016/0014-5793(93)81188-6; JANDROSITZ A, 1991, GENE, V107, P155, DOI 10.1016/0378-1119(91)90310-8; KHUDAIRI AK, 1972, AM SCI, V60, P696; KNOELL HE, 1974, EUR J BIOCHEM, V50, P245, DOI 10.1111/j.1432-1033.1974.tb03893.x; KOSUGA K, 1995, BBA-GENE STRUCT EXPR, V1260, P345, DOI 10.1016/0167-4781(94)00245-X; KRINSKY NI, 1979, PURE APPL CHEM, V51, P649, DOI 10.1351/pac197951030649; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Marin E, 1996, EMBO J, V15, P2331, DOI 10.1002/j.1460-2075.1996.tb00589.x; MATSUI K, 1994, BIOSCI BIOTECH BIOCH, V58, P140, DOI 10.1271/bbb.58.140; McDermott J C, 1973, Pure Appl Chem, V35, P29, DOI 10.1351/pac197335010029; MONEGER R, 1968, PHYSIOL VEG, V6, P367; NARULA AS, 1981, J AM CHEM SOC, V103, P2408, DOI 10.1021/ja00399a045; ONO T, 1982, BIOCHIM BIOPHYS ACTA, V709, P84, DOI 10.1016/0167-4838(82)90424-1; PALUMAA P, 1982, BIOORG CHEM, V11, P394, DOI 10.1016/0045-2068(82)90030-X; PAN ZQ, 1995, J BIOL CHEM, V270, P8487, DOI 10.1074/jbc.270.15.8487; PENG YL, 1994, J BIOL CHEM, V269, P3755; PURDIE JE, 1969, BIOCHIM BIOPHYS ACTA, V185, P122, DOI 10.1016/0005-2744(69)90288-5; ROCK CD, 1991, P NATL ACAD SCI USA, V88, P7496, DOI 10.1073/pnas.88.17.7496; Rockholm DC, 1996, PLANT PHYSIOL, V110, P697, DOI 10.1104/pp.110.2.697; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAKAKIBARA J, 1995, J BIOL CHEM, V270, P17, DOI 10.1074/jbc.270.1.17; Sambrook J, 1989, MOL CLONING LABORATO, P545; SCHMITT P, 1987, PHYTOCHEMISTRY, V26, P2709, DOI 10.1016/S0031-9422(00)83577-3; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SINGH RK, 1973, BIOCHEM J, V132, P649, DOI 10.1042/bj1320649; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; SONG WC, 1993, P NATL ACAD SCI USA, V90, P8519, DOI 10.1073/pnas.90.18.8519; SUKIGARA M, 1967, B CHEM SOC JPN, V40, P1077, DOI 10.1246/bcsj.40.1077; TESTA B, 1973, MOL PHARMACOL, V9, P10; VERWOERD TC, 1989, NUCLEIC ACIDS RES, V17, P2362, DOI 10.1093/nar/17.6.2362; VETTER HP, 1992, PLANT PHYSIOL, V100, P998, DOI 10.1104/pp.100.2.998; VICK BA, 1987, PLANT PHYSIOL, V85, P1073, DOI 10.1104/pp.85.4.1073; WADA K, 1989, J BIOCHEM, V105, P619, DOI 10.1093/oxfordjournals.jbchem.a122714; WOFSY L, 1962, BIOCHEMISTRY-US, V1, P1031, DOI 10.1021/bi00912a013; YAMAMOTO HY, 1979, PURE APPL CHEM, V51, P639, DOI 10.1351/pac197951030639; YOUNG A, 1989, Z NATURFORSCH C, V44, P959; ZIEGLER DM, 1988, DRUG METAB REV, V19, P1, DOI 10.3109/03602538809049617	68	131	147	2	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28861	28867		10.1074/jbc.271.46.28861	http://dx.doi.org/10.1074/jbc.271.46.28861			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910532	hybrid, Green Published			2022-12-27	WOS:A1996VT05200024
J	Lett, CM; Berghuis, AM; Frey, HE; Lepock, JR; Guillemette, JG				Lett, CM; Berghuis, AM; Frey, HE; Lepock, JR; Guillemette, JG			The role of a conserved water molecule in the redox-dependent thermal stability of iso-1-cytochrome c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE ISO-1-CYTOCHROME-C; SITE-DIRECTED MUTAGENESIS; AMINO-ACID REPLACEMENTS; HYDROGEN-BOND NETWORK; YEAST CYTOCHROME-C; PROTEIN STABILITY; TYROSINE-67; SUBSTITUTIONS; CONSEQUENCES; REDUCTION	Eukaryotic cytochromes c contain a buried mater molecule (Wat166) next to the heme that is associated through a network of hydrogen bonds to three invariant residues: tyrosine 67, asparagine 52, and threonine 78. Single-site mutations to two of these residues (Y67F, N52I, N52A) and the double-she mutation (Y67F/N52I) were introduced into Saccharomyces cerevisiae iso-1-cytochrome c to disrupt the hydrogen bonding network associated with Wat166. The N52I and Y67F/N52I mutations lead to a loss of Wat166 while N52A and Y67F modifications lead to the addition of a new water molecule (Wat166) at an adjacent site (Berghuis, A. M., Guillemette, J. G., McLendon, G., Sherman, F., Smith, M., and Brayer, G. D. (1994) J. Mol. Biol. 236, 786-799; Berghuis, A. M., Guillemette, J. G., Smith, M., and Brayer, G. D. (1994) J. Mol. Biol. 235, 1326-1341; Rafferty, S. P., Guillemette, J. G., Berghuis, A. M., Smith, M., Brayer, G. D., and Mauk, A. G. (1996) Biochemistry, 35, 10784-10792). We used differential scanning calorimetry (DSC) to determine the change in heat capacity (Delta C-P) and the temperature dependent enthalpy (Delta H-vH) for the thermal denaturation of both the oxidized and reduced forms of the iso-l cytochrome c variants. The relative stabilities were expressed as the difference in the free energy of denaturation (Delta G(D)) between the wild type and mutant proteins in both redox states. The disruption of the hydrogen bonding network results in increased stability for all of the mutant proteins in both redox states with the exception of the reduced Y67F variant which has approximately the same stability as the reduced wild type protein. For the oxidized proteins, Delta G(D) values of 1.3, 4.1, 1.5, and 5.8 kcal/mol were determined for N52A, N52I, Y67F, and Y67F/N52I, respectively. The oxidized proteins were 8.2-11.5 kcal/mol less stable than the reduced proteins due to a redox-dependent increase in the entropy of unfolding.	UNIV WATERLOO,DEPT CHEM,WATERLOO,ON N2L 3G1,CANADA; UNIV WATERLOO,GUELPH WATERLOO CTR GRAD WORK CHEM,WATERLOO,ON N2L 3G1,CANADA; UNIV WATERLOO,DEPT PHYS,WATERLOO,ON N2L 3G1,CANADA; MCMASTER UNIV,DEPT BIOCHEM,HAMILTON,ON L8S 4L8,CANADA	University of Waterloo; University of Guelph; University of Waterloo; University of Waterloo; McMaster University			Berghuis, Albert M/A-6495-2008	Berghuis, Albert/0000-0002-2663-025X				BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BERGHUIS AM, 1994, J MOL BIOL, V235, P1326, DOI 10.1006/jmbi.1994.1086; BERGHUIS AM, 1992, J MOL BIOL, V223, P959, DOI 10.1016/0022-2836(92)90255-I; BERGHUIS AM, 1994, J MOL BIOL, V236, P786, DOI 10.1006/jmbi.1994.1189; CHURG AK, 1986, BIOCHEMISTRY-US, V25, P1675, DOI 10.1021/bi00355a035; COHEN DS, 1995, J AM CHEM SOC, V117, P1675, DOI 10.1021/ja00111a001; CUTLER RL, 1987, PROTEIN ENG, V1, P95, DOI 10.1093/protein/1.2.95; DAS G, 1989, P NATL ACAD SCI USA, V86, P496, DOI 10.1073/pnas.86.2.496; DUNITZ JD, 1994, SCIENCE, V264, P670, DOI 10.1126/science.264.5159.670; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; FRAUENHOFF MM, 1992, PROTEINS, V14, P202, DOI 10.1002/prot.340140207; GAO Y, 1991, BIOCHEMISTRY-US, V30, P1928, DOI 10.1021/bi00221a028; GUILLEMETTE JG, 1994, BIOCHIMIE, V76, P592, DOI 10.1016/0300-9084(94)90136-8; HICKEY DR, 1991, J BIOL CHEM, V266, P11686; INGLIS SC, 1991, PROTEIN ENG, V4, P569, DOI 10.1093/protein/4.5.569; KOMARPANICUCCI S, 1994, BIOCHEMISTRY-US, V33, P10556, DOI 10.1021/bi00200a042; KOSHY TI, 1994, BIOCHEM J, V299, P347, DOI 10.1042/bj2990347; LANGEN R, 1992, J MOL BIOL, V224, P589, DOI 10.1016/0022-2836(92)90546-V; LEVITT M, 1993, STRUCTURE, V1, P223, DOI 10.1016/0969-2126(93)90011-5; LIGGINS JR, 1994, BIOCHEMISTRY-US, V33, P9209, DOI 10.1021/bi00197a024; LINSKEOCONNELL LI, 1995, BIOCHEMISTRY-US, V34, P7094, DOI 10.1021/bi00021a022; LUNTZ TL, 1989, P NATL ACAD SCI USA, V86, P3524, DOI 10.1073/pnas.86.10.3524; MARGOLIASH E, 1959, BIOCHEM J, V71, P570, DOI 10.1042/bj0710570; McGee WA, 1996, BIOCHEMISTRY-US, V35, P1995, DOI 10.1021/bi951228f; MEYER E, 1992, PROTEIN SCI, V1, P1543, DOI 10.1002/pro.5560011203; MOORE GR, 1990, CYTOCHROMES EVOLUTIO, P309; PACE CN, 1992, J MOL BIOL, V226, P29, DOI 10.1016/0022-2836(92)90121-Y; PIELAK GJ, 1995, BIOCHEMISTRY-US, V34, P3268, DOI 10.1021/bi00010a017; RAFFERTY SP, 1990, BIOCHEMISTRY-US, V29, P9365, DOI 10.1021/bi00492a009; Rafferty SP, 1996, BIOCHEMISTRY-US, V35, P10784, DOI 10.1021/bi960430v; SCHEJTER A, 1994, BIOCHEM J, V302, P95, DOI 10.1042/bj3020095; SCHELLMAN JA, 1987, ANNU REV BIOPHYS BIO, V16, P115, DOI 10.1146/annurev.bb.16.060187.000555; SCOTT RA, 1996, CYTOCHROME C MULTIDI, P1; SHIRLEY BA, 1992, BIOCHEMISTRY-US, V31, P725, DOI 10.1021/bi00118a013; SHORTLE D, 1989, J BIOL CHEM, V264, P5313; TAKANO T, 1981, J MOL BIOL, V153, P79, DOI 10.1016/0022-2836(81)90528-3; TEETER MM, 1991, ANNU REV BIOPHYS BIO, V20, P577, DOI 10.1146/annurev.bb.20.060191.003045; WALLACE CJA, 1989, J BIOL CHEM, V264, P15199; WHITFORD D, 1991, EUR J BIOCHEM, V200, P359, DOI 10.1111/j.1432-1033.1991.tb16193.x	39	46	46	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29088	29093		10.1074/jbc.271.46.29088	http://dx.doi.org/10.1074/jbc.271.46.29088			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910563	hybrid			2022-12-27	WOS:A1996VT05200055
J	Li, SW; Couet, J; Lisanti, MP				Li, SW; Couet, J; Lisanti, MP			Src tyrosine kinases, G(alpha) subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin - Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; TRANS-GOLGI-NETWORK; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; TRANSFORMING PROTEIN; PHEROMONE RESPONSE; 14-3-3 PROTEIN; SH3 DOMAINS; PP60C-SRC; ASSOCIATION	Caveolae are plasma membrane specializations present in most cell types, Caveolin, a 22-kDa integral membrane protein, is a principal structural and regulatory component of caveolae membranes. Previous studies have demonstrated that caveolin co-purifies with lipid modified signaling molecules, including G(alpha) subunits, H-ras c-Src, and other related Src family tyrosine kinases. In addition, it has been shown that caveolin interacts directly with G(alpha) subunits and H-Ras, preferentially recognizing the inactive conformation of these molecules. However, it is not known whether caveolin interacts directly or indirectly with Src family tyrosine kinases. Here, we examine the structural and functional interaction of caveolin with Src family tyrosine kinases. Caveolin was recombinantly expressed as a glutathione S-transferase fusion. Using an established in vitro binding assay, we find that caveolin interacts with wild-type Src (c-Src) but does not form a stable complex with mutationally activated Src (v-Src). Thus, it appears that caveolin prefers the inactive conformation of Src. Deletion mutagenesis indicates that the Src-interacting domain of caveolin is located within residues 82-101, a cytosolic membrane-proximal region of caveolin. A caveolin peptide derived hom this region (residues 82- 101) functionally suppressed the auto-activation of purified recombinant c-Src tyrosine kinase and Fyn, a related Src family tyrosine kinase. We further analyzed the effect of caveolin on c-Src activity in vivo by transiently co-expressing full-length caveolin and c-Src tyrosine kinase in 293T cells. Co-expression with caveolin dramatically suppressed the tyrosine kinase activity of c-Src as measured via an immune complex kinase assay. Thus, it appears that caveolin structurally and functionally interacts with wild-type c-Src via caveolin residues 82-101. Besides interacting with Src family kinases, this cytosolic caveolin domain (residues 82-101) has the following unique features. First,it is required to form multivalent homo-oligomers of caveolin. Second, it interacts with G-protein alpha-subunits and down-regulates their GTPase activity. Third, it binds to wild-type H-Ras. Fourth, it is membrane-proximal, suggesting that it may be involved in other potential protein-protein interactions. Thus, we have termed this 20-amino acid stretch of caveolin residues the caveolin scaffolding domain.	WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute			Li, Shengwen Calvin/H-1725-2012; Lisanti, Michael P/C-6866-2013; Lisanti, Michael/B-6131-2018	Li, Shengwen Calvin/0000-0002-9699-9204; Lisanti, Michael/0000-0003-2034-1382; Couet, Jacques/0000-0001-5409-8689	NATIONAL CANCER INSTITUTE [F32CA071326] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443] Funding Source: NIH RePORTER; NCI NIH HHS [F32 CA071326, CA-71326] Funding Source: Medline; NIGMS NIH HHS [GM-50443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BROWN MT, 1996, IN PRESS BIOCH BIOPH; BUSS JE, 1984, MOL CELL BIOL, V4, P2697, DOI 10.1128/MCB.4.12.2697; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FAN JY, 1983, J CELL SCI, V61, P219; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; FEDER D, 1990, J BIOL CHEM, V265, P8205; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; HENNIPMAN A, 1989, CANCER RES, V49, P516; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KRUEGER JG, 1982, CELL, V28, P889, DOI 10.1016/0092-8674(82)90068-X; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LEEUW T, 1995, SCIENCE, V270, P1210, DOI 10.1126/science.270.5239.1210; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P3863; Lisanti Michael P., 1995, Seminars in Developmental Biology, V6, P47, DOI 10.1016/S1044-5781(06)80084-8; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; LODISH HF, 1991, J BIOL CHEM, V266, P14835; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1988, BIOCHEM BIOPH RES CO, V154, P796, DOI 10.1016/0006-291X(88)90210-0; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; OSUSKY M, 1995, J BIOL CHEM, V270, P25729, DOI 10.1074/jbc.270.43.25729; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELLMAN D, 1985, P NATL ACAD SCI USA, V82, P1623, DOI 10.1073/pnas.82.6.1623; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; SEVERS NJ, 1988, J CELL SCI, V90, P341; SHOELSON SE, 1989, J BIOL CHEM, V264, P7831; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; SNYDER MA, 1984, VIROLOGY, V136, P375, DOI 10.1016/0042-6822(84)90174-0; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; SUMMERS M, 1987, MANUAL METHODS BARCU; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; TANG ZL, 1994, GENE, V147, P299, DOI 10.1016/0378-1119(94)90087-6; Taylor SJ, 1996, BIOESSAYS, V18, P9, DOI 10.1002/bies.950180105; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0	80	659	671	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29182	29190		10.1074/jbc.271.46.29182	http://dx.doi.org/10.1074/jbc.271.46.29182			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910575	Green Accepted, hybrid			2022-12-27	WOS:A1996VT05200067
J	Marquez, LA; RehaKrantz, LJ				Marquez, LA; RehaKrantz, LJ			Using 2-aminopurine fluorescence and mutational analysis to demonstrate an active role of bacteriophage T4 DNA polymerase in strand separation required for 3'->5'-exonuclease activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC ACID POLYMERASES; 5' EXONUCLEASE ACTIVITY; BIOCHEMICAL BASIS; KLENOW FRAGMENT; REPLICATION FIDELITY; MUTATOR; ANTIMUTATOR	The fluorescence of S-aminopurine deoxynucleotide positioned in a 3'-terminal mismatch was used to evaluate the pre-steady state kinetics of the 3' --> 5' exonuclease activity of bacteriophage T4 DNA polymerase on defined DNA substrates, DNA substrates with one, two, or three preformed terminal mispairs simulated increasing degrees of strand separation at a primer terminus. The effects of base pair stability and local DNA sequence on excision rates were investigated by using DNA substrates that were either relatively G + C- or A + T-rich. The importance of strand separation as a prerequisite to the hydrolysis of a terminal nucleotide was demonstrated by using a unique mutant DNA polymerase that could degrade single-stranded but not double-stranded DNA, unless two or more 3'-terminal nucleotides were unpaired. Our results led us to conclude that the reduced exonuclease activity of this mutant DNA polymerase on duplex DNA substrates is due to a defect in melting the primer terminus in preparation for the excision reaction, The mutated amino acid (serine substitution for glycine at codon 255) resides in a critical loop structure determined from a crystallographic study of an amino-terminal fragment of T4 DNA polymerase. These results suggest an active role for amino acid residues in the exonuclease domain of the T4 DNA polymerase in the strand separation step.	UNIV ALBERTA,DEPT BIOL SCI,EDMONTON,AB T6G 2E9,CANADA	University of Alberta			Marquez-Curtis, Leah A/M-7152-2015; Reha-Krantz, Linda/A-3748-2014	Marquez-Curtis, Leah A/0000-0002-4047-2227; Reha-Krantz, Linda/0000-0003-4497-423X				BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BESSMAN MJ, 1977, J MOL BIOL, V116, P115, DOI 10.1016/0022-2836(77)90122-X; BLOOM LB, 1994, BIOCHEMISTRY-US, V33, P7576, DOI 10.1021/bi00190a010; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; CARVER TE, 1994, P NATL ACAD SCI USA, V91, P10670, DOI 10.1073/pnas.91.22.10670; CONNOLLY BA, 1991, OLIGONUCLEOTIDES ANA, P162; COWART M, 1989, BIOCHEMISTRY-US, V28, P1975, DOI 10.1021/bi00431a004; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; ERITJA R, 1986, NUCLEIC ACIDS RES, V14, P5869, DOI 10.1093/nar/14.14.5869; FASSMAN GD, 1975, HDB BIOCH MOL BIOL N, V1, P589; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; GOPALAKRISHNAN V, 1994, J BIOL CHEM, V269, P21123; HERSHFIELD MS, 1972, J BIOL CHEM, V247, P3393; HOCHSTRASSER RA, 1994, BIOCHEMISTRY-US, V33, P11971, DOI 10.1021/bi00205a036; HUANG WM, 1972, J BIOL CHEM, V247, P3139; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; LIN TC, 1987, P NATL ACAD SCI USA, V84, P7000, DOI 10.1073/pnas.84.20.7000; MUZYCZKA N, 1972, J BIOL CHEM, V247, P7116; REDDY MK, 1992, J BIOL CHEM, V267, P14157; REHAKRANTZ LJ, 1993, J BIOL CHEM, V268, P27100; RehaKrantz LJ, 1995, METHOD ENZYMOL, V262, P323; REHAKRANTZ LJ, 1993, J VIROL, V67, P60, DOI 10.1128/JVI.67.1.60-66.1993; REHAKRANTZ LJ, 1991, P NATL ACAD SCI USA, V88, P2417, DOI 10.1073/pnas.88.6.2417; REHAKRANTZ LJ, 1988, J MOL BIOL, V202, P711, DOI 10.1016/0022-2836(88)90552-9; REHAKRANTZ LJ, 1994, J BIOL CHEM, V269, P5635; REHAKRANTZ LJ, 1995, TRENDS BIOCHEM SCI, V202, P133; SOWERS LC, 1986, P NATL ACAD SCI USA, V83, P5434, DOI 10.1073/pnas.83.15.5434; STOCKI SA, 1995, J MOL BIOL, V254, P15, DOI 10.1006/jmbi.1995.0595; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; Wang J, 1996, BIOCHEMISTRY-US, V35, P8110, DOI 10.1021/bi960178r	35	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28903	28911		10.1074/jbc.271.46.28903	http://dx.doi.org/10.1074/jbc.271.46.28903			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910538				2022-12-27	WOS:A1996VT05200030
J	Yebra, M; Parry, GCN; Stromblad, S; Mackman, N; Rosenberg, S; Mueller, BM; Cheresh, DA				Yebra, M; Parry, GCN; Stromblad, S; Mackman, N; Rosenberg, S; Mueller, BM; Cheresh, DA			Requirement of receptor-bound urokinase-type plasminogen activator for integrin alpha v beta 5-directed cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; IN-VITRO; EPITHELIAL-CELLS; U-PA; MONOCLONAL-ANTIBODIES; SIGNAL-TRANSDUCTION; BINDING REGION; SCATTER FACTOR; EGF RECEPTOR; HUMAN-PLASMA	The urokinase plasminogen activator (uPA) interacts with its cell surface receptor (uPAR), providing an inducible, localized cell surface proteolytic activity, thereby promoting cellular invasion. Evidence is provided for a novel function of cell surface-associated uPA . uPAR. Specifically, induction of cell surface expression of uPA uPAR by growth factors or phorbol ester was necessary for vitronectin-dependent carcinoma cell migration, an event mediated by integrin alpha v beta 5. Cell migration on vitronectin was blocked with either a soluble form of uPAR, an antibody that disrupts uPA binding to uPAR, or a monoclonal antibody to alpha v beta 5. Moreover, plasminogen activator inhibitor type 2 blocked this migration event but did not affect adhesion, suggesting a direct role for uPA enzyme activity in this process and that migration but not adhesion of these cells is regulated by uPA . uPAR. Growth factor-mediated induction of uPA . uPAR on the carcinoma cell surface promotes a specific motility event mediated by integrin alpha v beta 5, since cells transfected with the beta 3 integrin subunit expressed alpha v beta 3 and migrated on vitronectin independently of growth factors or uPA . uPAR expression, This relationship between alpha v beta 5 and the uPA uPAR system has significant implications for regulation of motility events associated with development, angiogenesis, and tumor metastasis.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; CHIRON CORP, EMERYVILLE, CA 94608 USA	Scripps Research Institute; Scripps Research Institute; Novartis				Stromblad, Staffan/0000-0002-1236-6339	NATIONAL CANCER INSTITUTE [R01CA045726, R37CA050286, R01CA050286] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054444] Funding Source: NIH RePORTER; NCI NIH HHS [CA-45726, CA-50286] Funding Source: Medline; NHLBI NIH HHS [HL54444] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BRODSKY FM, 1982, J IMMUNOL, V128, P129; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; CIAMBRONE GJ, 1992, J BIOL CHEM, V267, P13617; CONFORTI G, 1994, BLOOD, V83, P994; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; DELROSSO M, 1993, BIOCHEM BIOPH RES CO, V190, P347, DOI 10.1006/bbrc.1993.1054; DENT MAR, 1993, EUR J NEUROSCI, V5, P633, DOI 10.1111/j.1460-9568.1993.tb00529.x; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; GOLD LI, 1989, BIOCHEM J, V262, P529, DOI 10.1042/bj2620529; GOODSON RJ, 1994, P NATL ACAD SCI USA, V91, P7129, DOI 10.1073/pnas.91.15.7129; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; Higazi AAR, 1996, BLOOD, V88, P542, DOI 10.1182/blood.V88.2.542.bloodjournal882542; HOLTING T, 1995, EUR J ENDOCRINOL, V132, P229, DOI 10.1530/eje.0.1320229; HUBER K, 1984, J LAB CLIN MED, V103, P684; JENSEN PJ, 1993, J CELL PHYSIOL, V155, P333, DOI 10.1002/jcp.1041550214; KESSLER TL, 1993, FIBRINOLYSIS, V7, P31, DOI 10.1016/0268-9499(93)90052-W; Kindzelskii AL, 1996, J IMMUNOL, V156, P297; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; KOBAYASHI H, 1992, CANCER RES, V52, P3610; KOST C, 1992, J BIOL CHEM, V267, P12098; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; LEAVESLEY DI, 1992, J CELL BIOL, V117, P1101, DOI 10.1083/jcb.117.5.1101; LUND LR, 1995, BIOCHEM J, V310, P345, DOI 10.1042/bj3100345; MATTHAY MA, 1993, J CELL SCI, V106, P869; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MOHANAM S, 1993, CANCER RES, V53, P4143; MOSER TL, 1995, BIOCHEM J, V307, P867, DOI 10.1042/bj3070867; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NIP J, 1995, CANCER METAST REV, V14, P241, DOI 10.1007/BF00690295; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OSSOWSKI L, 1988, J CELL BIOL, V107, P2437, DOI 10.1083/jcb.107.6.2437; PADMANABHAN J, 1995, THROMB HAEMOSTASIS, V73, P829; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; QUIGLEY JP, 1987, P NATL ACAD SCI USA, V84, P2776, DOI 10.1073/pnas.84.9.2776; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; REINARTZ J, 1995, EXP CELL RES, V220, P274, DOI 10.1006/excr.1995.1316; Sambrook J., 2002, MOL CLONING LAB MANU; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; STAHL A, 1994, CANCER RES, V54, P3066; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; SUZUKI S, 1984, J BIOL CHEM, V259, P5307; VARKI NM, 1984, CANCER RES, V44, P681; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; VIRCA GD, 1990, BIOTECHNIQUES, V8, P370; WALTZ DA, 1994, J BIOL CHEM, V269, P14746; WEI Y, 1994, J BIOL CHEM, V269, P32380; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; XUE W, 1994, J IMMUNOL, V152, P4630; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; YEBRA M, 1995, MOL BIOL CELL, V6, P841, DOI 10.1091/mbc.6.7.841	54	208	214	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29393	29399		10.1074/jbc.271.46.29393	http://dx.doi.org/10.1074/jbc.271.46.29393			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910604	hybrid			2022-12-27	WOS:A1996VT05200096
J	Gibbs, VC; Takahashi, M; Aguet, M; Chuntharapai, A				Gibbs, VC; Takahashi, M; Aguet, M; Chuntharapai, A			A negative regulatory region in the intracellular domain of the human interferon-alpha receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; PHOSPHORYLATION; PATHWAY; PHOSPHATASE; ACTIVATION; BINDING; INTERLEUKIN-10; ASSOCIATION	Interferon-alpha (IFN-alpha)-mediated intracellular signaling is initiated by ligand-induced receptor dimerization, tyrosine phosphorylation of the Tyk2 and Jak1 tyrosine kinases, and subsequent phosphorylation of the Stat1 and Stat2 proteins. The IFN-alpha receptor consists of at least two distinct subunits. One subunit, IFNAR1, has low affinity binding for interferon yet is required for signal transduction. We introduced mutations in the cytoplasmic domain of human IFNAR1 in order to identify residues involved in the mediation of biological responses. We took advantage of the species specificity of the interferon receptors by analyzing human IFN-alpha-induced major histocompatibility complex class I antigen expression in mouse L929 cells stably transfected with mutant human receptors. The membrane proximal 60-amino acids were insufficient to signal a biological response even though within these residues Tyk2 and Stat2 binding sites have been identified. IFN-alpha-induced receptor tyrosine phosphorylation was not critical for signaling because mutation of Tyr residues to Phe did not prevent the biological response to IFN-alpha. The deletion of a 16-amino acid region highly homologous between species created a receptor which signals an enhanced response. Tyrosine dephosphorylation is a component of this enhanced response as mutation of the Tyr residues within this region to Phe resulted in a receptor with increased sensitivity to IFN. The known signaling molecules that interact with IFNAR1 are positive regulators of IFN-alpha function. The presence of this domain in the COOH-terminal region suggests that the receptor may interact with signaling molecules that negatively regulate interferon responses.	GENENTECH INC,DEPT MOL ONCOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT BIOANALYT TECHNOL,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech	Gibbs, VC (corresponding author), SFVAMC,SURG SERV 112,DEPT SURG,4150 CLEMENT ST,SAN FRANCISCO,CA 94131, USA.							AGUET M, 1984, VIROLOGY, V132, P211, DOI 10.1016/0042-6822(84)90105-3; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; CONSTANTINESCU SN, 1994, P NATL ACAD SCI USA, V91, P9602, DOI 10.1073/pnas.91.20.9602; DAVID M, 1993, J BIOL CHEM, V268, P6593; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVID M, 1995, MOL CELL BIOL, V15, P7050; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; HO ASY, 1993, P NATL ACAD SCI USA, V90, P11267, DOI 10.1073/pnas.90.23.11267; HO ASY, 1995, MOL CELL BIOL, V15, P5043; HWANG SY, 1995, P NATL ACAD SCI USA, V92, P11284, DOI 10.1073/pnas.92.24.11284; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LIM JK, 1993, BIOCHIM BIOPHYS ACTA, V1173, P314, DOI 10.1016/0167-4781(93)90129-2; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PLATANIAS LC, 1993, J IMMUNOL, V150, P3382; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; Yan H, 1996, MOL CELL BIOL, V16, P2074; YETTER A, 1995, J BIOL CHEM, V270, P18179, DOI 10.1074/jbc.270.31.18179	29	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28710	28716		10.1074/jbc.271.45.28710	http://dx.doi.org/10.1074/jbc.271.45.28710			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910507	hybrid			2022-12-27	WOS:A1996VU03300107
J	Cryns, VL; Bergeron, L; Zhu, H; Li, HL; Yuan, JY				Cryns, VL; Bergeron, L; Zhu, H; Li, HL; Yuan, JY			Specific cleavage of alpha-fodrin during Fas- and tumor necrosis factor-induced apoptosis is mediated by an interleukin-1 beta-converting enzyme Ced-3 protease distinct from the poly(ADP-ribose) polymerase protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH GENE CED-3; SMALL NUCLEAR RIBONUCLEOPROTEIN; PROGRAMMED CELL-DEATH; CONVERTING-ENZYME; CYSTEINE PROTEASE; IN-VITRO; IL-1-BETA-CONVERTING ENZYME; ICE/CED-3 PROTEASE; MULTIPLE PROTEASES; MAMMALIAN HOMOLOG	Interleukin 1 beta-converting enzyme (ICE)/Ced-3 proteases play a critical role in apoptosis. One well characterized substrate of these proteases is the DNA repair enzyme poly(ADP-ribose) polymerase. We report here that alpha-fodrin, an abundant membrane-associated cytoskeletal protein, is cleaved rapidly and specifically during Fas- and tumor necrosis factor-induced apopto sis; this cleavage is mediated by an ICE/Ced-3 protease distinct from the poly(ADP-ribose) polymerase protease. Studies in cells treated with these apoptotic stimuli reveal that both fodrin and poly(ADP-ribose) polymerase proteolysis are inhibited by acetyl-Tyr-Val-Ala-Asp chloromethyl ketone and CrmA, specific inhibitors of ICE/Ced-3 proteases. However, fodrin proteolysis can be distinguished from poly(ADP-ribose) polymerase prote olysis by its relative insensitivity to acetyl-Asp-Glu-Val-Asp aldehyde (DEVD-CHO), a selective inhibitor of a subset of ICE/Ced-3 proteases that includes CPP32. DEVD-CHO protects cells from Fas induced apoptosis but does not prevent fodrin proteolysis, indicating that cleavage of this protein can be uncoupled from apoptotic cell, death. Moreover, purified fodrin is cleaved in vitro by CPP32 (but not by ICE) into fragments of the same size observed in vivo during apoptosis. These findings suggest that fodrin proteolysis in vivo may reflect the activity of multiple ICE/Ced-3 proteases whose partial sensitivity to DEVD-CHO reflects a limited contribution from CPP32, or an ICE/Ced-3 protease less sensitive than CPP32 to DEVD-CHO inhibition.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP EAST,CARDIOVASC RES CTR,CHARLESTOWN,MA 02129	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital				Zhu, Hong/0000-0002-2575-4031	NATIONAL CANCER INSTITUTE [K08CA001752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012859, R37AG012859] Funding Source: NIH RePORTER; NCI NIH HHS [K08-CA01752-03] Funding Source: Medline; NIA NIH HHS [AG12859-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		An B, 1996, CANCER RES, V56, P438; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; CHOW SC, 1995, FEBS LETT, V364, P134, DOI 10.1016/0014-5793(95)00370-O; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; EASTMAN A, 1995, METHOD CELL BIOL, V46, P41; EMORI Y, 1987, P NATL ACAD SCI USA, V84, P3590, DOI 10.1073/pnas.84.11.3590; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FENTEANY G, 1994, P NATL ACAD SCI USA, V91, P3358, DOI 10.1073/pnas.91.8.3358; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; HARRIS AS, 1988, J NEUROSCI, V8, P2640; IIZUKA K, 1993, J MOL CELL CARDIOL, V25, P1101, DOI 10.1006/jmcc.1993.1122; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; MOON RT, 1990, J BIOL CHEM, V265, P4427; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WANG XD, 1995, J BIOL CHEM, V270, P18044, DOI 10.1074/jbc.270.30.18044; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHIVOTOVSKY B, 1995, EXP CELL RES, V221, P404, DOI 10.1006/excr.1995.1391	58	184	186	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31277	31282		10.1074/jbc.271.49.31277	http://dx.doi.org/10.1074/jbc.271.49.31277			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940132	Green Published, hybrid			2022-12-27	WOS:A1996VW68600043
J	Huang, CS; Ma, WY; Bowden, GT; Dong, ZG				Huang, CS; Ma, WY; Bowden, GT; Dong, ZG			Ultraviolet B-induced activated protein-1 activation does not require epidermal growth factor receptor but is blocked by a dominant negative PKC lambda/i	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-ZETA; XENOPUS-LAEVIS OOCYTES; SIGNAL-TRANSDUCTION; SUBSPECIES BLOCKS; PHORBOL ESTER; EGF RECEPTOR; FOS GENE; UV; ISOFORM; CELLS	The exposure of mammalian cells to UV irradiation leads to the activation of transcription factors such as activated protein-1 (AP-1) and NF kappa B. It is postulated that epidermal growth factor (EGF) receptor, but not protein kinase C (PKC), is the major membrane mediator in UV-induced signal transduction. Since UVB is responsible for most of the carcinogenic effects of sun exposure, we investigated the role of EGF receptors and PKC in UVB-induced AP-1 activation. Our results indicated that while the down-regulation of novel PKC (nPKC) and conventional PKC (cPKC) by pretreatment of cells with 12-O-tetradecanoyl phorbol-13-actetate cannot block UVB-induced AP-1 activity, it can block 12-O-tetradecanoyl phorbol-13-acetate-induced AP-I activity, Further, the dominant negative mutant PKC lambda/iota blocked UVB-induced AP-1 activity in all doses and time courses studied. In contrast, UVB-induced AP-1 activity from cells devoid of EGF receptor (B82) was not significantly different from that of the stable transfectants with a kinase-deficient EGF receptor (B82M721) or those with a wild-type EGF receptor (B82L) at all UVB irradiation doses and time courses studied, All of this evidence indicated that aPKC, but not EGF receptor, is involved in UVE-induced AP-1 activation.	UNIV MINNESOTA,HORMEL INST,AUSTIN,MN 55912; UNIV ARIZONA,ARIZONA HLTH SCI CTR,DEPT RADIAT ONCOL,TUCSON,AZ 85724	University of Minnesota System; University of Arizona; University of Arizona Health Sciences				Huang, Chuanshu/0000-0003-4133-5096				AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; ANGEL P, 1995, INDUCED GENE EXPRESS, P63; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BIRT DF, 1994, CARCINOGENESIS, V15, P2727, DOI 10.1093/carcin/15.12.2727; BIRT DF, 1994, CARCINOGENESIS, V15, P2341, DOI 10.1093/carcin/15.10.2341; BJORKOY G, 1995, J BIOL CHEM, V270, P21299; BROWN PH, 1993, ONCOGENE, V8, P877; BUSCHER M, 1988, ONCOGENE, V3, P301; Chapline C, 1996, J BIOL CHEM, V271, P6417, DOI 10.1074/jbc.271.11.6417; CHEN HX, 1993, J MED CHEM, V36, P4094, DOI 10.1021/jm00077a014; CRESPO P, 1995, BIOCHEM BIOPH RES CO, V213, P266, DOI 10.1006/bbrc.1995.2125; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; DONG LQ, 1995, J BIOL CHEM, V270, P25534, DOI 10.1074/jbc.270.43.25534; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; ELDREDGE ER, 1994, MOL CELL BIOL, V14, P7527, DOI 10.1128/MCB.14.11.7527; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHNO Y, 1989, P NATL ACAD SCI USA, V86, P3099; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; PARRISH JA, 1993, BIOCH PHYSL SKIN, V2, P713; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RONAI ZA, 1988, J VIROL, V62, P1057, DOI 10.1128/JVI.62.3.1057-1060.1988; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363, DOI 10.1073/pnas.71.9.3363; SHAH G, 1993, CANCER RES, V53, P38; SHEA CR, 1991, PHYSL BIOCH MOL BIOL, P910; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; STABERG B, 1983, J INVEST DERMATOL, V81, P517, DOI 10.1111/1523-1747.ep12522855; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STRICKLAND PT, 1986, J INVEST DERMATOL, V87, P272, DOI 10.1111/1523-1747.ep12696669; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0	48	102	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31262	31268		10.1074/jbc.271.49.31262	http://dx.doi.org/10.1074/jbc.271.49.31262			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940130	hybrid			2022-12-27	WOS:A1996VW68600041
J	Hobba, GD; Forbes, BE; Parkinson, EJ; Francis, GL; Wallace, JC				Hobba, GD; Forbes, BE; Parkinson, EJ; Francis, GL; Wallace, JC			The insulin-like growth factor (IGF) binding site of bovine insulin-like growth factor binding protein-2 (bIGFBP-2) probed by iodination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I; CHEMICAL MODIFICATION; DIRECTED MUTAGENESIS; TYROSINE RESIDUES; PROTEOLYSIS; RECEPTORS; H-1-NMR; MUTANTS; SERUM	The insulin-like growth factor (IGF) binding site of bovine insulin-like growth factor binding protein 2 (bIGFBP-2) has been probed by chemical iodination. Tyrosyl residues of bIGFBP-2 were reacted by chloramine T-mediated iodination. The modification patterns of free bIGFBP-2 and bIGFBP-2 associated with insulin-like growth factor II (IGF-II) were compared by tryptic mapping using electrospray mass spectrometry and N-terminal sequencing. The presence of bound IGF-II resulted in protection of tyrosine at position 60 from iodination measured by the relative loss of tyrosine specific fluorescence and the incorporation of the radioisotope I-125. In addition, the pattern of iodine incorporation of bIGFBP-2 was not different whether IGF-I or IGF-II was the protective ligand. bIGFBP-2, when iodinated alone sustained a 8-fold loss of binding affinity for IGF-I and a 4-fold loss in binding affinity for IGF-II. In contrast, bIGFBP-2 iodinated while complexed with either IGF-I or IGF-II retained the same binding affinity for IGF-I or IGF-II as non-iodinated bIGFBP-2. We conclude that tyrosine 60 Lies either in a region of bIGFBP-2 which directly interacts with both IGF-I and IGF-II or lies in a region of bIGFBP-2 which undergoes a conformational change that is important for IGF binding. Furthermore, iodination of tyrosine residues at positions 71, 98, 213, 226, and 269 has no detectable impact on binding of bIGFBP-2 to the IGFs.	COOPERAT RES CTR TISSUE GROWTH & REPAIR, ADELAIDE, SA 5005, AUSTRALIA; CSIRO, DIV HUMAN NUTR, ADELAIDE, SA 5000, AUSTRALIA	Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Hobba, GD (corresponding author), UNIV ADELAIDE, DEPT BIOCHEM, NORTH TERRACE, ADELAIDE, SA 5005, AUSTRALIA.		Parkinson-Lawrence, Emma/F-4085-2013; Forbes, Briony/R-1838-2019; , John/AAP-5150-2020	Forbes, Briony/0000-0003-4360-9927; Parkinson-Lawrence, Emma/0000-0002-3845-4847				BACH LA, 1993, J BIOL CHEM, V268, P9246; BAGLEY CJ, 1989, BIOCHEM J, V259, P665, DOI 10.1042/bj2590665; BAKER MS, 1990, BIOCHEM BIOPH RES CO, V166, P993, DOI 10.1016/0006-291X(90)90909-7; BAXTER RC, 1993, BIOCHEM J, V294, P847, DOI 10.1042/bj2940847; BAXTER RC, 1994, HORM RES, V42, P140, DOI 10.1159/000184186; BRINKMAN A, 1991, MOL ENDOCRINOL, V5, P987, DOI 10.1210/mend-5-7-987; BRINKMAN A, 1991, FEBS LETT, V291, P264, DOI 10.1016/0014-5793(91)81298-M; BUCK MA, 1989, ANAL BIOCHEM, V182, P295, DOI 10.1016/0003-2697(89)90597-6; CLEMMONS DR, 1992, ENDOCRINOLOGY, V131, P890, DOI 10.1210/en.131.2.890; CONOVER CA, 1994, J BIOL CHEM, V269, P7076; CONOVER CA, 1995, J BIOL CHEM, V270, P4395, DOI 10.1074/jbc.270.9.4395; COOKE RM, 1991, BIOCHEMISTRY-US, V30, P5484, DOI 10.1021/bi00236a022; COWGILL RW, 1965, BIOCHIM BIOPHYS ACTA, V94, P74, DOI 10.1016/0926-6585(65)90009-9; FORBES B, 1988, BIOCHEM BIOPH RES CO, V157, P196, DOI 10.1016/S0006-291X(88)80032-9; FRANCIS GL, 1993, BIOCHEM J, V293, P713, DOI 10.1042/bj2930713; GASCIERI MA, 1994, HORM RES, V41, P80; HUHTALA ML, 1986, BIOCHEM BIOPH RES CO, V141, P263, DOI 10.1016/S0006-291X(86)80363-1; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; JONES JI, 1993, GROWTH REGULAT, V3, P37; LEE CY, 1995, ENDOCRINOLOGY, V136, P668, DOI 10.1210/en.136.2.668; LEE PDK, 1993, P SOC EXP BIOL MED, V204, P4; MALY P, 1988, J BIOL CHEM, V263, P7068; MEANS GE, 1971, CHEM MODIFICATION PR, P181; MISTRY R, 1991, BIOCHEM J, V273, P685, DOI 10.1042/bj2730685; MOSS JA, 1991, J BIOL CHEM, V266, P909; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; SATO A, 1992, J BIOCHEM-TOKYO, V111, P529, DOI 10.1093/oxfordjournals.jbchem.a123791; SATO A, 1993, INT J PEPT PROT RES, V41, P433; SCHAFFER L, 1993, BIOCHIM BIOPHYS ACTA, V1203, P205, DOI 10.1016/0167-4838(93)90084-5; SOMMER A, 1991, MODERN CONCEPTS INSU, P715; SZABO L, 1988, BIOCHEM BIOPH RES CO, V151, P207, DOI 10.1016/0006-291X(88)90580-3; TERASAWA H, 1994, EMBO J, V13, P5590, DOI 10.1002/j.1460-2075.1994.tb06896.x; TORRES AM, 1995, J MOL BIOL, V248, P385, DOI 10.1006/jmbi.1995.0229; TSOMIDES TJ, 1993, ANAL BIOCHEM, V210, P129, DOI 10.1006/abio.1993.1162; UPTON Z, 1990, J MOL ENDOCRINOL, V5, P77, DOI 10.1677/jme.0.0050077; WANG JF, 1988, BIOCHEM BIOPH RES CO, V157, P718, DOI 10.1016/S0006-291X(88)80309-7	37	31	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30529	30536		10.1074/jbc.271.48.30529	http://dx.doi.org/10.1074/jbc.271.48.30529			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940022	hybrid			2022-12-27	WOS:A1996VV15800039
J	Mitterdorfer, J; Wang, ZY; Sinnegger, MJ; Hering, S; Striessnig, J; Grabner, M; Glossmann, H				Mitterdorfer, J; Wang, ZY; Sinnegger, MJ; Hering, S; Striessnig, J; Grabner, M; Glossmann, H			Two amino acid residues in the IIIS5 segment of L-type calcium channels differentially contribute to 1,4-dihydropyridine sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR DETERMINANTS; FUNCTIONAL EXPRESSION; SKELETAL-MUSCLE; MESSENGER-RNAS; CA2+ CHANNELS; MODULATION; ACTIVATOR; SUBUNIT; CELLS; BLOCK	The transmembrane segment IIIS5 of the L-type calcium channel alpha(1) subunit participates in the formation of the 1,4 dihydropyridine (DHP) interaction domain (Grabner, M,, Wang, Z., Hering, S., Striessnig, J., and Glossmann, H. (1996) Neuron 16, 207-218), We applied mutational analysis to identify amino acid residues within this segment that contribute to DHP sensitivity. DHP agonist and antagonist modulation of Ba2+ inward currents was assessed after coexpression of chimeric and mutant calcium channel alpha(1) subunits with alpha(2) delta and beta(1a) subunits in Xenopus oocytes. Whereas DHP antagonists required Thr-1066, DHP agonist modulation crucially depended on the additional presence of Gln-1070 (numbering according to alpha(1C-a)), which also further increased the sensitivity to DHP antagonists, Asp-955, which is found at the corresponding position in the calcium channel alpha(1S) subunit from carp skeletal muscle, displayed functional similarity to Gln-1070 with respect to DHP interaction, We conclude that these residues (Thr-1066 plus Gln-1070 or Asp-955), which are located in close vicinity on the same side of the putative a-helix of transmembrane segment IIIS5, form a crucial DHP binding motif.	INST BIOCHEM PHARMAKOL,A-6020 INNSBRUCK,AUSTRIA				Striessnig, Joerg/S-9334-2017; Glossmann, Hartmut/AAL-9790-2020; Tuluc, Petronel/C-2527-2011	Striessnig, Joerg/0000-0002-9406-7120; Brauns, Martina/0000-0002-0547-2731; glossmann, hartmut h./0000-0002-7392-3266				BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; Doring F, 1996, J BIOL CHEM, V271, P11745, DOI 10.1074/jbc.271.20.11745; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; GINAP T, 1993, NEUROSCI LETT, V156, P35, DOI 10.1016/0304-3940(93)90433-L; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; GRABNER M, 1991, P NATL ACAD SCI USA, V88, P727, DOI 10.1073/pnas.88.3.727; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HERING S, 1993, J GEN PHYSIOL, V101, P393, DOI 10.1085/jgp.101.3.393; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KASS RS, 1987, CIRC RES, V61, P1; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUNZE DL, 1992, MOL PHARMACOL, V42, P666; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Peterson BZ, 1996, J BIOL CHEM, V271, P5293, DOI 10.1074/jbc.271.10.5293; RAGSDALE DS, 1994, SCIENCE, V265, P1724, DOI 10.1126/science.8085162; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schuster A, 1996, EMBO J, V15, P2365, DOI 10.1002/j.1460-2075.1996.tb00592.x; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; STRIESSNIG J, 1993, CELL PHYSIOL BIOCHEM, V3, P295, DOI 10.1159/000154695; Sudhakar Pamidighantam V., 1996, Biophysical Journal, V70, pA306; TANG SQ, 1993, NEURON, V11, P1013, DOI 10.1016/0896-6273(93)90215-D; TRIGGLE DJ, 1992, CLEV CLIN J MED, V59, P617	28	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30330	30335		10.1074/jbc.271.48.30330	http://dx.doi.org/10.1074/jbc.271.48.30330			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939992	hybrid			2022-12-27	WOS:A1996VV15800009
J	Murphy, C; Nikodem, D; Howcroft, K; Weissman, JD; Singer, DS				Murphy, C; Nikodem, D; Howcroft, K; Weissman, JD; Singer, DS			Active repression of major histocompatibility complex class I genes in a human neuroblastoma cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; NF-KAPPA-B; EXPRESSION; BETA-2-MICROGLOBULIN; ANTIGENS; INTERFERON; SEQUENCES; ENHANCER; PROMOTER; DNA	Human neuronal cells express neither major histocompatibility complex (MHC) class I RNA nor cell surface molecules but can be induced to do so by various cytokines, In the present studies, we report that expression of MHC class I in a neuroblastoma cell line, CHP-126, is actively repressed. This repression is mediated by the combined effects of a series of upstream silencer elements. Removal of the silencers reveals not only an active promoter element but also the presence of an active enhancer, Four silencers have been identified and shown to have distinct sequences, binding factors, and patterns of function, One element is located between -724 and -697 base pairs (bp) and corresponds to a silencer involved in tissue-specific regulation of class I gene expression. Three additional elements occur between -503 and -402 bp, One of these corresponds to a c-jun, responsive element. Neither of the remaining elements corresponds to DNA sequences known to regulate expression of other genes, These data demonstrate that MHC class I expression normally is actively repressed in neuronal cells and suggest a model of rapid and specific triggering of class I in neuronal cells in response to infection.	NCI,EXPT IMMUNOL BRANCH,DBS,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								DREW P, 1995, J IMMUNOL, V155, P2096; DREW PD, 1993, J IMMUNOL, V150, P3300; Drew PD, 1995, J NEUROIMMUNOL, V63, P157, DOI 10.1016/0165-5728(95)00140-9; EHRLICH R, 1988, MOL CELL BIOL, V8, P695, DOI 10.1128/MCB.8.2.695; EHRLICH R, 1989, IMMUNOGENETICS, V30, P18, DOI 10.1007/BF02421465; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FRELS W I, 1990, New Biologist, V2, P1024; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HOWCROFT TK, 1993, EMBO J, V12, P3163, DOI 10.1002/j.1460-2075.1993.tb05985.x; HOWCROFT TK, 1993, SCIENCE, V260, P1320, DOI 10.1126/science.8493575; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; LAMPSON LA, 1984, P NATL ACAD SCI-BIOL, V81, P6476, DOI 10.1073/pnas.81.20.6476; LAMPSON LA, 1990, J IMMUNOL, V144, P512; LAVI E, 1988, J NEUROIMMUNOL, V18, P245, DOI 10.1016/0165-5728(88)90102-6; MIYAZAKI J, 1986, P NATL ACAD SCI USA, V83, P9537, DOI 10.1073/pnas.83.24.9537; MOZES E, 1993, SCIENCE, V261, P91, DOI 10.1126/science.8316860; NEUMANN H, 1995, SCIENCE, V269, P549, DOI 10.1126/science.7624779; SINGER DS, 1990, CRIT REV IMMUNOL, V10, P235; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TING JPY, 1987, J NEUROIMMUNOL, V14, P87, DOI 10.1016/0165-5728(87)90103-2; VANTVEER LJ, 1993, EMBO J, V12, P195, DOI 10.1002/j.1460-2075.1993.tb05645.x; WEISSMAN JD, 1991, MOL CELL BIOL, V11, P4217, DOI 10.1128/MCB.11.8.4217; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	23	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30992	30999		10.1074/jbc.271.48.30992	http://dx.doi.org/10.1074/jbc.271.48.30992			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940088	hybrid			2022-12-27	WOS:A1996VV15800105
J	Ohnuma, S; Narita, K; Nakazawa, T; Ishida, C; Takeuchi, Y; Ohto, C; Nishino, T				Ohnuma, S; Narita, K; Nakazawa, T; Ishida, C; Takeuchi, Y; Ohto, C; Nishino, T			A role of the amino acid residue located on the fifth position before the first aspartate-rich motif of farnesyl diphosphate synthase on determination of the final product	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CONSERVED ASPARTATE; MOLECULAR-CLONING; DOMAIN-II; GENE; PRENYLTRANSFERASE; PURIFICATION; SEQUENCES; PROTEINS	Farnesyl diphosphate (FPP) synthase catalyzes consecutive condensations of isopentenyl diphosphate with allylic substrates to give FPP, C-15 compound, as a final product and does not catalyze a condensation beyond FPP. Recently, it was observed that, in Bacillus stearothermophilus FPP synthase, a replacement of tyrosine with histidine at position 81, which is located on the fifth amino acid before the first aspartate-rich motif, caused the mutated FPP synthase to catalyze geranylgeranyl diphosphate (C-20) synthesis (Ohnuma, S.-i., Nakazawa, T., Hemmi, H., Hallberg, A.-M., Koyama, T., Ogura, K., and Nishino, T. (1996) J. Biol. Chem. 271, 10087-10095). Thus, we constructed 20 FPP synthases, each of which has a different amino acid at position 81, and analyzed them. All enzymes except for Y81P can catalyze the condensations of isopentenyl diphosphate. The final products and the product distributions are different from each other. Y81A, Y81G, and Y81S can produce hexaprenyl diphosphate (C-30) as their final product. The final product of Y81C, Y81H, Y81I, Y81L, Y81N, Y81T, and Y81V are geranylfarnesyl diphosphate (C-25), and Y81D, Y81E, Y81F, Y81K, Y81M, Y81Q, and Y81R cannot produce polyprenyl diphosphates more than geranylgeranyl diphosphate. Substitution of tryptophan does not affect the product specificity of FPP synthase. The average chain length of products is inversely proportional to the accessible surface area of substituted amino acid. However, no significant relation between the final chain length and the kinetic constants K-m and V-max are observed. These observations strongly indicate that the amino acid does not come into contact with the substrates but directly contacts the omega-terminal of an elongating allylic product. This interaction must prevent further condensation of isopentenyl diphosphate.	TOYOTA MOTOR CO LTD,BIO RES LAB,TOYOTA 47171,JAPAN	Toyota Motor Corporation	Ohnuma, S (corresponding author), TOHOKU UNIV,DEPT BIOCHEM & ENGN,AOBA KU,SENDAI,MIYAGI 98077,JAPAN.		Narita, Keishi/E-3539-2010; Ohto, Chikara/GQB-4702-2022	Narita, Keishi/0000-0002-7602-8523; Ohnuma, Shin-ichi/0000-0002-3305-5126				ASAI K, 1994, BIOCHEM BIOPH RES CO, V202, P340, DOI 10.1006/bbrc.1994.1933; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; CHEN AJ, 1994, PROTEIN SCI, V3, P600; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; JOLY A, 1993, J BIOL CHEM, V268, P26983; KOIKETAKESHITA A, 1995, J BIOL CHEM, V270, P18396, DOI 10.1074/jbc.270.31.18396; KOYAMA T, 1993, J BIOCHEM-TOKYO, V113, P355, DOI 10.1093/oxfordjournals.jbchem.a124051; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MARRERO PF, 1992, J BIOL CHEM, V267, P21873; OHNUMA S, 1991, J BIOL CHEM, V266, P23706; Ohnuma S, 1996, J BIOL CHEM, V271, P18831, DOI 10.1074/jbc.271.31.18831; OHNUMA S, 1994, J BIOL CHEM, V269, P14792; Ohnuma SI, 1996, J BIOL CHEM, V271, P10087, DOI 10.1074/jbc.271.17.10087; POULTER CD, 1982, BIOSYNTHESIS ISOPREN, P161; Sambrook J., 2002, MOL CLONING LAB MANU; SONG LS, 1994, P NATL ACAD SCI USA, V91, P3044, DOI 10.1073/pnas.91.8.3044; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004	21	116	133	3	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30748	30754		10.1074/jbc.271.48.30748	http://dx.doi.org/10.1074/jbc.271.48.30748			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940054	hybrid			2022-12-27	WOS:A1996VV15800071
J	Alevizopoulos, A; Mermod, N				Alevizopoulos, A; Mermod, N			Antagonistic regulation of a proline-rich transcription factor by transforming growth factor beta and tumor necrosis factor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN GENE-EXPRESSION; NUCLEAR FACTOR-I; ACTIVATED PROTEIN-KINASES; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; DNA-REPLICATION; CTF/NF-I; HA-RAS; RECEPTOR; JUN	Transforming growth factor beta (TGF-beta) and tumor necrosis factor alpha (TNF-alpha) often exhibit antagonistic actions on the regulation of various activities such as immune responses, cell growth, and gene expression. However, the molecular mechanisms involved in the mutually opposing effects of TGF-beta and TNF-alpha are unknown. Here, we report that binding sites for the transcription factor CTF/NF-I mediate antagonistic TGF-beta and TNF-alpha transcriptional regulation in NIH3T3 fibroblasts. TGF-beta induces the proline rich transactivation domain of specific CTF/NF-I family members, such as CTF-1, whereas TNF-alpha represses both the uninduced as well as the TGF-beta-induced CTF-1 transcriptional activity. CTF-1 is thus the first transcription factor reported to be repressed by TNF-alpha. The previously identified TGF-beta-responsive domain in the proline-rich transcriptional activation sequence of CTF-1 mediates both transcriptional induction and repression by the two growth factors, Analysis of potential signal transduction intermediates does not support a role for known mediators of TNF-alpha action, such as arachidonic acid, in CTF-1 regulation. However, overexpression of oncogenic forms of the small GTPase Ras or of the Raf-1 kinase represses CTF-1 transcriptional activity, as does TNF-alpha. Furthermore, TNF-alpha is unable to repress CTF-1 activity in NIH3T3 cells overexpressing ras or raf, suggesting that TNF-alpha regulates CTF-1 by a Ras-Raf kinase-dependent pathway, Mutagenesis studies demonstrated that the CTF-1 TGF-beta-responsive domain is not the primary target of regulatory phosphorylations. Interestingly, however, the domain mediating TGF-beta and TNF-alpha antagonistic regulation overlapped precisely the previously identified histone H3 interaction domain of CTF-1. These results identify CTF-1 as a molecular target of mutually antagonistic TGF-beta and TNF-alpha regulation, and they further suggest a molecular mechanism for the opposing effects of these growth factors on gene expression.	UNIV LAUSANNE,INST BIOL ANIM,CH-1015 LAUSANNE,SWITZERLAND	University of Lausanne								Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; ARMENDARIZBORUNDA J, 1992, J BIOL CHEM, V267, P14316; ARMENTERO MT, 1994, P NATL ACAD SCI USA, V91, P11537, DOI 10.1073/pnas.91.24.11537; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DIAZ A, 1993, J BIOL CHEM, V268, P10364; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; ESPEVIK T, 1988, J IMMUNOL, V140, P2312; GAILIT J, 1994, CURR OPIN CELL BIOL, V6, P717, DOI 10.1016/0955-0674(94)90099-X; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HELLER RA, 1992, CELL, V70, P47; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; INAGAKI Y, 1995, J BIOL CHEM, V270, P3353, DOI 10.1074/jbc.270.7.3353; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MARTINEZ E, 1991, MOL CELL BIOL, V11, P2937, DOI 10.1128/MCB.11.6.2937; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; NIEDERREITHER K, 1992, J CELL BIOL, V119, P1361, DOI 10.1083/jcb.119.5.1361; ODONNELL VB, 1995, BIOCHEM J, V310, P133, DOI 10.1042/bj3100133; QURESHI SA, 1992, J BIOL CHEM, V267, P17635; ROBERTS AB, 1992, MOL ENDOCRINOL, V6, P1921, DOI 10.1210/me.6.11.1921; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J., 2002, MOL CLONING LAB MANU; SANTAMBROGIO L, 1993, J IMMUNOL, V151, P1116; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SLACK JL, 1992, MOL CELL BIOL, V12, P4714, DOI 10.1128/MCB.12.10.4714; THORBECKE GJ, 1992, P NATL ACAD SCI USA, V89, P7375, DOI 10.1073/pnas.89.16.7375; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093	54	28	28	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29672	29681		10.1074/jbc.271.47.29672	http://dx.doi.org/10.1074/jbc.271.47.29672			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939900	hybrid			2022-12-27	WOS:A1996VU52500028
J	Barila, D; Plateroti, M; Nobili, F; Muda, AO; Xie, YH; Morimoto, T; Perozzi, G				Barila, D; Plateroti, M; Nobili, F; Muda, AO; Xie, YH; Morimoto, T; Perozzi, G			The Dri 42 gene, whose expression is up-regulated during epithelial differentiation, encodes a novel endoplasmic reticulum resident transmembrane protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; CELLS; INTESTINE; ANTIBODIES; BIOGENESIS; CHANNELS; BIOLOGY; MODEL; MOTIF; ACID	A search for novel genes that are up-regulated during development and differentiation of the epithelial cells of the intestinal mucosa led us to the isolation of the Dri 42 cDNA clone (Dri, differentially expressed in rat intestine), The nucleotide sequence of the full-length cDNA has shown that it encodes a 35.5-kDa protein with one consensus sequence for N-linked glycosylation and alternating hydrophilic and hydrophobic domains, To determine the intracellular localization of Dri 42 we have raised polyclonal antibodies in hens against a bacterially produced Dri 42-glutathione S-transferase fusion protein, Immunofluorescence detection with these anbibodies has shown specific staining of the endoplasmic reticulum (ER) in the relatively undifferentiated fetal rat intestinal cell line FRIC B and in sections of rat small intestine, ER membrane localization of Dri 42 was confirmed by laser confocal microscopy of polarized Madin-Darby canine kidney cells overexpressing a Dri 42-chloramphenicol acetyltransferase (CAT) fusion protein by transfection, Pulse labeling experiments on transiently transfected cells demonstrated that the protein does not acquire Golgi modifications up to 4 h after synthesis, thus indicating that Dri 42 is an ER resident protein, The transmembrane disposition of Dri 42 was studied using in vitro insertion of Dri 42-CAT fusion proteins into microsomal membranes, The fusion proteins consisted of several different lengths of truncated Dri 42 and a reporter protein, CAT, that was linked in-frame after each hydrophobic segment, We found that hydrophobic segments H1, H3, and H5 had a signal/anchor function, and that membrane insertion of Dri 42 was achieved co-translationally by the action of a series of alternating insertion signals and halt transfer signals, resulting in the exposure of both termini of the protein to the cytosolic side, The functional implications of the structure and localization of Dri 42, whose primary sequence does not share significant homology to any previously described protein, are discussed.	IST NAZL NUTR,I-00178 ROME,ITALY; UNIV ROMA LA SAPIENZA,DIPARTIMENTO MED SPERIMENTALE & PATOL,I-00185 ROME,ITALY; NYU,MED CTR,DEPT CELL BIOL,NEW YORK,NY 10016	Consiglio per la Ricerca in Agricoltura e L'analisi Dell'economia Agraria (CREA); Sapienza University Rome; New York University			Perozzi, Giuditta/AFV-2497-2022; Muda, Andrea Onetti/AAA-5105-2020; Plateroti, Michelina/F-2928-2017; Onetti Muda, Andrea/G-5384-2012; Barilà, Daniela/K-8506-2016; Perozzi, Giuditta/A-7460-2016	Onetti Muda, Andrea/0000-0002-0274-6178; Barilà, Daniela/0000-0002-6192-1562; Perozzi, Giuditta/0000-0003-1755-6104				ALAWQATI Q, 1995, CURR OPIN CELL BIOL, V7, P504, DOI 10.1016/0955-0674(95)80006-9; ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; BAILA D, 1995, BIOCHIM BIOPHYS ACTA, V1263, P133; BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BARILA D, 1994, EUR J BIOCHEM, V223, P701, DOI 10.1111/j.1432-1033.1994.tb19043.x; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BOYLE WJ, 1995, CURR OPIN GASTROEN, V11, P121, DOI 10.1097/00001574-199503000-00006; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CRABTREE GR, 1992, TRANSCRIPTIONAL REGU, P1063; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; EGAWA K, 1995, FEBS LETT, V372, P74, DOI 10.1016/0014-5793(95)00957-B; FISCHER B, 1993, BIOTECHNOL BIOENG, V41, P3, DOI 10.1002/bit.260410103; GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; McRoberts J. A., 1981, FUNCTIONALLY DIFFERE, P117; PLATEROTI M, 1993, EXP CELL RES, V208, P137, DOI 10.1006/excr.1993.1231; POLSON A, 1980, IMMUNOL COMMUN, V9, P475, DOI 10.3109/08820138009066010; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; RAJASEKARAN AK, 1994, MOL BIOL CELL, V5, P1093, DOI 10.1091/mbc.5.10.1093; RANALDI G, 1992, ANTIMICROB AGENTS CH, V36, P1374, DOI 10.1128/AAC.36.7.1374; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SKACH WR, 1994, J CELL BIOL, V125, P803, DOI 10.1083/jcb.125.4.803; SKACH WR, 1993, J BIOL CHEM, V268, P6903; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; VANOS CH, 1994, BBA-REV BIOMEMBRANES, V1197, P291; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; WU R, 1987, METHOD ENZYMOL, V152, P343; Xie YH, 1996, J BIOL CHEM, V271, P2563, DOI 10.1074/jbc.271.5.2563; XIE YH, 1995, J BIOL CHEM, V270, P11985, DOI 10.1074/jbc.270.20.11985	35	68	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29928	29936		10.1074/jbc.271.47.29928	http://dx.doi.org/10.1074/jbc.271.47.29928			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939937	hybrid			2022-12-27	WOS:A1996VU52500065
J	Brandstetter, H; Kuhne, A; Bode, W; Huber, R; vonderSaal, W; Wirthensohn, K; Engh, RA				Brandstetter, H; Kuhne, A; Bode, W; Huber, R; vonderSaal, W; Wirthensohn, K; Engh, RA			X-ray structure of active site-inhibited clotting factor Xa - Implications for drug design and substrate recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; PROTHROMBINASE COMPLEX; CRYSTALLOGRAPHIC REFINEMENT; MOLECULAR RECOGNITION; HIPPOCAMPAL-NEURONS; BOVINE TRYPSINOGEN; CRYSTAL-STRUCTURES; FACTOR-IXA; THROMBIN; RESOLUTION	The 3.0-Angstrom resolution x-ray structure of human des-Gla-coagulation factor Xa (fXa) has been determined in complex with the synthetic inhibitor DX-9065a. The binding geometry is characterized primarily by two interaction sites: the naphthamidine group is fixed in the S1 pocket by a typical salt bridge to Asp-189, while the pyrrolidine ring binds in the unique aryl-binding site (S4) of fXa. Unlike the large majority of inhibitor complexes with serine proteinases, Gly-216 (S3) does not contribute to hydrogen bond formation. In contrast to typical thrombin binding modes, the S2 site of fXa cannot be used by DX-9065a since it is blocked by Tyr-99, and the aryl-binding site (S4) of fXa is lined by carbonyl oxygen atoms that can accommodate positive charges. This has implications for natural substrate recognition as well as for drug design.	MAX PLANCK INST BIOCHEM, D-82125 MARTINSRIED, GERMANY; BOEHRINGER MANNHEIM GMBH, D-68305 MANNHEIM, GERMANY; BOEHRINGER MANNHEIM GMBH, D-82372 PENZBERG, GERMANY	Max Planck Society			Brandstetter, Hans/E-6754-2011	Brandstetter, Hans/0000-0002-6089-3045; Engh, Richard/0000-0002-6207-0560				BODE W, 1976, FEBS LETT, V68, P231, DOI 10.1016/0014-5793(76)80443-7; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; BRANDSTETTER H, 1992, J MOL BIOL, V226, P1085, DOI 10.1016/0022-2836(92)91054-S; BRANDSTETTER H, 1994, THESIS TU MUNCHEN; BREWER GJ, 1995, BRAIN RES, V683, P258, DOI 10.1016/0006-8993(95)00332-K; Brunger A. T., 1993, XPLOR SYSTEM XRAY CR; CHATTOPADHYAY A, 1992, J BIOL CHEM, V267, P12323; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; ENGH R, 1996, IN PRESS STRUCTURE; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; GABRIEL B, 1996, THESIS U REGENSBURG; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; HARA T, 1994, THROMB HAEMOSTASIS, V71, P314; HOPPE W, 1957, ACTA CRYSTALLOGR, V10, P750; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; HUBER R, 1965, ACTA CRYSTALLOGR, V19, P353, DOI 10.1107/S0365110X65003444; HUBER R, 1974, J MOL BIOL, V89, P73, DOI 10.1016/0022-2836(74)90163-6; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; KATAKURA S, 1993, BIOCHEM BIOPH RES CO, V197, P965, DOI 10.1006/bbrc.1993.2573; KATAKURA S, 1995, EUR J MED CHEM, V30, P387, DOI 10.1016/0223-5234(96)88248-1; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; LEE KR, 1995, J NEUROSURG, V83, P1045, DOI 10.3171/jns.1995.83.6.1045; LIN ZL, 1995, FEBS LETT, V370, P1, DOI 10.1016/0014-5793(95)00811-M; LIU Y, 1994, P NATL ACAD SCI USA, V91, P10300, DOI 10.1073/pnas.91.22.10300; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NIERODZIK ML, 1995, THROMB HAEMOSTASIS, V74, P282; NISHINO A, 1994, ACTA NEUROCHIR, P86; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; SINGH J, 1987, FEBS LETT, V224, P161, DOI 10.1016/0014-5793(87)80441-6; SMITHSWINTOSKY VL, 1995, J NEUROCHEM, V65, P1415; STUBBS MT, 1995, FEBS LETT, V375, P103, DOI 10.1016/0014-5793(95)01190-P; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; TURK D, 1992, THESIS TU MUNCHEN; WALKER RK, 1994, J BIOL CHEM, V269, P27441	39	276	288	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29988	29992		10.1074/jbc.271.47.29988	http://dx.doi.org/10.1074/jbc.271.47.29988			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939944	hybrid			2022-12-27	WOS:A1996VU52500072
J	Chestukhin, A; Muradov, K; Litovchick, L; Shaltiel, S				Chestukhin, A; Muradov, K; Litovchick, L; Shaltiel, S			The cleavage of protein kinase A by the kinase-splitting membranal proteinase is reproduced by meprin beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-PANCREATIC HYDROLYSIS; BRUSH-BORDER MEMBRANES; RAT-KIDNEY CORTEX; ACID PABA-PEPTIDE; MOUSE KIDNEY; CATALYTIC SUBUNIT; MICROVILLAR MEMBRANES; METALLO-ENDOPEPTIDASE; INSULIN-RECEPTOR; SMALL-INTESTINE	The Kinase-Splitting Membranal Proteinase (KSMP) is a metallo-endoproteinase that clips off the carboxyl terminus tail of the catalytic (C) subunit of protein kinase A to yield a truncated, catalytically inactive protein (C'), Here we report (a) a new procedure for the purification of KSMP, yielding a major protein band in SDS-polyacrylamide gel electrophoresis that correlates with the characteristic KSMP activity; (b) the sequence of tryptic peptides obtained from this band, suggesting an identity between this protein and meprin beta; (c) the immune-detection by specific anti-peptide antibodies of both the alpha and the beta subunits of meprin in KSMP preparations; (d) the stable expression of meprin beta in a mammalian cell line (293) to establish a clone that constitutively expresses the full-length precursor of meprin beta; and (e) the optimalization of the proteolytic activation of this precursor to obtain an enzyme exhibiting the specific KSMP cleavage, suggesting that KSMP is either derived from, or identical with, the meprin beta gene product, It is hoped that these results will shed light on the possible physiological role of KSMP and the way it may affect protein kinase A-mediated processes.	WEIZMANN INST SCI, DEPT REGULAT BIOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science				Litovchick, Larisa/0000-0002-9540-597X				ALHANATY E, 1979, BIOCHEM BIOPH RES CO, V89, P323, DOI 10.1016/0006-291X(79)90633-8; ALHANATY E, 1981, P NATL ACAD SCI-BIOL, V78, P3492, DOI 10.1073/pnas.78.6.3492; ALHANATY E, 1985, CURR TOP CELL REGUL, V27, P267; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BEYNON RJ, 1981, BIOCHEM J, V199, P591, DOI 10.1042/bj1990591; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BOND JS, 1986, CURR TOP CELL REGUL, V28, P263; BOND JS, 1983, BIOCHEM J, V209, P251, DOI 10.1042/bj2090251; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BOND JS, 1995, ZINC METALLOPROTEASE, P23; BUTLER PE, 1988, J BIOL CHEM, V263, P13419; Chestukhin A, 1996, J BIOL CHEM, V271, P10175, DOI 10.1074/jbc.271.17.10175; Chestukhin A, 1996, FEBS LETT, V382, P265, DOI 10.1016/0014-5793(96)00178-0; CHESTUKHIN A, 1995, ASBMB DBC ACS JOINT; CHOUDRY Y, 1991, BIOCHEM J, V280, P57, DOI 10.1042/bj2800057; CORBEIL D, 1992, FEBS LETT, V309, P203, DOI 10.1016/0014-5793(92)81095-4; DEJONGE H, 1987, EUR J BIOCHEM, V169, P503; EVERS C, 1978, MEMBRANE BIOCHEM, V1, P203, DOI 10.3109/09687687809063848; GOMISRUTH FX, 1993, J MOL BIOL, V229, P945, DOI 10.1006/jmbi.1993.1098; GORBEA CM, 1993, J BIOL CHEM, V268, P21035; GORBEA CM, 1991, ARCH BIOCHEM BIOPHYS, V290, P549, DOI 10.1016/0003-9861(91)90580-C; GORBEA KCM, 1994, MAMMALIAN BRUSH BORD, P89; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Harlow E., 1988, ANTIBODIES LAB MANUA; JIANG WP, 1992, J BIOL CHEM, V267, P9185; JOHNSON GD, 1994, J BIOL CHEM, V269, P7682; JOHNSON GD, 1992, J BIOL CHEM, V267, P13505; JOHNSON GD, 1993, J BIOL CHEM, V268, P17647; KAUSHAL GP, 1994, J CELL BIOL, V126, P1319, DOI 10.1083/jcb.126.5.1319; KENNY AJ, 1981, ACTA BIOL MED GER, V40, P1465; KENNY AJ, 1987, BIOCHEM J, V245, P515, DOI 10.1042/bj2450515; KENNY AJ, 1977, PROTEINASES MAMMALIA, P393; KORCGRODZICKI B, 1988, P NATL ACAD SCI USA, V85, P7541, DOI 10.1073/pnas.85.20.7541; KOUNNAS MZ, 1991, J BIOL CHEM, V266, P17350; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACADAM GC, 1990, INT J BIOCHEM, V22, P989, DOI 10.1016/0020-711X(90)90205-H; MARCHAND P, 1994, J BIOL CHEM, V269, P15388; MCDONALD JK, 1977, PROTEINASES MAMMALIA, V2, P311; MILHIET PE, 1994, BIOCHEM J, V300, P37, DOI 10.1042/bj3000037; ORTIZ ML, 1992, FEBS LETT, V296, P300, DOI 10.1016/0014-5793(92)80309-5; PORATH J, 1983, BIOCHEMISTRY-US, V22, P1621, DOI 10.1021/bi00276a015; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; SEGER R, 1989, EMBO J, V8, P435, DOI 10.1002/j.1460-2075.1989.tb03395.x; SEGER R, 1988, J BIOL CHEM, V263, P3496; SEGER R, 1993, INNOVATION PROTEASES, P231; SHALTIEL S, 1993, MOL CELL BIOCHEM, V128, P283, DOI 10.1007/BF01076778; SHALTIEL S, 1989, MECH REGULATION INTR, P188; STEPHENSON SL, 1988, BIOCHEM J, V255, P45, DOI 10.1042/bj2550045; STERCHI EE, 1983, J PEDIATR GASTR NUTR, V2, P539, DOI 10.1097/00005176-198302030-00024; STERCHI EE, 1982, CLIN SCI, V62, P557, DOI 10.1042/cs0620557; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; TITANI K, 1987, BIOCHEMISTRY-US, V26, P222, DOI 10.1021/bi00375a029; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; YAMAGUCHI T, 1994, LIFE SCI, V54, P381, DOI 10.1016/0024-3205(94)00795-0	55	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30272	30280		10.1074/jbc.271.47.30272	http://dx.doi.org/10.1074/jbc.271.47.30272			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939981	hybrid			2022-12-27	WOS:A1996VU52500109
J	White, JA; Guo, YD; Baetz, K; BeckettJones, B; Bonasoro, J; Hsu, KE; Dilworth, FJ; Jones, G; Petkovich, M				White, JA; Guo, YD; Baetz, K; BeckettJones, B; Bonasoro, J; Hsu, KE; Dilworth, FJ; Jones, G; Petkovich, M			Identification of the retinoic acid-inducible all-trans-retinoic acid 4-hydroxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							24-HYDROXYLASE GENE; INVIVO METABOLISM; ESCHERICHIA-COLI; INVITRO; EXPRESSION; ZEBRAFISH; FIN; TRANSCRIPTION; INHIBITION; LIAROZOLE	Retinoic acid (RA) metabolites of vitamin A are key regulators of gene expression involved in embryonic development and maintenance of epithelial tissues, The cellular effects of RA are dependent upon the complement of nuclear receptors expressed (RARs and RXRs), which transduce retinoid signals into transcriptional regulation, the presence of cellular retinoid-binding proteins (CRABP and CRBP), which may be involved in RA metabolism, and the activity of RA metabolizing enzymes, We have been using the zebrafish as a model to study these processes, To identify genes regulated by RA during exogenous RA exposure, we utilized mRNA differential display, We describe the isolation and characterization of a cDNA, P450RAI, encoding a novel member of the cytochrome P450 family, mRNA transcripts for P450RAI are expressed normally during gastrulation, and in a defined pattern in epithelial cells of the regenerating caudal fin in response to exogenous RA. In COS-1 cells transfected with the P450RAI cDNA, all-trans-RA is rapidly metabolized to more polar metabolites. We have identified 4-oxo-RA and 4-OH-RA as major metabolic products of this enzyme. P450RAI represents the first enzymatic component of RA metabolism to be isolated and characterized at the molecular level and provides key insight into regulation of retinoid homeostasis.	QUEENS UNIV,CANC RES LABS,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT PATHOL,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT MED,KINGSTON,ON K7L 3N6,CANADA	Queens University - Canada; Queens University - Canada; Queens University - Canada; Queens University - Canada			Baetz, Kristin/E-6859-2013	Dilworth, F. Jeffrey/0000-0002-6265-8102				AKIMENKO MA, 1995, DEV BIOL, V170, P243, DOI 10.1006/dbio.1995.1211; AKIMENKO MA, 1995, DEVELOPMENT, V121, P347; AKIYOSHISHIBATA M, 1994, EUR J BIOCHEM, V224, P335, DOI 10.1111/j.1432-1033.1994.00335.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Blumberg B, 1996, P NATL ACAD SCI USA, V93, P4873, DOI 10.1073/pnas.93.10.4873; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; CHAMBON P, 1995, RECENT PROG HORM RES, V50, P317; CHEN KS, 1995, BBA-GENE STRUCT EXPR, V1263, P1, DOI 10.1016/0167-4781(95)00060-T; DAWSON MI, 1990, METHOD ENZYMOL, V189, P1; DUELL EA, 1992, J CLIN INVEST, V90, P1269, DOI 10.1172/JCI115990; FIORELLA PD, 1993, J BIOL CHEM, V268, P21545; FROLIK CA, 1979, BIOCHEMISTRY-US, V18, P2092, DOI 10.1021/bi00577a039; Gotoh O., 1989, FRONTIERS BIOTRANSFO, V1, P195; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; JONES BB, 1995, MOL CELL BIOL, V15, P5226; KRAFT JC, 1994, BIOCHEM J, V301, P111, DOI 10.1042/bj3010111; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MADEN M, 1992, BIOESSAYS, V14, P431, DOI 10.1002/bies.950140702; MAKIN G, 1989, BIOCHEM J, V262, P173, DOI 10.1042/bj2620173; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MUINDI JRF, 1992, CANCER RES, V52, P2138; NAPOLI JL, 1987, ARCH BIOCHEM BIOPHYS, V255, P95, DOI 10.1016/0003-9861(87)90298-0; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OHYAMA Y, 1994, J BIOL CHEM, V269, P10545; PIJNAPPEL WWM, 1993, NATURE, V366, P340, DOI 10.1038/366340a0; REDDY AP, 1992, BIOCHEM J, V287, P833, DOI 10.1042/bj2870833; ROBERTS AB, 1979, J BIOL CHEM, V254, P6296; Takatsuka J, 1996, CANCER RES, V56, P675; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; VANWAUWE J, 1992, J PHARMACOL EXP THER, V261, P773; VANWAUWE JP, 1990, J PHARMACOL EXP THER, V252, P365; VANWAUWE JP, 1988, J PHARMACOL EXP THER, V245, P718; WHITE J, 1996, IN PRESS MEHTODS MOL; WHITE JA, 1994, DEVELOPMENT, V120, P1861; WILLIAMS JB, 1987, BIOCHEM PHARMACOL, V36, P1386, DOI 10.1016/0006-2952(87)90102-X; WOUTERS W, 1992, CANCER RES, V52, P2841; ZIEROLD C, 1995, J BIOL CHEM, V270, P1675, DOI 10.1074/jbc.270.4.1675	37	316	335	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29922	29927		10.1074/jbc.271.47.29922	http://dx.doi.org/10.1074/jbc.271.47.29922			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939936	hybrid			2022-12-27	WOS:A1996VU52500064
J	Camerer, E; Rottingen, JA; Iversen, JG; Prydz, H				Camerer, E; Rottingen, JA; Iversen, JG; Prydz, H			Coagulation factors VII and X induce Ca2+ oscillations in Madin-Darby canine kidney cells only when proteolytically active	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-TISSUE FACTOR; MOLECULAR-CLONING; ENDOTHELIAL-CELLS; RECEPTOR; CDNA; CALCIUM; EXPRESSION; PROTEIN; GENE	We have recently reported that the activated serine protease and blood coagulation Factor VII (FVIIa) can induce Ca2+ oscillations in Madin-Darby canine kidney cells. We now demonstrate a similar response by Madin-Darby canine kidney cells to the active coagulation Factor X (FXa), which is also a serine protease and a substrate of the tissue factor (TF)-FVIIa complex in the initiation of the coagulation cascade. The phosphatidyl inositol-specific phospholipase C inhibitor U73122 inhibited the signals elicited by both FVIIa and FXa. Lack of sensibility to the tyrosine kinase inhibitors herbimycin A, genistein, and the tyrphostin AG18 and discordance between TF expression and FVIIa responsiveness argued against TF acting as a cytokine-like receptor, with tyrosine kinase-mediated activation by FVIIa. As demonstrated using the protease inhibitor benzamidine and by specific active site inhibition with 1,5-dansyl-Glu-Gly-Arg chloromethyl ketone, both FVIIa and FXa lost their ability to elicit a calcium response when devoid of their proteolytic activity. Consistent with this, the native (zymogen) form of Factor X did not induce Ca2+ transients. Homologous but not heterologous inhibition of FVIIa- and FXa-evoked Ca2+ signals by 1,5-dansyl-Glu-Gly-Arg chloromethyl ketone-inactivated FVIIa and FXa suggested that each factor had its own specific cell surface anchoring receptor. The two coagulation factors did not show homologous desensitization as seen for thrombin stimulation. Studies with hirudin excluded involvement of the established activation pathway through thrombin itself. Lack of desensitization of the response to FVIIa or FXa by thrombin ruled out any involvement of proteinase activated receptor-1 (PAR-1), the thrombin receptor. We speculate that FXa and FVIIa may work via a receptor (possibly common) analogous to PAR-I or its functional homologue PAR-2. Although TF is essential for the FVIIa-induced signaling event; its role in the phosphatidyl inositol-specific phospholipase C-mediated Ca2+ signal may be in anchoring FVIIa to the cell surface rather than in transmembrane signal mediation.	BIOTECHNOL CTR OSLO,N-0371 OSLO,NORWAY; UNIV OSLO,INST BASIC MED SCI,DEPT PHYSIOL,LAB INTRACELLULAR SIGNALING,N-0316 OSLO,NORWAY	University of Oslo			Camerer, Eric/K-4161-2017	Camerer, Eric/0000-0002-6271-7125				ALTIERI DC, 1994, CELL IMMUNOL, V155, P372, DOI 10.1006/cimm.1994.1130; BACH R, 1988, J CELL BIOL, V107, P825; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; Camerer E, 1996, BLOOD, V88, P1339, DOI 10.1182/blood.V88.4.1339.bloodjournal8841339; CARMELIET P, 1995, THROMB HAEMOSTASIS, V69, P1177; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; DRAKE TA, 1989, J CELL BIOL, V109, P389, DOI 10.1083/jcb.109.1.389; ESMON CT, 1995, CURR BIOL, V5, P743, DOI 10.1016/S0960-9822(95)00150-3; FISHER KL, 1987, THROMB RES, V48, P89, DOI 10.1016/0049-3848(87)90349-5; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEIN L, 1994, J BIOL CHEM, V269, P27719; HJORT PF, 1957, SCAND J CLIN LAB I S, V9; Hwa JJ, 1996, CIRC RES, V78, P581, DOI 10.1161/01.RES.78.4.581; Mirza H, 1996, J CLIN INVEST, V97, P1705, DOI 10.1172/JCI118597; MORRISSEY JH, 1987, CELL, V50, P129, DOI 10.1016/0092-8674(87)90669-6; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; ROTNES JS, 1992, CELL CALCIUM, V13, P487, DOI 10.1016/0143-4160(92)90017-M; ROTTINGEN JA, 1995, J BIOL CHEM, V270, P4650, DOI 10.1074/jbc.270.9.4650; SANTULLI RJ, 1995, P NATL ACAD SCI USA, V92, P9151, DOI 10.1073/pnas.92.20.9151; SCARPATI EM, 1987, BIOCHEMISTRY-US, V26, P5234, DOI 10.1021/bi00391a004; Sevinsky JR, 1996, J CELL BIOL, V133, P293, DOI 10.1083/jcb.133.2.293; SPICER EK, 1987, P NATL ACAD SCI USA, V84, P5148, DOI 10.1073/pnas.84.15.5148; STEINBERG SF, 1985, THROMB HAEMOSTASIS, V54, P168	27	120	123	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29034	29042		10.1074/jbc.271.46.29034	http://dx.doi.org/10.1074/jbc.271.46.29034			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910556	hybrid			2022-12-27	WOS:A1996VT05200048
J	Espeso, EA; Penalva, MA				Espeso, EA; Penalva, MA			Three binding sites for the Aspergillus nidulans PacC zinc-finger transcription factor are necessary and sufficient for regulation by ambient pH of the isopenicillin N synthase gene promoter.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENICILLIN BIOSYNTHETIC GENE; MOLECULAR CHARACTERIZATION; EXPRESSION; SYNTHETASE; IPNA; ACVA	The isopenicillin N synthase (ipnA) gene, encoding a key penicillin biosynthetic enzyme in Aspergillus nidulans, represents a prototype of an alkaline-expressed gene. ipnA is under ambient pH regulation, and its promoter (ipnA(p)) contains binding sites for the zinc-finger transcription factor PacC. We show here that three of these sites, denoted ipnA2, ipnA3, and ipnA4AB, are efficiently recognized by the protein in an isolated sequence context. Single, double, and triple inactivation of these sites in any possible combination reduced promoter activity under alkaline conditions but had no effect under acidic conditions (under which promoter activity was low), as measured by the expression of wildtype and mutant ipnA(p)::lacZ fusion genes integrated in single copy into a common chromosomal location. This establishes a physiological role for these PacC binding sites and demonstrates a direct role for PacC in ambient pH regulation of ipnA gene expression. In addition, this confirms our previous proposal that PacC is an activator for alkaline-expressed genes. Notably, our experiments show that ipnA2, the highest affinity site for PacC in the ipnA(p), contributes relatively modestly to PacC-mediated activation. By contrast, the lower affinity sites ipnA3 and ipnA4AB contribute more substantially to regulation by ambient pH. Inactivation of these three binding sites reduced promoter activity under alkaline conditions to that observed under acidic conditions, showing that these three PacC sites at ipnA(p) are sufficient to account for its activation by alkaline ambient pH.	CSIC,CTR INVEST BIOL,DEPT MOL MICROBIOL,E-28006 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)			Espeso, Eduardo A/C-5259-2011; Penalva, Miguel A/G-2295-2015; Espeso, Eduardo A/AAC-7238-2022	Espeso, Eduardo A/0000-0002-5873-6059; Penalva, Miguel A/0000-0002-3102-2806; Espeso, Eduardo A/0000-0002-5873-6059				ARST HN, 1994, MOL GEN GENET, V245, P787, DOI 10.1007/BF00297286; BRAKHAGE AA, 1992, J BACTERIOL, V174, P3789, DOI 10.1128/JB.174.11.3789-3799.1992; CADDICK MX, 1986, MOL GEN GENET, V203, P346, DOI 10.1007/BF00333978; CLUTTERBUCK AJ, 1993, GENETIC MAPS LOCUS M, V3; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; DENISON SH, 1995, J BIOL CHEM, V270, P28519, DOI 10.1074/jbc.270.48.28519; ESPESO EA, 1993, EMBO J, V12, P3947, DOI 10.1002/j.1460-2075.1993.tb06072.x; ESPESO EA, 1994, FEBS LETT, V342, P43, DOI 10.1016/0014-5793(94)80581-4; ESPESO EA, 1992, MOL MICROBIOL, V6, P1457, DOI 10.1111/j.1365-2958.1992.tb00866.x; MACCABE AP, 1991, J BIOL CHEM, V266, P12646; MacCabe AP, 1996, MOL GEN GENET, V250, P367, DOI 10.1007/s004380050087; OREJAS M, 1995, GENE DEV, V9, P1622, DOI 10.1101/gad.9.13.1622; PEREZESTEBAN B, 1993, MOL MICROBIOL, V9, P881, DOI 10.1111/j.1365-2958.1993.tb01746.x; ROSSI A, 1990, FEMS MICROBIOL LETT, V66, P51, DOI 10.1016/0378-1097(90)90257-Q; Sarkar S, 1996, BIOCHEM SOC T, V24, P360, DOI 10.1042/bst0240360; Suarez T, 1996, MOL MICROBIOL, V20, P529, DOI 10.1046/j.1365-2958.1996.5421065.x; TILBURN J, 1983, GENE, V26, P205, DOI 10.1016/0378-1119(83)90191-9; TILBURN J, 1995, EMBO J, V14, P779, DOI 10.1002/j.1460-2075.1995.tb07056.x; XU HE, 1995, P NATL ACAD SCI USA, V92, P7677, DOI 10.1073/pnas.92.17.7677	19	84	91	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28825	28830		10.1074/jbc.271.46.28825	http://dx.doi.org/10.1074/jbc.271.46.28825			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910527	hybrid, Green Published			2022-12-27	WOS:A1996VT05200019
J	FernandezRachubinski, FA; Weiner, JH; Blajchman, MA				FernandezRachubinski, FA; Weiner, JH; Blajchman, MA			Regions flanking exon 1 regulate constitutive expression of the human antithrombin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE RECEPTORS; BINDING-PROTEIN; PROMOTER; TRANSCRIPTION; LIVER; CELLS; ELEMENT; RECOGNITION; SEQUENCES; INTERACTS	We have identified cis-acting elements and trans-acting factors that regulate constitutive expression of the human antithrombin gene. The activity of the sequences flanking the first exon of the gene was investigated using a luciferase-based reporter assay in transiently transfected HepG2, COS1, BSC40, and HeLa cells. Deletion analysis allowed the mapping of two elements able to promote antithrombin gene transcription in HepG2 and COS1 cells. The first element is located upstream of the first exon (-150/+68 nucleotides). The second element is in the first intervening sequence (+300/+700 nucleotides) and functions in an orientation opposite to that of the first. Footprint analysis showed three protected areas in the 5' upstream element at -92/-68 (element A), -14/+37 (element B), and -126/-100 nucleotides (element C). These elements acted as enhancers in luciferase reporter assays. Gel retardation analysis demonstrated that two liver-enriched transcription factors, hepatocyte nuclear factor 4 (HNF4) and CCAAT enhancer-binding protein (C/EBPa), bound to the 5' upstream element. HNF4 bound to elements A and C, whereas C/EBPa bound to element B. Element A also interacted with the ubiquitous nuclear hormone receptors chicken ovalbumin upstream promoter transcription factor 1 (COUP-TF1), thyroid hormone receptor alpha (TR alpha), peroxisome proliferator-activated receptor alpha(PPAR alpha), and retinoid X receptor alpha (RXR alpha). In HepG2 and BSC40 cells, HNF4, C/EBP alpha, and RXR alpha activated luciferase expression from a reporter construct containing the 5'-upstream minimal antithrombin gene promoter, while COUP-TF1, TR alpha, and HNF3 (alpha or beta) repressed such expression. Our results show that constitutive expression of the human antithrombin gene depends in part upon the interplay of these transcription factors and suggest that signaling pathways regulated by these factors can modulate antithrombin gene transcription.	MCMASTER UNIV,MED CTR,HSC 2N34,DEPT PATHOL,HAMILTON,ON L8N 3Z5,CANADA; UNIV ALBERTA,DEPT MED,EDMONTON,AB T6G 2H7,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA	McMaster University; University of Alberta; University of Alberta								BLAJCHMAN MA, 1992, BLOOD, V80, P2159; BOSSU JP, 1994, BIOCHEM BIOPH RES CO, V202, P822, DOI 10.1006/bbrc.1994.2004; BRUNEL F, 1991, NUCLEIC ACIDS RES, V19, P5237, DOI 10.1093/nar/19.19.5237; CARLSSON P, 1989, GENE, V77, P113, DOI 10.1016/0378-1119(89)90365-X; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Ciliberto Gennaro, 1993, P162; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GILLMAN MZ, 1986, MOL CELL BIOL, V6, P4305; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HOWELL BW, 1989, MOL CELL BIOL, V9, P2928, DOI 10.1128/MCB.9.7.2928; HUANG MN, 1992, J BIOL CHEM, V267, P15440; JANSENDURR P, 1992, NUCLEIC ACIDS RES, V20, P1243, DOI 10.1093/nar/20.6.1243; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; LECAM A, 1994, J BIOL CHEM, V269, P21532; Mangelsdorf David J., 1994, P319; MARCUS SL, 1993, P NATL ACAD SCI USA, V90, P5723, DOI 10.1073/pnas.90.12.5723; METZGER S, 1993, J BIOL CHEM, V268, P16831; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MIYATA KS, 1993, J BIOL CHEM, V268, P19169; OCHOA A, 1989, NUCLEIC ACIDS RES, V17, P119, DOI 10.1093/nar/17.1.119; PROCHOWNIK EV, 1985, NATURE, V316, P845, DOI 10.1038/316845a0; PROCHOWNIK EV, 1984, J BIOL CHEM, V259, P5386; ROBERTS HR, 1993, THROMB HAEMOSTASIS, V70, P1; SALIER JP, 1990, J BIOL CHEM, V265, P7062; SCHAEFFER E, 1993, J BIOL CHEM, V268, P23399; Sheffield WP, 1995, MOL BASIS THROMBOSIS, P355; SLADEK FM, 1994, TRANSCRIPTIONAL REGU, P1; TREMP GL, 1995, GENE AMST, V156, P192; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541	34	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29502	29512		10.1074/jbc.271.46.29502	http://dx.doi.org/10.1074/jbc.271.46.29502			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910619	hybrid			2022-12-27	WOS:A1996VT05200111
J	Hiesberger, T; Hodits, R; Ullrich, R; Exner, M; Kerjaschki, D; Schneider, WJ; Nimpf, J				Hiesberger, T; Hodits, R; Ullrich, R; Exner, M; Kerjaschki, D; Schneider, WJ; Nimpf, J			Receptor-associated protein and members of the low density lipoprotein receptor family share a common epitope - An extended model for the development of passive Heymann nephritis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN OOCYTE RECEPTOR; ALPHA-2-MACROGLOBULIN RECEPTOR; IMMUNOELECTRON MICROSCOPY; MULTIFUNCTIONAL RECEPTOR; ANTIGENIC COMPLEX; INSULIN-RECEPTOR; LIGAND-BINDING; 39-KDA PROTEIN; ANTI-IDIOTYPES; MEGALIN GP330	Heymann nephritis is an experimental rat model for human membranous glomerulonephritis. Two target antigens have been identified in the proximal tubule brush border of rat kidneys. One of them is megalin, a 600-kDa membrane protein that belongs to the family of low density lipoprotein receptor (LDLR)-related proteins. The other one is receptor-associated protein (RAP), a polypeptide of 40 kDa that associates with members of the LDLR family. Here we show that antibodies produced against recombinant human RAP strongly crossreact with the chicken oocyte receptor for very low density Lipoprotein and vitellogenin (LR8), and with two other members of the LDLR family, LDLR-related protein and megalin. The interaction of this antibody with LR8 showed binding characteristics exactly as those demonstrated for the physiological ligands of this receptor, in that binding of the antibody: (i) is Ca2+-dependent; (ii) is abolished by unfolding of the cysteine-rich binding domain by reduction; and (iii) interferes with the binding of very low density Lipoprotein and vitellogenin. Immunopurification of the LR8-specific subpopulation of the polyclonal antiserum yielded an IgG fraction strongly reacting with LR8 as well as with RAP. Using recombinant fragments of RAP and peptide mapping, the cross-reacting epitope(s) could be narrowed down to three short sequences (5-7 residues) in the COOH-terminal part of the protein. After immunization with RAP, anti-LR8 antibodies and anti-RAP antibodies arise simultaneously, indicating that the receptor-specific activity is not due to anti-idiotypic antibodies. These findings suggest the existence of a common epitope(s) on RAP and members of the LDL receptor family Based on these results, we present an extended molecular model for the development of passive Heymann nephritis.	BIOCTR,DEPT MOL GENET,A-1030 VIENNA,AUSTRIA; UNIV VIENNA,A-1030 VIENNA,AUSTRIA; UNIV VIENNA,DEPT CLIN PATHOL,SECT ULTRASTRUCT PATHOL & CELL BIOL,A-1090 VIENNA,AUSTRIA	University of Vienna; University of Vienna				Nimpf, Johannes/0000-0002-9273-3492				BARBER DL, 1991, J BIOL CHEM, V266, P18761; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BROWN MS, 1974, P NATL ACAD SCI USA, V71, P788, DOI 10.1073/pnas.71.3.788; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; BUJO H, 1995, J BIOL CHEM, V270, P23546, DOI 10.1074/jbc.270.40.23546; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; ELIAS D, 1984, J BIOL CHEM, V259, P6416; FARQUHAR MG, 1995, J AM SOC NEPHROL, V6, P35; GAULTON GN, 1986, ANNU REV IMMUNOL, V4, P253, DOI 10.1146/annurev.iy.04.040186.001345; GEORGE R, 1987, J BIOL CHEM, V262, P16838; HAYASHI K, 1989, J BIOL CHEM, V264, P3131; HERZ J, 1991, J BIOL CHEM, V266, P21232; HIESBERGER T, 1995, J BIOL CHEM, V270, P18219, DOI 10.1074/jbc.270.31.18219; JACOBSEN L, 1995, J BIOL CHEM, V270, P6468, DOI 10.1074/jbc.270.12.6468; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; KERJASCHKI D, 1986, KIDNEY INT, V30, P229, DOI 10.1038/ki.1986.175; KERJASCHKI D, 1992, P NATL ACAD SCI USA, V89, P11179, DOI 10.1073/pnas.89.23.11179; Kerjaschki D, 1996, J EXP MED, V183, P2007, DOI 10.1084/jem.183.5.2007; KERJASCHKI D, 1982, P NATL ACAD SCI-BIOL, V79, P5557, DOI 10.1073/pnas.79.18.5557; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MUKONO H, 1994, J BIOL CHEM, V269, P13238; NIMPF J, 1988, J LIPID RES, V29, P657; NIMPF J, 1994, J BIOL CHEM, V269, P212; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; ORLANDO RA, 1995, J AM SOC NEPHROL, V6, P61; PIETROMONACO S, 1990, P NATL ACAD SCI USA, V87, P1811, DOI 10.1073/pnas.87.5.1811; Raychowdhury R, 1996, AM J PATHOL, V148, P1613; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SCHNEIDER WJ, 1980, J BIOL CHEM, V255, P1442; Schneider Wolfgang J., 1995, Current Opinion in Lipidology, V6, P92, DOI 10.1097/00041433-199504000-00006; SEGE K, 1978, P NATL ACAD SCI USA, V75, P2443, DOI 10.1073/pnas.75.5.2443; SHECHTER Y, 1982, SCIENCE, V216, P542, DOI 10.1126/science.7041258; STEYRER E, 1990, J BIOL CHEM, V265, P19575; STIFANI S, 1988, BIOCHEM J, V250, P467, DOI 10.1042/bj2500467; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537	47	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28792	28797		10.1074/jbc.271.46.28792	http://dx.doi.org/10.1074/jbc.271.46.28792			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910522	hybrid			2022-12-27	WOS:A1996VT05200014
J	Meagher, JL; Huntington, JA; Fan, BQ; Gettins, PGW				Meagher, JL; Huntington, JA; Fan, BQ; Gettins, PGW			Role of arginine 132 and lysine 133 in heparin binding to and activation of antithrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL CHANGE; THROMBIN REACTION; VARIANT; SITE; MECHANISM; IDENTIFICATION; ACCELERATION; MODEL	The binding of heparin to antithrombin greatly accelerates the rate of inhibition of the target proteinases thrombin and factor Xa. Acceleration of the rate of inhibition of factor Xa involves a conformational change in antithrombin that is translated from the heparin binding site to the reactive center loop, A mechanism has been proposed for generation and propagation of the conformational change in which the binding of the negatively charged heparin reduces ionic repulsions be tween positively charged residues on and adjacent to the D-helix in the heparin binding site of antithrombin (van Boeckel, C. A. A., Grootenhuis, P. D. J., and Visser, A, (1994) Nature Struct, Biol, 1, 423-425), This charge neutralization is proposed to elongate the D-helix and initiate the conformational change which is then translated to the reactive center loop. Several basic residues, including arginine 132 and lysine 133, were predicted to be important both in heparin binding and in this mechanism of heparin activation, To test both the helix extension mechanism and the role of these two residues in heparin binding and factor Xa inhibition, we individually changed arginine 132 and lysine 133 to uncharged methionine by site-directed mutagenesis. The K-d values for binding of R132M and K133M variants to the high affinity pentasaccharide were weakened only 2.3- and 4.5-fold respectively, suggesting a location for R132 and K133 peripheral to the main pentasaccharide binding site. However, the K-d values for long chain high affinity heparin were weakened at least 17-fold for both R132M and K133M, indicating involvement of each residue in binding extended chain heparin species. These reductions in affinity were ionic strength-dependent. The rates of inhibition of factor Xa and thrombin by each variant, however, were indistinguishable from those of control antithrombin, and the accelerations of the rate of inhibition produced by heparin were normal. We conclude that neither arginine 132 nor lysine 133 plays an important role in the binding of heparin pentasaccharide or in the mechanism of heparin activation, suggesting that D-helix extension through charge neutralization is not the mechanism for transmission of conformational change from the heparin binding site to the reactive center region, Arginine 132 and lysine 133 do, however, play a role in tight binding of longer chain heparin species through ionic interactions.	UNIV ILLINOIS,DEPT BIOCHEM,CHICAGO,IL 60612; VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Vanderbilt University					NHLBI NIH HHS [HL49234] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049234, R37HL049234] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BORG JY, 1990, FEBS LETT, V266, P163, DOI 10.1016/0014-5793(90)81530-2; BORG JY, 1988, J CLIN INVEST, V81, P1292, DOI 10.1172/JCI113447; BRENNAN SO, 1987, FEBS LETT, V219, P431, DOI 10.1016/0014-5793(87)80266-1; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CHANG JY, 1989, J BIOL CHEM, V264, P3111; FAN BQ, 1994, BIOCHEMISTRY-US, V33, P14156, DOI 10.1021/bi00251a026; FAN BQ, 1993, J BIOL CHEM, V268, P17588; GANDRILLE S, 1990, J BIOL CHEM, V265, P18997; Garone L, 1996, BIOCHEMISTRY-US, V35, P8881, DOI 10.1021/bi960542m; GETTINS P, 1992, J BIOL CHEM, V267, P21946; GETTINS PGW, 1993, BIOCHEMISTRY-US, V32, P8385, DOI 10.1021/bi00084a001; GRIFFITH MJ, 1982, J BIOL CHEM, V257, P7360; GROOTENHUIS PDJ, 1991, J AM CHEM SOC, V113, P2743, DOI 10.1021/ja00007a058; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; KOIDE T, 1984, P NATL ACAD SCI-BIOL, V81, P289, DOI 10.1073/pnas.81.2.289; MILETICH JP, 1980, ANAL BIOCHEM, V105, P304, DOI 10.1016/0003-2697(80)90462-5; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; Olson Steven T., 1994, Perspectives in Drug Discovery and Design, V1, P479, DOI 10.1007/BF02171861; PETERSON CB, 1987, J BIOL CHEM, V262, P8061; PETERSON CB, 1985, J BIOL CHEM, V260, P610; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; TURKO IV, 1993, FEBS LETT, V335, P9, DOI 10.1016/0014-5793(93)80429-X; VANBOECKEL CAA, 1994, NAT STRUCT BIOL, V1, P423, DOI 10.1038/nsb0794-423; Zettlmeissl G, 1988, Behring Inst Mitt, P26	27	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29353	29358		10.1074/jbc.271.46.29353	http://dx.doi.org/10.1074/jbc.271.46.29353			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910598	hybrid			2022-12-27	WOS:A1996VT05200090
J	YamamotoHonda, R; Honda, Z; Ueki, K; Tobe, K; Kaburagi, Y; Takahashi, Y; Tamemoto, H; Suzuki, T; Itoh, K; Akanuma, Y; Yazaki, Y; Kadowaki, T				YamamotoHonda, R; Honda, Z; Ueki, K; Tobe, K; Kaburagi, Y; Takahashi, Y; Tamemoto, H; Suzuki, T; Itoh, K; Akanuma, Y; Yazaki, Y; Kadowaki, T			Mutant of insulin receptor substrate-1 incapable of activating phosphatidylinositol 3-kinase did not mediate insulin-stimulated maturation of Xenopus laevis oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; GLYCOGEN-SYNTHASE KINASE-3; SRC HOMOLOGY-2 DOMAINS; PROTEIN-KINASE; MAP KINASE; SIGNAL-TRANSDUCTION; MEIOTIC MATURATION; RAS PROTEINS; S6 KINASE; PHAS-I	Insulin receptor substrate-1 (IRS-1) is rapidly phosphorylated on multiple tyrosine residues in response to insulin and binds several Src homology 2 domain-containing proteins, thereby initiating downstream signaling. To assess the tyrosine phosphorylation sites that mediate relevant downstream signaling and biological effects, we created site-directed mutants of IRS-1 and overexpressed them in the Xenopus laevis oocyte. In oocytes overexpressing IRS-1 or IRS-1-895F (Tyr-895 replaced with phenylalanine), insulin activated phosphatidylinositol (PI) 3-kinase, p70 S6 kinase, and mitogen-activated protein kinase and induced oocyte maturation. In contrast, in oocytes overexpressing IRS-1-4F (Tyr-460, Tyr-608, Tyr-939, and Tyr-987 of IRS-1 replaced with phenylalanine), insulin did not activate PI 3-kinase, p70 S6 kinase, and mitogen-activated protein kinase and failed to induce oocyte maturation. These observations indicate that in X. laevis oocytes overexpressing IRS-1, the association of PI 3-kinase rather than Grb2 (growth factor-bound protein 2) with IRS-1 plays a major role in insulin induced oocyte maturation. Activation of PI 3-kinase may lie upstream of mitogen-activated protein kinase activation and p70 S6 kinase activation in response to insulin.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT INTERNAL MED & PHYS THERAPY,BUNKYO KU,TOKYO 113,JAPAN; ASAHI LIFE FDN,INST DIABET CARE & RES,CHIYODA KU,TOKYO 100,JAPAN	University of Tokyo; University of Tokyo; Asahi Life Foundation								ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; CHUANG LM, 1994, J BIOL CHEM, V269, P27645; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CUNG J, 1994, NATURE, V370, P71; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; FUKUDA M, 1994, J BIOL CHEM, V269, P33097; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; GRIGORESCU F, 1994, DIABETES, V43, pA3; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; HONDA Z, 1995, J BIOL CHEM, V270, P4840, DOI 10.1074/jbc.270.9.4840; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; ITOH F, 1992, EXP MED, V11, P382; JANICOT M, 1991, J BIOL CHEM, V266, P9382; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; KABURAGI Y, 1993, J BIOL CHEM, V268, P16610; KORN LJ, 1987, SCIENCE, V236, P1502; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LANE HA, 1992, EMBO J, V11, P1743, DOI 10.1002/j.1460-2075.1992.tb05226.x; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIU XJ, 1995, MOL CELL BIOL, V15, P3563; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MATSUOKA K, 1993, EMBO J, V12, P3467; MYERS MG, 1994, J BIOL CHEM, V269, P28783; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PONS S, 1995, MOL CELL BIOL, V15, P4453; ROCCHI S, 1995, ENDOCRINOLOGY, V136, P5291, DOI 10.1210/en.136.12.5291; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TOBE K, 1993, J BIOL CHEM, V268, P11167; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107	53	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28677	28681		10.1074/jbc.271.45.28677	http://dx.doi.org/10.1074/jbc.271.45.28677			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910502	hybrid			2022-12-27	WOS:A1996VU03300102
J	Roghani, M; Mohammadi, M; Schlessinger, J; Moscatelli, D				Roghani, M; Mohammadi, M; Schlessinger, J; Moscatelli, D			Induction of urokinase-type plasminogen activator by fibroblast growth factor (FGF)-2 is dependent on expression of FGF receptors and does not require activation of phospholipase C gamma 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPILLARY ENDOTHELIAL-CELLS; ELIMINATES PHOSPHATIDYLINOSITOL HYDROLYSIS; HEPARAN-SULFATE; POINT MUTATION; SIGNAL-TRANSDUCTION; TYROSINE KINASE; DNA-SYNTHESIS; C-GAMMA; BINDING; INTERNALIZATION	The roles of heparan sulfate proteoglgcans and tyrosine kinase fibroblast growth factor (FGF) receptors in mediating the induction of plasminogen activator (PA) by FGF-2 were investigated using L6 myoblast cells that normally do not express detectable FGF receptors. PA was induced by FGF-2 in a dose-dependent manner in L6 cells expressing transfected FGF receptor-1 but not in nontransfected cells or cells transfected with the vector alone. The PA produced in these cells was characterized as urokinase-type PA (uPA), Thus, expression of a tyrosine kinase FGF receptor was required for induction of uPA, Internalization of FGF through heparan sulfates does not seem to be involved in this response as soluble heparin and suramin at concentrations which inhibited FGF-2 binding to heparan sulfates but not receptors did not affect the induction of uPA by FGF-2, Mutant receptors in which the tyrosine kinase was inactivated were not able to respond to FGF-2, In contrast, mutation of the site of phospholipase C gamma 1 (PLC gamma) binding in the receptor, which causes loss of PLC gamma activation, had no effect on uPA induction by FGF-2. These results suggest that PLC gamma activation is not required for induction of uPA by FGF-2.	NYU,MED CTR,DEPT CELL BIOL,NEW YORK,NY 10016; NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University; New York University			Mohammadi, Moosa/ABA-6745-2020; kasaei, fahime/T-7197-2018	Mohammadi, Moosa/0000-0003-2434-9437; Moscatelli, David/0000-0002-4627-4213	NCI NIH HHS [CA34289, CA42229] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042229] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BURRUS LW, 1992, MOL CELL BIOL, V12, P5600, DOI 10.1128/MCB.12.12.5600; CLYMAN RI, 1994, CELL ADHES COMMUN, V1, P333, DOI 10.3109/15419069409097264; COFFEY RJ, 1987, J CELL PHYSIOL, V132, P143, DOI 10.1002/jcp.1041320120; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; Fannon M, 1996, J BIOL CHEM, V271, P17949, DOI 10.1074/jbc.271.30.17949; GANNOUNZAKI L, 1991, EXP CELL RES, V197, P272, DOI 10.1016/0014-4827(91)90433-U; GROSS JL, 1982, J CELL BIOL, V95, P947; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; ISACCHI A, 1991, P NATL ACAD SCI USA, V88, P2628, DOI 10.1073/pnas.88.7.2628; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; KELLER KM, 1989, BIOCHEMISTRY-US, V28, P8100, DOI 10.1021/bi00446a021; MIGNATTI P, 1991, J CELL BIOL, V113, P1193, DOI 10.1083/jcb.113.5.1193; MIGNATTI P, 1989, J CELL BIOL, V108, P671, DOI 10.1083/jcb.108.2.671; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MOSCATELLI D, 1989, J CELL BIOL, V109, P2519, DOI 10.1083/jcb.109.5.2519; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; MOSCATELLI D, 1988, BIOCHIM BIOPHYS ACTA, V948, P67, DOI 10.1016/0304-419X(88)90005-4; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; MOSCATELLI D, 1986, P NATL ACAD SCI USA, V83, P2091, DOI 10.1073/pnas.83.7.2091; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PRESTA M, 1986, MOL CELL BIOL, V6, P4060, DOI 10.1128/MCB.6.11.4060; PRESTA M, 1989, J CELL BIOL, V109, P1877, DOI 10.1083/jcb.109.4.1877; PRESTA M, 1989, J CELL PHYSIOL, V141, P517, DOI 10.1002/jcp.1041410310; QUARTO N, 1994, J CELL SCI, V107, P3201; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REILAND J, 1993, J CELL SCI, V105, P1085; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; RUSNATI M, 1993, J CELL PHYSIOL, V154, P152, DOI 10.1002/jcp.1041540119; Rusnati M, 1996, MOL BIOL CELL, V7, P369, DOI 10.1091/mbc.7.3.369; SAKSELA O, 1987, J CELL BIOL, V105, P957, DOI 10.1083/jcb.105.2.957; SOROKIN A, 1994, J BIOL CHEM, V269, P17056; SPIVAKKROIZMAN T, 1994, J BIOL CHEM, V269, P14419; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6	41	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31154	31159		10.1074/jbc.271.49.31154	http://dx.doi.org/10.1074/jbc.271.49.31154			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940113	hybrid			2022-12-27	WOS:A1996VW68600024
J	Shi, WX; Chammas, R; Varki, NM; Powell, L; Varki, A				Shi, WX; Chammas, R; Varki, NM; Powell, L; Varki, A			Sialic acid 9-O-acetylation on murine erythroleukemia cells affects complement activation, binding to I-type lectins, and tissue homing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-H; STRUCTURAL CHARACTERIZATION; ALTERNATIVE PATHWAY; MONOCLONAL-ANTIBODY; HUMAN-LEUKOCYTES; SIALOADHESIN; ADHESION; LYMPHOCYTES; RECEPTOR; FAMILY	O-Acetylation of the 9-hydroxyl group of sialic acids has been suggested to modify various recognition phenomena involving these molecules, but direct proof has been lacking in most situations. In the accompanying paper (Shi, W.-X., Chammas, R., and Varki, A. (1996) J. Biol. Chem. 261, 31517-31525), we report that the extent of 9-O-acetylation of cell surface sialic acids on murine erythroleukemia (MEL) cells can be modified by various manipulations, including differentiation, nocodazole treatment, and 9-O-acetyl esterase treatment. We have used this system to explore the putative roles of 9-O-acetylation in modulating alternative pathway complement activation, I-type lectin binding, and tissue homing, MEL cells are shown to be sensitive to lysis in vitro by the alternative pathway of human complement. Induced differentiation of the MEL cells causes resistance to lysis, and this correlates directly with extent of decrease in 9-O-acetylation. A similar resistance to alternative pathway lysis can be obtained by selective enzymatic removal of 9-O-acetyl groups from sialic acids. Conversely the increase in cell, surface 9-O-acetylation caused by nocodazole treatment correlates with increased sensitivity to alternative pathway lysis. Thus, a 9-O-acetyl group added to the side chain of cell. surface sialic acids may abrogate its normal function in restricting alternative pathway activation. Indeed, the binding of human complement factor H, a negative regulator of the alternative pathway, is shown to be blocked by O-acetylation of the sialic acids on MEL cells. MEL cells are also shown to have cell surface ligands for the I-type lectins sialoadhesin and CD22. Sialoadhesin (but not CD22) binding is selectively enhanced by differentiation-induced loss of cell surface 9-O-acetylation and by direct enzymatic removal of the ester groups, Thus, some sialoadhesin ligands are masked by 9-O-acetylation, presumably because the side chain is required for recognition, Since sialoadhesin is expressed on some macrophages in vice, we reasoned that tissue homing of MEL cells might be affected by O-acetylation. Indeed, enzymatic removal of cell surface 9-O-acetyl groups alters the tissue distribution of intravenously injected cells. In particular, de-O-acetylation caused significant increase in homing to the liver and spleen. These data demonstrate that cell surface 9-O-acetylation can affect a variety of biological recognition phenomena and provide a system for further exploration of the specific molecular mechanisms involved.	UNIV CALIF SAN DIEGO,CTR CANC,GLYCOBIOL PROGRAM,DIV CELLULAR & MOL MED,LA JOLLA,CA 92093	University of California System; University of California San Diego			Chammas, Roger/A-8004-2011	Chammas, Roger/0000-0003-0342-8726	NCI NIH HHS [P01-CA5869] Funding Source: Medline; NIGMS NIH HHS [R01-GM32373] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVERY VM, 1993, J IMMUNOL, V151, P5545; BLUM AS, 1987, P NATL ACAD SCI USA, V84, P8716, DOI 10.1073/pnas.84.23.8716; CONSTANTINEPATON M, 1986, NATURE, V324, P459, DOI 10.1038/324459a0; CROCKER PR, 1995, J CLIN INVEST, V95, P635, DOI 10.1172/JCI117708; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; DOLCI ED, 1989, J CELL SCI, V93, P191; DRAZBA J, 1991, DEV BIOL, V145, P154, DOI 10.1016/0012-1606(91)90221-N; FRASER IP, 1994, EUR J CELL BIOL, V64, P217; FREEMAN SD, 1995, BLOOD, V85, P2005, DOI 10.1182/blood.V85.8.2005.bloodjournal8582005; HANASAKI K, 1995, J BIOL CHEM, V270, P7533, DOI 10.1074/jbc.270.13.7533; HIGA HH, 1985, VIROLOGY, V144, P279, DOI 10.1016/0042-6822(85)90325-3; KAMERLING JP, 1982, BIOCHIM BIOPHYS ACTA, V714, P351, DOI 10.1016/0304-4165(82)90344-0; KAZATCHKINE MD, 1979, J IMMUNOL, V122, P75; KELM S, 1994, GLYCOCONJUGATE J, V11, P576, DOI 10.1007/BF00731309; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; KLEIN A, 1994, P NATL ACAD SCI USA, V91, P7782, DOI 10.1073/pnas.91.16.7782; KLOTZ FW, 1992, MOL BIOCHEM PARASIT, V51, P49, DOI 10.1016/0166-6851(92)90199-T; KNIEP B, 1992, BIOCHEM BIOPH RES CO, V187, P1343, DOI 10.1016/0006-291X(92)90450-Y; KNIEP B, 1993, BLOOD, V82, P1776; KNIEP B, 1995, J BIOL CHEM, V270, P30173; Law S.K.A., 1995, COMPLEMENT; LEVINE JM, 1984, J NEUROSCI, V4, P820; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982; MICHALEK MT, 1988, J IMMUNOL, V140, P1588; NATH D, 1995, J BIOL CHEM, V270, P26184, DOI 10.1074/jbc.270.44.26184; NYDEGGER UE, 1978, P NATL ACAD SCI USA, V75, P6078, DOI 10.1073/pnas.75.12.6078; OLLERT MW, 1995, J IMMUNOL, V155, P4955; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; SCHAUER R, 1991, Glycobiology, V1, P449, DOI 10.1093/glycob/1.5.449; Schauer R., 1982, CELL BIOL MONOGRAPHS, V10; SCHWARTING GA, 1983, J BIOL CHEM, V258, P5893; SHI WS, 1978, UNPUB J BIOL CHEM, V271, P31517; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; STICKL H, 1991, KLIN WOCHENSCHR, V69, P5, DOI 10.1007/BF01649046; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992; VARKI A, 1980, J EXP MED, V152, P532, DOI 10.1084/jem.152.3.532; VARKI A, 1991, CELL, V65, P65, DOI 10.1016/0092-8674(91)90408-Q; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; ZIMMER G, 1994, GLYCOBIOLOGY, V4, P343, DOI 10.1093/glycob/4.3.343; ZIPFEL PF, 1994, IMMUNOL TODAY, V15, P121, DOI 10.1016/0167-5699(94)90155-4	41	88	91	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31526	31532		10.1074/jbc.271.49.31526	http://dx.doi.org/10.1074/jbc.271.49.31526			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940168	hybrid			2022-12-27	WOS:A1996VW68600079
J	Corsi, AK; Schekman, R				Corsi, AK; Schekman, R			Mechanism of polypeptide translocation into the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							SIGNAL RECOGNITION PARTICLE; PROTEIN-CONDUCTING CHANNEL; SECRETORY PROTEINS; NASCENT CHAINS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; ALPHA-SUBUNIT; SEC PROTEINS; GTP-BINDING; ER MEMBRANE		UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOL & CELL BIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley								Bacher G, 1996, NATURE, V381, P248, DOI 10.1038/381248a0; Becker J, 1996, MOL CELL BIOL, V16, P4378; Borel AC, 1996, CELL, V85, P379, DOI 10.1016/S0092-8674(00)81116-2; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; Brodsky JL, 1996, TRENDS BIOCHEM SCI, V21, P122, DOI 10.1016/0968-0004(96)20010-6; BRODSKY JL, 1994, BIOL HEAT SHOCK PROT, P85; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; CONNOLLY T, 1993, J CELL BIOL, V123, P799, DOI 10.1083/jcb.123.4.799; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; ESNAULT Y, 1993, EMBO J, V12, P4083, DOI 10.1002/j.1460-2075.1993.tb06092.x; FELDHEIM D, 1993, MOL BIOL CELL, V4, P931, DOI 10.1091/mbc.4.9.931; FELDHEIM D, 1994, J CELL BIOL, V126, P935, DOI 10.1083/jcb.126.4.935; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HEDGE RS, 1996, CELL, V85, P217; HIGH S, 1993, J BIOL CHEM, V268, P26745; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KURIHARA T, 1993, MOL BIOL CELL, V4, P919, DOI 10.1091/mbc.4.9.919; LAURING B, 1995, P NATL ACAD SCI USA, V92, P5411, DOI 10.1073/pnas.92.12.5411; LAURING B, 1995, P NATL ACAD SCI USA, V92, P9435, DOI 10.1073/pnas.92.21.9435; LUTCKE H, 1995, EUR J BIOCHEM, V228, P531, DOI 10.1111/j.1432-1033.1995.0531m.x; LYMAN SK, 1995, J CELL BIOL, V131, P1163, DOI 10.1083/jcb.131.5.1163; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; Martoglio B, 1996, TRENDS CELL BIOL, V6, P142, DOI 10.1016/0962-8924(96)10001-5; MAYINGER P, 1993, EMBO J, V12, P659, DOI 10.1002/j.1460-2075.1993.tb05699.x; MAYINGER P, 1995, J CELL BIOL, V131, P1377, DOI 10.1083/jcb.131.6.1377; MILLER JD, 1995, J CELL BIOL, V128, P273, DOI 10.1083/jcb.128.3.273; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; OGG SC, 1995, CELL, V81, P1075, DOI 10.1016/S0092-8674(05)80012-1; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; PERARA E, 1986, SCIENCE, V232, P348, DOI 10.1126/science.3961485; Powers T, 1996, CURR BIOL, V6, P331, DOI 10.1016/S0960-9822(02)00484-0; RAPIEJKO PJ, 1994, MOL BIOL CELL, V5, P887, DOI 10.1091/mbc.5.8.887; RAPIEJKO PJ, 1992, J CELL BIOL, V117, P493, DOI 10.1083/jcb.117.3.493; Rapoport TA, 1996, CURR OPIN CELL BIOL, V8, P499, DOI 10.1016/S0955-0674(96)80027-5; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Romisch K., 1996, PROTEIN TARGETING, P101; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHLENSTEDT G, 1990, J BIOL CHEM, V265, P13960; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; Voigt S, 1996, J CELL BIOL, V134, P25, DOI 10.1083/jcb.134.1.25; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WANG S, 1995, J CELL BIOL, V130, P519, DOI 10.1083/jcb.130.3.519; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0	63	92	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30299	30302		10.1074/jbc.271.48.30299	http://dx.doi.org/10.1074/jbc.271.48.30299			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939984	hybrid			2022-12-27	WOS:A1996VV15800001
J	Datta, K; Bellacosa, A; Chan, TO; Tsichlis, PN				Datta, K; Bellacosa, A; Chan, TO; Tsichlis, PN			Akt is a direct target of the phosphatidylinositol 3-kinase - Activation by growth factors, v-src and v-Ha-ras, in Sf9 and mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; SIGNAL-TRANSDUCTION; DOMAIN; PP60C-SRC; HOMOLOGY; RAF-1; SITES	The Akt protooncogene encodes a serine-threonine protein kinase which is activated by growth factor-generated signals that are transduced via the phosphatidylinositol 3'-kinase (PI3-K). Earlier studies suggested that the activation of Akt by PB-K may be mediated by the binding of D-3-phosphorylated phosphoinositides to the Akt pleckstrin homology (PH) domain. On the basis of these studies, it was hypothesized that Abt is a direct PB-K target. To test this hypothesis, we reconstituted the pathway of Akt activation in baculovirus-infected Sf9 cells. The results showed that Akt, which is normally catalytically inactive in these cells, was activated when coexpressed with the activated PI3-K. Moreover, they showed that activated forms of c-Ha-ras (v-Ha-ras) and c-src (v-src or srcY527F), two molecules that transduce growth factor-generated signals, also activate Akt in a PI3-K-dependent manner in Sf9 as well as NIH 3T3 cells, The activation of Akt by both growth factors and v-ras and v-src (or srcY527F) depends on the integrity of the Akt PH domain and carboxyl-terminal tail. These results show that Akt activation via the PB-B: can be faithfully reproduced in baculovirus-infected Sf9 cells, The same results support the hypothesis that Akt is a direct target of the PI3-K and identify cytoplasmic signaling molecules that may contribute to the transduction of PI3-K/Akt activation signals.	FOX CHASE CANC CTR,PHILADELPHIA,PA 19111	Fox Chase Cancer Center				Chan, Tung/0000-0001-6574-9555	NCI NIH HHS [CA57436, CA06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057436, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; DATTA K, 1995, MOL CELL BIOL, V15, P2304; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0	19	253	257	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30835	30839		10.1074/jbc.271.48.30835	http://dx.doi.org/10.1074/jbc.271.48.30835			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940066	hybrid			2022-12-27	WOS:A1996VV15800083
J	Kumar, R; Chen, SM; Scheurer, D; Wang, QL; Duh, E; Sung, CH; Rehemtulla, A; Swaroop, A; Adler, R; Zack, DJ				Kumar, R; Chen, SM; Scheurer, D; Wang, QL; Duh, E; Sung, CH; Rehemtulla, A; Swaroop, A; Adler, R; Zack, DJ			The bZIP transcription factor Nrl stimulates rhodopsin promoter activity in primary retinal cell cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PROTEIN BINDING; SMALL MAF PROTEINS; RAT OPSIN GENE; RETINITIS-PIGMENTOSA; SEGMENTATION MUTANT; BOVINE RHODOPSIN; UPSTREAM REGION; BASIC DOMAIN; FACTOR NF-E2; EXPRESSION	In vitro DNA binding assays and transient transfection analysis with monkey kidney cells have implicated Nrl, a member of the Maf-Nrl subfamily of bZIP transcription factors, and the Nrl response element (NRE) in the regulation of rhodopsin expression, We have now further explored the role of the NRE and surrounding promoter elements. Using the yeast one-hybrid screen with integrated NRE and flanking DNA as bait, the predominant clone obtained was bovine Nrl. Recovery of truncated clones in the screen demonstrated that the carboxyl-terminal half of Nrl, which contains the basic and leucine zipper domains, is sufficient for DNA binding. To functionally dissect the rhodopsin promoter, transient expression studies with primary chick retinal cell cultures were performed. Deletion and mutation analyses identified two positive regulatory sequences: one between -40 and -84 base pairs (bp) and another between -84 and -130 bp. Activity of the -40 to -84 region was shown to be largely due to the NRE, On co-transfection with an NRL expression vector, there were 3-5-fold increases in the activity of rhodopsin promoter constructs containing an intact NRE but little or no effect with rhodopsin promoters containing a mutated or deleted NRE. Nrl was more effective than the related bZIP proteins, c-Fos and c-Jun, in stimulating rhodopsin promoter activity. The -84- to -130-bp region acted synergistically with the NRE to enhance both the level of basal expression and the degree of Nrl-mediated trans-activation. These studies support Nrl as a regulator of rhodopsin expression in vivo, identify an additional regulatory region just upstream of the NRE, and demonstrate the utility of primary retinal cell cultures for characterizing both the cis-acting response elements and trans-acting factors that regulate photoreceptor gene expression.	JOHNS HOPKINS UNIV,SCH MED,DEPT OPHTHALMOL,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,BALTIMORE,MD 21287; CORNELL UNIV,SCH MED,DEPT OPHTHALMOL,NEW YORK,NY 10021; CORNELL UNIV,SCH MED,DEPT CELL BIOL,NEW YORK,NY 10021; CORNELL UNIV,SCH MED,DEPT ANAT,NEW YORK,NY 10021; UNIV MICHIGAN,DEPT RADIAT ONCOL,ANN ARBOR,MI 48105; UNIV MICHIGAN,DEPT OPHTHALMOL & HUMAN GENET,ANN ARBOR,MI 48105	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Cornell University; Cornell University; Cornell University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Swaroop, Anand/0000-0002-1975-1141; Zack, Don/0000-0002-7966-1973	NATIONAL EYE INSTITUTE [R01EY009769, R01EY011307, F32EY006614, R01EY004859, F32EY006434] Funding Source: NIH RePORTER; NEI NIH HHS [EY09769, EY04859, EY06434, F32 EY006614, R01 EY011307] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADLER R, 1984, J CELL BIOL, V99, P1173, DOI 10.1083/jcb.99.3.1173; Adler R, 1990, Adv Exp Med Biol, V265, P147; ADLER R, 1993, INVEST OPHTH VIS SCI, V34, P1677; Ahmad I, 1995, DEV BRAIN RES, V90, P184, DOI 10.1016/0165-3806(96)83500-0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; BOGENMANN E, 1988, SCIENCE, V240, P76, DOI 10.1126/science.2451289; Chen SM, 1996, J BIOL CHEM, V271, P28549, DOI 10.1074/jbc.271.45.28549; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; EARNEST DJ, 1990, EXP NEUROL, V109, P353, DOI 10.1016/S0014-4886(05)80027-5; FARJO Q, 1993, GENOMICS, V18, P216, DOI 10.1006/geno.1993.1458; FROHMAN MA, 1993, DEVELOPMENT, V117, P925; GALE JM, 1992, J MOL BIOL, V224, P343, DOI 10.1016/0022-2836(92)90999-Z; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KERPPOLA TK, 1994, ONCOGENE, V9, P3149; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KIKUCHI T, 1993, MOL CELL BIOL, V13, P4400, DOI 10.1128/MCB.13.7.4400; KUMAR R, 1995, MOL GENETICS OCULAR, P139; KURSCHNER C, 1995, MOL CELL BIOL, V15, P246, DOI 10.1128/MCB.15.1.246; LEM J, 1991, NEURON, V6, P201, DOI 10.1016/0896-6273(91)90356-5; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; Liu Q, 1996, ONCOGENE, V12, P207; MCKAY IJ, 1994, DEVELOPMENT, V120, P2199; MORABITO MA, 1991, J BIOL CHEM, V266, P9667; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NATHANS J, 1984, P NATL ACAD SCI-BIOL, V81, P4851, DOI 10.1073/pnas.81.15.4851; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NATHANS J, 1987, ANNU REV NEUROSCI, V10, P163; Nie ZQ, 1996, J BIOL CHEM, V271, P2667, DOI 10.1074/jbc.271.5.2667; PIERANI A, 1995, MOL CELL BIOL, V15, P642; POLITI LE, 1988, INVEST OPHTH VIS SCI, V29, P534; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; Saga T, 1996, INVEST OPHTH VIS SCI, V37, P561; SAGAR SM, 1990, MOL BRAIN RES, V7, P17, DOI 10.1016/0169-328X(90)90068-O; Sambrook J., 2002, MOL CLONING LAB MANU; SHESHBERADARAN H, 1994, MOL CELL NEUROSCI, V5, P309, DOI 10.1006/mcne.1994.1037; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; TIMMERS AM, 1993, EXP EYE RES, V56, P257, DOI 10.1006/exer.1993.1034; TREISMAN JE, 1988, MOL CELL BIOL, V8, P1570, DOI 10.1128/MCB.8.4.1570; WANG MM, 1993, MOL CELL BIOL, V13, P5805, DOI 10.1128/MCB.13.9.5805; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C; WERNER M, 1990, J NEUROSCI RES, V25, P50, DOI 10.1002/jnr.490250107; YU X, 1993, BIOCHEM BIOPH RES CO, V191, P76, DOI 10.1006/bbrc.1993.1186; ZACK DJ, 1991, NEURON, V6, P187, DOI 10.1016/0896-6273(91)90355-4; ZACK DJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P1477, DOI 10.1001/archopht.1993.01090110043019	51	130	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29612	29618		10.1074/jbc.271.47.29612	http://dx.doi.org/10.1074/jbc.271.47.29612			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939891	hybrid			2022-12-27	WOS:A1996VU52500019
J	Kuntzweiler, TA; Arguello, JM; Lingrel, JB				Kuntzweiler, TA; Arguello, JM; Lingrel, JB			Asp(804) and Asp(808) in the transmembrane domain of the Na,K-ATPase alpha subunit are cation coordinating residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; RAT-KIDNEY NA+,K+-ATPASE; MEMBRANE H+-ATPASE; SARCOPLASMIC-RETICULUM; CARDIAC-GLYCOSIDES; OUABAIN BINDING; VOLTAGE-DEPENDENCE; ACTIVE-TRANSPORT; POTASSIUM-IONS; SODIUM	The functional roles of Asp(804) and Asp(808), located in the sixth transmembrane segment of the Na,R-ATPase alpha subunit, were examined. Nonconservative replacement of these residues yielded enzymes unable to support cell viability. Only the conservative substitution, Ala(808) --> Glu, was able to maintain the essential cation gradients (Van Huysse, J. W., Kuntzweiler, T. A., and Lingrel, J. B (1996) FEES Left. 389, 179-185). Asp(804) and Asp(808) were replaced by Ala, Asn, and Glu in the sheep alpha 1 subunit and expressed in a mouse cell line where [H-3]ouabain binding was utilized to probe the exogenous proteins. All of the heterologous proteins were targeted into the plasma membrane, bound ouabain and nucleotides, and adopted E(1)Na, E(1)ATP, and E(2)P conformations. K+ competition of ouabain binding to sheep alpha 1 and Asp(808) --> Glu enzymes displayed IC50 values of 4.11 mM (n(Hill) = 1.4) and 23.8 mM (n(Hill) = 1.6), respectively. All other substituted proteins lacked this K+-ouabain antagonism, e.g. 150 min KCl did not inhibit ouabain binding. Na+ antagonized ouabain binding to all the expressed isoforms, however, the proteins carrying nonconservative substitutions displayed reduced Hill coefficients (n(Hill) less than or equal to 2.0) compared to the control (n(Hill) less than or equal to 2.8), Therefore, Asp(804) and Asp(808) of the Na,K-ATPase are required for normal Na+ and K+ transport, possibly coordinating these cations during transport.	UNIV CINCINNATI, COLL MED, DEPT MOL GENET BIOCHEM & MICROBIOL, CINCINNATI, OH 45267 USA	University of Cincinnati			Arguello, Jose/D-1997-2012	Arguello, Jose/0000-0003-3940-6297	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028573, K14HL003373, F32HL008612] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28573, HL08612, HL03373] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; ARGUELLO JM, 1991, J BIOL CHEM, V266, P14627; ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; ARGUELLO JM, 1995, J BIOL CHEM, V270, P22764, DOI 10.1074/jbc.270.39.22764; Arguello JM, 1996, BIOPHYS J, V70, pTU370; ASKARI A, 1988, J BIOL CHEM, V263, P235; BAMBERG E, 1994, SODIUM PUMP STRUCTUR; BLOSTEIN R, 1983, J BIOL CHEM, V258, P7948; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CORNELIUS F, 1991, BIOCHIM BIOPHYS ACTA, V1071, P19, DOI 10.1016/0304-4157(91)90011-K; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DEWEER P, 1988, ANNU REV PHYSIOL, V50, P225, DOI 10.1146/annurev.physiol.50.1.225; DUNHAM ET, 1961, J PHYSIOL-LONDON, V156, P274, DOI 10.1113/jphysiol.1961.sp006675; ERDMANN E, 1973, BIOCHIM BIOPHYS ACTA, V330, P302, DOI 10.1016/0005-2736(73)90235-6; FENG JN, 1994, BIOCHEMISTRY-US, V33, P4218, DOI 10.1021/bi00180a015; FENG JN, 1995, CELL MOL BIOL RES, V41, P29; FORBUSH B, 1987, J BIOL CHEM, V262, P11116; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GOLDSHLEGGER R, 1987, J PHYSIOL-LONDON, V387, P331, DOI 10.1113/jphysiol.1987.sp016576; GREEN NM, 1989, BIOCHEM SOC T, V17, P972, DOI 10.1042/bst0170972; HANSEN O, 1973, BIOCHIM BIOPHYS ACTA, V311, P51, DOI 10.1016/0005-2736(73)90254-X; HANSEN O, 1984, PHARMACOL REV, V36, P143; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; JOHNSON CL, 1995, BIOCHEM J, V309, P187, DOI 10.1042/bj3090187; JOHNSON CL, 1995, ARCH BIOCHEM BIOPHYS, V317, P133, DOI 10.1006/abbi.1995.1145; JORGENSEN PL, 1992, MOL ASPECTS TRANSPOR, P1; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; Koster JC, 1996, J BIOL CHEM, V271, P2413, DOI 10.1074/jbc.271.5.2413; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUNTZWEILER TA, 1995, J BIOL CHEM, V270, P2993, DOI 10.1074/jbc.270.7.2993; KUNTZWEILER TA, 1995, J BIOL CHEM, V270, P16206, DOI 10.1074/jbc.270.27.16206; LANE LK, 1979, NA K ATPASE STRUCTUR; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; OBRIEN WJ, 1993, J BIOL CHEM, V268, P7707; Palasis M, 1996, J BIOL CHEM, V271, P14176, DOI 10.1074/jbc.271.24.14176; PEDEMONTE CH, 1988, J THEOR BIOL, V134, P165, DOI 10.1016/S0022-5193(88)80200-5; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; PEDEMONTE CH, 1988, BIOCHEMISTRY-US, V27, P7966, DOI 10.1021/bi00420a056; Pedersen PA, 1996, J BIOL CHEM, V271, P2514, DOI 10.1074/jbc.271.5.2514; Peluffo R. D., 1996, Biophysical Journal, V70, pA18; POST RL, 1972, J BIOL CHEM, V247, P6530; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; RAO R, 1993, J BIOL CHEM, V268, P6708; RAO R, 1992, BIOPHYS J, V62, P228, DOI 10.1016/S0006-3495(92)81808-8; SAGAR A, 1994, J GEN PHYSIOL, V103, P869, DOI 10.1085/jgp.103.5.869; SAMPOGNA RV, 1994, BIOPHYS J, V66, P1341, DOI 10.1016/S0006-3495(94)80925-7; SCHATZMANN HJ, 1965, BIOCHIM BIOPHYS ACTA, V94, P89, DOI 10.1016/0926-6585(65)90011-7; SCHULTHEIS PJ, 1993, J BIOL CHEM, V268, P22686; SHANISEKLER M, 1988, J BIOL CHEM, V263, P19331; VANHUYSSE JW, 1993, BIOCHEMISTRY-US, V32, P819, DOI 10.1021/bi00054a012; VanHuysse JW, 1996, FEBS LETT, V389, P179, DOI 10.1016/0014-5793(96)00578-9; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; WALLICK ET, 1988, METHOD ENZYMOL, V156, P201; YODA A, 1982, MOL PHARMACOL, V22, P700	62	93	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29682	29687		10.1074/jbc.271.47.29682	http://dx.doi.org/10.1074/jbc.271.47.29682			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939901	hybrid			2022-12-27	WOS:A1996VU52500029
J	Tchou, WW; Rom, WN; TchouWong, KM				Tchou, WW; Rom, WN; TchouWong, KM			Novel form of p21(WAF1)/(CIP1)/(SDI1) protein in phorbol ester-induced G(2)/M arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; CELL-CYCLE; P53-INDEPENDENT INDUCTION; TUMOR SUPPRESSION; GROWTH-INHIBITION; DOWN-REGULATION; LEUKEMIA-CELLS; P21; EXPRESSION; WAF1/CIP1	Cell cycle progression requires activation of different cyclin-dependent kinases (CDKs) which are positively regulated by cyclins and negatively regulated by CDK inhibitors. Growth inhibition of the Calu-1 lung carcinoma cells induced with the phorbol ester 12-O-tetra-decanoylphorbol-13-acetate (TPA), a potent activator of protein kinase C, is associated with G(2)/M arrest and induction of expression of a novel, faster-migrating form of p21(WAF1/CIP1/SDI1) (p21) protein, an inhibitor of cyclin-dependent kinases. This faster-migrating p21 protein was also expressed in TPA-treated A549 lung carcinoma cells which also exhibited G(2)/M arrest but not in TPA-treated U937 leukemia cells, which only expressed a slower-migrating form of p21 protein. However, reverse transcriptase-polymerase chain reaction and Southern analysis demonstrated no evidence of novel splice in TPA-treated Calu-1 cells. On the other hand, immuno-blotting analysis demonstrated that the faster-migrating p21 protein could be detected only by peptide antibody directed against the N terminus but not the C terminus, suggestive of truncation of the latter or protein modification that results in the loss of the C-terminal epitope. Correlation of G(2)/M arrest with expression of the faster-migrating p21 protein suggests that this novel form of p21 protein may be a mediator of G(2)/M arrest and growth inhibition.	NYU,MED CTR,DEPT MED,NEW YORK,NY 10016; NYU,MED CTR,DEPT ENVIRONM MED,NEW YORK,NY 10016; NYU,MED CTR,DEPT MICROBIOL,NEW YORK,NY 10016; NYU,MED CTR,DIV HEMATOL & ONCOL,NEW YORK,NY 10016; NYU,MED CTR,DIV PULM & CRIT CARE MED,NEW YORK,NY 10016	New York University; New York University; New York University; New York University; New York University				Rom, William/0000-0002-8793-7028	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051494] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035233] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51494] Funding Source: Medline; NIAID NIH HHS [AI35233] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BJORNBERG F, 1994, LYMPHOKINE CYTOK RES, V13, P203; CHEDID M, 1994, ONCOGENE, V9, P3021; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GRAFIA X, 1995, ONCOGENE, V11, P211; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; HARANO T, 1994, J BIOL CHEM, V269, P20305; HARPER JW, 1993, CELL, V75, P805; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG HP, 1994, ONCOGENE, V9, P3397; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LI Y, 1994, ONCOGENE, V9, P2261; MICHIELI P, 1994, CANCER RES, V54, P3391; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OKAMOTO A, 1995, CANCER RES, V55, P1448; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; QUELLE DE, 1995, CELL, V83, P993; REMOLDODONNELL E, 1994, J IMMUNOL, V152, P3595; SCHWALLER J, 1995, J CLIN INVEST, V95, P973, DOI 10.1172/JCI117806; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TCHOUWONG KM, 1992, MOL CELL BIOL, V12, P394, DOI 10.1128/MCB.12.1.394; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YEE NS, 1994, J BIOL CHEM, V269, P31991; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHANG W, 1995, CANCER RES, V55, P668	35	55	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29556	29560		10.1074/jbc.271.47.29556	http://dx.doi.org/10.1074/jbc.271.47.29556			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939883	hybrid			2022-12-27	WOS:A1996VU52500011
J	Froelich, CJ; Orth, K; Turbov, J; Seth, P; Gottlieb, R; Babior, B; Shah, GM; Bleackley, RC; Dixit, VM; Hanna, W				Froelich, CJ; Orth, K; Turbov, J; Seth, P; Gottlieb, R; Babior, B; Shah, GM; Bleackley, RC; Dixit, VM; Hanna, W			New paradigm for lymphocyte granule-mediated cytotoxicity - Target cells bind and internalize granzyme B, but an endosomolytic agent is necessary for cytosolic delivery and subsequent apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA FRAGMENTATION; LYSIS; INHIBITION; PROTEASES; PERFORIN; PHOSPHATIDYLSERINE; PURIFICATION; ADENOVIRUS; POLYMERASE; PATHWAYS	Lymphocyte granule-mediated apoptosis is postulated to entail the formation of membrane pores by perforin. Then soluble granzyme reaches the cytosol either through these pores or by reparative pinocytosis. We demonstrate here that Jurkat cells bind and internalize granzyme B via high affinity binding sites without toxic consequence. Apoptosis occurs, however, if sublytic perforin is added to targets washed free of soluble granzyme B, We suggest that granule-mediated apoptosis mimics viral strategies for cellular entry. Accordingly, co-internalization of granzyme B with adenovirus, a virus that escapes endosomes to reach the cytosol, also induced apoptosis. Poly(ADP-ribose) polymerase cleavage and processing of CPP32, ICE-LAP3, and Mch2 were detected at 30 min, while cytosolic acidification and DNA fragmentation occurred at 60 min. Annexin V binding and membrane permeabilization arose at 4 h. The concurrent activation of the Ced-3 proteases differed from the rate at which each cysteine protease is cleaved in vitro by granzyme B. Thus, granzyme B may not directly process these proteases in whole cells but rather may function by activating a more proximal enzyme. These results indicate that adenovirus-mediated delivery of granzyme B is suitable for elucidating biochemical events that accompany granule-mediated apoptosis.	NORTHWESTERN UNIV, EVANSTON HOSP, DEPT MED, EVANSTON, IL 60201 USA; UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA; NCI, MED BRANCH, NIH, BETHESDA, MD 20892 USA; SCRIPPS RES INST, DIV BIOCHEM, SAN DIEGO, CA 92037 USA; UNIV LAVAL, HOSP & RES CTR, UNIT HLTH & ENVIRONM, POLY ADP RIBOSE METAB GRP, QUEBEC CITY, PQ G1V 4G2, CANADA; UNIV ALBERTA, DEPT BIOCHEM, EDMONTON, AB T6G 2H7, CANADA	NorthShore University Health System; Northwestern University; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Scripps Research Institute; Laval University; University of Alberta			Shah, Girish M/A-5153-2008; dixit, vishva m/A-4496-2012; Orth, Kim/AAV-4421-2021	dixit, vishva m/0000-0001-6983-0326; Orth, Kim/0000-0002-0678-7620; Shah, Girish/0000-0002-9291-1164	NCI NIH HHS [CA68769] Funding Source: Medline; NIA NIH HHS [AG-13501] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA068769] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013501] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BLEACKLEY RC, 1988, IMMUNOL REV, V10, P5; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chinnaiyan AM, 1996, CURR BIOL, V6, P897, DOI 10.1016/S0960-9822(02)00614-0; CHRISTIAANSEN JE, 1985, P NATL ACAD SCI USA, V82, P4482, DOI 10.1073/pnas.82.13.4482; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; GORCZYCA W, 1993, CANCER RES, V53, P1945; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; GREBER UF, 1993, CELL, V75, P477, DOI 10.1016/0092-8674(93)90382-Z; Greenberg A H, 1995, Curr Top Microbiol Immunol, V198, P95; Gu Y, 1996, J BIOL CHEM, V271, P10816, DOI 10.1074/jbc.271.18.10816; HANNA WL, 1993, PROTEIN EXPRES PURIF, V4, P398, DOI 10.1006/prep.1993.1052; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HUDIG D, 1991, J IMMUNOL, V147, P1360; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; KAUFMANN SH, 1993, CANCER RES, V53, P3976; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; Meisenholder GW, 1996, J BIOL CHEM, V271, P16260, DOI 10.1074/jbc.271.27.16260; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; PODACK ER, 1995, CURR OPIN IMMUNOL, V7, P11, DOI 10.1016/0952-7915(95)80023-9; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; SETH P, 1994, BIOCHEM BIOPH RES CO, V205, P1318, DOI 10.1006/bbrc.1994.2809; SETH P, 1994, BIOCHEM BIOPH RES CO, V203, P582, DOI 10.1006/bbrc.1994.2222; SHAH GM, 1995, ANAL BIOCHEM, V227, P1, DOI 10.1006/abio.1995.1245; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; Sower LE, 1996, CELL IMMUNOL, V171, P159, DOI 10.1006/cimm.1996.0187; Sower LE, 1996, J IMMUNOL, V156, P2585; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; TSCHOPP J, 1990, ANNU REV IMMUNOL, V8, P279, DOI 10.1146/annurev.immunol.8.1.279; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Wagner Robert R., 1996, P561; ZYCHLINSKY A, 1991, J IMMUNOL, V146, P393	42	305	313	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29073	29079		10.1074/jbc.271.46.29073	http://dx.doi.org/10.1074/jbc.271.46.29073			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910561	hybrid			2022-12-27	WOS:A1996VT05200053
J	Medrano, FJ; Gasset, M; LopezZumel, C; Usobiaga, P; Garcia, JL; Menendez, M				Medrano, FJ; Gasset, M; LopezZumel, C; Usobiaga, P; Garcia, JL; Menendez, M			Structural characterization of the unligated and choline-bound forms of the major pneumococcal autolysin LytA amidase - Conformational transitions induced by temperature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; PROTEIN SECONDARY STRUCTURE; CIRCULAR-DICHROISM SPECTRA; STREPTOCOCCUS-PNEUMONIAE; ULTRAVIOLET-ABSORPTION; MUREIN HYDROLASES; DECONVOLUTION; PURIFICATION; DERIVATIVES; DOMAIN	The secondary and tertiary structures of the choline-dependent major pneumococcal autolysin LytA amidase and of its COOH-terminal domain, C-LytA, have been investigated by circular dichroism (CD) and Fourier transform infrared (FTIR) spectroscopy. Deconvolution analysis shows that the far-UV CD spectrum of both proteins is governed by chiral contributions, ascribed to aromatic residue clusters contained in the COOH-terminal module. The secondary structure of LytA, determined from the FTIR spectral features of the amide I' band, results in 19% of alpha-helix and tight loops, 47% of beta-sheets, 23% of turns, and 11% of irregular structures. Similar values are obtained for C-LytA. The addition of choline significantly modifies the far- and near-UV CD spectra of LytA and C-LytA. These changes are attributed to alterations in the environment of their aromatic clusters, since the FTIR spectra indicate that the secondary structure is essentially unaffected. CD choline titration curves at different wavelengths show the existence of two types of binding sites/subunit. Data analysis assuming protein dimerization upon saturation of the high affinity sites reveals positive cooperativity between the low affinity sites. Thermal denaturation of both proteins occurs with the formation of unfolding intermediates and the presence of residual secondary structure in the final denatured state. The irreversibility of the thermal denaturation of LytA and C-LytA results from the collapse of the polypeptide chain into intermolecular extended structures. At saturating concentrations, choline prevents the formation of these structures in the isolated COOH-terminal module.	CSIC,INST QUIM FIS ROCASOLANO,E-28006 MADRID,SPAIN; CSIC,CTR INVEST BIOL,E-28006 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)			Gasset, Maria/K-4339-2012; Menendez, Margarita/M-1795-2014; Medrano, Francisco Javier/ABF-9860-2020; Gasset, Maria/I-2050-2014; Espinosa, Manuel/M-5282-2019; Garcia Lopez, Jose Luis/G-9139-2015	Gasset, Maria/0000-0001-6436-4055; Menendez, Margarita/0000-0002-3267-4443; Gasset, Maria/0000-0001-6436-4055; Garcia Lopez, Jose Luis/0000-0002-9238-2485; Medrano, Francisco/0000-0002-8185-9751				ARRONDO JLR, 1993, PROG BIOPHYS MOL BIO, V59, P25; AUER HE, 1973, J AM CHEM SOC, V95, P3003, DOI 10.1021/ja00790a046; BERRY AM, 1989, INFECT IMMUN, V57, P2324, DOI 10.1128/IAI.57.8.2324-2330.1989; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; CUDELL DR, 1995, NATURE, V377, P435; DAY LA, 1973, BIOCHEMISTRY-US, V12, P5329, DOI 10.1021/bi00750a017; GALZI JL, 1994, CURR OPIN STRUC BIOL, V4, P554, DOI 10.1016/S0959-440X(94)90218-6; GARCIA E, 1988, P NATL ACAD SCI USA, V85, P914, DOI 10.1073/pnas.85.3.914; GARCIA JL, 1987, ARCH MICROBIOL, V149, P52, DOI 10.1007/BF00423136; GARCIA JL, 1994, J BACTERIOL, V176, P4066, DOI 10.1128/JB.176.13.4066-4072.1994; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; GOORMAGHTIGH E, 1995, PHYSICOCHEMICAL METH, P329; GORNETSCHELNOKOW U, 1993, EUR J BIOCHEM, V213, P1235, DOI 10.1111/j.1432-1033.1993.tb17874.x; GRISHINA IB, 1994, FARADAY DISCUSS, V99, P245, DOI 10.1039/fd9949900245; HOLTJE JV, 1975, J BIOL CHEM, V250, P6072; KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171, DOI 10.1128/CMR.3.2.171-196.1990; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACKAY JP, 1994, J AM CHEM SOC, V116, P4581, DOI 10.1021/ja00090a006; MANNING MC, 1988, BIOPHYS CHEM, V31, P77, DOI 10.1016/0301-4622(88)80011-5; Menendez M, 1995, EUR J BIOCHEM, V234, P887, DOI 10.1111/j.1432-1033.1995.887_a.x; MUGA A, 1991, BIOCHEMISTRY-US, V30, P2629, DOI 10.1021/bi00224a010; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; PERCZEL A, 1992, PROTEINS, V13, P57, DOI 10.1002/prot.340130106; PERCZEL A, 1991, PROTEIN ENG, V4, P669, DOI 10.1093/protein/4.6.669; SANCHEZPUELLES JM, 1990, GENE, V89, P69, DOI 10.1016/0378-1119(90)90207-8; SANZ JM, 1988, FEBS LETT, V232, P308, DOI 10.1016/0014-5793(88)80759-2; SANZ JM, 1992, MOL MICROBIOL, V6, P921, DOI 10.1111/j.1365-2958.1992.tb01542.x; SHAN F, 1990, LANCET, V335, P38; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; Susi H, 1986, METHOD ENZYMOL, V130, P91; Sussman JL, 1992, CURR OPIN STRUC BIOL, V2, P721; TOMASZ A, 1989, Pediatric Infectious Disease Journal, V8, P902, DOI 10.1097/00006454-198912000-00034; TOUMANEN E, 1985, J INFECT DIS, V11, P535; TOUMANEN E, 1995, NEW ENGL J MED, V332, P1280; Usobiaga P, 1996, J BIOL CHEM, V271, P6832, DOI 10.1074/jbc.271.12.6832; WILDER CL, 1992, BIOCHEMISTRY-US, V31, P27, DOI 10.1021/bi00116a006; Woody RW, 1974, PEPTIDES POLYPEPTIDE, P338; YANG JT, 1986, METHOD ENZYMOL, V130, P208	39	35	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29152	29161		10.1074/jbc.271.46.29152	http://dx.doi.org/10.1074/jbc.271.46.29152			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910572	Green Published, hybrid			2022-12-27	WOS:A1996VT05200064
J	Rhee, S; Ebensperger, C; Dembic, Z; Pestka, S				Rhee, S; Ebensperger, C; Dembic, Z; Pestka, S			The structure of the gene for the second chain of the human interferon-gamma receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; ACCESSORY FACTOR; SIGNAL-TRANSDUCTION; BINDING PROTEINS; PROMOTER REGION; CDNA SEQUENCE; HUMAN-CELLS; BETA CHAIN; EXPRESSION; CLONING	The gene for the second chain of the human interferon-gamma receptor was analyzed from cosmid DNA clones. The gene spans over 33 kilobases of DNA and contains seven exons. The signal peptide is encoded by exons 1 and 2, the extracellular domain by exons 2, 3, 4, 5, and by part of 6. Exon 6 also encodes the whole transmembrane domain and part of the intracellular domain. Exon 7 encodes the remainder of the intracellular domain and contains the 3'-untranslated region. The sequences at the exon/intron boundaries are well conserved with respect to canonical acceptor/donor sites (AG/GT). The 5'-flanking region was sequenced and analyzed for transcription factor binding sites. No TATA or CAAT boxes in the promoter region were identified. Consistent with the lack of a TATA box, analysis of the mRNAs by primer extension showed multiple transcription start sites. Promoter activity of the 5'-flanking region was investigated with a luciferase reporter gene and the cytomegalovirus minimal promoter. Segments of the 5' region with promoter activity were identified.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT MOL GENET & MICROBIOL,PISCATAWAY,NJ 08854; F HOFFMAN LA ROCHE AG,DEPT PRECLIN RES,CH-4002 BASEL,SWITZERLAND	Rutgers State University New Brunswick; Rutgers State University Medical Center; Roche Holding			Dembic, Zlatko/A-1833-2008	Dembic, Zlatko/0000-0002-9970-6497	NCI NIH HHS [R01-CA52363, R01-CA46465] Funding Source: Medline; NIAID NIH HHS [R01-AI/GM36450] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046465, R01CA052363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036450] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; BACH EA, 1995, SCIENCE, V270, P1215, DOI 10.1126/science.270.5239.1215; BECK TW, 1990, MOL CELL BIOL, V10, P3325, DOI 10.1128/MCB.10.7.3325; COFANO F, 1990, J BIOL CHEM, V265, P4064; COOK JR, 1994, J BIOL CHEM, V269, P7013; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; EBENSPERGER C, 1995, IN PRESS SCAND J IMM; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAY PW, 1989, P NATL ACAD SCI USA, V86, P8497, DOI 10.1073/pnas.86.21.8497; HEMMI S, 1989, P NATL ACAD SCI USA, V86, P9901, DOI 10.1073/pnas.86.24.9901; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HIBINO Y, 1991, J BIOL CHEM, V266, P6948; HUANG DH, 1988, J BIOL CHEM, V263, P12596; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHII S, 1986, SCIENCE, V232, P1410, DOI 10.1126/science.3012774; JUNG V, 1988, SOMAT CELL MOLEC GEN, V14, P583, DOI 10.1007/BF01535312; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAESTNER KH, 1994, GENOMICS, V20, P377, DOI 10.1006/geno.1994.1191; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOH J, 1993, J BIOL CHEM, V268, P15912; KOTENKO SV, 1995, J BIOL CHEM, V270, P20915, DOI 10.1074/jbc.270.36.20915; KUMAR CS, 1989, J BIOL CHEM, V264, P17939; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MUNRO S, 1989, P NATL ACAD SCI USA, V86, P9248, DOI 10.1073/pnas.86.23.9248; PERNIS A, 1995, SCIENCE, V269, P245, DOI 10.1126/science.7618088; RASHIDBAIGI A, 1986, P NATL ACAD SCI USA, V83, P384, DOI 10.1073/pnas.83.2.384; Sambrook J., 2002, MOL CLONING LAB MANU; SKRENTA H, 1996, EUR CYTOKINE NETW, V7, P622; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9	32	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28947	28952		10.1074/jbc.271.46.28947	http://dx.doi.org/10.1074/jbc.271.46.28947			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910544	hybrid			2022-12-27	WOS:A1996VT05200036
J	Wang, PH; Zweier, JL				Wang, PH; Zweier, JL			Measurement of nitric oxide and peroxynitrite generation in the postischemic heart - Evidence for peroxynitrite-mediated reperfusion injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARAMAGNETIC-RESONANCE SPECTROSCOPY; HYDROXYL RADICAL PRODUCTION; IN-VIVO; ACTIVATED MACROPHAGES; LIPID-PEROXIDATION; XANTHINE-OXIDASE; RELAXING FACTOR; SUPEROXIDE; DECOMPOSITION; ENDOTHELIUM	Altered nitric oxide (NO.) production is a critical factor in tissue reperfusion injury; however, controversy remains regarding these alterations and how they cause injury. Since superoxide (O-2(.-)) generation is triggered during the early period of reperfusion the cytotoxic oxidant peroxynitrite (ONOO-) could be formed, but it is not known if this occurs. Therefore electron paramagnetic resonance and chemiluminescence studies were performed of the magnitude and time course of NO., O-2(.-), and ONOO- formation in the postischemic heart. Isolated rat hearts were subjected either to normal perfusion or to reperfusion after 30 min of ischemia in the presence of the NO. trap Fe2+-N-methyl-D-glucamine dithiocarbamate with electron paramagnetic resonance measurements performed on the effluent. Although only trace signals were present prior to ischemia, prominent NO. adduct signals were seen during the first 2 min of reflow which were abolished by nitric oxide synthase (NOS) inhibition. Similar studies with the O-2(.-) trap 5,5 -dimethyl-1-pyrroline N-oxide demonstrated a burst of O-2(.-) generation over the first 2 min of reflow. Chemiluminescence measurements using 5-amino-2,2-dihydro-1,4-phthalazinedione (luminol) demonstrated a similar marked increase in ONOO- which was blocked by NOS inhibitors or superoxide dismutase. NOS inhibition or superoxide dismutase greatly enhanced the recovery of contractile function in postischemic hearts. Immunohistology demonstrated that the ONOO--mediated nitration product nitrotyrosine was formed in postischemic hearts but not in normally perfused controls. Thus, NO. formation is increased during the early period of reflow and reacts with O-2(.-) to form ONOO-, which results in amino acid nitration and cellular injury.	JOHNS HOPKINS BAYVIEW MED CTR,JOHNS HOPKINS MED INST,DEPT MED,DIV CARDIOL,BALTIMORE,MD 21224; JOHNS HOPKINS BAYVIEW MED CTR,JOHNS HOPKINS MED INST,ELECTRON PARAMAGNET RESONANCE CTR,BALTIMORE,MD 21224	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038324, R29HL038324] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38324] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUGUSTO O, 1994, ARCH BIOCHEM BIOPHYS, V310, P118, DOI 10.1006/abbi.1994.1147; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; BECKMAN JS, 1990, NATURE, V345, P27, DOI 10.1038/345027b0; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BLOUGH NV, 1985, INORG CHEM, V24, P3504; COOKE JP, 1993, CIRCULATION, V88, P2451, DOI 10.1161/01.CIR.88.5.2451; Crow J P, 1995, Curr Top Microbiol Immunol, V196, P57; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DELELLIS RA, 1981, BASIC TECHNIQUES IMM; DRAPIER JC, 1991, J BIOL CHEM, V266, P10162; FEIGL EO, 1988, NATURE, V331, P490, DOI 10.1038/331490a0; FINKELSTEIN E, 1982, MOL PHARMACOL, V21, P262; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; HESS ML, 1995, ANN THORAC SURG, V60, P760, DOI 10.1016/0003-4975(95)00574-5; HOGG N, 1992, BIOCHEM J, V281, P419, DOI 10.1042/bj2810419; IGNARRO LJ, 1986, J BIOL CHEM, V261, P4997; KING PA, 1992, J AM CHEM SOC, V114, P5430, DOI 10.1021/ja00039a068; KOOY NW, 1994, ARCH BIOCHEM BIOPHYS, V310, P352, DOI 10.1006/abbi.1994.1178; KUKREJA RC, 1992, CARDIOVASC RES, V26, P641, DOI 10.1093/cvr/26.7.641; LAI CS, 1994, FEBS LETT, V345, P120, DOI 10.1016/0014-5793(94)00422-6; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LEMERCIER JN, 1995, ARCH BIOCHEM BIOPHYS, V321, P31, DOI 10.1006/abbi.1995.1364; MA XL, 1993, CIRC RES, V72, P403, DOI 10.1161/01.RES.72.2.403; MARBAN E, 1989, CIRCULATION, V80, P17; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MONCADA S, 1986, P NATL ACAD SCI USA, V83, P9164, DOI 10.1073/pnas.83.23.9164; MONCADA S, 1991, PHARMACOL REV, V43, P109; MORDVINTCEV P, 1991, ANAL BIOCHEM, V199, P142, DOI 10.1016/0003-2697(91)90282-X; MORENO JJ, 1992, CHEM RES TOXICOL, V5, P425, DOI 10.1021/tx00027a017; MORITA K, 1995, J THORAC CARDIOV SUR, V110, P1200, DOI 10.1016/S0022-5223(95)70006-4; MORO MA, 1994, P NATL ACAD SCI USA, V91, P6702, DOI 10.1073/pnas.91.14.6702; PATEL VC, 1993, BIOCHEM BIOPH RES CO, V194, P234, DOI 10.1006/bbrc.1993.1809; POU S, 1992, J BIOL CHEM, V267, P24173; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; RADI R, 1993, BIOCHEM J, V290, P51, DOI 10.1042/bj2900051; RUBBO H, 1994, J BIOL CHEM, V269, P26066; SARAN M, 1994, CHEM-BIOL INTERACT, V90, P35, DOI 10.1016/0009-2797(94)90109-0; SHINOBU LA, 1984, ACTA PHARMACOL TOX, V54, P189; SQUADRITO GL, 1995, CHEM-BIOL INTERACT, V96, P203, DOI 10.1016/0009-2797(94)03591-U; THOMPSONGORMAN SL, 1990, J BIOL CHEM, V265, P6656; VANDERVLIET A, 1994, FEBS LETT, V339, P89, DOI 10.1016/0014-5793(94)80391-9; VILLA LM, 1994, P NATL ACAD SCI USA, V91, P12383, DOI 10.1073/pnas.91.26.12383; WINK DA, 1994, ANN NY ACAD SCI, V738, P69; XIA Y, 1995, J BIOL CHEM, V270, P18797, DOI 10.1074/jbc.270.32.18797; Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770; YU L, 1994, P NATL ACAD SCI USA, V91, P1691, DOI 10.1073/pnas.91.5.1691; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804; ZWEIER JL, 1988, J BIOL CHEM, V263, P1353; ZWEIER JL, 1995, J BIOL CHEM, V270, P304, DOI 10.1074/jbc.270.1.304; ZWEIER JL, 1989, J BIOL CHEM, V264, P18890	52	484	509	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29223	29230		10.1074/jbc.271.46.29223	http://dx.doi.org/10.1074/jbc.271.46.29223			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910581	hybrid			2022-12-27	WOS:A1996VT05200073
J	Chen, SM; Zack, DJ				Chen, SM; Zack, DJ			Ret 4, a positive acting rhodopsin regulatory element identified using a bovine retina in vitro transcription system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; HOMEOBOX-CONTAINING GENE; NUCLEAR-PROTEIN BINDING; RAT OPSIN GENE; TRANSGENIC MICE; IN-VITRO; INVITRO TRANSCRIPTION; VISUAL PIGMENTS; UPSTREAM REGION; PINEAL COMPLEX	Previous transgenic mouse studies demonstrated that the bovine rhodopsin sequence between -222 and +70 base pairs (bp) contains a minimal promoter, which is sufficient to direct photoreceptor cell-specific expression of a lacZ reporter gene. To more fully define the DNA regulatory elements and protein factors involved in regulating rhodopsin transcription, we have developed an in vitro transcription system derived from bovine retinal nuclear extracts. Retinal extracts, as compared to liver, HeLa, and Drosophila embryonic cell extracts, demonstrated preferential activity for the rhodopsin promoter. A template spanning the bovine rhodopsin upstream region from -590 to +15 bp showed significant activation relative to the basal activity seen with a TATA box containing -38 to +15 bp template. Deletion analysis indicated that the region between -85 and -38 bp contained significant positive regulatory activity. This activity was not observed with HeLa extracts, suggesting that it might be retina-specific. Systematic site-directed mutagenesis of the subregion from -64 to -38 bp indicated that sequences between -60 and -58 bp and between -48 and -40 bp harbor critical elements. The former sequence is part of the binding site for the retina-specific transcription factor Nrl, which has been implicated in rhodopsin regulation. Electrophoretic mobility shift assays showed that the latter sequence (-48 to -40 bp), and flanking DNA, designated Ret 4, is bound by both retina-specific and ubiquitously expressed protein factors. Shift assays with mutant oligomers further defined the putative recognition sequences for these protein factors. Together, our results suggest that multiple promoter elements and transcriptional factors are involved in regulating photoreceptor-specific rhodopsin transcription.	JOHNS HOPKINS UNIV,SCH MED,DEPT OPHTHALMOL,WILMER EYE INST,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21287	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University				Zack, Don/0000-0002-7966-1973	NATIONAL EYE INSTITUTE [R01EY009769, F32EY006614] Funding Source: NIH RePORTER; NEI NIH HHS [EY06614, EY09769, F32 EY006614] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADLER R, 1993, INVEST OPHTH VIS SCI, V34, P1677; Ahmad I, 1995, Brain Res Dev Brain Res, V90, P184; ARAKI M, 1992, DEV BRAIN RES, V69, P149, DOI 10.1016/0165-3806(92)90153-N; BAEHR W, 1988, FEBS LETT, V238, P253, DOI 10.1016/0014-5793(88)80490-3; Bellorini M, 1996, MOL CELL BIOL, V16, P503; BOGENMANN E, 1988, SCIENCE, V240, P76, DOI 10.1126/science.2451289; BORST D E, 1991, Journal of Cell Biology, V115, p312A; BUCHANAN KL, 1995, J IMMUNOL, V155, P4270; DENTE L, 1988, GENE DEV, V2, P259, DOI 10.1101/gad.2.2.259; DESJARDIN LE, 1993, J BIOL CHEM, V268, P6953; DesJardin LE, 1996, INVEST OPHTH VIS SCI, V37, P154; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIPOLO A, 1995, P NATL ACAD SCI USA, V92, P4016, DOI 10.1073/pnas.92.9.4016; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; DURAND B, 1994, MOL CELL BIOL, V14, P6839, DOI 10.1128/MCB.14.10.6839; GONG QH, 1993, MOL CELL BIOL, V13, P911, DOI 10.1128/MCB.13.2.911; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HISATAKE K, 1995, P NATL ACAD SCI USA, V92, P8195, DOI 10.1073/pnas.92.18.8195; KAMAKAKA RT, 1991, P NATL ACAD SCI USA, V88, P1024, DOI 10.1073/pnas.88.3.1024; KIKUCHI T, 1993, MOL CELL BIOL, V13, P4400, DOI 10.1128/MCB.13.7.4400; KUMAR R, 1996, IN PRESS J BIOL CHEM, V271; KUMAR R, 1995, MOL GENETICS OCULAR, P139; LEM J, 1991, NEURON, V6, P201, DOI 10.1016/0896-6273(91)90356-5; LINDELL TJ, 1970, SCIENCE, V170, P447, DOI 10.1126/science.170.3956.447; MASUDA H, 1994, TISSUE CELL, V26, P101, DOI 10.1016/0040-8166(94)90086-8; MIZUSHIMASUGANO J, 1986, P NATL ACAD SCI USA, V83, P8511, DOI 10.1073/pnas.83.22.8511; MORABITO MA, 1991, J BIOL CHEM, V266, P9667; NATHANS J, 1994, CELL, V78, P357, DOI 10.1016/0092-8674(94)90414-6; NATHANS J, 1984, P NATL ACAD SCI-BIOL, V81, P4851, DOI 10.1073/pnas.81.15.4851; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NATHANS J, 1992, BIOCHEMISTRY-US, V31, P4923, DOI 10.1021/bi00136a001; Nie ZQ, 1996, J BIOL CHEM, V271, P2667, DOI 10.1074/jbc.271.5.2667; PAO CI, 1995, J BIOL CHEM, V270, P24917, DOI 10.1074/jbc.270.42.24917; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; POLITI LE, 1988, INVEST OPHTH VIS SCI, V29, P534; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; SAMSON SLA, 1995, J BIOL CHEM, V270, P25194, DOI 10.1074/jbc.270.42.25194; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAYRE MH, 1993, CELL MOL BIOL RES, V39, P349; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; SHERIDAN PL, 1995, GENE DEV, V9, P2090, DOI 10.1101/gad.9.17.2090; SHESHBERADARAN H, 1994, MOL CELL NEUROSCI, V5, P309, DOI 10.1006/mcne.1994.1037; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; TAN SY, 1994, J BIOL CHEM, V269, P25684; TIMMERS AM, 1993, EXP EYE RES, V56, P257, DOI 10.1006/exer.1993.1034; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; TREISMAN JE, 1988, MOL CELL BIOL, V8, P1570, DOI 10.1128/MCB.8.4.1570; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C; WERNER M, 1990, J NEUROSCI RES, V25, P50, DOI 10.1002/jnr.490250107; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; YAMAKI K, 1990, J BIOL CHEM, V265, P20757; YOSHIKAWA T, 1994, ZOOL SCI, V11, P675; YU X, 1994, J MOL NEUROSCI, V5, P259, DOI 10.1007/BF02736726; YU X, 1993, BIOCHEM BIOPH RES CO, V191, P76, DOI 10.1006/bbrc.1993.1186; ZACK DJ, 1991, NEURON, V6, P187, DOI 10.1016/0896-6273(91)90355-4; ZACK DJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P1477, DOI 10.1001/archopht.1993.01090110043019; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZIMMERMAN K, 1990, MOL CELL BIOL, V10, P2096, DOI 10.1128/MCB.10.5.2096	62	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28549	28557		10.1074/jbc.271.45.28549	http://dx.doi.org/10.1074/jbc.271.45.28549			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910484	hybrid			2022-12-27	WOS:A1996VU03300084
J	Roshak, AK; Jackson, JR; McGough, K; ChabotFletcher, M; Mochan, E; Marshall, LA				Roshak, AK; Jackson, JR; McGough, K; ChabotFletcher, M; Mochan, E; Marshall, LA			Manipulation of distinct NF kappa B proteins alters interleukin-1 beta-induced human rheumatoid synovial fibroblast prostaglandin E(2) formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); ENDOPEROXIDE SYNTHASE-2 GENE; NUCLEAR FACTOR; ENDOTHELIAL-CELLS; RESPONSE ELEMENT; EXPRESSION; ACTIVATION; SUBUNIT; SITE; LIPOPOLYSACCHARIDE	Interleukin 1 beta (IL-1 beta) up-regulates human rheumatoid synovial fibroblast (RSF) 85-kDa phospholipase A(2) (PLA(2)) and mitogen-inducible cyclooxygenase (COX) II. Promoter regions for these genes contain a motif that closely resembles the ''classic'' NF kappa B consensus site, Immunoblot analysis identified NF kappa B1 (p50), RelA (p65), and c-Rel in RSF, Upon IL-1 beta-stimulation, p65 and c-Rel but not p50 protein levels were reduced suggesting nuclear translocation, IL-1 beta-induced RSF nuclear extracts contained a p65-containing complex, which bound to the classical NF kappa B consensus motif, An NF kappa B classical oligonucleotide decoy produced a concentration-dependent decrease in IL-1-stimulated PGE(2) production (IC50 = similar to 2 mu M), indicating a role of NF kappa B. Utilization of antisense technology showed that p65 but not p50 or c-Rel mediated IL-1 beta-stimulated PGE(2) formation, Treated RSF could not transcribe COX II or 85-kDa PLA(2) mRNA, which reduced their respective proteins, Interestingly, stimulated IL-8 production was not inhibited by the classical NF kappa B decoy but was reduced by treatment with antisense to both p65 and c-Rel supporting preferential binding of c-Rel-p65 to the ''alternative'' IL-8 kappa B motif, Taken together, these data provide the first direct evidence for a role of p65 in COX II and 85-kDa PLA(2) gene induction and support the IL-1 activation and participation of distinct NF kappa B protein dimers in RSF prostanoid and IL-8 formation.	SMITHKLINE BEECHAM PHARMACEUT, IMMUNOPHARMACOL, KING OF PRUSSIA, PA 19406 USA; PHILADELPHIA COLL OSTEOPATH MED, PHILADELPHIA, PA 19131 USA									ANGEL J, 1994, EUR J BIOCHEM, V226, P125, DOI 10.1111/j.1432-1033.1994.tb20033.x; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; DAYER JM, 1986, J CLIN INVEST, V77, P645, DOI 10.1172/JCI112350; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GILMAN SC, 1988, ARTHRITIS RHEUM, V31, P127, DOI 10.1002/art.1780310118; GODDARD DH, 1992, CYTOKINE, V4, P377, DOI 10.1016/1043-4666(92)90081-2; GOLFIELD AE, 1993, J EXP BIOL, V178, P1365; Handel ML, 1995, ARTHRITIS RHEUM, V38, P1762, DOI 10.1002/art.1780381209; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; HULKOWER KI, 1994, ARTHRITIS RHEUM-US, V37, P653, DOI 10.1002/art.1780370508; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; MIYASHITA A, 1995, NUCLEIC ACIDS RES, V23, P293, DOI 10.1093/nar/23.2.293; MORII H, 1994, BIOCHEM BIOPH RES CO, V205, P6, DOI 10.1006/bbrc.1994.2621; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; NARAYANAN R, 1993, MOL CELL BIOL, V13, P3802, DOI 10.1128/MCB.13.6.3802; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PARRY GCN, 1994, J BIOL CHEM, V269, P20823; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; Roshak A, 1996, J RHEUMATOL, V23, P420; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Schuster RL, 1993, P ANN S JAP LANDSL S, P1; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIPE JD, 1994, MEDIAT INFLAMM, V3, P243, DOI 10.1155/S0962935194000359; SOKOLOSKI JA, 1993, BLOOD, V82, P625; TANAKA H, 1994, NUCLEIC ACIDS RES, V22, P3069, DOI 10.1093/nar/22.15.3069; TAY A, 1994, BIOCHEM J, V304, P417, DOI 10.1042/bj3040417; TAY A, 1995, GENOMICS, V26, P138, DOI 10.1016/0888-7543(95)80093-2; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VELLANOWETH RL, 1994, LAB INVEST, V70, P784; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; ZIEGLERHEITBROCK HWL, 1993, J IMMUNOL, V151, P6986	39	165	176	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31496	31501		10.1074/jbc.271.49.31496	http://dx.doi.org/10.1074/jbc.271.49.31496			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940164	hybrid			2022-12-27	WOS:A1996VW68600075
J	Swift, LL				Swift, LL			Role of the golgi apparatus in the phosphorylation of apolipoprotein B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; RAT MAMMARY-GLAND; HEP G2 CELLS; CASEIN KINASE-ACTIVITY; ENDOPLASMIC-RETICULUM; INTRACELLULAR DEGRADATION; BREFELDIN-A; OLEIC-ACID; APO-B; SECRETION	Rat hepatic Golgi apparatus-rich fractions were utilized in an in vitro phosphorylation system containing [gamma-P-32]ATP to investigate the phosphorylation of apolipoproteins (ape) B48 and B100, Our results demonstrate that the Golgi apparatus contains a kinase(s) that phosphorylates both apoB48 and apoB100 as well as 290- and 460-kDa proteins recognized by antibody to apoB, We refer to the latter proteins as apoB57 and apoB90, respectively. Phosphorylations in the presence of Triton X-100, which increases the permeability of the membranes, or alamethicin, an ionophore that facilitates transmembrane diffusion of ATP, indicate that the active site of the kinase is on the luminal side of the membranes, However, studies with EDTA and EGTA, which are inhibitory to the kinase, suggest binding sites for Mg2+ and perhaps Ca2+ on the cytosolic membrane face. Phosphorylation of apoB was not stimulated by cAMP nor inhibited by protein kinase inhibitor peptide (5-24), indicating that cAMP dependent protein kinase was not involved in the phosphorylation process, Sodium carbonate treatment of the phosphorylated fraction, which permits separation of membrane and luminal contents, revealed that phosphorylated apoB90 and apoB57 are associated primarily with the membrane, whereas phosphorylated apoB48 is found in luminal contents as well as with the membranes, Phosphorylated apoB100 was found primarily with the membrane fraction, No evidence was found for phosphorylation of apoB in rough endoplasmic reticulum fractions. These studies demonstrate the importance of the Golgi apparatus as a subcellular site for the phosphorylation of apoB and suggest that apoB phosphorylation may be important in the assembly and secretion of apoB-containing lipoproteins.			Swift, LL (corresponding author), VANDERBILT UNIV,MED CTR N,SCH MED,DEPT PATHOL,C-3321,NASHVILLE,TN 37232, USA.							ADELI K, 1994, J BIOL CHEM, V269, P9166; Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; BEG ZH, 1994, J PROTEIN CHEM, V13, P509; BESCH HR, 1977, J BIOL CHEM, V252, P7905; BINGHAM EW, 1972, J BIOL CHEM, V247, P8193; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; CAPASSO JM, 1989, J BIOL CHEM, V264, P5233; CAPASSO JM, 1985, J BIOL CHEM, V260, P4879; CAREY DJ, 1981, J BIOL CHEM, V256, P989; CARTWRIGHT IJ, 1992, BIOCHEM J, V285, P153, DOI 10.1042/bj2850153; DASHTI N, 1989, J LIPID RES, V30, P1365; DAVIS RA, 1984, J BIOL CHEM, V259, P3383; DIXON JL, 1993, J LIPID RES, V34, P167; FARQUHAR MG, 1974, J CELL BIOL, V60, P8, DOI 10.1083/jcb.60.1.8; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GOLDFISC.S, 1971, J HISTOCHEM CYTOCHEM, V19, P349, DOI 10.1177/19.6.349; HIGGINS JA, 1988, FEBS LETT, V232, P405, DOI 10.1016/0014-5793(88)80780-4; HOEG JM, 1988, J LIPID RES, V29, P1215; HUANG G, 1988, BIOCHEMISTRY-US, V27, P1395, DOI 10.1021/bi00405a001; JACKSON TK, 1990, J CLIN INVEST, V86, P1746, DOI 10.1172/JCI114900; LEIGHTON JK, 1990, J LIPID RES, V31, P1663; MOBERLY JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P70, DOI 10.1016/0005-2760(90)90058-6; MORRE DJ, 1969, BIOCHEM BIOPH RES CO, V37, P813; PULLINGER CR, 1989, J LIPID RES, V30, P1065; REUBEN MA, 1988, J LIPID RES, V29, P1337; RINDRESS D, 1993, J BIOL CHEM, V268, P5139; ROSA P, 1992, J BIOL CHEM, V267, P12227; SATO R, 1990, J BIOL CHEM, V265, P11880; SIUTAMANGANO P, 1982, J BIOL CHEM, V257, P1463; SPARKS JD, 1988, J BIOL CHEM, V263, P5001; SWIFT LL, 1995, J LIPID RES, V36, P395; SWIFT LL, 1984, J LIPID RES, V25, P1; VARRO A, 1993, BIOCHEM J, V295, P813, DOI 10.1042/bj2950813; VEGH M, 1994, BBA-PROTEIN STRUCT M, V1205, P49, DOI 10.1016/0167-4838(94)90090-6; WANG CN, 1995, J BIOL CHEM, V270, P24924, DOI 10.1074/jbc.270.42.24924; WANG SY, 1982, J BIOL CHEM, V257, P3837; WEST DW, 1984, BIOCHEM J, V219, P181, DOI 10.1042/bj2190181; WEST DW, 1983, EUR J BIOCHEM, V137, P215, DOI 10.1111/j.1432-1033.1983.tb07817.x; WINDMUELLER HG, 1985, J LIPID RES, V26, P70; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6	43	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31491	31495						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940163				2022-12-27	WOS:A1996VW68600074
J	Eble, JA; Ries, A; Lichy, A; Mann, K; Stanton, H; Gavrilovic, J; Murphy, G; Kuhn, K				Eble, JA; Ries, A; Lichy, A; Mann, K; Stanton, H; Gavrilovic, J; Murphy, G; Kuhn, K			The recognition sites of the integrins alpha(1)beta(1) and alpha(2)beta(1) within collagen IV are protected against gelatinase A attack in the native protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COLLAGEN; POLYMORPHONUCLEAR LEUKOCYTES; PARTIAL-PURIFICATION; ENZYMATIC-PROPERTIES; TUMOR; DOMAIN; MATRIX; PROCOLLAGEN; ACTIVATION; CELLS	The susceptibility of three different solubilized forms of type IV collagen to gelatinase A cleavage and the concomitant effects on cell and integrin binding have been assessed, Dithiothreitol-solubilized Engelbreth-Holm Swarm (EHS) type TV collagen with disrupted intramolecular disulfide bonds in the CE3[N] region was cleaved N-terminally to the CB3[IV] region into the two characteristic 100-300-nm fragments at 30 degrees C and was totally degraded at 37 degrees C. This was reflected in the partial or total loss of the alpha(1) beta(1) and alpha(2) beta(1) integrin binding sites within this region, The ability of gelatinase A to cleave EHS type TV collagen preparations with intact interchain disulfide bonds in CB3[IV] only occurred at higher temperatures. Furthermore, no effect on binding of cells or isolated integrins to the gelatinase-treated collagen could be detected after treatment at 37 degrees C, Dimeric collagen TV of human placenta with intact disulfide bonds in the CB3[IV] region was not degraded at all by gelatinase A at 37 degrees C.	MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY; STRANGEWAYS RES LAB,DEPT CELL & MOL BIOL,CAMBRIDGE CB1 4RN,ENGLAND	Max Planck Society			Mann, Karlheinz/C-4254-2008	Gavrilovic, Jelena/0000-0002-5312-1784; STANTON, HEATHER/0000-0002-3427-5614				BOND MD, 1984, BIOCHEMISTRY-US, V23, P3077, DOI 10.1021/bi00308a035; BRAZEL D, 1988, EUR J BIOCHEM, V172, P35, DOI 10.1111/j.1432-1033.1988.tb13852.x; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; FESSLER LI, 1984, J BIOL CHEM, V259, P9783; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; Kuhn K, 1994, Trends Cell Biol, V4, P256, DOI 10.1016/0962-8924(94)90124-4; KUHN K, 1981, FEBS LETT, V125, P123, DOI 10.1016/0014-5793(81)81012-5; KUHN K, 1994, MATRIX BIOL, V14, P439; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIOTTA LA, 1979, P NATL ACAD SCI USA, V76, P2268, DOI 10.1073/pnas.76.5.2268; LIOTTA LA, 1981, BIOCHEMISTRY-US, V20, P100, DOI 10.1021/bi00504a017; MACKAY AR, 1990, J BIOL CHEM, V265, P21929; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MURPHY G, 1989, BIOCHEM J, V258, P463, DOI 10.1042/bj2580463; MURPHY G, 1982, BIOCHEM J, V203, P209, DOI 10.1042/bj2030209; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; MURPHY G, 1983, COLLAGEN REL RES, V3, P158; OBERBAUMER I, 1982, EMBO J, V1, P805, DOI 10.1002/j.1460-2075.1982.tb01251.x; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; RIES A, 1995, J BIOL CHEM, V270, P23790, DOI 10.1074/jbc.270.40.23790; SALO T, 1983, J BIOL CHEM, V258, P3058; SIEBOLD B, 1988, EUR J BIOCHEM, V176, P617, DOI 10.1111/j.1432-1033.1988.tb14321.x; SIEBOLD B, 1987, EUR J BIOCHEM, V168, P569, DOI 10.1111/j.1432-1033.1987.tb13455.x; STARK M, 1968, EUR J BIOCHEM, V6, P534, DOI 10.1111/j.1432-1033.1968.tb00477.x; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; VANDENBERG P, 1991, J CELL BIOL, V113, P1475, DOI 10.1083/jcb.113.6.1475; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; YURCHENCO PD, 1987, J CELL BIOL, V105, P2559, DOI 10.1083/jcb.105.6.2559	34	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30964	30970		10.1074/jbc.271.48.30964	http://dx.doi.org/10.1074/jbc.271.48.30964			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940084	hybrid			2022-12-27	WOS:A1996VV15800101
J	Graceffa, P; Adam, LP; Morgan, KG				Graceffa, P; Adam, LP; Morgan, KG			Strong interaction between caldesmon and calponin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; LIGHT-CHAIN PHOSPHORYLATION; ACTIVATED PROTEIN-KINASE; KILODALTON ACTIN-BINDING; DISULFIDE CROSS-LINKING; THIN-FILAMENTS; SEQUENCE-ANALYSIS; CHICKEN GIZZARD; H-CALDESMON; C-TERMINUS	Caldesmon was labeled at either Cys-153 in the NH2-terminal domain or Cys-580 in the COOH terminal domain with a 6-acryloyl-2-dimethylaminonaphthalene (acrylodan) fluorescence probe. The addition of smooth muscle calponin to Cys-580-labeled caldesmon resulted in an 18% drop in fluorescence intensity, which titrated with a stoichiometry of 0.9 and a binding constant of 9.5 x 10(7) M(-1). For Cys-153-labeled caldesmon, there was no change in fluorescence upon adding calponin. These findings indicate strong binding between calponin and the COOH-domain of caldesmon. The association was sensitive to ionic strength, suggesting that ionic interactions between calponin, a basic protein, and caldesmon, an acidic protein, contribute to the stabilization of the protein complex. That non-muscle acidic calponin interacts with caldesmon with a much reduced association constant of 3.5 x 10(6) M(-1) supports such a model. The binding between acidic calponin and caldesmon is strengthened to 1.8 x 10(7) M(-1) in the presence of Ca2+, which might bind to acidic residues of the calponin and partially neutralize its negative charge. The strong, specific binding between calponin and caldesmon suggests that this interaction occurs within smooth muscle cells and possibly plays a role in the regulation of contraction.			Graceffa, P (corresponding author), BOSTON BIOMED RES INST,20 STANIFORD ST,BOSTON,MA 02114, USA.			Morgan, Kathleen/0000-0003-3300-3630	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056035] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041637, R01AR030917] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56035] Funding Source: Medline; NIAMS NIH HHS [AR-30917, AR-41637] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAM LP, 1992, FEBS LETT, V302, P223, DOI 10.1016/0014-5793(92)80446-N; ADAM LP, 1993, FEBS LETT, V322, P56, DOI 10.1016/0014-5793(93)81110-L; ADAM LP, 1996, BIOCH SMOOTH MUSCLE, P167; APPLEGATE D, 1994, J BIOL CHEM, V269, P10683; BRYAN J, 1989, J BIOL CHEM, V264, P13873; FURST DO, 1986, EMBO J, V5, P251, DOI 10.1002/j.1460-2075.1986.tb04206.x; GERTHOFFER WT, 1991, AM J PHYSIOL, V261, pL15, DOI 10.1152/ajplung.1991.261.2.L15; GERTHOFFER WT, 1994, CAN J PHYSIOL PHARM, V72, P1410, DOI 10.1139/y94-203; GIMONA M, 1996, BIOCH SMOOTH MUSCLE, P91; GONG BJ, 1993, J BIOCHEM-TOKYO, V114, P453, DOI 10.1093/oxfordjournals.jbchem.a124197; GRABAREK Z, 1995, BIOCHEMISTRY-US, V34, P11872, DOI 10.1021/bi00037a027; GRACEFFA P, 1993, ARCH BIOCHEM BIOPHYS, V307, P21, DOI 10.1006/abbi.1993.1554; GRACEFFA P, 1988, J BIOL CHEM, V263, P14196; GRACEFFA P, 1991, J BIOL CHEM, V266, P20305; GRACEFFA P, 1995, J BIOL CHEM, V270, P30187; GRACEFFA P, 1992, ARCH BIOCHEM BIOPHYS, V297, P46, DOI 10.1016/0003-9861(92)90639-E; GRACEFFA P, 1993, BIOCHEM J, V294, P63, DOI 10.1042/bj2940063; HAEBERLE JR, 1994, CAN J PHYSIOL PHARM, V72, P1400, DOI 10.1139/y94-202; HAEBERLE JR, 1994, J BIOL CHEM, V269, P12424; Horowitz A, 1996, AM J PHYSIOL-HEART C, V270, pH1858, DOI 10.1152/ajpheart.1996.270.5.H1858; ITOH T, 1995, J BIOL CHEM, V270, P20400, DOI 10.1074/jbc.270.35.20400; JAWOROWSKI A, 1995, FEBS LETT, V365, P167, DOI 10.1016/0014-5793(95)00451-E; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KATSUYAMA H, 1992, J BIOL CHEM, V267, P14555; KHALIL RA, 1995, CIRC RES, V76, P1101, DOI 10.1161/01.RES.76.6.1101; LEHMAN W, 1991, J MUSCLE RES CELL M, V12, P221, DOI 10.1007/BF01745110; LEHMAN W, 1987, BIOCHIM BIOPHYS ACTA, V914, P35, DOI 10.1016/0167-4838(87)90158-0; LESZYK J, 1989, BIOCHEM BIOPH RES CO, V160, P1371, DOI 10.1016/S0006-291X(89)80155-X; Mabuchi K, 1996, J MUSCLE RES CELL M, V17, P243, DOI 10.1007/BF00124246; MAKUCH R, 1991, BIOCHEM J, V280, P33, DOI 10.1042/bj2800033; MANI RS, 1996, BIOCH SMOOTH MUSCLE, P105; MARSTON SB, 1991, BIOCHEM J, V279, P1; MORNET D, 1988, BIOCHEM BIOPH RES CO, V154, P564, DOI 10.1016/0006-291X(88)90177-5; MORRIS EP, 1984, BIOCHEMISTRY-US, V23, P2214, DOI 10.1021/bi00305a018; NORTH AJ, 1994, J CELL SCI, V107, P437; OBARA K, 1996, AM J PHYSIOL, V270, pC461; PARKER CA, 1994, AM J PHYSIOL-CELL PH, V267, pC1262, DOI 10.1152/ajpcell.1994.267.5.C1262; PFITZER G, 1993, P NATL ACAD SCI USA, V90, P5904, DOI 10.1073/pnas.90.13.5904; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; SMALL JV, 1995, BIOESSAYS, V17, P785, DOI 10.1002/bies.950170908; SMALL JV, 1992, EUR J BIOCHEM, V208, P559, DOI 10.1111/j.1432-1033.1992.tb17220.x; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SZAPACENKO A, 1985, FEBS LETT, V192, P9; TAKAHASHI K, 1991, J BIOL CHEM, V266, P13284; VANCOMPERNOLLE K, 1990, FEBS LETT, V274, P146, DOI 10.1016/0014-5793(90)81350-W; VELAZ L, 1989, J BIOL CHEM, V264, P9602; WALSH MP, 1994, CAN J PHYSIOL PHARM, V72, P919, DOI 10.1139/y94-130; WINDER SJ, 1991, ADV EXP MED BIOL, V304, P37; ZHANG YW, 1994, CAN J PHYSIOL PHARM, V72, P1386, DOI 10.1139/y94-200	52	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30336	30339		10.1074/jbc.271.48.30336	http://dx.doi.org/10.1074/jbc.271.48.30336			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939993	hybrid			2022-12-27	WOS:A1996VV15800010
J	Meric, F; Searfoss, AM; Wormington, M; Wolffe, AP				Meric, F; Searfoss, AM; Wormington, M; Wolffe, AP			Masking and unmasking maternal mRNA - The role of polyadenylation, transcription, splicing, and nuclear history	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS OOCYTE MATURATION; MESSENGER-RIBONUCLEOPROTEIN PARTICLES; ACID BINDING-PROTEINS; CYTOPLASMIC POLYADENYLATION; TRANSLATIONAL REGULATION; POLY(A) POLYMERASE; RNA TRANSLATION; SOMATIC-CELLS; FROG OOCYTES; 3' UTR	We establish that masked mRNAs synthesized from exogenous plasmid templates microinjected into the nuclei of Xenopus oocytes are translationally activated (unmasked) on oocyte maturation concomitant with polyadenylation. Synthetic mRNA injected into the cytoplasm of the oocyte is translated over an order of magnitude more efficiently than is the cognate mRNA synthesized in vivo. Both mRNA synthesized in vivo and mRNA microinjected into the oocyte cytoplasm require a cytoplasmic polyadenylation element in the 3'-untranslated region to activate translation on maturation. Although polyadenylation upon oocyte maturation can relieve the translational repression of mRNA synthesized in vivo, the excision of an intron within the nucleus does not relieve repression. We suggest that the translational repression coupled to the transcription process will more effectively repress inappropriate gene expression in the oocyte and offer the potential to achieve a wider range of gene regulation.	NICHHD,MOL EMBRYOL LAB,NIH,BETHESDA,MD 20892; UNIV VIRGINIA,DEPT BIOL,CHARLOTTESVILLE,VA 22903	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Virginia					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017691] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD 17691] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; BACHVAROVA RF, 1992, CELL, V69, P895, DOI 10.1016/0092-8674(92)90606-D; BALLANTYNE S, 1995, RNA, V1, P64; BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; BOUVET P, 1995, J BIOL CHEM, V270, P28297; BRADDOCK M, 1990, CELL, V62, P1123, DOI 10.1016/0092-8674(90)90389-V; BRADDOCK M, 1994, NUCLEIC ACIDS RES, V22, P5255, DOI 10.1093/nar/22.24.5255; BRADDOCK M, 1989, CELL, V58, P269, DOI 10.1016/0092-8674(89)90841-6; BRADDOCK M, 1991, NATURE, V350, P439, DOI 10.1038/350439a0; CONAWAY L, 1985, P NATL ACAD SCI USA, V82, P3949; Davidson E. H., 1986, GENE ACTIVITY EARLY; EVDOKIMOVA VM, 1995, J BIOL CHEM, V270, P3186, DOI 10.1074/jbc.270.7.3186; FOX CA, 1992, EMBO J, V11, P5021, DOI 10.1002/j.1460-2075.1992.tb05609.x; FOX CA, 1990, GENE DEV, V4, P2287, DOI 10.1101/gad.4.12b.2287; GEBAUER F, 1995, MOL CELL BIOL, V15, P1422; GUNKEL N, 1995, NUCLEIC ACIDS RES, V23, P405, DOI 10.1093/nar/23.3.405; Gurdon J.B., 1977, Methods Cell Biol, V16, P125; HAKE LE, 1994, CELL, V79, P617, DOI 10.1016/0092-8674(94)90547-9; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HEASMAN J, 1991, METHOD CELL BIOL, V34, P214; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KICK D, 1987, NUCLEIC ACIDS RES, V15, P4099, DOI 10.1093/nar/15.10.4099; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; MURRAY MT, 1991, J CELL BIOL, V112, P1, DOI 10.1083/jcb.112.1.1; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; RANJAN M, 1993, GENE DEV, V7, P1725, DOI 10.1101/gad.7.9.1725; RICHTER JD, 1984, NATURE, V309, P378, DOI 10.1038/309378a0; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; SALLES FJ, 1992, GENE DEV, V6, P1202, DOI 10.1101/gad.6.7.1202; SHEETS MD, 1995, NATURE, V374, P511, DOI 10.1038/374511a0; SHI YB, 1994, DEV BIOL, V161, P48, DOI 10.1006/dbio.1994.1006; STANDART N, 1994, CURR BIOL, V4, P939, DOI 10.1016/S0960-9822(00)00212-8; Standart Nancy, 1992, Seminars in Developmental Biology, V3, P367; TAFURI SR, 1993, J BIOL CHEM, V268, P24255; TOYODA T, 1992, DEV BIOL, V153, P150, DOI 10.1016/0012-1606(92)90099-3; VARNUM SM, 1990, GENE DEV, V4, P2278, DOI 10.1101/gad.4.12b.2278; WICKENS M, 1992, SEM DEV BIOL, V3, P399; WICKENS MP, 1983, J MOL BIOL, V163, P1, DOI 10.1016/0022-2836(83)90027-X; Wolffe A., 1995, CHROMATIN STRUCTURE; Wolffe AP, 1996, INT J BIOCHEM CELL B, V28, P247, DOI 10.1016/1357-2725(95)00141-7; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; WOODLAND HR, 1979, CELL, V18, P165, DOI 10.1016/0092-8674(79)90365-9; WORMINGTON M, 1994, BIOESSAYS, V16, P533, DOI 10.1002/bies.950160804; WORMINGTON M, 1991, METHOD CELL BIOL, V36, P167; Wormington M, 1996, EMBO J, V15, P900, DOI 10.1002/j.1460-2075.1996.tb00424.x; Wormington M, 1993, CURR OPIN CELL BIOL, V5, P950, DOI 10.1016/0955-0674(93)90075-2	48	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30804	30810		10.1074/jbc.271.48.30804	http://dx.doi.org/10.1074/jbc.271.48.30804			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940061	hybrid			2022-12-27	WOS:A1996VV15800078
J	Mikhailov, VS; Bogenhagen, DF				Mikhailov, VS; Bogenhagen, DF			Termination within oligo(dT) tracts in template DNA by DNA polymerase gamma occurs with formation of a DNA triplex structure and is relieved by mitochondrial single-stranded DNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS; SACCHAROMYCES-CEREVISIAE; SUBSTRATE-SPECIFICITY; 3'->5' EXONUCLEASE; CATALYTIC SUBUNIT; ESCHERICHIA-COLI; KLENOW FRAGMENT; POLYMERIZATION; REPLICATION; IDENTIFICATION	Xenopus laevis DNA polymerase gamma (pol gamma) exhibits low activity on a poly(dT)-oligo(dA) primer-template. We prepared a single-stranded phagemid template containing a dT(41) sequence to test the ability of pol gamma to extend a primer through a defined oligo(dT) tract. pol gamma terminates in the center of this dT,, sequence. This replication arrest is abrogated by addition of single stranded DNA-binding protein or by substitution of 7-deaza-dATP for dATP. These features are consistent with the formation of a T . A*T DNA tripler involving the primer stem. Replication arrest occurs under conditions that permit highly processive DNA synthesis by pol gamma. A similar replication arrest occurs for T7 DNA polymerase, which is also a highly processive DNA polymerase. These results suggest the possibility that DNA tripler formation can occur prior to dissociation of DNA polymerase. Primers with S'-oligo(dA) termini annealed to a template with a longer oligo(dT) tract are not efficiently extended by pol gamma unless single-stranded DNA-binding protein is added. Thus, one of the functions of single-stranded DNA-binding protein in mtDNA maintenance may be to enable pol gamma to successfully replicate through dT-rich sequences.	SUNY STONY BROOK,DEPT PHARMACOL SCI,STONY BROOK,NY 11794; RUSSIAN ACAD SCI,INST DEV BIOL,MOSCOW 117808,RUSSIA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Russian Academy of Sciences; Koltzov Institute of Developmental Biology of the Russian Academy of Sciences			Mikhailov, Victor S/O-2063-2016		NIGMS NIH HHS [GM29681] Funding Source: Medline; PHS HHS [04068] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029681] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARAN N, 1991, P NATL ACAD SCI USA, V88, P507, DOI 10.1073/pnas.88.2.507; BEESE LS, 1993, BIOCHEMISTRY-US, V32, P14095, DOI 10.1021/bi00214a004; BOGENHAGEN D, 1979, COLD SPRING HARB SYM, V43, P253, DOI 10.1101/SQB.1979.043.01.031; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; CURTH U, 1994, EUR J BIOCHEM, V221, P435, DOI 10.1111/j.1432-1033.1994.tb18756.x; DAYN A, 1992, P NATL ACAD SCI USA, V89, P11406, DOI 10.1073/pnas.89.23.11406; FOURY F, 1989, J BIOL CHEM, V264, P20552; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; GHRIR R, 1991, ARCH BIOCHEM BIOPHYS, V291, P395, DOI 10.1016/0003-9861(91)90152-9; GRAY H, 1992, J BIOL CHEM, V267, P5835; HACIA JG, 1994, BIOCHEMISTRY-US, V33, P6192, DOI 10.1021/bi00186a019; HOKE GD, 1990, ARCH BIOCHEM BIOPHYS, V282, P116, DOI 10.1016/0003-9861(90)90094-F; INSDORF NF, 1989, J BIOL CHEM, V264, P21498; INSDORF NF, 1989, J BIOL CHEM, V264, P21491; Kornberg A., 1992, DNA REPLICATION; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; LAPIDOT A, 1989, NUCLEIC ACIDS RES, V17, P883, DOI 10.1093/nar/17.3.883; LONGLEY MJ, 1991, J BIOL CHEM, V266, P24702; MIGNOTTE B, 1988, EUR J BIOCHEM, V174, P479, DOI 10.1111/j.1432-1033.1988.tb14123.x; Mikhailov VS, 1996, J BIOL CHEM, V271, P18939, DOI 10.1074/jbc.271.31.18939; OLSON MW, 1992, J BIOL CHEM, V267, P23136; ROPP PA, 1995, GENE, V165, P103, DOI 10.1016/0378-1119(95)00412-Y; SAMADASHWILY GM, 1993, EMBO J, V12, P4975, DOI 10.1002/j.1460-2075.1993.tb06191.x; SAMADASHWILY GM, 1994, GENE, V149, P127, DOI 10.1016/0378-1119(94)90421-9; Sambrook J., 2002, MOL CLONING LAB MANU; THOMMES P, 1995, J BIOL CHEM, V270, P21137, DOI 10.1074/jbc.270.36.21137; TIRANTI V, 1991, NUCLEIC ACIDS RES, V19, P4291, DOI 10.1093/nar/19.15.4291; TIRANTI V, 1993, GENE, V126, P219, DOI 10.1016/0378-1119(93)90370-I; VANDYCK E, 1992, EMBO J, V11, P3421, DOI 10.1002/j.1460-2075.1992.tb05421.x; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P860, DOI 10.1074/jbc.270.2.860; Ye F, 1996, NUCLEIC ACIDS RES, V24, P1481, DOI 10.1093/nar/24.8.1481	33	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30774	30780		10.1074/jbc.271.48.30774	http://dx.doi.org/10.1074/jbc.271.48.30774			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940057	hybrid			2022-12-27	WOS:A1996VV15800074
J	Malik, RK; Parsons, JT				Malik, RK; Parsons, JT			Integrin-dependent activation of the p70 ribosomal S6 kinase signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; FOCAL ADHESION KINASE; EXTRACELLULAR-MATRIX; CELL-ADHESION; PHOSPHATIDYLINOSITOL 3-KINASE; MESSENGER-RNA; MAMMALIAN PROTEIN; RAPAMYCIN; TRANSDUCTION; PP125(FAK)	Interaction of the cell surface integrin receptors with extracellular matrix proteins results in the activation of intracellular signaling pathways, including activation of the p42/p44 mitogen-activated protein kinases. The protein tyrosine kinase focal adhesion kinase, or FAK, is linked to integrin signaling and interacts with several molecules involved in signal transduction, Here we report that exposure of fibroblast cells to extracellular matrix proteins activates the p70/p85 ribosomal S6 kinase (S6K) pathway in a ligand dependent manner. Treatment of cells with inhibitors of phosphatidylinositol 3-kinase, or FRAP (FKBP 12/rapamycin-associated protein) blocks integrin-mediated activation of S6K. In contrast to the integrin-directed activation of the mitogen-activated protein kinases, cytochalasin D treatment does not inhibit S6K activation, Treatment with the protein tyrosine kinase inhibitors herbimycin A and genistein completely blocks S6K activation, indicating a requirement for tyrosine kinase activity. Overexpression of the COOH-terminal noncatalytic domain of FAK, FRNK (FAK-related non-kinase) in chick embryo cells results in a significant reduction in the integrin-mediated activation of S6K and a concomitant reduction in FAK tyrosine phosphorylation, These results indicate at least a partial requirement for FAK in the S6K activation pathway.	UNIV VIRGINIA,HLTH SCI CTR,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT PEDIAT,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia					NCI NIH HHS [CA29243, CA40042] Funding Source: Medline; NICHD NIH HHS [HD-28810] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028810] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R37CA029243, R01CA029243] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JC, 1993, DEVELOPMENT, V117, P1183; ALBELDA SM, 1993, LAB INVEST, V68, P4; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BLAU HM, 1991, J CELL BIOL, V112, P781, DOI 10.1083/jcb.112.5.781; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; BRYANT DL, 1984, MOL CELL BIOL, V4, P862, DOI 10.1128/MCB.4.5.862; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; DESIMONE DW, 1994, CURR OPIN CELL BIOL, V6, P747, DOI 10.1016/0955-0674(94)90103-1; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LANE HA, 1992, EMBO J, V11, P1743, DOI 10.1002/j.1460-2075.1992.tb05226.x; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LATHAM VM, 1994, J CELL BIOL, V126, P1211, DOI 10.1083/jcb.126.5.1211; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	51	52	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29785	29791		10.1074/jbc.271.47.29785	http://dx.doi.org/10.1074/jbc.271.47.29785			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939916	hybrid			2022-12-27	WOS:A1996VU52500044
J	Nagata, K; Ohashi, K; Nakano, T; Arita, H; Zong, C; Hanafusa, H; Mizuno, K				Nagata, K; Ohashi, K; Nakano, T; Arita, H; Zong, C; Hanafusa, H; Mizuno, K			Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; IGG FUSION PROTEINS; EXPRESSION ANALYSIS; V-RYK; C-MER; CLONING; BRAIN; FAMILY; GAS6; PROTOONCOGENE	Axl, Sky, and Mer, members of an Axl/Sky receptor tyrosine kinase subfamily, are typified by the cell adhesion molecule-related extracellular domain. The product of growth arrest-specific gene 6 (Gas6), structurally homologous to the anticoagulant protein S, was recently identified as the ligand for Axl and Sky, but the ligand for Mer remained unknown. We have now obtained evidence that Gas6 can also function as a ligand for Mer, Go-precipitation analysis, using soluble receptors of Axl, Sky, and Mer (Axl-Fc, Sky-Fc, and Mer-Fc) composed of the extracellular domain of receptors fused to the Fc domain of immunoglobulin G1, clearly showed that Case, but not protein S, specifically bound to Axl-Fc, Sky-Fc, and Mer-Fc fusion proteins, Quantitative kinetic analyses using a BIAcore biosensor instrument revealed dissociation constants (K-d) of the binding of rat Gas6 to Axl-Fc, Sky-Fc, and Mer-Fc are 0.4, 2.7, and 29 nM, respectively. We also found that Gas6 stimulated tyrosine phosphorylation of Axl, Sky, and Mer receptors ectopically expressed in Chinese hamster ovary cells. Taken together, these findings suggest that Gas6 is a common ligand for Axl, Sky, and Mer, all known members of an Axl/Sky receptor subfamily.	KYUSHU UNIV,FAC SCI,DEPT BIOL,FUKUOKA 81281,JAPAN; SHIONOGI & CO LTD,SHIONOGI RES LABS,OSAKA 553,JAPAN; ROCKEFELLER UNIV,MOL ONCOL LAB,NEW YORK,NY 10021	Kyushu University; Shionogi & Company Limited; Rockefeller University			Ohashi, Kazumasa/U-7028-2019; Mizuno, Kensaku/G-8631-2015	Ohashi, Kazumasa/0000-0001-7617-403X; 	NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER; NCI NIH HHS [CA44356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barbacid M, 1995, ANN NY ACAD SCI, V766, P442, DOI 10.1111/j.1749-6632.1995.tb26693.x; BENNETT BD, 1991, J BIOL CHEM, V266, P23060; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Friedman GC, 1996, CURR OPIN NEUROBIOL, V6, P127, DOI 10.1016/S0959-4388(96)80018-3; FUJIMOTO J, 1994, ONCOGENE, V9, P693; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GODOWSKI PJ, 1995, CELL, V82, P355, DOI 10.1016/0092-8674(95)90424-7; Goruppi S, 1996, ONCOGENE, V12, P471; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; GRAHAM DK, 1995, ONCOGENE, V10, P2349; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JIA R, 1992, J VIROL, V66, P5975, DOI 10.1128/JVI.66.10.5975-5987.1992; JIA R, 1994, J BIOL CHEM, V269, P1839; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; LAI C, 1994, ONCOGENE, V9, P2567; LING L, 1995, MOL CELL BIOL, V15, P6582; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MARK MR, 1992, J BIOL CHEM, V267, P26166; MARK MR, 1994, J BIOL CHEM, V269, P10720; NAKANO T, 1995, J BIOL CHEM, V270, P5702, DOI 10.1074/jbc.270.11.5702; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1995, J BIOCHEM, V117, P1267, DOI 10.1093/oxfordjournals.jbchem.a124854; OHASHI K, 1994, ONCOGENE, V9, P699; OHASHI K, 1995, J BIOL CHEM, V270, P22681, DOI 10.1074/jbc.270.39.22681; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; RESCIGNO J, 1991, ONCOGENE, V6, P1909; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; SUZUKI K, 1983, J BIOCHEM-TOKYO, V94, P699, DOI 10.1093/oxfordjournals.jbchem.a134409; TAYLOR ICA, 1995, J BIOL CHEM, V270, P6872, DOI 10.1074/jbc.270.12.6872; Toshima J, 1995, J BIOL CHEM, V270, P31331, DOI 10.1074/jbc.270.52.31331; TOSHIMA J, 1995, BIOCHEM BIOPH RES CO, V209, P656, DOI 10.1006/bbrc.1995.1549; TSUKAMOTO T, 1995, NAT GENET, V11, P395, DOI 10.1038/ng1295-395; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0	37	399	424	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30022	30027		10.1074/jbc.271.47.30022	http://dx.doi.org/10.1074/jbc.271.47.30022			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939948	hybrid			2022-12-27	WOS:A1996VU52500076
J	Pastorino, JG; Simbula, G; Yamamoto, K; Glascott, PA; Rothman, RJ; Farber, JL				Pastorino, JG; Simbula, G; Yamamoto, K; Glascott, PA; Rothman, RJ; Farber, JL			The cytotoxicity of tumor necrosis factor depends on induction of the mitochondrial permeability transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED-HEPATOCYTES; PHOSPHOLIPASE-C; CYCLOSPORINE-A; BENZODIAZEPINE RECEPTOR; DUAL ROLE; INHIBITION; MEMBRANE; TRANSPORT; CELLS; PORE	Complete prevention of the killing of L929 fibroblasts by tumor necrosis factor alpha (TNF) in the presence of 0.5 mu g/ml actinomycin D (ActD) was obtained with cyclosporin A (CyA), an inhibitor of the mitochondrial permeability transition (MPT), and aristolochic acid (ArA), a phospholipase A(2) inhibitor, Peripheral benzodiazepine receptor (PBzR) agonists (PK11195, FGIN 1-27, or chlorodiazepam), agents known to potentiate induction of the MPT, potentiated the cytotoxicity of TNF in the absence of ActD, an effect prevented by CyA plus ArA, The MPT was demonstrated independently of its effect on viability as the CyA-sensitive loss of rhodamine 123 fluorescence from cells preloaded with the dye, Treatment with TNF and ActD resulted in the loss of 80% of rhodamine fluorescence within 6 h, a time prior to any loss of viability, CyA plus ArA completely prevented this effect of TNF, Potentiation of the cytotoxicity of TNF by PBzR agonists was associated with induction of the MPT, as assessed by the loss of rhodamine fluorescence, CyA plus ArA completely prevented the loss of rhodamine 123, Ceramide replaced TNF in killing L929 fibroblasts, an effect also prevented by CyA plus Ark Ceramide in the presence of ActD resulted in the loss of rhodamine fluorescence, an effect that was again prevented by CyA plus ArA. In addition, CyA plus ArA prevented the ability of PBzR agonists to potentiate the cytotoxicity of ceramide, In the presence of each PBzR agonist, ceramide caused the loss of rhodamine fluorescence, an effect completely prevented by CyA plus ArA. D609, an inhibitor of phosphatidylcholine-specific phospholipase C, completely prevented the killing by TNF, but not by ceramide, in the presence of ActD, D609 prevented induction of the MPT occurring with TNF, but not with ceramide. Inhibitors of endocytosis, as well as lysosomotropic amines, prevented the cytotoxicity of TNF, but not that of ceramide, It is concluded that the MPT is causally linked to the genesis of irreversible cell injury with TNF, In the face of an inhibition of protein synthesis, the MPT occurs as a consequence of the formation of ceramide.	THOMAS JEFFERSON UNIV,DEPT PATHOL,PHILADELPHIA,PA 19107	Jefferson University			Simbula, Gabriella/AAN-4390-2020	Simbula, Gabriella/0000-0003-4946-532X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038305] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-38305] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANHOLT RRH, 1986, J BIOL CHEM, V261, P576; ARRIGONI E, 1987, BIOCHEM PHARMACOL, V36, P3697, DOI 10.1016/0006-2952(87)90022-0; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BASILE AS, 1986, J NEUROCHEM, V46, P305, DOI 10.1111/j.1471-4159.1986.tb12965.x; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; BEYAERT R, 1994, FEBS LETT, V340, P91; BIGDA J, 1994, J EXP MED, V180, P445, DOI 10.1084/jem.180.2.445; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; BROEKEMEIER KM, 1989, BIOCHEM BIOPH RES CO, V163, P561, DOI 10.1016/0006-291X(89)92174-8; CROMPTON M, 1988, BIOCHEM J, V255, P357; DAS SK, 1987, BIOCHEM PHARMACOL, V36, P2221, DOI 10.1016/0006-2952(87)90154-7; GLASCOTT PA, 1992, MOL PHARMACOL, V41, P1155; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Goossens V, 1996, J BIOL CHEM, V271, P192, DOI 10.1074/jbc.271.1.192; GROOTEN J, 1993, CYTOKINE, V5, P546, DOI 10.1016/S1043-4666(05)80003-1; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; KOHLER T, 1991, AGENTS ACTIONS, V32, P70; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LANCASTER JR, 1989, FEBS LETT, V248, P169, DOI 10.1016/0014-5793(89)80454-5; MATTHEWS N, 1983, BRIT J CANCER, V48, P405, DOI 10.1038/bjc.1983.205; MATTHEWS N, 1987, IMMUNOLOGY, V62, P153; MCENERY MW, 1992, J BIOENERG BIOMEMBR, V24, P63, DOI 10.1007/BF00769532; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MIZUMOTO K, 1994, MOL PHARMACOL, V46, P890; MULLERDECKER K, 1989, BIOCHEM BIOPH RES CO, V162, P198, DOI 10.1016/0006-291X(89)91981-5; OBEIRNE GB, 1990, EUR J BIOCHEM, V188, P131, DOI 10.1111/j.1432-1033.1990.tb15380.x; PASTORINO JG, 1994, J BIOL CHEM, V269, P31041; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; PASTORINO JG, 1995, AM J PHYSIOL-CELL PH, V268, pC676, DOI 10.1152/ajpcell.1995.268.3.C676; ROMEO E, 1992, J PHARMACOL EXP THER, V262, P971; RUFF MR, 1981, INFECT IMMUN, V31, P380, DOI 10.1128/IAI.31.1.380-385.1981; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SNYDER JW, 1992, BIOCHEM PHARMACOL, V44, P833, DOI 10.1016/0006-2952(92)90425-I; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VERMA A, 1988, MOL PHARMACOL, V34, P800; VISHWANATH BS, 1988, INFLAMMATION, V12, P549, DOI 10.1007/BF00914317; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WONG GHW, 1989, CELL, V58, P924; YAMAUCHI N, 1989, CANCER RES, V49, P1671; ZIMMERMAN RJ, 1989, CANCER RES, V49, P1644; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	48	242	247	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29792	29798		10.1074/jbc.271.47.29792	http://dx.doi.org/10.1074/jbc.271.47.29792			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939917	hybrid			2022-12-27	WOS:A1996VU52500045
J	Putkey, JA; Waxham, MN				Putkey, JA; Waxham, MN			A peptide model for calmodulin trapping by calcium/calmodulin-dependent protein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY PROTEIN; CA-2+ CALMODULIN; AUTOPHOSPHORYLATION SITES; BINDING; EXPRESSION; PHOSPHORYLATION; INHIBITION; SUBUNIT; MUTAGENESIS; MECHANISM	Autophosphorylation of Ca2+/calmodulin-dependent protein kinase II (CaM-kinase) induces a more than 1000-fold increase in calmodulin (CaM)-binding affinity by dramatically decreasing the off-rate for CaM. In this report, we investigate the molecular mechanism for this phenomenon by comparing the rate of dissociation of a novel fluorescently labeled CaM from two synthetic peptides and from the phosphorylated and nonphosphorylated forms of a recombinant preparation of CaM-kinase, Dissociation of a complex of CaM and CKII(296-312), a peptide representing close to the minimum CaM-binding domain of the alpha subunit of CaM-kinase, exhibited a fast off-rate of 5.0 s(-1). This was similar to the off-rate of 1.1 s(-1) for the dissociation of CaM from the nonphosphorylated form of CaM kinase. In contrast, dissociation of CaM from either autophosphorylated CaM-kinase or peptide CKII(290-314) was extremely slow with apparent off-rates of about 3-9x10(-5) s(-1). Along with information from the crystal structure of Ca2+/CaM bound to CKII(290-314) (Meador, W. E., Means, A. R., and Quiocho, F. A. (1993) Science 262, 1718-1721), our results suggest a model in which CaM-dependent autophosphorylation of CaM-kinase induces a conformational change in the region of the CaM-binding domain which allows the formation of additional stabilizing interactions with CaM, We predict that this involves amino acids 293-298 in CaM-kinase. The possible consequences of these observations on the reversibility of CaM trapping in native CaM-kinase are discussed.	UNIV TEXAS, SCH MED, DEPT BIOCHEM & MOL BIOL, HOUSTON, TX 77225 USA	University of Texas System	Putkey, JA (corresponding author), UNIV TEXAS, SCH MED, DEPT NEUROBIOL & ANAT, POB 20708, HOUSTON, TX 77225 USA.			Waxham, M. Neal/0000-0003-4801-1190	NHLBI NIH HHS [HL-45724] Funding Source: Medline; NINDS NIH HHS [NS-01509, NS-26086] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045724] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026086, K04NS001509, R56NS026086] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; COLBRAN RJ, 1988, J BIOL CHEM, V263, P18145; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; COLBRAN RJ, 1993, J BIOL CHEM, V268, P7163; COLBRAN RJ, 1990, J BIOL CHEM, V265, P11213; FONG YL, 1989, J BIOL CHEM, V264, P16759; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HANSON PI, 1992, J BIOL CHEM, V267, P17216; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Hudmon A, 1996, J BIOL CHEM, V271, P8800, DOI 10.1074/jbc.271.15.8800; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KELLY PT, 1988, P NATL ACAD SCI USA, V85, P4991, DOI 10.1073/pnas.85.14.4991; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; KWIATKOWSKI AP, 1989, BIOCHEMISTRY-US, V28, P5380, DOI 10.1021/bi00439a010; LOU LL, 1989, J NEUROSCI, V9, P2020; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MUKHERJI S, 1994, J BIOL CHEM, V269, P13744; PATTON BL, 1990, J BIOL CHEM, V265, P11204; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PUTKEY JA, 1987, METHOD ENZYMOL, V139, P303; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; SAITOH T, 1985, J CELL BIOL, V100, P835, DOI 10.1083/jcb.100.3.835; SHATZMAN AR, 1986, ANN NY ACAD SCI, V478, P233, DOI 10.1111/j.1749-6632.1986.tb15534.x; WAXHAM MN, 1990, P NATL ACAD SCI USA, V87, P1273, DOI 10.1073/pnas.87.4.1273; YAMAGATA Y, 1991, J BIOL CHEM, V266, P15391	31	75	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29619	29623		10.1074/jbc.271.47.29619	http://dx.doi.org/10.1074/jbc.271.47.29619			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939892	hybrid			2022-12-27	WOS:A1996VU52500020
J	Tirumalai, RS; Pargellis, CA; Landy, A				Tirumalai, RS; Pargellis, CA; Landy, A			Identification and characterization of the N-ethylmaleimide-sensitive site in lambda-integrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INT GENE-PRODUCT; BACTERIOPHAGE-LAMBDA; POLYACRYLAMIDE-GEL; PROTEIN; RECOMBINATION; SEQUENCE; DNA; BINDING; ELECTROPHORESIS; REGIONS	Integrase (Int) of bacteriophage lambda is a heterobivalent DNA binding protein and a type I topoisomerase. Upon modification with N-ethylmaleimide (NEM), a sulfhydryl-directed reagent, Int loses its capacity to bind ''arm-type'' DNA sequences and, consequently, to carry out recombination; however, its ability to bind ''core-type'' sequences and its topoisomerase activity are unaffected, In this report, the NEM-sensitive site was identified by modifying Int with [C-14]NEM. Following cleavage by formic acid, which cleaves Asp-Pro bonds, and fractionation on a Fractogel HW-50 (F) sizing column, the fragment containing the primary site of [C-14]NEM incorporation was subjected to amino acid sequencing. The results indicate that the primary site of [C-14]NEM incorporation is in the peptide-spanning amino acid residues 1-28, which contains a cysteine at position 25. To confirm that Cys-25 is the target of NEM reactivity, site-directed mutagenesis was used to change this cysteine to alanine or serine. The mutant protein is not chemically modified by NEM and shows no loss of activity after NEM treatment. The fact that C25A and C25S both retain full recombination activity indicates that the SH group of Cys-25 does not provide any critical contacts, either with arm-type DNA or with other parts of the Int protein to form the arm-type recognition pocket. The loss of arm-type DNA binding and the con-comitant loss of recombination function as a result of NEM modification must be due to the presence of the maleimide moiety and not due to loss of a critical cysteine contact.	BROWN UNIV,DIV BIOL & MED,PROVIDENCE,RI 02912; BOEHRINGER INGELHEIM PHARMACEUT INC,RIDGEFIELD,CT 06877	Brown University; Boehringer Ingelheim					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI013544, R01AI013544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033928] Funding Source: NIH RePORTER; NIAID NIH HHS [AI13544] Funding Source: Medline; NIGMS NIH HHS [GM33928] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES GFL, 1974, J BIOL CHEM, V249, P634; BETTER M, 1982, P NATL ACAD SCI-BIOL, V79, P5837, DOI 10.1073/pnas.79.19.5837; BONNER WM, 1984, METHOD ENZYMOL, V104, P460; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWER CF, 1967, ANAL BIOCHEM, V18, P248, DOI 10.1016/0003-2697(67)90007-3; CRAIG NL, 1988, ANNU REV GENET, V22, P77; DEVARGAS LM, 1988, CELL, V54, P923, DOI 10.1016/0092-8674(88)90107-9; GORIN G, 1966, ARCH BIOCHEM BIOPHYS, V115, P593, DOI 10.1016/0003-9861(66)90079-8; GREGORY JD, 1955, J AM CHEM SOC, V77, P3922, DOI 10.1021/ja01619a073; HAN YPW, 1994, J MOL BIOL, V235, P908, DOI 10.1006/jmbi.1994.1048; HOESS RH, 1980, P NATL ACAD SCI-BIOL, V77, P2482, DOI 10.1073/pnas.77.5.2482; KIKUCHI Y, 1979, P NATL ACAD SCI USA, V76, P3760, DOI 10.1073/pnas.76.8.3760; KIKUCHI Y, 1978, J BIOL CHEM, V253, P7149; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; Mizuuchi K, 1981, Cold Spring Harb Symp Quant Biol, V45 Pt 1, P429; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; PISZKIEW.D, 1970, BIOCHEM BIOPH RES CO, V40, P1173, DOI 10.1016/0006-291X(70)90918-6; ROSS W, 1983, CELL, V33, P261, DOI 10.1016/0092-8674(83)90355-0; ROSS W, 1982, P NATL ACAD SCI-BIOL, V79, P7724, DOI 10.1073/pnas.79.24.7724; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNETGER J, 1966, THESIS U FRANKFURT G; Smyth DG, 1960, J AM CHEM SOC, V82, P4600, DOI 10.1021/ja01502a039; SMYTH DG, 1964, BIOCHEM J, V91, P589, DOI 10.1042/bj0910589; SWANK RT, 1971, ANAL BIOCHEM, V39, P462, DOI 10.1016/0003-2697(71)90436-2; THOMPSON JF, 1987, J MOL BIOL, V195, P481, DOI 10.1016/0022-2836(87)90177-X	25	12	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29599	29604		10.1074/jbc.271.47.29599	http://dx.doi.org/10.1074/jbc.271.47.29599			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939889	hybrid			2022-12-27	WOS:A1996VU52500017
J	Zhuang, SB; Mabuchi, K; Wang, CLA				Zhuang, SB; Mabuchi, K; Wang, CLA			Heat treatment could affect the biochemical properties of caldesmon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CALDESMON; LIGHT CHAIN KINASE; THIN-FILAMENTS; ACTIN-TROPOMYOSIN; CHICKEN GIZZARD; MYOSIN INTERACTION; MOLECULAR-WEIGHT; CA-2+ REGULATION; BINDING PROTEIN; F-ACTIN	Smooth muscle caldesmon (CaD) exhibits apparent heat stability, A widely used purification procedure of CaD involves extensive heat treatment (Bretscher, A. (1984) J. Biol. Chem. 259, 12873-12880). CaD thus purified co-sediments with actin, inhibits actomyosin ATPase activity, and interacts with Ca2+/calmodulin, similarly to the unheated protein, On the other hand, heat-treated CaD binds to actin filaments in a tether-like fashion, whereas lengthwise binding dominates in vivo (Mabuchi, K., Lin, J. J.-C., and Wang, C.-L. A. (1993) J. Muscle Res. Cell Motil. 14, 54-64), suggesting that differences do exist between heat purified CaD and the native protein, We have isolated, without heat treatment, full-length recombinant chicken gizzard CaD overexpressed in insect cells (High-Five(TM)) using a baculovirus expression system, We found that such unheated CaD interacts with calmodulin 10 times stronger than does the heated CaD; its inhibitory action on actomyosin ATPase is reversed by a much lesser amount of calmodulin. Moreover, electron microscopic examination indicated that actin binding at the N-terminal region is more frequent in the unheated CaD, resulting in more lengthwise binding. These findings point to the fact that CaD is not entirely heat-stable; the C-terminal CaM-binding regions and the N-terminal actin binding region are possibly affected by heat treatment.	BOSTON BIOMED RES INST, MUSCLE RES GRP, BOSTON, MA 02114 USA	Boston Biomedical Research Institute					NIAMS NIH HHS [P01-AR41637] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041637] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; DEDMAN JR, 1983, METHOD ENZYMOL, V102, P1; Fiske CH, 1925, J BIOL CHEM, V66, P375; GRACEFFA P, 1993, ARCH BIOCHEM BIOPHYS, V307, P21, DOI 10.1006/abbi.1993.1554; GRACEFFA P, 1988, J BIOL CHEM, V263, P14196; GRACEFFA P, 1987, FEBS LETT, V218, P139, DOI 10.1016/0014-5793(87)81034-7; IKEBE M, 1978, J BIOCHEM, V83, P1643, DOI 10.1093/oxfordjournals.jbchem.a132077; KASTURI R, 1993, J BIOL CHEM, V268, P7958; KATAYAMA E, 1995, BIOPHYS J, V68, P2419, DOI 10.1016/S0006-3495(95)80424-8; KATSUYAMA H, 1992, J BIOL CHEM, V267, P14555; LEHMAN W, 1989, J MUSCLE RES CELL M, V10, P101, DOI 10.1007/BF01739966; LIN JJC, 1991, CELL MOTIL CYTOSKEL, V20, P95, DOI 10.1002/cm.970200203; LYNCH W, 1986, METHOD ENZYMOL, V134, P37; MABUCHI K, 1991, J STRUCT BIOL, V107, P22, DOI 10.1016/1047-8477(91)90027-T; MABUCHI K, 1993, J MUSCLE RES CELL M, V14, P54, DOI 10.1007/BF00132180; MALENCIK DA, 1989, BIOCHEMISTRY-US, V28, P8227, DOI 10.1021/bi00446a039; MARSTON SB, 1994, J BIOL CHEM, V269, P32104; MARSTON SB, 1991, BIOCHEM J, V279, P1; Matsumura F, 1993, CURR OPIN CELL BIOL, V5, P70, DOI 10.1016/S0955-0674(05)80010-9; MOODY C, 1990, J MUSCLE RES CELL M, V11, P176, DOI 10.1007/BF01766496; MORRIS EP, 1984, BIOCHEMISTRY-US, V23, P2214, DOI 10.1021/bi00305a018; NGAI PK, 1984, J BIOL CHEM, V259, P3656; NOMURA M, 1987, BIOCHEM BIOPH RES CO, V144, P936, DOI 10.1016/S0006-291X(87)80054-2; PHILLIPS JE, 1994, J BIOL CHEM, V269, P16696; PRITCHARD K, 1989, BIOCHEM J, V257, P839, DOI 10.1042/bj2570839; PRITCHARD K, 1988, SARCOMERIC NONSARCOM, P649; SHIRINSKY VP, 1988, BIOCHEM J, V255, P203; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SMITH CWJ, 1985, FEBS LETT, V184, P115, DOI 10.1016/0014-5793(85)80665-7; SOBUE K, 1982, BIOMED RES-TOKYO, V3, P188, DOI 10.2220/biomedres.3.188; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SOBUE K, 1985, BIOCHEM BIOPH RES CO, V132, P645, DOI 10.1016/0006-291X(85)91181-7; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; WALSH MP, 1983, METHOD ENZYMOL, V99, P279; WANG CLA, 1991, J BIOL CHEM, V266, P13958; WANG CLA, 1988, BIOCHEM BIOPH RES CO, V156, P1033, DOI 10.1016/S0006-291X(88)80948-3; WANG Z, 1994, J MUSCLE RES CELL M, V15, P646, DOI 10.1007/BF00121072; ZHAN Q, 1991, J BIOL CHEM, V266, P21810; ZHUANG SB, 1995, J BIOL CHEM, V270, P19964, DOI 10.1074/jbc.270.34.19964	40	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30242	30248		10.1074/jbc.271.47.30242	http://dx.doi.org/10.1074/jbc.271.47.30242			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939977	hybrid			2022-12-27	WOS:A1996VU52500105
J	Akiyama, T; Hogan, ME				Akiyama, T; Hogan, ME			Microscopic DNA flexibility analysis - Probing the base composition and ion dependence of minor groove compression with an artificial DNA bending agent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-HELIX FORMATION; 434 REPRESSOR; AFFINITY; OPERATOR; BINDING; THERMODYNAMICS; COMPLEXES; TETRAPLEX	We have used an artificial DNA bending agent to monitor the local. flexibility of the DNA helix as a function of Mg2+ cation concentration, sequence, and temperature. A DNA bending agent was constructed from a pair of triple helix-forming oligonucleotides connected by a flexible polymeric linker, which, when the Linker is short enough, causes a bend in a minor groove region separating the two sites of triple helix formation. The unique aspect of this system is that, since the bent region is not in direct contact with the linker or the triple helix-forming oligonucleotides, the free energy reflecting the bendability of the minor helix groove can be estimated from a comparison of binding affinity between the bent and unbent triple helices. A binding competition experiment and association and dissociation kinetic assays executed at 37 degrees C in the presence of 10 man Mg2+ have revealed an extremely small difference in binding affinity between bent (50 degrees) and straight triple helices, suggesting that DNA flexibility with respect to minor groove compression is extremely high and virtually independent of the sequence of the distorted duplex. This unexpectedly small difference in binding affinity was detected over the temperature range from 25 to 65 degrees C, and over a Mg2+ concentration range from 0.3 to 10 mM. Thus, these findings provide evidence that DNA bendability for minor groove compression is inherently high and independent of DNA sequence, temperature, or a 30-fold variation of Mg2+ ion concentration.	BAYLOR COLL MED,DEPT MOL PHYSIOL & BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine								AKIYAMA T, 1996, IN PRESS P NATL ACAD; ANDERSON JE, 1987, NATURE, V326, P846, DOI 10.1038/326846a0; BALDWIN JP, 1975, NATURE, V253, P245, DOI 10.1038/253245a0; BARKLEY MD, 1979, J CHEM PHYS, V70, P2991, DOI 10.1063/1.437838; BURLINGAME RW, 1985, SCIENCE, V228, P546, DOI 10.1126/science.3983639; CHEN HH, 1978, J BIOMOL STRUCT DYN, V2, P709; CLOAD ST, 1993, J AM CHEM SOC, V115, P5005, DOI 10.1021/ja00065a008; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DURLAND RH, 1991, BIOCHEMISTRY-US, V30, P9246, DOI 10.1021/bi00102a017; GARTENBERG MR, 1988, NATURE, V333, P824, DOI 10.1038/333824a0; GRAY HB, 1968, J MOL BIOL, V35, P111, DOI 10.1016/S0022-2836(68)80041-5; HARRINGTON RE, 1978, BIOPOLYMERS, V17, P919, DOI 10.1002/bip.1978.360170410; HOGAN M, 1983, NATURE, V304, P752, DOI 10.1038/304752a0; HOGAN ME, 1987, NATURE, V329, P263, DOI 10.1038/329263a0; JIN R, 1990, SCIENCE, V250, P543, DOI 10.1126/science.2237404; JIN RZ, 1992, P NATL ACAD SCI USA, V89, P8832, DOI 10.1073/pnas.89.18.8832; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; KORNBERG RD, 1974, SCIENCE, V184, P868, DOI 10.1126/science.184.4139.868; KOUDELKA GB, 1987, NATURE, V326, P886, DOI 10.1038/326886a0; KOUDELKA GB, 1992, NATURE, V355, P89, DOI 10.1038/355089a0; KOUDELKA GB, 1988, P NATL ACAD SCI USA, V85, P4633, DOI 10.1073/pnas.85.13.4633; KOVACIC RT, 1977, BIOCHEMISTRY-US, V16, P1490, DOI 10.1021/bi00626a038; LEVENE SD, 1986, J MOL BIOL, V189, P61, DOI 10.1016/0022-2836(86)90381-5; MAHER LJ, 1990, BIOCHEMISTRY-US, V29, P8820, DOI 10.1021/bi00489a045; Maniatis T, 1989, DECONTAMINATION DILU; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; MARINI JC, 1982, P NATL ACAD SCI-BIOL, V79, P7664, DOI 10.1073/pnas.79.24.7664; NOONBERG SB, 1995, NUCLEIC ACIDS RES, V23, P1956, DOI 10.1093/nar/23.11.1956; OLSON WK, 1993, J MOL BIOL, V232, P530, DOI 10.1006/jmbi.1993.1409; PILSCH DS, 1991, BIOCHEMISTRY-US, V30, P6081; ROUGEE M, 1992, BIOCHEMISTRY-US, V31, P9269, DOI 10.1021/bi00153a021; SARAI A, 1989, BIOCHEMISTRY-US, V28, P7842, DOI 10.1021/bi00445a046; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; Smith SB, 1996, SCIENCE, V271, P795, DOI 10.1126/science.271.5250.795; STRAUSS JK, 1994, SCIENCE, V266, P1829, DOI 10.1126/science.7997878; THOMAS TJ, 1983, NUCLEIC ACIDS RES, V11, P1919, DOI 10.1093/nar/11.6.1919; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VESNAVER G, 1991, P NATL ACAD SCI USA, V88, P3569, DOI 10.1073/pnas.88.9.3569; ZHURKIN VB, 1991, P NATL ACAD SCI USA, V88, P7046, DOI 10.1073/pnas.88.16.7046	40	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29126	29135		10.1074/jbc.271.46.29126	http://dx.doi.org/10.1074/jbc.271.46.29126			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910569	hybrid			2022-12-27	WOS:A1996VT05200061
J	Cao, YH; Ji, RW; Davidson, D; Schaller, J; Marti, D; Sohndel, S; McCance, SG; OReilly, MS; Llinas, M; Folkman, J				Cao, YH; Ji, RW; Davidson, D; Schaller, J; Marti, D; Sohndel, S; McCance, SG; OReilly, MS; Llinas, M; Folkman, J			Kringle domains of human angiostatin - Characterization of the anti-proliferative activity on endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; HUMAN PLASMINOGEN KRINGLE-4; FIBROBLAST GROWTH-FACTOR; LEWIS-LUNG-CARCINOMA; N-TERMINAL FRAGMENT; ANGIOGENESIS INHIBITOR; TUMOR ANGIOGENESIS; POTENT INHIBITOR; BINDING; PURIFICATION	Recently we have identified angiostatin, an endogenous angiogenesis inhibitor of 38 kDa which specifically blocks the growth of endothelial cells (O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. (1994) Cell 79, 315-328; Folkman, J. (1995) Nat. Med. 1, 27-31). Angiostatin was shown to represent an internal fragment of plasminogen containing the first four kringle structures. We now report on the inhibitory effects of individual or combined kringle structures of angiostatin on capillary endothelial cell proliferation. Recombinant kringle 1 and kringle 3 exhibit potent inhibitory activity with half-maximal concentrations (ED(50)) of 320 nM and 460 nM, respectively. Also, recombinant kringle 2 displays a significant inhibition, although decreased compared with both kringle 1 and kringle 3. In contrast, kringle 4 is an ineffective inhibitor of basic fibroblast growth factor-stimulated endothelial cell proliferation. Among the tandem kringle arrays, the recombinant kringle 2-3 fragment exerts inhibitory activity similar to kringle 2 alone. However, relative to kringle 2-3, a marked enhancement in inhibition is observed when individual kringle 2 and kringle 3 are added together to endothelial cells. This implies that it is necessary to open the cystine bridge between kringle 2 and kringle 3 to obtain the maximal inhibitory effect of kringle 2-3. An increased (<2-fold) inhibitory activity is observed for the kringle 1-3 fragment (ED(50) = 70 nM) compared with kringle 1-4 (ED(50) = 135 nn). These data indicate that the anti-proliferative activity of angiostatin on endothelial cells is shared by kringle 1, kringle 2, and kringle 3, but probably not by kringle 4 and that more potent inhibition results when kringle 4 is removed from angiostatin. Thus, in view of the variable lysine affinity of the homologous domains, it would appear that lysine binding capability does not correlate with the relative inhibitory effects of the kringle-containing constructs. However, as we also demonstrate, appropriate folding of kringle structures is essential for angiostatin to maintain its full anti-endothelial activity.	HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; ABBOTT LABS,DIV PHARMACEUT PROD,ABBOTT PK,IL 60064; UNIV BERN,INST BIOCHEM,CH-3012 BERN,SWITZERLAND; CARNEGIE MELLON UNIV,DEPT CHEM,PITTSBURGH,PA 15213; AMER BIOGENET SCI INC,S BEND,IN 46635; UNIV NOTRE DAME,DEPT CHEM,S BEND,IN 46556	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Abbott Laboratories; University of Bern; Carnegie Mellon University; University of Notre Dame				Davidson, Donald/0000-0002-8669-9814	NHLBI NIH HHS [HL 29409] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029409] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOUCK N, 1990, CANCER CELL-MON REV, V2, P179; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CAO Y, 1996, J BIOL CHEM, V271, P9154; CAO YH, 1995, J EXP MED, V182, P2069, DOI 10.1084/jem.182.6.2069; Cao YH, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037497; CLAPP C, 1993, ENDOCRINOLOGY, V133, P1292, DOI 10.1210/en.133.3.1292; CLEARY S, 1989, BIOCHEMISTRY-US, V28, P1884, DOI 10.1021/bi00430a068; COX M, 1994, CHEM PHYS LIPIDS, V67-8, P43, DOI 10.1016/0009-3084(94)90123-6; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; DONATE LE, 1994, PROTEIN SCI, V3, P2378, DOI 10.1002/pro.5560031222; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GUNZLER WA, 1982, H-S Z PHYSIOL CHEM, V363, P1155, DOI 10.1515/bchm2.1982.363.2.1155; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; HOCHSCHWENDER SM, 1983, ARCH BIOCHEM BIOPHYS, V223, P58, DOI 10.1016/0003-9861(83)90571-4; HOMANDBERG GA, 1985, AM J PATHOL, V120, P327; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; LUKKER NA, 1994, PROTEIN ENG, V7, P892; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MARTI D, 1994, EUR J BIOCHEM, V219, P455, DOI 10.1111/j.1432-1033.1994.tb19959.x; MARTI D, 1994, THESIS U BERNE SWITZ; Mathews II, 1996, BIOCHEMISTRY-US, V35, P2567, DOI 10.1021/bi9521351; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MENHART N, 1991, BIOCHEMISTRY-US, V30, P1948, DOI 10.1021/bi00221a031; MENHART N, 1993, BIOCHEMISTRY-US, V32, P8799, DOI 10.1021/bi00085a010; MULICHAK AM, 1991, BIOCHEMISTRY-US, V30, P10576, DOI 10.1021/bi00107a029; NELSON J, 1995, CANCER RES, V55, P3772; NGUYEN M, 1994, J NATL CANCER I, V86, P356, DOI 10.1093/jnci/86.5.356; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PENNICA D, 1983, NATURE, V301, P579; POWELL JR, 1981, BIOCHEM BIOPH RES CO, V102, P46, DOI 10.1016/0006-291X(81)91486-8; REJANTE MR, 1991, BIOCHEMISTRY-US, V30, P11081, DOI 10.1021/bi00110a010; REJANTE MR, 1994, EUR J BIOCHEM, V221, P939, DOI 10.1111/j.1432-1033.1994.tb18809.x; SENGER DR, 1990, CANCER RES, V50, P1774; Sohndel S, 1996, BIOCHEMISTRY-US, V35, P2357, DOI 10.1021/bi9520949; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; STRIETER RM, 1994, SCIENCE, V4, P155; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; WALZ DA, 1977, P NATL ACAD SCI USA, V74, P1969, DOI 10.1073/pnas.74.5.1969; WILSON C, 1993, P NATL ACAD SCI USA, V90, P7109, DOI 10.1073/pnas.90.15.7109; WINN ES, 1980, EUR J BIOCHEM, V104, P579, DOI 10.1111/j.1432-1033.1980.tb04461.x; WU TP, 1994, BLOOD COAGUL FIBRIN, V5, P157, DOI 10.1097/00001721-199404000-00001	54	347	437	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29461	29467		10.1074/jbc.271.46.29461	http://dx.doi.org/10.1074/jbc.271.46.29461			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910613	hybrid			2022-12-27	WOS:A1996VT05200105
J	Han, JD; Rubin, CS				Han, JD; Rubin, CS			Regulation of cytoskeleton organization and paxillin dephosphorylation by cAMP - Studies on murine Y1 adrenal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CYCLIC-AMP; TYROSINE KINASE; EXPRESSION; PHOSPHORYLATION; ACTIVATION; CLONING; GENE; PATHWAYS; ADHESION	Cyclic AMP induces corticosteroid production, differential gene transcription, and cell cycle arrest in adrenal cortex-derived Y1 cells. These responses follow a cAMP-controlled transformation in Y1 cell morphology: the conversion of flat epithelial cells into rounded, highly refractile cells with short processes. Little is known about effector proteins and mechanisms that link activated protein kinase A to the alteration in cell shape, We now report that cAMP causes rapid (less than or equal to 1 min) and selective tyrosine dephosphorylation of paxillin, a focal adhesion protein. Paxillin is maximally dephosphorylated before other physiological effects of cAMP are detected in Y1 cells. Dephosphopaxillin translocates from focal adhesions to the cytoplasm as stress fibers vanish and F-actin accumulates in membrane ruffles and cytoplasmic aggregates. Remnants of focal adhesion complexes dissociate from the cell cortex and coalesce into large structures that contain aggregated F-actin. Pervanadate, an inhibitor of protein-tyrosine phosphatases, abrogates all effects of cAMP. Conversely, genistein-sensitive protein-tyrosine kinase activity is essential for establishing epithelial morphology and reversing effects of cAMP in Y1 cells. Thus, cAMP/protein kinase A (PKA) actions are initially targeted to focal adhesions and cortical actin cytoskeleton; paxillin is an early and unexpected downstream target in a PKA-mediated signaling pathway, and protein-tyrosine phosphatase activity provides an essential link between PKA. activation and the control of cell shape.	ALBERT EINSTEIN COLL MED,DEPT MOL PHARMACOL,ATRAN LABS,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine				Han, Jing-Dong J./0000-0002-9270-7139	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022792] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22792] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEEBE SJ, 1986, ENZYMES, V17, P44; BRAUTIGAN DL, 1991, P NATL ACAD SCI USA, V88, P6696, DOI 10.1073/pnas.88.15.6696; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EVANS GA, 1994, J BIOL CHEM, V269, P23407; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; GARTON AJ, 1994, EMBO J, V13, P3763, DOI 10.1002/j.1460-2075.1994.tb06687.x; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUTMANN NS, 1978, J CELL PHYSIOL, V97, P451, DOI 10.1002/jcp.1040970320; HANDLER JD, 1988, J BIOL CHEM, V263, P13068; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; LAND M, 1994, J BIOL CHEM, V269, P9234; MOUW AR, 1989, J BIOL CHEM, V264, P1305; OSAWA S, 1984, J CELL BIOL, V99, P1335, DOI 10.1083/jcb.99.4.1335; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schimmer B P, 1980, Adv Cyclic Nucleotide Res, V13, P181; SCHIMMER BP, 1977, MOL CELL ENDOCRINOL, V8, P135, DOI 10.1016/0303-7207(77)90025-9; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; YASUMURA Y, 1966, CANCER RES, V26, P529	26	97	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29211	29215		10.1074/jbc.271.46.29211	http://dx.doi.org/10.1074/jbc.271.46.29211			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910579	hybrid			2022-12-27	WOS:A1996VT05200071
J	Hao, MM; Lowy, AM; Kapoor, M; Deffie, A; Liu, G; Lozano, G				Hao, MM; Lowy, AM; Kapoor, M; Deffie, A; Liu, G; Lozano, G			Mutation of phosphoserine 389 affects p53 function in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; TUMOR-SUPPRESSOR PROTEIN; DNA-BINDING FUNCTION; CELL-CYCLE CONTROL; SV40 LARGE-T; PHOSPHORYLATION SITE; MAMMALIAN-CELLS; 3T3 CELLS; GENE; TRANSFORMATION	To study the importance of phosphorylation for p53 transactivation function, we generated mutations at each of its known phosphorylated serine amino acids. Mutations of murine p53 serine residues individually to either alanine or glutamic acid at positions 7, 9, 12, 18, 37, 312, and 389 resulted in equivalent levels of transcriptional activation in standard transient transfection experiments. However, when p53 transcriptional activity was measured in cells that attain G(1) arrest upon contact inhibition, wild-type p53 was inactive, and only alteration at serine 389 to glutamic acid resulted in a functional p53 protein. This Ser --> Glu mutant also has an increased ability to bind DNA. Elimination of the phosphorylation site by substitution of an alanine amino acid resulted in loss of transcriptional activity. We also demonstrated that specific phosphorylation of p53 at serine 389 is induced by cyclin E overexpression in high-density cells. Our data establish for the first time that phosphorylation of p53 at serine 389 is important in activating its function in vivo.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOL GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [T32CA009599, R29CA047296, P30CA016672, R01CA047296] Funding Source: NIH RePORTER; NCI NIH HHS [2-T32-CA09599, CA47296, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DANG CV, 1989, J BIOL CHEM, V264, P18019; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DEFFIE A, 1995, MOL CELL BIOL, V15, P3926; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISCELLA M, 1994, ONCOGENE, V9, P3249; FISCELLA M, 1993, ONCOGENE, V8, P1519; FUCHS B, 1995, ONCOGENE, V10, P789; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HAO MM, 1993, ONCOGENE, V8, P299; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MAYR GA, 1995, CANCER RES, V55, P2410; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MIYASHITA T, 1995, CELL, V80, P293; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OKAMOTO K, 1994, EMBO J, V13, P4819; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; ROLLEY N, 1994, ONCOGENE, V9, P3067; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Shaw P, 1996, ONCOGENE, V12, P921; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x	53	101	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29380	29385		10.1074/jbc.271.46.29380	http://dx.doi.org/10.1074/jbc.271.46.29380			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910602	hybrid			2022-12-27	WOS:A1996VT05200094
J	Higaki, M; Sakaue, H; Ogawa, W; Kasuga, M; Shimokado, K				Higaki, M; Sakaue, H; Ogawa, W; Kasuga, M; Shimokado, K			Phosphatidylinositol 3-kinase-independent signal transduction pathway for platelet-derived growth factor-induced chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; BINDING PROTEIN-RHO; PHOSPHOINOSITIDE 3-KINASE; PHOSPHOLIPASE A(2); GLUCOSE-TRANSPORT; ACTIVATION; RECEPTOR; KINASE; INHIBITOR; WORTMANNIN	Platelet derived growth factor (PDGF)-BB is a potent chemoattractant for mesenchymal cells. Intracellular signal transduction for PDGF-induced chemotactic response has been reported to be dependent on phosphatidylinositol 3-kinase (PI3K) activation. Here, we report a PI3K-independent pathway operating for PDGF-induced chemotaxis in vascular smooth muscle cells and other cell types. Two different PI3K inhibitors, wortmannin (WT, 1 nM-1 mu M) and LY294002 (100 nM-10 mu m), did not inhibit PDGF-induced chemotaxis in smooth muscle cells and Swiss 3T3 cells, whereas WT inhibited activity of PI3K that were immunopurified from PDGF-stimulated cells as well as PI3K purified from cells that were stimulated with PDGF in the presence of the same concentrations of WT. Similarly, WT (100 nar) abolished the increase in intracellular phosphatidylinositol 3,4,5-triphosphate after PDGF stimulation. Furthermore, Chinese hamster ovary/Delta p85 cells overexpressing a dominant negative p85 subunit of PI3K showed a chemotactic response comparable to that of parental cells while showing a remarkable decrease in PI3K activity. Rapamycin, a specific inhibitor of pp70 S6 kinase, which is one of the well characterized downstreams of PI3K did not inhibit PDGF-induced chemotaxis. Both WT and LY294002 inhibited PDGF-induced amino acid uptake and actin-stress fiber reorganization and partly inhibited PDGF-induced glucose incorporation in Swiss 3T3 cells. Our findings indicate that, in vascular smooth muscle cells and other cell types, the signal transduction for PDGF-induced chemotaxis is independent of PI3K activity while the signal transduction for PDGF-induced amino acid uptake, glucose incorporation, and cytoskeletal reorganization is dependent on PI3K.	NATL CARDIOVASC CTR,RES INST,SUITA,OSAKA 565,JAPAN; KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,CHUO KU,KOBE,HYOGO 650,JAPAN	National Cerebral & Cardiovascular Center - Japan; Kobe University			OGAWA, Wataru/AAQ-9586-2020; Sakaue, Hiroshi/ABE-2337-2021	Sakaue, Hiroshi/0000-0002-2468-2363				BAR RS, 1989, ENDOCRINOLOGY, V124, P1841, DOI 10.1210/endo-124-4-1841; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; DERMAN MP, 1996, AM J PHYSIOL, V271, P4251; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; JOLYM, 1995, J BIOL CHEM, V270, P13225; KAMOHARA S, 1995, P NATL ACAD SCI USA, V92, P1077, DOI 10.1073/pnas.92.4.1077; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; MA YH, 1994, J BIOL CHEM, V269, P30734; MARX SO, 1995, CIRC RES, V76, P412, DOI 10.1161/01.RES.76.3.412; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; OKADA T, 1994, J BIOL CHEM, V269, P3563; OKADA T, 1994, J BIOL CHEM, V269, P3568; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; OWEN AJ, 1982, P NATL ACAD SCI-BIOL, V79, P3203, DOI 10.1073/pnas.79.10.3203; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; ROLLINS BJ, 1988, J BIOL CHEM, V263, P16523; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SHIMOKADO K, 1994, ARTERIOSCLER THROMB, V14, P973, DOI 10.1161/01.ATV.14.6.973; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VLAHOS CJ, 1992, FEBS LETT, V309, P242, DOI 10.1016/0014-5793(92)80781-B; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WENNSTROM S, 1994, ONCOGENE, V9, P651; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517; YOKOTA T, 1993, CIRCULATION, V88, P657; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; ZHANG J, 1993, J BIOL CHEM, V268, P22251	42	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29342	29346		10.1074/jbc.271.46.29342	http://dx.doi.org/10.1074/jbc.271.46.29342			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910596	hybrid			2022-12-27	WOS:A1996VT05200088
J	Ishida, T; Mizushima, S; Azuma, S; Kobayashi, N; Tojo, T; Suzuki, K; Aizawa, S; Watanabe, T; Mosialos, G; Kieff, E; Yamamoto, T; Inoue, J				Ishida, T; Mizushima, S; Azuma, S; Kobayashi, N; Tojo, T; Suzuki, K; Aizawa, S; Watanabe, T; Mosialos, G; Kieff, E; Yamamoto, T; Inoue, J			Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-CD40 MONOCLONAL-ANTIBODY; GROWTH-FACTOR RECEPTOR; DEATH DOMAIN; KAPPA-B; ACTIVATION MOLECULE; CROSS-LINKING; ANTIGEN; INTERACTS; FAMILY; PHOSPHORYLATION	CD40 signalings play crucial roles in B-cell function. To identify molecules which transduce CD40 signalings, we have utilized the yeast two-hybrid system to clone cDNAs encoding proteins that bind the cytoplasmic tail of CD40. A cDNA encoding a putative signal transducer, designated TRAF6, has been molecularly cloned. TRAF6 has a tumor necrosis factor receptor (TNFR)-associated factor (TRAF) domain in its carboxyl terminus and has a RING finger domain, a cluster of zinc fingers and a coiled coil domain, which are also present in other TRAF family proteins. TRAF6 does not associate with the cytoplasmic tails of TNFR2, CD30, lymphotoxin-beta receptor, and LMP1 of Epstein-Barr virus. Deletion analysis showed that residues 246-269 of CD40 which are required for its association with TRAF2, TRAF3, and TRAF5 are dispensable for its interaction with TRAF6, whereas residues 230-245 were required. Overexpression of TRAF6 activates transcription factor NF kappa B, and its TRAF-C domain suppresses NF kappa B activation triggered by CD40 lacking residues 246-277. These results suggest that TRAF6 could mediate the CD40 signal that is transduced by the amino-terminal domain (230-245) of the CD40 cytoplasmic region and appears to be independent of other known TRAF family proteins.	UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN; UNIV TOKYO,INST MED SCI,DEPT PATHOL,MINATO KU,TOKYO 108,JAPAN; MOCHIDA PHARMACEUT CO LTD,BIOSCI RES LAB,KITA KU,TOKYO 115,JAPAN; BRIGHAM & WOMENS HOSP,DIV INFECT DIS,BOSTON,MA 02115	University of Tokyo; University of Tokyo; Mochida Pharmaceutical Co Ltd; Harvard University; Brigham & Women's Hospital					NCI NIH HHS [CA4706] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BERBERICH I, 1994, J IMMUNOL, V153, P4357; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; CAMERINI D, 1991, J IMMUNOL, V147, P3165; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; DEFRANCE T, 1992, EUR J IMMUNOL, V22, P2831, DOI 10.1002/eji.1830221112; FARIS M, 1994, J EXP MED, V179, P1923, DOI 10.1084/jem.179.6.1923; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; INUI S, 1990, EUR J IMMUNOL, V20, P1747, DOI 10.1002/eji.1830200819; ISHIDA T, 1995, J IMMUNOL, V155, P5527; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; LING NR, 1987, LEUCOCYTE TYPING, V3, P302; MALLETT S, 1990, EMBO J, V9, P1063, DOI 10.1002/j.1460-2075.1990.tb08211.x; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; REN CL, 1994, J EXP MED, V179, P673, DOI 10.1084/jem.179.2.673; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHRIEVER F, 1989, J EXP MED, V169, P2043, DOI 10.1084/jem.169.6.2043; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; UCKUN FM, 1991, J BIOL CHEM, V266, P17478; Ware C F, 1995, Curr Top Microbiol Immunol, V198, P175	35	427	447	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28745	28748		10.1074/jbc.271.46.28745	http://dx.doi.org/10.1074/jbc.271.46.28745			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910514	hybrid			2022-12-27	WOS:A1996VT05200006
J	Nielsen, FS; Andersen, PS; Jensen, KF				Nielsen, FS; Andersen, PS; Jensen, KF			The B form of dihydroorotate dehydrogenase from Lactococcus lactis consists of two different subunits, encoded by the pyrDb and pyrK genes, and contains FMN, FAD, and [FeS] redox centers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; PURIFICATION; ENZYME	The B form of dihydroorotate dehydrogenase from Lactococcus lactis (DHOdehase B) is encoded by the pyrDb gene. However, recent genetic evidence has revealed that a co-transcribed gene, pyrK is needed to achieve the proper physiological function of the enzyme. We have purified DHOdehase B from two strains of Escherichia cold, which harbored either the pyrDb gene or both the pyrDb and the pyrK genes of L. lactis on multicopy plasmids. The enzyme encoded by pyrDb alone (herein called the delta-enzyme) was a bright yellow, dimeric protein that contained one molecule of tightly bound FMN per subunit. The delta-enzyme exhibited dihydroorotate dehydrogenase activity with dichloroindophenol, potassium hexacyanoferrate(III), and molecular oxygen as electron accepters but could not use NAD(+). The DHOdehase B purified from the E. coli strain that carried both the pyrDb and pyrK genes on a multicopy plasmid (herein called the GK-enzyme) was quite different, since it was formed as a complex of equal amounts of the two polypeptides, i.e. two PyrDB and two PyrK subunits. The GK-enzyme was orange-brown and contained 2 mol of FAD, 2 mol of FMN, and 2 mol of [2Fe-2S] redox clusters per mol of native protein as tightly bound prosthetic groups. The delta K-enzyme was able to use NAD(+) as well as dichloroindophenol, potassium hexacyanoferrate(III), and to some extent molecular oxygen as electron accepters for the conversion of dihydroorotate to orotate, and it was a considerably more efficient catalyst than the purified delta-enzyme. Based on these results and on analysis of published sequences, we propose that the architecture of the delta K-enzyme is representative for the dihydroorotate dehydrogenases from Gram-positive bacteria.	UNIV COPENHAGEN,CTR ENZYME RES,INST MOL BIOL,DK-1307 COPENHAGEN K,DENMARK; TECH UNIV DENMARK,INST BIOTECHNOL,DK-2800 LYNGBY,DENMARK; UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Copenhagen; Technical University of Denmark; University of Illinois System; University of Illinois Urbana-Champaign			Andersen, Paal S/H-2087-2015	Andersen, Paal S/0000-0001-5656-0427				ALEMAN V, 1967, J BIOL CHEM, V242, P4087; Andersen PS, 1996, J BACTERIOL, V178, P5005, DOI 10.1128/jb.178.16.5005-5012.1996; ANDERSEN PS, 1994, J BACTERIOL, V176, P3975, DOI 10.1128/JB.176.13.3975-3982.1994; COPELAND RA, 1995, ARCH BIOCHEM BIOPHYS, V323, P79, DOI 10.1006/abbi.1995.0012; DEUTSCHLE U, 1986, EMBO J, V5, P2987; FISCHER DS, 1964, CLIN CHEM, V10, P21, DOI 10.1016/0009-8981(64)90210-4; FORMAN HJ, 1978, ARCH BIOCHEM BIOPHYS, V191, P23, DOI 10.1016/0003-9861(78)90063-2; GHIM SY, 1994, MICROBIOL-UK, V140, P479, DOI 10.1099/00221287-140-3-479; HINES V, 1986, J BIOL CHEM, V261, P1386; HINES V, 1989, BIOCHEMISTRY-US, V28, P1222, DOI 10.1021/bi00429a040; Kahler AE, 1996, J BACTERIOL, V178, P5013, DOI 10.1128/jb.178.16.5013-5016.1996; Karibian D, 1978, Methods Enzymol, V51, P58; KING TE, 1967, METHOD ENZYMOL, V10, P634; KRUNGKRAI J, 1991, BIOCHEMISTRY-US, V30, P1934, DOI 10.1021/bi00221a029; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN JN, 1985, EUR J BIOCHEM, V151, P59, DOI 10.1111/j.1432-1033.1985.tb09068.x; LED JJ, 1983, EUR J BIOCHEM, V136, P469, DOI 10.1111/j.1432-1033.1983.tb07765.x; LI XT, 1995, J BACTERIOL, V177, P6866, DOI 10.1128/jb.177.23.6866-6873.1995; LIEBERMAN I, 1953, BIOCHIM BIOPHYS ACTA, V12, P223, DOI 10.1016/0006-3002(53)90141-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Miller J.H., 1972, EXPT MOL GENETICS; MILLER RW, 1971, ARCH BIOCHEM BIOPHYS, V146, P256, DOI 10.1016/S0003-9861(71)80063-2; MILLER RW, 1965, J BIOL CHEM, V240, P1453; MILLER RW, 1975, CAN J BIOCHEM CELL B, V53, P1288, DOI 10.1139/o75-175; Nielsen FS, 1996, PROTEIN SCI, V5, P857; PASCAL RA, 1983, BIOCHEMISTRY-US, V22, P171, DOI 10.1021/bi00270a025; QUINN CL, 1991, J BIOL CHEM, V266, P9113; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; UNTUCHGRAU R, 1982, FLAVINS FLAVOPROTEIN	29	65	67	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29359	29365		10.1074/jbc.271.46.29359	http://dx.doi.org/10.1074/jbc.271.46.29359			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910599	hybrid			2022-12-27	WOS:A1996VT05200091
J	Roy, B; Li, WW; Lee, AS				Roy, B; Li, WW; Lee, AS			Calcium-sensitive transcriptional activation of the proximal CCAAT regulatory element of the grp78/BiP promoter by the human nuclear factor CBF/NF-Y	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-STIMULATED ADENOSINE 5'-TRIPHOSPHATASE; CA2+-ATPASE INHIBITOR THAPSIGARGIN; RAT-LIVER NUCLEI; ENDOPLASMIC-RETICULUM; C-FOS; BINDING FACTOR; PROTEIN; GENES; EXPRESSION; IONOPHORE	Transcription of the gene encoding GRP78/BiP, a calcium-binding molecular chaperone localized in the endoplasmic reticulum, is induced in mammalian cells through gradual depletion of the intracellular calcium stores. The multimeric CCAAT binding factor, CBF/NF-Y, binds to the most proximal CCAAT regulatory element (C1) of the grp78 promoter required for both basal level expression and stress response. Using an in vitro transcription system, we show through factor competition and immunodepletion that the grp78 C1-mediated enhancement of transcription requires primarily CBF. Correlating with the previous observation that CBF binding to the 78C1 site is enhanced by EGTA and EDTA, these divalent cation chelators specifically stimulate 78C1-directed transcription. In contrast, increasing amounts of calcium ions are inhibitory. These results provide evidence that CBF is functionally important in transactivating the grp78 C1 transcriptional activity, and suggest a possible mechanism by which grp78 transcription is stimulated by calcium depletion. We further discovered that in addition to binding CBF, both the 78C1 element and the CBF binding site of the alpha 2(I) collagen promoter interact weakly with the multifunctional transcription factor YY1. Our studies show that the binding sites for CBF and YY1 are distinct for the two promoter sites, suggesting that YY1 and other interacting factors could exert differential effects on individual promoters bearing the same CBF site.	UNIV SO CALIF,SCH MED,DEPT BIOCHEM & MOL BIOL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,KENNETH NORRIS JR COMPREHENS CANC CTR,LOS ANGELES,CA 90033	University of Southern California; University of Southern California				Lee, Amy/0000-0002-0378-5443				ALEXANDRE S, 1991, MOL ENDOCRINOL, V5, P1862, DOI 10.1210/mend-5-12-1862; BACHS O, 1992, BIOCHIM BIOPHYS ACTA, V1113, P259, DOI 10.1016/0304-4157(92)90041-8; CAO XJ, 1995, J BIOL CHEM, V270, P494, DOI 10.1074/jbc.270.1.494; CHANG SC, 1989, MOL CELL BIOL, V9, P2153, DOI 10.1128/MCB.9.5.2153; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; DRUMMOND IAS, 1987, J BIOL CHEM, V262, P12801; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GUO B, 1995, P NATL ACAD SCI USA, V92, P10526, DOI 10.1073/pnas.92.23.10526; HECHTENBERG S, 1993, BIOCHEM J, V289, P757, DOI 10.1042/bj2890757; Humbert JP, 1996, J BIOL CHEM, V271, P478, DOI 10.1074/jbc.271.1.478; Kong SK, 1996, BIOCHEM BIOPH RES CO, V218, P595, DOI 10.1006/bbrc.1996.0105; LANINI L, 1992, J BIOL CHEM, V267, P11548; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LI WW, 1994, MOL CELL BIOL, V14, P5533, DOI 10.1128/MCB.14.8.5533; LI WWF, 1993, J BIOL CHEM, V268, P12003; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LIN AY, 1986, MOL CELL BIOL, V6, P1235, DOI 10.1128/MCB.6.4.1235; LIU ES, 1991, NUCLEIC ACIDS RES, V19, P5425, DOI 10.1093/nar/19.19.5425; MAITY SN, 1992, J BIOL CHEM, V267, P8286; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; NATESAN S, 1995, MOL CELL BIOL, V15, P5975; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; RAMAKRISHNAN M, 1996, IN PRESS J CELL PHYS; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RESENDEZ E, 1988, MOL CELL BIOL, V8, P4579, DOI 10.1128/MCB.8.10.4579; RESENDEZ E, 1986, J CELL BIOL, V103, P2145, DOI 10.1083/jcb.103.6.2145; ROY B, 1995, MOL CELL BIOL, V15, P2263; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHONTHAL A, 1991, P NATL ACAD SCI USA, V88, P7096, DOI 10.1073/pnas.88.16.7096; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THOMAS D, 1995, J BIOL CHEM, V270, P6429, DOI 10.1074/jbc.270.12.6429; WOODEN SK, 1991, MOL CELL BIOL, V11, P5612, DOI 10.1128/MCB.11.11.5612; YAMAGUCHI M, 1993, MOL CELL BIOCHEM, V125, P43, DOI 10.1007/BF00926833; YAMAGUCHI M, 1994, MOL CELL BIOCHEM, V131, P167, DOI 10.1007/BF00925953	37	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28995	29002		10.1074/jbc.271.46.28995	http://dx.doi.org/10.1074/jbc.271.46.28995			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910550	Green Accepted			2022-12-27	WOS:A1996VT05200042
J	Richardson, RM; Haribabu, B; Ali, H; Snyderman, R				Richardson, RM; Haribabu, B; Ali, H; Snyderman, R			Cross-desensitization among receptors for platelet activating factor and peptide chemoattractants - Evidence for independent regulatory pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; PHOSPHOLIPASE-C; 48-KDA PROTEIN; PHOSPHORYLATION; LEUKOCYTE; INTERLEUKIN-8; EXPRESSION; RHODOPSIN; KINASES; CLONING	Cross desensitization among receptors for peptide chemoattractants have been shown to involve two independent processes, receptor phosphorylation and inhibition of phospholipase C (PLC) activation. Receptors for lipid chemoattractants, i.e. platelet activating factor (PAF) and leukotriene B-4, did not inhibit the responses of peptide chemoattractant receptors, suggesting distinct signaling pathways. To examine cross-desensitization between receptors for lipid and peptide chemoattractants, cDNA encoding the PAF receptor (PAFR) was co-expressed into RBL-2H3 cells with cDNAs encoding receptors for either formylated peptides (FR), a product of the fifth component of complement (C5aR) or interleukin-8 A (IL-8RA). PAFR was homologously phosphorylated and desensitized by PAF, and cross-phosphorylated and cross-desensitized by fMet-Leu-Phe, C5a, and IL-8. In contrast, the receptors for peptide chemoattractants were neither cross-phosphorylated nor cross-desensitized by PAF. Staurosporine blocked cross-phosphorylation and cross-desensitization of the PAFR by peptide chemoattractants. Truncation of the cytoplasmic tail of PAFR (mPAFR) abolished its homologous and cross-phosphorylation. mPAFR was also resistant to cross-desensitization by peptide chemoattractants at the level of PLC activation. Interestingly, mPAFR mediated a sustained Ca2+ mobilization in response to PAF and was more active in inducing GTPase activity, phosphoinositide hydrolysis, secretion, and phospholipase D activation than the wild type PAFR. In contrast to PAFR, stimulation of the mPAFR cross-phosphorylated and cross-desensitized responses to IL-8RA. As expected, FR, which is resistant to cross-phosphorylation by C5aR and IL-8RA, was not phosphorylated by mPAFR. However, unlike C5aR and IL-8RA, mPAFR did not inhibit the ability of FR to activate PLC. Blocking Ca2+ influx inhibited mPAFR-mediated sustained Ca2+ response, phospholipase D activation and secretion, but not phosphoinositide hydrolysis and cross-phosphorylation and cross-desensitization of IL-8RA. The data herein suggest that cross-desensitization of PAFR by peptide chemoattractants is solely due to receptor phosphorylation. The PAFR and the peptide chemoattractant receptors do not cross-regulate each other at the level of PLC, suggesting distinct regulatory pathways.	DUKE UNIV,MED CTR,DEPT IMMUNOL,DURHAM,NC 27710	Duke University	Richardson, RM (corresponding author), DUKE UNIV,MED CTR,DEPT MED,BOX 3680,DURHAM,NC 27710, USA.		Bodduluri, Haribabu/A-2584-2010	Bodduluri, Haribabu/0000-0002-8261-3294	NHLBI NIH HHS [HL-54166] Funding Source: Medline; NIAID NIH HHS [AI-38910] Funding Source: Medline; NIDCR NIH HHS [DE-03738] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL054166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI038910, R01AI038910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE003738] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALI H, 1994, J BIOL CHEM, V269, P24557; ALI H, 1993, J BIOL CHEM, V268, P24247; AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; DHAR A, 1994, J BIOL CHEM, V269, P9123; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HONDA Z, 1995, J BIOL CHEM, V270, P4840, DOI 10.1074/jbc.270.9.4840; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HOSEY MM, 1994, REGULATION SIGNAL TR, P113; KRAUSE KH, 1985, J CLIN INVEST, V76, P1348, DOI 10.1172/JCI112109; Kuang YN, 1996, P NATL ACAD SCI USA, V93, P2964, DOI 10.1073/pnas.93.7.2964; KURUVILLA A, 1993, J IMMUNOL, V151, P637; LATTION AL, 1994, J BIOL CHEM, V269, P22887; LIGGETT SB, 1994, REGULATION CELLULAR, P71; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OZCELEBI F, 1995, MOL PHARMACOL, V48, P818; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; RICHARDON RM, 1995, J BIOL CHEM, V270, P27829, DOI 10.1074/jbc.270.46.27829; RICHARDSON RM, 1995, BIOCHEMISTRY-US, V34, P14193, DOI 10.1021/bi00043a025; SCHREIBER RE, 1994, J BIOL CHEM, V269, P326; SICILIANO SJ, 1990, J BIOL CHEM, V265, P19568; SNYDERMAN R, 1992, INFLAMMATION BASIC P, P421; STRADER CD, 1987, J BIOL CHEM, V262, P16439; TAKANO T, 1994, J BIOL CHEM, V269, P22453; THELEN M, 1994, CURR OPIN IMMUNOL, V6, P106, DOI 10.1016/0952-7915(94)90041-8; TOMHAVE E, 1994, J IMMUNOL, V154, P3267; TRUETT AP, 1988, P NATL ACAD SCI USA, V85, P1549, DOI 10.1073/pnas.85.5.1549; VERGHESE MW, 1987, J IMMUNOL, V138, P4374; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; YANG J, 1995, MOL PHARMACOL, V48, P477; Zhu X, 1996, P NATL ACAD SCI USA, V93, P2827, DOI 10.1073/pnas.93.7.2827	38	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28717	28724		10.1074/jbc.271.45.28717	http://dx.doi.org/10.1074/jbc.271.45.28717			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910508	hybrid			2022-12-27	WOS:A1996VU03300108
J	Arn, EA; Abelson, JN				Arn, EA; Abelson, JN			The 2'-5' RNA ligase of Escherichia coli - Purification, cloning, and genomic disruption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; ENDONUCLEASE; BACTERIA; EXTRACT; TRANSCRIPTION; SYNTHETASE; EXPRESSION; SEQUENCES; INTRONS	An RNA ligase previously detected in extracts of Escherichia coli is capable of joining Saccharomyces cerevisiae tRNA splicing intermediates in the absence of ATP to form a 2'-5' phosphodiester linkage (Greer, C., Javor, B., and Abelson, J. (1983) Cell 33, 899-906), This enzyme specifically ligates tRNA half-molecules containing nucleoside base modifications and shows a preference among different tRNA species, In order to investigate the function of this enzyme in RNA metabolism, the ligase was purified to homogeneity from E. coli lysate utilizing chromatographic techniques and separation of proteins by SDS-polyacrylamide gel electrophoresis. A single polypeptide of approximately 20 kilodaltons exhibited RNA ligase activity, The amino terminus of this protein was sequenced, and the open reading frame (ORF) encoding it was identified by a data base search, This ORF, which encodes a novel protein with a pre dieted molecular mass of 19.9 kDa, was amplified from E. coli genomic DNA and cloned, ORFs coding for highly similar proteins were detected in Methanococcus jannaschii and Bacillus stearothermophilus. The chromosomal gene encoding RNA ligase in E. coli was disrupted, abolishing ligase activity in cell lysates, Cells lacking ligase activity grew normally under laboratory conditions, However, moderate overexpression of the ligase protein led to slower growth rates and a temperature-sensitive phenotype in both wild-type and RNA ligase knockout strains, The RNA ligase reaction was studied in vitro using purified enzyme and was found to be reversible, indicating that this enzyme may perform cleavage or ligation in vivo.	CALTECH,DIV BIOL 14775,PASADENA,CA 91125	California Institute of Technology								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMITSUR M, 1987, EMBO J, V6, P2499, DOI 10.1002/j.1460-2075.1987.tb02532.x; ANDACHI Y, 1989, J MOL BIOL, V209, P37, DOI 10.1016/0022-2836(89)90168-X; ARNEZ JG, 1994, BIOCHEMISTRY-US, V33, P7560, DOI 10.1021/bi00190a008; BINISZKIEWICZ D, 1994, EMBO J, V13, P4629, DOI 10.1002/j.1460-2075.1994.tb06785.x; BJORK GR, 1987, ESCHERICHIA COLI SAL, V1, P719; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CORNET F, 1994, J BACTERIOL, V176, P3188, DOI 10.1128/jb.176.11.3188-3195.1994; EVANS CF, 1990, METHOD ENZYMOL, V181, P439; FILIPOWICZ W, 1983, CELL, V32, P547, DOI 10.1016/0092-8674(83)90474-9; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FUJITA N, 1994, NUCLEIC ACIDS RES, V22, P1637, DOI 10.1093/nar/22.9.1637; GEGENHEIMER P, 1983, J BIOL CHEM, V258, P8365; GREER CL, 1983, CELL, V33, P899, DOI 10.1016/0092-8674(83)90032-6; GREER CL, 1983, CELL, V32, P537, DOI 10.1016/0092-8674(83)90473-7; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HERTEL KJ, 1995, BIOCHEMISTRY-US, V34, P1744, DOI 10.1021/bi00005a031; KAWAMUKAI M, 1991, J BACTERIOL, V173, P2644, DOI 10.1128/jb.173.8.2644-2648.1991; KJEMS J, 1989, CAN J MICROBIOL, V35, P210, DOI 10.1139/m89-033; KOHARA Y, 1990, BACTERIAL CHROMOSOME, P29; KOMINE Y, 1990, J MOL BIOL, V212, P579, DOI 10.1016/0022-2836(90)90224-A; LIONG EC, 1994, MOL GEN GENET, V243, P343, DOI 10.1007/BF00301070; LOEWEN PC, 1994, ANNU REV MICROBIOL, V48, P53, DOI 10.1146/annurev.mi.48.100194.000413; PEEBLES CL, 1983, CELL, V32, P525, DOI 10.1016/0092-8674(83)90472-5; PERRET V, 1990, NATURE, V344, P787, DOI 10.1038/344787a0; PRZYKORSKA A, 1995, BIOCHIMIE, V77, P109, DOI 10.1016/0300-9084(96)88113-2; RAUHUT R, 1990, J BIOL CHEM, V265, P18180; REINHOLDHUREK B, 1992, NATURE, V357, P173, DOI 10.1038/357173a0; REYES VM, 1987, ANAL BIOCHEM, V166, P90, DOI 10.1016/0003-2697(87)90551-3; RUSCHE LN, 1995, MOL CELL BIOL, V15, P2933; SAMPSON JR, 1993, NUCLEIC ACIDS RES, V21, P4467, DOI 10.1093/nar/21.19.4467; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; TRUJILLO MA, 1987, EUR J BIOCHEM, V169, P167, DOI 10.1111/j.1432-1033.1987.tb13594.x; VICENTE M, 1991, MOL MICROBIOL, V5, P2085, DOI 10.1111/j.1365-2958.1991.tb02137.x; WALLACE RB, 1980, SCIENCE, V209, P1396, DOI 10.1126/science.6997991; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	36	52	57	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31145	31153		10.1074/jbc.271.49.31145	http://dx.doi.org/10.1074/jbc.271.49.31145			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940112	hybrid			2022-12-27	WOS:A1996VW68600023
J	Salgia, R; Avraham, S; Pisick, E; Li, JL; Raja, S; Greenfield, EA; Sattler, M; Avraham, H; Griffin, JD				Salgia, R; Avraham, S; Pisick, E; Li, JL; Raja, S; Greenfield, EA; Sattler, M; Avraham, H; Griffin, JD			The related adhesion focal tyrosine kinase forms a complex with paxillin in hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; PHOSPHORYLATION; BINDING; IDENTIFICATION; P210(BCR/ABL); PP125(FAK); ASSOCIATION; PROTEINS; PP125FAK; CLONING	Related adhesion focal tyrosine kinase (RAFTK), also known as proline-rich tyrosine kinase 2 and cellular adhesion kinase beta, has been recently cloned and characterized as a member of the focal adhesion kinase (FAR) subfamily. RAFTK has an overall 48% amino acid homology to p125(FAK) and contains a kinase domain but lacks a transmembrane region, myristylation sites, and Src homology region 2 and 3 domains. By Northern blot analysis, RAFTK is expressed in myeloid, lymphoid, and megakaryocytic hematopoietic cells. Like p125(FAK), we found that RAFTK interacts with the focal adhesion protein paxillin. In the lymphoid cell line BaF3 and the myeloid cell Line 32Dc13, RAFTK coprecipitates with paxillin. Using in vitro binding assays, RAFTK and paxillin were shown to bind directly, through a segment of paxillin that required amino acids 100-227 and a domain in the C terminus of RAFTK. In vitro, RAFTK could phosphorylate paxillin on tyrosine residues, These results suggest that RAFTK, as well as p125(FAK), may be important in phosphotyrosine-signaling events within the focal adhesion.	DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,BOSTON,MA 02115; DEACONESS HOSP,DIV HEMATOL & ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School			Li, J L/E-6100-2018; Li, Jian-Liang/AAE-9315-2019	Li, J L/0000-0002-6487-081X; Li, Jian-Liang/0000-0002-6487-081X; Avraham, Hava/0000-0002-7545-3640	NCI NIH HHS [CA60821] Funding Source: Medline; NHLBI NIH HHS [HL55445, HL51456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA060821] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051456, R01HL055445] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; GEIGER B, 1990, CELL DIFFER DEV, V32, P343, DOI 10.1016/0922-3371(90)90049-3; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; ILLE D, 1995, NATURE, V377, P539; KANNER SB, 1994, P NATL ACAD SCI USA, V91, P10484, DOI 10.1073/pnas.91.22.10484; KHARBANDA S, 1995, P NATL ACAD SCI USA, V92, P6132, DOI 10.1073/pnas.92.13.6132; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LI S, 1996, BLOOD, V88, P417; LI SL, 1995, HYBRIDOMA, V14, P341, DOI 10.1089/hyb.1995.14.341; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; PARSONS JT, 1994, J CELL SCI, P109; SALGIA R, 1995, ONCOGENE, V11, P1149; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sambrook J., 2002, MOL CLONING LAB MANU; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SATTLER M, 1995, EXP HEMATOL, V23, P1040; SATTLER S, 1996, ONCOGENE, V12, P839; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1994, J CELL SCI, V107, P1583	31	130	134	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31222	31226		10.1074/jbc.271.49.31222	http://dx.doi.org/10.1074/jbc.271.49.31222			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940124	hybrid			2022-12-27	WOS:A1996VW68600035
J	Williamson, TG; Mok, SS; Henry, A; Cappai, R; Lander, AD; Nurcombe, V; Beyreuther, K; Masters, CL; Small, DH				Williamson, TG; Mok, SS; Henry, A; Cappai, R; Lander, AD; Nurcombe, V; Beyreuther, K; Masters, CL; Small, DH			Secreted glypican binds to the amyloid precursor protein of Alzheimer's disease (APP) and inhibits APP-induced neurite outgrowth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; HUMAN-LUNG FIBROBLASTS; NERVE GROWTH-FACTOR; CELL-SURFACE; EXTRACELLULAR-MATRIX; NEUROBLASTOMA-CELLS; HIPPOCAMPAL-NEURONS; MONOCLONAL-ANTIBODY; CORE PROTEIN; PURIFICATION	The amyloid precursor protein (APP) of Alzheimer's disease has been shown to stimulate neurite outgrowth in vitro. The effect of APP on neurite outgrowth can be enhanced if APP is presented to neurons in substrate-bound form, in the presence of heparan sulfate proteog lycans. To identify specific heparan sulfate proteoglycans that bind to APP, conditioned medium from neonatal mouse brain cells was subjected to affinity chromatography with recombinant APP(695) as a ligand, Glypican bound strongly to the APP affinity column, Purified glypican bound to APP with an equilibrium dissociation constant of 2.8 nM and inhibited APP-induced neurite outgrowth from chick sympathetic neurons. The effect of glypican was specific for APP, as glypican did not inhibit laminin-induced neurite outgrowth, Furthermore, treatment of cultures with 4-methylumbelliferyl-beta-D-xyloside, a competitive inhibitor of proteoglycan glycanation, inhibited APP-induced neurite outgrowth but did not inhibit laminin-induced neurite outgrowth, This result suggests that endogenous proteoglycans are required for substrate-bound APP to stimulate neurite outgrowth, Secreted glypican may act to inhibit APP-induced neurite outgrowth in vivo by competing with endogenous proteoglycans for binding to APP.	UNIV MELBOURNE,DEPT PATHOL,PARKVILLE,VIC 3052,AUSTRALIA; UNIV MELBOURNE,DEPT ANAT & CELL BIOL,PARKVILLE,VIC 3052,AUSTRALIA; UNIV CALIF IRVINE,DEPT DEV & CELL BIOL,IRVINE,CA 92717; UNIV HEIDELBERG,CTR MOL BIOL,D-6900 HEIDELBERG,GERMANY; MENTAL HLTH RES INST,PARKVILLE,VIC 3052,AUSTRALIA	University of Melbourne; University of Melbourne; University of California System; University of California Irvine; Ruprecht Karls University Heidelberg; Florey Institute of Neuroscience & Mental Health			Lander, Arthur D/C-9008-2011; Lander, Arthur/L-2827-2019; Cappai, Roberto/B-3347-2010	Lander, Arthur D/0000-0002-4380-5525; Lander, Arthur/0000-0002-4380-5525; Cappai, Roberto/0000-0002-9505-8496	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026862] Funding Source: NIH RePORTER; NINDS NIH HHS [NS26862] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLINQUANT B, 1995, J CELL BIOL, V128, P919, DOI 10.1083/jcb.128.5.919; ARAKI W, 1991, BIOCHEM BIOPH RES CO, V181, P265, DOI 10.1016/S0006-291X(05)81412-3; BRONNERFRASER M, 1988, J CELL BIOL, V106, P1321, DOI 10.1083/jcb.106.4.1321; CAREY DJ, 1987, J CELL BIOL, V105, P1013, DOI 10.1083/jcb.105.2.1013; CHANDRASEKHAR S, 1987, ANAL BIOCHEM, V161, P103, DOI 10.1016/0003-2697(87)90658-0; CLARRIS HJ, 1995, DEV BRAIN RES, V88, P87, DOI 10.1016/0165-3806(95)00083-P; CLARRIS HJ, 1994, J NEUROSCI RES, V38, P248, DOI 10.1002/jnr.490380303; COLE GJ, 1986, NATURE, V320, P445, DOI 10.1038/320445a0; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DEMORENO MR, 1985, ANAL BIOCHEM, V151, P466, DOI 10.1016/0003-2697(85)90206-4; DEWITT DA, 1993, EXP NEUROL, V121, P149, DOI 10.1006/exnr.1993.1081; EDGAR D, 1981, NATURE, V289, P294, DOI 10.1038/289294a0; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GURWITZ D, 1990, J CELL PHYSIOL, V142, P155, DOI 10.1002/jcp.1041420119; HANTAZAMBROISE D, 1987, J NEUROSCI, V7, P2293; HEREMANS A, 1988, J BIOL CHEM, V263, P4731; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; JIN LW, 1994, J NEUROSCI, V14, P5461; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KARTHIKEYAN L, 1992, BIOCHEM BIOPH RES CO, V188, P395, DOI 10.1016/0006-291X(92)92398-H; KARTHIKEYAN L, 1994, J CELL SCI, V107, P3213; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBLANC AC, 1992, J NEUROSCI RES, V31, P635, DOI 10.1002/jnr.490310407; LETOURNEAU PC, 1994, J NEUROSCI, V14, P915, DOI 10.1523/JNEUROSCI.14-03-00915.1994; LITWACK ED, 1994, J NEUROSCI, V14, P3713; LOFFLER J, 1992, J NEUROCHEM, V59, P1316, DOI 10.1111/j.1471-4159.1992.tb08443.x; LORIES V, 1986, EUR J BIOCHEM, V158, P351, DOI 10.1111/j.1432-1033.1986.tb09758.x; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATTSON MP, 1994, J NEUROBIOL, V25, P439, DOI 10.1002/neu.480250409; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; MOIR RD, 1992, J NEUROCHEM, V59, P1490, DOI 10.1111/j.1471-4159.1992.tb08465.x; NARINDRASORASAK S, 1991, J BIOL CHEM, V266, P12878; NINOMIYA H, 1994, J NEUROCHEM, V63, P495; OHTA M, 1993, DEV BRAIN RES, V75, P151, DOI 10.1016/0165-3806(93)90019-7; QIU WQ, 1995, J NEUROSCI, V15, P2157, DOI 10.1523/JNEUROSCI.15-03-02157.1995; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SCHUBERT D, 1993, BRAIN RES, V629, P275, DOI 10.1016/0006-8993(93)91331-L; SMALL DH, 1994, J NEUROSCI, V14, P2117; SMALL DH, 1992, J NEUROSCI, V12, P4143; SNOW AD, 1992, J HISTOCHEM CYTOCHEM, V40, P105, DOI 10.1177/40.1.1370306; SNOW AD, 1988, AM J PATHOL, V133, P455; STIPP CS, 1994, J CELL BIOL, V124, P149, DOI 10.1083/jcb.124.1.149; SU JH, 1992, NEUROSCIENCE, V51, P801, DOI 10.1016/0306-4522(92)90521-3; WALICKE PA, 1988, EXP NEUROL, V102, P144, DOI 10.1016/0014-4886(88)90087-8; WILLIAMSON TG, 1995, J NEUROCHEM, V65, P2201; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	50	89	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31215	31221		10.1074/jbc.271.49.31215	http://dx.doi.org/10.1074/jbc.271.49.31215			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940123	hybrid, Green Published			2022-12-27	WOS:A1996VW68600034
J	Pontow, SE; Blum, JS; Stahl, PD				Pontow, SE; Blum, JS; Stahl, PD			Delayed activation of the mannose receptor following synthesis - Requirement for exit from the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; SECRETORY PATHWAY; BREFELDIN-A; GOLGI MEMBRANES; LIGAND-BINDING; G PROTEINS; CELLS; MACROPHAGES; GLYCOSYLATION; TRANSPORT	The macrophage mannose receptor specifically recognizes proteins and particles bearing mannose terminal oligosaccharide chains. In the present study, we examined the ability of newly synthesized receptor to bind ligand. Human monocyte-derived macrophages were pulse-labeled with [S-35]Met and prepared for affinity chromatography on mannose-Sepharose. Mannose receptor in the flow-through and eluted fractions was detected by fluorography following immunoprecipitation and gel electrophoresis, Labeled mannose receptor was found exclusively in the nonbinding fraction until 10 min of chase. Following a 60-min chase, 67-86% of newly synthesized receptor was precipitated from the bound column fraction. The half-time for development of receptor binding activity was determined to be 35-40 min compared with a 45-min half-time for development of endoglycosidase H resistance. Mannose receptor synthesized by cells incubated in brefeldin A required more than 120 min to acquire endoglycosidase H resistance and maximal binding activity. Inhibitors of N-linked oligosaccharide processing or of O-glycosylation had no effect on the development of mannose receptor binding activity. Monensin prevented terminal sialylation of oligosaccharide side chains but did not inhibit receptor activation. Inclusion of aluminum fluoride in the chase media reversibly inhibited development of endoglycosidase H resistance and mannose-binding activity. We conclude that the mannose receptor undergoes delayed activation following synthesis and suggest that the activating event(s) occur following exit of the receptor from the endoplasmic reticulum and prior to its entry into the trans-Golgi.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Stahl, Philip/D-6315-2012					ARAR C, 1995, J BIOL CHEM, V270, P3551, DOI 10.1074/jbc.270.8.3551; BURGOYNE RD, 1992, TRENDS BIOCHEM SCI, V17, P87; CHUNG KN, 1984, J BIOL CHEM, V259, P4637; DIAZ R, 1989, BIOCHEM J, V260, P127, DOI 10.1042/bj2600127; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DRICKAMER K, 1993, BIOCHEM SOC T, V21, P468; ELBEIN AD, 1987, METHOD ENZYMOL, V138, P661; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; FINAZZI D, 1994, J BIOL CHEM, V269, P13325; FREEDMAN R, 1987, NATURE, V329, P196, DOI 10.1038/329196a0; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hendriks R J, 1994, Subcell Biochem, V22, P101; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUAN SF, 1989, J BIOL CHEM, V264, P19271; LENNARTZ MR, 1989, J BIOL CHEM, V264, P2385; LENNARTZ MR, 1987, BIOCHEM J, V245, P705, DOI 10.1042/bj2450705; Lippincott-Schwartz J, 1993, Subcell Biochem, V21, P95; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; MULLIN NP, 1994, J BIOL CHEM, V269, P28405; POMMIER CG, 1984, BLOOD, V64, P858; PONTOW SE, 1992, INT REV CYTOL, V137B, P221; PONTOW SE, 1992, NATO ASI SERIES H, V91, P333; STAHL P, 1980, CELL, V19, P207, DOI 10.1016/0092-8674(80)90402-X; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TAYLOR ME, 1993, J BIOL CHEM, V268, P399; TAYLOR ME, 1993, BIOCHEM SOC T, V21, P468, DOI 10.1042/bst0210468; TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475; Varki A, 1994, Subcell Biochem, V22, P71; YOSHIMORI T, 1990, J BIOL CHEM, V265, P15984	36	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30736	30740		10.1074/jbc.271.48.30736	http://dx.doi.org/10.1074/jbc.271.48.30736			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940052	hybrid			2022-12-27	WOS:A1996VV15800069
J	Stefanis, L; Park, DS; Yan, CYI; Farinelli, SE; Troy, CM; Shelanski, ML; Greene, LA				Stefanis, L; Park, DS; Yan, CYI; Farinelli, SE; Troy, CM; Shelanski, ML; Greene, LA			Induction of CPP32-like activity in PC12 cells by withdrawal of trophic support - Dissociation from apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; DEATH GENE CED-3; INTERLEUKIN-1-BETA CONVERTING-ENZYME; POLY(ADP-RIBOSE) POLYMERASE; C-ELEGANS; IL-1-BETA-CONVERTING ENZYME; NEURONAL DIFFERENTIATION; PHEOCHROMOCYTOMA CELLS; SYMPATHETIC NEURONS; CYSTEINE PROTEASES	Inhibitors of interleukin-1 beta converting enzyme (ICE) and a related group of cysteine aspartases of the ICE/ced-3 family inhibit cell death in a variety of settings, including in PC12 cells and sympathetic neurons following withdrawal of trophic support. To assess the particular member(s) of the ICE/ced-3 family that are relevant to cell death and to position their activation within the apoptotic pathway, we have used specific substrates to measure ICE-like and CPP32-like enzymatic activity in naive and neuronally differentiated PC12 cells that had been deprived of trophic support (nerve growth factor and/or serum). Rapid induction of CPP32-like, but not ICE-like, activity was observed. c-Jun kinase activation and the action of bcl-2 and other survival agents, such as cell cycle blockers, a NO generator, N-acetylcysteine, aurintricarboxylic acid, and actinomycin D occurred at a point further upstream in the apoptotic pathway compared with the aspartase activation. In living cells, zVAD-FRIR, a pseudosubstrate aspartase inhibitor, blocked the activity/activation of the aspartase at concentrations about one order of magnitude lower than those required to promote survival, raising the possibility that the CPP32-like aspartase is not the main death effector in this model.	COLUMBIA UNIV COLL PHYS & SURG, DEPT NEUROL, TAUB CTR ALZHEIMERS DIS RES, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA	Columbia University; Columbia University	Stefanis, L (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DEPT PATHOL, TAUB CTR ALZHEIMERS DIS RES, 630 W 168TH ST, NEW YORK, NY 10032 USA.		Stefanis, Leonidas/AAD-7192-2019; Yan, Chao Yun Irene/B-4700-2011; Troy, Carol/ABC-2771-2020	Yan, Chao Yun Irene/0000-0003-0527-5719; Park, David/0000-0002-4490-3784				BATISTATOU A, 1993, J CELL BIOL, V122, P523, DOI 10.1083/jcb.122.3.523; BATISTATOU A, 1991, J CELL BIOL, V115, P461, DOI 10.1083/jcb.115.2.461; BATISTATOU A, 1993, J NEUROSCI, V13, P4422; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; DAVIES AM, 1995, TRENDS NEUROSCI, V18, P355, DOI 10.1016/0166-2236(95)93928-Q; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Farinelli SE, 1996, J NEUROSCI, V16, P2325; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FERRARI G, 1995, J NEUROSCI, V15, P2857; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MESNER PW, 1992, J CELL BIOL, V119, P1669, DOI 10.1083/jcb.119.6.1669; MILLER DK, 1993, J BIOL CHEM, V268, P18062; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OKADA N, 1995, J BIOL CHEM, V270, P16464, DOI 10.1074/jbc.270.27.16464; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SHAW E, 1990, ADV ENZYMOL RAMB, V63, P271; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Troy CM, 1996, P NATL ACAD SCI USA, V93, P5635, DOI 10.1073/pnas.93.11.5635; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YAN CYI, 1995, J BIOL CHEM, V270, P26827, DOI 10.1074/jbc.270.45.26827; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	53	148	148	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30663	30671		10.1074/jbc.271.48.30663	http://dx.doi.org/10.1074/jbc.271.48.30663			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940042	hybrid			2022-12-27	WOS:A1996VV15800059
J	Arakawa, T; Laneuville, O; Miller, CA; Lakkides, KM; Wingerd, BA; DeWitt, DL; Smith, WL				Arakawa, T; Laneuville, O; Miller, CA; Lakkides, KM; Wingerd, BA; DeWitt, DL; Smith, WL			Prostanoid receptors of murine NIH 3T3 and RAW 264.7 cells - Structure and expression of the murine prostaglandin EP4 receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTORS; ENDOPEROXIDE SYNTHASE-2 GENE; NORTHERN BLOT ANALYSIS; EP(2) SUBTYPE; MOLECULAR CHARACTERIZATION; TRANSCRIPTION FACTOR; FUNCTIONAL EXPRESSION; PROSTACYCLIN RECEPTOR; SIGNAL-TRANSDUCTION; PROMOTER SEQUENCES	Prostaglandin endoperoxide H synthase-1 (PGHS-1) is expressed constitutively in murine NIH 3T3 cells and RAW 264.7 cells. PGHS-2 is inducibly expressed in these cells following stimulation with serum or bacterial lipopolysaccharide (LPS), respectively. Reverse transcription-polymerase chain reaction (RT-PCR) analysis established that a variety of G protein-linked and peroxisomal proliferator-activated prostanoid receptors are expressed in both of these cell types. The levels of the EP2 and EP4 prostaglandin E(2) (PGE(2)) receptors and the prostaglandin I-2 receptor were changed in these cells by serum or LPS stimulation, Quantitative RT-PCR indicated that the mRNA for the murine EP4 receptor, the butaprost-insensitive PGE(2) receptor that couples to G(s), increases 1.5-3-fold in response to serum (NIH 3T3) or LPS (RAW 264.7) with a time course approximating the induction of PGHS-2 expression. To study expression of the EP4 receptor we isolated the mouse EP4 receptor gene; the gene is 10 kilobase pairs (kb) in length and, like other known prostanoid receptor genes, contains three exons and two introns, The first intron is 0.5 kb and is located 16 base pairs (bp) downstream of the translational start site. This is a different location than that of the first introns of other prostanoid receptor genes. The second intron is located immediately following the sixth transmembrane domain at the same position as the second intron of the thromboxane A(2) receptor, prostaglandin D-2 receptor, prostaglandin I-2 receptor, and one of the PGE(2) (EP1) receptor genes. A major transcriptional start was detected at -142 bp upstream of the translational start. There are a variety of putative cis-acting elements within 1.5 kb upstream of the translational start site and within the first intron. Promoter analyses of the EP4 receptor gene promoter in RAW 264.7 cells indicated that there is a constitutive negative regulatory region between -992 and -928 bp, a constitutive positive region between -928 and -554 bp, and an LPS/serum-responsive region between -554 and -116 bp.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK022042, R01DK022042] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK22042] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAM M, 1994, FEBS LETT, V338, P170, DOI 10.1016/0014-5793(94)80358-7; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AN SZ, 1993, BIOCHEM BIOPH RES CO, V197, P263, DOI 10.1006/bbrc.1993.2470; ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; BASTIEN L, 1994, J BIOL CHEM, V269, P11873; BATSHAKE B, 1995, EUR J BIOCHEM, V231, P809, DOI 10.1111/j.1432-1033.1995.tb20765.x; Breyer RM, 1996, AM J PHYSIOL-RENAL, V270, pF485, DOI 10.1152/ajprenal.1996.270.3.F485; BUCHER P, 1986, NUCLEIC ACIDS RES, V14, P10009, DOI 10.1093/nar/14.24.10009; COLEMAN RA, 1994, PROSTAGLANDINS, V47, P151, DOI 10.1016/0090-6980(94)90084-1; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EVETT GE, 1993, ARCH BIOCHEM BIOPHYS, V306, P169, DOI 10.1006/abbi.1993.1496; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FUNK CD, 1993, J BIOL CHEM, V268, P26767; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; HIRATA M, 1994, P NATL ACAD SCI USA, V91, P11192, DOI 10.1073/pnas.91.23.11192; HONDA A, 1993, J BIOL CHEM, V268, P7759; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; KANAI N, 1995, SCIENCE, V268, P866, DOI 10.1126/science.7754369; KATOH H, 1995, BBA-GEN SUBJECTS, V1244, P41, DOI 10.1016/0304-4165(94)00182-W; KATSUYAMA M, 1995, FEBS LETT, V372, P151, DOI 10.1016/0014-5793(95)00966-D; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1993, J BIOL CHEM, V268, P5425; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Morris JK, 1996, J BIOL CHEM, V271, P16633, DOI 10.1074/jbc.271.28.16633; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; NAMBA T, 1992, BIOCHEM BIOPH RES CO, V184, P1197, DOI 10.1016/S0006-291X(05)80009-9; NAMBA T, 1994, J BIOL CHEM, V269, P9986; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NISHIGAKI N, 1995, FEBS LETT, V364, P339, DOI 10.1016/0014-5793(95)00421-5; NUSING RM, 1993, J BIOL CHEM, V268, P25253; OGAWA Y, 1995, GENOMICS, V27, P142, DOI 10.1006/geno.1995.1016; REGAN JW, 1994, MOL PHARMACOL, V46, P213; RIESE J, 1994, J LEUKOCYTE BIOL, V55, P476, DOI 10.1002/jlb.55.4.476; Sambrook J., 2002, MOL CLONING LAB MANU; SANDO T, 1994, BIOCHEM BIOPH RES CO, V200, P1329, DOI 10.1006/bbrc.1994.1596; SIEBERT PD, 1993, BIOTECHNIQUES, V14, P244; SIROIS J, 1993, J BIOL CHEM, V268, P21931; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; SUGIMOTO Y, 1994, J BIOL CHEM, V269, P1356; TAKETO M, 1994, GENOMICS, V19, P585, DOI 10.1006/geno.1994.1113; TOH H, 1995, FEBS LETT, V361, P17, DOI 10.1016/0014-5793(95)00129-W; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; URADE Y, 1995, J LIPID MEDIAT CELL, V12, P257, DOI 10.1016/0929-7855(95)00032-L; USHIKUBI F, 1995, J LIPID MEDIAT CELL, V12, P343, DOI 10.1016/0929-7855(95)00022-I; WATABE A, 1993, J BIOL CHEM, V268, P20175; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; YANG JH, 1994, BIOCHEM BIOPH RES CO, V198, P999, DOI 10.1006/bbrc.1994.1142; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; ZHANG DE, 1994, J BIOL CHEM, V269, P11425; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	65	95	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29569	29575		10.1074/jbc.271.47.29569	http://dx.doi.org/10.1074/jbc.271.47.29569			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939885	hybrid			2022-12-27	WOS:A1996VU52500013
J	SilvaNeto, MAC; Atella, GC; Fialho, E; Paes, MC; Zingali, RB; Petretski, JH; Alves, EW; Masuda, H				SilvaNeto, MAC; Atella, GC; Fialho, E; Paes, MC; Zingali, RB; Petretski, JH; Alves, EW; Masuda, H			Isolation of a calcium-binding phosphoprotein from the oocytes and hemolymph of the blood-sucking insect Rhodnius prolixus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YOLK PROTEINS; VITELLOGENIN GENE; ELECTROPHORETIC GELS; PHOSVITIN; LIPOVITELLIN; EMBRYOGENESIS; EVOLUTION; VITELLIN; SEQUENCE; PHOSPHORYLATION	A novel calcium-binding phosphoprotein was isolated from the oocytes of the blood-sucking bug Rhodnius prolixus. This protein exhibits an apparent molecular mass of 18 kDa on gel filtration, but migrates as an 8-kDa band on N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine/SDS-polyacrylamide gels. It has a high content of serine (24% of the total number of residues), and phosphoserine is the sole amino acid phosphorylated in vivo. A similar protein was partially purified from the hemolymph. It resembles the oocyte form of the protein in its NH2-terminal sequence and its ability to be taken up by growing ovaries. Ca-45 binding to the oocyte phosphoprotein was determined after SDS-polyacrylamide gel electrophoresis followed by blotting on nitrocellulose membranes. Titration of Ca2+-binding sites shows a high capacity (congruent to 50 mol/mol of protein), but a low affinity (K-0.5, congruent to 10(-3) M). Based on these characteristics, we have named this protein Rhodnius calcium-binding phosphoprotein, It resembles phosvitin, a phosphoprotein present in the oocytes of nonmammalian vertebrates.	ESCOLA TECN FED QUIM RIO DE JANEIRO,BR-20010000 RIO JANEIRO,BRAZIL; UNIV ESTADUAL NORTE FLUMINENSE,CTR BIOCIENCIAS & BIOTECNOL,LAB QUIM & FUNCAO PROT & PEPTIDEOS,BR-28015620 S JOSE CAMPOS,RJ,BRAZIL	Universidade Estadual do Norte Fluminense	SilvaNeto, MAC (corresponding author), FED UNIV RIO DE JANEIRO,INST CIENCIAS BIOMED,DEPT BIOQUIM MED,POB 68041,BR-21941590 RIO JANEIRO,BRAZIL.		Atella, Georgia/AAK-7897-2020; PAES, MARCIA CRISTINA/AAL-9530-2021; Zingali, Russolina/G-4862-2012; Fialho, Eliane/AAF-8856-2019	Zingali, Russolina/0000-0003-3156-6923				ALLERTON SE, 1965, J BIOL CHEM, V240, P3892; BANASZAK L, 1991, ANNU REV BIOPHYS BIO, V20, P221, DOI 10.1146/annurev.biophys.20.1.221; BERGINK EW, 1974, J BIOL CHEM, V249, P2897; BYRNE BM, 1984, BIOCHEMISTRY-US, V23, P4275, DOI 10.1021/bi00314a003; BYRNE BM, 1989, PROG BIOPHYS MOL BIO, V53, P33, DOI 10.1016/0079-6107(89)90005-9; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CARDASIS CA, 1978, J CELL SCI, V77, P101; CHEN JS, 1994, J MOL BIOL, V237, P641, DOI 10.1006/jmbi.1994.1261; CHEN Y, 1992, J BIOL CHEM, V267, P24871; DANSAPETRETSKI M, 1995, J BIOL CHEM, V270, P10893, DOI 10.1074/jbc.270.18.10893; de Meis L, 1974, Biochemistry, V13, P2057, DOI 10.1021/bi00707a009; FLICKINGER RA, 1957, EXP CELL RES, V13, P312, DOI 10.1016/0014-4827(57)90010-1; Garcia ES, 1975, AN ACAD BRAS CIENC, V47, P539; GEORGE A, 1993, J BIOL CHEM, V268, P12624; GREENGARD O, 1964, BIOCHIM BIOPHYS ACTA, V90, P406, DOI 10.1016/0304-4165(64)90208-9; GRIZZUTI K, 1973, BIOCHEMISTRY-US, V12, P4399, DOI 10.1021/bi00746a016; HEGENAUER J, 1977, ANAL BIOCHEM, V78, P308, DOI 10.1016/0003-2697(77)90038-0; IZUMI S, 1994, J INSECT PHYSIOL, V40, P735, DOI 10.1016/0022-1910(94)90001-9; JAFFE LA, 1994, DEV BIOL, V164, P759; JOYAL JL, 1994, J BIOL CHEM, V269, P30039; KELLY GM, 1986, CAN J ZOOL, V64, P2425, DOI 10.1139/z86-362; KUNKEL JG, 1985, COMPREHENSIVE INSECT, V1, P83; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFLEUR GJ, 1995, J MOL EVOL, V41, P505, DOI 10.1007/BF00160323; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADDRELL SH, 1969, J EXP BIOL, V51, P71; MARSH ME, 1989, BIOCHEMISTRY-US, V28, P339, DOI 10.1021/bi00427a046; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MASUDA H, 1985, INSECT BIOCHEM, V15, P543, DOI 10.1016/0020-1790(85)90068-X; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MECHAM DK, 1949, J AM CHEM SOC, V71, P3670, DOI 10.1021/ja01179a028; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; MONTORZI M, 1995, BIOCHEMISTRY-US, V34, P10851, DOI 10.1021/bi00034a018; MONTORZI M, 1994, BIOCHEM BIOPH RES CO, V200, P1407, DOI 10.1006/bbrc.1994.1607; NARDELLI D, 1987, BIOCHEMISTRY-US, V26, P6397, DOI 10.1021/bi00394a014; OLIVEIRA PL, 1986, J INSECT PHYSIOL, V32, P859, DOI 10.1016/0022-1910(86)90101-0; OLIVEIRA PL, 1995, J BIOL CHEM, V270, P10897, DOI 10.1074/jbc.270.18.10897; OLIVEIRA PL, 1989, INSECT BIOCHEM, V19, P489; RAIKHEL AS, 1992, ANNU REV ENTOMOL, V37, P217, DOI 10.1146/annurev.en.37.010192.001245; REINHARD E, 1995, DEV BIOL, V170, P50, DOI 10.1006/dbio.1995.1194; ROMANS P, 1995, INSECT BIOCHEM MOLEC, V25, P939, DOI 10.1016/0965-1748(95)00037-V; Sander K., 1985, P319; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHARROCK WJ, 1992, J MOL BIOL, V226, P903, DOI 10.1016/0022-2836(92)90642-W; SHIRAISHI K, 1995, DEV BIOL, V170, P594, DOI 10.1006/dbio.1995.1239; SORENSEN ES, 1995, PROTEIN SCI, V4, P2040, DOI 10.1002/pro.5560041009; STRICKER SA, 1995, DEV BIOL, V170, P496, DOI 10.1006/dbio.1995.1232; TABORSKY G, 1980, J BIOL CHEM, V255, P2976; Tata J R, 1979, Recent Prog Horm Res, V35, P47; TREWITT PM, 1992, J MOL EVOL, V34, P478, DOI 10.1007/BF00160462; WAHLI W, 1988, TRENDS GENET, V4, P227, DOI 10.1016/0168-9525(88)90155-2; WALLACE RA, 1986, ANAL BIOCHEM, V157, P256, DOI 10.1016/0003-2697(86)90623-8; WALLACE RA, 1986, BIOCHEM J, V240, P871, DOI 10.1042/bj2400871; WANDEL M, 1995, J BIOL CHEM, V270, P6125; YANO K, 1994, FEBS LETT, V356, P207, DOI 10.1016/0014-5793(94)01265-2; ZHANG YJ, 1992, INSECT BIOCHEM MOLEC, V22, P293, DOI 10.1016/0965-1748(92)90067-O	56	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30227	30232		10.1074/jbc.271.47.30227	http://dx.doi.org/10.1074/jbc.271.47.30227			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939975				2022-12-27	WOS:A1996VU52500103
J	Springer, C; Kunzler, M; Balmelli, T; Braus, GH				Springer, C; Kunzler, M; Balmelli, T; Braus, GH			Amino acid and adenine cross-pathway regulation act through the same 5'-TGACTC-3' motif in the yeast HIS7 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; GENERAL CONTROL; PROTEIN; GCN4; DNA; BIOSYNTHESIS; SEQUENCE; AMIDOTRANSFERASE; MUTAGENESIS	The HIS7 gene of Saccharomyces cerevisiae encodes a bifunctional glutamine amidotransferase:cyclase catalyzing two reactions that lead to the formation of biosynthetic intermediates of the amino acid histidine and the purine adenine. The HIS7 gene is activated by GCN4p under environmental conditions of amino acid starvation through two synergistic upstream sites GCRE1 and GCRE2. The BAS1p-BAS2p complex activates the HIS7 gene in response to adenine limitation. For this activation the proximal GCN4p-binding site GCRE2 is required. GCN4p and BAS1p bind to GCRE2 in vitro. Under conditions of simultaneous amino acid starvation and adenine limitation the effects of GCN4p and BAS1/2p are additive and both factors are necessary for maximal HIS7 transcription. These results suggest that GCN4p and BAS1/2p are able to act simultaneously through the same DNA sequence in vivo and use this site independently from each other in a non-exclusive manner.	UNIV ERLANGEN NURNBERG,INST MICROBIOL BIOCHEM & GENET,D-91058 ERLANGEN,GERMANY	University of Erlangen Nuremberg			Braus, Gerhard H/G-3999-2012	Braus, Gerhard H/0000-0002-3117-5626; Kunzler, Markus/0000-0003-1275-0629				ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; ARNDT KT, 1987, SCIENCE, V237, P874, DOI 10.1126/science.3303332; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BRAUS G, 1989, EMBO J, V8, P939, DOI 10.1002/j.1460-2075.1989.tb03455.x; BRAZAS RM, 1993, MOL CELL BIOL, V13, P5524, DOI 10.1128/MCB.13.9.5524; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; DAIGNANFORNIER B, 1992, P NATL ACAD SCI USA, V89, P6746, DOI 10.1073/pnas.89.15.6746; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GIEBEL LB, 1990, NUCLEIC ACIDS RES, V18, P4947, DOI 10.1093/nar/18.16.4947; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; HIRST K, 1994, EMBO J, V13, P5410, DOI 10.1002/j.1460-2075.1994.tb06876.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KUENZLER M, 1993, J BACTERIOL, V175, P5548, DOI 10.1128/JB.175.17.5548-5558.1993; MANTSALA P, 1984, J BIOL CHEM, V259, P8478; MIOZZARI G, 1978, J BACTERIOL, V134, P48, DOI 10.1128/JB.134.1.48-59.1978; MOSCH HU, 1991, J BIOL CHEM, V266, P20453; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 2002, MOL CLONING LAB MANU; SENGSTAG C, 1987, NUCLEIC ACIDS RES, V15, P233, DOI 10.1093/nar/15.1.233; SIKORSKI RS, 1989, GENETICS, V122, P19; STOTZ A, 1993, CURR GENET, V24, P472, DOI 10.1007/BF00351708; STRUHL K, 1989, ANNU REV BIOCHEM, V58, P1051, DOI 10.1146/annurev.bi.58.070189.005155; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; VOGEL K, 1989, MOL CELL BIOL, V9, P2050, DOI 10.1128/MCB.9.5.2050; YOSHIDA K, 1989, MOL GEN GENET, V217, P40, DOI 10.1007/BF00330940; ZITOMER RS, 1976, J BIOL CHEM, V251, P6320	30	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29637	29643		10.1074/jbc.271.47.29637	http://dx.doi.org/10.1074/jbc.271.47.29637			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939895	hybrid			2022-12-27	WOS:A1996VU52500023
J	DinkovaKostova, AT; Gang, DR; Davin, LB; Bedgar, DL; Chu, A; Lewis, NG				DinkovaKostova, AT; Gang, DR; Davin, LB; Bedgar, DL; Chu, A; Lewis, NG			(+)-Pinoresinol/(+)-lariciresinol reductase from Forsythia intermedia - Protein purification, cDNA cloning, heterologous expression and comparison to isoflavone reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYTOALEXIN BIOSYNTHESIS; FLAVONOID SYNTHESIS; MOLECULAR-CLONING; CELL-CULTURES; LIGNANS; GENE; (+)-PINORESINOL; DEHYDROGENASE; SEQUENCE; DIHYDROFLAVONOL-4-REDUCTASE	Lignans are a widely distributed class of natural products, whose functions and distribution suggest that they are one of the earliest forms of defense to have evolved in vascular plants; some, such as podophyllotoxin and enterodiol, have important roles in cancer chemotherapy and prevention, respectively. Entry into lignan enzymology has been gained by the similar to 3000-fold purification of two isoforms of (+)-pinoresinol/(+)-lariciresinol reductase, a pivotal branchpoint enzyme in lignan biosynthesis. Both have comparable (similar to 34.9 kDa) molecular mass and kinetic (V-max/K-m) properties and catalyze sequential, NADPH-dependent, stereospecific, hydride transfers where the incoming hydride takes up the pro-R position. The gene encoding (+)-pinoresinol/(+)-lariciresinol reductase has been cloned and the recombinant protein heterologously expressed as a functional beta-galactosidase fusion protein. Its amino acid sequence reveals a strong homology to isoflavone reductase, a key branchpoint enzyme in isoflavonoid metabolism and primarily found in the Fabaceae (angiosperms). This is of great evolutionary significance since both lignans and isoflavonoids have comparable plant defense properties, as well as similar roles as phytoestrogens. Given that lignans are widespread from primitive plants onwards, whereas the isoflavone reductase-derived isoflavonoids are mainly restricted to the Fabaceae, it is tempting to speculate that this branch of the isoflavonoid pathway arose via evolutionary divergence from that giving the lignans.	WASHINGTON STATE UNIV, INST BIOL CHEM, PULLMAN, WA 99164 USA	Washington State University			Gang, David/B-1001-2013	Davin, Laurence/0000-0002-3248-6485; Lewis, Norman/0000-0001-5742-032X; Dinkova-Kostova, Albena/0000-0003-0316-9859				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSON JA, 1993, PHYTOCHEMISTRY, V32, P811, DOI 10.1016/0031-9422(93)85210-I; Ausubel FM, 1991, CURRENT PROTOCOLS MO; AXELSON M, 1981, FEBS LETT, V123, P337, DOI 10.1016/0014-5793(81)80322-5; Ayres D. C., 1990, LIGNANS, P12; BALLANCE GM, 1995, PLANT PHYSIOL, V107, P1027, DOI 10.1104/pp.107.3.1027; BELD M, 1989, PLANT MOL BIOL, V13, P491, DOI 10.1007/BF00027309; BINNS AN, 1987, P NATL ACAD SCI USA, V84, P980, DOI 10.1073/pnas.84.4.980; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P141; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P675; CHU A, 1993, J BIOL CHEM, V268, P27026; DAVIN LB, 1992, PHYTOCHEMISTRY, V31, P3869, DOI 10.1016/S0031-9422(00)97544-7; DAVIN LB, 1992, RECENT ADV PHYTOCHEM, V26, P325; DIXON RA, 1995, PHYSIOL PLANTARUM, V93, P385, DOI 10.1111/j.1399-3054.1995.tb02243.x; DONG ZD, 1996, PLANT CELL REP, V15, P516; FAURE M, 1990, PHYTOCHEMISTRY, V29, P3773, DOI 10.1016/0031-9422(90)85329-E; *GEN COMP GROUP IN, 1994, PROGR MAN WISC PACK; GNABRE JN, 1995, P NATL ACAD SCI USA, V92, P11239, DOI 10.1073/pnas.92.24.11239; Gottlieb O. R., 1989, NATURAL PRODUCTS WOO, P439; Graham L, 1993, ORIGIN LAND PLANTS; GRAHAM LE, 1996, IN PRESS J PLANT RES, V109; HARMATHA J, 1984, BIOCHEM SYST ECOL, V12, P95, DOI 10.1016/0305-1978(84)90015-2; HIBI N, 1994, PLANT CELL, V6, P723, DOI 10.1105/tpc.6.5.723; HORINOUCHI S, 1991, APPL ENVIRON MICROB, V57, P1386, DOI 10.1128/AEM.57.5.1386-1393.1991; HRYCYNA CA, 1993, BIOCHEMISTRY-US, V32, P11293, DOI 10.1021/bi00093a005; JORNVALL H, 1980, DEHYDROGENASES REQUI, P126; KATAYAMA T, 1993, PHYTOCHEMISTRY, V33, P581, DOI 10.1016/0031-9422(93)85452-W; KRISTIANSEN KN, 1991, MOL GEN GENET, V230, P49, DOI 10.1007/BF00290650; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS NG, 1994, ACS SYM SER, V562, P202; LEWIS NG, 1994, POLYPHENOLS ACTUALIT, V10, P17; MACKAY JJ, 1995, MOL GEN GENET, V247, P537, DOI 10.1007/BF00290344; MARKKANEN T, 1981, DRUG EXP CLIN RES, V7, P711; MORAN RG, 1984, ANAL BIOCHEM, V138, P196, DOI 10.1016/0003-2697(84)90788-7; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NIKAIDO T, 1981, CHEM PHARM BULL, V29, P3586; NISHIBE S, 1990, CHEM PHARM BULL, V38, P1763, DOI 10.1248/cpb.38.1763; OBLONG JE, 1993, BIOCHEMISTRY-US, V32, P7271, DOI 10.1021/bi00079a025; OSAWA T, 1985, AGR BIOL CHEM TOKYO, V49, P3351, DOI 10.1080/00021369.1985.10867272; PAIVA NL, 1994, ARCH BIOCHEM BIOPHYS, V312, P501, DOI 10.1006/abbi.1994.1338; PAIVA NL, 1991, PLANT MOL BIOL, V17, P653, DOI 10.1007/BF00037051; PARE PW, 1994, TETRAHEDRON LETT, V35, P4731, DOI 10.1016/S0040-4039(00)76953-X; Petrucco S, 1996, PLANT CELL, V8, P69, DOI 10.1105/tpc.8.1.69; RAHMAN MMA, 1990, PHYTOCHEMISTRY, V29, P1861, DOI 10.1016/0031-9422(90)85029-F; RICE P, 1996, PROGRAM MANUAL EGCG; Sambrook J, 1994, MOL CLONING LAB MANU; SCHRODER HC, 1990, Z NATURFORSCH C, V45, P1215; STELLWAGEN E, 1990, METHOD ENZYMOL, V182, P317; TAKEDA R, 1990, TETRAHEDRON LETT, V31, P4159, DOI 10.1016/S0040-4039(00)97569-5; TAKEDA R, 1990, BRYOPHYTES THEIR CHE, V29, P201; TIEMANN K, 1991, EUR J BIOCHEM, V200, P751, DOI 10.1111/j.1432-1033.1991.tb16241.x; WADA H, 1992, CHEM PHARM BULL, V40, P2099; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; ZHAO HF, 1990, ENDOCRINOLOGY, V127, P3237, DOI 10.1210/endo-127-6-3237	55	159	169	2	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29473	29482		10.1074/jbc.271.46.29473	http://dx.doi.org/10.1074/jbc.271.46.29473			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910615	hybrid			2022-12-27	WOS:A1996VT05200107
J	Chuang, TT; Paolucci, L; DeBlasi, A				Chuang, TT; Paolucci, L; DeBlasi, A			Inhibition of G protein-coupled receptor kinase subtypes by Ca2+/calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; CALMODULIN-BINDING; ADENYLATE-CYCLASE; RHODOPSIN KINASE; FAMILY; PHOSPHORYLATION; EXPRESSION; CALCIUM; GRK5; IDENTIFICATION	G protein-coupled receptor kinases (GRKs) are implicated in the homologous desensitization of G protein-coupled receptors. Six GRK subtypes have so far been identified, named GRK1 to GRK6. The functional state of the GRKs can be actively regulated in different ways. In particular, it was found that retinal rhodopsin kinase (GRK1), but not the ubiquitous beta ARK1 (GRK2), can be inhibited by the photoreceptor-specific Ca2+-binding protein recoverin through direct binding. The present study was aimed to investigate regulation of other GRKs by alternative Ca2+-binding proteins such as calmodulin (CaM). We found that G beta gamma-activated GRK2 and GRK3 were inhibited by CaM to similar extents (IC50 similar to 2 mu M), while a 50-fold more potent inhibitory effect was observed on GRK5 (IC50 = 40 nM). Inhibition by CaM was strictly dependent on Ca2+ and was prevented by the CaM inhibitor CaMBd. Since G beta gamma, which is a binding target of Ca2+/CaM, is critical for the activation of GRK2 and GRK3, it provides a possible site of interaction between these proteins. However, since GRK5 is G beta gamma-independent, an alternative mechanism is conceivable. A direct interaction between GRK5 and Ca2+/CaM was revealed using CaM-conjugated Sepharose 4B. This binding does not influence the catalytic activity as demonstrated using the soluble GRK substrate casein. Instead, Ca2+/CaM significantly reduced GRK5 binding to the membrane. The mechanism of GRK5 inhibition appeared to be through direct binding to Ca2+/CaM, resulting in inhibition of membrane association and hence receptor phosphorylation. The present study provides the first evidence for a regulatory effect of Ca2+/CaM on some GRK subtypes, thus expanding the range of different mechanisms regulating the functional states of these kinases.	IST RIC FARMACOL MARIO NEGRI,CONSORZIO MARIO NEGRI SUD,I-66030 SANTA MARIA IMBAR,ITALY	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS								ABRAMS TW, 1991, J NEUROSCI, V11, P2655; BENOVIC JL, 1986, NATURE, V321, P869, DOI 10.1038/321869a0; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; DEBLASI A, 1995, J CLIN INVEST, V95, P203, DOI 10.1172/JCI117641; DECASTRO E, 1995, BIOCHEM BIOPH RES CO, V216, P133, DOI 10.1006/bbrc.1995.2601; GNEGY ME, 1993, ANNU REV PHARMACOL, V33, P45, DOI 10.1146/annurev.pa.33.040193.000401; Haske TN, 1996, J BIOL CHEM, V271, P2941, DOI 10.1074/jbc.271.6.2941; Iacovelli L, 1996, MOL ENDOCRINOL, V10, P1138, DOI 10.1210/me.10.9.1138; INGLESE J, 1992, J BIOL CHEM, V267, P1422; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; KATADA T, 1987, J BIOL CHEM, V262, P11897; KLENCHIN VA, 1995, J BIOL CHEM, V270, P16147, DOI 10.1074/jbc.270.27.16147; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KUHN H, 1978, BIOCHEMISTRY-US, V21, P4389; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LAKEY T, 1985, BIOCHEM J, V225, P581, DOI 10.1042/bj2250581; MANGELS LA, 1992, BIOCHEM J, V283, P683, DOI 10.1042/bj2830683; Nagayama Y, 1996, J BIOL CHEM, V271, P10143, DOI 10.1074/jbc.271.17.10143; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PAPADOPOULOS V, 1990, ENDOCRINOLOGY, V126, P2465, DOI 10.1210/endo-126-5-2465; PARRUTI G, 1993, J BIOL CHEM, V268, P9753; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; PREMONT RT, 1996, J BIOL CHEM, V271, P6408; STOFFEL RH, 1994, J BIOL CHEM, V269, P27791; WILSON CJ, 1993, CURR BIOL, V3, P683, DOI 10.1016/0960-9822(93)90068-Y	36	86	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28691	28696		10.1074/jbc.271.45.28691	http://dx.doi.org/10.1074/jbc.271.45.28691			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910504	hybrid			2022-12-27	WOS:A1996VU03300104
J	Wang, Q; Forlino, A; Marini, JC				Wang, Q; Forlino, A; Marini, JC			Alternative splicing in COL1A1 mRNA leads to a partial null allele and two in-frame forms with structural defects in non-lethal osteogenesis imperfecta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POINT MUTATIONS; MESSENGER-RNA; COLLAGEN; PROCOLLAGEN; CHAIN; GENE; DELETION; DNA; HETEROGENEITY; TRANSLATION	We have identified a novel multiexon genomic deletion in one COL1A1 collagen allele that results in three alternative forms of mutant mRNA. This mutation occurs in a 9-year-old girl and her father, both affected with severe type III osteogenesis imperfecta (OI). We previously reported detection of a mismatch in their alpha 1(I) amino acids 558-861 region by RNA/RNA hybrid analysis (Orange, D. K., Gottesman, G. S., Lewis, M. B., and Marini, J. C. (1990) Nucleic Acids Res. 18, 4227-4286). Single Strand Conformational Polymorphism further localized the mRNA mutation to the amino acids 579-679 coding region. At the gene level, polymerase chain reaction (PCR) amplification of patient leukocyte DNA from the exon 33-38 region yielded the normal 1004-base pair (bp) fragment and an additional 442-bp fragment. Sequencing of the shorter genomic PCR product confirmed the presence of a 562-bp deletion, extending from the last 3 nucleotides (nt) of exon 34 to 156 nt from the 3'-end of intron 36. The genomic deletion was also detected in the clinically normal grandmother, who was confirmed to be a mosaic carrier. PCR amplification and RNase protection experiments were used to investigate the mRNA structure and occurrence of alternative splicing. One form of the mutant cDNA has a deletion with end points that are identical to the genomic deletion. This results in a combination deletion/insertion, with a deletion of amino acids 603-639 followed by an insertion of 156 nt from the 3'-end of intron 36. In addition, we found two alternatively spliced forms. One form uses a cryptic donor site in exon 34 and the exon 37 acceptor. The second form uses the normal exon 32 splice donor and exon 37 acceptor. Use of the cryptic donor results in a coding sequence that is out-of-frame. Both the retained intron form and the use of the exon 32 donor site result in coding sequences that are in-frame. This is the first report of a collagen defect in OI with alternative splicing generating both in-frame and out-of frame forms of mRNA. Although the in-frame forms constitute more than 60% of the mRNA from the mutant allele, no mutant protein chain was identified. Collagen produced by cultured OI osteoblasts showed a significant increase in the relative amount of type III collagen but no mutant alpha 1(I) chain.	NICHHD,SECT CONNECT TISSUE DISORDERS,HERITABLE DISORDERS BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Forlino, Antonella/H-5385-2015	Forlino, Antonella/0000-0002-6385-1182				BARSH GS, 1981, P NATL ACAD SCI-BIOL, V78, P5142, DOI 10.1073/pnas.78.8.5142; BARSH GS, 1985, P NATL ACAD SCI USA, V82, P2870, DOI 10.1073/pnas.82.9.2870; BATEMAN JF, 1994, BIOCHEM J, V302, P729, DOI 10.1042/bj3020729; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P5213, DOI 10.1021/bi00291a023; BONADIO J, 1985, J BIOL CHEM, V260, P1734; Byers Peter H., 1993, P317; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAIG D, 1992, NUCLEIC ACIDS RES, V20, P4987, DOI 10.1093/nar/20.19.4987; GENOVESE C, 1989, J BIOL CHEM, V264, P9632; GRANGE DK, 1990, NUCLEIC ACIDS RES, V18, P4227, DOI 10.1093/nar/18.14.4227; KADLER KE, 1995, BIOCHEM J, V311, P815; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; NICHOLLS AC, 1992, HUM GENET, V88, P627, DOI 10.1007/BF02265286; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; ROBEY PG, 1985, CALCIFIED TISSUE INT, V37, P453, DOI 10.1007/BF02557826; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101; VETTER U, 1991, J BONE MINER RES, V6, P501; WENSTRUP RJ, 1993, AM J MED GENET, V45, P228, DOI 10.1002/ajmg.1320450215; WESTERHAUSEN A, 1991, MATRIX, V11, P375, DOI 10.1016/S0934-8832(11)80191-5; WILLING MC, 1994, AM J HUM GENET, V55, P638; WILLING MC, 1988, J BIOL CHEM, V263, P8398	24	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28617	28623		10.1074/jbc.271.45.28617	http://dx.doi.org/10.1074/jbc.271.45.28617			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910493	hybrid			2022-12-27	WOS:A1996VU03300093
J	GarrettSinha, LA; Eberspaecher, H; Seldin, MF; deCrombrugghe, B				GarrettSinha, LA; Eberspaecher, H; Seldin, MF; deCrombrugghe, B			A gene for a novel zinc-finger protein expressed in differentiated epithelial cells and transiently in certain mesenchymal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRUPPEL-LIKE FACTOR; TRANSCRIPTION FACTOR; WILMS-TUMOR; BETA-THALASSEMIA; NERVOUS-SYSTEM; FACTOR EKLF; MOUSE; IDENTIFICATION; MICE; CHROMOSOME-4	We have identified a novel zinc-finger protein whose mRNA is expressed at high levels in the epidermal layer of the skin and in epithelial cells in the tongue, palate, esophagus, stomach, and colon of newborn mice, Expression in epithelial cells is first detected at the time of their differentiation during embryonic development. In addition, during early embryonic development there is expression in mesenchymal cells of the skeletal primordia and the metanephric kidney which is later down-regulated, The expression pattern suggests that the protein could be involved in terminal differentiation of several epithelial cell types and could also be involved in early differentiation of the skeleton and kidney. The carboxyl terminus of the protein contains three zinc fingers with a high degree of homology to erythroid kruppel-like factor and binds to DNA fragments containing CACCC motifs, The amino-terminal portion of the protein is proline and serine-rich and can function as a transcriptional activator, The chromosomal location of the gene was mapped using mouse interspecific backcrosses and was shown to localize to mouse chromosome 4 and to cosegregate with the thioredoxin gene.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL GENET,HOUSTON,TX 77030; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MICROBIOL,DURHAM,NC 27710	University of Texas System; UTMD Anderson Cancer Center; Duke University; Duke University			Garrett-Sinha, Lee Ann/K-5911-2019	Garrett-Sinha, Lee Ann/0000-0001-7806-4352	NCI NIH HHS [CA09299] Funding Source: Medline; NHGRI NIH HHS [HG00734] Funding Source: Medline; NHLBI NIH HHS [HL41264] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009299] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041264] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000734] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AHSEE KW, 1994, CANCER RES, V54, P1617; ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; BISHOP D T, 1985, Genetic Epidemiology, V2, P349, DOI 10.1002/gepi.1370020404; BRESLOW NE, 1982, JNCI-J NATL CANCER I, V68, P429; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CECI J, 1990, GENOMICS, V5, P699; CUTTING GR, 1992, GENOMICS, V12, P801, DOI 10.1016/0888-7543(92)90312-G; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FENG WC, 1994, J BIOL CHEM, V269, P1493; GAILANI MR, 1992, CELL, V69, P111, DOI 10.1016/0092-8674(92)90122-S; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GOUDIE DR, 1993, NAT GENET, V3, P165, DOI 10.1038/ng0293-165; Green EL, 1981, GENETICS PROBABILITY, P77; HAHN R, 1996, CELL, V85, P841; Hasegawa T, 1996, NUCLEIC ACIDS RES, V24, P3253, DOI 10.1093/nar/24.16.3253; HEPPELLPARTON A, 1995, GENOMICS, V26, P379, DOI 10.1016/0888-7543(95)80223-9; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JOHNSON DR, 1979, J EMBRYOL EXP MORPH, V53, P327; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Levi G, 1996, DEVELOPMENT, V122, P113; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Miura K, 1996, CANCER RES, V56, P1629; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; NARDELLI J, 1992, NUCLEIC ACIDS RES, V20, P4137, DOI 10.1093/nar/20.16.4137; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; PARROTT C, 1991, J VIROL, V65, P1414, DOI 10.1128/JVI.65.3.1414-1419.1991; PERKINS AC, 1995, NATURE, V375, P318; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sambrook J., 2002, MOL CLONING LAB MANU; SANKARAN L, 1992, ANAL BIOCHEM, V200, P180, DOI 10.1016/0003-2697(92)90296-J; SATO S, 1994, CANCER RES, V54, P5652; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; SELDIN MF, 1988, J EXP MED, V167, P688, DOI 10.1084/jem.167.2.688; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; TAKETO M, 1994, GENOMICS, V21, P251, DOI 10.1006/geno.1994.1252; TOPILKO P, 1994, NATURE, V371, P796, DOI 10.1038/371796a0; WATSON ML, 1994, METH MOL G, V5, P369; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; ZHAO GQ, 1993, P NATL ACAD SCI USA, V90, P8633, DOI 10.1073/pnas.90.18.8633	46	266	279	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31384	31390		10.1074/jbc.271.49.31384	http://dx.doi.org/10.1074/jbc.271.49.31384			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940147	hybrid			2022-12-27	WOS:A1996VW68600058
J	Rice, WJ; MacLennan, DH				Rice, WJ; MacLennan, DH			Scanning mutagenesis reveals a similar pattern of mutation sensitivity in transmembrane sequences M4, M5, and M6, but not in M8, of the Ca2+-ATPase of sarcoplasmic reticulum (SERCA1a)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING DOMAIN; FUNCTIONAL CONSEQUENCES; AMINO-ACIDS; CA-2+-ATPASE; ATPASE; SITE; TRANSPORT; GLUTAMINE; BOUNDARY; GLU(771)	Scanning mutagenesis was performed on all amino acids in transmembrane sequences M5, M6, and M8, which, together with M4, make up the Ca2+ binding domain of the Ca2+-ATPase of sarcoplasmic reticulum (SERCA1a), When these transmembrane sequences were displayed on a helical net, examination of the effects of 101 novel point mutations and 95 prior mutations carried out on 92 transmembrane amino acids revealed ''patches'' of sensitivity to mutation in M4, M5, and M6 but not in M8. The patches of mutation-sensitive residues spanned 6 of the 7 tiers of the helical net and covered about 240 degrees at their widest point in tiers 3 or 4 and 140 degrees in tiers 2 and 5. A contiguous column of mutation-insensitive hydrophobic amino acids was found in M4 and M6 and in tiers 4 to 7 of M5. A six-residue motif, (E/D)GLPA(T/V) in tiers 3 and 4 of M4 and Mg with Ca2+-binding residues Glu(309) and Asp(800) as the first residue, was highlighted by mutation sensitivity, Elements of the motif could also be discerned in M5, but reading in the C-terminal to N-terminal direction Mutation sensitivity in tier 5 of M4 mirrored mutation sensitivity of tier 5 in M6, although the amino acid sequences were not similar, The motif or its counterpart was found in a region in M4, M5, and Mg that is made up of tiny or small amino acids but is bounded by tiers with a larger percentage of bulky amino acids, Tiers 3, 4, and 5 of M4, M5, and M6 contain Ca2+ binding and affinity mutations, E(1)P to E(2)P block mutations and E(2)P dephosphorylation mutations, indicating an important role for these central tiers in Ca2+ binding and in the conformational changes that accompany Ca2+ translocation. Analysis of M8 revealed only a single mutation-sensitive residue, the Ca2+-binding amino acid, Glu(908). This residue and a mutation-insensitive residue, Ala(912) ,were the only vestiges of the motif that was found in M4 and M6. Additional mutations to Glu(908) provided further evidence for its role in Ca2+ binding, Since mutation of M8 failed to identify residues involved in blocking conformational changes or altering Ca2+ affinity, it is apparent that M8 plays a peripheral role in Ca2+ binding and translocation in comparison with M4, M5, and M6.	UNIV TORONTO, CHARLES H BEST INST, BANTING & BEST DEPT MED RES, TORONTO, ON M5G 1L6, CANADA	University of Toronto				Rice, William/0000-0002-5187-255X	NIAMS NIH HHS [R01 AR 39280] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039280] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSEN JP, 1995, J BIOL CHEM, V270, P908, DOI 10.1074/jbc.270.2.908; ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; ANDERSEN JP, 1994, FEBS LETT, V354, P93, DOI 10.1016/0014-5793(94)01100-1; ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; ANDERSEN JP, 1992, J BIOL CHEM, V267, P2767; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen L, 1996, J BIOL CHEM, V271, P10745, DOI 10.1074/jbc.271.18.10745; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1993, J BIOL CHEM, V268, P18359; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; INESI G, 1987, J BIOL CHEM, V262, P16338; Kimura Y, 1996, J BIOL CHEM, V271, P21726, DOI 10.1074/jbc.271.36.21726; KINGSTON RE, 1992, CURRENT PROTOCOLS MO; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; Rice WJ, 1996, BIOPHYS J, V70, pMAML6; SKERJANC IS, 1993, J BIOL CHEM, V268, P15944; TAYLOR WR, 1986, J THEOR BIOL, V119, P205, DOI 10.1016/S0022-5193(86)80075-3; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; VILSEN B, 1992, FEBS LETT, V306, P247, DOI 10.1016/0014-5793(92)81010-J; VILSEN B, 1991, J BIOL CHEM, V266, P18839; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WEBER K, 1969, J BIOL CHEM, V244, P4406; ZHANG Y, 1995, J BIOL CHEM, V270, P87, DOI 10.1074/jbc.270.1.87; ZHANG Z, 1995, J BIOL CHEM, V270, P16283; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238	34	95	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31412	31419		10.1074/jbc.271.49.31412	http://dx.doi.org/10.1074/jbc.271.49.31412			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940151	hybrid			2022-12-27	WOS:A1996VW68600062
J	Wu, LJ; Ruffing, N; Shi, XJ; Newman, W; Soler, D; Mackay, CR; Qin, SX				Wu, LJ; Ruffing, N; Shi, XJ; Newman, W; Soler, D; Mackay, CR; Qin, SX			Discrete steps in binding and signaling of interleukin-8 with its receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOTACTIC CYTOKINES; NEUTROPHIL CHEMOTAXIS; MONOCLONAL-ANTIBODIES; AMINO TERMINUS; IL-8 RECEPTOR; A RECEPTOR; RESIDUES; LIGAND; TRANSDUCTION; MUTAGENESIS	The mechanisms by which chemokines bind and signal through their receptors are complex and poorly understood. in the present study, we sought to dissect these processes and to map important functional domains of the two CXC chemokine (interleukin-8) receptors, CXCR1 (formally IL-8RA) and CXCR2 (formally IL-8RB), using blocking monoclonal antibodies (mAbs) to the receptors and a series of chimeras between CXCR1 and CXCR2. A panel of specific mAbs against CXCR1 or CXCR2, generated by immunizing mice with transfectants expressing either receptor, were shown to effectively block IL-8- and/or growth-related oncogene a (GRO alpha) -mediated Ligand binding, chemotaxis, elastase release, and VCAM-1 binding in CXCR1 and CXCR2 transfectants and/or human neutrophils. Of particular interest was an anti-CXCR1 mAb, 7D9, that inhibited chemotaxis, elastase release, and VCAM-1 binding but had no detectable effects on Ligand binding. The epitopes of these blocking mAbs were mapped by using a series of CXCR1/2 chimera transfectants and synthetic peptides, Most of the anti-CXCR1 antibodies, except 7D9, mapped to the amino acid sequence WDFDDL (CXCR1 residues 10-15), and all the anti-CXCR2 antibodies mapped to the amino acid sequence FEDFW (CXCR1 residues 6-10). The epitope of mAb 7D9 mainly involved a region within the first 45 residues of CXCR1, and it appeared to be conformation-sensitive. These results support a model in which the binding and signaling of IL-8 with its receptor occur in at least two discrete steps involving distinct domains of the receptor, This model is consistent with the notion that discrete conformational changes of the receptor secondary to ligand binding are required to trigger various biological responses. Moreover, the ligand binding and chemotaxis properties of each CXCR1/2 chimeric receptor to IL-8 and GRO alpha were determined, It was found that each is distinct in its ability to confer Ligand binding and chemotactic response to IL-8 and GRO alpha, and two conclusions could be made. 1) The N-terminal segment of CXCR1 is a dominant determinant of receptor subtype selectivity, consistent with previous studies using rabbit/human CXCR1/2 chimeras; and 2) the specificity determinant for Oil-On binding in CXCR2 involves sequences in the N terminus, distal to the first 15 residues, as well as other parts of the receptor.			Wu, LJ (corresponding author), LEUKOSITE INC,215 1ST ST,CAMBRIDGE,MA 02142, USA.		Mackay, Charles R/A-9673-2008	Mackay, Charles R/0000-0002-6338-7340				Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BROADDUS VC, 1994, J IMMUNOL, V152, P2960; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; CHUNTHARAPAI A, 1994, J IMMUNOL, V153, P5682; CHUNTHARAPAI A, 1994, J IMMUNOL, V152, P1783; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1994, J BIOL CHEM, V269, P16075; Damaj BB, 1996, J BIOL CHEM, V271, P12783, DOI 10.1074/jbc.271.22.12783; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; GEISER T, 1993, J BIOL CHEM, V268, P15419; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAMMOND MEW, 1995, J IMMUNOL, V155, P1428; Hammond MEW, 1996, J BIOL CHEM, V271, P8228, DOI 10.1074/jbc.271.14.8228; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; Jones SA, 1996, P NATL ACAD SCI USA, V93, P6682, DOI 10.1073/pnas.93.13.6682; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEONG SR, 1994, J BIOL CHEM, V269, P19343; MOSER B, 1993, J BIOL CHEM, V268, P7125; MULLIGAN MS, 1993, J IMMUNOL, V150, P5585; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Qin SX, 1996, EUR J IMMUNOL, V26, P640, DOI 10.1002/eji.1830260320; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SEKIDO N, 1993, NATURE, V365, P654, DOI 10.1038/365654a0; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Williams G, 1996, J BIOL CHEM, V271, P9579, DOI 10.1074/jbc.271.16.9579; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840	35	86	91	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31202	31209		10.1074/jbc.271.49.31202	http://dx.doi.org/10.1074/jbc.271.49.31202			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940121	hybrid			2022-12-27	WOS:A1996VW68600032
J	Hammes, A; OberdorfMaass, S; Jenatschke, S; Pelzer, T; Maass, AH; Gollnick, F; Meyer, R; Afflerbach, J; Neyses, L				Hammes, A; OberdorfMaass, S; Jenatschke, S; Pelzer, T; Maass, AH; Gollnick, F; Meyer, R; Afflerbach, J; Neyses, L			Expression of the plasma membrane Ca2+-ATPase in myogenic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAINS; CALCIUM-PUMP ISOFORMS; CA2+ PUMP; MOLECULAR-CLONING; CA-2+-TRANSPORTING ATPASE; FUNCTIONAL DOMAINS; SKELETAL-MUSCLE; MESSENGER-RNAS; GROWTH; DIFFERENTIATION	To study the physiological function of the plasma membrane calmodulin dependent calcium ATPase (PMCA) in intact cells, L6 myogenic cell lines stably overexpressing the human PMCA isoform 4CI (= human PMCA isoform 4b) were generated, Several independent L6 clones and controls stably transfected with the empty expression vector were analyzed in detail. The resting cytosolic calcium level in hPMCA4CI-overexpressing muscle cells (measured by the Fura-a method) was significantly reduced by 20-30% compared with controls. This was shown in a cytosolic window of 1322 single cells (p < 0.01). Furthermore, the differentiation process of these cells was remarkably accelerated compared with control myoblasts and parental nontransfected L6 cells as assessed by multinucleated myotube formation and creatine phosphokinase activity elevation. After 4 and 6 days of differentiation, PMCA-overexpressing L6 cells from four independent clones displayed a 3- and 4-fold higher creatine phosphokinase activity compared with controls (n = 5, p < 0.02). These results may extend the concept of the function of the PMCA from simple prevention of calcium overload to an active involvement in intracellular calcium regulation with potentially important consequences for cellular functions.	UNIV WURZBURG, DEPT MED, D-97080 WURZBURG, GERMANY; UNIV BONN, DEPT PHYSIOL, D-53111 BONN, GERMANY	University of Wurzburg; University of Bonn			Meyer, Rainer/H-5871-2013; Maass, Alexander/B-8534-2008; Neyses, Ludwig/AGY-7446-2022	Maass, Alexander/0000-0002-7936-360X; Hammes-Lewin, Annette/0000-0003-1663-8378				ADAMO HP, 1992, BIOCHEM J, V285, P791, DOI 10.1042/bj2850791; BORKE JL, 1989, AM J PHYSIOL, V257, pF842, DOI 10.1152/ajprenal.1989.257.5.F842; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT P, 1992, J BIOL CHEM, V267, P4376; BROWN EM, 1995, CELL, V83, P679, DOI 10.1016/0092-8674(95)90180-9; CARAFOLI E, 1994, J NEUROBIOL, V25, P312, DOI 10.1002/neu.480250311; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; ENDO T, 1987, CELL, V49, P515, DOI 10.1016/0092-8674(87)90454-5; ENYEDI A, 1991, J BIOL CHEM, V266, P8952; ENYEDI A, 1994, J BIOL CHEM, V269, P41; FLORINI JR, 1991, J BIOL CHEM, V266, P15917; GOLLNICK F, 1991, EUR J CELL BIOL, V55, P262; GREEB J, 1989, J BIOL CHEM, V264, P18569; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUERINI D, 1995, J BIOL CHEM, V270, P14643, DOI 10.1074/jbc.270.24.14643; HAMMES A, 1994, FASEB J, V8, P428, DOI 10.1096/fasebj.8.6.8168693; HEIM R, 1992, J BIOL CHEM, V267, P24476; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; KEETON TP, 1995, BIOCHEM J, V306, P779, DOI 10.1042/bj3060779; KEETON TP, 1993, J BIOL CHEM, V268, P2740; KRAIN B, 1996, IN PRESS BASIC RES C; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU BF, 1995, MOL BIOL CELL, V78, pA14; LIUU BF, 1996, J BIOL CHEM, V271, P5536; MEANS AR, 1994, FEBS LETT, V347, P1, DOI 10.1016/0014-5793(94)00492-7; NEYSES L, 1985, J BIOL CHEM, V260, P283; NIGGLI V, 1979, J BIOL CHEM, V254, P9955; OLIVER IT, 1955, BIOCHEM J, V61, P116, DOI 10.1042/bj0610116; ROSALKI SB, 1963, J LAB CLIN MED, V62, P159; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATZMANN HJ, 1966, EXPERIENTIA, V22, P364, DOI 10.1007/BF01901136; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SIMONS M, 1995, AM J PHYSIOL-CELL PH, V268, pC856, DOI 10.1152/ajpcell.1995.268.4.C856; SIMONS M, 1993, J BIOL CHEM, V268, P627; STAUFFER TP, 1993, J BIOL CHEM, V268, P25993; STAUFFER TP, 1995, J BIOL CHEM, V270, P12114; Strehler E E, 1990, Semin Cell Biol, V1, P283; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; STREHLER EE, 1989, P NATL ACAD SCI USA, V86, P6908, DOI 10.1073/pnas.86.18.6908; TOBWIN H, 1979, P NATL ACAD SCI USA, V76, P4350; WALDRON RT, 1994, J BIOL CHEM, V269, P11927; WOOD KV, 1991, BIOLUMINESCENCE AND CHEMILUMINESCENCE, P543; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	50	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30816	30822		10.1074/jbc.271.48.30816	http://dx.doi.org/10.1074/jbc.271.48.30816			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940063	hybrid, Green Published			2022-12-27	WOS:A1996VV15800080
J	Kellenberger, S; Scheuer, T; Catterall, WA				Kellenberger, S; Scheuer, T; Catterall, WA			Movement of the Na+ channel inactivation gate during inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE SODIUM-CHANNELS; SOMATIC-CELL LINE; SHAKER K-CHANNELS; RAT-BRAIN; ALPHA-SUBUNIT; ACETYLCHOLINE-RECEPTOR; MEMBRANE PATCHES; SEGMENT IVS6; EXPRESSION; CURRENTS	Phenylalanine 1489 in the inactivation gate of the rat brain IIA sodium channel cu subunit is required for stable inactivation. It is proposed to move into the intracellular mouth of the pore and occlude it during inactivation, but direct evidence for movement of this residue during inactivation has not been presented. We used the substituted cysteine accessibility method to test the availability of a cysteine residue substituted at position 1489 to modification by methanethiosulfonate reagents applied from the cytoplasmic side. Mutation of Phe-1489 to Cys results in a small (8%) fraction of noninactivating current, Ag+ and methanethiosulfonate reagents irreversibly slowed the inactivation rate and increased the fraction of noninactivating current of F1489C but not wild-type channels. Single channel analysis showed that modification slowed inactivation from both closed and open states and destabilized the inactivated state. Depolarization prevented rapid modification of Cys-1489 by these reagents, and the voltage dependence of their reaction rate correlated closely with steady-state inactivation, Modification was not detectably voltage-dependent at voltages more negative than channel gating. Our results show that, upon inactivation, Phe-1489 in the inactivation gate moves from an exposed and modifiable position outside the membrane electric field to a buried and inaccessible position, perhaps in or near the intracellular mouth of the channel pore.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle				Kellenberger, Stephan/0000-0003-1755-6198	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015751] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 15751] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ALDRICH RW, 1983, NATURE, V306, P436, DOI 10.1038/306436a0; ARMSTRONG CM, 1981, PHYSIOL REV, V61, P644, DOI 10.1152/physrev.1981.61.3.644; ARMSTRONG CM, 1973, J GEN PHYSIOL, V62, P375, DOI 10.1085/jgp.62.4.375; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; BENNETT PB, 1995, CIRC RES, V77, P584, DOI 10.1161/01.RES.77.3.584; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CHAHINE M, 1994, NEURON, V12, P281, DOI 10.1016/0896-6273(94)90271-2; Colquhoun David, 1995, P483; CUMMINS TR, 1996, BIOPHYS J, V51, P227; DANCE IG, 1986, POLYHEDRON, V5, P1037, DOI 10.1016/S0277-5387(00)84307-7; DEMO SD, 1991, NEURON, V7, P743, DOI 10.1016/0896-6273(91)90277-7; EAHOLTZ G, 1994, NEURON, V12, P1041, DOI 10.1016/0896-6273(94)90312-3; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; GONOI T, 1984, J NEUROSCI, V4, P2836; GONOI T, 1987, J GEN PHYSIOL, V89, P253, DOI 10.1085/jgp.89.2.253; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTMANN HA, 1994, CIRC RES, V75, P114, DOI 10.1161/01.RES.75.1.114; Hille B., 1992, IONIC CHANNELS EXCIT; HORN R, 1991, BIOPHYS J, V60, P433, DOI 10.1016/S0006-3495(91)82069-0; HORN R, 1984, J GEN PHYSIOL, V84, P505, DOI 10.1085/jgp.84.4.505; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; KUO CC, 1994, NEURON, V12, P819, DOI 10.1016/0896-6273(94)90335-2; MCPHEE JC, 1994, P NATL ACAD SCI USA, V91, P12346, DOI 10.1073/pnas.91.25.12346; MCPHEE JC, 1995, J BIOL CHEM, V270, P12025, DOI 10.1074/jbc.270.20.12025; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P977, DOI 10.1085/jgp.102.6.977; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P949, DOI 10.1085/jgp.102.6.949; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; OLEARY ME, 1995, J GEN PHYSIOL, V106, P641, DOI 10.1085/jgp.106.4.641; PATLAK J, 1982, J GEN PHYSIOL, V79, P333, DOI 10.1085/jgp.79.3.333; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; SCANLEY BE, 1990, J GEN PHYSIOL, V95, P411, DOI 10.1085/jgp.95.3.411; SCHEUER T, 1990, SCIENCE, V247, P854, DOI 10.1126/science.2154850; SCHEUER T, 1993, BIOPHYS J, V64, pA88; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; VASSILEV P, 1989, P NATL ACAD SCI USA, V86, P8147, DOI 10.1073/pnas.86.20.8147; VASSILEV PM, 1988, SCIENCE, V241, P1658, DOI 10.1126/science.2458625; WEST JW, 1992, NEURON, V8, P59, DOI 10.1016/0896-6273(92)90108-P; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	48	88	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30971	30979		10.1074/jbc.271.48.30971	http://dx.doi.org/10.1074/jbc.271.48.30971			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940085	hybrid			2022-12-27	WOS:A1996VV15800102
J	Nilius, B; Gerke, V; Prenen, J; Szucs, G; Heinke, S; Weber, K; Droogmans, G				Nilius, B; Gerke, V; Prenen, J; Szucs, G; Heinke, S; Weber, K; Droogmans, G			Annexin II modulates volume-activated chloride currents in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITE; LIGHT-CHAIN; CALPACTIN-I; MDCK CELLS; PROTEINS; P11; SUBSTRATE; CALCIUM; COMPLEX; CA2+	The membrane-associated, microfilament-binding protein annexin II is abundantly expressed in endothelial cells from calf pulmonary artery (CPAE cells). We have analyzed its role in the regulation of volume-activated chloride currents (I-Cl,I-vol) by loading the cells via the patch pipette with a peptide comprising the N-terminal 14 residues of annexin II. This sequence harbors the binding site for the intracellular annexin II ligand, p11, and the peptide interferes with the annexin II-p11 complex formation. Loading of a CPAE cell with this peptide caused a gradual decrease in the amplitude of I-Cl,I-vol during repetitive stimulations with a 28% hypotonic extracellular solution. This run down of the current was virtually absent in untreated cells and in cells that were loaded with a mutated li-amino acid peptide, which has a single amino acid replacement known to result in a more than 1000 times reduced affinity for binding to pll. We conclude that annexin II-p11 complex formation is either directly or indirectly involved in the activation of I-Cl,I-vol in endothelial cells.	UNIV MUNSTER,CELL RES GRP ENDOTHELIAL CELL BIOL,D-48149 MUNSTER,GERMANY; MAX PLANCK INST BIOPHYS CHEM,DEPT BIOCHEM,D-37077 GOTTINGEN,GERMANY	University of Munster; Max Planck Society	Nilius, B (corresponding author), KATHOLIEKE UNIV LEUVEN,FYSIOL LAB,CAMPUS GASTHUISBERG,HERESTR 49,B-3000 LOUVAIN,BELGIUM.		Szücs, Géza/A-2121-2008					BECKER T, 1990, EMBO J, V9, P4207, DOI 10.1002/j.1460-2075.1990.tb07868.x; CHAN HC, 1994, J BIOL CHEM, V269, P32464; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; GERKE V, 1992, ANNEXINS, P47; GLENNEY JR, 1987, BIOESSAYS, V7, P173, DOI 10.1002/bies.950070408; HARDER T, 1994, BBA-MOL CELL RES, V1223, P375, DOI 10.1016/0167-4889(94)90098-1; JOHNSSON N, 1988, EMBO J, V7, P2435, DOI 10.1002/j.1460-2075.1988.tb03089.x; KAETZEL MA, 1995, NEWS PHYSIOL SCI, V10, P171; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; KUBE E, 1992, J BIOL CHEM, V267, P14175; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOSS SE, 1995, NATURE, V378, P446, DOI 10.1038/378446a0; NEHER E, 1989, NEUROMUSCULAR JUNCTI, P65; NILIUS B, 1994, J GEN PHYSIOL, V103, P787, DOI 10.1085/jgp.103.5.787; NILIUS B, 1996, IN PRESS GEN PHARM, V27; OIKE M, 1994, P NATL ACAD SCI USA, V91, P2940, DOI 10.1073/pnas.91.8.2940; OIKE M, 1994, PFLUG ARCH EUR J PHY, V428, P569, DOI 10.1007/BF00374579; OSBORN M, 1988, EXP CELL RES, V175, P81, DOI 10.1016/0014-4827(88)90257-1; POWELL MA, 1987, BIOCHEM J, V247, P321, DOI 10.1042/bj2470321; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; STRANGE K, 1995, KIDNEY INT, V48, P994, DOI 10.1038/ki.1995.381; Szucs G, 1996, PFLUG ARCH EUR J PHY, V431, P540, DOI 10.1007/s004240050033; Szucs G, 1996, PFLUG ARCH EUR J PHY, V431, P467, DOI 10.1007/s004240050023; Szucs G, 1996, J MEMBRANE BIOL, V149, P189, DOI 10.1007/s002329900019; THIEL C, 1992, J CELL SCI, V103, P733; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEBER K, 1992, ANNEXINS, P61; ZOKAS L, 1987, J CELL BIOL, V105, P2111, DOI 10.1083/jcb.105.5.2111	33	65	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30631	30636		10.1074/jbc.271.48.30631	http://dx.doi.org/10.1074/jbc.271.48.30631			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940038	hybrid			2022-12-27	WOS:A1996VV15800055
J	Proux, V; Provot, S; FelderSchmittbuhl, MPF; Laugier, D; Calothy, G; Marx, M				Proux, V; Provot, S; FelderSchmittbuhl, MPF; Laugier, D; Calothy, G; Marx, M			Characterization of a leucine zipper-containing protein identified by retroviral insertion in avian neuroretina cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; C-MIL; MOLECULAR-CLONING; TRANSFORMING RETROVIRUS; LYMPHOMATOSIS VIRUS; SARCOMA VIRUS; GENE ENCODES; V-MIL; ONCOGENE; EXPRESSION	We reported previously that post-mitotic chicken embryonic neuroretina (NR) cells are induced to proliferate following in vitro infection with RAV-1, a retrovirus that does not carry an oncogene, NR cell multiplication results from the frequent activation and subsequent retroviral transduction of two related serine/threonine protein kinases, the c-mil/c-raf or c-Rmil/B-raf genes. We also showed that a very early event in the activation of these proto-oncogenes is the synthesis of chimeric mRNAs containing viral and cellular sequences joined by a splicing mechanism, In the current study, we have examined the ability of RAV-1 to induce proliferation of quail NR cells, By using the reverse transcription polymerase chain reaction technique, we identified, in several proliferating quail NR cultures infected with RAV-1, a chimeric mRNA containing cellular sequences joined to the RAV-1 splice donor site, These cellular sequences are derived from a gene designated RIG, which is expressed through a 1.9-kilobase (kb) mRNA detected in several embryonic tissues, A second transcript of 2.3 kb is specifically expressed in the NR, where both transcripts are developmentally regulated, The R10 cDNA encodes a 251-amino acid polypeptide that contains a leucine zipper motif, It exhibits significant similarity with the putative D52/N8L protein, encoded by an mRNA reported previously to be overexpressed in human breast and lung carcinomas, By using polyclonal antibodies specific for its amino-terminal and leucine zipper-containing regions, we identified the R10 gene product as a cytoplasmic protein of 23 kDa in cultured avian fibroblasts, A second protein of 30 kDa is detected in post-mitotic NR cells that express the 2,3-kb transcript, We also show, by in vitro transcription/translation and immunoprecipitation, that the R10 protein can readily form homodimers, presumably through its leucine zipper motif.	INST CURIE,UNITE MIXTE RECH 146 CNRS,LAB 110,CTR UNIV,F-91405 ORSAY,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay				PROVOT, SYLVAIN/0000-0003-4087-4450				Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; BECHADE C, 1988, J VIROL, V62, P1211; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BYRNE JA, 1995, CANCER RES, V55, P2896; Chen SL, 1996, ONCOGENE, V12, P741; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLL J, 1983, EMBO J, V2, P2189, DOI 10.1002/j.1460-2075.1983.tb01722.x; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; EZOE K, 1994, ONCOGENE, V9, P935; FELDER MP, 1991, J VIROL, V65, P3633, DOI 10.1128/JVI.65.7.3633-3640.1991; FELDER MP, 1994, J VIROL, V68, P4759, DOI 10.1128/JVI.68.8.4759-4767.1994; FELDER MP, 1993, J VIROL, V67, P6853, DOI 10.1128/JVI.67.11.6853-6856.1993; FELDER MP, 1994, FOLIA BIOL-PRAGUE, V40, P225; GALLO KA, 1994, J BIOL CHEM, V269, P15092; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; GUERMAH M, 1990, MOL CELL BIOL, V10, P3584, DOI 10.1128/MCB.10.7.3584; Harlow E., 1988, ANTIBODIES LAB MANUA; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; ING YL, 1994, ONCOGENE, V9, P1745; KAWAI S, 1992, VIROLOGY, V188, P778, DOI 10.1016/0042-6822(92)90532-T; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MARX M, 1988, J VIROL, V62, P4627, DOI 10.1128/JVI.62.12.4627-4633.1988; MARX M, 1988, EMBO J, V7, P3369, DOI 10.1002/j.1460-2075.1988.tb03209.x; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; PESSAC B, 1974, SCIENCE, V185, P709, DOI 10.1126/science.185.4152.709; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; REMAUT E, 1981, GENE, V15, P81, DOI 10.1016/0378-1119(81)90106-2; Sambrook J., 2002, MOL CLONING LAB MANU; SAMBUCETTI LC, 1986, SCIENCE, V234, P1417, DOI 10.1126/science.3491427; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; SAVITT JW, 1995, NEURON, V14, P253, DOI 10.1016/0896-6273(95)90283-X; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; TREISMAN JE, 1995, DEVELOPMENT, V121, P2835; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	50	25	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30790	30797		10.1074/jbc.271.48.30790	http://dx.doi.org/10.1074/jbc.271.48.30790			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940059	hybrid			2022-12-27	WOS:A1996VV15800076
J	Zalcman, G; Closson, V; Camonis, J; Honore, N; RousseauMerck, MF; Tavitian, A; Olofsson, B				Zalcman, G; Closson, V; Camonis, J; Honore, N; RousseauMerck, MF; Tavitian, A; Olofsson, B			RhoGDI-3 is a new GDP dissociation inhibitor (GDI) - Identification of a non-cytosolic GDI protein interacting with the small GTP-binding proteins rhoB and rhoG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; MOLECULAR-CLONING; REGULATORY PROTEIN; GROWTH-FACTOR; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; EXCHANGE PROTEINS; FAMILY GTPASES; CDC42 GTPASES; NADPH OXIDASE	RhoB is a small GTP-binding protein highly homologous to the RhoA protein. While RhoA is known to regulate the assembly of focal adhesions and stress fibers in response to growth factors, the function of RhoB re mains unknown. We have reported that the transient expression of the endogenous RhoB protein is regulated during the cell cycle, contrasting with the permanent RhoA protein expression (1). Using the yeast two-hybrid system to characterize proteins interacting with RhoB, we identified a new mouse Rho GDP dissociation inhibitor, referenced as RhoGDI-3. The NH2-terminal alpha helix of RhoGDI-3 is strongly amphipatic and differs thus from that found in previously described bovine, human, and yeast RhoGDI proteins and mouse and human D4/Ly-GDIs. Contrary to the cytosolic localization of all known GDI proteins, acting on Rab or Rho, RhoGDI-3 is associated to a Triton X-100-insoluble membranous or cytoskeletal subcellular fraction. In the two-hybrid system, RhoGDI-3 interacts specifically with GDP- and GTP-bound forms of post-translationally processed RhoB and RhoG proteins, both of which show a growth-regulated expression in mammalian cells. No interaction is found with RhoA, RhoC, or Rac1 proteins. We show that GDI-3 is able to inhibit GDP/GTP exchange of RhoB and to release GDP-bound but not GTP-bound RhoB from cell membranes.	INST CURIE,SECT RECH,UNITE INSERM 248,F-75231 PARIS 05,FRANCE; HOP ST LOUIS,INST GENET MOL,INSERM U301,F-75010 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			ZALCMAN, Gerard/P-4150-2015; ZALCMAN, Gérard/L-7809-2015; ZALCMAN, Gerard/M-8113-2019	ZALCMAN, Gérard/0000-0002-0343-9575; 				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; ARAKI S, 1990, J BIOL CHEM, V265, P13007; ARAKI S, 1995, J BIOL CHEM, V92, P2974; BERANGER F, 1994, MOL CELL BIOL, V14, P744, DOI 10.1128/MCB.14.1.744; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BOURMEYSTER N, 1994, BIOCHEM BIOPH RES CO, V205, P174, DOI 10.1006/bbrc.1994.2646; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CHUANG TH, 1993, J BIOL CHEM, V268, P775; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Dorseuil O, 1996, J BIOL CHEM, V271, P83, DOI 10.1074/jbc.271.1.83; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; HANCOCK JF, 1993, EMBO J, V12, P1915, DOI 10.1002/j.1460-2075.1993.tb05840.x; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORI Y, 1991, ONCOGENE, V6, P515; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; ISOMURA M, 1991, ONCOGENE, V6, P119; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; JANOUEIXLEROSEY I, 1995, J BIOL CHEM, V270, P14801, DOI 10.1074/jbc.270.24.14801; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; JUST I, 1994, J BIOL CHEM, V269, P10706; KIKUCHI A, 1992, J BIOL CHEM, V267, P14611; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; LEFFERS H, 1993, EXP CELL RES, V209, P165, DOI 10.1006/excr.1993.1298; LELIAS JM, 1993, P NATL ACAD SCI USA, V90, P1479, DOI 10.1073/pnas.90.4.1479; LEONARD D, 1992, J BIOL CHEM, V267, P22860; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MASUDA T, 1994, J BIOL CHEM, V269, P19713; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nomanbhoy TK, 1996, J BIOL CHEM, V271, P10004, DOI 10.1074/jbc.271.17.10004; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; PLATKO JV, 1995, P NATL ACAD SCI USA, V92, P2974, DOI 10.1073/pnas.92.7.2974; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QUINN MT, 1993, J BIOL CHEM, V268, P20983; REINHARD J, 1995, EMBO J, V14, P697, DOI 10.1002/j.1460-2075.1995.tb07048.x; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rose M, 1990, LAB COURSE MANUAL ME; ROUSSEAUMERCK MF, 1991, HUM GENET, V86, P350; SASAKI T, 1993, J BIOL CHEM, V268, P23959; SCHERLE P, 1993, P NATL ACAD SCI USA, V90, P7568, DOI 10.1073/pnas.90.16.7568; SEALE JW, 1994, PROTEIN SCI, V3, P1741, DOI 10.1002/pro.5560031014; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1995, ONCOGENE, V11, P39; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; ZALCMAN G, 1995, ONCOGENE, V10, P1935; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	64	96	97	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30366	30374		10.1074/jbc.271.48.30366	http://dx.doi.org/10.1074/jbc.271.48.30366			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939998	hybrid			2022-12-27	WOS:A1996VV15800015
J	DeMott, MS; Shen, BH; Park, MS; Bambara, RA; Zigman, S				DeMott, MS; Shen, BH; Park, MS; Bambara, RA; Zigman, S			Human RAD2 homolog 1 5'- to 3'-exo/endonuclease can efficiently excise a displaced DNA fragment containing a 5'-terminal abasic lesion by endonuclease activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBOSE-PHOSPHATE RESIDUES; APURINIC APYRIMIDINIC SITES; ESCHERICHIA-COLI; ELIMINATION REACTIONS; BETA-ELIMINATION; EXONUCLEASE-I; DAMAGED DNA; REPAIR; DEOXYRIBOPHOSPHODIESTERASE; POLYMERASE	Repair of abasic lesions, one of the most common types of damage found in DNA, is crucial to an organism's well-being, Studies in vitro indicate that after apurinic-apyrimidinic endonuclease cleaves immediately upstream of a baseless site, removal of the 8'-terminal sugar-phosphate residue is achieved by deoxyribophosphodiesterase activity, an enzyme-mediated beta-elimination reaction, or by endonucleolytic cleavage downstream of the baseless sugar, Synthesis and ligation complete repair. Eukaryotic RADS homolog 1 (RTH1) nuclease, by genetic and biochemical evidence, is involved in repair of modified DNA. Efficient endonucleolytic cleavage by RTH1 nuclease has been demonstrated for annealed primers that have unannealed 5'-tails, In vivo, such substrate structures could result from repair-related strand displacement synthesis, Using 5'-tailed substrates, we examined the ability of human RTH1 nuclease to efficiently remove 5'-terminal abasic residues, A series of upstream primers were used to increasingly displace an otherwise annealed downstream primer containing a 5'-terminal deoxyribose-5-phosphate. Until displacement of the first annealed nucleotide, substrates resisted cleavage, With further displacement, efficient cleavage occurred at the 3'-end of the tail, Therefore, in combination with strand displacement activity, RTH1 nucleases may serve as an important alternative to other pathways in repair of abasic sites in DNA.	UNIV ROCHESTER,MED CTR,DEPT OPHTHALMOL,SCH MED & DENT,ROCHESTER,NY 14642; UNIV ROCHESTER,MED CTR,DEPT BIOCHEM,SCH MED & DENT,ROCHESTER,NY 14642; LOS ALAMOS NATL LAB,DIV LIFE SCI,LOS ALAMOS,NM 87545	University of Rochester; University of Rochester; United States Department of Energy (DOE); Los Alamos National Laboratory			Park, Min Sung/HCH-2207-2022	Shen, Binghui/0000-0002-4408-407X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441] Funding Source: NIH RePORTER; NEI NIH HHS [EY00459] Funding Source: Medline; NIGMS NIH HHS [GM24441] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILLY V, 1989, BIOCHEM J, V259, P761, DOI 10.1042/bj2590761; BAILLY V, 1988, BIOCHEM J, V253, P553, DOI 10.1042/bj2530553; BARNES CJ, 1996, IN PRESS J BIOL CHEM, V271; DIANOV G, 1994, NUCLEIC ACIDS RES, V22, P993, DOI 10.1093/nar/22.6.993; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; FRANKLIN WA, 1988, EMBO J, V7, P3617, DOI 10.1002/j.1460-2075.1988.tb03240.x; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P139; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; JACQUIER A, 1992, YEAST, V8, P122; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033; MOSBAUGH DW, 1980, J BIOL CHEM, V255, P1743; MUN C, 1994, RADIAT RES, V138, P282, DOI 10.2307/3578599; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Murante RS, 1996, J BIOL CHEM, V271, P25888, DOI 10.1074/jbc.271.42.25888; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; OCONNOR TR, 1989, P NATL ACAD SCI USA, V86, P5222, DOI 10.1073/pnas.86.14.5222; PRICE A, 1991, BIOCHEMISTRY-US, V30, P8631, DOI 10.1021/bi00099a020; PRICE A, 1992, FEBS LETT, V300, P101, DOI 10.1016/0014-5793(92)80173-E; RANDERATH K, 1967, METHODS ENZYMOLOGY A, V12, P323; ROBINS P, 1994, J BIOL CHEM, V269, P28535; SANDIGURSKY M, 1992, NUCLEIC ACIDS RES, V20, P4699, DOI 10.1093/nar/20.18.4699; SANDIGURSKY M, 1994, NUCLEIC ACIDS RES, V22, P247, DOI 10.1093/nar/22.2.247; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; WALLACE SS, 1994, INT J RADIAT BIOL, V66, P579, DOI 10.1080/09553009414551661	36	65	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30068	30076		10.1074/jbc.271.47.30068	http://dx.doi.org/10.1074/jbc.271.47.30068			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939954	hybrid			2022-12-27	WOS:A1996VU52500082
J	Dinbergs, ID; Brown, L; Edelman, ER				Dinbergs, ID; Brown, L; Edelman, ER			Cellular response to transforming growth factor-beta 1 and basic fibroblast growth factor depends on release kinetics and extracellular matrix interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPILLARY ENDOTHELIAL-CELLS; PLASMINOGEN-ACTIVATOR PRODUCTION; HEPARIN-LIKE MOLECULES; FACTOR-BETA; TGF-BETA; SUSTAINED-RELEASE; DNA-SYNTHESIS; PROTEOLYTIC DEGRADATION; ANGIOGENIC ACTIVITY; BASEMENT-MEMBRANE	The extracellular matrix plays an important role in growth factor biology, serving as a potential platform for rapid growth factor mobilization or a sink for concentrated sequestration, We now demonstrate that when a growth factor binds reversibly to the matrix, its effects are augmented by this interaction, and when the factor is absorbed irreversibly to the extracellular matrix, it becomes sequestered. These findings call into question the notion that all growth factors are best presented to cells and tissues in a sustained and controlled fashion, In our studies, we examined basic fibroblast growth factor (bFGF) and transforming growth factor-beta 1 (TGF-beta 1) release kinetics from synthetically fabricated microsphere devices and naturally synthesized extracellular matrix. While the sustained release of bFGF was up to 3.0-fold more potent at increasing vascular endothelial and smooth muscle cell proliferation than bolus administration, the reverse was true for TGF-beta 1 A bolus of TGF-beta 1 inhibited vascular cells up to 3.8-fold more efficiently than the same amount of TGF-beta 1 if control-released. Both growth factors bound to the extracellular matrix, but only bFGF was released in a controlled fashion (2.8%/day). Contact with the extracellular matrix and subsequent release enhanced bFGF activity such that it was 86% more effective at increasing smooth muscle cell numbers than equal amounts of growth factor diluted from frozen stock. TGF-beta 1 remained tightly adherent, The small amount of TGF-beta 1 released from the extracellular matrix was similar to 30% less effective than bolus administration at inhibiting vascular endothelial and smooth muscle cell growth, Sustained growth factor release may be the preferable mode of administration, but only when a similar mode of metabolism is utilized endogenously.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Dinbergs, ID (corresponding author), HARVARD UNIV, MIT, DIV HLTH SCI & TECHNOL, CAMBRIDGE, MA 02139 USA.			Brown, Larry/0000-0001-7954-9140	NHLBI NIH HHS [HL/GM 49039] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AEBISCHER P, 1989, J NEUROSCI RES, V23, P282, DOI 10.1002/jnr.490230306; AHARONOV A, 1978, J BIOL CHEM, V253, P3970; AUFDEMORTE TB, 1992, J BONE JOINT SURG AM, V74A, P1153, DOI 10.2106/00004623-199274080-00004; BAIRD A, 1986, BIOCHEM BIOPH RES CO, V138, P476, DOI 10.1016/0006-291X(86)90305-0; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; Beck LS, 1990, GROWTH FACTORS, V3, P267, DOI 10.3109/08977199009003669; BENTZ H, 1995, P 21 ANN M SOC BIOM, P291; BERSCHT PC, 1994, BIOMATERIALS, V15, P593, DOI 10.1016/0142-9612(94)90209-7; BROWN GL, 1988, ANN SURG, V208, P788, DOI 10.1097/00000658-198812000-00019; CAMARATA PJ, 1992, NEUROSURGERY, V30, P313, DOI 10.1227/00006123-199203000-00001; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; CHLEBOUN JO, 1992, BIOCHEM BIOPH RES CO, V185, P510, DOI 10.1016/0006-291X(92)91654-9; COFFEY RJ, 1990, ANN NY ACAD SCI, V593, P285, DOI 10.1111/j.1749-6632.1990.tb16120.x; DAVIDSON JM, 1993, J CELL PHYSIOL, V155, P149, DOI 10.1002/jcp.1041550119; EDELMAN ER, 1990, P NATL ACAD SCI USA, V87, P3773, DOI 10.1073/pnas.87.10.3773; EDELMAN ER, 1992, J CLIN INVEST, V89, P465, DOI 10.1172/JCI115607; EDELMAN ER, 1991, BIOMATERIALS, V12, P619, DOI 10.1016/0142-9612(91)90107-L; EDELMAN ER, 1993, P NATL ACAD SCI USA, V90, P1513, DOI 10.1073/pnas.90.4.1513; FAVA RA, 1987, J CELL PHYSIOL, V131, P184, DOI 10.1002/jcp.1041310207; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; FOLKMAN J, 1988, AM J PATHOL, V130, P393; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; FRITZ IB, 1988, BIOL GROWTH FACTORS, P1; FUKUNAGA K, 1994, J PHARM PHARMACOL, V46, P168, DOI 10.1111/j.2042-7158.1994.tb03771.x; GAJDUSEK CM, 1993, J CELL PHYSIOL, V157, P133, DOI 10.1002/jcp.1041570118; GLOBUS RK, 1988, ENDOCRINOLOGY, V123, P98, DOI 10.1210/endo-123-1-98; GOLDSMITH KT, 1991, AM J PHYSIOL, V261, pL378, DOI 10.1152/ajplung.1991.261.6.L378; GOMBOTZ W, 1993, P INT S CONTROL REL, V20, P150; GOMBOTZ WR, 1993, J BIOMAT SCI-POLYM E, V5, P49; GONZALEZ AM, 1990, J CELL BIOL, V110, P753, DOI 10.1083/jcb.110.3.753; GOSPODAROWICZ D, 1979, EXP EYE RES, V28, P501, DOI 10.1016/0014-4835(79)90038-1; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; HEATH WF, 1991, BIOCHEMISTRY-US, V30, P5608, DOI 10.1021/bi00236a039; HICKEY MJ, 1994, BIOCHEM BIOPH RES CO, V201, P1066, DOI 10.1006/bbrc.1994.1813; HOFFMAN D, 1990, EXP NEUROL, V110, P39, DOI 10.1016/0014-4886(90)90049-X; HORTON WE, 1989, J CELL PHYSIOL, V141, P8, DOI 10.1002/jcp.1041410103; INOUE H, 1989, J CELL PHYSIOL, V138, P329, DOI 10.1002/jcp.1041380216; KHOURI RK, 1993, SURGERY, V114, P374; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KO C, 1995, ARTIF CELL BLOOD SUB, V23, P143, DOI 10.3109/10731199509117934; KOH GY, 1995, J CLIN INVEST, V95, P114, DOI 10.1172/JCI117627; KRESON CE, 1995, BRAIN RES, V680, P196; KSANDER GA, 1990, ANN SURG, V211, P288; LANGER R, 1991, J CELL BIOCHEM, V45, P340, DOI 10.1002/jcb.240450406; LIU SQ, 1992, BIOMATERIALS, V13, P50, DOI 10.1016/0142-9612(92)90095-6; LOGAN A, 1992, J ENDOCRINOL, V134, P157, DOI 10.1677/joe.0.1340157; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MAYSINGER D, 1992, NEUROSCI LETT, V140, P71, DOI 10.1016/0304-3940(92)90684-Y; MCCAFFREY TA, 1992, J CELL PHYSIOL, V152, P430, DOI 10.1002/jcp.1041520226; MEIKLE MC, 1994, BIOMATERIALS, V15, P513, DOI 10.1016/0142-9612(94)90017-5; MEIKLE MC, 1993, BIOMATERIALS, V14, P177, DOI 10.1016/0142-9612(93)90020-3; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; MURRAY JB, 1983, IN VITRO CELL DEV B, V19, P743; MUSTOE TA, 1987, SCIENCE, V237, P1333, DOI 10.1126/science.2442813; NATHAN A, 1995, P NATL ACAD SCI USA, V92, P8130, DOI 10.1073/pnas.92.18.8130; NUGENT MA, 1992, J BIOL CHEM, V267, P21256; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; NUGENT MA, 1992, MATER RES SOC SYMP P, V252, P273; PARALKAR VM, 1991, DEV BIOL, V143, P303, DOI 10.1016/0012-1606(91)90081-D; PARK CM, 1991, DEV BIOL, V148, P322, DOI 10.1016/0012-1606(91)90341-Y; PEPPER MS, 1993, EXP CELL RES, V204, P356, DOI 10.1006/excr.1993.1043; PERTOVAARA L, 1993, GROWTH FACTORS, V9, P81, DOI 10.3109/08977199308991584; PHILLIPS GD, 1990, P SOC EXP BIOL MED, V193, P197; PHILLIPS GD, 1993, J SUBMICR CYTOL PATH, V25, P149; POWELL EM, 1990, BRAIN RES, V515, P309, DOI 10.1016/0006-8993(90)90612-F; PRESTA M, 1991, CELL REGUL, V2, P719, DOI 10.1091/mbc.2.9.719; PRESTA M, 1989, J CELL PHYSIOL, V140, P68, DOI 10.1002/jcp.1041400109; PUOLAKKAINEN PA, 1995, J SURG RES, V58, P321, DOI 10.1006/jsre.1995.1050; PUOLAKKAINEN PA, 1994, GASTROENTEROLOGY, V107, P1319, DOI 10.1016/0016-5085(94)90533-9; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REDDY CC, 1994, BIOTECHNOL PROGR, V10, P377, DOI 10.1021/bp00028a006; Reddy CC, 1996, J CELL PHYSIOL, V166, P512, DOI 10.1002/(SICI)1097-4652(199603)166:3<512::AID-JCP6>3.0.CO;2-S; ROGELJ S, 1989, J CELL BIOL, V109, P823, DOI 10.1083/jcb.109.2.823; ROHRER B, 1994, EXP EYE RES, V58, P553, DOI 10.1006/exer.1994.1049; SAKSELA O, 1987, J CELL BIOL, V105, P957, DOI 10.1083/jcb.105.2.957; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SANDERS KB, 1991, CRIT REV EUKAR GENE, V1, P157; SCHULTZ GS, 1987, SCIENCE, V235, P350, DOI 10.1126/science.3492044; SEFTON MV, 1984, J PHARM SCI-US, V73, P1859, DOI 10.1002/jps.2600731258; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; SOMMER A, 1989, J CELL PHYSIOL, V138, P215, DOI 10.1002/jcp.1041380129; SPARGO BJ, 1995, J MICROENCAPSUL, V12, P247, DOI 10.3109/02652049509010293; SPORN MB, 1991, PEPTIDE GROWTH FACTO, P6; TANIGUCHI E, 1991, Nippon Ganka Gakkai Zasshi, V95, P52; TELFFT JA, 1995, P 21 ANN M SOC BIOM, P299; VLODAVSKY I, 1991, J CELL BIOCHEM, V45, P167, DOI 10.1002/jcb.240450208; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VLODAVSKY I, 1980, CELL, V19, P607, DOI 10.1016/S0092-8674(80)80037-7; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YAMAMURA K, 1995, J BIOMED MATER RES, V29, P203, DOI 10.1002/jbm.820290210; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHAN X, 1993, J BIOL CHEM, V268, P9611	95	90	118	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29822	29829		10.1074/jbc.271.47.29822	http://dx.doi.org/10.1074/jbc.271.47.29822			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939921	hybrid			2022-12-27	WOS:A1996VU52500049
J	Furukawa, M; Suzuki, Y; Ghoneim, MA; Tachibana, S; Hirose, S				Furukawa, M; Suzuki, Y; Ghoneim, MA; Tachibana, S; Hirose, S			Cryptic origin of SPAI, a plasma protein with a transglutaminase substrate domain and the WAP motif, revealed by in situ hybridization and immunohistochemistry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING ENZYMES; ELASTASE INHIBITOR; K+-ATPASE; SEQUENCE; ELAFIN; PURIFICATION; DIFFERENTIATION; INTESTINE; PEPTIDE; TISSUES	SPAI, originally isolated as a sodium/potassium-ATPase inhibitor and now considered to be a proteinase inhibitor of unknown specificity based on its similarity to elafin (an elastase inhibitor), is a new type of plasma protein that has a transglutaminase substrate domain, which serves as an anchoring sequence to be covalently cross-linked at target sites. To determine the source of SPAI, we carried out in situ hybridization and immunohistochemistry using an antisense cRNA probe and an antiserum against recombinant SPAI, respectively. Since previous RNase protection analysis had indicated that SPAI mRNA is almost exclusively expressed in the porcine small intestine, we used its frozen sections for the staining. The lower crypt was decorated with both the cRNA probe and antiserum, indicating that SPAI is synthesized and secreted by the enteroendocrine cells located near the crypt base. The native form of SPAI was also characterized by Western blotting. This result together with the previous biochemical and molecular biological characterizations may set the stage for identifying the physiological roles of the conceptually very interesting protein SPAI.	EISAI & CO LTD,TSUKUBA RES LABS,TSUKUBA,IBARAKI 30026,JAPAN	Eisai Co Ltd	Furukawa, M (corresponding author), TOKYO INST TECHNOL,DEPT BIOL SCI,MIDORI KU,4259 NAGATSUTA CHO,YOKOHAMA,KANAGAWA 226,JAPAN.		Ghoneim, Magdy/I-7904-2012	ghoneim, magdy/0000-0003-0185-3024				AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; ARAKI K, 1989, BIOCHEM BIOPH RES CO, V164, P496, DOI 10.1016/0006-291X(89)91747-6; ARAKI K, 1990, BIOCHEM BIOPH RES CO, V172, P42, DOI 10.1016/S0006-291X(05)80170-6; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; Dayal Y, 1991, ENDOCR PATHOL, P1; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HAND D, 1993, INT J DEV NEUROSCI, V11, P709, DOI 10.1016/0736-5748(93)90060-Q; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; ISHIZUKA N, 1991, BIOCHIM BIOPHYS ACTA, V1069, P259, DOI 10.1016/0005-2736(91)90133-S; KUROKI J, 1995, J BIOL CHEM, V270, P22428, DOI 10.1074/jbc.270.38.22428; LOEFFLER M, 1993, J THEOR BIOL, V160, P471, DOI 10.1006/jtbi.1993.1031; MCKENZIE RM, 1978, J DAIRY SCI, V61, P723, DOI 10.3168/jds.S0022-0302(78)83639-X; MOLHUIZEN HOF, 1993, J BIOL CHEM, V268, P12028; NARA K, 1994, J BIOCHEM, V115, P441, DOI 10.1093/oxfordjournals.jbchem.a124357; PARDUE ML, 1985, NUCLEIC ACID HYBRIDI, P179; PONDER BAJ, 1985, NATURE, V313, P689, DOI 10.1038/313689a0; SAHEKI T, 1992, BIOCHEM BIOPH RES CO, V185, P240, DOI 10.1016/S0006-291X(05)80981-7; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Tamechika I, 1996, J BIOL CHEM, V271, P7012, DOI 10.1074/jbc.271.12.7012; WIEDOW O, 1990, J BIOL CHEM, V265, P14791	23	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29517	29520		10.1074/jbc.271.47.29517	http://dx.doi.org/10.1074/jbc.271.47.29517			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939875	hybrid			2022-12-27	WOS:A1996VU52500003
J	Tunwell, REA; Lai, FA				Tunwell, REA; Lai, FA			Ryanodine receptor expression in the kidney and a non-excitable kidney epithelial cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-INDUCED CA2+ RELEASE; POLYMERASE CHAIN-REACTION; SKELETAL-MUSCLE; INOSITOL TRISPHOSPHATE; CHROMAFFIN CELLS; CHANNEL; BRAIN; STORE; OSCILLATIONS; SPECIFICITY	An oligonucleotide probe to a conserved 3' region within the three identified ryanodine receptor-calcium release channel isoforms hybridized to a single clone from a rabbit kidney cDNA library. The kidney clone encoded the carboxyl-terminal 338 amino acids within the putative transmembrane domain of the type 2 ryanodine receptor sequence. Reverse transcriptase-polymerase chain reaction with isoform-specific oligonucleotide primers demonstrated the presence of the type 2 ryanodine receptor transcript in rabbit kidney, as well as in a non-excitable cell line, LLC-RK1, derived from rabbit kidney epithelial cells. Amplification by rapid amplification of 51 cDNA ends indicated the kidney type 2 ryanodine receptor transcript extended >7000 base pairs from the stop codon and is therefore not homologous to the short RS R-1 transcript of similar to 2500 base pairs previously observed in rabbit brain, [H-3]Ryanodine binding and immunoblot analysis with a type 2 ryanodine receptor-specific antibody demonstrated that the native type 2 ryanodine receptor protein is expressed in the kidney. These observations suggest that the type 2 ryanodine receptor isoform may play a functional role in regulating intracellular calcium homeostasis in nonexcitable cells.	NATL INST MED RES,MRC,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research				Lai, Tony/0000-0003-2852-8547				BARMATZ VS, 1991, BIOCHEM J, V276, P41; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CHEEK TR, 1991, BIOCHEM J, V275, P697, DOI 10.1042/bj2750697; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; GUSE AH, 1993, BIOCHEM J, V291, P447, DOI 10.1042/bj2910447; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; ISLAM MS, 1992, FEBS LETT, V296, P287, DOI 10.1016/0014-5793(92)80306-2; KUWAJIMA G, 1992, NEURON, V9, P1133, DOI 10.1016/0896-6273(92)90071-K; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1989, J BIOENERG BIOMEMBR, V21, P227, DOI 10.1007/BF00812070; LAI FA, 1992, BIOCHEM J, V288, P553, DOI 10.1042/bj2880553; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LEDBETTER MW, 1994, J BIOL CHEM, V269, P31544; LESH RE, 1993, CIRC RES, V72, P481, DOI 10.1161/01.RES.72.2.481; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MACDONALD C, 1991, EXP CELL RES, V195, P458, DOI 10.1016/0014-4827(91)90396-C; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MCPHERSON PS, 1993, J BIOL CHEM, V268, P19785; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MIKOSHIBA K, 1993, TRENDS PHARMACOL SCI, V14, P86, DOI 10.1016/0165-6147(93)90069-V; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OTSU K, 1990, J BIOL CHEM, V265, P13472; SANCHEZBUENO A, 1993, BIOCHEM J, V291, P169, DOI 10.1042/bj2910169; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; SUZUKI M, 1991, AM J PHYSIOL, V260, pF757, DOI 10.1152/ajprenal.1991.260.5.F757; SWANN K, 1992, BIOCHEM J, V287, P79, DOI 10.1042/bj2870079; TAKESHIMA H, 1993, FEBS LETT, V322, P105, DOI 10.1016/0014-5793(93)81547-D; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9	33	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29583	29588		10.1074/jbc.271.47.29583	http://dx.doi.org/10.1074/jbc.271.47.29583			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939887	hybrid			2022-12-27	WOS:A1996VU52500015
J	Yoshida, Y; Kurosawa, N; Kanematsu, T; Kojima, N; Tsuji, S				Yoshida, Y; Kurosawa, N; Kanematsu, T; Kojima, N; Tsuji, S			Genomic structure and promoter activity of the mouse polysialic acid synthase gene (mST8Sia II) - Brain-specific expression from a tata-less GC-rich sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTALLY-REGULATED MEMBER; CELL-ADHESION MOLECULE; NEURON-SPECIFIC EXPRESSION; RECEPTOR GENE; SIALYLTRANSFERASE; CLONING; ALPHA-2,8-SIALYLTRANSFERASE; FAMILY; STX; MIGRATION	The mouse ST8Sia II (mST8Sia II/STX) gene encodes a neural cell adhesion molecule-specific polysialic acid synthase whose expression is regulated during the developmental stages of mouse brain, To elucidate the molecular mechanism by which the expression is tissue-specifically and developmentally regulated, we isolated the complete genomic DNA and characterized the promoter of the gene for mST8Sia II, The gene encoding mST8Sia II was found to span about 80 kilobases and to be composed of six exons. Primer extension and S1 nuclease protection analyses revealed that the transcription started from 167 nucleotides upstream of the translational initiation site, Promoter analyses of the 5'-flanking region of the mST8Sia II gene using a luciferase gene reporter system revealed strong promoter activity in retinoic acid-induced differentiated P19 cells, which highly express the mST8Sia II gene, Deletion analyses demonstrated that the minimal promoter activity detected for the proximal region 325 base pairs upstream from the translational initiation codon (-158 to +167) could be modulated by various sequences within the 9.5-kilobase 5'-flanking region, The minimal promoter was embedded in a GC-rich domain (74%, GC content), in which two Spl binding motifs as well as a long purine-rich region were found, but it lacked TATA and CAAT boxes, The positive regulatory region located between -159 and -659 contained two additional Sp1 binding motifs and a long pyrimidine-rich region, We also found that the minimal promoter region of the mST8Sia II gene was sufficient for expression of a reporter gene in mST8Sia II gene-expressing neural differentiated P19 cells but not in nonexpressing ones, Thus the TATA-less GC-rich minimal promoter region of mST8Sia II probably controls the cell type-specific expression of the mST8Sia II gene.	RIKEN,INST PHYS & CHEM RES,FRONTIER RES PROGRAM,WAKO,SAITAMA 35101,JAPAN	RIKEN			Yoshida, Yukiko/ABB-7218-2020	Yoshida, Yukiko/0000-0002-0629-0219; Kurosawa, Nobuyuki/0000-0002-1548-4541				BREEN KC, 1988, DEVELOPMENT, V104, P147; CHANG ML, 1995, GLYCOBIOLOGY, V5, P319, DOI 10.1093/glycob/5.3.319; CHIN LS, 1994, J BIOL CHEM, V269, P18507; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; FREDETTE B, 1993, J CELL BIOL, V123, P1867, DOI 10.1083/jcb.123.6.1867; FROTHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998; Kitagawa H, 1996, J BIOL CHEM, V271, P931, DOI 10.1074/jbc.271.2.931; KITAGAWA H, 1994, J BIOL CHEM, V269, P17872; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; Kojima N, 1996, J BIOL CHEM, V271, P22058, DOI 10.1074/jbc.271.36.22058; Kojima N, 1996, J BIOL CHEM, V271, P19457, DOI 10.1074/jbc.271.32.19457; KOJIMA N, 1995, FEBS LETT, V373, P119, DOI 10.1016/0014-5793(95)01024-9; Kurosawa N, 1996, J BIOL CHEM, V271, P15109, DOI 10.1074/jbc.271.25.15109; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MCCOY RD, 1985, J BIOL CHEM, V260, P2695; MINOWA MT, 1992, P NATL ACAD SCI USA, V89, P3045, DOI 10.1073/pnas.89.7.3045; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; ONO K, 1994, NEURON, V13, P595, DOI 10.1016/0896-6273(94)90028-0; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; TAKAMATSU K, 1994, CANCER RES, V54, P2598; TANG JC, 1994, NEURON, V13, P405, DOI 10.1016/0896-6273(94)90356-5; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; TSUJI S, 1996, IN PRESS GLYCOBIOLOG, V6; VIBERT M, 1989, EUR J BIOCHEM, V181, P33, DOI 10.1111/j.1432-1033.1989.tb14690.x; WANG C, 1994, J NEUROSCI, V14, P4446; WANG MM, 1993, MOL CELL BIOL, V13, P5805, DOI 10.1128/MCB.13.9.5805; WANG X, 1990, Glycobiology, V1, P25, DOI 10.1093/glycob/1.1.25; YOSHIDA KY, 1996, IN PRESS GLYCOBIOLOG, V6; YOSHIDA Y, 1995, J BIOCHEM-TOKYO, V118, P658, DOI 10.1093/oxfordjournals.jbchem.a124960; YOSHIDA Y, 1995, J BIOL CHEM, V270, P14628, DOI 10.1074/jbc.270.24.14628	41	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30167	30173		10.1074/jbc.271.47.30167	http://dx.doi.org/10.1074/jbc.271.47.30167			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939967	hybrid			2022-12-27	WOS:A1996VU52500095
J	Aoki, N; YamaguchiAoki, Y; Ullrich, A				Aoki, N; YamaguchiAoki, Y; Ullrich, A			RETRACTED: The novel protein-tyrosine phosphatase PTP20 is a positive regulator of PC12 cell neuronal differentiation (Retracted Article. See vol 285, 32678, 2010)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							NERVE GROWTH-FACTOR; INSULIN-RECEPTOR; CDNA CLONING; SH2 DOMAIN; EXPRESSION; KINASES; PRODUCT; GENE; RAS	A novel cytoplasmic protein-tyrosine phosphatase (PTPase) designated PTP20 was isolated from a PC12 cDNA Library and shown to positively regulate the differentiation process in PC12 cells. The PTP20 open reading frame of 453 amino acids contains a single tyrosine phosphatase catalytic domain and displays closest homology to members of the PTP-PEST protein-tyrosine phosphatase family. Transient expression of PTP20 in Rat-1 cells resulted in the expression of a 50-kDa protein which exhibited PTPase activity in vitro. Expression of the 2.3-kilobase PTP20 mRNA increased during differentiation of nerve growth factor (NGF)-stimulated PC12 cells. Consistent with this observation, stable overexpression of PTP20 in PC12 cells resulted in accelerated neurite formation following NGF treatment. These findings suggest a positive regulatory role of PTP20 in NGF-dependent neuronal differentiation of PC12 cells.	MAX PLANCK INST BIOCHEM, DEPT MOL BIOL, D-82152 MARTINSRIED, GERMANY	Max Planck Society								CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONNOLLY JL, 1984, J CELL BIOL, V98, P457, DOI 10.1083/jcb.98.2.457; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HASHIMOTO N, 1992, BIOCHEM J, V284, P569, DOI 10.1042/bj2840569; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LABBE D, 1994, FEBS LETT, V356, P351, DOI 10.1016/0014-5793(94)01305-5; LONGO FM, 1993, J BIOL CHEM, V268, P26503; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MEI L, 1994, J BIOL CHEM, V269, P12254; MORIYAMA T, 1994, FEBS LETT, V353, P305, DOI 10.1016/0014-5793(94)01064-1; MORIYAMA T, 1992, BIOCHEM BIOPH RES CO, V188, P34, DOI 10.1016/0006-291X(92)92346-Y; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; PAN MG, 1993, J BIOL CHEM, V268, P19284; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; SHARMA E, 1995, J BIOL CHEM, V270, P49, DOI 10.1074/jbc.270.1.49; TAKEKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P1223, DOI 10.1016/0006-291X(92)92335-U; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU YY, 1993, J CELL BIOL, V121, P409, DOI 10.1083/jcb.121.2.409; YANG Q, 1993, J BIOL CHEM, V268, P6622; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	31	38	42	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29422	29426		10.1074/jbc.271.46.29422	http://dx.doi.org/10.1074/jbc.271.46.29422			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910608	hybrid			2022-12-27	WOS:A1996VT05200100
J	Slekar, KH; Kosman, DJ; Culotta, VC				Slekar, KH; Kosman, DJ; Culotta, VC			The yeast copper zinc superoxide dismutase and the pentose phosphate pathway play overlapping roles in oxidative stress protection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ENCODING GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; SULFATE ASSIMILATION; TRANSKETOLASE GENE; STRUCTURAL GENE; ENZYME; SEQUENCE; PROTEIN; MUTANTS; SULFUR	In Saccharomyces cerevisiae, loss of cytosolic superoxide dismutase (Sod1) results in several air-dependent mutant phenotypes, including methionine auxotrophy and oxygen sensitivity. Here we report that these two sod1 Delta phenotypes were specifically suppressed by elevated expression of the TKL1 gene, encoding transketolase of the pentose phosphate pathway. The apparent connection between Sod1 and the pentose phosphate pathway prompted an investigation of mutants defective in glucose-6-phosphate dehydrogenase (Zwf1), which catalyzes the rate-limiting NADPH-producing step of this pathway. We confirmed that zwf1 Delta mutants are methionine auxotrophs and report that they also are oxygen-sensitive. We determined that a functional ZWF1 gene product was required for TKL1 to suppress sod1 Delta, leading us to propose that increased flux through the oxidative reactions of the pentose phosphate pathway can rescue sod1 methionine auxotrophy. To better understand this methionine growth requirement, we examined the sulfur compound requirements of sod1 Delta and zwf1 Delta mutants, and noted that these mutants exhibit the same apparent defect in sulfur assimilation. Our studies suggest that this defect results from the impaired redox status of aerobically grown sod1 and zwf1 mutants, implicating Sod1 and the pentose phosphate pathway as being critical for maintenance of the cellular redox state.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT ENVIRONM HLTH SCI, DIV TOXICOL SCI, BALTIMORE, MD 21205 USA; SUNY BUFFALO, DEPT BIOCHEM, BUFFALO, NY 14214 USA	Johns Hopkins University; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046787, R01GM050016, R37GM050016] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES07141] Funding Source: Medline; NIGMS NIH HHS [GM 50016, GM 46787] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FA, 1990, CURRENT PROTOCOLS MO; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BERMINGHAMMCDONOGH O, 1988, P NATL ACAD SCI USA, V85, P4789, DOI 10.1073/pnas.85.13.4789; BERTHON HA, 1992, BIOCHEMISTRY-US, V31, P12792, DOI 10.1021/bi00166a012; Bostek C C, 1989, AANA J, V57, P231; CHANG EC, 1990, J BACTERIOL, V172, P1840, DOI 10.1128/jb.172.4.1840-1845.1990; CHANG LY, 1988, J CELL BIOL, V107, P2169, DOI 10.1083/jcb.107.6.2169; CHAUNCEY TR, 1983, BIOCHIM BIOPHYS ACTA, V744, P304, DOI 10.1016/0167-4838(83)90204-2; CHEREST H, 1992, GENETICS, V130, P51; CULOTTA VC, 1994, J BIOL CHEM, V269, P25295; CULOTTA VC, 1995, J BIOL CHEM, V270, P29991; FLETCHER TS, 1992, BIOCHEMISTRY-US, V31, P1892, DOI 10.1021/bi00121a044; FLINT DH, 1993, J BIOL CHEM, V268, P25547; FRIDOVICH I, 1983, ANNU REV PHARMACOL, V23, P239, DOI 10.1146/annurev.pa.23.040183.001323; GALIAZZO F, 1991, EUR J BIOCHEM, V196, P545, DOI 10.1111/j.1432-1033.1991.tb15848.x; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; GONZALEZ.P, 1970, J BIOL CHEM, V245, P2371; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; GUIDOT DM, 1993, J BIOL CHEM, V268, P26699; Halliwell B., 1985, FREE RADICALS BIOL M, DOI 10.1016/0748-5514(85)90140-0; KELLER GA, 1991, P NATL ACAD SCI USA, V88, P7381, DOI 10.1073/pnas.88.16.7381; KLETZIEN RF, 1994, FASEB J, V8, P174, DOI 10.1096/fasebj.8.2.8119488; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; Lawrence C.W., 1978, METHODS YEAST GENETI, P178; LEE KS, 1994, J BIOL CHEM, V269, P19725; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; LIU XF, 1992, J BIOL CHEM, V267, P18298; LIU XF, 1994, MOL CELL BIOL, V14, P7037, DOI 10.1128/MCB.14.11.7037; MARRES CAM, 1985, EUR J BIOCHEM, V147, P153, DOI 10.1111/j.1432-1033.1985.tb08731.x; MASSELOT M, 1977, MOL GEN GENET, V154, P23, DOI 10.1007/BF00265572; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MoradasFerreira P, 1996, MOL MICROBIOL, V19, P651, DOI 10.1046/j.1365-2958.1996.403940.x; MULLER EGD, 1991, J BIOL CHEM, V266, P9194; NOGAE I, 1990, GENE, V96, P161, DOI 10.1016/0378-1119(90)90248-P; PANDOLFI PP, 1995, EMBO J, V14, P5209, DOI 10.1002/j.1460-2075.1995.tb00205.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAAFF I, 1990, EUR J BIOCHEM, V188, P597, DOI 10.1111/j.1432-1033.1990.tb15440.x; SCHAAFFGERSTENSCHLAGER I, 1993, CURR GENET, V24, P373, DOI 10.1007/BF00351843; SCHAAFFGERSTENSCHLAGER I, 1993, EUR J BIOCHEM, V217, P487, DOI 10.1111/j.1432-1033.1993.tb18268.x; SCHNEIDER JC, 1991, METHOD ENZYMOL, V194, P373; SUNDSTROM M, 1993, J BIOL CHEM, V268, P24346; THOMAS D, 1992, J GEN MICROBIOL, V138, P2021, DOI 10.1099/00221287-138-10-2021; THOMAS D, 1991, EMBO J, V10, P547, DOI 10.1002/j.1460-2075.1991.tb07981.x; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WOOD T, 1985, PENTOSE PHOSPHATE PA	46	174	178	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28831	28836		10.1074/jbc.271.46.28831	http://dx.doi.org/10.1074/jbc.271.46.28831			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910528	hybrid			2022-12-27	WOS:A1996VT05200020
J	Suidan, HS; Niclou, SP; Dreessen, J; Beltraminelli, N; Monard, D				Suidan, HS; Niclou, SP; Dreessen, J; Beltraminelli, N; Monard, D			The thrombin receptor is present in myoblasts and its expression is repressed upon fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH-FACTOR; RAT LUMBRICAL MUSCLES; AORTIC SMOOTH-MUSCLE; TERMINAL DIFFERENTIATION; MAP KINASE; FACTOR-BETA; NEURITE RETRACTION; MOUSE MYOBLASTS; PROTEIN-KINASES; NEURONAL CELLS	Cultured myoblasts derived from limb muscle of newborn rats express thrombin receptor immunoreactivity on their surface. Receptor expression is repressed upon myoblast fusion. This is due at least in part to a decrease in the amount of the thrombin receptor mRNA. Addition of thrombin triggers calcium transients only in mono- but not multinucleated muscle cells. Furthermore, thrombin increases the rate of myoblast proliferation that coincides with an activation of mitogen-activated protein kinase. Northern analysis of thrombin receptor mRNA expression in skeletal muscle showed that the transcript is present at a relatively high level at birth, but is almost undetectable in the adult. By in situ hybridization, the mRNA at birth appeared to be present mostly in mononucleated cells grouped in clusters, but not in muscle fibers. Very few nuclei surrounded by a mRNA signal were present on muscle sections of rats 24 days postnatally. These results suggest that the thrombin receptor plays a role in muscle development.	CIBA GEIGY LTD,CH-4002 BASEL,SWITZERLAND	Novartis	Suidan, HS (corresponding author), FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND.		Niclou, Simone/P-2304-2018	Niclou, Simone/0000-0002-3417-9534				BEECHER KL, 1994, J NEUROSCI RES, V37, P108, DOI 10.1002/jnr.490370115; BHAT NR, 1995, J CELL PHYSIOL, V165, P417, DOI 10.1002/jcp.1041650223; BIZIOS R, 1986, J CELL PHYSIOL, V128, P485, DOI 10.1002/jcp.1041280318; BRASS LF, 1993, THROMB HAEMOSTASIS, V70, P217; BRUNET A, 1994, ONCOGENE, V9, P3379; CAVANAUGH KP, 1990, J NEUROCHEM, V54, P1735, DOI 10.1111/j.1471-4159.1990.tb01228.x; CHEN LB, 1975, P NATL ACAD SCI USA, V72, P131, DOI 10.1073/pnas.72.1.131; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Chen X, 1995, BIOCHEM BIOPH RES CO, V217, P445, DOI 10.1006/bbrc.1995.2796; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; COUGHLIN SR, 1994, TRENDS CARDIOVAS MED, V4, P77, DOI 10.1016/1050-1738(94)90013-2; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EWTON DZ, 1988, J BIOL CHEM, V263, P4029; GLENN KC, 1979, NATURE, V278, P711, DOI 10.1038/278711a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HU JS, 1990, J BIOL CHEM, V265, P7914; HUANG CL, 1987, NATURE, V329, P849, DOI 10.1038/329849a0; ISHII K, 1993, J BIOL CHEM, V268, P9780; JALINK K, 1992, J CELL BIOL, V118, P411, DOI 10.1083/jcb.118.2.411; JENKINS AL, 1995, J CELL SCI, V108, P3059; KELVIN DJ, 1989, J CELL BIOL, V108, P169, DOI 10.1083/jcb.108.1.169; KOLODNEY MS, 1992, J CELL BIOL, V117, P73, DOI 10.1083/jcb.117.1.73; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; LAPOSATA M, 1983, BLOOD, V62, P549; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LIM RW, 1984, J CELL BIOL, V98, P739, DOI 10.1083/jcb.98.2.739; LIM RW, 1984, DEV BIOL, V105, P48, DOI 10.1016/0012-1606(84)90260-4; LIU Y, 1994, P NATL ACAD SCI USA, V91, P10300, DOI 10.1073/pnas.91.22.10300; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; NELSON PG, 1995, PERSPECT DEV NEUROBI, V2, P399; NELSON PG, 1996, M GERM NEUR SOC, P51; NELSON RB, 1990, DEV BRAIN RES, V54, P93, DOI 10.1016/0165-3806(90)90069-B; NEYLON CB, 1994, CIRC RES, V75, P733, DOI 10.1161/01.RES.75.4.733; NICLOU S, 1994, CELL MOL BIOL, V40, P421; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OLWIN BB, 1988, J CELL BIOL, V107, P761, DOI 10.1083/jcb.107.2.761; ONTALL M, 1978, AM J ANAT, V152, P539; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PILCHER BK, 1994, EXP CELL RES, V211, P368, DOI 10.1006/excr.1994.1100; PLANTIER JL, 1994, BRIT J HAEMATOL, V87, P755, DOI 10.1111/j.1365-2141.1994.tb06735.x; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; ROSS JJ, 1987, DEVELOPMENT, V100, P395; ROSS JJ, 1987, DEVELOPMENT, V100, P383; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHUBERT D, 1974, J CELL BIOL, V61, P398, DOI 10.1083/jcb.61.2.398; SOIFER SJ, 1994, AM J PATHOL, V144, P60; STEINBERG SF, 1991, CIRC RES, V68, P1216, DOI 10.1161/01.RES.68.5.1216; SUGAMA Y, 1992, J CELL BIOL, V119, P935, DOI 10.1083/jcb.119.4.935; SUIDAN HS, 1994, P NATL ACAD SCI USA, V91, P8112, DOI 10.1073/pnas.91.17.8112; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; Sullivan R, 1996, BLOOD, V87, P648, DOI 10.1182/blood.V87.2.648.bloodjournal872648; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; VIRDEE K, 1995, EUR J NEUROSCI, V7, P2159, DOI 10.1111/j.1460-9568.1995.tb00637.x; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WALZ DA, 1985, P SOC EXP BIOL MED, V180, P518; WEINSTEIN JR, 1995, J NEUROSCI, V15, P2906; Yoshida S, 1996, J CELL BIOL, V132, P181, DOI 10.1083/jcb.132.1.181	64	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29162	29169		10.1074/jbc.271.46.29162	http://dx.doi.org/10.1074/jbc.271.46.29162			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910573				2022-12-27	WOS:A1996VT05200065
J	Zhang, GH; Melvin, JE				Zhang, GH; Melvin, JE			Na+-dependent release of Mg2+ from an intracellular pool in rat sublingual mucous acini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRET RED-CELLS; MAGNESIUM TRANSPORT; CYTOSOLIC SODIUM; BLOOD-CELLS; COTRANSPORT; INFLUX; MG-2+; INDICATORS; CALCIUM; SYSTEM	Muscarinic stimulation induces release of Mg2+ from an intracellular pool in rat sublingual mucous acini (Zhang, G. H., and Melvin, J. E. (1992) J. Biol. Chem. 267, 20721-20727). In the present study we examined the interdependence of Mg2+ mobilization on intracellular Na+ and Ca2+ by monitoring the intracellular free concentrations of Na+ ([Na+](i)), Mg2+ ([Mg2+](i)), and Ca2+ ([Ca2+](i)) using ion-sensitive fluorescent indicators. Gramicidin increased the intracellular concentrations of all three ions. Comparable to agonist-stimulated mobilization of Mg2+, the gramicidin-induced [Mg2+](i) increase was independent of extracellular Mg2+ indicating release of Mg2+ from an intracellular pool. Clamping the [Ca2+](i) near 30 nM with the Ca2+-selective chelator BAPTA failed to alter the [Na+](i) or [Mg2+](i) increases generated by gramicidin. In contrast, depletion of intracellular Na+ markedly suppressed the muscarinic-stimulated [Mg2+](i) increase, whereas the [Ca2+](i) increase was similar to that seen in physiological extracellular Na+. These results revealed that intracellular Mg2+ mobilization did not directly relate to the [Ca2+](i), but required an increase in [Na+](i). Consistent with this hypothesis, increasing [Na+](i) by activating Na+ influx via the Na+/H+ exchanger also increased the [Mg2+]i(.) The Na+/Mg2+ exchange inhibitor quinidine suppressed both the gramicidin- and muscarinic-induced discharge of internal Mg2+. These results suggest that release of Mg2+ from an intracellular pool is mediated by a Na+ dependent Mg2+ transport mechanism in salivary acinar cells.	UNIV ROCHESTER, DEPT DENT RES, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, DEPT NEUROBIOL & ANAT, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester					NIDCR NIH HHS [DE10655, DE08921] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE008921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE010655, R37DE008921] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADAMS SR, 1989, J AM CHEM SOC, V111, P7957, DOI 10.1021/ja00202a042; BEYENBACH KW, 1990, MAGNESIUM TRACE ELEM, V9, P233; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; DAI LJ, 1991, J CLIN INVEST, V88, P1255, DOI 10.1172/JCI115429; DELPIRE E, 1991, J PHYSIOL-LONDON, V441, P219, DOI 10.1113/jphysiol.1991.sp018747; FERAY JC, 1986, BIOCHIM BIOPHYS ACTA, V856, P76, DOI 10.1016/0005-2736(86)90012-X; FLATMAN PW, 1990, J PHYSIOL-LONDON, V431, P11, DOI 10.1113/jphysiol.1990.sp018318; FLATMAN PW, 1988, J PHYSIOL-LONDON, V397, P471, DOI 10.1113/jphysiol.1988.sp017013; FLATMAN PW, 1991, ANNU REV PHYSIOL, V53, P259, DOI 10.1146/annurev.ph.53.030191.001355; GRUBBS RD, 1984, J BIOL CHEM, V259, P2184; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNTHER T, 1990, BIOCHIM BIOPHYS ACTA, V1023, P455, DOI 10.1016/0005-2736(90)90139-F; GYLFE E, 1990, BIOCHIM BIOPHYS ACTA, V1055, P82, DOI 10.1016/0167-4889(90)90094-T; HAROOTUNIAN AT, 1989, J BIOL CHEM, V264, P19458; MELVIN JE, 1991, AM J PHYSIOL, V261, pG1043, DOI 10.1152/ajpgi.1991.261.6.G1043; MINTA A, 1989, J BIOL CHEM, V264, P19449; NAUNTOFTE B, 1986, AM J PHYSIOL, V251, pC175, DOI 10.1152/ajpcell.1986.251.2.C175; NISHIURA A, 1988, PHARMACEUT RES, V5, P209, DOI 10.1023/A:1015985511653; QUAMME GA, 1990, AM J PHYSIOL, V259, pC521, DOI 10.1152/ajpcell.1990.259.3.C521; RAJU B, 1989, AM J PHYSIOL, V256, pC540, DOI 10.1152/ajpcell.1989.256.3.C540; RINK TJ, 1980, BIOCHIM BIOPHYS ACTA, V595, P15, DOI 10.1016/0005-2736(80)90243-6; ROTEVATN S, 1991, ACTA PHYSIOL SCAND, V142, P125; TURNER RJ, 1986, J MEMBRANE BIOL, V94, P143, DOI 10.1007/BF01871194; WONG MMY, 1991, SCIENCE, V254, P1014, DOI 10.1126/science.1948071; ZHANG GH, 1994, J BIOL CHEM, V269, P10352; ZHANG GH, 1993, AM J PHYSIOL, V264, pC54, DOI 10.1152/ajpcell.1993.264.1.C54; ZHANG GH, 1992, J BIOL CHEM, V267, P20721; ZHANG GH, 1995, FEBS LETT, V371, P52, DOI 10.1016/0014-5793(95)00869-B	28	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29067	29072		10.1074/jbc.271.46.29067	http://dx.doi.org/10.1074/jbc.271.46.29067			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910560	hybrid			2022-12-27	WOS:A1996VT05200052
J	Wallace, A; Koblan, KS; Hamilton, K; MarquisOmer, DJ; Miller, PJ; Mosser, SD; Omer, CA; Schaber, MD; Cortese, R; Oliff, A; Gibbs, JB; Pessi, A				Wallace, A; Koblan, KS; Hamilton, K; MarquisOmer, DJ; Miller, PJ; Mosser, SD; Omer, CA; Schaber, MD; Cortese, R; Oliff, A; Gibbs, JB; Pessi, A			Selection of potent inhibitors of farnesyl-protein transferase from a synthetic tetrapeptide combinatorial library	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS FARNESYLATION; PEPTIDE LIBRARY; FARNESYLTRANSFERASE; BINDING; PEPTIDOMIMETICS; IDENTIFICATION; CELLS	Inhibitors of farnesyl-protein transferase (FPTase) show promise as anticancer agents, Based on the sequence of the protein substrates of FPTase (the CAAX sequence), potent and selective peptidomimetic inhibitors have been developed; these compounds share with the peptide substrate a free thiol and a C-terminal carboxylate, We have used a synthetic tetrapeptide combinatorial library to screen for new leads devoid of these features: the peptides were C-terminally amidated, and no free thiol was included in the combinatorial building blocks, To compensate for this negative bias, an expanded set of 68 amino acids was used, including both L and D as web as many non-coded residues, Sixteen individual tetrapeptides derived from the consensus were synthesized and tested; all were active, showing IC50 values ranging from low micromolar to low nanomolar, The most active peptide, D-tryptophan-D-methionine-D-4-chlorophenylalanine-L-gamma-carboxyglutamic acid (K-i = 2 nM), is also very selective showing Little inhibitory activity against the related enzyme geranylgeranyl-protein transferase type I (IC50 > 50 mu M). In contrast to CAAX-based peptidomimetics, D-tryptophan-D-methionine-D-4-chlorophenylalanine-L-gamma-carboxyglutamic acid appeared to mimic the iso prenoid substrate farnesyl diphosphate as determined by kinetic and physical measurements, D-Tryptophan-D-methionine-D-4-chlorophenylalanine-L-gamma-carboxyglutamic acid was a competitive inhibitor of FPTase with respect to farnesyl diphosphate substrate and uncompetitive with respect to CAAX substrate, Furthermore, we demonstrated that FPTase undergoes ligand dependent conformational changes in its circular dichroism spectrum and that D-Typtophan-D-methionine-D-4-chlorophenylalanine-L-gamma-carboxyglutamic acid induced a conformational change identical to that observed with farnesyl diphosphate ligand.	IST RIC BIOL MOL P ANGELETTI,I-00040 POMEZIA,ROME,ITALY; MERCK RES LABS,DEPT CANC RES,W POINT,PA 19486; MERCK RES LABS,PHARMACEUT RES DEPT,W POINT,PA 19486	Merck & Company; Merck & Company; Merck & Company								BIANCHI E, 1995, J MOL BIOL, V247, P154, DOI 10.1006/jmbi.1994.0129; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; Dolence JM, 1995, BIOCHEMISTRY-US, V34, P16687, DOI 10.1021/bi00051a017; DOOLEY CT, 1993, P NATL ACAD SCI USA, V90, P10811, DOI 10.1073/pnas.90.22.10811; EICHLER J, 1993, BIOCHEMISTRY-US, V32, P11035, DOI 10.1021/bi00092a013; FURFINE ES, 1995, BIOCHEMISTRY-US, V34, P6857, DOI 10.1021/bi00020a032; FURKA A, 1991, INT J PEPT PROT RES, V37, P487, DOI 10.1111/j.1399-3011.1991.tb00765.x; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; Hamilton A., 1995, DRUG NEWS PERSPECT, V8, P138; HOUGHTEN RA, 1991, NATURE, V354, P82; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; NIGAM M, 1993, J BIOL CHEM, V268, P20695; OMER CA, 1995, METHOD ENZYMOL, V250, P3; PINILLA C, 1994, BIOCHEM J, V301, P847, DOI 10.1042/bj3010847; PINILLA C, 1992, BIOTECHNIQUES, V13, P901; POMPLIANO DL, 1993, BIOCHEMISTRY-US, V32, P8341, DOI 10.1021/bi00083a038; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; SINGH SB, 1993, TETRAHEDRON, V49, P5917, DOI 10.1016/S0040-4020(01)87178-7; TAMANOI F, 1993, TRENDS BIOCHEM SCI, V18, P349, DOI 10.1016/0968-0004(93)90072-U; WALLACE A, 1994, PEPTIDE RES, V7, P27	26	49	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31306	31311		10.1074/jbc.271.49.31306	http://dx.doi.org/10.1074/jbc.271.49.31306			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940136	hybrid			2022-12-27	WOS:A1996VW68600047
J	Agius, L; Peak, M; Newgard, CB; GomezFoix, AM; Guinovart, JJ				Agius, L; Peak, M; Newgard, CB; GomezFoix, AM; Guinovart, JJ			Evidence for a role of glucose-induced translocation of glucokinase in the control of hepatic glycogen synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY PROTEIN; LIVER GLUCOKINASE; METABOLIC CONTROL; RAT HEPATOCYTES; INSULIN; EXPRESSION; FRUCTOSE; CELLS; GENE; PROMOTER	Glucokinase reversibly partitions between a bound and a free state in the hepatocyte in response to the metabolic status of the cell. Maximum binding occurs at low [glucose] (<5 mM) and minimum binding at high [glucose] or in the presence of sorbitol or fructose. In this study we determined the binding characteristics of glucokinase in the hepatocyte in situ, by adenovirus-mediated glucokinase overexpression combined with the digitonin-permeabilization technique. We also determined the sensitivity of glycogen synthesis to changes in either total glucokinase overexpression or in free glucokinase activity. Glucokinase overexpression is associated with an increase in both free and bound activity, with an overall decrease in the proportion of bound activity, In hepatocytes incubated at low [glucose] (0-5 mM), glucokinase binding involves a high-affinity binding site with a K-d of similar to 0.1 mu M and a binding capacity of similar to 3 pmol/mg total cell protein and low-affinity binding with a K-d of similar to 1.6 mu M. Increasing glucose concentration to 20 mM causes a dose-dependent increase in the K-d of the high-affinity site to similar to 0.6 mu M, and this effect was mimicked by 50 mu M sorbitol, a precursor of fructose 1-P, confirming that this site is the regulatory protein of glucokinase. Glycogen synthesis determined from the incorporation of [2-H-3,U-C-14]glucose into glycogen at 5 man or 10 mM glucose was very sensitive to small increases in total glucokinase activity and correlated more closely with the increase in free glucokinase activity. The relation between glycogenic flux and glucokinase activity is sigmoidal. Expression of the sensitivity of glycogen synthesis to glucokinase activity as the control coefficient reveals that the coefficient is greater for the incorporation of 2-tritium (which occurs exclusively by the direct pathway) than for incorporation of C-14 label (which involves direct and indirect pathways) and is greater at 5 mM glucose (when glucokinase is maximally sequestered at its high-affinity site) than at 10 mM glucose. The results support the hypothesis that compartmentation of glucokinase in the hepatocyte increases the sensitivity of glycogen synthesis to small changes in total glucokinase activity and that glucose-induced translocation of glucokinase has a major role in the acute control of glycogen synthesis.	UNIV TEXAS,SW MED CTR,GIFFORD LABS DIABET RES,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; UNIV BARCELONA,DEPT BIOQUIM & BIOL MOL,E-08028 BARCELONA,SPAIN	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Barcelona	Agius, L (corresponding author), MED SCH NEWCASTLE UPON TYNE,DEPT MED,FRAMLINGTON PL,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.			Peak, Matthew/0000-0003-1909-3211	PHS HHS [P5H2598801] Funding Source: Medline; Wellcome Trust Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); Wellcome Trust(Wellcome TrustEuropean Commission)		AGIUS L, 1990, BIOCHEM J, V271, P387, DOI 10.1042/bj2710387; AGIUS L, 1990, BIOCHEM J, V266, P91, DOI 10.1042/bj2660091; AGIUS L, 1995, BIOCHEM J, V309, P711, DOI 10.1042/bj3090711; AGIUS L, 1993, BIOCHEM J, V296, P785, DOI 10.1042/bj2960785; AGIUS L, 1994, BIOCHEM J, V298, P237, DOI 10.1042/bj2980237; AGIUS L, 1994, BIOCHEM J, V303, P841, DOI 10.1042/bj3030841; AGIUS L, 1993, BIOCHEM J, V289, P255, DOI 10.1042/bj2890255; ATKINSON DE, 1977, CELLULAR ENERGY META, P139; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; DAVIES DR, 1990, EUR J BIOCHEM, V192, P283, DOI 10.1111/j.1432-1033.1990.tb19225.x; DETHEUX M, 1991, EUR J BIOCHEM, V294, P551; FELL DA, 1985, EUR J BIOCHEM, V148, P555, DOI 10.1111/j.1432-1033.1985.tb08876.x; FELL DA, 1992, BIOCHEM J, V286, P313, DOI 10.1042/bj2860313; Hue L, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P247; HUGHES SD, 1991, J BIOL CHEM, V266, P4521; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; JETTON TL, 1994, J BIOL CHEM, V269, P3641; Kacser H, 1979, BIOCHEM SOC T, V7, P1149, DOI 10.1042/bst0071149; Katz J, 1976, Curr Top Cell Regul, V10, P237; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MAGNUSON MA, 1993, NUTRITION GENE EXPRE, P143; MASSAGUE J, 1977, FEBS LETT, V82, P317, DOI 10.1016/0014-5793(77)80610-8; NEWGARD CB, 1990, BIOCHEM SOC T, V18, P851, DOI 10.1042/bst0180851; Newsholme E A, 1976, Biochem Soc Symp, P61; NOUSPIKEL T, 1992, EUR J BIOCHEM, V210, P365, DOI 10.1111/j.1432-1033.1992.tb17430.x; ODoherty RM, 1996, J BIOL CHEM, V271, P20524, DOI 10.1074/jbc.271.34.20524; VANDERCAMMEN A, 1993, BIOCHEM J, V294, P551, DOI 10.1042/bj2940551; VANDERCAMMEN A, 1990, EUR J BIOCHEM, V191, P483, DOI 10.1111/j.1432-1033.1990.tb19147.x; VANDERCAMMEN A, 1991, EUR J BIOCHEM, V200, P545, DOI 10.1111/j.1432-1033.1991.tb16217.x; VANSCHAFTINGEN E, 1994, DIABETOLOGIA, V327, pS43; WALKER D. G., 1966, ESSAYS BIOCHEM, V2, P33; WALS PA, 1994, J BIOL CHEM, V269, P18343	33	134	135	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30479	30486		10.1074/jbc.271.48.30479	http://dx.doi.org/10.1074/jbc.271.48.30479			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940014	hybrid			2022-12-27	WOS:A1996VV15800031
J	McKay, BS; Annis, DS; Honda, S; Christie, D; Kunicki, TJ				McKay, BS; Annis, DS; Honda, S; Christie, D; Kunicki, TJ			Molecular requirements for assembly and function of a minimized human integrin alpha(IIIb)beta(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET GLYCOPROTEIN-IIB; AMINO-ACID-SEQUENCE; BETA(3) SUBUNIT; I-DOMAIN; CRYSTAL-STRUCTURE; HUMAN FIBRONECTIN; LIGAND-BINDING; CELL-ADHESION; EXPRESSION; RECEPTOR	Integrin subunit compatibility within and between species plays a major role in heterodimer assembly and ligand specificity. As an example, human alpha(IIb) pairs only with human beta(3) and does not assemble a heterodimer with beta(3) from other species. We use interspecies subunit chimeras to identify molecular requirements for subunit compatibility and show that species-restricted heterodimer assembly depends on a unique hexapeptide VGSDNH in an extended loop of the hypothetical human beta(3) MIDAS domain. This allows us to express alpha(IIb)(1-233) and beta(3)(111-318) as a soluble, mini-integrin that retains RGD-dependent ligand recognition. Thus, in the case of one integrin, alpha(IIb)beta(3), the molecular requirements for integrin subunit compatibility and ligand recognition are intimately related.	Scripps Res Inst, DEPT MOL & EXPT MED, DIV EXPT HEMOSTASIS & THROMBOSIS, LA JOLLA, CA 92017 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92017 USA	Scripps Research Institute; Scripps Research Institute			McKay, Brian/E-5602-2012	McKay, Brian/0000-0002-2893-3959	NHLBI NIH HHS [HL-46979] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046979] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BAJT ML, 1994, J BIOL CHEM, V269, P20913; BASANI RB, 1995, BLOOD, V86, P201; BENNETT JS, 1993, J BIOL CHEM, V268, P3580; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CIEUTAT AM, 1993, BIOCHEM BIOPH RES CO, V193, P771, DOI 10.1006/bbrc.1993.1692; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; FAIRBANKS MB, 1995, FEBS LETT, V369, P197, DOI 10.1016/0014-5793(95)00747-W; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FITZGERALD LA, 1987, BIOCHEMISTRY-US, V26, P8158, DOI 10.1021/bi00399a021; GULINO D, 1995, EUR J BIOCHEM, V227, P108, DOI 10.1111/j.1432-1033.1995.tb20365.x; HONDA S, 1995, J BIOL CHEM, V270, P11947, DOI 10.1074/jbc.270.20.11947; HONDA S, 1995, BLOOD, V86, P234, DOI 10.1182/blood.V86.1.234.bloodjournal861234; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KING SL, 1995, J VIROL, V69, P3237, DOI 10.1128/JVI.69.5.3237-3239.1995; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; KODANDAPANI R, 1995, J BIOL CHEM, V270, P2268, DOI 10.1074/jbc.270.5.2268; KOUNS WC, 1994, BLOOD, V84, P1108; KUNICKI TJ, 1995, BLOOD CELL MOL DIS, V21, P131, DOI 10.1006/bcmd.1995.0015; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; LEE JO, 1995, CELL, V80, P931; Loftus JC, 1996, J BIOL CHEM, V271, P2033, DOI 10.1074/jbc.271.4.2033; LOFTUS JC, 1987, P NATL ACAD SCI USA, V840, P7114; MIMURA H, 1994, ENDOCRINOLOGY, V134, P1061, DOI 10.1210/en.134.3.1061; MOYLE M, 1991, J BIOL CHEM, V266, P19650; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; RANSOM DG, 1993, DEV BIOL, V160, P265, DOI 10.1006/dbio.1993.1304; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SHEPPARD D, 1990, J BIOL CHEM, V265, P11502; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TOMIYAMA Y, 1992, J BIOL CHEM, V267, P18085; TUCKWELL D, 1995, J CELL SCI, V108, P1629; WIPPLER J, 1994, J BIOL CHEM, V269, P8754; YUAN Q, 1991, INT IMMUNOL, V3, P1373	36	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30544	30547		10.1074/jbc.271.48.30544	http://dx.doi.org/10.1074/jbc.271.48.30544			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940024	hybrid			2022-12-27	WOS:A1996VV15800041
J	Aulak, KS; Liu, J; Wu, JY; Hyatt, SL; Puppi, M; Henning, SJ; Hatzoglou, M				Aulak, KS; Liu, J; Wu, JY; Hyatt, SL; Puppi, M; Henning, SJ; Hatzoglou, M			Molecular sites of regulation of expression of the rat cationic amino acid transporter gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECOTROPIC RETROVIRAL RECEPTOR; CELL-SURFACE RECEPTOR; MESSENGER-RNA; MURINE RETROVIRUSES; PHOSPHOENOLPYRUVATE CARBOXYKINASE; LIVER-REGENERATION; POSTTRANSCRIPTIONAL REGULATION; INDUCTION-PATTERNS; MAMMALIAN-CELLS; SYSTEM Y(+)	Cat-1 is a protein with a dual function, a high affinity, low capacity cationic amino acid transporter of the y(+) system and the receptor for the ecotropic retrovirus. We have suggested that Cat-1 is required in the regenerating liver for the transport of cationic amino acids and polyamines in the late G(1) phase, a process that is essential for liver cells to enter mitosis, In our earlier studies we had shown that the cat-1 gene is silent in the quiescent liver but is induced in response to hormones, insulin, and glucocorticoids, and partial hepatectomy, Here we demonstrate that cat-1 is a classic delayed early growth response gene in the regenerating liver, since induction of its expression is sensitive to cycloheximide, indicating that protein synthesis is required. The peak of accumulation of the cat-1 mRNA (9-fold) by 3 h was not associated with increased transcriptional activity of the cat-1 gene in the regenerating liver, indicating posttranscriptional regulation of expression of this gene, Induction of the cat-1 gene results in the accumulation of two mRNA species (7.9 and 3.4 kilobase pairs (kb)). Both mRNAs hybridize with the previously described rat cat-1/2.9-kb cDNA clone, However, the 3' end of a longer rat cat-1 cDNA (rat cat-1/6.5-kb) hybridizes only to the 7.9-kb mRNA transcript, Sequence analysis of this clone indicated that the two mRNA species result from the use of alternative polyadenylation signals, The 6.5-kb clone contains a number of AT-rich mRNA destabilizing sequences which is reflected in the half-life of the cat-1 mRNAs (90 min for 7.9-kb mRNA and 250 min for 3.4-kb mRNA), Treatment of rats with cycloheximide superinduces the level of the 7.9-kb cat-1 mRNA in the kidney, spleen, and brain, but not in the liver, suggesting that cell type-specific labile factors are involved in its regulation, We conclude that the need for protein synthesis for induction of the cat-1 mRNA, the short lived nature of the mRNAs, and the multiple sites for regulation of gene expression indicate a tight control of expression of the caf-l gene within the regenerating liver and suggest that y(+) cationic amino acid transport in liver cells is regulated at the molecular level.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT NUTR,CLEVELAND,OH 44106; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Case Western Reserve University; Baylor College of Medicine; Baylor College of Medicine			Henning, Susan/A-9356-2009		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK047431] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47431-0182] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBRITTON LM, 1993, J VIROL, V67, P2091, DOI 10.1128/JVI.67.4.2091-2096.1993; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BEALE EG, 1985, J BIOL CHEM, V260, P748; CHEESEMAN CI, 1991, PROG BIOPHYS MOL BIO, V55, P71, DOI 10.1016/0079-6107(91)90001-9; CHRISTENSEN HM, 1994, J EXP BIOL, V196, P151; CLOSS EI, 1993, J BIOL CHEM, V268, P20796; CLOSS EI, 1993, J VIROL, V67, P2097, DOI 10.1128/JVI.67.4.2097-2102.1993; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; CORNFORD EM, 1980, AM J PHYSIOL, V238, pH553, DOI 10.1152/ajpheart.1980.238.4.H553; DEKLEIJN DPV, 1994, FEBS LETT, V353, P255, DOI 10.1016/0014-5793(94)01055-2; DESSERWIEST L, 1975, CELL TISSUE KINET, V8, P1, DOI 10.1111/j.1365-2184.1975.tb01201.x; Durante W, 1996, J BIOL CHEM, V271, P11838, DOI 10.1074/jbc.271.20.11838; EGLI CM, 1995, MOL CELL BIOL, V15, P2466; ESPAT NJ, 1994, ANN SURG ONCOL, V1, P147, DOI 10.1007/BF02303559; FINLEY KD, 1995, P NATL ACAD SCI USA, V92, P9378, DOI 10.1073/pnas.92.20.9378; GARREAU H, 1983, NUCLEIC ACIDS RES, V11, P8473, DOI 10.1093/nar/11.23.8473; GREAVES DR, 1985, J MOL BIOL, V185, P461, DOI 10.1016/0022-2836(85)90064-6; GROOT CJ, 1984, BIOCHEM BIOPH RES CO, V124, P882; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; HANDLOGTEN ME, 1984, J BIOL CHEM, V259, P3519; HATZOGLOU M, 1995, SOMAT CELL MOLEC GEN, V21, P265, DOI 10.1007/BF02255781; HUTSON RG, 1994, BIOCHEM J, V304, P745, DOI 10.1042/bj3040745; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; KAKUDA DK, 1994, J EXP BIOL, V196, P93; Kakuda DK, 1993, TRANSGENE, V1, P91; KATZ RA, 1983, BIOCHIM BIOPHYS ACTA, V739, P258, DOI 10.1016/0167-4781(83)90099-4; KAVANAUGH MP, 1994, J BIOL CHEM, V269, P15445; KILBERG MS, 1986, TRENDS BIOCHEM SCI, V11, P183, DOI 10.1016/0968-0004(86)90138-6; KILBERG MS, 1993, ANNU REV NUTR, V13, P137, DOI 10.1146/annurev.nu.13.070193.001033; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KRUBKE J, 1987, J GEN VIROL, V68, P3091, DOI 10.1099/0022-1317-68-12-3091; KRUYS V, 1994, BIOCHIMIE, V76, P862, DOI 10.1016/0300-9084(94)90188-0; LOW BC, 1995, J BIOL CHEM, V270, P27577, DOI 10.1074/jbc.270.46.27577; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; MACLEOD CL, 1994, J EXP BIOL, V196, P109; Maniatis T., 1982, MOL CLONING; MARKOVICH D, 1993, J BIOL CHEM, V268, P1362; MOHN KL, 1991, MOL CELL BIOL, V11, P1393, DOI 10.1128/MCB.11.3.1393; MOHN KL, 1990, J BIOL CHEM, V265, P21914; MORELLO D, 1993, ONCOGENE, V8, P1921; MORRIS JG, 1978, SCIENCE, V199, P431, DOI 10.1126/science.619464; PETERSEN DD, 1989, P NATL ACAD SCI USA, V86, P7800, DOI 10.1073/pnas.86.20.7800; PUPPI M, 1995, P SOC EXP BIOL MED, V209, P38, DOI 10.3181/00379727-209-43875; REIZER J, 1993, PROTEIN SCI, V2, P20, DOI 10.1002/pro.5560020103; ROSA JL, 1992, BIOCHEM J, V287, P113, DOI 10.1042/bj2870113; ROSA JL, 1992, P NATL ACAD SCI USA, V89, P3746, DOI 10.1073/pnas.89.9.3746; SCHERER G, 1982, P NATL ACAD SCI-BIOL, V79, P7205, DOI 10.1073/pnas.79.23.7205; Simmons WW, 1996, J BIOL CHEM, V271, P11694, DOI 10.1074/jbc.271.20.11694; SOBCZAK J, 1989, ONCOGENE, V4, P1503; STEER CJ, 1995, FASEB J, V9, P1396, DOI 10.1096/fasebj.9.14.7589980; STOLL J, 1993, J NEUROCHEM, V60, P1956, DOI 10.1111/j.1471-4159.1993.tb13428.x; WANG H, 1992, J BIOL CHEM, V267, P23617; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WANG H, 1994, VIROLOGY, V202, P1058, DOI 10.1006/viro.1994.1439; WHITE MF, 1982, J BIOL CHEM, V257, P4450; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; WILKINSON MF, 1991, J EXP MED, V174, P269, DOI 10.1084/jem.174.1.269; WU JY, 1994, J VIROL, V68, P1615, DOI 10.1128/JVI.68.3.1615-1623.1994; YOSHIMOTO T, 1993, J VIROL, V67, P1310, DOI 10.1128/JVI.67.3.1310-1314.1993; YOSHIMOTO T, 1991, VIROLOGY, V185, P10, DOI 10.1016/0042-6822(91)90748-Z; YOSHIMOTO T, 1992, J VIROL, V66, P4377, DOI 10.1128/JVI.66.7.4377-4381.1992	61	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29799	29806		10.1074/jbc.271.47.29799	http://dx.doi.org/10.1074/jbc.271.47.29799			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939918	hybrid			2022-12-27	WOS:A1996VU52500046
J	Guilherme, A; Klarlund, JK; Krystal, G; Czech, MP				Guilherme, A; Klarlund, JK; Krystal, G; Czech, MP			Regulation of phosphatidylinositol 3,4,5-trisphosphate 5'-phosphatase activity by insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; ACTIVATED PROTEIN-KINASE; RAT ADIPOSE-CELLS; RECEPTOR SUBSTRATE-1; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; GLUT4 TRANSLOCATION; WORTMANNIN; IRS-1; PHOSPHORYLATION	Polyphosphoinositides are thought to be mediators of cellular signaling pathways as well as regulators of cytoskeletal elements and membrane trafficking events. It has recently been demonstrated that a class of phos phatidylinositol (PI) 3,4,5-P-3 5'-phosphatases contains SH2 domains and proline-rich regions, which are present in many signaling proteins. We report here that insulin stimulation of Chinese hamster ovary cells (CHO-T) expressing human insulin receptors causes an 8-10-fold increase in PI 3,4,5-P-3 5'-phosphatase activity in anti-phosphotyrosine immunoprecipitates of the cell lysates, This insulin-sensitive polyphosphoinositide 5'-phosphatase did not catalyze dephosphorylation of PI 4,5-P-2. No change in 5'-phosphatase activity was detected in insulin receptor or IRS-1 immune complexes in response to insulin. However, insulin treatment of CHO-T cells markedly increased the PI 3,4,5-P-3 5'-phosphatase activity associated with She and Grb2. The insulin-regulated polyphosphoinositide 5'-phosphatase was not immunoreactive with antibody raised against the recently cloned SHIP 5'-phosphatase reported to associate with She and Grb2 in B lymphocytes. These data demonstrate that insulin causes formation of complexes containing a PI 3,4,5-P-3 5'-phosphatase, and Shc or Grb2, or both, suggesting an important role of this enzyme in insulin signaling.	UNIV MASSACHUSETTS,MED CTR,PROGRAM MOL MED,WORCESTER,MA 01605; UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOL BIOL,WORCESTER,MA 01605; UNIV BRITISH COLUMBIA,BRITISH COLUMBIA CANC AGCY,TERRY FOX LAB,VANCOUVER,BC V5Z 1L3,CANADA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; British Columbia Cancer Agency; University of British Columbia				Krystal, Gerald/0000-0002-1961-6281	NIDDK NIH HHS [DK30648, DK30898] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030898, R01DK030648, R01DK030898] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; HARUTA T, 1995, J BIOL CHEM, V270, P27991; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JACKSON SP, 1995, EMBO J, V14, P4490, DOI 10.1002/j.1460-2075.1995.tb00128.x; Kabuyama Y, 1996, EUR J BIOCHEM, V238, P350, DOI 10.1111/j.1432-1033.1996.0350z.x; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; KELLY KL, 1993, J BIOL CHEM, V268, P4291; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LIPS DL, 1989, J BIOL CHEM, V264, P19911; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NORRIS FA, 1994, J BIOL CHEM, V269, P8716; OKADA T, 1994, J BIOL CHEM, V269, P3568; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; QUON MJ, 1994, J BIOL CHEM, V269, P27920; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; Waters SB, 1996, J BIOL CHEM, V271, P18224, DOI 10.1074/jbc.271.30.18224; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; WHITE MF, 1994, J BIOL CHEM, V269, P1; Woscholski R, 1995, J BIOL CHEM, V270, P31001, DOI 10.1074/jbc.270.52.31001; YU KT, 1984, J BIOL CHEM, V259, P5277	44	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29533	29536		10.1074/jbc.271.47.29533	http://dx.doi.org/10.1074/jbc.271.47.29533			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939879	hybrid			2022-12-27	WOS:A1996VU52500007
J	Jenkins, BJ; Bagley, CJ; Woodcock, J; Lopez, AF; Gonda, TJ				Jenkins, BJ; Bagley, CJ; Woodcock, J; Lopez, AF; Gonda, TJ			Interacting residues in the extracellular region of the common beta subunit of the human granulocyte-macrophage colony-stimulating factor, interleukin (IL)-3, and IL-5 receptors involved in constitutive activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH SIGNAL-TRANSDUCTION; HUMAN GM-CSF; CYTOPLASMIC DOMAIN; ALPHA-CHAIN; ERYTHROPOIETIN RECEPTOR; EXPRESSION CLONING; POINT MUTATIONS; LIGAND-BINDING; TUMORIGENICITY; MOLECULES	A previous study using random mutagenesis identified an activating mutation in the common beta subunit (h beta c) of the human granulocyte-macrophage colony stimulating factor, interleukin-3, and interleukin-5 receptors in which an isoleucine residue (Ile(374)) in the extracellular region of h beta c is replaced by asparagine (Jenkins, B. J., D'Andrea, R., and Gonda, T. J. (1995) EMBO J 14, 4276-4287), To investigate the mechanism by which this mutation (I374N) acts, we employed site-directed mutagenesis to explore predictions based on a structural model of h beta c, We focused on possible interactions between Ile(374) and other hydrophobic residues in its vicinity and found that replacement of two such residues, Leu(356) and Trp(358), With asparagine resulted in constitutive activation of h beta c, Hydrophilic substitutions at both of these positions and at position 374 resulted in the greatest degree of activation, as measured by the growth rate of factor-independent cells, while hydrophobic substitutions had lesser or no effects, Moreover, these ''weak'' substitutions appeared to synergize, since factor-independent cells expressing the double mutants I374F/W358F and I374F/L356A showed substantially higher growth rates than the single mutants, Taken together, these results suggest that Ile(374) normally interacts with Leu(356) and Trp(358), and that disruption of these interactions results in a conformational change in h beta c that leads to constitutive activity, A model relating this notion to the predicted structure and to ligand- and alpha subunit-dependent activation of h beta c is proposed.	INST MED & VET SCI,DIV HUMAN IMMUNOL,ADELAIDE,SA 5000,AUSTRALIA	Institute Medical & Veterinary Science Australia	Jenkins, BJ (corresponding author), INST MED & VET SCI,HANSON CTR CANC RES,FROME RD,ADELAIDE,SA 5000,AUSTRALIA.		jenkins, brendan/J-7854-2012; jenkins, brendan/A-2401-2009; Lopez, Angel F/E-2260-2011	Jenkins, Brendan/0000-0002-7552-4656; Woodcock, Joanna/0000-0001-5127-9687; Lopez, Angel F/0000-0001-7430-0135				ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARRY SC, 1994, J BIOL CHEM, V269, P8488; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CONTRERAS MA, 1983, METHOD ENZYMOL, V92, P277; DANDREA R, 1994, BLOOD, V83, P2802, DOI 10.1182/blood.V83.10.2802.2802; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; EDER M, 1994, J BIOL CHEM, V269, P30173; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOODALL GJ, 1993, GROWTH FACTORS, V8, P87, DOI 10.3109/08977199309046929; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; JENKINS BJ, 1995, EMBO J, V14, P4276, DOI 10.1002/j.1460-2075.1995.tb00102.x; JOHNSON GR, 1980, J CELL PHYSIOL, V103, P371, DOI 10.1002/jcp.1041030302; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mui Alice L.-F., 1994, Progress in Growth Factor Research, V5, P15, DOI 10.1016/0955-2235(94)90015-9; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; MUTO A, 1995, BIOCHEM BIOPH RES CO, V208, P368, DOI 10.1006/bbrc.1995.1347; PAGLEY CJ, 1995, J LEUKOCYTE BIOL, V57, P739; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RAYNER JR, 1994, MOL CELL BIOL, V14, P880, DOI 10.1128/MCB.14.2.880; SAKAMAKI K, 1993, J BIOL CHEM, V268, P15833; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; Stomski FC, 1996, MOL CELL BIOL, V16, P3035; Sun QY, 1996, BLOOD, V87, P83; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; WARD LD, 1994, J BIOL CHEM, V269, P23286; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WOODCOCK JM, 1994, EMBO J, V13, P5176, DOI 10.1002/j.1460-2075.1994.tb06848.x; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; ZOLA H, 1990, J IMMUNOL METHODS, V135, P247, DOI 10.1016/0022-1759(90)90278-4	43	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29707	29714		10.1074/jbc.271.47.29707	http://dx.doi.org/10.1074/jbc.271.47.29707			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939904	hybrid			2022-12-27	WOS:A1996VU52500032
J	Murakami, M; Nakatani, Y; Kudo, I				Murakami, M; Nakatani, Y; Kudo, I			Type II secretory phospholipase A(2) associated with cell surfaces via C-terminal heparin-binding lysine residues augments stimulus-initiated delayed prostaglandin generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; MESSENGER-RNA SYNTHESIS; RAT MESANGIAL CELLS; FORSKOLIN-INDUCED SYNTHESIS; TUMOR-NECROSIS-FACTOR; MOUSE MAST-CELLS; CYTOSOLIC PHOSPHOLIPASE-A2; GENE-EXPRESSION; EXTRACELLULAR PHOSPHOLIPASE-A2; PLATELET PHOSPHOLIPASE-A2	Type II secretory phospholipase A(2) (sPLA(2)) has been shown to be induced by a variety of proinflammatory stimuli and, therefore, has been implicated in the inflammatory process. In order to determine whether association of sPLA(2) with cell surfaces via heparan sulfate proteoglycan is important for its effects on cellular functions, we have identified the critical domain in sPLA(2) for heparin and cell surface binding and examined its role in cellular prostaglandin (PG) biosynthesis. Replacement of several conserved Lys residues in the C-terminal region of mouse and rat sPLA(2)s by Glu resulted in a marked reduction of their capacities to bind to heparin and mammalian cell surfaces without affecting their enzymatic activities toward dispersed phospholipid as a substrate. CHO cells stably transfected with wild-type sPLA(2) released about twice as much arachidonic acid (AA) during culture for 10 h with fetal calf serum and interleukin-1 beta than cells transfected with vector alone, whereas the ability to enhance AA release was impaired in sPLA(2) mutants incapable of binding to cell surfaces. AA released by wild-type sPLA(2)-transfected CHO cells was metabolized to prostaglandin E(2) via prostaglandin endoperoxide H synthase (PGHS)-2 after IL-1 beta stimulation, revealing a particular functional linkage of sPLA(2) to PGHS-(2). In contrast, A23187-initiated immediate AA release over 30 min was not affected by sPLA(2) overexpression, Taken together, these results suggest that sPLA(2) expressed endogenously and anchored on cell surfaces via its C-terminal heparin-binding domain is involved in the PGHS-2-dependent delayed PG biosynthesis initiated by growth factors and cytokines during long term culture.	SHOWA UNIV,SCH PHARMACEUT SCI,DEPT HLTH CHEM,SHINAGAWA KU,TOKYO 142,JAPAN	Showa University								ANGEL J, 1994, EUR J BIOCHEM, V226, P125, DOI 10.1111/j.1432-1033.1994.tb20033.x; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BARTOLI F, 1994, J BIOL CHEM, V269, P15625; CHANG HW, 1987, J BIOCHEM, V102, P147, DOI 10.1093/oxfordjournals.jbchem.a122026; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHEPENIK KP, 1994, J BIOL CHEM, V269, P21786; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DOLE VP, 1960, J BIOL CHEM, V235, P2595; DUA R, 1994, EUR J BIOCHEM, V221, P481, DOI 10.1111/j.1432-1033.1994.tb18761.x; FONTEH AN, 1994, J IMMUNOL, V152, P5438; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; FUJITA H, 1995, BIOCHEM BIOPH RES CO, V209, P293, DOI 10.1006/bbrc.1995.1502; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; HANASAKI K, 1992, BIOCHIM BIOPHYS ACTA, V1127, P233, DOI 10.1016/0005-2760(92)90226-L; HARA S, 1995, BBA-LIPID LIPID MET, V1257, P11, DOI 10.1016/0005-2760(95)00011-Z; HARA S, 1991, J BIOCHEM, V110, P163, DOI 10.1093/oxfordjournals.jbchem.a123550; HARA S, 1989, J BIOCHEM-TOKYO, V105, P395, DOI 10.1093/oxfordjournals.jbchem.a122675; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; HIDI R, 1993, J IMMUNOL, V151, P5613; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; HORIGOME K, 1987, J BIOCHEM-TOKYO, V101, P625, DOI 10.1093/jb/101.3.625; INADA M, 1994, J BIOL CHEM, V269, P26338; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; KOMADA M, 1989, J BIOCHEM-TOKYO, V106, P545, DOI 10.1093/oxfordjournals.jbchem.a122890; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Locati M, 1996, J BIOL CHEM, V271, P6010, DOI 10.1074/jbc.271.11.6010; LOMONTE B, 1994, J BIOL CHEM, V269, P29867; LYONSGIORDANO B, 1989, BIOCHEM BIOPH RES CO, V164, P488, DOI 10.1016/0006-291X(89)91746-4; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MOUNIER C, 1993, EUR J BIOCHEM, V216, P169, DOI 10.1111/j.1432-1033.1993.tb18129.x; MURAKAMI M, 1995, J LIPID MEDIAT CELL, V12, P119, DOI 10.1016/0929-7855(95)00013-G; MURAKAMI M, 1991, FEBS LETT, V294, P247, DOI 10.1016/0014-5793(91)81440-J; MURAKAMI M, 1995, J BIOL CHEM, V270, P22653, DOI 10.1074/jbc.270.39.22653; MURAKAMI M, 1992, EUR J BIOCHEM, V209, P257, DOI 10.1111/j.1432-1033.1992.tb17284.x; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; MURAKAMI M, 1995, J EXP MED, V182, P197, DOI 10.1084/jem.182.1.197; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; MURAKAMI M, 1990, FEBS LETT, V268, P113, DOI 10.1016/0014-5793(90)80986-S; MURAKAMI M, 1988, J BIOCHEM-TOKYO, V104, P884, DOI 10.1093/oxfordjournals.jbchem.a122577; MURAKAMI M, 1990, BIOCHIM BIOPHYS ACTA, V1043, P34, DOI 10.1016/0005-2760(90)90107-9; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; NAKANO T, 1990, FEBS LETT, V261, P171, DOI 10.1016/0014-5793(90)80663-4; NAKANO T, 1990, J BIOL CHEM, V265, P12745; NAKAZATO Y, 1991, J BIOL CHEM, V266, P14119; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OKA S, 1991, J BIOL CHEM, V266, P9956; OWADA Y, 1994, MOL BRAIN RES, V25, P364, DOI 10.1016/0169-328X(94)90174-0; PERNAS P, 1991, BIOCHEM BIOPH RES CO, V178, P1298, DOI 10.1016/0006-291X(91)91035-B; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; PRUZANSKI W, 1990, J RHEUMATOL, V17, P1386; Reddy ST, 1996, J BIOL CHEM, V271, P186, DOI 10.1074/jbc.271.1.186; REDDY ST, 1994, J BIOL CHEM, V269, P15473; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; Roshak A, 1996, J RHEUMATOL, V23, P420; SCHALKWIJK C, 1991, BIOCHEM BIOPH RES CO, V180, P46, DOI 10.1016/S0006-291X(05)81252-5; SCHALKWIJK C, 1992, J BIOL CHEM, V267, P8846; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SUGA H, 1993, EUR J BIOCHEM, V218, P807, DOI 10.1111/j.1432-1033.1993.tb18435.x; TAKAMURA H, 1987, J BIOL CHEM, V262, P2262; VIAL D, 1995, J BIOL CHEM, V270, P17327, DOI 10.1074/jbc.270.29.17327; WEISS J, 1994, J BIOL CHEM, V269, P26331; WIJKANDER J, 1995, J BIOL CHEM, V270, P26543, DOI 10.1074/jbc.270.44.26543; WINKLER JD, 1993, BIOCHEM J, V291, P825, DOI 10.1042/bj2910825; WU T, 1994, J CLIN INVEST, V93, P571, DOI 10.1172/JCI117009	82	121	121	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30041	30051		10.1074/jbc.271.47.30041	http://dx.doi.org/10.1074/jbc.271.47.30041			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939951	hybrid			2022-12-27	WOS:A1996VU52500079
J	Rajas, F; Gire, V; Rousset, B				Rajas, F; Gire, V; Rousset, B			Involvement of a membrane-bound form of glutamate dehydrogenase in the association of lysosomes to microtubules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFIED THYROID LYSOSOMES; ENDOCYTIC VESICLES; CYTOPLASMIC DYNEIN; BINDING PROTEIN; FUSION INVITRO; LATE ENDOSOMES; CELLS; IDENTIFICATION; KINESIN; TRANSPORT	A 50-kDa membrane protein corresponding to a membrane-bound isoform of glutamate dehydrogenase was proposed as a molecular species that could mediate lysosome-microtubule interactions. This protein, isolated from purified lysosome membranes, is a peripheral membrane protein with an ATP-dependent microtubule binding activity, We have produced antibodies against the purified 50-kDa protein to investigate its role in the association of lysosomes to microtubules using a cell-free reconstitution assay and cell microinjection, Pretreatment of purified lysosomes with the antibodies inhibited the association of these vesicles to microtubules. The blocking effect of antibodies was demonstrated by a differential sedimentation method and negative staining electron microscopy, allowing us to quantify the amount of microtubules interacting with lysosomes and the proportion of lysosomes bound to microtubules, respectively, Affinity-purified antibodies microinjected into intact cells altered the distribution of lysosomes that appeared less clustered in the vicinity of nuclei, The antibody-induced lysosome dispersion was assessed by quantitative videomicroscope analyses. These data show that the 50-kDa membrane protein could act, through its microtubule binding activity, as a molecule of attachment of lysosomes to microtubules. This membrane-bound isoform of glutamate dehydrogenase could be involved in the microtubule-dependent perinuclear localization of lysosomes.	RTH LAENNEC,FAC MED,INSERM U369,F-69372 LYON 08,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			Gire, Véronique/AAC-2218-2020; Gire, Veronique/N-7553-2017; RAJAS, Fabienne/P-4091-2016	RAJAS, Fabienne/0000-0002-9233-7633; Gire, Veronique/0000-0002-9009-2185				ALQUIER C, 1985, BIOCHEM J, V232, P529, DOI 10.1042/bj2320529; AMIENTO F, 1993, J CELL BIOL, V123, P1373; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; CARLIER MF, 1980, BIOCHEM BIOPH RES CO, V96, P1761, DOI 10.1016/0006-291X(80)91378-9; COLLOT M, 1984, P NATL ACAD SCI-BIOL, V81, P788, DOI 10.1073/pnas.81.3.788; DEBRABANDER M, 1988, CELL MOTIL CYTOSKEL, V9, P30, DOI 10.1002/cm.970090105; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; GOLTZ JS, 1992, P NATL ACAD SCI USA, V89, P7026, DOI 10.1073/pnas.89.15.7026; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; Harlow E., 1988, ANTIBODIES LAB MANUA; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; KELLY RB, 1990, CELL, V61, P5, DOI 10.1016/0092-8674(90)90206-T; KOSTROUCH Z, 1991, ENDOCRINOLOGY, V129, P2202, DOI 10.1210/endo-129-4-2202; KREIS TE, 1989, EUR J CELL BIOL, V49, P128; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN SXH, 1992, J CELL SCI, V101, P125; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; MITHIEUX G, 1988, BIOCHIM BIOPHYS ACTA, V971, P29; MITHIEUX G, 1988, BIOCHIM BIOPHYS ACTA, V969, P121, DOI 10.1016/0167-4889(88)90067-5; MITHIEUX G, 1989, J BIOL CHEM, V264, P4664; MUNARISILEM Y, 1990, J CELL PHYSIOL, V145, P414, DOI 10.1002/jcp.1041450305; NOIVA R, 1992, J BIOL CHEM, V267, P3553; PARTON RG, 1991, J CELL BIOL, V113, P261, DOI 10.1083/jcb.113.2.261; PIATIGORSKY J, 1989, CELL, V57, P197, DOI 10.1016/0092-8674(89)90956-2; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; PREISS T, 1993, J BIOL CHEM, V268, P25423; RAJAS F, 1993, BIOCHEM J, V295, P447, DOI 10.1042/bj2950447; RICKARD JE, 1991, J BIOL CHEM, V266, P17597; RICKARD JE, 1990, J CELL BIOL, V110, P1623, DOI 10.1083/jcb.110.5.1623; ROUSSET B, 1988, STRTUCTURE FUNCTIONS, P313; SCHEEL J, 1991, J BIOL CHEM, V266, P18141; SCHEEL J, 1990, J CELL SCI, V96, P711; SCHROER TA, 1988, J CELL BIOL, V107, P1785, DOI 10.1083/jcb.107.5.1785; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; SCHROER TA, 1991, ANNU REV PHYSIOL, V53, P629, DOI 10.1146/annurev.ph.53.030191.003213; SELMI S, 1989, ARCH BIOCHEM BIOPHYS, V273, P170, DOI 10.1016/0003-9861(89)90176-8; SELMI S, 1988, BIOCHEM J, V253, P523, DOI 10.1042/bj2530523; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; SWANSON J, 1987, P NATL ACAD SCI USA, V84, P1921, DOI 10.1073/pnas.84.7.1921; SWANSON JA, 1992, J CELL SCI, V103, P201; TONG PY, 1988, J BIOL CHEM, V263, P2585; TOYOSHIMA I, 1992, J CELL BIOL, V118, P1121, DOI 10.1083/jcb.118.5.1121; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247	49	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29882	29890		10.1074/jbc.271.47.29882	http://dx.doi.org/10.1074/jbc.271.47.29882			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939930	hybrid			2022-12-27	WOS:A1996VU52500058
J	Huffine, ME; Scholtz, JM				Huffine, ME; Scholtz, JM			Energetic implications for protein phosphorylation - Conformational stability of HPr variants that mimic phosphorylated forms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTAINING PHOSPHOCARRIER PROTEIN; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; PHOSPHOTRANSFERASE SYSTEMS; CRYSTAL-STRUCTURE; PHOSPHOENOLPYRUVATE; BACTERIA; KINASE; COOPERATIVITY; CONSEQUENCES	The HPr protein from Bacillus subtilis is a key protein in the phosphoenolpyruvate-sugar transport system. HPr has two biological phosphorylation sites. The active site histidine is transiently phosphorylated in the phosphotransferase reaction while phosphorylation of serine 46 diminishes the activity of HPr. Here, we use protein engineering and equilibrium protein folding experiments to determine if the two phosphorylation events are energetically coupled. Our approach is to use structural mimics of the two phosphorylated forms of HPr, where histidine 15 is replaced by a negatively charged glutamate and serine 46 is changed to an aspartate, both alone and in combination. The thermodynamic analysis of the differences in conformational stability between the single and double mutants shows that the two phosphorylation sites are not energetically coupled in the HPr protein. We also show that single mutants of the active site histidine residue can have dramatic effects on the conformational stability of HPr. Combined with structural information the method employed here will be of general use in unraveling the biological effects of phosphorylation on protein activity.	TEXAS A&M UNIV,CTR MACROMOL DESIGN,DEPT MED BIOCHEM & GENET,DEPT BIOCHEM & BIOPHYS,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station								ALBER T, 1989, ANNU REV BIOCHEM, V58, P765, DOI 10.1146/annurev.biochem.58.1.765; BARFORD D, 1989, NATURE, V340, P609, DOI 10.1038/340609a0; COX S, 1994, CURR OPIN STRUC BIOL, V4, P893, DOI 10.1016/0959-440X(94)90272-0; DOIG AJ, 1995, PROTEIN SCI, V4, P1325, DOI 10.1002/pro.5560040708; GOLDSMITH EJ, 1994, CURR OPIN STRUC BIOL, V4, P833, DOI 10.1016/0959-440X(94)90264-X; HERZBERG O, 1992, P NATL ACAD SCI USA, V89, P2499, DOI 10.1073/pnas.89.6.2499; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; HOROVITZ A, 1990, J MOL BIOL, V214, P613, DOI 10.1016/0022-2836(90)90275-Q; HOROVITZ A, 1990, J MOL BIOL, V216, P1031, DOI 10.1016/S0022-2836(99)80018-7; HURLEY JH, 1990, J BIOL CHEM, V265, P3599; JOHNSON LN, 1993, ANNU REV BIOPH BIOM, V22, P199, DOI 10.1146/annurev.bb.22.060193.001215; KENNEY LJ, 1995, P NATL ACAD SCI USA, V92, P8866, DOI 10.1073/pnas.92.19.8866; KIM YH, 1993, J BIOL CHEM, V268, P18513; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREBS EG, 1956, BIOCHIM BIOPHYS ACTA, V20, P150, DOI 10.1016/0006-3002(56)90273-6; MONERA S, 1995, BIOCHEMISTRY-US, V34, P11062; MOTOJIMA K, 1993, FEBS LETT, V319, P75, DOI 10.1016/0014-5793(93)80040-2; Nicholson EM, 1996, BIOCHEMISTRY-US, V35, P11369, DOI 10.1021/bi960863y; Pace C N, 1986, Methods Enzymol, V131, P266; PACE CN, 1990, BIOCHEMISTRY-US, V29, P2564, DOI 10.1021/bi00462a019; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; PULLEN K, 1995, PROTEIN SCI, V4, P2478, DOI 10.1002/pro.5560041204; RAJAGOPAL P, 1994, BIOCHEMISTRY-US, V33, P15271, DOI 10.1021/bi00255a008; REIZER J, 1992, J BIOL CHEM, V267, P9158; REIZER J, 1989, EMBO J, V8, P2111, DOI 10.1002/j.1460-2075.1989.tb03620.x; REIZER J, 1984, J BACTERIOL, V160, P333, DOI 10.1128/JB.160.1.333-340.1984; RICHARDSON JS, 1988, SCIENCE, V240, P1645; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCHOLTZ JM, 1995, PROTEIN SCI, V4, P35; SERRANO L, 1990, BIOCHEMISTRY-US, V29, P9343, DOI 10.1021/bi00492a006; Thapar R, 1996, BIOCHEMISTRY-US, V35, P11268, DOI 10.1021/bi960349s; WITTEKIND M, 1992, PROTEIN SCI, V1, P1363, DOI 10.1002/pro.5560011016; WOLODKO WT, 1994, J BIOL CHEM, V269, P10883	35	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28898	28902		10.1074/jbc.271.46.28898	http://dx.doi.org/10.1074/jbc.271.46.28898			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910537	hybrid			2022-12-27	WOS:A1996VT05200029
J	Murphy, BJ; Rogers, J; Perdichizzi, AP; Colvin, AA; Catterall, WA				Murphy, BJ; Rogers, J; Perdichizzi, AP; Colvin, AA; Catterall, WA			cAMP-dependent phosphorylation of two sites in the alpha subunit of the cardiac sodium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NA+ CHANNEL; SELECTIVE PHOSPHORYLATION; FUNCTIONAL EXPRESSION; VENTRICULAR MYOCYTES; SKELETAL-MUSCLE; CELL LINE; MODULATION; ISOFORM; ANTIBODIES	The voltage-sensitive Na+ channel is responsible for generating action potentials in the heart which are critical for coordinated cardiac muscle contraction. Cardiac Na+ channels are regulated by cAMP-dependent phosphorylation, but the sites of phosphorylation are not known. Using mammalian cells expressing the rat cardiac Na+ channel (rH1) alpha subunit and site-specific antibodies, we have shown that the a subunit of rat heart Na+ channel is phosphorylated selectively by cAMP-dependent protein kinase (PKA) in vitro and in intact cells. Analysis of the sites of phosphorylation by two-dimensional phosphopeptide mapping and site-directed mutagenesis of fusion proteins revealed that the cardiac a subunit is phosphorylated selectively in vitro by PKA on Ser(526) and Ser(529) in the intracellular loop connecting homologous domains I and II (L(I-II)). These two residues were phosphorylated in intact cells expressing the rH1 alpha subunit when PKA was activated. Our results define a different pattern of phosphorylation of L(I-II) of cardiac and brain Na+ channels and implicate phosphorylation of Ser(526) and Ser(529) in the differential regulation of cardiac and brain Na+ channels by PKA.	UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle					NHLBI NIH HHS [P01 HL44948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		COHEN SA, 1993, CIRC RES, V73, P735, DOI 10.1161/01.RES.73.4.735; COSTA MRC, 1982, J BIOL CHEM, V257, P7918; COSTA MRC, 1984, J BIOL CHEM, V259, P8210; CRIBBS LL, 1990, FEBS LETT, V275, P195, DOI 10.1016/0014-5793(90)81470-9; DeJongh KS, 1996, BIOCHEMISTRY-US, V35, P10392, DOI 10.1021/bi953023c; FROHNWIESER B, 1995, PFLUG ARCH EUR J PHY, V430, P751, DOI 10.1007/BF00386171; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; GERSHON E, 1992, J NEUROSCI, V12, P3743; GORDON D, 1988, BIOCHEMISTRY-US, V27, P7032, DOI 10.1021/bi00418a054; GORDON D, 1987, P NATL ACAD SCI USA, V84, P8682, DOI 10.1073/pnas.84.23.8682; HARDIE DG, 1993, PROTEIN PHOSPHORYLAT, P61; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KALLEN RG, 1990, NEURON, V4, P233, DOI 10.1016/0896-6273(90)90098-Z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1992, NEURON, V8, P1151, DOI 10.1016/0896-6273(92)90135-Z; MATSUDA JJ, 1992, CIRC RES, V70, P199, DOI 10.1161/01.RES.70.1.199; MEGGIO F, 1981, BIOCHIM BIOPHYS ACTA, V662, P94, DOI 10.1016/0005-2744(81)90228-X; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MURPHY BJ, 1992, J BIOL CHEM, V267, P16129; MURPHY BJ, 1993, J BIOL CHEM, V268, P27355; ONO K, 1989, AM J PHYSIOL, V256, pC1131, DOI 10.1152/ajpcell.1989.256.6.C1131; ONO K, 1993, CIRC RES, V72, P807, DOI 10.1161/01.RES.72.4.807; QU YS, 1994, P NATL ACAD SCI USA, V91, P3289, DOI 10.1073/pnas.91.8.3289; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; ROSSIE S, 1987, J BIOL CHEM, V262, P12735; SCHREIBMAYER W, 1994, RECEPTOR CHANNEL, V2, P339; SCHUBERT B, 1989, SCIENCE, V245, P516, DOI 10.1126/science.2547248; Smith RD, 1996, J NEUROSCI, V16, P1965; SUNAMI A, 1991, PFLUG ARCH EUR J PHY, V419, P415, DOI 10.1007/BF00371125; WEST JW, 1992, NEURON, V8, P59, DOI 10.1016/0896-6273(92)90108-P; WHITE MM, 1991, MOL PHARMACOL, V39, P604; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	32	85	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28837	28843		10.1074/jbc.271.46.28837	http://dx.doi.org/10.1074/jbc.271.46.28837			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910529	hybrid			2022-12-27	WOS:A1996VT05200021
J	Durner, J; Klessig, DF				Durner, J; Klessig, DF			Salicylic acid is a modulator of tobacco and mammalian catalases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC ACQUIRED-RESISTANCE; PLANT-DISEASE RESISTANCE; NADPH-BINDING-SITE; HYDROGEN-PEROXIDE; DEFENSE RESPONSES; MOSAIC-VIRUS; 2,6-DICHLOROISONICOTINIC ACID; LIVER CATALASE; 2 INDUCERS; RAT-LIVER	Salicylic acid (SA) plays a key role in the establishment of resistance to microbial pathogens in many plants. The discovery that SA inhibits catalase from tobacco led us to suggest that H2O2 acts as second messenger to activate plant defenses, Detailed analyses of SA's interaction with tobacco and mammalian catalases indicate that SA acts as an electron donor for the peroxidative cycle of catalase. When H2O2 fluxes were relatively low (1 mu M/min or less), SA inhibited catalase, consistent with its suggested signaling function via H2O2. However, significant inhibition was only observed at 100 mu M SA or more, a level reached in infected, but not in uninfected, leaves. This inhibition was probably due to siphoning catalase into the slow peroxidative reaction. Surprisingly, SA was also able to protect catalase from inactivation by damaging levels of H2O2 (lower millimolar range), which is generally assumed to reflect accumulation of inactive ferro-oxy intermediates. SA did so by supporting or substituting for the protective function of-catalase-bound NADPH. These results add new features to SA's interaction with heme enzymes and its in vivo redox properties. Thus, SA, in addition to its proposed signaling function, may also have an important antioxidant role in containing oxidative processes associated with plant defense responses.	RUTGERS STATE UNIV, WAKSMAN INST, PISCATAWAY, NJ 08855 USA; RUTGERS STATE UNIV, DEPT MOL BIOL & BIOCHEM, PISCATAWAY, NJ 08855 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick								AEBI H, 1984, METHOD ENZYMOL, V105, P121; BI YM, 1995, PLANT J, V8, P235, DOI 10.1046/j.1365-313X.1995.08020235.x; Bonagura CA, 1996, BIOCHEMISTRY-US, V35, P6107, DOI 10.1021/bi960122x; CHEN ZX, 1995, P NATL ACAD SCI USA, V92, P4134, DOI 10.1073/pnas.92.10.4134; CHEN ZX, 1993, SCIENCE, V262, P1883, DOI 10.1126/science.8266079; CHEN ZX, 1993, P NATL ACAD SCI USA, V90, P9533, DOI 10.1073/pnas.90.20.9533; CONRATH U, 1995, P NATL ACAD SCI USA, V92, P7143, DOI 10.1073/pnas.92.16.7143; DANGL JL, 1995, CELL, V80, P363, DOI 10.1016/0092-8674(95)90485-9; DEISSEROTH A, 1970, PHYSIOL REV, V50, P319, DOI 10.1152/physrev.1970.50.3.319; DELUCA DC, 1995, ARCH BIOCHEM BIOPHYS, V320, P129, DOI 10.1006/abbi.1995.1350; DEMPSEY DA, 1995, B I PASTEUR, V93, P167, DOI 10.1016/0020-2452(96)81488-6; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; DOKE N, 1988, PHYSIOL MOL PLANT P, V32, P163, DOI 10.1016/S0885-5765(88)80013-4; DURNER J, 1995, P NATL ACAD SCI USA, V92, P11312, DOI 10.1073/pnas.92.24.11312; ENYEDI AJ, 1992, P NATL ACAD SCI USA, V89, P2480, DOI 10.1073/pnas.89.6.2480; Escobar JA, 1996, FREE RADICAL BIO MED, V20, P285, DOI 10.1016/0891-5849(95)02037-3; FEUERS RJ, 1993, FREE RADICAL BIO MED, V15, P223, DOI 10.1016/0891-5849(93)90063-Z; FITA I, 1985, P NATL ACAD SCI USA, V82, P1604, DOI 10.1073/pnas.82.6.1604; GAFFNEY T, 1993, SCIENCE, V261, P754, DOI 10.1126/science.261.5122.754; GALARIS D, 1988, ARCH BIOCHEM BIOPHYS, V262, P221, DOI 10.1016/0003-9861(88)90184-1; GOLDACRE PL, 1953, ARCH BIOCHEM BIOPHYS, V43, P169, DOI 10.1016/0003-9861(53)90096-4; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; GUAN LQ, 1995, P NATL ACAD SCI USA, V92, P5930, DOI 10.1073/pnas.92.13.5930; HALLIWELL B, 1988, FASEB J, V2, P2867, DOI 10.1096/fasebj.2.13.2844616; HALLIWELL B, 1995, FOOD CHEM TOXICOL, V33, P601, DOI 10.1016/0278-6915(95)00024-V; HAVIR EA, 1987, PLANT PHYSIOL, V84, P450, DOI 10.1104/pp.84.2.450; Havir EA, 1996, PHYTOCHEMISTRY, V41, P699, DOI 10.1016/0031-9422(95)00674-5; HILLAR A, 1994, BIOCHEM J, V300, P531, DOI 10.1042/bj3000531; Hook DWA, 1996, FEBS LETT, V382, P281, DOI 10.1016/0014-5793(96)00134-2; ITOH M, 1962, CAN J BIOCHEM PHYS, V40, P1327; JOUVE HM, 1986, ARCH BIOCHEM BIOPHYS, V248, P71, DOI 10.1016/0003-9861(86)90402-9; KATO S, 1976, Annals of the Phytopathological Society of Japan, V42, P472, DOI 10.3186/jjphytopath.42.472; KETTLE AJ, 1991, BIOCHEM PHARMACOL, V41, P1485, DOI 10.1016/0006-2952(91)90565-M; KIRKMAN HN, 1987, J BIOL CHEM, V262, P660; KITLAR T, 1994, PROTEIN SCI, V3, P696; KONO Y, 1982, J BIOL CHEM, V257, P5751; LEON J, 1995, PLANT PHYSIOL, V108, P1673, DOI 10.1104/pp.108.4.1673; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; LUCK H, 1957, BIOCHEM Z, V328, P411; MALAMY J, 1992, PLANT J, V2, P643, DOI 10.1111/j.1365-313X.1992.tb00133.x; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; MEHDY MC, 1994, PLANT PHYSIOL, V105, P467, DOI 10.1104/pp.105.2.467; Metraux J. P., 1991, Advances in molecular genetics of plant-microbe interactions. Vol. 1. Proceedings of the 5th international symposium on the molecular genetics of plant-microbe interactions, Interlaken, Switzerland, September 9-14, 1990., P432; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; MORIKOFERZWEZ S, 1970, EXPERIENTIA, V26, P945, DOI 10.1007/BF02114120; MULLEN RT, 1993, PLANT PHYSIOL, V103, P477, DOI 10.1104/pp.103.2.477; NEUENSCHWANDER U, 1995, PLANT J, V8, P227, DOI 10.1046/j.1365-313X.1995.08020227.x; NI WT, 1991, PLANT CELL, V3, P737, DOI 10.1105/tpc.3.7.737; OGURA Y, 1950, J BIOCHEM-TOKYO, V37, P153, DOI 10.1093/oxfordjournals.jbchem.a126187; ORLANDI EW, 1992, PHYSIOL MOL PLANT P, V40, P173, DOI 10.1016/0885-5765(92)90058-4; OSHINO N, 1973, ARCH BIOCHEM BIOPHYS, V159, P704, DOI 10.1016/0003-9861(73)90510-9; OTTALLAHKOLAC M, 1995, EUR J BIOCHEM, V228, P506; Ou PM, 1996, J BIOCHEM BIOPH METH, V31, P59, DOI 10.1016/0165-022X(95)00039-T; OU PM, 1994, BIOCHEM J, V303, P935, DOI 10.1042/bj3030935; PUPPO A, 1988, PLANTA, V173, P405, DOI 10.1007/BF00401028; Ruffer M, 1995, FEBS LETT, V377, P175, DOI 10.1016/0014-5793(95)01334-2; Russell RB, 1996, PROTEIN ENG, V9, P107, DOI 10.1093/protein/9.2.107; RYALS J, 1994, PLANT PHYSIOL, V104, P1109, DOI 10.1104/pp.104.4.1109; SANCHEZCASAS P, 1994, PLANT PHYSIOL, V106, P1675, DOI 10.1104/pp.106.4.1675; SAVENKOVA MI, 1994, J BIOL CHEM, V269, P20394; Scandalios J. G., 1994, Causes of photooxidative stress and amelioration of defense systems in plants., P275; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; Schonbaum G. R., 1976, ENZYMES, V13, P363, DOI [10.1016/S1874-6047(08)60245-0, DOI 10.1016/S1874-6047(08)60245-0]; SIMINIS CI, 1994, PLANT PHYSIOL, V105, P1375, DOI 10.1104/pp.105.4.1375; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; SUMMERMATTER K, 1995, PLANT PHYSIOL, V108, P1379, DOI 10.1104/pp.108.4.1379; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085; WHITE RF, 1979, VIROLOGY, V99, P410, DOI 10.1016/0042-6822(79)90019-9; WILLEKENS H, 1995, MOL BREEDING, V1, P207, DOI 10.1007/BF02277422; YASMINEH WG, 1991, CANCER RES, V51, P3990; ZAMOCKY M, 1995, FEBS LETT, V367, P241, DOI 10.1016/0014-5793(95)00568-T; ZELITCH I, 1991, PLANT PHYSIOL, V97, P1592, DOI 10.1104/pp.97.4.1592	72	224	258	0	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28492	28501		10.1074/jbc.271.45.28492	http://dx.doi.org/10.1074/jbc.271.45.28492			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910477	hybrid			2022-12-27	WOS:A1996VU03300077
J	Li, CH; Ramjeesingh, M; Wang, W; Garami, E; Hewryk, M; Lee, D; Rommens, JM; Galley, K; Bear, CE				Li, CH; Ramjeesingh, M; Wang, W; Garami, E; Hewryk, M; Lee, D; Rommens, JM; Galley, K; Bear, CE			ATPase activity of the cystic fibrosis transmembrane conductance regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHINESE-HAMSTER OVARY; CFTR CHLORIDE CHANNELS; CL CHANNEL; P-GLYCOPROTEIN; BINDING; CELLS; HYDROLYSIS; PROTEINS; GENE; PURIFICATION	The gene mutated in cystic fibrosis codes for the cystic fibrosis transmembrane conductance regulator (CFTR), a cyclic AMP-activated chloride channel thought to be critical for salt and water transport by epithelial cells. Plausible models exist to describe a role for ATP hydrolysis in CFTR channel activity; however, biochemical evidence that CFTR possesses intrinsic ATPase activity is lacking, In this study, we report the first measurements of the rate of ATP hydrolysis by purified, reconstituted CFTR. The mutation CFTRG551D resides within a motif conserved in many nucleotidases and is known to cause severe human disease. Following reconstitution the mutant protein exhibited both defective ATP hydrolysis and channel gating, providing direct evidence that CFTR utilizes ATP to gate its channel activity.	HOSP SICK CHILDREN,RES INST,DIV CELL BIOL,TORONTO,ON M5G 1X8,CANADA; HOSP SICK CHILDREN,RES INST,DIV GENET,TORONTO,ON M5G 1X8,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Rommens, Johanna/AAT-7465-2021	Garami, Elizabeth/0000-0003-1295-4007				AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BEAR C, 1992, AM J PHYSIOL, V262, pC261; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BERGER HA, 1993, J BIOL CHEM, V268, P2037; BIRNBAUMER L, 1983, EUR J BIOCHEM, V136, P107, DOI 10.1111/j.1432-1033.1983.tb07712.x; CARSON MR, 1993, AM J PHYSIOL, V265, pL27, DOI 10.1152/ajplung.1993.265.1.L27; DOUSMANIS AG, 1996, BIOPHYS J, V70, P127; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KO YH, 1995, J BIOL CHEM, V270, P22093, DOI 10.1074/jbc.270.38.22093; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI CH, 1993, NAT GENET, V3, P311, DOI 10.1038/ng0493-311; Li CH, 1996, J BIOL CHEM, V271, P11623, DOI 10.1074/jbc.271.20.11623; MANAVALAN P, 1995, FEBS LETT, V366, P87, DOI 10.1016/0014-5793(95)00463-J; ORIORDAN CR, 1995, J BIOL CHEM, V270, P17033, DOI 10.1074/jbc.270.28.17033; RACKER E, 1985, RECONSTITUTION TRANS, P37; REDDY MM, 1996, AM J PHYSIOL, V40, pC35; RIORDAN JR, 1989, SCIENCE, V245, P1066; SCHULTZ BD, 1995, J GEN PHYSIOL, V105, P329, DOI 10.1085/jgp.105.3.329; SCHULTZ BD, 1993, PEDIATR PULM, V9, pR37; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SEIBERT FS, 1995, J BIOL CHEM, V270, P2158, DOI 10.1074/jbc.270.5.2158; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHAROM FJ, 1995, BIOCHEM J, V308, P381, DOI 10.1042/bj3080381; SIGURDSON WJ, 1987, J EXP BIOL, V127, P191; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; TSUI LC, 1995, AM J RESP CRIT CARE, V151, pS47, DOI 10.1164/ajrccm/151.3_Pt_2.S47; TUMA PL, 1993, J BIOL CHEM, V268, P17240; VIGERS GA, 1968, BIOCHEM BIOPH RES CO, V30, P83, DOI 10.1016/0006-291X(68)90716-X; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; WINTER MC, 1994, BIOPHYS J, V66, P1398, DOI 10.1016/S0006-3495(94)80930-0; WOODBURY DJ, 1990, BIOPHYS J, V58, P833, DOI 10.1016/S0006-3495(90)82429-2; Yike I, 1996, PROTEIN SCI, V5, P89	45	218	221	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28463	28468		10.1074/jbc.271.45.28463	http://dx.doi.org/10.1074/jbc.271.45.28463			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910473	hybrid			2022-12-27	WOS:A1996VU03300073
J	Michell, BJ; Stapleton, D; Mitchelhill, KI; House, CM; Katsis, F; Witters, LA; Kemp, BE				Michell, BJ; Stapleton, D; Mitchelhill, KI; House, CM; Katsis, F; Witters, LA; Kemp, BE			Isoform-specific purification and substrate specificity of the 5'-AMP-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA CARBOXYLASE; YEAST SNF1; SYNTHETIC PEPTIDES; AMP; PHOSPHORYLATION; ACTIVATION; REDUCTASE; INACTIVATION	The 5'-AMP-activated protein kinase (AMPK) mediates several cellular responses to metabolic stress, Rat liver contains at least two isoforms of this enzyme, either alpha(1) or alpha(2) catalytic subunits together with beta and gamma noncatalytic subunits in a trimeric complex, The alpha(1) isoform is purified using a peptide substrate affinity chromatography column with ADR1 (222-234)P-229 (LKKLTRRPSFSAQ), corresponding to the cAMP-dependent protein kinase phosphorylation site in the yeast transcriptional activator of the ADH2 gene, ADR1, This peptide is phosphorylated at Ser(230) by AMPK alpha(1) with a K-m of 3.8 mu M and a V-max of 4.8 mu mol/min/mg compared to the commonly used rat acetyl-CoA carboxylase (73-87)A(77)R(86-87) peptide substrate, HMRSAMSGLHLVKRR, with a K-m of 33.3 mu M and a V-max of 8.1 mu mol/min/mg. Thus, the AMPK exhibits some overlapping specificity with the cAMP-dependent protein kinase. The rat liver AMPK alpha(1) isoform has a K-cat similar to 250-fold higher than the AMPK alpha(2) isoform isolated from rat liver. The AMPK alpha(1) isoform readily phosphorylates peptides corresponding to the reported AMPK phosphorylation sites in rat, chicken, and yeast acetyl-CoA carboxylase and rat hydroxymethylglutaryl-CoA reductase but not phosphorylase kinase, Based on previous peptide substrate specificity studies (Dale, S., Wilson W. A., Edelman, A. M., and Hardie, G. (1995) FEBS Lett. 361, 191-195) using partially purified enzyme and variants of the peptide AMARAASAAALARRR, it was proposed that the AMPK preferred the phosphorylation site motif Phi(X, beta)XXS/TXXX Phi (Phi, hydrophobic; beta, basic), In good AMPK alpha(1) peptide substrates, a hydrophobic residue at the P-5 position is conserved but not at the P+4 position. Oxidation of the Met residues in the rat acetyl-CoA carboxylase (73-87)A(77)R(86-87) peptide increased the K-m 6-fold and reduced the V-max to 4% of the reduced peptide.	DARTMOUTH COLL SCH MED, DEPT MED, DIV ENDOCRINE METAB, HANOVER, NH 03755 USA; DARTMOUTH COLL SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA	Dartmouth College; Dartmouth College	Michell, BJ (corresponding author), ST VINCENTS INST MED RES, 41 VICTORIA PARADE, FITZROY, VIC 3065, AUSTRALIA.		Kemp, Bruce E/L-2633-2014; Kemp, Bruce/G-9602-2019	Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035712] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35712] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIANCHI A, 1990, J BIOL CHEM, V265, P1502; CARLING D, 1989, BIOCHIM BIOPHYS ACTA, V1012, P81, DOI 10.1016/0167-4889(89)90014-1; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; Davies SP, 1995, FEBS LETT, V377, P421, DOI 10.1016/0014-5793(95)01368-7; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; DENIS CL, 1991, J BIOL CHEM, V266, P17932; Gao G, 1996, J BIOL CHEM, V271, P8675, DOI 10.1074/jbc.271.15.8675; GILLESPIE JG, 1992, FEBS LETT, V306, P59, DOI 10.1016/0014-5793(92)80837-7; HARDIE DG, 1992, BIOCHIM BIOPHYS ACTA, V1123, P231, DOI 10.1016/0005-2760(92)90001-C; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; KEMP BE, 1991, METHOD ENZYMOL, V200, P121; KEMP BE, 1994, PROTEIN KINASES, P30; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; PEARSON RB, 1993, PROTEIN PHOSPHORYLAT, P265; SATO R, 1993, P NATL ACAD SCI USA, V90, P261; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; STAPLETON D, 1994, J BIOL CHEM, V269, P29343; TIPPER JP, 1982, BIOCHIM BIOPHYS ACTA, V715, P162, DOI 10.1016/0304-4165(82)90354-3; WEEKES J, 1993, FEBS LETT, V334, P335, DOI 10.1016/0014-5793(93)80706-Z; WEEKES J, 1994, EUR J BIOCHEM, V219, P751, DOI 10.1111/j.1432-1033.1994.tb18554.x; WOODGETT JR, 1991, METHOD ENZYMOL, V200, P169; WOODS A, 1994, J BIOL CHEM, V269, P19509	28	83	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28445	28450		10.1074/jbc.271.45.28445	http://dx.doi.org/10.1074/jbc.271.45.28445			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910470	hybrid			2022-12-27	WOS:A1996VU03300070
J	Shum, L; Turck, DW; Derynck, R				Shum, L; Turck, DW; Derynck, R			Cysteines 153 and 154 of transmembrane transforming growth factor-alpha are palmitoylated and mediate cytoplasmic protein association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL DOMAIN; TGF-ALPHA; DEVELOPMENTAL EXPRESSION; NUCLEOTIDE-SEQUENCE; LIPID MODIFICATIONS; MENETRIERS DISEASE; SIGNALING PATHWAYS; MOLECULAR-CLONING; TRANSGENIC MICE; FATTY ACYLATION	Transforming growth factor-alpha (TGF-alpha) is synthesized as a transmembrane protein with a highly conserved, short cytoplasmic domain that is rich in cysteines. TGF-alpha is a prototype of a large family of growth factors involved in cell-cell communication. We have shown previously that transmembrane TGF-alpha associates with a kinase activity and two proteins of 106 and 86 kDa. In this study, we have used site-directed mutagenesis of the cytoplasmic domain of TGF-alpha to define the structural requirements for these protein interactions. Whereas the cytoplasmic domain of TGF-alpha was not essential for association with transmembrane p106, deletion of the C-terminal 8 amino acids, including a cysteine pair, abolished the interaction with p86 and greatly reduced the kinase activity associated with transmembrane TGF-alpha. Replacement of these 2 cysteines by serines similarly reduced the association of p86 with transmembrane TGF-alpha. Using a combination of mutational analysis and direct microsequencing, we have determined that this cysteine pair was palmitoylated. We therefore conclude that these cysteines play a critical role in the interaction of TGF-alpha with associated proteins and in the function of this protein complex. The palmitoylation of these cysteines suggests a possibly dynamic role of fatty acid modification in the integrity and function of the transmembrane TGF-alpha complex.	UNIV CALIF SAN FRANCISCO,DEPT GROWTH & DEV,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,INST CARDIOVASC RES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL CANCER INSTITUTE [R01CA054826] Funding Source: NIH RePORTER; NCI NIH HHS [CA54826] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASELGA J, 1993, J BIOL CHEM, V271, P3279; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; CHIANG T, 1991, CARCINOGENESIS, V12, P529; DAUTIGNY A, 1985, FEBS LETT, V188, P33, DOI 10.1016/0014-5793(85)80869-3; DEMPSEY PJ, 1992, GASTROENTEROLOGY, V103, P1950, DOI 10.1016/0016-5085(92)91455-D; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; DERYNCK R, 1987, CANCER RES, V47, P707; ELDER JT, 1989, SCIENCE, V243, P811, DOI 10.1126/science.2916128; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GLENN GM, 1993, J VIROL, V67, P1945, DOI 10.1128/JVI.67.4.1945-1952.1993; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; HACKETT M, 1994, SCIENCE, V266, P433, DOI 10.1126/science.7939682; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HARANO T, 1994, J BIOL CHEM, V269, P20305; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; KAUFMAN JF, 1984, J BIOL CHEM, V259, P7230; LEE DC, 1985, MOL CELL BIOL, V5, P3644, DOI 10.1128/MCB.5.12.3644; MACAULAY SL, 1995, BIOCHEM J, V306, P811, DOI 10.1042/bj3060811; MAGEE AI, 1992, BIOCHEM SOC T, V20, P497, DOI 10.1042/bst0200497; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; MASSAGUE J, 1983, J BIOL CHEM, V258, P3614; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROSS EM, 1995, CURR BIOL, V5, P107, DOI 10.1016/S0960-9822(95)00026-1; RUTLEDGE BJ, 1992, GENE DEV, V6, P1503, DOI 10.1101/gad.6.8.1503; Sambrook J., 2002, MOL CLONING LAB MANU; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; SCHULTZ AM, 1988, ANNU REV CELL BIOL, V4, P611, DOI 10.1146/annurev.cb.04.110188.003143; SCOTT J, 1983, SCIENCE, V221, P236, DOI 10.1126/science.6602382; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SHUM L, 1994, J CELL BIOL, V125, P903, DOI 10.1083/jcb.125.4.903; STOFFEL W, 1983, H-S Z PHYSIOL CHEM, V364, P1455, DOI 10.1515/bchm2.1983.364.2.1455; STROOBANT P, 1985, CELL, V42, P383, DOI 10.1016/S0092-8674(85)80133-1; SUTTON R, 1995, COMP BIOCHEM PHYS B, V110, P697, DOI 10.1016/0305-0491(94)00208-C; TAKAGI H, 1992, J CLIN INVEST, V90, P1161, DOI 10.1172/JCI115936; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WILCOX JN, 1988, MOL CELL BIOL, V8, P3415, DOI 10.1128/MCB.8.8.3415; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; Zurfluh LL, 1990, GROWTH FACTORS, V3, P257, DOI 10.3109/08977199009003668	62	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28502	28508		10.1074/jbc.271.45.28502	http://dx.doi.org/10.1074/jbc.271.45.28502			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910478	hybrid			2022-12-27	WOS:A1996VU03300078
J	Sakatsume, O; Tsutsui, H; Wang, YF; Gao, H; Tang, XR; Yamauchi, T; Murata, T; Itakura, K; Yokoyama, KK				Sakatsume, O; Tsutsui, H; Wang, YF; Gao, H; Tang, XR; Yamauchi, T; Murata, T; Itakura, K; Yokoyama, KK			Binding of THZif-1, a MAZ-like zinc finger protein to the nuclease-hypersensitive element in the promoter region of the c-MYC protooncogene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-HELIX FORMATION; IN-VITRO; EMBRYONIC LETHALITY; BURKITT-LYMPHOMA; TRANSCRIPTIONAL INITIATION; FORMING OLIGONUCLEOTIDES; TARGETED DISRUPTION; MODULATE EXPRESSION; REGULATORY ELEMENTS; CHROMATIN STRUCTURE	A detailed analysis is reported of the binding of the zinc finger protein THZif-1 to the nuclease hypersensitive element (NHE) in the promoter region of the c-MYC gene using the electrophoretic mobility shift assay and a series of mutants of a fusion protein composed of glutathione S-transferase and THZif-1. The THZif-1 protein bound specifically to the single-stranded (ss) pyrimidine-rich DNA of the NHE (ss c-myc NHE-C) with an apparent dissociation constant (K-d(app)) of 0.077 mu M. By contrast, no binding to the single-stranded purine rich DNA of the NHE (ss c-myc NHE-me(5)C) was detected. Moreover, the binding affinity of THZif-1 protein was S-fold higher for the single-stranded 5-methyl-2'-deoxycytidine derivative of NHE (ss c-myc NHE-me(5)C) than for the unmethylated NHE, in the case of the binding of THZif-1 to methylated double-stranded (ds) NHE (ds c-myc NHE-me(5)CG), no significant binding to the DNA was observed. The decrease in binding: to DNA of THZif-1 was significant in the case of mutated ds c-myc NHE, in which more than two sites of deoxycytidine residues were methylated, However, the binding affinity of THZif-1 protein for methylated and for unmethylated triple-helical DNA of the NHE was almost identical, Moreover, the domain of the THZif-1 protein that made the major contribution to binding to ss c-myc NHE-C or ss c-myc NHE-me(5)C corresponded to the amino-terminal second zinc finger motif. Taken together, the results indicate that the THZif-1 protein exhibits preferential DNA-binding activity with ss c-myc NHE-C, ds c-myc NHE-CG, and ts c-myc NHE but not with ss c-myc NHE-G and ds c-myc NRE-me(5)CG in vitro.	INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, TSUKUBA, IBARAKI 305, JAPAN; SHANGHAI UNIV SCI & TECHNOL, DEPT MATH, SHANGHAI, PEOPLES R CHINA; W CHINA UNIV MED SCI, DEPT MED GENET, SHENYANG, PEOPLES R CHINA; CITY HOPE NATL MED CTR, BECKMAN RES INST, DEPT MOL GENET, DUARTE, CA 91010 USA	RIKEN; University of Shanghai for Science & Technology; Sichuan University; City of Hope; Beckman Research Institute of City of Hope				Sakatsume, Osamu/0000-0003-1340-3661				ARCINAS M, 1994, ONCOGENE, V9, P2699; ASSELIN C, 1989, ONCOGENE, V4, P549; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BOLES TC, 1987, BIOCHEMISTRY-US, V26, P367, DOI 10.1021/bi00376a006; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; CHRISTMAN JK, 1995, P NATL ACAD SCI USA, V92, P7347, DOI 10.1073/pnas.92.16.7347; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CONREY AJ, 1988, CELL, V55, P887; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DURLAND RH, 1991, BIOCHEMISTRY-US, V30, P9246, DOI 10.1021/bi00102a017; DYSON PJ, 1985, EMBO J, V4, P2885, DOI 10.1002/j.1460-2075.1985.tb04018.x; EBBINGHAUS SW, 1993, J CLIN INVEST, V92, P2433, DOI 10.1172/JCI116850; EHRLICH M, 1981, SCIENCE, V212, P1350, DOI 10.1126/science.6262918; EICK D, 1989, EMBO J, V8, P1965, DOI 10.1002/j.1460-2075.1989.tb03602.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; FIRULLI AB, 1994, ARCH BIOCHEM BIOPHYS, V310, P236, DOI 10.1006/abbi.1994.1162; GLASER RL, 1990, J MOL BIOL, V211, P751, DOI 10.1016/0022-2836(90)90075-W; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389; HALL DJ, 1990, ONCOGENE, V5, P47; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HELM CW, 1993, GYNECOL ONCOL, V49, P339, DOI 10.1006/gyno.1993.1136; Kawasaki H, 1996, ARTIF ORGANS, V20, P836, DOI 10.1111/j.1525-1594.1996.tb04556.x; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KINNIBURGH AJ, 1989, NUCLEIC ACIDS RES, V17, P7771, DOI 10.1093/nar/17.19.7771; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; KITABAYASHI I, 1992, EMBO J, V11, P167, DOI 10.1002/j.1460-2075.1992.tb05039.x; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MAYFIELD C, 1994, J BIOL CHEM, V269, P18232; MAYFIELD C, 1994, BIOCHEMISTRY-US, V33, P3358, DOI 10.1021/bi00177a029; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; MICHELOTTI EF, 1995, J BIOL CHEM, V270, P9494, DOI 10.1074/jbc.270.16.9494; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; MOBERG KH, 1992, ONCOGENE, V7, P411; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; ORSON FM, 1991, NUCLEIC ACIDS RES, V19, P3435, DOI 10.1093/nar/19.12.3435; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; PYRC JJ, 1992, BIOCHEMISTRY-US, V31, P4102, DOI 10.1021/bi00131a029; RAJAGOPAL P, 1989, NATURE, V339, P637, DOI 10.1038/339637a0; SAWAI S, 1993, DEVELOPMENT, V117, P1445; SCHMID P, 1989, SCIENCE, V243, P226, DOI 10.1126/science.2911736; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; TOTH M, 1990, J MOL BIOL, V214, P673, DOI 10.1016/0022-2836(90)90285-T; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; XODO LE, 1991, NUCLEIC ACIDS RES, V19, P5625, DOI 10.1093/nar/19.20.5625; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363; YOKOYAMA K, 1990, PROSPECT ANTISENSE N, P35; YOKOYAMA K, 1991, ANTISENSE RNA DNA, P335	76	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31322	31333		10.1074/jbc.271.49.31322	http://dx.doi.org/10.1074/jbc.271.49.31322			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940139	hybrid			2022-12-27	WOS:A1996VW68600050
J	Sarkissian, M; Winne, A; Lafyatis, R				Sarkissian, M; Winne, A; Lafyatis, R			The mammalian homolog of suppressor-of-white-apricot regulates alternative mRNA splicing of CD45 exon 4 and fibronectin IIICS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR RIBONUCLEOPROTEIN; IMMUNODEFICIENCY-VIRUS TYPE-1; PROTEIN-PROTEIN INTERACTIONS; SR-PROTEINS; PREMESSENGER RNA; SITE SELECTION; BINDING SPECIFICITIES; TYROSINE-PHOSPHATASE; FUNCTIONAL DOMAINS	We have previously described human (HsSWAP) and mouse (MmSWAP) homologs to the Drosophila alternative splicing regulator suppressor-of-white-apricot (su(w(a)) or DmSWAP), DmSWAP was formally defined as an alternative splicing regulator by studies showing that it autoregulates splicing of its own pre-mRNA. We report here that mammalian SWAP regulates its own splicing, and also the splicing of fibronectin and CD45. Using an in vivo system of cell transfection, mammalian SWAP regulated 5' splice site selection in splicing of its own second intron, SWAP enhanced splicing to the distal 5' splice site, whereas the SR protein ASF/SF2 enhanced splicing to the proximal site, SWAP also regulated alternative splicing of the fibronectin IIICS region by promoting exclusion of the entire IIICS region, In contrast, ASF/SF2 stimulated inclusion of the entire IIICS region. Finally, SWAP regulated splicing of CD45 exon 4, promoting exclusion of this exon, an effect also seen with ASF/SF2, Experiments using SWAP deletion mutants showed that splicing regulation of the fibronectin IIICS region and CD45 exon 4 requires a region including a carboxyl-terminal arginine/serine (WS)-rich motif, Since WS motifs of various splicing proteins have been shown to interact with each other, these results suggest that the WS motif in SWAP may regulate splicing, at least in part, through interactions with other R/S containing splicing factors.	BOSTON UNIV, SCH MED, CTR ARTHRITIS, BOSTON, MA 02118 USA	Boston University				Lafyatis, Robert/0000-0002-9398-5034	NIAMS NIH HHS [P60AR20613] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020613] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKBAR AN, 1988, J IMMUNOL, V140, P2171; AMENDT BA, 1995, MOL CELL BIOL, V15, P4606; AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BIRKELAND ML, 1989, P NATL ACAD SCI USA, V86, P6734, DOI 10.1073/pnas.86.17.6734; BROSI R, 1993, SCIENCE, V262, P102, DOI 10.1126/science.8211112; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; CAPUTI M, 1994, NUCLEIC ACIDS RES, V22, P1018, DOI 10.1093/nar/22.6.1018; CHOU TB, 1987, EMBO J, V6, P4095, DOI 10.1002/j.1460-2075.1987.tb02755.x; DENHEZ F, 1994, J BIOL CHEM, V269, P16170; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; HERSHBERGER RP, 1990, MOL CELL BIOL, V10, P662, DOI 10.1128/MCB.10.2.662; HUH GS, 1994, GENE DEV, V8, P1561, DOI 10.1101/gad.8.13.1561; HUMPHREY MB, 1995, MOL CELL BIOL, V15, P3979; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LAFYATIS R, 1994, NATO ADV SCI INST SE, V80, P59; LAVIGUEUR A, 1993, GENE DEV, V7, P2405, DOI 10.1101/gad.7.12a.2405; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; LYNCH KW, 1995, GENE DEV, V9, P284, DOI 10.1101/gad.9.3.284; MARDON HJ, 1992, J CELL SCI, V103, P423; MAYEDA A, 1992, P NATL ACAD SCI USA, V89, P1301, DOI 10.1073/pnas.89.4.1301; MAYEDA A, 1993, MOL CELL BIOL, V13, P2993, DOI 10.1128/MCB.13.5.2993; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PIRROTTA V, 1984, EMBO J, V3, P563, DOI 10.1002/j.1460-2075.1984.tb01847.x; RAMCHATESINGH J, 1995, MOL CELL BIOL, V15, P4898; ROGERS PR, 1992, J IMMUNOL, V148, P4054; ROTHSTEIN DM, 1992, J BIOL CHEM, V267, P7139; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; SPIKES DA, 1994, NUCLEIC ACIDS RES, V22, P4510, DOI 10.1093/nar/22.21.4510; STAFFA A, 1995, MOL CELL BIOL, V15, P4597; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; STREULI M, 1989, EMBO J, V8, P787, DOI 10.1002/j.1460-2075.1989.tb03439.x; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; YANG XM, 1994, P NATL ACAD SCI USA, V91, P6924, DOI 10.1073/pnas.91.15.6924; ZACHAR ZZ, 1987, EMBO J, V6, P4105, DOI 10.1002/j.1460-2075.1987.tb02756.x; ZAHLER AM, 1993, MOL CELL BIOL, V13, P4023, DOI 10.1128/MCB.13.7.4023; ZAHLER AM, 1995, P NATL ACAD SCI USA, V92, P2642, DOI 10.1073/pnas.92.7.2642; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	54	48	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31106	31114		10.1074/jbc.271.49.31106	http://dx.doi.org/10.1074/jbc.271.49.31106			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940107	hybrid			2022-12-27	WOS:A1996VW68600018
J	Slotboom, DJ; Lolkema, JS; Konings, WN				Slotboom, DJ; Lolkema, JS; Konings, WN			Membrane topology of the C-terminal half of the neuronal, glial, and bacterial glutamate transporter family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; HIGH-AFFINITY; RAT-BRAIN; FUNCTIONAL EXPRESSION; SEQUENCE; PROTEINS; DOMAINS; GLT-1	Secondary glutamate transporters in neuronal and glial cells in the mammalian central nervous system remove the excitatory neurotransmitter glutamate from the synaptic cleft and prevent the extracellular glutamate concentration to rise above neurotoxic levels. Secondary structure prediction algorithms predict 6 trans membrane helices in the first half of the transporters but fail in the C-terminal half where no clear helix-loop-helix motif is resolved in the hydropathy profile of the primary sequences. A number of previous studies have emphasized the importance of the C-terminal half of the molecules for the function. Here we determine the membrane topology of the C-terminal half of the glutamate transporters by applying the phoA gene fusion technique to the homologous bacterial glutamate transporter of Bacillus stearothermophilus. High sequence conservation and very similar hydropathy profiles in the C-terminal half warrant a similar folding as in the glutamate transporters of the mammalian central nervous system, The C-terminal half contains four putative transmembrane helices. The strong hydrophobic moment and substitution moment of the most C-terminal helix X that point to opposite faces of the helix suggest that the helix faces the lipid environment with its least conserved, hydrophobic face and the interior of the protein with its well conserved, hydrophilic face, Residues that were shown before to be critical for function cluster in helix X and VII.	UNIV GRONINGEN,DEPT MICROBIOL,GRONINGEN BIOMOL SCI & BIOTECHNOL INST,NL-9751 NN HAREN,NETHERLANDS	University of Groningen			Konings, Wilhelmus N./C-7063-2013					CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CONRADT M, 1995, J BIOL CHEM, V270, P25207, DOI 10.1074/jbc.270.42.25207; DONNELLY D, 1993, PROTEIN SCI, V2, P55; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Gaillard I, 1996, BIOCHEMISTRY-US, V35, P6150, DOI 10.1021/bi953005v; GRUNEWALD M, 1995, J BIOL CHEM, V270, P17017, DOI 10.1074/jbc.270.28.17017; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; KANAI Y, 1995, J BIOL CHEM, V270, P16561, DOI 10.1074/jbc.270.28.16561; KANAI Y, 1993, FASEB J, V7, P1450, DOI 10.1096/fasebj.7.15.7903261; KANAI Y, 1992, NATURE, V360, P367; KANNER BI, 1993, FEBS LETT, V325, P95, DOI 10.1016/0014-5793(93)81421-U; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MICHAELIS S, 1986, J BACTERIOL, V167, P160, DOI 10.1128/jb.167.1.160-167.1986; PINES G, 1995, J BIOL CHEM, V270, P17093, DOI 10.1074/jbc.270.29.17093; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Pourcher T, 1996, BIOCHEMISTRY-US, V35, P4161, DOI 10.1021/bi9527496; REES DC, 1989, SCIENCE, V245, P510, DOI 10.1126/science.2667138; ROTHSTEIN JD, 1993, P NATL ACAD SCI USA, V90, P6591, DOI 10.1073/pnas.90.14.6591; Sambrook J., 2002, MOL CLONING LAB MANU; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; TOLNER B, 1992, MOL MICROBIOL, V6, P2845, DOI 10.1111/j.1365-2958.1992.tb01464.x; TOLNER B, 1992, J BACTERIOL, V174, P2391, DOI 10.1128/JB.174.7.2391-2393.1992; TOLNER B, 1995, J BACTERIOL, V177, P2863, DOI 10.1128/jb.177.10.2863-2869.1995; VANDENBERG RJ, 1995, J BIOL CHEM, V270, P17668, DOI 10.1074/jbc.270.30.17668; vanGeest M, 1996, J BIOL CHEM, V271, P25582, DOI 10.1074/jbc.271.41.25582	26	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31317	31321		10.1074/jbc.271.49.31317	http://dx.doi.org/10.1074/jbc.271.49.31317			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940138	hybrid, Green Published			2022-12-27	WOS:A1996VW68600049
J	Wan, JX; Blakeley, SD; Dennis, DT; Ko, K				Wan, JX; Blakeley, SD; Dennis, DT; Ko, K			Transit peptides play a major role in the preferential import of proteins into leucoplasts and chloroplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE 1,5-BISPHOSPHATE CARBOXYLASE; CHLOROPHYLL-A/B PROTEIN; OUTER ENVELOPE MEMBRANE; THYLAKOID MEMBRANE; BINDING PROTEIN; SMALL SUBUNIT; TRANSPORT; PRECURSORS; PLANTS; LOCALIZATION	The in vitro import characteristics of six different precursors of plastid proteins were assessed to determine differences in the protein import pathways of leucoplasts and chloroplasts. Five of these precursor proteins are destined to different subchloroplast sites, and one is a leucoplast stromal precursor protein. The results indicate that some of these precursors can be imported equally into both plastid types and others preferentially into one type of plastid versus the other. The ability of plastids to import different proteins correlates with the in vivo steady state levels of these proteins. Additional differences were also observed in the intraorganellar portion of the translocation pathway for two thylakoidal proteins. The differences in import characteristics were found to be predominantly governed by information in the transit peptides, since attachment of the various transit peptides to different plastid and foreign proteins demonstrated that the import behavior of the proteins is transferable with the transit sequence. These results indicate that the import mechanisms of leucoplasts and chloroplasts are sufficiently different such that the plastids respond differently to the information present in the transit peptides.	QUEENS UNIV, DEPT BIOL, KINGSTON, ON K7L 3N6, CANADA	Queens University - Canada								BARTLETT SG, 1982, METHODS CHLOROPLAST, P1081; BOYLE SA, 1986, PLANT PHYSIOL, V81, P817, DOI 10.1104/pp.81.3.817; CLINE K, 1988, PLANT PHYSIOL, V86, P1120, DOI 10.1104/pp.86.4.1120; CLINE K, 1985, J BIOL CHEM, V260, P3691; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; DEBOER D, 1988, EMBO J, V7, P2631, DOI 10.1002/j.1460-2075.1988.tb03115.x; FISCHER K, 1994, J BIOL CHEM, V269, P25754; GREENWOOD JS, 1982, CAN J BOT, V60, P1751, DOI 10.1139/b82-222; HALPIN C, 1989, FEBS LETT, V258, P32, DOI 10.1016/0014-5793(89)81608-4; HAND JM, 1989, EMBO J, V8, P3195, DOI 10.1002/j.1460-2075.1989.tb08478.x; HOFFMAN NE, 1987, P NATL ACAD SCI USA, V84, P8844, DOI 10.1073/pnas.84.24.8844; JOYARD J, 1983, J BIOL CHEM, V258, P1; KEEGSTRA K, 1989, CELL, V56, P247, DOI 10.1016/0092-8674(89)90898-2; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KLOSGEN RB, 1991, MOL GEN GENET, V225, P297, DOI 10.1007/BF00269862; KLOSGEN RB, 1989, MOL GEN GENET, V217, P155, DOI 10.1007/BF00330955; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPPA GK, 1988, J BIOL CHEM, V263, P14996; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; SCHINDLER C, 1986, ARCH BIOCHEM BIOPHYS, V247, P211, DOI 10.1016/0003-9861(86)90550-3; SCHMIDT GW, 1986, ANNU REV BIOCHEM, V55, P879; Scott SV, 1996, J CELL BIOL, V132, P63, DOI 10.1083/jcb.132.1.63; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SMEEKENS S, 1987, PLANT MOL BIOL, V9, P377, DOI 10.1007/BF00014912; STRZALKA K, 1987, BIOCHEM BIOPH RES CO, V149, P799, DOI 10.1016/0006-291X(87)90438-4; Theg Steven M., 1993, Trends in Cell Biology, V3, P186, DOI 10.1016/0962-8924(93)90212-J; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDENBROECK G, 1985, NATURE, V313, P358, DOI 10.1038/313358a0; VANDENBROECK G, 1988, PLANT SCI, V58, P171, DOI 10.1016/0168-9452(88)90006-4; VIITANEN PV, 1988, J BIOL CHEM, V263, P15000; WAN JX, 1995, J BIOL CHEM, V270, P16731, DOI 10.1074/jbc.270.28.16731; WEISBEEK P, 1987, PROGR PHOTOSYNTHESIS, V4, P569; WU CB, 1994, J BIOL CHEM, V269, P32264	34	52	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31227	31233		10.1074/jbc.271.49.31227	http://dx.doi.org/10.1074/jbc.271.49.31227			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940125	hybrid			2022-12-27	WOS:A1996VW68600036
J	Wang, JJ; Breslow, E; Sykes, BD				Wang, JJ; Breslow, E; Sykes, BD			Differential binding of desmopressin and vasopressin to neurophysin-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE NEUROPHYSINS; PEPTIDE; OXYTOCIN; IDENTIFICATION; CONFORMATION	Desmopressin is a synthetic analog of the peptide hormone vasopressin in which the N-terminal alpha-amino group has been removed and L-arginine in position 8 has been replaced by D-arginine, Using H-1-NMR spectroscopy, we show that desmopressin binds to neurophysin-II, whereas deamino-vasopressin does not bind, Thus, the change in configuration at Arg(8) causes a significant difference in the binding of these hormones to neurophysin-II, We have determined the structure of desmopressin bound to neurophysin-II: using two-dimensional H-1 nuclear magnetic resonance-transferred nuclear Overhauser effect techniques, A common binding motif for vasopressin and desmopressin is proposed that includes a positive charge group along with the hydrophobic surface formed by the side chains of Tyr(2) and a beta-methylene provided by Phe-3, In vasopressin, the positive charge is provided by the N-terminal NEI, whereas in desmopressin, the side chain of Arg-8 contributes the positive charge. The type II beta-turn found in residues Cys(6)-Pro(7)-D-Arg(8)-Gly(9) of the bound structure of desmopressin folds the Arg(8) side chain back toward the disulfide-bond loop, which allows the positive charged side chain of Arg(8) to participate in binding, Such a type II beta-turn is not found in deamino-vasopressin in the presence of neurophysin-II.	UNIV ALBERTA, DEPT BIOCHEM, PROT ENGN NETWORK CTR EXCELLENCE, EDMONTON, AB T6G 2S2, CANADA; CORNELL UNIV, COLL MED, DEPT BIOCHEM, NEW YORK, NY 10021 USA	University of Alberta; Cornell University								BRESLOW E, 1990, ADV ENZYMOL RAMB, V63, P1; BRESLOW E, 1973, BIOCHEMISTRY-US, V12, P4644, DOI 10.1021/bi00747a016; BRESLOW E, 1966, P NATL ACAD SCI USA, V56, P640, DOI 10.1073/pnas.56.2.640; CAMPBELL AP, 1991, J MOL BIOL, V222, P405, DOI 10.1016/0022-2836(91)90219-V; CARLSON J, 1981, BIOCHEM BIOPH RES CO, V100, P455, DOI 10.1016/S0006-291X(81)80118-0; CHEN LQ, 1991, P NATL ACAD SCI USA, V88, P4240, DOI 10.1073/pnas.88.10.4240; FASSINA G, 1988, J BIOL CHEM, V263, P13539; JOST K, 1987, CRC HDB NEUROHYPOPHY, V2, P97; LIAN LY, 1994, METHOD ENZYMOL, V239, P657; LIPPENS G, 1993, BIOCHEMISTRY-US, V32, P9423, DOI 10.1021/bi00087a022; LIVE DH, 1987, BIOCHEMISTRY-US, V26, P6415, DOI 10.1021/bi00394a018; LORD ST, 1979, INT J PEPT PROT RES, V13, P71; Rose JP, 1996, NAT STRUCT BIOL, V3, P163, DOI 10.1038/nsb0296-163; WAGNER G, 1986, J MOL BIOL, V187, P131, DOI 10.1016/0022-2836(86)90413-4; WANG J, 1993, TECHNIQUES PROTEIN C, V4, P569; WANG JJ, 1995, INT J PEPT PROT RES, V45, P471; WANG JJ, 1995, J AM CHEM SOC, V117, P8627, DOI 10.1021/ja00138a019; WHITTAKER BA, 1985, BIOCHEMISTRY-US, V24, P2782, DOI 10.1021/bi00332a028; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; Wuthrich K., 1986, NMR PROTEINS NUCL AC	20	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31354	31359		10.1074/jbc.271.49.31354	http://dx.doi.org/10.1074/jbc.271.49.31354			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940142	hybrid			2022-12-27	WOS:A1996VW68600053
J	Kornilova, E; Sorkina, T; Beguinot, L; Sorkin, A				Kornilova, E; Sorkina, T; Beguinot, L; Sorkin, A			Lysosomal targeting of epidermal growth factor receptors via a kinase-dependent pathway is mediated by the receptor carboxyl-terminal residues 1022-1123	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A431 CELLS; DOWN-REGULATION; EGF RECEPTOR; POSTENDOCYTIC TRAFFICKING; DIRECT VISUALIZATION; HUMAN-FIBROBLASTS; ENDOCYTIC SYSTEM; KB CELLS; INTERNALIZATION; DEGRADATION	Binding of epidermal growth factor (EGF) to its receptor induces rapid internalization and degradation of both ligand and receptor via the lysosomal pathway, To study the mechanism of intracellular sorting of EGF-EGF receptor complexes to lysosomes, NIH 3T3 cells transfected with wild-type and mutant EGF receptors were employed, The kinetics of I-125-EGF trafficking was analyzed using low concentrations of the ligand to avoid saturation of the specific sorting system. The relative size of the pool of internalized I-125-EGF-receptor complexes that were capable of recycling decreased as receptors traversed the endosomal system, The rate of I-125-EGF sequestration from the recycling pathway correlated with the rate of I-125-EGF transition from early to late endosomes as measured by Percoll gradient fractionation. Deletion of the last 63 amino acids of the EGF receptor cytoplasmic tail did not inhibit the process of sequestration and targeting to the late endosomes and lysosomes. Truncation of the 123 residues, however, resulted in impaired lysosomal targeting and increased recycling of EGF, Receptor mutant in which 165 residues were deleted displayed maximal ability to recycle and a minimal extent of sorting to the late endosomes. The data suggest that two regions of the EGF receptor molecule, residues 1022-1063 and to a lesser extent residues 1063-1123, contribute in the regulation of routing of EGF receptors to the degradation pathway, The kinase-negative receptor mutant recycled EGF more intensively compared with the wild-type receptor, and the transport of this mutant to late endosomes was inhibited. These results support the view that the receptor kinase activity is important for ligand-induced sorting of EGF receptors to the pathway of lysosomal degradation.	UNIV COLORADO, HLTH SCI CTR, DEPT PHARMACOL, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, CTR CANC, DENVER, CO 80262 USA; RUSSIAN ACAD SCI, INST CYTOL, ST PETERSBURG 194064, RUSSIA; DIBIT, ONCOL MOL LAB, I-20132 MILAN, ITALY; CNR, INST NEUROSCI & BIOMMAGINI, I-20132 MILAN, ITALY	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS; Consiglio Nazionale delle Ricerche (CNR)			Kornilova, Elena Sergeevna/AAB-5559-2021	Sorkin, Alexander/0000-0002-4446-1920; Kornilova, Elena/0000-0002-2951-6292				BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CARPENTIER JL, 1987, J CELL BIOL, V105, P2751, DOI 10.1083/jcb.105.6.2751; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COKER KJ, 1994, P NATL ACAD SCI USA, V91, P6967, DOI 10.1073/pnas.91.15.6967; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FELDER S, 1992, J CELL BIOL, V117, P203, DOI 10.1083/jcb.117.1.203; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; Griffiths G, 1991, Trends Cell Biol, V1, P5, DOI 10.1016/0962-8924(91)90047-D; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; HELIN K, 1991, ONCOGENE, V6, P825; HERBST JJ, 1994, J BIOL CHEM, V269, P12865; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HUECKSTEADT T, 1986, J BIOL CHEM, V261, P8655; KORNILOVA ES, 1992, ONCOGENE, V7, P511; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; LAI WH, 1989, J CELL BIOL, V109, P2751, DOI 10.1083/jcb.109.6.2751; LUND KA, 1990, J BIOL CHEM, V265, P15713; LYALL RM, 1985, J CELL PHYSIOL, V122, P166, DOI 10.1002/jcp.1041220125; MARSH EW, 1995, J CELL BIOL, V129, P1509, DOI 10.1083/jcb.129.6.1509; MCKANNA JA, 1979, P NATL ACAD SCI USA, V76, P5689, DOI 10.1073/pnas.76.11.5689; MILLER K, 1986, J CELL BIOL, V102, P500, DOI 10.1083/jcb.102.2.500; MILOSO M, 1995, J BIOL CHEM, V270, P19557, DOI 10.1074/jbc.270.33.19557; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; SCHWARTZ AL, 1984, J CELL BIOL, V98, P732, DOI 10.1083/jcb.98.2.732; SELVA E, 1993, J BIOL CHEM, V268, P2250; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1991, J BIOL CHEM, V266, P8355; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; SORKIN A, 1989, BIOCHIM BIOPHYS ACTA, V1011, P88, DOI 10.1016/0167-4889(89)90083-9; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; SORKIN A, 1991, J CELL BIOL, V112, P55, DOI 10.1083/jcb.112.1.55; SORKIN A, 1992, ENDOCYTOSIS, P181; SORKIN AD, 1988, EXP CELL RES, V175, P192, DOI 10.1016/0014-4827(88)90266-2; STARBUCK C, 1992, BIOTECHNOL PROGR, V8, P132, DOI 10.1021/bp00014a007; STOORVOGEL W, 1987, J CELL BIOL, V104, P1261, DOI 10.1083/jcb.104.5.1261; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; VELU TJ, 1989, MOL CELL BIOL, V9, P1772, DOI 10.1128/MCB.9.4.1772; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; WILEY HS, 1991, J BIOL CHEM, V266, P11083	44	97	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30340	30346		10.1074/jbc.271.48.30340	http://dx.doi.org/10.1074/jbc.271.48.30340			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939994	hybrid			2022-12-27	WOS:A1996VV15800011
J	Lowe, M; Kreis, TE				Lowe, M; Kreis, TE			In vivo assembly of coatomer, the COP-I coat precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; GOLGI MEMBRANES REQUIRES; GTP-BINDING PROTEIN; ENDOPLASMIC-RETICULUM; BREFELDIN-A; BETA-COP; ORGANELLE STRUCTURE; GUANINE-NUCLEOTIDE; VESICLES; SUBUNIT	Coatomer, a seven-subunit hetero-oligomeric complex, is the major component of the COP-I membrane coat of transport vesicles of the early secretory pathway, We have followed the assembly of this complex in vivo by pulse-chase experiments and immunoprecipitation of native coatomer subunits and found that it is an ordered process that takes 1-2 h to complete. During assembly, direct interactions between alpha-, beta'- and delta-COP, beta- and delta-COP, and gamma-, zeta-, and delta-COP occur. Coatomer, once it has assembled, is stable with a half-life of similar to 28 h. No significant amounts of partial coatomer complexes have been detected, The only subunit to exist at steady state out of the complex is zeta-COP, which has a similar half-life to coatomer subunits within the complex. Assembly is inhibited by brefeldin A, suggesting that it may be a regulated process. These results describe for the first time in vivo assembly of a coat protein complex involved in membrane traffic and extend our knowledge of how coatomer is structured.	UNIV GENEVA,DEPT BIOL CELLULAIRE,CH-1211 GENEVA,SWITZERLAND	University of Geneva								Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; BACHURSKI CJ, 1994, MOL CELL BIOL, V14, P4076, DOI 10.1128/MCB.14.6.4076; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; Cosson P, 1996, EMBO J, V15, P1792, DOI 10.1002/j.1460-2075.1996.tb00528.x; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; ELAZAR Z, 1994, J CELL BIOL, V124, P415, DOI 10.1083/jcb.124.4.415; GERICH B, 1995, P NATL ACAD SCI USA, V92, P3229, DOI 10.1073/pnas.92.8.3229; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; HARRISONLAVOIE KJ, 1993, EMBO J, V12, P2847, DOI 10.1002/j.1460-2075.1993.tb05946.x; HARTER C, 1995, FEBS LETT, V369, P89, DOI 10.1016/0014-5793(95)00621-F; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kreis TE, 1995, ANNU REV CELL DEV BI, V11, P677, DOI 10.1146/annurev.cb.11.110195.003333; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; KUGE O, 1993, J CELL BIOL, V123, P1727, DOI 10.1083/jcb.123.6.1727; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lowe M, 1995, J BIOL CHEM, V270, P31364, DOI 10.1074/jbc.270.52.31364; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; Sheff D, 1996, J BIOL CHEM, V271, P7230, DOI 10.1074/jbc.271.12.7230; STENBECK G, 1992, FEBS LETT, V314, P195, DOI 10.1016/0014-5793(92)80973-K; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WHITNEY JA, 1995, CELL, V83, P703	31	42	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30725	30730		10.1074/jbc.271.48.30725	http://dx.doi.org/10.1074/jbc.271.48.30725			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940050	hybrid			2022-12-27	WOS:A1996VV15800067
J	Osborn, MT; Chambers, TC				Osborn, MT; Chambers, TC			Role of the stress-activated/c-Jun NH2-terminal protein kinase pathway in the cellular response to adriamycin and other chemotherapeutic drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; RESISTANCE MDR1 GENE; DNA-DAMAGING AGENTS; MULTIDRUG RESISTANCE; DEATH APOPTOSIS; MAMMALIAN-CELLS; CARCINOMA-CELLS; HEAT-SHOCK; PHOSPHORYLATION; P53	c-Jun NH2-terminal protein kinase (JNK), a member of the mitogen activated protein kinase family, is activated in response to many stressful stimuli including heat shock, UV irradiation, protein synthesis inhibitors, and inflammatory cytokines, In this study, we investigated whether JNK plays a role in the cellular response to different drugs commonly used in cancer chemotherapy. Treatment of human KB-3 carcinoma cells with Adriamycin resulted in a time and dose dependent activation of JNK of up to 40-fold. Treatment with vinblastine or etoposide (VP-16) also activated JNK, with maximum increases of 6.5- and 4.3 fold, respectively, Consistent with these findings, increased c-Jun phosphorylation was observed after drug treatment of cells, In contrast, none of the drugs significantly activated the extracellular response kinase/mitogen activated protein kinase pathway, Since these drugs are transport substrates for the MDR1 gene product, P-glycoprotein, JNK was assayed in two multidrug-resistant (MDR) KB cell lines, KB-A1 and KB-V1, selected for resistance to Adriamycin and vinblastine, respectively. Relative to KB-3 cells, basal JNK activity was increased 7-fold in KB-A1 cells and 4-fold in KB-V1 cells, with no change in JNK protein expression, indicating that JNK is present in a more highly activated form in the MDR cell lines. Under conditions optimal for JNK activation, Adriamycin, vinblastine, and VP 16 all induced MDR1 mRNA expression in KB-3 cells. Our findings suggest that JNK activation is an important component of the cellular response to several structurally and functionally distinct anticancer drugs and may also play a role in the MDR phenotype.	UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOL BIOL,LITTLE ROCK,AR 72205	University of Arkansas System; University of Arkansas Medical Sciences								ANAND S, 1995, CANCER LETT, V88, P101, DOI 10.1016/0304-3835(94)03617-R; CHAUDHARY PM, 1993, J NATL CANCER I, V85, P632, DOI 10.1093/jnci/85.8.632; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHIN KV, 1990, J BIOL CHEM, V265, P221; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KASTAN MB, 1991, CANCER RES, V51, P6304; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEE JM, 1995, CANCER METAST REV, V14, P149, DOI 10.1007/BF00665797; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; MIZUMOTO K, 1994, MOL PHARMACOL, V46, P890; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; REED JC, 1995, HEMATOL ONCOL CLIN N, V9, P451, DOI 10.1016/S0889-8588(18)30104-7; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SHEN DW, 1986, J BIOL CHEM, V261, P7762; SKLADANOWSKI A, 1993, BIOCHEM PHARMACOL, V46, P375, DOI 10.1016/0006-2952(93)90512-U; TISHLER RB, 1993, CANCER RES, V53, P2212; TISHLER RB, 1995, CANCER RES, V55, P6021; TSUKIDATE K, 1993, AM J PATHOL, V143, P918; UCHIUMI T, 1993, FEBS LETT, V326, P11, DOI 10.1016/0014-5793(93)81750-T; UEDA K, 1987, J BIOL CHEM, V262, P505; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; YAN MH, 1994, NATURE, V372, P798; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	37	209	215	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30950	30955		10.1074/jbc.271.48.30950	http://dx.doi.org/10.1074/jbc.271.48.30950			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940082	hybrid			2022-12-27	WOS:A1996VV15800099
J	Casimir, DA; Ntambi, JM				Casimir, DA; Ntambi, JM			cAMP activates the expression of stearoyl-CoA desaturase gene 1 during early preadipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3T3-L1 ADIPOCYTE DIFFERENTIATION; TRANSCRIPTION FACTOR; DIETARY-REGULATION; INDUCTION; BINDING; ENHANCER; ACID; CARBOXYLASE; PROMOTER; AP-2	Stearoyl-CoA desaturase gene 1 (scd1) mRNA levels were induced during the Ist day of 3T3-L1 differentiation. scd1 expression had previously been observed only in late-stage differentiation, during the period of triacylglycerol accumulation. The induction of 3T3-L1 differentiation requires treatment with insulin, dexamethasone, and an agent that increases intracellular cAMP levels, Treatment of preadipocytes with cAMP-elevating agents caused an increase in scd1 mRNA concentrations, Insulin and dexamethasone had no effect on scd1 mRNA expression in preadipocytes, The increase in mRNA resulted from transcriptional activation of the scd1 gene. 8-Bromo-cAMP treatment of differentiated adipocytes had no effect on scd1 mRNA levels, suggesting a preadipocyte-specific effect. The increase in scd1 mRNA occurred maximally after 6 h of cAMP treatment and was shown to require protein synthesis. Deletion and mutagenesis analyses have localized the cAMP response to sequence within the first 250 base pairs of the 5'-flanking region of the scd1 gene. Treatment with phorbol ester enhanced the induction of scd1 mRNA by cAMP, suggesting the involvement of AP-2 as a mediator of the cAMP response. The induction of scd1 expression by cAMP during early differentiation was distinct from that observed during late adipocyte development. This early expression presents a novel regulated function of scd1 during the differentiation process, independent of its lipogenic role in late adipocyte development, The induction of scd1 also introduces a role for cAMP in 3T3-L1 differentiation.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; UNIV WISCONSIN,DEPT NUTR SCI,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42825] Funding Source: Medline; NIGMS NIH HHS [T32 GM07215] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BERNLOHR DA, 1985, J BIOL CHEM, V260, P5563; Casimir DA, 1996, DIFFERENTIATION, V60, P203, DOI 10.1046/j.1432-0436.1996.6040203.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KADESCH T, 1986, MOL CELL BIOL, V6, P2593, DOI 10.1128/MCB.6.7.2593; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LOVE JD, 1985, ANAL BIOCHEM, V150, P429, DOI 10.1016/0003-2697(85)90532-9; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLER CW, 1996, IN PRESS ENDOCRINOLO; NAGAE Y, 1988, NUCLEIC ACIDS RES, V16, P10363, DOI 10.1093/nar/16.21.10363; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NTAMBI JM, 1995, PROSTAG LEUKOTR ESS, V52, P117, DOI 10.1016/0952-3278(95)90009-8; NTAMBI JM, 1995, PROG LIPID RES, V34, P139, DOI 10.1016/0163-7827(94)00010-J; NTAMBI JM, 1992, J BIOL CHEM, V267, P10925; PARK K, 1993, J BIOL CHEM, V268, P17811; PHILLIPS M, 1995, J CELL SCI, V108, P395; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SADOWSKI HB, 1992, J BIOL CHEM, V266, P4722; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; TAE HJ, 1995, J BIOL CHEM, V270, P21487, DOI 10.1074/jbc.270.37.21487; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X	30	44	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29847	29853		10.1074/jbc.271.47.29847	http://dx.doi.org/10.1074/jbc.271.47.29847			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939924	hybrid			2022-12-27	WOS:A1996VU52500052
J	Coletta, M; Ascenzi, P; DAvino, R; diPrisco, G				Coletta, M; Ascenzi, P; DAvino, R; diPrisco, G			Proton-linked subunit kinetic heterogeneity for carbon monoxide binding to hemoglobin from Chelidonichthys kumu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LASER PHOTOLYSIS; LIGAND-BINDING; T-STATE; OXYGEN; PH; DEOXYHEMOGLOBIN; REACTIVITY; MYOGLOBIN; MECHANISM; BOND	The pH dependence of CO binding kinetics to Chelidonichthys kumu hemoglobin (Hb) and human adult Hb has been investigated between pH 2.0 and 9.0 at 20 degrees C. For both Hbs, CO binding kinetics is characterized by two proton linked transitions, with different pK(a) values for alpha- and beta-chains in C. kumu Hb, leading to a relevant functional kinetic heterogeneity at most pH values, On the other hand, in human adult Hb the CO binding does not display a functional heterogeneity, Lowering the pH from 9 to 6 brings about a decrease of the CO binding rate constants, to a different extent for human adult Hb and the two chains of C. kumu Hb, Further lowering the pH from 6 to 2 induces an enhancement of CO binding rate constants, probably related to the protonation of proximal His(F8) N-epsilon atom and the cleavage (or severe weakening) of the His(F8)-Fe bond, The presence of physiological concentrations of ATP (approximate to 3 mM) affects the pH dependence of CO binding kinetics to C. kumu, Moreover, the effect of temperature (between 8 degrees C and 38 degrees C) on CO binding kinetics has been investigated in the absence of ATP at different pH values. These results allow to interpret the functional kinetic heterogeneity of C. kumu Hb on the basis of different regulatory aspects in the alpha and beta subunits, as suggested by structural considerations.	THIRD UNIV ROME,DEPT BIOL,I-00154 ROME,ITALY; INST PROT BIOCHEM & ENZYMOL,CONSIGLIO NAZL RICH,I-80125 NAPLES,ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR)	Coletta, M (corresponding author), UNIV CAMERINO,DEPT MOL CELLULAR & ANIM BIOL,VIA FILIPPO CAMERINI 2,I-62032 CAMERINO,ITALY.		Coletta, Massimo/N-9049-2015; Coletta, Massimiliano/GSN-5927-2022	COLETTA, Massimiliano/0000-0002-5489-9467				ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P2; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; Brunori M, 1975, Curr Top Cell Regul, V9, P1; CAMARDELLA L, 1992, J MOL BIOL, V224, P449, DOI 10.1016/0022-2836(92)91007-C; COLETTA M, 1992, FEBS LETT, V296, P184, DOI 10.1016/0014-5793(92)80375-Q; COLETTA M, 1985, J BIOL CHEM, V260, P4151; COLETTA M, 1988, J BIOL CHEM, V263, P18286; COLETTA M, 1993, BIOCHIM BIOPHYS ACTA, V1162, P309, DOI 10.1016/0167-4838(93)90295-3; COLETTA M, 1990, J BIOL CHEM, V265, P4828; Eyring H, 1935, J CHEM PHYS, V3, P107, DOI 10.1063/1.1749604; FAGO A, 1993, EUR J BIOCHEM, V218, P829, DOI 10.1111/j.1432-1033.1993.tb18438.x; GIARDINA B, 1978, BIOCHEM J, V175, P407, DOI 10.1042/bj1750407; HO C, 1987, BIOCHEMISTRY-US, V26, P6299, DOI 10.1021/bi00394a001; HO C, 1992, ADV PROTEIN CHEM, V43, P153, DOI 10.1016/S0065-3233(08)60555-0; IKEDASAITO M, 1980, J MOL BIOL, V138, P845, DOI 10.1016/0022-2836(80)90068-6; ITO N, 1995, J MOL BIOL, V250, P648, DOI 10.1006/jmbi.1995.0405; KNUTH A, 1979, ACTA HAEMATOL-BASEL, V61, P121, DOI 10.1159/000207643; MARDEN MC, 1988, BIOCHEMISTRY-US, V27, P1659, DOI 10.1021/bi00405a041; MATHEWS AJ, 1989, J BIOL CHEM, V264, P16573; MATTHEW JB, 1979, BIOCHEMISTRY-US, V18, P1919, DOI 10.1021/bi00577a011; MIYAJI R, 1966, CLIN CHIM ACTA, V14, P624; NOBLE RW, 1970, J BIOL CHEM, V245, P6628; OLSON JS, 1971, J BIOL CHEM, V246, P5919; PERUTZ MF, 1990, ANNU REV PHYSIOL, V52, P1; PERUTZ MF, 1979, ANNU REV BIOCHEM, V48, P327, DOI 10.1146/annurev.bi.48.070179.001551; PHILO JS, 1990, J BIOL CHEM, V265, P139; Riggs A., 1981, Methods in Enzymology, V76, P5; SAFFRAN WA, 1978, J BIOL CHEM, V253, P3171; SAWICKI CA, 1977, J BIOL CHEM, V252, P7538; SAWICKI CA, 1976, J BIOL CHEM, V251, P1533; SMERDON SJ, 1993, BIOCHEMISTRY-US, V32, P5132, DOI 10.1021/bi00070a023	31	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29859	29864		10.1074/jbc.271.47.29859	http://dx.doi.org/10.1074/jbc.271.47.29859			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939926	hybrid			2022-12-27	WOS:A1996VU52500054
J	Fuentes, GM; Palaniappan, C; Fay, PJ; Bambara, RA				Fuentes, GM; Palaniappan, C; Fay, PJ; Bambara, RA			Strand displacement synthesis in the central polypurine tract region of HIV-1 promotes DNA to DNA strand transfer recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE-TRANSCRIPTASE; VIRUS; GENOMES; RNA	Two distinct plus strand initiation sites have been identified in human immunodeficiency virus (HN), the central polypurine tract (cPPT) and the polypurine tract located just upstream of the U3 region (US-PPT), When synthesis from the U3-PPT reaches the cPPT, the elongating primer causes limited strand displacement of the product created from the cPPT, We examined whether reverse transcriptase (RT) catalyzed strand transfer recombination is promoted by this process. Using a substrate having the viral sequence of the displaced region, we measured transfer of an elongating DNA primer from a donor DNA to an acceptor DNA, Strand transfer synthesis was only efficient when RT was performing strand displacement synthesis, Transfer efficiency was directly related to acceptor concentration but independent of the reaction time. Transfer could occur to accepters containing 80, 40, or 20 nucle otides of homology with the template DNA. Using different accepters, we found that DNA to DNA transfer occurred at positions throughout the donor template, except near the 5' end. This shows that a number of the sequences downstream of the cPPT region can promote transfer, but once synthesis has progressed to the point where the downstream segment is completely displaced transfer is not allowed, When the DNA to DNA transfer reactions were performed using a template containing nonviral sequences, the transfer efficiency dropped significantly. This indicates that transfer efficiency is determined by the sequences of the templates used, HIV-RT RNase H-dependent strand transfer between RNA templates is well documented. We propose a quite different mechanism for DNA to DNA transfer, consistent with the ability of RNase H minus RT to perform this reaction, If these DNA to DNA transfer events occur in vivo, they will result in plus strand recombination.	UNIV ROCHESTER,SCH MED & DENT,DEPT MICROBIOL & IMMUNOL,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT MED,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,CTR CANC,ROCHESTER,NY 14642	University of Rochester; University of Rochester; University of Rochester; University of Rochester					NCI NIH HHS [CA11198] Funding Source: Medline; NIGMS NIH HHS [GM 49573, 1F 31 GM 17200-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573, F31GM017200] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHARNEAU P, 1991, J VIROL, V65, P2415, DOI 10.1128/JVI.65.5.2415-2421.1991; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; Fuentes GM, 1996, J BIOL CHEM, V271, P1966, DOI 10.1074/jbc.271.4.2063; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; JUNGHANS RP, 1982, J VIROL, V43, P544, DOI 10.1128/JVI.43.2.544-554.1982; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; LeGrice SFJ, 1995, METHOD ENZYMOL, V262, P130, DOI 10.1016/0076-6879(95)62015-X; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; SKALKA AM, 1983, J CELL BIOL, V294, P75; WHITCOMB JM, 1992, ANNU REV CELL BIOL, V8, P275, DOI 10.1146/annurev.cb.08.110192.001423	18	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29605	29611		10.1074/jbc.271.47.29605	http://dx.doi.org/10.1074/jbc.271.47.29605			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939890	hybrid			2022-12-27	WOS:A1996VU52500018
J	Liu, J; Barry, CE; Besra, GS; Nikaido, H				Liu, J; Barry, CE; Besra, GS; Nikaido, H			Mycolic acid structure determines the fluidity of the mycobacterial cell wall	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBERCULOSIS; IDENTIFICATION; PERMEABILITY; BIOSYNTHESIS; RESISTANT; SMEGMATIS; CHELONAE	The low permeability of the mycobacterial cell wall is thought to contribute to the well known resistance of mycobacteria to antibiotics and chemotherapeutic agents, We have used differential scanning calorimetry to demonstrate that the high temperature phase transition observed in purified cell walls, usually in the 60-70 degrees C range, suggestive of a lipid environment of extremely low fluidity, can also be observed in whole organisms and in cell walls from which much of the free lipids was removed by extraction with Triton X-114, A survey of seven mycobacterial species demonstrated that this high temperature transition was a general property of these organisms, Cell walls isolated from two Corynebacterium species, which contain much shorter corynemycolic acids, displayed a much lower temperature transition, suggesting that the transition temperature was directly correlated to the length of mycolic acid. Methyl esters of mycolic acids were found to have a phase transition temperature that was linearly related to the amount of fl ans-mycolate. Both Mycobacterium avium and M. smegmatis responded to increasing growth temperature by increasing the proportion of trans-mycolate and displaying a correspondingly higher melting temperature, Whole cells of M. smegmatis grown at higher temperature allowed a less rapid influx of two lipophilic agents, norfloxacin and chenodeoxycholate. These results provide strong evidence that the nature of mycolic acid plays a crucial role in determining the fluidity and permeability of mycobacterial cell wall.	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720; NIAID,ROCKY MT LABS,TB RES UNIT,HAMILTON,MT 59840; COLORADO STATE UNIV,DEPT MICROBIOL,FT COLLINS,CO 80523	University of California System; University of California Berkeley; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Colorado State University			Barry, III, Clifton/H-3839-2012; Liu, Jun/AAC-9209-2019; Barry, Clifton E/ABE-7992-2020	Barry, III, Clifton/0000-0002-2927-270X; Liu, Jun/0000-0002-0522-6733; Barry, Clifton E/0000-0002-2927-270X; Besra, Gurdyal/0000-0002-5605-0395	Intramural NIH HHS [Z01 AI000783-11] Funding Source: Medline; NIAID NIH HHS [AI-18357, AI-09644, AI-33702] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033702, R37AI009644, R22AI018357, R37AI018357, R01AI009644, R01AI018357] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABA T, 1989, J BIOCHEM-TOKYO, V106, P81, DOI 10.1093/oxfordjournals.jbchem.a122825; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; BRENNAN PJ, 1989, REV INFECT DIS, V11, pS420; Dewa T, 1996, J AM CHEM SOC, V118, P3435, DOI 10.1021/ja953905z; Dobson G., 1985, CHEM METHODS BACTERI, P237; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; GALEY WR, 1973, J GEN PHYSIOL, V61, P727, DOI 10.1085/jgp.61.6.727; GEORGE KM, 1995, J BIOL CHEM, V270, P27292, DOI 10.1074/jbc.270.45.27292; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; HAMID ME, 1993, J GEN MICROBIOL, V139, P2203, DOI 10.1099/00221287-139-9-2203; JARLIER V, 1990, J BACTERIOL, V172, P1418, DOI 10.1128/jb.172.3.1418-1423.1990; JARLIER V, 1994, FEMS MICROBIOL LETT, V123, P1; KANEDA K, 1995, MICROBIOL IMMUNOL, V39, P563, DOI 10.1111/j.1348-0421.1995.tb02243.x; KANEDA K, 1988, J GEN MICROBIOL, V134, P2213; Lewis R.N.A.H., 1991, STRUCTURE BIOL MEMBR, P73; Liu J, 1996, J BACTERIOL, V178, P3791, DOI 10.1128/jb.178.13.3791-3795.1996; LIU J, 1995, P NATL ACAD SCI USA, V92, P11254, DOI 10.1073/pnas.92.24.11254; LUTTON ES, 1967, FATTY ACIDS THEIR 4, P2588; Minnikin D. E., 1980, MICROBIOLOGICAL CLAS, P189; Minnikin D. E., 1988, BACTERIAL CELL SURFA, P125; MINNIKIN DE, 1982, BIOL MYCOBACTERIA, V1, P95; NIKAIDO H, 1993, MOL MICROBIOL, V8, P1025, DOI 10.1111/j.1365-2958.1993.tb01647.x; Nikaido H., 1990, MEMBRANE TRANSPORT I, P165; SNYDER F, 1959, BIOCHIM BIOPHYS ACTA, V34, P244; TAKAYAMA K, 1978, AM REV RESPIR DIS, V118, P113; TORIYAMA S, 1978, FEBS LETT, V95, P111, DOI 10.1016/0014-5793(78)80063-5; TRIAS J, 1994, MOL MICROBIOL, V14, P283, DOI 10.1111/j.1365-2958.1994.tb01289.x; TRIAS J, 1992, SCIENCE, V258, P1479, DOI 10.1126/science.1279810; YUAN Y, 1995, P NATL ACAD SCI USA, V92, P6630, DOI 10.1073/pnas.92.14.6630	30	220	232	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29545	29551		10.1074/jbc.271.47.29545	http://dx.doi.org/10.1074/jbc.271.47.29545			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939881	hybrid			2022-12-27	WOS:A1996VU52500009
J	Powers, C; Krutzsch, H; Gardner, K				Powers, C; Krutzsch, H; Gardner, K			Modulation of JunD center dot AP-1 DNA binding activity by AP-1-associated factor 1 (AF-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TRANSACTIVATOR TAX; TRANSCRIPTION FACTORS; SIGNALING PATHWAY; GENE FAMILY; FOS GENE; T-CELLS; JUN; AP-1; PROTEIN; PHOSPHORYLATION	AP-1-associated factor 1 (AF-1), is a novel protein complex that dramatically enhances the assembly of JunD-containing dimers onto AP-1 consensus sites. We describe the partial purification of AF-1 from nuclear extracts of the T-cell line MLA 144 by ionic, hydrophobic and gel filtration chromatography. AF-1 is a DNA-binding protein composed of low molecular mass polypeptides of 7-17 kDa that exists in solution as a 34-kDa complex. JunD interactions with DNA are accelerated in the presence of AF-1 through the formation of a true tri-molecular complex with JunD dimers and DNA that assembles much more rapidly on DNA than JunD alone. DNA binding analysis of AF-1 interaction with JunD . AP-1 and DNA shows that AF-1 increases the DNA binding affinity of JunD for AP-1 sites over 100-fold. DNA cleavage footprint analysis of isolated AF-1 . JunD DNA complexes shows that the ternary complex makes nearly twice as many contacts with DNA than JunD dimers alone. AF-1 interacts readily, but differentially with Jun homodimers and Jun . Fos heterodimers. These findings distinguish AF-1 as a significant protein-specific modulator of AP-1 . JunD in T-cells.	NCI,PATHOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Powers, Ciaran/E-3890-2011					ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P7298; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; AVOTS A, 1995, IMMUNOBIOLOGY, V193, P254, DOI 10.1016/S0171-2985(11)80551-6; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BUSCH SJ, 1990, ONCOGENE, V5, P1549; CLIPSTONE NA, 1994, J BIOL CHEM, V269, P26431; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; GARDNER K, 1994, J BIOL CHEM, V269, P32963; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LIN A, 1993, ADV SEC MESS PHOSPH, V28, P255; LOEWENSTEIN YL, 1995, J VIROL, V69, P3017; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MCKNIGHT SL, 1991, SCI AM, V264, P54, DOI 10.1038/scientificamerican0491-54; MONTECLARO FS, 1993, P NATL ACAD SCI USA, V90, P6726, DOI 10.1073/pnas.90.14.6726; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; QUINN JP, 1989, MOL CELL BIOL, V9, P4713, DOI 10.1128/MCB.9.11.4713; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; ULLMAN KS, 1993, GENE DEV, V7, P188, DOI 10.1101/gad.7.2.188; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	34	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30089	30095		10.1074/jbc.271.47.30089	http://dx.doi.org/10.1074/jbc.271.47.30089			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939957	hybrid			2022-12-27	WOS:A1996VU52500085
J	Konstantopoulos, N; Clark, S				Konstantopoulos, N; Clark, S			Reduced cell attachment and phosphorylation of focal adhesion kinase associated with expression of a mutant insulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; ACTIN STRESS FIBERS; SWISS 3T3 CELLS; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; INDUCED ACTIVATION; CROSS-TALK; PAXILLIN; BINDING	Insulin signaling results in rapid changes to the cell cytoskeleton, and it has recently been shown that insulin stimulates the dephosphorylation of the cytoskeletal-associated tyrosine kinase, focal adhesion kinase (pp125(FAK)). We report here that mutation of two tryptic cleavage sites (Lys(164) and Lys(582) --> Asn; 2N) in the insulin receptor alpha-subunit results in a cell-line (CHO.2N-10) with altered morphology associated with an increase in cell size, a decrease in cell adhesiveness, and a decrease in pp125(FAK) tyrosine phosphorylation in the absence of insulin (45.2 +/- 9.7% compared to nontransfected Chinese hamster ovary (CHO) cells). In contrast to pp125(FAK) paxillin phosphorylation was similar in all cell Lines despite lower levels (61.0 +/- 10.4% compared to CHO cells) of paxillin protein in CHO.2N-10 cells. We observed comparable protein levels of pp125(FAK) and the structural focal adhesion protein, vinculin, in all cell Lines. Despite underphosphorylation of pp125(FAK) in the basal state, insulin stimulation of CHO.2N-10 cells still resulted in dephosphorylation of pp125(FAK). CHO.2N-10 and CHO.T (overexpress wild-type insulin receptor) cells have similar insulin binding characteristics, insulin-stimulated autokinase and peptide phosphorylation, and insulin-stimulated pp185/IRS-1 phosphorylation. Our results suggest that the insulin receptor may play an important role in cell-matrix interactions, such as modulating cell adhesion and inducing cell architecture changes.	DEAKIN UNIV,INST HUMAN NUTR,MALVERN,VIC 3144,AUSTRALIA; UNIV MELBOURNE,PO ROYAL MELBOURNE HOSP,DEPT MED,PARKVILLE,VIC 3050,AUSTRALIA	Deakin University; Royal Melbourne Hospital; University of Melbourne								AHMAD F, 1995, J BIOL CHEM, V270, P20503, DOI 10.1074/jbc.270.35.20503; BARON V, 1992, J BIOL CHEM, V267, P23290; BAUER JS, 1993, J CELL BIOL, V122, P209, DOI 10.1083/jcb.122.1.209; BENNETT PA, 1993, J CELL SCI, V106, P891; BERGMAN M, 1995, MOL CELL BIOL, V15, P711; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN HC, 1994, J BIOL CHEM, V269, P31229; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK S, 1991, BIOCHEM J, V276, P27, DOI 10.1042/bj2760027; Clark S, 1990, Methods Mol Biol, V5, P559, DOI 10.1385/0-89603-150-0:559; CLARK S, 1993, BIOCHEM J, V292, P217, DOI 10.1042/bj2920217; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GILMORE AP, 1995, NATURE, V373, P197, DOI 10.1038/373197a0; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KNIGHT JB, 1995, J BIOL CHEM, V270, P10199, DOI 10.1074/jbc.270.17.10199; Konstantopoulos N, 1996, BIOCHEM J, V314, P387, DOI 10.1042/bj3140387; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P24328; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; Li PM, 1996, J CELL BIOCHEM, V61, P31, DOI 10.1002/(SICI)1097-4644(19960401)61:1<31::AID-JCB5>3.0.CO;2-3; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES CD, 1995, J CELL SCI, V108, P225; Paz K, 1996, J BIOL CHEM, V271, P6998, DOI 10.1074/jbc.271.12.6998; PILLAY TS, 1995, J BIOL CHEM, V270, P991, DOI 10.1074/jbc.270.3.991; RANKIN S, 1994, J BIOL CHEM, V269, P704; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SEGER R, 1994, J BIOL CHEM, V269, P25699; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; Ugi S, 1996, J BIOL CHEM, V271, P12595, DOI 10.1074/jbc.271.21.12595; UGI S, 1994, FEBS LETT, V340, P216, DOI 10.1016/0014-5793(94)80141-X; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	54	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28960	28968		10.1074/jbc.271.46.28960	http://dx.doi.org/10.1074/jbc.271.46.28960			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910546	hybrid			2022-12-27	WOS:A1996VT05200038
J	Ohno, H; Fournier, MC; Poy, G; Bonifacino, JS				Ohno, H; Fournier, MC; Poy, G; Bonifacino, JS			Structural determinants of interaction of tyrosine-based sorting signals with the adaptor medium chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; TRANSFERRIN RECEPTOR INTERNALIZATION; CYTOPLASMIC DOMAIN; PLASMA-MEMBRANE; COATED PITS; COMPLEX AP-2; AMINO-ACID; CLATHRIN; PROTEINS; ENDOCYTOSIS	Many integral membrane proteins contain tyrosine-based signals within their cytoplasmic domains that mediate internalization from the cell surface and targeting to lysosomal compartments. internalization depends on an interaction of the tyrosine-based signals with the clathrin-associated adaptor complex AP-2 at the plasma membrane, whereas lysosomal targeting involves interaction of the signals with an analogous complex, AP-1, at the trans-Golgi network. Recent studies have identified the medium chains mu(2) of AP-2 and mu(1) of AP-1 as the recognition molecules for tyrosine-based signals. We have now investigated the structural determinants for interaction of the signals with mu(2) and mu(1). The position of the signals was found to be an important determinant of interactions with mu(2) and mu(1); signals were most effective when present at the carboxyl terminus of a polypeptide sequence. Another important determinant of interactions was the identity of residues surrounding the critical tyrosine residue. Mutation of some residues affected interactions with mu(2) and mu(1) similarly, whereas other mutations had differential effects. These observations suggest that both the position and the exact sequence of tyrosine-based sorting signals are major determinants of selectivity in their interaction with clathrin-associated adaptor complexes.	NICHHD,CELL BIOL & METAB BRANCH,NIH,BETHESDA,MD 20892; NIDDK,GENET & BIOCHEM BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Ohno, Hiroshi/L-7899-2014	Ohno, Hiroshi/0000-0001-8776-9661; Bonifacino, Juan S./0000-0002-5673-6370				BOLL W, 1995, CURR BIOL, V5, P1168, DOI 10.1016/S0960-9822(95)00233-8; BONIFACINO JS, 1996, P ASS AM PHYSIC, V4, P285; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; CHANG MP, 1993, EMBO J, V12, P2169, DOI 10.1002/j.1460-2075.1993.tb05865.x; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; FAMBROUGH DM, 1988, J CELL BIOL, V106, P61, DOI 10.1083/jcb.106.1.61; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; GILBOA L, 1995, J BIOL CHEM, V270, P7061, DOI 10.1074/jbc.270.13.7061; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HOLNESS CL, 1993, BLOOD, V81, P1607; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KIRCHHAUSEN T, 1991, J BIOL CHEM, V266, P11153; KIRCHHAUSEN T, 1993, CURR OPIN STRUC BIOL, V3, P182, DOI 10.1016/S0959-440X(05)80150-2; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LINDSTEDT R, 1995, IMMUNITY, V3, P561, DOI 10.1016/1074-7613(95)90127-2; MARKS MS, 1995, J CELL BIOL, V131, P351, DOI 10.1083/jcb.131.2.351; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; NAIM HY, 1994, J BIOL CHEM, V269, P3928; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PEVSNER J, 1994, GENE, V146, P279, DOI 10.1016/0378-1119(94)90306-9; PONNAMBALAM S, 1990, J BIOL CHEM, V265, P4814; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SOSA MA, 1993, J BIOL CHEM, V268, P12537; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; ZHOU SY, 1995, TRENDS BIOCHEM SCI, V20, P470	45	253	254	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29009	29015		10.1074/jbc.271.46.29009	http://dx.doi.org/10.1074/jbc.271.46.29009			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910552	hybrid			2022-12-27	WOS:A1996VT05200044
J	Siciliano, JC; Toutant, M; Derkinderen, P; Sasaki, T; Girault, JA				Siciliano, JC; Toutant, M; Derkinderen, P; Sasaki, T; Girault, JA			Differential regulation of proline-rich tyrosine kinase 2 cell adhesion kinase beta (PYK2/CAK beta) and pp125(FAK) by glutamate and depolarization in rat hippocampus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; MUTANT MICE; PHOSPHORYLATION; BRAIN; ACID; SYNAPTOSOMES; ASSOCIATION; INHIBITORS; 3-KINASE; SLICES	The mechanisms by which stimuli that raise cytosolic free Ca2+ concentrations in neurons can increase protein tyrosine phosphorylation are not known. Using rat hippocampal slices and cortical synaptosomes, we have examined the regulation of two highly related cytoplasmic tyrosine kinases, pp125 focal adhesion kinase (pp125(FAK)) and proline-rich tyrosine kinase 2/cell adhesion kinase beta (PYK2/CAK beta). Membrane depolarization increased tyrosine phosphorylation of PYK2/CAK beta and pp125(FAK). These effects were blocked by EGTA or by protein kinase C inhibitors (RO31-8220; GF109203X) and mimicked by ionomycin or phorbol 12-myristate 13-acetate, in the case of pp125(FAK), or their combination in the case of PYK2/CAK beta. Glutamate and specific agonists of ionotropic (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate and N-methyl-D-aspartate) or metabotropic (trans-1-aminocyclopentane-1,3,-dicarboxylate) glutamate receptors stimulated the phosphorylation of pp125(FAK), but not of PYK2/CAK beta. Glutamate effects were prevented by GF109203X. Thus, in hippocampal slices, tyrosine phosphorylation of pp125(FAK) and PYK2/CARP are regulated differentially by pathways involving Ca2+ and protein kinase C. pp125(FAK) and PYK2/CAK beta may provide specific links between neuronal activity, increases in cytosolic Ca2+ and protein tyrosine phosphorylation, which may be important for neuronal survival, and synaptic plasticity.	COLL FRANCE,INSERM,CHAIRE NEUROPHARMACOL,U114,F-75231 PARIS 05,FRANCE; FAC MED,DEPT HISTOL,MONTEVIDEO 11800,URUGUAY; SAPPORO MED UNIV,CANC RES INST,DEPT BIOCHEM,SAPPORO,HOKKAIDO 060,JAPAN	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universidad de la Republica, Uruguay; Sapporo Medical University			Girault, Jean-Antoine/F-7518-2013; Derkinderen, Pascal/K-2393-2015	Girault, Jean-Antoine/0000-0002-7900-1705; Siciliano, Julio/0000-0002-9731-2945				AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BENGISGARBER C, 1995, CELL SIGNAL, V7, P721, DOI 10.1016/0898-6568(95)00040-V; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Boxall AR, 1996, NEURON, V16, P805, DOI 10.1016/S0896-6273(00)80100-2; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BURGAYA F, 1995, EUR J NEUROSCI, V7, P1810, DOI 10.1111/j.1460-9568.1995.tb00700.x; Burgaya F, 1996, MOL BRAIN RES, V37, P63, DOI 10.1016/0169-328X(95)00273-U; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Derkinderen P, 1996, SCIENCE, V273, P1719, DOI 10.1126/science.273.5282.1719; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; GIRAULT JA, 1990, J NEUROSCI, V10, P1124; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GRANT SGN, 1995, GENE DEV, V9, P1909, DOI 10.1101/gad.9.15.1909; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HAMMERSTAD JP, 1972, BRAIN RES, V47, P401, DOI 10.1016/0006-8993(72)90648-8; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Herzog H, 1996, GENOMICS, V32, P484, DOI 10.1006/geno.1996.0149; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MALENKA RC, 1994, CELL, V78, P535, DOI 10.1016/0092-8674(94)90517-7; Menegoz M, 1995, NEUROREPORT, V7, P125, DOI 10.1097/00001756-199512290-00030; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHOEPP D, 1990, TRENDS PHARMACOL SCI, V11, P508, DOI 10.1016/0165-6147(90)90052-A; SICILIANO JC, 1994, J NEUROCHEM, V62, P950; SICILIANO JC, 1992, NEUROPROTOCOLS, V1, P185; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stemmer P, 1991, Curr Opin Neurobiol, V1, P53, DOI 10.1016/0959-4388(91)90010-5; TANAKA C, 1994, ANNU REV NEUROSCI, V17, P551, DOI 10.1146/annurev.ne.17.030194.003003; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WOODROW S, 1992, J NEUROCHEM, V59, P857, DOI 10.1111/j.1471-4159.1992.tb08323.x; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	38	129	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28942	28946		10.1074/jbc.271.46.28942	http://dx.doi.org/10.1074/jbc.271.46.28942			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910543				2022-12-27	WOS:A1996VT05200035
J	Smulders, RHPH; Carver, JA; Lindner, RA; vanBoekel, MAM; Bloemendal, H; deJong, WW				Smulders, RHPH; Carver, JA; Lindner, RA; vanBoekel, MAM; Bloemendal, H; deJong, WW			Immobilization of the C-terminal extension of bovine alpha A-crystallin reduces chaperone-like activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; B-CRYSTALLIN; QUATERNARY STRUCTURE; NONLENTICULAR TISSUES; H-1-NMR SPECTROSCOPY; LENS CRYSTALLINS; NMR-SPECTROSCOPY; IDENTIFICATION; EXPRESSION; DISEASE	alpha-Crystallins occur as multimeric complexes, which are able to suppress precipitation of unfolding proteins. Although the mechanism of this chaperone-like activity is unknown, the affinity of alpha-crystallin for aggregation-prone proteins is probably based on hydrophobic interactions. alpha-Crystallins expose a considerable hydrophobic surface to solution, but nevertheless they are very stable and highly soluble. An explanation for this paradox may be that alpha-crystallin subunits have a polar and unstructured C-terminal extension that functions as a sort of solubilizer. In this paper we have described five alpha A-crystallins in which charged and hydrophobic residues were inserted in the C-terminal extension. Introduction of lysine, arginine, and aspartate does not substantially influence chaperone-like activity. In contrast, introduction of a hydrophobic tryptophan greatly diminishes functional activity. CD experiments indicate that this mutant has a normal secondary structure and fluorescence measurements show that the inserted tryptophan is located in a polar environment. However, NMR spectroscopy clearly demonstrates that the presence of the tryptophan residue dramatically reduces the flexibility of the C-terminal extension. Furthermore, the introduction of this tryptophan results in a considerably decreased thermostability of the protein. We conclude that changing the polarity of the C-terminal extension of alpha A-crystallin by insertion of a highly hydrophobic residue can seriously disturb structural and functional integrity.	UNIV NIJMEGEN,DEPT BIOCHEM,NL-6500 HB NIJMEGEN,NETHERLANDS; UNIV WOLLONGONG,DEPT CHEM,WOLLONGONG,NSW 2522,AUSTRALIA	Radboud University Nijmegen; University of Wollongong			Carver, John Adrian/J-3825-2014	Carver, John Adrian/0000-0002-2441-8108	NEI NIH HHS [EY09683] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009683] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BINDELS JG, 1979, OPHTHALMIC RES, V11, P711; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARVER JA, 1992, FEBS LETT, V311, P143, DOI 10.1016/0014-5793(92)81386-Z; CARVER JA, 1995, FEBS LETT, V369, P305, DOI 10.1016/0014-5793(95)00770-A; CARVER JA, 1995, BBA-PROTEIN STRUCT M, V1252, P251, DOI 10.1016/0167-4838(95)00146-L; CARVER JA, 1993, BIOCHIM BIOPHYS ACTA, V1164, P22, DOI 10.1016/0167-4838(93)90107-3; CARVER JA, 1994, EXP EYE RES, V59, P231, DOI 10.1006/exer.1994.1101; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; CHIESI M, 1990, MOL CELL BIOCHEM, V97, P129; CREIGHTON TE, 1993, PROTEINS STRUCTURE M, P270; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; DEJONG WW, 1994, PROG RETIN EYE RES, V13, P391, DOI 10.1016/1350-9462(94)90018-3; DERETIC D, 1994, J BIOL CHEM, V269, P16853; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; GROOTJANS JJ, 1995, J BIOL CHEM, V270, P22855, DOI 10.1074/jbc.270.39.22855; HENDRIKS W, 1988, EUR J BIOCHEM, V174, P133, DOI 10.1111/j.1432-1033.1988.tb14072.x; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1993, AM J PATHOL, V143, P487; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JAKOB U, 1993, J BIOL CHEM, V268, P1517; JEENER J, 1979, J CHEM PHYS, V48, P286; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; KELLEY MJ, 1993, J BIOL CHEM, V268, P18844; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LeBreton ER, 1996, INT J PEPT PROT RES, V47, P9; LOWE J, 1992, J PATHOL, V166, P61, DOI 10.1002/path.1711660110; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; MERCK KB, 1993, J BIOL CHEM, V268, P1046; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RAMAN B, 1995, FEBS LETT, V365, P133, DOI 10.1016/0014-5793(95)00440-K; RAMAN B, 1994, J BIOL CHEM, V269, P27264; RENKAWEK K, 1994, ACTA NEUROPATHOL, V87, P155, DOI 10.1007/BF00296185; SIEZEN RJ, 1983, BIOCHIM BIOPHYS ACTA, V748, P56, DOI 10.1016/0167-4838(83)90027-4; SINGH K, 1995, FEBS LETT, V372, P283, DOI 10.1016/0014-5793(95)00980-N; SMULDERS RHP, 1995, EUR J BIOCHEM, V232, P854; SMULDERS RHPH, 1995, J BIOL CHEM, V270, P13916, DOI 10.1074/jbc.270.23.13916; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUREWICZ WK, 1995, BIOCHEMISTRY-US, V34, P9655, DOI 10.1021/bi00030a001; TAKEMOTO L, 1994, EXP EYE RES, V59, P239, DOI 10.1006/exer.1994.1103; TARDIEU A, 1986, J MOL BIOL, V192, P711, DOI 10.1016/0022-2836(86)90023-9; VANDENIJSSEL PRLA, 1994, FEBS LETT, V355, P54, DOI 10.1016/0014-5793(94)01175-3; VANDENOETELAAR PJM, 1989, BIOCHIM BIOPHYS ACTA, V995, P91, DOI 10.1016/0167-4838(89)90238-0; VANNOORT JM, 1995, NATURE, V375, P798, DOI 10.1038/375798a0; VOORTER CEM, 1986, EUR J BIOCHEM, V160, P203; VOORTER CEM, 1992, FEBS LETT, V309, P111, DOI 10.1016/0014-5793(92)81075-W; WALSH MT, 1991, J BIOL CHEM, V266, P20079; WANG KY, 1994, J BIOL CHEM, V269, P13601; WISTOW G, 1985, FEBS LETT, V181, P1, DOI 10.1016/0014-5793(85)81102-9; WISTOW G, 1993, EXP EYE RES, V56, P729, DOI 10.1006/exer.1993.1090; Wuthrich K, 1986, NMR PROTEINS NUCL AC	60	117	118	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29060	29066		10.1074/jbc.271.46.29060	http://dx.doi.org/10.1074/jbc.271.46.29060			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910559	hybrid, Green Published			2022-12-27	WOS:A1996VT05200051
J	Khoo, KH; Douglas, E; Azadi, P; Inamine, JM; Besra, GS; Mikusova, K; Brennan, PJ; Chatterjee, D				Khoo, KH; Douglas, E; Azadi, P; Inamine, JM; Besra, GS; Mikusova, K; Brennan, PJ; Chatterjee, D			Truncated structural variants of lipoarabinomannan in ethambutol drug-resistant strains of Mycobacterium smegmatis - Inhibition of arabinan biosynthesis by ethambutol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOMBARDMENT MASS-SPECTROMETRY; CELL-WALL; NONREDUCING TERMINI; MYCOLIC ACID; BOVIS BCG; TUBERCULOSIS; ARABINOGALACTAN; MACROPHAGES; FEATURES; BIOGENESIS	The anti-tuberculosis drug, ethambutol (Emb), was previously shown to inhibit the synthesis of arabinans of both the cell wall arabinogalactan (AG) and lipoarabinomannan (LAM) of Mycobacterium tuberculosis and other mycobacteria. However, an Emb-resistant mutant, isolated by consecutive passage of the Mycobacterium smegmatis parent strain in media containing increasing concentrations of Emb, while synthesizing a normal version of AG, produced truncated forms of LAM when maintained on 10 mu g/ml Emb (Mikusova, K., Slayden, R. A., Besra, G. S., and Brennan, P. J. (1995) Antimicrob. Agents Chemother. 39, 2482-2489). We have now isolated and characterized the truncated LAMs made by both the resistant mutant and a recombinant strain transfected with a plasmid containing the emb region from Mycobacterium avium which encodes for Emb resistance. By chemical analysis, endoarabinanase digestion, high pH anion exchange chromatography, and mass spectrometry analyses, truncation was demonstrated as primarily a consequence of selective and partial inhibition of the synthesis of the linear arabinan terminal motif, which constitutes a substantial portion of the arabinan termini in LAM but not of AG. However, at higher concentrations, Emb also affected the general biosynthesis of arabinan destined for both AG and LAM, resulting in severely truncated LAM as well as AG with a reduced Ara:Gal ratio. The results suggested that Emb exerts its antimycobacterial effect by inhibiting an array of arabinosyltransferases involved in the biosynthesis of arabinans unique to the mycobacterial cell wall. It was further concluded that the uniquely branched terminal Ara(6) motif common to both AG and LAM is an essential structural entity for a functional cell wall and, consequently, that the biosynthetic machinery responsible for its synthesis is the effective target of Emb in its role as a potent anti-tuberculosis drug.	COLORADO STATE UNIV, DEPT MICROBIOL, FT COLLINS, CO 80523 USA; UNIV GEORGIA, COMPLEX CARBOHYDRATE RES CTR, ATHENS, GA 30602 USA	Colorado State University; University System of Georgia; University of Georgia			Khoo, Kay-Hooi/E-1989-2019; Mikusova, Katarina/I-3622-2014	Khoo, Kay-Hooi/0000-0003-2906-406X; Besra, Gurdyal/0000-0002-5605-0395	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018357, U19AI038087, R01AI018357, R22AI018357] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 18357, AI 38087, AI 01185] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERSHEIM PETER, 1967, CARBOHYD RES, V5, P340, DOI 10.1016/S0008-6215(00)80510-8; BESRA GS, 1995, BIOCHEMISTRY-US, V34, P4257, DOI 10.1021/bi00013a015; Besra Gurdyal S., 1994, P285; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; CHAN J, 1991, INFECT IMMUN, V59, P1755, DOI 10.1128/IAI.59.5.1755-1761.1991; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6234; CHATTERJEE D, 1991, J BIOL CHEM, V266, P9652; CHATTERJEE D, 1993, GLYCOBIOLOGY, V3, P497, DOI 10.1093/glycob/3.5.497; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; DAFFE M, 1993, CARBOHYD RES, V249, P383, DOI 10.1016/0008-6215(93)84102-C; DELL A, 1994, METHOD ENZYMOL, V230, P108; DENG LY, 1995, ANTIMICROB AGENTS CH, V39, P694, DOI 10.1128/AAC.39.3.694; DRAPER P, 1982, BIOL MYCOBACTERIA, V1, P9; FORBES M, 1962, J BACTERIOL, V84, P1099, DOI 10.1128/JB.84.5.1099-1103.1962; HUNTER SW, 1990, J BIOL CHEM, V265, P9272; JACOBS WR, 1991, METHOD ENZYMOL, V204, P537; KAPLAN G, 1987, J IMMUNOL, V138, P3028; KHANOLKAR SR, 1989, J MED MICROBIOL, V28, P157, DOI 10.1099/00222615-28-3-157; KHOO KH, 1995, J BIOL CHEM, V270, P12380, DOI 10.1074/jbc.270.21.12380; KILBURN JO, 1981, ANTIMICROB AGENTS CH, V20, P401, DOI 10.1128/AAC.20.3.401; LEE RE, 1995, J AM CHEM SOC, V117, P11829, DOI 10.1021/ja00153a002; LEOPOLD K, 1993, ANAL BIOCHEM, V208, P57, DOI 10.1006/abio.1993.1008; MCNEIL MR, 1994, GLYCOBIOLOGY, V4, P165, DOI 10.1093/glycob/4.2.165; MCNEIL MR, 1991, RES MICROBIOL, V142, P451, DOI 10.1016/0923-2508(91)90120-Y; MIKUSOVA K, 1995, ANTIMICROB AGENTS CH, V39, P2484, DOI 10.1128/AAC.39.11.2484; MOHR MD, 1995, RAPID COMMUN MASS SP, V9, P808; PAULIN LG, 1985, ANTIMICROB AGENTS CH, V28, P157, DOI 10.1128/AAC.28.1.157; PRINZIS S, 1993, J GEN MICROBIOL, V139, P2649, DOI 10.1099/00221287-139-11-2649; SCHLESINGER LS, 1994, J IMMUNOL, V152, P4070; SIBLEY LD, 1988, INFECT IMMUN, V56, P1232, DOI 10.1128/IAI.56.5.1232-1236.1988; SILVE G, 1993, ANTIMICROB AGENTS CH, V37, P1536, DOI 10.1128/AAC.37.7.1536; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; TAKAYAMA K, 1979, ANTIMICROB AGENTS CH, V16, P240, DOI 10.1128/AAC.16.2.240; TAKAYAMA K, 1989, ANTIMICROB AGENTS CH, V33, P1493, DOI 10.1128/AAC.33.9.1493; THOMAS JP, 1961, AM REV RESPIR DIS, V83, P891; VENISSE A, 1993, J BIOL CHEM, V268, P12401; WINDER FG, 1982, BIOL MYCOBACTERIA, V1, P417; WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328	38	98	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28682	28690		10.1074/jbc.271.45.28682	http://dx.doi.org/10.1074/jbc.271.45.28682			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910503	hybrid			2022-12-27	WOS:A1996VU03300103
J	Romano, C; Yang, WL; OMalley, KL				Romano, C; Yang, WL; OMalley, KL			Metabotropic glutamate receptor 5 is a disulfide-linked dimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPLASMIC BINDING-PROTEINS; LIGAND-BINDING; SMOOTH-MUSCLE; RAT-BRAIN; BETA-2-ADRENERGIC RECEPTOR; MOLECULAR CHARACTERIZATION; AGONIST SELECTIVITY; KINASE ACTIVATION; RESPONSES; AFFINITY	The sequences of the metabotropic glutamate receptors (mGluRs) show Little homology with other members of the G protein-coupled receptor family and exhibit several distinctive features, including a large N-terminal extracellular domain with 17 cysteines in conserved positions. Here we demonstrate that MGluR5, as well as other mGluRs, behave as species approximately twice as large as expected from their sequence, but reducing conditions cause a decrease to the predicted molecular mass. Co-immunoprecipitation experiments using wild type and epitope-tagged receptors demonstrate that this is due to specific, disulfide-dependent dimerization of the receptor. The intermolecular disulfide that mediates dimerization occurs in the extracellular domain, within about 17 kDa from the N terminus.	WASHINGTON UNIV, SCH MED, DEPT VISUAL SCI, ST LOUIS, MO 63110 USA	Washington University (WUSTL)	Romano, C (corresponding author), WASHINGTON UNIV, SCH MED, DEPT OPHTHALMOL & VISUAL SCI, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA.		soler, martha maricel m gomez/L-6025-2014	soler, martha maricel m gomez/0000-0002-4412-8108	NEI NIH HHS [EY02687, EY09370] Funding Source: Medline; NIA NIH HHS [AG11355] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009370, P30EY002687] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG011355] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABE T, 1992, J BIOL CHEM, V267, P13361; ADAMS MD, 1989, J BIOL CHEM, V264, P15739; BAUDE A, 1993, NEURON, V11, P771, DOI 10.1016/0896-6273(93)90086-7; BONE EA, 1988, PEPTIDES, V9, P373, DOI 10.1016/0196-9781(88)90273-2; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CARMANKRZAN M, 1984, AGENTS ACTIONS, V14, P561; DICKENSON JM, 1994, BIOCHEM PHARMACOL, V48, P1721, DOI 10.1016/0006-2952(94)90457-X; DOHLMAN HG, 1990, BIOCHEMISTRY-US, V29, P2335, DOI 10.1021/bi00461a018; DONALDSON J, 1986, BRIT J PHARMACOL, V87, P191, DOI 10.1111/j.1476-5381.1986.tb10171.x; DONALDSON J, 1987, BRIT J PHARMACOL, V90, P263, DOI 10.1111/j.1476-5381.1987.tb16848.x; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; EATON SA, 1993, EUR J NEUROSCI, V5, P186, DOI 10.1111/j.1460-9568.1993.tb00484.x; Gioannini T L, 1989, J Mol Recognit, V2, P44, DOI 10.1002/jmr.300020107; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; ISHII T, 1993, J BIOL CHEM, V268, P2836; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KUSUI T, 1994, BIOCHEMISTRY-US, V33, P12968, DOI 10.1021/bi00248a005; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MICHALAK M, 1992, BIOCHIM BIOPHYS ACTA, V1111, P247, DOI 10.1016/0005-2736(92)90317-F; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; NODA K, 1994, J BIOL CHEM, V269, P6743; NOMURA A, 1994, CELL, V77, P361, DOI 10.1016/0092-8674(94)90151-1; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Petralia RS, 1996, NEUROSCIENCE, V71, P949, DOI 10.1016/0306-4522(95)00533-1; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; PIN JP, 1995, BIOCHEM SOC T, V23, P91, DOI 10.1042/bst0230091; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; REYNOLDS IJ, 1990, BRIT J PHARMACOL, V101, P178, DOI 10.1111/j.1476-5381.1990.tb12109.x; ROMANO C, 1995, J COMP NEUROL, V355, P455, DOI 10.1002/cne.903550310; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; Sucher N J, 1990, Neuroreport, V1, P29, DOI 10.1097/00001756-199009000-00009; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; TANG LH, 1993, J PHYSIOL-LONDON, V465, P303, DOI 10.1113/jphysiol.1993.sp019678; TERMAN BI, 1986, J BIOL CHEM, V261, P5603; VIGNES M, 1992, NEUROCHEM INT, V21, P229, DOI 10.1016/0197-0186(92)90152-H; WEI JW, 1980, N-S ARCH PHARMACOL, V314, P51, DOI 10.1007/BF00498431; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; Wisden W, 1993, Curr Opin Neurobiol, V3, P291, DOI 10.1016/0959-4388(93)90120-N	46	428	438	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28612	28616		10.1074/jbc.271.45.28612	http://dx.doi.org/10.1074/jbc.271.45.28612			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910492	hybrid			2022-12-27	WOS:A1996VU03300092
J	Aiyar, J; Rizzi, JP; Gutman, GA; Chandy, KG				Aiyar, J; Rizzi, JP; Gutman, GA; Chandy, KG			The signature sequence of voltage-gated potassium channels projects into the external vestibule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CHANNEL; CHARYBDOTOXIN BLOCK; MUTANT CYCLES; PORE; MECHANISM; TETRAETHYLAMMONIUM; CONTRIBUTE; MUTATIONS; INTERFACE; PROTEIN	A highly conserved motif, GYGD, contributes to the formation of the ion selectivity filter in voltage-gated K+ channels and is thought to interact with the scorpion toxin residue, Lys(27). By probing the pore of the Kv1.3 channel with synthetic kaliotoxin-Lys(27) mutants, each containing a non-natural lysine analog of a different length, and using mutant cycle analysis, we determined the spatial locations of Tyr(400) and Asp(402) in the GYGD moth, relative to His(404) located at the base of the outer vestibule. Our data indicate that the terminal amines of the shorter Lys(27) analogs lie close to His(404) and to Asp(402) while Lys(27) itself interacts with Tyr(400). Based on these data, we developed a molecular model of this region of the channel. The junction between the outer vestibule and the pore is defined by a ring (similar to 8-9-Angstrom diameter) formed from alternating Asp(402) and His(404) residues. Tyr(400) lies 4-6 Angstrom deeper into the pore, and its interaction with kaliotoxin-Lys(27) is in competition with K+ ions, Studies with dimeric Kv1.3 constructs suggest that two Tyr(400) residues in the tetramer are sufficient to bind K+ ions. Thus, at least part of the K+ channel signature sequence extends into a shallow trough at the center of a wide external vestibule.	UNIV CALIF IRVINE, COLL MED, DEPT MICROBIOL & MOL GENET, IRVINE, CA 92697 USA; UNIV CALIF IRVINE, COLL MED, DEPT MICROBIOL & MOL GENET, IRVINE, CA 92697 USA; AMGEN INC, BOULDER, CO 80301 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; Amgen					NIAID NIH HHS [AI24783] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024783] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIYAR J, 1994, BIOPHYS J, V67, P2261, DOI 10.1016/S0006-3495(94)80710-6; AIYAR J, 1995, NEURON, V15, P1169, DOI 10.1016/0896-6273(95)90104-3; CHANDY KG, 1995, HDB RECEPTORS CHANNE, P1; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CROSS A, 1996, NEURON, V16, P399; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; Goldstein SAN, 1996, NEURON, V16, P717, DOI 10.1016/S0896-6273(00)80092-6; GOLDSTEIN SAN, 1993, BIOPHYS J, V65, P1613, DOI 10.1016/S0006-3495(93)81200-1; GRISSMER S, 1990, P NATL ACAD SCI USA, V87, P9411, DOI 10.1073/pnas.87.23.9411; GUY HR, 1994, SOC GEN PHY, V49, P197; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; JAN LY, 1992, ANNU REV PHYSIOL, V54, P535, DOI 10.1146/annurev.physiol.54.1.535; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; KAVANAUGH MP, 1991, J BIOL CHEM, V266, P7583; KIRSCH GE, 1995, BIOPHYS J, V68, P1804, DOI 10.1016/S0006-3495(95)80357-7; KUMPF RA, 1993, SCIENCE, V261, P1708, DOI 10.1126/science.8378771; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; LOPEZ GA, 1994, NATURE, V367, P179, DOI 10.1038/367179a0; MACKINNON R, 1988, J GEN PHYSIOL, V91, P335, DOI 10.1085/jgp.91.3.335; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; Naranjo D, 1996, NEURON, V16, P123, DOI 10.1016/S0896-6273(00)80029-X; PARK CS, 1992, NEURON, V9, P307, DOI 10.1016/0896-6273(92)90169-E; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; SOREQ H, 1992, METHOD ENZYMOL, V207, P225	27	106	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31013	31016		10.1074/jbc.271.49.31013	http://dx.doi.org/10.1074/jbc.271.49.31013			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940091	hybrid			2022-12-27	WOS:A1996VW68600002
J	Lagriffoul, A; Charpentier, N; Carrette, J; Tougard, C; Bockaert, J; Homburger, V				Lagriffoul, A; Charpentier, N; Carrette, J; Tougard, C; Bockaert, J; Homburger, V			Secretion of protease nexin-1 by C6 glioma cells is under the control of a heterotrimeric G protein, G(o1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN-G(O); ANTERIOR-PITUITARY-CELLS; NEURITE-PROMOTING FACTOR; ALPHA-SUBUNIT; INHIBITORY ACTIVITY; NEURONAL CELLS; EXOCYTOSIS; BRAIN; EXPRESSION; MASTOPARAN	Heterotrimeric G(o) proteins have recently been described as regulators of vesicular traffic. The G(o) alpha gene encodes, by alternative splicing, two G(o) alpha polypeptides, G(o1)alpha and G(o2)alpha. By immunofluorescence and electron microscopy, we detected G(o1)alpha on the membrane of small intracellular vesicles in C6 glioma cells. After stable transfection of these cells, overexpression of G(o1)alpha but not G(o2)alpha was followed by a rise in the secretion of a serine protease inhibitor, protease nexin-1 (PN-1). This secretion was enhanced as a function of the amount of expressed G(o1)alpha. Metabolic cell labeling indicated that this increase in PN-1 secretion was not the result of an enhancement in PN-1 biosynthesis or a decrease in its uptake, but revealed a potential role of G(o1)alpha in the regulation of vesicular PN-1 trafficking. Furthermore,regulation of vesicular PN-1 trafficking. Furthermore, activators of G(o) proteins, mastoparan and a peptide derived from the amino terminus of the growth cone-associated protein GAP43, increased PN-1 secretion in parental and G(o1)alpha-overexpressing cells. Brefeldin A, an inhibitor of vesicular traffic, inhibited both basal and mastoparan-stimulated PN-1 secretions. These results indicate, that in C6 glioma cells, PN-1 secretion could be regulated by both G(o1)alpha expression and activation.	INSERM,CNRS UPR 9023,INSERM,CTR PHARMACOL & ENDOCRINOL,F-34095 MONTPELLIER 05,FRANCE; COLL FRANCE,CNRS URA 1115,F-75231 PARIS 5,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UDICE-French Research Universities; PSL Research University Paris; College de France								AHNERTHILGER G, 1994, EUR J CELL BIOL, V65, P26; ARIDOR M, 1993, SCIENCE, V262, P1569, DOI 10.1126/science.7504324; Barr F A, 1992, Trends Cell Biol, V2, P91, DOI 10.1016/0962-8924(92)90001-4; BIRNBAUMER L, 1995, J RECEPT SIGNAL TR R, V15, P213; BLEUEL A, 1995, J NEUROSCI RES, V42, P562, DOI 10.1002/jnr.490420414; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRABET P, 1988, J NEUROSCI, V8, P701; BRABET P, 1993, HDB EXPT PHARM, P429; BRINKLEY BR, 1967, J CELL BIOL, V35, P279, DOI 10.1083/jcb.35.1.279; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHARPENTIER N, 1993, J BIOL CHEM, V268, P8980; COON HG, 1989, P NATL ACAD SCI USA, V86, P1703, DOI 10.1073/pnas.86.5.1703; CUNNINGHAM DD, 1992, ANN NY ACAD SCI, V674, P228, DOI 10.1111/j.1749-6632.1992.tb27491.x; GARIBAY JLR, 1991, BIOCHIM BIOPHYS ACTA, V1094, P193, DOI 10.1016/0167-4889(91)90008-L; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLENN KC, 1980, J BIOL CHEM, V255, P6609; GLOOR S, 1986, CELL, V47, P687; GUENTHER J, 1985, EMBO J, V4, P1963, DOI 10.1002/j.1460-2075.1985.tb03878.x; HARRISWARRICK RM, 1988, NEURON, V1, P27, DOI 10.1016/0896-6273(88)90206-1; HELMS JB, 1995, FEBS LETT, V369, P84, DOI 10.1016/0014-5793(95)00620-O; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HOFFMANN MC, 1992, NEUROSCIENCE, V49, P397, DOI 10.1016/0306-4522(92)90105-B; HOWARD EW, 1986, J BIOL CHEM, V261, P14184; HSU WH, 1990, J BIOL CHEM, V265, P11220; JOYCEBRADY M, 1991, J BIOL CHEM, V266, P6859; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KOMATSU M, 1993, J BIOL CHEM, V268, P23297; LANG J, 1995, EMBO J, V14, P3635, DOI 10.1002/j.1460-2075.1995.tb00033.x; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; LLEDO PM, 1992, NEURON, V8, P455, DOI 10.1016/0896-6273(92)90273-G; Luini Alberto, 1993, Trends in Cell Biology, V3, P290, DOI 10.1016/0962-8924(93)90002-I; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MONARD D, 1973, P NATL ACAD SCI USA, V70, P1894, DOI 10.1073/pnas.70.6.1894; MONARD D, 1988, TRENDS NEUROSCI, V11, P541, DOI 10.1016/0166-2236(88)90182-8; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; MULLER L, 1994, MOL CELL NEUROSCI, V5, P556, DOI 10.1006/mcne.1994.1068; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; REFOLO LM, 1991, J NEUROSCI, V11, P3888; REINHARD E, 1994, J NEUROSCI RES, V37, P256, DOI 10.1002/jnr.490370211; ROUOT B, 1992, MOL PHARMACOL, V41, P273; SCHMID SL, 1995, FASEB J, V9, P1445, DOI 10.1096/fasebj.9.14.7589986; SCOTTI AL, 1994, J NEUROSCI RES, V37, P156; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; STRITTMATTER SM, 1994, J NEUROSCI, V14, P5503; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; TOUGARD C, 1986, AM J ANAT, V175, P161, DOI 10.1002/aja.1001750206; TSUKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P2974, DOI 10.1073/pnas.88.8.2974; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VANDONGEN AMJ, 1988, SCIENCE, V242, P1433, DOI 10.1126/science.3144040; VAUGHAN PJ, 1993, J BIOL CHEM, V268, P3720; VITALE N, 1994, J BIOL CHEM, V269, P30293; VITALE N, 1993, J BIOL CHEM, V268, P14715; WAGNER SL, 1989, P NATL ACAD SCI USA, V86, P8284, DOI 10.1073/pnas.86.21.8284	60	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31508	31516		10.1074/jbc.271.49.31508	http://dx.doi.org/10.1074/jbc.271.49.31508			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940166	hybrid			2022-12-27	WOS:A1996VW68600077
J	Vito, P; Wolozin, B; Ganjei, JK; Iwasaki, K; Lacana, E; DAdamio, L				Vito, P; Wolozin, B; Ganjei, JK; Iwasaki, K; Lacana, E; DAdamio, L			Requirement of the familial Alzheimer's disease gene PS2 for apoptosis - Opposing effect of ALG-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL HYBRIDOMAS; DNA FRAGMENTATION; CLONAL ELIMINATION; MISSENSE MUTATIONS; SELF-TOLERANCE; ENTEROTOXIN-B; IN-SITU; DEATH; ACTIVATION; ANTIGEN	ALG-3, a truncated mouse homologue of the chromosome I familial Alzheimer's disease gene PS2, rescues T hybridoma 3DO cells from T-cell receptor-induced apoptosis by inhibiting Fas ligand induction and Fas signaling, Here we show that ALG-3 transfected 3DO cells express a COOH-terminal PS2 polypeptide, Overexpression of PS2 in ALG-3 transfected 3DO cells reconstitutes sensitivity to receptor-induced cell death, suggesting that the artificial PS2 polypeptide functions as a dominant negative mutant of PS2, ALG-3 and antisense PS2 protect PC12 cells from glutamate-induced apoptosis but not from death induced by hydrogen peroxide or the free radical MPP(+). Thus, the PS2 gene is required for some forms of cell death in diverse cell types, and its function is opposed by ALG-3.	NIAID,T CELL MOL BIOL UNIT,CELLULAR & MOL IMMUNOL LAB,NIH,BETHESDA,MD 20892; NIMH,UNIV ALZHEIMER BIOL,CLIN SCI LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)			vito, pasquale/ABF-5505-2020	vito, pasquale/0000-0002-5721-7716; D'Adamio, Luciano/0000-0002-9820-4882; D'Adamio, Luciano/0000-0002-2204-9441				ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; CURRAN J, 1988, EMBO J, V7, P245, DOI 10.1002/j.1460-2075.1988.tb02806.x; DADAMIO L, 1993, EUR J IMMUNOL, V23, P747, DOI 10.1002/eji.1830230327; DADAMIO L, 1992, J IMMUNOL, V149, P3550; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; GSCHWIND M, 1995, J NEUROCHEM, V65, P292; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KAWABE Y, 1990, J EXP MED, V172, P1065, DOI 10.1084/jem.172.4.1065; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; KISELOW P, 1988, NATURE, V335, P730; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LASSMANN H, 1995, ACTA NEUROPATHOL, V89, P35, DOI 10.1007/BF00294257; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHI YF, 1990, J IMMUNOL, V144, P3326; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WOLOZIN B, 1996, IN PRESS SCIENCE; WOOD KA, 1993, NEURON, V11, P621, DOI 10.1016/0896-6273(93)90074-2	32	127	130	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31025	31028		10.1074/jbc.271.49.31025	http://dx.doi.org/10.1074/jbc.271.49.31025			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940094	hybrid			2022-12-27	WOS:A1996VW68600005
J	Yerushalmi, H; Lebendiker, M; Schuldiner, S				Yerushalmi, H; Lebendiker, M; Schuldiner, S			Negative dominance studies demonstrate the oligomeric structure of EmrE, a multidrug antiporter from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTOSE PERMEASE; MEMBRANE-PROTEIN; RESISTANCE; GENE; COMPLEMENTATION; BACTERIA; CARRIER; HUMANS	EmrE, the smallest known ion-coupled transporter, is an Escherichia coli 12-kDa protein 80% helical and soluble in organic solvents, EmrE is a polyspecific antiporter that exchanges hydrogen ions with aromatic toxic cations such as methyl viologen. Since it is many times smaller than the classical consensus 12 transmembrane segments transporters, it was particularly interesting to determine its oligomeric state, For this purpose, a series of nonfunctional mutants has been generated and characterized to test their effect on the activity of the wild-type protein upon mixing, As opposed to the wild type, these mutants do not confer resistance to methyl viologen, ethidium bromide, or a series of other toxicants, Co expression of each of the nonfunctional mutants with the wild-type protein results in a reduction in the ability of the functional transporter to confer resistance to several toxicants. To perform mixing experiments in vitro, all the mutants have been purified by extraction with organic solvents, reconstituted in proteoliposomes, and found to be inactive, When co-reconstituted with wild-type protein, they inhibit the activity of the latter in a dose-dependent form up to full inhibition. We assume that this inhibition is due to the formation of mixed oligomers in which the presence of one nonfunctional subunit causes full inactivation, A binomial analysis of the results based on the latter assumptions do not provide statistically significant answers but suggests that the oligomer is composed of three subunits, The results described provide the first in vitro demonstration of the functional oligomeric structure of an ion-coupled transporter.	HEBREW UNIV JERUSALEM, ALEXANDER SILBERMAN INST LIFE SCI, IL-91904 JERUSALEM, ISRAEL	Hebrew University of Jerusalem			Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237				Arkin IT, 1996, BIOCHEMISTRY-US, V35, P7233, DOI 10.1021/bi960094i; BIBI E, 1992, P NATL ACAD SCI USA, V89, P1524, DOI 10.1073/pnas.89.5.1524; CURIALE MS, 1984, J BACTERIOL, V157, P211, DOI 10.1128/JB.157.1.211-217.1984; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; GRINIUS L, 1992, PLASMID, V27, P119, DOI 10.1016/0147-619X(92)90012-Y; GRINIUS LL, 1994, J BIOL CHEM, V269, P29998; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; KABACK HR, 1992, BIOCHIM BIOPHYS ACTA, V1101, P210, DOI 10.1016/0005-2728(92)90227-S; KLINGENBERG M, 1993, J BIOENERG BIOMEMBR, V25, P447, DOI 10.1007/BF01108402; Lebendiker M, 1996, J BIOL CHEM, V271, P21193, DOI 10.1074/jbc.271.35.21193; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MIESCHENDAHL M, 1981, P NATL ACAD SCI-BIOL, V78, P7652, DOI 10.1073/pnas.78.12.7652; PAULSEN IT, 1995, J BACTERIOL, V177, P2827, DOI 10.1128/jb.177.10.2827-2833.1995; Paulsen IT, 1996, MOL MICROBIOL, V19, P1167, DOI 10.1111/j.1365-2958.1996.tb02462.x; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WANG KW, 1995, NEURON, V14, P1303, DOI 10.1016/0896-6273(95)90277-5; WRIGHT JK, 1983, FEBS LETT, V162, P11; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856	27	100	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31044	31048		10.1074/jbc.271.49.31044	http://dx.doi.org/10.1074/jbc.271.49.31044			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940098	hybrid			2022-12-27	WOS:A1996VW68600009
J	Jans, DA; Jans, P; Briggs, LJ; Sutton, V; Trapani, JA				Jans, DA; Jans, P; Briggs, LJ; Sutton, V; Trapani, JA			Nuclear transport of granzyme B (fragmentin-2) - Dependence on perforin in vivo and cytosolic factors in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTO-TOXIC LYMPHOCYTES; SV40 T-ANTIGEN; PORE-FORMING PROTEIN; NATURAL-KILLER-CELLS; II SITE FLANKING; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; DNA FRAGMENTATION; POLY(ADP-RIBOSE) POLYMERASE; NUCLEOCYTOPLASMIC TRANSPORT	Cytotoxic T and natural killer cells are able to kill their target cells through synergistic action of the pore-forming protein perforin and the serine protease granzyme B, resulting in very distinctive nuclear changes typical of apoptosis. Whereas perforin acts at the membrane, granzyme B appears to be both capable of entering the cytoplasm of target cells and accumulating in isolated nuclei, In this study we examine nuclear transport of fluoresceinated granzyme B both in vivo in intact cells in the presence of perforin and in vitro in semipermeabilized cells using confocal laser scanning microscopy. Granzyme B alone was observed to enter the cytoplasm of intact cells but did not accumulate in nuclei, In the presence of sublytic concentrations of perforin, however, it accumulated strongly in intact cell nuclei to levels maximally about 1.5 times those in the cytoplasm after about 2.5 h, In vitro nuclear transport assays showed maximal levels of nuclear and nucleolar accumulation of granzyme B of about 2.5- and 3-fold those in the cytoplasm, In contrast to signal-dependent nuclear accumulation of SV40 large tumor antigen (T-Ag) fusion proteins in vitro, nuclear/nucleolar import of granzyme B was independent of ATP and not inhibitable by the non-hydrolyzable GTP analog GTP gamma S (guanosine 5'-O-(3-thiotriphosphate)). Similar to T-Ag fusion proteins, however, granzyme B nuclear and nucleolar accumulation was dependent on exogenously added cytosol, Specific inhibitors of granzyme B protease activity had no effect on nuclear/nucleolar accumulation, implying that proteolytic activity was not essential for nuclear targeting, The results imply that granzyme B (32 kDa) may be transported from the cytoplasm to the nucleus through passive diffusion and accumulate by binding to nuclear/nucleolar factors in a cytosolic factor-mediated process, Active and passive nuclear transport properties were normal in the presence of unlabeled granzyme B, implying that the nuclear envelope and pore complex are not granzyme B substrates.	AUSTIN RES INST, CELLULAR CYTOTOX LAB, HEIDELBERG, VIC 3084, AUSTRALIA	Austin Research Institute	Jans, DA (corresponding author), AUSTRALIAN NATL UNIV, JOHN CURTIN SCH MED RES, DIV BIOCHEM & MOL BIOL, NUCL SIGNALLING LAB, POB 334, CANBERRA, ACT 2601, AUSTRALIA.		Briggs, Lyndall J/A-7549-2011	Trapani, Joseph/0000-0003-0983-1532				BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG TW, 1980, J IMMUNOL, V124, P1028; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CLEVER J, 1991, P NATL ACAD SCI USA, V88, P7333, DOI 10.1073/pnas.88.16.7333; CROUCH MF, 1991, FASEB J, V5, P200, DOI 10.1096/fasebj.5.2.1900794; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DUKE RC, 1989, J EXP MED, V170, P1451, DOI 10.1084/jem.170.4.1451; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; ELDAR H, 1992, EXP CELL RES, V202, P259, DOI 10.1016/0014-4827(92)90073-H; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; HEPLER PK, 1994, P NATL ACAD SCI USA, V91, P2176, DOI 10.1073/pnas.91.6.2176; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HUDIG D, 1991, J IMMUNOL, V147, P1360; JANS DA, 1995, J BIOL CHEM, V270, P17064, DOI 10.1074/jbc.270.29.17064; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; JANS DA, 1994, ONCOGENE, V9, P2961; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; JANS DA, 1994, FASEB J, V8, P841, DOI 10.1096/fasebj.8.11.8070633; KAUFMANN SH, 1993, CANCER RES, V53, P3976; LAMY F, 1993, J BIOL CHEM, V268, P8398; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LEACH KL, 1992, J BIOL CHEM, V267, P21816; LIU CC, 1986, J EXP MED, V164, P2061, DOI 10.1084/jem.164.6.2061; LOBE CG, 1986, P NATL ACAD SCI USA, V83, P1448, DOI 10.1073/pnas.83.5.1448; MAEDA Y, 1992, EMBO J, V11, P3695, DOI 10.1002/j.1460-2075.1992.tb05454.x; MARTIN K, 1991, CELL, V67, P117, DOI 10.1016/0092-8674(91)90576-K; MARTIN K, 1991, J VIROL, V65, P232, DOI 10.1128/JVI.65.1.232-244.1991; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; MORELAND RB, 1987, MOL CELL BIOL, V7, P4048, DOI 10.1128/MCB.7.11.4048; NAKAJIMA H, 1994, J IMMUNOL, V152, P1057; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; ORTALDO JR, 1992, J LEUKOCYTE BIOL, V52, P483, DOI 10.1002/jlb.52.5.483; PASTERNACK MS, 1991, J BIOL CHEM, V266, P14703; PEARSON D, 1991, EXP CELL RES, V192, P315, DOI 10.1016/0014-4827(91)90193-X; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; Pinkoski MJ, 1996, J BIOL CHEM, V271, P10225, DOI 10.1074/jbc.271.17.10225; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHMID J, 1987, J IMMUNOL, V139, P250; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; Schmitz M L, 1991, Trends Cell Biol, V1, P130, DOI 10.1016/0962-8924(91)90118-S; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHIVER JW, 1992, CELL, V71, P315, DOI 10.1016/0092-8674(92)90359-K; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SMYTH MJ, 1995, IMMUNOL TODAY, V16, P202, DOI 10.1016/0167-5699(95)80122-7; TRAPANI JA, 1994, J BIOL CHEM, V269, P18359; TRAPANI JA, 1993, BIOCHEM BIOPH RES CO, V195, P910, DOI 10.1006/bbrc.1993.2131; TRAPANI JA, 1988, P NATL ACAD SCI USA, V85, P6924, DOI 10.1073/pnas.85.18.6924; Trapani JA, 1996, J BIOL CHEM, V271, P4127; WALASCHEWSKI U, 1995, METHOD MOL CELL BIOL, V5, P87; Xiao CY, 1996, J BIOL CHEM, V271, P6451, DOI 10.1074/jbc.271.11.6451; XUE ZX, 1993, EUR J CELL BIOL, V62, P13; YAN C, 1993, J CELL BIOL, V123, P1081, DOI 10.1083/jcb.123.5.1081; Ymer S, 1996, BIOTECHNIQUES, V20, P834; YOUNG JD, 1986, CELL, V46, P641, DOI 10.1016/0092-8674(86)90336-3	69	94	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30781	30789		10.1074/jbc.271.48.30781	http://dx.doi.org/10.1074/jbc.271.48.30781			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940058	hybrid			2022-12-27	WOS:A1996VV15800075
J	Szapary, D; Xu, M; Simons, SS				Szapary, D; Xu, M; Simons, SS			Induction properties of a transiently transfected glucocorticoid-responsive gene vary with glucocorticoid receptor concentration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE AMINOTRANSFERASE GENE; PROTEIN-PROTEIN INTERACTIONS; HUMAN PROGESTERONE-RECEPTOR; THYROID-HORMONE RECEPTOR; HUMAN ESTROGEN-RECEPTOR; TRANSCRIPTIONAL ACTIVATION FUNCTIONS; DNA-BINDING; DEXAMETHASONE 21-MESYLATE; NUCLEAR-LOCALIZATION; STEROID-RECEPTORS	Transient transfections of steroid receptors have yielded much of the data used to construct the current models of steroid hormone action, These experiments invariably examine the ability of receptors to regulate transcription when occupied by saturating concentrations of steroid, We now report that other induction properties of a transiently transfected gene are not constant but vary with the concentration of transiently transfected glucocorticoid receptors, Thus, the percentage of maximal induction seen with subsaturating concentrations of glucocorticoid could be dramatically increased, and an antiglucocorticoid could be converted into a partial glucocorticoid, simply by increasing the concentration of glucocorticoid receptors. This behavior was observed in HeLa cells, containing endogenous receptors, or in CV-1 cells, containing almost no endogenous receptor, with either homologous or heterologous receptors, These increases were relatively insensitive to the concentration of reporter gene, suggesting the titration of some transcription factor(s) involved in regulating the position of the glucocorticoid dose-response curve and the agonist activity of an antiglucocorticoid. This property of transfected glucocorticoid receptors required a full-length, functionally active receptor but was retained, albeit reduced in magnitude, in the absence of binding to a glucocorticoid response element, Furthermore, this phenomenon was specific in that the A form of the human progesterone receptor had no effect under the same conditions, These variations in induction properties of antiglucocorticoids and of subsaturating concentrations of glucocorticoid, in a manner that was proportional to the amount of transfected receptor, reveal processes that are not operative with saturating concentrations of glucocorticoid. These variations also demonstrate that caution should be exercised in making mechanistic conclusions based solely on experiments conducted with saturating concentrations of glucocorticoid.	NIDDK, STEROID HORMONES SECT, MOL & CELLULAR BIOL LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								ALROY I, 1992, NUCLEIC ACIDS RES, V20, P1045, DOI 10.1093/nar/20.5.1045; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; BANIAHMAD C, 1995, MOL ENDOCRINOL, V9, P34, DOI 10.1210/me.9.1.34; BAUMANN H, 1993, BIOCHEMISTRY-US, V32, P13463, DOI 10.1021/bi00212a011; BECK CA, 1993, P NATL ACAD SCI USA, V90, P4441, DOI 10.1073/pnas.90.10.4441; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; CHALBOS D, 1994, J BIOL CHEM, V269, P23007; CHALEPAKIS G, 1990, DNA CELL BIOL, V9, P355, DOI 10.1089/dna.1990.9.355; DANIELSEN M, 1987, MOL ENDOCRINOL, V1, P816, DOI 10.1210/mend-1-11-816; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINKEL T, 1993, J BIOL CHEM, V268, P5; GAGNE D, 1988, J STEROID BIOCHEM, V31, P917, DOI 10.1016/0022-4731(88)90333-0; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; HOECK W, 1992, J STEROID BIOCHEM, V41, P283, DOI 10.1016/0960-0760(92)90353-K; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; ING NH, 1992, J BIOL CHEM, V267, P17617; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KASTNER P, 1990, J BIOL CHEM, V265, P12163; KAZMI SMI, 1993, ENDOCRINOLOGY, V133, P1230, DOI 10.1210/en.133.3.1230; KRALLI A, 1995, P NATL ACAD SCI USA, V92, P4701, DOI 10.1073/pnas.92.10.4701; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LANZ RB, 1994, ENDOCRINOLOGY, V135, P2183, DOI 10.1210/en.135.5.2183; LEDOUARIN B, 1995, NUCLEIC ACIDS RES, V23, P876, DOI 10.1093/nar/23.5.876; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MCDONNELL DP, 1992, P NATL ACAD SCI USA, V89, P10563, DOI 10.1073/pnas.89.22.10563; MCDONNELL DP, 1994, J STEROID BIOCHEM, V48, P425, DOI 10.1016/0960-0760(94)90190-2; MCEWAN IJ, 1993, MOL CELL BIOL, V13, P399, DOI 10.1128/MCB.13.1.399; MIESFELD R, 1987, SCIENCE, V236, P423, DOI 10.1126/science.3563519; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; NORDEEN SK, 1993, MOL ENDOCRINOL, V7, P731, DOI 10.1210/me.7.6.731; OSHIMA H, 1993, J BIOL CHEM, V268, P26858; OSHIMA H, 1992, MOL ENDOCRINOL, V6, P416, DOI 10.1210/me.6.3.416; OSHIMA H, 1992, ENDOCRINOLOGY, V130, P2106, DOI 10.1210/en.130.4.2106; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; SARTORIUS CA, 1993, J BIOL CHEM, V268, P9262; SIMONS SS, 1987, J BIOL CHEM, V262, P9676; SIMONS SS, 1994, VITAM HORM, V49, P49; SIMONS SS, 1992, MOL ENDOCRINOL, V6, P995, DOI 10.1210/me.6.7.995; SIMONS SS, 1981, P NATL ACAD SCI-BIOL, V78, P3541, DOI 10.1073/pnas.78.6.3541; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P11202, DOI 10.1073/pnas.90.23.11202; SPANJAARD RA, 1993, MOL ENDOCRINOL, V7, P12, DOI 10.1210/me.7.1.12; STRICKLAND S, 1981, P NATL ACAD SCI-BIOL, V78, P1366, DOI 10.1073/pnas.78.3.1366; SZAPARY D, 1992, ENDOCRINOLOGY, V130, P3492, DOI 10.1210/en.130.6.3492; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WEHLE H, 1995, STEROIDS, V60, P368, DOI 10.1016/0039-128X(94)00067-M; WRIGHT APH, 1992, J BIOL CHEM, V267, P11191; Xu M, 1996, J BIOL CHEM, V271, P21430, DOI 10.1074/jbc.271.35.21430; ZILLIACUS J, 1991, J BIOL CHEM, V266, P3101	61	71	71	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30576	30582		10.1074/jbc.271.48.30576	http://dx.doi.org/10.1074/jbc.271.48.30576			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940029	hybrid			2022-12-27	WOS:A1996VV15800046
J	vanVlijmen, BJM; vanDijk, KW; vantHof, HB; vanGorp, PJJ; vanderZee, A; vanderBoom, H; Breuer, ML; Hofker, MH; Havekes, LM				vanVlijmen, BJM; vanDijk, KW; vantHof, HB; vanGorp, PJJ; vanderZee, A; vanderBoom, H; Breuer, ML; Hofker, MH; Havekes, LM			In the absence of endogenous mouse apolipoprotein E, apolipoprotein E*2(Arg-158->Cys) transgenic mice develop more severe hyperlipoproteinemia than apolipoprotein E*3-Leiden transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; E-DEFICIENT MICE; III HYPERLIPOPROTEINEMIA; MESSENGER-RNA; ATHEROSCLEROSIS; HYPERCHOLESTEROLEMIA; METABOLISM; BINDING; EXPRESSION; INHIBITION	Apolipoprotein E*2(Arg-158 --> Cys) (APOE*2) transgenic mice were generated and compared to the previously generated apolipoprotein E*3-Leiden (APOE*3-Leiden) transgenic mice to study the variable expression of hyperlipoproteinemia associated with these two APOE variants. In the presence of the endogenous mouse Apoe gene, the expression of the APOE*3-Leiden gene resulted in slightly elevated levels of serum cholesterol as compared with control mice (2.7 +/- 0.5 versus 2.1 +/- 0.2 mmol/liter, respectively), whereas the expression of the APOE*2 (Arg-158 --> Cys) gene did not affect serum cholesterol levels, even after high/fat cholesterol-feeding, The extreme cholesterol level usually found in apoE-deficient mice (Apoe(-/-) mice; 23.6 +/- 5.0 mmol/liter) could be rescued by introducing the APOE*3-Leiden gene (APOE*3-Leiden . Apoe(-/-); 3.6 +/- 1.5 mmol/liter), whereas the expression of the APOE*2(Arg-158 --> Cys) gene in Apoe(-/-) mice minimally reduced serum cholesterol levels (APOE*2 . Apoe(-/-); 16.6 +/- 2.9 mmol/liter), In vivo very low density lipoprotein (VLDL) turnover studies revealed that APOE*2 . Apoe(-/-) VLDL and APOE*3-Leiden . Apoe(-/-) VLDL display strongly reduced fractional catabolic rates as compared with control mouse VLDL (4.0 and 6.1 versus 22.1 pools/h), In vitro low density lipoprotein (LDL) receptor binding studies using HepG2 and J774 cells showed that APOE*2 . Apoe(-/-) VLDL is completely defective in binding to the LDL receptor, whereas APOE*3-Leiden . Apoe(-/-) VLDL still displayed a considerable binding activity to the LDL receptor, After transfection of APOE*(2) . Apoe(-/-) and APOE*3-Leiden . Apoe(-/-) mice with adenovirus carrying the gene for the receptor-associated protein (AdCMV-RAP), serum lipid levels strongly increased (15.3 to 42.8 and 1.4 to 15.3 mmol/liter for cholesterol and 5.0 to 35.7 and 0.3 to 20.7 mmol/liter for triglycerides, respectively), This indicates that RAP-sensitive receptors, possibly the LDL receptor-related protein (LRP), mediate the plasma clearance of both APOE*2 . Apoe(-/-) and APOE*3-Leiden . Apoe(-/-) VLDL. We conclude that in vivo the APOE*2 variant is completely defective in LDL receptor binding but not in binding to LRP, whereas for the APOE*3-Leiden mutant both LRP and LDL receptor binding activity are only mildly affected. As a consequence of this difference, APOE*2 . Apoe(-/-) develop more severe hypercholesterolemia than APOE*3-Leiden . Apoe(-/-) mice.	TNO, PG, GAUBIUS LAB, NL-2301 CE LEIDEN, NETHERLANDS; LEIDEN UNIV, DEPT HUMAN GENET, NL-2300 RC LEIDEN, NETHERLANDS; LEIDEN UNIV, DEPT MOL CARCINOGENESIS, NL-2300 RC LEIDEN, NETHERLANDS; ACAD HOSP LEIDEN, DEPT CARDIOL, NL-2300 RA LEIDEN, NETHERLANDS; ACAD HOSP LEIDEN, DEPT INTERNAL MED, NL-2300 RA LEIDEN, NETHERLANDS	Netherlands Organization Applied Science Research; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)			van Gorp, Patrick/S-3892-2019; van Dijk, Ko Willems/AAT-4681-2021; van Dijk, Ko Willems/A-1798-2008; van Gorp, Patrick/L-9580-2018	van Gorp, Patrick/0000-0002-0355-5349; van Dijk, Ko Willems/0000-0002-2172-7394; van Dijk, Ko Willems/0000-0002-2172-7394; van Gorp, Patrick/0000-0002-0355-5349				BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BREWER HB, 1983, ANN INTERN MED, V98, P623, DOI 10.7326/0003-4819-98-5-623; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; DEKNIJFF P, 1991, J CLIN INVEST, V88, P643, DOI 10.1172/JCI115349; DEMANT T, 1991, J CLIN INVEST, V88, P1490, DOI 10.1172/JCI115459; EHNHOLM C, 1984, P NATL ACAD SCI-BIOL, V81, P5566, DOI 10.1073/pnas.81.17.5566; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; GHISELLI G, 1981, SCIENCE, V214, P1239, DOI 10.1126/science.6795720; Groot PHE, 1996, ARTERIOSCL THROM VAS, V16, P926, DOI 10.1161/01.ATV.16.8.926; Hendriks WL, 1996, BIOCHEM J, V314, P563, DOI 10.1042/bj3140563; HIGUCHI K, 1992, J LIPID RES, V33, P1753; HOGAN B, 1986, MANIPULATING MOUSE E; HOLMQUIST L, 1978, ANAL BIOCHEM, V88, P457, DOI 10.1016/0003-2697(78)90444-X; JI ZS, 1994, J BIOL CHEM, V269, P13421; JI ZS, 1994, J BIOL CHEM, V269, P2764; Jong MC, 1996, ARTERIOSCL THROM VAS, V16, P934, DOI 10.1161/01.ATV.16.8.934; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P5693, DOI 10.1073/pnas.79.18.5693; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSIS AJ, 1987, J BIOL CHEM, V262, P7594; Mahley Jr RWRS, 1989, METABOLIC BASIS INHE, P1195; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1990, CURRENT OPINION LIPI, V1, P87; MCCONATHY WJ, 1989, FEBS LETT, V251, P250, DOI 10.1016/0014-5793(89)81464-4; MULDER M, 1991, BIOCHIM BIOPHYS ACTA, V1081, P308, DOI 10.1016/0005-2760(91)90287-R; MULDER M, 1994, ATHEROSCLEROSIS, V108, P183, DOI 10.1016/0021-9150(94)90113-9; NISHINA PM, 1990, J LIPID RES, V31, P859; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; RALL SC, 1992, J INTERN MED, V231, P653, DOI 10.1111/j.1365-2796.1992.tb01254.x; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; Rensen PCN, 1996, J BIOL CHEM, V271, P14791, DOI 10.1074/jbc.271.25.14791; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SHACHTER NS, 1993, J LIPID RES, V34, P1699; VANDENMAAGDENBERG AMJM, 1993, J BIOL CHEM, V268, P10540; VANREE JH, 1994, ATHEROSCLEROSIS, V111, P25, DOI 10.1016/0021-9150(94)90188-0; vanVlijmen BJM, 1996, J CLIN INVEST, V97, P1184, DOI 10.1172/JCI118532; VANVLIJMEN BJM, 1994, J CLIN INVEST, V93, P1403, DOI 10.1172/JCI117117; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; ZANNIS VI, 1984, J BIOL CHEM, V259, P5495; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	40	46	46	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30595	30602		10.1074/jbc.271.48.30595	http://dx.doi.org/10.1074/jbc.271.48.30595			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940032	hybrid, Green Published			2022-12-27	WOS:A1996VV15800049
J	Cassano, S; Gallo, A; Buccigrossi, V; Porcellini, A; Cerillo, R; Gottesman, ME; Avvedimento, EV				Cassano, S; Gallo, A; Buccigrossi, V; Porcellini, A; Cerillo, R; Gottesman, ME; Avvedimento, EV			Membrane localization of cAMP-dependent protein kinase amplifies cAMP signaling to the nucleus in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; REGULATORY SUBUNIT; TRANSCRIPTION; EXPRESSION; CREB	The A126 cell line, in contrast to its PC12 parent, does not differentiate, accumulate nuclear cAMP-dependent protein kinase A (PKA) catalytic subunit, or transcribe cAMP-dependent promoters in response to cAMP. Total PKA is reduced by 50% and is partly resistant to cAMP-induced dissociation in vivo. Unlike PC12, where PKAII is membrane-associated, PKAII is exclusively cytosolic in A126, Cotransfection with the RII anchor protein (AKAP75) and the PKA catalytic subunit (C-PKA) restored cAMP-induced transcription to levels found in PC12. These data indicate that membrane-bound PKAII amplifies cAMP signaling to the nucleus and suggest that cAMP-mediated responses are specified by the type and cellular localization of the PKA isoform.	UNIV NAPLES,FAC MED,DIPARTIMENTO BIOL & PATOL MOL & CELL,I-80131 NAPLES,ITALY; COLUMBIA UNIV,INST CANC RES,NEW YORK,NY 10032; UNIV REGGIO CALABRIA,FAC MED CATANZARO,DIPARTIMENTO MED SPERIMENTALE,I-88100 CATANZARO,ITALY	University of Naples Federico II; Columbia University; Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria			Porcellini, Antonio/AAC-6097-2019; Porcellini, Antonio/E-1900-2011	Porcellini, Antonio/0000-0001-6882-9518; CASSANO, SILVANA/0000-0001-9868-7936				BEEBE SJ, 1986, ENZYMES, V17, P43; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CARR DW, 1992, TRENDS BIOCHEM SCI, V17, P246, DOI 10.1016/0968-0004(92)90402-U; CARR DW, 1993, J BIOL CHEM, V268, P20729; DAMON DH, 1990, J CELL BIOL, V110, P1333, DOI 10.1083/jcb.110.4.1333; DECAMILLI P, 1986, J CELL BIOL, V103, P189, DOI 10.1083/jcb.103.1.189; Feliciello A, 1996, J BIOL CHEM, V271, P25350, DOI 10.1074/jbc.271.41.25350; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; GINTY DD, 1991, J BIOL CHEM, V266, P15325; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; HUFFAKER T, 1984, J CELL PHYSIOL, V120, P188, DOI 10.1002/jcp.1041200212; Maniatis T., 1982, MOL CLONING; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; TORTORA G, 1990, J BIOL CHEM, V265, P18067; VANBUSKIRK R, 1985, MOL CELL BIOL, V5, P1984, DOI 10.1128/MCB.5.8.1984; Ventra C, 1996, J NEUROCHEM, V66, P1752; WEBER W, 1986, BIOCHEMISTRY-US, V25, P5661, DOI 10.1021/bi00367a047	28	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29870	29875		10.1074/jbc.271.47.29870	http://dx.doi.org/10.1074/jbc.271.47.29870			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939928	hybrid			2022-12-27	WOS:A1996VU52500056
J	Garnier, G; Circolo, A; Colten, HR				Garnier, G; Circolo, A; Colten, HR			Constitutive expression of murine complement factor B gene is regulated by the interaction of its upstream promoter with hepatocyte nuclear factor 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE RECEPTOR SUPERFAMILY; CELL GROWTH-FACTOR; MOLECULAR MAP; OVERLAP EXTENSION; ACTING ELEMENTS; MAMMALIAN-CELLS; LYMPHOCYTES-B; BINDING-SITE; TRANSCRIPTION; REGION	Factor B (Bf) is a constituent of the alternative pathway of complement activation encoded within the major histocompatibility complex, Transcription of the murine gene from two initiation sites generates two Bf mRNA species differing in size and tissue distribution, Striking genetic, tissue-specific differences in Bf mRNA levels at extrahepatic sites (kidney and intestine) among mouse strains correlate with a DNA sequence polymorphism in the 5'-flanking region of the gene and differential nuclear protein binding at the Bf upstream transcriptional initiation site (UIS), To ascertain the functional consequences of this polymorphism in the Bf promoter, we analyzed the effects of strain-specific sequences in the Bf 5' region on the expression of a chloramphenicol acetyltransferase (CAT) reporter gene transfected in human and mouse hepatoma cells, The CAT activity and mRNA level produced when transcription was driven by the sequence of strains with high extrahepatic expression were reduced to background levels when the sequence specific to the low expressor strains was used, Eighty percent of this difference was accounted for by a point substitution that affects DNA-protein interaction at the UIS, the sequence of higher affinity conferring higher expression, Hepatocyte nuclear factor 4 (HNF-4), derived from HepG2, mouse liver and kidney or cell-free translation of HNF-4 RNA, is the nuclear protein that preferentially binds to the high expressor UIS, Bf-CAT is not expressed in cells that lack HNF-4 (CV-1), However, co-transfection of HNF-4 into CV-I cells drives Bf-CAT expression and reproduces the differences derived from the substitution that affect HNF-4 binding in vitro. These data show that interaction of HNF-4 with polymorphic variants of the upstream Bf promoter is the major determinant of strain-specific extrahepatic factor B expression.	WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110	Washington University (WUSTL)					NIAID NIH HHS [AI24836, AI24739] Funding Source: Medline; NICHD NIH HHS [HD17461] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD017461] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024739, R01AI024836, R37AI024739] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALPER CA, 1980, CLIN IMMUNOL IMMUNOP, V16, P84, DOI 10.1016/0090-1229(80)90169-5; AMBRUS JL, 1991, J BIOL CHEM, V266, P3702; ASHFIELD R, 1994, EMBO J, V13, P5656, DOI 10.1002/j.1460-2075.1994.tb06904.x; ASHFIELD R, 1991, EMBO J, V10, P4197, DOI 10.1002/j.1460-2075.1991.tb04998.x; CARROLL MC, 1984, NATURE, V307, P237, DOI 10.1038/307237a0; CHAPLIN DD, 1983, P NATL ACAD SCI-BIOL, V80, P6947, DOI 10.1073/pnas.80.22.6947; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Colten HR, 1993, COMPLEMENT HLTH DIS, V20, P127; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FALUS A, 1987, J IMMUNOL, V138, P856; GARNIER G, 1995, J IMMUNOL, V154, P3275; GARNIER G, 1992, J EXP MED, V175, P471, DOI 10.1084/jem.175.2.471; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GOTZE O, 1979, J EXP MED, V149, P372, DOI 10.1084/jem.149.2.372; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HALL RE, 1982, J EXP MED, V156, P834, DOI 10.1084/jem.156.3.834; HIRANI S, 1985, CELL IMMUNOL, V92, P235, DOI 10.1016/0008-8749(85)90005-X; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; ING NH, 1992, J BIOL CHEM, V267, P17617; ISHIKAWA N, 1990, J BIOL CHEM, V265, P19040; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KATZ Y, 1989, J IMMUNOL, V142, P3862; KATZ Y, 1989, EUR J IMMUNOL, V19, P983, DOI 10.1002/eji.1830190605; KAWAMURA N, 1992, BIOCHEM J, V283, P705, DOI 10.1042/bj2830705; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LEIJH PCJ, 1982, J IMMUNOL, V129, P332; MALIK S, 1995, NUCLEIC ACIDS RES, V23, P1536, DOI 10.1093/nar/23.9.1536; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; MORRIS KM, 1982, J CLIN INVEST, V70, P906, DOI 10.1172/JCI110687; MULLER U, 1987, EMBO J, V6, P369, DOI 10.1002/j.1460-2075.1987.tb04764.x; Naughton MA, 1996, J IMMUNOL, V156, P3051; NONAKA M, 1989, MOL CELL BIOCHEM, V89, P1; NONAKA M, 1990, MOL CELL BIOL, V10, P6283, DOI 10.1128/MCB.10.12.6283; NONAKA M, 1989, J IMMUNOL, V142, P1377; OGAMI K, 1990, J BIOL CHEM, V265, P9808; PASSWELL J, 1988, J CLIN INVEST, V82, P1676, DOI 10.1172/JCI113780; PETERS MG, 1988, J EXP MED, V168, P1225, DOI 10.1084/jem.168.4.1225; PRAZ F, 1986, J EXP MED, V163, P1349, DOI 10.1084/jem.163.5.1349; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; RAMADORI G, 1985, J EXP MED, V162, P930, DOI 10.1084/jem.162.3.930; RAMADORI G, 1985, J IMMUNOL, V135, P3645; REIJNEN MJ, 1992, P NATL ACAD SCI USA, V89, P6300, DOI 10.1073/pnas.89.14.6300; REIJNEN MJ, 1993, BLOOD, V82, P151, DOI 10.1182/blood.V82.1.151.bloodjournal821151; REUE K, 1988, J BIOL CHEM, V263, P6857; ROTHER K, 1988, COMPLEMENT SYSTEM; ROTTMAN JN, 1993, J BIOL CHEM, V268, P11994; Sambrook J., 2002, MOL CLONING LAB MANU; SEGAL S, 1986, BASIC METHODS MOL BI, P286; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STRUNK RC, 1985, J CLIN INVEST, V76, P985, DOI 10.1172/JCI112099; STRUNK RC, 1985, J BIOL CHEM, V260, P5280; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; WU LC, 1987, CELL, V48, P331, DOI 10.1016/0092-8674(87)90436-3	57	10	10	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30205	30211		10.1074/jbc.271.47.30205	http://dx.doi.org/10.1074/jbc.271.47.30205			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939972	hybrid			2022-12-27	WOS:A1996VU52500100
J	Muthalif, MM; Benter, IF; Uddin, MR; Malik, KU				Muthalif, MM; Benter, IF; Uddin, MR; Malik, KU			Calcium/calmodulin-dependent protein kinase II alpha mediates activation of mitogen-activated protein kinase and cytosolic phospholipase A(2) in norepinephrine-induced arachidonic acid release in rabbit aortic smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; ANTISENSE OLIGONUCLEOTIDES; PROSTAGLANDIN SYNTHESIS; TYROSINE KINASE; STIMULI; MEMBRANE; PHOSPHORYLATION; EXPRESSION; MECHANISM; INHIBITOR	We have investigated the contribution of Ca2+/calmodulin dependent protein kinase II (CaM kinase II) and mitogen-activated protein kinase (MAP kinase) in norepinephrine (NE)-induced arachidonic acid (AA) release in rabbit aortic vascular smooth muscle cells (VSMC), NE enhanced release of AA via activation of cytosolic phospholipase A(2) (cPLA(2)) but not secretory PLA(2) in VSMC prelabeled with [H-3]AA. NE (10 mu M) enhanced CaM kinase II and MAP kinase activity, In cells transiently transfected with antisense oligonucleotides complementary to the translation initiation sites of CaM kinase II and MAP kinase, NE-induced AA release was inhibited by 100 and 35% respectively. Treatment of cells with PD-098059, a MAP kinase kinase inhibitor, or with MAP kinase antisense oligonucleotide reduced NE-induced activation of MAP kinase and cPLA(2). NE-induced MAP kinase and cPLA(2) activation was also inhibited in cells treated with a CaM kinase II inhibitor, KN-93, or with CaM kinase II antisense oligonucleotide. On the other hand, inhibition of MAP kinase kinase with PD-098059 or of MAP kinase with antisense oligonucleotides did not alter the NE-induced increase in CaM kinase II activity, Phosphorylation of MAP kinase and CaM kinase II by NE, studied by P-32 incorporation and immune complex kinase assays, was inhibited by KN-93. Collectively, these data suggest that CaM kinase II can activate MAP kinase, which in turn activates cPLA(2) to release AA for prostacyclin synthesis in the rabbit VSMC. This novel pathway for activation of MAP kinase by CaM kinase II appears to be mediated through stimulation of MAP kinase kinase, Activation of adrenergic receptors with NE in VSMC caused translocation of CaM kinase II, MAP kinase, and cPLA(2) to the nuclear envelope only in the presence of extracellular Ca2+. Okadaic acid, which increased phosphorylation and activity, did not translocate these enzymes, Therefore, it appears that in rabbit VSMC, NE, by promoting extracellular Ca2+ influx, increases CaM kinase II activity, leading to activation of MAP kinase and cPLA(2) and translocation to the nuclear envelope, resulting in release of AA from the nuclear envelope for prostacyclin synthesis.	UNIV TENNESSEE, CTR HLTH SCI, DEPT PHARMACOL, COLL MED, MEMPHIS, TN 38163 USA; SO COLL OPTOMETRY, MEMPHIS, TN 38104 USA; LE MOYNE COLL, MEMPHIS, TN 38126 USA	University of Tennessee System; University of Tennessee Health Science Center			Benter, Ibrahim Fadil/AAY-2527-2020		PHS HHS [19134] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CAPRIOTTI AM, 1988, J BIOL CHEM, V263, P10029; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; LESLIE CC, 1990, METHOD ENZYMOL, V187, P216; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MALIK KU, 1988, AM J MED SCI, V295, P280, DOI 10.1097/00000441-198804000-00011; NEBIGIL C, 1990, J PHARMACOL EXP THER, V254, P633; NEBIGIL C, 1993, J PHARMACOL EXP THER, V266, P1113; NEUFELD EJ, 1985, J CELL BIOL, V101, P573, DOI 10.1083/jcb.101.2.573; QIU ZH, 1994, J BIOL CHEM, V269, P19480; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; SA G, 1995, J BIOL CHEM, V270, P2360, DOI 10.1074/jbc.270.5.2360; SADOSHIMA J, 1995, CIRC RES, V76, P1; SCHALKWIJK CG, 1990, BIOCHIM BIOPHYS ACTA, V1044, P139, DOI 10.1016/0005-2760(90)90229-Q; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WATERMAN WH, 1995, BIOCHEM BIOPH RES CO, V209, P271, DOI 10.1006/bbrc.1995.1499; WINITZ S, 1994, J BIOL CHEM, V269, P1889; Xing MB, 1996, J CLIN INVEST, V97, P1302, DOI 10.1172/JCI118546	33	144	146	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30149	30157		10.1074/jbc.271.47.30149	http://dx.doi.org/10.1074/jbc.271.47.30149			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939965	hybrid			2022-12-27	WOS:A1996VU52500093
J	Tai, TAC; Jennermann, C; Brown, KK; Oliver, BB; MacGinnitie, MA; Wilkison, WO; Brown, HR; Lehmann, JM; Kliewer, SA; Morris, DC; Graves, RA				Tai, TAC; Jennermann, C; Brown, KK; Oliver, BB; MacGinnitie, MA; Wilkison, WO; Brown, HR; Lehmann, JM; Kliewer, SA; Morris, DC; Graves, RA			Activation of the nuclear receptor peroxisome proliferator-activated gamma promotes brown adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCOUPLING PROTEIN GENE; RETINOID-X-RECEPTOR; ADIPOSE-TISSUE THERMOGENESIS; OB OB MICE; INSULIN-RESISTANCE; TRANSGENIC MICE; LIPID-METABOLISM; BINDING-PROTEIN; MESSENGER-RNA; FATTY-ACIDS	Brown adipose tissue (BAT) functions in non-shivering and diet-induced thermogenesis via its capacity for uncoupled mitochondrial respiration. BAT dysfunction in rodents is associated with severe defects in energy homeostasis, resulting in obesity and hyperglycemia. Here, we report that the nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR gamma), a prostaglandin-activated transcription factor recently implicated as a central regulator of white adipose tissue differentiation, also regulates brown adipocyte function. PPAR gamma is abundantly expressed in both embryonic and adult BAT. Treatment of CD-1 rats with the PPAR gamma-selective ligand BRL49653, an anti-diabetic drug of the thiazolidinedione class, results in marked increases in the mass of interscapular BAT. In vitro, BRL49653 induces the terminal differentiation of the brown preadipocyte cell line HIB-1B as judged by both changes in cell morphology and expression of uncoupling protein and other adipocyte-specific mRNAs. These data demonstrate that PPAR gamma is a key regulatory factor in brown adipocytes and suggest that PPAR gamma functions not only in the storage of excess energy in white adipose tissue but also in its dissipation in BAT.	UNIV CHICAGO, DEPT MED, GASTROENTEROL SECT, CHICAGO, IL 60637 USA; GLAXO WELLCOME INC, RES & DEV, DEPT MOL PHARMACOL, RES TRIANGLE PK, NC 27709 USA; GLAXO WELLCOME INC, RES & DEV, DEPT PHARMACOL, RES TRIANGLE PK, NC 27709 USA; GLAXO WELLCOME INC, RES & DEV, DEPT CELL BIOL, RES TRIANGLE PK, NC 27709 USA; GLAXO WELLCOME INC, RES & DEV, DEPT MOL BIOCHEM, RES TRIANGLE PK, NC 27709 USA; GLAXO WELLCOME INC, RES & DEV, DEPT PATHOL, RES TRIANGLE PK, NC 27709 USA	University of Chicago; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026678] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK26678] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZ R, 1995, J BIOL CHEM, V270, P5666, DOI 10.1074/jbc.270.10.5666; CASSARDDOULCIER AM, 1994, J BIOL CHEM, V269, P24335; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; COLCA JR, 1990, NEW ANTIDIABETIC DRU, P255; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GLICK Z, 1987, Journal of Obesity and Weight Regulation, V6, P170; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; HAMANN A, 1995, DIABETES, V44, P1266, DOI 10.2337/diabetes.44.11.1266; Hamann A, 1996, ENDOCRINOLOGY, V137, P21, DOI 10.1210/en.137.1.21; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HIMMSHAGEN J, 1985, INT J OBESITY, V9, P17; HIMMSHAGEN J, 1990, FASEB J, V4, P2890, DOI 10.1096/fasebj.4.11.2199286; HIMMSHAGEN J, 1989, PROG LIPID RES, V28, P67, DOI 10.1016/0163-7827(89)90009-X; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; IBRAHIMI A, 1994, MOL PHARMACOL, V46, P1070; KELLER H, 1993, ANN NY ACAD SCI, V684, P157, DOI 10.1111/j.1749-6632.1993.tb32279.x; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KEMNITZ JW, 1994, DIABETES, V43, P204, DOI 10.2337/diabetes.43.2.204; KLAUS S, 1994, J CELL SCI, V107, P313; KLAUS S, 1991, INT J BIOCHEM, V23, P791, DOI 10.1016/0020-711X(91)90062-R; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KOZAK UC, 1994, MOL CELL BIOL, V14, P59, DOI 10.1128/MCB.14.1.59; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; MERCER SW, 1986, FEBS LETT, V195, P12, DOI 10.1016/0014-5793(86)80120-X; MERCER SW, 1987, J NUTR, V117, P2147; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; RABELO R, 1995, ENDOCRINOLOGY, V136, P1003, DOI 10.1210/en.136.3.1003; ROSS SR, 1992, P NATL ACAD SCI USA, V89, P7561, DOI 10.1073/pnas.89.16.7561; ROTHWELL NJ, 1987, MOL CELL ENDOCRINOL, V51, P253, DOI 10.1016/0303-7207(87)90035-9; ROTHWELL NJ, 1979, NATURE, V281, P31, DOI 10.1038/281031a0; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Sears IB, 1996, MOL CELL BIOL, V16, P3410; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; THURLBY PL, 1987, BIOSCIENCE REP, V7, P573, DOI 10.1007/BF01119774; TONTONOZ P, 1994, NUCLEIC ACIDS RES, V22, P5628, DOI 10.1093/nar/22.25.5628; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Trayhurn P, 1988, Prog Clin Biol Res, V265, P69; TRAYHURN P, 1990, INT J OBESITY, V1, P17; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	49	140	149	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29909	29914		10.1074/jbc.271.47.29909	http://dx.doi.org/10.1074/jbc.271.47.29909			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939934	hybrid			2022-12-27	WOS:A1996VU52500062
J	Wickner, W; Leonard, MR				Wickner, W; Leonard, MR			Escherichia coli preprotein translocase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							MALTOSE-BINDING PROTEIN; SIGNAL RECOGNITION PARTICLE; INNER MEMBRANE-VESICLES; SECA PROTEIN; PLASMA-MEMBRANE; TRIGGER FACTOR; INVITRO TRANSLOCATION; SUPPRESSOR MUTATIONS; CYTOPLASMIC MEMBRANE; SEQUENCE RECOGNITION				Wickner, W (corresponding author), DARTMOUTH COLL, SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA.							ARKOWITZ RA, 1993, EMBO J, V12, P243, DOI 10.1002/j.1460-2075.1993.tb05650.x; BASSILANA M, 1993, BIOCHEMISTRY-US, V32, P2626, DOI 10.1021/bi00061a021; BIEKERBRADY K, 1992, EMBO J, V11, P3165, DOI 10.1002/j.1460-2075.1992.tb05393.x; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; CHEN L, 1986, J BACTERIOL, V167, P389, DOI 10.1128/jb.167.1.389-392.1986; CHEN LL, 1987, NATURE, V328, P164, DOI 10.1038/328164a0; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; CUNNINGHAM K, 1989, P NATL ACAD SCI USA, V86, P8630, DOI 10.1073/pnas.86.22.8630; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DANIELS CJ, 1981, P NATL ACAD SCI-BIOL, V78, P5396, DOI 10.1073/pnas.78.9.5396; DATE T, 1980, P NATL ACAD SCI-BIOL, V77, P4669, DOI 10.1073/pnas.77.8.4669; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; DIERSTEIN R, 1986, EMBO J, V5, P427, DOI 10.1002/j.1460-2075.1986.tb04228.x; DOUVILLE K, 1994, J BIOL CHEM, V269, P18705; DOUVILLE K, 1995, J BIOL CHEM, V270, P20106, DOI 10.1074/jbc.270.34.20106; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; EMR SD, 1981, CELL, V23, P79, DOI 10.1016/0092-8674(81)90272-5; ENEQUIST HG, 1981, EUR J BIOCHEM, V116, P227, DOI 10.1111/j.1432-1033.1981.tb05323.x; FLOWER AM, 1994, J BACTERIOL, V176, P5607, DOI 10.1128/JB.176.18.5607-5614.1994; GANNON PM, 1989, J BACTERIOL, V171, P813, DOI 10.1128/jb.171.2.813-818.1989; GELLER BL, 1986, P NATL ACAD SCI USA, V83, P4219, DOI 10.1073/pnas.83.12.4219; HANADA M, 1994, J BIOL CHEM, V269, P23625; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; ITO K, 1982, J BIOL CHEM, V257, P9895; JOLY JC, 1994, P NATL ACAD SCI USA, V91, P4703, DOI 10.1073/pnas.91.11.4703; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KANDROR O, 1995, EMBO J, V14, P6021, DOI 10.1002/j.1460-2075.1995.tb00290.x; KATO M, 1992, J BIOL CHEM, V267, P413; KIM YJ, 1994, CELL, V78, P845; KUMAMOTO CA, 1989, GENE, V75, P167, DOI 10.1016/0378-1119(89)90393-4; LILL R, 1988, CELL, V54, P1013, DOI 10.1016/0092-8674(88)90116-X; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; MATSUYAMA S, 1992, BIOCHIM BIOPHYS ACTA, V1122, P77, DOI 10.1016/0167-4838(92)90130-6; MCFARLAND L, 1993, J BACTERIOL, V175, P2255, DOI 10.1128/JB.175.8.2255-2262.1993; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; NISHIYAMA K, 1994, EMBO J, V13, P3272, DOI 10.1002/j.1460-2075.1994.tb06628.x; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; OSBORNE RS, 1993, EMBO J, V12, P3391, DOI 10.1002/j.1460-2075.1993.tb06013.x; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; POGLIANO KJ, 1994, J BACTERIOL, V176, P804, DOI 10.1128/jb.176.3.804-814.1994; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; RANDALL LL, 1983, CELL, V33, P231, DOI 10.1016/0092-8674(83)90352-5; RANDALL LL, 1994, BIOL HEAT SHOCK PROT, P285; RHOADS DB, 1984, J BACTERIOL, V159, P63, DOI 10.1128/JB.159.1.63-70.1984; ROLLO EE, 1988, J BACTERIOL, V170, P3281, DOI 10.1128/jb.170.7.3281-3282.1988; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHMIDT MG, 1988, J BACTERIOL, V170, P3404, DOI 10.1128/jb.170.8.3404-3414.1988; SILVER P, 1981, CELL, V25, P341, DOI 10.1016/0092-8674(81)90052-0; Uchida K, 1995, J BIOL CHEM, V270, P30862, DOI 10.1074/jbc.270.52.30862; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; WEAVER AJ, 1992, J STRUCT BIOL, V109, P87, DOI 10.1016/1047-8477(92)90040-H; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; ZIMMERMANN R, 1983, J BIOL CHEM, V258, P3920	68	101	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29514	29516		10.1074/jbc.271.47.29514	http://dx.doi.org/10.1074/jbc.271.47.29514			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939874	hybrid			2022-12-27	WOS:A1996VU52500002
J	Kimble, RB; Srivastava, S; Ross, FP; Matayoshi, A; Pacifici, R				Kimble, RB; Srivastava, S; Ross, FP; Matayoshi, A; Pacifici, R			Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1- and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-MARROW CULTURES; RECEPTOR ANTAGONIST; GENE-EXPRESSION; UP-REGULATION; FACTOR-I; DIFFERENTIATION; PROLIFERATION; RESORPTION; PROMOTER; BINDING	To analyze how estrogen blocks osteoclastogenesis, we investigated the effects of ovariectomy on osteoclast (OC) formation in co-cultures of purified OC precursors and purified stromal cells (SC). OC formation was higher in co-cultures containing SC from ovariectomized mice than in those containing SC from sham-operated mice, thus suggesting that estrogen regulates osteoclastogenesis by targeting SC. Ovariectomy also increased the mononuclear cell secretion of interleukin (IL)-1) and tumor necrosis factor (TNF) and the SC production of macrophage colony-stimulating factor (M-CSF), Osteoclastogenesis and SC production of M-CSF were not blocked by in vitro estrogen treatment but were decreased by in viva treatment of donor mice with either estrogen or a combination of the IL-1 inhibitor, IL-1 receptor antagonist, and the TNF inhibitor, TNF binding protein. IL-1 and TNF production were also blocked by in vivo estrogen treatment, demonstrating that the increased bone marrow levels of IL-1 and TNF characteristic of ovariectomized mice induce the formation of a SC population characterized by a high production of M-CSF and increased pro-osteoclastogenic activity. Since in co-cultures of SC and OC precursors M-CSF levels correlated with OC production (r = 0.7, p < 0.0001), the data also indicate that the pro-osteoclastogenic activity of SC is proportional to their secretion of M-CSF. The ability of estrogen to decrease SC production of M-CSF and the pro-osteoclastogenic activity of these cells by regulating IL-1 and TNF production is a previously undescribed mechanism by which estrogen do cvn-regulates osteoclastogenesis.	BARNES JEWISH HOSP, DIV BONE & MINERAL DIS, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL)					NIAMS NIH HHS [AR 41412, AR 42404] Funding Source: Medline; NIA NIH HHS [AG 13534] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042404, R01AR041412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013534] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABBOUD SL, 1991, BLOOD, V78, P103; ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; AREND WP, 1991, J CLIN INVEST, V88, P1445, DOI 10.1172/JCI115453; BELLIDO T, 1993, ENDOCRINOLOGY, V133, P553, DOI 10.1210/en.133.2.553; BRAITMAN LE, 1983, ANN INTERN MED, V99, P269, DOI 10.7326/0003-4819-99-2-269; CHAPLIN DD, 1992, TUMOR NECROSIS FACTO, P197; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOHISY DR, 1987, J BIOL CHEM, V262, P15922; DEXTER TM, 1977, J CELL PHYSIOL, V91, P335, DOI 10.1002/jcp.1040910303; DEXTER TM, 1990, MOL CONTROL HAEMOPOI, P86; DINARELLO CA, 1991, BLOOD, V77, P1627; FALKENBURG JHF, 1991, BLOOD, V78, P658; FIORELLI G, 1995, P NATL ACAD SCI USA, V92, P2672, DOI 10.1073/pnas.92.7.2672; GAZIT D, 1994, J BONE MINER RES, V9; GIRASOLE G, 1994, J CLIN INVEST, V93, P1516, DOI 10.1172/JCI117130; GUILBERT LJ, 1986, J BIOL CHEM, V261, P4024; GULSHAN S, 1990, SCAND J IMMUNOL, V31, P691, DOI 10.1111/j.1365-3083.1990.tb02820.x; HARRINGTON MA, 1991, GENE, V102, P165, DOI 10.1016/0378-1119(91)90074-L; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HART DM, 1993, J NIH RES, V5, P66; HOROWITZ MC, 1993, SCIENCE, V260, P626, DOI 10.1126/science.8480174; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; KALU DN, 1990, P SOC EXP BIOL MED, V195, P70; KIMBLE RB, 1995, ENDOCRINOLOGY, V136, P3054, DOI 10.1210/en.136.7.3054; KIMBLE RB, 1994, J CLIN INVEST, V93, P1959, DOI 10.1172/JCI117187; KITAZAWA R, 1994, J CLIN INVEST, V94, P2397, DOI 10.1172/JCI117606; LADNER MB, 1988, P NATL ACAD SCI USA, V85, P6706, DOI 10.1073/pnas.85.18.6706; LOKESHWAR BL, 1988, J IMMUNOL, V141, P483; MACDONALD BR, 1986, J BONE MINER RES, V1, P227; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; MIYAKE K, 1991, J CELL BIOL, V114, P557, DOI 10.1083/jcb.114.3.557; MODDERMAN WE, 1994, EXP HEMATOL, V22, P194; OURSLER MJ, 1991, P NATL ACAD SCI USA, V88, P6613, DOI 10.1073/pnas.88.15.6613; OURSLER MJ, 1993, ENDOCRINOLOGY, V132, P1373, DOI 10.1210/en.132.3.1373; PASSERI G, 1993, ENDOCRINOLOGY, V133, P822, DOI 10.1210/en.133.2.822; Perkins SL, 1995, AM J PHYSIOL-ENDOC M, V269, pE1024, DOI 10.1152/ajpendo.1995.269.6.E1024; PFEILSCHIFTER J, 1989, J BONE MINER RES, V4, P113, DOI 10.1002/jbmr.5650040116; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; SUVA LJ, 1991, MOL ENDOCRINOL, V5, P829, DOI 10.1210/mend-5-6-829; TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461; VANDERPLUIJM G, 1991, ENDOCRINOLOGY, V129, P1596; WEUSTEN JJAM, 1986, ACTA ENDOCRINOL-COP, V112, P409, DOI 10.1530/acta.0.1120409	44	217	241	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28890	28897		10.1074/jbc.271.46.28890	http://dx.doi.org/10.1074/jbc.271.46.28890			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910536	hybrid			2022-12-27	WOS:A1996VT05200028
J	Kuhn, FJP; Knopf, CW				Kuhn, FJP; Knopf, CW			Herpes simplex virus type 1 DNA polymerase - Mutational analysis of the 3'-5'-exonuclease domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXONUCLEASE ACTIVE-SITE; 3'-5' EXONUCLEASE; ESCHERICHIA-COLI; AMINO-ACID; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; CATALYTIC SUBUNIT; UL42 PROTEIN; STRAIN ANGELOTTI; GENE	Like true DNA replicases, herpes simplex virus type 1 DNA polymerase is equipped with a proofreading 3'-5'-exonuclease, In order to assess the functional significance of conserved residues in the putative exonuclease domain, we introduced point mutations as well as deletions within and near the conserved motifs' exonuclease (Exo) I, II, and III of the DNA polymerase gene from a phosphonoacetic acid-resistant derivative of herpes simplex virus-1 strain ANG. We examined the catalytic activities of the partially purified enzymes after overexpression by recombinant baculovirus. Mutations of the motifs' Exo I (D368A, E370A) and Exo III (Y577F, D581A) yielded enzymes without detectable and severely impaired 3'-5'-exonuclease activities, respectively. Except for the Exo I mutations, all other Exo mutations examined affected both exonuclease and polymerization activities. Mutant enzymes D368A, E370A, Y557S, and D581A showed a significant ability to extend mispaired primer termini. Mutation Y557S resulted in a strong reduction of the 3'-5'-exonuclease activity and in a polymerase activity that was hyperresistant to phosphonoacetic acid. The results of the mutational analysis provide evidence for a tight linkage of polymerase and 3'-5'-exonuclease activity in the herpesviral enzyme.	DEUTSCH KREBSFORSCHUNGSZENTRUM,DEPT GENOMFORSCH & BIOINFORMAT 0841,D-69120 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)			Kuehn, Frank JP/H-5889-2018					BARNES MH, 1992, GENE, V111, P43, DOI 10.1016/0378-1119(92)90601-K; BAYER S, 1990, THESIS U HEIDELBERG; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BLANCO L, 1992, GENE, V112, P139, DOI 10.1016/0378-1119(92)90316-H; BOULET A, 1989, EMBO J, V8, P1849, DOI 10.1002/j.1460-2075.1989.tb03580.x; BROWN M, 1977, J GEN VIROL, V36, P361, DOI 10.1099/0022-1317-36-2-361; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHUNG DW, 1991, P NATL ACAD SCI USA, V88, P11197, DOI 10.1073/pnas.88.24.11197; COEN DM, 1991, ANTIVIR RES, V15, P287, DOI 10.1016/0166-3542(91)90010-O; CRUTE JJ, 1989, J BIOL CHEM, V264, P19266; CULLMANN G, 1993, GENE, V134, P191, DOI 10.1016/0378-1119(93)90093-I; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; DIGARD P, 1993, J VIROL, V67, P1159, DOI 10.1128/JVI.67.3.1159-1168.1993; DOWNEY KM, 1990, BIOESSAYS, V12, P231, DOI 10.1002/bies.950120507; FREEMONT P S, 1986, Proteins Structure Function and Genetics, V1, P66, DOI 10.1002/prot.340010111; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; GALLO ML, 1989, J VIROL, V63, P5023, DOI 10.1128/JVI.63.12.5023-5029.1989; GIBBS JS, 1991, MOL CELL BIOL, V11, P4786, DOI 10.1128/MCB.11.9.4786; GOTTLIEB J, 1990, J VIROL, V64, P5976, DOI 10.1128/JVI.64.12.5976-5987.1990; HAFFEY ML, 1990, J VIROL, V64, P5008, DOI 10.1128/JVI.64.10.5008-5018.1990; HALL JD, 1995, J GEN VIROL, V76, P2999, DOI 10.1099/0022-1317-76-12-2999; HALL JD, 1989, NUCLEIC ACIDS RES, V17, P9231, DOI 10.1093/nar/17.22.9231; HART GJ, 1992, FEBS LETT, V305, P97, DOI 10.1016/0014-5793(92)80872-E; HERNANDEZ TR, 1990, J BIOL CHEM, V265, P11227; ISHINO Y, 1994, J BIOL CHEM, V269, P14655; JOYCE CM, 1982, J BIOL CHEM, V257, P1958; JOYCE JM, 1994, ANN REV BIOCH, V63, P777; KNOPF CW, 1990, EUR J BIOCHEM, V191, P263, DOI 10.1111/j.1432-1033.1990.tb19119.x; KNOPF CW, 1988, BIOCHIM BIOPHYS ACTA, V951, P298, DOI 10.1016/0167-4781(88)90100-5; KNOPF CW, 1986, NUCLEIC ACIDS RES, V14, P8225, DOI 10.1093/nar/14.20.8225; KNOPF CW, 1987, J GEN VIROL, V68, P1429, DOI 10.1099/0022-1317-68-5-1429; KNOPF HW, 1988, THESIS U HEIDELBERG; KNOPF KW, 1979, EUR J BIOCHEM, V98, P231, DOI 10.1111/j.1432-1033.1979.tb13181.x; KNOPF KW, 1981, J VIROL, V39, P746, DOI 10.1128/JVI.39.3.746-757.1981; KNOPF KW, 1994, FRONTIERS VIROLOGY, V3, P87; KUHN FJP, 1995, THESIS U HEIDELBERG; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maxam A M, 1980, Methods Enzymol, V65, P499; MORRISON A, 1992, NUCLEIC ACIDS RES, V20, P375, DOI 10.1093/nar/20.2.375; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; MULLEN GP, 1990, J BIOL CHEM, V265, P14327; ODONNELL ME, 1987, J BIOL CHEM, V262, P4252; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; Possee RD., 1992, BACULOVIRUS EXPRESSI; REHAKRANTZ LJ, 1993, J BIOL CHEM, V268, P27100; REHAKRANTZ LJ, 1991, P NATL ACAD SCI USA, V88, P2417, DOI 10.1073/pnas.88.6.2417; RUSCITTI T, 1992, J BIOL CHEM, V267, P16806; Sambrook J., 2002, MOL CLONING LAB MANU; SAWADOGO M, 1991, NUCLEIC ACIDS RES, V19, P674, DOI 10.1093/nar/19.3.674; SHANAFELT AB, 1991, BIOTECHNIQUES, V11, P330; SIMON M, 1991, EMBO J, V10, P2165, DOI 10.1002/j.1460-2075.1991.tb07751.x; SO AG, 1992, CRIT REV BIOCHEM MOL, V27, P129, DOI 10.3109/10409239209082561; SOENGAS MS, 1992, EMBO J, V11, P4227, DOI 10.1002/j.1460-2075.1992.tb05517.x; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; STOCKI SA, 1995, J MOL BIOL, V254, P15, DOI 10.1006/jmbi.1995.0595; STRICK R, 1993, THESIS U HEIDELBERG; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WANG X, 1983, J GEN VIROL, V64, P2229, DOI 10.1099/0022-1317-64-10-2229; WANG Y, 1992, J VIROL, V66, P1814, DOI 10.1128/JVI.66.3.1814-1816.1992; WEISSBACH A, 1973, J BIOL CHEM, V248, P6270; WEISSHART K, 1988, EUR J BIOCHEM, V174, P707, DOI 10.1111/j.1432-1033.1988.tb14155.x; WEISSHART K, 1994, J BIOL CHEM, V269, P22788; ZHANG J, 1991, BIOCHEMISTRY-US, V30, P11742, DOI 10.1021/bi00115a002; ZHU WG, 1994, NUCLEIC ACIDS RES, V22, P5177, DOI 10.1093/nar/22.24.5177	67	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29245	29254						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910584				2022-12-27	WOS:A1996VT05200076
J	Ogata, Y; Mizushima, T; Kataoka, K; Kita, K; Miki, T; Sekimizu, K				Ogata, Y; Mizushima, T; Kataoka, K; Kita, K; Miki, T; Sekimizu, K			DnaK heat shock protein of Escherichia coli maintains the negative supercoiling of DNA against thermal stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEX FACTOR-F; RNA-POLYMERASE; SIGMA-32 SYNTHESIS; ATPASE ACTIVITY; TRANSCRIPTIONAL CONTROL; ENZYMATIC REPLICATION; BACTERIOPHAGE-LAMBDA; SUPERHELICAL TURNS; REGULATORY GENE; PLASMID DNA	Plasmid DNA in exponentially growing Escherichia coli immediately relaxes after heat shock, and the relaxed state of DNA rapidly reverts to the original state with exposure to conditions of heat shock. We have now obtained genetic and biochemical evidence indicating that DnaK heat shock protein off. coli, a prokaryotic homologue of hsp70, is involved in this re-supercoiling of DNA. As re-supercoiling of DNA did not occur in an rpoH amber mutant, it seems likely that heat shock proteins are required for this reaction, Plasmid DNA in a dnaK deletion mutant relaxed excessively after temperature shift-up, and the re-supercoiling of DNA was not observed. DNAs incubated with a crude cell extract prepared from the dnaK mutant were more relaxed than seen with the extract from its isogenic wild-type strain, and the addition of purified DnaK protein to the mutant extract led to an increase in the negative supercoiling of DNA. Moreover, reaction products of purified DNA gyrase more negatively supercoiled in the presence of DnaK protein, Based on these results, we propose that DnaK protein plays a role in maintaining the negative supercoiling of DNA against thermal stress.	KYUSHU UNIV, FAC PHARMACEUT SCI, DEPT MICROBIOL, HIGASHI KU, FUKUOKA 81282, JAPAN; UNIV TOKYO, INST MED SCI, DEPT PARASITOL, MINATO KU, TOKYO 108, JAPAN	Kyushu University; University of Tokyo				Kita, Kiyoshi/0000-0002-0426-4308; Ogata, Yasuyuki/0000-0003-0316-0109				Ashburner M., 1982, HEAT SHOCK BACTERIA, P1; BAKER TA, 1988, CELL, V55, P113, DOI 10.1016/0092-8674(88)90014-1; BALKE VL, 1987, J BACTERIOL, V169, P4499, DOI 10.1128/jb.169.10.4499-4506.1987; BLASZCZAK A, 1995, EMBO J, V14, P5085, DOI 10.1002/j.1460-2075.1995.tb00190.x; BUKAU B, 1990, EMBO J, V9, P4027, DOI 10.1002/j.1460-2075.1990.tb07624.x; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; DRLICA K, 1984, MICROBIOL REV, V48, P273, DOI 10.1128/MMBR.48.4.273-289.1984; FUJITA N, 1987, MOL GEN GENET, V210, P10, DOI 10.1007/BF00337752; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; FUNNELL BE, 1986, J BIOL CHEM, V261, P5616; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLDSTEIN E, 1984, P NATL ACAD SCI-BIOL, V81, P4046, DOI 10.1073/pnas.81.13.4046; GROSSMAN AD, 1987, GENE DEV, V1, P179, DOI 10.1101/gad.1.2.179; HILL CW, 1981, P NATL ACAD SCI-BIOL, V78, P7069, DOI 10.1073/pnas.78.11.7069; HUPP TR, 1993, J BIOL CHEM, V268, P13137; HUPP TR, 1993, J BIOL CHEM, V268, P13143; HWANG DS, 1990, J BIOL CHEM, V265, P19244; KAMATHLOEB AS, 1991, J BACTERIOL, V173, P3904, DOI 10.1128/JB.173.12.3904-3906.1991; Kaneko T, 1996, MOL GEN GENET, V250, P593; Kataoka K, 1996, J BIOL CHEM, V271, P24806, DOI 10.1074/jbc.271.40.24806; KAWASAKI Y, 1990, MOL GEN GENET, V220, P277; KELLER W, 1975, P NATL ACAD SCI USA, V72, P4876, DOI 10.1073/pnas.72.12.4876; KUSUKAWA N, 1989, EMBO J, V8, P3517, DOI 10.1002/j.1460-2075.1989.tb08517.x; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T, 1989, MOL CLONING; MARGER WH, 1995, MICROBIOL REV, V59, P506; MCCARTY JS, 1994, J BACTERIOL, V176, P764, DOI 10.1128/jb.176.3.764-780.1994; MCCARTY JS, 1991, P NATL ACAD SCI USA, V88, P9513, DOI 10.1073/pnas.88.21.9513; MIKI T, 1988, J MOL BIOL, V201, P327, DOI 10.1016/0022-2836(88)90141-6; MIKI T, 1992, J MOL BIOL, V225, P39, DOI 10.1016/0022-2836(92)91024-J; MIZUSHIMA T, 1993, MOL GEN GENET, V238, P1; MIZUSHIMA T, 1994, FEMS MICROBIOL LETT, V121, P333, DOI 10.1016/0378-1097(94)90313-1; MIZUUCHI K, 1984, J BIOL CHEM, V259, P9199; MORIMOTO R I, 1990, P1; NAGAI H, 1991, P NATL ACAD SCI USA, V88, P10515, DOI 10.1073/pnas.88.23.10515; NEIDHARDT FC, 1981, BIOCHEM BIOPH RES CO, V100, P894, DOI 10.1016/S0006-291X(81)80257-4; NEIDHARDT FC, 1984, ANNU REV GENET, V18, P295, DOI 10.1146/annurev.ge.18.120184.001455; OGATA Y, 1994, MOL GEN GENET, V244, P451, DOI 10.1007/BF00583895; OGATA Y, 1993, BIOCHEM BIOPH RES CO, V197, P34, DOI 10.1006/bbrc.1993.2437; PAEK KH, 1987, J BACTERIOL, V169, P283, DOI 10.1128/jb.169.1.283-290.1987; PANAGIOTIDIS CA, 1994, J BIOL CHEM, V269, P16643; POLISSI A, 1995, FEMS MICROBIOL REV, V17, P159; PRUSS GJ, 1989, CELL, V56, P521, DOI 10.1016/0092-8674(89)90574-6; SAKAKIBARA Y, 1988, J BACTERIOL, V170, P972, DOI 10.1128/jb.170.2.972-979.1988; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; STRAUS D, 1990, GENE DEV, V4, P2202, DOI 10.1101/gad.4.12a.2202; STRAUS DB, 1987, NATURE, V329, P348, DOI 10.1038/329348a0; TAYLOR WE, 1984, CELL, V38, P371, DOI 10.1016/0092-8674(84)90492-6; TILLY K, 1983, CELL, V34, P641, DOI 10.1016/0092-8674(83)90396-3; TILLY K, 1986, J BACTERIOL, V168, P1155, DOI 10.1128/jb.168.3.1155-1158.1986; TOBE T, 1984, MOL GEN GENET, V195, P10, DOI 10.1007/BF00332716; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANG JY, 1992, MOL MICROBIOL, V6, P1861, DOI 10.1111/j.1365-2958.1992.tb01358.x; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; YAMAMORI T, 1982, P NATL ACAD SCI-BIOL, V79, P860, DOI 10.1073/pnas.79.3.860; YAMAMORI T, 1980, J BACTERIOL, V142, P843, DOI 10.1128/JB.142.3.843-851.1980; YURA T, 1993, ANNU REV MICROBIOL, V47, P321, DOI 10.1146/annurev.mi.47.100193.001541; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425; ZYLICZ M, 1984, J BIOL CHEM, V259, P8820; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437	67	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29407	29414		10.1074/jbc.271.46.29407	http://dx.doi.org/10.1074/jbc.271.46.29407			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910606	hybrid			2022-12-27	WOS:A1996VT05200098
J	Skripkin, E; Paillart, JC; Marquet, R; Blumenfeld, M; Ehresmann, B; Ehresmann, C				Skripkin, E; Paillart, JC; Marquet, R; Blumenfeld, M; Ehresmann, B; Ehresmann, C			Mechanisms of inhibition of in vitro dimerization of HIV type I RNA by sense and antisense oligonucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SEQUENCE-SPECIFIC INHIBITION; REVERSE TRANSCRIPTION; INFECTED-CELLS; GENOMIC RNA; TARGET RNA; REPLICATION; COMPLEMENTARY; RECOMBINATION; PROTEIN	Retroviruses display a strong selective pressure to maintain the dimeric nature of their genomic RNAs, suggesting that dimerization is essential for viral replication. Recently, we identified the cis-element required for initiation of human immunodeficiency virus type I (HIV-I) RNA dimerization in vitro. The dimerization initiation site (DIS) is a hairpin structure containing a self complementary sequence in the loop. We proposed that dimerization is initiated by a loop-loop kissing interaction involving the self-complementary sequence present in each monomer. We tested the ability of sense and antisense oligonucleotides targeted against the DIS to interfere with a preformed viral RNA dimer. Self-dimerization and inhibition properties of the tested oligonucleotides are dictated by the nature of the loop. An RNA loop is absolutely required in the case of sense oligonucleotides, whereas the nature and the sequence of the stem is not important. They form reversible loop-loop interactions and act as competitive inhibitors. Antisense oligonucleotides are less efficient in self-dimerization and are more potent inhibitors than sense oligonucleotides. They are less sensitive to the nature of the loop than the antisense oligonucleotides. Antisense hairpins with either RNA or DNA stems are able to form highly stable and irreversible complexes with viral RNA, resulting from complete extension of base pairing initiated by loop-loop interaction.	INST BIOL MOL & CELLULAIRE, CNRS, UNITE PROPRE RECH 9002, F-67084 STRASBOURG, FRANCE; GENSET, F-75011 PARIS, FRANCE	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Paillart, Jean-Christophe/A-4171-2010	Paillart, Jean-Christophe/0000-0003-1647-8917; Marquet, Roland/0000-0002-4209-3976				Agrawal S, 1992, Antisense Res Dev, V2, P261; AGRAWAL S, 1989, P NATL ACAD SCI USA, V86, P7790, DOI 10.1073/pnas.86.20.7790; AGRAWAL S, 1988, P NATL ACAD SCI USA, V85, P7079, DOI 10.1073/pnas.85.19.7079; Agrawal S., 1994, J BIOTECH HEALTHCARE, V1, P167; ANAZODO MI, 1995, J VIROL, V69, P1794, DOI 10.1128/JVI.69.3.1794-1801.1995; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; BERKHOUT B, 1995, ANTIVIR RES, V26, P101, DOI 10.1016/0166-3542(94)00068-J; BERTRAND EL, 1994, EMBO J, V13, P2904, DOI 10.1002/j.1460-2075.1994.tb06585.x; BIETH E, 1990, NUCLEIC ACIDS RES, V18, P119, DOI 10.1093/nar/18.1.119; BORDIER B, 1995, P NATL ACAD SCI USA, V92, P9383, DOI 10.1073/pnas.92.20.9383; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y; EGUCHI Y, 1991, J MOL BIOL, V220, P831, DOI 10.1016/0022-2836(91)90356-B; EGUCHI Y, 1991, ANNU REV BIOCHEM, V60, P631, DOI 10.1146/annurev.bi.60.070191.003215; GOODCHILD J, 1988, P NATL ACAD SCI USA, V85, P5507, DOI 10.1073/pnas.85.15.5507; GORELICK RJ, 1990, ADV MOL BIOL TARGETE, P257; GRAHAM GJ, 1990, P NATL ACAD SCI USA, V87, P5817, DOI 10.1073/pnas.87.15.5817; GREGORIAN RS, 1995, J MOL BIOL, V248, P968, DOI 10.1006/jmbi.1995.0275; Haddrick M, 1996, J MOL BIOL, V259, P58, DOI 10.1006/jmbi.1996.0301; HOMANN M, 1993, J MOL BIOL, V233, P7, DOI 10.1006/jmbi.1993.1480; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; KIM HJ, 1994, VIROLOGY, V198, P336, DOI 10.1006/viro.1994.1037; KITTLE JD, 1989, J MOL BIOL, V210, P561, DOI 10.1016/0022-2836(89)90132-0; LAUGHREA M, 1994, BIOCHEMISTRY-US, V33, P13464, DOI 10.1021/bi00249a035; Laughrea M, 1996, BIOCHEMISTRY-US, V35, P1589, DOI 10.1021/bi951838f; LISZIEWICZ J, 1994, P NATL ACAD SCI USA, V91, P7942, DOI 10.1073/pnas.91.17.7942; LISZIEWICZ J, 1993, P NATL ACAD SCI USA, V90, P3860, DOI 10.1073/pnas.90.9.3860; MARQUET R, 1994, NUCLEIC ACIDS RES, V22, P145, DOI 10.1093/nar/22.2.145; MARQUET R, 1991, NUCLEIC ACIDS RES, V19, P2349, DOI 10.1093/nar/19.9.2349; McBride MS, 1996, J VIROL, V70, P2963, DOI 10.1128/JVI.70.5.2963-2973.1996; MIRABELLI CK, 1993, ANTISENSE RES APPL, P7; MURIAUX D, 1995, J BIOL CHEM, V270, P8209, DOI 10.1074/jbc.270.14.8209; MYERS G, 1995, HUMAN RETROVIRUSES A, pIA2; PAILLART JC, 1994, J BIOL CHEM, V269, P27486; Paillart JC, 1996, P NATL ACAD SCI USA, V93, P5572, DOI 10.1073/pnas.93.11.5572; PAILLART JC, 1996, IN PRESS J VIROL; PANGANIBAN AT, 1988, SCIENCE, V241, P1064, DOI 10.1126/science.2457948; PERSSON C, 1990, EMBO J, V9, P3767, DOI 10.1002/j.1460-2075.1990.tb07590.x; Riesner D., 1991, ADV ELECTROPHORESIS, V4, P169; SCZAKIEL G, 1992, ANN NY ACAD SCI, V660, P268, DOI 10.1111/j.1749-6632.1992.tb21080.x; SIMONS RW, 1993, ANTISENSE RES APPLIC, P97; SKRIPKIN E, 1994, P NATL ACAD SCI USA, V91, P4945, DOI 10.1073/pnas.91.11.4945; STUHLMANN H, 1992, J VIROL, V66, P2378, DOI 10.1128/JVI.66.4.2378-2388.1992; SULLENGER BA, 1990, CELL, V63, P601, DOI 10.1016/0092-8674(90)90455-N; TAKAYAMA KM, 1990, CRIT REV BIOCHEM MOL, V25, P155, DOI 10.3109/10409239009090608; TEMIN HM, 1993, P NATL ACAD SCI USA, V90, P6900, DOI 10.1073/pnas.90.15.6900; TOMIZAWA J, 1990, J MOL BIOL, V212, P683, DOI 10.1016/0022-2836(90)90230-J; VICKERS T, 1991, NUCLEIC ACIDS RES, V19, P3359, DOI 10.1093/nar/19.12.3359; WAGNER EGH, 1994, ANNU REV MICROBIOL, V48, P713, DOI 10.1146/annurev.mi.48.100194.003433	49	36	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28812	28817		10.1074/jbc.271.46.28812	http://dx.doi.org/10.1074/jbc.271.46.28812			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910525	hybrid			2022-12-27	WOS:A1996VT05200017
J	Kusk, P; John, S; Fragoso, G; Michelotti, J; Hager, GL				Kusk, P; John, S; Fragoso, G; Michelotti, J; Hager, GL			Characterization of an NF-1/CTF family member as a functional activator of the mouse mammary tumor virus long terminal repeat 5' enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; TGGCA-BINDING PROTEIN; TRANSGENIC MICE; DNA-REPLICATION; GLUCOCORTICOID REGULATION; TRANSCRIPTION FACTOR; PROVIRAL ACTIVATION; RESPONSIVE ELEMENT; ONCOGENE INT-1; ADENOVIRUS DNA	The long terminal repeat of the mouse mammary tumor virus restricts virus expression primarily to the mammary epithelium. The extreme 5' end of the long terminal repeat contains an enhancer that has been associated with tissue-specific expression of the virus. A total of six functional cis-acting elements have been identified in the enhancer. Although proteins binding to these elements have been reported, only one has been identified; this factor, mp5, is identical or closely related to the transcription factor AP-2 (Mellentin-Michelotti, J., John, S., Pennie, W. D., Williams, T., and Hager, G. L. (1994) J. Biol. Chem. 269, 31983-31990). The other factors are hitherto unidentified and poorly described. We report here the characterization of another of the six elements, previously referred to as the F3 site (Mink, S., Hartig, E., Jennewein, P., Doppler, W., and Cato, A. C. (1992) Mol. Cell Biol, 12, 4906-4918), We show that the F3 binding activity and AP-2 act synergistically to enhance mouse mammary tumor virus-directed transcription, but only in the presence of glucocorticoid hormone, The F3 element has an NF-l-like half-site, but the activity recognizing this element has binding characteristics distinct from the NF-1/CTF family as well as the rest of the CCAAT-binding proteins. We conclude that the F3 activity represents a new member of the NF-1/CTF family.	NCI,LAB RECEPTOR BIOL & GENE EXPRESS,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ALAM T, 1993, J BIOL CHEM, V268, P15681; BENOR S, 1993, MOL CELL BIOL, V13, P331, DOI 10.1128/MCB.13.1.331; BORGMEYER U, 1984, NUCLEIC ACIDS RES, V12, P4295, DOI 10.1093/nar/12.10.4295; BUETTI E, 1989, NUCLEIC ACIDS RES, V17, P3065, DOI 10.1093/nar/17.8.3065; BUETTI E, 1986, J MOL BIOL, V190, P379, DOI 10.1016/0022-2836(86)90009-4; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; GUNZBURG WH, 1992, BIOCHEM J, V283, P625; HENRARD D, 1988, J VIROL, V62, P3046, DOI 10.1128/JVI.62.8.3046-3049.1988; HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KENNEDY GC, 1990, J BIOL CHEM, V265, P6279; KRUSE U, 1994, FEBS LETT, V348, P46, DOI 10.1016/0014-5793(94)00585-0; KUSK P, 1995, MOL ENDOCRINOL, V9, P1180, DOI 10.1210/me.9.9.1180; LEEGWATER PAJ, 1985, EMBO J, V4, P1515, DOI 10.1002/j.1460-2075.1985.tb03811.x; LEFEBVRE P, 1991, MOL CELL BIOL, V11, P2529, DOI 10.1128/MCB.11.5.2529; MELLENTINMICHELOTTI J, 1994, J BIOL CHEM, V269, P31983; MIKSICEK R, 1987, EMBO J, V6, P1355, DOI 10.1002/j.1460-2075.1987.tb02375.x; MINK S, 1992, MOL CELL BIOL, V12, P4906, DOI 10.1128/MCB.12.11.4906; MIWA K, 1987, P NATL ACAD SCI USA, V84, P4939, DOI 10.1073/pnas.84.14.4939; MOK E, 1992, J VIROL, V66, P7529, DOI 10.1128/JVI.66.12.7529-7532.1992; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P6177, DOI 10.1073/pnas.80.20.6177; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; OSTROWSKI MC, 1983, MOL CELL BIOL, V3, P2045, DOI 10.1128/MCB.3.11.2045; PARKS WP, 1976, CELL, V8, P87, DOI 10.1016/0092-8674(76)90189-6; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; ROSS SR, 1990, MOL CELL BIOL, V10, P5822, DOI 10.1128/MCB.10.11.5822; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SONNENBERG A, 1987, EMBO J, V6, P121, DOI 10.1002/j.1460-2075.1987.tb04728.x; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STEWART TA, 1988, MOL CELL BIOL, V8, P473, DOI 10.1128/MCB.8.1.473; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VANLEEUWEN F, 1995, SEMIN CANCER BIOL, V6, P127, DOI 10.1006/scbi.1995.0018; VANOOYEN A, 1984, CELL, V39, P233, DOI 10.1016/0092-8674(84)90209-5; WORKMAN JL, 1985, BIOCHEMISTRY-US, V24, P4731, DOI 10.1021/bi00339a004; YANAGAWA S, 1991, J VIROL, V65, P526, DOI 10.1128/JVI.65.1.526-531.1991	47	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31269	31276		10.1074/jbc.271.49.31269	http://dx.doi.org/10.1074/jbc.271.49.31269			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940131	hybrid			2022-12-27	WOS:A1996VW68600042
J	Magnifico, A; Tagliabue, E; Buto, S; Ardini, E; Castronovo, V; Colnaghi, MI; Menard, S				Magnifico, A; Tagliabue, E; Buto, S; Ardini, E; Castronovo, V; Colnaghi, MI; Menard, S			Peptide G, containing the binding site of the 67-kDa laminin receptor, increases and stabilizes laminin binding to cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST CARCINOMAS; MELANOMA-CELLS; PROGNOSTIC-SIGNIFICANCE; SURFACE LAMININ; TUMOR INVASION; EXPRESSION; INTEGRIN; AFFINITY; METASTASIS; PROTEIN	We investigated the effect of peptide G, a synthetic peptide derived from the sequence of the 37-kDa laminin receptor precursor, on the interaction of laminin in two tumor cell lines one of which produces laminin and one of which does not, Addition of peptide G to the culture medium induced a significant increase in the amount of endogenous laminin detectable on the cell membrane of both cell lines, Moreover, pretreatment of exogenous laminin with peptide G dramatically increased laminin binding on both cell lines, Kinetics analysis of membrane-bound labeled laminin revealed a 3-fold decrease in the k(d) of peptide G-treated laminin compared with untreated or unrelated or scrambled peptide-treated laminin, Moreover, the affinity constant of peptide cr-treated laminin increased S-fold, with a doubling of the number of laminin binding sites, as de termined by Scatchard analysis, Expression of the VLA6 integrin receptor on the cell membrane increased after incubation with peptide G-treated laminin, However, the lower binding inhibition of peptide G-treated laminin after anti-VLA6 antibody or cation chelation treatment indicates that membrane molecules in addition to integrin receptors are involved in the recognition of peptide G-modified laminin, These ''new'' laminin-binding proteins also mediated cell adhesion to laminin, the first step in tumor invasion, Together, the data suggest that peptide G increases and stabilizes laminin binding on tumor cells, involving surface receptors that normally do not take part in this interaction, This might explain the abundant clinical and experimental data suggesting a key role for the 67-kDa laminin receptor in the interaction between cancer cells and the basement membrane glycoprotein laminin during tumor invasion and metastasis.	IST NAZL TUMORI, DIV EXPT ONCOL E, I-20133 MILAN, ITALY; UNIV LIEGE, METASTASIS RES LAB, B-4000 LIEGE 1, BELGIUM	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Liege			Tagliabue, Elda/B-9377-2017	Tagliabue, Elda/0000-0001-9877-2903				ALBELDA SM, 1993, LAB INVEST, V68, P4; BOTTINI C, 1993, INT J CANCER, V54, P261, DOI 10.1002/ijc.2910540217; CANEVARI S, 1985, J NATL CANCER I, V75, P831, DOI 10.1093/jnci/75.5.831; CASALINI P, 1991, INT J CANCER, V48, P284, DOI 10.1002/ijc.2910480222; CASTRONOVO V, 1991, CANCER RES, V51, P5672; CASTRONOVO V, 1991, J BIOL CHEM, V266, P20440; CASTRONOVO V, 1993, INVAS METAST, V13, P1; CASTRONOVO V, 1991, BIOCHEM BIOPH RES CO, V177, P177, DOI 10.1016/0006-291X(91)91965-F; CASTRONOVO V, 1990, AM J PATHOL, V137, P1373; CIOCE V, 1991, J NATL CANCER I, V83, P29, DOI 10.1093/jnci/83.1.29; DAVIS CM, 1991, EXP CELL RES, V193, P262, DOI 10.1016/0014-4827(91)90095-C; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; FELDMAN LE, 1991, CANCER RES, V51, P1065; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; GROSSO LE, 1991, BIOCHEMISTRY-US, V30, P3346, DOI 10.1021/bi00227a026; GUO NH, 1992, J BIOL CHEM, V267, P17743; HAND PH, 1985, CANCER RES, V45, P2713; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Karpatova M, 1996, J CELL BIOCHEM, V60, P226; KLEINMAN HK, 1991, ARCH BIOCHEM BIOPHYS, V290, P320, DOI 10.1016/0003-9861(91)90547-V; KLEINMAN HK, 1988, P NATL ACAD SCI USA, V85, P1282, DOI 10.1073/pnas.85.4.1282; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; LIOTTA LA, 1983, LAB INVEST, V49, P636; LIOTTA LA, 1986, CANCER RES, V46, P1; MALINOFF HL, 1984, INT J CANCER, V33, P651, DOI 10.1002/ijc.2910330516; MARTIGNONE S, 1992, CLIN EXP METASTAS, V10, P379, DOI 10.1007/BF00133466; MARTIGNONE S, 1993, J NATL CANCER I, V85, P398, DOI 10.1093/jnci/85.5.398; MECHAM RP, 1991, J CELL BIOL, V113, P187, DOI 10.1083/jcb.113.1.187; MERCURIO AM, 1995, TRENDS CELL BIOL, V5, P419, DOI 10.1016/S0962-8924(00)89100-X; PELLEGRINI R, 1994, INT J CANCER, P116; PELLEGRINI R, 1995, BREAST CANCER RES TR, V35, P195, DOI 10.1007/BF00668209; RAMOS DM, 1990, CANCER RES, V50, P728; RAO CN, 1989, BIOCHEMISTRY-US, V28, P7476, DOI 10.1021/bi00444a047; ROMANOV V, 1994, CELL ADHES COMMUN, V2, P201, DOI 10.3109/15419069409004438; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; TARABOLETTI G, 1993, J NATL CANCER I, V85, P235, DOI 10.1093/jnci/85.3.235; VARANI J, 1983, AM J PATHOL, V111, P27; WANG KS, 1992, J VIROL, V66, P4992, DOI 10.1128/JVI.66.8.4992-5001.1992; WEWER UM, 1987, CANCER RES, V47, P5691; YOW HK, 1988, P NATL ACAD SCI USA, V85, P6394, DOI 10.1073/pnas.85.17.6394	40	43	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31179	31184		10.1074/jbc.271.49.31179	http://dx.doi.org/10.1074/jbc.271.49.31179			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940117	hybrid			2022-12-27	WOS:A1996VW68600028
J	Chook, YM; Gish, GD; Kay, CM; Pai, EF; Pawson, T				Chook, YM; Gish, GD; Kay, CM; Pai, EF; Pawson, T			The Grb2-mSos1 complex binds phosphopeptides with higher affinity than Grb2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; EXCHANGE FACTOR SON; MAP KINASE PHOSPHORYLATION; TERMINAL SH3 DOMAIN; SIGNAL-TRANSDUCTION; PHOSPHOTYROSINE MOTIFS; TYROSINE KINASES; RAS; ACTIVATION; RECEPTOR	Epidermal growth factor (EGF) stimulation leads to autophosphorylation of the epidermal growth factor receptor (EGFR) and tyrosine phosphorylation of Shc. The Grb2 SH2 domain binds to Tyr(1068) of EGFR and Tyr(317) of Shc while its SH3 domains bind to mSos1. Therefore, EGF treatment potentially results in the formation of several multimeric signaling complexes, including EGFR-Grb2-mSos1, EGFR-Shc-Grb2-mSos1, and Shc-Grb2-mSos1, linking the receptor to activation of the Ras GTPase. We have purified Grb2, mSos1, and the Grb2-mSos1 complex to high homogeneity, and used these isolated proteins to obtain binding affinities of mSos1 for Grb2 and of either Grb2 or Grb2-mSos1 for phosphotyrosine-containing peptides. mSos1 bound Grb2 with a K-D of 0.4 mu M; the stoichiometry of the Grb2-mSos1 complex was 1:1. An EGFR-derived phosphopeptide bound Grb2 with a K-D of 0.7 mu M, whereas the Shc-derived phosphopeptide bound Grb2 with a K-D of 0.2 mu M. Since Grb2 exists in a stable complex with mSos1, and both proteins can exist in a constitutive complex in unstimulated cells, we performed phosphopeptide binding studies on the Grb2-mSos1 complex to gain a better understanding of binding events in the intact cell. Grb2-mSos1 bound to both EGFR- and Shc-derived phosphopeptides with higher affinities (K-D of 0.3 mu M and 31 nM, respectively) than Grb2 alone. These findings suggest that the proximity of mSos1 to Grb2 in the complex can influence the interactions of the Grb2 SH2 domain with phosphopeptides and raise the possibility that in the Grb2-mSos1 complex the SH2 and SH3 domains of Grb2 are not independent of each other but may be indirectly linked by mSos1.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, PROGRAM MOL BIOL & CANC, TORONTO, ON M5G 1X5, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO, ON M5S 1A8, CANADA; UNIV ALBERTA, DEPT BIOCHEM, MRC, GRP PROT STRUCT & FUNCT, EDMONTON, AB T6G 2H7, CANADA; PROT ENGN NETWORK CTR EXCELLENCE, EDMONTON, AB T6G 2H7, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Alberta			Chook, Yuh Min/AAA-9549-2019; Pai, Emil/R-8908-2019; Pai, Emil F/D-2526-2013; Gish, Gerald D/C-7228-2017; Pawson, Tony J/E-4578-2013	Pai, Emil/0000-0002-1162-7242; 				BABUL J, 1969, ANAL BIOCHEM, V28, P216, DOI 10.1016/0003-2697(69)90172-9; BASU T, 1994, ONCOGENE, V9, P3483; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUDAY L, 1995, ONCOGENE, V11, P1327; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; GELIN BR, 1983, J MOL BIOL, V171, P489, DOI 10.1016/0022-2836(83)90042-6; GOUDREAU N, 1994, NAT STRUCT BIOL, V1, P898, DOI 10.1038/nsb1294-898; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; LEMMON MA, 1994, J BIOL CHEM, V269, P31653; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SATOH T, 1992, J BIOL CHEM, V267, P24149; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; TERASAWA H, 1994, NAT STRUCT BIOL, V1, P891, DOI 10.1038/nsb1294-891; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; Waters SB, 1996, J BIOL CHEM, V271, P18224, DOI 10.1074/jbc.271.30.18224; WITTEKIND M, 1994, BIOCHEMISTRY-US, V33, P13531, DOI 10.1021/bi00250a004; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	38	63	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30472	30478		10.1074/jbc.271.48.30472	http://dx.doi.org/10.1074/jbc.271.48.30472			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940013	hybrid			2022-12-27	WOS:A1996VV15800030
J	Fenton, SE; Groce, NS; Lee, DC				Fenton, SE; Groce, NS; Lee, DC			Characterization of the mouse epidermal growth factor promoter and 5'-flanking region - Role for an atypical TATA sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOPE FIBROMA VIRUS; FACTOR-ALPHA; MESSENGER-RNA; SUBMANDIBULAR-GLAND; FACTOR GENE; BINDING-SITE; EXPRESSION; TRANSCRIPTION; CELLS; LOCALIZATION	As a step toward delineating mechanisms that regulate its activity, we have characterized the mouse epidermal growth factor (EGF) promoter, Primer extension and S1 nuclease analyses identified prominent (+1/+2) and minor (+28) transcription start sites, with the dominant +1/+2 site located 33 bases downstream from a TTTAAA sequence, A restriction fragment that spanned these start sites and contained 390 base pairs of 6'-flanking sequence directed transcription from the +1/+2 site in vitro in the presence of HeLa cell nuclear extracts. Additionally, it promoted expression of a coupled luciferase reporter gene in transfected cell lines, The inclusion of additional 5'-flanking sequence either stimulated or inhibited luciferase expression depending on the cell line. Approximately 2 kilobases of EGF 5'-flanking sequence was determined and found to contain several motifs with partial homology to steroid hormone response elements. Despite this fact and evidence that EGF expression might be regulated by androgens in vitro, EGF promoter-luciferase constructs were not steroid-responsive in cells cotransfected with steroid receptor expression vectors. An oligonucleotide containing the aforementioned TTTAAA sequence specifically bound TATA-binding protein and TFILA in gel shift assays, and an EGF promoter-luciferase construct in which the core TA dinucleotide was mutated to CG was not active in transfected cells. These data suggest that the TTTAAA sequence functions as an atypical TATA box.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT MICROBIOL & IMMUNOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Chesters, Heather/C-6089-2009		NCI NIH HHS [CA63775, CA43793, CA09156] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009156, F32CA063775, R01CA043793] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER AJ, 1993, MOL CELL BIOL, V13, P6326, DOI 10.1128/MCB.13.10.6326; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARTHE PL, 1974, ENDOCRINOLOGY, V95, P1019, DOI 10.1210/endo-95-4-1019; BARTON CM, 1991, J PATHOL, V163, P111, DOI 10.1002/path.1711630206; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BLASBAND AJ, 1990, MOL CELL BIOL, V10, P2111, DOI 10.1128/MCB.10.5.2111; BULLOCK LP, 1975, ENDOCRINOLOGY, V97, P189, DOI 10.1210/endo-97-1-189; CARPENTER G, 1990, PEPTIDE GROWTH FACTO, V1; CHANG W, 1987, MOL CELL BIOL, V7, P535, DOI 10.1128/MCB.7.1.535; CHANG W, 1990, VIROLOGY, V179, P926, DOI 10.1016/0042-6822(90)90170-V; CHAPDELAINE P, 1991, DNA CELL BIOL, V10, P49, DOI 10.1089/dna.1991.10.49; COHEN S, 1962, J BIOL CHEM, V237, P1555; DIAUGUSTINE RP, 1988, ENDOCRINOLOGY, V122, P2355, DOI 10.1210/endo-122-6-2355; ELDER JB, 1978, NATURE, V271, P466, DOI 10.1038/271466a0; FENTON SE, 1991, BIOCHEM BIOPH RES CO, V181, P1063, DOI 10.1016/0006-291X(91)92045-L; FOWLER JE, 1988, J UROLOGY, V139, P857, DOI 10.1016/S0022-5347(17)42662-0; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; GREGORY H, 1975, NATURE, V257, P325, DOI 10.1038/257325a0; GUBITS RM, 1986, ENDOCRINOLOGY, V119, P1382, DOI 10.1210/endo-119-3-1382; GUZOWSKI JF, 1993, J VIROL, V67, P5098, DOI 10.1128/JVI.67.9.5098-5108.1993; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOSOI K, 1992, ENDOCRINOLOGY, V130, P1044, DOI 10.1210/en.130.2.1044; ISAACS JT, 1991, S GROWTH FACT REPROD; KIM Y, 1995, BIOL CHEM H-S, V376, P431; KOHLER M, 1989, ANTICANCER RES, V9, P1537; LEE DC, 1995, PHARMACOL REV, V47, P51; LUND SD, 1991, MOL CELL BIOL, V11, P5426, DOI 10.1128/MCB.11.11.5426; MORRELL JI, 1987, J HISTOCHEM CYTOCHEM, V35, P1053, DOI 10.1177/35.10.3624850; MULLICK J, 1995, BIOCHEMISTRY-US, V34, P13729, DOI 10.1021/bi00042a003; PASCALL JC, 1988, J MOL ENDOCRINOL, V1, P5, DOI 10.1677/jme.0.0010005; PASCALL JC, 1989, J ENDOCRINOL, V121, P501, DOI 10.1677/joe.0.1210501; PIERCE AJ, 1992, NUCLEIC ACIDS RES, V20, P6583, DOI 10.1093/nar/20.24.6583; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; RALL LB, 1985, NATURE, V313, P228, DOI 10.1038/313228a0; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; SALIDO EC, 1990, DIFFERENTIATION, V45, P38, DOI 10.1111/j.1432-0436.1990.tb00454.x; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASADA R, 1993, BIOCHEM BIOPH RES CO, V190, P1173, DOI 10.1006/bbrc.1993.1173; SCOTT J, 1983, SCIENCE, V221, P236, DOI 10.1126/science.6602382; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SNEDEKER SM, 1991, P NATL ACAD SCI USA, V88, P276, DOI 10.1073/pnas.88.1.276; SUGIYAMA K, 1990, CANCER, V63, P1557; TAVIANINI MA, 1984, J BIOL CHEM, V259, P1798; TODARO GJ, 1976, NATURE, V264, P26, DOI 10.1038/264026a0; TODARO GJ, 1978, CANCER RES, V38, P4147; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; YAMAHARA M, 1988, VIRCHOWS ARCH A, V412, P301, DOI 10.1007/BF00750255	53	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30870	30878		10.1074/jbc.271.48.30870	http://dx.doi.org/10.1074/jbc.271.48.30870			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940071	hybrid			2022-12-27	WOS:A1996VV15800088
J	Gessner, JE; Grussenmeyer, T; Dumbsky, M; Schmidt, RE				Gessner, JE; Grussenmeyer, T; Dumbsky, M; Schmidt, RE			Separate promoters from proximal and medial control regions contribute to the natural killer cell-specific transcription of the human Fc gamma RIII-A (CD16-A) receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR MESANGIAL CELLS; BINDING-SITE; EXPRESSION; ACTIVATION; IGG; NEUTROPHILS; IDENTIFICATION; CHAIN; ACID; LINE	The molecular events governing the differentiation pathway of natural killer (Mt) cells are not well understood. The phenotype of mature NK cells is specified by the expression of the low affinity Fc receptor for IgG (human Fc gamma RIII, CD16) encoded by the Fc gamma RIII-A gene. Here we report that the Pprox promoter (-198/-10) of Fc gamma RIII-A stimulated by its own intron enhancer (+10/+712) was only one of the cis-elements that target the expression of a reporter gene in the immature NK cell line, YT. The transcription start sites of the Fc gamma RIII-A a2/3 and a5/6 splice alternatives in NK cells were mapped to the medial -1817/-850 Fc gamma RIII-A control region. Two promoters, Pmedl (-942/-850) and Pmed2 (-1376/-1123) resided in this region and controlled for the initiation of these transcript classes encoding the known Fc gamma RIII-A receptor protein. Deletion mapping studies demonstrated that the 93 base pairs -942/-850 Pmedl sequence was sufficient to confer cell type specific expression in YT cells. The 5' end of Pmedl (-942 to -921) was required for full promoter function indicating the presence of an important sequence motif recognized by a YT-specific factor. Our data suggest that this motif might be a useful tool for subsequent identification of putative transcription factors uniquely active in YT and Nh cells.			Gessner, JE (corresponding author), HANNOVER MED SCH,DEPT CLIN IMMUNOL,KONSTANTY GUTSCHOW STR 8,D-30625 HANNOVER,GERMANY.		Grussenmeyer, Thomas/B-9859-2009	Grussenmeyer, Thomas/0000-0002-6236-9976				ANDERSON P, 1990, P NATL ACAD SCI USA, V87, P2274, DOI 10.1073/pnas.87.6.2274; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEVERS HC, 1993, IMMUNOL TODAY, V14, P591, DOI 10.1016/0167-5699(93)90198-T; COLLINS SJ, 1987, BLOOD, V70, P1233; GESSNER JE, 1995, IMMUN INFEKT, V23, P67; GESSNER JE, 1995, IMMUNOBIOLOGY, V193, P341, DOI 10.1016/S0171-2985(11)80564-4; GESSNER JE, 1995, J BIOL CHEM, V270, P1350, DOI 10.1074/jbc.270.3.1350; GUMPERZ JE, 1995, NATURE, V378, P245, DOI 10.1038/378245a0; HOFFMEYER F, 1995, J IMMUNOL, V155, P4016; HUNDT M, 1992, EUR J IMMUNOL, V22, P811, DOI 10.1002/eji.1830220327; KOIZUMI H, 1993, MOL CELL BIOL, V13, P6690, DOI 10.1128/MCB.13.11.6690; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; LEIDEN JM, 1992, IMMUNOL TODAY, V13, P22, DOI 10.1016/0167-5699(92)90200-Q; Li M, 1996, J EXP MED, V183, P1259, DOI 10.1084/jem.183.3.1259; PELTZ GA, 1989, P NATL ACAD SCI USA, V86, P1013, DOI 10.1073/pnas.86.3.1013; PHILLIPS JH, 1991, EUR J IMMUNOL, V21, P895, DOI 10.1002/eji.1830210406; RADEKE HH, 1994, J IMMUNOL, V153, P1281; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; ROBERTSON MJ, 1990, BLOOD, V76, P2421; STOCKL J, 1995, J IMMUNOL, V154, P5452; Tamm A, 1996, J BIOL CHEM, V271, P3659; UCIECHOWSKI P, 1992, EUR J IMMUNOL, V22, P1635, DOI 10.1002/eji.1830220643; UCIECHOWSKI P, 1992, IMMUNOBIOLOGY, V165, P28; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; WERFEL T, 1989, J IMMUNOL, V142, P1102; YODOI J, 1985, J IMMUNOL, V134, P1623; ZHOU MJ, 1994, J CELL BIOL, V125, P1407, DOI 10.1083/jcb.125.6.1407	27	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30755	30764		10.1074/jbc.271.48.30755	http://dx.doi.org/10.1074/jbc.271.48.30755			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940055	hybrid			2022-12-27	WOS:A1996VV15800072
J	Furlong, EEM; Keon, NK; Thornton, FD; Rein, T; Martin, F				Furlong, EEM; Keon, NK; Thornton, FD; Rein, T; Martin, F			Expression of a 74-kDa nuclear factor 1 (NF1) protein is induced in mouse mammary gland involution - Involution-enhanced occupation of a twin NF1 binding element in the testosterone-repressed prostate message-2/clustertin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-SPECIFIC TRANSCRIPTION; ADENOVIRUS DNA-REPLICATION; HORMONE PROXIMAL SILENCER; FACTOR-I FAMILY; GENE-EXPRESSION; EXTRACELLULAR-MATRIX; CELL-DEATH; EPITHELIAL-CELLS; SULFATED GLYCOPROTEIN-2; BASEMENT-MEMBRANE	Testosterone repressed prostate message-2 (TRPM-2)/clusterin gene expression is rapidly induced in early involution of the mouse mammary gland, after weaning, and in the rat ventral prostate, after castration, A search for involution-enhanced DNaseI footprints in the proximal mouse TRPM-2/clusterin gene promoter led to the identification and characterization (by DNase I footprinting and EMSA) of a twin nuclear factor 1 (NF1) binding element at -356/-309, relative to the proposed transcription start site; nuclear extracts from 2-day involuting mouse mammary gland showed an enhanced footprint over the proximal NF1 element; extracts from involuting prostate showed enhanced occupancy of both NF1 binding elements. Subsequent EMSA and Western analysis led to the detection of a 74-kDa NF1 protein whose expression is triggered in early involution in the mouse mammary gland; such an induced protein is not found in the involuting rat ventral prostate, This protein was not found in lactation where three other NF1 proteins of 114, 68, and 46 kDa were detected. Reiteration of the epithelial cell apoptosis associated with early mammary gland involution, in vitro, in a primary cell culture system, triggered the appearance of the 74-kDa NF1, Overlaying the cells with laminin-rich extracellular matrix suppressed the apoptosis and the expression of the 74-kDa NF1 and, in the presence of lactogenic hormones, initiated milk protein gene expression and the expression of two of the lactation-associated NF1 proteins (68 and 46 kDa), This study, thus, identifies for the first time the occurrence of a switch in expression of different members of the family of NF1 transcription factors as mammary epithelial cells move from the differentiated to the involution/apoptotic state, and it is likely that the involution-specific 74-kDa NF1 accounts for the enhanced NF1 footprint detected on the TRPM-2/clusterin promoter with extracts of mouse mammary gland.	NATL UNIV IRELAND UNIV COLL DUBLIN,DEPT PHARMACOL,DUBLIN 4,IRELAND; NATL UNIV IRELAND UNIV COLL DUBLIN,CTR BIOTECHNOL,DUBLIN 4,IRELAND; UNIV MUNICH,INST BIOCHEM,D-8000 MUNICH 2,GERMANY	University College Dublin; University College Dublin; University of Munich				Furlong, Eileen/0000-0002-9544-8339; Rein, Theo/0000-0003-2850-4289				ADAMS AD, 1995, J BIOL CHEM, V270, P6975, DOI 10.1074/jbc.270.12.6975; AMEMIYA K, 1992, J BIOL CHEM, V267, P14204; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; APT D, 1994, NUCLEIC ACIDS RES, V22, P3825, DOI 10.1093/nar/22.19.3825; APT D, 1993, J VIROL, V67, P4455, DOI 10.1128/JVI.67.8.4455-4463.1993; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; ARENDS MJ, 1990, AM J PATHOL, V136, P593; AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, V2; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; BARCELLOSHOFF MH, 1989, DEVELOPMENT, V105, P223; BETTUZZI S, 1991, BIOCHEM BIOPH RES CO, V175, P810, DOI 10.1016/0006-291X(91)91637-R; BLUM JL, 1988, J CELL PHYSIOL, V135, P13, DOI 10.1002/jcp.1041350103; BORGMEYER U, 1984, NUCLEIC ACIDS RES, V12, P4295, DOI 10.1093/nar/12.10.4295; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; EARNSHAW WC, 1995, TRENDS CELL BIOL, V5, P217, DOI 10.1016/S0962-8924(00)89006-6; ENGLISH HF, 1987, PROSTATE, V11, P229, DOI 10.1002/pros.2990110304; EUL J, 1989, EMBO J, V8, P83, DOI 10.1002/j.1460-2075.1989.tb03351.x; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GOUNARI F, 1990, EMBO J, V9, P559, DOI 10.1002/j.1460-2075.1990.tb08143.x; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GRISWOLD MD, 1986, BIOCHEMISTRY-US, V25, P7265, DOI 10.1021/bi00371a003; GURLEY LR, 1973, BIOCHEMISTRY-US, V12, P237, DOI 10.1021/bi00726a010; HAY RT, 1985, EMBO J, V1, P421; HENNIGHAUSEN LG, 1982, EUR J BIOCHEM, V125, P131, DOI 10.1111/j.1432-1033.1982.tb06660.x; INOUE T, 1990, J BIOL CHEM, V265, P19065; IVANOV V I, 1990, Molekulyarnaya Biologiya (Moscow), V24, P1605; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; KAWAMURA H, 1993, BIOCHEM BIOPH RES CO, V192, P1424, DOI 10.1006/bbrc.1993.1575; KIRSZBAUM L, 1989, EMBO J, V8, P711, DOI 10.1002/j.1460-2075.1989.tb03430.x; LEE EYH, 1984, J CELL BIOL, V98, P8831; LI S, 1995, MOL CELL BIOL, V15, P2063; LI S, 1994, J BIOL CHEM, V269, P14235; LUBON H, 1987, NUCLEIC ACIDS RES, V15, P2103, DOI 10.1093/nar/15.5.2103; LUBON H, 1988, BIOCHEM J, V256, P391, DOI 10.1042/bj2560391; LUND RL, 1996, DEVELOPMENT CAMB, V122, P181; MARTI A, 1994, ONCOGENE, V9, P1213; MINK S, 1992, MOL CELL BIOL, V12, P4906, DOI 10.1128/MCB.12.11.4906; MUL YM, 1992, EMBO J, V11, P751, DOI 10.1002/j.1460-2075.1992.tb05108.x; NEBL G, 1994, J BIOL CHEM, V269, P7371; NOVAK A, 1992, J BIOL CHEM, V267, P12986; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; Rajput B, 1996, J BIOL CHEM, V271, P5131, DOI 10.1074/jbc.271.9.5131; REIFELMILLER AE, 1994, J BIOL CHEM, V269, P23861; REIN T, 1995, J BIOL CHEM, V270, P19643, DOI 10.1074/jbc.270.33.19643; ROBIDOUX S, 1992, MOL CELL BIOL, V12, P3796, DOI 10.1128/MCB.12.9.3796; ROSKELLEY CD, 1995, CURR OPIN CELL BIOL, V7, P736, DOI 10.1016/0955-0674(95)80117-0; ROY RJ, 1994, EUR J BIOCHEM, V225, P419, DOI 10.1111/j.1432-1033.1994.00419.x; ROY RJ, 1994, EUR J BIOCHEM, V219, P799, DOI 10.1111/j.1432-1033.1994.tb18560.x; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SAWCZUK IS, 1989, KIDNEY INT, V35, P1315, DOI 10.1038/ki.1989.128; SENSIBAR JA, 1991, ENDOCRINOLOGY, V128, P2091, DOI 10.1210/endo-128-4-2091; STRANGE R, 1992, DEVELOPMENT, V115, P49; STREULI CH, 1995, J CELL BIOL, V129, P591, DOI 10.1083/jcb.129.3.591; STREULI CH, 1990, J CELL BIOL, V110, P1405; STREULI CH, 1995, J BIOL CHEM, V270, P21639, DOI 10.1074/jbc.270.37.21639; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; STUDZINSKI GP, 1995, CELL GROWTH APOPTOSI, P132; SZABO P, 1995, J BIOL CHEM, V270, P10212, DOI 10.1074/jbc.270.17.10212; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; WASTON CJ, 1991, NUCLEIC ACIDS RES, V19, P6603; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WONG P, 1994, EUR J BIOCHEM, V221, P917, DOI 10.1111/j.1432-1033.1994.tb18807.x; WONG P, 1993, J BIOL CHEM, V268, P5021; YULEE LY, 1986, NUCLEIC ACIDS RES, V14, P1883, DOI 10.1093/nar/14.4.1883	70	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29688	29697		10.1074/jbc.271.47.29688	http://dx.doi.org/10.1074/jbc.271.47.29688			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939902	hybrid			2022-12-27	WOS:A1996VU52500030
J	Nicolini, G; Miloso, M; Moroni, MC; Beguinot, L; Scotto, L				Nicolini, G; Miloso, M; Moroni, MC; Beguinot, L; Scotto, L			Post-transcriptional control regulates transforming growth factor alpha in the human carcinoma KB cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIH 3T3 CELLS; MESSENGER-RNA; EGF-RECEPTOR; AUTOCRINE GROWTH; GENE-EXPRESSION; PHORBOL ESTER; INTERLEUKIN-3; PHENOTYPE; CANCER	Expression of epidermal growth factor receptor (EGF-R) antisense RNA results in a drastic reduction of EGF-R levels in the human carcinoma KB cell line and induces a reversion of their transformed phenotype (Moroni, M. C., Willingham, M. C., and Beguinot, L. (1992) J. Biol. Chem. 267, 2714-2722), We used parental and EGF-R antisense KB clones as a genetic system to study, in the same cell line, the role of transforming growth factor alpha (TGF-alpha) in the establishment and maintenance of the transformed phenotype, KB cells produce TGF-alpha mRNA, and their conditioned medium is able to sustain growth of antisense cells, mimicking the effect of exogenous EGF or TGF-alpha. In antisense cells there is a marked reduction of TGF-alpha mRNA steady-state levels. In addition, the decrease in TGF-alpha parallels the levels of residual EGF-R in the various antisense clones, indicating a direct correlation between receptors and growth factor levels, The addition of exogenous TGF-alpha (10 ng/ml) to antisense clones induces TGF-alpha levels. The half-life of TGF-alpha mRNA is 40-60 min in antisense cells and more than 8 h in parental KB cells, as determined by actinomycin D decay curves. This result indicates a predominant regulation of TGF-alpha mRNA at the post-transcriptional level. Nuclear Min-on experiments show that there is only a marginal effect at the transcriptional level, We conclude that the autocrine loop responsible for the transformed phenotype of the human carcinoma KB cell line is dependent on both elevated levels of EGF-R and the presence of TGF-alpha, In addition, TGF-alpha is able to induce its own mRNA via a signal due to activation of the EGF-R acting predominantly at the post-transcriptional level.	HOSP SAN RAFFAELE,DIBIT,ONCOL MOL LAB,I-20132 MILAN,ITALY; HOSP SAN RAFFAELE,CNR,IST NEUROSCI & BIOIMMAGINI,I-20132 MILAN,ITALY	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele			Miloso, Mariarosaria/AAC-7373-2021; Moroni, Maria Cristina/H-7044-2018; NIcolini, Gabriella/AAK-9155-2020	Moroni, Maria Cristina/0000-0003-2409-5764; NICOLINI, GABRIELLA/0000-0002-6241-4538				AUSBEL FM, 1994, CURRENT PROTOCOLS MO, V4; AUSBEL FM, 1994, CURRENT PROTOCOLS MO, V1; BEGUINOT L, 1986, J BIOL CHEM, V261, P1801; BJORGE JD, 1989, J BIOL CHEM, V264, P4021; BROWDER TM, 1989, MOL CELL BIOL, V9, P204, DOI 10.1128/MCB.9.1.204; CARE A, 1986, EMBO J, V5, P905, DOI 10.1002/j.1460-2075.1986.tb04302.x; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; COFFEY RJ, 1992, CELL GROWTH DIFFER, V3, P347; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; CUTITTA F, 1985, NATURE, V316, P823; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; DERYNCK R, 1987, CANCER RES, V47, P702; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; IMANISHI K, 1989, BRIT J CANCER, V59, P761, DOI 10.1038/bjc.1989.159; JINNO Y, 1988, NUCLEIC ACIDS RES, V16, P4957, DOI 10.1093/nar/16.11.4957; JU WD, 1991, NEW BIOL, V3, P380; MALDEN LT, 1989, INT J CANCER, V43, P380, DOI 10.1002/ijc.2910430305; Maniatis T, 1989, DECONTAMINATION DILU; MILOSO M, 1995, J BIOL CHEM, V270, P19557, DOI 10.1074/jbc.270.33.19557; MORONI MC, 1992, J BIOL CHEM, V267, P2714; MUELLER SG, 1989, MOL ENDOCRINOL, V3, P976, DOI 10.1210/mend-3-6-976; NISTER M, 1988, CANCER RES, V48, P3910; PAULSSON Y, 1987, NATURE, V328, P715, DOI 10.1038/328715a0; QIAN JF, 1993, GENE, V132, P291; SIDDIQI I, 1995, BIOCHEM BIOPH RES CO, V215, P309, DOI 10.1006/bbrc.1995.2467; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; TAKEKURA N, 1991, INT J CANCER, V47, P938, DOI 10.1002/ijc.2910470626; TODD R, 1989, CARCINOGENESIS, V10, P1553, DOI 10.1093/carcin/10.8.1553; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; VANOBBERGHENSCHILLING E, 1988, J BIOL CHEM, V263, P7741; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WARNER SJC, 1987, J EXP MED, V165, P1316, DOI 10.1084/jem.165.5.1316; WATANABE T, 1994, J BIOL CHEM, V269, P9966; YOSHIDA K, 1990, JPN J CANCER RES, V81, P43, DOI 10.1111/j.1349-7006.1990.tb02505.x	37	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30290	30296		10.1074/jbc.271.47.30290	http://dx.doi.org/10.1074/jbc.271.47.30290			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939983	hybrid			2022-12-27	WOS:A1996VU52500111
J	Zhou, JQ; Tan, CK; So, AG; Downey, KM				Zhou, JQ; Tan, CK; So, AG; Downey, KM			Purification and characterization of the catalytic subunit of human DNA polymerase delta expressed in baculovirus-infected insect cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEAR ANTIGEN; AUXILIARY PROTEIN; CALF THYMUS; REPLICATION; GENE; EPSILON	The catalytic subunit of human DNA polymerase delta has been overexpressed in insect cells by a recombinant baculovirus. The recombinant protein has a M(r) = similar to 125,000 and is recognized by polyclonal antisera against N-terminal and C-terminal peptides of the catalytic subunit of human DNA polymerase delta, The recombinant protein was purified to near homogeneity (approximately 1200-fold) from insect cells by chromatography on DEAE-cellulose, phosphocellulose, heparin-agarose, and single-stranded DNA-cellulose, The purified protein had both DNA polymerase and 3'-5' exonuclease activities. The properties of the recombinant catalytic subunit were compared with those of the native heterodimeric DNA polymerase delta isolated from fetal calf thymus, and the enzymes were found to differ in several respects. Although the native heterodimer is equally active with either Mn2+ or Mg2+ as divalent cation activator, the recombinant catalytic subunit is approximately 5-fold more active in Mn2+ than in Mg2+. The most striking difference between the two proteins is the response to the proliferating cell nuclear antigen (PCNA). The activity and processivity of native DNA polymerase delta are markedly stimulated by PCNA whereas it has no effect on the recombinant catalytic subunit. These results suggest that the small subunit of DNA polymerase delta is essential for functional interaction with PCNA.	UNIV MIAMI,SCH MED,DEPT MED,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOL BIOL,MIAMI,FL 33101	University of Miami; University of Miami					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026206] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK26206] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; Arroyo MP, 1996, J BIOL CHEM, V271, P15971, DOI 10.1074/jbc.271.27.15971; BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; BOULET A, 1989, EMBO J, V8, P1849, DOI 10.1002/j.1460-2075.1989.tb03580.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN WC, 1993, J BIOL CHEM, V268, P21706; BROWN WC, 1993, J BIOL CHEM, V268, P982; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; CHANG LS, 1995, GENOMICS, V28, P411, DOI 10.1006/geno.1995.1169; Chiang CS, 1995, GENE, V166, P237, DOI 10.1016/0378-1119(95)00567-6; CHIANG CS, 1993, P NATL ACAD SCI USA, V90, P9105, DOI 10.1073/pnas.90.19.9105; CHUNG DW, 1991, P NATL ACAD SCI USA, V88, P11197, DOI 10.1073/pnas.88.24.11197; Downey KM, 1995, METHOD ENZYMOL, V262, P84; GOULIAN M, 1990, J BIOL CHEM, V265, P16402; HINDGES R, 1995, GENE, V158, P241, DOI 10.1016/0378-1119(95)00065-E; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MYWT, 1991, J BIOL CHEM, V266, P2423; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; McConnell M, 1996, BIOCHEMISTRY-US, V35, P8268, DOI 10.1021/bi9530649; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; Sambrook J., 2002, MOL CLONING LAB MANU; SIMON M, 1991, EMBO J, V10, P2165, DOI 10.1002/j.1460-2075.1991.tb07751.x; TAN CK, 1986, J BIOL CHEM, V261, P2310; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; YANG CL, 1992, NUCLEIC ACIDS RES, V20, P735, DOI 10.1093/nar/20.4.735; ZENG XR, 1994, J BIOL CHEM, V269, P24027; ZHANG P, 1995, J BIOL CHEM, V270, P7993, DOI 10.1074/jbc.270.14.7993; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x	29	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29740	29745		10.1074/jbc.271.47.29740	http://dx.doi.org/10.1074/jbc.271.47.29740			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939909	hybrid			2022-12-27	WOS:A1996VU52500037
J	Zhu, H; Ownby, DW; Riggs, CK; Nolasco, NJ; Stoops, JK; Riggs, AF				Zhu, H; Ownby, DW; Riggs, CK; Nolasco, NJ; Stoops, JK; Riggs, AF			Assembly of the gigantic hemoglobin of the earthworm Lumbricus terrestris - Roles of subunit equilibria, non-globin linker chains, and valence of the heme iron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORSE SPLEEN APOFERRITIN; POTATO BETA-AMYLASE; BRILLIANT BLUE-R; EXTRACELLULAR HEMOGLOBIN; LIGHT-SCATTERING; ORNITHINE DECARBOXYLASE; OXYGENATION PROPERTIES; BOVINE THYROGLOBULIN; TETRAMERIC COMPONENT; CONFORMATIONAL DRIFT	The extracellular hemoglobin of the earthworm Lumbricus terrestris has four major kinds of O-2-binding chains: a, b, and c (forming a disulfide-linked trimer), and chain d. Non-heme, non-globin structural chains, ''linkers,'' are also present, Light-scattering techniques have been used to show that the ferrous CO saturated abe trimer and chain d form an (abcd)(4) complex of 285 kDa at neutral pH. Formation of the full-sized 4-MDa molecule requires the addition of linker chains in the proportion of two linkers per (abcd)(4) and occurs much more rapidly in the presence of 10 mM calcium. This stoichiometry is supported not only by direct quantitative analysis of the intact hemoglobin but also by the fact that the addition of 50% of the proposed stoichiometric quantity of linkers results in the conversion of 50% of the (abcd)(4) to full-sized molecules, Isolated CO-saturated abe trimers self-associate to (abc)(2) and higher aggregates up to an apparent limit of (abc)(10) similar to 550 kDa, The CO-saturated chain d forms dimers, (d)(2), and tetramers, (d)(4). Oxidation of the (abcd)(4) complex with ferricyanide causes complete dissociation of chain d from the abe trimer, but addition of CN- maintains the (abcd)(4) complex, Valence hybrids have also been studied, The ferrous CO-saturated abe trimer and met (ferric) chain d also associate to form (abcd)(4), but the met abe trimer and ferrous CO-saturated chain d do not, Oxidation of the abc trimer and chain d to the ferric form causes the formation of a characteristic hemichrome spectrum with a maximum at 565 nm and a shoulder near 530 nm, These results show that interactions between the abe trimer and chain d are strongly dependent on the ligand and valence state of the heme iron, Light-scattering measurements reveal that oxidation of the intact Hb produces a significant drop In molecular mass from 4.1 to 3.6 MDa. Inclusion of CN- prevents this drop, These experiments indicate that oxidation causes the Hb to shed subunits, The observations provide an explanation for the wide variations in the molecular mass of L. terrestris Hb that have been observed previously.	UNIV TEXAS,DEPT ZOOL,AUSTIN,TX 78712; UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL & LAB MED,HOUSTON,TX 77030	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Health Science Center Houston					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046278, R01GM035847] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35847, GM 46278] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackers G K, 1970, Adv Protein Chem, V24, P343, DOI 10.1016/S0065-3233(08)60245-4; AROSIO P, 1978, J BIOL CHEM, V253, P4451; ASCOLI F, 1978, J MOL BIOL, V119, P191, DOI 10.1016/0022-2836(78)90433-3; BALL EH, 1986, ANAL BIOCHEM, V155, P23, DOI 10.1016/0003-2697(86)90218-6; BENESCH R, 1964, SCIENCE, V144, P68, DOI 10.1126/science.144.3614.68; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3018; BICKAR D, 1984, J BIOL CHEM, V259, P777; BOFFI A, 1991, J BIOL CHEM, V266, P17898; CANN JR, 1970, INTERACTING MACROMOL, P249; COBB JA, 1992, J BIOL CHEM, V267, P1183; COHN EJ, 1943, PROTEINS AMINO ACIDS, P340; CRICHTON RR, 1973, BIOCHEM J, V131, P855, DOI 10.1042/bj1310855; DAVID MM, 1974, J MOL BIOL, V87, P89, DOI 10.1016/0022-2836(74)90561-0; EDELHOCH H, 1960, J BIOL CHEM, V235, P1326; ELBAUM D, 1974, BIOCHEMISTRY-US, V13, P1268, DOI 10.1021/bi00703a033; FARMER TB, 1991, BIOL MASS SPECTROM, V20, P796, DOI 10.1002/bms.1200201209; FUSHITANI K, 1986, J BIOL CHEM, V261, P8414; FUSHITANI K, 1991, J BIOL CHEM, V266, P10275; GARLICK RL, 1979, ARCH BIOCHEM BIOPHYS, V194, P13, DOI 10.1016/0003-9861(79)90590-3; GIBSON QH, 1969, J BIOL CHEM, V244, P4668; GOSS DJ, 1975, BIOCHEMISTRY-US, V14, P5461, DOI 10.1021/bi00696a012; GROS G, 1978, BIOPHYS J, V22, P453, DOI 10.1016/S0006-3495(78)85499-X; GUIRARD BM, 1980, J BIOL CHEM, V255, P5960; HACKERT ML, 1994, J BACTERIOL, V176, P7391, DOI 10.1128/JB.176.23.7391-7394.1994; HARRINGT.JP, 1973, BIOCHIM BIOPHYS ACTA, V328, P61, DOI 10.1016/0005-2795(73)90330-9; HERSKOVITS TT, 1986, BIOCHEMISTRY-US, V25, P931, DOI 10.1021/bi00352a029; HERSKOVITS TT, 1975, BIOCHEMISTRY-US, V14, P4964, DOI 10.1021/bi00693a027; HEUSTERSPREUTE M, 1981, FEBS LETT, V129, P322, DOI 10.1016/0014-5793(81)80193-7; HOARE RJ, 1975, NATURE, V255, P653, DOI 10.1038/255653a0; KAPP OH, 1984, J BIOL CHEM, V259, P628; KEILIN D, 1961, NATURE, V190, P717, DOI 10.1038/190717a0; KING L, 1986, BIOCHEMISTRY-US, V25, P3632, DOI 10.1021/bi00360a023; Kruis A, 1936, Z PHYS CHEM B-CHEM E, V34, P13; Martin PD, 1996, J MOL BIOL, V255, P170, DOI 10.1006/jmbi.1996.0014; Martin PD, 1996, J MOL BIOL, V255, P154, DOI 10.1006/jmbi.1996.0013; MCMEEKIN TL, 1962, BIOCHEM BIOPH RES CO, V7, P151, DOI 10.1016/0006-291X(62)90165-1; MERCKEN L, 1985, NATURE, V316, P647, DOI 10.1038/316647a0; MILLER KI, 1988, BIOCHEMISTRY-US, V27, P7282, DOI 10.1021/bi00419a016; MITCHELL DT, 1995, J MOL BIOL, V251, P421, DOI 10.1006/jmbi.1995.0445; MOMANY C, 1995, J MOL BIOL, V252, P643, DOI 10.1006/jmbi.1995.0526; OWNBY DW, 1993, J BIOL CHEM, V268, P13539; PILZ I, 1980, INT J BIOL MACROMOL, V2, P279, DOI 10.1016/0141-8130(80)90045-8; RACHMILEWITZ EA, 1971, J BIOL CHEM, V246, P3356; RAWITCH AB, 1993, ARCH BIOCHEM BIOPHYS, V300, P271, DOI 10.1006/abbi.1993.1038; RICHTER GW, 1967, BIOCHEMISTRY-US, V6, P2871, DOI 10.1021/bi00861a031; ROCHE J, 1965, STUDIES COMPARATIVE, V23, P62; ROSSIFANELLI MR, 1970, ARCH BIOCHEM BIOPHYS, V141, P278; RUSSELL DW, 1983, J BIOL CHEM, V258, P2674; SCHATZ M, 1995, J STRUCT BIOL, V114, P28, DOI 10.1006/jsbi.1995.1003; SCHROETER JP, 1992, J STRUCT BIOL, V109, P235, DOI 10.1016/1047-8477(92)90036-A; Schroeter JP, 1996, J STRUCT BIOL, V116, P131, DOI 10.1006/jsbi.1996.0021; Sharma PK, 1996, J BIOL CHEM, V271, P8754, DOI 10.1074/jbc.271.15.8754; SILVA JL, 1989, J BIOL CHEM, V264, P15863; SILVA JL, 1993, ANNU REV PHYS CHEM, V44, P89, DOI 10.1146/annurev.pc.44.100193.000513; STOOPS JK, 1991, J ELECTRON MICR TECH, V18, P157, DOI 10.1002/jemt.1060180210; Svedberg T, 1932, NATURE, V130, P434; TAL M, 1985, J BIOL CHEM, V260, P9976; TAM LT, 1993, J BIOL CHEM, V268, P26972; Tanford C., 1961, PHYSICAL CHEM MACROM, P275; TODA H, 1993, EUR J BIOCHEM, V216, P25, DOI 10.1111/j.1432-1033.1993.tb18112.x; UNSER M, 1987, ULTRAMICROSCOPY, V23, P39, DOI 10.1016/0304-3991(87)90225-7; VANASSENDELFT OW, 1965, CLIN CHIM ACTA, V11, P571, DOI 10.1016/0009-8981(65)90015-X; VANASSENDELFT OW, 1970, SPECTROPHOTOMETRY HA, P57; VANDERWALT B, 1978, J BIOL CHEM, V253, P1853; VINOGRADOV SN, 1986, P NATL ACAD SCI USA, V83, P8034, DOI 10.1073/pnas.83.21.8034; VINOGRADOV SN, 1991, J BIOL CHEM, V266, P13091; WEBER G, 1986, BIOCHEMISTRY-US, V25, P3626, DOI 10.1021/bi00360a022; WOLF HU, 1984, CLIN CHIM ACTA, V136, P95, DOI 10.1016/0009-8981(84)90251-1; WOOD EJ, 1976, BIOCHEM J, V153, P589, DOI 10.1042/bj1530589; WYATT PJ, 1993, J CHROMATOGR, V648, P27, DOI 10.1016/0021-9673(93)83285-Z; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S; WYATT PJ, 1993, LC GC-MAG SEP SCI, V11, P862; XIE Q, 1996, IN PRESS BIOCH ACTA; YOSHIDA N, 1991, J BIOCHEM-TOKYO, V110, P196, DOI 10.1093/oxfordjournals.jbchem.a123556; Zhu H, 1996, J BIOL CHEM, V271, P29999, DOI 10.1074/jbc.271.47.29999; ZIMM BH, 1948, J CHEM PHYS, V16, P1099, DOI 10.1063/1.1746740; 1930, INT CRIT TABLES, V7, P64	77	75	77	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30007	30021		10.1074/jbc.271.47.30007	http://dx.doi.org/10.1074/jbc.271.47.30007			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939947	hybrid			2022-12-27	WOS:A1996VU52500075
J	Kimura, K; Suzuki, H; Daiho, T; Yamasaki, K; Kanazawa, T				Kimura, K; Suzuki, H; Daiho, T; Yamasaki, K; Kanazawa, T			Identification of arginyl residues located at the ATP binding site of sarcoplasmic reticulum Ca2+-ATPase - Modification with 1,2-cyclohexanedione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; PROTON-TRANSLOCATING ATPASE; PLASMA-MEMBRANE ATPASE; ACTIVE-SITE; ADENOSINE-TRIPHOSPHATASE; FUNCTIONAL CONSEQUENCES; CONFORMATIONAL CHANGE; FLUORESCEIN ISOTHIOCYANATE; CA-2+-TRANSPORTING ATPASE; MECHANISTIC IMPLICATIONS	Sarcoplasmic reticulum vesicles were treated with 1,2-cyclohexanedione (CHD) in sodium berate (pH 8.0), The Ca2+-ATPase activity was completely inhibited, Inhibition of Mg . ATP and Mg . ADP binding to the high affinity ATP binding site as well as inhibition of phosphorylation with ATP occurred simultaneously with the inhibition of the Ca2+-ATPase activity. Phosphorylation with acetyl phosphate was not inhibited, The Ca2+-ATPase was strongly protected by Mg . ATP, Mg . ADP, and Mg . AMP against this inhibition, Binding of acetyl phosphate or P-i to the enzyme gave no protection, Phosphorylation with acetyl phosphate also had no protective effect, Peptide mapping of the tryptic digests, detection of peptides containing CHD-modified arginyl residues with Girard's reagent T, and sequencing revealed that Arg-489, Arg-505, and Arg-678 were modified with CHD. Arg-489 and Arg-678 were almost completely protected by Mp . ATP against this modification, but partially protected by prelabeling with fluorescein 5-isothiocyanate, which occupies the adenosine binding region in the ATP binding site, In contrast, Arg-505 was slightly protected by Mg . ATP and almost completely protected by prelabeling with fluorescein 5-isothiocyanate, Taken together, these findings suggest that Arg-489 and Arg-678 are located in or near the region occupied by the triphosphate moiety of ATP, either or both of these residues being in or close to the region occupied by the alpha-phosphoryl group in the high affinity ATP binding site and involved in the CHD-induced inhibition of this enzyme and that Arg-505 is very close to (but slightly out of) the adenosine binding region in the ATP binding site. The acetyl phosphatase activity and phosphorylation with P-i were also inhibited by the CHD treatment, but the inhibitions were considerably slower than those described above, This suggests that the arginyl residues involved in these inhibitions are distinct from that involved in the inhibition of the Ca2+-ATPase activity.	ASAHIKAWA MED COLL,DEPT BIOCHEM,ASAHIKAWA,HOKKAIDO 078,JAPAN; ASAHIKAWA MED COLL,DEPT INTERNAL MED 3,ASAHIKAWA,HOKKAIDO 078,JAPAN	Asahikawa Medical College; Asahikawa Medical College								ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALLEN G, 1976, FEBS LETT, V63, P188, DOI 10.1016/0014-5793(76)80223-2; ANDERSEN JP, 1985, J MEMBRANE BIOL, V88, P187, DOI 10.1007/BF01868432; ARAV R, 1983, J BIOL CHEM, V258, P433; BARRABIN H, 1984, BIOCHEMISTRY-US, V23, P1542, DOI 10.1021/bi00302a031; BASTIDE F, 1973, Journal of Biological Chemistry, V248, P8385; BISHOP JE, 1989, BIOPHYS J, V55, pA204; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; COHN WE, 1957, METHOD ENZYMOL, V3, P867, DOI 10.1016/S0076-6879(57)03464-3; DAIHO T, 1994, J BIOL CHEM, V269, P11060; DAIHO T, 1993, BIOCHEMISTRY-US, V32, P10021, DOI 10.1021/bi00089a018; DEGANI C, 1973, J BIOL CHEM, V248, P8222; DUPONT Y, 1978, NATURE, V273, P396, DOI 10.1038/273396a0; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; EVANS PR, 1979, NATURE, V279, P500, DOI 10.1038/279500a0; Fersht A., 1985, ENZYME STRUCTURE MEC; FLETTERICK RJ, 1975, P NATL ACAD SCI USA, V72, P38, DOI 10.1073/pnas.72.1.38; FRIEDMAN Z, 1970, FEBS LETT, V11, P69, DOI 10.1016/0014-5793(70)80494-X; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GREEN NM, 1986, CIBA F SYMP, V122, P93; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; HEGYVARY C, 1971, J BIOL CHEM, V246, P5234; HESSE JE, 1984, P NATL ACAD SCI-BIOL, V81, P4746, DOI 10.1073/pnas.81.15.4746; IMAMURA Y, 1984, J BIOCHEM, V95, P1305, DOI 10.1093/oxfordjournals.jbchem.a134736; KANAZAWA T, 1973, J BIOL CHEM, V248, P3163; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; KOLAND JG, 1986, J BIOL CHEM, V261, P5936; KUBOTA T, 1993, BIOCHIM BIOPHYS ACTA, V1163, P131, DOI 10.1016/0167-4838(93)90174-P; LACAPERE JJ, 1993, BIOCHEMISTRY-US, V32, P3414, DOI 10.1021/bi00064a027; LIPMANN F, 1945, J BIOL CHEM, V159, P21; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MAEDA M, 1990, J BIOL CHEM, V265, P9027; MAKINOSE M, 1967, PFLUG ARCH GES PHYS, V294, pR82; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; MCINTOSH DB, 1992, J BIOL CHEM, V267, P22328; MCINTOSH DB, 1992, J BIOL CHEM, V267, P5301; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P906, DOI 10.1016/0005-2736(73)90395-7; MISSIAEN L, 1989, BIOCHEM J, V264, P609, DOI 10.1042/bj2640609; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MUALEM S, 1979, NATURE, V277, P238, DOI 10.1038/277238a0; MURPHY AJ, 1976, BIOCHEM BIOPH RES CO, V70, P1048, DOI 10.1016/0006-291X(76)91008-1; NAKAMURA S, 1994, J BIOL CHEM, V269, P16015; PATTHY L, 1975, J BIOL CHEM, V250, P557; PATTHY L, 1979, EUR J BIOCHEM, V99, P309, DOI 10.1111/j.1432-1033.1979.tb13258.x; PICK U, 1980, BIOCHIM BIOPHYS ACTA, V626, P255, DOI 10.1016/0005-2795(80)90216-0; PICK U, 1981, FEBS LETT, V123, P127, DOI 10.1016/0014-5793(81)80035-X; PUCELL A, 1971, J BIOL CHEM, V246, P3389; RAESS BU, 1985, MOL PHARMACOL, V27, P444; RIORDAN JF, 1979, MOL CELL BIOCHEM, V26, P71; ROSS DC, 1991, J BIOL CHEM, V266, P4613; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SIEBERS A, 1992, J BIOL CHEM, V267, P12717; STADTMAN ER, 1957, METHOD ENZYMOL, V3, P228, DOI 10.1016/S0076-6879(57)03379-0; STEFANOVA HI, 1993, BIOCHEMISTRY-US, V32, P356, DOI 10.1021/bi00052a044; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; VERMA AK, 1988, J BIOL CHEM, V263, P14152; VILSEN B, 1991, J BIOL CHEM, V266, P16157; WALLMARK B, 1980, J BIOL CHEM, V255, P5313; WASSARMAN PM, 1971, J MOL BIOL, V60, P509, DOI 10.1016/0022-2836(71)90185-9; WELLS TNC, 1994, BIOCHEMISTRY-US, V33, P5777, DOI 10.1021/bi00185a015; YAMAGATA K, 1993, J BIOL CHEM, V268, P20930; YAMAMOTO H, 1988, J BIOCHEM-TOKYO, V103, P452, DOI 10.1093/oxfordjournals.jbchem.a122291; YAMAMOTO H, 1989, J BIOCHEM-TOKYO, V106, P1121, DOI 10.1093/oxfordjournals.jbchem.a122976; YAMAMOTO T, 1967, J BIOCHEM-TOKYO, V62, P558, DOI 10.1093/oxfordjournals.jbchem.a128706; YAMASAKI K, 1994, J BIOL CHEM, V269, P4129	71	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28933	28941		10.1074/jbc.271.46.28933	http://dx.doi.org/10.1074/jbc.271.46.28933			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910542	hybrid			2022-12-27	WOS:A1996VT05200034
J	Song, LX; Fricker, LD				Song, LX; Fricker, LD			Tissue distribution and characterization of soluble and membrane-bound forms of metallocarboxypeptidase D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYPEPTIDASE-E; FURIN; VESICLES; ENZYME; GENE; RAT; PH; PURIFICATION; ENDOPROTEASE; INHIBITION	Metallocarboxypeptidase D (CPD) is a recently discovered 180-kDa membrane-bound carboxypeptidase E-like enzyme (Song, L. and Fricker, L. D. (1995) J. Biol. Chem. 270, 25007-25013). In the present study, a soluble CPD-like activity has been purified to homogeneity and characterized. On denaturing polyacrylamide gels, the soluble enzyme from bovine pituitary glands appears as two bands of 170 and 135 kDa which are converted to 155 and 115 kDa by endoglycosidase F. Both of the soluble forms of CPD are recognized by an antisera raised against CPD purified from rat brain membranes. The partial N-terminal amino acid sequences of the two soluble forms are identical to each other and to the predicted N terminus of duck gp180. The soluble and membrane forms of CPD have similar pH optima, inhibitor specificities, and kinetic parameters for substrate hydrolysis. CPD-Like enzymatic activity is detected in all rat tissues examined, with highest levels in pituitary, brain, and adrenal. Western blot analysis indicates that both soluble and membrane forms of CPD are present in rat brain, heart, Liver, and kidney. At least four distinct 100-180-kDa forms of CPD are detected on Western blots, although an antiserum raised against the C-terminal region of rat CPD recognizes only the 180-kDa membrane-bound form. The finding that CPD is widely distributed suggests a broad role for this enzyme in the processing of proteins that transit the secretory pathway.	ALBERT EINSTEIN COLL MED,DEPT MOL PHARMACOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NIDA NIH HHS [DA-04494, DA-00194] Funding Source: Medline; NIDDK NIH HHS [DK-51271] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051271] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K02DA000194, R01DA004494] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; [Anonymous], 1995, METH NEUROSCI; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; EIPPER BA, 1992, J BIOL CHEM, V267, P4008; EIPPER BA, 1988, ANNU REV PHYSIOL, V50, P333, DOI 10.1146/annurev.ph.50.030188.002001; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; FRICKER LD, 1989, MOL ENDOCRINOL, V3, P666, DOI 10.1210/mend-3-4-666; FRICKER LD, 1991, PEPTIDE BIOSYNTHESIS, P199; GARTEN W, 1994, BIOCHIMIE, V76, P217, DOI 10.1016/0300-9084(94)90149-X; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; JOHNSON RG, 1976, J BIOL CHEM, V251, P2189; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; KUROKI K, 1995, J BIOL CHEM, V270, P15022, DOI 10.1074/jbc.270.25.15022; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; Rovere C, 1996, ENDOCRINOLOGY, V137, P2954, DOI 10.1210/en.137.7.2954; RUSSELL JT, 1984, J BIOL CHEM, V259, P9496; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; Seidah NG, 1996, P NATL ACAD SCI USA, V93, P3388, DOI 10.1073/pnas.93.8.3388; SETTLE SH, 1995, P NATL ACAD SCI USA, V92, P9470, DOI 10.1073/pnas.92.21.9470; SKIDGEL RA, 1988, TRENDS PHARMACOL SCI, V9, P299, DOI 10.1016/0165-6147(88)90015-6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONG LX, 1995, J BIOL CHEM, V270, P25007, DOI 10.1074/jbc.270.42.25007; STEINER DF, 1992, J BIOL CHEM, V267, P23435; Varlamov O, 1996, J BIOL CHEM, V271, P13981, DOI 10.1074/jbc.271.24.13981; VARLAMOV O, UNPUB; ZHENG M, 1994, J NEUROSCI, V14, P4656	30	65	66	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28884	28889		10.1074/jbc.271.46.28884	http://dx.doi.org/10.1074/jbc.271.46.28884			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910535				2022-12-27	WOS:A1996VT05200027
J	Trapaidze, N; Keith, DE; Cvejic, S; Evans, CJ; Devi, LA				Trapaidze, N; Keith, DE; Cvejic, S; Evans, CJ; Devi, LA			Sequestration of the delta opioid receptor - Role of the C terminus in agonist-mediated internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; COATED PIT FORMATION; SEQUENCE; PHOSPHORYLATION; ENDOCYTOSIS; EXPRESSION	The primary structure of the opioid receptors have revealed that many of the structural features that are conserved in other G protein-coupled receptors are also conserved in the opioid receptors. Upon exposure to agonists, some G protein-coupled receptors internalize rapidly, whereas other structurally homologous G protein-coupled receptors do not. It is not known whether opioid receptors are regulated by rapid endocytosis. In transfected Chinese hamster ovary cells expressing the epitope-tagged wild type delta opioid receptor, exposure to 100 nM [D-Ala(2),D-Leu(5)]enkephalin causes internalization of the receptor within 30 min as determined by confocal microscopy, The rate of internalization of the wild type receptor is rapid with a half-maximal reduction by about 10 min, as determined by the reduction in mean surface receptor fluorescence intensity measured using flow cytometry. In contrast, the cells expressing receptors lacking the C-terminal 15 or 37 amino acids exhibit a substantially slower rate of internalization. Furthermore, the cells expressing receptors with point mutations of any of the Ser/Thr between Ser(344) and Ser(363) in the C-terminal tail exhibit a significant reduction in the rate of receptor internalization. These results suggest that a portion of the C-terminal tail is involved in receptor internalization. Agents that block the formation of clathrin-coated pits considerably reduce the extent of agonist-mediated internalization of the wild type receptor. Taken together, these results suggest that the mild type opioid receptor undergoes rapid agonist-mediated internalization via a classic endocytic pathway and that a portion of the C-terminal tail plays an important role in this internalization process.	NYU,SCH MED,DEPT PHARMACOL,NEW YORK,NY 10016; NYU,SCH MED,KAPLAN COMPREHENS CANC CTR,NEW YORK,NY 10016; UNIV CALIF LOS ANGELES,DEPT PSYCHIAT & BEHAV SCI,LOS ANGELES,CA 90024	New York University; New York University; University of California System; University of California Los Angeles			Devi P, Lakshmi/GXM-5982-2022	Devi P, Lakshmi/0000-0001-9274-4776	NATIONAL INSTITUTE ON DRUG ABUSE [R56DA008863, P50DA005010, R01DA008863, R37DA008863] Funding Source: NIH RePORTER; NIDA NIH HHS [DA08863, P50 DA005010, DA05010, R01 DA008863] Funding Source: Medline; NINDS NIH HHS [NS1788] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARDEN JR, 1995, J NEUROCHEM, V65, P1636; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; CHENG PY, 1995, J NEUROSCI, V15, P5976; CHEUNG AH, 1988, MOL PHARMACOL, V34, P128; Cvejic S, 1996, J BIOL CHEM, V271, P4073; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; ELDE R, 1995, ANN NY ACAD SCI, V757, P390, DOI 10.1111/j.1749-6632.1995.tb17497.x; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P1979; Hermans E, 1996, MOL PHARMACOL, V49, P365; Herz A., 1993, OPIOIDS; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HUNYADY L, 1995, J BIOL CHEM, V270, P16602, DOI 10.1074/jbc.270.28.16602; Jockers R, 1996, J BIOL CHEM, V271, P9355, DOI 10.1074/jbc.271.16.9355; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; KIEFFER BL, 1992, P NATL ACAD SCI USA, V89, P12048, DOI 10.1073/pnas.89.24.12048; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; NANTEL F, 1993, MOL PHARMACOL, V43, P548; PEI G, 1995, MOL PHARMACOL, V48, P173; PETANCESKA S, 1992, J BIOL CHEM, V267, P26038; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; SCHMID I, 1988, CYTOMETRY, V9, P533, DOI 10.1002/cyto.990090605; SLICE LW, 1994, J BIOL CHEM, V269, P21755; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; UHL GR, 1994, TRENDS NEUROSCI, V17, P89, DOI 10.1016/0166-2236(94)90110-4; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; YU SS, 1993, J BIOL CHEM, V268, P337; ZHANG J, J BIOL CHEM, V271, P18302	30	149	151	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29279	29285		10.1074/jbc.271.46.29279	http://dx.doi.org/10.1074/jbc.271.46.29279			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910588	hybrid, Green Accepted			2022-12-27	WOS:A1996VT05200080
J	Filtz, TM; Paterson, A; Harden, TK				Filtz, TM; Paterson, A; Harden, TK			Purification and gr protein subunit regulation of a phospholipase C-beta from Xenopus laevis oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SUBUNITS; PHOSPHATIDYLINOSITOL PATHWAY; SEQUENCE DETERMINATION; TURKEY ERYTHROCYTES; MOLECULAR-CLONING; RECEPTOR; ACTIVATION; ACETYLCHOLINE; METABOLISM; COUPLES	Xenopus oocytes exhibit both pertussis toxin-sensitive and -insensitive inositol lipid signaling responses to G protein-coupled receptor activation. The G protein subunits G alpha(i), G alpha(o), G alpha(q), G alpha(s), and G(beta gamma) all have been proposed to function as activators of phospholipase C in oocytes. Ma et al. (Ma, H.-W., Blitzer, R, D., Healy, E. C., Premont, R. T., Landau, E. M., and Iyengar, R. J. Biol. Chem. 268, 19915-19918) cloned a Xenopus phospholipase C (PLC-beta X) that exhibits homology to the PLC-beta class of isoenzymes. Although this enzyme was proposed to function as a signaling protein in the pertussis toxin sensitive inositol Lipid signaling pathway of oocytes, its regulation by G protein subunits has not been directly assessed. As such we have utilized baculovirus-promoted overexpression of PLC-beta X in Sf9 insect cells and have purified a recombinant 150-kDa isoenzyme. PLC-beta X catalyzes hydrolysis of phosphatidylinositol(4,5)bisphosphate and phosphatidylinositol(4)monophosphate, and reaction velocity is de pendent on Ca2+. Recombinant PLC-beta X was activated by both G alpha(q), and G(beta gamma). PLC-beta X exhibited a higher apparent affinity for G alpha(q) than G(beta gamma), and G alpha(q) was more efficacious than G(beta gamma) at lower concentrations of PLC-beta X Relative to other PLC-beta isoenzymes, PLC-beta X was less sensitive to stimulation by Ga-q than PLC-beta 1 but similar to PLC-beta 2 and PLC-beta T, PLC beta X was more sensitive to stimulation by G(beta gamma) than PLC-beta 1 but less sensitive than PLC-beta 2 and PLC-beta T. in contrast PLC-beta X was not activated by the pertussis toxin substrate G proteins G alpha(i1), G alpha(i2), G alpha(i3), or G alpha(o). These results are consistent with the idea that PLC-PX is regulated by alpha-subunits of the G(q) family and by G(beta gamma) and do not support the idea that alpha-subunits of pertussis toxin-sensitive G proteins are directly involved in regulation of this protein.	UNIV N CAROLINA, SCH MED, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine				Filtz, Theresa/0000-0002-5348-1114	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057391, R37GM029536, F32GM016918, R01GM029536] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM16918, GM29536] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; BLITZER RD, 1993, J BIOL CHEM, V268, P7532; BOYER JL, 1992, J BIOL CHEM, V267, P25451; DELAPENA P, 1995, J BIOL CHEM, V270, P3554, DOI 10.1074/jbc.270.8.3554; GILLO B, 1987, J PHYSIOL-LONDON, V392, P349, DOI 10.1113/jphysiol.1987.sp016784; GUTTRIDGE KL, 1995, P NATL ACAD SCI USA, V92, P1297, DOI 10.1073/pnas.92.5.1297; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; KANEKO S, 1992, FEBS LETT, V299, P179, DOI 10.1016/0014-5793(92)80242-9; KASAHARA J, 1994, FEBS LETT, V355, P41, DOI 10.1016/0014-5793(94)01170-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MA HW, 1993, J BIOL CHEM, V268, P19915; MIYAMAE T, 1993, FEBS LETT, V333, P311, DOI 10.1016/0014-5793(93)80677-M; MORIARTY TM, 1988, P NATL ACAD SCI USA, V85, P8865, DOI 10.1073/pnas.85.23.8865; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; MORIARTY TM, 1989, J BIOL CHEM, V264, P13524; MORRIS AJ, 1990, J BIOL CHEM, V265, P13501; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NAKAMURA K, 1994, J PHYSIOL-LONDON, V474, P35, DOI 10.1113/jphysiol.1994.sp020000; OLATE J, 1989, FEBS LETT, V244, P188, DOI 10.1016/0014-5793(89)81190-1; OLATE J, 1990, FEBS LETT, V268, P27, DOI 10.1016/0014-5793(90)80964-K; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PADRELL E, 1991, J BIOL CHEM, V266, P9771; PARK DG, 1993, J BIOL CHEM, V268, P4573; PATERSON A, 1995, CELL SIGNAL, V7, P709, DOI 10.1016/0898-6568(95)00039-R; PATERSON A, IN PRESS PRACTICAL A; SHAPIRA H, 1994, FEBS LETT, V348, P89, DOI 10.1016/0014-5793(94)00570-2; STEHNOBITTEL L, 1995, J BIOL CHEM, V270, P30068; UEDA H, 1995, MOL BRAIN RES, V32, P166, DOI 10.1016/0169-328X(95)00077-6; Waldo GL, 1996, BIOCHEM J, V316, P559, DOI 10.1042/bj3160559; WALDO GL, 1994, METHOD ENZYMOL, V237, P182	31	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31121	31126		10.1074/jbc.271.49.31121	http://dx.doi.org/10.1074/jbc.271.49.31121			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940109	hybrid, Green Published			2022-12-27	WOS:A1996VW68600020
J	Kouranov, A; Schnell, DJ				Kouranov, A; Schnell, DJ			Protein translocation at the envelope and thylakoid membranes of chloroplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							SIGNAL RECOGNITION PARTICLE; PRECURSOR PROTEINS; IMPORT MACHINERY; GTP-BINDING; CDNA CLONE; TRANSIT SEQUENCE; TRANSPORT; IDENTIFICATION; REQUIREMENT; PATHWAY		RUTGERS STATE UNIV,DEPT BIOL SCI,NEWARK,NJ 07102	Rutgers State University Newark; Rutgers State University New Brunswick								ABAD MS, 1989, PLANT PHYSIOL, V90, P117, DOI 10.1104/pp.90.1.117; AUCHINCLOSS AH, 1992, J BIOL CHEM, V267, P10439; CLINE K, 1985, J BIOL CHEM, V260, P3691; CLINE K, 1992, J BIOL CHEM, V267, P2688; Cline K, 1996, ANNU REV CELL DEV BI, V12, P1, DOI 10.1146/annurev.cellbio.12.1.1; FRANKLIN AE, 1993, J BIOL CHEM, V268, P22175; FRIEDMAN AL, 1989, PLANT PHYSIOL, V89, P993, DOI 10.1104/pp.89.3.993; GRAY JC, 1995, TRENDS CELL BIOL, V5, P243, DOI 10.1016/S0962-8924(00)89018-2; HALPIN C, 1989, EMBO J, V8, P3917, DOI 10.1002/j.1460-2075.1989.tb08572.x; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; HOFFMAN NE, 1994, PLANT PHYSIOL, V105, P295, DOI 10.1104/pp.105.1.295; HORNIAK L, 1993, FEBS LETT, V334, P241, DOI 10.1016/0014-5793(93)81720-K; HUANG LQ, 1992, PLANT PHYSIOL, V99, P247, DOI 10.1104/pp.99.1.247; HULFORD A, 1994, J BIOL CHEM, V269, P3251; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KEEGSTRA K, 1995, PHYSIOL PLANTARUM, V93, P157, DOI 10.1034/j.1399-3054.1995.930122.x; Kessler F, 1996, P NATL ACAD SCI USA, V93, P7684, DOI 10.1073/pnas.93.15.7684; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; KIRWIN PM, 1989, EMBO J, V8, P2251, DOI 10.1002/j.1460-2075.1989.tb08349.x; KO K, 1995, J BIOL CHEM, V270, P28601, DOI 10.1074/jbc.270.48.28601; KO K, 1992, J BIOL CHEM, V267, P2986; LAIDLER V, 1995, J BIOL CHEM, V270, P17664, DOI 10.1074/jbc.270.30.17664; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; LUBECK L, 1996, EMBO J, V15, P4230; Ma YK, 1996, J CELL BIOL, V134, P315, DOI 10.1083/jcb.134.2.315; MICHL D, 1994, EMBO J, V13, P1310, DOI 10.1002/j.1460-2075.1994.tb06383.x; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; MOULD RM, 1991, J BIOL CHEM, V266, P12189; NAKAI M, 1994, J BIOL CHEM, V269, P31338; OLSEN LJ, 1992, J BIOL CHEM, V267, P433; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; PAIN D, 1987, P NATL ACAD SCI USA, V84, P3288, DOI 10.1073/pnas.84.10.3288; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; ROBINSON C, 1984, EUR J BIOCHEM, V142, P337, DOI 10.1111/j.1432-1033.1984.tb08291.x; SCHNELL DJ, 1993, J CELL BIOL, V120, P103, DOI 10.1083/jcb.120.1.103; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SCHNELL DJ, 1995, CELL, V83, P521, DOI 10.1016/0092-8674(95)90090-X; Scott SV, 1996, J CELL BIOL, V132, P63, DOI 10.1083/jcb.132.1.63; SEEDORF M, 1995, PLANT J, V7, P401, DOI 10.1046/j.1365-313X.1995.7030401.x; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SMITH TA, 1994, J CELL BIOL, V126, P365, DOI 10.1083/jcb.126.2.365; THEG SM, 1989, J BIOL CHEM, V264, P6730; TRANEL PJ, 1995, EMBO J, V14, P2436, DOI 10.1002/j.1460-2075.1995.tb07241.x; VANDERVERE PS, 1995, P NATL ACAD SCI USA, V92, P7177, DOI 10.1073/pnas.92.16.7177; VANTHOF R, 1995, FEBS LETT, V361, P35, DOI 10.1016/0014-5793(95)00135-V; VIITANEN PV, 1988, J BIOL CHEM, V263, P15000; VOELKER R, 1995, EMBO J, V14, P3905, DOI 10.1002/j.1460-2075.1995.tb00062.x; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x; Wickner W, 1996, J BIOL CHEM, V271, P29514, DOI 10.1074/jbc.271.47.29514; WU CB, 1994, J BIOL CHEM, V269, P32264; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633; YUAN JG, 1994, J BIOL CHEM, V269, P18463	53	30	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31009	31012		10.1074/jbc.271.49.31009	http://dx.doi.org/10.1074/jbc.271.49.31009			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940090	hybrid			2022-12-27	WOS:A1996VW68600001
J	Liu, F; Hill, DE; Chernoff, J				Liu, F; Hill, DE; Chernoff, J			Direct binding of the proline-rich region of protein tyrosine phosphatase 1B to the src homology 3 domain of p130(Cas)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED CELL-ADHESION; ENDOPLASMIC-RETICULUM; TERMINAL SEQUENCE; HUMAN-PLACENTA; SH3 DOMAINS; KINASE; PHOSPHORYLATION; P130; CRK; TRANSFORMATION	Protein tyrosine phosphatase 1B (PTP1B) is an abundant intracellular enzyme that is thought to act as a negative regulator of certain signaling pathways. The C terminus of PTP1B contains two proline-rich regions which conform to the canonical class II Src homology 3 domain binding motif, Pro-X-X-Pro-X-Arg. In this study, we establish that PTP1B interacts with Crk, Grb2, and p130(Cas) in vitro and with at least one of these, p130(Cas), in intact cells. The interaction of PTP1B and p130(Cas) is independent of tyrosine phosphorylation but can be disrupted by replacing two critical proline residues in the proline rich domain of PTP1B between amino acids 301 and 315. When wild-type PTP1B is expressed in 3Y1-v-crk cells, p130(Cas) shows substantial dephosphorylation, whereas the PTP1B proline mutant does not have this effect. In 3Y1 and 3Y1 v-crk-transformed fibroblasts, almost all of the total PTP1B and about 40% of total p130(Cas) co-sediment with membranes composed primarily of endoplasmic reticulum. These results suggest that the proline-rich domain between amino acids 301 and 315 in PTP1B binds Src homology 3-containing proteins and that p130(Cas) may be a physiological target of this phosphatase in cells.	FOX CHASE CANC CTR, PHILADELPHIA, PA 19111 USA; TEMPLE UNIV, DEPT CHEM, PHILADELPHIA, PA 19122 USA; ONCOGENE RES PROD, CAMBRIDGE, MA 02142 USA	Fox Chase Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Hill, David E/B-6617-2011; Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836	NCI NIH HHS [R01 CA58836, CA-06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058836, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; AVRUCH J, 1971, BIOCHIM BIOPHYS ACTA, V233, P334, DOI 10.1016/0005-2736(71)90331-2; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; CHIDA K, 1994, MOL CELL BIOL, V14, P3782, DOI 10.1128/MCB.14.6.3782; COOL DE, 1992, P NATL ACAD SCI USA, V89, P5422, DOI 10.1073/pnas.89.12.5422; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEUTSCHER MP, 1990, METHOD ENZYMOL, V182, P220; DEUTSCHER MP, 1990, METHOD ENZYMOL, V182, P62; Falet H, 1996, FEBS LETT, V383, P165, DOI 10.1016/0014-5793(96)00232-3; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; FRANGIENI JV, 1996, EMBO J, V12, P4843; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Law SF, 1996, MOL CELL BIOL, V16, P3327; LORENZEN JA, 1995, J CELL BIOL, V131, P631, DOI 10.1083/jcb.131.3.631; Lotti LV, 1996, MOL CELL BIOL, V16, P1946; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; McMillan D. Randy, 1994, Current Opinion in Biotechnology, V5, P540, DOI 10.1016/0958-1669(94)90071-X; MERCHENTHALER I, 1993, J COMP NEUROL, V336, P378, DOI 10.1002/cne.903360306; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; PATCH LA, 1995, J CELL SCI, V108, P1371; PENG ZY, 1995, ONCOGENE, V11, P1955; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHIEVELLA AR, 1993, CELL GROWTH DIFFER, V4, P239; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; SHIFRIN VI, 1993, J BIOL CHEM, V268, P25376; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZANDER NF, 1993, ONCOGENE, V8, P1175	50	208	217	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31290	31295		10.1074/jbc.271.49.31290	http://dx.doi.org/10.1074/jbc.271.49.31290			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940134	hybrid			2022-12-27	WOS:A1996VW68600045
J	Saeki, K; Tokuda, K; Fukuyama, K; Matsubara, H; Nadanami, K; Go, M; Itoh, S				Saeki, K; Tokuda, K; Fukuyama, K; Matsubara, H; Nadanami, K; Go, M; Itoh, S			Site-specific mutagenesis of Rhodobacter capsulatus ferredoxin I, FdxN, that functions in nitrogen fixation - Role of extra residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; RHODOPSEUDOMONAS-CAPSULATA; AZOTOBACTER-VINELANDII; RHIZOBIUM-MELILOTI; GENETIC-ANALYSIS; PROTEIN REARRANGEMENT; DIRECTED MUTAGENESIS; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; REDOX POTENTIALS	One of the two [4Fe-4S] type clusters of the Rhodobacter capsulatus ferredoxin I, FdxN, was modified through site-specific mutagenesis of the distinctive features of the second cluster-binding motif, Cys(38)-X(2)-Cys(41)-X(8)-Cys(50)-X(8)-Cys(50)-X(3)-Cys(59). First, various mutagenized products were tested to learn whether they could rescue the decreased capacity of an fdxN-null strain MSA1 to fix nitrogen: the phenotype of MSA1 was reassessed to Nif(s) (slow growth by nitrogen fixation) from our previous description of Nif(-) (Saeki, K., Suetsugu, Y., Tokuda, H., Miyatake, P., Young, D. A., Marrs, B. L. and Matsubara, H. (1991) J. Biol. Chem. 266, 12889-12895). Substitution of Cys(59) to Ser yielded an almost fully active product, while that of Cys(54) did not. Gradual deletions and deletion-substitution of the 8 residues between Cys(41) and Cys(50) also yielded active products. Second, three of the modified FdxN proteins were subjected to purification. Only the GA protein, whose 8 residues between positions 42 and 49 were replaced by the Gly-Ala sequence, was purified. The GA protein and the authentic FdxN showed similar optical properties. The two clusters in the former had E(m) values of -490 and -430 mV, while those in the latter had an identical value of -490 mV, when determined by EPR analysis. It was concluded that: 1) Cys(59) is not a ligand to [4Fe-4S] clusters but is important for structural integrity, 2) the residues between positions 42 and 49 may form a ''loop-out'' from a structure analogous to the Peptococcus aerogenes ferredoxin, and 3) the loop-out region does not have functional significance in nitrogen fixation but may be responsible for maintaining the highly negative redox potential of one of the two clusters.	NAGOYA UNIV,GRAD SCH SCI,DIV BIOL SCI,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN; NATL INST BASIC BIOL,OKAZAKI,AICHI 444,JAPAN	Nagoya University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Saeki, K (corresponding author), OSAKA UNIV,GRAD SCH SCI,DEPT BIOL,TOYONAKA,OSAKA 560,JAPAN.		Saeki, Kazuhiko/F-9904-2013; Saeki, Kazuhiko/ABC-8447-2020	Saeki, Kazuhiko/0000-0002-4198-9754; Saeki, Kazuhiko/0000-0002-4198-9754				ADMAN ET, 1973, J BIOL CHEM, V248, P3987; BACKES G, 1991, J AM CHEM SOC, V113, P2055, DOI 10.1021/ja00006a027; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; Dutton P L, 1978, Methods Enzymol, V54, P411; EBELING S, 1988, J BACTERIOL, V170, P1999, DOI 10.1128/jb.170.4.1999-2001.1988; FLEISCHMANN RD, 1995, SCIENCE, V269, P498; FUKUYAMA K, 1988, J MOL BIOL, V199, P183, DOI 10.1016/0022-2836(88)90388-9; HALLENBECK PC, 1982, BIOCHIM BIOPHYS ACTA, V681, P168, DOI 10.1016/0005-2728(82)90020-2; HALLENBECK PC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P97, DOI 10.1016/S0005-2728(05)80088-X; HASE T, 1977, J BIOCHEM, V81, P1745, DOI 10.1093/oxfordjournals.jbchem.a131635; HASE T, 1978, J BIOCHEM, V83, P1321, DOI 10.1093/oxfordjournals.jbchem.a132039; HOWARD JB, 1991, ADV PROTEIN CHEM, V42, P199; HUBER JG, 1995, BIOCHEMISTRY-US, V34, P194, DOI 10.1021/bi00001a024; JENSEN GM, 1994, BIOCHEMISTRY-US, V33, P10911, DOI 10.1021/bi00202a010; JOERGER RD, 1990, J BACTERIOL, V172, P3400, DOI 10.1128/jb.172.6.3400-3408.1990; JOERGER RD, 1988, J BACTERIOL, V170, P1475, DOI 10.1128/jb.170.4.1475-1487.1988; JOUANNEAU Y, 1995, BBA-BIOENERGETICS, V1232, P33, DOI 10.1016/0005-2728(95)00106-X; KLIPP W, 1989, MOL GEN GENET, V216, P293, DOI 10.1007/BF00334368; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANGEN R, 1992, J BIOL CHEM, V267, P25625; MARTIN AE, 1990, P NATL ACAD SCI USA, V87, P598, DOI 10.1073/pnas.87.2.598; MASEPOHL B, 1992, MOL GEN GENET, V233, P33, DOI 10.1007/BF00587558; MATHEWS R, 1974, J BIOL CHEM, V249, P4326; MATSUBARA H, 1992, ADV INORG CHEM, V38, P223, DOI 10.1016/S0898-8838(08)60065-3; MAYO SL, 1990, J PHYS CHEM-US, V94, P8897, DOI 10.1021/j100389a010; MINAMI Y, 1984, J BIOCHEM-TOKYO, V96, P585, DOI 10.1093/oxfordjournals.jbchem.a134873; MORENOVIVIAN C, 1989, J BACTERIOL, V171, P2591, DOI 10.1128/jb.171.5.2591-2598.1989; MULLIGAN ME, 1988, J BACTERIOL, V170, P4406, DOI 10.1128/jb.170.9.4406-4410.1988; Naud I, 1996, EUR J BIOCHEM, V237, P399, DOI 10.1111/j.1432-1033.1996.0399k.x; NAUD I, 1994, EUR J BIOCHEM, V222, P933, DOI 10.1111/j.1432-1033.1994.tb18942.x; PRINCE RC, 1987, J BIOL CHEM, V262, P5125; ROBSON R, 1986, EMBO J, V5, P1159, DOI 10.1002/j.1460-2075.1986.tb04341.x; SAEKI K, 1990, NUCLEIC ACIDS RES, V18, P1060, DOI 10.1093/nar/18.4.1060; SAEKI K, 1991, J BIOL CHEM, V266, P12889; SAEKI K, 1993, PLANT CELL PHYSIOL, V34, P185; SAEKI K, 1990, J BIOCHEM-TOKYO, V108, P476; SAEKI K, 1992, RES PHOTOSYNTHESIS, V4, P43; Sambrook J., 2002, MOL CLONING LAB MANU; SCHATT E, 1989, J BACTERIOL, V171, P6218, DOI 10.1128/jb.171.11.6218-6226.1989; SCHMEHL M, 1993, MOL GEN GENET, V241, P602, DOI 10.1007/BF00279903; SHEN B, 1995, P NATL ACAD SCI USA, V92, P10064, DOI 10.1073/pnas.92.22.10064; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; SUETSUGU Y, 1991, FEBS LETT, V292, P13, DOI 10.1016/0014-5793(91)80822-K; TANAKA M, 1974, BIOCHEMISTRY-US, V13, P2953, DOI 10.1021/bi00711a026; TANAKA M, 1974, BIOCHEMISTRY-US, V14, P1938; TAYLOR DP, 1983, J BACTERIOL, V154, P580, DOI 10.1128/JB.154.2.580-590.1983; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VONSTERNBERG R, 1993, BIOCHIM BIOPHYS ACTA, V1144, P435, DOI 10.1016/0005-2728(93)90131-X; WEAVER PF, 1975, ARCH MICROBIOL, V105, P207, DOI 10.1007/BF00447139; WILLISON JC, 1993, GENE, V133, P39, DOI 10.1016/0378-1119(93)90222-O; YAKUNIN A F, 1987, Biokhimiya, V52, P1977; YAKUNIN AF, 1983, BIOCHIM BIOPHYS ACTA, V725, P298, DOI 10.1016/0005-2728(83)90203-7; YAKUNIN AF, 1993, J BACTERIOL, V175, P6775, DOI 10.1128/jb.175.21.6775-6780.1993; YEN HC, 1976, J BACTERIOL, V126, P619, DOI 10.1128/JB.126.2.619-629.1976; YOUNG DA, 1989, MOL GEN GENET, V218, P1, DOI 10.1007/BF00330558	56	14	15	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31399	31406		10.1074/jbc.271.49.31399	http://dx.doi.org/10.1074/jbc.271.49.31399			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940149	hybrid			2022-12-27	WOS:A1996VW68600060
J	Vanags, DM; PornAres, MI; Coppola, S; Burgess, DH; Orrenius, S				Vanags, DM; PornAres, MI; Coppola, S; Burgess, DH; Orrenius, S			Protease involvement in fodrin cleavage and phosphatidylserine exposure in apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PHOSPHOLIPID ASYMMETRY; HUMAN ERYTHROCYTE-MEMBRANE; PLATELET PLASMA-MEMBRANE; PROGRAMMED CELL-DEATH; INTERLEUKIN-1-BETA CONVERTING-ENZYME; SPIN-LABELED PHOSPHOLIPIDS; FAS-MEDIATED APOPTOSIS; GENE CED-3; IL-1-BETA-CONVERTING ENZYME; PHAGOCYTE RECOGNITION	A detailed kinetic analysis of three extranuclear end points of apoptosis, phosphatidylserine exposure, alpha-fodrin degradation, and plasma membrane blebbing, was performed and compared with nuclear fragmentation and the activation of the intertleukin-1 beta-converting enzyme (ICE)-like proteases in Jurkat T lymphocytes stimulated by anti-Fas monoclonal antibody (anti-Fas mAb) and in monocytic U937 cells stimulated by tumor necrosis factor (TNF) and cycloheximide. Phosphatidylserine exposure was quantitated by plasma clotting time, as well as annexin V-fluorescein isothiocyanate binding, and the ICE-like protease activity was examined by the cleavage of a specific fluorogenic peptide substrate Ac-Asp-Glu-Val-Asp-amino-4-methylcoumarin. VAD-chloromethylketone (VAD-cmk), an inhibitor of ICE-like proteases, effectively inhibited ICE-like activity in both cell types studied, whereas the calpain inhibitor calpeptin was ineffective. VAD-cmk also effectively inhibited all three extranuclear events, as well as nuclear fragmentation, in Jurkat cells stimulated by anti-Fas monoclonal antibody, indicating that ICE-like proteases play an important role in the regulation of this apoptotic system, Calpain inhibitors were ineffective in this system. TNF-induced extranuclear and nuclear changes in U937 cells were inhibited by calpeptin but were not as effectively inhibited by VAD-cmk as in Jurkat cells. This suggests that ICE-like enzymes predominate in anti-Fas monoclonal antibody-stimulated Jurkat cells, whereas proteases affected by calpain inhibitors as well as the ICE-like enzymes are involved in the signaling of apoptotic events in TNF-induced U937 cells, Importantly, the two apoptotic systems seem to be regulated by different proteases.			Vanags, DM (corresponding author), KAROLINSKA INST,INST ENVIRONM MED,DIV TOXICOL,BOX 210,S-17177 STOCKHOLM,SWEDEN.		Coppola, Simona/A-6638-2015	Coppola, Simona/0000-0001-7851-9409				ATSMA DE, 1995, CIRC RES, V76, P1071, DOI 10.1161/01.RES.76.6.1071; BASSE F, 1993, BIOCHEMISTRY-US, V32, P2337, DOI 10.1021/bi00060a027; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BLACK RA, 1989, J BIOL CHEM, V264, P5323; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BROWN DG, 1993, J BIOL CHEM, V268, P3037; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CHARD PS, 1995, NEUROSCIENCE, V65, P1099, DOI 10.1016/0306-4522(94)00548-J; CHIU D, 1981, BLOOD, V58, P398; CHOW SC, 1995, FEBS LETT, V364, P134, DOI 10.1016/0014-5793(95)00370-O; COMFURIUS P, 1990, BIOCHIM BIOPHYS ACTA, V1026, P153, DOI 10.1016/0005-2736(90)90058-V; CONNOR J, 1994, J BIOL CHEM, V269, P2399; COTTER TG, 1992, CANCER RES, V52, P997; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; EDELSTEIN CL, 1995, P NATL ACAD SCI USA, V92, P7662, DOI 10.1073/pnas.92.17.7662; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FADOK VA, 1992, J IMMUNOL, V148, P2207; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FOX JEB, 1987, BLOOD, V69, P537; FOX JEB, 1990, J CELL BIOL, V111, P483, DOI 10.1083/jcb.111.2.483; GAFFET P, 1995, EUR J CELL BIOL, V67, P336; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GOODMAN SR, 1988, CRIT REV BIOCHEM MOL, V23, P171, DOI 10.3109/10409238809088319; HAEST CWM, 1978, BIOCHIM BIOPHYS ACTA, V509, P21, DOI 10.1016/0005-2736(78)90004-4; HAEST CWM, 1976, BIOCHIM BIOPHYS ACTA, V436, P353, DOI 10.1016/0005-2736(76)90199-1; HARRIS AS, 1988, J BIOL CHEM, V263, P15754; HARRIS AS, 1990, P NATL ACAD SCI USA, V87, P3009, DOI 10.1073/pnas.87.8.3009; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KUYPERS FA, 1993, BLOOD, V81, P1051; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN OC, 1987, J BIOL CHEM, V262, P5890; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; OPDENKAMP JAF, 1979, ANNU REV BIOCHEM, V48, P47, DOI 10.1146/annurev.bi.48.070179.000403; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; SIMS PJ, 1989, J BIOL CHEM, V264, P17049; SMEETS EF, 1994, BBA-BIOMEMBRANES, V1195, P281, DOI 10.1016/0005-2736(94)90268-2; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; SULPICE JC, 1994, J BIOL CHEM, V269, P6347; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THIAGARAJAN P, 1991, J BIOL CHEM, V266, P24302; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILLIAMS MS, 1994, J IMMUNOL, V153, P4247; WILLIAMSON P, 1992, BIOCHEMISTRY-US, V31, P6355, DOI 10.1021/bi00142a027; WILLIAMSON P, 1987, FEBS LETT, V219, P316, DOI 10.1016/0014-5793(87)80243-0; WILLIAMSON P, 1994, MOL MEMBR BIOL, V11, P199, DOI 10.3109/09687689409160430; WILLIAMSON P, 1982, CELL, V30, P725, DOI 10.1016/0092-8674(82)90277-X; WYLLIE AH, 1980, INT REV CYTOL, V68, P2251; YOKOTA M, 1995, STROKE, V26, P1901, DOI 10.1161/01.STR.26.10.1901; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZACHOWSKI A, 1990, EXPERIENTIA, V46, P644, DOI 10.1007/BF01939703; ZACHOWSKI A, 1987, BIOCHIM BIOPHYS ACTA, V897, P197, DOI 10.1016/0005-2736(87)90328-2; ZHIVOTOVSKY B, 1995, EXP CELL RES, V221, P204; ZWAAL RFA, 1993, BIOCHEM SOC T, V21, P248, DOI 10.1042/bst0210248	75	349	356	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31075	31085		10.1074/jbc.271.49.31075	http://dx.doi.org/10.1074/jbc.271.49.31075			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940103	hybrid			2022-12-27	WOS:A1996VW68600014
J	Fukuda, M; Kojima, T; Kabayama, H; Mikoshiba, K				Fukuda, M; Kojima, T; Kabayama, H; Mikoshiba, K			Mutation of the pleckstrin homology domain of Bruton's tyrosine kinase in immunodeficiency impaired inositol 1,3,4,5-tetrakisphosphate binding capacity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; GTPASE-ACTIVATING PROTEIN; BETA-GAMMA-SUBUNITS; PH DOMAIN; FAMILY; MEMBER	Bruton's tyrosine kinase (Btk), a cytoplasmic protein-tyrosine kinase, plays a pivotal role in B cell activation and development. Mutations in the pleckstrin homology (PH) domain of the Btk gene cause human X-linked agammaglobulinemia (XLA) and murine X-linked immunodeficiency (Xid). In this paper, we report that the PH domain of Btk functions as an inositol 1,3,4,5-tetrakisphosphate (IP4), inositol 1,3,4,5,6-pentakisphosphate, and inositol 1,2,3,4,5,6-hexakisphosphate (IP6) binding domain (K-d of approximately 40 nM for IP4), and that all of the XLA (Phe replaced by Ser at position 25 (F25S), R28H, T33P, V64F, and V113D) and Xid mutations (R28C) found in the PH domain result in a dramatic reduction of IP4 binding activity. Furthermore, the rare alternative splicing variant, with 33 amino acids deleted in the PH domain, corresponding to exon 3 of the Btk gene, also impaired IP4 binding capacity. In contrast, a gain-of-function mutant called Btk*, which carries a E41K mutation in the PH domain, binds IP6 with two times higher affinity than the wild type. Our data suggest that B cell differentiation is closely correlated with the IP4 binding capacity of the PH domain of Btk.	UNIV TOKYO,INST MED SCI,DEPT MOL NEUROBIOL,MINATO KU,TOKYO 108,JAPAN; ERATO,CALCIOSIGNAL NET PROJECT,TOKYO 153,JAPAN	University of Tokyo; Japan Science & Technology Agency (JST)	Fukuda, M (corresponding author), INST PHYS & CHEM RES,RIKEN,TSUKUBA LIFE SCI CTR,MOL NEUROBIOL LAB,3-1-1 KOYADAI,TSUKUBA,IBARAKI 305,JAPAN.		Fukuda, MItsunori/I-1511-2015; Kabayama, Hiroyuki/AAC-2070-2021; Mikoshiba, Katsuhiko/N-7943-2015	Fukuda, MItsunori/0000-0002-8620-5853; Kabayama, Hiroyuki/0000-0002-5482-1950; 				CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Fukuda M, 1996, J BIOL CHEM, V271, P18838, DOI 10.1074/jbc.271.31.18838; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; MANO H, 1995, BLOOD, V85, P343; MOUNTFORD JC, 1994, BBA-MOL CELL RES, V1222, P101, DOI 10.1016/0167-4889(94)90030-2; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VIHINEN M, 1994, FEBS LETT, V350, P263, DOI 10.1016/0014-5793(94)00783-7; Vihinen M, 1996, NUCLEIC ACIDS RES, V24, P160, DOI 10.1093/nar/24.1.160; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	24	180	184	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30303	30306		10.1074/jbc.271.48.30303	http://dx.doi.org/10.1074/jbc.271.48.30303			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939985	hybrid			2022-12-27	WOS:A1996VV15800002
J	Xie, XS				Xie, XS			Reconstitution of ATPase activity from individual subunits of the clathrin-coated vesicle proton pump - The requirement and effect of three small subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; SACCHAROMYCES-CEREVISIAE; TRANSLOCATING ATPASE; 14-KDA SUBUNIT; YEAST; GENE; ACIDIFICATION; POLYPEPTIDE; ENCODES; PROTEIN	The vacuolar-type proton pump of clathrin coated vesicles is composed of two general domains, a peripheral, catalytic sector (V-C) and a transmembranous proton channel (V-B). In its native form, the enzyme can hydrolyze both MgATP and CaATP, whereas V-C, when separated from V-B, loses its MgATPase activity and switches to a state that can hydrolyze only CaATP. Further dissociation of V-C results in subcomplexes that are depleted of one or more subunits and lack ATPase activity altogether. Reconstitution of recombinant sub units to these biochemically prepared subcomplexes has demonstrated the necessity of polypeptides of 70, 58, 40, and 33 kDa (subunits A, B, C, and E, respectively) for CaATPase activity of the V-C complex. The current studies demonstrate that mixtures of these four recombinant subunits cannot support CaATPase activity in the absence of a biochemically prepared subcomplex. Investigation of the other components required for ATPase activity has led to the identification of three additional polypeptides present in preparations of V-C, with apparent molecular masses of 15, 14, and 10 kDa. Each of these proteins was found to activate ATPase activity of mixtures of subunits A, B, C, and E. In addition, ATPase reconstituted from these individual subunits hydrolyses ATP, not only in the presence of Ca2+ but also in the presence of Mg2+. Investigation of the individual properties of these three subunits revealed that the 10-kDa polypeptide is subunit F, as determined by immunoblot analysis. This subunit had no effect on MgATPase activity of V-C but stimulated CaATPase activity B-fold in the presence of subunit D. Under optimal conditions the 14-kDa component resulted in a 10-fold stimulation and the 15-kDa component a 20-fold stimulation of MgATPase activity; based on this observation, the 14- and 15-kDa polypeptides were named subunits G and H, respectively. In addition, proton pumping activity was reconstituted through the reassembly of subunits A-H with V-B and SFD, a previously described pump component composed of polypeptides of 50 and 57 kDa (Xie, X. S, Crider, B.P., Ma, Y. M., and Stone, D. K. (1994) J. Biol. Chem. 269, 25809-25815). Together, these experiments completely define the catalytic center of the vacuolar proton pump of clathrin-coated vesicles.			Xie, XS (corresponding author), UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DIV MOL TRANSPORT,DALLAS,TX 75235, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033627] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33627] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPERN RJ, 1990, KIDNEY; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; ARAI H, 1987, J BIOL CHEM, V262, P8796; BOWMAN BJ, 1992, J BIOENERG BIOMEMBR, V24, P361, DOI 10.1007/BF00762529; FOURY F, 1990, J BIOL CHEM, V265, P18554; GRAF R, 1994, J BIOL CHEM, V269, P3767; GRAF R, 1995, P GER ZOOL SOC, P103; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KIBAK H, 1992, J BIOENERG BIOMEMBR, V24, P415, DOI 10.1007/BF00762534; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTSSON JP, 1994, J BIOL CHEM, V269, P24979; NELSON H, 1994, J BIOL CHEM, V269, P24150; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; Peng SB, 1996, J BIOL CHEM, V271, P3324, DOI 10.1074/jbc.271.6.3324; PENG SB, 1994, J BIOL CHEM, V269, P27778; PENG SB, 1994, J BIOL CHEM, V269, P11356; PENG SB, 1993, J BIOL CHEM, V268, P23519; PENG SB, 1995, J BIOL CHEM, V270, P16926; PRESTON RA, 1989, P NATL ACAD SCI USA, V86, P7027, DOI 10.1073/pnas.86.18.7027; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHIH CK, 1988, MOL CELL BIOL, V8, P3094, DOI 10.1128/MCB.8.8.3094; STONE DK, 1984, J BIOL CHEM, V259, P2701; STONE DK, 1988, KIDNEY INT, V33, P403; SZE H, 1992, J BIOENERG BIOMEMBR, V24, P371, DOI 10.1007/BF00762530; XIE XS, 1994, J BIOL CHEM, V269, P25809; XIE XS, 1988, J BIOL CHEM, V263, P9859	29	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30980	30985						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940086				2022-12-27	WOS:A1996VV15800103
J	Yao, M; Kow, YW				Yao, M; Kow, YW			Cleavage of insertion/deletion mismatches, flap and pseudo-Y DNA structures by deoxyinosine 3'-endonuclease from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURE-SPECIFIC ENDONUCLEASE; SIMPLE REPETITIVE DNA; HUMAN MSH2 PROTEIN; MICROSATELLITE INSTABILITY; HETERODUPLEX DNA; 3' EXONUCLEASE; REPAIR; SEQUENCES; EXTRACTS; YEAST	Deoxyinosine 3'-endonuclease, an Escherichia coli repair enzyme that recognizes and cleaves DNA containing deoxyinosine and base mismatches, can cleave heteroduplexes containing a hairpin or unpaired loop. These DNA structures, referred to as insertion/deletion mismatches (IDM), are abnormal intermediate structures generated during replication of repetitive DNA sequences. In addition, the enzyme also cleaved the 5'-single-stranded tails of flap and pseudo-Y DNA structures, suggesting that deoxyinosine 3'-endonuclease is a bacterial functional homologue of human FEN1 and yeast RTH1 nucleases, These biochemical properties suggest that deoxyinosine S'-endonuclease might be important in the repair of IDM structures generated in lagging strand during DNA replication.	EMORY UNIV,SCH MED,DEPT RADIAT ONCOL,DIV CANC BIOL,ATLANTA,GA 30335	Emory University					NIGMS NIH HHS [GM 37216] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037216] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLATTNER FR, 1993, NUCLEIC ACIDS RES, V21, P5408; CARRAWAY M, 1993, J BACTERIOL, V175, P3972, DOI 10.1128/JB.175.13.3972-3980.1993; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; FISHEL R, 1989, J BACTERIOL, V171, P3046, DOI 10.1128/jb.171.6.3046-3052.1989; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HIRAOKA LR, 1995, GENOMICS, V25, P220, DOI 10.1016/0888-7543(95)80129-A; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; LAHUE RS, 1987, P NATL ACAD SCI USA, V84, P1482, DOI 10.1073/pnas.84.6.1482; LEACH DRF, 1994, BIOESSAYS, V16, P893, DOI 10.1002/bies.950161207; LEVINSON G, 1987, NUCLEIC ACIDS RES, V15, P5323, DOI 10.1093/nar/15.13.5323; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; Miret JJ, 1996, NUCLEIC ACIDS RES, V24, P721, DOI 10.1093/nar/24.4.721; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; ROBINS P, 1994, J BIOL CHEM, V269, P28535; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; SPEICHER MR, 1995, ONCOL RES, V7, P267; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; SZANKASI P, 1995, SCIENCE, V267, P1166, DOI 10.1126/science.7855597; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; WAGA S, 1994, J BIOL CHEM, V269, P10923; YAO M, 1995, J BIOL CHEM, V270, P28609, DOI 10.1074/jbc.270.48.28609; YAO M, 1994, J BIOL CHEM, V269, P31390; YAO M, 1994, J BIOL CHEM, V269, P16260	33	60	66	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30672	30676		10.1074/jbc.271.48.30672	http://dx.doi.org/10.1074/jbc.271.48.30672			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940043	hybrid			2022-12-27	WOS:A1996VV15800060
J	Ishida, R; Iwai, M; Marsh, KL; Austin, CA; Yano, T; Shibata, M; Nozaki, N; Hara, A				Ishida, R; Iwai, M; Marsh, KL; Austin, CA; Yano, T; Shibata, M; Nozaki, N; Hara, A			Threonine 1342 in human topoisomerase II alpha is phosphorylated throughout the cell cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; C-TERMINAL DOMAIN; DNA TOPOISOMERASE; SACCHAROMYCES-CEREVISIAE; MITOTIC CHROMOSOMES; IN-VIVO; DEPENDENT PHOSPHORYLATION; ANTITUMOR DRUGS; PHORBOL ESTER; PROTEIN	To investigate the relationship between the modulation of topoisomerase II activity and its phosphorylation state during the cell cycle, a monoclonal antibody against C-terminal peptide (residues 1335-1350) of topoisomerase II alpha containing a consensus sequence of casein kinase II, TDDE and its phosphorylated threonine were prepared, In an enzyme-linked immunosorbent assay, the antibody, named PT1342, recognized the immunogenic phosphopeptide but not the non-phosphorylated form of the peptide. The PT1342 antibody reacted only with a 170-kDa protein from HeLa cells and recognized anti-topoisomerase II alpha immunoprecipitants. Furthermore, the antibody did not react with the human topoisomerase II alpha mutated at codon 1342 from threonine to alanine, showing that PT1342 was directed against the phosphorylated threonine 1342. To examine the level of phosphorylation of threonine 1342 of topoisomerase II alpha through the cell cycle, HeLa cells were stained simultaneously for phosphorylated topoisomerase II alpha and DNA and analyzed by flow cytometry, Cells in the G(2)-M phase contained about double the PT1341-reacted topoisomerase II alpha than did cells in G(1) or S phases, The antibody stained the nuclei in interphase and mitotic chromosomes and its periphery, as seen with anti-topoisomerase II alpha antibody, Thus, threonine 1342 in topoisomerase II alpha is phosphorylated throughout the cell cycle.	AICHI CANC CTR,RES INST,BIOCHEM LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; GIFU PHARMACEUT UNIV,DEPT BIOCHEM,GIFU 502,JAPAN; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT BIOCHEM & GENET,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; MED & BIOL LABS,NAGANO 396,JAPAN; KANAGAWA DENT COLL,DEPT ORAL BIOCHEM,YOKOSUKA,KANAGAWA 238,JAPAN	Aichi Cancer Center; Gifu Pharmaceutical University; Newcastle University - UK; Kanagawa Dental College	Ishida, R (corresponding author), AICHI CANC CTR,RES INST,LAB CHEMOTHERAPY,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN.			Austin, Caroline/0000-0002-1921-5947; West, Katherine/0000-0002-5994-8969				ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; AUSTIN CA, 1995, J BIOL CHEM, V270, P15739, DOI 10.1074/jbc.270.26.15739; BOJANOWSKI K, 1993, J BIOL CHEM, V268, P22920; BURDEN DA, 1993, BIOCHEM J, V293, P297, DOI 10.1042/bj2930297; BURDEN DA, 1994, BIOCHEMISTRY-US, V33, P14651, DOI 10.1021/bi00253a001; CARDENAS ME, 1993, J CELL SCI, V104, P219; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CARDENAS ME, 1993, J CELL SCI, V104, P533; CARON PR, 1994, MOL CELL BIOL, V14, P3197, DOI 10.1128/MCB.14.5.3197; CARON PR, 1993, MOL BIOL DNA TOPOISO, P207; CORBETT AH, 1992, J BIOL CHEM, V267, P20513; CRENSHAW DG, 1993, J BIOL CHEM, V268, P21328; DANG Q, 1994, J MOL BIOL, V243, P10, DOI 10.1006/jmbi.1994.1626; DARKINRATTRAY SJ, 1991, BIOCHIM BIOPHYS ACTA, V1088, P285, DOI 10.1016/0167-4781(91)90065-T; DARPA P, 1989, BIOCHIM BIOPHYS ACTA, V989, P163, DOI 10.1016/0304-419X(89)90041-3; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; DUGUET M, 1983, NUCLEIC ACIDS RES, V11, P1059, DOI 10.1093/nar/11.4.1059; EARNSHAW WC, 1988, BIOESSAYS, V9, P147, DOI 10.1002/bies.950090502; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; ESTEY E, 1987, BIOCHEMISTRY-US, V26, P4338, DOI 10.1021/bi00388a023; FISHER D, 1993, EXP CELL RES, V209, P255; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; HECK MMS, 1989, J BIOL CHEM, V264, P15161; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; HSIANG YH, 1988, CANCER RES, V48, P3230; ISHIDA R, 1995, CANCER RES, V55, P2299; ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341; ISHIDA R, 1991, CANCER RES, V51, P4909; ISHIMI Y, 1995, J MOL BIOL, V247, P835, DOI 10.1006/jmbi.1995.0183; KIM RA, 1989, J MOL BIOL, V208, P257, DOI 10.1016/0022-2836(89)90387-2; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Meisner H, 1991, CURR OPIN CELL BIOL, V3, P474, DOI 10.1016/0955-0674(91)90076-B; MULNERLORILLON O, 1990, EUR J BIOCHEM, V193, P529, DOI 10.1111/j.1432-1033.1990.tb19368.x; NISHIZAWA K, 1991, J BIOL CHEM, V266, P3074; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; ROTTMANN M, 1987, EMBO J, V6, P3939, DOI 10.1002/j.1460-2075.1987.tb02735.x; SAHYOUN N, 1986, P NATL ACAD SCI USA, V83, P1603, DOI 10.1073/pnas.83.6.1603; SAIJO M, 1992, BIOCHEMISTRY-US, V31, P359, DOI 10.1021/bi00117a007; SANDER M, 1984, P NATL ACAD SCI-BIOL, V81, P6938, DOI 10.1073/pnas.81.22.6938; SHIOZAKI K, 1992, J CELL BIOL, V119, P1023, DOI 10.1083/jcb.119.5.1023; STEVEN WS, 1994, EXP CELL RES, V211, P275; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; TAKANO H, 1991, CANCER RES, V51, P3951; TAN KB, 1992, CANCER RES, V52, P231; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WAKAMIYA T, 1993, CHEM LETT, P1401, DOI 10.1246/cl.1993.1401; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WASSERMAN RA, 1993, CANCER RES, V53, P3591; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WELLS NJ, 1994, J BIOL CHEM, V269, P29746; YANO T, 1991, BIOCHEM BIOPH RES CO, V175, P1144, DOI 10.1016/0006-291X(91)91685-6; ZWELLING LA, 1989, J BIOL CHEM, V264, P16411	63	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30077	30082		10.1074/jbc.271.47.30077	http://dx.doi.org/10.1074/jbc.271.47.30077			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939955	hybrid			2022-12-27	WOS:A1996VU52500083
J	Yu, H; Li, X; Marchetto, GS; Dy, R; Hunter, D; Calvo, B; Dawson, TL; Wilm, M; Anderegg, RJ; Graves, LM; Earp, HS				Yu, H; Li, X; Marchetto, GS; Dy, R; Hunter, D; Calvo, B; Dawson, TL; Wilm, M; Anderegg, RJ; Graves, LM; Earp, HS			Activation of a novel calcium-dependent protein-tyrosine kinase - Correlation with c-jun N-terminal kinase but not mitogen-activated protein kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR MESANGIAL CELLS; SMOOTH-MUSCLE CELLS; ANGIOTENSIN-II; SIGNALING PATHWAY; PHOSPHORYLATION; IDENTIFICATION; CDC42	Many G protein-coupled receptors (e.g. that of angiotensin II) activate phospholipase C beta, initially increasing intracellular calcium and activating protein kinase C. In the WB and GN4 rat liver epithelial cell lines, agonist-induced calcium signals also stimulate tyrosine phosphorylation and subsequently increase the activity of c-Jun N-terminal kinase (JNK), We have now purified the major calcium-dependent tyrosine kinase (CADTK), and by peptide and nucleic acid sequencing identified it as a rat homologue of human PYK2. CADTK/PYK2 is most closely related to p125(FAK) and both enzymes are expressed in WE and GN4 cells, Angiotensin II, which only slightly increases p125(FAK) tyrosine phosphorylation in GN4 cells, substantially increased CADTK tyrosine autophosphorylation and kinase activity, Agonists for other G protein-coupled receptors (e.g. LPA), or those increasing intracellular calcium (thapsigargin), also stimulated CADTK. In comparing the two rat liver cell lines, GN4 cells exhibited similar to 5-fold greater angiotensin II- and thapsigargin-dependent CADTK activation than WB cells, Although maximal JNK activation by stress-dependent pathways (e.g. UV and anisomycin) was equivalent in the two cell lines, calcium-dependent JNK activation was B-fold greater in GN4, correlating with CADTK activation. In contrast to JNK, the thapsigargin-dependent calcium signal did not activate mitogen-activated protein kinase and Ang II-dependent mitogen-activated protein kinase activation was not correlated with CADTK activation. Finally, while some stress-dependent activators of the JNK pathway (NaCl and sorbitol) stimulated CADTK, others (anisomycin, UV, and TNF alpha) did not, In summary, cells expressing CADTK/PYK2 appear to have two alternative JNK activation pathways: one stress-activated and the other calcium-dependent.	UNIV N CAROLINA,SCH MED,LINEBERGER COMPREHENS CANC CTR,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT PHARMACOL,CHAPEL HILL,NC 27599; EUROPEAN MOL BIOL LAB,PROT & PEPTIDE GRP,D-69012 HEIDELBERG,GERMANY; GLAXO WELLCOME INC,RES & DEV,RES TRIANGLE PK,NC 27709	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; European Molecular Biology Laboratory (EMBL); GlaxoSmithKline			Graves, Lee/AAG-5470-2021	Dawson, Thomas/0000-0003-3878-1722; Wilm, Matthias/0000-0002-5461-6834	NIDDK NIH HHS [DK 31683] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031683] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; BRAUN HP, 1995, ANN REV PHYSL, V57, P417; BUTCHER RD, 1993, BIOCHEM BIOPH RES CO, V196, P1280, DOI 10.1006/bbrc.1993.2391; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; COX AD, 1995, METHOD ENZYMOL, V255, P195; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; EARP HS, J BIOL CHEM, V270, P28440; FORCE T, 1991, J BIOL CHEM, V266, P6650; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; SALLES JP, 1993, J BIOL CHEM, V268, P12805; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHORB W, 1994, J BIOL CHEM, V269, P19626; SHEVCHENKO A, 1996, IN PRESS ANAL CHEM; STABEL S, 1994, SEMIN CANCER BIOL, V5, P277; TSAO MS, 1985, CANCER RES, V45, P5134; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; YAN MH, 1994, NATURE, V372, P798; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	36	242	246	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29993	29998		10.1074/jbc.271.47.29993	http://dx.doi.org/10.1074/jbc.271.47.29993			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939945	hybrid			2022-12-27	WOS:A1996VU52500073
J	Zhang, L; Plow, EF				Zhang, L; Plow, EF			A discrete site modulates activation of I domains - Application to integrin alpha(M)beta(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL INHIBITORY FACTOR; PLATELET GLYCOPROTEIN-IB; MONOCLONAL-ANTIBODIES; COMPLEMENT RECEPTOR; CRYSTAL-STRUCTURE; CR3 CD11B/CD18; FACTOR BINDING; A-DOMAIN; IDENTIFICATION; MAC-1	A central characteristic of integrin adhesion receptors is their capacity to become activated, thereby enhancing their affinity for ligands. Here, we report the identification of a discrete site within the I domain of integrin alpha(M) beta(2), which modulates the adhesive activity of this receptor. Based upon the crystal structure, this region is composed of two short and spatially proximal loops, E(162)QLKKSKTL and Q(190)NNPNPRS. Mutations in these loops yield receptors which support spontaneous cell adhesion to fibrinogen, whereas mutation of an adjacent region and wild-type receptors require activation to adhere to this substrate. An activating monoclonal antibody enhanced the adhesive activity of one but not the other loop mutants, suggesting that the activation states of these two mutant receptors were not identical. Given that similar I domains exist in several other integrin alpha subunits and non-integrin proteins, and possibly in all integrin beta subunits, these two loop segments may represent a universal target for controlling integrin activation and the function of other I domain-containing proteins. In support of this hypothesis, several naturally occurring mutations that activate von Willebrand factor map to the same loops of its I(A) domain.			Zhang, L (corresponding author), CLEVELAND CLIN FDN,DEPT MOL CARDIOL,JOSEPH J JACOBS CTR THROMBOSIS & VASC BIOL,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043721, R01HL038292, R29HL043721] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43721, HL38292] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ANDERSON DC, 1986, J IMMUNOL, V137, P15; BAJT ML, 1992, J BIOL CHEM, V267, P22211; BARNARD JW, 1995, J IMMUNOL, V155, P4876; BILSLAND CAG, 1994, J IMMUNOL, V152, P4582; DAVIS GE, 1992, EXP CELL RES, V200, P242, DOI 10.1016/0014-4827(92)90170-D; DIAMOND MS, 1993, J CELL BIOL, V120, P10311; DOOLITTLE RF, 1967, ARCH BIOCHEM BIOPHYS, V118, P456, DOI 10.1016/0003-9861(67)90374-8; GAMBLE JR, 1985, P NATL ACAD SCI USA, V82, P8667, DOI 10.1073/pnas.82.24.8667; GINSBURG D, 1993, THROMB HAEMOSTASIS, V69, P177; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; MATSUSHITA T, 1995, J BIOL CHEM, V270, P13406, DOI 10.1074/jbc.270.22.13406; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26419; ORLTEPP S, 1995, EUR J IMMUNOL, V25, P637; PHILLIPS DR, 1977, J BIOL CHEM, V252, P2121; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RABB H, 1993, J IMMUNOL, V151, P990; ROSS GD, 1982, J EXP MED, V155, P96, DOI 10.1084/jem.155.1.96; SHAPPELL SB, 1990, J IMMUNOL, V144, P2702; SUGIMOTO M, 1991, J BIOL CHEM, V266, P18172; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; VIOLETTE SM, 1995, J IMMUNOL, V155, P3092; Weiss EJ, 1996, NEW ENGL J MED, V334, P1090, DOI 10.1056/NEJM199604253341703; ZHANG L, 1990, BIOCHEMISTRY-US, V29, P10828, DOI 10.1021/bi00500a016; Zhang L, 1996, J BIOL CHEM, V271, P18211, DOI 10.1074/jbc.271.30.18211; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	27	50	58	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29953	29957		10.1074/jbc.271.47.29953	http://dx.doi.org/10.1074/jbc.271.47.29953			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939940	hybrid			2022-12-27	WOS:A1996VU52500068
J	Burikhanov, R; Coulonval, K; Pirson, I; Lamy, F; Dumont, JE; Roger, PP				Burikhanov, R; Coulonval, K; Pirson, I; Lamy, F; Dumont, JE; Roger, PP			Thyrotropin via cyclic AMP induces insulin receptor expression and insulin co-stimulation of growth and amplifies insulin and insulin-like growth factor signaling pathways in dog thyroid epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTORS; DEOXYRIBONUCLEIC-ACID SYNTHESIS; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; GENE-EXPRESSION; GLUCOCORTICOID REGULATION; FOLLICULAR CELL; PHORBOL ESTER; SOMATOMEDIN-C; FRTL-5 CELLS	Despite the similarity of their receptors and signal transduction pathways, insulin is regarded as a regulator of glucose, protein, and lipid metabolism, whereas insulin-like growth factors (IGF-I and IGF-II) mainly act as mitogenic hormones. In the dog thyroid primary culture model, the triggering of DNA synthesis by thyrotropin (TSH) through cAMP, or by cAMP-independent factors including epidermal growth factor, hepatocyte growth factor and phorbol esters, requires insulin or IGFs as comitogenic factors. In the present study, in TSH-treated cells, IGF-I receptors and insulin receptors were paradoxically equivalent in their capacity to elicit the comitogenic pathway, which, however, was mediated only by IGF-I receptors in dog thyroid cells stimulated by cAMP-independent mitogens. Moreover, prior cell exposure to TSH or forskolin increased their responsiveness to insulin, IGF-I, and IGF-II, as seen on DNA synthesis and activation of a common insulin/IGF signaling pathway. To understand these observations, binding characteristics and expression of insulin and IGF-I receptors were examined. To analyze IGF-I receptor characteristics, the unexpected interference of a huge presence of IGF-binding proteins at the cell membrane was avoided using labeled Long R(3) IGF-I instead of IGF-I, Strikingly, TSH, through cAMP, time-dependently induced insulin binding and insulin receptor mRNA and protein accumulation without any effect on IGF-I receptors. These findings constitute a first example of an induction of insulin receptor gene expression by a cAMP-mediated hormone, In dog thyroid cells, this allows low physiological insulin concentrations to act as a comitogenic factor and might explain in part the enhanced responsiveness to IGFs in response to TSH. This raises the possibility that TSH-insulin interactions may play a role in the regulation of thyroid growth and function in vivo.	FREE UNIV BRUSSELS,INST INTERDISCIPLINARY RES,B-1070 BRUSSELS,BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel				Roger, Pierre/0000-0002-5812-1783				ADASHI EY, 1986, J BIOL CHEM, V261, P3923; BAGCHI N, 1981, ENDOCRINOLOGY, V109, P1428, DOI 10.1210/endo-109-5-1428; BAPTIST M, 1995, EXP CELL RES, V221, P160, DOI 10.1006/excr.1995.1363; BARON V, 1991, BIOCHEMISTRY-US, V30, P9365, DOI 10.1021/bi00102a033; BASERGA R, 1994, CELL PROLIFERAT, V27, P63, DOI 10.1111/j.1365-2184.1994.tb01406.x; BRIATA P, 1990, BIOCHEM BIOPH RES CO, V170, P1184, DOI 10.1016/0006-291X(90)90518-R; CONDORELLI G, 1992, ENDOCRINOLOGY, V130, P1615, DOI 10.1210/en.130.3.1615; CONOVER A, 1989, HORM METAB RES, V21, P59, DOI 10.1055/s-2007-1009151; CONTOR L, 1988, MOL CELL BIOL, V8, P2494, DOI 10.1128/MCB.8.6.2494; DEMEYTS P, 1994, HORM RES, V42, P152, DOI 10.1159/000184188; DENTON RM, 1995, EUR J BIOCHEM, V227, P597, DOI 10.1111/j.1432-1033.1995.tb20179.x; DESHUQUOIS B, 1993, ANN ENEODRINOL PARIS, V54, P373; DREMIER S, 1994, ENDOCRINOLOGY, V135, P135, DOI 10.1210/en.135.1.135; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; FRANCIS GL, 1992, J MOL ENDOCRINOL, V8, P213, DOI 10.1677/jme.0.0080213; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GIORGINO F, 1993, J CLIN INVEST, V91, P2020, DOI 10.1172/JCI116424; HOFMANN C, 1989, J BIOL CHEM, V264, P8606; IshShalom D, 1995, ANN NY ACAD SCI, V766, P409, DOI 10.1111/j.1749-6632.1995.tb26690.x; JOLIN T, 1970, ENDOCRINOLOGY, V87, P99, DOI 10.1210/endo-87-1-99; KING GL, 1980, J CLIN INVEST, V66, P130, DOI 10.1172/JCI109826; KLINMAN D, 1995, ENDOCRINOLOGY, V136, P2531; KOONTZ JW, 1981, SCIENCE, V211, P947, DOI 10.1126/science.7008195; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; LAMY F, 1993, J BIOL CHEM, V268, P8398; LEE JK, 1994, MOL ENDOCRINOL, V8, P625, DOI 10.1210/me.8.5.625; LEROITH D, 1994, HORM RES, V41, P74, DOI 10.1159/000183964; LI SL, 1993, BIOCHEM BIOPH RES CO, V196, P92, DOI 10.1006/bbrc.1993.2220; MACIEL RMB, 1988, J CLIN INVEST, V82, P1546, DOI 10.1172/JCI113764; MAMULA PW, 1990, DIABETES CARE, V13, P288, DOI 10.2337/diacare.13.3.288; MASTICK CC, 1994, ENDOCRINOLOGY, V135, P214, DOI 10.1210/en.135.1.214; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; MCKEON C, 1994, ADV EXP MED BIOL MCK, V343, P79; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; OSTEROP APRM, 1994, BIOCHEMISTRY-US, V33, P7453, DOI 10.1021/bi00189a053; PAPA V, 1990, CANCER RES, V50, P7858; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; PERICAS I, 1977, ACTA ENDOCRINOL-COP, V86, P128, DOI 10.1530/acta.0.0860128; PIETRZKOWSKI Z, 1992, CANCER RES, V52, P6447; POHL V, 1990, J CELL BIOL, V111, P663, DOI 10.1083/jcb.111.2.663; RANDAZZO PA, 1990, EXP CELL RES, V190, P31, DOI 10.1016/0014-4827(90)90140-6; REUSE S, 1991, EXP CELL RES, V196, P210, DOI 10.1016/0014-4827(91)90253-Q; ROGER P, 1988, J CLIN ENDOCR METAB, V66, P1158, DOI 10.1210/jcem-66-6-1158; ROGER PP, 1987, EXP CELL RES, V172, P282, DOI 10.1016/0014-4827(87)90387-9; ROGER PP, 1987, J CELL PHYSIOL, V130, P58, DOI 10.1002/jcp.1041300110; Roger PP, 1995, VITAM HORM, V51, P59, DOI 10.1016/S0083-6729(08)61038-9; ROGER PP, 1983, FEBS LETT, V157, P323, DOI 10.1016/0014-5793(83)80569-9; ROGER PP, 1986, CANCER RES, V46, P895; ROHLIK QT, 1987, BIOCHEM BIOPH RES CO, V149, P276, DOI 10.1016/0006-291X(87)91635-4; RUSSELL WE, 1984, P NATL ACAD SCI-BIOL, V81, P2389, DOI 10.1073/pnas.81.8.2389; SAAD MJA, 1994, MOL ENDOCRINOL, V8, P545, DOI 10.1210/me.8.5.545; SIDDLE K, 1994, HORM RES, V41, P56, DOI 10.1159/000183962; SMITH P, 1986, ENDOCRINOLOGY, V119, P1439, DOI 10.1210/endo-119-4-1439; STADTMAUER L, 1986, J BIOL CHEM, V261, P3402; TAKADA K, 1990, J CLIN INVEST, V86, P1548, DOI 10.1172/JCI114874; TAKAHASHI S, 1990, ENDOCRINOLOGY, V126, P736, DOI 10.1210/endo-126-2-736; TAKAHASHI SI, 1991, J BIOL CHEM, V266, P7834; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; TANTI JF, 1987, BIOCHEM J, V245, P19, DOI 10.1042/bj2450019; THOMAS GA, 1994, J PATHOL, V173, P355, DOI 10.1002/path.1711730411; TONG ZQ, 1994, GEN COMP ENDOCR, V94, P374, DOI 10.1006/gcen.1994.1093; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P133, DOI 10.1210/endo-122-1-133; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P127, DOI 10.1210/endo-122-1-127; VANOBBERGHENSCHILLING E, 1983, EXP CELL RES, V147, P369, DOI 10.1016/0014-4827(83)90219-7; WERNER H, 1994, VITAM HORM, V48, P1, DOI 10.1016/S0083-6729(08)60495-1; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILLIAMS DW, 1989, MOL CELL ENDOCRINOL, V61, P139, DOI 10.1016/0303-7207(89)90199-8; XU B, 1995, J BIOL CHEM, V270, P29825	68	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29400	29406		10.1074/jbc.271.46.29400	http://dx.doi.org/10.1074/jbc.271.46.29400			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910605	hybrid			2022-12-27	WOS:A1996VT05200097
J	Fiedler, B; ScheinerBobis, G				Fiedler, B; ScheinerBobis, G			Transmembrane topology of alpha- and beta-subunits of Na+,K+-ATPase derived from beta-galactosidase fusion proteins expressed in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SITE-DIRECTED MUTAGENESIS; ATP BINDING-SITE; NA+/K+-ATPASE; CATALYTIC SUBUNIT; ESCHERICHIA-COLI; SODIUM-PUMP; NA/K-ATPASE; IMMUNOELECTRON MICROSCOPY; EXTRACELLULAR DOMAIN	Various models of the transmembrane topology of the Na+,KC-ATPase predict either 8 or 10 membrane spans for the alpha-subunit and one to three membrane spans for the beta-subunit. Structure/function analysis, however, requires precise knowledge about the folding of enzymes. Therefore, the intention of this work was to establish a transmembrane topology model for the subunits of Na+,K+-ATPase. The bacterial enzyme beta-galactosidase was fused to the C termini of truncated alpha- and beta-subunits of Na+,K+-ATPase. Fusions were generated at Arg(60) (LTTAR(60)), Glu(116) (AATEE(116)), Ala(247) (VEGTA(247)), Leu(311) (YTWEL(311)), Ala(444) (VAGDA(444)), Ala(789) (IFIIA(789)) Met(809) (LGTDM(809)), Asp(884) (RVTWD(884)), IIe(946) (MKNKI(946)), and Arg(972) (GVALR(972)) of the sheep alpha(1)-subunit and at Pro(236) (LGGYP(236)) of the dog beta-subunit. The fusion constructs were expressed in yeast cells for studies on the localization of the fused reporter enzyme. Activity measurements of the reporter enzyme revealed that only intracellular fusion sites lead to active beta-galactosidase. Indirect immunofluorescence microscopy with cells expressing alpha(1)/beta-galacosidase and beta/beta-galactosidase hybrid proteins demonstrated that inactive beta-galactosidase is associated with the yeast plasma membrane and can be detected from the extracellular side. The data obtained suggest that Pro(236) of the beta-subunit is located on the extracellular surface, corresponding to a model with one transmembrane segment, and that the alpha-subunit of the Na+,K+-ATPase consists of 10 membrane-associated spans, They also suggest that a stretch of the alpha(1)-subunit between membrane spans M7 and M8 might be hidden within the membrane, surrounded by the other hydrophobic spans, in analogy to the P-loop of Na+ or K+ channels and to the ''hourglass'' structure of water channels.	UNIV GIESSEN,INST BIOCHEM & ENDOKRINOL,FACHBEREICH VET MED,D-35392 GIESSEN,GERMANY	Justus Liebig University Giessen								ANDERBERG SJ, 1995, BIOCHEMISTRY-US, V34, P9508, DOI 10.1021/bi00029a027; ANTOLOVIC R, 1991, EUR J BIOCHEM, V199, P195, DOI 10.1111/j.1432-1033.1991.tb16109.x; ARYSTARKHOVA E, 1995, J BIOL CHEM, V270, P8785, DOI 10.1074/jbc.270.15.8785; ARYSTARKHOVA E, 1992, J BIOL CHEM, V267, P13694; BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BAMBERG K, 1992, BIOCHIM BIOPHYS ACTA, V1131, P69, DOI 10.1016/0167-4781(92)90100-E; BAYER R, 1990, BIOCHEMISTRY-US, V29, P2251, DOI 10.1021/bi00461a007; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CANFIELD VA, 1993, BIOCHEMISTRY-US, V32, P13782, DOI 10.1021/bi00213a005; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CHEN CY, 1984, NUCLEIC ACIDS RES, V12, P8951, DOI 10.1093/nar/12.23.8951; EAKLE KA, 1995, J BIOL CHEM, V270, P13937, DOI 10.1074/jbc.270.23.13937; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FAGAN MJ, 1994, J MOL EVOL, V38, P57; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; FROSHAUER S, 1988, J MOL BIOL, V200, P501, DOI 10.1016/0022-2836(88)90539-6; GLYNN IM, 1993, J PHYSIOL-LONDON, V462, P1; GOLDSHLEGER R, 1995, BIOCHEMISTRY-US, V34, P8668, DOI 10.1021/bi00027a016; GREEN NM, 1989, BIOCHEM SOC T, V17, P972, DOI 10.1042/bst0170972; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; HAMRICK M, 1993, J BIOL CHEM, V268, P24367; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACOBSON RH, 1992, J MOL BIOL, V223, P1177, DOI 10.1016/0022-2836(92)90269-P; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JORGENSEN PL, 1982, J BIOL CHEM, V257, P7435; JUNG JS, 1994, J BIOL CHEM, V269, P14648; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KARLISH SJD, 1992, ACTA PHYSIOL SCAND, V146, P69; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; KIRSCH GE, 1995, BIOPHYS J, V68, P1804, DOI 10.1016/S0006-3495(95)80357-7; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; LIN JL, 1995, J BIOL CHEM, V270, P6942, DOI 10.1074/jbc.270.12.6942; LINGREL JB, 1992, J BIOENERG BIOMEMBR, V24, P263; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MCDONOUGH AA, 1990, FASEB J, V4, P1598, DOI 10.1096/fasebj.4.6.2156741; MILLER RP, 1988, BIOCHIM BIOPHYS ACTA, V954, P50, DOI 10.1016/0167-4838(88)90054-4; MOHRAZ M, 1994, J BIOL CHEM, V269, P2929; NING G, 1993, FEBS LETT, V336, P521, DOI 10.1016/0014-5793(93)80868-U; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; OVCHINNIKOV YA, 1988, FEBS LETT, V227, P230, DOI 10.1016/0014-5793(88)80904-9; POST RL, 1965, J BIOL CHEM, V240, P1437; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; ROSE M, 1983, METHOD ENZYMOL, V101, P167; Sambrook J, 1989, MOL CLONING LAB MANU, V1-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEINERBOBIS G, 1994, MOL PHARMACOL, V45, P1132; SCHEINERBOBIS G, 1994, BBA-BIOMEMBRANES, V1193, P226, DOI 10.1016/0005-2736(94)90157-0; SCHULTHEIS PJ, 1993, J BIOL CHEM, V268, P22686; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SKOU JC, 1992, J BIOENERG BIOMEMBR, V24, P249; SKOU JC, 1988, METHOD ENZYMOL, V156, P1; STOKES DL, 1994, FEBS LETT, V346, P32, DOI 10.1016/0014-5793(94)00297-5; TOMASELLI GF, 1995, BIOPHYS J, V68, P1814, DOI 10.1016/S0006-3495(95)80358-9; TRAN CM, 1994, J BIOL CHEM, V269, P6558; TRAN CM, 1994, BIOCHEMISTRY-US, V33, P4140, DOI 10.1021/bi00180a006; VLADIMIROVA NM, 1995, BBA-BIOMEMBRANES, V1233, P175, DOI 10.1016/0005-2736(94)00247-M; Xie YH, 1996, J BIOL CHEM, V271, P2563, DOI 10.1074/jbc.271.5.2563; YOON KL, 1994, J BIOL CHEM, V269, P28249; ZHANG YZ, 1991, FASEB J, V5, P3108, DOI 10.1096/fasebj.5.15.1720751	69	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29312	29320		10.1074/jbc.271.46.29312	http://dx.doi.org/10.1074/jbc.271.46.29312			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910592	hybrid			2022-12-27	WOS:A1996VT05200084
J	Iynedjian, PB; Marie, S; Wang, HY; Gjinovci, A; Nazaryan, K				Iynedjian, PB; Marie, S; Wang, HY; Gjinovci, A; Nazaryan, K			Liver-specific enhancer of the glucokinase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; POLYMERASE CHAIN-REACTION; PANCREATIC BETA-CELL; HYPERSENSITIVE SITES; MESSENGER-RNA; RAT-LIVER; EXPRESSION; PROMOTER; INSULIN; TRANSCRIPTION	Glucokinase gene regions that are important for liver specific expression of the enzyme have been functionally identified using transient transfection of rat hepatocytes. Maximal luciferase activity was elicited by a reporter plasmid with 3.4 kilobase pairs of genomic DNA flanking the liver glucokinase promoter. Deletion of a gene fragment between -1000 and -600 with respect to the start of transcription resulted in a 60% decrease in luciferase activity. Further reduction, close to background level, occurred upon deletion of a 90-base pair sequence between -123 and -34. Reporter plasmids with the liver glucokinase promoter and any length of flanking sequence were minimally active in INS-1 insulinoma cells, and conversely reporters with the beta-cell-specific promoter were ineffective in primary hepatocytes. In FTO-2B hepatoma cells, a differentiated line expressing many liver-specific traits but not the endogenous glucokinase gene, the promoter proximal region between -123 and -34 markedly stimulated the expression of transfected plasmids above background. However, addition of the flanking region up to -1000 inhibited luciferase expression. The gene fragment from -1003 to -707 was shown to be a bona fide, hepatocyte-specific enhancer by the following criteria: 1) it stimulated reporter expression by more than 10- and 5-fold when inserted directly upstream of the glucokinase TATA box or complete promoter, respectively, regardless of orientation; 2) it stimulated gene expression from the heterologous SV 40 promoter 4-fold; 3) it was also effective from a downstream position; and 4) in contrast to the enhancer effect in primary hepatocytes, the sequence acted as a silencer in FTO-2B cells and was neutral in INS-1 cells. Both the promoter proximal and the enhancer regions were marked by DNase I hypersensitive sites in the chromatin of primary hepatocytes but not hepatoma or insulinoma cells. Seven footprinted elements termed A through G were mapped in the enhancer by the in vitro DNase I protection assay. Elements A-C may bind liver enriched factors, because they were not protected by spleen nuclear extract. In hepatocyte transfection, the downstream half of the enhancer containing elements A-C was about half as effective as the complete enhancer in stimulating glucokinase promoter activity. Site-directed mutagenesis of element A virtually abrogated the activity of the half enhancer, whereas mutation of element C had a more moderate effect. The sequence between -732 and -578 upstream of the liver start of transcription in the human glucokinase gene displays 79% sequence identity with the downstream half of the rat enhancer. The human gene fragment ligated to the minimal rat liver glucokinase promoter was shown to work as an enhancer in the hepatocyte transfection system.	UNIV GENEVA,SCH MED,DIV CLIN BIOCHEM & DIABET RES,CH-1211 GENEVA,SWITZERLAND	University of Geneva				Nazaryan, Karen/0000-0002-5231-3928				ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BOSSARD P, 1993, EUR J BIOCHEM, V215, P883, DOI 10.1111/j.1432-1033.1993.tb18106.x; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BURCH JBE, 1983, CELL, V33, P65, DOI 10.1016/0092-8674(83)90335-5; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; IYNEDJIAN PB, 1988, J BIOL CHEM, V263, P740; IYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838, DOI 10.1073/pnas.86.20.7838; IYNEDJIAN PB, 1987, J BIOL CHEM, V262, P6032; IYNEDJIAN PB, 1995, J CLIN INVEST, V95, P1966, DOI 10.1172/JCI117880; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; JETTON TL, 1994, J BIOL CHEM, V269, P3641; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; KILLARY AM, 1984, CELL, V38, P523, DOI 10.1016/0092-8674(84)90507-5; KINGSTON RE, 1990, CURRENT PROTOCOLS MO; KLIMEK F, 1993, CARCINOGENESIS, V14, P1857, DOI 10.1093/carcin/14.9.1857; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MARIE S, 1993, J BIOL CHEM, V268, P23881; Parsa R, 1996, EUR J BIOCHEM, V236, P214, DOI 10.1111/j.1432-1033.1996.00214.x; PERRIN S, 1990, NUCLEIC ACIDS RES, V18, P7433, DOI 10.1093/nar/18.24.7433; *PROM CORP, 1993, TECHN B PROM CORP, V101; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; SALAVERT A, 1982, J BIOL CHEM, V257, P13404; Sambrook J., 2002, MOL CLONING LAB MANU; SHELTON KD, 1992, MOL CELL BIOL, V12, P4578, DOI 10.1128/MCB.12.10.4578; Sladek FM, 1992, CURR OPIN GENET DEV, V2, P256, DOI 10.1016/S0959-437X(05)80282-5; STEWART AF, 1991, NUCLEIC ACIDS RES, V19, P3157, DOI 10.1093/nar/19.11.3157; TANIZAWA Y, 1992, MOL ENDOCRINOL, V6, P1070, DOI 10.1210/me.6.7.1070	35	23	23	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29113	29120		10.1074/jbc.271.46.29113	http://dx.doi.org/10.1074/jbc.271.46.29113			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910567	hybrid			2022-12-27	WOS:A1996VT05200059
J	vandenBerg, MA; deJongGubbels, P; Kortland, CJ; vanDijken, JP; Pronk, JT; Steensma, HY				vandenBerg, MA; deJongGubbels, P; Kortland, CJ; vanDijken, JP; Pronk, JT; Steensma, HY			The two acetyl-coenzyme A synthetases of Saccharomyces cerevisiae differ with respect to kinetic properties and transcriptional regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A SYNTHETASE; CHEMOSTAT CULTURES; METABOLIC FLUXES; GLUCOSE; YEASTS; GENE; PHYSIOLOGY; ACETATE; ETHANOL; GROWTH	Saccharomyces cerevisiae contains two structural genes, ACS1 and ACS2, each encoding an active acetyl-coenzyme A synthetase. Characterization of enzyme activities in cell-free extracts from strains expressing either of the two genes revealed differences in the catalytic properties of the two enzymes, The K-m for ac etate of Acs1p was about 30-fold lower than that of Acs2p and Acs1p, but not Acs2p, could use propionate as a substrate, Enzyme activity measurements and mRNA analyses showed that ACS1 and ACS2 were both expressed during carbon-limited growth on glucose, ethanol, and acetate in aerobic chemostat cultures, In anaerobic glucose-limited cultures, only the ACS2 gene was expressed, Based on these facts, the products of the ACS1 and ACS2 genes were identified as the previously described ''aerobic'' and ''non-aerobic'' forms of acetyl-coenzyme A synthetase, respectively, Batch and glucose-pulse experiments revealed that transcription of ACS1 is subject to glucose repression, A mutant strain lacking Acs2p was unable to grow on glucose in batch cultures, but grew readily in aerobic glucose limited chemostat cultures, in which the low residual glucose concentration alleviated glucose repression. Experiments in which ethanol was pulsed to aerobic ethanol-limited chemostat cultures indicated that, in addition to glucose, ethanol also repressed ACS1 transcription, although to a lesser extent, In contrast, transcription of ACS2 was slightly induced by ethanol and glucose, Absence of ACS2 prevented complete glucose repression of ACS1, indicating that ACS2 (in)directly is involved in the transcriptional regulation of ACS1.	DELFT UNIV TECHNOL,KLUYVER LAB BIOTECHNOL,NL-2628 BC DELFT,NETHERLANDS; LEIDEN UNIV,INST MOL PLANT SCI,NL-2333 AL LEIDEN,NETHERLANDS	Delft University of Technology; Leiden University; Leiden University - Excl LUMC				Pronk, Jack/0000-0002-5617-4611				DEJONGGUBBELS P, 1995, YEAST, V11, P407, DOI 10.1002/yea.320110503; DEVICENZI DL, 1970, FED PROC, V3551, P872; DEVIRGILIO C, 1992, YEAST, V8, P1043, DOI 10.1002/yea.320081207; Flikweert MT, 1996, YEAST, V12, P247, DOI 10.1002/(SICI)1097-0061(19960315)12:3<247::AID-YEA911>3.0.CO;2-I; FRENKEL EP, 1977, J BIOL CHEM, V252, P504; GRUNDY FJ, 1993, MOL MICROBIOL, V10, P259, DOI 10.1111/j.1365-2958.1993.tb01952.x; HOLZER H, 1957, BIOCHEM Z, V329, P175; KLEIN HP, 1979, J BACTERIOL, V137, P179, DOI 10.1128/JB.137.1.179-184.1979; KLEIN HP, 1971, J BACTERIOL, V106, P596, DOI 10.1128/JB.106.2.596-602.1971; KRATZER S, 1995, GENE, V161, P75, DOI 10.1016/0378-1119(95)00289-I; LOMBARDO A, 1992, MOL CELL BIOL, V12, P2941, DOI 10.1128/MCB.12.7.2941; MERCADO JJ, 1994, EUR J BIOCHEM, V224, P473, DOI 10.1111/j.1432-1033.1994.00473.x; PETRIK M, 1983, J GEN MICROBIOL, V135, P43; POSTMA E, 1989, APPL ENVIRON MICROB, V53, P468; PRONK JT, 1994, MICROBIOL-SGM, V140, P601, DOI 10.1099/00221287-140-3-601; PRONK JT, 1994, MICROBIOL-UK, V140, P717, DOI 10.1099/00221287-140-4-717; SATYANAR.T, 1973, J BACTERIOL, V115, P600, DOI 10.1128/JB.115.2.600-606.1973; SATYANARAYANA T, 1974, BIOCHIM BIOPHYS ACTA, V341, P396, DOI 10.1016/0005-2744(74)90232-0; SATYANARAYANA T, 1976, ARCH BIOCHEM BIOPHYS, V174, P480, DOI 10.1016/0003-9861(76)90376-3; SATYANARAYANA T, 1974, P 4 INT S YEASTS VIE; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SIERKSTRA LN, 1992, YEAST, V8, P1077, DOI 10.1002/yea.320081210; VANDENBERG MA, 1995, EUR J BIOCHEM, V231, P704; VANURK H, 1990, APPL ENVIRON MICROB, V56, P281, DOI 10.1128/AEM.56.1.281-287.1990; VANURK H, 1988, YEAST, V4, P283, DOI 10.1002/yea.320040406; VERDUYN C, 1991, ANTON LEEUW INT J G, V60, P325, DOI 10.1007/BF00430373; VERDUYN C, 1990, J GEN MICROBIOL, V136, P395, DOI 10.1099/00221287-136-3-395; VERDUYN C, 1992, YEAST, V8, P501, DOI 10.1002/yea.320080703; ZONNEVELD BJM, 1986, J MICROBIOL METH, V4, P287, DOI 10.1016/0167-7012(86)90040-0	29	183	195	3	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28953	28959		10.1074/jbc.271.46.28953	http://dx.doi.org/10.1074/jbc.271.46.28953			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910545	hybrid, Green Published			2022-12-27	WOS:A1996VT05200037
J	Waterhouse, N; Kumar, S; Song, QH; Strike, P; Sparrow, L; Dreyfuss, G; Alnemri, ES; Litwack, G; Lavin, M; Watters, D				Waterhouse, N; Kumar, S; Song, QH; Strike, P; Sparrow, L; Dreyfuss, G; Alnemri, ES; Litwack, G; Lavin, M; Watters, D			Heteronuclear ribonucleoproteins C1 and C2, components of the spliceosome, are specific targets of interleukin 1 beta-converting enzyme-like proteases in apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; HETEROGENEOUS NUCLEAR-RNA; ICE-LIKE PROTEASES; CONVERTING-ENZYME; POLY(ADP-RIBOSE) POLYMERASE; BINDING-PROTEINS; PREMESSENGER RNA; GENE CED-3; IL-1-BETA-CONVERTING ENZYME; MAMMALIAN HOMOLOG	Apoptosis induced by a variety of agents results in the proteolytic cleavage of a number of cellular substrates by enzymes related to interleukin 1 beta-converting enzyme (ICE). A small number of substrates for these enzymes have been identified to date, including enzymes involved in DNA repair processes: poly(ADP-ribose) polymerase and DNA-dependent protein kinase. We describe here for the first time the specific cleavage of the heteronuclear ribonucleoproteins (hnRNPs) C1 and C2 in apoptotic cells induced to undergo apoptosis by a variety of stimuli, including ionizing radiation, etoposide, and ceramide. No cleavage was observed in cells that are resistant to apoptosis induced by ionizing radiation. Protease inhibitor data implicate the involvement of an ICE-like protease in the cleavage of hnRNP C. Using recombinant ICE-like proteases and purified hnRNP C proteins in. vitro, we show that the C proteins are cleaved by Mch3 alpha and CPP32 and, to a lesser extent, by Mch2 alpha, but not by ICE, Nedd2, Tx, or the cytotoxic T-cell protease granzyme B. The results described here demonstrate that the hnRNP C proteins, abundant nuclear proteins thought to be involved in RNA splicing, belong to a critical set of protein substrates that are cleaved by ICE-like proteases during apoptosis.	QUEENSLAND INST MED RES, PO ROYAL BRIBANE HOSP, QUEENSLAND CANC FUND RES UNIT, BRISBANE, QLD 4029, AUSTRALIA; UNIV QUEENSLAND, DEPT SURG, ST LUCIA, QLD 4072, AUSTRALIA; HANSON CTR CANC RES, ADELAIDE, SA 5000, AUSTRALIA; CSIRO, DIV BIOMOL ENGN, PARKVILLE, VIC 3052, AUSTRALIA; UNIV PENN, SCH MED,HOWARD HUGHES MED INST,RES LABS, DEPT BIOCHEM & BIOPHYS, PHILADELPHIA, PA 19104 USA; THOMAS JEFFERSON UNIV, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, PHILADELPHIA, PA 19107 USA	QIMR Berghofer Medical Research Institute; University of Queensland; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Howard Hughes Medical Institute; University of Pennsylvania; Jefferson University; Jefferson University			Lavin, Martin F/F-5961-2014; Waterhouse, Nigel/I-9813-2016; Dreyfuss, Gideon/D-1218-2013; Kumar, Sharad/AAX-7787-2020; Watters, Dianne J/E-6007-2010	Lavin, Martin F/0000-0002-5940-4769; Dreyfuss, Gideon/0000-0001-8129-8774; Kumar, Sharad/0000-0001-7126-9814; Watters, Dianne J/0000-0002-2555-5825				Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; COMPTON MM, 1987, J BIOL CHEM, V262, P8288; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DREYFUSS G, 1984, MOL CELL BIOL, V4, P1104, DOI 10.1128/MCB.4.6.1104; DREYFUSS G, 1984, J CELL BIOL, V99, pA233, DOI 10.1083/jcb.99.6.1997; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GORLACH M, 1994, J BIOL CHEM, V269, P23074; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; Harvey NL, 1996, GENES CELLS, V1, P673, DOI 10.1046/j.1365-2443.1996.00255.x; HOLCOMB ER, 1984, J BIOL CHEM, V259, P31; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Khanna KK, 1996, CELL DEATH DIFFER, V3, P315; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Kumar S, 1996, CELL DEATH DIFFER, V3, P255; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MAYRAND SH, 1993, P NATL ACAD SCI USA, V90, P7764, DOI 10.1073/pnas.90.16.7764; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOORE CL, 1988, EMBO J, V7, P3159, DOI 10.1002/j.1460-2075.1988.tb03183.x; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; PINOLROMA S, 1993, MOL CELL BIOL, V13, P5762, DOI 10.1128/MCB.13.9.5762; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Song QZ, 1996, J EXP MED, V184, P619, DOI 10.1084/jem.184.2.619; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SWANSON MS, 1987, MOL CELL BIOL, V7, P1731, DOI 10.1128/MCB.7.5.1731; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; TAZI J, 1993, NATURE, V363, P283, DOI 10.1038/363283a0; TEH BS, 1991, INT J IMMUNOPHARMACO, V13, P1117, DOI 10.1016/0192-0561(91)90163-2; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1994, BIOCHEMISTRY-US, V33, P3934, DOI 10.1021/bi00179a020; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WANG XD, 1995, J BIOL CHEM, V270, P18044, DOI 10.1074/jbc.270.30.18044; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Whyte M, 1996, TRENDS CELL BIOL, V6, P245, DOI 10.1016/0962-8924(96)20025-X; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1995, CURR OPIN CELL BIOL, V7, P211, DOI 10.1016/0955-0674(95)80030-1	62	103	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29335	29341		10.1074/jbc.271.46.29335	http://dx.doi.org/10.1074/jbc.271.46.29335			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910595	hybrid			2022-12-27	WOS:A1996VT05200087
J	Hollenberg, AN; Monden, T; Madura, JP; Lee, K; Wondisford, FE				Hollenberg, AN; Monden, T; Madura, JP; Lee, K; Wondisford, FE			Function of nuclear co-repressor protein on thyroid hormone response elements is regulated by the receptor A/B domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTOR; BETA-SUBUNIT GENE; ONCOGENE PRODUCT; X RECEPTOR; V-ERBA; LIGAND; TRANSCRIPTION; BINDING; PLASMID; ALPHA	Recently, a family of nuclear co-repressor proteins (TRACs) have been identified that interact with thyroid hormone (TR) and retinoic acid receptors to mediate Ligand-independent repression of gene transcription. In this report, we have cloned and characterized a human TRAC, which when expressed as a truncated protein lacking its repressing domains, can abolish endogenous cellular TRAC activity. Use of this inhibitor has uncovered a differential function of TRACs on negative versus positive thyroid hormone response elements and has demonstrated the importance of the TR A/B domain in modulating TRAC function. Thus, isoform-specific functions of the TR may be mediated by their functional interaction with co-repressor proteins.	BETH ISRAEL HOSP, DEPT MED, THYROID UNIT, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School					NIDDK NIH HHS [DK-43653, DK-49126, DK-02354] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049126, R29DK043653, K08DK002354] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BIGLER J, 1995, EMBO J, V14, P5710, DOI 10.1002/j.1460-2075.1995.tb00258.x; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DAMM K, 1993, P NATL ACAD SCI USA, V90, P10668, DOI 10.1073/pnas.90.22.10668; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; HOLLENBERG AN, 1995, MOL ENDOCRINOL, V9, P540, DOI 10.1210/me.9.5.540; HOLLENBERG AN, 1995, J BIOL CHEM, V270, P14274, DOI 10.1074/jbc.270.24.14274; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HSU JH, 1995, ENDOCRINOLOGY, V136, P421, DOI 10.1210/en.136.2.421; KAISER P, 1993, BIOTECHNIQUES, V14, P552; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKHAM BE, 1990, J BIOL CHEM, V265, P6489; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MOGHAL N, 1995, MOL CELL BIOL, V15, P3945; NORMAN MF, 1989, J BIOL CHEM, V264, P12063; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; SJOBERG M, 1995, MOL CELL BIOL, V15, P4718; TomicCanic M, 1996, J BIOL CHEM, V271, P1416, DOI 10.1074/jbc.271.3.1416; Tong GX, 1996, MOL CELL BIOL, V16, P1909; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WONDISFORD FE, 1989, J BIOL CHEM, V264, P14601; WONDISFORD FE, 1993, J BIOL CHEM, V268, P2749; Wood WM, 1989, J BIOL CHEM, V61, P497; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	38	82	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28516	28520		10.1074/jbc.271.45.28516	http://dx.doi.org/10.1074/jbc.271.45.28516			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910480	hybrid			2022-12-27	WOS:A1996VU03300080
J	Liebmann, C; Graness, A; Boehmer, A; Kovalenko, M; Adomeit, A; Steinmetzer, T; Nurnberg, B; Wetzker, R; Boehmer, FD				Liebmann, C; Graness, A; Boehmer, A; Kovalenko, M; Adomeit, A; Steinmetzer, T; Nurnberg, B; Wetzker, R; Boehmer, FD			Tyrosine phosphorylation of G(s alpha) and inhibition of bradykinin-induced activation of the cyclic AMP pathway in A431 cells by epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNITS; REGULATORY PROTEIN; ADENYLATE-CYCLASE; CARCINOMA-CELLS; BINDING; IDENTIFICATION; STIMULATION; MEMBRANES	An increasing amount of experimental data suggest that cross-talk exists between pathways involving tyrosine kinases and heterotrimeric G proteins. In a previous study, we demonstrated that bradykinin (BK) increases the intracellular accumulation of cAMP in the human epidermoid carcinoma cell line A431 by stimulating adenylate cyclase activity via a stimulatory G protein (G(s alpha)) (Liebmann, C., Graness, A., Ludwig, B., Adomeit, A., Boehmer, A., Boehmer, F.-D., Nurnberg, B., and Wetzker, R. (1996) Biochem. J. 318, 109-118). Here, we present several lines of evidence indicating the ability of epidermal growth factor (EGF) to suppress BK-induced activation of the cAMP pathway in A431 cells via tyrosine phosphorylation of G(s alpha). G(s alpha) was specifically immunoprecipitated from A431 cells using the anti-alpha(s) antiserum AS 348. Tyrosine phosphorylation of G(s alpha) was detectable in EGF-pretreated cells with monoclonal anti-phosphotyrosine antibodies. Additionally, A431 cells were labeled with [P-32]orthophosphate in vivo and treated with EGF, and the resolved immunoprecipitates were subjected to amino acid analysis. The results clearly indicate that EGF induces tyrosine phosphorylation of G(s alpha) in A431 cells. Treatment of A431 cells with EGF decreased BK-induced cAMP accumulation in intact cells as well as the stimulation of adenylate cyclase by Bg, NaF, and guanyl nucleotides, but not by forskolin. Also, EGF treatment abolished both the BK- and isoprenaline-induced stimulation of guanosine 5'-O-(3-[S-35]thiotriphosphate) binding to G(s alpha). In contrast, the BK-evoked, G(q)-mediated stimulation of inositol phosphate formation in A431 cells was not affected by EGF pretreatment. Thus, EGF-induced tyrosine phosphorylation of G(s alpha) is accompanied by a loss of its susceptibility to G protein-coupled receptors and its ability to stimulate adenylate cyclase via guanyl nucleotide exchange. me propose that G(s alpha) may represent a key regulatory protein in the cross talk between the signal transduction pathways of BK and EGF in A431 cells.	UNIV JENA, MAX PLANCK GESELL, ARBEITSGRP MOL ZELLBIOL, FAK MED, D-07747 JENA, GERMANY; UNIV JENA, FAK MED, DEPT BIOCHEM 2, D-07743 JENA, GERMANY; FREE UNIV BERLIN, INST PHARMAKOL, D-14195 BERLIN, GERMANY	Friedrich Schiller University of Jena; Max Planck Society; Friedrich Schiller University of Jena; Free University of Berlin	Liebmann, C (corresponding author), UNIV JENA, INST BIOCHEM & BIOPHYS, BIOL PHARMAZEUT FAK, PHILOSOPHENWEG 12, D-07743 JENA, GERMANY.		Wetzker, Reinhard/AAD-8713-2019	Nurnberg, Bernd/0000-0002-5995-6555				ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; HOSOI K, 1993, J CELL PHYSIOL, V157, P1, DOI 10.1002/jcp.1041570102; KOICH W, 1993, NATURE, V364, P249; KRUPINSKI J, 1988, J BIOL CHEM, V263, P12333; LAUGWITZ KL, 1994, METHOD ENZYMOL, V237, P283; LIANG M, 1991, J BIOL CHEM, V266, P13342; LIEBMANN C, 1991, EUR J PHARM-MOLEC PH, V207, P67, DOI 10.1016/S0922-4106(05)80039-2; LIEBMANN C, 1994, EUR J PHARM-MOLEC PH, V288, P35, DOI 10.1016/0922-4106(94)90007-8; Liebmann C, 1996, BIOCHEM J, V313, P109, DOI 10.1042/bj3130109; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOYERS JS, 1995, BIOCHEM J, V305, P411, DOI 10.1042/bj3050411; NAIR BG, 1990, J BIOL CHEM, V265, P21317; NAIR BG, 1993, BIOCHEM PHARMACOL, V46, P1239, DOI 10.1016/0006-2952(93)90473-A; NAKAJIMA Y, 1992, J BIOL CHEM, V267, P2437; NURNBERG B, 1994, BIOCHEM J, V300, P387; Poppleton H, 1996, J BIOL CHEM, V271, P6947, DOI 10.1074/jbc.271.12.6947; REUSDOMIANO S, 1995, FASEB J, V9, P1059; SCHULTZ G, 1983, METHOD ENZYMAT AN, V4, P369; SPICHER K, 1994, BIOCHEM BIOPH RES CO, V198, P906, DOI 10.1006/bbrc.1994.1129; TEITELBAUM I, 1990, J BIOL CHEM, V265, P4218; TILLY BC, 1987, BIOCHEM J, V244, P129, DOI 10.1042/bj2440129	29	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31098	31105		10.1074/jbc.271.49.31098	http://dx.doi.org/10.1074/jbc.271.49.31098			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940106	hybrid			2022-12-27	WOS:A1996VW68600017
J	Hill, RE; Himmeldirk, K; Kennedy, IA; Pauloski, RM; Sayer, BG; Wolf, E; Spenser, ID				Hill, RE; Himmeldirk, K; Kennedy, IA; Pauloski, RM; Sayer, BG; Wolf, E; Spenser, ID			The biogenetic anatomy of vitamin B-6 - A C-13 NMR investigation of the biosynthesis of pyridoxol in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4-HYDROXY-L-THREONINE; 1-DEOXY-D-XYLULOSE; PRECURSOR; ORIGIN	It is shown by incorporation experiments with C-13 bond-labeled substrates, followed by analysis by means of C-13 NMR spectroscopy, that two compounds, 1-deoxy-D-xylulose (12) and 4-hydroxy-L-threonine (13), serve as precursors of pyridoxol (vitamin B-6) (1) in Escherichia coli. Together, these two compounds account for the entire C8N skeleton of the vitamin. 1-Deoxy-D-xylulose supplies the intact C-5 unit, C-2',2,3,4,4' of pyridoxol. 4-Hydroxy-L-threonine undergoes decarboxylation in supplying the intact C3N unit, N-1,C-6,5,5'. Both precursors are ultimately derived from glucose. The C-5 unit of pyridoxol that is derived from l-deoxy-D-xylulose originates by union of a triose phosphate (yielding C-3,4,4') with pyruvic acid (which decarboxylates to yield C-2',2). D-Erythroate (11) enters the C-3 unit, C-6,5,5', and is therefore an intermediate on the route from glucose into 4-hydroxy-L-threonine.	MCMASTER UNIV,DEPT CHEM,HAMILTON,ON L8S 4M1,CANADA; MCMASTER UNIV,DEPT PATHOL,HAMILTON,ON L8S 4M1,CANADA	McMaster University; McMaster University					NIGMS NIH HHS [GM 50778] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050778] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BADDILEY J, 1952, J CHEM SOC, P2583, DOI 10.1039/jr9520002583; Bain AD, 1996, CROAT CHEM ACTA, V69, P681; BROOKS HG, 1966, J HETEROCYCLIC CHEM, V3, P126, DOI 10.1002/jhet.5570030203; DEMPSEY WB, 1971, J BACTERIOL, V108, P1001, DOI 10.1128/JB.108.3.1001-1007.1971; DREWKE C, 1993, FEBS LETT, V318, P125, DOI 10.1016/0014-5793(93)80005-F; HILL RE, 1970, SCIENCE, V169, P773, DOI 10.1126/science.169.3947.773; HILL RE, 1971, J AM CHEM SOC, V93, P518; HILL RE, 1972, J BIOL CHEM, V247, P1869; HILL RE, 1977, J AM CHEM SOC, V99, P4179, DOI 10.1021/ja00454a058; HILL RE, 1989, J AM CHEM SOC, V111, P1916, DOI 10.1021/ja00187a076; HILL RE, 1987, J BIOL CHEM, V262, P7463; HILL RE, 1974, CAN J BIOCHEM CELL B, V52, P271, DOI 10.1139/o74-042; HILL RE, 1986, J CHEM SOC CHEM COMM, P612, DOI 10.1039/c39860000612; HILL RE, 1975, J CHEM SOC PERK T 1, P1622, DOI 10.1039/p19750001622; HILL RE, 1973, CAN J BIOCHEM CELL B, V51, P1412, DOI 10.1139/o73-185; HILL RE, 1986, VITAMIN B6 PYRIDOX A, P417; HIMMELDIRK K, 1996, J CHEM SOC CHEM COMM, P1187; IWANOW A, 1984, J AM CHEM SOC, V106, P1840, DOI 10.1021/ja00318a051; KENNEDY IA, 1995, CAN J CHEM, V73, P1329, DOI 10.1139/v95-164; KENNEDY IA, 1995, J AM CHEM SOC, V117, P1661, DOI 10.1021/ja00110a032; KOMIOTIS D, 1995, EUR J MED CHEM, V30, P321, DOI 10.1016/0223-5234(96)88240-7; LAM HM, 1990, J BACTERIOL, V172, P6518, DOI 10.1128/jb.172.11.6518-6528.1990; MAU TK, 1996, J BACTERIOL, V178, P2445; NOTHEIS C, 1995, BBA-PROTEIN STRUCT M, V1247, P265, DOI 10.1016/0167-4838(94)00235-9; Postma P. W., 1996, ESCHERICHIA COLI SAL, V1, P1149; POTTIE M, 1994, B SOC CHIM BELG, V103, P285; SPENSER ID, 1995, NAT PROD REP, V12, P555, DOI 10.1039/np9951200555; VELLA GJ, 1981, J BIOL CHEM, V256, P469; VELLA GJ, 1982, J BIOL CHEM, V257, P4008; VELLA GJ, 1980, J BIOL CHEM, V255, P3042; WOLF E, 1995, J ORG CHEM, V60, P6937, DOI 10.1021/jo00126a052; WOLF E, 1995, J CHEM SOC CHEM COMM, P1339, DOI 10.1039/c39950001339; YOKOTA A, 1986, AGR BIOL CHEM TOKYO, V50, P2517, DOI 10.1080/00021369.1986.10867789; YOKOTA A, 1984, AGR BIOL CHEM TOKYO, V48, P149, DOI 10.1080/00021369.1984.10866109; ZHAO GS, 1995, J BACTERIOL, V177, P883, DOI 10.1128/jb.177.4.883-891.1995; ZHAO GS, 1995, J BACTERIOL, V177, P2804, DOI 10.1128/jb.177.10.2804-2812.1995; Zhao GS, 1996, FEMS MICROBIOL LETT, V135, P275, DOI 10.1016/0378-1097(95)00466-1	37	103	108	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30426	30435		10.1074/jbc.271.48.30426	http://dx.doi.org/10.1074/jbc.271.48.30426			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940007	hybrid			2022-12-27	WOS:A1996VV15800024
J	Salamero, J; LeBorgne, R; Saudrais, C; Goud, B; Hoflack, B				Salamero, J; LeBorgne, R; Saudrais, C; Goud, B; Hoflack, B			Expression of major histocompatibility complex class II molecules in HeLa cells promotes the recruitment of AP-1 Golgi-specific assembly proteins on Golgi membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; INVARIANT CHAIN CONTAINS; ENDOSOMAL COMPARTMENTS; ANTIGEN PRESENTATION; CYTOPLASMIC TAIL; POPULATIONS; CLATHRIN; ADAPTERS; RECEPTOR; BINDING	The newly synthesized major histocompatibility complex (MHC) class II molecules, an alpha beta dimer associated with the Ii invariant chain, must be targeted to endosomal, lysosomal enzyme-rich compartments in order to bind and present immunogenic peptides, The precise route followed by this complex at the exit of the trans Golgi network, the last sorting station of the biosynthetic pathway, is poorly understood, We show here that overexpression of alpha beta Ii complexes in HeLa cells promotes the first step of clathrin-coat assembly in vitro, that is the ARF-dependent translocation of AP-1 Golgi-specific assembly proteins on membranes, In contrast, alpha beta dimers alone or associated with Ii lacking most of its cytoplasmic domain fail to recruit AP-1, This study strongly suggests that the invariant chain (Ii) is responsible for the AP-l-dependent sorting of the alpha beta dimers in the trans-Golgi network of HeLa cells and that the MHC class II molecules are, like the mannose 6-phosphate receptors, transported directly from this compartment to endosomes via clathrin-coated vesicles.	EUROPEAN MOL BIOL LAB,D-69012 HEIDELBERG,GERMANY; INST CURIE,LAB MECANISMES MOL TRANSPORT INTRACELLULAIRE,UMR 144 CNRS,F-75005 PARIS,FRANCE	European Molecular Biology Laboratory (EMBL); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite			Goud, Bruno/GWC-4807-2022; HOFLACK, Bernard/AAZ-6668-2020	LE BORGNE, Roland/0000-0001-6892-278X; salamero, jean/0000-0002-2610-5826				BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BHAKDI S, 1993, MED MICROBIOL IMMUN, V182, P167; BONNEROT C, 1995, IMMUNITY, V3, P335, DOI 10.1016/1074-7613(95)90118-3; BREMNES B, 1994, J CELL SCI, V107, P2021; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P999; GLICKMAN JN, 1993, J CELL BIOL, V123, P99, DOI 10.1083/jcb.123.1.99; Glickman JN, 1996, J CELL BIOL, V132, P769, DOI 10.1083/jcb.132.5.769; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; Harding CV, 1993, CURR OPIN CELL BIOL, V5, P596, DOI 10.1016/0955-0674(93)90128-D; HUMBERT M, 1993, EUR J IMMUNOL, V23, P3158, DOI 10.1002/eji.1830231218; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; LEBORGNE R, 1993, J BIOL CHEM, V268, P22552; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; MELLMAN I, 1995, CURR OPIN CELL BIOL, V7, P564, DOI 10.1016/0955-0674(95)80014-X; NEEFJES J J, 1991, Current Opinion in Cell Biology, V3, P601, DOI 10.1016/0955-0674(91)90029-X; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NIJENHUIS M, 1994, EUR J IMMUNOL, V24, P873, DOI 10.1002/eji.1830240415; PIETERS J, 1993, J CELL SCI, V106, P831; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561	25	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30318	30321		10.1074/jbc.271.48.30318	http://dx.doi.org/10.1074/jbc.271.48.30318			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939989	hybrid			2022-12-27	WOS:A1996VV15800006
J	Cao, JA; Rehemtulla, A; Bahou, W; Zucker, S				Cao, JA; Rehemtulla, A; Bahou, W; Zucker, S			Membrane type matrix metalloproteinase 1 activates pro-gelatinase A without furin cleavage of the N-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY; VONWILLEBRAND-FACTOR; 72-KDA GELATINASE; TISSUE INHIBITOR; CELLS; PRECURSOR; IDENTIFICATION; ANGIOGENESIS; COLLAGENASE; EXPRESSION	Membrane type matrix metalloproteinase 1 (MT-MMP1), a novel 63-kDa member of the matrix metalloproteinase family, is a membrane-anchored enzyme and an activator for gelatinase A. In addition to its C-terminal hydrophobic transmembrane domain, MT-MMP1 has an insertion of 11 amino acids between its propeptide and catalytic domain encrypted with a RRKR recognition motif for the paired basic amino acid cleaving enzyme, furin. In this report, we investigated whether the cleavage of the RRKR motif of MT-MMP1 by Golgi-associated furin is analogous to a similar enzyme activation mechanism observed with stromelysin-3. Mutant forms of MT-MMP1 were cotransfected into COS-1 cells with cDNAs for pro-gelatinase A and/or furin. Immunoprecipitation and immunoblotting using specific antibodies were employed to characterize cell proteins, Whereas furin readily cleaved soluble MT-MMP1 lacking the transmembrane domain (Delta MT-MMP1), a soluble stromelysin-1/Delta MT-MMP1 chimera without the RRKR basic motif was resistant to furin-induced cleavage. COS-1 cells cotransfected with wild type MT-MMP1 cDNA and furin cDNA demonstrated a 63-kDa protein (latent enzyme) on SDS-polyacrylamide gel electrophoresis rather than the anticipated lower molecular weight activated enzyme. Inhibition of furin activity with alpha 1-protease inhibitor(Pittsburgh) (a furin inhibitor) did not affect the pro-gelatinase A activation mechanism in COS-1 cells cotransfected with MT-MMP1 and pro-gelatinase A cDNAs. Furthermore, substitution of the RRKR motif of MT-MMP1 with alanine residues by site-directed mutagenesis resulted in the same 63-kDa protein without loss of pro-gelatinase A activation function. These data indicate that furin-induced activation of MT-MMP1 is not a prerequisite for pro-gelatinase A activation, The mechanism of activation of cell-bound MT-MMP1 remains to be elucidated.	VET ADM MED CTR,DEPT VET AFFAIRS MED CTR,DEPT MED,NORTHPORT,NY 11768; VET ADM MED CTR,DEPT VET AFFAIRS MED CTR,RES DEPT,NORTHPORT,NY 11768; SUNY STONY BROOK,DEPT MED,STONY BROOK,NY 11794; UNIV MICHIGAN,DEPT RADIOTHERAPY,ANN ARBOR,MI 48109	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Michigan System; University of Michigan					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002431] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-49149, HL-02431] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P6684, DOI 10.1021/bi00187a039; Foda HD, 1996, LAB INVEST, V74, P538; Imai K, 1996, CANCER RES, V56, P2707; KLUXEN FW, 1993, ANAL BIOCHEM, V208, P352, DOI 10.1006/abio.1993.1060; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MILHIET PE, 1995, BIOCHEM J, V309, P683, DOI 10.1042/bj3090683; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Puente XS, 1996, CANCER RES, V56, P944; REHEMTULLA A, 1993, BIOCHEMISTRY-US, V32, P11586, DOI 10.1021/bi00094a015; REHEMTULLA A, 1992, BLOOD, V79, P2349; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; STRICKLAND DK, 1988, BIOCHEMISTRY-US, V27, P1458, DOI 10.1021/bi00405a010; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; WASLEY LC, 1993, J BIOL CHEM, V268, P8458; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; ZUCKER S, 1995, J BIOL CHEM, V270, P23730, DOI 10.1074/jbc.270.40.23730; ZUCKER S, 1987, CANCER RES, V47, P1608	28	98	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30174	30180		10.1074/jbc.271.47.30174	http://dx.doi.org/10.1074/jbc.271.47.30174			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939968	hybrid			2022-12-27	WOS:A1996VU52500096
J	Chen, XC; Xu, HD; Tai, PC				Chen, XC; Xu, HD; Tai, PC			A significant fraction of functional SecA is permanently embedded in the membrane - SecA cycling on and off the membrane is not essential during protein translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI PLASMA-MEMBRANE; PROTON MOTIVE FORCE; ESCHERICHIA-COLI; PREPROTEIN TRANSLOCASE; SECRETORY PROTEIN; PRECURSOR PROTEIN; INNER MEMBRANE; ACIDIC PHOSPHOLIPIDS; ALKALINE-PHOSPHATASE; ESSENTIAL COMPONENT	SecA has been suggested to cycle on and off the cytoplasmic membrane of Escherichia coli during protein translocation, We have reconstituted S-35-SecA onto SecA-depleted membrane vesicles and followed the fate of the membrane-associated S-35-SecA during protein translocation. Some S-35-SecA was released from the membranes in a translocation-independent manner. However, a significant fraction of S-35-SecA remained on the membranes even after incubation with excess SecA. This fraction of S-35-SecA was shown to be integrated into the membrane and was active in protein translocation, indicating that SecA cycling on and off membrane is not required for protein translocation. Proteolysis experiments did not support the model of SecA insertion and deinsertion during protein translocation; instead, a major 48-kDa domain was found persistently embedded in the membrane regardless of translocation status, Thus, in addition to catalyzing ATP hydrolysis, certain domains of SecA probably play an important structural role in the translocation machinery, perhaps forming part of the protein-conducting channels.	GEORGIA STATE UNIV, DEPT BIOL, ATLANTA, GA 30303 USA	University System of Georgia; Georgia State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034766] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34766] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKITA M, 1990, J BIOL CHEM, V265, P8164; AKITA M, 1991, BIOCHEM BIOPH RES CO, V174, P211, DOI 10.1016/0006-291X(91)90507-4; ARKOWITZ RA, 1993, EMBO J, V12, P243, DOI 10.1002/j.1460-2075.1993.tb05650.x; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BIEKERBRADY K, 1992, EMBO J, V11, P3165, DOI 10.1002/j.1460-2075.1992.tb05393.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREUKINK E, 1995, J BIOL CHEM, V270, P7902, DOI 10.1074/jbc.270.14.7902; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; BRUSILOW WSA, 1993, MOL MICROBIOL, V9, P419, DOI 10.1111/j.1365-2958.1993.tb01703.x; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; CHEN L, 1985, J BACTERIOL, V161, P973, DOI 10.1128/JB.161.3.973-980.1985; CHEN L, 1986, J BACTERIOL, V167, P389, DOI 10.1128/jb.167.1.389-392.1986; CHEN LL, 1987, NATURE, V328, P164, DOI 10.1038/328164a0; CHEN LL, 1985, P NATL ACAD SCI USA, V82, P4384, DOI 10.1073/pnas.82.13.4384; CHUN SY, 1994, J BACTERIOL, V176, P4197, DOI 10.1128/jb.176.14.4197-4203.1994; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DOLAN KM, 1991, J BIOL CHEM, V266, P23329; DOUVILLE K, 1995, J BIOL CHEM, V270, P20106, DOI 10.1074/jbc.270.34.20106; DRIESSEN AJM, 1993, BIOCHEMISTRY-US, V32, P13190, DOI 10.1021/bi00211a030; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; ERNST F, 1994, J BIOL CHEM, V269, P12840; FANDL J, 1990, J BIOENERG BIOMEMBR, V22, P369, DOI 10.1007/BF00763173; FANDL JP, 1988, P NATL ACAD SCI USA, V85, P8953, DOI 10.1073/pnas.85.23.8953; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HASAN SM, 1978, J BACTERIOL, V133, P108, DOI 10.1128/JB.133.1.108-113.1978; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; HOFFSCHUTE HK, 1994, J BIOL CHEM, V269, P12833; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KAWASAKI H, 1989, FEBS LETT, V242, P431, DOI 10.1016/0014-5793(89)80516-2; KIM YJ, 1994, CELL, V78, P845; KIMURA E, 1991, J BIOL CHEM, V266, P6600; KOONIN EV, 1992, FEBS LETT, V298, P6, DOI 10.1016/0014-5793(92)80009-6; LIEBKE HH, 1987, J BACTERIOL, V169, P1174, DOI 10.1128/jb.169.3.1174-1181.1987; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; NISHIYAMA K, 1991, BIOCHIM BIOPHYS ACTA, V1065, P89, DOI 10.1016/0005-2736(91)90015-Z; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; OLIVER DB, 1993, MOL MICROBIOL, V7, P159, DOI 10.1111/j.1365-2958.1993.tb01107.x; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; OLIVER DB, 1990, J BIOENERG BIOMEMBR, V22, P311, DOI 10.1007/BF00763170; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; Rajapandi T, 1996, MOL MICROBIOL, V20, P43, DOI 10.1111/j.1365-2958.1996.tb02487.x; RHOADS DB, 1984, J BACTERIOL, V159, P63, DOI 10.1128/JB.159.1.63-70.1984; ROLLO EE, 1988, J BACTERIOL, V170, P3281, DOI 10.1128/jb.170.7.3281-3282.1988; SALAVATI R, 1995, RNA, V1, P745; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHMIDT MG, 1988, J BACTERIOL, V170, P3404, DOI 10.1128/jb.170.8.3404-3414.1988; SHIOZUKA K, 1990, J BIOL CHEM, V265, P18843; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; TAI PC, 1991, METHOD CELL BIOL, V34, P167; TAI PC, 1992, ANTON LEEUW INT J G, V61, P105, DOI 10.1007/BF00580615; THOM JR, 1988, J BACTERIOL, V170, P5654, DOI 10.1128/jb.170.12.5654-5661.1988; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; WATANABE M, 1990, P NATL ACAD SCI USA, V87, P1960, DOI 10.1073/pnas.87.5.1960; WATANABE M, 1993, P NATL ACAD SCI USA, V90, P9011, DOI 10.1073/pnas.90.19.9011; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; YAMADA H, 1989, J BIOL CHEM, V264, P18577	65	76	78	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29698	29706		10.1074/jbc.271.47.29698	http://dx.doi.org/10.1074/jbc.271.47.29698			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939903	hybrid			2022-12-27	WOS:A1996VU52500031
J	Chou, DKH; Jungalwala, FB				Chou, DKH; Jungalwala, FB			N-acetylglucosaminyl transferase regulates the expression of the sulfoglucuronyl glycolipids in specific cell types in cerebellum during development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; CHONDROITIN SULFATE PROTEOGLYCANS; NERVOUS-SYSTEM; HNK-1-REACTIVE ANTIGENS; HNK-1 ANTIBODY; L2/HNK-1 CARBOHYDRATE; MOUSE CEREBELLUM; GLUCURONIC-ACID; MONOCLONAL IGM; MURINE MUTANTS	In the adult cerebellum, sulfoglucuronyl glycolipids (SGGLs) are specifically localized in Purkinje cells and their dendrites in the molecular layer. Other major cell types such as granule neurons and glial cells lack SGGLs. To explain the cell specific localization and the known biphasic expression of SGGLs, enzymic activities of four glycosyltransferases involved in the biosynthesis of SGGLs were studied in murine cerebellar mutants, in distinct cellular layers of rat cerebellum, and in isolated granule neurons during development. The enzymes studied were lactosylceramide: N-acetylglucosaminyl transferase (GlcNAc-Tr), lactotriaosylceramide:galactosyltransferase, neolactotetraosylceramide:glucuronyltransferase, and glucuronylglycolipid:sulfotransferase. In the cerebellum of Purkinje cell-deficient mutants, such as (pcd/pcd) and lurcher (Lc/+) where Purkinje cells are lost, GlcNAc-Tr was absent, but the other three glycosyltransferase were not severely affected. This indicated that the latter three enzymes were localized in other cell types, such as in mature granule neurons and glial cells, in addition to that in Purkinje cells, and the lack of SGGLs in these mutants was due to absence of GlcNAc-Tr. Analyses of the enzymes in the specific micro-dissected cellular layers also showed that Purkinje cell layer and molecular layer (where Purkinje cell dendrites are localized) contained all four enzymes. However, granule neurons and glial cells in the white matter lacked GlcNAc-Tr, but expressed the other three enzymes. It was concluded that the absence of SGGLs in adult granule neurons and glial cells was due to specific deficiency of the GlcNAc-Tr. Although adult granule neurons lacked GlcNAc-Tr and therefore SGGLs, isolated granule neurons from the neonatal cerebellum contained all four enzymes necessary for the synthesis of SGGLs. With development, the activity of GlcNAc-Tr in the isolated granule neurons declined but the other enzymes were not as affected, indicating that immature granule neurons were capable of synthesizing SGGLs and with maturation the synthesis was down-regulated. This also explains the biphasic expression of SGGLs in the developing cerebellum.	EUNICE KENNEDY SHRIVER CTR MENTAL RETARDAT INC, DEPT BIOCHEM, WALTHAM, MA 02254 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School					NICHD NIH HHS [P01-HD05505] Funding Source: Medline; NINDS NIH HHS [R01-NS 24405] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD005505] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024405] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLENDOERFER KL, 1995, MOL CELL NEUROSCI, V6, P381, DOI 10.1006/mcne.1995.1029; ARIGA T, 1987, J BIOL CHEM, V262, P848; BRAUN PE, 1982, J NEUROCHEM, V39, P1261, DOI 10.1111/j.1471-4159.1982.tb12563.x; Chou DKH, 1996, GLYCOCONJUGATE J, V13, P295, DOI 10.1007/BF00731504; CHOU DKH, 1990, J NEUROCHEM, V54, P1598, DOI 10.1111/j.1471-4159.1990.tb01210.x; CHOU DKH, 1993, J BIOL CHEM, V268, P21727; CHOU DKH, 1987, J NEUROCHEM, V49, P865, DOI 10.1111/j.1471-4159.1987.tb00974.x; CHOU DKH, 1994, J NEUROCHEM, V62, P307; CHOU DKH, 1991, J BIOL CHEM, V266, P17941; CHOU DKH, 1988, J NEUROCHEM, V50, P1655, DOI 10.1111/j.1471-4159.1988.tb03056.x; CHOU DKH, 1990, J NEUROCHEM, V54, P1589, DOI 10.1111/j.1471-4159.1990.tb01209.x; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; CHOU DKH, 1993, J BIOL CHEM, V268, P330; CHOU DKH, 1991, J NEUROCHEM, V57, P852, DOI 10.1111/j.1471-4159.1991.tb08229.x; CHOU DKH, 1994, T AM SOC NEUROCHEM, V25, P127; CHOU DKH, 1994, J NEUROCHEM S, V64, P562; CHOU KH, 1985, BIOCHEM BIOPH RES CO, V128, P383, DOI 10.1016/0006-291X(85)91690-0; DIEPERINK ME, 1992, J NEUROSCI, V12, P2177; HATTEN ME, 1985, J CELL BIOL, V100, P384, DOI 10.1083/jcb.100.2.384; HOLLEY JA, 1987, DEV NEUROSCI-BASEL, V9, P105, DOI 10.1159/000111613; HOLMES EH, 1991, ARCH BIOCHEM BIOPHYS, V288, P87, DOI 10.1016/0003-9861(91)90168-I; HOLMES EH, 1987, J BIOL CHEM, V262, P15649; ILYAS AA, 1990, J NEUROCHEM, V55, P594, DOI 10.1111/j.1471-4159.1990.tb04175.x; JESSELL TM, 1990, ANNU REV NEUROSCI, V13, P227, DOI 10.1146/annurev.ne.13.030190.001303; JUNGALWALA FB, 1994, NEUROCHEM RES, V19, P945, DOI 10.1007/BF00968704; KROG L, 1992, APMIS, V100, P53; KRUEGER RC, 1992, J BIOL CHEM, V267, P12149; KUNEMUND V, 1988, J CELL BIOL, V106, P213, DOI 10.1083/jcb.106.1.213; LOWRY OH, 1953, J HISTOCHEM CYTOCHEM, V1, P420, DOI 10.1177/1.6.420; MARGOLIS RK, 1987, BIOCHEM BIOPH RES CO, V145, P1142, DOI 10.1016/0006-291X(87)91556-7; MCGARRY RC, 1983, NATURE, V306, P376, DOI 10.1038/306376a0; NAIR SM, 1993, J COMP NEUROL, V332, P282, DOI 10.1002/cne.903320303; PRASADARAO N, 1990, J HISTOCHEM CYTOCHEM, V38, P1193, DOI 10.1177/38.8.1694876; PRASADARAO N, 1990, J NEUROCHEM, V55, P2024, DOI 10.1111/j.1471-4159.1990.tb05791.x; SCHACHNER M, 1989, CIBA F SYMP, V145, P156; SCHMITZ B, 1994, GLYCOCONJUGATE J, V11, P345, DOI 10.1007/BF00731208; SCHWARTING GA, 1987, DEV BIOL, V120, P65, DOI 10.1016/0012-1606(87)90104-7; STULTS CLM, 1993, ARCH BIOCHEM BIOPHYS, V303, P125, DOI 10.1006/abbi.1993.1263; Svennerholm L, 1980, Adv Exp Med Biol, V125, P11; VOGEL M, 1991, BIOCHEM J, V278, P199, DOI 10.1042/bj2780199; WERNECKE H, 1985, J NEUROIMMUNOL, V9, P115, DOI 10.1016/S0165-5728(85)80012-6; YAMAMOTO M, 1985, P NATL ACAD SCI USA, V82, P3045, DOI 10.1073/pnas.82.9.3045	42	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28868	28874		10.1074/jbc.271.46.28868	http://dx.doi.org/10.1074/jbc.271.46.28868			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910533	hybrid			2022-12-27	WOS:A1996VT05200025
J	Karoor, V; Malbon, CC				Karoor, V; Malbon, CC			Insulin-like growth factor receptor-1 stimulates phosphorylation of the beta(2)-adrenergic receptor in vivo on sites distinct from those phosphorylated in response to insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-MEDIATED PATHWAYS; BETA-ADRENERGIC-RECEPTOR; MASS-SPECTROMETRY; CROSS-REGULATION; TYROSINE KINASE; SIGNAL	G-protein-linked receptors have been shown to be substrates for growth factor receptors with intrinsic tyrosine kinase activity typified by the ability of insulin to both phosphorylate tyrosyl residues in the C terminus of and to counter-regulate the action of the beta(2)-adrenergic receptor (Karoor, V., Baltensperger, K., Paul, H., Czech, M. P., and Malbon, C, C, (1995) J. Biol. Chem, 270, 25305-25308). Insulin-like growth factor-1 (IGF-1), another member of the growth factor family operating via receptors with intrinsic tyrosine kinase, is shown in the present work to stimulate in vivo the phosphorylation of the beta(2)-adrenergic receptor. Analysis of tryptic digests prepared from phosphorylated beta(2)-adrenergic receptors of IGF-1-treated, metabolically labeled smooth muscle cells was performed using reversed-phase high performance liquid chromatography, two-dimensional peptide mapping, and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. The results of these separate analyses reveal that IGF-1 stimulates phosphorylation predominantly on tyrosyl residues Y132/141 of the second intracellular loop of the beta(2)-adrenergic receptor rather than the C-terminal region targeted by the activated insulin receptor (Y350/354, Y364), although both growth factors block beta-adrenergic agonist action. These data demonstrate selective phosphorylation of a G-protein-linked receptor by receptor tyrosine kinases for insulin and IGF-1 mapping to spatially distinct regions of this heptihelical membrane receptor.	SUNY STONY BROOK, SCH MED, DIABET & METAB DIS RES CTR, DEPT MOL PHARMACOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			malbon, craig/ABF-3604-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025410] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25410] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baltensperger K, 1996, J BIOL CHEM, V271, P1061, DOI 10.1074/jbc.271.2.1061; BALTENSPERGER K, 1992, P NATL ACAD SCI USA, V89, P7885, DOI 10.1073/pnas.89.17.7885; CROUCH MF, 1991, FASEB J, V5, P200, DOI 10.1096/fasebj.5.2.1900794; CZECH MP, 1980, J CLIN INVEST, V66, P574, DOI 10.1172/JCI109889; ENGLAND PJ, 1976, ANAL BIOCHEM, V75, P429, DOI 10.1016/0003-2697(76)90096-8; GEAHLEN RL, 1989, PEPTIDES PROTEIN PHO, P239; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; HADCOCK JR, 1992, J BIOL CHEM, V267, P26017; HADCOCK JR, 1990, J BIOL CHEM, V265, P14784; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; Karoor V, 1996, PROG NEUROBIOL, V48, P555, DOI 10.1016/0301-0082(96)00004-4; KAROOR V, 1995, J BIOL CHEM, V270, P25305, DOI 10.1074/jbc.270.43.25305; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; LIAO PC, 1994, ANAL BIOCHEM, V219, P9, DOI 10.1006/abio.1994.1224; Liu WW, 1996, P NATL ACAD SCI USA, V93, P8258, DOI 10.1073/pnas.93.16.8258; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PORT JD, 1992, J BIOL CHEM, V267, P8468; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YIP TT, 1992, FEBS LETT, V308, P149, DOI 10.1016/0014-5793(92)81264-M; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	23	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29347	29352		10.1074/jbc.271.46.29347	http://dx.doi.org/10.1074/jbc.271.46.29347			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910597	hybrid			2022-12-27	WOS:A1996VT05200089
J	Levin, G; Chikvashvili, D; SingerLahat, D; Peretz, T; Thornhill, WB; Lotan, I				Levin, G; Chikvashvili, D; SingerLahat, D; Peretz, T; Thornhill, WB; Lotan, I			Phosphorylation of a K+ channel alpha subunit modulates the inactivation conferred by a beta subunit - Involvement of cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION CHANNELS; POTASSIUM CHANNELS; DENDROTOXIN ACCEPTOR; BINDING-PROPERTIES; XENOPUS-OOCYTES; PROTEIN-KINASE; RAT-BRAIN; DIVERSITY; PURIFICATION; ASSOCIATION	Voltage-gated K+ channels isolated from mammalian brain are composed of alpha and beta subunits. Interaction between coexpressed K(V)1.1 (alpha) and K-V beta 1.1 (beta) subunits confers rapid inactivation on the delayed rectifier-type current that is observed when alpha subunits are expressed alone. Integrating electrophysiological and biochemical analyses, we show that the inactivation of the alpha beta current is not complete even when alpha is saturated with beta, and the alpha beta current has an inherent sustained compo nent, indistinguishable from a pure alpha current. We further show that basal and protein kinase A-induced phosphorylations at Ser-446 of the alpha protein increase the extent, but not the rate, of inactivation of the alpha beta channel, without affecting the association between alpha and beta. In addition, the extent of inactivation is increased by agents that lead to microfilament depolymerization. The effects of phosphorylation and of microfilament depolymerization are not additive. Taken together, we suggest that phosphorylation, via a mechanism that involves the interaction of the alpha beta channel with microfilaments, enhances the extent of inactivation of the channel. Furthermore, phosphorylation at Ser-446 also increases current amplitudes of the alpha beta channel as was shown before for the alpha channel. Thus, phosphorylation enhances in concert inactivation and current amplitudes, thereby leading to a substantial increase in A-type activity.	TEL AVIV UNIV,SACKLER SCH MED,DEPT PHYSIOL & PHARMACOL,IL-69978 RAMAT AVIV,ISRAEL; MT SINAI HOSP,MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10029	Tel Aviv University; Sackler Faculty of Medicine; Icahn School of Medicine at Mount Sinai								ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P549, DOI 10.1085/jgp.70.5.549; COVARRUBIAS M, 1994, NEURON, V13, P1403, DOI 10.1016/0896-6273(94)90425-1; CROW T, 1988, TRENDS NEUROSCI, V11, P136, DOI 10.1016/0166-2236(88)90138-5; Dascal N., 1992, METHODS MOL BIOL VOL, VVolume 13, P205; DRAIN P, 1994, NEURON, V12, P1097, DOI 10.1016/0896-6273(94)90317-4; FUKODA J, 1981, NATURE, V294, P82; Heinemann SH, 1995, FEBS LETT, V377, P383, DOI 10.1016/0014-5793(95)01377-6; Heinemann SH, 1996, J PHYSIOL-LONDON, V493, P625, DOI 10.1113/jphysiol.1996.sp021409; HONORE E, 1992, EMBO J, V11, P2465, DOI 10.1002/j.1460-2075.1992.tb05311.x; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; IVANINA T, 1994, BIOCHEMISTRY-US, V33, P8786, DOI 10.1021/bi00195a021; JAN LY, 1990, TRENDS NEUROSCI, V13, P415, DOI 10.1016/0166-2236(90)90123-R; JOHNSON BD, 1993, NEURON, V10, P797, DOI 10.1016/0896-6273(93)90196-X; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; LEVIN G, 1995, J BIOL CHEM, V270, P14611, DOI 10.1074/jbc.270.24.14611; LOPATIN AN, 1994, J GEN PHYSIOL, V103, P203, DOI 10.1085/jgp.103.2.203; MANGEAT P, 1984, J CELL BIOL, V99, pS95, DOI 10.1083/jcb.99.1.95s; MORALES MJ, 1995, J BIOL CHEM, V270, P6272, DOI 10.1074/jbc.270.11.6272; Nakahira K, 1996, J BIOL CHEM, V271, P7084, DOI 10.1074/jbc.271.12.7084; PARCEJ DN, 1989, BIOCHEM J, V257, P899, DOI 10.1042/bj2570899; Peretz T, 1996, FEBS LETT, V381, P71, DOI 10.1016/0014-5793(96)00085-3; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; REHM H, 1989, FEBS LETT, V249, P224, DOI 10.1016/0014-5793(89)80628-3; REHM H, 1988, BIOCHEM BIOPH RES CO, V153, P231, DOI 10.1016/S0006-291X(88)81213-0; RETTIG J, 1992, EMBO J, V11, P2473, DOI 10.1002/j.1460-2075.1992.tb05312.x; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RHODES KJ, 1995, J NEUROSCI, V15, P5360; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; SCHREIBMAYER W, 1994, PFLUG ARCH EUR J PHY, V426, P453, DOI 10.1007/BF00388310; SCOTT VES, 1990, J BIOL CHEM, V265, P20094; SEWING S, 1996, NEURON, V16, P1; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; STUHMER W, 1991, ANNU REV BIOPHYS BIO, V20, P65, DOI 10.1146/annurev.biophys.20.1.65; UNDROVINAS AI, 1995, AM J PHYSIOL-HEART C, V269, pH203, DOI 10.1152/ajpheart.1995.269.1.H203; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8	39	65	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29321	29328		10.1074/jbc.271.46.29321	http://dx.doi.org/10.1074/jbc.271.46.29321			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910593	hybrid			2022-12-27	WOS:A1996VT05200085
J	Prassl, R; Chapman, JM; Nigon, F; Sara, M; Eschenburg, S; Betzel, C; Saxena, A; Laggner, P				Prassl, R; Chapman, JM; Nigon, F; Sara, M; Eschenburg, S; Betzel, C; Saxena, A; Laggner, P			Crystallization and preliminary x-ray analysis of a low density lipoprotein from human plasma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APOLIPOPROTEIN-B-100; RECEPTOR; SEQUENCE; SCATTERING; MICROSCOPY; PATHWAY; DOMAINS	Single crystals of human plasma low density lipoprotein (LDL), the major transport vehicle for cholesterol in blood, have been produced with a view to analysis of the three-dimensional structure by x-ray crystallography. Crystals with dimensions of approximately 200 x 100 x 50 mu m have been reproducibly obtained from highly homogeneous LDL particle subspecies, isolated in the density ranges d = 1.0271-1.0297 g/ml and d = 1.0297-1.0327 g/ml. Electron microscopic imaging of ultrathin-sectioned preparations of the crystals confirmed the existence of a regular, quasihexagonal arrangement of spherical particles of approximately 18 nn in diameter, thereby resembling the dimensions characteristic of LDL after dehydration and fixation. X-ray diffraction with synchrotron radiation under cryogenic conditions revealed the presence of well resolved diffraction spots, to a resolution of about 29 Angstrom. The diffraction patterns are indexed in terms of a triclinic lattice with unit cell dimensions of a = 16.1 nm, b = 39.0 nm, c = 43.9 nm; alpha 96.2 degrees, beta = 92.1 degrees, gamma = 102 degrees, and with space group P1.	AUSTRIAN ACAD SCI, INST BIOPHYS & XRAY STRUCTURE RES, A-8010 GRAZ, AUSTRIA; INSERM, U321, F-75651 PARIS, FRANCE; AGR UNIV VIENNA, CTR ULTRASTRUCT RES, A-1010 VIENNA, AUSTRIA; DESY, EMBL OUTSTN, D-22603 HAMBURG, GERMANY	Austrian Academy of Sciences; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Natural Resources & Life Sciences, Vienna; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)			Prassl, Ruth/AAE-1523-2021; Betzel, Christian/G-8105-2018	Betzel, Christian/0000-0002-3879-5019; Prassl, Ruth/0000-0002-1010-9494				ATKINSON D, 1977, P NATL ACAD SCI USA, V74, P1042, DOI 10.1073/pnas.74.3.1042; BANUELOS S, 1995, J BIOL CHEM, V270, P29910, DOI 10.1074/jbc.270.50.29910; BAUMSTARK M, 1983, BIOCHIM BIOPHYS ACTA, V751, P108, DOI 10.1016/0005-2760(83)90262-X; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHAPMAN MJ, 1988, J LIPID RES, V29, P442; CHEN SH, 1986, J BIOL CHEM, V261, P2918; DECKELBAUM RJ, 1977, J BIOL CHEM, V252, P744; DECKELBAUM RJ, 1975, SCIENCE, V190, P392, DOI 10.1126/science.170681; DEJAGER S, 1993, J LIPID RES, V34, P295; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GULIKKRZYWICKI T, 1979, J MOL BIOL, V131, P475, DOI 10.1016/0022-2836(79)90003-2; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; LAGGNER P, 1978, EUR J BIOCHEM, V84, P227, DOI 10.1111/j.1432-1033.1978.tb12160.x; LAGGNER P, 1995, NATO ADV SCI INST SE, V451, P371; LAGGNER P, 1981, J BIOL CHEM, V256, P1832; LUZZATI V, 1979, J MOL BIOL, V131, P435, DOI 10.1016/0022-2836(79)90002-0; MARGOLIS S, 1966, J BIOL CHEM, V241, P485; MEYER DF, 1995, BIOCHEM J, V310, P407, DOI 10.1042/bj3100407; MULLER K, 1978, EUR J BIOCHEM, V82, P73, DOI 10.1111/j.1432-1033.1978.tb11998.x; NIGON F, 1991, J LIPID RES, V32, P1741; OTWINOWSKY Z, 1991, DENZO FILM PROCESSIN; RODGERS DW, 1994, STRUCTURE, V2, P1135, DOI 10.1016/S0969-2126(94)00116-2; SCHUSTER B, 1995, P NATL ACAD SCI USA, V92, P2059; SPIN JM, 1995, BIOPHYS J, V68, P2115, DOI 10.1016/S0006-3495(95)80392-9; SPURR AR, 1969, J ULTRA MOL STRUCT R, V26, P31, DOI 10.1016/S0022-5320(69)90033-1; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; STUHRMANN HB, 1975, P NATL ACAD SCI USA, V72, P2270, DOI 10.1073/pnas.72.6.2270; TRIPLETT RB, 1978, J LIPID RES, V19, P478; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0	29	16	16	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28731	28733		10.1074/jbc.271.46.28731	http://dx.doi.org/10.1074/jbc.271.46.28731			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910510	hybrid			2022-12-27	WOS:A1996VT05200002
J	Shen, H; Dowhan, W				Shen, H; Dowhan, W			Reduction of CDP-diacylglycerol synthase activity results in the excretion of inositol by Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; PHOSPHOLIPID BIOSYNTHESIS; PHOSPHATIDYLSERINE SYNTHASE; ESCHERICHIA-COLI; MOLECULAR-CLONING; YEAST; GENE; DNA; EXPRESSION; ENZYMES	A yeast mutant, cdg1, was isolated on the basis of an inositol excretion phenotype. This mutant exhibited pleiotropic deficiencies in phospholipid biosynthesis, including reduced levels of CDP-diacylglycerol (DAG) synthase activity (KIig, L. S., Homann, M. J., Kohlwein, S. D. Kelley, M. J., Henry, S. A., and Carman, G. M. (1988) J. Bacteriol. 170, 1878-1886). In this study we present evidence that the molecular basis for the inositol excretion phenotype is a G(305)/A(305) point mutation (Cys(102) --> Tyr substitution) within the CDS1 gene (encodes CDP-DAG synthase) of this mutant. Expression of CDP-DAG synthase activity from a plasmid-borne copy of the CDS1 gene in the cdg1 mutant was not down-regulated, and this expression also corrected the inositol excretion phenotype. Introduction of the above mutated gene (CDS1*) controlled by its endogenous promoter on a single copy plasmid into a cds1-null background reconstituted a transformant with the cdg1 phenotype, including reduced CDP-DAG synthase activity, elevated phosphatidylserine synthase activity, and inositol excretion into the growth medium. Expression of CDS1* in a single copy in the cdg1 mutant raised CDP-DAG synthase activity from 15 to 30% of derepressed wild-type yeast levels but still did not correct the inositol excretion phenotype, CDP-DAG synthase activity was not regulated in response to precursors of phospholipid biosynthesis in the cdg1 mutant either with or without a transcopy of the CDS1* gene. An open reading frame was identified 5' to the CDS1 locus, YBR0314, which also resulted in inositol excretion when present in trans in multiple copies.	UNIV TEXAS, SCH MED, DEPT BIOCHEM & MOL BIOL, HOUSTON, TX 77225 USA	University of Texas System								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASHBURNER BP, 1995, MOL CELL BIOL, V15, P1709; BONNER JJ, 1991, GENE, V104, P113, DOI 10.1016/0378-1119(91)90475-Q; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; CARMAN GM, 1992, METHOD ENZYMOL, V209, P242; CARMAN GM, 1992, METHOD ENZYMOL, V209, P298; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; CARMAN GM, 1992, METHOD ENZYMOL, V209, P305; CULBERTSON MR, 1975, GENETICS, V80, P23; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIFCO, 1984, DEH CULT MED REAG MI, V10th; Dowhan W, 1995, ADV CELL MOL BIOL M, V4, P189, DOI [10.1016/S1874-5172(06)80013-1, DOI 10.1016/S1874-5172(06)80013-1]; FERBEYRE G, 1993, BIOTECHNIQUES, V14, P386; FUJIMURA HA, 1993, BIOTECHNIQUES, V14, P538; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GREENBERG ML, 1982, GENETICS, V100, P19; HENRY SA, 1984, ANNU REV GENET, V18, P207; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HOMANN MJ, 1987, J BACTERIOL, V169, P533, DOI 10.1128/jb.169.2.533-539.1987; HOMANN MJ, 1985, J BACTERIOL, V163, P1265, DOI 10.1128/JB.163.3.1265-1266.1985; HROMY MJ, 1986, J BIOL CHEM, V261, P15572; ICHO T, 1985, J BIOL CHEM, V260, P2078; JANITOR M, 1993, CURR GENET, V24, P307, DOI 10.1007/BF00336781; KELLEY MJ, 1987, J BIOL CHEM, V262, P14563; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KINNEY AJ, 1990, J BACTERIOL, V172, P4115, DOI 10.1128/jb.172.7.4115-4117.1990; KINNEY AJ, 1988, P NATL ACAD SCI USA, V85, P7962, DOI 10.1073/pnas.85.21.7962; KINNEY AJ, 1990, J BACTERIOL, V172, P1133, DOI 10.1128/jb.172.2.1133-1136.1990; KLIG LS, 1988, J BACTERIOL, V170, P1878, DOI 10.1128/jb.170.4.1878-1886.1988; KUCHLER K, 1986, J BACTERIOL, V165, P901, DOI 10.1128/jb.165.3.901-910.1986; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAI K, 1994, J BIOL CHEM, V269, P2245; LETTS VA, 1985, J BACTERIOL, V163, P560, DOI 10.1128/JB.163.2.560-567.1985; MCGEE TP, 1994, J BACTERIOL, V176, P6861, DOI 10.1128/JB.176.22.6861-6868.1994; NICKELS JT, 1994, J BIOL CHEM, V269, P11018; NIKOLOFF DM, 1994, J BIOL CHEM, V269, P7402; NIKOLOFF DM, 1991, ANNU REV GENET, V25, P559; PRESUTTI C, 1991, EMBO J, V10, P2215, DOI 10.1002/j.1460-2075.1991.tb07757.x; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; RALEIGH EA, 1989, CURRENT PROTOCOLS MO, V1; RINE J, 1991, METHOD ENZYMOL, V194, P239; Shen HF, 1996, J BIOL CHEM, V271, P789, DOI 10.1074/jbc.271.2.789; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SMITS PHM, 1994, YEAST, V10, pS75, DOI 10.1002/yea.320100010; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; WU L, 1995, NATURE, V373, P216, DOI 10.1038/373216a0	48	21	22	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29043	29048		10.1074/jbc.271.46.29043	http://dx.doi.org/10.1074/jbc.271.46.29043			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910557	hybrid			2022-12-27	WOS:A1996VT05200049
J	Cahill, CM; Waterman, WR; Xie, Y; Auron, PE; Calderwood, SK				Cahill, CM; Waterman, WR; Xie, Y; Auron, PE; Calderwood, SK			Transcriptional repression of the prointerleukin 1 beta gene by heat shock factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; EXPRESSION; INTERLEUKIN-1; CELLS; BINDING; LIPOPOLYSACCHARIDE; TRANSDUCTION; TEMPERATURE; ACTIVATION; SEQUENCE	Heat shock factor 1 activates the promoters of heat shock genes at elevated temperatures through its interaction with heat shock elements. We have examined a new role for heat shock factor 1 in the repression of the prointerluekin 1 beta gene in human monocytes responding to stimulation with lipopolysaccharide. Both exposure to elevated temperatures and heat-independent heat shock factor 1 expression repressed the transcription of the prointerleukin 1 beta gene, and repression was strictly dependent on an intact consensus heat shock element in the prointerleukin 1 beta promoter to which heat shock factor 1 bound. This is the first demonstration of heat shock factor 1 as a transcriptional repressor and suggests a role for the factor in the counter-regulation of cytokine gene transcription.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,JOINT CTR RADIAT THERAPY,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School					NCI NIH HHS [CA47407, CA50642] Funding Source: Medline; NIAID NIH HHS [AI27850] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047407, R01CA050642] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027850] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; AURON PE, 1994, EUR CYTOKINE NETW, V5, P573; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BRUCE JL, 1993, CANCER RES, V53, P12; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; DINARELLO CA, 1986, CANCER RES, V46, P6236; FENTON MJ, 1988, J IMMUNOL, V140, P2267; FENTON MJ, 1987, J IMMUNOL, V138, P3972; HAHN GM, 1982, HYPERTHERMIA CANCER, P7; HENSOLD JO, 1990, MOL CELL BIOL, V10, P1600, DOI 10.1128/MCB.10.4.1600; HUNT C, 1990, GENE, V87, P199, DOI 10.1016/0378-1119(90)90302-8; JAKOBSEN BK, 1988, MOL CELL BIOL, V8, P5040, DOI 10.1128/MCB.8.11.5040; KAPPEL M, 1991, IMMUNOLOGY, V73, P304; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KNUDSEN PJ, 1987, J IMMUNOL, V139, P4129; KOMINATO Y, 1995, MOL CELL BIOL, V15, P59; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; SCHILLER P, 1985, J MOL BIOL, V203, P97; SCHMIDT JA, 1988, J IMMUNOL, V141, P2027; SORGER PK, 1987, EMBO J, V6, P3035, DOI 10.1002/j.1460-2075.1987.tb02609.x; VELASCO S, 1991, J CLIN INVEST, V87, P1674, DOI 10.1172/JCI115184; Voellmy Richard, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P357; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; ZHANG Y, 1993, MOL CELL BIOL, V13, P3831, DOI 10.1128/MCB.13.6.3831; [No title captured]	28	164	175	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24874	24879						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8926278				2022-12-27	WOS:A1996VM67400086
J	Lawn, RM; Pearle, AD; Kunz, LL; Rubin, EM; Reckless, J; Metcalfe, JC; Grainger, DJ				Lawn, RM; Pearle, AD; Kunz, LL; Rubin, EM; Reckless, J; Metcalfe, JC; Grainger, DJ			Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein(a) mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; GROWTH-FACTOR-BETA; EXPRESSING HUMAN APOLIPOPROTEIN(A); LOW-DENSITY-LIPOPROTEIN; TRANSFORMING GROWTH-FACTOR-BETA-1; FACTOR-BETA-1; DISEASE; ATHEROGENESIS; ACTIVATION; TAMOXIFEN	Apolipoprotein(a) (apo(a)), the distinguishing protein of atherogenic lipoprotein(a), directs accumulation of the lipoprotein(a) particle to sites in the arterial wall where atherosclerotic lipid lesions develop in man and in transgenic mice expressing human apo(a). It has been proposed that focal apo(a) accumulation in the transgenic mouse vessel wall causes the observed severe local inhibition of transforming growth factor-beta (TGF-beta) activity and the consequent activation of the smooth muscle cells, which subsequently accumulate lipid to form lesions if the mice are fed a high fat diet, We show that blocking formation of these vascular lesions by two independent mechanisms, tamoxifen treatment and increasing high density lipoprotein, also abolishes apo(a) accumulation, inhibition of TGF-beta activity, and activation of smooth muscle cells. The data are consistent with a feedback mechanism in which an initial accumulation of apo(a) inhibits local TGF-beta activity, leading to further accumulation of apo(a). Breaking the feedback loop prevents smooth muscle cell activation and therefore lipid lesion development.	NEORX CORP,SEATTLE,WA 98119; UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,BERKELEY,CA 94720; UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Cambridge	Lawn, RM (corresponding author), STANFORD UNIV,SCH MED,FALK CARDIOVASC RES CTR,300 PASTEUR DR,STANFORD,CA 94305, USA.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Assmann G, 1996, AM J CARDIOL, V77, P1179, DOI 10.1016/S0002-9149(96)00159-2; BJORKERUD S, 1991, ARTERIOSCLER THROMB, V63, P515; Bostom AG, 1996, JAMA-J AM MED ASSOC, V276, P544, DOI 10.1001/jama.276.7.544; BOTTALICO LA, 1991, J BIOL CHEM, V266, P22866; CAMPBELL JH, 1985, ARTERIOSCLEROSIS, V5, P318, DOI 10.1161/01.ATV.5.4.318; CHIESA G, 1992, J BIOL CHEM, V267, P24369; COLLETTA AA, 1991, J CLIN INVEST, V87, P277, DOI 10.1172/JCI114983; CUSHING GL, 1989, ARTERIOSCLEROSIS, V9, P593, DOI 10.1161/01.ATV.9.5.593; GALLUCCI BB, 1982, AM J SURG PATHOL, V6, P293, DOI 10.1097/00000478-198206000-00002; GAMBLE JR, 1988, SCIENCE, V242, P97; GIACHELLI C, 1991, BIOCHEM BIOPH RES CO, V177, P867, DOI 10.1016/0006-291X(91)91870-I; GRAINGER DJ, 1993, BIOCHEM J, V294, P109, DOI 10.1042/bj2940109; GRAINGER DJ, 1995, NAT MED, V1, P74, DOI 10.1038/nm0195-74; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; GRAINGER DJ, 1995, NAT MED, V1, P1067, DOI 10.1038/nm1095-1067; GRAINGER DJ, 1995, BIOL REV, V70, P571, DOI 10.1111/j.1469-185X.1995.tb01652.x; GRAINGER DJ, 1993, SCIENCE, V260, P1655, DOI 10.1126/science.8503012; HEARN JA, 1992, AM J CARDIOL, V69, P736, DOI 10.1016/0002-9149(92)90497-M; JURGENS G, 1995, STROKE, V26, P1841, DOI 10.1161/01.STR.26.10.1841; KOJIMA S, 1991, J CELL BIOL, V113, P1439, DOI 10.1083/jcb.113.6.1439; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; LEFER AM, 1993, P NATL ACAD SCI USA, V90, P1018, DOI 10.1073/pnas.90.3.1018; LI HM, 1995, J CLIN INVEST, V95, P122, DOI 10.1172/JCI117628; LIU AC, 1994, J LIPID RES, V35, P2263; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; MAJESKY MW, 1991, J CLIN INVEST, V88, P904, DOI 10.1172/JCI115393; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; Mosedale DE, 1996, J HISTOCHEM CYTOCHEM, V44, P1043, DOI 10.1177/44.9.8773570; NABEL EG, 1993, P NATL ACAD SCI USA, V90, P10759, DOI 10.1073/pnas.90.22.10759; NACHMAN RL, 1992, BLOOD, V79, P1897, DOI 10.1182/blood.V79.8.1897.bloodjournal7981897; Nielsen LB, 1996, CIRC RES, V78, P615, DOI 10.1161/01.RES.78.4.615; OWENS GK, 1988, J CELL BIOL, V107, P771, DOI 10.1083/jcb.107.2.771; PALABRICA TM, 1995, NAT MED, V1, P256, DOI 10.1038/nm0395-256; PITAS RE, 1990, J BIOL CHEM, V265, P12722; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SCHAEFER EJ, 1994, JAMA-J AM MED ASSOC, V271, P999, DOI 10.1001/jama.271.13.999; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; SHEWMON DA, 1994, ARTERIOSCLER THROMB, V14, P1586, DOI 10.1161/01.ATV.14.10.1586; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SORENSEN KE, 1994, J CLIN INVEST, V93, P50, DOI 10.1172/JCI116983; TERRES W, 1995, CIRCULATION, V91, P948, DOI 10.1161/01.CIR.91.4.948; TSURUMI Y, 1995, J AM COLL CARDIOL, V26, P1242, DOI 10.1016/0735-1097(95)00321-5; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; WILLIAMS JK, 1993, ARTERIOSCLER THROMB, V13, P548, DOI 10.1161/01.ATV.13.4.548; WOLF YG, 1994, J CLIN INVEST, V93, P1172, DOI 10.1172/JCI117070; ZYSOW BR, 1997, IN PRESS ARTERIOSCLE	51	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31367	31371		10.1074/jbc.271.49.31367	http://dx.doi.org/10.1074/jbc.271.49.31367			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940144	hybrid			2022-12-27	WOS:A1996VW68600055
J	Gao, P; Malbon, CC				Gao, P; Malbon, CC			Differentiation of F9 teratocarcinoma stem cells to primitive endoderm is regulated by the G(i alpha 2)/G(s alpha) axis via phospholipase C and not adenylylcyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; RETINOIC ACID; GS-ALPHA; MESSENGER-RNA; EXPRESSION; ACTIVATION; SUBUNIT; GAMMA; PLASMINOGEN; INDUCTION	Morphogen-induced decline in G(i alpha) triggers F9 teratocarcinoma stem cells to progress to primitive endoderm via activation of protein kinase C and mitogen-activated protein kinase (Gao, P., and Malbon, C. C, (1996) J. Biol. Chem. 271, 9002-9008). Constitutive expression of G(i alpha 2) blocks, whereas expression of G(s alpha) provokes, progression to primitive endoderm, permitting identification of the effectors of the response-utilizing chimera created between G(i alpha 2) and G(s alpha). N-terminal substitution of G(s alpha) with G(i alpha 2) sequence to create chimera G(i alpha 2 (1-54))/G(s alpha) produced a chimera that activated adenylylcyclase but abolished progression to primitive endoderm and activation of phospholipase C, C-terminal substitution of G(s alpha) with G(i alpha 2) sequence to G(s alpha)/G(i alpha 2 (320-355)) enhanced the ability of G(i alpha 2) to promote progression, The Q205L-activated mutant of G(i alpha 2) suppresses, whereas the G225T-activated mutant of G(s alpha) strongly activates phospholipase C and progression in these cells, The N-terminal region of G(s alpha) (residues 62-86) appears to act as a dominant switch for the G(s alpha)- (activation) versus G(i alpha 2)- (suppression) mediated control of phospholipase C and progression to primitive endoderm.	SUNY STONY BROOK,MED CTR,DEPT MOL PHARMACOL,SCH MED,HSC,DIABET & METAB DIS RES CTR,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			malbon, craig/ABF-3604-2020					ANDRADEGORDON P, 1986, BIOCHEMISTRY-US, V25, P4033, DOI 10.1021/bi00362a007; Bell R M, 1986, Methods Enzymol, V124, P353; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; CHAN SDH, 1990, J BIOL CHEM, V265, P20081; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DARROW AL, 1990, METHOD ENZYMOL, V190, P110; GALVINPARTON PA, 1990, J BIOL CHEM, V265, P1771; Gao P, 1996, J BIOL CHEM, V271, P9002, DOI 10.1074/jbc.271.15.9002; GAO P, 1995, AM J PHYSIOL-CELL PH, V268, pC1460, DOI 10.1152/ajpcell.1995.268.6.C1460; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; GUPTA SK, 1991, J CELL BIOCHEM, V47, P359, DOI 10.1002/jcb.240470410; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LAROSA GJ, 1988, P NATL ACAD SCI USA, V85, P329, DOI 10.1073/pnas.85.2.329; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; PREISS JE, 1987, METHOD ENZYMOL, V141, P294; RICKLES RJ, 1988, J BIOL CHEM, V263, P1563; ROBISHAW JD, 1986, J BIOL CHEM, V261, P9587; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; Venkatakrishnan G, 1996, J BIOL CHEM, V271, P5066; WATKINS DC, 1994, BIOCHEM J, V299, P593, DOI 10.1042/bj2990593; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; WORLEY PF, 1987, NATURE, V325, P159, DOI 10.1038/325159a0; WU TCJ, 1992, DIFFERENTIATION, V51, P219, DOI 10.1111/j.1432-0436.1992.tb00699.x; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z	26	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30692	30698		10.1074/jbc.271.48.30692	http://dx.doi.org/10.1074/jbc.271.48.30692			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940046	hybrid			2022-12-27	WOS:A1996VV15800063
J	Menhart, N; Mitchell, T; Lusitani, D; Topouzian, N; Fung, LWM				Menhart, N; Mitchell, T; Lusitani, D; Topouzian, N; Fung, LWM			Peptides with more than one 106-amino acid sequence motif are needed to mimic the structural stability of spectrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE SPECTRIN; SECONDARY STRUCTURE; HEREDITARY ELLIPTOCYTOSIS; CONFORMATIONAL UNIT; LIMITED PROTEOLYSIS; MOLECULAR-STRUCTURE; CIRCULAR-DICHROISM; SEGMENTAL MOBILITY; ALPHA-SPECTRIN; SITE	The primary sequence of human erythrocyte spectrin contains repetitive homologous sequence motifs of approximately 106 amino acids with 22 such motifs in the alpha-subunit and 17 in the beta-subunit. These homologous sequence motifs have been proposed to form domains with a triple-helical bundle type structure (Speicher, D. W., and Marchesi, V, T, (1984) Nature 311, 177-180; Parry, D. A. D., Dixon, T. W,, and Cohen, C. (1992) Biophys. J. 61, 858-867). In this study, we show that these sequence motifs, while they do form compact proteolytically resistant units, are not completely independent, Peptides composed of two or three such motifs in tandem are substantially more stable than peptides composed of a single motif, as measured by proteolysis or by fluorescence or circular dichroism studies of urea or thermal denaturation, Circular dichroism and infrared spectroscopy measurements also indicate that these larger, more stable peptides exhibit greater secondary structure. In these respects, the peptides with tandem sequence motifs are more similar to intact spectrin than the peptide with a single sequence motif, Thus, we conclude that peptides with more than one sequence motif model spec trin more adequately than the peptides with one sequence motif, and that these sequence motifs are not completely independent domains.	LOYOLA UNIV, DEPT CHEM, CHICAGO, IL 60626 USA	Loyola University Chicago								BAKLOUTI F, 1992, BLOOD, V79, P2464; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BOIVIN P, 1990, UCLA SYM BI, V118, P235; BUDZYNSKI DM, 1992, BIOCHEMISTRY-US, V31, P3653, DOI 10.1021/bi00129a014; CALVERT R, 1980, EUR J BIOCHEM, V107, P355; COETZER T, 1990, UCLA SYM BI, V118, P211; DELAUNAY J, 1993, SEMIN HEMATOL, V30, P21; EFTINK MR, 1994, BIOPHYS J, V66, P482, DOI 10.1016/S0006-3495(94)80799-4; FONTANA A, 1986, BIOCHEMISTRY-US, V25, P1847, DOI 10.1021/bi00356a001; FREIFELDER D, 1982, PHYSICAL BIOCH, P691; GALLAGHER PG, 1993, BLOOD, V82, P2210; GILMORE AP, 1994, EUR J BIOCHEM, V225, P235, DOI 10.1111/j.1432-1033.1994.00235.x; HARTWIG JH, 1994, PROTEIN PROFILE, V1, P711; KAHANA E, 1994, J MOL BIOL, V235, P1271, DOI 10.1006/jmbi.1994.1080; LABRAKE CC, 1993, BIOCHEMISTRY-US, V32, P10296, DOI 10.1021/bi00090a004; LUSITANI DM, 1994, J BIOL CHEM, V269, P25955; MACDONALD RI, 1994, P NATL ACAD SCI USA, V91, P1299, DOI 10.1073/pnas.91.4.1299; Mach H, 1995, Methods Mol Biol, V40, P91; MANNING MC, 1989, J PHARMACEUT BIOMED, V7, P1103, DOI 10.1016/0731-7085(89)80049-4; MARCHESI SL, 1989, RED BLOOD CELL MEMBR, P77; MOHANDAS N, 1994, ANNU REV BIOPH BIOM, V23, P787, DOI 10.1146/annurev.bb.23.060194.004035; NOVOTNY J, 1987, FEBS LETT, V211, P185, DOI 10.1016/0014-5793(87)81433-3; PARKER JC, 1986, PHYSL MEMBRANE DISOR, P785; PARRY DAD, 1992, BIOPHYS J, V61, P858, DOI 10.1016/S0006-3495(92)81893-3; Ralston G, 1996, BIOCHEMISTRY-US, V35, P5257, DOI 10.1021/bi952224d; RALSTON GB, 1978, J SUPRAMOL STR CELL, V8, P361, DOI 10.1002/jss.400080313; RALSTON GB, 1979, BIOCHIM BIOPHYS ACTA, V579, P20, DOI 10.1016/0005-2795(79)90083-7; Royer C A, 1995, Methods Mol Biol, V40, P65; ROYER CA, 1993, PROTEIN SCI, V2, P1844, DOI 10.1002/pro.5560021106; SAHR KE, 1990, J BIOL CHEM, V265, P4434; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; SPEICHER DW, 1992, J BIOL CHEM, V267, P14775; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; SPEICHER DW, 1993, J BIOL CHEM, V268, P4227; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; STEER BA, 1995, BIOCHEMISTRY-US, V34, P7225, DOI 10.1021/bi00021a038; TSE WT, 1990, J CLIN INVEST, V86, P909, DOI 10.1172/JCI114792; WINKELMANN JC, 1993, BLOOD, V81, P3173; WINOGRAD E, 1991, P NATL ACAD SCI USA, V88, P10788, DOI 10.1073/pnas.88.23.10788; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097	41	32	33	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30410	30416		10.1074/jbc.271.48.30410	http://dx.doi.org/10.1074/jbc.271.48.30410			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940005	hybrid			2022-12-27	WOS:A1996VV15800022
J	Hara, N; Tsuchiya, M; Shimoyama, M				Hara, N; Tsuchiya, M; Shimoyama, M			Glutamic acid 207 in rodent T-cell RT6 antigens is essential for arginine-specific ADP-ribosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION MARKER RT6; ALLOANTIGEN RT6.1; SKELETAL-MUSCLE; RAT LYMPHOCYTES; RIBOSYLTRANSFERASE; SEQUENCE; NAD; NUCLEOTIDE; AUTOMODIFICATION; CONSERVATION	A rat T-cell antigen RT6.1 catalyzes NAD glycohydrolysis but not ADP-ribose transfer, even though the antigen has significant amino acid identity with eucaryotic arginine-specific ADP-ribosyltransferases. Since a highly conserved Glu in the catalytic region of these transferases is substituted with Gin at position 207 in RT6.1, we replaced the Gin with Glu, Asp, or Ale, by site-directed mutagenesis. The Glu-207 mutant produced ADP-ribosylarginine during incubation with NAD and L-arginine, The Asp-207 mutant but not the Ala 207 mutant produced ADP-ribosylarginine, but at a lower rate. In contrast, these mutations affected NAD glycohydrolase activity of RT6.1 to a much lesser extent. Kinetic studies of transferase reaction revealed that k(cat) of the Glu-207 mutant increased compared to findings with the Asp-207 mutant. Moreover, the mouse homologue of rat RT6 last arginine-specific ADP ribosyltransferase activity when Glu-207 was replaced with Grin. Thus, Glu-207 in rodent T cell RT6 antigens is essential for transfer reaction of ADP-ribose to arginine.	SHIMANE MED UNIV,DEPT BIOCHEM,IZUMO,SHIMANE 693,JAPAN	Shimane University								DAVIS T, 1995, GENE, V164, P371, DOI 10.1016/0378-1119(95)00504-Y; GREINER DL, 1987, J EXP MED, V166, P461, DOI 10.1084/jem.166.2.461; HAAG F, 1995, EUR J IMMUNOL, V25, P2355, DOI 10.1002/eji.1830250835; HAAG F, 1990, NUCLEIC ACIDS RES, V18, P1047, DOI 10.1093/nar/18.4.1047; HSIA JA, 1985, J BIOL CHEM, V260, P6187; KOCH F, 1990, P NATL ACAD SCI USA, V87, P964, DOI 10.1073/pnas.87.3.964; KOCH F, 1990, NUCLEIC ACIDS RES, V18, P3636, DOI 10.1093/nar/18.12.3636; KOCH F, 1988, IMMUNOLOGY, V65, P259; KOCH F, 1986, J EXP MED, V164, P1338, DOI 10.1084/jem.164.4.1338; KOCH T, 1994, VIROLOGY, V203, P294, DOI 10.1006/viro.1994.1487; KochNolte F, 1996, J BIOL CHEM, V271, P7686, DOI 10.1074/jbc.271.13.7686; MACHAMA T, 1996, FEBS LETT, V388, P189; MAEHAMA T, 1995, J BIOL CHEM, V270, P22747, DOI 10.1074/jbc.270.39.22747; MEKALANOS JJ, 1983, NATURE, V306, P551, DOI 10.1038/306551a0; MOSS J, 1992, J BIOL CHEM, V267, P10481; OHNO T, 1995, ANAL BIOCHEM, V231, P115, DOI 10.1006/abio.1995.1510; OKAZAKI IJ, 1994, BIOCHEMISTRY-US, V33, P12828, DOI 10.1021/bi00209a014; PERELLE S, 1995, INFECT IMMUN, V63, P4967, DOI 10.1128/IAI.63.12.4967-4967.1995; SHIMOYAMA M, 1992, POSTTRANSLATIONAL MO, P183; SOMAN G, 1991, BIOCHEM BIOPH RES CO, V176, P301, DOI 10.1016/0006-291X(91)90924-V; TAKADA T, 1994, J BIOL CHEM, V269, P9420; TAKADA T, 1995, J BIOL CHEM, V270, P541, DOI 10.1074/jbc.270.2.541; TSUCHIYA M, 1986, ANAL BIOCHEM, V157, P381, DOI 10.1016/0003-2697(86)90641-X; TSUCHIYA M, 1994, J BIOL CHEM, V269, P27451; vanDamme J, 1996, FEBS LETT, V380, P291, DOI 10.1016/0014-5793(96)00052-X; WANG J, 1994, J IMMUNOL, V153, P4048; Williamson K., 1990, ADP RIBOSYLATING TOX, P493; WONIGEIT K, 1987, TRANSPLANT P, V19, P296; YAMADA K, 1994, ARCH BIOCHEM BIOPHYS, V308, P31, DOI 10.1006/abbi.1994.1004; YAMAMOTO T, 1987, J BACTERIOL, V169, P1852; ZOLKIEWSKA A, 1992, P NATL ACAD SCI USA, V89, P11352, DOI 10.1073/pnas.89.23.11352	31	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29552	29555		10.1074/jbc.271.47.29552	http://dx.doi.org/10.1074/jbc.271.47.29552			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939882	hybrid			2022-12-27	WOS:A1996VU52500010
J	Lin, TA; Lawrence, JC				Lin, TA; Lawrence, JC			Control of the translational regulators PHAS-I and PHAS-II by insulin and AMP in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; HEAT-STABLE PROTEIN; RAT ADIPOSE-TISSUE; P70 S6 KINASE; INITIATION-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; FAT-CELLS; PHOSPHORYLATION; RAPAMYCIN; WORTMANNIN	The eukaryotic initiation factor 4E (eIF-4E)-binding proteins PHAS-I and PHAS-II were found to have overlapping but different patterns of expression in tissues, Both PHAS proteins were expressed in 3T3-L1 adipocytes, in which insulin stimulated their phosphorylation, promoted dissociation of PHAS eIF-4E complexes, and decreased the ability of both to bind exogenous eIF-4E. The effects of insulin were attenuated by rapamycin and wortmannin, two agents that block activation of p70(S6K). Unlike PHAS-I, PHAS-II was readily phosphorylated by cAMP-dependent protein kinase in vitro; however, the effects of insulin on both PHAS proteins were attenuated by agents that increase intracellular cAMP, by cAMP derivatives, and by phosphodiesterase inhibitors. These agents also markedly inhibited the activation of p70(S6K). In summary, our results indicate that PHAS-I and -II are controlled by the mammalian target of rapamycin and p70(S6K) Signaling pathway and that in 3T3-L1 adipocytes this pathway is inhibited by increased cAMP.	UNIV VIRGINIA, HLTH SCI CTR, SCH MED, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, SCH MED, DEPT MED, CHARLOTTESVILLE, VA 22908 USA; ST LOUIS UNIV, SCH MED, DEPT MOL BIOL & PHARMACOL, ST LOUIS, MO 63110 USA	University of Virginia; University of Virginia; Saint Louis University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR41180] Funding Source: Medline; NIDDK NIH HHS [DK28312] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Azpiazu I, 1996, J BIOL CHEM, V271, P5033; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BLACKSHEAR PJ, 1982, BIOCHEM J, V204, P817, DOI 10.1042/bj2040817; BLACKSHEAR PJ, 1983, BIOCHEM J, V214, P11, DOI 10.1042/bj2140011; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; BRUNN GJ, 1996, IN PRESS EMBO J; Chasin M, 1976, Adv Cyclic Nucleotide Res, V7, P225; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DIGGLE TA, 1995, BIOCHEM J, V306, P135, DOI 10.1042/bj3060135; DIGGLE TA, 1992, BIOCHEM J, V282, P729, DOI 10.1042/bj2820729; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FREDERICKSON RM, 1992, CELL BIOL, V3, P107; FROST V, 1995, J BIOL CHEM, V270, P26698, DOI 10.1074/jbc.270.44.26698; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIMBALL SR, 1994, ANNU REV PHYSIOL, V56, P321, DOI 10.1146/annurev.ph.56.030194.001541; Kimball SR, 1996, AM J PHYSIOL-CELL PH, V270, pC705, DOI 10.1152/ajpcell.1996.270.2.C705; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence JC, 1995, INT CONGR SER, V1100, P622; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; LIN TA, 1996, IN PRESS DIABETOLOGI; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; MADER S, 1995, BIOCHIMIE, V77, P40, DOI 10.1016/0300-9084(96)88102-8; MADER S, 1995, MOL CELL BIOL, V15, P4990; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PETRITSCH C, 1995, J BIOL CHEM, V270, P26619, DOI 10.1074/jbc.270.44.26619; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; RAMAKRISHNA S, 1983, BIOCHEM BIOPH RES CO, V117, P758, DOI 10.1016/0006-291X(83)91662-5; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; Scott PH, 1996, BIOCHEM J, V318, P965, DOI 10.1042/bj3180965; STERN BD, 1993, PROTEIN EXPRES PURIF, V4, P320, DOI 10.1006/prep.1993.1041; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329	43	84	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30199	30204		10.1074/jbc.271.47.30199	http://dx.doi.org/10.1074/jbc.271.47.30199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939971	hybrid			2022-12-27	WOS:A1996VU52500099
J	Aman, MJ; Tayebi, N; Obiri, NI; Puri, RK; Modi, WS; Leonard, WJ				Aman, MJ; Tayebi, N; Obiri, NI; Puri, RK; Modi, WS; Leonard, WJ			cDNA cloning and characterization of the human interleukin 13 receptor alpha chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE CLEAVAGE SITES; LIGAND-BINDING; GAMMA-CHAIN; B-CELLS; CYTOKINE; EXPRESSION; MONOCYTES; SUBUNITS; IL-4	We have cloned cDNAs corresponding to the human interleukin 13 receptor alpha chain (IL-13R alpha). The protein has 76% homology to murine IL-13R alpha, with 95% amino acid identity in the cytoplasmic domain. Only weak IL-13 binding activity was found in cells transfected with only IL-13R alpha; however, the combination of both IL-13R alpha and IL-4R alpha resulted in substantial binding activity, with a K-d of approximately 400 pM, indicating that both chains are essential components of the IL-13 receptor. Whereas IL-13R alpha serves as an alternative accessory protein to the common cytokine receptor gamma chain (gamma(c)) for IL-4 signaling, it could not replace the function of gamma(c) in allowing enhanced IL-2 binding activity. Nevertheless, the overall size and length of the cytoplasmic domain of IL-13R alpha and gamma(c) are similar, and like gamma(c), IL-13R alpha is located on chromosome X.	NHLBI,LAB MOL IMMUNOL,NIH,BETHESDA,MD 20892; NIMH,CLIN NEUROSCI BRANCH,NIH,BETHESDA,MD 20892; US FDA,CTR BIOL EVALUAT & RES,DIV CELLULAR & GENE THERAPIES,BETHESDA,MD 20892; NCI,FREDERICK CANC RES & DEV CTR,SCI APPLICAT INT CORP,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Leonard, Warren/AAA-1397-2022					BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; Chaouchi N, 1996, BLOOD, V87, P1022, DOI 10.1182/blood.V87.3.1022.bloodjournal8731022; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; JOHNSON K, 1994, EUR CYTOKINE NETW, V5, P23; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; LOWENTHAL JW, 1987, J EXP MED, V166, P1156, DOI 10.1084/jem.166.4.1156; MALEFYT RD, 1993, J IMMUNOL, V151, P6370; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Murata T, 1995, J BIOL CHEM, V270, P30829, DOI 10.1074/jbc.270.51.30829; MUZIO M, 1994, BLOOD, V83, P1738, DOI 10.1182/blood.V83.7.1738.bloodjournal8371738; OBIRI NI, 1995, J BIOL CHEM, V270, P13869; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SANA TR, 1994, BIOCHEMISTRY-US, V17, P5838; SMERZBERTLING C, 1995, J BIOL CHEM, V270, P966, DOI 10.1074/jbc.270.2.966; VITA N, 1995, J BIOL CHEM, V270, P3512, DOI 10.1074/jbc.270.8.3512; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WANG HM, 1987, J EXP MED, V166, P1055, DOI 10.1084/jem.166.4.1055; WLOWAWER A, 1993, PROTEIN SCI, V2, P1373; WU ZN, 1995, J BIOL CHEM, V270, P16045, DOI 10.1074/jbc.270.27.16045; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3	28	267	305	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29265	29270		10.1074/jbc.271.46.29265	http://dx.doi.org/10.1074/jbc.271.46.29265			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910586	hybrid			2022-12-27	WOS:A1996VT05200078
J	Burden, DA; Kingma, PS; FroelichAmmon, SJ; Bjornsti, MA; Patchan, MW; Thompson, RB; Osheroff, N				Burden, DA; Kingma, PS; FroelichAmmon, SJ; Bjornsti, MA; Patchan, MW; Thompson, RB; Osheroff, N			Topoisomerase II etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPLOITING MECHANISTIC DIFFERENCES; DROSOPHILA-MELANOGASTER; SEQUENCE SPECIFICITY; ANTINEOPLASTIC DRUGS; RELIGATION REACTION; INTERACTION DOMAINS; INHIBITORS; YEAST; RESISTANCE; BINDING	Topoisomerase II is the target for several highly active anticancer drugs that induce cell death by enhancing enzyme-mediated DNA scission. Although these agents dramatically increase levels of nucleic acid cleavage in a site-specific fashion, little is understood regarding the mechanism by which they alter the DNA site selectivity of topoisomerase II. Therefore, a series of kinetic and binding experiments were carried out to determine the mechanistic basis by which the anticancer drug, etoposide, enhances cleavage complex formation at 22 specific nucleic acid sequences. In general, maximal levels of DNA scission (i.e. C-max) varied over a considerably larger range than did the apparent affinity of etoposide (i.e. K-m) for these sites, and there was no correlation between these two kinetic parameters. Furthermore, enzyme drug binding and order of addition experiments indicated that etoposide and topoisomerase II form a kinetically competent complex in the absence of DNA. These findings suggest that etoposide topoisomerase II (rather than etoposide DNA) interactions mediate cleavage complex formation. Finally, rates of religation at specific sites correlated inversely with C-max values, indicating that maximal levels of etoposide-induced scission reflect the ability of the drug to inhibit religation at specific sequences rather than the affinity of the drug for site-specific enzyme-DNA complexes.	VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT MED,NASHVILLE,TN 37232; THOMAS JEFFERSON UNIV,DEPT BIOCHEM & MOL BIOL,PHILADELPHIA,PA 19107; UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21201	Vanderbilt University; Vanderbilt University; Jefferson University; University System of Maryland; University of Maryland Baltimore				Patchan, Marcia/0000-0002-0485-0403	NCI NIH HHS [CA58755, 5 T32 CA09582] Funding Source: Medline; NIGMS NIH HHS [GM33944] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009582, R01CA058755] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RD, 1994, MUTAT RES-FUND MOL M, V309, P109, DOI 10.1016/0027-5107(94)90048-5; BECK WT, 1993, ADV ENZYME REGUL, V33, P113; BELANI CP, 1994, CANCER CHEMOTH PHARM, V34, pS118, DOI 10.1007/BF00684875; Berger JM, 1996, CURR OPIN STRUC BIOL, V6, P84, DOI 10.1016/S0959-440X(96)80099-6; BIGIONI M, 1996, BIOCHEMISTRY-US, V35, P1153; CAPRANICO G, 1992, EUR J CANCER, V28A, P2055, DOI 10.1016/0959-8049(92)90255-Z; CAPRANICO G, 1994, J BIOL CHEM, V269, P25004; CAPRANICO G, 1993, BIOCHEMISTRY-US, V32, P3038, DOI 10.1021/bi00063a015; CAPRANICO G, 1990, NUCLEIC ACIDS RES, V18, P6611, DOI 10.1093/nar/18.22.6611; CAPRANICO G, 1994, J MOL BIOL, V235, P1218, DOI 10.1006/jmbi.1994.1075; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CHOW KC, 1988, MOL PHARMACOL, V34, P467; CORBETT AH, 1992, J BIOL CHEM, V267, P683; CORBETT AH, 1993, J BIOL CHEM, V268, P14394; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; Cozzarelli N.R., 1990, DNA TOPOLOGY ITS BIO; COZZARELLI NR, 1980, CELL, V22, P327, DOI 10.1016/0092-8674(80)90341-4; DEVORE R, 1992, SEMIN ONCOL, V19, P40; DILLEHAY LE, 1989, MUTAT RES, V215, P15, DOI 10.1016/0027-5107(89)90213-3; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; ELSEA SH, 1995, J BIOL CHEM, V270, P1913, DOI 10.1074/jbc.270.4.1913; FERGUSON LR, 1994, ENVIRON MOL MUTAGEN, V24, P245, DOI 10.1002/em.2850240402; FREUDENREICH CH, 1993, EMBO J, V12, P2085, DOI 10.1002/j.1460-2075.1993.tb05857.x; FREUDENREICH CH, 1994, P NATL ACAD SCI USA, V91, P11007, DOI 10.1073/pnas.91.23.11007; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P14998, DOI 10.1074/jbc.270.25.14998; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P28018; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GALE KC, 1990, BIOCHEMISTRY-US, V29, P9538, DOI 10.1021/bi00493a007; GEWIRTZ DA, 1991, BIOCHEM PHARMACOL, V42, P2253, DOI 10.1016/0006-2952(91)90227-V; GOTO T, 1984, CELL, V36, P1073, DOI 10.1016/0092-8674(84)90057-6; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; HIGGINS NP, 1982, NUCLEIC ACIDS RES, V10, P6833, DOI 10.1093/nar/10.21.6833; HOLDEN JA, 1995, AM J CLIN PATHOL, V104, P54, DOI 10.1093/ajcp/104.1.54; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HSIANG YH, 1988, CANCER RES, V48, P3230; KNAB AM, 1993, J BIOL CHEM, V268, P22322; LIU LF, 1994, ADV PHARM, V29; NELSON WG, 1987, CANCER RES, V47, P3246; Nitiss J L, 1994, Adv Pharmacol, V29A, P103; NITISS JL, 1993, CANCER RES, V53, P89; OSHEROFF N, 1994, CANCER CHEMOTH PHARM, V34, pS19, DOI 10.1007/BF00684859; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; POMMIER Y, 1991, NUCLEIC ACIDS RES, V19, P5973, DOI 10.1093/nar/19.21.5973; POMMIER Y, 1994, CANCER INVEST, V12, P530, DOI 10.3109/07357909409021413; Pommier Y., 1996, CANC CHEMOTHERAPY BI, P435; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROSE D, 1990, CELL, V60, P1009, DOI 10.1016/0092-8674(90)90349-J; Sambrook J., 2002, MOL CLONING LAB MANU; SANDER M, 1987, J MOL BIOL, V194, P219, DOI 10.1016/0022-2836(87)90370-6; SANDER M, 1983, J BIOL CHEM, V258, P8421; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Segel I.H., 1975, ENZYME KINETICS; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; SINHA BK, 1995, DRUGS, V49, P11, DOI 10.2165/00003495-199549010-00002; SPITZNER JR, 1995, MOL PHARMACOL, V48, P238; SULLIVAN DM, 1987, CANCER RES, V47, P3973; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; ZECHIEDRICH EL, 1989, BIOCHEMISTRY-US, V28, P6229, DOI 10.1021/bi00441a014	65	129	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29238	29244		10.1074/jbc.271.46.29238	http://dx.doi.org/10.1074/jbc.271.46.29238			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910583	hybrid			2022-12-27	WOS:A1996VT05200075
J	Hodder, AN; Crewther, PE; Matthew, MLSM; Reid, GE; Moritz, RL; Simpson, RJ; Anders, RF				Hodder, AN; Crewther, PE; Matthew, MLSM; Reid, GE; Moritz, RL; Simpson, RJ; Anders, RF			The disulfide bond structure of Plasmodium apical membrane antigen-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; SEQUENCE-ANALYSIS; LIQUID-CHROMATOGRAPHY; MEROZOITE ANTIGEN; SURFACE-ANTIGEN; I AMA-1; FALCIPARUM; SUPERFAMILY; PREDICTION; PEPTIDES	Apical membrane antigen-1 (AMA-1) of Plasmodium falciparum is one of the leading asexual blood stage antigens being considered for inclusion in a malaria vaccine. The ability of this molecule to induce a protective immune response has been shown to be dependent upon a conformation stabilized by disulfide bonds. In this study we have utilized the reversed-phase high performance liquid chromatography of dithiothreitol-reduced and nonreduced tryptic digests of Plasmodium chabaudi AMA-1 secreted from baculovirus-infected insect cells, in conjunction with N-terminal sequencing and electrospray-ionization mass spectrometry, to identify and assign disulfide-linked peptides. All 16 cysteine residues that are conserved in all known sequences of AMA-1 are incorporated into intramolecular disulfide bonds. Six of the eight bonds have been assigned unequivocally, whereas the two unassigned disulfide bonds connect two Cys-Xaa-Cys sequences separated by 14 residues. The eight disulfide bonds fall into three nonoverlapping groups that define three possible subdomains within the AMA-1 ectodomain. Although the pattern of disulfide bonds within subdomain III has not been fully elucidated, one of only two possible linkage patterns closely resembles the cystine knot motif found in growth factors. Sites of amino acid substitutions in AMA-1 that are well separated in the primary sequence are clustered by the disulfide bonds in subdomains II and III. These findings are consistent with the conclusion that these amino acid substitutions are defining conformational disulfide bond-dependent epitopes that are recognized by protective immune responses.	WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA; UNIV MELBOURNE,COOPERAT RES CTR VACCINE TECHNOL,MELBOURNE,VIC 3052,AUSTRALIA; UNIV MELBOURNE,DEPT MICROBIOL,MELBOURNE,VIC 3052,AUSTRALIA; LUDWIG INST CANC RES,JOINT PROT STRUCT LAB,MELBOURNE BRANCH,MELBOURNE,VIC 3050,AUSTRALIA	Walter & Eliza Hall Institute; University of Melbourne; University of Melbourne; Ludwig Institute for Cancer Research	Hodder, AN (corresponding author), COOPERAT RES CTR VACCINE TECHNOL,PO ROYAL MELBOURNE HOSP,MELBOURNE,VIC 3050,AUSTRALIA.		Moritz, Robert L/B-9222-2011	Anders, Robin/0000-0002-0693-4547; Reid, Gavin/0000-0002-9675-1444; Simpson, Richard/0000-0002-9834-0796				ANDERS RF, 1993, MOL IMMUNOLOGICAL CO, P169; CHENG Q, 1994, MOL BIOCHEM PARASIT, V65, P183, DOI 10.1016/0166-6851(94)90127-9; COLLINS WE, 1994, AM J TROP MED HYG, V51, P711, DOI 10.4269/ajtmh.1994.51.711; DEANS JA, 1984, MOL BIOCHEM PARASIT, V11, P189, DOI 10.1016/0166-6851(84)90065-3; DEANS JA, 1988, PARASITE IMMUNOL, V10, P535, DOI 10.1111/j.1365-3024.1988.tb00241.x; DUTTA S, 1995, MOL BIOCHEM PARASIT, V73, P267, DOI 10.1016/0166-6851(95)00112-E; ISAACS NW, 1995, CURR OPIN STRUC BIOL, V5, P391, DOI 10.1016/0959-440X(95)80102-2; KRISHNA RG, 1993, METHODS IN PROTEIN SEQUENCE ANALYSIS, P167; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Marshall VM, 1996, MOL BIOCHEM PARASIT, V77, P109, DOI 10.1016/0166-6851(96)02583-2; MARSHALL VM, 1989, MOL BIOCHEM PARASIT, V37, P281, DOI 10.1016/0166-6851(89)90160-6; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MORITZ RL, 1992, J CHROMATOGR, V599, P119; MORITZ RL, 1995, TECH PROT CHEM, V6, P311, DOI 10.1016/S1080-8914(06)80039-6; MORITZ RL, 1992, J MICROCOLUMN SEP, V4, P485, DOI 10.1002/mcs.1220040604; Moritz Robert L., 1994, Methods (Orlando), V6, P213, DOI 10.1006/meth.1994.1024; NARUM DL, 1994, MOL BIOCHEM PARASIT, V67, P59, DOI 10.1016/0166-6851(94)90096-5; PETERSON MG, 1989, MOL CELL BIOL, V9, P3151, DOI 10.1128/MCB.9.7.3151; PETERSON MG, 1990, MOL BIOCHEM PARASIT, V39, P279, DOI 10.1016/0166-6851(90)90067-V; REID GE, 1995, ELECTROPHORESIS, V16, P1120, DOI 10.1002/elps.11501601189; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; THOMAS AW, 1990, MOL BIOCHEM PARASIT, V42, P285, DOI 10.1016/0166-6851(90)90172-I; THOMAS AW, 1984, MOL BIOCHEM PARASIT, V13, P187, DOI 10.1016/0166-6851(84)90112-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATERS AP, 1991, MOL BIOCHEM PARASIT, V44, P141, DOI 10.1016/0166-6851(91)90230-4	28	220	230	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29446	29452		10.1074/jbc.271.46.29446	http://dx.doi.org/10.1074/jbc.271.46.29446			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910611				2022-12-27	WOS:A1996VT05200103
J	Hoyal, CR; Thomas, AP; Forman, HJ				Hoyal, CR; Thomas, AP; Forman, HJ			Hydroperoxide-induced increases in intracellular calcium due to annexin VI translocation and inactivation of plasma membrane Ca2+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ALVEOLAR MACROPHAGES; RESPIRATORY BURST; HYDROGEN-PEROXIDE; BUTYL HYDROPEROXIDE; MITOCHONDRIA; PROTEIN; PHOSPHOLIPASE-A2; LIPOCORTINS; INHIBITION; OXIDATION	Oxidative stress can cause changes in intracellular free calcium concentration ([Ca2+](i)) that resemble those occurring under normal cell signaling. In the alveolar macrophage, hydroperoxide-induced elevation of [Ca2+](i) modulates the respiratory burst and other important physiologic functions. The source of Ca2+ released by hydroperoxide is intracellular but separate from the endoplasmic reticulum pool released by receptor-mediated stimuli (Hoyal, C. R., Gozal, E., Zhou, H., Foldenauer, K., and Forman, H. J. (1996) Arch. Biochem. Biophys. 326, 166-171). Previous studies in other cells have suggested that mitochondria are a potential source of oxidant-induced [Ca2+](i) elevation. In this study we have identified another potential source of hydroperoxide-releasable intracellular calcium, that bound to annexin VI on the inner surface of the plasma membrane. Translocation of annexin VI from the membrane during exposure to t-butyl hydroperoxide matched elevation of [Ca2+](i) as a function of time and t-butyl hydroperoxide concentration. The translocation was possibly due to a combination of ATP depletion and oxidative modification of membrane lipids and proteins, A sustained increase in [Ca2+](i) occurring > 50 pmol/10(6) cells (50 mu M under these conditions) appeared to be a consequence of membrane Ca2+-ATPase dysfunction. These results suggest that exposure to oxidative stress results in early alterations to the plasma membrane and concomitant release of Ca2+ into the cytosol. In addition it suggests a mechanism for participation of annexin VI translocation that may underlie the alterations in macrophage function by oxidative stress.	UNIV SO CALIF,SCH PHARM,DEPT MOL PHARMACOL & TOXICOL,LOS ANGELES,CA 90033; UNIV SO CALIF,DEPT PATHOL,LOS ANGELES,CA 90033; THOMAS JEFFERSON UNIV,DEPT ANAT PATHOL & CELL BIOL,PHILADELPHIA,PA 19107	University of Southern California; University of Southern California; Jefferson University			Thomas, Andrew/C-6755-2013	Thomas, Andrew/0000-0002-9026-7467; Forman, Henry Jay/0000-0001-5838-2791	NHLBI NIH HHS [HL37556] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037556] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELLOMO G, 1984, EUR J BIOCHEM, V140, P1, DOI 10.1111/j.1432-1033.1984.tb08058.x; BOWLES AL, 1979, AM REV RESPIR DIS, V120, P541; COMERA C, 1990, EUR J BIOCHEM, V188, P139, DOI 10.1111/j.1432-1033.1990.tb15381.x; CROMPTON MR, 1988, EMBO J, V7, P21, DOI 10.1002/j.1460-2075.1988.tb02779.x; CROWELL RE, 1995, AM J RESP CELL MOL, V12, P190, DOI 10.1165/ajrcmb.12.2.7865216; DAVIDSON FF, 1989, BIOCHEM PHARMACOL, V38, P3645, DOI 10.1016/0006-2952(89)90567-4; DAVIDSON FF, 1990, J BIOL CHEM, V265, P5602; DESJARDINS M, 1994, J BIOL CHEM, V269, P32194; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; EDWARDS HC, 1995, MOL CELL BIOCHEM, V149, P293, DOI 10.1007/BF01076591; FORMAN HJ, 1980, J BIOL CHEM, V255, P9879; FORMAN HJ, 1982, J APPL PHYSIOL, V53, P685, DOI 10.1152/jappl.1982.53.3.685; FORMAN HJ, 1993, ACTIVE OXYGENS, LIPID PEROXIDES, AND ANTIOXIDANTS, P149; GAMALEY IA, 1994, CELL SIGNAL, V6, P949, DOI 10.1016/0898-6568(94)90028-0; GEISOW MJ, 1986, TRENDS BIOCHEM SCI, V11, P420, DOI 10.1016/0968-0004(86)90176-3; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hofer AM, 1996, FASEB J, V10, P302, DOI 10.1096/fasebj.10.2.8641563; Hoyal CR, 1996, ARCH BIOCHEM BIOPHYS, V326, P166, DOI 10.1006/abbi.1996.0061; KAETZEL MA, 1995, NEWS PHYSIOL SCI, V10, P171; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; LIVINGSTON FR, 1992, ARCH BIOCHEM BIOPHYS, V299, P83, DOI 10.1016/0003-9861(92)90247-T; LU Y, 1995, BIOCHEMISTRY-US, V34, P10777, DOI 10.1021/bi00034a010; MOORE RB, 1992, BLOOD, V79, P1334; MURPHY JK, 1995, FREE RADICAL BIO MED, V18, P37, DOI 10.1016/0891-5849(94)00101-O; MURPHY JK, 1993, AM J RESP CELL MOL, V9, P505, DOI 10.1165/ajrcmb/9.5.505; OOSTING RS, 1990, AM J PHYSIOL, V259, pL87, DOI 10.1152/ajplung.1990.259.2.L87; OWENS RJ, 1984, EMBO J, V3, P945, DOI 10.1002/j.1460-2075.1984.tb01912.x; RAO GN, 1995, BBA-MOL CELL RES, V1265, P67, DOI 10.1016/0167-4889(95)91997-Z; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; ROBISON TW, 1995, ARCH BIOCHEM BIOPHYS, V318, P215, DOI 10.1006/abbi.1995.1223; ROHN TT, 1993, BIOCHEM PHARMACOL, V46, P525, DOI 10.1016/0006-2952(93)90530-A; ROHN TT, 1993, BIOCHIM BIOPHYS ACTA, V1153, P67, DOI 10.1016/0005-2736(93)90277-7; SMITH PD, 1994, P NATL ACAD SCI USA, V91, P2713, DOI 10.1073/pnas.91.7.2713; SOMLYO AP, 1985, NATURE, V314, P622, DOI 10.1038/314622a0; SUDHOF TC, 1988, P NATL ACAD SCI USA, V85, P664, DOI 10.1073/pnas.85.3.664; TAGOE CE, 1994, BIOCHIM BIOPHYS ACTA, P272; VILE G, 1990, BIOCHEM PHARMACOL, V39, P769, DOI 10.1016/0006-2952(90)90157-G; YOSHIZAKI H, 1990, J BIOCHEM-TOKYO, V107, P43, DOI 10.1093/oxfordjournals.jbchem.a123009	40	66	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29205	29210		10.1074/jbc.271.46.29205	http://dx.doi.org/10.1074/jbc.271.46.29205			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910578	hybrid			2022-12-27	WOS:A1996VT05200070
J	Huang, YD; Schwendner, SW; Rall, SC; Mahley, RW				Huang, YD; Schwendner, SW; Rall, SC; Mahley, RW			Hypolipidemic and hyperlipidemic phenotypes in transgenic mice expressing human apolipoprotein E2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEINS; III HYPERLIPOPROTEINEMIA; FAMILIAL DYSBETALIPOPROTEINEMIA; HEPATIC LIPASE; PLASMA-LIPOPROTEINS; MARKED REDUCTION; E DEFICIENCY; A-I; DIET; ATHEROSCLEROSIS	Transgenic mice mere produced that expressed different plasma levels (3-60 mg/dl) of human apolipoprotein (ape) E2(Arg(158) --> Cys), which is associated with the recessive form of human type III hyperlipoproteinemia (HLP). In transgenic mice fed a normal chow diet, low levels of apoE2 (< 10 mg/dl) did not significantly alter the lipid phenotype. Mice expressing intermediate levels of apoE2 (10-30 mg/dl) had a 50-60% decrease in total cholesterol compared with nontransgenic mice. The decrease was almost entirely due to a reduction in high density lipoprotein (HDL) cholesterol. These hypolipidemic apoE2 transgenic mice were cross-bred with human apoB transgenic mice, which have increased total cholesterol and low density Lipoprotein (LDL) levels. The apoE2/apoB double transgenics revealed that expression of apoE2 on the background of human apoB overexpression resulted in a substantial decrease in LDL and HDL cholesterol and a corresponding accumulation of very low density Lipoproteins (VLDL) and intermediate density lipoproteins (mt). Thus, the double transgenics had a lipid phenotype resembling human type III HLP. In contrast to the hypolipidemic mice, mice expressing high levels of apoE2 (>50 mg/dl) were hyperlipidemic. The VLDL and IDL in these mice were significantly increased and cholesterol-enriched and had other characteristics of remnant lipoproteins. Upon agarose gel electrophoresis, the VLDL and IDL from both intermediate and high expressers migrated more slowly toward the beta position compared with the pre-beta-mobility of nontransgenic mouse VLDL and IDL. Thus, depending on plasma apoE2 levels, the expression of human apoE2 in the transgenic mice leads to either a hypolipidemic or hyperlipidemic phenotype. This animal model provides the opportunity to study the factors that cause hypolipidemia and those that precipitate the hyperlipidemia of type III HLP.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [HL47660] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; DEKNIJFF P, 1991, J CLIN INVEST, V88, P643, DOI 10.1172/JCI115349; DESILVA HV, 1994, J LIPID RES, V35, P1297; DESILVA HV, 1994, J BIOL CHEM, V269, P2324; DONG LM, 1994, J BIOL CHEM, V269, P22358; FAN JL, 1994, P NATL ACAD SCI USA, V91, P8724, DOI 10.1073/pnas.91.18.8724; FAZIO S, 1994, ARTERIOSCLER THROMB, V14, P1873, DOI 10.1161/01.ATV.14.11.1873; FAZIO S, 1992, J BIOL CHEM, V267, P6941; FAZIO S, 1993, J CLIN INVEST, V92, P1497, DOI 10.1172/JCI116728; GOLDERNOVOSELSKY E, 1992, J BIOL CHEM, V267, P20787; HAVEL RJ, 1983, J CLIN INVEST, V72, P379, DOI 10.1172/JCI110978; HAVEL RJ, 1980, J CLIN INVEST, V66, P1351, DOI 10.1172/JCI109988; HORIE Y, 1992, J BIOL CHEM, V267, P1962; JI ZS, 1994, J BIOL CHEM, V269, P13421; MABUCHI H, 1989, METABOLISM, V38, P115, DOI 10.1016/0026-0495(89)90249-7; Mahley R. W., 1991, CURR OPIN LIPIDOL, V2, P170; MAHLEY RW, 1994, ANN NY ACAD SCI, V737, P39, DOI 10.1111/j.1749-6632.1994.tb44300.x; MAHLEY RW, 1984, ADV INTERNAL MED, V29, P385; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1990, CURRENT OPINION LIPI, V1, P87; MAHLEY RW, 1995, METABOLIC MOL BASES, P1953; MCLEAN JW, 1984, J BIOL CHEM, V259, P6498; MORGANROTH J, 1975, ANN INTERN MED, V82, P158, DOI 10.7326/0003-4819-82-2-158; MORTIMER BC, 1994, ARTERIOSCLER THROMB, V14, P1542, DOI 10.1161/01.ATV.14.10.1542; PETERSON J, 1986, BIOCHIM BIOPHYS ACTA, V878, P65, DOI 10.1016/0005-2760(86)90344-9; PURCELLHUYNH DA, 1995, J CLIN INVEST, V95, P2246, DOI 10.1172/JCI117915; RALL SC, 1989, J CLIN INVEST, V83, P1095, DOI 10.1172/JCI113988; RALL SC, 1992, J INTERN MED, V231, P653, DOI 10.1111/j.1365-2796.1992.tb01254.x; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SCOTT J, 1990, CURRENT OPINION LIPI, V1, P96; SHIMANO H, 1992, P NATL ACAD SCI USA, V89, P1750, DOI 10.1073/pnas.89.5.1750; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; THUREN T, 1992, BIOCHEMISTRY-US, V31, P2332, DOI 10.1021/bi00123a018; THUREN T, 1991, J BIOL CHEM, V266, P4853; UTERMANN G, 1979, CLIN GENET, V15, P37; UTERMANN G, 1977, NATURE, V269, P604, DOI 10.1038/269604a0; UTERMANN G, 1985, DIABETES OBESITY HYP, V3, P11; VANDENMAAGDENBERG AMJM, 1993, J BIOL CHEM, V268, P10540; VANVLIJMEN BJM, 1994, J CLIN INVEST, V93, P1403, DOI 10.1172/JCI117117; WEISGRABER KH, 1982, J BIOL CHEM, V257, P2518; ZHAO SP, 1994, ARTERIOSCLER THROMB, V14, P1705, DOI 10.1161/01.ATV.14.11.1705; ZHAO SP, 1994, CLIN CHEM, V40, P1559	43	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29146	29151		10.1074/jbc.271.46.29146	http://dx.doi.org/10.1074/jbc.271.46.29146			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910571	hybrid			2022-12-27	WOS:A1996VT05200063
J	Jarvis, TC; Wincott, FE; Alby, LJ; McSwiggen, JA; Beigelman, L; Gustofson, J; DiRenzo, A; Levy, K; Arthur, M; MatulicAdamic, J; Karpeisky, A; Gonzalez, C; Woolf, TM; Usman, N; Stinchcomb, DT				Jarvis, TC; Wincott, FE; Alby, LJ; McSwiggen, JA; Beigelman, L; Gustofson, J; DiRenzo, A; Levy, K; Arthur, M; MatulicAdamic, J; Karpeisky, A; Gonzalez, C; Woolf, TM; Usman, N; Stinchcomb, DT			Optimizing the cell efficacy of synthetic ribozymes - Site selection and chemical modifications of ribozymes targeting the proto-oncogene c-myb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; HAMMERHEAD RIBOZYMES; IN-VIVO; ANTISENSE OLIGODEOXYNUCLEOTIDES; NUCLEOTIDE-SEQUENCE; CATALYTIC ACTIVITY; MESSENGER-RNA; EXPRESSION; PROTOONCOGENE; INHIBITION	Expression of the proto-oncogene c-myb is necessary for proliferation of vascular smooth muscle cells. We have developed synthetic hammerhead ribozymes that recognize and cleave c-myb RNA, thereby inhibiting cell proliferation. Herein, we describe a method for the selection of hammerhead ribozyme cleavage sites and optimization of chemical modifications that maximize cell efficacy. In vitro assays were used to determine the relative accessibility of the ribozyme target sites for binding and cleavage. Several ribozymes thus identified showed efficacy in inhibiting smooth muscle cell proliferation relative to catalytically inactive controls. A combination of modifications including several phosphorothioate linkages at the 5'-end of the ribozyme and an extensively modified catalytic core resulted in substantially increased cell efficacy. A variety of different 2'-modifications at positions U4 and U7 that confer nuclease resistance gave comparable levels of cell efficacy. The lengths of the ribozyme binding arms were varied; optimal cell efficacy was observed with relatively short sequences (13-15 total nucleotides). These synthetic ribozymes have potential as therapeutics for hyperproliferative disorders such as restenosis and cancer. The chemical moths that give optimal ribozyme activity in smooth muscle cell assays may be applicable to other cell types and other molecular targets.			Jarvis, TC (corresponding author), RIBOZYME PHARMACEUT INC,BOULDER,CO 80301, USA.			Stinchcomb, Dan/0000-0002-3634-7503; Karpeisky, Alexander/0000-0002-9226-8789				BEIGELMAN L, 1995, NUCLEOS NUCLEOT, V14, P907, DOI 10.1080/15257779508012499; BEIGELMAN L, 1995, J BIOL CHEM, V270, P25702, DOI 10.1074/jbc.270.43.25702; BEIGELMAN L, 1995, NUCLEOS NUCLEOT, V14, P895, DOI 10.1080/15257779508012497; BROWN KE, 1992, J BIOL CHEM, V267, P4625; BROWN S, 1996, IN PRESS RIBOZYME PR; CECH TR, 1992, CURR OPIN STRUC BIOL, V2, P605, DOI DOI 10.1016/0959-440X(92)90093-M; CHRISTOFFERSEN RE, 1994, J MOL STRUC-THEOCHEM, V311, P273; FEDOR MJ, 1990, P NATL ACAD SCI USA, V87, P1668, DOI 10.1073/pnas.87.5.1668; Flory CM, 1996, P NATL ACAD SCI USA, V93, P754, DOI 10.1073/pnas.93.2.754; FORRESTER JS, 1991, J AM COLL CARDIOL, V17, P758, DOI 10.1016/S0735-1097(10)80196-2; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; HIJIYA N, 1994, P NATL ACAD SCI USA, V91, P4499, DOI 10.1073/pnas.91.10.4499; JACKSON CL, 1992, HYPERTENSION, V20, P713, DOI 10.1161/01.HYP.20.6.713; Jarvis TC, 1996, RNA, V2, P419; KIEHNTOPF M, 1994, EMBO J, V13, P4645, DOI 10.1002/j.1460-2075.1994.tb06787.x; KINDY MS, 1986, J BIOL CHEM, V261, P2865; LANDAU C, 1994, NEW ENGL J MED, V330, P981, DOI 10.1056/NEJM199404073301407; LANGE W, 1993, LEUKEMIA, V7, P1786; LYNGSTADAAS SP, 1995, EMBO J, V14, P5224, DOI 10.1002/j.1460-2075.1995.tb00207.x; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MELANI C, 1991, CANCER RES, V51, P2897; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P11823, DOI 10.1073/pnas.89.24.11823; SARMIENTO UM, 1994, ANTISENSE RES DEV, V4, P99, DOI 10.1089/ard.1994.4.99; SELIGER H, 1994, NEW DEV FIELD ANTISE, P681; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SIOUD M, 1994, J MOL BIOL, V242, P619, DOI 10.1006/jmbi.1994.1612; SNYDER DS, 1993, BLOOD, V82, P600; SYMONS RH, 1994, CURR OPIN STRUC BIOL, V4, P322, DOI 10.1016/S0959-440X(94)90099-X; TUSCHL T, 1995, CURR OPIN STRUC BIOL, V5, P296, DOI 10.1016/0959-440X(95)80090-5; UHLMANN E, 1990, CHEM REV, V90, P544; USMAN N, 1995, CATALYTIC RNA RIBOZY, P285; WINCOTT F, 1995, NUCLEIC ACIDS RES, V23, P2677, DOI 10.1093/nar/23.14.2677	32	71	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29107	29112		10.1074/jbc.271.46.29107	http://dx.doi.org/10.1074/jbc.271.46.29107			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910566				2022-12-27	WOS:A1996VT05200058
J	Smart, EJ; Ying, YS; Donzell, WC; Anderson, RGW				Smart, EJ; Ying, YS; Donzell, WC; Anderson, RGW			A role for caveolin in transport of cholesterol from endoplasmic reticulum to plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED-CELLS; MA104 CELLS; RECEPTOR; PROTEIN; FOLATE; INTERNALIZATION; PALMITOYLATION; LOCALIZATION; PROGESTERONE; POTOCYTOSIS	Caveolin is a 22-kDa membrane protein found associated with a coat material decorating the inner membrane surface of caveolae. A remarkable feature of this protein is its ability to migrate from caveolae directly to the endoplasmic reticulum (ER) when membrane cholesterol is oxidized. We now present evidence caveolin is involved in transporting newly synthesized cholesterol from the ER directly to caveolae. MA104 cells and normal human fibroblasts transported new cholesterol to caveolae with a half-time of similar to 10 min. The cholesterol then rapidly flowed from caveolae to non-caveolae membrane. Cholesterol moved out of caveolae even when the supply of fresh cholesterol from the ER was interrupted. Treatment of cells with 10 mu g/ml progesterone blocked cholesterol movement from ER to caveolae. Simultaneously, caveolin accumulated in the lumen of the ER, suggesting cholesterol transport is linked to caveolin movement. Caveolae fractions from cells expressing caveolin were enriched in cholesterol 3-4-fold, while the same fractions from cells lacking caveolin were not enriched. Cholesterol transport to the cell surface was nearly 4 times more rapid in cells expressing caveolin than in matched cells lacking caveolin.	UNIV TEXAS, SW MED CTR, DEPT CELL BIOL & NEUROSCI, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NHLBI NIH HHS [HL 20948] Funding Source: Medline; NIGMS NIH HHS [GM 43169, GM 15631] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043169, F32GM015631] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; BERGERON M, 1994, CELL TISSUE RES, V277, P297, DOI 10.1007/s004410050156; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CONRAD PA, 1995, J CELL BIOL, V131, P1424; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; FAN JG, 1991, J BIOL CHEM, V266, P14862; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; KAMEN BA, 1986, P NATL ACAD SCI USA, V83, P5983, DOI 10.1073/pnas.83.16.5983; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE Y, 1985, J BIOL CHEM, V260, P5592; LANGE Y, 1994, J BIOL CHEM, V269, P3411; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Metherall JE, 1996, J BIOL CHEM, V271, P2627, DOI 10.1074/jbc.271.5.2627; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; PALADE GE, 1968, J CELL BIOL, V37, P633, DOI 10.1083/jcb.37.3.633; PALADE GE, 1953, J APPL PHYS, V24, P1424; PANINI SR, 1987, J BIOL CHEM, V262, P14435; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Smart EJ, 1995, COLD SPRING HARB SYM, V60, P243, DOI 10.1101/SQB.1995.060.01.028; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1996, J CELL BIOL, V134, P1169, DOI 10.1083/jcb.134.5.1169; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; TRIGATTI BL, 1991, J BIOL CHEM, V266, P22621; URBANI L, 1990, J BIOL CHEM, V265, P1919; VANDENBERG CW, 1995, J CELL BIOL, V131, P669, DOI 10.1083/jcb.131.3.669; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445	43	475	487	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29427	29435		10.1074/jbc.271.46.29427	http://dx.doi.org/10.1074/jbc.271.46.29427			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910609	hybrid			2022-12-27	WOS:A1996VT05200101
J	Cheng, F; Heinegard, D; Fransson, LA; Bayliss, M; Bielicki, J; Hopwood, J; Yoshida, K				Cheng, F; Heinegard, D; Fransson, LA; Bayliss, M; Bielicki, J; Hopwood, J; Yoshida, K			Variations in the chondroitin sulfate-protein linkage region of aggrecans from bovine nasal and human articular cartilages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWARM RAT CHONDROSARCOMA; TRYPSIN-INHIBITOR; SEQUENCE-ANALYSIS; DERMATAN SULFATE; SHARK CARTILAGE; PROTEOGLYCANS; OLIGOSACCHARIDES; FIBROBLASTS; RESIDUES; CHAINS	Aggrecan-derived chondroitin sulfate (CS) chains, released by beta-elimination, were derivatized with p-aminobenzoic acid or p-aminophenol; radioiodinated; and subjected to graded or complete degradations by chondroitin ABC lyase to generate linkage region fragments of the basic structure Delta GlyUA-GalNAc-GlcUA-Gal-Gal-Xyl-R (where Delta GlyUA represents 4,5-unsaturated glycuronic acid, and R is the adduct), by chondroitin AC lyase to generate the shorter fragment Delta GlyUA-Gal-Gal-Xyl-R, or by chondroitin C lyase to generate the same fragment when it was linked to a 6-O-sulfated or unsulfated GalNac at the nonreducing end. Fragments were separated by size using gel chromatography, by charge using ion-exchange chromatography, and by size/charge using electrophoresis and then characterized by stepwise degradations from the nonreducing end by using mercuric acetate to remove all terminal Delta GlyUA, by bacterial glycuronidase to remove the same residue when linked to unsulfated or 6-O-sulfated GalNAc/Gal, by mammalian 4-sulfatase to remove sulfate from terminal GalNAc 4-O-sulfate, by chondro-4-sulfatase to remove 4-O-sulfate from other GalNAc/Gal residues, and by beta-galactosidase to remove terminal Gal. Results with CS from bovine nasal cartilage aggrecan show that, in nearly all chains, Xyl and probably also the first Gal are unsubstituted, whereas the second Gal is 4-O-sulfated in one CS chain out of five. The first disaccharide repeat is sulfated at C-4 of GalNAc in one chain out of three and unsulfated in the other two. A sulfated first disaccharide is always joined to an unsulfated GlcUA-Gal-Gal sequence. In contrast, CS from human articular cartilage usually has a sulfated first disaccharide repeat. In CS from young human cartilage, sulfate groups are mostly at C-4 of GalNAc in the major part of the chain, but at C-6 in the nonreducing distal portion. In CS from old cartilage, sulfation at C-6 of GalNAc is a major feature from the nonreducing end down to approximately positions 4 and 5 from the linkage region, where GalNAc 4-O-sulfate is common.	KENNEDY INST,LONDON W6 7DW,ENGLAND; ADELAIDE CHILDRENS HOSP INC,DEPT CHEM PATHOL,ADELAIDE,SA 5006,AUSTRALIA; SEIKAGAKU CORP,TOKYO RES INST,HIGASHIYAMATO,TOKYO 207,JAPAN	University of Oxford; Seikagaku Corporation	Cheng, F (corresponding author), LUND UNIV,DEPT CELL & MOL BIOL,SECT CELL & MATRIX BIOL,POB 94,S-22100 LUND,SWEDEN.							ANSON DS, 1992, BIOCHEM J, V284, P789, DOI 10.1042/bj2840789; BAYLISS MT, 1978, BIOCHEM J, V176, P683, DOI 10.1042/bj1760683; Bayliss MT, 1995, ACTA ORTHOP SCAND, V66, P22, DOI 10.3109/17453679509157642; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; CHENG F, 1994, GLYCOBIOLOGY, V4, P685, DOI 10.1093/glycob/4.5.685; CHENG F, 1992, GLYCOBIOLOGY, V2, P553, DOI 10.1093/glycob/2.6.553; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; DEWAARD P, 1992, J BIOL CHEM, V267, P6036; FRANSSON LA, 1990, BIOCHEM J, V269, P381, DOI 10.1042/bj2690381; FRANSSON LA, 1985, J BIOL CHEM, V260, P4722; FRANSSON LA, 1992, BIOCHIM BIOPHYS ACTA, V1137, P287, DOI 10.1016/0167-4889(92)90149-6; HABUCHI O, 1977, J BIOL CHEM, V252, P4570; HEINEGARD D, 1987, METHOD ENZYMOL, V144, P319; Heinegard Dick, 1993, P189; KAPLAN D, 1959, NATURE, V183, P1267, DOI 10.1038/1831267a0; KARAMANOS NK, 1995, ANAL BIOCHEM, V225, P220, DOI 10.1006/abio.1995.1147; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LAINE RA, 1994, GLYCOBIOLOGY, V4, P759, DOI 10.1093/glycob/4.6.759; Liu J, 1995, GLYCOBIOLOGY, V5, P765, DOI 10.1093/glycob/5.8.765; LUDWIGS U, 1987, BIOCHEM J, V245, P795, DOI 10.1042/bj2450795; MATHEWS MB, 1966, J CLIN INVEST, V45, P1103, DOI 10.1172/JCI105416; OEGEMA TR, 1984, J BIOL CHEM, V259, P1720; OTOTANI N, 1987, CARBOHYD RES, V159, P25, DOI 10.1016/S0008-6215(00)90003-X; Roden L., 1972, METHODS ENZYMOLOGY, V28, P73; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; SHIBATA S, 1992, J BIOL CHEM, V267, P6548; SUGAHARA K, 1991, EUR J BIOCHEM, V202, P805, DOI 10.1111/j.1432-1033.1991.tb16436.x; SUGAHARA K, 1992, J BIOL CHEM, V267, P6027; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; SUZUKI S, 1968, J BIOL CHEM, V243, P3580; YAMADA S, 1995, GLYCOBIOLOGY, V5, P335, DOI 10.1093/glycob/5.3.335; YAMADA S, 1995, EUR J BIOCHEM, V233, P687, DOI 10.1111/j.1432-1033.1995.687_2.x; Yoshida K., 1993, DERMATAN SULFATE PRO, P55	33	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28572	28580		10.1074/jbc.271.45.28572	http://dx.doi.org/10.1074/jbc.271.45.28572			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910487	hybrid			2022-12-27	WOS:A1996VU03300087
J	Tang, NM; Ho, CY; Katze, MG				Tang, NM; Ho, CY; Katze, MG			The 58-kDa cellular inhibitor of the double stranded RNA-dependent protein kinase requires the tetratricopeptide repeat 6 and DnaJ motifs to stimulate protein synthesis in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION FACTOR-II; ADENOVIRUS VAI RNA; TRANSLATIONAL CONTROL; MESSENGER-RNA; MALIGNANT TRANSFORMATION; MOLECULAR CHAPERONES; GENE-EXPRESSION; ALPHA-SUBUNIT; P68 KINASE; SNAP HELIX	Double stranded RNA-dependent protein kinase (PKR) is a double stranded RNA-activated, interferon-induced serine-threonine kinase that participates in both the antiviral and antiproliferative properties of interferon. We previously found that influenza virus inhibited PKR function by recruiting or activating a cellular inhibitor termed P58(IPK). The present study was undertaken to complement our earlier analyses, which demonstrated that P58(IPK) efficiently inhibited PKR autophosphorylation and activity in vitro. We now report that P58(IPK) down-regulates PKR and, in turn, stimulates protein synthetic rates inside the cell. Using transfection analysis, we show that P58(IPK) stimulates translation of secreted embryonic alkaline phosphatase reporter gene mRNA. Furthermore, we found that at least two regions of the P58(IPK) molecule were required for PKR inhibitory activity in COS-1 cells: (i) the DnaJ similarity region at the carboxyl terminus (amino acids 391-504); and (ii) the tetratricopeptide repeat 6 (TPR6) domain (amino acids 222-255) located in the middle of the P58(IPK) protein and within the eukaryotic protein synthesis initiation factor 2 alpha homology region. P58(IPK) variants lacking either one of these regions were unable to stimulate secreted embryonic alkaline phosphatase protein synthetic rates. Consistent with this data is the observation that the Delta TPR6 mutant (the P58(IPK) variant lacking the TPR6 motif) failed to block PKR activity in vitro. Based on these data and our earlier in vitro functional and PKR-P58(IPK) binding analyses, a revised model of PKR regulation by P58(IPK) is presented.	UNIV WASHINGTON, DEPT MICROBIOL, SCH MED, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle					NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00166] Funding Source: Medline; NIAID NIH HHS [AI 22646] Funding Source: Medline; NIGMS NIH HHS [T32 GM07270] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBER GN, 1995, MOL CELL BIOL, V15, P3138; BARBER GN, 1994, P NATL ACAD SCI USA, V91, P4278, DOI 10.1073/pnas.91.10.4278; BEATTIE E, 1991, VIROLOGY, V183, P419, DOI 10.1016/0042-6822(91)90158-8; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BLACK TL, 1989, J VIROL, V63, P2244, DOI 10.1128/JVI.63.5.2244-2251.1989; CARROLL K, 1993, J BIOL CHEM, V268, P12837; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; COLTHURST DR, 1987, EUR J BIOCHEM, V166, P357, DOI 10.1111/j.1432-1033.1987.tb13523.x; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; DAVIES MV, 1993, J VIROL, V67, P1688, DOI 10.1128/JVI.67.3.1688-1692.1993; Davis S, 1996, P NATL ACAD SCI USA, V93, P508, DOI 10.1073/pnas.93.1.508; EDERY I, 1989, CELL, V56, P303, DOI 10.1016/0092-8674(89)90904-5; GALABRU J, 1987, J BIOL CHEM, V262, P15538; Gale M, 1996, MOL CELL BIOL, V16, P4172; GHADGE GD, 1991, P NATL ACAD SCI USA, V88, P7140, DOI 10.1073/pnas.88.16.7140; GIANTINI M, 1989, J VIROL, V63, P2415, DOI 10.1128/JVI.63.6.2415-2421.1989; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; HOHFELD J, 1995, CELL, V83, P589; HOVANESSIAN AG, 1991, J INTERFERON RES, V11, P199, DOI 10.1089/jir.1991.11.199; JARAMILLO ML, 1995, CANCER INVEST, V13, P327, DOI 10.3109/07357909509094468; KATZE MG, 1987, EMBO J, V6, P689, DOI 10.1002/j.1460-2075.1987.tb04809.x; KATZE MG, 1996, TRANSLATIONAL CONTRO, P607; Katze Michael G., 1995, Trends in Microbiology, V3, P75, DOI 10.1016/S0966-842X(00)88880-0; KAUFMAN RJ, 1985, P NATL ACAD SCI USA, V82, P689, DOI 10.1073/pnas.82.3.689; KAUFMAN RJ, 1987, MOL CELL BIOL, V7, P1568, DOI 10.1128/MCB.7.4.1568; KEMP BE, 1991, METHOD ENZYMOL, V201, P287; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Korth MJ, 1996, GENE, V170, P181, DOI 10.1016/0378-1119(95)00883-7; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; LEE TG, 1994, MOL CELL BIOL, V14, P2331, DOI 10.1128/MCB.14.4.2331; LEE TG, 1992, J BIOL CHEM, V267, P14238; LEE TG, 1990, P NATL ACAD SCI USA, V87, P6208, DOI 10.1073/pnas.87.16.6208; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LI JH, 1991, EUR J BIOCHEM, V195, P41, DOI 10.1111/j.1432-1033.1991.tb15673.x; LLOYD RM, 1992, J VIROL, V66, P6878, DOI 10.1128/JVI.66.12.6878-6884.1992; MATHEWS MB, 1996, TRANSLATIONAL CONTRO, P505; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT, P1; OHKI M, 1986, J BIOL CHEM, V261, P1778; PETRYSHYN R, 1984, J BIOL CHEM, V259, P4736; Polyak SJ, 1996, J BIOL CHEM, V271, P1702, DOI 10.1074/jbc.271.3.1702; RICE AP, 1985, J VIROL, V54, P894, DOI 10.1128/JVI.54.3.894-898.1985; SCHNEIDER RJ, 1996, TRANSLATIONAL CONTRO, P575; SELIGER LS, 1992, VIROLOGY, V187, P202, DOI 10.1016/0042-6822(92)90308-C; SIKORSKI RS, 1993, MOL CELL BIOL, V13, P1212, DOI 10.1128/MCB.13.2.1212; SIKORSKI RS, 1991, COLD SH Q B, V56, P663; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; SMITH RL, 1995, GENE DEV, V9, P2903, DOI 10.1101/gad.9.23.2903; SVENSSON C, 1984, MOL CELL BIOL, V4, P736, DOI 10.1128/MCB.4.4.736; SVENSSON C, 1985, EMBO J, V4, P957, DOI 10.1002/j.1460-2075.1985.tb03724.x; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TZAMARIAS D, 1988, EMBO J, V7, P3547, DOI 10.1002/j.1460-2075.1988.tb03231.x; WILLIAMS BRG, 1995, SEMIN VIROL, V6, P191, DOI 10.1006/smvy.1995.0024; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	64	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28660	28666		10.1074/jbc.271.45.28660	http://dx.doi.org/10.1074/jbc.271.45.28660			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910500	hybrid			2022-12-27	WOS:A1996VU03300100
J	Akiyama, Y; Kihara, A; Tokuda, H; Ito, K				Akiyama, Y; Kihara, A; Tokuda, H; Ito, K			FtsH (HflB) is an ATP-dependent protease selectively acting on SecY and some other membrane proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI FTSH; PREPROTEIN TRANSLOCASE; GENE; MUTATIONS; INVOLVEMENT; DEGRADATION; COMPLEX; CELL; RECONSTITUTION; MITOCHONDRIA	The FtsH protein is a membrane-bound ATPase of Escherichia coli that was proposed to be involved in membrane protein assembly as well as degradation of some unstable proteins, SecY, a subunit of protein translocase, is FtsH dependently degraded in vivo when it fails to associate with its partner (the SecE protein), We constructed a series of mutants in which mutations were introduced into conserved residues in the two ATP binding consensus sequences or the zinc binding sequence of FtsH, We purified wild-type and mutant FtsH proteins by making use of a polyhistidine tag attached to their carboxyl termini, Complementation analysis and ATPase activity assays in vitro indicated that, of the two sets of ATP binding sequence motifs, the one located C-terminally (Al) is essential for ATPase activity and in two functioning of FtsH, Wild-type FtsH protein degraded purified SecY in an ATP hydrolysis-dependent manner in vitro. Mutant proteins without ATPase activity were inactive in proteolysis. A zinc binding motif mutant showed a decreased proteolytic activity. SecY and FtsH were cross linkable with each other in the membrane, provided that FtsH had an ATPase-inactivating mutation, These results demonstrate that FtsH binds to and degrades SecY, its Al motif and the zinc binding motif being important for the proteolytic activity. FtsH-dependent proteolysis was also demonstrated for SecY in crude membrane extracts, whereas a majority of other membrane proteins were not degraded, indicating that FtsH has high selectivity in protein degradation.	UNIV TOKYO, INST MOL & CELLULAR BIOSCI, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo	Akiyama, Y (corresponding author), KYOTO UNIV, DEPT CELL BIOL, INST VIRUS RES, KYOTO 60601, JAPAN.		KIHARA, AKIO/A-3802-2012	KIHARA, AKIO/0000-0001-5889-0788				AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AKIYAMA Y, 1990, BIOCHEM BIOPH RES CO, V167, P711, DOI 10.1016/0006-291X(90)92083-C; AKIYAMA Y, 1994, J BIOL CHEM, V269, P5218; AKIYAMA Y, 1994, J BIOL CHEM, V269, P5225; AKIYAMA Y, 1995, J BIOL CHEM, V270, P23485, DOI 10.1074/jbc.270.40.23485; AKIYAMA Y, 1985, EMBO J, V4, P3351, DOI 10.1002/j.1460-2075.1985.tb04088.x; AKIYAMA Y, 1995, MOL GEN GENET, V249, P202, DOI 10.1007/BF00290367; Arlt H, 1996, CELL, V85, P875, DOI 10.1016/S0092-8674(00)81271-4; BABA T, 1994, P NATL ACAD SCI USA, V91, P4539, DOI 10.1073/pnas.91.10.4539; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; CHAN KM, 1986, ANAL BIOCHEM, V157, P375, DOI 10.1016/0003-2697(86)90640-8; DOUVILLE K, 1995, J BIOL CHEM, V270, P20106, DOI 10.1074/jbc.270.34.20106; FLOWER AM, 1995, EMBO J, V14, P884, DOI 10.1002/j.1460-2075.1995.tb07070.x; Guelin E, 1996, FEBS LETT, V381, P42, DOI 10.1016/0014-5793(96)00074-9; HERMAN C, 1993, P NATL ACAD SCI USA, V90, P10861, DOI 10.1073/pnas.90.22.10861; HERMAN C, 1995, P NATL ACAD SCI USA, V92, P3516, DOI 10.1073/pnas.92.8.3516; HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X; IOST I, 1995, EMBO J, V14, P3252, DOI 10.1002/j.1460-2075.1995.tb07328.x; KIHARA A, 1995, P NATL ACAD SCI USA, V92, P4532, DOI 10.1073/pnas.92.10.4532; KIHARA A, 1996, IN PRESS EMBO J, V15; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MATSUYAMA S, 1990, FEBS LETT, V269, P96, DOI 10.1016/0014-5793(90)81128-B; MURPHY CK, 1994, P NATL ACAD SCI USA, V91, P2557, DOI 10.1073/pnas.91.7.2557; NAKAI T, 1995, MOL CELL BIOL, V15, P4441; NISHIYAMA K, 1994, EMBO J, V13, P3272, DOI 10.1002/j.1460-2075.1994.tb06628.x; PAJIC A, 1994, FEBS LETT, V353, P201, DOI 10.1016/0014-5793(94)01046-3; SHIBA K, 1984, EMBO J, V3, P631, DOI 10.1002/j.1460-2075.1984.tb01859.x; SHIMOIKE T, 1995, J BIOL CHEM, V270, P5519, DOI 10.1074/jbc.270.10.5519; Silhavy T. J., 1984, EXPT GENE FUSIONS; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; TAURA T, 1993, J BACTERIOL, V175, P7771, DOI 10.1128/JB.175.24.7771-7775.1993; TAURA T, 1994, MOL GEN GENET, V243, P261, DOI 10.1007/BF00301061; TOMOYASU T, 1993, J BACTERIOL, V175, P1352, DOI 10.1128/JB.175.5.1352-1357.1993; TOMOYASU T, 1995, EMBO J, V14, P2551, DOI 10.1002/j.1460-2075.1995.tb07253.x; TOMOYASU T, 1993, J BACTERIOL, V175, P1344, DOI 10.1128/JB.175.5.1344-1351.1993; Weber ER, 1996, MOL BIOL CELL, V7, P307, DOI 10.1091/mbc.7.2.307	37	136	138	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31196	31201		10.1074/jbc.271.49.31196	http://dx.doi.org/10.1074/jbc.271.49.31196			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940120	hybrid			2022-12-27	WOS:A1996VW68600031
J	Contreras, JA; Karlsson, M; Osterlund, T; Laurell, H; Svensson, A; Holm, C				Contreras, JA; Karlsson, M; Osterlund, T; Laurell, H; Svensson, A; Holm, C			Hormone-sensitive lipase is structurally related to acetylcholinesterase, bile salt-stimulated lipase, and several fungal lipases - Building of a three-dimensional model for the catalytic domain of hormone-sensitive lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CANDIDA-RUGOSA LIPASE; GEOTRICHUM-CANDIDUM; LIPOPROTEIN-LIPASE; PANCREATIC LIPASE; ADIPOSE-TISSUE; ACTIVE-SITE; SEQUENCE; PROTEIN; IDENTIFICATION	Hormone-sensitive Lipase is the key enzyme in the mobilization of fatty acids from adipose tissue, thereby playing a crucial role in the overall energy homeostasis in mammals, Its activity is stimulated by catecholamines through cAMP-dependent phosphorylation of a single serine, a process that is prevented by insulin, This regulatory property is unique to this enzyme among all known Lipases and has been acquired during evolution through insertion of a regulatory module into an ancestral Lipase, Sequence alignments have failed to detect significant homology between hormone-sensitive lipase and the rest of the mammalian lipases and esterases, to which this enzyme is only very distantly related, In the present work, Fee report the finding of a remarkable secondary structure homology between hormone-sensitive Lipase and the enzymes from a superfamily of esterases and lipases that includes acetylcholinesterase, bile salt-stimulated lipase, and several fungal lipases. This finding, based on the identification of the secondary structure elements in the hormone-sensitive lipase sequence, has allowed us to construct a three-dimensional model for the catalytic domain of hormone-sensitive Lipase, The model reveals the topological organization, predicts the components of the catalytic triad, suggests a three-dimensional localization of the regulatory module, and provides a valuable tool for the future study of structural and functional aspects of this metabolically important enzyme.	LUND UNIV,DEPT MOL BIOPHYS,S-22100 LUND,SWEDEN	Lund University	Contreras, JA (corresponding author), LUND UNIV,DEPT CELL & MOL BIOL,POB 94,S-22100 LUND,SWEDEN.			Laurell, Henrik/0000-0001-7328-935X; Osterlund, Torben/0000-0002-2047-767X				AUYOUNG J, 1992, P NATL ACAD SCI USA, V89, P4094, DOI 10.1073/pnas.89.9.4094; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CYGLER M, 1993, PROTEIN SCI, V2, P366; DEREWENDA ZS, 1993, ADV PROTEIN CHEM, V45, P1; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FREDRIKSON G, 1981, J BIOL CHEM, V256, P6311; GARTON AJ, 1990, EUR J BIOCHEM, V191, P245, DOI 10.1111/j.1432-1033.1990.tb19116.x; GARTON AJ, 1989, EUR J BIOCHEM, V179, P249, DOI 10.1111/j.1432-1033.1989.tb14548.x; GJELLESVIK DR, 1994, EUR J BIOCHEM, V226, P603, DOI 10.1111/j.1432-1033.1994.tb20086.x; GROCHULSKI P, 1994, PROTEIN SCI, V3, P82; GROCHULSKI P, 1993, J BIOL CHEM, V268, P12843; Guex N., 1996, Experientia (Basel), V52, pA26; HEMILA H, 1994, BBA-LIPID LIPID MET, V1210, P249, DOI 10.1016/0005-2760(94)90129-5; HOLM C, 1987, BIOCHEM BIOPH RES CO, V148, P99, DOI 10.1016/0006-291X(87)91081-3; HOLM C, 1988, SCIENCE, V241, P1503, DOI 10.1126/science.3420405; HOLM C, 1994, FEBS LETT, V344, P234, DOI 10.1016/0014-5793(94)00403-X; LANGIN D, 1993, P NATL ACAD SCI USA, V90, P4897, DOI 10.1073/pnas.90.11.4897; LANGIN D, 1993, TRENDS BIOCHEM SCI, V18, P466, DOI 10.1016/0968-0004(93)90007-A; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI ZG, 1994, GENOMICS, V24, P259, DOI 10.1006/geno.1994.1614; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Osterlund T, 1996, BIOCHEM J, V319, P411, DOI 10.1042/bj3190411; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SCHRAG JD, 1993, J MOL BIOL, V230, P575, DOI 10.1006/jmbi.1993.1171; STRALFORS P, 1984, P NATL ACAD SCI-BIOL, V81, P3317, DOI 10.1073/pnas.81.11.3317; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TILBEURGH H, 1992, NATURE, V359, P159; UPPENBERG J, 1994, STRUCTURE, V2, P293, DOI 10.1016/S0969-2126(00)00031-9; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; VERNET T, 1993, J BIOL CHEM, V268, P26212; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; YEAMAN SJ, 1990, BIOCHIM BIOPHYS ACTA, V1052, P128, DOI 10.1016/0167-4889(90)90067-N	35	84	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31426	31430		10.1074/jbc.271.49.31426	http://dx.doi.org/10.1074/jbc.271.49.31426			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940153	hybrid			2022-12-27	WOS:A1996VW68600064
J	Finegold, AA; Shatwell, KP; Segal, AW; Klausner, RD; Dancis, A				Finegold, AA; Shatwell, KP; Segal, AW; Klausner, RD; Dancis, A			Intramembrane bis-heme motif for transmembrane electron transport conserved in a yeast iron reductase and the human NADPH oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; SACCHAROMYCES-CEREVISIAE; CYTOCHROME-B; FERRIC REDUCTASE; GENE; PHAGOCYTES; LOCATION; PROTEIN; SYSTEM	A plasma membrane iron reductase, required for cellular iron acquisition by Saccharomyces cerevisiae, and the human phagocytic NADPH oxidase, implicated in cellular defense, contain low potential plasma membrane b cytochromes that share elements of structure and function, Four critical histidine residues in the FRE1 protein of the iron reductase were identified by site-directed mutagenesis, Individual mutation of each histidine to alanine eliminated the entire heme spectrum without affecting expression of the apoprotein, documenting the specificity of the requirement for the histidine residues, These critical residues are predicted to coordinate a bis-heme structure between transmembrane domains of the FRE1 protein. The histidine residues are conserved in the related gp91(phox) protein of the NADPH oxidase of human granulocytes, predicting the sites of heme coordination in that protein complex, Similarly spaced histidine residues have also been implicated in heme binding by organelle b cytochromes with little overall sequence similarity to the plasma membrane b cytochromes. This bis-heme motif may play a role in transmembrane electron transport by distinct families of polytopic b cytochromes.	NICHHD,CELL BIOL & METAB BRANCH,NIH,BETHESDA,MD 20892; UNIV LONDON UNIV COLL,SCH MED,DEPT MED,LONDON WC1E 6JJ,ENGLAND	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of London; University College London; UCL Medical School				Segal, Anthony/0000-0001-7602-9043	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; CLAROS MG, 1995, EUR J BIOCHEM, V228, P762, DOI 10.1111/j.1432-1033.1995.0762m.x; CRAMER WA, 1990, ENERGY TRANSDUCTION, P330; CROSS AR, 1995, J BIOL CHEM, V270, P17075, DOI 10.1074/jbc.270.29.17075; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; Groom QJ, 1996, PLANT J, V10, P515, DOI 10.1046/j.1365-313X.1996.10030515.x; HURST JK, 1991, J BIOL CHEM, V266, P1627; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lesuisse E, 1996, J BIOL CHEM, V271, P13578, DOI 10.1074/jbc.271.23.13578; LESUISSE E, 1989, J GEN MICROBIOL, V135, P257; LI F, 1994, BLOOD, V84, P53, DOI 10.1182/blood.V84.1.53.bloodjournal84153; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; QUINN MT, 1992, J BIOL CHEM, V267, P7303; ROMAN DG, 1993, MOL CELL BIOL, V13, P4342, DOI 10.1128/MCB.13.7.4342; Roos D, 1996, BLOOD, V87, P1663; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SARASTE M, 1984, FEBS LETT, V166, P367, DOI 10.1016/0014-5793(84)80114-3; Segal A W, 1993, Immunodeficiency, V4, P167; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; Shatwell KP, 1996, J BIOL CHEM, V271, P14240, DOI 10.1074/jbc.271.24.14240; SIKORSKI RS, 1989, GENETICS, V122, P19; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7; THRASHER AJ, 1995, BLOOD, V86, P761, DOI 10.1182/blood.V86.2.761.bloodjournal862761; WIDGER WR, 1984, P NATL ACAD SCI-BIOL, V81, P674, DOI 10.1073/pnas.81.3.674	27	154	161	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31021	31024		10.1074/jbc.271.49.31021	http://dx.doi.org/10.1074/jbc.271.49.31021			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940093	hybrid			2022-12-27	WOS:A1996VW68600004
J	Carel, K; Kummer, JL; Schubert, C; Leitner, W; Heidenreich, KA; Draznin, B				Carel, K; Kummer, JL; Schubert, C; Leitner, W; Heidenreich, KA; Draznin, B			Insulin stimulates mitogen-activated protein kinase by a Ras-independent pathway in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MEK KINASE; NETWORK; CELLS; REQUIREMENT; COMPONENTS; CASCADE; P21RAS	To characterize tissue-specific differences in insulin signaling, we compared the mechanisms of mitogen-activated protein (MAP) kinase activation by insulin in the mitogenically active 3T3-L1 fibroblasts with the metabolically active 3T3-L1 adipocytes. In both cell lines, insulin significantly increased p21(ras). GTP loading (1.5-2-fold) and MAP kinase activity (5-8-fold). Inhibition of Ras farnesylation with lovastatin blocked activation of p21(ras) and Raf-1 kinase in both 3T3-L1 fibroblasts and 3T3-L1 adipocytes. In 3T3-L1 fibroblasts, this was accompanied by an inhibition of the stimulatory effect of insulin on MAP kinase. In contrast, in 3T3-L1 adipocytes, despite an inhibition of activation of p21(ras) and Raf-1 by lovastatin, insulin continued to stimulate MAP kinase activity. Fractionation of the cell lysates on the FPLC Mono-Q column revealed that lovastatin inhibited insulin stimulation of ERK2 (and, to a lesser extent, ERK1) in 3T3-L1 fibroblasts and had no effect on the insulin-stimulated ERK2 in 3T3-L1 adipocytes. These results demonstrate an important distinction between the mechanism of insulin signaling in the metabolically and mitogenically active cells. Insulin activates MAP kinase by the Pas-dependent pathway in the 3T3-L1 fibroblasts and by the Pas-independent pathway in the 3T3-L1 adipocytes.	VET AFFAIRS MED CTR,SECT ENDOCRINOL 111H,MED RES SERV,DENVER,CO 80220; VET AFFAIRS MED CTR,DEPT MED,DENVER,CO 80220; VET AFFAIRS MED CTR,DEPT PHARMACOL,DENVER,CO 80220; UNIV COLORADO,HLTH SCI CTR,DENVER,CO 80220	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								AHN NG, 1991, J BIOL CHEM, V266, P4220; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DePaolo D, 1996, MOL CELL BIOL, V16, P1450; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DRAZNIN B, 1993, J BIOL CHEM, V268, P19998; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HAYSTEAD CMM, 1994, J BIOL CHEM, V269, P12804; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; REUSCH JEB, 1995, J BIOL CHEM, V270, P2036, DOI 10.1074/jbc.270.5.2036; Schubert C, 1996, J BIOL CHEM, V271, P15311, DOI 10.1074/jbc.271.26.15311; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; WHITE MF, 1994, J BIOL CHEM, V269, P1; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	29	37	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30625	30630		10.1074/jbc.271.48.30625	http://dx.doi.org/10.1074/jbc.271.48.30625			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940037	hybrid			2022-12-27	WOS:A1996VV15800054
J	Hamilton, TG; Flynn, GC				Hamilton, TG; Flynn, GC			Cer1p, a novel hsp70-related protein required for posttranslational endoplasmic reticulum translocation in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; SACCHAROMYCES-CEREVISIAE; CARBOXYPEPTIDASE-Y; SEC PROTEINS; MEMBRANES; TRANSPORT; HOMOLOG; GENE; BIP; INVERTASE	Proteins enter the secretory pathway by translocation across the endoplasmic reticulum (ER) membrane, In Saccharomyces cerevisiae, import of proteins into the ER occurs both cotranslationally and posttranslationally, Presumably, the cotranslational targeting to the ER membrane is directed by the signal recognition particle, as demonstrated in other eukaryotic systems, The deletion of a gene, called CER1, inhibits the translocation of proteins that enter the ER posttranslationally, but not those that enter cotranslationally. This translocation defect is more pronounced at lower temperatures. A strain possessing a null mutation of CER1 in combination with a kar2 temperature-sensitive mutation displays synthetic growth defects, whereas overexpression of the ER DnaJ homolog Scj1p suppresses the translocation defect in cer1 Delta strains, CER1 is predicted to encode a 100-kDa polypeptide, residing in the ER lumen that is related to the hsp70 family of molecular chaperones.	UNIV OREGON,INST MOL BIOL,EUGENE,OR 97403	University of Oregon								BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BLUMBERG H, 1991, NATURE, V349, P627, DOI 10.1038/349627a0; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; CHIRICO WJ, 1988, NATURE, V332, P800; Craven RA, 1996, EMBO J, V15, P2640, DOI 10.1002/j.1460-2075.1996.tb00624.x; DAVIS NG, 1993, J CELL BIOL, V122, P53, DOI 10.1083/jcb.122.1.53; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HANSEN W, 1988, J CELL BIOL, V106, P1075, DOI 10.1083/jcb.106.4.1075; JOHNSSON N, 1994, EMBO J, V13, P2686, DOI 10.1002/j.1460-2075.1994.tb06559.x; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; NGSEE JK, 1989, MOL CELL BIOL, V9, P3400, DOI 10.1128/MCB.9.8.3400; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; RASMUSSEN SW, 1994, YEAST, V10, pS69, DOI 10.1002/yea.320100009; RASSOW J, 1995, TRENDS CELL BIOL, V5, P207, DOI 10.1016/S0962-8924(00)89001-7; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHLENSTEDT G, 1995, J CELL BIOL, V129, P979, DOI 10.1083/jcb.129.4.979; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WANG TF, 1993, J BIOL CHEM, V268, P26049; WAY JC, 1993, CELL, V74, P5	30	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30610	30613		10.1074/jbc.271.48.30610	http://dx.doi.org/10.1074/jbc.271.48.30610			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940034	hybrid			2022-12-27	WOS:A1996VV15800051
J	Herrero, I; SanchezPrieto, J				Herrero, I; SanchezPrieto, J			cAMP-dependent facilitation of glutamate release by beta-adrenergic receptors in cerebrocortical nerve terminals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; PROTEIN-KINASE; CYCLIC-AMP; SYNAPTIC TRANSMISSION; HIPPOCAMPAL-NEURONS; ARACHIDONIC-ACID; CALCIUM CHANNELS; RAT HIPPOCAMPUS; DENTATE GYRUS; PHOSPHORYLATION	We have investigated the presence of a cAMP-protein kinase A-dependent pathway in cerebrocortical nerve terminals and its role in the modulation of glutamate release. The activation of adenylyl cyclase with forskolin enhances intrasynaptosomal cAMP and induces Ca2+-dependent glutamate release. The membrane permeant analogue dibutyryl cAMP mimics this facilitatory effect, whereas the inactive compound 1,9-dideoxyforskolin is without effect. This cAMP-induced facilitation is consistent with the induction of spontaneous action potentials that are abolished by the Nat channel blocker tetrodotoxin and by reducing nerve terminal excitability with arachidonic acid. We have also demonstrated that a beta-adrenergic receptor is linked to this pathway because isoproterenol increases cAMP levels and glutamate release, and both actions are antagonized by the receptor antagonist propanolol and the protein kinase A inhibitors H89 and 8-chloroadenosine 3',5'-monophosphorothioate ((R(p))-isomer). The finding that the increase in cytoplasmic free Ca2+ concentration induced by synaptic activity reduces the concentration of agonist required to maximally activate adenylyl cyclase suggests that this enzyme may act as a coincidence detector, integrating glutamatergic neurotransmission and noradrenaline release.	UNIV COMPLUTENSE MADRID, FAC VET, DEPT BIOQUIM, E-28040 MADRID, SPAIN	Complutense University of Madrid				Sanchez-Prieto, Jose/0000-0002-8513-3501				BARRIE AP, 1991, J NEUROCHEM, V57, P1398, DOI 10.1111/j.1471-4159.1991.tb08306.x; BOLSHAKOV VY, 1995, NEUROPHARMACOLOGY, V34, P1581, DOI 10.1016/0028-3908(95)00127-R; CHAVEZNORIEGA LE, 1994, J NEUROSCI, V14, P310; CHAVEZNORIEGA LE, 1992, BRAIN RES, V574, P85, DOI 10.1016/0006-8993(92)90803-H; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COLWELL CS, 1995, J NEUROSCI, V15, P1704, DOI 10.1523/JNEUROSCI.15-03-01704.1995; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; DALY JW, 1982, J NEUROCHEM, V38, P532, DOI 10.1111/j.1471-4159.1982.tb08660.x; DUNWIDDIE TV, 1980, BRIT J PHARMACOL, V69, P59, DOI 10.1111/j.1476-5381.1980.tb10883.x; FOEHRING RC, 1989, J NEUROPHYSIOL, V61, P245, DOI 10.1152/jn.1989.61.2.245; FRASER DD, 1993, NEURON, V11, P633, DOI 10.1016/0896-6273(93)90075-3; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; FYKSE EM, 1995, J NEUROSCI, V15, P2385, DOI 10.1523/JNEUROSCI.15-03-02385.1995; GRAY R, 1987, NATURE, V327, P620, DOI 10.1038/327620a0; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAAS HL, 1983, NATURE, V302, P432, DOI 10.1038/302432a0; HELL JW, 1995, EMBO J, V14, P3036, DOI 10.1002/j.1460-2075.1995.tb07306.x; HERRERO I, 1991, J NEUROCHEM, V57, P718, DOI 10.1111/j.1471-4159.1991.tb03805.x; HERRERO I, 1991, NEUROSCI LETT, V126, P41, DOI 10.1016/0304-3940(91)90366-2; HERRERO I, 1992, NATURE, V360, P163, DOI 10.1038/360163a0; HOPKINS WF, 1988, J NEUROPHYSIOL, V59, P667, DOI 10.1152/jn.1988.59.2.667; Huang CC, 1996, J NEUROSCI, V16, P1026; Huang YY, 1996, NEURON, V16, P611, DOI 10.1016/S0896-6273(00)80080-X; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; MADISON DV, 1982, NATURE, V299, P636, DOI 10.1038/299636a0; MAGISTRETTI PJ, 1984, NATURE, V308, P280, DOI 10.1038/308280a0; MCMAHON HT, 1991, J NEUROCHEM, V56, P86, DOI 10.1111/j.1471-4159.1991.tb02566.x; MCMAHON HT, 1992, J BIOL CHEM, V267, P21338; MONS N, 1995, P NATL ACAD SCI USA, V92, P8473, DOI 10.1073/pnas.92.18.8473; MOORE RY, 1979, ANNU REV NEUROSCI, V2, P113, DOI 10.1146/annurev.ne.02.030179.000553; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; PARFITT KD, 1992, HIPPOCAMPUS, V2, P59, DOI 10.1002/hipo.450020108; Raman IM, 1996, NEURON, V16, P415, DOI 10.1016/S0896-6273(00)80059-8; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; SMELLIE FW, 1979, LIFE SCI, V24, P2475, DOI 10.1016/0024-3205(79)90458-2; STANTON PK, 1985, BRAIN RES, V361, P276, DOI 10.1016/0006-8993(85)91299-5; TIBBS GR, 1989, J NEUROCHEM, V53, P1693, DOI 10.1111/j.1471-4159.1989.tb09232.x; VERHAGE M, 1991, NEURON, V6, P517, DOI 10.1016/0896-6273(91)90054-4; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482	43	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30554	30560		10.1074/jbc.271.48.30554	http://dx.doi.org/10.1074/jbc.271.48.30554			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940026	hybrid			2022-12-27	WOS:A1996VV15800043
J	RodriguezTarduchy, G; Sahuquillo, AG; Alarcon, B; Bragado, R				RodriguezTarduchy, G; Sahuquillo, AG; Alarcon, B; Bragado, R			Apoptosis but not other activation events is inhibited by a mutation in the transmembrane domain of T cell receptor beta that impairs CD3 xi association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUREUS ENTEROTOXIN-B; TANDEM SH2 DOMAINS; ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; ZETA-CHAIN; FAS-LIGAND; GENETIC RECONSTITUTION; ENDOPLASMIC-RETICULUM; TCR/CD3 COMPLEX; ZAP-70 BIND	The transmembrane domain of T cell receptor (TCR) beta contains a conserved immunoreceptor tyrosine-based activation-like motif consisting of a duplicated YXXL sequence. The motif is also present in TCR gamma, the equivalent chain to TCR beta in gamma delta T lymphocytes but is absent in TCR alpha and TCR delta. To determine the putative role of this sequence in TCR-CD3 complex assembly and signal transduction, a TCR beta chain cDNA was mutated in the C-terminal tyrosine of the moth, cloned in an expression vector, and transfected into TCR beta-negative Jurkat cells. Transfectants of the mutated chain (MUT) expressed, on average, much less TCR-CD3 complex on the membrane than wild type TCR beta transfectants. Radiolabeling experiments suggested that the mutation caused a loose association of the CD36 chain resulting in a defective assembly. However, stimulation of high TCR-CD3 expressing wild type and MUT clones with monoclonal antibodies and Staphylococcus aureus enterotoxin B resulted in similar levels of CD25 and CD69 expression, interleukin-2 secretion, and TCR CD3 complex downregulation. By contrast, MUT cells were clearly resistant to activation-induced cell death, and they did not express CD95-ligand upon activation. These results suggest a differentiated intracellular signaling pathway leading to apoptosis in which Tyr-TM11 of the immunoreceptor tyrosine-based activation motif-like motif and CD3 zeta appear to be involved.	UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOL SEVERO OCHOA,MADRID 28049,SPAIN; FDN JIMENEZ DIAZ,DEPT IMMUNOL,MADRID 28040,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)			Alarcon, Balbino/N-9648-2016	Alarcon, Balbino/0000-0001-7820-1070				ALARCON B, 1988, J BIOL CHEM, V263, P2953; ALCOVER A, 1988, EMBO J, V7, P1973, DOI 10.1002/j.1460-2075.1988.tb03035.x; AOE T, 1995, J EXP MED, V181, P1881, DOI 10.1084/jem.181.5.1881; BLUMBERG RS, 1991, EUR J IMMUNOL, V21, P473, DOI 10.1002/eji.1830210233; BRUCKER T, 1995, J EXP MED, V181, P1653; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CAMBIER JC, 1992, CURR OPIN IMMUNOL, V4, P257, DOI 10.1016/0952-7915(92)90074-O; Campbell K S, 1994, Semin Immunol, V6, P393, DOI 10.1006/smim.1994.1049; CHAN AC, 1992, CURR OPIN IMMUNOL, V4, P246, DOI 10.1016/0952-7915(92)90072-M; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; ETTINGER R, 1995, J IMMUNOL, V154, P4302; FINKE JH, 1993, CANCER RES, V53, P5613; GRUPP SA, 1995, J EXP MED, V181, P161, DOI 10.1084/jem.181.1.161; HALL C, 1991, INT IMMUNOL, V3, P359, DOI 10.1093/intimm/3.4.359; HEWITT CRA, 1992, J EXP MED, V175, P1493, DOI 10.1084/jem.175.6.1493; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876; MALISSEN B, 1993, CURR OPIN IMMUNOL, V5, P324, DOI 10.1016/0952-7915(93)90049-X; MANOLIOS N, 1991, EMBO J, V10, P1643, DOI 10.1002/j.1460-2075.1991.tb07687.x; MANOLIOS N, 1994, EUR J IMMUNOL, V24, P84, DOI 10.1002/eji.1830240114; NAKAGOMI H, 1993, CANCER RES, V53, P5610; NIEDERGANG F, 1995, J BIOL CHEM, V270, P12839, DOI 10.1074/jbc.270.21.12839; NOCENTINI G, 1995, EUR J IMMUNOL, V25, P1405, DOI 10.1002/eji.1830250540; PLEIMAN CM, 1994, J IMMUNOL, V152, P2837; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; SALMERON A, 1995, J IMMUNOL, V154, P1675; SANCHO J, 1989, J BIOL CHEM, V264, P20760; SHINKAI Y, 1995, IMMUNITY, V2, P401; SHORES EW, 1994, SCIENCE, V266, P1047, DOI 10.1126/science.7526464; STEVENS TL, 1994, J IMMUNOL, V152, P4397; STRAUS DB, 1993, J EXP MED, V178, P1523, DOI 10.1084/jem.178.5.1523; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; VIGNAUX F, 1995, J EXP MED, V181, P781, DOI 10.1084/jem.181.2.781; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x; YAO XR, 1995, J IMMUNOL, V155, P652	41	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30417	30425		10.1074/jbc.271.48.30417	http://dx.doi.org/10.1074/jbc.271.48.30417			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940006	hybrid			2022-12-27	WOS:A1996VV15800023
J	Ryden, M; Imamura, T; Jornvall, H; Belluardo, N; Neveu, I; Trupp, M; Okadome, T; tenDijke, P; Ibanez, CF				Ryden, M; Imamura, T; Jornvall, H; Belluardo, N; Neveu, I; Trupp, M; Okadome, T; tenDijke, P; Ibanez, CF			A novel type I receptor serine-threonine kinase predominantly expressed in the adult central nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GROWTH-FACTOR; TGF-BETA RECEPTOR; MEMBRANE PROTEOGLYCAN; HETEROMERIC COMPLEX; SIGNALING RECEPTORS; ACTIVIN; CLONING; CELLS; BETAGLYCAN; NEURONS	Receptor serine-threonine kinases (RSTK) mediate inhibitory as well as stimulatory signals for growth and differentiation by binding to members of the transforming growth factor-beta (TGF-beta) superfamily. Over 12 different RSTKs have been isolated so far, displaying wide expression in peripheral tissues and in the nervous system. Here we report the isolation and characterization of a novel type I RSTK termed activin receptor-like kinase-7 (ALK-7) that, unlike other members of this receptor family, is predominantly expressed in the adult central nervous system. The ALK-7 gene encodes a 55-kDa cell-surface protein that exhibits up to 78% amino acid sequence identity in the kinase domain to previously isolated type I receptors for TGF-beta and activin. In the extracellular domain, however, ALK-7 is more divergent, displaying comparable similarities with all members of the ALK subfamily. RNase protection and in situ hybridization studies demonstrated a highly specific mRNA distribution restricted to neurons in several regions of the adult rat central nervous system, including cerebellum, hippocampus, and nuclei of the brainstem. Receptor reconstitution and cross-linking experiments indicated that ALK-7 can form complexes with type II RSTKs for TGF-beta and activin in a ligand-dependent manner, although direct binding of ALK-7 to ligand in these complexes could not be demonstrated. The specific expression pattern of ALK-7, restricted to the postnatal central nervous system, indicates that this receptor may play an important role in the maturation and maintenance of several neuronal subpopulations.	KAROLINSKA INST,MOL NEUROBIOL LAB,DEPT NEUROSCI,S-17177 STOCKHOLM,SWEDEN; LUDWIG INST CANC RES,CTR BIOMED,S-75124 UPPSALA,SWEDEN; UNIV CATANIA,IST FISIOL UMANA,I-95125 CATANIA,ITALY	Karolinska Institutet; Ludwig Institute for Cancer Research; University of Catania			Neveu, Isabelle/K-2387-2015; Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; Neveu, Isabelle/0000-0003-4665-7844				Arenas E, 1995, NEURON, V15, P1465, DOI 10.1016/0896-6273(95)90024-1; Arenas E, 1996, MOL PSYCHIATR, V1, P179; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BAARENDS WM, 1994, DEVELOPMENT, V120, P189; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CONSTAM DB, 1994, EUR J NEUROSCI, V6, P766, DOI 10.1111/j.1460-9568.1994.tb00988.x; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FLANDERS KC, 1991, DEVELOPMENT, V113, P183; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; ICHIJO H, 1993, BIOCHEM BIOPH RES CO, V194, P1508, DOI 10.1006/bbrc.1993.1995; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRIEGLSTEIN K, 1995, INT J DEV NEUROSCI, V13, P301, DOI 10.1016/0736-5748(94)00062-8; LEE SJ, 1991, P NATL ACAD SCI USA, V88, P4250, DOI 10.1073/pnas.88.10.4250; LEGRAND J, 1979, TRENDS NEUROSCI, V2, P234, DOI 10.1016/0166-2236(79)90091-2; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIU F, 1995, MOL CELL BIOL, V15, P3479; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; Mehler M. F., 1993, Society for Neuroscience Abstracts, V19, P416; Neveu I, 1996, J CELL BIOL, V133, P631, DOI 10.1083/jcb.133.3.631; PELTON RW, 1991, J CELL BIOL, V115, P1091, DOI 10.1083/jcb.115.4.1091; PELTON RW, 1990, DEVELOPMENT, V110, P609; POULSEN KT, 1994, NEURON, V13, P1245, DOI 10.1016/0896-6273(94)90062-0; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; SALAZARGRUESO EF, 1991, NEUROREPORT, V2, P505, DOI 10.1097/00001756-199109000-00002; SAWCHENKO PE, 1988, NATURE, V334, P615, DOI 10.1038/334615a0; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1993, ONCOGENE, V8, P2879; TOMIZAWA K, 1995, MOL BRAIN RES, V28, P122, DOI 10.1016/0169-328X(94)00199-O; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; VIVIEN D, 1995, EXP CELL RES, V221, P60, DOI 10.1006/excr.1995.1352; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WHITTEMORE SR, 1993, BRAIN RES, V615, P27, DOI 10.1016/0006-8993(93)91111-5; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P1995; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	46	66	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30603	30609		10.1074/jbc.271.48.30603	http://dx.doi.org/10.1074/jbc.271.48.30603			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940033	hybrid			2022-12-27	WOS:A1996VV15800050
J	Liu, L; Jefferson, AB; Zhang, XL; Norris, FA; Majerus, PW; Krystal, G				Liu, L; Jefferson, AB; Zhang, XL; Norris, FA; Majerus, PW; Krystal, G			A novel phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase associates with the interleukin-3 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTORS; INOSITOL POLYPHOSPHATE 5-PHOSPHATASE; TYROSINE-PHOSPHORYLATED PROTEINS; SIGNAL-TRANSDUCTION; ERYTHROPOIETIN RECEPTOR; PHOSPHOINOSITIDE 3-KINASE; HEMATOPOIETIC-CELLS; GENE FAMILY; KINASE	To gain insight into the intracellular signaling cascades that are activated by the binding of interleukin-3 (IL-3) to its target cells, we have embarked on the identification of proteins that are associated with the IL-3 receptor (IL-3R). In a previous study we reported that a 110-kDa serine/threonine protein kinase is constitutively associated with the IL-3R and activated following IL-3 stimulation, We now report that a phosphatidylinositol-3,4,5-trisphosphate (PtdIns-3,4,5-P-3) 5-phosphatase (5-ptase) is also constitutively associated with the IL-3R. This 5-ptase is magnesium-dependent and removes the B-position phosphate from PtdIns-3,4,5-P-3 but does not metabolize PtdIns-4,5-P-2, inositol (Ins)-1,3,4,5-P-4, or Ins-1,4,5-P-3. This substrate specificity distinguishes it from any previously characterized 5-ptase. Interestingly, it may be bound indirectly via phosphatidylinositol 3-kinase (PI 3-kinase), another enzyme that is constitutively bound to the IL-3R. However, unlike PI 3-kinase which becomes activated following IL-3 stimulation, this receptor-associated 5-ptase activity does not increase following IL-3 stimulation, and its primary function may be to keep the principal in vivo product of PI 3-kinase, PtdIns-3,4,5-P-3, at low levels in unstimulated cells, to terminate the PI 3-kinase signal following IL-3 stimulation or to metabolize PtdIns-3,4,5-P-3 to a metabolically active second messenger, i.e. PtdIns-3,4-P-2.	UNIV BRITISH COLUMBIA, BRITISH COLUMBIA CANC AGCY, TERRY FOX LAB, VANCOUVER, BC V5Z 1L3, CANADA; UNIV WASHINGTON, SCH MED, ST LOUIS, MO 63110 USA	British Columbia Cancer Agency; University of British Columbia; Washington University (WUSTL)				Krystal, Gerald/0000-0002-1961-6281	NHLBI NIH HHS [HL16634, HL55672] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016634, R37HL016634, R01HL055672] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DAMEN JE, 1993, BLOOD, V81, P3204; DAMEN JE, 1993, BLOOD, V82, P2296; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DURONIO V, 1992, J BIOL CHEM, V267, P21856; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; GOLD MR, 1994, J BIOL CHEM, V269, P5403; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; HARPUR AG, 1992, ONCOGENE, V7, P1347; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; ISFORT R, 1988, J BIOL CHEM, V263, P19203; ISFORT RJ, 1988, P NATL ACAD SCI USA, V85, P7982, DOI 10.1073/pnas.85.21.7982; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; JACKSON SP, 1995, EMBO J, V14, P4490, DOI 10.1002/j.1460-2075.1995.tb00128.x; JEFFERSON AB, 1995, J BIOL CHEM, V270, P9370, DOI 10.1074/jbc.270.16.9370; KANAKURA Y, 1990, BLOOD, V76, P706; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KRYSTAL G, 1991, HEMATOL PATHOL, V5, P141; LINNEKIN D, 1990, BIOCHEM J, V271, P317, DOI 10.1042/bj2710317; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LIU L, 1994, J BIOL CHEM, V269, P16774; LIU L, 1995, J BIOL CHEM, V270, P22422, DOI 10.1074/jbc.270.38.22422; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; MITCHELL CA, 1989, J BIOL CHEM, V264, P8873; MIYAJIMA A, 1993, BLOOD, V82, P1960; MUI ALF, 1992, J BIOL CHEM, V267, P16523; NORRIS FA, 1994, J BIOL CHEM, V269, P8716; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OKUDA K, 1992, BLOOD, V79, P2880; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RAO P, 1995, J BIOL CHEM, V270, P6886, DOI 10.1074/jbc.270.12.6886; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SORENSEN P, 1989, J BIOL CHEM, V264, P19253; SORENSEN PHB, 1989, BLOOD, V73, P406; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOKER A, 1995, J BIOL CHEM, V270, P29525, DOI 10.1074/jbc.270.49.29525; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; Woscholski R, 1995, J BIOL CHEM, V270, P31001, DOI 10.1074/jbc.270.52.31001; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; ZHANG XL, 1995, P NATL ACAD SCI USA, V92, P4853, DOI 10.1073/pnas.92.11.4853; ZHU XY, 1994, J BIOL CHEM, V269, P5518; ZUCKER M, 1995, J BIOL CHEM, V270, P27817	56	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29729	29733		10.1074/jbc.271.47.29729	http://dx.doi.org/10.1074/jbc.271.47.29729			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939907	hybrid			2022-12-27	WOS:A1996VU52500035
J	Seiffert, D; Loskutoff, DJ				Seiffert, D; Loskutoff, DJ			Type 1 plasminogen activator inhibitor induces multimerization of plasma vitronectin - A suggested mechanism for the generation of the tissue form of vitronectin in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; SOMATOMEDIN-B DOMAIN; S-PROTEIN; STRUCTURAL REQUIREMENTS; UROKINASE RECEPTOR; BINDING-PROTEIN; HEPARIN; IDENTIFICATION; PURIFICATION; COMPLEMENT	The conformation and degree of multimerization of vitronectin (Vn) appears to be of critical importance for its functions, but little is known about the underlying mechanisms that control Vn multimerization. We report that Vn secreted by cultured hepatoma cells is present as a mixture of monomeric and multimeric forms. A single protein of M(r) 45,000 co-purified with hepatoma cell-derived Vn, which was immunologically identified as type 1 plasminogen activator inhibitor (PAI-1). The possibility that PAI-1 may modulate Vn multimerization was investigated. The addition of active PAI-1 to unfractionated plasma containing Vn monomers resulted in the formation of covalently and noncovalently associated Vn multimers and expression of conformationally sensitive epitopes. In contrast, inactive forms of PAI-1 did not efficiently induce Vn multimerization and conformational change, Gel filtration analysis revealed that Vn remained multimeric after dissociation from PAI-1. Vn multimers were also assembled using purified monomeric Vn and PAI-1, suggesting that a plasma cofactor was not required to induce Vn multimerization. This study provides insights into physiological mechanism responsible for the generation of homomultimeric Vn, a multimeric form of Vn that is not in complex with other proteins and which expresses a functional repertoire distinct from that of plasma Vn.			Seiffert, D (corresponding author), SCRIPPS RES INST, DEPT VASC BIOL VB3, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NHLBI NIH HHS [HL50704, HL31950] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL050704, P01HL031950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BITTORF SV, 1993, J BIOL CHEM, V268, P24838; BOOTH NA, 1992, ANN NY ACAD SCI, V667, P70, DOI 10.1111/j.1749-6632.1992.tb51599.x; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; EHRLICH HJ, 1992, J BIOL CHEM, V267, P11606; GEBB C, 1986, J BIOL CHEM, V261, P6698; Harlow E., 1988, ANTIBODIES LAB MANUA; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HILDEBRAND A, 1989, J BIOL CHEM, V264, P15429; HOGASEN K, 1992, J BIOL CHEM, V267, P23076; IZUMI M, 1989, BIOCHIM BIOPHYS ACTA, V990, P101, DOI 10.1016/S0304-4165(89)80019-4; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KRUITHOF EKO, 1987, BLOOD, V70, P1645; KVASSMAN JO, 1995, FIBRINOLYSIS, V9, P215, DOI 10.1016/S0268-9499(08)80062-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOSKUTOFF DJ, 1991, FIBRINOLYSIS, V5, P197, DOI 10.1016/0268-9499(91)90001-K; MIMURO J, 1987, BLOOD, V70, P721; NASKI MC, 1993, J BIOL CHEM, V268, P12367; PANETTI TS, 1993, J BIOL CHEM, V268, P11492; PANETTI TS, 1993, J BIOL CHEM, V268, P11988; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; SANE DC, 1990, J BIOL CHEM, V265, P3543; SCHLEEF RR, 1989, J CLIN INVEST, V83, P1747, DOI 10.1172/JCI114076; SCHLEEF RR, 1985, J LAB CLIN MED, V106, P408; SEIFFERT D, 1990, J CELL BIOL, V111, P1283, DOI 10.1083/jcb.111.3.1283; Seiffert D, 1996, J BIOL CHEM, V271, P5474, DOI 10.1074/jbc.271.10.5474; Seiffert D, 1996, BLOOD, V88, P552, DOI 10.1182/blood.V88.2.552.bloodjournal882552; SEIFFERT D, 1995, FEBS LETT, V368, P155, DOI 10.1016/0014-5793(95)00630-R; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; TOMASINI BR, 1988, BLOOD, V72, P903; Voelker Wolfgang, 1993, Journal of Histochemistry and Cytochemistry, V41, P1823; WALTZ DA, 1994, J BIOL CHEM, V269, P14746; WEI Y, 1994, J BIOL CHEM, V269, P32380; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; ZANETTI A, 1994, BLOOD, V84, P1116, DOI 10.1182/blood.V84.4.1116.bloodjournal8441116	38	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29644	29651		10.1074/jbc.271.47.29644	http://dx.doi.org/10.1074/jbc.271.47.29644			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939896	hybrid			2022-12-27	WOS:A1996VU52500024
J	Sessler, AM; Kaur, N; Palta, JP; Ntambi, JM				Sessler, AM; Kaur, N; Palta, JP; Ntambi, JM			Regulation of stearoyl-CoA desaturase 1 mRNA stability by polyunsaturated fatty acids in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED GENE-EXPRESSION; MESSENGER-RNA DEGRADATION; ADIPOSE CELL LINE; RAT-LIVER; 3'-UNTRANSLATED REGION; RECEPTOR SYNTHESIS; MOUSE-LIVER; DIFFERENTIATION; PREADIPOCYTES; TRANSCRIPTION	The effects of arachidonic acid (20:4, n-6) and other fatty acids on the expression of stearoyl-CoA desaturase gene 1 were investigated in fully differentiated 3T3-L1 adipocytes. Treatment of 3T3-L1 adipocytes with arachidonic acid resulted in a decrease in stearoyl-CoA desaturase (Scd) enzyme activity and scd1 mRNA, Arachidonic acid did not alter the transcription of the scd1 gene, whereas the half-life of the scd1 mRNA was reduced from 25.1 to 8.5 h, Blocking the conversion of arachidonic acid to eicosanoids by pretreatment of the cells with cyclooxygenase, lipoxygenase, or cytochrome P-450 epoxygenase inhibitors did not reverse the inhibition caused by arachidonic acid, indicating that eicosanoid synthesis is not necessary for the repression of scd1 mRNA expression. Treatment of adipocytes with linoleic (18:2, n-6) and linolenic (18:3, n-3) acids also resulted in inhibition of scd1 mRNA accumulation. By contrast, oleic acid (18:1, n-9) and stearic acid (18:0) had no effect on scd1 mRNA levels. Taken together, these results suggest that polyunsaturated fatty acids repress the expression of the scd1 gene in mature adipocytes by reducing the stability of scd1 mRNA.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; UNIV WISCONSIN,DEPT HORT,MADISON,WI 53706; UNIV WISCONSIN,DEPT NUTR SCI,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042825] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42825] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTA JA, 1994, J BIOL CHEM, V269, P4532; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BERNLOHR DA, 1985, J BIOL CHEM, V260, P5563; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CLANDININ MT, 1991, FASEB J, V5, P2761, DOI 10.1096/fasebj.5.13.1916101; CLARKE SD, 1990, J NUTR, V120, P225, DOI 10.1093/jn/120.2.225; CLARKE SD, 1993, PROG LIPID RES, V32, P139, DOI 10.1016/0163-7827(93)90013-M; CLARKE SD, 1994, ANNU REV NUTR, V14, P83, DOI 10.1146/annurev.nu.14.070194.000503; COLEMAN RA, 1978, J BIOL CHEM, V253, P7256; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; ENOCH HG, 1976, J BIOL CHEM, V251, P5095; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1979, J CELL PHYSIOL, V101, P169, DOI 10.1002/jcp.1041010119; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Jeffcoat R, 1979, Essays Biochem, V15, P1; JUMP DB, 1993, P NATL ACAD SCI USA, V90, P8454, DOI 10.1073/pnas.90.18.8454; JUMP DB, 1994, J LIPID RES, V35, P1076; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; KASTURI I, 1982, J BIOL CHEM, V257, P12224; LANDSCHULZ KT, 1994, BIOCHEM BIOPH RES CO, V200, P763, DOI 10.1006/bbrc.1994.1516; LIIMATTA M, 1994, MOL ENDOCRINOL, V8, P1147, DOI 10.1210/me.8.9.1147; Long SD, 1996, BIOCHEM BIOPH RES CO, V220, P949, DOI 10.1006/bbrc.1996.0512; MACKALL JC, 1976, J BIOL CHEM, V251, P6462; Marzluff William F., 1992, Gene Expression, V2, P93; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MONTGOMERY MR, 1977, MOL PHARMACOL, V13, P60; NAGAE Y, 1988, NUCLEIC ACIDS RES, V16, P10363, DOI 10.1093/nar/16.21.10363; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; NTAMBI JM, 1992, J BIOL CHEM, V267, P10925; PALTA JP, 1993, PLANT PHYSIOL, V103, P793, DOI 10.1104/pp.103.3.793; REED BC, 1980, P NATL ACAD SCI-BIOL, V77, P285, DOI 10.1073/pnas.77.1.285; REED BC, 1981, J BIOL CHEM, V256, P3917; Rosen O M, 1979, Recent Prog Horm Res, V35, P477; SALATI LM, 1986, ARCH BIOCHEM BIOPHYS, V246, P82, DOI 10.1016/0003-9861(86)90451-0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWARTZ RS, 1982, BIOCHIM BIOPHYS ACTA, V711, P316, DOI 10.1016/0005-2760(82)90041-8; SEMENKOVICH CF, 1989, J BIOL CHEM, V264, P9030; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SPECTOR AA, 1985, J LIPID RES, V26, P1015; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; TEBBEY PW, 1994, J BIOL CHEM, V269, P639; THEIDE MA, 1986, J BIOL CHEM, V261, P13230; WEINER FR, 1991, J BIOL CHEM, V266, P23525; WOLFORD JK, 1995, BIOCHEM BIOPH RES CO, V211, P819, DOI 10.1006/bbrc.1995.1885	48	117	127	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29854	29858		10.1074/jbc.271.47.29854	http://dx.doi.org/10.1074/jbc.271.47.29854			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939925	hybrid			2022-12-27	WOS:A1996VU52500053
J	Tisdale, EJ; Balch, WE				Tisdale, EJ; Balch, WE			Rab2 is essential for the maturation of pre-Golgi intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEINS; STOMATITIS-VIRUS GLYCOPROTEIN; N-TERMINAL DOMAIN; SEMI-INTACT CELLS; ENDOPLASMIC-RETICULUM; VESICULAR TRANSPORT; SECRETORY PATHWAY; RNA-POLYMERASE; IN-VITRO; COMPARTMENTS	The small GTPase Rab2 is a resident of pre-Golgi intermediates and required for protein transport from the endoplasmic reticulum (ER) to the Golgi complex (Tisdale, E. J., Bourne, J. R,, Khosravi-Far, R., Der, C, J,, and Balch, W. E, (1992) J. Cell Biol. 119, 749-761). The Rab2 protein, Like all small GTPases, contains conserved GTP-binding domains as well as hypervariable carboxyl-terminal and amino-terminal domains. While the role of the carboxyl terminus in specific membrane localization is well recognized, the potential role of the variable NR,terminus remains to be clarified. To determine whether the NH, terminus of Rab2 was required for its activity in vivo, a trans dominant mutant of Rab2 that inhibits ER to Golgi transport was progressively truncated and analyzed for its effect on vesicular stomatitis virus glycoprotein transport in a vaccinia-based transient expression system. Deletion of the first 14 aminoterminal residues resulted in the loss of the inhibitory properties of the mutant without affecting its posttranslational processing or membrane association. To assess the potential role of the NH, terminus in Rab2 function, a peptide corresponding to the first 13 amino acids following the initiator methionine was introduced into an in vitro assay that efficiently reconstitutes transport of vesicular stomatitis virus glycoprotein from the ER to the Golgi stack. This peptide was a potent inhibitor of transport. Biochemical and morphological studies revealed that the peptide strongly interfered with assembly of pre-Golgi intermediates which mediate segregation of anterograde and retrograde transported proteins en route to the Golgi. The combined results suggest that the NH2, terminus of Rab2 is required for its function and for direct interaction with components of the transport machinery involved in the maturation of pre-Golgi intermediates.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NCI NIH HHS [CA 58689] Funding Source: Medline; NCRR NIH HHS [RR07273] Funding Source: Medline; NIGMS NIH HHS [GM 42336] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR007273] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042336] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; Balch W. E., 1993, Methods (Orlando), V5, P258, DOI 10.1006/meth.1993.1032; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BANNYKH S, 1996, IN PRESS J CELL BIOL, V135; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BECKERS CJM, 1990, J BIOL CHEM, V265, P18298; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CASEY PJ, 1992, J LIPID RES, V33, P1; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; FABBRI M, 1994, J BIOL CHEM, V269, P26848; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KRIJNSELOCKER J, 1994, J CELL BIOL, V124, P55, DOI 10.1083/jcb.124.1.55; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; OKA T, 1994, J CELL BIOL, V124, P425, DOI 10.1083/jcb.124.4.425; PETER F, 1994, J CELL BIOL, V126, P1393, DOI 10.1083/jcb.126.6.1393; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; SANFORD JC, 1995, MOL BIOL CELL, V6, P71, DOI 10.1091/mbc.6.1.71; SARASTE J, 1987, J CELL BIOL, V105, P2021, DOI 10.1083/jcb.105.5.2021; SARASTE J, 1995, J CELL SCI, V108, P1541; SARASTE J, 1991, J CELL SCI, V100, P415; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SIMONS K, 1993, NEURON, V5, P613; STEELEMORTIMER O, 1994, EMBO J, V13, P34, DOI 10.1002/j.1460-2075.1994.tb06232.x; STENMARK H, 1994, EMBO J, V13, P575, DOI 10.1002/j.1460-2075.1994.tb06295.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; WEIDMAN PJ, 1994, J CELL BIOL, V127, P1815, DOI 10.1083/jcb.127.6.1815; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	44	106	108	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29372	29379		10.1074/jbc.271.46.29372	http://dx.doi.org/10.1074/jbc.271.46.29372			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910601				2022-12-27	WOS:A1996VT05200093
J	Fu, DX; Sine, SM				Fu, DX; Sine, SM			Asymmetric contribution of the conserved disulfide loop to subunit oligomerization and assembly of the nicotinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR DISSECTION; LIGAND-BINDING; DELTA-SUBUNIT; GAMMA-SUBUNIT; IDENTIFICATION; SELECTIVITY; INTERFACES; RESIDUES; SITE	The acetylcholine receptor (AChR) at the motor synapse is a pentamer of homologous subunits with the composition alpha(2) beta gamma delta. Owing to the circular arrangement of subunits that forms a central ion channel, each subunit interface contains contributions from opposite faces of each subunit, designated + and -. Common to all subunits of the AChR and members of its superfamily is a disulfide loop formed between cysteines 128 and 142 of the major extracellular domain, To gain insight into the structural contribution of the disulfide loop and its possible location, we mutated the invariant proline at position 136 to glycine (P136G) and examined subunit assembly. When introduced into any AChR subunit, P136G disrupted assembly by affecting the - face of the subunit, suggesting equivalent positioning of the loop in each subunit and localization to the - face, Also, the contribution of the loop in the overall assembly process differed for each subunit. In the beta and gamma subunits, P136G prevented assembly of higher order heteroligomers, whereas in the alpha and delta subunits, P136G prevented transport of assembled pentamers to the cell surface, The results demonstrate asymmetry in the contribution of the disulfide loop to formation of subunit interfaces, and that the loop in each subunit contributes at different stages of assembly.	MAYO CLIN & MAYO FDN,DEPT PHYSIOL & BIOPHYS,ROCHESTER,MN 55905	Mayo Clinic				Fu, Dax/0000-0002-2663-1316	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031744, R37NS031744] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 31744] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLOUNT P, 1990, J CELL BIOL, V111, P2613, DOI 10.1083/jcb.111.6.2613; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; COCKCROFT VB, 1990, PROTEINS, V8, P386, DOI 10.1002/prot.340080412; CRIADO M, 1986, BIOCHEMISTRY-US, V25, P2839, DOI 10.1021/bi00358a015; CZAJKOWSKI C, 1993, P NATL ACAD SCI USA, V90, P6285, DOI 10.1073/pnas.90.13.6285; FU DX, 1994, J BIOL CHEM, V269, P26152; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; GULLICK WJ, 1983, BIOCHEMISTRY-US, V22, P3312, DOI 10.1021/bi00283a003; KREIENKAMP HJ, 1995, NEURON, V14, P635, DOI 10.1016/0896-6273(95)90320-8; LEE BS, 1991, J BIOL CHEM, V266, P11448; MISHINA M, 1985, NATURE, V313, P364, DOI 10.1038/313364a0; NUMA S, 1989, COLD SPRING HARB SYM, V48, P57; ROSE GD, 1985, ADV PROTEIN CHEM, V37, P1, DOI 10.1016/S0065-3233(08)60063-7; SINE S, 1979, J BIOL CHEM, V254, P3315; SINE SM, 1991, J BIOL CHEM, V266, P19369; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; SUMIKAWA K, 1992, J BIOL CHEM, V267, P6286	19	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31479	31484		10.1074/jbc.271.49.31479	http://dx.doi.org/10.1074/jbc.271.49.31479			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940161	hybrid			2022-12-27	WOS:A1996VW68600072
J	Shyu, JF; Inoue, D; Baron, R; Horne, WC				Shyu, JF; Inoue, D; Baron, R; Horne, WC			The deletion of 14 amino acids in the seventh transmembrane domain of a naturally occurring calcitonin receptor isoform alters ligand binding and selectively abolishes coupling to phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3',5'-CYCLIC ADENOSINE-MONOPHOSPHATE; VASOACTIVE-INTESTINAL-PEPTIDE; HORMONE-RELATED PEPTIDE; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; RAT OSTEOCLASTS; CHROMOSOMAL LOCALIZATION; NEUROKININ-1 RECEPTOR; PARATHYROID-HORMONE; SALMON-CALCITONIN	The cDNA that encodes the rabbit calcitonin receptor was cloned by screening a rabbit osteoclast library. Reverse transcription-polymerase chain reaction amplification of calcitonin receptor sequences from rabbit osteoclast RNA yielded cDNAs that encode two isoforms of the calcitonin receptor. One isoform is homologous to the Cia isoform previously identified in multiple cell types and species, while the second, designated CTR Delta e13, is a previously unidentified isoform that is apparently generated by alternative splicing during mRNA processing that deletes exon 13, resulting in the absence of 14 amino acids in the predicted seventh transmembrane domain. Expression of mRNA transcripts encoding the two isoforms varies in a tissue-specific manner, with CTR Delta e13 accounting for less than 15% of the total calcitonin receptor mRNA in osteoclasts, kidney, and brain, but comprising at least 50% of the transcripts in skeletal muscle and lung. The two isoforms were expressed, and the ligand binding and signal transduction properties were characterized. Deletion of the residues in the seventh transmembrane domain in CTR Delta e13 reduced the binding affinity for salmon and human calcitonin by more than 10-fold and approximately a-fold, respectively, resulting in a receptor that failed to discriminate between the two forms of calcitonin. Both isoforms activated adenylyl cyclase, with EC(50) values consistent with the difference in ligand affinities. In contrast, only the Cia isoform, but not the CTR Delta 13 isoform, activated phospholipase C. Thus, while the CTR Delta e13 remains active despite the deletion of a significant portion of its seventh transmembrane domain, it has significantly altered ligand recognition and signal transduction properties.	YALE UNIV,SCH MED,DEPT ORTHOPAED,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06520	Yale University; Yale University					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE004724, R37DE004724] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-04724] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AINO H, 1995, GENE, V164, P301, DOI 10.1016/0378-1119(95)00391-I; Aiyar N, 1996, J BIOL CHEM, V271, P11325, DOI 10.1074/jbc.271.19.11325; ALBRANDT K, 1995, ENDOCRINOLOGY, V136, P5377, DOI 10.1210/en.136.12.5377; ALBRANDT K, 1993, FEBS LETT, V325, P225, DOI 10.1016/0014-5793(93)81078-E; ARVINTE T, 1993, J BIOL CHEM, V268, P4608; Ausubel FM., 2006, ENZYMATIC MANIPULATI; Azria M., 1989, CALCITONINS PHYSL PH; BEAUMONT K, 1993, MOL PHARMACOL, V44, P493; BURCELIN R, 1995, GENE, V164, P305, DOI 10.1016/0378-1119(95)00472-I; CANFIELD VA, 1993, BIOCHEMISTRY-US, V32, P13782, DOI 10.1021/bi00213a005; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; CHAKRABORTY M, 1994, P NATL ACAD SCI USA, V91, P2115, DOI 10.1073/pnas.91.6.2115; CHAKRABORTY M, 1991, SCIENCE, V251, P1078, DOI 10.1126/science.1847755; DELTOSO R, 1989, EMBO J, V8, P4025; DING C, 1995, J BONE MINER RES, V10, pS484; EGERTON M, 1995, J MOL ENDOCRINOL, V14, P179, DOI 10.1677/jme.0.0140179; EPAND RM, 1985, INT J PEPT PROT RES, V25, P105; FEGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413; FINDLAY DM, 1994, MOL ENDOCRINOL, V8, P1691, DOI 10.1210/me.8.12.1691; FONG TM, 1992, J BIOL CHEM, V267, P25664; FORCE T, 1992, AM J PHYSIOL, V262, pF1110, DOI 10.1152/ajprenal.1992.262.6.F1110; FRENDO JL, 1994, FEBS LETT, V342, P214, DOI 10.1016/0014-5793(94)80503-2; GORN AH, 1992, J CLIN INVEST, V90, P1726, DOI 10.1172/JCI116046; GORN AH, 1995, J CLIN INVEST, V95, P2680, DOI 10.1172/JCI117970; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HUANG RRC, 1994, BIOCHEMISTRY-US, V33, P3007, DOI 10.1021/bi00176a033; IKEGAME M, 1995, J BONE MINER RES, V10, P59; KENNEY MA, 1993, BIOCHEM BIOPH RES CO, V197, P8, DOI 10.1006/bbrc.1993.2433; KONG XF, 1994, BIOCHEM BIOPH RES CO, V200, P1290, DOI 10.1006/bbrc.1994.1591; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KUESTNER RE, 1994, MOL PHARMACOL, V46, P246; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; LOVENBERG TW, 1995, P NATL ACAD SCI USA, V92, P836, DOI 10.1073/pnas.92.3.836; MCCUAIG KA, 1994, P NATL ACAD SCI USA, V91, P5051, DOI 10.1073/pnas.91.11.5051; MOORE EE, 1995, MOL ENDOCRINOL, V9, P959, DOI 10.1210/me.9.8.959; NUSSENZVEIG DR, 1995, ENDOCRINOLOGY, V136, P2047, DOI 10.1210/en.136.5.2047; NUSSENZVEIG DR, 1994, J BIOL CHEM, V269, P28123; Offermanns S, 1996, MOL ENDOCRINOL, V10, P566, DOI 10.1210/me.10.5.566; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; SEXTON PM, 1993, MOL ENDOCRINOL, V7, P815, DOI 10.1210/me.7.6.815; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; SREEDHARAN SP, 1995, P NATL ACAD SCI USA, V92, P2939, DOI 10.1073/pnas.92.7.2939; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SU YJ, 1992, ENDOCRINOLOGY, V131, P1497, DOI 10.1210/en.131.3.1497; TEZUKA K, 1992, BIOCHEM BIOPH RES CO, V186, P911, DOI 10.1016/0006-291X(92)90832-6; TsaiMorris CH, 1996, J BIOL CHEM, V271, P14519, DOI 10.1074/jbc.271.24.14519; YAMIN M, 1994, ENDOCRINOLOGY, V135, P2635, DOI 10.1210/en.135.6.2635; ZAIDI M, 1990, J ENDOCRINOL, V126, P473, DOI 10.1677/joe.0.1260473; ZOLNIEROWICZ S, 1994, J BIOL CHEM, V269, P19530	51	66	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31127	31134		10.1074/jbc.271.49.31127	http://dx.doi.org/10.1074/jbc.271.49.31127			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940110	hybrid			2022-12-27	WOS:A1996VW68600021
J	Yoder, JA; Yen, RWC; Vertino, PM; Bestor, TH; Baylin, SB				Yoder, JA; Yen, RWC; Vertino, PM; Bestor, TH; Baylin, SB			New 5' regions of the murine and human genes for DNA (cytosine-5)-methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING PATHWAY; METHYLTRANSFERASE; METHYLATION; EXPRESSION; CELLS; EMBRYOS; CANCER; DOMAIN; CDNA	DNA (cytosine-5)-methyltransferases (EC 2.1.1.37) maintain patterns of methylated cytosine residues in the mammalian genome; faithful maintenance of methylation patterns is required for normal development of mice, and aberrant methylation patterns are associated with certain human tumors and developmental abnormalities. The organization of coding sequences at the 5'-end of the murine and human DNA methyltransferase genes was investigated, and the DNA methyltransferase open reading frame was found to be longer than previously suspected, Expression of the complete open read ing frame by in vitro transcription-translation and by transfection of expression constructs into COS7 cells resulted in the production of an active DNA methyltransferase of the same apparent mass as the endogenous protein, while translation from the second in-frame ATG codon produced a slightly smaller but fully active protein, Characterization of mRNA 5' sequences and the intron-exon structure of the 5' region of the murine and human genes indicated that a previously described promoter element (Rouleau, J., Tanigawa, G., and Szyf, M. (1992) J. Biol, Chen, 267, 7368-7377) actually Lies in an intron that is more than 5 kilobases downstream of the transcription start sites.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT GENET & DEV,NEW YORK,NY 10032; JOHNS HOPKINS UNIV,SCH MED,JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21231	Columbia University; Johns Hopkins University; Johns Hopkins Medicine			Yoder, Jeffrey A./I-5329-2019	Yoder, Jeffrey A./0000-0002-6083-1311	NATIONAL CANCER INSTITUTE [R01CA043318, R01CA060610] Funding Source: NIH RePORTER; NCI NIH HHS [CA60610, CA43318] Funding Source: Medline; NIGMS NIH HHS [GM00616] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BESTOR TH, 1993, CURR BIOL, V3, P384, DOI 10.1016/0960-9822(93)90209-7; BESTOR TH, 1990, PHILOS T ROY SOC B, V326, P179, DOI 10.1098/rstb.1990.0002; BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2; Bestor TH, 1996, NAT GENET, V12, P363, DOI 10.1038/ng0496-363; CARLSON LL, 1992, GENE DEV, V6, P2536, DOI 10.1101/gad.6.12b.2536; CZANK A, 1991, GENE, V109, P259, DOI 10.1016/0378-1119(91)90618-L; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; HAKE LE, 1993, J BIOL CHEM, V268, P4788; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; Jones PA, 1996, CANCER RES, V56, P2463; KOZAK M, 1995, P NATL ACAD SCI USA, V92, P2662, DOI 10.1073/pnas.92.7.2662; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI E, 1993, COLD SPRING HARB SYM, V58, P297, DOI 10.1101/SQB.1993.058.01.035; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MONK M, 1987, DEVELOPMENT, V99, P371; Rost B, 1996, METHOD ENZYMOL, V266, P525; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; ROULEAU J, 1992, J BIOL CHEM, V267, P7368; Sambrook J., 2002, MOL CLONING LAB MANU; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; TAJIMA S, 1995, J BIOCHEM-TOKYO, V117, P1050, DOI 10.1093/oxfordjournals.jbchem.a124805; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287	34	83	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31092	31097		10.1074/jbc.271.49.31092	http://dx.doi.org/10.1074/jbc.271.49.31092			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940105	hybrid			2022-12-27	WOS:A1996VW68600016
J	Blaschke, UK; Hedbom, E; Bruckner, P				Blaschke, UK; Hedbom, E; Bruckner, P			Distinct isoforms of chicken decorin contain either one or two dermatan sulfate chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEATS; BOVINE ARTICULAR-CARTILAGE; KERATAN SULFATE; CORE PROTEIN; MONOCLONAL-ANTIBODIES; SMALL PROTEOGLYCAN; COLLAGEN FIBRILS; II DECORIN; BINDING; CORNEAL	Decorin, a member of a family of proteins with leucine-rich repeat motifs, is a widely distributed extracellular matrix proteoglycan that is thought to be responsible for the structure, tissue organization, and surface properties of fibrils. In mammals, decorin carries one chondroitin/dermatan sulfate chain as a distinction from its homologue, biglycan, which contains two glycosaminoglycan chains. With the aim to study decorin-collagen interactions in chicken, where the fibrillar organization of cartilage collagens is best understood, we have isolated decorin-related proteoglycans from sternal cartilage of 10-day-old broiler chickens. Small chondroitin/dermatan sulfate proteoglycans were resolved by hydrophobic interaction chromatography into two fractions, DCN I and DCN II. Both forms contained dermatan sulfate and, in addition, keratan sulfate chains. Tryptic fingerprinting revealed that the core proteins of DCN I and DCN II were identical. The protein was identified as decorin by amino-terminal sequencing. DCN II was found to contain two dermatan sulfate chains, whereas DCN I had a single dermatan sulfate chain. The dermatan sulfate attachment sites are located near the NH2 terminus of the core protein, i.e. at Ser-4 and Ser-16 in DCN II and at Ser-4 in DCN I. The keratan sulfate attachment sites are located in the central portion of the core protein, at Asn-179 and Asn-230. The presence of two dermatan sulfate chains renders the chicken proteoglycan DCN II structurally similar to mammalian biglycan. Interestingly, biglycan has not been detected in chicken. Therefore, in birds, DCN II may function as a biglycan substitute.	UNIV MUNSTER, INST PHYSIOL CHEM & PATHOBIOCHEM, D-48149 MUNSTER, GERMANY	University of Munster			Bruckner, Peter/F-4817-2019	Bruckner, Peter/0000-0002-5566-5611				ANTONSSON P, 1991, J BIOL CHEM, V266, P16859; BENGTSSON E, 1995, J BIOL CHEM, V270, P25639, DOI 10.1074/jbc.270.43.25639; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P20613; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; BRUCKNER P, 1994, MICROSC RES TECHNIQ, V28, P378, DOI 10.1002/jemt.1070280504; CATERSON B, 1983, J BIOL CHEM, V258, P8848; CHOI HU, 1989, J BIOL CHEM, V264, P2876; CHOPRA RK, 1985, BIOCHEM J, V232, P277, DOI 10.1042/bj2320277; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; EIKENBERRY EF, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P133; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FLEISCHMAJER R, 1991, J STRUCT BIOL, V106, P82, DOI 10.1016/1047-8477(91)90065-5; FONT B, 1993, J BIOL CHEM, V268, P25015; FORMATO M, 1994, CARBOHYD RES, V255, P27, DOI 10.1016/S0008-6215(00)90969-8; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HUBER S, 1988, J BIOL CHEM, V263, P752; INGROSSO D, 1989, BIOCHEM BIOPH RES CO, V162, P1528, DOI 10.1016/0006-291X(89)90848-6; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; KAJAVA AV, 1995, STRUCTURE, V3, P867, DOI 10.1016/S0969-2126(01)00222-2; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KRESSE H, 1993, EXPERIENTIA, V49, P403, DOI 10.1007/BF01923585; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landon, 1977, Methods Enzymol, V47, P145; LENNON DP, 1991, MATRIX, V11, P412, DOI 10.1016/S0934-8832(11)80196-4; LI W, 1992, ARCH BIOCHEM BIOPHYS, V296, P190, DOI 10.1016/0003-9861(92)90562-B; MANN DM, 1990, J BIOL CHEM, V265, P5317; MCBAIN JA, 1992, BIOCHEM J, V287, P131, DOI 10.1042/bj2870131; MIDURA RJ, 1989, J BIOL CHEM, V264, P1423; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; NEAME PJ, 1994, J BIOL CHEM, V269, P21547; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; POGANY G, 1994, ARCH BIOCHEM BIOPHYS, V313, P102, DOI 10.1006/abbi.1994.1365; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; SCOTT JE, 1992, FASEB J, V6, P2639, DOI 10.1096/fasebj.6.9.1612287; SHINOMURA T, 1992, J BIOL CHEM, V267, P1265; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOGEL KG, 1985, J BIOL CHEM, V260, P9298; VOGEL KG, 1987, COLLAGEN REL RES, V7, P105; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; ZEBROWER ME, 1986, ANAL BIOCHEM, V157, P93, DOI 10.1016/0003-2697(86)90201-0	47	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30347	30353		10.1074/jbc.271.48.30347	http://dx.doi.org/10.1074/jbc.271.48.30347			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8939995	hybrid			2022-12-27	WOS:A1996VV15800012
J	Fricker, LD; Berman, YL; Leiter, EH; Devi, LA				Fricker, LD; Berman, YL; Leiter, EH; Devi, LA			Carboxypeptidase E activity is deficient in mice with the fat mutation - Effect on peptide processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENKEPHALIN-SYNTHESIZING CARBOXYPEPTIDASE; IDENTIFICATION; PURIFICATION; EXPRESSION; PITUITARY; ENZYME; FURIN; CDNA; CONVERTASE; SEQUENCE	Carboxypeptidase E (CPE) is involved in the biosynthesis of many peptide hormones and neurotransmitters. Mice with the fat mutation have previously been found to have a point mutation in the cpe gene, and to have greatly reduced levels of CPE-like enzyme activity in the pituitary and pancreatic islets (Naggert, J. It., Fricker, L. D., Varlamov, O., Nishina, P. M., Rouille, Y., Steiner, D. F., Carroll, R. J., Paigen, B. J., and Leiter, E. H. (1995) Nat. Genet. 10, 135-142). In the present report, we examined CPE-like activity and peptide processing in several tissues of C57BLKS/LtJ-Cpe(fat)/Cpe(fat) mutant (Cpe(fat)/Cpe(fat) mice. whereas CPE-like activity is detected in homogenates of Cpe(fat)/Cpe(fat) mouse tissues, the majority of this activity is not due to CPE based on the sensitivity to p-chloromercuriphenyl sulfonate. In addition, the Cpe(fat)/Cpe(fat) activity does not bind to a substrate affinity column under conditions that bind CPE. Furthermore, the enzyme activity and immunoreactive properties' of the activity purified from Cpe(fat)/Cpe(fat) brain are distinct from those of CPE. Taken together, these data suggest that CPE is completely inactive in the Cpe(fat)/Cpe(fat) mice, and that all of the CPE-like activity is due to other carboxypeptidases such as carboxypeptidase D. Levels of Leu-enkephalin in Cpe(fat)/Cpe(fat) mouse brain are approximately 5-fold lower than those in control brain. Treatment of the Cpe(fat)/Cpe(fat) brain extract with carboxypeptidase B restores the level of Leu-enkephalin to the level in control brain. Interestingly, the large molecular weight enkephalin-containing peptides are elevated 2-3-fold in Cpe(fat)/Cpe(fat) mouse brain. These data indicate that CPE plays an important role in the processing of peptide hormones in various tissues, but that other carboxypeptidases also contribute to peptide processing. Furthermore, the increase in levels of high molecular weight enkephalin peptides in the Cpe(fat)/Cpe(fat) mouse suggests that CPE is required for efficient peptide processing by the endopeptidases.	NYU, MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA; JACKSON LAB, BAR HARBOR, ME 04609 USA	New York University; Jackson Laboratory	Fricker, LD (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL PHARMACOL, 1300 MORRIS PK AVE, BRONX, NY 10461 USA.		Devi P, Lakshmi/GXM-5982-2022	Devi P, Lakshmi/0000-0001-9274-4776	NIDA NIH HHS [DA-04494, T32 DA-07254, DA-00194] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007254, R01DA004494, K02DA000194] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		[Anonymous], 1995, METH NEUROSCI; BERMAN YL, 1995, J BIOL CHEM, V270, P23845, DOI 10.1074/jbc.270.40.23845; CHESNEAU V, 1994, J BIOL CHEM, V269, P2056; CONE RI, 1982, NEUROPEPTIDES, V3, P97, DOI 10.1016/0143-4179(82)90005-1; DEVI L, 1989, MOL ENDOCRINOL, V3, P1852, DOI 10.1210/mend-3-11-1852; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; EIPPER BA, 1986, TRENDS NEUROSCI, V9, P463, DOI 10.1016/0166-2236(86)90149-9; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; FRICKER LD, 1983, J BIOL CHEM, V258, P950; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; FRICKER LD, 1989, MOL ENDOCRINOL, V3, P666, DOI 10.1210/mend-3-4-666; FRICKER LD, 1982, P NATL ACAD SCI-BIOL, V79, P3886, DOI 10.1073/pnas.79.12.3886; FRICKER LD, 1991, PEPTIDE BIOSYNTHESIS, P199; HE GP, 1995, NATURE, V378, P92, DOI 10.1038/378092a0; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KUROKI K, 1994, J VIROL, V68, P2091, DOI 10.1128/JVI.68.4.2091-2096.1994; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; PARKINSON D, 1990, J BIOL CHEM, V265, P17101; Rovere C, 1996, ENDOCRINOLOGY, V137, P2954, DOI 10.1210/en.137.7.2954; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SKIDGEL RA, 1988, TRENDS PHARMACOL SCI, V9, P299, DOI 10.1016/0165-6147(88)90015-6; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SONG LX, 1995, J BIOL CHEM, V270, P25007, DOI 10.1074/jbc.270.42.25007; Steiner D. F., 1991, PEPTIDE BIOSYNTHESIS, P1; Varlamov O, 1996, J BIOL CHEM, V271, P13981, DOI 10.1074/jbc.271.24.13981; WEBB E C, 1986, European Journal of Biochemistry, V157, P1; WEBER E, 1982, BIOCHEM BIOPH RES CO, V108, P81, DOI 10.1016/0006-291X(82)91834-4; YI Z, 1993, J BIOL CHEM, V268, P5615; ZHENG M, 1994, J NEUROSCI, V14, P4656; Zhu X, 1996, P NATL ACAD SCI USA, V93, P4919, DOI 10.1073/pnas.93.10.4919	34	127	129	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30619	30624		10.1074/jbc.271.48.30619	http://dx.doi.org/10.1074/jbc.271.48.30619			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940036	hybrid			2022-12-27	WOS:A1996VV15800053
J	Fukasawa, KM; Fukasawa, K; Kanari, M; Fujii, S; Harada, M				Fukasawa, KM; Fukasawa, K; Kanari, M; Fujii, S; Harada, M			Molecular cloning and expression of rat liver aminopeptidase B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; LEUKOTRIENE-A4 HYDROLASE; ARGININE AMINOPEPTIDASE; SKELETAL-MUSCLE; PURIFICATION; PROTEIN; ENZYME; CDNA; INHIBITION; BESTATIN	We isolated, by immunological screening of a Uni-ZAP XR cDNA Library constructed from rat liver mRNAs, a cDNA clone with 2212 base pairs encoding aminopeptidase B (EC 3.4.11.6). The open reading frame encodes a 649-amino acid protein with a theoretical molecular mass of 72,545 Da and bears the consensus sequence of the zinc metalloexopeptidases, indicating that the enzyme belongs to this family, which includes aminopeptidase A, aminopeptidase N, and leukotriene-A(4) hydrolase. Escherichia coli SOLR cells infected with the pBluescript phagemid excised from the Uni-ZAP XR vector containing the aminopeptidase B cDNA had a high L-arginyl-beta-naphthylamidase activity. The recombinant protein was purified to homogeneity from the recombinant E. coli extracts. The enzyme had Cl--dependent aminopeptidase activity specifically restricted to the Arg and Lye derivatives and contained 1 mol of zinc per mol of the enzyme.	SHINSHU UNIV,SCH MED,DEPT OBSTET & GYNECOL,MATSUMOTO,NAGANO 390,JAPAN	Shinshu University	Fukasawa, KM (corresponding author), MATSUMOTO DENT COLL,DEPT ORAL BIOCHEM,SHIOJIRI,NAGANO 39907,JAPAN.							BARELLI H, 1992, BIOCHEM J, V287, P621, DOI 10.1042/bj2870621; BELHACENE N, 1993, EUR J IMMUNOL, V23, P1848; CADEL S, 1995, MOL CELL ENDOCRINOL, V110, P149, DOI 10.1016/0303-7207(95)03529-G; CAPRIOGLIO DR, 1993, J BIOL CHEM, V268, P14310; FLORES M, 1993, BIOCHIMIE, V75, P861, DOI 10.1016/0300-9084(93)90040-Y; GOLDBARG JA, 1958, CANCER, V11, P283, DOI 10.1002/1097-0142(195803/04)11:2<283::AID-CNCR2820110209>3.0.CO;2-8; HARBESON SL, 1988, BIOCHEMISTRY-US, V27, P7301, DOI 10.1021/bi00419a019; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HOPSU VK, 1964, LIFE SCI, V3, P1449, DOI 10.1016/0024-3205(64)90087-6; HOPSU VK, 1966, ARCH BIOCHEM BIOPHYS, V114, P567, DOI 10.1016/0003-9861(66)90381-X; HOPSU VK, 1966, ARCH BIOCHEM BIOPHYS, V114, P557, DOI 10.1016/0003-9861(66)90380-8; ISHIURA S, 1987, J BIOCHEM-TOKYO, V102, P1023, DOI 10.1093/oxfordjournals.jbchem.a122140; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; KAWATA S, 1980, J BIOCHEM, V88, P1025, DOI 10.1093/oxfordjournals.jbchem.a133053; KIRSCHKE H, 1976, ACTA BIOL MED GER, V35, P285; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKINEN KK, 1978, BIOCHEM J, V175, P1051; MAKINEN KK, 1971, INT J PROT RES, V3, P41; MAKITA N, 1992, FEBS LETT, V299, P273, DOI 10.1016/0014-5793(92)80130-9; MANTLE D, 1985, EUR J BIOCHEM, V147, P307, DOI 10.1111/j.1432-1033.1985.tb08751.x; MCDERMOTT JR, 1988, J NEUROCHEM, V50, P176, DOI 10.1111/j.1471-4159.1988.tb13246.x; McDonald J.K., 1986, EXOPEPTIDASES, VVolume 2, P48; MEDINA JF, 1991, BIOCHEM BIOPH RES CO, V176, P1516, DOI 10.1016/0006-291X(91)90459-K; MEDINA JF, 1991, P NATL ACAD SCI USA, V88, P7620, DOI 10.1073/pnas.88.17.7620; MINAMI M, 1987, J BIOL CHEM, V262, P13873; MINAMI M, 1995, GENE, V161, P249, DOI 10.1016/0378-1119(95)00179-A; NAGATA Y, 1991, ENZYME, V45, P165, DOI 10.1159/000468885; NANUS DM, 1993, P NATL ACAD SCI USA, V90, P7069, DOI 10.1073/pnas.90.15.7069; NISHIMURA T, 1983, EUR J BIOCHEM, V137, P23, DOI 10.1111/j.1432-1033.1983.tb07790.x; OCAIN TD, 1987, BIOCHEM BIOPH RES CO, V145, P1038, DOI 10.1016/0006-291X(87)91540-3; OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; PARSONS ME, 1979, INT J BIOCHEM, V10, P217, DOI 10.1016/0020-711X(79)90037-5; PIEROTTI A, 1990, BIOCHEMISTRY-US, V29, P10323, DOI 10.1021/bi00497a006; PONTREMOLI S, 1980, EUR J BIOCHEM, V110, P421, DOI 10.1111/j.1432-1033.1980.tb04883.x; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; ROSS E, 1973, ANAL BIOCHEM, V54, P304, DOI 10.1016/0003-2697(73)90280-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARGENT MG, 1987, ANAL BIOCHEM, V163, P476, DOI 10.1016/0003-2697(87)90251-X; SINGH H, 1978, J BIOL CHEM, V253, P4319; SODERLING E, 1983, ARCH BIOCHEM BIOPHYS, V220, P1, DOI 10.1016/0003-9861(83)90380-6; SODERLING E, 1983, ARCH BIOCHEM BIOPHYS, V220, P11, DOI 10.1016/0003-9861(83)90381-8; SUDA H, 1976, ARCH BIOCHEM BIOPHYS, V177, P196, DOI 10.1016/0003-9861(76)90429-X; TAYLOR A, 1993, TRENDS BIOCHEM SCI, V18, P167; UMEZAWA H, 1983, J ANTIBIOT, V36, P1572, DOI 10.7164/antibiotics.36.1572; UMEZAWA H, 1976, J ANTIBIOT, V29, P97, DOI 10.7164/antibiotics.29.97; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WATT VM, 1989, J BIOL CHEM, V264, P5480; WU Q, 1990, P NATL ACAD SCI USA, V87, P993, DOI 10.1073/pnas.87.3.993; YAMADA M, 1994, FEBS LETT, V342, P53, DOI 10.1016/0014-5793(94)80583-0	51	39	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30731	30735		10.1074/jbc.271.48.30731	http://dx.doi.org/10.1074/jbc.271.48.30731			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940051	hybrid			2022-12-27	WOS:A1996VV15800068
J	Tanimura, A; Turner, RJ				Tanimura, A; Turner, RJ			Inositol 1,4,5-trisphosphate-dependent oscillations of luminal [Ca2+] in permeabilized HSY cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM OSCILLATIONS; FLUORESCENT INDICATOR; INTRACELLULAR STORES; RELEASE; TRISPHOSPHATE; STIMULATION; HEPATOCYTES; CHANNELS; KINASE; WAVES	Oscillations in intracellular Ca2+ concentration ([Ca2+](i)) are thought to play an important role in phosphoinositide-linked Ca2+ signaling events, We demonstrate corresponding inositol 1,4,5-trisphosphate (IP3) dependent oscillations of Ca2+ concentration within the lumen of the IP3-sensitive stores ([Ca2+](L)) of saponin-permeabilized HSY cells by monitoring [Ca2+](L) with the fluorescent Ca2+ indicator Mag-fura-a, The associated openings and closings of the IP3-sensitive Ca2+ release channel were detected via quenching of Mag-fura-a fluorescence due to the entry of Mn2+, a Ca2+ surrogate, into the stores, Evidence for complimentary Ca2+ oscillations at the external surface of the stores was provided by the membrane-bound Ca2+ probe Calcium Green C-18. The permeabilization of saponin-treated HSY cells to macromolecules was confirmed by demonstrating that permeabilized cells readily took up and lost (t(1/2) approximate to 46 s) a fluorescently tagged 70-kDa dextran. Our results impose a number of constraints on possible mechanisms for [Ca2+](i) oscillations. In addition, they support recent proposals that [Ca2+](i) oscillations arise directly from the (biphasic) effects of Ca2+ itself on IP3-sensitive Ca2+ channel activity.	NIDR,CLIN INVEST & PATIENT CARE BRANCH,NIH,BETHESDA,MD 20892; HLTH SCI UNIV HOKKAIDO,DEPT DENT PHARMACOL,ISHIKARI,HOKKAIDO 06102,JAPAN	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Health Sciences University of Hokkaido								ATRI A, 1993, BIOPHYS J, V65, P1727, DOI 10.1016/S0006-3495(93)81191-3; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; CHATTON JY, 1995, FEBS LETT, V368, P165, DOI 10.1016/0014-5793(95)00632-J; DEYOUNG GW, 1992, P NATL ACAD SCI USA, V89, P9895, DOI 10.1073/pnas.89.20.9895; FEWTRELL C, 1993, ANNU REV PHYSIOL, V55, P427, DOI 10.1146/annurev.physiol.55.1.427; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; LI YX, 1995, AM J PHYSIOL-CELL PH, V269, pC1079, DOI 10.1152/ajpcell.1995.269.5.C1079; LI YX, 1994, P NATL ACAD SCI USA, V91, P58, DOI 10.1073/pnas.91.1.58; LLOYD QP, 1995, J BIOL CHEM, V270, P22445, DOI 10.1074/jbc.270.38.22445; MORAN A, 1993, AM J PHYSIOL, V265, pC1405, DOI 10.1152/ajpcell.1993.265.5.C1405; PATTON LL, 1991, IN VITRO CELL DEV B, V27, P779; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; RAJU B, 1989, AM J PHYSIOL, V256, pC540, DOI 10.1152/ajpcell.1989.256.3.C540; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601; SHORT AD, 1993, J BIOL CHEM, V268, P25887; SNEYD J, 1995, FASEB J, V9, P1463, DOI 10.1096/fasebj.9.14.7589988; Tanimura A, 1996, J CELL BIOL, V132, P607, DOI 10.1083/jcb.132.4.607; TSE FW, 1994, P NATL ACAD SCI USA, V91, P9750, DOI 10.1073/pnas.91.21.9750; YANAGAWA T, 1986, VIRCHOWS ARCH B, V51, P187, DOI 10.1007/BF02899028; ZHANG BX, 1993, J BIOL CHEM, V268, P10997	24	32	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30904	30908		10.1074/jbc.271.48.30904	http://dx.doi.org/10.1074/jbc.271.48.30904			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940075	hybrid			2022-12-27	WOS:A1996VV15800092
J	Yang, RJ; Gerstenfeld, LC				Yang, RJ; Gerstenfeld, LC			Signal transduction pathways mediating parathyroid hormone stimulation of bone sialoprotein gene expression in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS EXPRESSION; DEPENDENT PROTEIN-KINASE; TYROSINE-HYDROXYLASE GENE; TRANSCRIPTIONAL REGULATION; TRANSGENIC MICE; BINDING-PROTEINS; CELL-LINE; CAMP; HYBRIDIZATION; RECEPTOR	Bone sialoprotein is a major noncollagenous protein of bone, Parathyroid hormone (PTH) was shown to cause a 2-4-fold increase in the steady-state levels of bone sialoprotein mRNAs within primary cultures of embryonic osteoblasts. The induction could be mimicked by both forskolin and phorbol 12-myristate 13-acetate and was not inhibited by cycloheximide. Transient expression of a similar to 1200-base pair avian 5' bsp promoter/reporter construct demonstrated similar inductions as mRNA levels, Co-transfection of an expression plasmid encoding heat-stable inhibitor of cAMP-dependent protein kinase, a peptide inhibitor of PKA, decreased both the basal and PTH-induced bsp transcription, while co-expression of the catalytic subunit of PKA-induced bsp expression 3-fold, Protein kinase C activation, on the other hand, did not appear to work through its activation of c-fos, since co-transfection of an expression clone for c-fos had no effect. Interestingly, heat-stable inhibitor of cAMP-dependent protein kinase also inhibited the phorbol 12-myristate 13-acetate induction, suggesting that the protein kinase C acts through some form of interaction with the cAMP/PKA pathway, A half-cAMP response element site in the bsp promoter was identified as the cis-acting element that mediated the PTH response by the transient transfections with reporter constructs containing nested deletions of the promoter or a heterologous promoter containing the cAMP response element, In conclusion, these data indicate that PTH stimulation of bsp gene expression is specific to osteoblasts and mediated by changing cellular cAMP/PKA levels, They further suggest that although protein kinase C is capable of stimulating the gene by itself, it plays a minimal role in mediating the PTH induction of bone sialoprotein.	CHILDRENS HOSP,LAB STUDY SKELETAL DIS & REHABIL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School				/0000-0002-0477-1211	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022400] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007112, P01AR034078] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01 AR 34078, AR07112] Funding Source: Medline; NICHD NIH HHS [R01 HD22400] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BASUDEV H, 1995, ACTA DIABETOL, V32, P32, DOI 10.1007/BF00581042; BIANCO P, 1991, CALCIFIED TISSUE INT, V49, P421, DOI 10.1007/BF02555854; BOHMANN D, 1988, COLD SPRING HARB SYM, V53, P695, DOI 10.1101/SQB.1988.053.01.079; CANDELIERE GA, 1995, NEW ENGL J MED, V332, P1546, DOI 10.1056/NEJM199506083322304; CHATTON B, 1994, ONCOGENE, V9, P375; CHEN JK, 1991, MATRIX, V11, P133, DOI 10.1016/S0934-8832(11)80217-9; CIVITELLI R, 1988, AM J PHYSIOL, V255, pE660, DOI 10.1152/ajpendo.1988.255.5.E660; CLAUSS IM, 1993, DEV DYNAM, V197, P146, DOI 10.1002/aja.1001970207; CLOHISY JC, 1992, MOL ENDOCRINOL, V6, P1834, DOI 10.1210/me.6.11.1834; CLOSS EI, 1990, J CELL BIOL, V111, P1313, DOI 10.1083/jcb.111.3.1313; COSMAN F, 1989, J BONE MINER RES, V4, P413; DAY RN, 1989, J BIOL CHEM, V264, P431; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Fitzpatrick L. A., 1992, DISORDERS BONE MINER, P123; Gerstenfeld LC, 1996, ENDOCRINOLOGY, V137, P3957, DOI 10.1210/en.137.9.3957; GERSTENFELD LC, 1988, J CELL BIOL, V106, P979, DOI 10.1083/jcb.106.3.979; GERSTENFELD LC, 1987, DEV BIOL, V122, P49, DOI 10.1016/0012-1606(87)90331-9; GERSTENFELD LC, 1995, ANN NY ACAD SCI, V760, P67, DOI 10.1111/j.1749-6632.1995.tb44621.x; GROVE JR, 1989, J BIOL CHEM, V264, P19506; GUNNESSHEY M, 1989, BONE, V10, P447, DOI 10.1016/8756-3282(89)90077-X; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOWARD GA, 1981, P NATL ACAD SCI-BIOL, V78, P3204, DOI 10.1073/pnas.78.5.3204; HUNTER GK, 1993, P NATL ACAD SCI USA, V90, P8562, DOI 10.1073/pnas.90.18.8562; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KIM KS, 1994, J NEUROCHEM, V63, P834; KIM KS, 1993, P NATL ACAD SCI USA, V90, P3471, DOI 10.1073/pnas.90.8.3471; KREAM BE, 1993, MOL ENDOCRINOL, V7, P399, DOI 10.1210/me.7.3.399; KRONENBERG HM, 1994, PRRIMER METABOLIC BO, P58; LEE K, 1994, ENDOCRINOLOGY, V134, P441, DOI 10.1210/en.134.1.441; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MCKNIGHT SL, 1980, NUCLEIC ACIDS RES, V8, P5949, DOI 10.1093/nar/8.24.5949; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MIDURA RJ, 1994, J BIOL CHEM, V269, P13200; MUFF R, 1994, MOL CELL ENDOCRINOL, V100, P35, DOI 10.1016/0303-7207(94)90275-5; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; NODA M, 1989, J CELL BIOL, V108, P713, DOI 10.1083/jcb.108.2.713; PARTRIDGE NC, 1994, J CELL BIOCHEM, V55, P321, DOI 10.1002/jcb.240550308; RAFIDI K, 1994, GENE, V140, P163, DOI 10.1016/0378-1119(94)90540-1; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCOTT DK, 1992, MOL ENDOCRINOL, V6, P2153, DOI 10.1210/me.6.12.2153; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; TAM CS, 1982, ENDOCRINOLOGY, V110, P506, DOI 10.1210/endo-110-2-506; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; YANG R, 1996, IN PRESS J CELL BIOC; YANG RJ, 1995, J BONE MINER RES, V10, P632; ZU YL, 1993, ONCOGENE, V8, P2749	57	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29839	29846		10.1074/jbc.271.47.29839	http://dx.doi.org/10.1074/jbc.271.47.29839			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939923	hybrid			2022-12-27	WOS:A1996VU52500051
J	Biener, Y; Feinstein, R; Mayak, M; Kaburagi, Y; Kadowaki, T; Zick, Y				Biener, Y; Feinstein, R; Mayak, M; Kaburagi, Y; Kadowaki, T; Zick, Y			Annexin II is a novel player in insulin signal transduction - Possible association between annexin II phosphorylation and insulin receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PROTEIN-TYROSINE KINASE; INSULINOMIMETIC AGENTS H2O2; CALPACTIN-I; PHOSPHOLIPID-BINDING; JUXTAMEMBRANE REGION; MEDIATED ENDOCYTOSIS; MULTIVESICULAR BODY; DOWN-REGULATION; INTACT-CELLS	Annexin II is a Ca2+-, phospholipid-, and actin- binding protein that was implicated in the regulation of vesicular traffic and endosome fusion. It is a known substrate for protein kinases including the platelet-derived growth factor receptor, src protein-tyrosine kinase, and protein kinase C. In the present study we investigated the possible involvement of annexin II in insulin signal transduction. Phosphorylation of annexin II in response to insulin treatment of intact Chinese hamster ovary (CHO)-T cells was detected by 5 min and reached maximal levels after a 2-3-h incubation with the hormone, However, unlike other receptor substrates, annexin II failed to undergo insulin induced Tyr phosphorylation under conditions where receptor internalization was inhibited. This was evident in CHO cells, overexpressing the insulin receptor, in which internalization was inhibited either by tyrosine kinase inhibitors or by lowering the temperature to 4 degrees C, and in CHO cells overexpressing various insulin receptor mutants in which normal internalization was impaired. Hence, Tyr phosphorylation of annexin II could be part of the internalization and sorting mechanism of the insulin receptor.	WEIZMANN INST SCI, DEPT MOL CELL BIOL, IL-76100 REHOVOT, ISRAEL; UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN	Weizmann Institute of Science; University of Tokyo			Zick, Yehiel/K-1479-2012					ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BACKER JM, 1991, J CELL BIOL, V115, P1535, DOI 10.1083/jcb.115.6.1535; BACKER JM, 1990, J BIOL CHEM, V265, P16450; BENLEVY R, 1992, J BIOL CHEM, V267, P17304; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BRAMBILLA R, 1991, BIOCHEM J, V278, P447, DOI 10.1042/bj2780447; BURGOYNE RD, 1994, TRENDS BIOCHEM SCI, V19, P231, DOI 10.1016/0968-0004(94)90143-0; CAMA A, 1992, J BIOL CHEM, V267, P8383; CARPENTIER JL, 1984, J BIOL CHEM, V259, P4190; CARPENTIER JL, 1994, ANN NY ACAD SCI, V733, P266, DOI 10.1111/j.1749-6632.1994.tb17276.x; CARPENTIER JL, 1981, J CELL BIOL, V91, P17, DOI 10.1083/jcb.91.1.17; CARPENTIER JL, 1995, J BIOL CHEM, V270, P5001, DOI 10.1074/jbc.270.10.5001; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; FAVA RA, 1984, J BIOL CHEM, V259, P2636; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FUTTER CE, 1993, J CELL BIOL, V120, P77, DOI 10.1083/jcb.120.1.77; GLENNEY J, 1986, P NATL ACAD SCI USA, V83, P4258, DOI 10.1073/pnas.83.12.4258; GLENNEY JR, 1991, METHOD ENZYMOL, V196, P65; GOULD KL, 1986, MOL CELL BIOL, V6, P2738, DOI 10.1128/MCB.6.7.2738; GREENBERG ME, 1983, CELL, V33, P767, DOI 10.1016/0092-8674(83)90019-3; Gruenberg Jean, 1993, Trends in Cell Biology, V3, P224, DOI 10.1016/0962-8924(93)90116-I; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HAFT CR, 1994, J BIOL CHEM, V269, P26286; HARDER T, 1993, J CELL BIOL, V123, P1119, DOI 10.1083/jcb.123.5.1119; HARI J, 1987, J BIOL CHEM, V262, P15341; HEFFETZ D, 1992, BIOCHEM J, V288, P631, DOI 10.1042/bj2880631; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; JOHNSSON N, 1988, EMBO J, V7, P2435, DOI 10.1002/j.1460-2075.1988.tb03089.x; JOHNSTONE SA, 1992, J BIOL CHEM, V267, P25976; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; KABURAGI Y, 1993, J BIOL CHEM, V268, P16610; KARASIK A, 1988, J BIOL CHEM, V263, P18558; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LARKIN JM, 1986, J CELL BIOL, V103, P2619, DOI 10.1083/jcb.103.6.2619; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; MARSHALL S, 1981, DIABETES, V30, P746, DOI 10.2337/diab.30.9.746; Moss S. E, 1992, ANNEXINS; NAKATA T, 1990, J CELL BIOL, V110, P13, DOI 10.1083/jcb.110.1.13; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OGAWA W, 1994, J BIOL CHEM, V269, P29602; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PERROTTI N, 1987, P NATL ACAD SCI USA, V84, P3137, DOI 10.1073/pnas.84.10.3137; PILCH PF, 1983, J CELL BIOL, V96, P133, DOI 10.1083/jcb.96.1.133; POWELL MA, 1987, BIOCHEM J, V247, P321, DOI 10.1042/bj2470321; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; SARIS CJM, 1986, CELL, V46, P201, DOI 10.1016/0092-8674(86)90737-3; SAWYER ST, 1985, J BIOL CHEM, V260, P8233; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEGER R, 1995, J BIOL CHEM, V270, P28325; SENDA T, 1994, CELL TISSUE RES, V277, P51; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUNG CK, 1994, J BIOL CHEM, V269, P12503; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; YAMADA K, 1995, J BIOL CHEM, V270, P3115, DOI 10.1074/jbc.270.7.3115; ZOKAS L, 1987, J CELL BIOL, V105, P2111, DOI 10.1083/jcb.105.5.2111	69	67	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29489	29496		10.1074/jbc.271.46.29489	http://dx.doi.org/10.1074/jbc.271.46.29489			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910617				2022-12-27	WOS:A1996VT05200109
J	Sala, A; DeLuca, A; Giordano, A; Peschle, C				Sala, A; DeLuca, A; Giordano, A; Peschle, C			The retinoblastoma family member p107 binds to B-MYB and suppresses its autoregulatory activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINES; PROLIFERATION; EXPRESSION; REQUIREMENT; ACTIVATION; INHIBITION; GROWTH	It was recently reported that B-MYB can overcome p107-induced growth arrest. Here we show that B-MYB autoregulation of its own transcription is specifically suppressed by p107 and transient transfection assays with p107 deletion constructs determined that the carboxyl terminus of the protein, containing the major pocket region, was associated with inhibition of B-MYB-dependent transactivation. Consistent with these results, co-immunoprecipitation studies showed that p107 interacted in vivo with B-MYB through its pocket and carboxyl terminus domain. Thus, B-MYB-dependent promotion of cell proliferation and gene transactivation might be specifically repressed by the growth suppressor p107 through direct interaction with B-MYB.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PATHOL ANAT & CELL BIOL,PHILADELPHIA,PA 19107; IST SUPER SANITA,LAB EMATOL ONCOL,I-00161 ROME,ITALY	Jefferson University; Istituto Superiore di Sanita (ISS)	Sala, A (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MICROBIOL & IMMUNOL,KIMMEL CANC INST,BLSB BLDG,PHILADELPHIA,PA 19107, USA.		sala, arturo/C-4959-2008; De Luca, Antonio/AAD-9562-2020; Giordano, Antonio/F-1927-2010	De Luca, Antonio/0000-0002-3905-6154; Giordano, Antonio/0000-0002-5959-016X; Sala, Arturo/0000-0002-2841-7866	NATIONAL CANCER INSTITUTE [R01CA060999] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA60999-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARSURA M, 1992, BLOOD, V79, P2708; ARSURA M, 1994, BLOOD, V83, P1778, DOI 10.1182/blood.V83.7.1778.bloodjournal8371778; Bies J, 1996, ONCOGENE, V12, P355; CLAUDIO PP, 1994, CANCER RES, V54, P5556; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GOLAY J, 1991, BLOOD, V77, P149; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; Marhamati DJ, 1996, J BIOL CHEM, V271, P3359; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; SATTERWHITE DJ, 1994, CELL GROWTH DIFFER, V5, P789; Sitzmann J, 1996, ONCOGENE, V12, P1889; TASHIRO S, 1995, ONCOGENE, V10, P1699; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	16	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28738	28740		10.1074/jbc.271.46.28738	http://dx.doi.org/10.1074/jbc.271.46.28738			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910512	hybrid			2022-12-27	WOS:A1996VT05200004
J	Li, SW; Song, KS; Koh, SS; Kikuchi, A; Lisanti, MP				Li, SW; Song, KS; Koh, SS; Kikuchi, A; Lisanti, MP			Baculovirus-based expression of mammalian caveolin in Sf21 insect cells A model system for the biochemical and morphological study of caveolae biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICH MEMBRANE DOMAINS; TRANS-GOLGI-NETWORK; PLASMA-MEMBRANE; TRANSFORMED-CELLS; PROTEIN-COMPONENT; VESICLES; VIP21-CAVEOLIN; TYROSINE; SEQUENCE; SURFACE	Caveolae were originally defined morphologically as 50-100 nm noncoated vesicular organelles located at or near the plasma membrane. Caveolin, a vesicular integral membrane protein of 21 kDa, is a principal protein component of caveolae membranes in vivo. Caveolin interacts with itself to form high molecular mass oligomers, suggesting that it might play a structural role in the formation of caveolae membranes. However, it remains controversial whether recombinant expression of caveolin is necessary or sufficient to generate caveolae membranes in vivo. To directly address this issue, we have taken a different experimental approach by exploiting a heterologous expression system. Here, we have recombinantly expressed mammalian caveolin in Sf21 insect cells using baculovirus-based vectors. Two isoforms of caveolin have been identified that differ at their extreme N terminus; alpha-caveolin contains residues 1-178, and beta-caveolin contains residues 32-178. After recombinant expression in Sf21 insect cells, both alpha- and beta-caveolin formed SDS-resistant high molecular mass oligomers of the same size as native caveolin. Morphologically, expression of either caveolin isoform resulted in the intracellular accumulation of a homogeneous population of caveolae-sized vesicles with a diameter between 50 and 120 nm (80.3 +/- 14.8 nm). This indicates that each caveolin isoform can independently generate these structures and that caveolin residues 1-31 are not required for this process. Using caveolin as a marker protein and a detergent-free procedure to purify caveolae from mammalian cells, we purified these recombinant caveolin-induced vesicles from insect cells. These purified recombinant vesicles: (i) have the same buoyant density as mammalian caveolae; (ii) appear as similar to 50-100 nm membranous structures by whole mount electron microscopy; and (iii) contain similar to 95% of the recombinantly expressed caveolin protein by Western blotting. Immuno-labeling of these structures with anti-caveolin IgG confirmed that they contain caveolin. Thus, ectopic overexpression of caveolin in this heterologous system is sufficient to drive th formation of caveolae-like vesicles. Further functional analysis demonstrated that caveolin was capable of interacting with a known caveolin-interacting protein, Ha-Ras, when coexpressed in insect cells by co-infection with two recombinant baculoviruses. Taken together, our results demonstrate that baculovirus-based expression of caveolin in insect cells provides an attractive experimental system for studying the biogenesis of caveolae.	WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; HIROSHIMA UNIV, SCH MED, MINAMI KU, HIROSHIMA 734, JAPAN	Massachusetts Institute of Technology (MIT); Whitehead Institute; Hiroshima University			Li, Shengwen Calvin/H-1725-2012; Lisanti, Michael P/C-6866-2013; Lisanti, Michael/B-6131-2018	Li, Shengwen Calvin/0000-0002-9699-9204; Lisanti, Michael/0000-0003-2034-1382	NCI NIH HHS [F32 CA071326, CA-71326] Funding Source: Medline; NIGMS NIH HHS [GM-50443] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA071326] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FAN JY, 1983, J CELL SCI, V61, P219; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; GIMPL G, 1995, BIOCHEMISTRY-US, V34, P13794, DOI 10.1021/bi00042a010; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; IZUMI T, 1988, ANAT REC, V220, P225, DOI 10.1002/ar.1092200302; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P3863; Lisanti Michael P., 1995, Seminars in Developmental Biology, V6, P47, DOI 10.1016/S1044-5781(06)80084-8; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LODISH HF, 1991, J BIOL CHEM, V266, P14835; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; PARK S, 1992, J BIOL CHEM, V267, P11612; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SEVERS NJ, 1988, J CELL SCI, V90, P341; SIMIONESCU N, 1975, J CELL BIOL, V64, P586, DOI 10.1083/jcb.64.3.586; SIMIONESCU N, 1983, HISTOLOGY CELL TISSU, P371; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445	44	122	124	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28647	28654		10.1074/jbc.271.45.28647	http://dx.doi.org/10.1074/jbc.271.45.28647			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910498	hybrid			2022-12-27	WOS:A1996VU03300098
J	Jin, RZ; Zhou, XM; Novick, RP				Jin, RZ; Zhou, XM; Novick, RP			The inactive pT181 initiator heterodimer, RepC/C*, binds but fails to induce melting of the plasmid replication origin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCUS-AUREUS; PROTEIN; SPECIFICITY; DNA	Staphylococcus aureus plasmid pT181 replicates via a rolling circle mechanism, The synthesis of the pT181 initiator protein (RepC) is regulated by antisense RNAs, and RepC is inactivated after usage by the attachment of an oligonucleotide to one of its subunits. The inactivated heterodimeric RepC/C* has been shown be unable to initiate replication in vitro (Rasooly, A and Novick, R. P. (1993) Science 262, 1048-1050). The inactive RepC/C* has been found to be very stable and constitute about 90-95% of the total RepC antigen inside the cell. We studied the specific interaction of the RepC/C and RepC/C* complex with the pT181 double strand origin. The results indicated that RepC/C and RepC/C* footprint supercoiled DNA differently although their footprints on Linear DNA are similar; we also find that RepC/C is able to enhance cruciform extrusion while RepC/C* cannot. RepC/C* binds and bends the double strand origin much more weakly than does RepC/C. These results suggest that the attached oligonucleotide induces a conformational change in the RepC/C* molecule that is responsible for its lack of activity.	NYU,MED CTR,DEPT MOL PATHOGENESIS,SKIRBALL INST BIOMOL MED,NEW YORK,NY 10016	New York University				Novick, richard/0000-0003-4418-7893	NIGMS NIH HHS [R01-GM14372] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM014372] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DIAZ R, 1981, NATURE, V289, P326, DOI 10.1038/289326a0; GENNARO ML, 1989, J MOL BIOL, V205, P355, DOI 10.1016/0022-2836(89)90346-X; GRALLA JD, 1993, FOOTPRINTING TECHNIQ, P107; IORDANESCU S, 1989, MOL GEN GENET, V217, P481, DOI 10.1007/BF02464921; KOEPSEL RR, 1986, SCIENCE, V233, P1316, DOI 10.1126/science.3749879; KOEPSEL RR, 1985, P NATL ACAD SCI USA, V82, P6845, DOI 10.1073/pnas.82.20.6845; KOEPSEL RR, 1986, P NATL ACAD SCI USA, V83, P5484, DOI 10.1073/pnas.83.15.5484; NOIROT P, 1990, P NATL ACAD SCI USA, V87, P8560, DOI 10.1073/pnas.87.21.8560; NOVICK RP, 1972, J MOL BIOL, V68, P285, DOI 10.1016/0022-2836(72)90214-8; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; RASOOLY A, 1993, SCIENCE, V262, P1048, DOI 10.1126/science.8235621; WANG PZ, 1993, EMBO J, V12, P45, DOI 10.1002/j.1460-2075.1993.tb05630.x	12	14	14	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31086	31091		10.1074/jbc.271.49.31086	http://dx.doi.org/10.1074/jbc.271.49.31086			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940104	hybrid			2022-12-27	WOS:A1996VW68600015
J	Yun, CH; Song, M; Ahn, T; Kim, H				Yun, CH; Song, M; Ahn, T; Kim, H			Conformational change of cytochrome p450 1A2 induced by sodium chloride	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; BETA-NAPHTHOFLAVONE; CIRCULAR-DICHROISM; RAPID METHOD; REDUCTASE; PURIFICATION; FORMS; NOMENCLATURE; REPLACEMENT; EXPRESSION	Recently, it was reported that the activity of rabbit P450 1A2 is markedly increased at elevated sodium phosphate concentration. Here, the possible structural change of rabbit P450 1A2 accompanying the NaCl-induced increase in its enzyme activity is investigated by fluorescence spectroscopy, circular dichroism, and absorption spectroscopy, It was found that NaCl increased alpha-helix content and lowered beta-sheet content of P450 1A2 in the presence as well as in the absence of a phospholipid. Intrinsic fluorescence emissions also increased with increasing NaCl concentration. The low spin iron configuration of P450 1A2 shifted toward the high spin configuration in response to the increased salt concentration, The effect of increased potassium phosphate and NaCl on the P450 1A2 activity was also studied. It was found that the activity increase of rabbit P450 1A2 occurs concomitantly with the conformational change including raised alpha-helix content.	KOREA ADV INST SCI & TECHNOL,DEPT BIOL SCI,TAEJON 305701,SOUTH KOREA	Korea Advanced Institute of Science & Technology (KAIST)	Yun, CH (corresponding author), PAI CHAI UNIV,DEPT BIOCHEM,SEO KU,439-6, DOMA DONG,TAEJON 302735,SOUTH KOREA.			Yun, Chul-Ho/0000-0003-2685-2968				ALTERMAN MA, 1990, BIOMED CHROMATOGR, V4, P221, DOI 10.1002/bmc.1130040510; CHIANG YL, 1979, ARCH BIOCHEM BIOPHYS, V195, P178, DOI 10.1016/0003-9861(79)90339-4; COON MJ, 1973, DRUG METAB DISPOS, V1, P92; GrahamLorence S, 1996, FASEB J, V10, P206, DOI 10.1096/fasebj.10.2.8641554; Guengerich F. Peter, 1994, P1259; GUENGERICH FP, 1983, BIOCHEMISTRY-US, V22, P2811, DOI 10.1021/bi00281a007; GUENGERICH FP, 1982, BIOCHEMISTRY-US, V21, P6019, DOI 10.1021/bi00266a045; GUENGERICH FP, 1979, BIOCHEMISTRY-US, V18, P5442, DOI 10.1021/bi00591a029; GUENGERICH FP, 1978, J BIOL CHEM, V253, P7931; HAUGEN DA, 1976, J BIOL CHEM, V251, P7929; IMAOKA S, 1992, BIOCHEMISTRY-US, V31, P6063, DOI 10.1021/bi00141a015; Jansson I, 1996, ARCH BIOCHEM BIOPHYS, V325, P265, DOI 10.1006/abbi.1996.0033; LANGE R, 1980, EUR J BIOCHEM, V107, P441; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OMURA T, 1964, J BIOL CHEM, V239, P2370; PALMER G, 1992, J BIOL CHEM, V267, P665; POHL RJ, 1980, ANAL BIOCHEM, V107, P150, DOI 10.1016/0003-2697(80)90505-9; POMPON D, 1988, EUR J BIOCHEM, V177, P285, DOI 10.1111/j.1432-1033.1988.tb14375.x; PORTER TD, 1991, J BIOL CHEM, V266, P13469; SANDHU P, 1994, ARCH BIOCHEM BIOPHYS, V309, P168, DOI 10.1006/abbi.1994.1099; SCHENKMAN JB, 1994, ARCH BIOCHEM BIOPHYS, V314, P234, DOI 10.1006/abbi.1994.1435; TAMBURINI PP, 1984, BIOCHEMISTRY-US, V23, P4526, DOI 10.1021/bi00315a004; Timasheff S.N., 1989, PROTEIN STRUCTURE PR, P331; TRETIAKOV VE, 1989, ARCH BIOCHEM BIOPHYS, V275, P429, DOI 10.1016/0003-9861(89)90389-5; VOZNESENSKY AI, 1994, J BIOL CHEM, V269, P15724; VOZNESENSKY AI, 1992, J BIOL CHEM, V267, P14669; WAGNER SL, 1987, BIOCHEMISTRY-US, V26, P2343, DOI 10.1021/bi00382a040; WHITE RE, 1982, J BIOL CHEM, V257, P3073; YAMAZAKI H, 1995, BIOCHEMISTRY-US, V34, P8380, DOI 10.1021/bi00026a020; YANG JT, 1986, METHOD ENZYMOL, V130, P208	30	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31312	31316		10.1074/jbc.271.49.31312	http://dx.doi.org/10.1074/jbc.271.49.31312			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940137	hybrid			2022-12-27	WOS:A1996VW68600048
J	Jia, YP; Kumar, A; Patel, SS				Jia, YP; Kumar, A; Patel, SS			Equilibrium and stopped-flow kinetic studies of interaction between T7 RNA polymerase and its promoters measured by protein and 2-aminopurine fluorescence changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; T7-RNA POLYMERASE; RRNB P1; RATE CONSTANTS; TRANSCRIPTION; COMPLEXES; DNA; BACTERIOPHAGE-T7; GENE; EXPRESSION	The mechanism of bacteriophage T7 RNA polymerase binding to its promoter DNA was investigated using stopped-flow and equilibrium methods, To measure the kinetics of protein-DNA interactions in real time, changes in tryptophan fluorescence in the polymerase and 2-aminopurine (2-AP) fluorescence in the promoter DNA upon binary complex formation were used as probes, The protein fluorescence changes measured conformational changes in the polymerase whereas the fluorescence changes of 2-AP base, substituted in place of dA in the initiation region (-4 to +4), measured structural changes in the promoter DNA, such as DNA melting, The kinetic studies, carried out in the absence of the initiating nucleotide, are consistent with a two-step DNA binding mechanism, E + D reversible arrow(K)1 ED(a) (k)-2 reversible arrow(k)2 ED(b) where the RNA polymerase forms an initial weak ED, complex rapidly with an equilibrium association constant K-1, The ED(a) complex then undergoes a conformational change to ED(1), wherein RNA polymerase is specifically and tightly bound to the promoter DNA. Both the polymerase and the promoter DNA may undergo structural changes during this isomerization step, The isomerization of ED(a) to ED(b) is a fast step relative to the rate of transcription initiation and its rate does not limit transcription initiation, To understand how T7 RNA polymerase modulates its transcriptional efficiency at various promoters at the level of DNA binding, comparative studies with two natural T7 promoters, Phi 10 and Phi 3.8, were conducted, The results indicate that kinetics, the bimolecular rate constant of DNA binding, k(on) (K1K2), and the dissociation rate constant, k(off) (h(-2)), and thermodynamics, the equilibrium constants of the two steps (K-1 and k(2)/k(-2)) both play a role in modulating the transcriptional efficiency at the level of DNA binding, Thus, the 2-fold lower k(on), the 4-fold higher k(off), and the 2-5-fold weaker equilibrium interactions together make Phi 3.8 a weaker promoter relative to Phi 10.	OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210	University System of Ohio; Ohio State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM051966, R01GM051966] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51966] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAMBERL.M, 1970, NATURE, V228, P227, DOI 10.1038/228227a0; Chamberlin M., 1982, ENZYMES, V15, P87; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; FERSHT AR, 1971, J MOL BIOL, V60, P279, DOI 10.1016/0022-2836(71)90294-4; FOX JJ, 1958, J AM CHEM SOC, V80, P1669, DOI 10.1021/ja01540a041; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; IKEDA RA, 1992, J BIOL CHEM, V267, P2640; Johnson K. A., 1992, ENZYMES, V20, P1, DOI DOI 10.1016/S1874-6047(08)60019-0; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KING GC, 1986, BIOCHEMISTRY-US, V25, P36, DOI 10.1021/bi00349a006; KOTANI H, 1987, NUCLEIC ACIDS RES, V15, P2653, DOI 10.1093/nar/15.6.2653; MARTIN CT, 1987, BIOCHEMISTRY-US, V26, P2690, DOI 10.1021/bi00384a006; Millar DP, 1996, CURR OPIN STRUC BIOL, V6, P322, DOI 10.1016/S0959-440X(96)80050-9; MOFFATT BA, 1984, J MOL BIOL, V173, P265, DOI 10.1016/0022-2836(84)90194-3; MULLER DK, 1989, BIOCHEMISTRY-US, V28, P3306, DOI 10.1021/bi00434a028; NEWLANDS JT, 1991, J MOL BIOL, V220, P569, DOI 10.1016/0022-2836(91)90101-B; OAKLEY JL, 1979, BIOCHEMISTRY-US, V18, P528, DOI 10.1021/bi00570a023; OHLSEN KL, 1992, J BIOL CHEM, V267, P19813; OSTERMAN HL, 1981, BIOCHEMISTRY-US, V20, P4884, DOI 10.1021/bi00520a013; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; ROE JH, 1985, J MOL BIOL, V184, P441, DOI 10.1016/0022-2836(85)90293-1; SOUSA R, 1994, J MOL BIOL, V244, P6, DOI 10.1006/jmbi.1994.1699; SUH WC, 1993, SCIENCE, V259, P358, DOI 10.1126/science.8420002; TRAVERS AA, 1987, CRIT REV BIOCHEM MOL, V22, P181, DOI 10.3109/10409238709101483; WARD DC, 1969, J BIOL CHEM, V244, P1228; WELLINGTON SR, 1993, J BIOL CHEM, V268, P7205; Zhang X, 1996, J MOL BIOL, V258, P14, DOI 10.1006/jmbi.1996.0230	29	99	101	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30451	30458		10.1074/jbc.271.48.30451	http://dx.doi.org/10.1074/jbc.271.48.30451			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940010	hybrid			2022-12-27	WOS:A1996VV15800027
J	Sarmay, G; Koncz, G; Gergely, J				Sarmay, G; Koncz, G; Gergely, J			Human type II Fc gamma receptors inhibit B cell activation by interacting with the p21(ras)-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CROSS-LINKING; TYROSINE PHOSPHORYLATION; LYMPHOCYTES; SHC; IMMUNOGLOBULIN; P21(RAS); COMPLEX; FC-GAMMA-RIIB1; STIMULATION	Co-ligation of antigen receptors and type II Fc gamma receptors (Fc gamma RIIb) on B cells interrupts signal transduction and ultimately inhibits antibody production. We have identified p52 She in the Fc gamma RIIb1-specific immunoprecipitates isolated from the membrane fraction of BL41 Burkitt lymphoma cells following B cell receptor-Fc gamma RIIb1 co-ligation. The insolubilized synthetic peptide representing the phosphorylated form of the tyrosine-based inhibitory moth of Fc gamma RIIb also binds She from the lysates of activated but not from resting BL41 cells. This suggests that the binding does not depend on the interaction of Fc gamma RIIb1-phosphotyrosine with the SH2 domain of She. Tyr phosphorylation of Fc gamma RIIb1-associated She is low, indicating an impaired function. She is implicated in regulating p21(ras) activation; thus, we have compared p21(ras) activities in BL41 cells treated in different ways. p21(ras) activity is reduced when B cell receptor and Fc gamma RIIb1 are co-ligated. p21(ras) couples protein-tyrosine kinase-dependent events to the Ser/Thr kinase-mediated signaling pathway leading to the activation of mitogen-activated protein kinases (MAPK). Our results show that B cell receptor-Fc gamma RIIb1 co-crosslinking partially inhibits mitogen-activated protein kinase activity. We conclude that Fc gamma RIIb1-dependent inhibition of human B cell activation may be based on interrupting signal transduction between protein-tyrosine kinases and the p21(ras)/mitogen-activated protein kinase-dependent activation pathway.	VIENNA INT RES COOPERAT CTR, SFI, VIENNA, AUSTRIA		Sarmay, G (corresponding author), EOTVOS LORAND UNIV, DEPT IMMUNOL, IMMUNOREGULAT LAB, JAVORKA SANDOR U 14, H-2131 GOD, HUNGARY.		Sarmay, Gabriella/AAF-3460-2020; Koncz, Gabor/AAL-4415-2021	Koncz, Gabor/0000-0002-4888-6838				Bewarder N, 1996, MOL CELL BIOL, V16, P4735; BUDDE P, 1994, J BIOL CHEM, V269, P30636; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CHAN PL, 1971, IMMUNOLOGY, V21, P967; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DIEGEL ML, 1994, J BIOL CHEM, V269, P11409; DISATNIK MH, 1994, P NATL ACAD SCI USA, V91, P559, DOI 10.1073/pnas.91.2.559; GOTTSCHALK AR, 1994, J IMMUNOL, V152, P2115; GRAZIADEI L, 1990, NATURE, V347, P396, DOI 10.1038/347396a0; HENRY C, 1968, J EXP MED, V128, P133, DOI 10.1084/jem.128.1.133; KLAUS GGB, 1985, IMMUNOLOGY, V56, P321; KUMAR G, 1995, BIOCHEM J, V307, P215, DOI 10.1042/bj3070215; LAZARUS AH, 1993, J EXP MED, V178, P1765, DOI 10.1084/jem.178.5.1765; MCMAHON SB, 1995, J EXP MED, V181, P417, DOI 10.1084/jem.181.1.417; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; Okabayashi Y, 1996, J BIOL CHEM, V271, P5265; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; Rapp W., 1990, INNOVATION PERSPECTI, P205; SARMAY G, 1995, IMMUNOL LETT, V44, P125, DOI 10.1016/0165-2478(95)00203-H; SARMAY G, 1994, P NATL ACAD SCI USA, V91, P4140, DOI 10.1073/pnas.91.10.4140; SARMAY G, 1995, EUR J IMMUNOL, V25, P262, DOI 10.1002/eji.1830250143; SAXTON TM, 1994, J IMMUNOL, V153, P623; SHEN ZH, 1994, J IMMUNOL, V152, P3017; SMIT L, 1994, J BIOL CHEM, V269, P20209; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TORDAI A, 1994, J BIOL CHEM, V269, P7538; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	30	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30499	30504						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940017				2022-12-27	WOS:A1996VV15800034
J	Asano, Y; Ito, H; Dairi, T; Kato, Y				Asano, Y; Ito, H; Dairi, T; Kato, Y			An alkaline D-stereospecific endopeptidase with beta-lactamase activity from Bacillus cereus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; GENE; CLONING; AMINOPEPTIDASE; HYDROLYSIS; PEPTIDASE; PROTEIN	We purified a novel extracellular D-stereospecific endopeptidase, alkaline D-peptidase (D-stereospecific peptide hydrolase, EC 3.4.11.-), to homogeneity from the culture broth of the soil bacterium Bacillus cereus strain DF4-B. The M(r) of the enzyme was 37,952, and it was composed of a single polypeptide chain. The optimal pH for activity was similar to 10.3, The enzyme was strictly D-stereospecific toward oligopeptides composed of D-phenylalanine such as (D-Phe)(3) and (D-Phe)(4). The enzyme also acted to a lesser extent on (D-Phe)(6), Boc-(D-Phe)(4) (where Boc is tert-butoxycarbonyl), Boc-(D-Phe)(4) methyl ester, Boc-(D-Phe)(3) methyl ester, Boc (D-Phe)(2), (D-Phe)(2), and others, but not upon their corresponding peptides composed of L-Phe, (D-Ala)(n) (n = 2-5), (D-Val)(3), and (D-Leu)(2), The mode of action of the enzyme was clarified with synthetic substrates ((D-Phe)(2)-D-Tyr and D-Tyr-(D-Phe)(2)) and eight stereoisomers of (Phe)(3). The enzyme had beta-lactamase activity toward ampicillin and penicillin G, although carboxypeptidase DD and D-aminopeptidase activities were undetectable. The gene coding for alkaline D-peptidase (adp) was cloned into plasmid pUC118, and a 1164-base pair open reading frame consisting of 388 codons was identified as the adp gene, The predicted polypeptide was similar to carboxypeptidase DD from Streptomyces R61, penicillin-binding proteins from Streptomyces lactamdurans and Bacillus subtilis, and class C beta-lactamases, Thus, the enzyme was categorized as a new ''penicillin-recognizing enzyme.''			Asano, Y (corresponding author), TOYAMA PREFECTURAL UNIV,BIOTECHNOL RES CTR,5180 KUROKAWA,TOYAMA 93903,JAPAN.		Asano, Yasuhisa/K-5898-2016; Dairi, Tohru/A-5448-2012	Asano, Yasuhisa/0000-0003-3645-3952; Dairi, Tohru/0000-0002-3406-7970				ADAM M, 1990, BIOCHEM J, V270, P525, DOI 10.1042/bj2700525; AKINO T, 1989, APPL ENVIRON MICROB, V55, P3178, DOI 10.1128/AEM.55.12.3178-3183.1989; ASANO Y, 1992, FRONTIERS AND NEW HORIZONS IN AMINO ACID RESEARCH, P333; ASANO Y, 1989, J BIOL CHEM, V264, P14233; ASANO Y, 1992, BIOCHEMISTRY-US, V31, P2316, DOI 10.1021/bi00123a016; COQUE JJR, 1993, EMBO J, V12, P631, DOI 10.1002/j.1460-2075.1993.tb05696.x; DUEZ C, 1987, EUR J BIOCHEM, V162, P509, DOI 10.1111/j.1432-1033.1987.tb10669.x; FRERE JM, 1985, CRC CR REV MICROBIOL, V11, P299; GALLENI M, 1988, BIOCHEM J, V250, P753, DOI 10.1042/bj2500753; HOBBS M, 1991, MOL MICROBIOL, V5, P543, DOI 10.1111/j.1365-2958.1991.tb00726.x; JORIS B, 1985, BIOCHEM J, V228, P241, DOI 10.1042/bj2280241; JORIS B, 1986, BIOCHEM J, V239, P581, DOI 10.1042/bj2390581; LINDBERG F, 1986, EUR J BIOCHEM, V156, P441, DOI 10.1111/j.1432-1033.1986.tb09601.x; Maniatis T., 1982, MOL CLONING; MCKAY DB, 1992, J GEN MICROBIOL, V138, P701, DOI 10.1099/00221287-138-4-701; MEZES PSF, 1983, FEBS LETT, V161, P195, DOI 10.1016/0014-5793(83)81006-0; Milton S. C. F., 1992, SCIENCE, V256, P1445; POPHAM DL, 1993, J BACTERIOL, V175, P2917, DOI 10.1128/JB.175.10.2917-2925.1993; PRATT RF, 1984, P NATL ACAD SCI-BIOL, V81, P1302, DOI 10.1073/pnas.81.5.1302; REYNOLDS PE, 1994, MOL MICROBIOL, V13, P1065, DOI 10.1111/j.1365-2958.1994.tb00497.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEEHAN JC, 1965, J AM CHEM SOC, V87, P2492, DOI 10.1021/ja01089a034; SIMONEN M, 1993, MICROBIOL REV, V57, P109, DOI 10.1128/MMBR.57.1.109-137.1993; Sneath P. H., 1986, BERGEYS MANUAL SYSTE, V2, P1104; SUGIE M, 1986, AGR BIOL CHEM TOKYO, V50, P1397, DOI 10.1080/00021369.1986.10867589; TAKASE K, 1988, J BIOL CHEM, V263, P11548; TARBELL DS, 1972, P NATL ACAD SCI USA, V69, P730, DOI 10.1073/pnas.69.3.730; VAUGHAN JR, 1952, J AM CHEM SOC, V74, P676, DOI 10.1021/ja01123a028	28	59	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30256	30262		10.1074/jbc.271.47.30256	http://dx.doi.org/10.1074/jbc.271.47.30256			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939979	hybrid			2022-12-27	WOS:A1996VU52500107
J	Codina, J; Kone, BC; DelmasMata, JT; Dubose, TD				Codina, J; Kone, BC; DelmasMata, JT; Dubose, TD			Functional expression of the colonic H+,K+-ATPase alpha-subunit - Pharmacologic properties and assembly with X(+),K+-ATPase beta-subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT DISTAL COLON; K+-ATPASE; GASTRIC H+,K+-ATPASE; GENE FAMILY; OUABAIN; H,K-ATPASE; CLONING; KIDNEY; NA+; NA+,K+-ATPASE	The functional and pharmacological properties of the a-subunit of the colonic H+,K+-ATPase (alpha(C)) were studied in Xenopus laevis oocytes. alpha(C) was injected with different rat beta-subunits, the beta-subunit of the gastric H+,K+-ATPase (beta(G), the only H+,K+-ATPase beta-subunit identified in rat), or the beta(1)-subunit of the Na+,K+-ATPase (beta(1)) (associated with the basolateral Na+,K+-ATPase, but also expressed in the epithelial apical membranes of rat distal colon) (Marxer, A., Stieger, B., Quarini, A., Kashgarian, M., and Hauri, H. P. (1989) J. Cell Biol. 109, 1057-1069). The effect of the different beta-subunits was studied by measuring Rb-86(+) uptake (a K+ congener) in the presence or absence of Sch-28080 and ouabain. Significant Na+-independent Rb-86(+) uptake was observed only when alpha(C) was coexpressed with one of the beta-subunits. The expressed alpha(C) beta(1) and alpha(C) beta(G) complexes were not inhibited by Sch-28080, were only partially sensitive to ouabain (IC50 = 400-600 mu M, in the presence of external 1 mm KCl), and exhibited comparable K+ activation kinetics. Coexpression of alpha(C) with epitope-tagged beta(G) or beta(1), followed by immunopurification of the alpha beta complexes, confirmed stable assembly of alpha(C) beta(G) and alpha(C) beta(1) complexes. Since the beta(1)-subunit, but not the alpha(1)-subunit, of Na+,K+-ATPase is expressed in the apical membrane of rat colonocytes, our data support the view that, in rat distal colon, the beta(1)-subunit may play a surrogate role as the beta-subunit for the colonic H+,K+-ATPase.	UNIV TEXAS,SCH MED,DEPT INTERNAL MED,DIV RENAL DIS & HYPERTENS,HOUSTON,TX 77030; UNIV TEXAS,SCH MED,DEPT INTEGRAT BIOL,HOUSTON,TX 77030	University of Texas System; University of Texas System					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047981, R29DK047981, R01DK030603] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-30603, DK-47981] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAMSE SI, 1995, BIOCHEM BIOPH RES CO, V207, P1003, DOI 10.1006/bbrc.1995.1284; Ahn KY, 1996, AM J PHYSIOL-RENAL, V271, pF314, DOI 10.1152/ajprenal.1996.271.2.F314; Ahn KY, 1996, AM J PHYSIOL-RENAL, V270, pF557, DOI 10.1152/ajprenal.1996.270.4.F557; CANESSA CM, 1992, EMBO J, V11, P1681, DOI 10.1002/j.1460-2075.1992.tb05218.x; CHEVAL L, 1991, AM J PHYSIOL, V260, pF800, DOI 10.1152/ajprenal.1991.260.6.F800; Cougnon M, 1996, J BIOL CHEM, V271, P7277, DOI 10.1074/jbc.271.13.7277; CROWSON MS, 1992, J BIOL CHEM, V267, P13740; DELCASTILLO JR, 1994, AM J PHYSIOL, V266, pG1083, DOI 10.1152/ajpgi.1994.266.6.G1083; DELCASTILLO JR, 1991, AM J PHYSIOL, V261, pG1005, DOI 10.1152/ajpgi.1991.261.6.G1005; DUBOSE TD, 1995, AM J PHYSIOL-RENAL, V269, pF500, DOI 10.1152/ajprenal.1995.269.4.F500; EAKLE KA, 1995, J BIOL CHEM, V270, P13937, DOI 10.1074/jbc.270.23.13937; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FOSTER ES, 1985, GASTROENTEROLOGY, V88, P41, DOI 10.1016/S0016-5085(85)80130-X; GALLAGHAN JM, 1995, AM J PHYSIOL, V268, pF363; GRISHIN AV, 1994, FEBS LETT, V349, P144, DOI 10.1016/0014-5793(94)00655-5; HORISBERGER JD, 1991, J BIOL CHEM, V266, P19131; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JAISSER F, 1993, PFLUG ARCH EUR J PHY, V425, P446, DOI 10.1007/BF00374871; JAISSER F, 1993, J CELL BIOL, V123, P1421, DOI 10.1083/jcb.123.6.1421; JAISSER F, 1995, AM J PHYSIOL, V39, pC679; Kone BC, 1996, MINER ELECTROL METAB, V22, P349; LEE JS, 1995, J CLIN INVEST, V96, P2002, DOI 10.1172/JCI118247; LEMAS MV, 1994, J BIOL CHEM, V269, P18651; MARXER A, 1989, J CELL BIOL, V109, P1057, DOI 10.1083/jcb.109.3.1057; MCDONOUGH AA, 1994, AM J PHYSIOL-CELL PH, V267, pC901, DOI 10.1152/ajpcell.1994.267.4.C901; MODYANOV NN, 1995, AM J PHYSIOL-CELL PH, V269, pC992, DOI 10.1152/ajpcell.1995.269.4.C992; Palasis M, 1996, J BIOL CHEM, V271, P14176, DOI 10.1074/jbc.271.24.14176; PANDIYAN V, 1992, GASTROENTEROLOGY, V102, P1846, DOI 10.1016/0016-5085(92)90304-H; Parent L, 1995, BIOPHYS J, V69, P1801, DOI 10.1016/S0006-3495(95)80050-0; RABON E, 1985, J BIOL CHEM, V260, P200; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHULL GE, 1990, J BIOL CHEM, V265, P12123; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SUSUKI Y, 1993, JPN J PHYSL, V43, P291; SVERDLOV ED, 1991, GENETICA, V85, P91, DOI 10.1007/BF00056110; VACHON V, 1995, BIOCHEMISTRY-US, V34, P15157, DOI 10.1021/bi00046a023; WALLMARK B, 1987, J BIOL CHEM, V262, P2077; WATANABE T, 1990, AM J PHYSIOL, V258, pG506, DOI 10.1152/ajpgi.1990.258.4.G506; WATANABE T, D21854 GEN; WINGO CS, 1995, AM J PHYSIOL-RENAL, V269, pF1, DOI 10.1152/ajprenal.1995.269.1.F1; YOUNESIBRAHIM M, 1995, AM J PHYSIOL-RENAL, V268, pF1141, DOI 10.1152/ajprenal.1995.268.6.F1141; YOUNG RM, 1987, J BIOL CHEM, V262, P4905	43	79	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29759	29763		10.1074/jbc.271.47.29759	http://dx.doi.org/10.1074/jbc.271.47.29759			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939912	hybrid			2022-12-27	WOS:A1996VU52500040
J	Ghanta, J; Shen, CL; Kiessling, LL; Murphy, RM				Ghanta, J; Shen, CL; Kiessling, LL; Murphy, RM			A strategy for designing inhibitors of beta-amyloid toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; CELL-DEATH; PEPTIDE; PROTEIN; AMYLOIDOGENICITY; PATHOGENESIS; FRAGMENTS	beta-Amyloid peptide is the major protein component of Alzheimer's plaques. When aggregated into amyloid fibrils, the peptide is toxic to neuronal cells. Here, an approach to the design of inhibitors of beta-amyloid toxicity is described; in this strategy, a recognition element, which interacts specifically with beta-amyloid, is combined with a disrupting element, which alters beta-amyloid aggregation pathways. The synthesis, biophysical characterization, and biological activity of such an inhibitor is reported, This prototype inhibitor is composed of residues 15-25 of beta-amyloid peptide, designed to function as the recognition element, linked to an oligolysine disrupting element. The inhibitor does not alter the apparent secondary structure of beta-amyloid nor prevent its aggregation; rather, it causes changes in aggregation kinetics and higher order structural characteristics of the aggregate. Evidence for these effects includes changes in fibril morphology and a reduction in thioflavin T fluorescence, In addition to its influence on the physical properties of beta-amyloid aggregates, the inhibitor completely blocks beta-amyloid toxicity to PC-12 cells. Together, these data suggest that this general strategy for design of beta-amyloid toxicity inhibitors is effective, Significantly, these results demonstrate that complete disruption of amyloid fibril formation is not necessary for abrogation of toxicity.	UNIV WISCONSIN,DEPT CHEM,MADISON,WI 53706; UNIV WISCONSIN,DEPT CHEM ENGN,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison			Kiessling, Laura L/A-4074-2008	Kiessling, Laura/0000-0001-6829-1500				CAMILLERI P, 1994, FEBS LETT, V341, P256, DOI 10.1016/0014-5793(94)80467-2; Esler WP, 1996, BIOCHEMISTRY-US, V35, P749, DOI 10.1021/bi951685w; FRASER PE, 1994, J MOL BIOL, V244, P64, DOI 10.1006/jmbi.1994.1704; FRASER PE, 1991, BIOPHYS J, V60, P1190, DOI 10.1016/S0006-3495(91)82154-3; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HALVERSON K, 1990, BIOCHEMISTRY-US, V29, P2639, DOI 10.1021/bi00463a003; HILBICH C, 1992, J MOL BIOL, V228, P460, DOI 10.1016/0022-2836(92)90835-8; Hughes SR, 1996, P NATL ACAD SCI USA, V93, P2065, DOI 10.1073/pnas.93.5.2065; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JOACHIM CL, 1992, ALZ DIS ASSOC DIS, V6, P7, DOI 10.1097/00002093-199205000-00003; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; LEE JP, 1995, BIOCHEMISTRY-US, V34, P5191, DOI 10.1021/bi00015a033; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Lomakin A, 1996, P NATL ACAD SCI USA, V93, P1125, DOI 10.1073/pnas.93.3.1125; PIKE CJ, 1993, J NEUROSCI, V13, P1676; POLLACK SJ, 1995, NEUROSCI LETT, V197, P211, DOI 10.1016/0304-3940(95)11939-T; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; SHEN CL, 1995, BIOPHYS J, V69, P640, DOI 10.1016/S0006-3495(95)79940-4; SHEN CL, 1993, BIOPHYS J, V65, P2383, DOI 10.1016/S0006-3495(93)81312-2; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; TERZI E, 1995, J MOL BIOL, V252, P633, DOI 10.1006/jmbi.1995.0525; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; UEDA K, 1994, BRAIN RES, V639, P240, DOI 10.1016/0006-8993(94)91736-1; WONG CW, 1985, P NATL ACAD SCI USA, V82, P8729, DOI 10.1073/pnas.82.24.8729; WOOD SJ, 1995, BIOCHEMISTRY-US, V34, P724, DOI 10.1021/bi00003a003; Wood SJ, 1996, J BIOL CHEM, V271, P4086	26	208	226	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29525	29528		10.1074/jbc.271.47.29525	http://dx.doi.org/10.1074/jbc.271.47.29525			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939877	hybrid			2022-12-27	WOS:A1996VU52500005
J	Koller, E; Ranscht, B				Koller, E; Ranscht, B			Differential targeting of T- and N-cadherin in polarized epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE UVOMORULIN; PROTEIN TYROSINE KINASES; GLYCOSYL-PHOSPHATIDYLINOSITOL; CYTOPLASMIC DOMAIN; MEMBRANE-PROTEINS; ANCHORED PROTEINS; SURFACE POLARITY; MDCK CELLS; EXPRESSION; SIGNAL	To test whether glycosyl phosphatidylinositol-linked T-cadherin is a component of cell junctions like classical cadherins, we have examined its distribution and targeting in polarized epithelial cells. In vivo, T-cadherin was detected on the apical cell surface of the chick intestinal epithelium. In cultures of transfected Madin-Darby canine kidney cells, T-cadherin was also expressed apically, whereas classical N-cadherin resided basolaterally, Both cadherins were directly targeted to their respective membrane domains, Mutant proteins were expressed in Madin-Darby canine kidney cells to identify the regions responsible for differential cadherin localization. N Delta cyt, an N-cadherin cytoplasmic domain deletion mutant, was stably distributed basolaterally, This mutant was transported to both the apical and basolateral membrane compartments, followed by preferential removal from the apical surface, T-N Delta cyt, a T-cadherin mutant with the N-cadherin cytoplasmic domain deletion, was localized basolaterally, whereas N-T-GPI, a GPI-anchored N-cadherin mutant, resided at the apical domain, The T-cadherin carboxyl-terminal 76 amino acids contain the apical targeting signal and include the signal for GPI anchor attachment. Basolateral localization of N-cadherin is achieved through targeting signals in the cytoplasmic domain, Thus, GPI-linked T-cadherin is not a component of cell junctions, consistent with a function as a recognition rather than a cell adhesion molecule.	BURNHAM INST, LA JOLLA CANC RES CTR, LA JOLLA, CA 92307 USA	Sanford Burnham Prebys Medical Discovery Institute					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048077] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48077] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMERONGEN HM, 1989, J CELL BIOL, V109, P2129, DOI 10.1083/jcb.109.5.2129; BEHRENS J, 1985, J CELL BIOL, V101, P1307, DOI 10.1083/jcb.101.4.1307; BERNDORFF D, 1994, J CELL BIOL, V125, P1353, DOI 10.1083/jcb.125.6.1353; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; CHEN YT, 1995, COLD SPRING HARBO S, V60, P34; CIFUENTESDIAZ C, 1994, DEVELOPMENT, V120, P1; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; Doyle D. D., 1995, Molecular Biology of the Cell, V6, p403A; FREDETTE BJ, 1994, J NEUROSCI, V14, P7331; FREDETTE BJ, 1996, IN PRESS DEV CAMB; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GONZAQLESMARISC.L, 1985, J MEMBRANE BIOL, V96, P113; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; GUMBINER BM, 1993, NEURON, V11, P551, DOI 10.1016/0896-6273(93)90068-3; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; HOESSLI D, 1985, EXP CELL RES, V156, P239, DOI 10.1016/0014-4827(85)90278-2; HOPKINS CR, 1991, CELL, V66, P827, DOI 10.1016/0092-8674(91)90427-Z; IMHOF BA, 1983, CELL, V35, P667, DOI 10.1016/0092-8674(83)90099-5; KIRKPATRICK C, 1995, CURR OPIN GENET DEV, V5, P56, DOI 10.1016/S0959-437X(95)90054-3; KODUKULA K, 1993, J CELL BIOL, V120, P657, DOI 10.1083/jcb.120.3.657; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; Nagafuchi A, 1993, Semin Cell Biol, V4, P175, DOI 10.1006/scel.1993.1021; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NELSON WJ, 1986, J CELL BIOL, V103, P1751, DOI 10.1083/jcb.103.5.1751; OJAKIAN GK, 1994, J CELL SCI, V107, P561; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; RANSCHT B, 1991, NEURON, V7, P391, DOI 10.1016/0896-6273(91)90291-7; RANSCHT B, 1991, DEVELOPMENT, V111, P15; RODRIGUEZBOULAN E, 1989, METHOD CELL BIOL, V32, P37; SACRISTAN MP, 1993, J NEUROSCI RES, V34, P664, DOI 10.1002/jnr.490340610; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SHENOYSCARIA AM, 1992, J IMMUNOL, V149, P3535; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VEGASALAS DE, 1987, J CELL BIOL, V104, P1249, DOI 10.1083/jcb.104.5.1249; VESTAL DJ, 1992, J CELL BIOL, V119, P451, DOI 10.1083/jcb.119.2.451; VOLK T, 1984, EMBO J, V3, P2249, DOI 10.1002/j.1460-2075.1984.tb02123.x; WOLLNER DA, 1992, J CELL BIOL, V116, P889, DOI 10.1083/jcb.116.4.889; ZISCH AH, 1995, MOL CELL NEUROSCI, V6, P263, DOI 10.1006/mcne.1995.1021; [No title captured]	50	41	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30061	30067		10.1074/jbc.271.47.30061	http://dx.doi.org/10.1074/jbc.271.47.30061			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939953	hybrid			2022-12-27	WOS:A1996VU52500081
J	Linder, B; Jin, ZJ; Freedman, JH; Rubin, CS				Linder, B; Jin, ZJ; Freedman, JH; Rubin, CS			Molecular characterization of a novel, developmentally regulated small embryonic chaperone from Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; HEAT-SHOCK PROTEINS; ALPHA-CRYSTALLIN; ACTIN POLYMERIZATION; BINDING-PROTEIN; C-ELEGANS; II-BETA; GENE; EXPRESSION; CLONING	Low molecular weight chaperones inhibit protein aggregation and facilitate refolding of partially denatured polypeptides in cells subjected to physical and chemical stresses. The nematode Caenorhabditis elegans provides a system amenable for investigations on roles for chaperone proteins in normal homeostasis and development, We characterized a C. elegans gene and cDNAs that encode a novel, small embryonic chaperone-like protein (SEC-1) that is composed of 159 amino acids, The central core of SEC-1 (residues 45-126) is similar to 40% identical with a corresponding segment of mammalian Hsp27 and alpha B crystallin, Expression of SEC-1 in Escherichia coli confers thermotolerance on the bacterium. SEC-1 mRNA is evident only in C. elegans oocytes and developing embryos. Translation and accumulation of SEC-1 protein is temporally coupled with a prolonged burst of intense protein synthesis and rapid mitogenesis during early embryogenesis. As the rate of protein synthesis decreases during late embryogenesis, levels of SEC-1 and its cognate mRNA decline precipitously. Induction/deinduction of SEC-1 is precisely regulated by intrinsic developmental factors rather than extrinsic stresses, In vivo injection of C. elegans oocytes with antisense oligonucleotides that complement the 5'-end of SEC-1 mRNA arrests nematode development at an early stage after fertilization, Thus, SEC-1 appears to be adapted to perform essential functions in early embryogenesis.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOL PHARMACOL,ATRAN LABS,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PEDIAT,ATRAN LABS,BRONX,NY 10461; DUKE UNIV,SCH ENVIRONM,DURHAM,NC 27708	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Duke University					NATIONAL CANCER INSTITUTE [R01CA061337] Funding Source: NIH RePORTER; NCI NIH HHS [CA 61337] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CHRETIEN P, 1989, J CELL BIOL, V137, P7; CIOCCA DR, 1993, JNCI-J NATL CANCER I, V85, P1558, DOI 10.1093/jnci/85.19.1558; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FREEDMAN JH, 1993, J BIOL CHEM, V268, P2554; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HESCHL MFP, 1989, DNA-J MOLEC CELL BIO, V8, P233, DOI 10.1089/dna.1.1989.8.233; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HU E, 1991, J BIOL CHEM, V266, P19796; HU ED, 1990, J BIOL CHEM, V265, P5072; IWAKI A, 1990, J BIOL CHEM, V265, P22197; JAKOB U, 1993, J BIOL CHEM, V268, P1517; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JONES D, 1986, J BIOL CHEM, V261, P2006; KENYON C, 1988, SCIENCE, V240, P1448, DOI 10.1126/science.3287621; LAND M, 1994, J BIOL CHEM, V269, P9234; LANDRY J, 1992, J BIOL CHEM, V267, P794; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LU XY, 1990, J BIOL CHEM, V265, P3293; MERCK KB, 1993, J BIOL CHEM, V268, P1046; MIRON T, 1988, EUR J BIOCHEM, V178, P543, DOI 10.1111/j.1432-1033.1988.tb14481.x; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; NOVER L, HEAT SHOCK RESPONSE, P41; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; QUAXJEUKEN Y, 1985, P NATL ACAD SCI USA, V82, P5819, DOI 10.1073/pnas.82.17.5819; REEDER RH, 1983, CELL, V35, P449, DOI 10.1016/0092-8674(83)90178-2; ROSS LH, 1995, J BIOL CHEM, V270, P22066, DOI 10.1074/jbc.270.37.22066; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RUSSNAK RH, 1985, MOL CELL BIOL, V5, P1268, DOI 10.1128/MCB.5.6.1268; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155; SLICE LW, 1990, J BIOL CHEM, V265, P256; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; SNUTCH TP, 1988, GENE, V64, P241, DOI 10.1016/0378-1119(88)90339-3; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; SULSTON J, 1988, NEMATODE CAENORHABDI, P123; Sulston J., 1988, NEMATODE CAENORHABDI, P603; WADSWORTH WG, 1988, P NATL ACAD SCI USA, V85, P8435, DOI 10.1073/pnas.85.22.8435; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Wood W. B., 1988, NEMATODE C ELEGANS, P215; WOOD WB, 1980, DEV BIOL, V74, P446, DOI 10.1016/0012-1606(80)90445-5; [No title captured]	54	36	39	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30158	30166		10.1074/jbc.271.47.30158	http://dx.doi.org/10.1074/jbc.271.47.30158			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939966	hybrid			2022-12-27	WOS:A1996VU52500094
J	Jault, JM; Dou, C; Grodsky, NB; Matsui, T; Yoshida, M; Allison, WS				Jault, JM; Dou, C; Grodsky, NB; Matsui, T; Yoshida, M; Allison, WS			The alpha(3)beta(3)gamma subcomplex of the F-1-ATPase from the thermophilic Bacillus PS3 with the beta T165S substitution does not entrap inhibitory MgADP in a catalytic site during turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; NUCLEOTIDE-BINDING-SITES; GLYCINE-RICH SEQUENCE; STEADY-STATE KINETICS; ESCHERICHIA-COLI; ATP HYDROLYSIS; NONCATALYTIC SITES; BETA-SUBUNIT; F1 ATPASE; ALPHA-3-BETA-3 COMPLEX	The hydrolytic properties of the mutant alpha(3)(beta T165S)(3) gamma and wild-type alpha(3) beta(3) gamma subcomplexes of TF1 have been compared. Whereas the wild-type complex hydrolyzes 50 mu M ATP in three kinetic phases, the mutant complex hydrolyzes 50 mu M ATP with a linear rate. After incubation with a slight excess of ADP in the presence of Mg2+, the wild-type complex hydrolyzes 2 mM ATP with a long lag. In contrast, prior incubation of the mutant complex under these conditions does not affect the kinetics of ATP hydrolysis. The ATPase activity of the wild-type complex is stimulated 4-fold by 0.1% lauryl dimethylamine oxide, whereas this concentration of lauryl dimethylamine oxide inhibits the mutant complex by 25%. Compared with the wild-type complex, the activity of the mutant complex is much less sensitive to turnover-dependent inhibition by azide. This comparison suggests that the mutant complex does not-entrap substantial inhibitory MgADP in a catalytic site during turnover, which is supported by the following observations. ATP hydrolysis catalyzed by the wild-type complex is progressively inhibited by increasing concentrations of Mg2+ in the assay medium, whereas the mutant complex is insensitive to increasing concentrations of Mg2+. A Lineweaver-Burk plot constructed from rates of hydrolysis of 20-2000 mu M ATP by the wild-type complex is biphasic, exhibiting apparent K-m values of 30 Cur and 470 mu M with corresponding k(cat) values of 26 and 77 s(-1). In contrast; a Lineweaver-Burk plot for the mutant complex is linear in this range of ATP concentration, displaying a K-m of 133 mu M and a k(cat) of 360 s(-1).	UNIV CALIF SAN DIEGO, SCH MED, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA; TOKYO INST TECHNOL, RESOURCES UTILIZAT RES LAB, YOKOHAMA, KANAGAWA 227, JAPAN	University of California System; University of California San Diego; Tokyo Institute of Technology			jault, jean-michel/G-2086-2012	jault, jean-michel/0000-0003-1743-2777	NIGMS NIH HHS [GM-16974] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Allison WS, 1995, BIOCHEM SOC T, V23, P752, DOI 10.1042/bst0230752; ALLISON WS, 1992, J BIOENERG BIOMEMBR, V24, P469, DOI 10.1007/BF00762364; AMANO T, 1994, FEBS LETT, V351, P1, DOI 10.1016/0014-5793(94)00796-9; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULYGIN VV, 1991, BIOCHEM J, V276, P149, DOI 10.1042/bj2760149; Cross RL, 1992, MOL MECHANISMS BIOEN, P317; DROBINSKAYA IY, 1985, FEBS LETT, V182, P419, DOI 10.1016/0014-5793(85)80346-X; EBEL RE, 1975, J BIOL CHEM, V250, P191; GRESSER MJ, 1982, J BIOL CHEM, V257, P2030; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; GUERRERO KJ, 1990, J BIOL CHEM, V265, P16280; Guggenheim EA, 1926, PHILOS MAG, V2, P538; HATEFI Y, 1993, EUR J BIOCHEM, V218, P759, DOI 10.1111/j.1432-1033.1993.tb18431.x; HYNDMAN DJ, 1994, J BIOL CHEM, V269, P28871; Jault JM, 1995, BIOCHEMISTRY-US, V34, P16412, DOI 10.1021/bi00050a023; JAULT JM, 1993, J BIOL CHEM, V268, P1558; JAULT JM, 1994, J BIOL CHEM, V269, P319; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KAGAWA Y, 1989, FEBS LETT, V249, P67, DOI 10.1016/0014-5793(89)80017-1; KASHO VN, 1984, J BIOENERG BIOMEMBR, V16, P407, DOI 10.1007/BF00743235; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; MILGROM YM, 1989, BIOCHIM BIOPHYS ACTA, V975, P50, DOI 10.1016/S0005-2728(89)80200-2; MILGROM YM, 1991, J BIOL CHEM, V266, P11551; MIWA K, 1989, P NATL ACAD SCI USA, V86, P6484, DOI 10.1073/pnas.86.17.6484; MUELLER DM, 1994, EUR J BIOCHEM, V222, P991, DOI 10.1111/j.1432-1033.1994.tb18950.x; MUELLER DM, 1989, J BIOL CHEM, V264, P16552; MURATALIEV MB, 1991, BIOCHEMISTRY-US, V30, P8305, DOI 10.1021/bi00098a004; MURATALIEV MB, 1992, BIOCHEMISTRY-US, V31, P12885, DOI 10.1021/bi00166a025; OMOTE H, 1992, J BIOL CHEM, V267, P20571; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PAIK SR, 1994, BIOCHEMISTRY-US, V33, P126, DOI 10.1021/bi00167a016; PAIK SR, 1993, J BIOENERG BIOMEMBR, V25, P679; PAIK SR, 1994, BIOCHEMISTRY-US, V33, P125; PEDERSEN PL, 1993, J BIOL CHEM, V268, P9937; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RECKTENWALD D, 1977, FEBS LETT, V76, P25, DOI 10.1016/0014-5793(77)80113-0; ROVERI OA, 1985, FEBS LETT, V192, P123, DOI 10.1016/0014-5793(85)80056-9; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SAUGER F, 1980, J MOL BIOL, V143, P161; SCHUSTER SM, 1975, J BIOL CHEM, V250, P7848; SHEN HG, 1994, J BIOL CHEM, V269, P9424; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; TAKEYAMA M, 1990, J BIOL CHEM, V265, P21279; VASILYEVA EA, 1982, BIOCHEM J, V202, P15, DOI 10.1042/bj2020015; VASILYEVA EA, 1982, BIOCHEM J, V202, P9, DOI 10.1042/bj2020009; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEBER J, 1993, J BIOL CHEM, V268, P20126; Weber J, 1996, J BIOL CHEM, V271, P3474; WONG SY, 1984, BIOCHEMISTRY-US, V23, P5004, DOI 10.1021/bi00316a027; YOHDA M, 1988, BIOCHIM BIOPHYS ACTA, V933, P156, DOI 10.1016/0005-2728(88)90065-5; YOKOYAMA K, 1989, J BIOL CHEM, V264, P21837; YOSHIDA M, 1981, J BIOL CHEM, V256, P148; YOSHIDA M, 1983, J BIOL CHEM, V258, P4407; YOSHIDA M, 1986, J BIOL CHEM, V261, P5714; ZHOU JM, 1988, BIOCHEMISTRY-US, V27, P5129, DOI 10.1021/bi00414a027	58	62	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28818	28824		10.1074/jbc.271.46.28818	http://dx.doi.org/10.1074/jbc.271.46.28818			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910526	hybrid			2022-12-27	WOS:A1996VT05200018
J	Laughlin, MR; Thompson, D				Laughlin, MR; Thompson, D			The regulatory role for magnesium in glycolytic flux of the human erythrocyte	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MODEL; CELL	P-31 NMR was used to measure the intracellular free magnesium concentration ([Mg2+](i)) in human erythrocytes while [Mg2+](i) was changed between 0.01 and 1.2 mM using the divalent cationophore A23187. C-13 NMR and [2-C-13]glucose were used to determine the kinetic effects of [Mg2+](i) by measuring the flux through several parts of the glucose pathway. Glucose utilization was strongly dependent on [Mg2+](i), With half-maximal flux occurring at 0.03 mM. The rate-limiting step was most likely at phosphofructokinase, which has a K-m(Mg2+) Of 0.025 mM in the purified enzyme, Phosphorylated glycolytic intermediate concentration was also strongly dependent on [Mg2+](i) and [MgATP], and glucose transport plus hexokinase may have been partially rate-determining at [Mg2+](i) below similar to 0.1 mM. The pentose phosphate shunt activity was too low to determine the dependence on [Mg2+](i). Phosphoglycerate kinase and 2,3-diphosphoglycerate mutase fluxes were also measured, but were not rate-limiting for glycolysis and showed no Mg2+ dependence. Human erythrocyte [Mg2+](i) varies between 0.2 mM (oxygenated) and 0.6 an (deoxygenated), well above the measured [Mg2+](i(1/2)). It is unlikely, then, that [Mg2+](i) plays a regulatory role in normal erythrocyte glycolysis.			Laughlin, MR (corresponding author), GEORGE WASHINGTON UNIV,MED CTR,DEPT SURG,ROSS HALL 550,2300 EYE ST NW,WASHINGTON,DC 20037, USA.							ENGSTROM I, 1993, SCAND J CLIN LAB INV, V53, P239, DOI 10.3109/00365519309088415; ENGSTROM I, 1993, CLIN CHIM ACTA, V219, P113, DOI 10.1016/0009-8981(93)90202-F; FERREIRA HG, 1976, NATURE, V259, P47, DOI 10.1038/259047a0; FLATMAN P, 1977, NATURE, V267, P360, DOI 10.1038/267360a0; GERBER G, 1974, EUR J BIOCHEM, V45, P39, DOI 10.1111/j.1432-1033.1974.tb03527.x; GEVEN WB, 1991, CLIN CHEM, V37, P206; GRIMES AJ, 1960, ANAEROBIC GLYCOLYSIS; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; MINAKAMI S, 1966, J BIOCHEM, V59, P145, DOI 10.1093/oxfordjournals.jbchem.a128275; MOSHER TJ, 1992, MAGNET RESON MED, V24, P163, DOI 10.1002/mrm.1910240117; MURPHY JR, 1960, J LAB CLIN MED, V55, P286; OTTO M, 1974, EUR J BIOCHEM, V49, P169, DOI 10.1111/j.1432-1033.1974.tb03822.x; PALSSON BO, 1989, RED CELL 7 ANN ARB C, P133; PONCE J, 1971, BIOCHIM BIOPHYS ACTA, V250, P63, DOI 10.1016/0005-2744(71)90120-3; RUDE RK, 1991, MAGNESIUM TRACE ELEM, V92, P117; SCHRADER MC, 1993, BIOCHIM BIOPHYS ACTA, V1182, P162, DOI 10.1016/0925-4439(93)90138-Q; TILTON WM, 1991, J LAB CLIN MED, V118, P146; TONGYAI S, 1989, AM J PHYSIOL, V257, pC270, DOI 10.1152/ajpcell.1989.257.2.C270	18	39	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28977	28983		10.1074/jbc.271.46.28977	http://dx.doi.org/10.1074/jbc.271.46.28977			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910548	hybrid			2022-12-27	WOS:A1996VT05200040
J	Mazzorana, M; Snellman, A; Kivirikko, KI; vanderRest, M; Pihlajaniemi, T				Mazzorana, M; Snellman, A; Kivirikko, KI; vanderRest, M; Pihlajaniemi, T			Involvement of prolyl 4-hydroxylase in the assembly of trimeric minicollagen XII - Study in a baculovirus expression system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; SITE-DIRECTED MUTAGENESIS; BETA-SUBUNIT; HISTIDINE-RESIDUES; MOLECULAR-CLONING; ALPHA-SUBUNIT; COLLAGEN-XIV; PROCOLLAGEN; IDENTIFICATION; HYDROXYLATION	We have shown previously that hydroxylation played a critical role in the trimer assembly and disulfide bonding of the three constituent alpha chains of a minicollagen composed of the extreme C-terminal collagenous (COL1) and noncollagenous (NC1) domains of type XII collagen in HeLa cells (Mazzorana, M., Gruffat, H., Sergeant, A., and van der Rest, M. (1993) J. Biol. Chem. 268, 3029-3032). We have further characterized the involvement of prolyl 4-hydroxylase in the assembly of the three alpha chains to form trimeric disulfide-bonded type XII minicollagen in an insect cell expression system. For this purpose, type XII minicollagen was produced in insect cells from baculovirus vectors, alone or together with wild-type human prolyl 4-hydroxylase or with the human enzyme mutated in the catalytic site of its alpha or beta subunits or with the individual alpha or beta subunits. When type XII minicollagen was produced alone, negligible amounts of disulfide-bonded trimers were found to be produced by the cells. However, coproduction of the collagen with the two subunits of the wild-type human enzyme dramatically increased the amount of disulfide-bonded trimeric type XII minicollagen molecules. In contrast, coproduction of the collagen with alpha subunits that had a mutation completely inactivating the human enzyme failed to enhance the trimer assembly. These results directly show that an active prolyl 4-hydroxylase is required for the assembly of disulfide-bonded trimers of type XII minicollagen.	UNIV OULU, BIOCTR, COLLAGEN RES UNIT, FIN-90220 OULU, FINLAND; UNIV OULU, DEPT MED BIOCHEM, FIN-90220 OULU, FINLAND	University of Oulu; University of Oulu	Mazzorana, M (corresponding author), INST BIOL & CHIM PROT, CNRS, UPR 412, 7 PASSAGE VERCORS, F-69367 LYON 07, FRANCE.			Pihlajaniemi, Taina/0000-0002-1664-9045; MAZZORANA, Marlene/0000-0002-3956-4319				BACHINGER HP, 1981, J BIOL CHEM, V256, P3193; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9; BROWN JC, 1994, MATRIX BIOL, V14, P287, DOI 10.1016/0945-053X(94)90194-5; BROWN JC, 1993, J CELL BIOL, V120, P557, DOI 10.1083/jcb.120.2.557; BROWN M, 1977, J GEN VIROL, V36, P361, DOI 10.1099/0022-1317-36-2-361; BRUCKNER P, 1981, EUR J BIOCHEM, V118, P607, DOI 10.1111/j.1432-1033.1981.tb05562.x; BRUCKNER P, 1984, EUR J BIOCHEM, V140, P391, DOI 10.1111/j.1432-1033.1984.tb08114.x; DOEGE KJ, 1986, J BIOL CHEM, V261, P8924; DUBLET B, 1987, J BIOL CHEM, V262, P17724; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FESSLER LI, 1974, J BIOL CHEM, V249, P7637; FONT B, 1993, J BIOL CHEM, V268, P25015; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; FUKAI N, 1994, METHOD ENZYMOL, V245, P3; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; GORDON MK, 1987, P NATL ACAD SCI USA, V84, P6040, DOI 10.1073/pnas.84.17.6040; GRUENWALD S, 1993, BACULOVIRUS VECTOR E, P1; KEENE DR, 1991, J CELL BIOL, V113, P971, DOI 10.1083/jcb.113.4.971; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; KOIVU J, 1987, J BIOL CHEM, V262, P6447; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERG A, 1995, J BIOL CHEM, V270, P9926, DOI 10.1074/jbc.270.17.9926; Lamberg A, 1996, J BIOL CHEM, V271, P11988, DOI 10.1074/jbc.271.20.11988; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; LUNSTRUM GP, 1992, J BIOL CHEM, V267, P20087; MALITSCHEK B, 1991, BIOTECHNIQUES, V11, P177; Mayne R, 1993, CURR OPIN CELL BIOL, V5, P883, DOI 10.1016/0955-0674(93)90039-S; MAZZORANA M, 1993, J BIOL CHEM, V268, P3029; MAZZORANA M, 1995, MATRIX BIOL, V14, P583, DOI 10.1016/S0945-053X(05)80007-1; MYLLYLA R, 1992, BIOCHEM J, V286, P923, DOI 10.1042/bj2860923; NISHIYAMA T, 1994, J BIOL CHEM, V269, P28193; PARKKONEN T, 1988, BIOCHEM J, V256, P1005, DOI 10.1042/bj2561005; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; SUGRUE SP, 1989, J CELL BIOL, V109, P939, DOI 10.1083/jcb.109.2.939; SUGRUE SP, 1991, INVEST OPHTH VIS SCI, V32, P1876; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; VANDERPLAATS GN, 1993, STRUCT OPTIMIZATION, V6, P1, DOI 10.1007/BF01743168; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; VEIJOLA J, 1994, J BIOL CHEM, V269, P26746; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x; WATT SL, 1992, J BIOL CHEM, V267, P20093; Wickham T J, 1995, Methods Mol Biol, V39, P385	47	18	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29003	29008		10.1074/jbc.271.46.29003	http://dx.doi.org/10.1074/jbc.271.46.29003			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910551	hybrid			2022-12-27	WOS:A1996VT05200043
J	Schulein, R; Rutz, C; Rosenthal, W				Schulein, R; Rutz, C; Rosenthal, W			Membrane targeting and determination of transmembrane topology of the human vasopressin V2 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN; TRANSLOCATION; ORIENTATION; INSERTION; REQUIRES; CLONING	The human vasopressin V2 receptor belongs to the large family of G-protein-coupled receptors, which possess seven transmembrane helices, an extracellular N terminus and an intracellular C terminus. We have determined the sequence requirements of the V2 receptor for membrane insertion and correct topology for the inner membrane of Escherichia coli with the PhoA/LacZ gene fusion system. In addition, we have studied the signals for ifs membrane insertion and correct topology for the membrane of the endoplasmic reticulum of the authentic eucaryotic transport system. To this end, we have extended the PhoA/LacZ gene fusion system for the first time to eucaryotic cells, i.e. transiently transfected COS.M6 cells. Truncated V2 receptor sequences were fused to PhoA and LacZ and expressed in both E. coli and COS.M6 cells. Cells were fractionated, and LacZ/PhoA activity assays and immunoblots were performed. We show here that a V2 receptor fragment consisting of the N terminus, the first transmembrane segment and the first cytoplasmic loop (71 amino acids) provided sufficient information for membrane insertion and correct orientation (extracellular N terminus) in both procaryotic and eucaryotic cells. Our data differ substantially from those obtained for the human Pz-adrenergic receptor expressed in E. coli (Lacatena, R. M., Cellini, A. Scavizzi, F., and Tocchini-Valentini, G. P. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 10521-10525). To establish correct topology, the beta(2)-adrenergic receptor requires a larger receptor portion, including the three N-terminal transmembrane segments and/or parts of the second cytoplasmic loop. The present data show that the observations made for the beta(2)-adrenergic receptor cannot be applied to G-protein-coupled receptors generally.	UNIV GIESSEN,RUDOLF BUCHHEIM INST PHARMAKOL,D-35392 GIESSEN,GERMANY; FORSCHUNGSINST MOL PHARMAKOL,D-10315 BERLIN,GERMANY	Justus Liebig University Giessen								ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; DRIESSEN AJM, 1994, J MEMBRANE BIOL, V142, P145; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HENN DK, 1995, P NATL ACAD SCI USA, V92, P7425, DOI 10.1073/pnas.92.16.7425; HIGH S, 1991, J CELL BIOL, V113, P25, DOI 10.1083/jcb.113.1.25; HIGH S, 1992, Current Opinion in Cell Biology, V4, P581, DOI 10.1016/0955-0674(92)90075-N; JUNGNICKEL B, 1994, FEBS LETT, V346, P73, DOI 10.1016/0014-5793(94)00367-X; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; KOSHLAND D, 1980, CELL, V20, P749, DOI 10.1016/0092-8674(80)90321-9; LACATENA RM, 1994, P NATL ACAD SCI USA, V91, P10521, DOI 10.1073/pnas.91.22.10521; LOLAIT SJ, 1992, NATURE, V357, P336, DOI 10.1038/357336a0; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MANOIL C, 1990, J BACTERIOL, V172, P1035, DOI 10.1128/jb.172.2.1035-1042.1990; MARULLO S, 1988, P NATL ACAD SCI USA, V85, P7551, DOI 10.1073/pnas.85.20.7551; Miller J. H, 1972, EXPT MOL GENETICS; Perbal B., 1988, PRACTICAL GUIDE MOL; SAMBROOK J, 1989, MOL CLINING LAB MANU; SCHULEIN R, 1992, MOL GEN GENET, V234, P155; Schulein R, 1996, BIOCHEM J, V313, P611, DOI 10.1042/bj3130611; SPIESS M, 1995, FEBS LETT, V369, P76, DOI 10.1016/0014-5793(95)00551-J; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8	25	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28844	28852		10.1074/jbc.271.46.28844	http://dx.doi.org/10.1074/jbc.271.46.28844			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910530	hybrid			2022-12-27	WOS:A1996VT05200022
J	Christodoulidou, A; Bouriotis, V; Thireos, G				Christodoulidou, A; Bouriotis, V; Thireos, G			Two sporulation-specific chitin deacetylase-encoding genes are required for the ascospore wall rigidity of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUCOR-ROUXII; COLLETOTRICHUM-LINDEMUTHIANUM; CELL-CYCLE; YEAST; CHITOSAN; PURIFICATION; DITYROSINE; MATURATION; SYNTHASE-3; CSD2	The formation of the ascospore wall of Saccharomyces cerevisiae requires the coordinate activity of enzymes involved in the biosynthesis of its components such as chitosan, the deacetylated form of chitin, We have cloned the CDA1 and CDA2 genes which together account for the total chitin deacetylase activity of the organism. We hare shown that expression of these genes is restricted to a distinct time period during sporulation. The two genes are functionally redundant, each contributing equally to the total chitin deacetylase activity. Diploids disrupted for both genes sporulate as efficiently as wild type cells, and the resulting mutant spores are viable under standard laboratory conditions. However, they fail to emit the natural fluorescence of yeast spores imparted by the dityrosine residues of the outermost ascospore wall layer. Moreover, mutant spores are relatively sensitive to hydrolytic enzymes, ether, and heat shock, a fact that underscores the importance of the CDA genes for the proper formation of the ascospore wall.	FDN RES & TECHNOL HELLAS, INST MOL BIOL & BIOTECHNOL, GR-71110 IRAKLION, GREECE; UNIV CRETE, DEPT BIOL, IRAKLION, CRETE, GREECE	Foundation for Research & Technology - Hellas (FORTH); University of Crete								ALFONSO C, 1995, CURR MICROBIOL, V30, P49, DOI 10.1007/BF00294524; ARAKI Y, 1975, EUR J BIOCHEM, V55, P71, DOI 10.1111/j.1432-1033.1975.tb02139.x; ARAKI Y, 1988, METHOD ENZYMOL, V161, P510; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BALLOU CE, 1977, P NATL ACAD SCI USA, V74, P4351, DOI 10.1073/pnas.74.10.4351; Bartnicki-Garcia S., 1989, CHITIN CHITOSAN, P23; BARTNICKIGARCIA S, 1962, BIOCHIM BIOPHYS ACTA, V58, P102, DOI 10.1016/0006-3002(62)90822-3; BRIZA P, 1986, J BIOL CHEM, V261, P4288; BRIZA P, 1990, J BIOL CHEM, V265, P15118; BRIZA P, 1988, J BIOL CHEM, V263, P11569; BRIZA P, 1990, GENE DEV, V4, P1775, DOI 10.1101/gad.4.10.1775; BULAWA CE, 1992, MOL CELL BIOL, V12, P1764, DOI 10.1128/MCB.12.4.1764; BULAWA CE, 1993, ANNU REV MICROBIOL, V47, P505, DOI 10.1146/annurev.micro.47.1.505; CHOI WJ, 1994, MOL CELL BIOL, V14, P7685, DOI 10.1128/MCB.14.12.7685; CID VJ, 1995, MICROBIOL REV, V59, P345, DOI 10.1128/MMBR.59.3.345-386.1995; DAVIS LL, 1984, BIOCHEMISTRY-US, V23, P1065, DOI 10.1021/bi00301a005; DAVIS LL, 1984, J GEN MICROBIOL, V130, P2095; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P9509; DRISCOLLPENN M, 1984, MOL CELL BIOL, V4, P520; GAO XD, 1995, J BIOCHEM, V117, P257, DOI 10.1093/jb/117.2.257; HEPWORTH SR, 1995, MOL CELL BIOL, V15, P3934; JOHN M, 1993, P NATL ACAD SCI USA, V90, P2564; KAFETZOPOULOS D, 1993, P NATL ACAD SCI USA, V90, P8005, DOI 10.1073/pnas.90.17.8005; KAFETZOPOULOS D, 1993, P NATL ACAD SCI USA, V90, P2564, DOI 10.1073/pnas.90.7.2564; KATHODA S, 1984, AGR BIOL CHEM TOKYO, V48, P895; KAUSS H, 1983, PLANT SCI LETT, V28, P231, DOI 10.1016/S0304-4211(83)80014-5; KLIS FM, 1994, YEAST, V10, P851, DOI 10.1002/yea.320100702; KREGERVANRIJ NJW, 1978, ARCH MICROBIOL, V117, P73, DOI 10.1007/BF00689354; LAW DTS, 1988, MOL CELL BIOL, V8, P912, DOI 10.1128/MCB.8.2.912; MILLER JJ, 1989, YEASTS; MITCHELL AP, 1994, MICROBIOL REV, V58, P56, DOI 10.1128/MMBR.58.1.56-70.1994; PAMMER M, 1992, YEAST, V8, P1089, DOI 10.1002/yea.320081211; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SHAW JA, 1991, J CELL BIOL, V114, P111, DOI 10.1083/jcb.114.1.111; STRATFORD M, 1994, YEAST, V10, P1741, DOI 10.1002/yea.320101307; TSIGOS I, 1995, J BIOL CHEM, V270, P26286, DOI 10.1074/jbc.270.44.26286; VALDIVIESO MH, 1991, J CELL BIOL, V114, P101, DOI 10.1083/jcb.114.1.101	37	90	94	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31420	31425		10.1074/jbc.271.49.31420	http://dx.doi.org/10.1074/jbc.271.49.31420			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940152	hybrid			2022-12-27	WOS:A1996VW68600063
J	Pullner, A; Mautner, J; Albert, T; Eick, D				Pullner, A; Mautner, J; Albert, T; Eick, D			Nucleosomal structure of active and inactive c-myc genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; BURKITTS-LYMPHOMA CELLS; FAR UPSTREAM ELEMENT; CHROMATIN STRUCTURE; TRANSCRIPTIONAL ELONGATION; PROMOTER SHIFT; REPRESSES TRANSCRIPTION; TRANS-ACTIVATION; PROTEIN-BINDING; DOWN-REGULATION	The nucleosomal structure of active and inactive c-myc genes has been analyzed in detail in undifferentiated and differentiated cells of the promyelocytic leukemia cell Line HL60. The c-myc P2 promoter was never found in nucleosomal configuration, no matter whether c-myc was expressed or not. Differences in the nucleosomal structure, however, were found in the promoter upstream region proximal to a previously described DNase I-hypersensitive site I, at the P0 promoter, and at the P1 promoter and upstream thereof. In these regions nucleosomes were detected in differentiated but not undifferentiated HL60 cells. Similar patterns of nucleosomes as found for active and inactive c-myc genes in HL60 cells were found for active and inactive episomal c-myc genes in stably transfected B cell Lines. In these cell lines three activation stages could be described for episomal c-myc constructs: (i) uninducible, (ii) inducible, and (iii) induced. Significant differences in the nucleosomal structure of c-myc were observed for the uninducible and inducible stages, but not for the inducible and induced stages.	GSF MUNICH, FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT, INST KLIN MOL BIOL & TUMOR GENET, D-81377 MUNICH, GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health				Albert, Thomas Karl/0000-0002-2488-0706				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ARCINAS M, 1994, ONCOGENE, V9, P2699; AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BAZAR L, 1995, ONCOGENE, V10, P2229; BENTLEY DL, 1995, CURR OPIN GENET DEV, V5, P210, DOI 10.1016/0959-437X(95)80010-7; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; BRYS A, 1994, P NATL ACAD SCI USA, V91, P4915, DOI 10.1073/pnas.91.11.4915; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DALLAFAVERA R, 1982, NATURE, V299, P61; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DUFORT D, 1994, MOL CELL BIOL, V14, P4251, DOI 10.1128/MCB.14.6.4251; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; DYSON PJ, 1985, EMBO J, V4, P2885, DOI 10.1002/j.1460-2075.1985.tb04018.x; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; FAHRLANDER PD, 1985, EMBO J, V4, P3195, DOI 10.1002/j.1460-2075.1985.tb04065.x; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HORTNAGEL K, 1995, ONCOGENE, V10, P1393; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KOHLHUBER F, 1993, ONCOGENE, V8, P1099; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; KUMAR S, 1991, J MOL BIOL, V222, P45, DOI 10.1016/0022-2836(91)90736-P; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LANG JC, 1991, ONCOGENE, V6, P2067; LAVENU A, 1994, ONCOGENE, V9, P527; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Mautner J, 1996, ONCOGENE, V12, P1299; MAUTNER J, 1995, NUCLEIC ACIDS RES, V23, P72, DOI 10.1093/nar/23.1.72; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; MICHELOTTI EF, 1995, J BIOL CHEM, V270, P9494, DOI 10.1074/jbc.270.16.9494; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; POLACK A, 1991, ONCOGENE, V6, P2033; POLACK A, 1993, EMBO J, V12, P3913, DOI 10.1002/j.1460-2075.1993.tb06069.x; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STROBL LJ, 1993, ONCOGENE, V8, P1437; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; WITTIG B, 1992, EMBO J, V11, P4653, DOI 10.1002/j.1460-2075.1992.tb05567.x; WOLF DA, 1995, NUCLEIC ACIDS RES, V23, P3373, DOI 10.1093/nar/23.17.3373; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2	63	26	26	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31452	31457		10.1074/jbc.271.49.31452	http://dx.doi.org/10.1074/jbc.271.49.31452			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940157	hybrid			2022-12-27	WOS:A1996VW68600068
J	Richieri, GV; Ogata, RT; Kleinfeld, AM				Richieri, GV; Ogata, RT; Kleinfeld, AM			Thermodynamic and kinetic properties of fatty acid interactions with rat liver fatty acid-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENT-PROBE ADIFAB; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; LIGAND-BINDING; RESOLUTION; ADIPOCYTE; APOPROTEIN; CYTOSOL; FAMILY	Fatty acid-binding protein from rat liver (L-FABP) binds 2 fatty acids (FA) per protein, in contrast to FABPs from adipocyte, heart, and intestine, for which binding and structural studies are consistent with a single FA binding site, To understand better the unique characteristics of L-FABP, we have carried out equilibrium binding and kinetic measurements of long- chain FA us ing the fluorescent probes of free fatty acids (FFA), ADIFAB and ADIFAB2, to monitor the concentration of FFA in the reaction of FA with L-FABP, We found that the dissociation constants (K-d) ranged from about 1 nM to 4 mu M, being largest for myristate at 45 degrees C and smallest for oleate at 10 degrees C, and that 2 FA were bound per L-FABP for all temperatures and Fk The binding measurements also revealed that at temperatures below 37 degrees C, affinities for the two binding sites differ by between 5- and 20-fold but as the temperature was increased, the affinities converge toward equal values, Off-rate constants (K-off were similar for all FA and for temperatures between 10 and 45 degrees C, ranged from about 0.1 s(-1) to 50 s(-1). Moreover, for all FA, k(off) values for dissociation from both the high and low affinity sites were similar, indicating that binding affinity differences at the lower temperatures reflect lower on-rates for binding to the ion: affinity site, The temperature at which the affinities of the two sites become equivalent depends upon the FA; higher temperatures (45-50 degrees C) are required for the unsaturated FA and myristate than for the longer chain saturated FA (<37 degrees C. This transition from different to equivalent affinity binding sites at specific tempera tures reflects a nonlinear van't Hoff behavior of the high affinity site, which in turn is a reflection of large heat capacity changes (between -0.6 and -1.2 kcal K-1 mol(-1)) that accompany FA binding to the high affinity site, These heat capacity changes, which are unique to L-FABP, do not appear to be correlated with a significant conformational change upon ligand binding, The differences between long chain saturated and unsaturated FA suggest that the conformation of FA bound to L-FABP may differ with both FA type and temperature, and that, in comparison to other FABPs, L-FABP may have distinctly different effects on saturated and unsaturated FA metabolism.	INST MED BIOL,LA JOLLA,CA 92037						NIGMS NIH HHS [GM46931] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046931] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BASS NM, 1988, INT REV CYTOL, V111, P143, DOI 10.1016/S0074-7696(08)61733-7; BRECHER P, 1984, J BIOL CHEM, V259, P3395; BRUNAUER LS, 1994, BIOCHEMISTRY-US, V33, P4527, DOI 10.1021/bi00181a013; Cantor C.R., 1980, BIOPHYS CHEM; CISTOLA DP, 1989, J BIOL CHEM, V264, P2700; Guinto ER, 1996, BIOCHEMISTRY-US, V35, P8800, DOI 10.1021/bi9608828; HAUNERLAND NH, 1994, BIOCHEMISTRY-US, V33, P12378, DOI 10.1021/bi00207a004; JAKOBY MG, 1993, BIOCHEMISTRY-US, V32, P872, DOI 10.1021/bi00054a019; KIM HK, 1992, J BIOL CHEM, V267, P77; Kleinfeld Alan M., 1996, Biophysical Journal, V70, pA236; Kurian E, 1996, BIOCHEMISTRY-US, V35, P3865, DOI 10.1021/bi952589y; LALONDE JM, 1994, J BIOL CHEM, V269, P25339; LEVI AJ, 1969, J CLIN INVEST, V48, P2156, DOI 10.1172/JCI106182; LOWE JB, 1987, J BIOL CHEM, V262, P5931; MISHKIN S, 1975, AM J PHYSIOL, V228, P1634, DOI 10.1152/ajplegacy.1975.228.6.1634; NAGHIBI H, 1995, P NATL ACAD SCI USA, V92, P5597, DOI 10.1073/pnas.92.12.5597; NEMECZ G, 1991, ARCH BIOCHEM BIOPHYS, V286, P300, DOI 10.1016/0003-9861(91)90044-J; OCKNER RK, 1972, SCIENCE, V177, P56, DOI 10.1126/science.177.4043.56; Oliveberg M, 1996, BIOCHEMISTRY-US, V35, P2738, DOI 10.1021/bi950967t; RICHIERI GV, 1992, J BIOL CHEM, V267, P23495; RICHIERI GV, 1995, J BIOL CHEM, V270, P15076, DOI 10.1074/jbc.270.25.15076; RICHIERI GV, 1995, J LIPID RES, V36, P229; RICHIERI GV, 1993, BIOCHEMISTRY-US, V32, P7574, DOI 10.1021/bi00080a032; Richieri GV, 1996, J BIOL CHEM, V271, P11291, DOI 10.1074/jbc.271.19.11291; RICHIERI GV, 1994, J BIOL CHEM, V269, P23918; Rolf B, 1995, BBA-LIPID LIPID MET, V1259, P245, DOI 10.1016/0005-2760(95)00170-0; SACCHETTINI JC, 1992, J BIOL CHEM, V267, P23534; SACCHETTINI JC, 1993, J BIOL CHEM, V268, P18399; STORCH J, 1989, J BIOL CHEM, V264, P8708; SWEETSER DA, 1986, J BIOL CHEM, V261, P5553; TAKAHASHI K, 1983, EUR J BIOCHEM, V136, P589, DOI 10.1111/j.1432-1033.1983.tb07781.x; THUMSER AEA, 1994, BIOCHEM J, V297, P103, DOI 10.1042/bj2970103; VEERKAMP JH, 1992, BIOCHEM SOC T, V20, P801, DOI 10.1042/bst0200801; VEERKAMP JH, 1991, BIOCHIM BIOPHYS ACTA, V1081, P1, DOI 10.1016/0005-2760(91)90244-C; XU ZH, 1993, J BIOL CHEM, V268, P7874; YOUNG ACM, 1994, STRUCTURE, V2, P523, DOI 10.1016/S0969-2126(00)00052-6; ZANOTTI G, 1992, J BIOL CHEM, V267, P18541	38	49	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31068	31074		10.1074/jbc.271.49.31068	http://dx.doi.org/10.1074/jbc.271.49.31068			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940102	hybrid			2022-12-27	WOS:A1996VW68600013
J	Zhao, J; Paganini, L; Mucke, L; Gordon, M; Refolo, L; Carman, M; Sinha, S; Oltersdorf, T; Lieberburg, I; McConlogue, L				Zhao, J; Paganini, L; Mucke, L; Gordon, M; Refolo, L; Carman, M; Sinha, S; Oltersdorf, T; Lieberburg, I; McConlogue, L			beta-secretase processing of the beta-amyloid precursor protein in transgenic mice is efficient in neurons but inefficient in astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; MESSENGER-RNA; REACTIVE ASTROCYTES; A-BETA; EXPRESSION; PEPTIDE; DAMAGE; BRAINS; CELLS; GENE	Alzheimer's disease is characterized by the extracellular deposition of beta-amyloid peptide (A beta) in cerebral plaques and evidence is accumulating that amyloid is neurotoxic, A beta is derived from the beta-amyloid precursor protein (APP). Proteolytic processing of APP by the enzyme, beta-secretase, produces the N terminus of A beta, and releases a secreted ectodomain of APP (beta-s-APP), To develop animal models for measuring beta-secretase activity in specific brain cells in vivo, we have targeted the expression of the full-length human APP to either neurons or astrocytes in transgenic mice using the neuron-specific enolase (NSE) promoter or a modified glial. fibrillary acidic protein (GFAP) gene, respectively, The APP cDNAs expressed were mutated (KM to NL at 670/671) to encode amino acid substitutions that enhance amyloidogenic processing in vitro, Western analyses revealed abundant production of beta-s-APP in the brains of NSE-APP mice and enzyme-linked immunosorbent assay analyses showed production of A beta in fetal primary mixed brain cultures and brain homogenates from these transgenic animals, Because the NSE promoter drives expression primarily in neurons, this provides in vivo evidence that the beta-secretase cleavage necessary for generation of beta-s-APP and A beta is efficiently performed in neurons, In contrast, only little beta-s-APP was detected in brain homogenates of GFAP-APP mice, indicating that astrocytes show very little beta-secretase activity in vivo. This provides strong in vivo evidence that the major source of A beta in brain is from neurons and not from astrocytes.	ATHENA NEUROSCI INC, S SAN FRANCISCO, CA 94080 USA; UNIV CALIF SAN FRANCISCO, GLADSTONE MOL NEUROBIOL PROGRAM, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, DEPT NEUROL, SAN FRANCISCO, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco				Mucke, Lennart/0000-0001-6256-9559	NATIONAL INSTITUTE ON AGING [R37AG011385, R01AG011385] Funding Source: NIH RePORTER; NIA NIH HHS [AG11385] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABE K, 1991, NEUROSCI LETT, V125, P172, DOI 10.1016/0304-3940(91)90020-T; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHOI T, 1991, MOL CELL BIOL, V11, P3070, DOI 10.1128/MCB.11.6.3070; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DELACOURTE A, 1990, NEUROLOGY, V40, P33, DOI 10.1212/WNL.40.1.33; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FORSSPETTER S, 1990, NEURON, V5, P187, DOI 10.1016/0896-6273(90)90308-3; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HUANG MTF, 1990, MOL CELL BIOL, V10, P1805, DOI 10.1128/MCB.10.4.1805; JOHNSON WB, 1995, GLIA, V13, P174, DOI 10.1002/glia.440130304; JOHNSONWOOD K, 1996, P NATL ACAD SCI US; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; KNOPS J, 1995, J BIOL CHEM, V270, P2419, DOI 10.1074/jbc.270.6.2419; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; MUCKE L, 1991, NEW BIOL, V3, P465; MUCKE L, 1994, BRAIN RES, V666, P151, DOI 10.1016/0006-8993(94)90767-6; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PALMITER RD, 1991, P NATL ACAD SCI USA, V88, P478, DOI 10.1073/pnas.88.2.478; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; QUON D, 1991, NATURE, V352, P239, DOI 10.1038/352239a0; ROCKENSTEIN EM, 1995, J BIOL CHEM, V270, P28257; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TINAKARAN G, 1996, J BIOL CHEM, V271, P9390; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; WALLACE WC, 1995, J NEUROSCI, V15, P4896; WISNIEWSKI HM, 1992, ANN NY ACAD SCI, V673, P270	39	78	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31407	31411		10.1074/jbc.271.49.31407	http://dx.doi.org/10.1074/jbc.271.49.31407			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940150	hybrid			2022-12-27	WOS:A1996VW68600061
J	Akeson, AL; Woods, CW; Hsieh, LC; Bohnke, RA; Ackermann, BL; Chan, KY; Robinson, JL; Yanofsky, SD; Jacobs, JW; Barrett, RW; Bowlin, TL				Akeson, AL; Woods, CW; Hsieh, LC; Bohnke, RA; Ackermann, BL; Chan, KY; Robinson, JL; Yanofsky, SD; Jacobs, JW; Barrett, RW; Bowlin, TL			AF12198, a novel low molecular weight antagonist, selectively binds the human type I interleukin (IL)-1 receptor and blocks in vivo responses to IL-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDENTIFICATION; RESOLUTION; IL-1-BETA; SITES	Interleukin-1 (IL-1) -alpha and -beta are potent regulators of inflammatory responses, The naturally occurring interleukin-1 receptor antagonist (IL-1ra) is effective in vitro and in vivo in modulating biological responses to IL-1, We have previously reported the discovery of IL-1 antagonist peptides from the search of phage display libraries, Further characterization of this group of peptides has led to a 15-mer, AF12198, Ac-FEWTPGWYQJYALPL-NH2 (J represents the unnatural amino acid, 2-azetidine-1-carboxylic acid), with both in vitro and in vivo IL-1 antagonist activity, AF12198 selectively binds the human type I IL-1 receptor but not the human type II receptor or the murine type I receptor, In vitro, AF12198 inhibits IL-1-induced IL-8 production by human dermal fibroblasts with a half-maximal inhibition concentration or IC50 of 25 nM and IL-1-induced intercellular adhesion molecule-1 (ICAM-1) expression by endothelial cells with an IC50 of 9 nM. When given as an intravenous infusion to cynomolgus monkeys, AF12198 blocks ex vitro IL-1 induction of IL-6 and down modulates in vivo induction of IL-6. This is the first small molecule to show IL-1 receptor antagonist activity in vivo.	AFFYMAX,PALO ALTO,CA 94304		Akeson, AL (corresponding author), HOECHST MARION ROUSSEL,2110 E GALBRAITH RD,CINCINNATI,OH 45215, USA.							AKESON A, 1996, IN PRESS J PHARM TOX; AREND WP, 1995, ARTHRITIS RHEUM, V38, P151, DOI 10.1002/art.1780380202; CASINIRAGGI V, 1995, J IMMUNOL, V154, P2434; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; EVANS RJ, 1995, J BIOL CHEM, V270, P11477, DOI 10.1074/jbc.270.19.11477; FISCHER E, 1991, AM J PHYSIOL, V261, pR442, DOI 10.1152/ajpregu.1991.261.2.R442; GIELDS GB, 1990, INT J PEPT PROT RES, V35, P161; GRAVES BJ, 1990, BIOCHEMISTRY-US, V29, P2679, DOI 10.1021/bi00463a009; GRUTTER MG, 1994, PROTEIN ENG, V7, P663, DOI 10.1093/protein/7.5.663; LABRIOLATOMPKINS E, 1991, P NATL ACAD SCI USA, V88, P11182, DOI 10.1073/pnas.88.24.11182; LEWTHWAITE J, 1995, ANN RHEUM DIS, V54, P591, DOI 10.1136/ard.54.7.591; Makarov SS, 1996, P NATL ACAD SCI USA, V93, P402, DOI 10.1073/pnas.93.1.402; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; PIQUET PF, 1993, CYTOKINE, V5, P57; PRIESTLE JP, 1989, P NATL ACAD SCI USA, V86, P9667, DOI 10.1073/pnas.86.24.9667; SCHREUDER H, 1995, FEBS LETT, V373, P39, DOI 10.1016/0014-5793(95)01009-4; SCHREUDER HA, 1995, EUR J BIOCHEM, V227, P838, DOI 10.1111/j.1432-1033.1995.tb20209.x; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SYMONS JA, 1995, P NATL ACAD SCI USA, V92, P1714, DOI 10.1073/pnas.92.5.1714; VIGERS GPA, 1994, J BIOL CHEM, V269, P14284; Yanofsky SD, 1996, P NATL ACAD SCI USA, V93, P7381, DOI 10.1073/pnas.93.14.7381	22	38	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30517	30523		10.1074/jbc.271.48.30517	http://dx.doi.org/10.1074/jbc.271.48.30517			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940020	hybrid			2022-12-27	WOS:A1996VV15800037
J	Muniz, M; Alonso, M; Hidalgo, J; Velasco, A				Muniz, M; Alonso, M; Hidalgo, J; Velasco, A			A regulatory role for cAMP-dependent protein kinase in protein traffic along the exocytic route	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; TRANS-GOLGI NETWORK; SECRETORY VESICLE FORMATION; CANINE KIDNEY-CELLS; ENDOPLASMIC-RETICULUM; INTERMEDIATE COMPARTMENT; MEMBRANE-PROTEIN; MDCK CELLS; COMPLEX; PHOSPHORYLATION	The influence of protein kinase A activity on transport of newly synthesized vesicular stomatitis virus G glycoprotein along the exocytic pathway was examined. Transport of vesicular stomatitis virus G glycoprotein to the cell surface was inhibited by N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), a selective inhibitor of protein kinase A. This block occurred at the exit of the Golgi complex, whereas transport through the Golgi compartments or from the endoplasmic reticulum to the Golgi was decreased in the presence of H-89. As judged by immunofluorescence endoplasmic reticulum to Golgi transport was accelerated in cells incubated with activators of protein kinase A such as isobutylmethylxanthine (IBMX) or forskolin (FK). Treatment with IBMX and FR also increased transport from the trans-Golgi network to the cell surface. During incubation with IBMX and Fh, the organization of the Golgi complex was altered showing intercisternae fusion and miscompartmentalization of resident proteins. These structural changes affected both the kinetics of acquisition of endoglycosidase H resistance and transport activities. These data support a differential regulatory role for protein kinase A in different transport steps along the exocytic pathway. In particular, transport from the trans-Golgi network to the cell surface was dependent on protein kinase A activity. In addition, the results suggest the involvement of this enzyme on the maintenance of the Golgi complex organization.	UNIV SEVILLE, FAC BIOL, DEPT CELL BIOL, E-41012 SEVILLE, SPAIN	University of Sevilla			IBIS, EUCARIONTES/H-7494-2016; muñiz, manuel/Q-2890-2019	muñiz, manuel/0000-0001-8011-6991				AKITA Y, 1994, J BIOL CHEM, V269, P4653; BALCH WE, 1986, J BIOL CHEM, V261, P4681; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BERGMANN JE, 1989, METHOD CELL BIOL, V32, P85; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; Buccione R, 1996, J BIOL CHEM, V271, P3523; CARDONE MH, 1994, J CELL BIOL, V124, P717, DOI 10.1083/jcb.124.5.717; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COLOMBO MI, 1994, J BIOL CHEM, V269, P14919; DAVIDSON HW, 1992, J CELL BIOL, V116, P1343, DOI 10.1083/jcb.116.6.1343; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; EKER P, 1994, J BIOL CHEM, V269, P18607; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; HANSEN SH, 1994, J CELL BIOL, V126, P677, DOI 10.1083/jcb.126.3.677; Jilling T, 1996, J BIOL CHEM, V271, P4381; KEHLENBACH RH, 1994, NATURE, V372, P804; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG J, 1995, EMBO J, V14, P3635, DOI 10.1002/j.1460-2075.1995.tb00033.x; LEFRANCOIS L, 1982, VIROLOGY, V121, P157, DOI 10.1016/0042-6822(82)90125-8; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; LOTTI LV, 1992, J CELL BIOL, V118, P43, DOI 10.1083/jcb.118.1.43; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MONTMAYEUR JP, 1994, SCIENCE, V263, P95, DOI 10.1126/science.8272874; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; OHASHI M, 1994, J BIOL CHEM, V269, P24897; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PEREZVILAR J, 1991, J BIOL CHEM, V266, P23967; PIMPLIKAR SW, 1994, J BIOL CHEM, V269, P19054; RIOS RM, 1992, EMBO J, V11, P1723, DOI 10.1002/j.1460-2075.1992.tb05224.x; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SEKSEK O, 1995, J BIOL CHEM, V270, P4967, DOI 10.1074/jbc.270.10.4967; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STREHLER BL, 1965, METHOD ENZYMAT AN, P559; TAKUMA T, 1994, J BIOL CHEM, V269, P22124; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; WOODMAN PG, 1992, J CELL BIOL, V116, P331, DOI 10.1083/jcb.116.2.331	44	59	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30935	30941		10.1074/jbc.271.48.30935	http://dx.doi.org/10.1074/jbc.271.48.30935			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940080	Green Published, hybrid			2022-12-27	WOS:A1996VV15800097
J	Smith, JD; Miyata, M; Ginsberg, M; Grigaux, C; Shmookler, E; Plump, AS				Smith, JD; Miyata, M; Ginsberg, M; Grigaux, C; Shmookler, E; Plump, AS			Cyclic AMP induces apolipoprotein E binding activity and promotes cholesterol efflux from a macrophage cell line to apolipoprotein acceptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; PROTEIN-KINASE-C; A-I; INTRACELLULAR CHOLESTEROL; MOUSE MACROPHAGES; HUMAN FIBROBLASTS; E GENE; EXPRESSION; RECEPTOR; SURFACE	RAW 264 mouse macrophage cells were stably transfected with human apolipoprotein E (apoE) expression vectors. Clonal derivatives were characterized for expression of the human apoE2, apoE3, and apoE4 isoforms. An apoE4-expressing clonal cell line and a non-expressing clonal control cell line were loaded overnight with either [H-3]cholesterol or [H-3]choline, The cells were washed and incubated for 24 h in serum-free medium with or without the addition of 8-bromo-cyclic AMP (8-Br-cAMP), Only the apoE-secreting cells and only in the presence of 8-Br-cAMP released large amounts of labeled cholesterol or phosphatidylcholine into the medium, Mass analyses of cellular free and esterified cholesterol confirmed the results of the labeling studies; a decrease in cellular cholesterol content was observed in the 8-Br-cAMP-treated apoE-secreting cells, concurrent with an increase in cholesterol found in the medium. FPLC analysis of the medium demonstrated that 8-Br-cAMP treatment of the apoE-secreting cells led to an increased size fraction and amount of a peak of secreted cholesterol which comigrated with apoE, The 8-Br-cAMP-mediated increase in cholesterol efflux was also observed in non-apoE-secreting cells incubated with exogenous apoE or apoAI, and the effect of apoE was saturable, The apoE2, apoE3, and apoE4 isoforms were equally efficient in promoting 8-Br-cAMP-dependent cholesterol efflux, Reductive methylation of apoE abolished its ability to promote 8-Br-cAMP-dependent cholesterol efflux, Brefeldin A and monensin, inhibitors of protein processing through the Golgi, both blocked the 8-Br-cAMP stimulation of cholesterol efflux to exogenous apoE, 8-Br-cAMP induced specific apoE and apoAI binding, but not apoE degradation, by the RAW cells. We present a model wherein cAMP induces a membrane apolipoprotein receptor that does not lead to endocytosis and degradation, but instead promotes the transfer of lipids to apolipoproteins, which can then be released from the cell.			Smith, JD (corresponding author), ROCKEFELLER UNIV,BIOCHEM GENET & METAB LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.		Smith, Jonathan D./H-9723-2013	Smith, Jonathan D./0000-0002-0415-386X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054591] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL54591] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; BASU SK, 1981, P NATL ACAD SCI-BIOL, V78, P7545, DOI 10.1073/pnas.78.12.7545; BASU SK, 1983, SCIENCE, V219, P871, DOI 10.1126/science.6823554; BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; BERG KA, 1988, MOL CELL BIOCHEM, V84, P29; BRINTON EA, 1989, J CLIN INVEST, V84, P262, DOI 10.1172/JCI114149; BROWN MS, 1979, J CELL BIOL, V82, P597, DOI 10.1083/jcb.82.3.597; BURCH RM, 1988, J PHARMACOL EXP THER, V244, P765; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; DAS HK, 1985, J BIOL CHEM, V260, P6240; DELAMATRE J, 1986, BIOCHIM BIOPHYS ACTA, V875, P419, DOI 10.1016/0005-2760(86)90061-5; EMI M, 1988, GENOMICS, V3, P373, DOI 10.1016/0888-7543(88)90130-9; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRAENKELCONRAT H, 1957, METHOD ENZYMOL, V4, P247, DOI 10.1016/0076-6879(57)04059-8; FREEMAN DA, 1987, J BIOL CHEM, V262, P13061; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GRANOT E, 1990, J LIPID RES, V31, P2133; HARA H, 1991, J BIOL CHEM, V266, P3080; HERSCOVITZ H, 1992, J LIPID RES, V33, P791; HUANG YD, 1994, P NATL ACAD SCI USA, V91, P1834, DOI 10.1073/pnas.91.5.1834; INNERARITY TL, 1986, ARTERIOSCLEROSIS, V6, P114, DOI 10.1161/01.ATV.6.1.114; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; KARLIN JB, 1987, J BIOL CHEM, V262, P12557; KRUTH HS, 1994, J BIOL CHEM, V269, P24511; MADDEN EA, 1986, CANCER RES, V46, P617; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MAZZONE T, 1987, J BIOL CHEM, V262, P11657; MAZZONE T, 1994, J LIPID RES, V35, P1345; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P12131; MENDEZ AJ, 1994, J CLIN INVEST, V94, P1698, DOI 10.1172/JCI117515; MENDEZ AJ, 1995, J BIOL CHEM, V270, P5891, DOI 10.1074/jbc.270.11.5891; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; ORAM JF, 1987, J BIOL CHEM, V262, P2405; PETTY HR, 1989, BIOCHIM BIOPHYS ACTA, V1012, P284, DOI 10.1016/0167-4889(89)90110-9; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; PRACK MM, 1994, BIOCHEMISTRY-US, V33, P5049, DOI 10.1021/bi00183a007; RALL SC, 1986, METHOD ENZYMOL, V128, P273; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; ROTHBLAT GH, 1991, CURR OPIN LIPIDOL, V2, P288; SCHMITZ G, 1985, EMBO J, V4, P613, DOI 10.1002/j.1460-2075.1985.tb03674.x; SMITH JD, 1988, J BIOL CHEM, V263, P8300; SMITH JD, 1990, J BIOL CHEM, V265, P14709; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; VIA DP, 1985, BIOCHIM BIOPHYS ACTA, V833, P417, DOI 10.1016/0005-2760(85)90099-2; WEISGRABER KH, 1978, J BIOL CHEM, V253, P9053; WERB Z, 1983, J CELL BIOL, V97, P1113, DOI 10.1083/jcb.97.4.1113; WILLNOW TE, 1992, J BIOL CHEM, V267, P26171; WISSLER RW, 1994, ATHEROSCLEROSIS, V108, pS3, DOI 10.1016/0021-9150(94)90149-X; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028	51	150	158	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30647	30655		10.1074/jbc.271.48.30647	http://dx.doi.org/10.1074/jbc.271.48.30647			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940040	hybrid			2022-12-27	WOS:A1996VV15800057
J	Aucoin, JM; Pishko, EJ; Baker, DP; Kantrowitz, ER				Aucoin, JM; Pishko, EJ; Baker, DP; Kantrowitz, ER			Engineered complementation in Escherichia coli aspartate transcarbamoylase - Heterotropic regulation by quaternary structure stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONCERTED ALLOSTERIC TRANSITION; CATALYTIC CHAIN; DOMAIN CLOSURE; MODEL; N-(PHOSPHONACETYL)-L-ASPARTATE; CARBAMOYLTRANSFERASE; ACTIVATION; BEHAVIOR; CTP; ATP	Escherichia coli aspartate transcarbamoylase regulates pyrimidine biosynthesis by altering its activity homotropically in response to one of its substrates and heterotropically in response to nucleotide effecters, The mechanism of this regulation involves two structurally and functionally different forms of the enzyme, one with low activity and low affinity for substrates (T state) and the other with high activity and high affinity for substrates (R state), Heterotropic regulation may be due to the direct transmission of a regulatory ''signal'' between the regulatory site and the active site some 60 Angstrom away and/or may involve altering the relative stability of the two forms of the enzyme, By combining a T state-stabilized mutant version of the enzyme, previously thought to have a defect in a heterotropic transmission pathway, with a known R state-stabilized mutant enzyme, we were able to restore some properties of the wild-type enzyme, These data imply that the relative stabilization of the T and R states of the enzyme is in part responsible for the homotropic and heterotropic properties of aspartate transcarbamoylase and that direct pathways for transmission of the heterotropic signals are unlikely.	BOSTON COLL,DEPT CHEM,MERKERT CHEM CTR,CHESTNUT HILL,MA 02167	Boston College				Aucoin, Jennifer/0000-0001-9595-3020	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026237] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26237] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLLINS KD, 1971, J BIOL CHEM, V246, P6599; FETLER L, 1995, BIOCHEMISTRY-US, V34, P15654, DOI 10.1021/bi00048a008; GERHART JC, 1967, J BIOL CHEM, V242, P2886; GERHART JC, 1962, J BIOL CHEM, V237, P891; HOWLETT GJ, 1977, BIOCHEMISTRY-US, V16, P5091, DOI 10.1021/bi00642a023; JONES ME, 1955, J AM CHEM SOC, V77, P819, DOI 10.1021/ja01608a101; KANTROWITZ ER, 1988, SCIENCE, V241, P669, DOI 10.1126/science.3041592; KANTROWITZ ER, 1990, TRENDS BIOCHEM SCI, V15, P53, DOI 10.1016/0968-0004(90)90176-C; KIM KH, 1987, J MOL BIOL, V196, P853, DOI 10.1016/0022-2836(87)90410-4; KRAUSE KL, 1985, P NATL ACAD SCI USA, V82, P1643, DOI 10.1073/pnas.82.6.1643; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P276, DOI 10.1021/bi00401a042; LEE BH, 1995, J BIOL CHEM, V270, P15620, DOI 10.1074/jbc.270.26.15620; LIPSCOMB WN, 1994, ADV ENZYMOL RAMB, V68, P67; NEWTON CJ, 1990, BIOCHEMISTRY-US, V29, P1444, DOI 10.1021/bi00458a015; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; PASTRALANDIS SC, 1981, ANAL BIOCHEM, V118, P358, DOI 10.1016/0003-2697(81)90594-7; PASTRALANDIS SC, 1978, J BIOL CHEM, V253, P4624; REICHARD P, 1956, ACTA CHEM SCAND, V10, P548, DOI 10.3891/acta.chem.scand.10-0548; SILVER RS, 1983, J MOL BIOL, V168, P729, DOI 10.1016/S0022-2836(83)80072-2; STEVENS RC, 1990, BIOCHEM BIOPH RES CO, V171, P1312, DOI 10.1016/0006-291X(90)90829-C; TAUC P, 1990, J MOL BIOL, V214, P327, DOI 10.1016/0022-2836(90)90164-H; TAUC P, 1994, PROTEIN SCI, V3, P1998, DOI 10.1002/pro.5560031112; THIRY L, 1978, J MOL BIOL, V125, P515, DOI 10.1016/0022-2836(78)90314-5; VANVLIET F, 1991, P NATL ACAD SCI USA, V88, P9180, DOI 10.1073/pnas.88.20.9180; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WILD JR, 1989, P NATL ACAD SCI USA, V86, P46, DOI 10.1073/pnas.86.1.46; XI XG, 1994, J MOL BIOL, V242, P139, DOI 10.1006/jmbi.1994.1565	28	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29865	29869		10.1074/jbc.271.47.29865	http://dx.doi.org/10.1074/jbc.271.47.29865			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939927	hybrid			2022-12-27	WOS:A1996VU52500055
J	Barnes, CJ; Wahl, AF; Shen, BH; Park, MS; Bambara, RA				Barnes, CJ; Wahl, AF; Shen, BH; Park, MS; Bambara, RA			Mechanism of tracking and cleavage of adduct-damaged DNA substrates by the mammalian 5'- to 3'-exonuclease endonuclease RAD2 homologue 1 or flap endonuclease 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; POLYMERASE-EPSILON; 3' EXONUCLEASE; CALF THYMUS; DRUG CIS-DIAMMINEDICHLOROPLATINUM(II); REPLICATION; YEAST; CISPLATIN; RESISTANCE; ENCODES	The mammalian 5'- to 3'-exonuclease/endonuclease, called RAD2 homologue 1 or flap endonuclease 1, has a unique cleavage activity, dependent on specific substrate structure. On a primer-template, in which the primer has an unannealed 5'-tail, endonucleolytic cleavage near the annealing point releases the tail intact. Entering at the 5'-end, the nuclease tracks along the entire tail to the point of cleavage, Genetic analyses suggest that this nuclease removes DNA adducts in vivo (Sommers, C. H., Miller, E. J., Dujon, B., Prakash, S., and Prakash, L. (1995) J. Biol. Chem. 270, 4193-4196). Micrococcal nuclease footprinting shows that after tracking the nuclease protects a region of the tail 25 nucleotides long, adjacent to the cleavage site. Substrates with adducts at specific locations were used to assess the mechanism of RAD2 homologue 1 nuclease tracking and its ability to cleave modified DNA. Either a conventional cis-diamminedichloroplatinum (II) (CDDP) or a bulky CDDP derivative was placed within or beyond the region protected by the nuclease. The nuclease cleaved the tail of both substrates. In contrast, a CDDP adduct just adjacent to the expected cleavage point was inhibitory. A CDDP adduct at the very 5'-end of the tail was also cleaved. The nuclease could remove tails containing adducts on the sugar-phosphate backbone. Apparently, the nuclease is designed to slide over various types of damage on single stranded DNA and then cut past the damaged site.	UNIV ROCHESTER, MED CTR, DEPT BIOCHEM, SCH MED & DENT, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, CTR CANC, ROCHESTER, NY 14642 USA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, GROWTH REGULAT DEPT, SEATTLE, WA 98121 USA; LOS ALAMOS NATL LAB, DIV LIFE SCI, LOS ALAMOS, NM 87545 USA	University of Rochester; University of Rochester; Bristol-Myers Squibb; United States Department of Energy (DOE); Los Alamos National Laboratory			Park, Min Sung/HCH-2207-2022	Shen, Binghui/0000-0002-4408-407X	NIGMS NIH HHS [GM24441] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BAMBARA RA, 1995, PROG NUCLEIC ACID RE, V51, P93, DOI 10.1016/S0079-6603(08)60877-6; BELLON SF, 1990, BIOPHYS CHEM, V35, P179, DOI 10.1016/0301-4622(90)80007-T; BELLON SF, 1991, BIOCHEMISTRY-US, V30, P8026, DOI 10.1021/bi00246a021; BUDD ME, 1995, J BIOL CHEM, V270, P26766, DOI 10.1074/jbc.270.45.26766; BUDD ME, 1996, IN PRESS MOL CELL BI; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; CANON JL, 1990, EUR J CANCER, V26, P1, DOI 10.1016/0277-5379(90)90247-Q; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; COHEN GL, 1979, SCIENCE, V203, P1014, DOI 10.1126/science.370979; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HABRAKEN Y, 1995, J BIOL CHEM, V270, P30194; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; HABRAKEN Y, 1994, J BIOL CHEM, V269, P31342; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1995, J BIOL CHEM, V270, P4503, DOI 10.1074/jbc.270.9.4503; HUANG L, 1993, BIOCHEMISTRY-US, V32, P841, DOI 10.1021/bi00054a015; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; LEE SH, 1991, J BIOL CHEM, V266, P22707; LYAMICHEV V, 1993, SCIENCE, V193, P963; MARROT L, 1989, BIOCHEMISTRY-US, V28, P1454, DOI 10.1021/bi00430a005; MELLISH KJ, 1994, INT J CANCER, V59, P65, DOI 10.1002/ijc.2910590114; MEUSER TC, 1996, CELL, V85, P1101; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; MURANTE RS, 1996, IN PRESS J BIOL CHEM, V271; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; NATHANEL T, 1990, J VIROL, V64, P5912; OBERLISCHRAMMLI AE, 1994, INT J CANCER, V59, P629, DOI 10.1002/ijc.2910590509; ROBINS P, 1994, J BIOL CHEM, V269, P28535; SCANLON KJ, 1989, CANCER INVEST, V7, P581, DOI 10.3109/07357908909017533; SCOVELL WM, 1982, BIOCHEM BIOPH RES CO, V107, P1138, DOI 10.1016/0006-291X(82)90640-4; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; SIBGHATULLAH, 1989, NUCLEIC ACIDS RES, V17, P4471, DOI 10.1093/nar/17.12.4471; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; SIEGAL G, 1992, J BIOL CHEM, V267, P13629; SIEGAL G, 1992, J BIOL CHEM, V267, P3991; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; SORRENSEN CM, 1988, CANCER RES, V48, P6703; SORRENSON CM, 1990, J NATL CANCER I, V82, P749; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; TURCHI JJ, 1993, J BIOL CHEM, V268, P1536; USHAY HM, 1982, J BIOCH, V20, P3744; WAGA S, 1994, J BIOL CHEM, V269, P10923; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7	51	45	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29624	29631		10.1074/jbc.271.47.29624	http://dx.doi.org/10.1074/jbc.271.47.29624			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939893	hybrid			2022-12-27	WOS:A1996VU52500021
J	Fagan, AM; Bu, GJ; Sun, YL; Daugherty, A; Holtzman, DM				Fagan, AM; Bu, GJ; Sun, YL; Daugherty, A; Holtzman, DM			Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL NERVOUS-SYSTEM; SPORADIC ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; TYPE-4 ALLELE; CELL-LINE; EXPRESSION; NEURONS; GROWTH; IDENTIFICATION; CHOLESTEROL	Presence of the epsilon 4 allele of apolipoprotein E (apoE) is a risk factor for Alzheimer's disease (AD), although the mechanism(s) by which it confers this risk is unknown. ApoE may play a direct role in AD neuropathology by modulating neuronal structure, We previously showed that apoE3-containing beta-very low density lipoprotein (beta-VLDL) can stimulate neurite outgrowth to a significantly greater extent than apoE4-enriched beta-VLDL in a central nervous system-derived neuronal cell line and that this effect is mediated by interaction with the low density lipoprotein receptor-related protein (LRP). To determine whether similar differences exist when apoE is associated with other lipoprotein particles, the effects of high density lipoprotein (HDL) derived from plasma and cerebrospinal fluid were defined. ApoE3-enriched HDL significantly enhanced neurite outgrowth as com pared with apoE4-enriched HDL, and the majority of this stimulation was blocked in the presence of the receptor-associated protein or a neutralizing antibody to LRP. We also found that cholesterol esterification in the presence of apoE-containing plasma HDL was attenuated in fibroblasts lacking LRP. Therefore, apoE-containing HDL dan serve as an LRP ligand, and apoE isoform-specific effects on neurite outgrowth are observed when HDL is the carrier particle.	WASHINGTON UNIV,SCH MED,DEPT BIOL MOL,CTR STUDY NERVOUS SYST INJURY,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PHARMACOL,CTR STUDY NERVOUS SYST INJURY,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT & MOL BIOL & PHAR,DIV CARDIOVASC,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Fagan, AM (corresponding author), WASHINGTON UNIV,SCH MED,DEPT NEUROL,CTR STUDY NERVOUS SYST INJURY,ST LOUIS,MO 63110, USA.		Daugherty, Alan/C-8282-2009	Daugherty, Alan/0000-0003-2093-3775				BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; BU GJ, 1994, J BIOL CHEM, V269, P18521; BU GJ, 1993, J BIOL CHEM, V268, P13002; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DAUGHERTY A, 1988, ARTERIOSCLEROSIS, V8, P768, DOI 10.1161/01.ATV.8.6.768; DAVIES CA, 1987, J NEUROL SCI, V78, P151, DOI 10.1016/0022-510X(87)90057-8; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; FLOOD DG, 1986, CAN J NEUROL SCI, V13, P475; HANDELMANN GE, 1992, J LIPID RES, V33, P1677; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1984, J LIPID RES, V25, P1277; MAYEUX R, 1993, ANN NEUROL, V34, P752, DOI 10.1002/ana.410340527; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; NATHAN BP, 1995, J BIOL CHEM, V270, P19791, DOI 10.1074/jbc.270.34.19791; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; OKUIZUMI K, 1994, NAT GENET, V7, P10, DOI 10.1038/ng0594-10b; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; PITAS RE, 1987, J BIOL CHEM, V262, P14352; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; REBECK GW, 1993, NEURON, V11, P575; ROHEIM PS, 1979, P NATL ACAD SCI USA, V76, P4646, DOI 10.1073/pnas.76.9.4646; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHEFF SW, 1990, NEUROBIOL AGING, V11, P29, DOI 10.1016/0197-4580(90)90059-9; SNIPES JG, 1986, P NATL ACAD SCI USA, V83, P1130; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WILLNOW TE, 1994, J CELL SCI, V107, P719; ZHOU J, 1994, P NATL ACAD SCI USA, V91, P3824, DOI 10.1073/pnas.91.9.3824	36	185	187	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30121	30125		10.1074/jbc.271.47.30121	http://dx.doi.org/10.1074/jbc.271.47.30121			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939961	hybrid			2022-12-27	WOS:A1996VU52500089
J	Vezza, R; Habib, A; Li, HW; Lawson, JA; FitzGerald, GA				Vezza, R; Habib, A; Li, HW; Lawson, JA; FitzGerald, GA			Regulation of cyclooxygenases by protein kinase C - Evidence against the importance of direct enzyme phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE-2; COUPLED RECEPTOR KINASES; HUMAN ENDOTHELIAL-CELLS; PHORBOL ESTER; SUBSTRATE-SPECIFICITY; SELECTIVE-INHIBITION; G/H SYNTHASE-1; EXPRESSION; ASPIRIN; PHOSPHATASES	Cyclooxygenases (COXs) are key prostaglandin biosynthetic enzymes. While COX-1 expression is largely constitutive, COX-2 is highly regulated by cytokines, growth factors, and tumor promoters, such as the protein kinase C (PKC) activator, phorbol la-myristate 13-acetate (PMA). While phosphorylation of transcription factors may regulate COX transcription, the existence of PKC consensus sequences suggests that direct enzyme phosphorylation might also regulate differential expression of the enzymes, Nevertheless, phosphorylation of both human recombinant COX-1 and COX-2 by rat brain PKC in vitro was minimal, as was phosphorylation of peptides based on PKC consensus sequences in COX-1 (less than 4% of the phosphorylation of the PKC-alpha pseudosubstrate peptide), Similarly, phosphorylation of the corresponding COX-2 peptides was not observed using either the phosphocellulose paper absorption method or electrospray mass spectrometry, MEG-01 and NTH 3T3 cells were labeled with [P-32]orthophosphate to investigate COX phosphorylation in vivo. COX-2 synthesis was induced by PMA (100 nM) or serum stimulation in NIH 3T3 cells, COX-1 was expressed constitutively in MEG-01 cells. Specific poly clonal antibodies raised against sequences of human COX-1 (Ala(24)-Cys(35)) and COX-2 (Asn(588)-Lys(598)) were used for immunoprecipitation, Neither COX-1 nor COX-2 was phosphorylated in vice, irrespective of the presence of a phosphatase inhibitor (1 mu M okadaic acid), Although COX-1 and COX-2 are differentially regulated, no differences were observed in terms of susceptibility to phosphorylation by PKC either in vitro or in vivo. Despite regulated expression of COX-2 by PMA and the existence of consensus sequences for PKC phosphorylation, it appears that it is an unfavorable substrate for this enzyme.	UNIV PENN,CTR EXPT THERAPEUT,STELLAR CHANCE LABS 905,PHILADELPHIA,PA 19104	University of Pennsylvania			Habib, Aida/H-8647-2019; FitzGerald, Garret A/A-4222-2010	Habib, Aida/0000-0001-6027-0043; 	NHLBI NIH HHS [HL54500] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054500] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson GD, 1996, J CLIN INVEST, V97, P2672, DOI 10.1172/JCI118717; BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; BLANCO A, 1995, BIOCHEM J, V312, P419, DOI 10.1042/bj3120419; BLUE ML, 1987, J IMMUNOL, V139, P3949; BLUMBERG PM, 1988, CANCER RES, V48, P1; BOTT CM, 1994, J IMMUNOL, V153, P1; BROWNER M, 1996, W HARV FDN S NEW TAR, P19; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; HABIB A, 1993, J BIOL CHEM, V268, P23448; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HIRASAWA N, 1995, J IMMUNOL, V154, P5391; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IWAMI G, 1995, J BIOL CHEM, V270, P12481, DOI 10.1074/jbc.270.21.12481; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; JONES DA, 1993, J BIOL CHEM, V268, P9049; KARGMAN SL, 1995, CANCER RES, V55, P2556; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KINSELLA BT, 1994, J BIOL CHEM, V269, P29914; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; KWON YG, 1994, J BIOL CHEM, V269, P4839; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MANCINI JA, 1994, FEBS LETT, V342, P33, DOI 10.1016/0014-5793(94)80579-2; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; NAKADATE T, 1987, J BIOL CHEM, V262, P11507; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; PRATICO D, 1995, J BIOL CHEM, V270, P9800, DOI 10.1074/jbc.270.17.9800; RAZ A, 1988, J BIOL CHEM, V263, P3022; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; TRACY S, 1995, J BIOL CHEM, V270, P10587, DOI 10.1074/jbc.270.18.10587; VALMU L, 1995, J IMMUNOL, V155, P1175	40	24	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30028	30033		10.1074/jbc.271.47.30028	http://dx.doi.org/10.1074/jbc.271.47.30028			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939949	hybrid			2022-12-27	WOS:A1996VU52500077
J	Wiedemann, P; Giehl, K; Almo, SC; Fedorov, AA; Girvin, M; Steinberger, P; Rudiger, M; Ortner, M; Sippl, M; Dolecek, C; Kraft, D; Jockusch, B; Valenta, R				Wiedemann, P; Giehl, K; Almo, SC; Fedorov, AA; Girvin, M; Steinberger, P; Rudiger, M; Ortner, M; Sippl, M; Dolecek, C; Kraft, D; Jockusch, B; Valenta, R			Molecular and structural analysis of a continuous birch profilin epitope defined by a monoclonal antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEIN; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; PEPTIDE-SYNTHESIS; POLLEN ALLERGEN; ANTIGEN COMPLEX; CDNA CLONING; AMINO-ACID; EXPRESSION; IDENTIFICATION	The interaction of a mouse monoclonal antibody (4A6) and birch profilin, a structurally well conserved actin and phosphoinositide-binding protein and cross-reactive allergen, was characterized, In contrast to serum IgE from allergic patients, which shows cross-reactivity with most plants, monoclonal antibody 4A6 selectively reacted with tree pollen profilins. Using synthetic overlapping peptides, a continuous hexapeptide epitope was identified. The exchange of a single amino acid (Gln-47 --> Glu) within the epitope was found to abolish the bind ing of monoclonal antibody 4A6 to other plant profilins. The MMR analyses of the birch and the nonreactive timothy grass profilin peptides showed that the loss of binding was not due to major structural differences. Both peptides adopted extended conformations similar to that observed for the epitope in the x-ray crystal structure of the native birch profilin. Binding studies with peptides and birch profilin mutants generated by in vitro mutagenesis demonstrated that the change of Gln-47 to acidic amino acids (e.g. Glu or Asp) led to electrostatic repulsion of monoclonal antibody 4A6. In conclusion the molecular and structural analyses of the interaction of a monoclonal antibody with a continuous peptide epitope, recognized in a conformation similar to that displayed on the native protein, are presented.	UNIV VIENNA,AKH,INST GEN & EXPT PATHOL,A-1090 VIENNA,AUSTRIA; TECH UNIV CAROLO WILHELMINA BRAUNSCHWEIG,INST ZOOL,DEPT CELL BIOL,D-38106 BRAUNSCHWEIG,GERMANY; ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461; SALZBURG UNIV,CTR APPL MOL ENGN,A-5020 SALZBURG,AUSTRIA	University of Vienna; Braunschweig University of Technology; Yeshiva University; Albert Einstein College of Medicine; Salzburg University				Valenta, Rudolf/0000-0001-5944-3365; Steinberger, Peter/0000-0001-6848-4097	NIGMS NIH HHS [GM 53807] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053807] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMO SC, 1994, J MOL BIOL, V236, P950, DOI 10.1006/jmbi.1994.1200; AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; ARCHER SJ, 1994, FEBS LETT, V337, P145, DOI 10.1016/0014-5793(94)80262-9; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; Battey, 1986, BASIC METHODS MOL BI; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BERZOFSKY JA, 1985, SCIENCE, V229, P932, DOI 10.1126/science.2410982; BJORKEGREN C, 1993, FEBS LETT, V333, P123, DOI 10.1016/0014-5793(93)80388-B; BRADEN BC, 1995, FASEB J, V9, P9, DOI 10.1096/fasebj.9.1.7821765; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DROBAK BK, 1994, PLANT J, V6, P389, DOI 10.1046/j.1365-313X.1994.06030389.x; ENGVALL E, 1972, J IMMUNOL, V109, P129; FEDOROV AA, 1994, J MOL BIOL, V241, P480, DOI 10.1006/jmbi.1994.1522; FERNANDEZ JA, 1994, BIOCHEMISTRY-US, V33, P11073, DOI 10.1021/bi00203a003; GEFTER ML, 1977, SOMAT CELL GENET, V3, P231, DOI 10.1007/BF01551818; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GEYSEN HM, 1985, P NATL ACAD SCI USA, V82, P178, DOI 10.1073/pnas.82.1.178; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GIEHL K, 1994, EUR J BIOCHEM, V226, P681, DOI 10.1111/j.1432-1033.1994.tb20096.x; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; GRIESINGER C, 1987, J MAGN RESON, V75, P261, DOI 10.1016/0022-2364(87)90035-7; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; JEMMERSON R, 1989, MOL IMMUNOL, V26, P301, DOI 10.1016/0161-5890(89)90084-9; KAISER DA, 1989, CELL MOTIL CYTOSKEL, V14, P251, DOI 10.1002/cm.970140211; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; Machesky Laura M., 1993, Trends in Cell Biology, V3, P381, DOI 10.1016/0962-8924(93)90087-H; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MERTENS N, 1995, BIO-TECHNOL, V13, P175, DOI 10.1038/nbt0295-175; METZLER WJ, 1994, J BIOL CHEM, V269, P4620; MITTERMANN I, 1995, PLANT MOL BIOL, V27, P137, DOI 10.1007/BF00019185; NAVON A, 1995, J BIOL CHEM, V270, P4255, DOI 10.1074/jbc.270.9.4255; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; RIHS HP, 1994, INT ARCH ALLERGY IMM, V105, P190, DOI 10.1159/000236824; Rothkegel M, 1996, J CELL SCI, V109, P83; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SEIBERLER S, 1994, EMBO J, V13, P3481, DOI 10.1002/j.1460-2075.1994.tb06654.x; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SIPPL MJ, 1992, PROTEIN SCI, V1, P625, DOI 10.1002/pro.5560010509; SIPPL MJ, 1990, J MOL BIOL, V213, P859, DOI 10.1016/S0022-2836(05)80269-4; SOHN RH, 1994, BIOESSAYS, V7, P165; STAIGER CJ, 1994, CURR BIOL, V4, P215, DOI 10.1016/S0960-9822(00)00050-6; STAIGER CJ, 1993, PLANT J, V4, P631, DOI 10.1046/j.1365-313X.1993.04040631.x; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUSANI M, 1995, BIOCHEM BIOPH RES CO, V215, P250, DOI 10.1006/bbrc.1995.2460; TANAKA M, 1985, EUR J BIOCHEM, V151, P291, DOI 10.1111/j.1432-1033.1985.tb09099.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TULIP WR, 1990, COLD SPRING HARB SYM, V54, P257; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1993, J BIOL CHEM, V268, P22777; VALENTA R, 1994, BIOCHEM BIOPH RES CO, V199, P106, DOI 10.1006/bbrc.1994.1201; VALLIER P, 1992, CLIN EXP ALLERGY, V22, P774, DOI 10.1111/j.1365-2222.1992.tb02818.x; VANZIJL PCM, 1995, J MAGN RESON SER A, V113, P265, DOI 10.1006/jmra.1995.1092; VRTALA S, 1996, IN PRESS BIOCH BIOPH; WEHLAND J, 1984, EMBO J, V3, P1295, DOI 10.1002/j.1460-2075.1984.tb01965.x; Wuthrich K, 1986, NMR PROTEINS NUCL AC	64	35	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29915	29921		10.1074/jbc.271.47.29915	http://dx.doi.org/10.1074/jbc.271.47.29915			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939935	hybrid			2022-12-27	WOS:A1996VU52500063
J	Zhu, H; Hargrove, M; Xie, Q; Nozaki, Y; Linse, K; Smith, SS; Olson, JS; Riggs, AF				Zhu, H; Hargrove, M; Xie, Q; Nozaki, Y; Linse, K; Smith, SS; Olson, JS; Riggs, AF			Stoichiometry of subunits and heme content of hemoglobin from the earthworm Lumbricus terrestris	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRILLIANT BLUE-R; EXTRACELLULAR HEMOGLOBIN; QUATERNARY STRUCTURE; DISSOCIATION; PROTEIN; GLOBIN; CHAINS; REASSOCIATION; TRIMER; MODEL	The extracellular hemoglobin (Hb) of the earthworm, Lumbricus terrestris, has four major O-2-binding chains, a, b, c (forming a disulfide-linked trimer), and d (''monomer''), Additional structural chains, ''linkers,'' are required for the assembly of the similar to 200-polypeptide molecule, The proportion of linker chains had been reported to be one-third of the total mass on the basis of densitometry of Coomassie Blue-stained SDS-gels, Reverse-phase high performance liquid chromatography (HPLC), however, gave 16.3% linkers on the basis of both 220-nm absorbance and amino acid analysis (Ownby, D. W., Zhu, H., Schneider, K., Beavis, R. C., Chait, B. C., and Riggs, A. F. (1993) J. Biol. Chem. 268, 13539-13547). The subunit proportions have now been redetermined by SDS capillary electrophoresis as a test of the HPLC results, The electrophoresis, monitored at 214 nm, avoided the use of Coomassie Blue and provided results identical with those obtained by HPLC, Capillary electrophoresis monitored at both 214 and 415 nm was used to show that linker chains do not bind heme, Heme content has been found to be 2.9% by determination of hemin, amino acid analysis and dry weight, Measurement of the rate of hemin loss from oxidized L. ferrestris Hb shows that high rates of loss can account for values of heme content significantly below 2.9% (or 0.26% iron).	UNIV TEXAS,DEPT ZOOL,AUSTIN,TX 78712; UNIV TEXAS,PROT MICROANAL FACIL,AUSTIN,TX 78712; RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77005; RICE UNIV,KECK CTR COMPUTAT BIOL,HOUSTON,TX 77005; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; Rice University; Rice University; Duke University				Olson, John/0000-0002-0760-5403	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035847, R01GM035649] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47020] Funding Source: Medline; NIGMS NIH HHS [GM 35649, GM 35847] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALL EH, 1986, ANAL BIOCHEM, V155, P23, DOI 10.1016/0003-2697(86)90218-6; BENESCH RE, 1995, J BIOL CHEM, V270, P13785, DOI 10.1074/jbc.270.23.13785; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; CAMERON BF, 1965, ANAL BIOCHEM, V11, P164, DOI 10.1016/0003-2697(65)90002-3; DEDUVE C, 1948, ACTA CHEM SCAND, V2, P264, DOI 10.3891/acta.chem.scand.02-0264; FROSSARD P, 1982, BIOCHIM BIOPHYS ACTA, V704, P524, DOI 10.1016/0167-4838(82)90076-0; FUSHITANI K, 1988, J BIOL CHEM, V263, P6502; FUSHITANI K, 1991, J BIOL CHEM, V266, P10275; Fushitani K, 1996, BBA-PROTEIN STRUCT M, V1292, P273, DOI 10.1016/0167-4838(95)00214-6; GIBSON QH, 1991, J BIOL CHEM, V266, P13097; HARGROVE MS, 1994, J BIOL CHEM, V269, P4207; HARGROVE MS, 1995, THESIS W MARSH RICE; KAPP OH, 1984, J BIOL CHEM, V259, P628; LEVIN O, 1963, J MOL BIOL, V6, P95, DOI 10.1016/S0022-2836(63)80084-4; MAINWARING MG, 1986, J BIOL CHEM, V261, P899; MATSUBARA H, 1969, BIOCHEM BIOPH RES CO, V35, P175, DOI 10.1016/0006-291X(69)90263-0; NOZAKI Y, 1986, ARCH BIOCHEM BIOPHYS, V249, P437, DOI 10.1016/0003-9861(86)90020-2; OWNBY DW, 1993, J BIOL CHEM, V268, P13539; ROCHE J, 1960, BIOCHIM BIOPHYS ACTA, V41, P182, DOI 10.1016/0006-3002(60)90397-8; ROYER WE, 1988, J BIOL CHEM, V263, P13762; SCHATZ M, 1995, J STRUCT BIOL, V114, P28, DOI 10.1006/jsbi.1995.1003; SHISHIKURA F, 1987, J BIOL CHEM, V262, P3123; SHLOM JM, 1973, J BIOL CHEM, V248, P7904; SUZUKI T, 1993, J BIOL CHEM, V268, P13548; SUZUKI T, 1990, J BIOL CHEM, V265, P12168; TAL M, 1985, J BIOL CHEM, V260, P9976; VANASSENDELFT OW, 1970, SPECTROPHOTOMETRY HA, P100; VINOGRADOV SN, 1982, ANAL BIOCHEM, V120, P111, DOI 10.1016/0003-2697(82)90325-6; VINOGRADOV SN, 1977, BIOCHIM BIOPHYS ACTA, V492, P136, DOI 10.1016/0005-2795(77)90221-5; VINOGRADOV SN, 1986, P NATL ACAD SCI USA, V83, P8034, DOI 10.1073/pnas.83.21.8034; VINOGRADOV SN, 1991, J BIOL CHEM, V266, P13091; VINOGRADOV SN, 1991, COMP BIOCHEM PHYS B, V98, P187, DOI 10.1016/0305-0491(91)90165-A; Weber K, 1972, Methods Enzymol, V26, P3; WOLF HU, 1984, CLIN CHIM ACTA, V136, P95, DOI 10.1016/0009-8981(84)90251-1; XIE Q, 1996, IN PRESS BIOCH BIOPH; ZHANG L, 1991, J BIOL CHEM, V266, P24698; Zhu H, 1996, J BIOL CHEM, V271, P30007, DOI 10.1074/jbc.271.47.30007	37	30	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29999	30006		10.1074/jbc.271.47.29999	http://dx.doi.org/10.1074/jbc.271.47.29999			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939946	hybrid			2022-12-27	WOS:A1996VU52500074
J	Bloch, DB; delaMonte, SM; Guigaouri, P; Filippov, A; Bloch, KD				Bloch, DB; delaMonte, SM; Guigaouri, P; Filippov, A; Bloch, KD			Identification and characterization of a leukocyte-specific component of the nuclear body	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; PRIMARY BILIARY-CIRRHOSIS; RECEPTOR-ALPHA GENE; ZINC-FINGER; CELL-LINE; TRANSCRIPTION FACTOR; VIRUS-INFECTION; PML PROTEIN; RAR-ALPHA; EXPRESSION	The nuclear body (NB) is a cellular organelle that is involved in the pathogenesis of acute promyelocytic leukemia and viral infection. The NB is also a target of antibodies in the serum of patients with the autoimmune disease primary biliary cirrhosis. In this study, serum from a patient with primary biliary cirrhosis was used to identify a cDNA encoding a novel component of the NB, a 140-kDa protein designated Sp140. The predicted amino acid sequence of the amino-terminal portion of Sp140 was similar to Sp100, a previously identified NB protein. The carboxyl portion of Sp140 contained a zinc-finger domain and a bromodomain, motifs that are present in proteins regulating gene transcription. High levels of Sp140 mRNA were detected in human spleen and peripheral blood leukocytes, but not other human tissues. The level of SP140 mRNA in myeloid precursor cell lines HL60 and NB4 markedly increased in response to chemically induced cellular differentiation. Immunohistochemical techniques were used to demonstrate that SP140 localized to the NB in differentiated HL60 and NB4 cells. The location of Sp140 in the NB, and expression of this gene in cells involved in host defense, suggest that Sp140 may be involved in the pathogenesis of acute promyelocytic leukemia and viral infection.	HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02129 USA; MASSACHUSETTS GEN HOSP, GEN MED SERV, ARTHRIT UNIT, BOSTON, MA 02129 USA; MASSACHUSETTS GEN HOSP, GEN MED SERV, CARDIOVASC RES CTR, BOSTON, MA 02129 USA; MASSACHUSETTS GEN HOSP, GEN MED SERV, CTR CANC, DIV NEUROPATHOL, BOSTON, MA 02129 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital			de la monte, suzanne/L-7670-2019	de la monte, suzanne/0000-0001-5886-2306; Bloch, Donald/0000-0002-6828-4754	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL045895] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK051179] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45895] Funding Source: Medline; NIAMS NIH HHS [AR01866] Funding Source: Medline; NIDDK NIH HHS [DK51179] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BRASCH K, 1992, EXP CELL RES, V202, P211, DOI 10.1016/0014-4827(92)90068-J; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COLLINS SJ, 1987, BLOOD, V70, P1233; DANIEL MT, 1993, BLOOD, V82, P1858; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVANS J, 1991, ARTHRITIS RHEUM, V34, P731, DOI 10.1002/art.1780340614; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GULDNER HH, 1992, J IMMUNOL, V149, P4067; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAPLAN MM, 1987, NEW ENGL J MED, V316, P521, DOI 10.1056/NEJM198702263160907; KOKEN MHM, 1995, CR ACAD SCI III-VIE, V318, P733; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KORIOTH F, 1995, J CELL BIOL, V130, P1, DOI 10.1083/jcb.130.1.1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANOTTE M, 1991, BLOOD, V77, P1080; LEE RT, 1988, J CLIN INVEST, V81, P431, DOI 10.1172/JCI113337; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; LYGEROU Z, 1994, NUCLEIC ACIDS RES, V22, P5332, DOI 10.1093/nar/22.24.5332; MAUL GG, 1994, J GEN VIROL, V75, P1223, DOI 10.1099/0022-1317-75-6-1223; MAUL GG, 1993, J GEN VIROL, V74, P2679, DOI 10.1099/0022-1317-74-12-2679; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; SCHLEIF R, 1988, SCIENCE, V241, P1182, DOI 10.1126/science.2842864; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STERNSDORF T, 1995, SCAND J IMMUNOL, V42, P257, DOI 10.1111/j.1365-3083.1995.tb03652.x; STRUHL K, 1989, TRENDS BIOCHEM SCI, V14, P137, DOI 10.1016/0968-0004(89)90145-X; STUURMAN N, 1992, J CELL SCI, V101, P773; SZOSTECKI C, 1992, SCAND J IMMUNOL, V36, P555, DOI 10.1111/j.1365-3083.1992.tb03224.x; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WARRELL RP, 1993, BLOOD, V82, P1949, DOI 10.1182/blood.V82.7.1949.bloodjournal8271949; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; XIE KW, 1993, MOL CELL BIOL, V13, P6170, DOI 10.1128/MCB.13.10.6170; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359	52	80	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29198	29204		10.1074/jbc.271.46.29198	http://dx.doi.org/10.1074/jbc.271.46.29198			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910577	Green Published, hybrid			2022-12-27	WOS:A1996VT05200069
J	Kono, M; Yoshida, Y; Kojima, N; Tsuji, S				Kono, M; Yoshida, Y; Kojima, N; Tsuji, S			Molecular cloning and expression of a fifth type of alpha,8-sialyltransferase (ST8Sia V) - Its substrate specificity is similar to that of SAT-V/III, which synthesize G(D1c), G(T1a), G(Q1b) and G(T3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTALLY-REGULATED MEMBER; RAT-LIVER GOLGI; G(D3) SYNTHASE; ALPHA-2,8-SIALYLTRANSFERASE; GANGLIOSIDES; BIOSYNTHESIS; GENE; CDNA; STX	The cDNAs encoding a new alpha 2,8-sialyltransferase (ST8Sia V) were cloned from a mouse brain cDNA library by means of a polymerase chain reaction-based method using the nucleotide sequence information on mouse ST8Sia I (G(D3) synthase) and mouse ST8Sia III (Sia alpha 2,3Gal beta 1,4GlcNAc alpha 2,8-sialyltransferase) both of which exhibit activity toward glycolipids. The predicted amino acid sequence of ST8Sia V shows 36.1% and 15.0% identity to those of mouse ST8Sia I and III, respectively. The recombinant protein A-fused ST8Sia V expressed in COS-7 cells exhibited an alpha 2,8-sialyltransferase activity toward G(M1b), G(D1a), G(T1b), and G(D3), and synthesized G(D1c), G(T1a), G(Q1b), and G(T3), respectively. The apparent K-m values for G(M1b), G(D1a), G(T1b) and G(D3) were 1.1, 0.082, 0.070, and 0.28 mM, respectively. However, ST8Sia V did not exhibit activity toward G(M3). Thus, the substrate specificity of ST8Sia V is different from those of ST8Sia I and III, both of which exhibit activity toward G(M3). Transfection of the ST8Sia V gene into COS-7 cells, which express G(D1a) as a major glycolipid, led to the expression of determinants for monoclonal antibody 4F10, which recognizes G(T1a) and G(Q1b), suggesting that ST8Sia V exhibits activity toward gangliosides G(D1a) and/or G(T1b) in vivo. The expression of the ST8Sia V gene was tissue- and developmental stage-specific, and was clearly different from those of other alpha 2,8-sialyltransferase genes. The ST8Sia V gene was strongly expressed in the brain and weakly in other tissues such as the liver. In addition, its expression was greater in the adult than fetal brain. These results strongly indicate that ST8Sia V is a candidate for SAT-V, the alpha 2,8-sialyltransferase involved in G(D1c), G(T1a), G(Q1b), and G(T3) synthesis.	INST PHYS & CHEM RES,FRONTIER RES PROGRAM,WAKO,SAITAMA 35101,JAPAN	RIKEN			Yoshida, Yukiko/ABB-7218-2020	Yoshida, Yukiko/0000-0002-0629-0219; Kono, Mari/0000-0003-2447-4350				ANDO S, 1983, NEUROCHEM INT, V5, P507, DOI 10.1016/0197-0186(83)90043-8; CHANG ML, 1995, GLYCOBIOLOGY, V5, P319, DOI 10.1093/glycob/5.3.319; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; IBER H, 1991, EUR J BIOCHEM, V195, P115, DOI 10.1111/j.1432-1033.1991.tb15683.x; IBER H, 1992, GLYCOBIOLOGY, V2, P137, DOI 10.1093/glycob/2.2.137; Kitagawa H, 1996, J BIOL CHEM, V271, P931, DOI 10.1074/jbc.271.2.931; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; Kojima N, 1996, J BIOL CHEM, V271, P19457, DOI 10.1074/jbc.271.32.19457; KOJIMA N, 1995, FEBS LETT, V373, P119, DOI 10.1016/0014-5793(95)01024-9; Kurosawa N, 1996, J BIOL CHEM, V271, P15109, DOI 10.1074/jbc.271.25.15109; LEE YC, 1993, EUR J BIOCHEM, V216, P377, DOI 10.1111/j.1432-1033.1993.tb18155.x; LEE YC, 1994, J BIOL CHEM, V269, P10028; Nakayama J, 1996, J BIOL CHEM, V271, P3684; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; SAMBROOK J, 1989, MOL C LONING LAB MAN; SASAKI K, 1994, J BIOL CHEM, V269, P15950; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; TSUJI S, 1996, IN PRESS GLYCOBIOLOG; WATANABE Y, 1995, GLYCOCONJUGATE J, V12, P555; YAMAMOTO H, 1990, J NEUROCHEM, V54, P513, DOI 10.1111/j.1471-4159.1990.tb01901.x; YOSHIDA Y, 1996, IN PRESS GLYCOBIOLOG; YOSHIDA Y, 1995, J BIOCHEM-TOKYO, V118, P685; YOSHIDA Y, 1995, J BIOL CHEM, V270, P1628	27	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29366	29371		10.1074/jbc.271.46.29366	http://dx.doi.org/10.1074/jbc.271.46.29366			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910600	hybrid			2022-12-27	WOS:A1996VT05200092
J	Laser, B; Meda, P; Constant, I; Philippe, J				Laser, B; Meda, P; Constant, I; Philippe, J			The caudal-related homeodomain protein Cdx-2/3 regulates glucagon gene expression in islet cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; BOX-CONTAINING GENE; HOMEOBOX GENE; INSULIN GENE; PROMOTER ELEMENT; TRANSGENIC MICE; MESSENGER-RNA; DNA-BINDING; TRANSCRIPTION; SEQUENCES	Glucagon gene transcription in the endocrine pancreas is regulated by at least four cis-acting DNA control elements. We showed previously that G1 is critical for alpha cell-specific expression. G1 contains three AT-rich sequences important for promoter function, which represent candidate binding sites for homeodomain transcription factors. Performing reverse transcription-polymerase chain reaction amplifications with degenerate oligonucleotide primers homologous to the Antennapedia homeobox, cDNA clones corresponding to the caudal-related gene cdx-2/3 were predominantly obtained from glucagon-producing cells and primary non-beta cells. From RNase protection and polymerase chain reaction analyses, cdx-2/3 turned out to be the only caudal-related gene that is expressed at significant levels in cells of the endocrine pancreas, Cdx-2/3 binds with high affinity to an AT-rich motif of G1, which matches the consensus binding site of caudal-related proteins. In the glucagon-producing hamster cell line InR1G9, Cdx-2/3 is a subunit of complex B3 formed on G1. Alternative splicing generates two cdx-2/3 transcripts in islet cells, coding for a full-length protein and an amino-terminally truncated isoform. Although both isoforms bind G1 with similar affinity, only the full-length Cdx-2/3 A protein activates glucagon gene transcription in non-glucagon-producing cells, transcriptional activation being dose-dependent. We therefore conclude that the caudal-related gene cdx-2/3 is implicated in the transcriptional control of glucagon gene expression in the alpha cells of the islets of Langerhans.	CTR MED UNIV GENEVA,DEPT MORPHOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva	Laser, B (corresponding author), CTR MED UNIV GENEVA,DEPT MED,1 RUE MICHEL SERVET,CH-1211 GENEVA 4,SWITZERLAND.							ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BARON A, 1987, EMBO J, V6, P2977, DOI 10.1002/j.1460-2075.1987.tb02603.x; BEACHY PA, 1993, MOL CELL BIOL, V13, P6941, DOI 10.1128/MCB.13.11.6941; BONNER CA, 1995, GENOMICS, V28, P206, DOI 10.1006/geno.1995.1132; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; CORDIERBUSSAT M, 1995, MOL CELL BIOL, V15, P3904; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; DEAROLF CR, 1989, NATURE, V341, P340, DOI 10.1038/341340a0; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DRUCKER DJ, 1988, J BIOL CHEM, V263, P13475; Drummond F, 1996, EUR J BIOCHEM, V236, P670, DOI 10.1111/j.1432-1033.1996.t01-1-00670.x; EFRAT S, 1988, NEURON, V1, P605, DOI 10.1016/0896-6273(88)90110-9; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; FRUMKIN A, 1994, DEVELOPMENT, V120, P253; GALANG CK, 1993, MOL CELL BIOL, V13, P4609, DOI 10.1128/MCB.13.8.4609; GAMER LW, 1993, MECH DEVELOP, V43, P71, DOI 10.1016/0925-4773(93)90024-R; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GIORDANO E, 1993, AM J PHYSIOL, V265, pC358, DOI 10.1152/ajpcell.1993.265.2.C358; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HART C P, 1987, Genomics, V1, P182, DOI 10.1016/0888-7543(87)90011-5; HODGES D, 1994, ADV GENET, V31, P207, DOI 10.1016/S0065-2660(08)60399-5; HU YL, 1993, J BIOL CHEM, V268, P27214; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; JAMES R, 1994, J BIOL CHEM, V269, P15229; Jin TR, 1996, MOL CELL BIOL, V16, P19; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YC, 1992, J BIOL CHEM, V267, P10705; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; MACFARLANE WM, 1994, BIOCHEM J, V303, P625, DOI 10.1042/bj3030625; MARGALIT Y, 1993, NUCLEIC ACIDS RES, V21, P4915, DOI 10.1093/nar/21.21.4915; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; MLODZIK M, 1985, EMBO J, V4, P2961, DOI 10.1002/j.1460-2075.1985.tb04030.x; MOJSOV S, 1986, J BIOL CHEM, V261, P1880; MOREL C, 1995, J BIOL CHEM, V270, P3046, DOI 10.1074/jbc.270.7.3039; NORTHROP JL, 1994, DEV BIOL, V161, P490, DOI 10.1006/dbio.1994.1047; NOVAK U, 1987, EUR J BIOCHEM, V164, P553, DOI 10.1111/j.1432-1033.1987.tb11162.x; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; OIE HK, 1983, ENDOCRINOLOGY, V112, P1070, DOI 10.1210/endo-112-3-1070; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; PETERSON RL, 1992, MECH DEVELOP, V37, P151, DOI 10.1016/0925-4773(92)90077-W; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PHILIPPE J, 1994, DIABETES, V43, P523, DOI 10.2337/diabetes.43.4.523; PHILIPPE J, 1987, J CLIN INVEST, V79, P351, DOI 10.1172/JCI112819; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; PHILIPPE J, 1995, J BIOL CHEM, V270, P3039, DOI 10.1074/jbc.270.7.3039; PHILIPPE J, 1994, ENDOCR REV, V2, P21; POWERS AC, 1990, DIABETES, V39, P406, DOI 10.2337/diabetes.39.4.406; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; RENUCCI A, 1992, EMBO J, V11, P1459, DOI 10.1002/j.1460-2075.1992.tb05190.x; RUBIN MR, 1987, MOL CELL BIOL, V7, P3836, DOI 10.1128/MCB.7.10.3836; RUDNICK A, 1994, P NATL ACAD SCI USA, V91, P12203, DOI 10.1073/pnas.91.25.12203; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SAMBROOK E, 1989, MOL CLONING LAB MANU; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SERRANO J, 1993, BIOCHEM BIOPH RES CO, V190, P270, DOI 10.1006/bbrc.1993.1041; SERUP P, 1995, BIOCHEM J, V310, P997, DOI 10.1042/bj3100997; Stein S, 1996, MECH DEVELOP, V55, P91, DOI 10.1016/0925-4773(95)00494-7; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; TAKAKI R, 1986, IN VITRO CELL DEV B, V22, P120; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG M, 1995, J BIOL CHEM, V270, P12646, DOI 10.1074/jbc.270.21.12584; WINKLER M, 1991, CURR GENET, V20, P495, DOI 10.1007/BF00334778; XU X, 1994, DEVELOPMENT, V120, P277	72	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28984	28994		10.1074/jbc.271.46.28984	http://dx.doi.org/10.1074/jbc.271.46.28984			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910549	hybrid			2022-12-27	WOS:A1996VT05200041
J	Wilkin, F; Savonet, V; Radulescu, A; Petermans, J; Dumont, JE; Maenhaut, C				Wilkin, F; Savonet, V; Radulescu, A; Petermans, J; Dumont, JE; Maenhaut, C			Identification and characterization of novel genes modulated in the thyroid of dogs treated with methimazole and propylthiouracil	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED MOUSE CELLS; HEAT-SHOCK PROTEINS; MAMMALIAN-CELLS; GROWTH-FACTORS; CYCLIC-AMP; MOLECULAR-CLONING; TYROSINE KINASE; RESPONSE GENES; PHORBOL ESTERS; EXPRESSION	Induction of cell proliferation by mitogen or growth factor stimulation leads to the specific stimulation or repression of a large number of genes. To better understand differentiated epithelial cell growth regulation, we have initiated a study to identify genes which are regulated by the thyrotropin-dependent mitogenic pathway in dog thyroid cells. A thyroid cDNA library was prepared from a methimazole and propylthiouracil-treated dog and differentially screened with probes derived from control or stimulated thyroids. Among 19 clones isolated, 6 encode known proteins (inwardly rectifying potassium channel, nucleosome assembly protein, ribosomal protein L7, elongation factor 1 alpha, non-muscle myosin light chain, and heat shock protein 90 beta). The 13 others correspond to proteins whose function is unknown, Among them, 5 correspond to mRNAs whose expression was modulated by mitogenic stimulation of thyrocytes in primary culture, A preliminary characterization of two of these cDNAs is reported: clone 5, which might represent a novel, atypical protein kinase, and clone 3, which contains ankyrin-like repeats, suggesting that it might interact with other proteins.	FREE UNIV BRUSSELS,INST RECH INTERDISCIPLINAIRE,B-1070 BRUSSELS,BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel								ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BEELER JF, 1994, MOL CELL BIOL, V14, P982, DOI 10.1128/MCB.14.2.982; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BUREL C, 1992, EXPERIENTIA, V48, P629, DOI 10.1007/BF02118307; CATELLI MG, 1989, BIOCHEM J, V258, P895, DOI 10.1042/bj2580895; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COCLET J, 1989, CLIN ENDOCRINOL, V31, P655, DOI 10.1111/j.1365-2265.1989.tb01290.x; DREMIER S, 1994, ENDOCRINOLOGY, V135, P135, DOI 10.1210/en.135.1.135; Dumont J E, 1971, Vitam Horm, V29, P287; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERRIS DK, 1988, P NATL ACAD SCI USA, V85, P3850, DOI 10.1073/pnas.85.11.3850; GALAND P, 1995, LEUKEMIA, V9, P1075; GE L, 1995, J CELL BIOCHEM, V57, P331, DOI 10.1002/jcb.240570217; GERARD CM, 1989, MOL CELL ENDOCRINOL, V61, P23, DOI 10.1016/0303-7207(89)90186-X; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARA E, 1988, GENE, V70, P97; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; ISHIMI Y, 1983, J BIOCHEM-TOKYO, V94, P735, DOI 10.1093/oxfordjournals.jbchem.a134414; ISHIMI Y, 1987, EUR J BIOCHEM, V162, P19, DOI 10.1111/j.1432-1033.1987.tb10535.x; JACQUIERSARLIN MR, 1995, J BIOL CHEM, V270, P14094, DOI 10.1074/jbc.270.23.14094; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LINZER DIH, 1983, P NATL ACAD SCI-BIOL, V80, P4271, DOI 10.1073/pnas.80.14.4271; MAENHAUT C, 1992, J BIOL CHEM, V267, P3000; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; ROGER P, 1985, EUR J BIOCHEM, V122, P239; ROGER PP, 1986, CANCER RES, V46, P898; Roger PP, 1995, VITAM HORM, V51, P59, DOI 10.1016/S0083-6729(08)61038-9; ROGER PP, 1984, MOL CELL ENDOCRINOL, V36, P79, DOI 10.1016/0303-7207(84)90087-X; ROGER PP, 1982, MOL CELL ENDOCRINOL, V26, P165, DOI 10.1016/0303-7207(82)90014-4; ROGER PP, 1983, FEBS LETT, V157, P323, DOI 10.1016/0014-5793(83)80569-9; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SIMON HU, 1994, BIOCHEM J, V297, P389, DOI 10.1042/bj2970389; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VINCENT S, 1993, ONCOGENE, V8, P1603; WICK M, 1994, J CELL SCI, V107, P227; ZIEMIECKI A, 1986, BIOCHEM BIOPH RES CO, V138, P1298, DOI 10.1016/S0006-291X(86)80424-7	48	37	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28451	28457		10.1074/jbc.271.45.28451	http://dx.doi.org/10.1074/jbc.271.45.28451			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910471	hybrid			2022-12-27	WOS:A1996VU03300071
J	Begum, N; Ragolia, L				Begum, N; Ragolia, L			cAMP counter-regulates insulin-mediated protein phosphatase-2A inactivation in rat skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; DEPENDENT ACTIVATION; KINASE; GROWTH; 2A; INHIBITION; SUBUNIT	In this study, we examined the mechanism of recently reported inactivation of protein phosphatase-2A (PP-2A) by insulin (Srinivasan, IM., and Begum, N, (1994) J. Biol. Chem, 269, 12514-12520) and its counter-regulation by cAMP agonists, Exposure of L6 myotubes to insulin resulted in a rapid inhibition of PP-W that was accompanied by a 3-fold increase in the phosphotyrosine content of the immunoprecipitated PP-2A catalytic subunit, Pretreatment with (S-p) cAMP, a cAMP agonist, completely blocked insulin-mediated inhibition of PP-2A activity and decreased the tyrosine phosphorylation of PP-2A catalytic subunit to control levels. To understand the mechanism of counter regulation of PP-2A by (S-p)-cAMP, cells were pretreated with sodium orthovanadate, an inhibitor of phosphotyrosine phosphatases. Vanadate prevented the effect of (S-p)-cAMP on PP-2A activity and increased the phosphorylation status of PP-2A catalytic subunit to the level observed with insulin, Wortmannin, a phosphatidylinositol 8-kinase inhibitor, and rapamycin, an inhibitor of 70-kDa S6 kinase activation, prevented insulin-mediated inactivation of PP-2A, suggesting that these pathways may participate in insulin mediated phosphorylation and inactivation of PP-2A These results show that insulin signaling results in a rapid inactivation of PP-PA by increased tyrosine phosphorylation and cAMP agonists counter-regulate insulin's effect on PP-2A by decreasing phosphorylation, presumably via an activated phosphatase.	SUNY STONY BROOK, SCH MED, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Begum, N (corresponding author), WINTHROP UNIV HOSP, DIABET RES LABS, 259 1ST ST, MINEOLA, NY 11501 USA.		Ragolia, Louis/AAW-2383-2021	Ragolia, Louis/0000-0002-8292-5159				AHMAD F, 1995, AM J PHYSIOL-ENDOC M, V268, pE932, DOI 10.1152/ajpendo.1995.268.5.E932; BARNES GN, 1995, J NEUROCHEM, V64, P340; Begum N, 1996, EUR J BIOCHEM, V238, P214, DOI 10.1111/j.1432-1033.1996.0214q.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brautigan David L., 1993, Molecular and Cellular Biochemistry, V127-128, P121, DOI 10.1007/BF01076763; BRAUTIGAN DL, 1993, ADV PROT PHOSPHATASE, V7, P49; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; Chajry N, 1996, EUR J BIOCHEM, V235, P97, DOI 10.1111/j.1432-1033.1996.00097.x; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; ERHARDT P, 1995, MOL CELL BIOL, V15, P5524; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GUO H, 1993, J BIOL CHEM, V268, P11193; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; MAYEROWITCH J, 1992, BIOCHEMISTRY-US, V31, P10338; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; OKADA T, 1994, J BIOL CHEM, V269, P3568; PETRITSCH C, 1995, J BIOL CHEM, V270, P22619; REUDIGER R, 1991, MOL CELL BIOL, V11, P4282; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SRINIVASAN M, 1994, J BIOL CHEM, V269, P12514; STEVENSON BR, 1993, P NATL ACAD SCI USA, V90, P10305; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XIE HY, 1994, J BIOL CHEM, V269, P1981; Zhang WR, 1996, MOL ENDOCRINOL, V10, P575, DOI 10.1210/me.10.5.575	33	73	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31166	31171		10.1074/jbc.271.49.31166	http://dx.doi.org/10.1074/jbc.271.49.31166			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940115	hybrid			2022-12-27	WOS:A1996VW68600026
J	Friedman, WJ; Thakur, S; Seidman, L; Rabson, AB				Friedman, WJ; Thakur, S; Seidman, L; Rabson, AB			Regulation of nerve growth factor mRNA by interleukin-1 in rat hippocampal astrocytes is mediated by NF kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MESSENGER-RNA; TUMOR-NECROSIS-FACTOR; GENE-EXPRESSION; TRANSCRIPTION FACTOR; INTERFERON-GAMMA; VIRUS TYPE-1; FACTOR-ALPHA; FACTOR NGF; AGED RATS; CELLS	Cytokines such as interleukin-1 beta (IL-1) are produced in the brain during development and during inflammatory processes that result from lesions or disease. One function of IL-1 in the brain appears to be the stimulation of astrocytes to proliferate and produce a variety of cytokines and trophic factors, including nerve growth factor. The mechanisms by which IL-1 exerts its actions on astrocytes remain poorly defined. We present evidence that this cytokine elicits activation of the NF kappa B transcription factor and that this transcription factor mediates effects of Il-1 on nerve growth factor mRNA expression. Elucidation of the processes by which cytokines activate astrocytes and influence trophic factor expression may provide insight into mechanisms governing inflammatory processes within the central nervous system.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT NEUROSCI & CELL BIOL,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT MOL GENET & MICROBIOL,PISCATAWAY,NJ 08854; CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center					NINDS NIH HHS [NS 31357] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS031357] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AYERLELIEVRE C, 1988, SCIENCE, V240, P1339, DOI 10.1126/science.2897715; BANDTLOW CE, 1987, EMBO J, V6, P891, DOI 10.1002/j.1460-2075.1987.tb04835.x; BAUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BENVENISTE EN, 1992, NEUROIMMUNOENDOCRINO, V52, P106; BIELINSKA A, 1990, SCIENCE, V250, P997, DOI 10.1126/science.2237444; CARMANKRZAN M, 1991, J NEUROCHEM, V56, P636, DOI 10.1111/j.1471-4159.1991.tb08197.x; CAULEY K, 1994, P NATL ACAD SCI USA, V91, P390, DOI 10.1073/pnas.91.1.390; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; D'MELLO S R, 1991, Molecular and Cellular Neuroscience, V2, P157, DOI 10.1016/1044-7431(91)90008-C; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; ECK SL, 1993, MOL CELL BIOL, V13, P6530, DOI 10.1128/MCB.13.10.6530; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; FAGARASAN MO, 1990, P NATL ACAD SCI USA, V87, P7871, DOI 10.1073/pnas.87.20.7871; FISCHER W, 1987, NATURE, V329, P65, DOI 10.1038/329065a0; FISCHER W, 1989, EUR J NEUROSCI, V1, P34, DOI 10.1111/j.1460-9568.1989.tb00772.x; FRIEDMAN WJ, 1990, J NEUROSCI RES, V27, P374, DOI 10.1002/jnr.490270316; FRIEDMAN WJ, 1992, J NEUROSCI RES, V33, P37, DOI 10.1002/jnr.490330106; GIMBLE JM, 1988, J VIROL, V62, P4104, DOI 10.1128/JVI.62.11.4104-4112.1988; HEFTI F, 1986, ANN NEUROL, V20, P275, DOI 10.1002/ana.410200302; HEFTI F, 1984, BRAIN RES, V293, P305, DOI 10.1016/0006-8993(84)91237-X; HENGERER B, 1990, P NATL ACAD SCI USA, V87, P3899, DOI 10.1073/pnas.87.10.3899; HERTZ L, 1990, IMMUNOL TODAY, V11, P265, DOI 10.1016/0167-5699(90)90106-J; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; KALTSCHMIDT B, 1993, MOL ASPECTS MED, V14, P171, DOI 10.1016/0098-2997(93)90004-W; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; KOOP EB, 1995, ADV IMMUNOL, V58, P1; LARGE TH, 1986, SCIENCE, V234, P352, DOI 10.1126/science.3764415; LARKFORS L, 1987, MOL BRAIN RES, V3, P55, DOI 10.1016/0169-328X(87)90044-1; LARKFORS L, 1987, J NEUROSCI RES, V18, P525, DOI 10.1002/jnr.490180404; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIEBERMAN AP, 1989, P NATL ACAD SCI USA, V86, P6348, DOI 10.1073/pnas.86.16.6348; LINDHOLM D, 1987, NATURE, V330, P658, DOI 10.1038/330658a0; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LIPTAY S, 1994, MOL CELL BIOL, V14, P7695, DOI 10.1128/MCB.14.12.7695; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; LU B, 1991, J NEUROSCI, V11, P318; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MONTERO CN, 1988, J NEUROSCI, V8, P2986; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; OLSON L, 1992, J NEURAL TRANSM-PARK, V4, P79, DOI 10.1007/BF02257624; OMALLEY EK, 1994, BRAIN RES, V647, P83, DOI 10.1016/0006-8993(94)91401-X; RATTNER A, 1993, EMBO J, V12, P4261, DOI 10.1002/j.1460-2075.1993.tb06110.x; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J VIROL, V66, P6288, DOI 10.1128/JVI.66.11.6288-6293.1992; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SPARACIO SM, 1992, J NEUROIMMUNOL, V39, P231, DOI 10.1016/0165-5728(92)90257-L; SPRANGER M, 1990, EUR J NEUROSCI, V2, P69, DOI 10.1111/j.1460-9568.1990.tb00382.x; SWINGLER S, 1994, BIOCHEM BIOPH RES CO, V203, P623, DOI 10.1006/bbrc.1994.2228; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; THAKUR S, 1994, ONCOGENE, V9, P2335; Troy CM, 1996, J NEUROSCI, V16, P253; VIDOVIC M, 1990, J NEUROIMMUNOL, V30, P189, DOI 10.1016/0165-5728(90)90103-T; WHITTEMORE SR, 1987, J NEUROSCI, V7, P244; WHITTEMORE SR, 1986, P NATL ACAD SCI USA, V83, P817, DOI 10.1073/pnas.83.3.817; WHITTEMORE SR, 1988, J NEUROSCI RES, V20, P403, DOI 10.1002/jnr.490200402; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231	59	89	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31115	31120		10.1074/jbc.271.49.31115	http://dx.doi.org/10.1074/jbc.271.49.31115			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940108	hybrid			2022-12-27	WOS:A1996VW68600019
J	Kudlicki, W; Odom, OW; Kramer, G; Hardesty, B				Kudlicki, W; Odom, OW; Kramer, G; Hardesty, B			Binding of an N-terminal rhodanese peptide to DnaJ and to ribosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA; CONFORMATIONAL-CHANGES; BOVINE LIVER; SYSTEM; ACTIVATION; PROTEINS; ATPASE; CYCLE; TRANSLATION; GROEL	A peptide corresponding to the N-terminal 17 amino acids of bovine rhodanese was fluorescently labeled with a coumarin derivative at its primary amino group(s) and then purified by high performance liquid chromatography. This peptide interacted with the molecular chaperone DnaJ in the absence of other chaperones and ATP, In the presence of ATP, the molecular chaperone DnaK bound to the DnaJ-peptide complex, but not to the peptide alone, The chaperone GrpE appeared to cause the release of the peptide bound to the ternary complex in the presence of ATP but not in the presence of ADP, This nucleotide apparently stabilized the complex, The peptide also bound to salt-washed Escherichia coli 70 S ribosomes, specifically to 50 S ribosomal subunits, not to 30 S subunits, DnaJ plus DnaK interacted with the peptide on the ribosome, GrpE caused dissociation of the peptide from the ribosome; ATP was required for this reaction, It was inhibited by ADP, A comparable series of chaperone-mediated reactions is assumed to occur with the N-terminal segment of the nascent polypeptide to facilitate its folding on ribosomes.	UNIV TEXAS,DEPT CHEM & BIOCHEM,AUSTIN,TX 78712	University of Texas System; University of Texas Austin								BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; EISENSTEIN M, 1994, SUPRAMOLECULAR STRUC, P213; FARR CD, 1995, BIOCHEMISTRY-US, V34, P15574, DOI 10.1021/bi00047a024; FEDOROV AN, 1995, P NATL ACAD SCI USA, V92, P1227, DOI 10.1073/pnas.92.4.1227; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; JORDAN R, 1995, J BIOL CHEM, V270, P4563, DOI 10.1074/jbc.270.9.4563; KAMATHLOEB AS, 1995, J BIOL CHEM, V270, P30051; KOLB VA, 1994, EMBO J, V13, P3631, DOI 10.1002/j.1460-2075.1994.tb06670.x; KUDLICKI W, 1995, BIOCHEMISTRY-US, V34, P14284, DOI 10.1021/bi00044a003; KUDLICKI W, 1994, J BIOL CHEM, V269, P16549; KUDLICKI W, 1994, J MOL BIOL, V244, P319, DOI 10.1006/jmbi.1994.1732; KUDLICKI W, 1995, J MOL BIOL, V252, P203, DOI 10.1006/jmbi.1995.0488; KUDLICKI W, 1995, J BIOL CHEM, V270, P10650, DOI 10.1074/jbc.270.18.10650; KUDLICKI W, 1992, ANAL BIOCHEM, V206, P389, DOI 10.1016/0003-2697(92)90383-I; KUDLICKI W, 1996, IN PRESS PROTEIN FOL; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; MERRILL GA, 1992, J PROTEIN CHEM, V11, P193, DOI 10.1007/BF01025225; MILLER DM, 1991, J BIOL CHEM, V266, P4686; ODOM OW, 1980, BIOCHEMISTRY-US, V19, P5947, DOI 10.1021/bi00567a001; PALLEROS DR, 1994, J BIOL CHEM, V269, P13107; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345	25	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31160	31165		10.1074/jbc.271.49.31160	http://dx.doi.org/10.1074/jbc.271.49.31160			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940114	hybrid			2022-12-27	WOS:A1996VW68600025
J	Leprini, A; Gherzi, R; Siri, A; Querze, G; Viti, F; Zardi, L				Leprini, A; Gherzi, R; Siri, A; Querze, G; Viti, F; Zardi, L			The human tenascin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURITE GROWTH; MESSENGER-RNA; ADULT-MOUSE; IN-VITRO; JANUSIN; RESTRICTIN; MOLECULE; FAMILY; LOCALIZATION; FIBRONECTIN	The human tenascin-R gene encodes a multidomain protein belonging to the tenascin family, until now detected only in the central nervous system, During embryo development, tenascin-R is presumed to play a pivotal role in axonal path finding through its adhesive and repulsive properties, Recently, the primary structure of human tenascin-R has been elucidated (Carnemolla, B., Leprini, A., Borsi, L., Querze, G., Urbini, S., and Zardi, L. (1996) J. Biol. Chem. 271, 8157-8160). As a further step to investigate the role of human tenascin-R we defined the structure of its gene, The gene, which spans a region of chromosome 1 approximately 85 kilobases in length, consists of 21 exons, ranging in size from 90 to >670 base pairs, The sequence analysis of intron splice donor and acceptor sites revealed that the position of introns in human tenascin-R are precisely conserved in the other two tenascin family members, tenascin-C and tenascin-X, The determination of intronic sequences flanking the exon boundaries will allow investigation of whether mutations may be responsible for altered function of the gene product(s) leading to central nervous system development defects.	IST NAZL RIC CANC, CELL BIOL LAB, I-16132 GENOA, ITALY	University of Genoa; IRCCS AOU San Martino IST			Gherzi, Roberto/AAA-7256-2020	Gherzi, Roberto/0000-0001-8654-0611				BARTSCH U, 1993, GLIA, V9, P57, DOI 10.1002/glia.440090108; BRISTOW J, 1993, J CELL BIOL, V122, P265, DOI 10.1083/jcb.122.1.265; Carnemolla B, 1996, J BIOL CHEM, V271, P8157, DOI 10.1074/jbc.271.14.8157; CHIQUETEHRISMANN R, 1994, PERSPECT DEV NEUROBI, V2, P3; Erickson HP, 1993, CURR OPIN CELL BIOL, V5, P869, DOI 10.1016/0955-0674(93)90037-Q; ERICKSON HP, 1994, PERSPECT DEV NEUROBI, V2, P9; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FUSS B, 1993, J CELL BIOL, V120, P1237, DOI 10.1083/jcb.120.5.1237; GEFFROTIN C, 1995, EUR J BIOCHEM, V231, P83, DOI 10.1111/j.1432-1033.1995.0083f.x; GHERZI R, 1995, J BIOL CHEM, V270, P3429, DOI 10.1074/jbc.270.7.3429; GULCHER JR, 1991, P NATL ACAD SCI USA, V88, P9438, DOI 10.1073/pnas.88.21.9438; LOCHTER A, 1993, J NEUROSCI, V13, P3986; MATSUMOTO K, 1994, J CELL BIOL, V125, P483, DOI 10.1083/jcb.125.2.483; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NORENBERG U, 1992, NEURON, V8, P849, DOI 10.1016/0896-6273(92)90199-N; NORENBERG U, 1995, J CELL BIOL, V130, P473, DOI 10.1083/jcb.130.2.473; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; PESHEVA P, 1989, J CELL BIOL, V109, P1765, DOI 10.1083/jcb.109.4.1765; RATHJEN FG, 1991, DEVELOPMENT, V113, P151; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHACHNER M, 1994, PERSPECT DEV NEUROBI, V2, P33; SCHWAB ME, 1993, ANNU REV NEUROSCI, V16, P565, DOI 10.1146/annurev.ne.16.030193.003025; TAYLOR J, 1993, J NEUROSCI RES, V35, P347, DOI 10.1002/jnr.490350402; WINTERGERST ES, 1993, EUR J NEUROSCI, V5, P299, DOI 10.1111/j.1460-9568.1993.tb00497.x	24	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	1996	271	49					31251	31254		10.1074/jbc.271.49.31251	http://dx.doi.org/10.1074/jbc.271.49.31251			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VW686	8940128	hybrid			2022-12-27	WOS:A1996VW68600039
J	Davies, SA; Goodwin, SF; Kelly, DC; Wang, ZS; Sozen, MA; Kaiser, K; Dow, JAT				Davies, SA; Goodwin, SF; Kelly, DC; Wang, ZS; Sozen, MA; Kaiser, K; Dow, JAT			Analysis and inactivation of vha55, the gene encoding the vacuolar ATPase B-subunit in Drosophila melanogaster reveals a larval lethal phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY ACTIVE-TRANSPORT; TOBACCO HORNWORM MIDGUT; INSECT V-ATPASE; H+-ATPASE; PLASMA-MEMBRANE; MALPIGHIAN TUBULES; FINE-STRUCTURE; MANDUCA-SEXTA; PUMP; CELLS	Vacuolar ATPases play major roles in endomembrane and plasma membrane proton transport in eukaryotes. A Drosophila melanogaster cDNA encoding vha55, the 55-kDa vacuolar ATPase (V-ATPase) regulatory B-subunit, was characterized and mapped to 87C2-4 on chromosome 3R. A fly line was identified that carried a single lethal P-element insertion within the coding portion of gene, and its LacZ reporter gene revealed elevated expression in Malpighian tubules, rectum, antennal palps, and oviduct, regions where V-ATPases are believed to play a plasma membrane, rather than an endomembrane, role. The P-element vha55 insertion was shown to be allelic to a known lethal complementation group 1(3)SzA (=l(3)87Ca) at 87C, for which many alleles have been described previously. Deletions of the locus have been shown to be larval lethal, whereas point mutations show a range of phenotypes hom subvital to embryonic lethal, implying that severe alleles confer a partial dominant negative phenotype. The P-element null allele of vha55 was shown also to suppress ectopic sex combs in Polycomb males, suggesting that transcriptional silencing may be modulated by genes other than those with known homeotic or DNA binding functions.	UNIV GLASGOW,DIV MOL GENET,INST BIOMED & LIFE SCI,GLASGOW G11 6NU,LANARK,SCOTLAND	University of Glasgow			Dow, Julian/M-2371-2019	Dow, Julian/0000-0002-9595-5146; Goodwin, Stephen/0000-0002-0552-4140				ANDERSON E, 1966, J CELL BIOL, V31, P107, DOI 10.1083/jcb.31.1.107; ANRAKU Y, 1992, J EXP BIOL, V172, P67; AOTA S, 1988, NUCLEIC ACIDS RES, V16, pR315, DOI 10.1093/nar/16.suppl.r315; Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; BERNASCONI P, 1989, FEBS LETT, V251, P132, DOI 10.1016/0014-5793(89)81442-5; BERTRAM G, 1991, J INSECT PHYSIOL, V37, P201, DOI 10.1016/0022-1910(91)90070-G; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; BROWN D, 1992, J EXP BIOL, V172, P231; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIOFFI M, 1983, TISSUE CELL, V15, P781, DOI 10.1016/0040-8166(83)90050-2; CIOFFI M, 1979, TISSUE CELL, V11, P467, DOI 10.1016/0040-8166(79)90057-0; DEFRANCO PE, 1995, J AM SOC NEPHROL, V6, P295; DIMITRIADIS VK, 1991, J INSECT PHYSIOL, V37, P167, DOI 10.1016/0022-1910(91)90067-A; DOW JAT, 1992, J EXP BIOL, V172, P355; DOW JAT, 1984, AM J PHYSIOL, V246, pR633, DOI 10.1152/ajpregu.1984.246.4.R633; DOW JAT, 1994, J EXP BIOL, V197, P421; DOW JAT, 1994, ORGANELLAR PROTON AT, P75; GAUSZ J, 1979, GENETICS, V93, P917; GHISLAIN M, 1992, YEAST, V8, P791, DOI 10.1002/yea.320080913; GILL SS, 1991, ARCH BIOCHEM BIOPHYS, V291, P92, DOI 10.1016/0003-9861(91)90109-V; Gloor G. B., 1992, DROSOPHILA INFORMATI, V71, P148; GLUCK S, 1992, J EXP BIOL, V172, P29; GU HH, 1990, NUCLEIC ACIDS RES, V18, P7446, DOI 10.1093/nar/18.24.7446; Guo YQ, 1996, BBA-BIOMEMBRANES, V1283, P4, DOI 10.1016/0005-2736(96)00103-4; Guo YQ, 1996, GENE, V172, P239, DOI 10.1016/0378-1119(96)00057-1; HARVEY WR, 1983, AM J PHYSIOL, V244, pR163, DOI 10.1152/ajpregu.1983.244.2.R163; HARVEY WR, 1983, J EXP BIOL, V106, P91; KAISER K, 1990, P NATL ACAD SCI USA, V87, P1686, DOI 10.1073/pnas.87.5.1686; KENNISON JA, 1988, P NATL ACAD SCI USA, V85, P8136, DOI 10.1073/pnas.85.21.8136; KLEIN U, 1992, J EXP BIOL, V172, P345; LEWIS EB, 1954, AM NAT, V88, P225, DOI 10.1086/281833; Liu Q, 1996, J BIOL CHEM, V271, P2018, DOI 10.1074/jbc.271.4.2018; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MOEHRLE A, 1994, DEV GENET, V15, P478, DOI 10.1002/dvg.1020150606; MYERS M, 1993, J BIOL CHEM, V268, P9184; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1991, TRENDS PHARMACOL SCI, V12, P71, DOI 10.1016/0165-6147(91)90501-I; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; NOVAK FJS, 1992, BIOCHIM BIOPHYS ACTA, V1132, P67, DOI 10.1016/0167-4781(92)90053-3; ODonnell MJ, 1996, J EXP BIOL, V199, P1163; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; RUBIN GM, 1988, SCIENCE, V240, P1453, DOI 10.1126/science.3131880; SCHWEIKL H, 1989, J BIOL CHEM, V264, P11136; STONE DK, 1990, KIDNEY INT, V38, P649, DOI 10.1038/ki.1990.255; WIECZOREK H, 1991, J BIOL CHEM, V266, P15340; WIECZOREK H, 1992, J EXP BIOL, V172, P335	49	100	114	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	1996	271	48					30677	30684		10.1074/jbc.271.48.30677	http://dx.doi.org/10.1074/jbc.271.48.30677			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VV158	8940044	hybrid			2022-12-27	WOS:A1996VV15800061
J	Duyvis, MG; Wassink, H; Haaker, H				Duyvis, MG; Wassink, H; Haaker, H			Pre-steady-state kinetics of nitrogenase from Azotobacter vinelandii - Evidence for an ATP-induced conformational change of the nitrogenase complex as part of the reaction mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLEBSIELLA-PNEUMONIAE NITROGENASE; MOLYBDENUM-IRON PROTEIN; MOFE-PROTEIN; ELECTRON-TRANSFER; SODIUM DITHIONITE; FE-PROTEIN; P-CLUSTERS; REDUCTION; SIMULATION; DISSOCIATION	The pre-steady-state electron transfer reactions of nitrogenase from Azotobact With reduced nitrogenase proteins after the initial absorbance increase at 430 nm (which is associated with electron transfer from the Fe protein to the MoFe protein and is complete in 50 ms) the absorbance decreases, which, dependent on the ratio [Av2]/[Av1], is followed by an increase of the absorbance. The mixing of reductant-free nitrogenase proteins with MgATP leads after 20 ms to a decrease of the absorbance, which could be fitted (from 0.05 to 1 s) with a single exponential decay with a rate constant k(obs)=6.6+/-0.8 s(-1). This reaction of nitrogenase was measured at different wavelengths. The data indicate the formation of a species with a blue shift of the absorbance of metal-sulfur clusters of nitrogenase from 430 to 360 nm. The absorbance decrease at 430 nm observed (after 50 ms) in the case of the reduced nitrogenase proteins could only be simulated well if, after the initial electron transfer from the Fe protein to the MoFe protein and before dissociation of the nitrogenase complex, an additional reaction was assumed. The rate constant of this reaction was of the same order as the rate constant of the MgATP-dependent pre-steady-state proton production by nitrogenase from A. vinelandii: k(obs)=14+/-4 s(-1) with reduced nitrogenase proteins and k(obs)=6+/-2 s(-1) with dithionite-free nitrogenase proteins (Duyvis, M. G., Wassink, H., and Haaker, H. (1994) Eur. J. Biochem, 225, 881-890). It is proposed that in the presence and absence of reductant, the observed absorbance decrease at 430 nm of nitrogenase is caused by a change of the conformation of the nitrogenase complex, as a consequence of hydrolysis of MgATP.	AGR UNIV WAGENINGEN, DEPT BIOCHEM, NL-6703 HA WAGENINGEN, NETHERLANDS	Wageningen University & Research								ASHBY GA, 1987, BIOCHEM J, V246, P455, DOI 10.1042/bj2460455; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BOLIN JT, 1993, ACS SYM SER, V535, P186; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; CHAN MK, 1993, SCIENCE, V260, P792, DOI 10.1126/science.8484118; DUYVIS MG, 1994, EUR J BIOCHEM, V225, P881, DOI 10.1111/j.1432-1033.1994.0881b.x; Duyvis MG, 1996, FEBS LETT, V380, P233, DOI 10.1016/0014-5793(96)00019-1; FISHER K, 1991, BIOCHEM J, V279, P81, DOI 10.1042/bj2790081; FOGUEL D, 1995, J BIOL CHEM, V270, P28759, DOI 10.1074/jbc.270.48.28759; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HADFIELD KL, 1969, BIOCHEMISTRY-US, V8, P5103, DOI 10.1021/bi00840a064; HOWARD JB, 1994, ANNU REV BIOCHEM, V63, P235, DOI 10.1146/annurev.bi.63.070194.001315; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; Lowe D. J., 1995, Nitrogen fixation: fundamentals and applications. Proceedings of the 10th International Congress on Nitrogen Fixation, St. Petersburg, Russia, May 28-June 3 1995., P103; LOWE DJ, 1984, BIOCHEM J, V224, P877, DOI 10.1042/bj2240877; LOWE DJ, 1990, BIOCHEM J, V272, P621, DOI 10.1042/bj2720621; LOWE DJ, 1984, BIOCHEM J, V224, P895, DOI 10.1042/bj2240895; LOWE DJ, 1993, BIOCHEM J, V292, P93, DOI 10.1042/bj2920093; MENSINK RE, 1992, EUR J BIOCHEM, V208, P295, DOI 10.1111/j.1432-1033.1992.tb17186.x; MENSINK RE, 1992, EUR J BIOCHEM, V208, P289, DOI 10.1111/j.1432-1033.1992.tb17185.x; MULLER F, 1973, BIOCHEMISTRY-US, V12, P4654; PETERS JW, 1995, J BIOL CHEM, V270, P27007, DOI 10.1074/jbc.270.45.27007; PIERIK AJ, 1993, EUR J BIOCHEM, V212, P51, DOI 10.1111/j.1432-1033.1993.tb17632.x; Renner KA, 1996, BIOCHEMISTRY-US, V35, P5353, DOI 10.1021/bi960441o; THORNELEY RNF, 1984, BIOCHEM J, V224, P903, DOI 10.1042/bj2240903; THORNELEY RNF, 1983, BIOCHEM J, V215, P393, DOI 10.1042/bj2150393; TITTSWORTH RC, 1993, J AM CHEM SOC, V115, P9763, DOI 10.1021/ja00074a050	27	15	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					29632	29636		10.1074/jbc.271.47.29632	http://dx.doi.org/10.1074/jbc.271.47.29632			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939894	hybrid			2022-12-27	WOS:A1996VU52500022
J	Hausner, W; Wettach, J; Hethke, C; Thomm, M				Hausner, W; Wettach, J; Hethke, C; Thomm, M			Two transcription factors related with the eucaryal transcription factors TATA-binding protein and transcription factor IIB direct promoter recognition by an archaeal RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE TRANSCRIPTION; METHANOCOCCUS-THERMOLITHOTROPHICUS; FACTOR-TFIIB; ARCHAEBACTERIAL PROMOTER; SULFOLOBUS-SHIBATAE; GENES; EUKARYOTES; ELEMENT; BOX; EXPRESSION	We reported previously that cell-free transcription in the Archaea Methanococcus and Pyrococcus depends upon two archaeal transcription factors, archaeal transcription factor A (aTFA) and archaeal transcription factor B (aTFB), In the genome of Pyrococcus genes encoding putative homologues of eucaryal transcription factors TATA-binding protein (TBP) and TFIIB have been detected, Here, we report that Escherichia coli synthesized Pyrococcus homologues of TBP and TFIIB are able to replace endogenous aTFB and aTFA in cell-free transcription reactions, Antibodies raised against archaeal TBP and TFIIB bind to polypeptides of identical molecular mass in the aTFB and aTFA fraction. These data identify aTFB as archaeal TBP and aTFA as the archaeal homologue of TFIIB, At the Pyrococcus glutamate dehydrogenase (gdh) promoter these two bacterially produced transcription factors and endogenous RNA polymerase are sufficient to direct accurate and active initiation of transcription, DNase I protection experiments revealed Pyrococcus-TBP producing a characteristic footprint between position -20 and -34 centered around the TATA box of gdh promoter, Pyrococcus-TFIIB did not bind to the TATA box but bound cooperatively with Pyrococcus-TBP generating an extended DNase I footprinting pattern ranging from position -19 to -42, These data suggest that the Pyrococcus homologue of TFIIB associates with the TBP-promoter binary complex as its eucaryal counterpart, but in contrast to eucaryal TFIIB, it causes an extension of the protection to the region upstream of the TATA box.	CHRISTIAN ALBRECHTS UNIV KIEL,INST ALLGEMEINE MIKROBIOL,D-24118 KIEL,GERMANY	University of Kiel								CRETI R, 1993, NUCLEIC ACIDS RES, V21, P2942, DOI 10.1093/nar/21.12.2942; FREY G, 1990, NUCLEIC ACIDS RES, V18, P1361, DOI 10.1093/nar/18.6.1361; GOHL HP, 1995, NUCLEIC ACIDS RES, V23, P3837, DOI 10.1093/nar/23.19.3837; GOHL HP, 1992, MOL GEN GENET, V231, P286, DOI 10.1007/BF00279802; GROPP F, 1986, SYST APPL MICROBIOL, V7, P95, DOI 10.1016/S0723-2020(86)80130-8; HAUSNER W, 1991, J MOL BIOL, V222, P495, DOI 10.1016/0022-2836(91)90492-O; HAUSNER W, 1993, J BIOL CHEM, V268, P24047; HAUSNER W, 1995, J BIOL CHEM, V270, P17649, DOI 10.1074/jbc.270.30.17649; HETHKE C, 1996, NUCLEIC ACIDS RES, V12, P2369; HUDEPOHL U, 1990, P NATL ACAD SCI USA, V87, P5851, DOI 10.1073/pnas.87.15.5851; LEE S, 1995, NATURE, V376, P609, DOI 10.1038/376609a0; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; MARSH TL, 1994, P NATL ACAD SCI USA, V91, P4180, DOI 10.1073/pnas.91.10.4180; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; OUZOUNIS C, 1992, CELL, V71, P189, DOI 10.1016/0092-8674(92)90347-F; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; QURESHI SA, 1995, NUCLEIC ACIDS RES, V23, P1775, DOI 10.1093/nar/23.10.1775; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P6077, DOI 10.1073/pnas.92.13.6077; RASHID N, 1995, GENE, V166, P139, DOI 10.1016/0378-1119(95)00603-2; REITER WD, 1990, P NATL ACAD SCI USA, V87, P9509, DOI 10.1073/pnas.87.24.9509; ROWLANDS T, 1994, SCIENCE, V264, P1326, DOI 10.1126/science.8191287; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOMM M, 1988, NUCLEIC ACIDS RES, V16, P151, DOI 10.1093/nar/16.1.151; WETTACH J, 1995, P NATL ACAD SCI USA, V92, P472, DOI 10.1073/pnas.92.2.472; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	27	96	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	1996	271	47					30144	30148		10.1074/jbc.271.47.30144	http://dx.doi.org/10.1074/jbc.271.47.30144			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU525	8939964	hybrid			2022-12-27	WOS:A1996VU52500092
J	Martin, SJ; Finucane, DM; AmaranteMendes, GP; OBrien, GA; Green, DR				Martin, SJ; Finucane, DM; AmaranteMendes, GP; OBrien, GA; Green, DR			Phosphatidylserine externalization during CD95-induced apoptosis of cells and cytoplasts requires ICE/CED-3 protease activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITRONECTIN RECEPTOR; RECOGNITION; NUCLEUS; DEATH; MACROPHAGES; BCL-2	Phosphatidylserine (PS), a lipid normally confined to the inner leaflet of the plasma membrane, is exported to the outer plasma membrane leaflet during apoptosis to serve as a trigger for recognition of apoptotic cells by phagocytes. The mechanism of PS export during apoptosis is not known nor is it clear whether the nuclear changes that typify apoptosis contribute in any way to this event. Here, we demonstrate that ligation of the CD95 (Fas/APO-1) molecule on Jurkat cytoplasts induces dramatic PS externalization similar to that observed during apoptosis of intact cells. Apoptosis of both cells and cytoplasts was associated with proteolytic processing of CPP32, a member of the interleukin-1 beta converting enzyme (ICE)/CED-3 protease family, to its active form. Fodrin, a component of the cortical cytoskeleton, also underwent proteolytic cleavage during apoptosis of both cytoplasts and intact cells. Strikingly, CPP32 activation, fodrin proteolysis, and PS externalization were all inhibited in the presence of peptide inhibitors of ICE/CED-3 family proteases. These data provide strong support for the notion that the cell death machinery is extranuclear and is likely to be comprised of one or more members of the ICE/CED-3 family and that activation of this machinery does not require nuclear participation.	LA JOLLA INST ALLERGY & IMMUNOL,DIV CELLULAR IMMUNOL,LA JOLLA,CA 92121	La Jolla Institute for Immunology			Green, Douglas R/N-8083-2018; Mendes, Gustavo P Amarante/C-8187-2012	Green, Douglas R/0000-0002-7332-1417; Mendes, Gustavo P Amarante/0000-0002-7851-6205; Martin, Seamus/0000-0002-8539-3143	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052735, R37GM052735] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52735] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; Casiano CA, 1996, J EXP MED, V184, P765, DOI 10.1084/jem.184.2.765; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; FADOK VA, 1992, J IMMUNOL, V149, P4029; FADOK VA, 1992, J IMMUNOL, V148, P2207; GUDAS JM, 1986, J CELL PHYSIOL, V128, P441, DOI 10.1002/jcp.1041280313; HASLETT C, 1994, PHILOS T ROY SOC B, V345, P327, DOI 10.1098/rstb.1994.0113; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; MARTIN SJ, 1994, TRENDS BIOCHEM SCI, V19, P26, DOI 10.1016/0968-0004(94)90170-8; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAKAJIMA H, 1995, J EXP MED, V181, P1905, DOI 10.1084/jem.181.5.1905; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463	27	308	312	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28753	28756		10.1074/jbc.271.46.28753	http://dx.doi.org/10.1074/jbc.271.46.28753			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910516	hybrid			2022-12-27	WOS:A1996VT05200008
J	Mukherjee, JJ; Chung, T; Ways, DK; Kiss, Z				Mukherjee, JJ; Chung, T; Ways, DK; Kiss, Z			Protein kinase C alpha is a major mediator of the stimulatory effect of phorbol ester on phospholipase D-mediated hydrolysis of phosphatidylethanolamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIH 3T3 FIBROBLASTS; INDUCED DNA-SYNTHESIS; RAT FIBROBLASTS; PHOSPHATIDYLCHOLINE HYDROLYSIS; HYDROGEN-PEROXIDE; KIDNEY-CELLS; D ACTIVATION; OVEREXPRESSION; EPSILON; MECHANISMS	Stimulation of phospholipase D (PLD)-mediated hydrolysis of phosphatidylcholine (PtdCho) by phorbol 12-myristate 13-acetate (PMA) has been shown to be mediated by the alpha- and beta I-isoforms of protein kinase C (PKC). To determine the role of various PKC isozymes in the regulation of PLD-mediated phosphatidylethanolamine (PtdEtn) hydrolysis, MCF-7 human breast carcinoma cells overexpressing the alpha- and theta-isoforms, and R6 rat fibroblasts overexpressing the alpha-, beta I-, and epsilon-isoforms were used. In the vector control MCF-7 cells, which contain low levels of PKC-alpha, PMA (100 nM) had only small effects on the hydrolysis of PtdEtn (1.1-1.35-fold) and PtdCho (1.15-1.6-fold). Stable expression of PKC-alpha in MCF-7 cells, which was accompanied by increased levels of the beta I- and theta-isoforms as well, greatly enhanced both PMA-induced PLD-mediated formation of phosphatidylethanol (similar to 5-fold) and the hydrolysis of PtdEtn (2.5-2.9-fold) and PtdCho (5.5-7.2-fold). The effects of PMA on the hydrolysis of PtdEtn (and PtdCho) in MCF-7/PKC-alpha cells mere significantly inhibited by 0.5-3 mu M concentrations of Go 6976, a selective inhibitor of the conventional PKC subfamily. Stable expression of PKC-alpha in R6 fibroblasts enhanced, at a shorter (10 min) incubation time, the effects of PMA on the hydrolysis of both PtdEtn and, to a lesser extent, PtdCho. In contrast, stable expression of PKC-beta I in R6 fibroblasts, which originally did not contain this enzyme, enhanced the effects of PMA only on PtdCho, but not PtdEtn, hydrolysis. Overexpression of either PKC-theta in MCF-7 cells or PKC-epsilon in R6 and NIH 3T3 fibroblasts had no detectable effects on PMA-induced hydrolysis of PtdEtn. Collectively, the results suggest that PKC-alpha has a major role in the mediation of phorbol ester action on PtdEtn hydrolysis, while PtdCho hydrolysis may be regulated by both the alpha and beta I isoforms.	UNIV MINNESOTA,HORMEL INST,AUSTIN,MN 55912; LILLY CORP CTR,LILLY RES LABS,INDIANAPOLIS,IN 46285	University of Minnesota System; Eli Lilly								BAIER G, 1993, J BIOL CHEM, V268, P4997; BALBOA MA, 1994, J BIOL CHEM, V269, P10511; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLOBE GC, 1993, J BIOL CHEM, V268, P658; CACACE AM, 1993, ONCOGENE, V8, P2095; CONRICODE KM, 1994, FEBS LETT, V342, P149, DOI 10.1016/0014-5793(94)80490-7; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; ELDAR H, 1993, J BIOL CHEM, V268, P12560; EXTON JH, 1990, J BIOL CHEM, V265, P1; FISK HA, 1992, J CELL PHYSIOL, V153, P589, DOI 10.1002/jcp.1041530321; HII CST, 1991, J BIOL CHEM, V266, P20238; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; KISS Z, 1994, ARCH BIOCHEM BIOPHYS, V311, P430, DOI 10.1006/abbi.1994.1258; KISS Z, 1994, BIOCHEM J, V300, P751, DOI 10.1042/bj3000751; KISS Z, 1994, BIOCHEM J, V302, P649, DOI 10.1042/bj3020649; KISS Z, 1989, J BIOL CHEM, V264, P1483; KISS Z, 1995, FEBS LETT, V365, P146, DOI 10.1016/0014-5793(95)00445-F; Kiss Z, 1996, BIOCHEM BIOPH RES CO, V218, P505, DOI 10.1006/bbrc.1996.0090; Kiss Z, 1996, BIOCHEM BIOPH RES CO, V220, P125, DOI 10.1006/bbrc.1996.0368; Kiss Z, 1996, FEBS LETT, V381, P67, DOI 10.1016/0014-5793(96)00084-1; KISS Z, 1995, FEBS LETT, V371, P185, DOI 10.1016/0014-5793(95)00902-L; KISS Z, 1992, BIOCHEM J, V288, P853, DOI 10.1042/bj2880853; KISS Z, 1993, FEBS LETT, V333, P229, DOI 10.1016/0014-5793(93)80659-I; LOPEZ I, 1995, J BIOL CHEM, V270, P19465, DOI 10.1074/jbc.270.33.19465; MARQUEZ C, 1992, J IMMUNOL, V149, P2560; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MIZUNUMA M, 1993, BIOCHIM BIOPHYS ACTA, V1168, P213; NATARAJAN V, 1993, J BIOL CHEM, V268, P930; PAI JK, 1991, P NATL ACAD SCI USA, V88, P598, DOI 10.1073/pnas.88.2.598; TOMONO M, 1995, BIOCHEM BIOPH RES CO, V213, P980, DOI 10.1006/bbrc.1995.2225; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335	34	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					28912	28917		10.1074/jbc.271.46.28912	http://dx.doi.org/10.1074/jbc.271.46.28912			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910539	hybrid			2022-12-27	WOS:A1996VT05200031
J	Mullins, C; Meyer, HA; Hartmann, E; Green, N; Fang, H				Mullins, C; Meyer, HA; Hartmann, E; Green, N; Fang, H			Structurally related Spc1p and Spc2p of yeast signal peptidase complex are functionally distinct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SHUTTLE VECTORS; SEC11 PROTEIN; GENE; PURIFICATION; GLYCOPROTEIN; POLYPEPTIDES; CONTAINS; SUBUNIT	Two subunits of the mammalian signal peptidase complex, SPC12 and SPC25, share similar membrane topologies with the majority of each protein oriented toward the cytoplasm. Such similarities may suggest that these proteins perform redundant functions in signal peptidase activity. In the present study, we addressed this issue through analysis of the yeast homologs to SPC12 and SPC25, Spc1p and Spc2p. We show that both Spc1p and Spc2p are nonessential for signal peptidase activity and growth of yeast cells and that null mutations in the genes encoding Spc1p and Spc2p are synthetically lethal with a conditional mutation affecting Sec11p, an essential subunit of yeast signal peptidase. However, a high copy plasmid encoding Spc1p suppresses the conditional sec11 mutation, whereas the corresponding plasmid encoding Spc2p does not suppress sec11. Moreover, Spc2p, but not Spc1p, is important for signal peptidase activity and cell viability at high temperatures. These results indicate that although both Spc1p and Spc2p are noncatalytic, they are functionally distinct. Evidence is also presented that a double mutant lacking Spc1p and Spc2p grows well relative to wild type yeast cells, indicating that the signal peptidase complex missing at least two of its subunits is sufficient for signal peptidase activity in vivo.	MAX DELBRUCK CTR MOL MED,D-13125 BERLIN,GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Mullins, C (corresponding author), VANDERBILT UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,NASHVILLE,TN 37232, USA.		Hartmann, Enno/C-5687-2013		NATIONAL CANCER INSTITUTE [T32CA009385] Funding Source: NIH RePORTER; NCI NIH HHS [2 T32 CA09385-11] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschul SF, 1990, J MOL BIOL, V215, P403; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; Fang H, 1996, J BIOL CHEM, V271, P16460, DOI 10.1074/jbc.271.28.16460; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; GREEN N, 1992, MOL CELL BIOL, V12, P276, DOI 10.1128/MCB.12.1.276; GREENBURG G, 1989, J BIOL CHEM, V264, P15762; GREENBURG G, 1994, J BIOL CHEM, V269, P25354; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1442; Kalies KU, 1996, J BIOL CHEM, V271, P3925; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MULLINS C, 1995, J BIOL CHEM, V270, P17139, DOI 10.1074/jbc.270.29.17139; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; SHELNESS GS, 1988, J BIOL CHEM, V263, P17063; SHELNESS GS, 1990, J BIOL CHEM, V265, P9512; SHELNESS GS, 1993, J BIOL CHEM, V268, P5201; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEVENS TB, 1982, CELL, V30, P443; Von Heijne Gunnar, 1994, V22, P1; YADEAU JT, 1991, P NATL ACAD SCI USA, V88, P517, DOI 10.1073/pnas.88.2.517; ZWIZINSKI C, 1980, J BIOL CHEM, V255, P7973	29	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1996	271	46					29094	29099		10.1074/jbc.271.46.29094	http://dx.doi.org/10.1074/jbc.271.46.29094			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VT052	8910564	hybrid			2022-12-27	WOS:A1996VT05200056
